<SEC-DOCUMENT>0001628280-21-023213.txt : 20211112
<SEC-HEADER>0001628280-21-023213.hdr.sgml : 20211112
<ACCEPTANCE-DATETIME>20211112171626
ACCESSION NUMBER:		0001628280-21-023213
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		66
CONFORMED PERIOD OF REPORT:	20210930
FILED AS OF DATE:		20211112
DATE AS OF CHANGE:		20211112

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CUMBERLAND PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001087294
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33637
		FILM NUMBER:		211404867

	BUSINESS ADDRESS:	
		STREET 1:		2525 WEST END AVENUE
		STREET 2:		SUITE 950
		CITY:			NASHVILLE,
		STATE:			TN
		ZIP:			37203
		BUSINESS PHONE:		615-255-0068

	MAIL ADDRESS:	
		STREET 1:		2525 WEST END AVENUE
		STREET 2:		SUITE 950
		CITY:			NASHVILLE
		STATE:			TN
		ZIP:			37203
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>cpix-20210930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:719f38f6-81ec-4e77-a876-c86386f0dd09,g:3c5f884f-ec0b-48db-97a2-96993ede30b3,d:8e8bdb91dc894234b9d87e17a18b54fd--><html xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:cpix="http://www.cumberlandpharma.com/20210930" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>cpix-20210930</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80L2ZyYWc6ODk0NTg5NTU0MWNiNGQzYWFjY2U2ZDFkODcxNmI4ODYvdGFibGU6NTczZThlZjFjZTVkNGNkNzljZTcwYWE4ZDQ3OWMyNWMvdGFibGVyYW5nZTo1NzNlOGVmMWNlNWQ0Y2Q3OWNlNzBhYThkNDc5YzI1Y181LTEtMS0xLTk1NTg_cb626646-506a-4773-ac71-5f2cad713dc8">2021</ix:nonNumeric><ix:nonNumeric contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80L2ZyYWc6ODk0NTg5NTU0MWNiNGQzYWFjY2U2ZDFkODcxNmI4ODYvdGFibGU6NTczZThlZjFjZTVkNGNkNzljZTcwYWE4ZDQ3OWMyNWMvdGFibGVyYW5nZTo1NzNlOGVmMWNlNWQ0Y2Q3OWNlNzBhYThkNDc5YzI1Y182LTEtMS0xLTk1NTg_c6478a7c-da3a-4b2d-a18c-094fdad418d7">Q3</ix:nonNumeric><ix:nonNumeric contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" format="ixt:fixed-false" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80L2ZyYWc6ODk0NTg5NTU0MWNiNGQzYWFjY2U2ZDFkODcxNmI4ODYvdGFibGU6NTczZThlZjFjZTVkNGNkNzljZTcwYWE4ZDQ3OWMyNWMvdGFibGVyYW5nZTo1NzNlOGVmMWNlNWQ0Y2Q3OWNlNzBhYThkNDc5YzI1Y183LTEtMS0xLTk1NTg_28954d82-22f1-466a-afde-42cf97abdc80">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80L2ZyYWc6ODk0NTg5NTU0MWNiNGQzYWFjY2U2ZDFkODcxNmI4ODYvdGV4dHJlZ2lvbjo4OTQ1ODk1NTQxY2I0ZDNhYWNjZTZkMWQ4NzE2Yjg4Nl83OA_2bdee78c-154e-4d86-88a8-03ce3ee1095d">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80L2ZyYWc6ODk0NTg5NTU0MWNiNGQzYWFjY2U2ZDFkODcxNmI4ODYvdGV4dHJlZ2lvbjo4OTQ1ODk1NTQxY2I0ZDNhYWNjZTZkMWQ4NzE2Yjg4Nl83OQ_bfd22206-570a-4a0c-9502-ece83f38b7bb">0001087294</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="cpix-20210930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i997bd44925334429a7698804c0800bcd_I20211108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-11-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i5fc3bb3df16548c98cacace445d903da_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb172cb6365440839665fd6ec022472c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i5cfdffb6c8a4411a95e4596b0bd91b7c_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2722c94900c4f68be9dd446637b8348_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb58760ea84940319b35492cd1910735_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:ClinigenHealthcareLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifca7f9fa06d14f85a52cbd81ac170d2c_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:ClinigenHealthcareLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45bdfab35dd74d60ac86fc023b908b73_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:ClinigenHealthcareLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8c8802e62b74a919450a1c6017bba7e_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:ClinigenHealthcareLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6fa410e0219e41c3b8a23d8140a1ca8c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ae7216a773d47d889c5f34d67e867fe_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90ac8e9aca0748058577add35fc3a6f9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f67242cec184569be979f0eab3bb2dd_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1925af7a08774bc4a2752a9cd6b75c35_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf2c0f582f1a48b1b7132666868a1789_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4167fc9dfbd441ed853e3173c4f077bf_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4f1350ea2fc4eb18dc553f1c359d775_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94a852cb675745e89723e30ec61bfcee_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98ca8db1bbc14991a38ad2f127cdc3f7_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9ade7c2b96049c891663efff729f1ef_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia79d5a078419401d86bc7174c913bcf6_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8cac0f57d4c4aa1bf61accf6f74bfda_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62b7e40824ec46c1a5d32166d46d8910_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i374ad433cb0d4675ae41fef76147919d_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7d9f053c7b34fd799481310c6ca1498_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06622f546c724e4289669409575c7f9d_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5c699d5da91427e80a66ec6b1991b3a_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70a1ecea99f7485195b3405682bd0c55_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9fb60215b0504a758fcf2dfe00ea4b97_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00b5fc7364e347f39acdca8004cef0f9_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i786c6ae7dd8d4840bb2995fce1423b07_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c344dec4461400991796893b71c39f3_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1cdf0875abf4833a9b0038791a1ea6c_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e43169536834b7daa78040307754845_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1adc976609fe48d4b014ec48f05e022c_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i169b3e774913430bb6c450a8d1cd8300_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i659fa119f70c4793a43053cddb879d71_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50909170032a4c00a004f6dd1808751c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42e8ab4712444a43a1f231cb65ac3dcd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idecbe529c8e14131b56433eb5e130916_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c8473bff64c498ab624fafa4cca5132_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i781a96ef93c24d05bb7f12625a033ec0_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38154999f15f41cca19a77a5f4d0ccac_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d845908b01747ac9d721fff45f53abf_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32deafcb20a948cf995118abdf3ce1a4_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2593ac397b63496686231e5a4d277b3b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8320ae6bb40c49b4b91522210805d996_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief227cab10a245ff9baa903632237a80_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83fce5d3edda4b1cbab16d0e4a53c979_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe562d54463741e8949d25484a516053_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f91139b751f41ee943e86bdb734f2f4_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ea7194dbc454dbdbc6632db38bf6066_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic49c90ad54954ba9a5f89e54eb1dfedb_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1e3b4d188524c1791c80059e8f7515a_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64b2d71ddb0c448d9959f1b9a74a7dad_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i10df7b4f9a35418da7673ef6ae315d51_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae1347d2d1d84aa3a135e3245bdf0d90_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9cc79eb883d54f61bdec225f436b82c9_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56aafc7718c145c8b150a8e54f33a5d2_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1da3f9dccc043f1b509c4e381803002_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied663adb59564577989ed6d27ea6493f_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>cpix:Segment</xbrli:measure></xbrli:unit><xbrli:context id="i2b064560ae764b05aee16232fc2b982f_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:AcetadoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9189ef3c405466780ff2b301ce69072_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:AcetadoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib543c8c5c4a0438eb3b83a9549c72767_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:KristaloseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i851181d1e03446adb4d2b6f666a489e7_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:KristaloseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i343ad32279094a2585bfa47056ea0769_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OmeclamoxPakMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf76fee1053a41f897bb2b308eda43b7_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OmeclamoxPakMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a175b2126f3439e978ef755a5187703_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1221e6e62b0d4437aa038a1593455cdb_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide5a86375216464d9ebfdf112640aff3_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:KristaloseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d2eab230e924fb094455dfdb93d19f6_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:KristaloseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib32ee538452d4d108fd0d0249f232e4e_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:CaldolorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie38185217cb649a98c782f849b956b81_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:CaldolorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb5e5973ac81495ca434caa4250ad1e6_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f2cff2563f6434383fad1a3433a95bf_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87b67bdb94e6413eab1ada4bb36a71b7_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VaprisolMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70e186cdc2a444de9d34c6b0a9840fa3_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VaprisolMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0301ef84e6814fc1afd5bda0bb02be0c_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VaprisolMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10d6fa0a80234f6fbdf7f486df4beed1_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VaprisolMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba2b0e3ce8dc46a892511cbd1f0b38cf_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:AcetadoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2075e961d64a4c4184f2117135160c9e_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:AcetadoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67bca755a168477fb7af6f54edd41311_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:CaldolorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i369b52ac1f754a4a9275b8917dc3bb9d_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:CaldolorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2206c2c78e3347cf9fd2bb7625961847_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OmeclamoxPakMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64299c3a88d84d888de7a4e8264da6a1_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OmeclamoxPakMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica59276837544b3e89921005c9db373f_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:RediTrexMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d8203f933864c8d869320c4b6ce16d2_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:RediTrexMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if79d16ca01cf493f84c3a1bcbcf07c1d_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:RediTrexMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3900d92fcea4358838f65d608ad8088_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:RediTrexMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d6efd6bd2c041769f9fbf0d1a3e5685_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1571108ca25f4e179a9d14073629ae96_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8cf12a139ea74881b685de000f63434e_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idbd3b5d4865547179a8bf7fbe50a430c_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7beb09efdc954e3387adf27b4cc99538_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c591eb458184e3baae21c9c26245264_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32601382eaeb463ba862531b12def23c_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76c8b1e743d441a3ad6f81bc894366dd_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i890f0fecec4a4eb899b3171ad304df32_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d7014c036534d1ab07ea1c7138ece74_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2fb3c2ea35a146918884002eb0319cb9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">cpix:IfetrobanClinicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85407d87b0cc40608f88c792ee3187bc_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">cpix:IfetrobanClinicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="ifd0c03fd249e4e64a76675f06c950be1_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67e0bde90efc45a7a814f5c68fb0096f_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">srt:OfficeBuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i6b60adc716c54226bd1b0d9f82b62a4c_I20100513"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2010-05-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d045c0da7504a3081ac01dc90d95aed_I20160131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3eac19ab71204baa8b814cd80e8e55ab_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i545187d4937e41ec99d80966b809dd78_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b890701c9304f309d867768f2a90a7b_D20171101-20171130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-11-01</xbrli:startDate><xbrli:endDate>2017-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib59b0ab18a9847a48768cc76def0c5ce_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7109429b4bb94262ab81694be586f875_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i448fcba2bca740069897cf519754695f_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie91a73f23b39413ca4897ecef5e9c6b9_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cpix:IncentiveStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie35d5d79a31d4a97ada4dc5eb118435d_I20211028"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cpix:FifthAmendmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i433310853533429eb0bd0de42c8cb8c0_D20200814-20200814"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-14</xbrli:startDate><xbrli:endDate>2020-08-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7857ace04dd14acd90de8bfdfc44e2ad_D20200814-20200814"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-14</xbrli:startDate><xbrli:endDate>2020-08-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia066a8f68c2c4b2bb8d23f93616af446_D20200814-20200814"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-14</xbrli:startDate><xbrli:endDate>2020-08-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c79a3c371c84f16b64c6d20ef3f26bd_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29e07103e7b54d69af01f448919f0979_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5729693e898c46118beacc910390b13c_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f0ec15fc71f49aca22d17a26142e958_D20200420-20200420"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-20</xbrli:startDate><xbrli:endDate>2020-04-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f3eb3a61d724b16837687fe50bb6592_I20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:WinHealthInvestmentSingaporeLtdDomain</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i10ede8aae6b6477eb6df1f13d1f8042a_I20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:WinHealthInvestmentSingaporeLtdDomain</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic25c3441c5a0477ebd8c769c3ea98555_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57f795672a2a465e9209a65e0162f0b4_D20181101-20181130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-11-01</xbrli:startDate><xbrli:endDate>2018-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id08ba9ef8fce4ef0b1aebddae7a819be_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0463cd68913447b0aec736a9a21b1701_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf562c30b2d9493a84db87baebada783_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7d1c3dbcd4b4c6eabe94af067f29d41_D20161101-20161130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-11-01</xbrli:startDate><xbrli:endDate>2016-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb1ab73ec0354946b843823c167cac73_D20161101-20161130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-11-01</xbrli:startDate><xbrli:endDate>2016-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9fbce1ec780d49a78a390da0ae5f4c6c_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a2ac195a36045adacdf507f9366ba39_I20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0899d206bf0144cb8f97b035bbc59bdc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab3199a2232b4c38950a9c717c8b9171_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c783d360e1948c18a55f375b9840bca_D20191001-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:ClinigenHealthcareLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54eac56082574a4c986a915dc06c3af5_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i8e8bdb91dc894234b9d87e17a18b54fd_1"></div><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WASHINGTON, DC 20549</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xL2ZyYWc6M2RkOWU5NmIzN2E5NDFiYmJmZGQzMTAzZmZiYjNmYzQvdGV4dHJlZ2lvbjozZGQ5ZTk2YjM3YTk0MWJiYmZkZDMxMDNmZmJiM2ZjNF8xOTc0_413f7ba7-e2d7-436a-8c53-feb9f8cd07ef">10-Q</ix:nonNumeric> </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Mark One)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" format="ixt:fixed-true" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xL2ZyYWc6M2RkOWU5NmIzN2E5NDFiYmJmZGQzMTAzZmZiYjNmYzQvdGFibGU6ZmZkZGI4YTQ0NDg5NGE1NmJhY2FlNTk3YzhhNjRkYjYvdGFibGVyYW5nZTpmZmRkYjhhNDQ0ODk0YTU2YmFjYWU1OTdjOGE2NGRiNl8wLTAtMS0xLTk1NTg_0193c29b-07e6-4626-b4b6-5b4b054e6863">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xL2ZyYWc6M2RkOWU5NmIzN2E5NDFiYmJmZGQzMTAzZmZiYjNmYzQvdGV4dHJlZ2lvbjozZGQ5ZTk2YjM3YTk0MWJiYmZkZDMxMDNmZmJiM2ZjNF8xMzA_b4ca3137-0810-4842-98d1-620cf0993095">September 30, 2021</ix:nonNumeric> </span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" format="ixt:fixed-false" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xL2ZyYWc6M2RkOWU5NmIzN2E5NDFiYmJmZGQzMTAzZmZiYjNmYzQvdGFibGU6YWM5M2U4YzMwNDdiNGJiMGE0MDNhYjdjMzdhZWY4YzAvdGFibGVyYW5nZTphYzkzZThjMzA0N2I0YmIwYTQwM2FiN2MzN2FlZjhjMF8wLTAtMS0xLTk1NTg_ce9f6d89-702f-45c0-8e61-a2522acd25a8">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;.</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission file number: <ix:nonNumeric contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xL2ZyYWc6M2RkOWU5NmIzN2E5NDFiYmJmZGQzMTAzZmZiYjNmYzQvdGV4dHJlZ2lvbjozZGQ5ZTk2YjM3YTk0MWJiYmZkZDMxMDNmZmJiM2ZjNF8xOTc4_36805ec4-cee7-4afa-801f-1742a659163e">001-33637</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xL2ZyYWc6M2RkOWU5NmIzN2E5NDFiYmJmZGQzMTAzZmZiYjNmYzQvdGV4dHJlZ2lvbjozZGQ5ZTk2YjM3YTk0MWJiYmZkZDMxMDNmZmJiM2ZjNF8xOTY5_4cf731a1-abc1-422a-9c7b-5330e5e0ce7c">Cumberland Pharmaceuticals Inc.</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact Name of Registrant as Specified In Its Charter)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:48.532%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xL2ZyYWc6M2RkOWU5NmIzN2E5NDFiYmJmZGQzMTAzZmZiYjNmYzQvdGFibGU6YTM3MjY2MzViN2FiNGVjZmIzOGE5YzQzM2IwZDMyMjgvdGFibGVyYW5nZTphMzcyNjYzNWI3YWI0ZWNmYjM4YTljNDMzYjBkMzIyOF8wLTAtMS0xLTk1NTg_8583c7e4-a8b7-4425-9c38-63f67826b600">Tennessee</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xL2ZyYWc6M2RkOWU5NmIzN2E5NDFiYmJmZGQzMTAzZmZiYjNmYzQvdGFibGU6YTM3MjY2MzViN2FiNGVjZmIzOGE5YzQzM2IwZDMyMjgvdGFibGVyYW5nZTphMzcyNjYzNWI3YWI0ZWNmYjM4YTljNDMzYjBkMzIyOF8wLTItMS0xLTk1NTg_6f20bc22-eb7c-4658-b1b3-084391b2a373">62-1765329</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or Other Jurisdiction of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporation or Organization)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Identification No.)</span></div></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xL2ZyYWc6M2RkOWU5NmIzN2E5NDFiYmJmZGQzMTAzZmZiYjNmYzQvdGFibGU6YTM3MjY2MzViN2FiNGVjZmIzOGE5YzQzM2IwZDMyMjgvdGFibGVyYW5nZTphMzcyNjYzNWI3YWI0ZWNmYjM4YTljNDMzYjBkMzIyOF8zLTAtMS0xLTk1NTgvdGV4dHJlZ2lvbjo5ZTFmYTY1YWJjMTY0YmZlOTVlYWE5ZDY1N2EyMTdhNl81_b5979669-f620-46bc-9dbf-9c4cabcab966">2525 West End Avenue</ix:nonNumeric>, <ix:nonNumeric contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xL2ZyYWc6M2RkOWU5NmIzN2E5NDFiYmJmZGQzMTAzZmZiYjNmYzQvdGFibGU6YTM3MjY2MzViN2FiNGVjZmIzOGE5YzQzM2IwZDMyMjgvdGFibGVyYW5nZTphMzcyNjYzNWI3YWI0ZWNmYjM4YTljNDMzYjBkMzIyOF8zLTAtMS0xLTk1NTgvdGV4dHJlZ2lvbjo5ZTFmYTY1YWJjMTY0YmZlOTVlYWE5ZDY1N2EyMTdhNl85_e78457b9-2afe-4c2b-b82e-2f2567bd5d4c">Suite 950</ix:nonNumeric>,</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xL2ZyYWc6M2RkOWU5NmIzN2E5NDFiYmJmZGQzMTAzZmZiYjNmYzQvdGFibGU6YTM3MjY2MzViN2FiNGVjZmIzOGE5YzQzM2IwZDMyMjgvdGFibGVyYW5nZTphMzcyNjYzNWI3YWI0ZWNmYjM4YTljNDMzYjBkMzIyOF8zLTAtMS0xLTk1NTgvdGV4dHJlZ2lvbjo5ZTFmYTY1YWJjMTY0YmZlOTVlYWE5ZDY1N2EyMTdhNl8xMw_75339330-5a44-452f-9806-700c80e6b3bf">Nashville</ix:nonNumeric>, <ix:nonNumeric contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xL2ZyYWc6M2RkOWU5NmIzN2E5NDFiYmJmZGQzMTAzZmZiYjNmYzQvdGFibGU6YTM3MjY2MzViN2FiNGVjZmIzOGE5YzQzM2IwZDMyMjgvdGFibGVyYW5nZTphMzcyNjYzNWI3YWI0ZWNmYjM4YTljNDMzYjBkMzIyOF8zLTAtMS0xLTk1NTgvdGV4dHJlZ2lvbjo5ZTFmYTY1YWJjMTY0YmZlOTVlYWE5ZDY1N2EyMTdhNl8xNw_4323f3b1-7adb-4ac9-b793-7e689744eb90">Tennessee</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xL2ZyYWc6M2RkOWU5NmIzN2E5NDFiYmJmZGQzMTAzZmZiYjNmYzQvdGFibGU6YTM3MjY2MzViN2FiNGVjZmIzOGE5YzQzM2IwZDMyMjgvdGFibGVyYW5nZTphMzcyNjYzNWI3YWI0ZWNmYjM4YTljNDMzYjBkMzIyOF8zLTItMS0xLTk1NTg_de47de8e-7def-40af-a663-b858ad864ead">37203</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Address of Principal Executive Offices)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Zip Code)</span></div></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xL2ZyYWc6M2RkOWU5NmIzN2E5NDFiYmJmZGQzMTAzZmZiYjNmYzQvdGV4dHJlZ2lvbjozZGQ5ZTk2YjM3YTk0MWJiYmZkZDMxMDNmZmJiM2ZjNF8xOTcw_431485a3-0c85-4366-8baf-d5389ef35036">615</ix:nonNumeric>) <ix:nonNumeric contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xL2ZyYWc6M2RkOWU5NmIzN2E5NDFiYmJmZGQzMTAzZmZiYjNmYzQvdGV4dHJlZ2lvbjozZGQ5ZTk2YjM3YTk0MWJiYmZkZDMxMDNmZmJiM2ZjNF8xOTc5_d4442311-1438-4c31-8204-2a61f56d85ca">255-0068</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Registrant&#8217;s Telephone Number, Including Area Code)</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.269%"><tr><td style="width:1.0%"></td><td style="width:31.774%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.587%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.585%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.587%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.767%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities registered pursuant to Section 12(b) of the Act:</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading Symbol</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name of exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xL2ZyYWc6M2RkOWU5NmIzN2E5NDFiYmJmZGQzMTAzZmZiYjNmYzQvdGFibGU6OGVkMTI3NTMwNjQ2NDJhZjhkMDQ1M2M3Y2JlNDExMTQvdGFibGVyYW5nZTo4ZWQxMjc1MzA2NDY0MmFmOGQwNDUzYzdjYmU0MTExNF8yLTAtMS0xLTk1NTg_dbc6485a-9b04-48d9-ab1e-933fafa8d685">Common stock, no par value</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xL2ZyYWc6M2RkOWU5NmIzN2E5NDFiYmJmZGQzMTAzZmZiYjNmYzQvdGFibGU6OGVkMTI3NTMwNjQ2NDJhZjhkMDQ1M2M3Y2JlNDExMTQvdGFibGVyYW5nZTo4ZWQxMjc1MzA2NDY0MmFmOGQwNDUzYzdjYmU0MTExNF8yLTItMS0xLTk1NTg_ce24b53b-7247-410b-ad91-432b01c6b5ac">CPIX</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xL2ZyYWc6M2RkOWU5NmIzN2E5NDFiYmJmZGQzMTAzZmZiYjNmYzQvdGFibGU6OGVkMTI3NTMwNjQ2NDJhZjhkMDQ1M2M3Y2JlNDExMTQvdGFibGVyYW5nZTo4ZWQxMjc1MzA2NDY0MmFmOGQwNDUzYzdjYmU0MTExNF8yLTQtMS0xLTk1NTg_a291ec19-e1df-41ae-9b90-3e40561e3ef8">Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xL2ZyYWc6M2RkOWU5NmIzN2E5NDFiYmJmZGQzMTAzZmZiYjNmYzQvdGV4dHJlZ2lvbjozZGQ5ZTk2YjM3YTk0MWJiYmZkZDMxMDNmZmJiM2ZjNF8xOTcx_a1197e3d-0243-4955-858b-e5861b80cc79">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files.)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xL2ZyYWc6M2RkOWU5NmIzN2E5NDFiYmJmZGQzMTAzZmZiYjNmYzQvdGV4dHJlZ2lvbjozZGQ5ZTk2YjM3YTk0MWJiYmZkZDMxMDNmZmJiM2ZjNF8xOTcz_0ecac0a7-c30d-45ed-afd0-a854de4113ed">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.291%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.736%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.431%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.923%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.434%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Large&#160;accelerated&#160;filer</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accelerated&#160;filer</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xL2ZyYWc6M2RkOWU5NmIzN2E5NDFiYmJmZGQzMTAzZmZiYjNmYzQvdGFibGU6MTlkZWY3YjM0OGE0NGQxMTg0Y2I0MDVkNjk3MTJlOTEvdGFibGVyYW5nZToxOWRlZjdiMzQ4YTQ0ZDExODRjYjQwNWQ2OTcxMmU5MV8xLTAtMS0xLTk1NTg_a13d1c57-8798-413c-b5aa-c8cb048eeeff">Non-accelerated filer</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" format="ixt:fixed-true" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xL2ZyYWc6M2RkOWU5NmIzN2E5NDFiYmJmZGQzMTAzZmZiYjNmYzQvdGFibGU6MTlkZWY3YjM0OGE0NGQxMTg0Y2I0MDVkNjk3MTJlOTEvdGFibGVyYW5nZToxOWRlZjdiMzQ4YTQ0ZDExODRjYjQwNWQ2OTcxMmU5MV8xLTUtMS0xLTk1NTg_e9748f51-9a1a-4a17-b634-37be966893d1">&#9746;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Emerging growth company</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" format="ixt:fixed-false" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xL2ZyYWc6M2RkOWU5NmIzN2E5NDFiYmJmZGQzMTAzZmZiYjNmYzQvdGFibGU6MTlkZWY3YjM0OGE0NGQxMTg0Y2I0MDVkNjk3MTJlOTEvdGFibGVyYW5nZToxOWRlZjdiMzQ4YTQ0ZDExODRjYjQwNWQ2OTcxMmU5MV8yLTItMS0xLTk1NTg_821ed55f-0c00-421e-a584-5e383491ef49">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to&#160;Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" format="ixt:fixed-false" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xL2ZyYWc6M2RkOWU5NmIzN2E5NDFiYmJmZGQzMTAzZmZiYjNmYzQvdGV4dHJlZ2lvbjozZGQ5ZTk2YjM3YTk0MWJiYmZkZDMxMDNmZmJiM2ZjNF8xOTcy_0ec90156-7610-4193-b1bb-515ad245e4fb">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate the number of shares outstanding of each of the issuer&#8217;s classes of common stock, as of the latest practicable date: <ix:nonFraction unitRef="shares" contextRef="i997bd44925334429a7698804c0800bcd_I20211108" decimals="INF" format="ixt:num-dot-decimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xL2ZyYWc6M2RkOWU5NmIzN2E5NDFiYmJmZGQzMTAzZmZiYjNmYzQvdGV4dHJlZ2lvbjozZGQ5ZTk2YjM3YTk0MWJiYmZkZDMxMDNmZmJiM2ZjNF8xOTM0_ab701435-31e9-4fbd-bbbe-411e26afa1cb">14,809,628</ix:nonFraction> shares of common stock as of November&#160;8, 2021.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="margin-top:9pt"><span><br/></span></div><div id="i8e8bdb91dc894234b9d87e17a18b54fd_7"></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:82.331%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.469%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8e8bdb91dc894234b9d87e17a18b54fd_10">PART I &#8211; FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8e8bdb91dc894234b9d87e17a18b54fd_10">1</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;padding-right:-18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8e8bdb91dc894234b9d87e17a18b54fd_13">Item&#160;1. Financial Statements (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8e8bdb91dc894234b9d87e17a18b54fd_13">1</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8e8bdb91dc894234b9d87e17a18b54fd_16">Condensed Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8e8bdb91dc894234b9d87e17a18b54fd_16">1</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8e8bdb91dc894234b9d87e17a18b54fd_19">Condensed Consolidated Statements of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8e8bdb91dc894234b9d87e17a18b54fd_19">2</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8e8bdb91dc894234b9d87e17a18b54fd_22">Condensed Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8e8bdb91dc894234b9d87e17a18b54fd_22">3</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8e8bdb91dc894234b9d87e17a18b54fd_25">Condensed Consolidated Statements of Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8e8bdb91dc894234b9d87e17a18b54fd_25">4</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8e8bdb91dc894234b9d87e17a18b54fd_28">Notes to the Unaudited Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8e8bdb91dc894234b9d87e17a18b54fd_28">5</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8e8bdb91dc894234b9d87e17a18b54fd_58">Item&#160;2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8e8bdb91dc894234b9d87e17a18b54fd_58">15</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8e8bdb91dc894234b9d87e17a18b54fd_79">Item&#160;3. Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8e8bdb91dc894234b9d87e17a18b54fd_79">28</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8e8bdb91dc894234b9d87e17a18b54fd_82">Item&#160;4. Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8e8bdb91dc894234b9d87e17a18b54fd_82">28</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8e8bdb91dc894234b9d87e17a18b54fd_85">PART II &#8211; OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8e8bdb91dc894234b9d87e17a18b54fd_85">29</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8e8bdb91dc894234b9d87e17a18b54fd_88">Item&#160;1. Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8e8bdb91dc894234b9d87e17a18b54fd_88">29</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8e8bdb91dc894234b9d87e17a18b54fd_91">Item&#160;1A. Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8e8bdb91dc894234b9d87e17a18b54fd_91">29</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8e8bdb91dc894234b9d87e17a18b54fd_94">Item&#160;2. Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8e8bdb91dc894234b9d87e17a18b54fd_94">29</a></span></div></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8e8bdb91dc894234b9d87e17a18b54fd_97">Item&#160;6. Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8e8bdb91dc894234b9d87e17a18b54fd_97">30</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8e8bdb91dc894234b9d87e17a18b54fd_100">SIGNATURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8e8bdb91dc894234b9d87e17a18b54fd_100">31</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i8e8bdb91dc894234b9d87e17a18b54fd_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I &#8211; FINANCIAL INFORMATION</span></div><div id="i8e8bdb91dc894234b9d87e17a18b54fd_13"></div><div style="-sec-extract:summary;margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1. Financial Statements (Unaudited)</span></div><div id="i8e8bdb91dc894234b9d87e17a18b54fd_16"></div><div style="-sec-extract:summary;margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:58.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.516%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.518%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfMy0xLTEtMS05NTU4_787d08f4-2adf-45cf-8ada-8543d9c4b7c2">25,843,231</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb172cb6365440839665fd6ec022472c_I20201231" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfMy0zLTEtMS05NTU4_20b75322-7cc4-45af-a7b9-5bad822d5257">24,753,796</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfNS0xLTEtMS05NTU4_6164065d-c25f-42e4-aed6-8dd4a5841b0f">9,850,530</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb172cb6365440839665fd6ec022472c_I20201231" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfNS0zLTEtMS05NTU4_e5d96494-3cdc-41c5-8e4a-906eb5f179a1">12,377,713</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfNi0xLTEtMS05NTU4_4091615e-1774-4c16-aa12-07e5ffc72fe1">10,262,769</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb172cb6365440839665fd6ec022472c_I20201231" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfNi0zLTEtMS05NTU4_13de659e-a85f-4081-b06d-3f0c52b59079">10,638,157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfNy0xLTEtMS05NTU4_568cd97a-6a6c-4229-9766-4c44f00313a8">1,259,098</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb172cb6365440839665fd6ec022472c_I20201231" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfNy0zLTEtMS05NTU4_b5991ed0-da52-464e-8879-f96ae93c44a2">2,199,926</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfOC0xLTEtMS05NTU4_4f9a7cdd-26b3-4189-ab38-3d0c2752e571">47,215,628</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb172cb6365440839665fd6ec022472c_I20201231" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfOC0zLTEtMS05NTU4_65f340e6-74d7-4cfb-8680-658c8b0c7355">49,969,592</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfOS0xLTEtMS05NTU4_0a7c4539-54b6-4642-9ec1-09646f9defe7">9,476,737</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb172cb6365440839665fd6ec022472c_I20201231" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfOS0zLTEtMS05NTU4_a3509e15-8629-4f7b-bfda-f1d4dc62d644">11,656,742</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfMTAtMS0xLTEtOTU1OA_004f0d13-8464-41b7-9449-bf9485368979">493,488</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb172cb6365440839665fd6ec022472c_I20201231" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfMTAtMy0xLTEtOTU1OA_c827415f-8dde-4bd9-9046-8ad08abe9049">574,169</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfMTEtMS0xLTEtOTU1OA_920a2aaf-4d92-4bf8-a5dc-58ff9573a845">24,918,830</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb172cb6365440839665fd6ec022472c_I20201231" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfMTEtMy0xLTEtOTU1OA_1a9fc573-d3af-4646-aafd-ca0c7bba6963">28,118,316</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Goodwill" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfMTItMS0xLTEtOTU1OA_7254f054-db53-436c-9ae6-407968371295">882,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb172cb6365440839665fd6ec022472c_I20201231" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Goodwill" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfMTItMy0xLTEtOTU1OA_713236f1-498e-41a5-9fa9-38897a12caf9">882,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfMTMtMS0xLTEtOTU1OA_03898100-deee-4659-8993-7d7a00a7e0cb">1,282,275</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb172cb6365440839665fd6ec022472c_I20201231" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfMTMtMy0xLTEtOTU1OA_863fa60a-3bd3-4571-9ab0-fd2514ae1214">2,028,148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfMTQtMS0xLTEtOTU1OA_801dd865-0a0e-49e3-bc13-7bd89a23b7d2">3,301,816</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb172cb6365440839665fd6ec022472c_I20201231" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfMTQtMy0xLTEtOTU1OA_3f1cd0a6-9066-4941-82a0-79fd010cd287">3,234,338</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfMTUtMS0xLTEtOTU1OA_6706308c-7f71-4f21-972f-a8ad2870ec2e">87,570,774</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb172cb6365440839665fd6ec022472c_I20201231" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfMTUtMy0xLTEtOTU1OA_82aecfa9-2487-419d-a33e-917eac28150e">96,463,305</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND EQUITY</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfMTgtMS0xLTEtOTU1OA_e8ba911c-7e76-467c-b067-eb434552668d">9,233,383</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb172cb6365440839665fd6ec022472c_I20201231" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfMTgtMy0xLTEtOTU1OA_be938f19-8780-42e5-8abd-ed1477094964">13,396,286</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfMTktMS0xLTEtOTU1OA_2e433f39-34c1-4921-a1eb-2c04de7596b4">1,094,187</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb172cb6365440839665fd6ec022472c_I20201231" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfMTktMy0xLTEtOTU1OA_bf87e2d5-b8e2-423f-a2f7-8d0c2eb7ad8b">1,016,779</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfMjAtMS0xLTEtOTU1OA_3a3e9276-4446-462c-a7f5-4e7eef72aa6d">7,617,913</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb172cb6365440839665fd6ec022472c_I20201231" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfMjAtMy0xLTEtOTU1OA_725654e5-26d7-4902-9849-bd17c75541fc">11,254,381</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfMjEtMS0xLTEtOTU1OA_d3d1b324-a332-4b6d-a876-cb7d8d486075">17,945,483</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb172cb6365440839665fd6ec022472c_I20201231" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfMjEtMy0xLTEtOTU1OA_b49161b8-b618-488e-b4a6-773df0e33080">25,667,446</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revolving line of credit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermLineOfCredit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfMjItMS0xLTEtOTU1OA_af71ed23-ef84-4ab4-95f6-8d24a4bf3e9c">15,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb172cb6365440839665fd6ec022472c_I20201231" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermLineOfCredit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfMjItMy0xLTEtOTU1OA_7a2cac12-dbbc-42cb-9a68-445a8d1da521">15,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease noncurrent liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfMjMtMS0xLTEtOTU1OA_ac21f239-47a9-4048-b4e5-fb6a30904c23">229,605</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb172cb6365440839665fd6ec022472c_I20201231" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfMjMtMy0xLTEtOTU1OA_04dacca8-58ff-48be-bfca-d19061523658">1,059,693</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930" decimals="0" format="ixt:num-dot-decimal" name="cpix:OtherLongTermObligationsExcludingCurrentPortion" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfMjQtMS0xLTEtOTU1OA_c19e5623-3ca3-42df-8206-a6ce00f2578f">7,749,421</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb172cb6365440839665fd6ec022472c_I20201231" decimals="0" format="ixt:num-dot-decimal" name="cpix:OtherLongTermObligationsExcludingCurrentPortion" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfMjQtMy0xLTEtOTU1OA_a62c5665-b11d-4da6-a66d-afb64849d36e">7,862,772</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfMjUtMS0xLTEtOTU1OA_73ff469a-33c7-4e34-b6de-c03e5cbf5c37">40,924,509</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb172cb6365440839665fd6ec022472c_I20201231" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfMjUtMy0xLTEtOTU1OA_21c45af4-7bbb-4e9f-93c5-e8cc48452fdc">49,589,911</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfMjYtMS0xLTEtOTU1OA_66f332c8-513c-4391-89f7-80f43f532cdc"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="idb172cb6365440839665fd6ec022472c_I20201231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfMjYtMy0xLTEtOTU1OA_339a1c3d-e189-4d33-8982-7a811ac1d9a2"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shareholders&#8217; equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock&#8212;<ix:nonFraction unitRef="usdPerShare" contextRef="idb172cb6365440839665fd6ec022472c_I20201231" decimals="INF" format="ixt:fixed-zero" name="us-gaap:CommonStockNoParValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfMjktMC0xLTEtOTU1OC90ZXh0cmVnaW9uOjVjNjY5YmEwMWIwNzRiZWE5ZWZmYWFhMWRlZDI3YmRhXzE3_9a3bc384-8dfc-4d87-8e86-c41e535e62b9"><ix:nonFraction unitRef="usdPerShare" contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:CommonStockNoParValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfMjktMC0xLTEtOTU1OC90ZXh0cmVnaW9uOjVjNjY5YmEwMWIwNzRiZWE5ZWZmYWFhMWRlZDI3YmRhXzE3_d7c4882b-b860-43a2-8bfd-14b2f3796291">no</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfMjktMC0xLTEtOTU1OC90ZXh0cmVnaW9uOjVjNjY5YmEwMWIwNzRiZWE5ZWZmYWFhMWRlZDI3YmRhXzMx_1c740f40-7da7-456f-95fa-9268f3238850"><ix:nonFraction unitRef="shares" contextRef="idb172cb6365440839665fd6ec022472c_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfMjktMC0xLTEtOTU1OC90ZXh0cmVnaW9uOjVjNjY5YmEwMWIwNzRiZWE5ZWZmYWFhMWRlZDI3YmRhXzMx_53125269-be7e-42ef-9921-6f2a51910e59">100,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfMjktMC0xLTEtOTU1OC90ZXh0cmVnaW9uOjVjNjY5YmEwMWIwNzRiZWE5ZWZmYWFhMWRlZDI3YmRhXzUz_6b190ba3-e572-4622-ba7a-b37fdcadfb15"><ix:nonFraction unitRef="shares" contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfMjktMC0xLTEtOTU1OC90ZXh0cmVnaW9uOjVjNjY5YmEwMWIwNzRiZWE5ZWZmYWFhMWRlZDI3YmRhXzUz_bb67aab8-19d8-476d-8916-e107f319fb15">14,850,526</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="idb172cb6365440839665fd6ec022472c_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfMjktMC0xLTEtOTU1OC90ZXh0cmVnaW9uOjVjNjY5YmEwMWIwNzRiZWE5ZWZmYWFhMWRlZDI3YmRhXzYw_4c6882e3-b738-41e7-a85b-56aacaf9ed05"><ix:nonFraction unitRef="shares" contextRef="idb172cb6365440839665fd6ec022472c_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfMjktMC0xLTEtOTU1OC90ZXh0cmVnaW9uOjVjNjY5YmEwMWIwNzRiZWE5ZWZmYWFhMWRlZDI3YmRhXzYw_8d49a5ab-c46e-42ea-a4f8-80205bda09b4">14,988,429</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of September 30, 2021 and December 31, 2020, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfMjktMS0xLTEtOTU1OA_9c6d8501-d714-4356-87c0-7924d6ddc4ef">48,612,935</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb172cb6365440839665fd6ec022472c_I20201231" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfMjktMy0xLTEtOTU1OA_769b8ef2-f306-486a-9e63-a06957175847">49,121,523</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained earnings (deficit)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfMzAtMS0xLTEtOTU1OA_3b15b693-c359-4ce7-b87f-511e55fa1eef">1,790,903</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb172cb6365440839665fd6ec022472c_I20201231" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfMzAtMy0xLTEtOTU1OA_5d68e1b4-1c75-4931-a323-8e5fc3315e24">2,131,013</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total shareholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfMzEtMS0xLTEtOTU1OA_c5e3a62d-c398-4bf2-bdea-affe7c7df09f">46,822,032</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb172cb6365440839665fd6ec022472c_I20201231" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfMzEtMy0xLTEtOTU1OA_c9407c7c-e82b-42a2-ab9c-ea2529d40ef9">46,990,510</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfMzItMS0xLTEtOTU1OA_cad970f6-47ee-4c47-b6c9-68e9a38d0b2f">175,767</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb172cb6365440839665fd6ec022472c_I20201231" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfMzItMy0xLTEtOTU1OA_1ea42f2e-d2d2-4282-b4f5-ac7cb8cbeda9">117,116</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfMzMtMS0xLTEtOTU1OA_423074bc-2abb-4837-80ba-f1b03dfed65d">46,646,265</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb172cb6365440839665fd6ec022472c_I20201231" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfMzMtMy0xLTEtOTU1OA_0ee8ed29-747b-41b1-85ea-72ef916138ac">46,873,394</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfMzQtMS0xLTEtOTU1OA_0ab55b8c-68bc-426b-8dd2-9ef966d2fbfe">87,570,774</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb172cb6365440839665fd6ec022472c_I20201231" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfMzQtMy0xLTEtOTU1OA_72a379ed-af9c-48c1-b7a0-22bff9f116e2">96,463,305</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying Notes to Unaudited Condensed Consolidated Financial Statements. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i8e8bdb91dc894234b9d87e17a18b54fd_19"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.333%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cfdffb6c8a4411a95e4596b0bd91b7c_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMi0xLTEtMS05NTU4_6f46574a-47f1-4e7e-83a2-11d516edf5df">8,072,540</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2722c94900c4f68be9dd446637b8348_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMi0zLTEtMS05NTU4_781307c7-4873-440a-a67f-16f5e8051428">9,250,689</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMi01LTEtMS05NTU4_8fe8b1e2-7d0e-48d4-832c-abcbb47375bc">27,665,182</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMi03LTEtMS05NTU4_b207bca1-855a-42c8-a38f-b516c62c0810">27,179,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and expenses:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cfdffb6c8a4411a95e4596b0bd91b7c_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfNC0xLTEtMS05NTU4_30ab3989-a784-4170-8210-f4be533b3726">1,328,027</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2722c94900c4f68be9dd446637b8348_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfNC0zLTEtMS05NTU4_1c21b574-e3de-4cec-ad57-4f7203ac943f">2,142,839</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfNC01LTEtMS05NTU4_2b82165b-3391-40fe-a80f-40a5f1978c1e">5,486,005</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfNC03LTEtMS05NTU4_e0b06033-3b40-42d4-9e09-9da2d367ea4e">6,387,002</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling and marketing</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cfdffb6c8a4411a95e4596b0bd91b7c_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingAndMarketingExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfNS0xLTEtMS05NTU4_d52d2797-a9a4-423f-8498-e0bc613433b4">3,800,288</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2722c94900c4f68be9dd446637b8348_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingAndMarketingExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfNS0zLTEtMS05NTU4_f398d241-1297-4a49-8c83-c0fda68dc2e6">3,587,842</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingAndMarketingExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfNS01LTEtMS05NTU4_1e12fbb7-fcb2-46f9-a167-e40e704bcd35">11,709,445</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingAndMarketingExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfNS03LTEtMS05NTU4_5730eef7-534c-4101-962f-a45a5ba9752c">11,160,924</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cfdffb6c8a4411a95e4596b0bd91b7c_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfNi0xLTEtMS05NTU4_05867931-330e-4627-af39-5446206d6911">1,453,873</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2722c94900c4f68be9dd446637b8348_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfNi0zLTEtMS05NTU4_2e927709-7a9e-45c2-971b-eedb8d26f8cd">1,230,335</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfNi01LTEtMS05NTU4_3c87e122-3c97-43b7-b1da-8b80290d7f0a">4,071,638</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfNi03LTEtMS05NTU4_707984ff-0726-49c9-bee3-3fb751c02d13">4,374,392</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cfdffb6c8a4411a95e4596b0bd91b7c_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfNy0xLTEtMS05NTU4_7ad913a9-6ea3-457d-a36c-183a1bc3f50e">2,039,799</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2722c94900c4f68be9dd446637b8348_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfNy0zLTEtMS05NTU4_cd118aae-c492-4977-9b43-f06bef4041a6">2,381,273</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfNy01LTEtMS05NTU4_51a66d19-bed2-4820-943b-44d902fd58d7">6,367,438</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfNy03LTEtMS05NTU4_2dea87ad-3e9a-4662-a320-d4b528758da6">6,608,321</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cfdffb6c8a4411a95e4596b0bd91b7c_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfOC0xLTEtMS05NTU4_9eddcd2e-8186-4a8b-83dc-8a4d3cdabb2d">1,013,948</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2722c94900c4f68be9dd446637b8348_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfOC0zLTEtMS05NTU4_a8010101-60c6-47cc-bc0d-16bc9147d98f">1,117,086</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfOC01LTEtMS05NTU4_cefad2e7-9dff-44fd-bdce-dfe606df4451">3,354,080</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfOC03LTEtMS05NTU4_887a51b6-b6be-4f90-b32b-ea605eea9dec">3,284,610</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total costs and expenses</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cfdffb6c8a4411a95e4596b0bd91b7c_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostsAndExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfOS0xLTEtMS05NTU4_9c2c75c1-9664-463c-b7ef-84f47727fa13">9,635,935</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2722c94900c4f68be9dd446637b8348_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostsAndExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfOS0zLTEtMS05NTU4_30f0355f-3abd-47b9-b804-f2432eeab0bc">10,459,375</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostsAndExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfOS01LTEtMS05NTU4_91cbb7d5-4f2f-4682-9016-39e0ee0e3387">30,988,606</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostsAndExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfOS03LTEtMS05NTU4_10c21e8b-bb5c-47c1-927b-370d46368b2a">31,815,249</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5cfdffb6c8a4411a95e4596b0bd91b7c_D20210701-20210930" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMTAtMS0xLTEtOTU1OA_ae1a9867-e350-43ac-bfe5-1bea13f9f96e">1,563,395</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie2722c94900c4f68be9dd446637b8348_D20200701-20200930" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMTAtMy0xLTEtOTU1OA_aed8b499-3963-46c0-8e86-e674dbcf5105">1,208,686</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMTAtNS0xLTEtOTU1OA_7f0a5665-0b83-4f2a-bc2b-9d5a18a632c0">3,323,424</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMTAtNy0xLTEtOTU1OA_285e5679-4ce2-4028-bb45-76b0e4029e6f">4,635,649</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cfdffb6c8a4411a95e4596b0bd91b7c_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMTEtMS0xLTEtOTU1OA_b79c0005-d793-42ad-8871-3e5affea3b4c">7,394</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2722c94900c4f68be9dd446637b8348_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMTEtMy0xLTEtOTU1OA_33714327-17f9-432a-bbd7-05e7bdb63b6b">12,004</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMTEtNS0xLTEtOTU1OA_e5c8d4b5-17d5-4c4a-8a7f-2f627a542e07">19,411</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMTEtNy0xLTEtOTU1OA_41104900-f351-491a-bab1-b30b9fd15234">70,553</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cfdffb6c8a4411a95e4596b0bd91b7c_D20210701-20210930" decimals="0" format="ixt:fixed-zero" name="us-gaap:OtherIncome" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMTItMS0xLTEtOTU1OA_dd85f6d7-3a80-400d-b618-f051b8483b96">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2722c94900c4f68be9dd446637b8348_D20200701-20200930" decimals="0" format="ixt:fixed-zero" name="us-gaap:OtherIncome" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMTItMy0xLTEtOTU1OA_9d09f8e6-d7c4-4f40-a2a4-b171d5f6123e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherIncome" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMTItNS0xLTEtOTU1OA_0e4fd688-c910-4bc8-a68f-9b8c0c944e76">2,187,140</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930" decimals="0" format="ixt:fixed-zero" name="us-gaap:OtherIncome" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMTItNy0xLTEtOTU1OA_55a923b2-ca81-4b0e-a82e-ebace9edccc2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5cfdffb6c8a4411a95e4596b0bd91b7c_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMTMtMS0xLTEtOTU1OA_67f8592b-00b5-4034-a33b-ecd29f48ef95">20,021</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie2722c94900c4f68be9dd446637b8348_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMTMtMy0xLTEtOTU1OA_1ddd391c-88a9-4c1f-bbe0-4f9e226a4b32">75,210</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMTMtNS0xLTEtOTU1OA_65623fa4-671a-43c5-bde5-8562e9b49515">70,297</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMTMtNy0xLTEtOTU1OA_bc5b3654-4886-420f-a374-45cc9684a22a">227,730</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from continuing operations before income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5cfdffb6c8a4411a95e4596b0bd91b7c_D20210701-20210930" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMTQtMS0xLTEtOTU1OA_0c797158-a708-4ac6-8d37-0262cd0dd6fa">1,576,022</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie2722c94900c4f68be9dd446637b8348_D20200701-20200930" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMTQtMy0xLTEtOTU1OA_2569ea11-8714-4d6c-baf4-e91df255bc78">1,271,892</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMTQtNS0xLTEtOTU1OA_5e69759b-231d-41c7-ba19-5564cd6e1ce0">1,187,170</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMTQtNy0xLTEtOTU1OA_8b452270-9963-4838-9755-92ce0bae4762">4,792,826</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax (expense) benefit</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5cfdffb6c8a4411a95e4596b0bd91b7c_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMTUtMS0xLTEtOTU1OA_b869375d-639f-4754-abf2-01920f3599d8">7,458</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie2722c94900c4f68be9dd446637b8348_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMTUtMy0xLTEtOTU1OA_aa81b9db-f796-42d9-83d8-c60ef02c0315">3,728</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMTUtNS0xLTEtOTU1OA_30ff0664-3748-402f-8681-afd87fbec2c7">22,375</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMTUtNy0xLTEtOTU1OA_335dcc55-efaa-477d-9b65-d9261b0045d2">45,423</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5cfdffb6c8a4411a95e4596b0bd91b7c_D20210701-20210930" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMTYtMS0xLTEtOTU1OA_3656b68a-e37c-4633-8dd8-a003efd3e39e">1,583,480</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie2722c94900c4f68be9dd446637b8348_D20200701-20200930" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMTYtMy0xLTEtOTU1OA_ec6850d2-e817-4b14-9487-ff3e910e4c91">1,275,620</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMTYtNS0xLTEtOTU1OA_4c64bffd-ba77-41a6-8d18-51bfc653c845">1,209,545</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMTYtNy0xLTEtOTU1OA_85fb5be7-0aae-4020-9da3-9e25c9015f6a">4,838,249</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb58760ea84940319b35492cd1910735_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMTctMS0xLTEtOTU1OA_86849bd9-9c34-42dc-a4b6-2061e77af27b">496,787</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca7f9fa06d14f85a52cbd81ac170d2c_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMTctMy0xLTEtOTU1OA_0fe8db84-b272-4c9f-a304-4c34cd7b14a3">777,916</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45bdfab35dd74d60ac86fc023b908b73_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMTctNS0xLTEtOTU1OA_1acd7b61-10d3-4d57-a3bb-db27abac79f0">1,491,004</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8c8802e62b74a919450a1c6017bba7e_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMTctNy0xLTEtOTU1OA_841b8fa5-722e-49de-805f-6e1ba99049bf">2,334,811</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5cfdffb6c8a4411a95e4596b0bd91b7c_D20210701-20210930" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMTgtMS0xLTEtOTU1OA_ff808f60-a689-42b1-b71a-d3683b123ee4">1,086,693</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie2722c94900c4f68be9dd446637b8348_D20200701-20200930" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMTgtMy0xLTEtOTU1OA_4509f6be-b34d-4bbe-b84e-cdb293c90119">497,704</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMTgtNS0xLTEtOTU1OA_ae2476e8-c4f3-48c3-8213-5c212995ddb4">281,459</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMTgtNy0xLTEtOTU1OA_3a624214-4eec-4a5b-928a-eb7a9881e84b">2,503,438</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (income) loss at subsidiary attributable to noncontrolling interests</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cfdffb6c8a4411a95e4596b0bd91b7c_D20210701-20210930" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMTktMS0xLTEtOTU1OA_95b61dfc-d977-4115-94c6-54e0d0af5a99">31,415</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2722c94900c4f68be9dd446637b8348_D20200701-20200930" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMTktMy0xLTEtOTU1OA_2141b745-6e38-4f81-959c-3756a18c45c0">15,967</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMTktNS0xLTEtOTU1OA_ce0a12c3-7567-454b-93ce-355822e98dea">58,651</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMTktNy0xLTEtOTU1OA_f17bcff7-0f96-4279-931e-32336eb1034d">47,806</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to common shareholders</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5cfdffb6c8a4411a95e4596b0bd91b7c_D20210701-20210930" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMjAtMS0xLTEtOTU1OA_8e25e5e8-98f3-44fe-bcfe-7cb6ae67a6e0">1,055,278</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie2722c94900c4f68be9dd446637b8348_D20200701-20200930" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMjAtMy0xLTEtOTU1OA_4df57ef8-bc72-4d47-97d5-a0535ac6e0d4">481,737</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMjAtNS0xLTEtOTU1OA_5cb25c6b-5d1e-43e1-a9db-72676163fbcd">340,110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMjAtNy0xLTEtOTU1OA_f7aef4bc-6f7d-491b-8a3f-1c613544acf4">2,455,632</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings (loss) per share attributable to common shareholders</span></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- Continuing operations - basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i5cfdffb6c8a4411a95e4596b0bd91b7c_D20210701-20210930" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMjItMS0xLTEtOTU1OA_c3ee7aaf-3a59-42cd-940a-86344d472155">0.10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ie2722c94900c4f68be9dd446637b8348_D20200701-20200930" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMjItMy0xLTEtOTU1OA_e9a75676-a793-4eb3-85fb-048dbf56209e">0.08</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMjItNS0xLTEtOTU1OA_b0a294d3-17b1-4601-a366-4fe9f21c4be0">0.08</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMjItNy0xLTEtOTU1OA_cda5bd02-15e1-473c-812c-74665fa1fe4d">0.31</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- Discontinued operations - basic</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5cfdffb6c8a4411a95e4596b0bd91b7c_D20210701-20210930" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMjMtMS0xLTEtOTU1OA_37f3b733-baaf-4885-bf03-c35f039ca671">0.03</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie2722c94900c4f68be9dd446637b8348_D20200701-20200930" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMjMtMy0xLTEtOTU1OA_bab9de8c-5909-4833-b95a-6100886a552d">0.05</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMjMtNS0xLTEtOTU1OA_928e6367-0e20-47fc-9aa7-165419cb71eb">0.10</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMjMtNy0xLTEtOTU1OA_a5dbfd8d-da81-4d2e-99b3-639e22d701d2">0.15</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i5cfdffb6c8a4411a95e4596b0bd91b7c_D20210701-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMjQtMS0xLTEtOTU1OA_faad5f17-3f38-4945-98da-5539c2be542d">0.07</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ie2722c94900c4f68be9dd446637b8348_D20200701-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMjQtMy0xLTEtOTU1OA_86b37b93-22c3-4dfd-bfe1-cd362d65aa78">0.03</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMjQtNS0xLTEtOTU1OA_a166b8d6-4829-434d-b0a4-41dcc0e1ab67">0.02</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMjQtNy0xLTEtOTU1OA_989cb314-176e-4a6d-903b-7ce71e9e7714">0.16</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- Continuing operations - diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i5cfdffb6c8a4411a95e4596b0bd91b7c_D20210701-20210930" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMjYtMS0xLTEtOTU1OA_2551170e-c478-440a-807a-3ecc39c0c8e9">0.10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ie2722c94900c4f68be9dd446637b8348_D20200701-20200930" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMjYtMy0xLTEtOTU1OA_e55be91d-017f-4f3b-8125-0783557edcc2">0.08</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMjYtNS0xLTEtOTU1OA_ed699d40-1314-4c13-bdb5-9ff9f8c481c8">0.08</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMjYtNy0xLTEtOTU1OA_65b47aa0-3662-4ea9-9da8-c2b69a32a832">0.31</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- Discontinued operations - diluted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5cfdffb6c8a4411a95e4596b0bd91b7c_D20210701-20210930" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMjctMS0xLTEtOTU1OA_9765f3af-225f-496c-97ee-9241f98051c2">0.03</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie2722c94900c4f68be9dd446637b8348_D20200701-20200930" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMjctMy0xLTEtOTU1OA_15fc1ada-b89e-4061-a698-326ecf4cfdb3">0.05</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMjctNS0xLTEtOTU1OA_b4bac775-1172-46db-b64d-6c3011ba516d">0.10</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMjctNy0xLTEtOTU1OA_3624f2a6-007b-41dc-ac2a-0f85f44e9264">0.15</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i5cfdffb6c8a4411a95e4596b0bd91b7c_D20210701-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMjgtMS0xLTEtOTU1OA_07e652a8-0c5b-47b7-9c3a-111848dece26">0.07</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ie2722c94900c4f68be9dd446637b8348_D20200701-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMjgtMy0xLTEtOTU1OA_fe830645-ab82-48af-85e3-456b5dcbc53d">0.03</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMjgtNS0xLTEtOTU1OA_51ea79d0-37ad-4ad4-8e73-5b994ed87c28">0.02</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMjgtNy0xLTEtOTU1OA_0307a832-9abe-4cc4-8ea6-470da96f1710">0.16</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5cfdffb6c8a4411a95e4596b0bd91b7c_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMzAtMS0xLTEtOTU1OA_b5e1a767-1b86-4012-89bc-7628a19420c8">14,880,887</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie2722c94900c4f68be9dd446637b8348_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMzAtMy0xLTEtOTU1OA_7ddc136a-92bb-439a-a38a-0bfad779387e">15,134,583</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMzAtNS0xLTEtOTU1OA_8cdb33ce-1515-4327-ae98-f1d30f78e45a">14,939,919</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMzAtNy0xLTEtOTU1OA_3cebfc23-7264-4ddc-9953-b2de72843968">15,206,179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- diluted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5cfdffb6c8a4411a95e4596b0bd91b7c_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMzEtMS0xLTEtOTU1OA_206d45ec-0dfd-4dad-a09c-708e034903c8">14,880,887</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie2722c94900c4f68be9dd446637b8348_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMzEtMy0xLTEtOTU1OA_3069879d-a3f8-4c09-bc47-66a88a16ffee">15,134,583</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMzEtNS0xLTEtOTU1OA_680872eb-8fa6-4a35-8e4b-96a35c60f7b4">15,139,904</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMzEtNy0xLTEtOTU1OA_74c47ba6-d296-4d83-a36d-d18b2064f105">15,206,179</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying Notes to Unaudited Condensed Consolidated Financial Statements.</span></div><div style="margin-bottom:17pt;margin-top:17pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i8e8bdb91dc894234b9d87e17a18b54fd_22"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.028%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfMy0xLTEtMS05NTU4_89bfef20-b1e6-47a1-9dc7-06a201e0829a">281,459</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfMy0zLTEtMS05NTU4_fee615d1-5da9-49f1-89bc-c9c0d4a4e145">2,503,438</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfNC0xLTEtMS05NTU4_34dd9ba9-dc08-41b3-82bc-363744572af1">1,491,004</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfNC0zLTEtMS05NTU4_5d8096f7-9702-46a6-93db-e69127d604a8">2,334,811</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfNS0xLTEtMS05NTU4_5f0e04d7-a344-4a4b-9c88-542330d012a4">1,209,545</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfNS0zLTEtMS05NTU4_960860b7-f805-41c7-895a-ac3c5e8bf7e7">4,838,249</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net income (loss) from continuing operations to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfNy0xLTEtMS05NTU4_ee98fdcd-e62c-4b78-a6f6-82432089e45e">3,529,245</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfNy0zLTEtMS05NTU4_c94fdef7-2015-4ca1-ac13-6e31fcd40fd2">3,524,684</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfOC0xLTEtMS05NTU4_a3a99d85-8b3f-4c71-b706-09dbc9f771e0">517,081</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfOC0zLTEtMS05NTU4_7ad89641-b6e2-4fd2-a657-a14bc60fad4f">805,338</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease in non-cash contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfOS0xLTEtMS05NTU4_4e9f354a-5943-4277-a009-e945dcf7cb59">632,646</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfOS0zLTEtMS05NTU4_0e2e4688-563d-479b-87bd-e057de35e705">806,390</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease (increase) in cash surrender value of life insurance policies over premiums paid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="cpix:IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfMTAtMS0xLTEtOTU1OA_9afe2f51-0b85-42b2-9a50-dbbce7721d86">52,070</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930" decimals="0" sign="-" format="ixt:num-dot-decimal" name="cpix:IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfMTAtMy0xLTEtOTU1OA_33d45e09-c9b4-436b-9181-f8a415404be2">169,406</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncash interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfFinancingCosts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfMTEtMS0xLTEtOTU1OA_9ebcbfae-b3f1-4dd6-9460-56a8bb51eefe">33,943</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfFinancingCosts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfMTEtMy0xLTEtOTU1OA_e65dfc73-2a12-4051-ad8f-221d3db3618d">36,197</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on forgiveness of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:UnrealizedGainLossOnInvestments" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfMTItMS0xLTEtOTU1OA_a4383df0-61d1-447f-af4c-33329a82adb5">2,187,140</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930" decimals="0" format="ixt:fixed-zero" name="us-gaap:UnrealizedGainLossOnInvestments" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfMTItMy0xLTEtOTU1OA_40ed77d8-fec4-414d-a305-19e4a0be869b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net changes in assets and liabilities affecting operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfMTQtMS0xLTEtOTU1OA_2e2d328c-bd25-44f4-9295-f1401a59a137">2,527,183</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfMTQtMy0xLTEtOTU1OA_b0ea097f-859d-472a-8adb-5d2e95b91f6b">1,817,490</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInInventories" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfMTUtMS0xLTEtOTU1OA_57d3a116-49a7-439a-89e8-e5e19e852dd6">2,555,393</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInInventories" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfMTUtMy0xLTEtOTU1OA_a03c6e2d-7ef8-4f3b-82ac-4a8639060a8d">1,696,668</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets and other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfMTYtMS0xLTEtOTU1OA_9310532c-e3ef-4b11-9d1a-3db005ddf056">1,627,350</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfMTYtMy0xLTEtOTU1OA_ce8bf223-c5ed-4abe-a55f-0c73f0333954">1,962,024</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" decimals="0" sign="-" format="ixt:num-dot-decimal" name="cpix:IncreaseDecreaseInCurrentOperatingLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfMTctMS0xLTEtOTU1OA_f73493d4-2516-49ec-8d56-5424edcf497a">2,873,596</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="cpix:IncreaseDecreaseInCurrentOperatingLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfMTctMy0xLTEtOTU1OA_90aee167-8384-48a9-b892-c44c544c27f9">3,248,450</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfMTgtMS0xLTEtOTU1OA_0fb1458a-c29a-41df-a17b-c96348b3efa4">943,439</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfMTgtMy0xLTEtOTU1OA_62404fce-cf1b-44c8-ab3e-c0704d7899d9">1,585,584</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by operating activities from continuing operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfMTktMS0xLTEtOTU1OA_3bf04005-f194-4bbd-9382-7d432fd4761a">2,891,759</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfMTktMy0xLTEtOTU1OA_c76cd51f-6dd2-4cd4-87e6-10a6acff5d68">2,395,054</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfMjAtMS0xLTEtOTU1OA_e654619d-3272-4f04-b314-4c818df3b60e">1,491,004</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfMjAtMy0xLTEtOTU1OA_d3129d7a-782c-4e0c-91fc-872a74d1f0d0">2,166,086</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfMjEtMS0xLTEtOTU1OA_870ac2ae-ade4-471d-852e-ec36975d6c63">4,382,763</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfMjEtMy0xLTEtOTU1OA_da16e351-3095-4cfd-a84b-3d53cf653613">4,561,140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions to property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfMjMtMS0xLTEtOTU1OA_ebcb64fe-ac43-4ffc-84db-23880130db8c">94,485</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfMjMtMy0xLTEtOTU1OA_c915a898-b0c5-4818-98ef-324aa659c261">95,189</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from surrender of life insurance policies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" decimals="0" format="ixt:fixed-zero" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfMjQtMS0xLTEtMTA1NDY_f298de6e-c85e-4bb4-ab7a-380f560ce1f3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfMjQtMy0xLTEtMTA1NDY_2ad0b218-2536-4817-9596-c380cf4d417b">460,888</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Note receivable investment funding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfMjQtMS0xLTEtOTU1OA_eda3c378-0513-4882-ae8b-862d975224d5">200,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930" decimals="0" format="ixt:fixed-zero" name="us-gaap:PaymentsToAcquireInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfMjQtMy0xLTEtOTU1OA_6ee9712a-80e4-48a6-a397-7907f29acbc2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions to intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfMjUtMS0xLTEtOTU1OA_926d3e0c-7e31-4710-8d16-a3218196a913">180,613</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfMjUtMy0xLTEtOTU1OA_c5095c68-b18f-4f34-a68d-5cf4036cb471">1,807,467</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfMjYtMS0xLTEtOTU1OA_ffc6f38a-fb40-46d2-ac84-cbfe38356f13">475,098</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfMjYtMy0xLTEtOTU1OA_6f7754a7-2950-49c4-baa9-9a2c64dc0c97">1,441,768</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Borrowings on line of credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromRepaymentsOfLinesOfCredit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfMjktMS0xLTEtOTU1OA_ae85fed8-ca82-4f11-982e-bdfcaea8dc0c">45,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromRepaymentsOfLinesOfCredit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfMjktMy0xLTEtOTU1OA_d8c83a67-e135-47b0-ab0b-00cc3a205b5b">44,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayments on line of credit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfNotesPayable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfMzAtMS0xLTEtOTU1OA_f4a8db35-27de-4a2e-ab10-732838abc052">45,000,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfNotesPayable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfMzAtMy0xLTEtOTU1OA_a51d2968-02b4-430b-8aa3-9eeccb17cc54">45,500,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payment of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfMzEtMS0xLTEtOTU1OA_27389069-bbbc-4c75-888a-953e490697fe">1,792,573</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfMzEtMy0xLTEtOTU1OA_48a6634a-dce4-400b-8685-2f29b34ee020">834,014</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of subsidiary shares from noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" decimals="0" format="ixt:fixed-zero" name="us-gaap:PaymentsForRepurchaseOfRedeemableNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfMzItMS0xLTEtOTU1OA_3b6a4a18-d9aa-4aab-9615-0a1d8230b5ff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRepurchaseOfRedeemableNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfMzItMy0xLTEtOTU1OA_1802f395-adcf-41ce-beb8-248285472068">800,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfMzMtMS0xLTEtOTU1OA_74417a53-889d-4979-88af-96c305f4ae88">1,025,657</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfMzMtMy0xLTEtOTU1OA_d948002e-b969-4bdc-8231-cc4de64dc7d0">1,551,463</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfMzQtMS0xLTEtOTU1OA_f00c6231-ecc8-41b8-a509-e8f50d9ec00b">2,818,230</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfMzQtMy0xLTEtOTU1OA_1980d3ac-9334-43dd-936f-70067baf296b">4,685,477</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfMzUtMS0xLTEtOTU1OA_24c47d4f-6042-4d09-a4f6-f84d25ec3405">1,089,435</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfMzUtMy0xLTEtOTU1OA_7b68fff9-947a-49a5-be2d-249a99935a48">1,566,105</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of period</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb172cb6365440839665fd6ec022472c_I20201231" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfMzYtMS0xLTEtOTU1OA_0919de68-75d1-4a72-9895-f28f493019e9">24,753,796</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fa410e0219e41c3b8a23d8140a1ca8c_I20191231" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfMzYtMy0xLTEtOTU1OA_860d7006-5a2c-4bbb-990c-33f7a028878c">28,212,635</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfMzctMS0xLTEtOTU1OA_f5e31f82-39b9-4de8-92d4-0c82043a1730">25,843,231</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ae7216a773d47d889c5f34d67e867fe_I20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfMzctMy0xLTEtOTU1OA_978bbe5f-89a2-4ad4-924d-4fe9b1a75eb2">26,646,530</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying Notes to Unaudited Condensed Consolidated Financial Statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i8e8bdb91dc894234b9d87e17a18b54fd_25"></div><hr style="page-break-after:always"/><div style="min-height:33.75pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:31.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.757%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Common stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Retained earnings (deficit)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Noncontrolling interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total equity</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i90ac8e9aca0748058577add35fc3a6f9_I20191231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjNkOGQ1NGE4MzFlZTQzNjlhOGI4OTg1Y2JkZDdkOGYyL3RhYmxlcmFuZ2U6M2Q4ZDU0YTgzMWVlNDM2OWE4Yjg5ODVjYmRkN2Q4ZjJfMi0xLTEtMS05NTU4_249ec781-bdca-4a10-8125-8603765510a3">15,263,555</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90ac8e9aca0748058577add35fc3a6f9_I20191231" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjNkOGQ1NGE4MzFlZTQzNjlhOGI4OTg1Y2JkZDdkOGYyL3RhYmxlcmFuZ2U6M2Q4ZDU0YTgzMWVlNDM2OWE4Yjg5ODVjYmRkN2Q4ZjJfMi0zLTEtMS05NTU4_870e48c4-b831-428c-aeff-6b2a40dc00cb">49,914,478</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f67242cec184569be979f0eab3bb2dd_I20191231" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjNkOGQ1NGE4MzFlZTQzNjlhOGI4OTg1Y2JkZDdkOGYyL3RhYmxlcmFuZ2U6M2Q4ZDU0YTgzMWVlNDM2OWE4Yjg5ODVjYmRkN2Q4ZjJfMi01LTEtMS05NTU4_567665d0-f88c-4f2f-b952-5721a65712f5">1,208,395</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1925af7a08774bc4a2752a9cd6b75c35_I20191231" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjNkOGQ1NGE4MzFlZTQzNjlhOGI4OTg1Y2JkZDdkOGYyL3RhYmxlcmFuZ2U6M2Q4ZDU0YTgzMWVlNDM2OWE4Yjg5ODVjYmRkN2Q4ZjJfMi03LTEtMS05NTU4_36f12a5f-6da4-44a5-94e5-e768c1bca7fc">37,620</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fa410e0219e41c3b8a23d8140a1ca8c_I20191231" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjNkOGQ1NGE4MzFlZTQzNjlhOGI4OTg1Y2JkZDdkOGYyL3RhYmxlcmFuZ2U6M2Q4ZDU0YTgzMWVlNDM2OWE4Yjg5ODVjYmRkN2Q4ZjJfMi05LTEtMS05NTU4_77241509-dc84-4f83-b3f4-a8f8e12ef9f3">51,085,253</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaf2c0f582f1a48b1b7132666868a1789_D20200101-20200331" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjNkOGQ1NGE4MzFlZTQzNjlhOGI4OTg1Y2JkZDdkOGYyL3RhYmxlcmFuZ2U6M2Q4ZDU0YTgzMWVlNDM2OWE4Yjg5ODVjYmRkN2Q4ZjJfMy0xLTEtMS05NTU4_aa9262da-6fcb-458a-b15e-7dc3624dd465">219,850</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf2c0f582f1a48b1b7132666868a1789_D20200101-20200331" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjNkOGQ1NGE4MzFlZTQzNjlhOGI4OTg1Y2JkZDdkOGYyL3RhYmxlcmFuZ2U6M2Q4ZDU0YTgzMWVlNDM2OWE4Yjg5ODVjYmRkN2Q4ZjJfMy0zLTEtMS05NTU4_6563001a-87be-4d8b-82e2-adb204cbd866">264,574</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4167fc9dfbd441ed853e3173c4f077bf_D20200101-20200331" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjNkOGQ1NGE4MzFlZTQzNjlhOGI4OTg1Y2JkZDdkOGYyL3RhYmxlcmFuZ2U6M2Q4ZDU0YTgzMWVlNDM2OWE4Yjg5ODVjYmRkN2Q4ZjJfMy05LTEtMS05NTU4_2f4d8726-1de5-4065-8f2e-477ffc8fbfa2">264,574</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iaf2c0f582f1a48b1b7132666868a1789_D20200101-20200331" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjNkOGQ1NGE4MzFlZTQzNjlhOGI4OTg1Y2JkZDdkOGYyL3RhYmxlcmFuZ2U6M2Q4ZDU0YTgzMWVlNDM2OWE4Yjg5ODVjYmRkN2Q4ZjJfNC0xLTEtMS05NTU4_1775f463-8b18-4147-90cb-757703376146">164,866</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf2c0f582f1a48b1b7132666868a1789_D20200101-20200331" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjNkOGQ1NGE4MzFlZTQzNjlhOGI4OTg1Y2JkZDdkOGYyL3RhYmxlcmFuZ2U6M2Q4ZDU0YTgzMWVlNDM2OWE4Yjg5ODVjYmRkN2Q4ZjJfNC0zLTEtMS05NTU4_f53c8451-abaa-44b6-a448-fbbbb3a488f4">441,624</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4167fc9dfbd441ed853e3173c4f077bf_D20200101-20200331" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjNkOGQ1NGE4MzFlZTQzNjlhOGI4OTg1Y2JkZDdkOGYyL3RhYmxlcmFuZ2U6M2Q4ZDU0YTgzMWVlNDM2OWE4Yjg5ODVjYmRkN2Q4ZjJfNC05LTEtMS05NTU4_88fcf9e9-412f-4903-88c1-e80ad0d62b0f">441,624</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic4f1350ea2fc4eb18dc553f1c359d775_D20200101-20200331" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjNkOGQ1NGE4MzFlZTQzNjlhOGI4OTg1Y2JkZDdkOGYyL3RhYmxlcmFuZ2U6M2Q4ZDU0YTgzMWVlNDM2OWE4Yjg5ODVjYmRkN2Q4ZjJfNS01LTEtMS05NTU4_e05d9dae-6d70-4646-b1a5-c4246b2829b5">1,055,620</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i94a852cb675745e89723e30ec61bfcee_D20200101-20200331" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjNkOGQ1NGE4MzFlZTQzNjlhOGI4OTg1Y2JkZDdkOGYyL3RhYmxlcmFuZ2U6M2Q4ZDU0YTgzMWVlNDM2OWE4Yjg5ODVjYmRkN2Q4ZjJfNS03LTEtMS05NTU4_df04729c-97ac-4b13-85aa-2902531e1579">9,525</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4167fc9dfbd441ed853e3173c4f077bf_D20200101-20200331" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjNkOGQ1NGE4MzFlZTQzNjlhOGI4OTg1Y2JkZDdkOGYyL3RhYmxlcmFuZ2U6M2Q4ZDU0YTgzMWVlNDM2OWE4Yjg5ODVjYmRkN2Q4ZjJfNS05LTEtMS05NTU4_494a1d21-b392-46e3-8a13-738fde1c33ee">1,065,145</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, March 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i98ca8db1bbc14991a38ad2f127cdc3f7_I20200331" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjNkOGQ1NGE4MzFlZTQzNjlhOGI4OTg1Y2JkZDdkOGYyL3RhYmxlcmFuZ2U6M2Q4ZDU0YTgzMWVlNDM2OWE4Yjg5ODVjYmRkN2Q4ZjJfNi0xLTEtMS05NTU4_54089366-d285-48d9-a06a-eb833875fbd1">15,318,539</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98ca8db1bbc14991a38ad2f127cdc3f7_I20200331" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjNkOGQ1NGE4MzFlZTQzNjlhOGI4OTg1Y2JkZDdkOGYyL3RhYmxlcmFuZ2U6M2Q4ZDU0YTgzMWVlNDM2OWE4Yjg5ODVjYmRkN2Q4ZjJfNi0zLTEtMS05NTU4_8611b822-a493-4416-8f88-f23e7f8414ac">49,737,428</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9ade7c2b96049c891663efff729f1ef_I20200331" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjNkOGQ1NGE4MzFlZTQzNjlhOGI4OTg1Y2JkZDdkOGYyL3RhYmxlcmFuZ2U6M2Q4ZDU0YTgzMWVlNDM2OWE4Yjg5ODVjYmRkN2Q4ZjJfNi01LTEtMS05NTU4_eab4248e-a346-4ea9-8ea5-e8e431160c1d">152,775</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia79d5a078419401d86bc7174c913bcf6_I20200331" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjNkOGQ1NGE4MzFlZTQzNjlhOGI4OTg1Y2JkZDdkOGYyL3RhYmxlcmFuZ2U6M2Q4ZDU0YTgzMWVlNDM2OWE4Yjg5ODVjYmRkN2Q4ZjJfNi03LTEtMS05NTU4_0aee0b40-0b28-41c0-8fc8-11f58ff8bd26">47,145</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8cac0f57d4c4aa1bf61accf6f74bfda_I20200331" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjNkOGQ1NGE4MzFlZTQzNjlhOGI4OTg1Y2JkZDdkOGYyL3RhYmxlcmFuZ2U6M2Q4ZDU0YTgzMWVlNDM2OWE4Yjg5ODVjYmRkN2Q4ZjJfNi05LTEtMS05NTU4_f134c8c7-20db-4387-bd25-7f968ffc3628">49,843,058</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:31.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.757%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, March 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i98ca8db1bbc14991a38ad2f127cdc3f7_I20200331" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjA5YTFmYmRmMmVhMzQ1ODM5ZmJlYWM5NDVjM2RjNjI2L3RhYmxlcmFuZ2U6MDlhMWZiZGYyZWEzNDU4MzlmYmVhYzk0NWMzZGM2MjZfMS0xLTEtMS05NTU4_5bfae5c9-3e1a-4eef-a52c-4ba0f1f3ec03">15,318,539</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98ca8db1bbc14991a38ad2f127cdc3f7_I20200331" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjA5YTFmYmRmMmVhMzQ1ODM5ZmJlYWM5NDVjM2RjNjI2L3RhYmxlcmFuZ2U6MDlhMWZiZGYyZWEzNDU4MzlmYmVhYzk0NWMzZGM2MjZfMS0zLTEtMS05NTU4_b5ef76f9-1ec4-433c-b5b6-17af7dd32a3f">49,737,428</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9ade7c2b96049c891663efff729f1ef_I20200331" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjA5YTFmYmRmMmVhMzQ1ODM5ZmJlYWM5NDVjM2RjNjI2L3RhYmxlcmFuZ2U6MDlhMWZiZGYyZWEzNDU4MzlmYmVhYzk0NWMzZGM2MjZfMS01LTEtMS05NTU4_fe236be2-a610-49ec-87d8-5280e1433e0d">152,775</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia79d5a078419401d86bc7174c913bcf6_I20200331" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjA5YTFmYmRmMmVhMzQ1ODM5ZmJlYWM5NDVjM2RjNjI2L3RhYmxlcmFuZ2U6MDlhMWZiZGYyZWEzNDU4MzlmYmVhYzk0NWMzZGM2MjZfMS03LTEtMS05NTU4_df26d6b8-d73e-4ab8-9f83-bbed51a74fd1">47,145</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8cac0f57d4c4aa1bf61accf6f74bfda_I20200331" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjA5YTFmYmRmMmVhMzQ1ODM5ZmJlYWM5NDVjM2RjNjI2L3RhYmxlcmFuZ2U6MDlhMWZiZGYyZWEzNDU4MzlmYmVhYzk0NWMzZGM2MjZfMS05LTEtMS05NTU4_c915cc4c-08d2-4087-bb3e-42c158d86c4f">49,843,058</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i62b7e40824ec46c1a5d32166d46d8910_D20200401-20200630" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjA5YTFmYmRmMmVhMzQ1ODM5ZmJlYWM5NDVjM2RjNjI2L3RhYmxlcmFuZ2U6MDlhMWZiZGYyZWEzNDU4MzlmYmVhYzk0NWMzZGM2MjZfMi0xLTEtMS05NTU4_d4cfa378-3e97-4226-9f36-cfada6799107">4,200</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62b7e40824ec46c1a5d32166d46d8910_D20200401-20200630" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjA5YTFmYmRmMmVhMzQ1ODM5ZmJlYWM5NDVjM2RjNjI2L3RhYmxlcmFuZ2U6MDlhMWZiZGYyZWEzNDU4MzlmYmVhYzk0NWMzZGM2MjZfMi0zLTEtMS05NTU4_478d70a1-0421-4ea7-bace-469cc002673c">278,349</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i374ad433cb0d4675ae41fef76147919d_D20200401-20200630" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjA5YTFmYmRmMmVhMzQ1ODM5ZmJlYWM5NDVjM2RjNjI2L3RhYmxlcmFuZ2U6MDlhMWZiZGYyZWEzNDU4MzlmYmVhYzk0NWMzZGM2MjZfMi05LTEtMS05NTU4_6b0d670b-02c0-42cc-9616-e33cb046b7bd">278,349</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i62b7e40824ec46c1a5d32166d46d8910_D20200401-20200630" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockRepurchasedDuringPeriodShares" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjA5YTFmYmRmMmVhMzQ1ODM5ZmJlYWM5NDVjM2RjNjI2L3RhYmxlcmFuZ2U6MDlhMWZiZGYyZWEzNDU4MzlmYmVhYzk0NWMzZGM2MjZfMy0xLTEtMS05NTU4_548841a5-a7fe-4c8f-9b0d-aed043cc0421">141,463</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i62b7e40824ec46c1a5d32166d46d8910_D20200401-20200630" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjA5YTFmYmRmMmVhMzQ1ODM5ZmJlYWM5NDVjM2RjNjI2L3RhYmxlcmFuZ2U6MDlhMWZiZGYyZWEzNDU4MzlmYmVhYzk0NWMzZGM2MjZfMy0zLTEtMS05NTU4_5e038516-2bee-4e44-b618-aafe273d4184">769,648</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i374ad433cb0d4675ae41fef76147919d_D20200401-20200630" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjA5YTFmYmRmMmVhMzQ1ODM5ZmJlYWM5NDVjM2RjNjI2L3RhYmxlcmFuZ2U6MDlhMWZiZGYyZWEzNDU4MzlmYmVhYzk0NWMzZGM2MjZfMy05LTEtMS05NTU4_1fe53f37-d0ff-4dfa-8134-e5bf6512d102">769,648</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7d9f053c7b34fd799481310c6ca1498_D20200401-20200630" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjA5YTFmYmRmMmVhMzQ1ODM5ZmJlYWM5NDVjM2RjNjI2L3RhYmxlcmFuZ2U6MDlhMWZiZGYyZWEzNDU4MzlmYmVhYzk0NWMzZGM2MjZfNC01LTEtMS05NTU4_ea0a7385-18e0-45e3-9407-ab943f001e46">918,275</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i06622f546c724e4289669409575c7f9d_D20200401-20200630" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjA5YTFmYmRmMmVhMzQ1ODM5ZmJlYWM5NDVjM2RjNjI2L3RhYmxlcmFuZ2U6MDlhMWZiZGYyZWEzNDU4MzlmYmVhYzk0NWMzZGM2MjZfNC03LTEtMS05NTU4_c202d4bd-4445-42ef-b424-f112d53358b5">22,314</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i374ad433cb0d4675ae41fef76147919d_D20200401-20200630" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjA5YTFmYmRmMmVhMzQ1ODM5ZmJlYWM5NDVjM2RjNjI2L3RhYmxlcmFuZ2U6MDlhMWZiZGYyZWEzNDU4MzlmYmVhYzk0NWMzZGM2MjZfNC05LTEtMS05NTU4_9e4e5268-37ae-4e06-9ed6-0bb9098f08ee">940,589</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, June 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib5c699d5da91427e80a66ec6b1991b3a_I20200630" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjA5YTFmYmRmMmVhMzQ1ODM5ZmJlYWM5NDVjM2RjNjI2L3RhYmxlcmFuZ2U6MDlhMWZiZGYyZWEzNDU4MzlmYmVhYzk0NWMzZGM2MjZfNS0xLTEtMS05NTU4_ba6e9aef-46ff-43b9-b878-63a20e112f39">15,181,276</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5c699d5da91427e80a66ec6b1991b3a_I20200630" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjA5YTFmYmRmMmVhMzQ1ODM5ZmJlYWM5NDVjM2RjNjI2L3RhYmxlcmFuZ2U6MDlhMWZiZGYyZWEzNDU4MzlmYmVhYzk0NWMzZGM2MjZfNS0zLTEtMS05NTU4_ae912d4a-a419-4caf-8c49-de60e29cfb21">49,246,129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i70a1ecea99f7485195b3405682bd0c55_I20200630" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjA5YTFmYmRmMmVhMzQ1ODM5ZmJlYWM5NDVjM2RjNjI2L3RhYmxlcmFuZ2U6MDlhMWZiZGYyZWEzNDU4MzlmYmVhYzk0NWMzZGM2MjZfNS01LTEtMS05NTU4_b0ee6887-8eef-4bbb-8054-7681ab6e31ec">765,500</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9fb60215b0504a758fcf2dfe00ea4b97_I20200630" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjA5YTFmYmRmMmVhMzQ1ODM5ZmJlYWM5NDVjM2RjNjI2L3RhYmxlcmFuZ2U6MDlhMWZiZGYyZWEzNDU4MzlmYmVhYzk0NWMzZGM2MjZfNS03LTEtMS05NTU4_28ea7e25-8915-42e9-b1b1-e76c15087935">69,459</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00b5fc7364e347f39acdca8004cef0f9_I20200630" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjA5YTFmYmRmMmVhMzQ1ODM5ZmJlYWM5NDVjM2RjNjI2L3RhYmxlcmFuZ2U6MDlhMWZiZGYyZWEzNDU4MzlmYmVhYzk0NWMzZGM2MjZfNS05LTEtMS05NTU4_cd97b5f7-7028-4dea-9797-50d5b9f33f13">48,411,170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:31.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.757%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, June 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib5c699d5da91427e80a66ec6b1991b3a_I20200630" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjkxZTY2MTlmZmQ3ZDRiNTJhYTAxZDEyOWMyM2M1NjJmL3RhYmxlcmFuZ2U6OTFlNjYxOWZmZDdkNGI1MmFhMDFkMTI5YzIzYzU2MmZfMC0xLTEtMS05NTU4_1c203fe2-7e6c-4fcb-9c67-a0836994c554">15,181,276</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5c699d5da91427e80a66ec6b1991b3a_I20200630" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjkxZTY2MTlmZmQ3ZDRiNTJhYTAxZDEyOWMyM2M1NjJmL3RhYmxlcmFuZ2U6OTFlNjYxOWZmZDdkNGI1MmFhMDFkMTI5YzIzYzU2MmZfMC0zLTEtMS05NTU4_99d65948-277a-4607-b69e-c3fb47ca8650">49,246,129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i70a1ecea99f7485195b3405682bd0c55_I20200630" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjkxZTY2MTlmZmQ3ZDRiNTJhYTAxZDEyOWMyM2M1NjJmL3RhYmxlcmFuZ2U6OTFlNjYxOWZmZDdkNGI1MmFhMDFkMTI5YzIzYzU2MmZfMC01LTEtMS05NTU4_4a10dfdb-303d-467b-83df-a3dcab39e02d">765,500</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9fb60215b0504a758fcf2dfe00ea4b97_I20200630" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjkxZTY2MTlmZmQ3ZDRiNTJhYTAxZDEyOWMyM2M1NjJmL3RhYmxlcmFuZ2U6OTFlNjYxOWZmZDdkNGI1MmFhMDFkMTI5YzIzYzU2MmZfMC03LTEtMS05NTU4_132d0d50-1764-4f1d-a4a1-6f70c7c05f5a">69,459</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00b5fc7364e347f39acdca8004cef0f9_I20200630" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjkxZTY2MTlmZmQ3ZDRiNTJhYTAxZDEyOWMyM2M1NjJmL3RhYmxlcmFuZ2U6OTFlNjYxOWZmZDdkNGI1MmFhMDFkMTI5YzIzYzU2MmZfMC05LTEtMS05NTU4_8d4cc7d0-10d9-4e36-a097-78c1845f90af">48,411,170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i786c6ae7dd8d4840bb2995fce1423b07_D20200701-20200930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjkxZTY2MTlmZmQ3ZDRiNTJhYTAxZDEyOWMyM2M1NjJmL3RhYmxlcmFuZ2U6OTFlNjYxOWZmZDdkNGI1MmFhMDFkMTI5YzIzYzU2MmZfMS0xLTEtMS05NTU4_f5763c6c-263b-4113-af40-f9c3eb0a0921">4,450</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i786c6ae7dd8d4840bb2995fce1423b07_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjkxZTY2MTlmZmQ3ZDRiNTJhYTAxZDEyOWMyM2M1NjJmL3RhYmxlcmFuZ2U6OTFlNjYxOWZmZDdkNGI1MmFhMDFkMTI5YzIzYzU2MmZfMS0zLTEtMS05NTU4_69e7894c-997a-43c8-9c42-5e40f06986e0">262,415</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2722c94900c4f68be9dd446637b8348_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjkxZTY2MTlmZmQ3ZDRiNTJhYTAxZDEyOWMyM2M1NjJmL3RhYmxlcmFuZ2U6OTFlNjYxOWZmZDdkNGI1MmFhMDFkMTI5YzIzYzU2MmZfMS05LTEtMS05NTU4_7e1d0225-6b3d-4e13-ac7c-b5fc997896f9">262,415</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i786c6ae7dd8d4840bb2995fce1423b07_D20200701-20200930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjkxZTY2MTlmZmQ3ZDRiNTJhYTAxZDEyOWMyM2M1NjJmL3RhYmxlcmFuZ2U6OTFlNjYxOWZmZDdkNGI1MmFhMDFkMTI5YzIzYzU2MmZfNC0xLTEtMS05NTU4_90846027-9740-4424-9c38-aec27c588373">101,354</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i786c6ae7dd8d4840bb2995fce1423b07_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjkxZTY2MTlmZmQ3ZDRiNTJhYTAxZDEyOWMyM2M1NjJmL3RhYmxlcmFuZ2U6OTFlNjYxOWZmZDdkNGI1MmFhMDFkMTI5YzIzYzU2MmZfNC0zLTEtMS05NTU4_dfb96313-1a84-4e4d-a62b-78e38155311d">332,504</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie2722c94900c4f68be9dd446637b8348_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjkxZTY2MTlmZmQ3ZDRiNTJhYTAxZDEyOWMyM2M1NjJmL3RhYmxlcmFuZ2U6OTFlNjYxOWZmZDdkNGI1MmFhMDFkMTI5YzIzYzU2MmZfNC05LTEtMS05NTU4_55cd4e29-c0f6-4bfc-9a74-b3af62d6a38e">332,504</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c344dec4461400991796893b71c39f3_D20200701-20200930" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjkxZTY2MTlmZmQ3ZDRiNTJhYTAxZDEyOWMyM2M1NjJmL3RhYmxlcmFuZ2U6OTFlNjYxOWZmZDdkNGI1MmFhMDFkMTI5YzIzYzU2MmZfNS01LTEtMS05NTU4_62f43be1-5943-4466-a95c-8abde503d415">481,737</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1cdf0875abf4833a9b0038791a1ea6c_D20200701-20200930" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjkxZTY2MTlmZmQ3ZDRiNTJhYTAxZDEyOWMyM2M1NjJmL3RhYmxlcmFuZ2U6OTFlNjYxOWZmZDdkNGI1MmFhMDFkMTI5YzIzYzU2MmZfNS03LTEtMS05NTU4_1e0050b6-80e6-45f8-9b89-20b381a71206">15,967</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie2722c94900c4f68be9dd446637b8348_D20200701-20200930" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjkxZTY2MTlmZmQ3ZDRiNTJhYTAxZDEyOWMyM2M1NjJmL3RhYmxlcmFuZ2U6OTFlNjYxOWZmZDdkNGI1MmFhMDFkMTI5YzIzYzU2MmZfNS05LTEtMS05NTU4_4f3390c0-88a2-4ae0-994d-e8d11a4352d8">497,704</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, September 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1e43169536834b7daa78040307754845_I20200930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjkxZTY2MTlmZmQ3ZDRiNTJhYTAxZDEyOWMyM2M1NjJmL3RhYmxlcmFuZ2U6OTFlNjYxOWZmZDdkNGI1MmFhMDFkMTI5YzIzYzU2MmZfNi0xLTEtMS05NTU4_321a406d-5ff5-4794-ad2d-02192e50d59f">15,084,372</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,084,372&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e43169536834b7daa78040307754845_I20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjkxZTY2MTlmZmQ3ZDRiNTJhYTAxZDEyOWMyM2M1NjJmL3RhYmxlcmFuZ2U6OTFlNjYxOWZmZDdkNGI1MmFhMDFkMTI5YzIzYzU2MmZfNi0zLTEtMS05NTU4_6cf60caa-0d71-47b9-b84e-0c83df3122c6">49,176,040</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1adc976609fe48d4b014ec48f05e022c_I20200930" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjkxZTY2MTlmZmQ3ZDRiNTJhYTAxZDEyOWMyM2M1NjJmL3RhYmxlcmFuZ2U6OTFlNjYxOWZmZDdkNGI1MmFhMDFkMTI5YzIzYzU2MmZfNi01LTEtMS05NTU4_c01b96b7-c824-405a-b3ad-bc340d6c26b0">1,247,237</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i169b3e774913430bb6c450a8d1cd8300_I20200930" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjkxZTY2MTlmZmQ3ZDRiNTJhYTAxZDEyOWMyM2M1NjJmL3RhYmxlcmFuZ2U6OTFlNjYxOWZmZDdkNGI1MmFhMDFkMTI5YzIzYzU2MmZfNi03LTEtMS05NTU4_4e47f670-e308-4daf-8767-cc9dfb6e4532">85,426</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ae7216a773d47d889c5f34d67e867fe_I20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjkxZTY2MTlmZmQ3ZDRiNTJhYTAxZDEyOWMyM2M1NjJmL3RhYmxlcmFuZ2U6OTFlNjYxOWZmZDdkNGI1MmFhMDFkMTI5YzIzYzU2MmZfNi05LTEtMS05NTU4_bfde1c53-8ddb-4a1c-a27e-5c5949897d3e">47,843,377</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:31.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.757%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:31.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.757%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Common stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Retained earnings (deficit)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Noncontrolling interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total equity</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i659fa119f70c4793a43053cddb879d71_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjU5NDcxYjdiMDhkZjRjYzJiMjY1ODFjOTMyOTY4YmJiL3RhYmxlcmFuZ2U6NTk0NzFiN2IwOGRmNGNjMmIyNjU4MWM5MzI5NjhiYmJfMi0xLTEtMS05NTU4_7057cc7e-0b59-4ae3-9bff-60cdd185c2d1">14,988,429</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i659fa119f70c4793a43053cddb879d71_I20201231" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjU5NDcxYjdiMDhkZjRjYzJiMjY1ODFjOTMyOTY4YmJiL3RhYmxlcmFuZ2U6NTk0NzFiN2IwOGRmNGNjMmIyNjU4MWM5MzI5NjhiYmJfMi0zLTEtMS05NTU4_04aad0b1-30c4-4ea9-8c85-7eadc6329b3a">49,121,523</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50909170032a4c00a004f6dd1808751c_I20201231" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjU5NDcxYjdiMDhkZjRjYzJiMjY1ODFjOTMyOTY4YmJiL3RhYmxlcmFuZ2U6NTk0NzFiN2IwOGRmNGNjMmIyNjU4MWM5MzI5NjhiYmJfMi01LTEtMS05NTU4_134c4d4b-8582-480c-abfd-edc4fc3b5b73">2,131,013</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i42e8ab4712444a43a1f231cb65ac3dcd_I20201231" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjU5NDcxYjdiMDhkZjRjYzJiMjY1ODFjOTMyOTY4YmJiL3RhYmxlcmFuZ2U6NTk0NzFiN2IwOGRmNGNjMmIyNjU4MWM5MzI5NjhiYmJfMi03LTEtMS05NTU4_2844278d-dff4-4ebd-95ec-f5bdda877b84">117,116</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb172cb6365440839665fd6ec022472c_I20201231" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjU5NDcxYjdiMDhkZjRjYzJiMjY1ODFjOTMyOTY4YmJiL3RhYmxlcmFuZ2U6NTk0NzFiN2IwOGRmNGNjMmIyNjU4MWM5MzI5NjhiYmJfMi05LTEtMS05NTU4_38a0f3f4-23af-4b4f-b382-4f44689f4eee">46,873,394</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idecbe529c8e14131b56433eb5e130916_D20210101-20210331" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjU5NDcxYjdiMDhkZjRjYzJiMjY1ODFjOTMyOTY4YmJiL3RhYmxlcmFuZ2U6NTk0NzFiN2IwOGRmNGNjMmIyNjU4MWM5MzI5NjhiYmJfMy0xLTEtMS05NTU4_f7574844-4415-4104-a39e-24dc40d3967f">187,759</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idecbe529c8e14131b56433eb5e130916_D20210101-20210331" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjU5NDcxYjdiMDhkZjRjYzJiMjY1ODFjOTMyOTY4YmJiL3RhYmxlcmFuZ2U6NTk0NzFiN2IwOGRmNGNjMmIyNjU4MWM5MzI5NjhiYmJfMy0zLTEtMS05NTU4_39c408b4-5326-4ef0-8db1-91b7443aef10">162,960</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c8473bff64c498ab624fafa4cca5132_D20210101-20210331" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjU5NDcxYjdiMDhkZjRjYzJiMjY1ODFjOTMyOTY4YmJiL3RhYmxlcmFuZ2U6NTk0NzFiN2IwOGRmNGNjMmIyNjU4MWM5MzI5NjhiYmJfMy05LTEtMS05NTU4_80dd1e2a-1faa-4304-bacb-a245970d3b8f">162,960</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="idecbe529c8e14131b56433eb5e130916_D20210101-20210331" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockRepurchasedDuringPeriodShares" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjU5NDcxYjdiMDhkZjRjYzJiMjY1ODFjOTMyOTY4YmJiL3RhYmxlcmFuZ2U6NTk0NzFiN2IwOGRmNGNjMmIyNjU4MWM5MzI5NjhiYmJfNC0xLTEtMS05NTU4_1efaf449-3113-4fb4-8146-3e31a727ee9a">91,724</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idecbe529c8e14131b56433eb5e130916_D20210101-20210331" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjU5NDcxYjdiMDhkZjRjYzJiMjY1ODFjOTMyOTY4YmJiL3RhYmxlcmFuZ2U6NTk0NzFiN2IwOGRmNGNjMmIyNjU4MWM5MzI5NjhiYmJfNC0zLTEtMS05NTU4_6b4b8000-6c07-4605-89cd-79d6da8ce99d">303,088</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5c8473bff64c498ab624fafa4cca5132_D20210101-20210331" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjU5NDcxYjdiMDhkZjRjYzJiMjY1ODFjOTMyOTY4YmJiL3RhYmxlcmFuZ2U6NTk0NzFiN2IwOGRmNGNjMmIyNjU4MWM5MzI5NjhiYmJfNC05LTEtMS05NTU4_bf24bea5-836f-44bd-8f74-ec90a1aaab61">303,088</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i781a96ef93c24d05bb7f12625a033ec0_D20210101-20210331" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjU5NDcxYjdiMDhkZjRjYzJiMjY1ODFjOTMyOTY4YmJiL3RhYmxlcmFuZ2U6NTk0NzFiN2IwOGRmNGNjMmIyNjU4MWM5MzI5NjhiYmJfNS01LTEtMS05NTU4_31948089-7fbc-4e01-89b3-e4de20e48278">166,828</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38154999f15f41cca19a77a5f4d0ccac_D20210101-20210331" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjU5NDcxYjdiMDhkZjRjYzJiMjY1ODFjOTMyOTY4YmJiL3RhYmxlcmFuZ2U6NTk0NzFiN2IwOGRmNGNjMmIyNjU4MWM5MzI5NjhiYmJfNS03LTEtMS05NTU4_edf6efd5-2f19-4adb-933f-aa4d76c1d65a">22,167</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c8473bff64c498ab624fafa4cca5132_D20210101-20210331" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjU5NDcxYjdiMDhkZjRjYzJiMjY1ODFjOTMyOTY4YmJiL3RhYmxlcmFuZ2U6NTk0NzFiN2IwOGRmNGNjMmIyNjU4MWM5MzI5NjhiYmJfNS05LTEtMS05NTU4_f3adc67d-9fcf-484c-b8e3-4b3953e8bfcd">144,661</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9d845908b01747ac9d721fff45f53abf_I20210331" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjU5NDcxYjdiMDhkZjRjYzJiMjY1ODFjOTMyOTY4YmJiL3RhYmxlcmFuZ2U6NTk0NzFiN2IwOGRmNGNjMmIyNjU4MWM5MzI5NjhiYmJfNi0xLTEtMS05NTU4_eed539f4-4f00-4335-8742-e54d7ee5d7fe">15,084,464</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d845908b01747ac9d721fff45f53abf_I20210331" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjU5NDcxYjdiMDhkZjRjYzJiMjY1ODFjOTMyOTY4YmJiL3RhYmxlcmFuZ2U6NTk0NzFiN2IwOGRmNGNjMmIyNjU4MWM5MzI5NjhiYmJfNi0zLTEtMS05NTU4_3681e437-53cd-4eff-aae2-556ddd42dab1">48,981,395</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i32deafcb20a948cf995118abdf3ce1a4_I20210331" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjU5NDcxYjdiMDhkZjRjYzJiMjY1ODFjOTMyOTY4YmJiL3RhYmxlcmFuZ2U6NTk0NzFiN2IwOGRmNGNjMmIyNjU4MWM5MzI5NjhiYmJfNi01LTEtMS05NTU4_83fef89f-98c5-4766-b63f-489ddd93e58a">1,964,185</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2593ac397b63496686231e5a4d277b3b_I20210331" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjU5NDcxYjdiMDhkZjRjYzJiMjY1ODFjOTMyOTY4YmJiL3RhYmxlcmFuZ2U6NTk0NzFiN2IwOGRmNGNjMmIyNjU4MWM5MzI5NjhiYmJfNi03LTEtMS05NTU4_3ceb856f-31f0-4939-bf14-e49625105dd7">139,283</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8320ae6bb40c49b4b91522210805d996_I20210331" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjU5NDcxYjdiMDhkZjRjYzJiMjY1ODFjOTMyOTY4YmJiL3RhYmxlcmFuZ2U6NTk0NzFiN2IwOGRmNGNjMmIyNjU4MWM5MzI5NjhiYmJfNi05LTEtMS05NTU4_d82bb52f-c66b-46c2-8206-2f24681b9542">46,877,927</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:31.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.757%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9d845908b01747ac9d721fff45f53abf_I20210331" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjhkYTkyNzEzNWJjODQ1YzViYzNkZTcxOTdhN2RiOWZlL3RhYmxlcmFuZ2U6OGRhOTI3MTM1YmM4NDVjNWJjM2RlNzE5N2E3ZGI5ZmVfMS0xLTEtMS05NTU4_eed539f4-4f00-4335-8742-e54d7ee5d7fe">15,084,464</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d845908b01747ac9d721fff45f53abf_I20210331" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjhkYTkyNzEzNWJjODQ1YzViYzNkZTcxOTdhN2RiOWZlL3RhYmxlcmFuZ2U6OGRhOTI3MTM1YmM4NDVjNWJjM2RlNzE5N2E3ZGI5ZmVfMS0zLTEtMS05NTU4_3681e437-53cd-4eff-aae2-556ddd42dab1">48,981,395</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i32deafcb20a948cf995118abdf3ce1a4_I20210331" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjhkYTkyNzEzNWJjODQ1YzViYzNkZTcxOTdhN2RiOWZlL3RhYmxlcmFuZ2U6OGRhOTI3MTM1YmM4NDVjNWJjM2RlNzE5N2E3ZGI5ZmVfMS01LTEtMS05NTU4_83fef89f-98c5-4766-b63f-489ddd93e58a">1,964,185</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2593ac397b63496686231e5a4d277b3b_I20210331" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjhkYTkyNzEzNWJjODQ1YzViYzNkZTcxOTdhN2RiOWZlL3RhYmxlcmFuZ2U6OGRhOTI3MTM1YmM4NDVjNWJjM2RlNzE5N2E3ZGI5ZmVfMS03LTEtMS05NTU4_3ceb856f-31f0-4939-bf14-e49625105dd7">139,283</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8320ae6bb40c49b4b91522210805d996_I20210331" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjhkYTkyNzEzNWJjODQ1YzViYzNkZTcxOTdhN2RiOWZlL3RhYmxlcmFuZ2U6OGRhOTI3MTM1YmM4NDVjNWJjM2RlNzE5N2E3ZGI5ZmVfMS05LTEtMS05NTU4_d82bb52f-c66b-46c2-8206-2f24681b9542">46,877,927</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief227cab10a245ff9baa903632237a80_D20210401-20210630" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjhkYTkyNzEzNWJjODQ1YzViYzNkZTcxOTdhN2RiOWZlL3RhYmxlcmFuZ2U6OGRhOTI3MTM1YmM4NDVjNWJjM2RlNzE5N2E3ZGI5ZmVfMi0zLTEtMS05NTU4_0ea014be-e665-481a-a9d0-b00ea2aa91b8">191,954</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83fce5d3edda4b1cbab16d0e4a53c979_D20210401-20210630" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjhkYTkyNzEzNWJjODQ1YzViYzNkZTcxOTdhN2RiOWZlL3RhYmxlcmFuZ2U6OGRhOTI3MTM1YmM4NDVjNWJjM2RlNzE5N2E3ZGI5ZmVfMi05LTEtMS05NTU4_881bb181-1369-496b-8b7d-14238b167570">191,954</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ief227cab10a245ff9baa903632237a80_D20210401-20210630" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjhkYTkyNzEzNWJjODQ1YzViYzNkZTcxOTdhN2RiOWZlL3RhYmxlcmFuZ2U6OGRhOTI3MTM1YmM4NDVjNWJjM2RlNzE5N2E3ZGI5ZmVfMy0xLTEtMS05NTU4_5d25d73a-3bd3-4372-b246-162f8e5bec85">158,405</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief227cab10a245ff9baa903632237a80_D20210401-20210630" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjhkYTkyNzEzNWJjODQ1YzViYzNkZTcxOTdhN2RiOWZlL3RhYmxlcmFuZ2U6OGRhOTI3MTM1YmM4NDVjNWJjM2RlNzE5N2E3ZGI5ZmVfMy0zLTEtMS05NTU4_a8b15ca7-722b-4183-94ca-19c176e2260a">484,965</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i83fce5d3edda4b1cbab16d0e4a53c979_D20210401-20210630" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjhkYTkyNzEzNWJjODQ1YzViYzNkZTcxOTdhN2RiOWZlL3RhYmxlcmFuZ2U6OGRhOTI3MTM1YmM4NDVjNWJjM2RlNzE5N2E3ZGI5ZmVfMy05LTEtMS05NTU4_f0f44ab9-6591-48bd-a1e1-071a34ce8e9e">484,965</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe562d54463741e8949d25484a516053_D20210401-20210630" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjhkYTkyNzEzNWJjODQ1YzViYzNkZTcxOTdhN2RiOWZlL3RhYmxlcmFuZ2U6OGRhOTI3MTM1YmM4NDVjNWJjM2RlNzE5N2E3ZGI5ZmVfNC01LTEtMS05NTU4_2d024e0b-c223-46cc-96f3-231eb3a685d2">1,228,560</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f91139b751f41ee943e86bdb734f2f4_D20210401-20210630" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjhkYTkyNzEzNWJjODQ1YzViYzNkZTcxOTdhN2RiOWZlL3RhYmxlcmFuZ2U6OGRhOTI3MTM1YmM4NDVjNWJjM2RlNzE5N2E3ZGI5ZmVfNC03LTEtMS05NTU4_22fe06fd-d63c-49af-a421-db55884b35bb">5,069</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83fce5d3edda4b1cbab16d0e4a53c979_D20210401-20210630" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjhkYTkyNzEzNWJjODQ1YzViYzNkZTcxOTdhN2RiOWZlL3RhYmxlcmFuZ2U6OGRhOTI3MTM1YmM4NDVjNWJjM2RlNzE5N2E3ZGI5ZmVfNC05LTEtMS05NTU4_c23b1e29-ce32-40a8-b16b-34dedbbf01db">1,223,491</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7ea7194dbc454dbdbc6632db38bf6066_I20210630" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjhkYTkyNzEzNWJjODQ1YzViYzNkZTcxOTdhN2RiOWZlL3RhYmxlcmFuZ2U6OGRhOTI3MTM1YmM4NDVjNWJjM2RlNzE5N2E3ZGI5ZmVfNS0xLTEtMS05NTU4_dcc08780-96f8-4ffe-9174-8c6bfdb9acb0">14,926,059</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ea7194dbc454dbdbc6632db38bf6066_I20210630" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjhkYTkyNzEzNWJjODQ1YzViYzNkZTcxOTdhN2RiOWZlL3RhYmxlcmFuZ2U6OGRhOTI3MTM1YmM4NDVjNWJjM2RlNzE5N2E3ZGI5ZmVfNS0zLTEtMS05NTU4_705b4090-f883-42e7-97b6-503eae1789be">48,688,384</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic49c90ad54954ba9a5f89e54eb1dfedb_I20210630" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjhkYTkyNzEzNWJjODQ1YzViYzNkZTcxOTdhN2RiOWZlL3RhYmxlcmFuZ2U6OGRhOTI3MTM1YmM4NDVjNWJjM2RlNzE5N2E3ZGI5ZmVfNS01LTEtMS05NTU4_6476049d-65f5-4999-aa4b-150e410bba73">735,625</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie1e3b4d188524c1791c80059e8f7515a_I20210630" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjhkYTkyNzEzNWJjODQ1YzViYzNkZTcxOTdhN2RiOWZlL3RhYmxlcmFuZ2U6OGRhOTI3MTM1YmM4NDVjNWJjM2RlNzE5N2E3ZGI5ZmVfNS03LTEtMS05NTU4_a9046c90-144e-4d48-be67-98e3ee61a55b">144,352</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64b2d71ddb0c448d9959f1b9a74a7dad_I20210630" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjhkYTkyNzEzNWJjODQ1YzViYzNkZTcxOTdhN2RiOWZlL3RhYmxlcmFuZ2U6OGRhOTI3MTM1YmM4NDVjNWJjM2RlNzE5N2E3ZGI5ZmVfNS05LTEtMS05NTU4_97ec6cbf-7a4f-49be-b398-310dbe615c6b">47,808,407</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:31.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.757%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7ea7194dbc454dbdbc6632db38bf6066_I20210630" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjBjNDExMWRjOGQyZTQ0MzdhZTc0YmI5YzNjNjc5YmIwL3RhYmxlcmFuZ2U6MGM0MTExZGM4ZDJlNDQzN2FlNzRiYjljM2M2NzliYjBfMS0xLTEtMS05NTU4_4e8dc3a0-51a6-4572-a2bd-824edb0988e6">14,926,059</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ea7194dbc454dbdbc6632db38bf6066_I20210630" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjBjNDExMWRjOGQyZTQ0MzdhZTc0YmI5YzNjNjc5YmIwL3RhYmxlcmFuZ2U6MGM0MTExZGM4ZDJlNDQzN2FlNzRiYjljM2M2NzliYjBfMS0zLTEtMS05NTU4_a3b29f55-e4d1-4600-98ba-bfe88d4b8015">48,688,384</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic49c90ad54954ba9a5f89e54eb1dfedb_I20210630" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjBjNDExMWRjOGQyZTQ0MzdhZTc0YmI5YzNjNjc5YmIwL3RhYmxlcmFuZ2U6MGM0MTExZGM4ZDJlNDQzN2FlNzRiYjljM2M2NzliYjBfMS01LTEtMS05NTU4_142089ed-56e3-477f-9f4d-9163676c17c7">735,625</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie1e3b4d188524c1791c80059e8f7515a_I20210630" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjBjNDExMWRjOGQyZTQ0MzdhZTc0YmI5YzNjNjc5YmIwL3RhYmxlcmFuZ2U6MGM0MTExZGM4ZDJlNDQzN2FlNzRiYjljM2M2NzliYjBfMS03LTEtMS05NTU4_507da33e-e52a-46bb-a4b2-c010cdec7854">144,352</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64b2d71ddb0c448d9959f1b9a74a7dad_I20210630" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjBjNDExMWRjOGQyZTQ0MzdhZTc0YmI5YzNjNjc5YmIwL3RhYmxlcmFuZ2U6MGM0MTExZGM4ZDJlNDQzN2FlNzRiYjljM2M2NzliYjBfMS05LTEtMS05NTU4_e33e63bd-631c-4d12-93c3-91b8d135ad90">47,808,407</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i10df7b4f9a35418da7673ef6ae315d51_D20210701-20210930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjBjNDExMWRjOGQyZTQ0MzdhZTc0YmI5YzNjNjc5YmIwL3RhYmxlcmFuZ2U6MGM0MTExZGM4ZDJlNDQzN2FlNzRiYjljM2M2NzliYjBfMi0xLTEtMS05NTU4_81d6eb07-e689-4ff0-9df5-18284e21cc0d">875</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10df7b4f9a35418da7673ef6ae315d51_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjBjNDExMWRjOGQyZTQ0MzdhZTc0YmI5YzNjNjc5YmIwL3RhYmxlcmFuZ2U6MGM0MTExZGM4ZDJlNDQzN2FlNzRiYjljM2M2NzliYjBfMi0zLTEtMS05NTU4_f24ef08c-4098-4b4e-90e9-ca8f2947a940">162,167</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cfdffb6c8a4411a95e4596b0bd91b7c_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjBjNDExMWRjOGQyZTQ0MzdhZTc0YmI5YzNjNjc5YmIwL3RhYmxlcmFuZ2U6MGM0MTExZGM4ZDJlNDQzN2FlNzRiYjljM2M2NzliYjBfMi05LTEtMS05NTU4_169057ed-308d-4e43-bcac-1ee1eceedb54">162,167</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i10df7b4f9a35418da7673ef6ae315d51_D20210701-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjBjNDExMWRjOGQyZTQ0MzdhZTc0YmI5YzNjNjc5YmIwL3RhYmxlcmFuZ2U6MGM0MTExZGM4ZDJlNDQzN2FlNzRiYjljM2M2NzliYjBfMy0xLTEtMS05NTU4_0f04d063-90b1-4855-9ea8-e0b45a74bb2d">76,408</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i10df7b4f9a35418da7673ef6ae315d51_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjBjNDExMWRjOGQyZTQ0MzdhZTc0YmI5YzNjNjc5YmIwL3RhYmxlcmFuZ2U6MGM0MTExZGM4ZDJlNDQzN2FlNzRiYjljM2M2NzliYjBfMy0zLTEtMS05NTU4_5f9244e3-7211-427c-b9a3-053f221d3623">237,616</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5cfdffb6c8a4411a95e4596b0bd91b7c_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjBjNDExMWRjOGQyZTQ0MzdhZTc0YmI5YzNjNjc5YmIwL3RhYmxlcmFuZ2U6MGM0MTExZGM4ZDJlNDQzN2FlNzRiYjljM2M2NzliYjBfMy05LTEtMS05NTU4_9ddf6a86-bd00-480e-8c87-2b6bc6f20ce4">237,616</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae1347d2d1d84aa3a135e3245bdf0d90_D20210701-20210930" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjBjNDExMWRjOGQyZTQ0MzdhZTc0YmI5YzNjNjc5YmIwL3RhYmxlcmFuZ2U6MGM0MTExZGM4ZDJlNDQzN2FlNzRiYjljM2M2NzliYjBfNC01LTEtMS0xMDI2Nw_cbeaa059-71c9-4b37-b89d-73d8fd6d7c0f">1,055,278</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9cc79eb883d54f61bdec225f436b82c9_D20210701-20210930" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjBjNDExMWRjOGQyZTQ0MzdhZTc0YmI5YzNjNjc5YmIwL3RhYmxlcmFuZ2U6MGM0MTExZGM4ZDJlNDQzN2FlNzRiYjljM2M2NzliYjBfNC03LTEtMS0xMTgyMw_bba45812-ec40-4220-90ee-24ee4964cd26">31,415</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5cfdffb6c8a4411a95e4596b0bd91b7c_D20210701-20210930" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjBjNDExMWRjOGQyZTQ0MzdhZTc0YmI5YzNjNjc5YmIwL3RhYmxlcmFuZ2U6MGM0MTExZGM4ZDJlNDQzN2FlNzRiYjljM2M2NzliYjBfNC05LTEtMS05NTU4_341bb227-f07f-4bc9-9d1b-3939ea4b1db3">1,086,693</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, September 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i56aafc7718c145c8b150a8e54f33a5d2_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjBjNDExMWRjOGQyZTQ0MzdhZTc0YmI5YzNjNjc5YmIwL3RhYmxlcmFuZ2U6MGM0MTExZGM4ZDJlNDQzN2FlNzRiYjljM2M2NzliYjBfNS0xLTEtMS05NTU4_8dc93544-2123-452a-829f-d0d73c3b0bef">14,850,526</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56aafc7718c145c8b150a8e54f33a5d2_I20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjBjNDExMWRjOGQyZTQ0MzdhZTc0YmI5YzNjNjc5YmIwL3RhYmxlcmFuZ2U6MGM0MTExZGM4ZDJlNDQzN2FlNzRiYjljM2M2NzliYjBfNS0zLTEtMS05NTU4_909af3b1-353b-4168-8cfa-408168fb7c16">48,612,935</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib1da3f9dccc043f1b509c4e381803002_I20210930" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjBjNDExMWRjOGQyZTQ0MzdhZTc0YmI5YzNjNjc5YmIwL3RhYmxlcmFuZ2U6MGM0MTExZGM4ZDJlNDQzN2FlNzRiYjljM2M2NzliYjBfNS01LTEtMS05NTU4_41b7e1e7-83aa-4dbd-a223-934a3f5e6d50">1,790,903</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ied663adb59564577989ed6d27ea6493f_I20210930" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjBjNDExMWRjOGQyZTQ0MzdhZTc0YmI5YzNjNjc5YmIwL3RhYmxlcmFuZ2U6MGM0MTExZGM4ZDJlNDQzN2FlNzRiYjljM2M2NzliYjBfNS03LTEtMS05NTU4_b0d20a4f-9c66-44f0-8a11-94010dd8c102">175,767</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjBjNDExMWRjOGQyZTQ0MzdhZTc0YmI5YzNjNjc5YmIwL3RhYmxlcmFuZ2U6MGM0MTExZGM4ZDJlNDQzN2FlNzRiYjljM2M2NzliYjBfNS05LTEtMS05NTU4_270319a0-ab49-4b31-8eaa-3c63149042c5">46,646,265</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:31.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.757%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="30" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">See accompanying Notes to Unaudited Condensed Consolidated Financial Statements.</span></div></td></tr></table></div><div><span><br/></span></div><div style="height:24.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i8e8bdb91dc894234b9d87e17a18b54fd_28"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div id="i8e8bdb91dc894234b9d87e17a18b54fd_31"></div><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(1) <ix:nonNumeric contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zMS9mcmFnOjc4MTgyYzdiODkwMzRkOTdhYWUyNDJlZGY3MzU3NmU5L3RleHRyZWdpb246NzgxODJjN2I4OTAzNGQ5N2FhZTI0MmVkZjczNTc2ZTlfMTAwMzE_454135b1-1a94-46f8-8aba-ffa26ed95177" continuedAt="ie7d20157115b462f9cc97b78b68913e7" escape="true">ORGANIZATION AND BASIS OF PRESENTATION</ix:nonNumeric></span></div><ix:continuation id="ie7d20157115b462f9cc97b78b68913e7" continuedAt="ie6458d9bf1e64e9ea4de62c7044807f1"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland Pharmaceuticals Inc. (&#8220;Cumberland,&#8221; the &#8220;Company,&#8221; or as used in the context of &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221;) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products.  The Company's primary target markets are hospital acute care, gastroenterology and rheumatology. These medical specialties are characterized by relatively concentrated prescriber bases that the Company believes can be penetrated effectively by small, targeted sales forces. Cumberland is dedicated to providing innovative products that improve quality of care for patients and address unmet or poorly met medical needs.  The Company promotes its approved products through its hospital and field sales forces in the United States and is establishing a network of international partners to bring its medicines to patients in their countries.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland focuses its resources on maximizing the commercial potential of its products, as well as developing new product candidates, and has both internal development and commercial capabilities. The Company&#8217;s products are manufactured by third parties, which are overseen by Cumberland&#8217;s quality control and manufacturing professionals. The Company works closely with its third-party distribution partners to make its products available in the United States.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, the accompanying unaudited condensed consolidated financial statements of the Company have been prepared on a basis consistent with the December 31, 2020, audited consolidated financial statements and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly present the information set forth herein. All significant intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements have been prepared in accordance with the regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;), and certain information and disclosures have been condensed or omitted as permitted by the SEC for interim period presentation. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes included in our Annual Report on Form 10-K for the year ended December 31, 2020 (the &#8220;2020 Annual Report on Form 10-K&#8221;). The results of operations for the three and nine months ended September 30, 2021, are not necessarily indicative of the results to be expected for the entire fiscal year or any future period.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Discontinued Operations</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed further in Note 9, during May 2019, Cumberland entered into a Dissolution Agreement  ("Dissolution Agreement") with Clinigen Healthcare Limited ("Clinigen") in which the Company returned the exclusive rights to commercialize Ethyol</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Totect</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States to Clinigen. Under the terms of the Dissolution Agreement, Cumberland is no longer involved directly or indirectly with the distribution, marketing and promotion of either Ethyol or Totect or any competing products following December 31, 2019. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's exit from Ethyol and Totect meets the accounting criteria to be reported as discontinued operations and the discontinued operating results have been presented in the financial statements and footnotes to reflect the discontinued status of Ethyol and Totect. Refer to Note 9, for additional information.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revision of prior period condensed consolidated statement of cash flows presentation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has made a revision to prior period amounts to conform to the current year presentation of the cash surrender value of life insurance policies over premiums paid on the condensed consolidated statement of cash flows.  The revised amounts were previously included as net changes in assets affecting operating activities.  These revisions have no net effect on the reported net cash provided by operating activities nor any impact on the reported operating results or balance sheet for the 2020 period presented.  </span></div><div style="margin-bottom:8pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19 Pandemic </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the U.S. declared a health care emergency following the outbreak of the SARS-CoV-2, a novel strain of coronavirus that causes COVID-19, a respiratory illness.  </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland has remained open for business, as the Company is considered to be essential by the United States Department of Homeland Security. The Company has implemented measures to address the impact of the novel coronavirus on the business and taken appropriate action to protect its employees, secure the supply chain, and support the patients who can benefit from its medicines.  All of the Company's employees have been given the opportunity to work remotely, and those that wish to work from Cumberland's office and laboratories are encouraged to practice the behaviors outlined by the Centers for Disease Control.  </span></div></ix:continuation><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><ix:continuation id="ie6458d9bf1e64e9ea4de62c7044807f1" continuedAt="i1821fbfe3bc44050837995ac5e4925a6"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Throughout the pandemic, Cumberland has faced the same headwinds affecting other companies that rely on hospital admissions and patient visits to drive revenue.  Our business and our clinical studies were impacted as less patients sought elective surgeries and our access to medical facilities was substantially limited.  During 2020 and 2021, we carefully monitored our supply chain during the pandemic including the flow of raw materials into the plants that manufacture our products as well as the batches of finished product emerging from those facilities. Several of our brands were negatively impacted by the lockdowns and postponement of physician office visits and elective procedures. However, we are fortunate to have a diversified product portfolio, with other brands delivering a strong performance.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland relies on third-party organizations around the world to supply components, manufacture and distribute its products. The Company is aware that it may experience revenue loss, supply interruptions, time delays and incur unplanned expenses as a result of the impact of the ongoing COVID-19 pandemic.   The Company continues to monitor the COVID-19 pandemic situation both in the U.S. and internationally in order to maintain its employees&#8217; safety and well-being, while also keeping its business operating.  Given the uncertainty, magnitude and impact of such changes, the Company is unable to quantify the impact on the future results as of the date of this filing.</span></div><ix:nonNumeric contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zMS9mcmFnOjc4MTgyYzdiODkwMzRkOTdhYWUyNDJlZGY3MzU3NmU5L3RleHRyZWdpb246NzgxODJjN2I4OTAzNGQ5N2FhZTI0MmVkZjczNTc2ZTlfMTAwMzI_3a7841ca-7519-41ae-91eb-bbe84bc731f4" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Guidance</span></div><div style="margin-bottom:6pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements - Not Yet Adopted</span></div><div style="margin-bottom:6pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board ("FASB") issued ASU No. 2016-13, &#8220;Financial Instruments-Credit Losses,&#8221; which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other instruments, companies will be required to use a new forward-looking &#8220;expected loss&#8221; model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, companies will measure credit losses in a manner similar to what they do today, except that the losses will be recognized as allowances rather than as reductions in the amortized cost of the securities. Companies will have to disclose additional information, including information they use to track credit quality by year of origination for most financing receivables. Companies will apply the ASU&#8217;s provisions as a cumulative-effect adjustment, if any, to retained earnings as of the beginning of the first reporting period in which the guidance is adopted.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Related to ASU No. 2016-13 discussed above, in May 2019, the FASB issued ASU 2019-05, "Financial Instruments-Credit Losses (Topic 326): Targeted Transition Relief" which provides transition relief for ASU 2016-13 by providing entities with an alternative to irrevocably elect the fair value option for eligible financial assets measured at amortized cost upon adoption of the new credit losses standard. Certain eligibility requirements must be met and the election must be applied on an instrument-by-instrument basis. The election is not available for either available-for-sale or held-to-maturity debt securities. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will adopt both ASU 2016-13 and ASU 2019-05 on January 1, 2023. The adoption of ASU 2016-13 and ASU 2019-05 are not expected to have a material impact on the Company&#8217;s consolidated financial statements.</span></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Policies:</span></div><ix:nonNumeric contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zMS9mcmFnOjc4MTgyYzdiODkwMzRkOTdhYWUyNDJlZGY3MzU3NmU5L3RleHRyZWdpb246NzgxODJjN2I4OTAzNGQ5N2FhZTI0MmVkZjczNTc2ZTlfMTAwMzU_2fff1938-59dd-444d-801f-b299631abdd1" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Use of Estimates</span></div><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management of the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period.  Actual results could differ from those estimates under different assumptions and conditions.  The Company's most significant estimates include: (1) its allowances for chargebacks and accruals for rebates and product returns, (2) the allowances for obsolescent or unmarketable inventory and (3) valuation of a contingent consideration liability associated with a business combination.</span></div></ix:nonNumeric><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><ix:nonNumeric contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zMS9mcmFnOjc4MTgyYzdiODkwMzRkOTdhYWUyNDJlZGY3MzU3NmU5L3RleHRyZWdpb246NzgxODJjN2I4OTAzNGQ5N2FhZTI0MmVkZjczNTc2ZTlfMTAwMzY_7ccfbc10-8b2c-455c-a58c-8d7144bc8c96" continuedAt="i792e6e2739284229b8035d6ae4505a35" escape="true">Operating Segments</ix:nonNumeric></span></div></ix:continuation><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i1821fbfe3bc44050837995ac5e4925a6"><ix:continuation id="i792e6e2739284229b8035d6ae4505a35">The Company has <ix:nonFraction unitRef="segment" contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zMS9mcmFnOjc4MTgyYzdiODkwMzRkOTdhYWUyNDJlZGY3MzU3NmU5L3RleHRyZWdpb246NzgxODJjN2I4OTAzNGQ5N2FhZTI0MmVkZjczNTc2ZTlfOTIyNQ_1e7893e3-e3b9-4055-b4eb-4c6de5ad02f0">one</ix:nonFraction> operating segment which is specialty pharmaceutical products. Management has chosen to organize the Company based on the type of products sold. Operating segments are identified as components of an enterprise about which separate discrete financial information is evaluated by the chief operating decision maker, or decision-making group, in making decisions regarding resource allocation and assessing performance. The Company, which uses consolidated financial information in determining how to allocate resources and assess performance, has concluded that our specialty pharmaceutical products compete in similar economic markets and similar circumstances.  Substantially all of the Company&#8217;s assets are located in the United States and total revenues are primarily attributable to U.S.&#160;customers.</ix:continuation></ix:continuation> </span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i8e8bdb91dc894234b9d87e17a18b54fd_34"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(2) <ix:nonNumeric contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNC9mcmFnOmQyY2ZkOGMzZjBkMzQxZWY4NWM0ZDRkYzM2OTQ3NjNlL3RleHRyZWdpb246ZDJjZmQ4YzNmMGQzNDFlZjg1YzRkNGRjMzY5NDc2M2VfNDI1_26b21939-0832-4e2d-99c4-98d2376f2724" continuedAt="ia18c050a6c684061a1c53868a588c0a0" escape="true">EARNINGS (LOSS) PER SHARE</ix:nonNumeric></span></div><ix:continuation id="ia18c050a6c684061a1c53868a588c0a0"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNC9mcmFnOmQyY2ZkOGMzZjBkMzQxZWY4NWM0ZDRkYzM2OTQ3NjNlL3RleHRyZWdpb246ZDJjZmQ4YzNmMGQzNDFlZjg1YzRkNGRjMzY5NDc2M2VfNDI3_45196b7b-e2ff-4caa-a182-02ca58cf409d" continuedAt="i31c80e73c7384c1d9d551454027859c9" escape="true">The following table reconciles the numerator and denominator used to calculate diluted earnings (loss) per share for the three and nine months ended September 30, 2021 and 2020:</ix:nonNumeric></span></div><div style="text-align:justify"><ix:continuation id="i31c80e73c7384c1d9d551454027859c9"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.987%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5cfdffb6c8a4411a95e4596b0bd91b7c_D20210701-20210930" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNC9mcmFnOmQyY2ZkOGMzZjBkMzQxZWY4NWM0ZDRkYzM2OTQ3NjNlL3RhYmxlOjYxZTdjZDNjMmM5ZTRkYzQ5MzI4MWE4ZjQ5MzgzMjA2L3RhYmxlcmFuZ2U6NjFlN2NkM2MyYzllNGRjNDkzMjgxYThmNDkzODMyMDZfMy0xLTEtMS05NTU4_3656b68a-e37c-4633-8dd8-a003efd3e39e">1,583,480</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie2722c94900c4f68be9dd446637b8348_D20200701-20200930" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNC9mcmFnOmQyY2ZkOGMzZjBkMzQxZWY4NWM0ZDRkYzM2OTQ3NjNlL3RhYmxlOjYxZTdjZDNjMmM5ZTRkYzQ5MzI4MWE4ZjQ5MzgzMjA2L3RhYmxlcmFuZ2U6NjFlN2NkM2MyYzllNGRjNDkzMjgxYThmNDkzODMyMDZfMy0zLTEtMS05NTU4_ec6850d2-e817-4b14-9487-ff3e910e4c91">1,275,620</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb58760ea84940319b35492cd1910735_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNC9mcmFnOmQyY2ZkOGMzZjBkMzQxZWY4NWM0ZDRkYzM2OTQ3NjNlL3RhYmxlOjYxZTdjZDNjMmM5ZTRkYzQ5MzI4MWE4ZjQ5MzgzMjA2L3RhYmxlcmFuZ2U6NjFlN2NkM2MyYzllNGRjNDkzMjgxYThmNDkzODMyMDZfNC0xLTEtMS05NTU4_86849bd9-9c34-42dc-a4b6-2061e77af27b">496,787</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca7f9fa06d14f85a52cbd81ac170d2c_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNC9mcmFnOmQyY2ZkOGMzZjBkMzQxZWY4NWM0ZDRkYzM2OTQ3NjNlL3RhYmxlOjYxZTdjZDNjMmM5ZTRkYzQ5MzI4MWE4ZjQ5MzgzMjA2L3RhYmxlcmFuZ2U6NjFlN2NkM2MyYzllNGRjNDkzMjgxYThmNDkzODMyMDZfNC0zLTEtMS05NTU4_0fe8db84-b272-4c9f-a304-4c34cd7b14a3">777,916</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5cfdffb6c8a4411a95e4596b0bd91b7c_D20210701-20210930" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNC9mcmFnOmQyY2ZkOGMzZjBkMzQxZWY4NWM0ZDRkYzM2OTQ3NjNlL3RhYmxlOjYxZTdjZDNjMmM5ZTRkYzQ5MzI4MWE4ZjQ5MzgzMjA2L3RhYmxlcmFuZ2U6NjFlN2NkM2MyYzllNGRjNDkzMjgxYThmNDkzODMyMDZfNS0xLTEtMS05NTU4_06c37d4c-3b8e-4e9d-9a49-fdc7ea9995d1">1,086,693</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie2722c94900c4f68be9dd446637b8348_D20200701-20200930" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNC9mcmFnOmQyY2ZkOGMzZjBkMzQxZWY4NWM0ZDRkYzM2OTQ3NjNlL3RhYmxlOjYxZTdjZDNjMmM5ZTRkYzQ5MzI4MWE4ZjQ5MzgzMjA2L3RhYmxlcmFuZ2U6NjFlN2NkM2MyYzllNGRjNDkzMjgxYThmNDkzODMyMDZfNS0zLTEtMS05NTU4_1cc0f468-27ca-4623-bd4d-04fecde16f42">497,704</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (income) loss at subsidiary attributable to noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cfdffb6c8a4411a95e4596b0bd91b7c_D20210701-20210930" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNC9mcmFnOmQyY2ZkOGMzZjBkMzQxZWY4NWM0ZDRkYzM2OTQ3NjNlL3RhYmxlOjYxZTdjZDNjMmM5ZTRkYzQ5MzI4MWE4ZjQ5MzgzMjA2L3RhYmxlcmFuZ2U6NjFlN2NkM2MyYzllNGRjNDkzMjgxYThmNDkzODMyMDZfNi0xLTEtMS05NTU4_95b61dfc-d977-4115-94c6-54e0d0af5a99">31,415</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2722c94900c4f68be9dd446637b8348_D20200701-20200930" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNC9mcmFnOmQyY2ZkOGMzZjBkMzQxZWY4NWM0ZDRkYzM2OTQ3NjNlL3RhYmxlOjYxZTdjZDNjMmM5ZTRkYzQ5MzI4MWE4ZjQ5MzgzMjA2L3RhYmxlcmFuZ2U6NjFlN2NkM2MyYzllNGRjNDkzMjgxYThmNDkzODMyMDZfNi0zLTEtMS05NTU4_2141b745-6e38-4f81-959c-3756a18c45c0">15,967</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to common shareholders</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5cfdffb6c8a4411a95e4596b0bd91b7c_D20210701-20210930" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNC9mcmFnOmQyY2ZkOGMzZjBkMzQxZWY4NWM0ZDRkYzM2OTQ3NjNlL3RhYmxlOjYxZTdjZDNjMmM5ZTRkYzQ5MzI4MWE4ZjQ5MzgzMjA2L3RhYmxlcmFuZ2U6NjFlN2NkM2MyYzllNGRjNDkzMjgxYThmNDkzODMyMDZfNy0xLTEtMS05NTU4_8e25e5e8-98f3-44fe-bcfe-7cb6ae67a6e0">1,055,278</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie2722c94900c4f68be9dd446637b8348_D20200701-20200930" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNC9mcmFnOmQyY2ZkOGMzZjBkMzQxZWY4NWM0ZDRkYzM2OTQ3NjNlL3RhYmxlOjYxZTdjZDNjMmM5ZTRkYzQ5MzI4MWE4ZjQ5MzgzMjA2L3RhYmxlcmFuZ2U6NjFlN2NkM2MyYzllNGRjNDkzMjgxYThmNDkzODMyMDZfNy0zLTEtMS05NTU4_4df57ef8-bc72-4d47-97d5-a0535ac6e0d4">481,737</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding &#8211; basic</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5cfdffb6c8a4411a95e4596b0bd91b7c_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNC9mcmFnOmQyY2ZkOGMzZjBkMzQxZWY4NWM0ZDRkYzM2OTQ3NjNlL3RhYmxlOjYxZTdjZDNjMmM5ZTRkYzQ5MzI4MWE4ZjQ5MzgzMjA2L3RhYmxlcmFuZ2U6NjFlN2NkM2MyYzllNGRjNDkzMjgxYThmNDkzODMyMDZfOS0xLTEtMS05NTU4_b5e1a767-1b86-4012-89bc-7628a19420c8">14,880,887</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie2722c94900c4f68be9dd446637b8348_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNC9mcmFnOmQyY2ZkOGMzZjBkMzQxZWY4NWM0ZDRkYzM2OTQ3NjNlL3RhYmxlOjYxZTdjZDNjMmM5ZTRkYzQ5MzI4MWE4ZjQ5MzgzMjA2L3RhYmxlcmFuZ2U6NjFlN2NkM2MyYzllNGRjNDkzMjgxYThmNDkzODMyMDZfOS0zLTEtMS05NTU4_7ddc136a-92bb-439a-a38a-0bfad779387e">15,134,583</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of other securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5cfdffb6c8a4411a95e4596b0bd91b7c_D20210701-20210930" decimals="0" format="ixt:fixed-zero" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNC9mcmFnOmQyY2ZkOGMzZjBkMzQxZWY4NWM0ZDRkYzM2OTQ3NjNlL3RhYmxlOjYxZTdjZDNjMmM5ZTRkYzQ5MzI4MWE4ZjQ5MzgzMjA2L3RhYmxlcmFuZ2U6NjFlN2NkM2MyYzllNGRjNDkzMjgxYThmNDkzODMyMDZfMTAtMS0xLTEtOTU1OA_bf99d36d-91d8-4d26-9d88-a39c983f0874">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie2722c94900c4f68be9dd446637b8348_D20200701-20200930" decimals="0" format="ixt:fixed-zero" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNC9mcmFnOmQyY2ZkOGMzZjBkMzQxZWY4NWM0ZDRkYzM2OTQ3NjNlL3RhYmxlOjYxZTdjZDNjMmM5ZTRkYzQ5MzI4MWE4ZjQ5MzgzMjA2L3RhYmxlcmFuZ2U6NjFlN2NkM2MyYzllNGRjNDkzMjgxYThmNDkzODMyMDZfMTAtMy0xLTEtOTU1OA_2f272c37-da51-4356-beb0-a57c619788e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding &#8211; diluted</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5cfdffb6c8a4411a95e4596b0bd91b7c_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNC9mcmFnOmQyY2ZkOGMzZjBkMzQxZWY4NWM0ZDRkYzM2OTQ3NjNlL3RhYmxlOjYxZTdjZDNjMmM5ZTRkYzQ5MzI4MWE4ZjQ5MzgzMjA2L3RhYmxlcmFuZ2U6NjFlN2NkM2MyYzllNGRjNDkzMjgxYThmNDkzODMyMDZfMTEtMS0xLTEtOTU1OA_206d45ec-0dfd-4dad-a09c-708e034903c8">14,880,887</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie2722c94900c4f68be9dd446637b8348_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNC9mcmFnOmQyY2ZkOGMzZjBkMzQxZWY4NWM0ZDRkYzM2OTQ3NjNlL3RhYmxlOjYxZTdjZDNjMmM5ZTRkYzQ5MzI4MWE4ZjQ5MzgzMjA2L3RhYmxlcmFuZ2U6NjFlN2NkM2MyYzllNGRjNDkzMjgxYThmNDkzODMyMDZfMTEtMy0xLTEtOTU1OA_3069879d-a3f8-4c09-bc47-66a88a16ffee">15,134,583</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:58.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.516%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.518%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.987%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNC9mcmFnOmQyY2ZkOGMzZjBkMzQxZWY4NWM0ZDRkYzM2OTQ3NjNlL3RhYmxlOjliMDI5ZWFiYjZiNDQ3MDhhMmJmMGYzZDEyNTk5ZGViL3RhYmxlcmFuZ2U6OWIwMjllYWJiNmI0NDcwOGEyYmYwZjNkMTI1OTlkZWJfNC0xLTEtMS05NTU4_4c64bffd-ba77-41a6-8d18-51bfc653c845">1,209,545</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNC9mcmFnOmQyY2ZkOGMzZjBkMzQxZWY4NWM0ZDRkYzM2OTQ3NjNlL3RhYmxlOjliMDI5ZWFiYjZiNDQ3MDhhMmJmMGYzZDEyNTk5ZGViL3RhYmxlcmFuZ2U6OWIwMjllYWJiNmI0NDcwOGEyYmYwZjNkMTI1OTlkZWJfNC0zLTEtMS05NTU4_85fb5be7-0aae-4020-9da3-9e25c9015f6a">4,838,249</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45bdfab35dd74d60ac86fc023b908b73_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNC9mcmFnOmQyY2ZkOGMzZjBkMzQxZWY4NWM0ZDRkYzM2OTQ3NjNlL3RhYmxlOjliMDI5ZWFiYjZiNDQ3MDhhMmJmMGYzZDEyNTk5ZGViL3RhYmxlcmFuZ2U6OWIwMjllYWJiNmI0NDcwOGEyYmYwZjNkMTI1OTlkZWJfNS0xLTEtMS05NTU4_1acd7b61-10d3-4d57-a3bb-db27abac79f0">1,491,004</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8c8802e62b74a919450a1c6017bba7e_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNC9mcmFnOmQyY2ZkOGMzZjBkMzQxZWY4NWM0ZDRkYzM2OTQ3NjNlL3RhYmxlOjliMDI5ZWFiYjZiNDQ3MDhhMmJmMGYzZDEyNTk5ZGViL3RhYmxlcmFuZ2U6OWIwMjllYWJiNmI0NDcwOGEyYmYwZjNkMTI1OTlkZWJfNS0zLTEtMS05NTU4_841b8fa5-722e-49de-805f-6e1ba99049bf">2,334,811</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNC9mcmFnOmQyY2ZkOGMzZjBkMzQxZWY4NWM0ZDRkYzM2OTQ3NjNlL3RhYmxlOjliMDI5ZWFiYjZiNDQ3MDhhMmJmMGYzZDEyNTk5ZGViL3RhYmxlcmFuZ2U6OWIwMjllYWJiNmI0NDcwOGEyYmYwZjNkMTI1OTlkZWJfNi0xLTEtMS05NTU4_4dba1ef6-53d1-42f8-8c8d-2ffd0332f6c6">281,459</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNC9mcmFnOmQyY2ZkOGMzZjBkMzQxZWY4NWM0ZDRkYzM2OTQ3NjNlL3RhYmxlOjliMDI5ZWFiYjZiNDQ3MDhhMmJmMGYzZDEyNTk5ZGViL3RhYmxlcmFuZ2U6OWIwMjllYWJiNmI0NDcwOGEyYmYwZjNkMTI1OTlkZWJfNi0zLTEtMS05NTU4_72f6cf1b-b278-4755-bba1-690b049afff5">2,503,438</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) at subsidiary attributable to noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNC9mcmFnOmQyY2ZkOGMzZjBkMzQxZWY4NWM0ZDRkYzM2OTQ3NjNlL3RhYmxlOjliMDI5ZWFiYjZiNDQ3MDhhMmJmMGYzZDEyNTk5ZGViL3RhYmxlcmFuZ2U6OWIwMjllYWJiNmI0NDcwOGEyYmYwZjNkMTI1OTlkZWJfNy0xLTEtMS05NTU4_ce0a12c3-7567-454b-93ce-355822e98dea">58,651</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNC9mcmFnOmQyY2ZkOGMzZjBkMzQxZWY4NWM0ZDRkYzM2OTQ3NjNlL3RhYmxlOjliMDI5ZWFiYjZiNDQ3MDhhMmJmMGYzZDEyNTk5ZGViL3RhYmxlcmFuZ2U6OWIwMjllYWJiNmI0NDcwOGEyYmYwZjNkMTI1OTlkZWJfNy0zLTEtMS05NTU4_f17bcff7-0f96-4279-931e-32336eb1034d">47,806</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to common shareholders</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNC9mcmFnOmQyY2ZkOGMzZjBkMzQxZWY4NWM0ZDRkYzM2OTQ3NjNlL3RhYmxlOjliMDI5ZWFiYjZiNDQ3MDhhMmJmMGYzZDEyNTk5ZGViL3RhYmxlcmFuZ2U6OWIwMjllYWJiNmI0NDcwOGEyYmYwZjNkMTI1OTlkZWJfOC0xLTEtMS05NTU4_5cb25c6b-5d1e-43e1-a9db-72676163fbcd">340,110</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNC9mcmFnOmQyY2ZkOGMzZjBkMzQxZWY4NWM0ZDRkYzM2OTQ3NjNlL3RhYmxlOjliMDI5ZWFiYjZiNDQ3MDhhMmJmMGYzZDEyNTk5ZGViL3RhYmxlcmFuZ2U6OWIwMjllYWJiNmI0NDcwOGEyYmYwZjNkMTI1OTlkZWJfOC0zLTEtMS05NTU4_f7aef4bc-6f7d-491b-8a3f-1c613544acf4">2,455,632</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding &#8211; basic</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNC9mcmFnOmQyY2ZkOGMzZjBkMzQxZWY4NWM0ZDRkYzM2OTQ3NjNlL3RhYmxlOjliMDI5ZWFiYjZiNDQ3MDhhMmJmMGYzZDEyNTk5ZGViL3RhYmxlcmFuZ2U6OWIwMjllYWJiNmI0NDcwOGEyYmYwZjNkMTI1OTlkZWJfMTAtMS0xLTEtOTU1OA_8cdb33ce-1515-4327-ae98-f1d30f78e45a">14,939,919</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNC9mcmFnOmQyY2ZkOGMzZjBkMzQxZWY4NWM0ZDRkYzM2OTQ3NjNlL3RhYmxlOjliMDI5ZWFiYjZiNDQ3MDhhMmJmMGYzZDEyNTk5ZGViL3RhYmxlcmFuZ2U6OWIwMjllYWJiNmI0NDcwOGEyYmYwZjNkMTI1OTlkZWJfMTAtMy0xLTEtOTU1OA_3cebfc23-7264-4ddc-9953-b2de72843968">15,206,179</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of other securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNC9mcmFnOmQyY2ZkOGMzZjBkMzQxZWY4NWM0ZDRkYzM2OTQ3NjNlL3RhYmxlOjliMDI5ZWFiYjZiNDQ3MDhhMmJmMGYzZDEyNTk5ZGViL3RhYmxlcmFuZ2U6OWIwMjllYWJiNmI0NDcwOGEyYmYwZjNkMTI1OTlkZWJfMTEtMS0xLTEtOTU1OA_605da32d-fcf5-4109-8a79-0d27864d7f97">199,985</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930" decimals="0" format="ixt:fixed-zero" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNC9mcmFnOmQyY2ZkOGMzZjBkMzQxZWY4NWM0ZDRkYzM2OTQ3NjNlL3RhYmxlOjliMDI5ZWFiYjZiNDQ3MDhhMmJmMGYzZDEyNTk5ZGViL3RhYmxlcmFuZ2U6OWIwMjllYWJiNmI0NDcwOGEyYmYwZjNkMTI1OTlkZWJfMTEtMy0xLTEtOTU1OA_b7b9a4ed-aabc-4e09-b4f1-13c2ea1d4302">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding &#8211; diluted</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNC9mcmFnOmQyY2ZkOGMzZjBkMzQxZWY4NWM0ZDRkYzM2OTQ3NjNlL3RhYmxlOjliMDI5ZWFiYjZiNDQ3MDhhMmJmMGYzZDEyNTk5ZGViL3RhYmxlcmFuZ2U6OWIwMjllYWJiNmI0NDcwOGEyYmYwZjNkMTI1OTlkZWJfMTItMS0xLTEtOTU1OA_680872eb-8fa6-4a35-8e4b-96a35c60f7b4">15,139,904</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNC9mcmFnOmQyY2ZkOGMzZjBkMzQxZWY4NWM0ZDRkYzM2OTQ3NjNlL3RhYmxlOjliMDI5ZWFiYjZiNDQ3MDhhMmJmMGYzZDEyNTk5ZGViL3RhYmxlcmFuZ2U6OWIwMjllYWJiNmI0NDcwOGEyYmYwZjNkMTI1OTlkZWJfMTItMy0xLTEtOTU1OA_74c47ba6-d296-4d83-a36d-d18b2064f105">15,206,179</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2021 and 2020, restricted stock awards and options to purchase <ix:nonFraction unitRef="shares" contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNC9mcmFnOmQyY2ZkOGMzZjBkMzQxZWY4NWM0ZDRkYzM2OTQ3NjNlL3RleHRyZWdpb246ZDJjZmQ4YzNmMGQzNDFlZjg1YzRkNGRjMzY5NDc2M2VfMjQ4_c4b236a3-aad2-42f6-9b3f-a778532730c3">158,900</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNC9mcmFnOmQyY2ZkOGMzZjBkMzQxZWY4NWM0ZDRkYzM2OTQ3NjNlL3RleHRyZWdpb246ZDJjZmQ4YzNmMGQzNDFlZjg1YzRkNGRjMzY5NDc2M2VfMjU1_c475d801-9266-4d56-8a11-b84fca1875bd">197,210</ix:nonFraction> shares of common stock, respectively, were outstanding but were not included in the computation of diluted earnings per share because the effect would be antidilutive.</span></div></ix:continuation><div id="i8e8bdb91dc894234b9d87e17a18b54fd_37"></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(3) <ix:nonNumeric contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNy9mcmFnOmZhYjQ3ZTJiZjBhZTQ3MTc4YjdkOGZjNmZmMzExMzYwL3RleHRyZWdpb246ZmFiNDdlMmJmMGFlNDcxNzhiN2Q4ZmM2ZmYzMTEzNjBfMjU3NQ_1531aca6-8f7d-4f5a-92b9-225d8b4fdab2" continuedAt="i800249fa2b024bb6ba439a72dbcef57e" escape="true">REVENUES</ix:nonNumeric></span></div><ix:continuation id="i800249fa2b024bb6ba439a72dbcef57e" continuedAt="i5701a740fb47444c934aaad5d65be907"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Revenues</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for revenues from contracts with customers under ASC 606, which became effective January 1, 2018. </span></div><div style="margin-top:8pt;text-align:justify"><ix:nonNumeric contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" name="us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNy9mcmFnOmZhYjQ3ZTJiZjBhZTQ3MTc4YjdkOGZjNmZmMzExMzYwL3RleHRyZWdpb246ZmFiNDdlMmJmMGFlNDcxNzhiN2Q4ZmM2ZmYzMTEzNjBfMjU3OQ_6e8723dd-0e9c-4e15-94e7-da617c69baec" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s net revenues consisted of the following for the three and nine months ended September 30, 2021 and 2020:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Products:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kristalose</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b064560ae764b05aee16232fc2b982f_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNy9mcmFnOmZhYjQ3ZTJiZjBhZTQ3MTc4YjdkOGZjNmZmMzExMzYwL3RhYmxlOjc1ZWU0YjlmNmU1YjRhYTZhZWEwZTM1ZGQzZmE4NTUwL3RhYmxlcmFuZ2U6NzVlZTRiOWY2ZTViNGFhNmFlYTBlMzVkZDNmYTg1NTBfMy0xLTEtMS05NTU4_b715d0d9-0526-4ec0-b9c5-9d63854e4b5b">4,012,746</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9189ef3c405466780ff2b301ce69072_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNy9mcmFnOmZhYjQ3ZTJiZjBhZTQ3MTc4YjdkOGZjNmZmMzExMzYwL3RhYmxlOjc1ZWU0YjlmNmU1YjRhYTZhZWEwZTM1ZGQzZmE4NTUwL3RhYmxlcmFuZ2U6NzVlZTRiOWY2ZTViNGFhNmFlYTBlMzVkZDNmYTg1NTBfMy0zLTEtMS05NTU4_40ba5e81-fcb0-4362-9f31-7b796c2c6e45">3,615,557</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib543c8c5c4a0438eb3b83a9549c72767_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNy9mcmFnOmZhYjQ3ZTJiZjBhZTQ3MTc4YjdkOGZjNmZmMzExMzYwL3RhYmxlOjc1ZWU0YjlmNmU1YjRhYTZhZWEwZTM1ZGQzZmE4NTUwL3RhYmxlcmFuZ2U6NzVlZTRiOWY2ZTViNGFhNmFlYTBlMzVkZDNmYTg1NTBfMy01LTEtMS05NTU4_c4cec850-b5cd-4b3e-a364-57a695a932fc">12,286,729</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i851181d1e03446adb4d2b6f666a489e7_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNy9mcmFnOmZhYjQ3ZTJiZjBhZTQ3MTc4YjdkOGZjNmZmMzExMzYwL3RhYmxlOjc1ZWU0YjlmNmU1YjRhYTZhZWEwZTM1ZGQzZmE4NTUwL3RhYmxlcmFuZ2U6NzVlZTRiOWY2ZTViNGFhNmFlYTBlMzVkZDNmYTg1NTBfMy03LTEtMS05NTU4_c3aff0bd-99da-4696-a1fb-f112b43c42d9">10,387,046</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vibativ</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i343ad32279094a2585bfa47056ea0769_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNy9mcmFnOmZhYjQ3ZTJiZjBhZTQ3MTc4YjdkOGZjNmZmMzExMzYwL3RhYmxlOjc1ZWU0YjlmNmU1YjRhYTZhZWEwZTM1ZGQzZmE4NTUwL3RhYmxlcmFuZ2U6NzVlZTRiOWY2ZTViNGFhNmFlYTBlMzVkZDNmYTg1NTBfNC0xLTEtMS05NTU4_d2a514f6-bc85-4d76-84a3-581ae3ca6690">1,896,584</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf76fee1053a41f897bb2b308eda43b7_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNy9mcmFnOmZhYjQ3ZTJiZjBhZTQ3MTc4YjdkOGZjNmZmMzExMzYwL3RhYmxlOjc1ZWU0YjlmNmU1YjRhYTZhZWEwZTM1ZGQzZmE4NTUwL3RhYmxlcmFuZ2U6NzVlZTRiOWY2ZTViNGFhNmFlYTBlMzVkZDNmYTg1NTBfNC0zLTEtMS05NTU4_63f7b646-7f06-4718-81cf-677173d193cd">2,813,249</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a175b2126f3439e978ef755a5187703_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNy9mcmFnOmZhYjQ3ZTJiZjBhZTQ3MTc4YjdkOGZjNmZmMzExMzYwL3RhYmxlOjc1ZWU0YjlmNmU1YjRhYTZhZWEwZTM1ZGQzZmE4NTUwL3RhYmxlcmFuZ2U6NzVlZTRiOWY2ZTViNGFhNmFlYTBlMzVkZDNmYTg1NTBfNC01LTEtMS05NTU4_797af799-1dd4-496c-b11b-64ff4c9660b0">8,799,891</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1221e6e62b0d4437aa038a1593455cdb_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNy9mcmFnOmZhYjQ3ZTJiZjBhZTQ3MTc4YjdkOGZjNmZmMzExMzYwL3RhYmxlOjc1ZWU0YjlmNmU1YjRhYTZhZWEwZTM1ZGQzZmE4NTUwL3RhYmxlcmFuZ2U6NzVlZTRiOWY2ZTViNGFhNmFlYTBlMzVkZDNmYTg1NTBfNC03LTEtMS05NTU4_18885835-bca3-4034-ae40-ec1503683622">8,551,125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Caldolor</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide5a86375216464d9ebfdf112640aff3_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNy9mcmFnOmZhYjQ3ZTJiZjBhZTQ3MTc4YjdkOGZjNmZmMzExMzYwL3RhYmxlOjc1ZWU0YjlmNmU1YjRhYTZhZWEwZTM1ZGQzZmE4NTUwL3RhYmxlcmFuZ2U6NzVlZTRiOWY2ZTViNGFhNmFlYTBlMzVkZDNmYTg1NTBfNS0xLTEtMS05NTU4_4ecd3416-3be0-4137-b77a-084667a1bde0">1,255,669</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d2eab230e924fb094455dfdb93d19f6_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNy9mcmFnOmZhYjQ3ZTJiZjBhZTQ3MTc4YjdkOGZjNmZmMzExMzYwL3RhYmxlOjc1ZWU0YjlmNmU1YjRhYTZhZWEwZTM1ZGQzZmE4NTUwL3RhYmxlcmFuZ2U6NzVlZTRiOWY2ZTViNGFhNmFlYTBlMzVkZDNmYTg1NTBfNS0zLTEtMS05NTU4_96821b96-9f8c-4cda-8d66-222bf9410a62">1,416,146</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib32ee538452d4d108fd0d0249f232e4e_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNy9mcmFnOmZhYjQ3ZTJiZjBhZTQ3MTc4YjdkOGZjNmZmMzExMzYwL3RhYmxlOjc1ZWU0YjlmNmU1YjRhYTZhZWEwZTM1ZGQzZmE4NTUwL3RhYmxlcmFuZ2U6NzVlZTRiOWY2ZTViNGFhNmFlYTBlMzVkZDNmYTg1NTBfNS01LTEtMS05NTU4_63e26ee5-444b-420f-bbdf-8d62b3f3f1f9">3,734,273</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie38185217cb649a98c782f849b956b81_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNy9mcmFnOmZhYjQ3ZTJiZjBhZTQ3MTc4YjdkOGZjNmZmMzExMzYwL3RhYmxlOjc1ZWU0YjlmNmU1YjRhYTZhZWEwZTM1ZGQzZmE4NTUwL3RhYmxlcmFuZ2U6NzVlZTRiOWY2ZTViNGFhNmFlYTBlMzVkZDNmYTg1NTBfNS03LTEtMS05NTU4_f35bed30-7729-4eee-ae38-6037a38c4f22">3,677,434</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vaprisol</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb5e5973ac81495ca434caa4250ad1e6_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNy9mcmFnOmZhYjQ3ZTJiZjBhZTQ3MTc4YjdkOGZjNmZmMzExMzYwL3RhYmxlOjc1ZWU0YjlmNmU1YjRhYTZhZWEwZTM1ZGQzZmE4NTUwL3RhYmxlcmFuZ2U6NzVlZTRiOWY2ZTViNGFhNmFlYTBlMzVkZDNmYTg1NTBfNi0xLTEtMS05NTU4_bcdc676d-e769-47f8-9e93-4a6af5dae191">325,774</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f2cff2563f6434383fad1a3433a95bf_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNy9mcmFnOmZhYjQ3ZTJiZjBhZTQ3MTc4YjdkOGZjNmZmMzExMzYwL3RhYmxlOjc1ZWU0YjlmNmU1YjRhYTZhZWEwZTM1ZGQzZmE4NTUwL3RhYmxlcmFuZ2U6NzVlZTRiOWY2ZTViNGFhNmFlYTBlMzVkZDNmYTg1NTBfNi0zLTEtMS05NTU4_14b486ec-0bd1-4898-bb20-f5e8383adc00">406,162</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87b67bdb94e6413eab1ada4bb36a71b7_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNy9mcmFnOmZhYjQ3ZTJiZjBhZTQ3MTc4YjdkOGZjNmZmMzExMzYwL3RhYmxlOjc1ZWU0YjlmNmU1YjRhYTZhZWEwZTM1ZGQzZmE4NTUwL3RhYmxlcmFuZ2U6NzVlZTRiOWY2ZTViNGFhNmFlYTBlMzVkZDNmYTg1NTBfNi01LTEtMS05NTU4_531a4f67-3812-4d7b-b851-f55ca5fa72ea">1,861,130</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e186cdc2a444de9d34c6b0a9840fa3_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNy9mcmFnOmZhYjQ3ZTJiZjBhZTQ3MTc4YjdkOGZjNmZmMzExMzYwL3RhYmxlOjc1ZWU0YjlmNmU1YjRhYTZhZWEwZTM1ZGQzZmE4NTUwL3RhYmxlcmFuZ2U6NzVlZTRiOWY2ZTViNGFhNmFlYTBlMzVkZDNmYTg1NTBfNi03LTEtMS05NTU4_c31d8057-e712-41e2-9a8c-fb2cec4a248d">790,817</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acetadote</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0301ef84e6814fc1afd5bda0bb02be0c_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNy9mcmFnOmZhYjQ3ZTJiZjBhZTQ3MTc4YjdkOGZjNmZmMzExMzYwL3RhYmxlOjc1ZWU0YjlmNmU1YjRhYTZhZWEwZTM1ZGQzZmE4NTUwL3RhYmxlcmFuZ2U6NzVlZTRiOWY2ZTViNGFhNmFlYTBlMzVkZDNmYTg1NTBfNy0xLTEtMS05NTU4_be1eda32-358a-4637-973c-011b99e02535">368,733</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10d6fa0a80234f6fbdf7f486df4beed1_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNy9mcmFnOmZhYjQ3ZTJiZjBhZTQ3MTc4YjdkOGZjNmZmMzExMzYwL3RhYmxlOjc1ZWU0YjlmNmU1YjRhYTZhZWEwZTM1ZGQzZmE4NTUwL3RhYmxlcmFuZ2U6NzVlZTRiOWY2ZTViNGFhNmFlYTBlMzVkZDNmYTg1NTBfNy0zLTEtMS05NTU4_8332fef3-e4a9-44d8-ad11-1ef54e387727">218,462</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba2b0e3ce8dc46a892511cbd1f0b38cf_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNy9mcmFnOmZhYjQ3ZTJiZjBhZTQ3MTc4YjdkOGZjNmZmMzExMzYwL3RhYmxlOjc1ZWU0YjlmNmU1YjRhYTZhZWEwZTM1ZGQzZmE4NTUwL3RhYmxlcmFuZ2U6NzVlZTRiOWY2ZTViNGFhNmFlYTBlMzVkZDNmYTg1NTBfNy01LTEtMS05NTU4_40b59073-22bc-4624-b110-4dcc10f7f41d">638,704</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2075e961d64a4c4184f2117135160c9e_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNy9mcmFnOmZhYjQ3ZTJiZjBhZTQ3MTc4YjdkOGZjNmZmMzExMzYwL3RhYmxlOjc1ZWU0YjlmNmU1YjRhYTZhZWEwZTM1ZGQzZmE4NTUwL3RhYmxlcmFuZ2U6NzVlZTRiOWY2ZTViNGFhNmFlYTBlMzVkZDNmYTg1NTBfNy03LTEtMS05NTU4_f267816f-c3dc-49ff-b1c1-3e8d6c459f9a">1,527,173</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Omeclamox-Pak</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67bca755a168477fb7af6f54edd41311_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNy9mcmFnOmZhYjQ3ZTJiZjBhZTQ3MTc4YjdkOGZjNmZmMzExMzYwL3RhYmxlOjc1ZWU0YjlmNmU1YjRhYTZhZWEwZTM1ZGQzZmE4NTUwL3RhYmxlcmFuZ2U6NzVlZTRiOWY2ZTViNGFhNmFlYTBlMzVkZDNmYTg1NTBfOC0xLTEtMS05NTU4_45967abd-c12f-4676-9e2c-1e3bc25499eb">22,689</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i369b52ac1f754a4a9275b8917dc3bb9d_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNy9mcmFnOmZhYjQ3ZTJiZjBhZTQ3MTc4YjdkOGZjNmZmMzExMzYwL3RhYmxlOjc1ZWU0YjlmNmU1YjRhYTZhZWEwZTM1ZGQzZmE4NTUwL3RhYmxlcmFuZ2U6NzVlZTRiOWY2ZTViNGFhNmFlYTBlMzVkZDNmYTg1NTBfOC0zLTEtMS05NTU4_a978c324-8dac-4cc2-adbe-bf474d3b5e4d">516,066</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2206c2c78e3347cf9fd2bb7625961847_D20210101-20210930" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNy9mcmFnOmZhYjQ3ZTJiZjBhZTQ3MTc4YjdkOGZjNmZmMzExMzYwL3RhYmxlOjc1ZWU0YjlmNmU1YjRhYTZhZWEwZTM1ZGQzZmE4NTUwL3RhYmxlcmFuZ2U6NzVlZTRiOWY2ZTViNGFhNmFlYTBlMzVkZDNmYTg1NTBfOC01LTEtMS05NTU4_eed0fb91-555b-4171-94dc-a07afa3ca379">451,683</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64299c3a88d84d888de7a4e8264da6a1_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNy9mcmFnOmZhYjQ3ZTJiZjBhZTQ3MTc4YjdkOGZjNmZmMzExMzYwL3RhYmxlOjc1ZWU0YjlmNmU1YjRhYTZhZWEwZTM1ZGQzZmE4NTUwL3RhYmxlcmFuZ2U6NzVlZTRiOWY2ZTViNGFhNmFlYTBlMzVkZDNmYTg1NTBfOC03LTEtMS05NTU4_dacbc3b7-5e42-48e1-b1ab-ebba0035bb20">640,435</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RediTrex</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica59276837544b3e89921005c9db373f_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNy9mcmFnOmZhYjQ3ZTJiZjBhZTQ3MTc4YjdkOGZjNmZmMzExMzYwL3RhYmxlOjc1ZWU0YjlmNmU1YjRhYTZhZWEwZTM1ZGQzZmE4NTUwL3RhYmxlcmFuZ2U6NzVlZTRiOWY2ZTViNGFhNmFlYTBlMzVkZDNmYTg1NTBfOS0xLTEtMS05NTU4_2feb4625-fa02-4d92-9863-fbba89eb19a8">11,459</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d8203f933864c8d869320c4b6ce16d2_D20200701-20200930" decimals="0" format="ixt:fixed-zero" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNy9mcmFnOmZhYjQ3ZTJiZjBhZTQ3MTc4YjdkOGZjNmZmMzExMzYwL3RhYmxlOjc1ZWU0YjlmNmU1YjRhYTZhZWEwZTM1ZGQzZmE4NTUwL3RhYmxlcmFuZ2U6NzVlZTRiOWY2ZTViNGFhNmFlYTBlMzVkZDNmYTg1NTBfOS0zLTEtMS05NTU4_90e04b12-42da-42f9-ad8f-f506afdf6003">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if79d16ca01cf493f84c3a1bcbcf07c1d_D20210101-20210930" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNy9mcmFnOmZhYjQ3ZTJiZjBhZTQ3MTc4YjdkOGZjNmZmMzExMzYwL3RhYmxlOjc1ZWU0YjlmNmU1YjRhYTZhZWEwZTM1ZGQzZmE4NTUwL3RhYmxlcmFuZ2U6NzVlZTRiOWY2ZTViNGFhNmFlYTBlMzVkZDNmYTg1NTBfOS01LTEtMS05NTU4_1a62f132-804a-4a37-8260-0b224d0637d8">13,291</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3900d92fcea4358838f65d608ad8088_D20200101-20200930" decimals="0" format="ixt:fixed-zero" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNy9mcmFnOmZhYjQ3ZTJiZjBhZTQ3MTc4YjdkOGZjNmZmMzExMzYwL3RhYmxlOjc1ZWU0YjlmNmU1YjRhYTZhZWEwZTM1ZGQzZmE4NTUwL3RhYmxlcmFuZ2U6NzVlZTRiOWY2ZTViNGFhNmFlYTBlMzVkZDNmYTg1NTBfOS03LTEtMS05NTU4_4a6e8da3-122d-455f-b241-eaff3c73e5ab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenue</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d6efd6bd2c041769f9fbf0d1a3e5685_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNy9mcmFnOmZhYjQ3ZTJiZjBhZTQ3MTc4YjdkOGZjNmZmMzExMzYwL3RhYmxlOjc1ZWU0YjlmNmU1YjRhYTZhZWEwZTM1ZGQzZmE4NTUwL3RhYmxlcmFuZ2U6NzVlZTRiOWY2ZTViNGFhNmFlYTBlMzVkZDNmYTg1NTBfMTAtMS0xLTEtOTU1OA_fc5c19a4-ab1e-4bd2-b9cf-4004082f324d">178,886</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1571108ca25f4e179a9d14073629ae96_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNy9mcmFnOmZhYjQ3ZTJiZjBhZTQ3MTc4YjdkOGZjNmZmMzExMzYwL3RhYmxlOjc1ZWU0YjlmNmU1YjRhYTZhZWEwZTM1ZGQzZmE4NTUwL3RhYmxlcmFuZ2U6NzVlZTRiOWY2ZTViNGFhNmFlYTBlMzVkZDNmYTg1NTBfMTAtMy0xLTEtOTU1OA_79c09d38-4aa3-4992-8f2c-de5df9d3ffc3">265,047</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cf12a139ea74881b685de000f63434e_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNy9mcmFnOmZhYjQ3ZTJiZjBhZTQ3MTc4YjdkOGZjNmZmMzExMzYwL3RhYmxlOjc1ZWU0YjlmNmU1YjRhYTZhZWEwZTM1ZGQzZmE4NTUwL3RhYmxlcmFuZ2U6NzVlZTRiOWY2ZTViNGFhNmFlYTBlMzVkZDNmYTg1NTBfMTAtNS0xLTEtOTU1OA_558f692d-3089-4277-8ea5-29151151b7f3">809,429</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbd3b5d4865547179a8bf7fbe50a430c_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNy9mcmFnOmZhYjQ3ZTJiZjBhZTQ3MTc4YjdkOGZjNmZmMzExMzYwL3RhYmxlOjc1ZWU0YjlmNmU1YjRhYTZhZWEwZTM1ZGQzZmE4NTUwL3RhYmxlcmFuZ2U6NzVlZTRiOWY2ZTViNGFhNmFlYTBlMzVkZDNmYTg1NTBfMTAtNy0xLTEtOTU1OA_fac5f00f-89f8-4736-a229-122f163e68dc">1,605,570</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cfdffb6c8a4411a95e4596b0bd91b7c_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNy9mcmFnOmZhYjQ3ZTJiZjBhZTQ3MTc4YjdkOGZjNmZmMzExMzYwL3RhYmxlOjc1ZWU0YjlmNmU1YjRhYTZhZWEwZTM1ZGQzZmE4NTUwL3RhYmxlcmFuZ2U6NzVlZTRiOWY2ZTViNGFhNmFlYTBlMzVkZDNmYTg1NTBfMTEtMS0xLTEtOTU1OA_b6ac83bd-0458-4369-9a85-f470187e7f82">8,072,540</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2722c94900c4f68be9dd446637b8348_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNy9mcmFnOmZhYjQ3ZTJiZjBhZTQ3MTc4YjdkOGZjNmZmMzExMzYwL3RhYmxlOjc1ZWU0YjlmNmU1YjRhYTZhZWEwZTM1ZGQzZmE4NTUwL3RhYmxlcmFuZ2U6NzVlZTRiOWY2ZTViNGFhNmFlYTBlMzVkZDNmYTg1NTBfMTEtMy0xLTEtOTU1OA_19f350b8-1c28-49a7-bf10-2f42e94db843">9,250,689</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNy9mcmFnOmZhYjQ3ZTJiZjBhZTQ3MTc4YjdkOGZjNmZmMzExMzYwL3RhYmxlOjc1ZWU0YjlmNmU1YjRhYTZhZWEwZTM1ZGQzZmE4NTUwL3RhYmxlcmFuZ2U6NzVlZTRiOWY2ZTViNGFhNmFlYTBlMzVkZDNmYTg1NTBfMTEtNS0xLTEtOTU1OA_0094e52f-9c3c-4142-a794-86eaf014acc6">27,665,182</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNy9mcmFnOmZhYjQ3ZTJiZjBhZTQ3MTc4YjdkOGZjNmZmMzExMzYwL3RhYmxlOjc1ZWU0YjlmNmU1YjRhYTZhZWEwZTM1ZGQzZmE4NTUwL3RhYmxlcmFuZ2U6NzVlZTRiOWY2ZTViNGFhNmFlYTBlMzVkZDNmYTg1NTBfMTEtNy0xLTEtOTU1OA_bc779da5-b1ab-41b7-b6de-50878abe327d">27,179,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Omeclamox-Pak revenue for the first, second and third quarter of 2021 was the result of Cumberland currently being out of commercial inventory of this product.  The packager for our Omeclamox-Pak product encountered financial difficulties due to the impact of COVID-19.  They are under new management and are in the process of a reorganization. Discussions with the packager are ongoing.  In the third quarter of 2021, the amounts noted were normal adjustments by channel partners.  Net revenue was  negatively impacted by product returns during the periods. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Revenues</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has agreements with international partners for commercialization of the Company's products with associated payments included in other revenues. Those agreements provide that each of the partners are responsible for seeking regulatory approvals for the product, and following approval, each partner will be responsible for the ongoing distribution and sales in the respective international territories. The Company provides a dossier for product registration and maintains responsibility for the relevant intellectual property. Cumberland is typically entitled to receive a non-refundable, up-front payment at the time each agreement is executed as consideration for the product dossier and for the rights to the distinct intellectual property rights in the respective international territory. These agreements also typically provide for additional payments upon a partner&#8217;s achievement of a defined regulatory approval and sales milestones. The Company may also be entitled to receive royalties on future sales of the products and a transfer price on supplies.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractual payments associated with the partner&#8217;s achievement of regulatory approvals, sales milestones and royalties on future sales are recognized as revenue upon occurrence, or at such time that the Company has a high degree of confidence that the revenue would not be reversed in a subsequent period.</span></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i5701a740fb47444c934aaad5d65be907">Other revenues also include funding from federal grant programs including those secured by CET through the Small Business Administration as well as lease income generated by CET&#8217;s Life Sciences Center. The Life Sciences Center is a research center that provides scientists with access to flexible lab space and other resources to develop biomedical products. Grant revenue from these programs totaled approximately $<ix:nonFraction unitRef="usd" contextRef="i7beb09efdc954e3387adf27b4cc99538_D20210701-20210930" decimals="-4" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNy9mcmFnOmZhYjQ3ZTJiZjBhZTQ3MTc4YjdkOGZjNmZmMzExMzYwL3RleHRyZWdpb246ZmFiNDdlMmJmMGFlNDcxNzhiN2Q4ZmM2ZmYzMTEzNjBfMjUxNQ_e38456b6-7808-436d-8cb6-1af633fc202d">0.02</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i9c591eb458184e3baae21c9c26245264_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNy9mcmFnOmZhYjQ3ZTJiZjBhZTQ3MTc4YjdkOGZjNmZmMzExMzYwL3RleHRyZWdpb246ZmFiNDdlMmJmMGFlNDcxNzhiN2Q4ZmM2ZmYzMTEzNjBfMjUyMg_484f8b73-8f0c-41ba-ae46-dd3d1f82e948">0.1</ix:nonFraction> million for the three months ended September 30, 2021 and 2020</ix:continuation>, and $<ix:nonFraction unitRef="usd" contextRef="i32601382eaeb463ba862531b12def23c_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNy9mcmFnOmZhYjQ3ZTJiZjBhZTQ3MTc4YjdkOGZjNmZmMzExMzYwL3RleHRyZWdpb246ZmFiNDdlMmJmMGFlNDcxNzhiN2Q4ZmM2ZmYzMTEzNjBfMTA5OTUxMTYzMDM3MQ_e3a1a333-4731-4893-82f3-be05efc8581a">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i76c8b1e743d441a3ad6f81bc894366dd_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNy9mcmFnOmZhYjQ3ZTJiZjBhZTQ3MTc4YjdkOGZjNmZmMzExMzYwL3RleHRyZWdpb246ZmFiNDdlMmJmMGFlNDcxNzhiN2Q4ZmM2ZmYzMTEzNjBfMTA5OTUxMTYzMDM4NA_1550654f-ba5a-4006-b699-93b2f67aeb94">0.7</ix:nonFraction> million for the nine months ended September 30, 2021 and 2020, respectively.</span></div><div id="i8e8bdb91dc894234b9d87e17a18b54fd_40"></div><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(4) <ix:nonNumeric contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80MC9mcmFnOjQ4NGJiOWQyMmRlMzQ5OThiNGViZDhkOWVmNTk4Y2EwL3RleHRyZWdpb246NDg0YmI5ZDIyZGUzNDk5OGI0ZWJkOGQ5ZWY1OThjYTBfMjE2NQ_f9f5755f-ff5c-4d39-8f56-b7c16e52bfc6" continuedAt="i3306631bc5bd4bb788812298eb9003ee" escape="true">INVENTORIES</ix:nonNumeric></span></div><div style="text-align:justify"><ix:continuation id="i3306631bc5bd4bb788812298eb9003ee" continuedAt="i95e2d05784524731ad974b68cb95cc0a"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company works closely with third parties to manufacture and package finished goods for sale.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the arrangements with the manufacturer or packager, the Company will either take title to the finished goods at the time of shipment or at the time of arrival at the Company&#8217;s warehouses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company then holds such goods in inventory until distribution and sale. These finished goods inventories are stated at the lower of cost or net realizable value with cost determined using the first-in, first-out method.</span></ix:continuation></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><ix:continuation id="i95e2d05784524731ad974b68cb95cc0a"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continually evaluates inventory for potential losses due to excess, obsolete or slow-moving goods by comparing sales history and projections to the inventory on hand. When evidence indicates that the carrying value may not be recoverable, a charge is taken to reduce the inventory to its current net realizable value.  At September 30, 2021 and December 31, 2020, the Company had recognized and maintained cumulative net realizable value charges for potential obsolescence and discontinuance losses of approximately $<ix:nonFraction unitRef="usd" contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:InventoryValuationReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80MC9mcmFnOjQ4NGJiOWQyMmRlMzQ5OThiNGViZDhkOWVmNTk4Y2EwL3RleHRyZWdpb246NDg0YmI5ZDIyZGUzNDk5OGI0ZWJkOGQ5ZWY1OThjYTBfMTAzOA_fa408c45-20a7-4a34-a5ed-e06b546e3fa2">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="idb172cb6365440839665fd6ec022472c_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:InventoryValuationReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80MC9mcmFnOjQ4NGJiOWQyMmRlMzQ5OThiNGViZDhkOWVmNTk4Y2EwL3RleHRyZWdpb246NDg0YmI5ZDIyZGUzNDk5OGI0ZWJkOGQ5ZWY1OThjYTBfMTA0NQ_127d42c6-8d00-406d-9c1e-194145fbe302">0.2</ix:nonFraction> million, respectively.  </span></div><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is responsible for the purchase of the active pharmaceutical ingredient (&#8220;API&#8221;) for Kristalose and maintains the inventory at third-party packagers. As that API is consumed in production, the value of the API is transferred from raw materials to finished goods.  API for the Company's Vaprisol brand is also included in the raw materials inventory at September 30, 2021 and December 31, 2020.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consigned inventory represents Authorized Generic inventory stored with Perrigo until shipment.   </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the Vibativ acquisition, Cumberland acquired API and work in process inventories of $<ix:nonFraction unitRef="usd" contextRef="i890f0fecec4a4eb899b3171ad304df32_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:InventoryNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80MC9mcmFnOjQ4NGJiOWQyMmRlMzQ5OThiNGViZDhkOWVmNTk4Y2EwL3RleHRyZWdpb246NDg0YmI5ZDIyZGUzNDk5OGI0ZWJkOGQ5ZWY1OThjYTBfMTYzNA_d3cebd19-55eb-470b-bfec-5b243c70155c">15.6</ix:nonFraction> million that were all initially classified as non-current inventories at the date of acquisition.  At September 30, 2021 and December 31, 2020, total non-current inventory, including Vibativ and ifetroban, was $<ix:nonFraction unitRef="usd" contextRef="i5d7014c036534d1ab07ea1c7138ece74_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80MC9mcmFnOjQ4NGJiOWQyMmRlMzQ5OThiNGViZDhkOWVmNTk4Y2EwL3RleHRyZWdpb246NDg0YmI5ZDIyZGUzNDk5OGI0ZWJkOGQ5ZWY1OThjYTBfMTA5OTUxMTYyOTk0NQ_4ab0569c-c14e-4492-9b69-18f6d19f72c8">9.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i890f0fecec4a4eb899b3171ad304df32_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80MC9mcmFnOjQ4NGJiOWQyMmRlMzQ5OThiNGViZDhkOWVmNTk4Y2EwL3RleHRyZWdpb246NDg0YmI5ZDIyZGUzNDk5OGI0ZWJkOGQ5ZWY1OThjYTBfMTA5OTUxMTYyOTk1NA_874de2f0-2f47-4f8f-9188-998b4b02e087">11.7</ix:nonFraction> million, respectively. The Company had $<ix:nonFraction unitRef="usd" contextRef="i5d7014c036534d1ab07ea1c7138ece74_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:InventoryFinishedGoods" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80MC9mcmFnOjQ4NGJiOWQyMmRlMzQ5OThiNGViZDhkOWVmNTk4Y2EwL3RleHRyZWdpb246NDg0YmI5ZDIyZGUzNDk5OGI0ZWJkOGQ5ZWY1OThjYTBfMTg0OQ_2ed9aba5-9edc-492b-8cdc-1e3a690c1101">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i890f0fecec4a4eb899b3171ad304df32_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:InventoryFinishedGoods" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80MC9mcmFnOjQ4NGJiOWQyMmRlMzQ5OThiNGViZDhkOWVmNTk4Y2EwL3RleHRyZWdpb246NDg0YmI5ZDIyZGUzNDk5OGI0ZWJkOGQ5ZWY1OThjYTBfMTg1Ng_5eea83b7-3275-4299-b37f-fff4ff11c4fa">2.1</ix:nonFraction> million of Vibativ finished goods included in non-current inventory at September 30, 2021 and December 31, 2020, respectively.  The Company also has obtained $<ix:nonFraction unitRef="usd" contextRef="i2fb3c2ea35a146918884002eb0319cb9_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:InventoryNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80MC9mcmFnOjQ4NGJiOWQyMmRlMzQ5OThiNGViZDhkOWVmNTk4Y2EwL3RleHRyZWdpb246NDg0YmI5ZDIyZGUzNDk5OGI0ZWJkOGQ5ZWY1OThjYTBfMTk3OA_b3d9ee24-5d32-4dfb-8196-00c2d48a3aba"><ix:nonFraction unitRef="usd" contextRef="i85407d87b0cc40608f88c792ee3187bc_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:InventoryNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80MC9mcmFnOjQ4NGJiOWQyMmRlMzQ5OThiNGViZDhkOWVmNTk4Y2EwL3RleHRyZWdpb246NDg0YmI5ZDIyZGUzNDk5OGI0ZWJkOGQ5ZWY1OThjYTBfMTk3OA_f0bd8122-1a02-4f83-ac77-b4afdd80cd26">0.4</ix:nonFraction></ix:nonFraction>&#160;million of finished goods in non-current inventory for API related to its ifetroban clinical initiatives at September 30, 2021 and December 31, 2020. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><ix:nonNumeric contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80MC9mcmFnOjQ4NGJiOWQyMmRlMzQ5OThiNGViZDhkOWVmNTk4Y2EwL3RleHRyZWdpb246NDg0YmI5ZDIyZGUzNDk5OGI0ZWJkOGQ5ZWY1OThjYTBfMjE2Ng_6d16846e-cb06-47a4-8900-fd09792f72f2" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2021 and December 31, 2020 the Company's net inventories consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:57.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.430%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.681%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.431%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and work in process</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80MC9mcmFnOjQ4NGJiOWQyMmRlMzQ5OThiNGViZDhkOWVmNTk4Y2EwL3RhYmxlOjliYjQyZTEwYmNiNzRlNjU5OWM1MWRiOTZhNTIxMmQ0L3RhYmxlcmFuZ2U6OWJiNDJlMTBiY2I3NGU2NTk5YzUxZGI5NmE1MjEyZDRfMi0yLTEtMS05NTU4_52255f9a-f9a5-44b9-a075-0b0113724cc3">13,782,630</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb172cb6365440839665fd6ec022472c_I20201231" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80MC9mcmFnOjQ4NGJiOWQyMmRlMzQ5OThiNGViZDhkOWVmNTk4Y2EwL3RhYmxlOjliYjQyZTEwYmNiNzRlNjU5OWM1MWRiOTZhNTIxMmQ0L3RhYmxlcmFuZ2U6OWJiNDJlMTBiY2I3NGU2NTk5YzUxZGI5NmE1MjEyZDRfMi00LTEtMS05NTU4_082938bd-a415-430e-947d-2f7f7b9e89ca"><ix:nonFraction unitRef="usd" contextRef="idb172cb6365440839665fd6ec022472c_I20201231" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80MC9mcmFnOjQ4NGJiOWQyMmRlMzQ5OThiNGViZDhkOWVmNTk4Y2EwL3RhYmxlOjliYjQyZTEwYmNiNzRlNjU5OWM1MWRiOTZhNTIxMmQ0L3RhYmxlcmFuZ2U6OWJiNDJlMTBiY2I3NGU2NTk5YzUxZGI5NmE1MjEyZDRfMi00LTEtMS05NTU4_906783ec-d2af-4d21-9732-091f7e7352c1">16,223,162</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consigned inventory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80MC9mcmFnOjQ4NGJiOWQyMmRlMzQ5OThiNGViZDhkOWVmNTk4Y2EwL3RhYmxlOjliYjQyZTEwYmNiNzRlNjU5OWM1MWRiOTZhNTIxMmQ0L3RhYmxlcmFuZ2U6OWJiNDJlMTBiY2I3NGU2NTk5YzUxZGI5NmE1MjEyZDRfMy0yLTEtMS05NTU4_0d78d7c6-ff7a-4083-890b-d2408268a4cc">144,583</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb172cb6365440839665fd6ec022472c_I20201231" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80MC9mcmFnOjQ4NGJiOWQyMmRlMzQ5OThiNGViZDhkOWVmNTk4Y2EwL3RhYmxlOjliYjQyZTEwYmNiNzRlNjU5OWM1MWRiOTZhNTIxMmQ0L3RhYmxlcmFuZ2U6OWJiNDJlMTBiY2I3NGU2NTk5YzUxZGI5NmE1MjEyZDRfMy00LTEtMS05NTU4_51de1e87-e7ef-4372-b545-96bb85039d94"><ix:nonFraction unitRef="usd" contextRef="idb172cb6365440839665fd6ec022472c_I20201231" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80MC9mcmFnOjQ4NGJiOWQyMmRlMzQ5OThiNGViZDhkOWVmNTk4Y2EwL3RhYmxlOjliYjQyZTEwYmNiNzRlNjU5OWM1MWRiOTZhNTIxMmQ0L3RhYmxlcmFuZ2U6OWJiNDJlMTBiY2I3NGU2NTk5YzUxZGI5NmE1MjEyZDRfMy00LTEtMS05NTU4_564a45e6-e8c7-4bb4-8024-c3d990ff3216">128,005</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80MC9mcmFnOjQ4NGJiOWQyMmRlMzQ5OThiNGViZDhkOWVmNTk4Y2EwL3RhYmxlOjliYjQyZTEwYmNiNzRlNjU5OWM1MWRiOTZhNTIxMmQ0L3RhYmxlcmFuZ2U6OWJiNDJlMTBiY2I3NGU2NTk5YzUxZGI5NmE1MjEyZDRfNC0yLTEtMS05NTU4_7fdd8ea8-8cfa-497a-9b82-c7679d7efe1f">5,812,293</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb172cb6365440839665fd6ec022472c_I20201231" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80MC9mcmFnOjQ4NGJiOWQyMmRlMzQ5OThiNGViZDhkOWVmNTk4Y2EwL3RhYmxlOjliYjQyZTEwYmNiNzRlNjU5OWM1MWRiOTZhNTIxMmQ0L3RhYmxlcmFuZ2U6OWJiNDJlMTBiY2I3NGU2NTk5YzUxZGI5NmE1MjEyZDRfNC00LTEtMS05NTU4_2c8730e5-fba8-4578-a00b-a080bdb48a68"><ix:nonFraction unitRef="usd" contextRef="idb172cb6365440839665fd6ec022472c_I20201231" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80MC9mcmFnOjQ4NGJiOWQyMmRlMzQ5OThiNGViZDhkOWVmNTk4Y2EwL3RhYmxlOjliYjQyZTEwYmNiNzRlNjU5OWM1MWRiOTZhNTIxMmQ0L3RhYmxlcmFuZ2U6OWJiNDJlMTBiY2I3NGU2NTk5YzUxZGI5NmE1MjEyZDRfNC00LTEtMS05NTU4_a80a1ef7-1394-4e54-a23b-aadacdab3e00">5,943,732</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80MC9mcmFnOjQ4NGJiOWQyMmRlMzQ5OThiNGViZDhkOWVmNTk4Y2EwL3RhYmxlOjliYjQyZTEwYmNiNzRlNjU5OWM1MWRiOTZhNTIxMmQ0L3RhYmxlcmFuZ2U6OWJiNDJlMTBiY2I3NGU2NTk5YzUxZGI5NmE1MjEyZDRfNS0yLTEtMS05NTU4_663fc4b7-39e2-46f6-8f84-d3070a4649d0">19,739,506</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb172cb6365440839665fd6ec022472c_I20201231" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80MC9mcmFnOjQ4NGJiOWQyMmRlMzQ5OThiNGViZDhkOWVmNTk4Y2EwL3RhYmxlOjliYjQyZTEwYmNiNzRlNjU5OWM1MWRiOTZhNTIxMmQ0L3RhYmxlcmFuZ2U6OWJiNDJlMTBiY2I3NGU2NTk5YzUxZGI5NmE1MjEyZDRfNS00LTEtMS05NTU4_3adbed54-4d5e-4360-b3d0-2d5d89425076">22,294,899</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">less non-current inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80MC9mcmFnOjQ4NGJiOWQyMmRlMzQ5OThiNGViZDhkOWVmNTk4Y2EwL3RhYmxlOjliYjQyZTEwYmNiNzRlNjU5OWM1MWRiOTZhNTIxMmQ0L3RhYmxlcmFuZ2U6OWJiNDJlMTBiY2I3NGU2NTk5YzUxZGI5NmE1MjEyZDRfNi0yLTEtMS05NTU4_1b1b0259-48c4-487b-b5cf-3651f88ef0e4">9,476,737</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb172cb6365440839665fd6ec022472c_I20201231" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80MC9mcmFnOjQ4NGJiOWQyMmRlMzQ5OThiNGViZDhkOWVmNTk4Y2EwL3RhYmxlOjliYjQyZTEwYmNiNzRlNjU5OWM1MWRiOTZhNTIxMmQ0L3RhYmxlcmFuZ2U6OWJiNDJlMTBiY2I3NGU2NTk5YzUxZGI5NmE1MjEyZDRfNi00LTEtMS05NTU4_e8de5d18-2729-4ad0-b514-412dd551c3b3">11,656,742</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories classified as current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80MC9mcmFnOjQ4NGJiOWQyMmRlMzQ5OThiNGViZDhkOWVmNTk4Y2EwL3RhYmxlOjliYjQyZTEwYmNiNzRlNjU5OWM1MWRiOTZhNTIxMmQ0L3RhYmxlcmFuZ2U6OWJiNDJlMTBiY2I3NGU2NTk5YzUxZGI5NmE1MjEyZDRfNy0yLTEtMS05NTU4_ff6d04fc-6a3f-4dfd-bfc0-a29604136553">10,262,769</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb172cb6365440839665fd6ec022472c_I20201231" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80MC9mcmFnOjQ4NGJiOWQyMmRlMzQ5OThiNGViZDhkOWVmNTk4Y2EwL3RhYmxlOjliYjQyZTEwYmNiNzRlNjU5OWM1MWRiOTZhNTIxMmQ0L3RhYmxlcmFuZ2U6OWJiNDJlMTBiY2I3NGU2NTk5YzUxZGI5NmE1MjEyZDRfNy00LTEtMS05NTU4_bf4ebc7e-94e4-46f3-badc-bae858aaf1d8">10,638,157</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div id="i8e8bdb91dc894234b9d87e17a18b54fd_43"></div><div style="margin-top:8pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(5) <ix:nonNumeric contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80My9mcmFnOjk4YzU1ZDJjY2UxMDQ3MWZiZDE5MDI2MjgxM2JjZjRlL3RleHRyZWdpb246OThjNTVkMmNjZTEwNDcxZmJkMTkwMjYyODEzYmNmNGVfMTk3OA_fd0673d3-5ce2-4535-a5d9-f1aeac19171d" continuedAt="i7a75ec14f686481c9a6bbcb7a00999f6" escape="true">LEASES</ix:nonNumeric></span></div><ix:continuation id="i7a75ec14f686481c9a6bbcb7a00999f6"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland&#8217;s significant operating leases include the lease of approximately <ix:nonFraction unitRef="sqft" contextRef="ifd0c03fd249e4e64a76675f06c950be1_I20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AreaOfRealEstateProperty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80My9mcmFnOjk4YzU1ZDJjY2UxMDQ3MWZiZDE5MDI2MjgxM2JjZjRlL3RleHRyZWdpb246OThjNTVkMmNjZTEwNDcxZmJkMTkwMjYyODEzYmNmNGVfOTQ_ce1e9220-ef32-45fc-b7cf-e49ef510d576">25,500</ix:nonFraction> square feet of office space in Nashville, Tennessee for its corporate headquarters.  This lease currently expires in October 2022.  The Company's operating leases also include the lease of approximately <ix:nonFraction unitRef="sqft" contextRef="i67e0bde90efc45a7a814f5c68fb0096f_I20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AreaOfRealEstateProperty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80My9mcmFnOjk4YzU1ZDJjY2UxMDQ3MWZiZDE5MDI2MjgxM2JjZjRlL3RleHRyZWdpb246OThjNTVkMmNjZTEwNDcxZmJkMTkwMjYyODEzYmNmNGVfMzAw_eb4a03e1-b8ae-40a3-85ec-d570c5113a29">14,200</ix:nonFraction> square feet of wet laboratory and office space in Nashville, Tennessee by CET, our majority-owned subsidiary, where it operates the CET Life Sciences Center.  This lease currently expires in April 2023. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities are recorded as the present value of remaining lease payments not yet paid for the lease term discounted using the incremental borrowing rate associated with each lease. Operating lease right-of-use assets represent operating lease liabilities adjusted for lease incentives and initial direct costs. As Cumberland&#8217;s leases do not contain implicit borrowing rates, the incremental borrowing rates were calculated based on information available at January 1, 2019. Incremental borrowing rates reflect the Company&#8217;s estimated interest rates for collateralized borrowings over similar lease terms.  The weighted-average incremental borrowing rate used to discount the present value of the remaining lease payments is <ix:nonFraction unitRef="number" contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80My9mcmFnOjk4YzU1ZDJjY2UxMDQ3MWZiZDE5MDI2MjgxM2JjZjRlL3RleHRyZWdpb246OThjNTVkMmNjZTEwNDcxZmJkMTkwMjYyODEzYmNmNGVfMTI0OA_2d76f378-da2f-4b82-a7c3-0b40798dc339">7.42</ix:nonFraction>%. The weighted-average remaining lease term at September 30, 2021 is <ix:nonNumeric contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80My9mcmFnOjk4YzU1ZDJjY2UxMDQ3MWZiZDE5MDI2MjgxM2JjZjRlL3RleHRyZWdpb246OThjNTVkMmNjZTEwNDcxZmJkMTkwMjYyODEzYmNmNGVfMTMwMw_cb651dca-3da6-49f5-a8c2-d4898c278cdc">1.2</ix:nonNumeric> years.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lease Position</span></div><ix:nonNumeric contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" name="cpix:AssetsAndLiabilitiesLesseeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80My9mcmFnOjk4YzU1ZDJjY2UxMDQ3MWZiZDE5MDI2MjgxM2JjZjRlL3RleHRyZWdpb246OThjNTVkMmNjZTEwNDcxZmJkMTkwMjYyODEzYmNmNGVfMTk3OQ_ead4bb19-3276-4229-a689-d63dbe2018b6" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2021 and December 31, 2020 , the Company's lease assets and liabilities were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Right-of-Use Assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80My9mcmFnOjk4YzU1ZDJjY2UxMDQ3MWZiZDE5MDI2MjgxM2JjZjRlL3RhYmxlOjAxNTUzNDY5NGIyNjQwNWNiODgzODJlYmJmZTZlZGI3L3RhYmxlcmFuZ2U6MDE1NTM0Njk0YjI2NDA1Y2I4ODM4MmViYmZlNmVkYjdfMS0yLTEtMS05NTU4_03898100-deee-4659-8993-7d7a00a7e0cb">1,282,275</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb172cb6365440839665fd6ec022472c_I20201231" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80My9mcmFnOjk4YzU1ZDJjY2UxMDQ3MWZiZDE5MDI2MjgxM2JjZjRlL3RhYmxlOjAxNTUzNDY5NGIyNjQwNWNiODgzODJlYmJmZTZlZGI3L3RhYmxlcmFuZ2U6MDE1NTM0Njk0YjI2NDA1Y2I4ODM4MmViYmZlNmVkYjdfMS00LTEtMS05NTU4_37ee8221-5fb0-4021-9da4-00c47ee19b21">2,028,148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease Liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80My9mcmFnOjk4YzU1ZDJjY2UxMDQ3MWZiZDE5MDI2MjgxM2JjZjRlL3RhYmxlOjU2YWY4M2IxZDI4ZTQ0YmJhNzYyMjhiYjFmYzhhNGQ2L3RhYmxlcmFuZ2U6NTZhZjgzYjFkMjhlNDRiYmE3NjIyOGJiMWZjOGE0ZDZfMS0yLTEtMS05NTU4_2e433f39-34c1-4921-a1eb-2c04de7596b4">1,094,187</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb172cb6365440839665fd6ec022472c_I20201231" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80My9mcmFnOjk4YzU1ZDJjY2UxMDQ3MWZiZDE5MDI2MjgxM2JjZjRlL3RhYmxlOjU2YWY4M2IxZDI4ZTQ0YmJhNzYyMjhiYjFmYzhhNGQ2L3RhYmxlcmFuZ2U6NTZhZjgzYjFkMjhlNDRiYmE3NjIyOGJiMWZjOGE0ZDZfMS00LTEtMS05NTU4_5444717e-03d4-4aae-b706-03fe5eee67e4">1,016,779</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease noncurrent liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80My9mcmFnOjk4YzU1ZDJjY2UxMDQ3MWZiZDE5MDI2MjgxM2JjZjRlL3RhYmxlOjU2YWY4M2IxZDI4ZTQ0YmJhNzYyMjhiYjFmYzhhNGQ2L3RhYmxlcmFuZ2U6NTZhZjgzYjFkMjhlNDRiYmE3NjIyOGJiMWZjOGE0ZDZfMy0yLTEtMS05NTU4_ac21f239-47a9-4048-b4e5-fb6a30904c23">229,605</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb172cb6365440839665fd6ec022472c_I20201231" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80My9mcmFnOjk4YzU1ZDJjY2UxMDQ3MWZiZDE5MDI2MjgxM2JjZjRlL3RhYmxlOjU2YWY4M2IxZDI4ZTQ0YmJhNzYyMjhiYjFmYzhhNGQ2L3RhYmxlcmFuZ2U6NTZhZjgzYjFkMjhlNDRiYmE3NjIyOGJiMWZjOGE0ZDZfMy00LTEtMS05NTU4_33c77651-a926-495c-b2e7-10d92b256397">1,059,693</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930" decimals="0" format="ixt:num-dot-decimal" name="cpix:LeaseLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80My9mcmFnOjk4YzU1ZDJjY2UxMDQ3MWZiZDE5MDI2MjgxM2JjZjRlL3RhYmxlOjU2YWY4M2IxZDI4ZTQ0YmJhNzYyMjhiYjFmYzhhNGQ2L3RhYmxlcmFuZ2U6NTZhZjgzYjFkMjhlNDRiYmE3NjIyOGJiMWZjOGE0ZDZfNC0yLTEtMS05NTU4_94ab13ee-3a95-4fd1-9cd5-7e087475d25a">1,323,792</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb172cb6365440839665fd6ec022472c_I20201231" decimals="0" format="ixt:num-dot-decimal" name="cpix:LeaseLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80My9mcmFnOjk4YzU1ZDJjY2UxMDQ3MWZiZDE5MDI2MjgxM2JjZjRlL3RhYmxlOjU2YWY4M2IxZDI4ZTQ0YmJhNzYyMjhiYjFmYzhhNGQ2L3RhYmxlcmFuZ2U6NTZhZjgzYjFkMjhlNDRiYmE3NjIyOGJiMWZjOGE0ZDZfNC00LTEtMS05NTU4_44b00de6-b348-4030-8772-2419a4261b7f">2,076,472</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumulative future minimum sublease income under non-cancelable operating subleases totals approximately $<ix:nonFraction unitRef="usd" contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LessorOperatingLeasePaymentsToBeReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80My9mcmFnOjk4YzU1ZDJjY2UxMDQ3MWZiZDE5MDI2MjgxM2JjZjRlL3RleHRyZWdpb246OThjNTVkMmNjZTEwNDcxZmJkMTkwMjYyODEzYmNmNGVfMTUxMA_061ec92c-9b5e-42ad-91fe-7b3b9071690b">0.1</ix:nonFraction> million and will be paid through the leases ending in October 2022 and April 2023. Future minimum lease payments under non-cancelable operating leases (with initial or remaining lease terms in excess of one year) are as follows:</span></div></ix:nonNumeric><div style="margin-bottom:6pt"><ix:nonNumeric contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80My9mcmFnOjk4YzU1ZDJjY2UxMDQ3MWZiZDE5MDI2MjgxM2JjZjRlL3RleHRyZWdpb246OThjNTVkMmNjZTEwNDcxZmJkMTkwMjYyODEzYmNmNGVfMTk4MA_c7686295-6060-4904-bb25-afd463471d17" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.554%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Maturity of Lease Liabilities at September 30, 2021</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80My9mcmFnOjk4YzU1ZDJjY2UxMDQ3MWZiZDE5MDI2MjgxM2JjZjRlL3RhYmxlOjg1MDVmNWNhNDVjNDQ1ZjQ4NWMwZmRmYjdhNjZiOGNiL3RhYmxlcmFuZ2U6ODUwNWY1Y2E0NWM0NDVmNDg1YzBmZGZiN2E2NmI4Y2JfMS0yLTEtMS05NTU4_f3c41a5d-d2ee-41de-86f2-480ce6f9126d">295,038</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80My9mcmFnOjk4YzU1ZDJjY2UxMDQ3MWZiZDE5MDI2MjgxM2JjZjRlL3RhYmxlOjg1MDVmNWNhNDVjNDQ1ZjQ4NWMwZmRmYjdhNjZiOGNiL3RhYmxlcmFuZ2U6ODUwNWY1Y2E0NWM0NDVmNDg1YzBmZGZiN2E2NmI4Y2JfMi0yLTEtMS05NTU4_898b543d-e22f-4964-8f2e-6b6b708fff94">1,019,313</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80My9mcmFnOjk4YzU1ZDJjY2UxMDQ3MWZiZDE5MDI2MjgxM2JjZjRlL3RhYmxlOjg1MDVmNWNhNDVjNDQ1ZjQ4NWMwZmRmYjdhNjZiOGNiL3RhYmxlcmFuZ2U6ODUwNWY1Y2E0NWM0NDVmNDg1YzBmZGZiN2E2NmI4Y2JfMy0yLTEtMS05NTU4_3235881e-2165-4f96-974f-908e882f6170">92,478</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930" decimals="0" format="ixt:fixed-zero" name="cpix:LesseeOperatingLeaseLiabilityToBePaidAfterYearThree" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80My9mcmFnOjk4YzU1ZDJjY2UxMDQ3MWZiZDE5MDI2MjgxM2JjZjRlL3RhYmxlOjg1MDVmNWNhNDVjNDQ1ZjQ4NWMwZmRmYjdhNjZiOGNiL3RhYmxlcmFuZ2U6ODUwNWY1Y2E0NWM0NDVmNDg1YzBmZGZiN2E2NmI4Y2JfNC0yLTEtMS05NTU4_0d2752e6-9c2a-4171-a5f4-d3080d1919c7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80My9mcmFnOjk4YzU1ZDJjY2UxMDQ3MWZiZDE5MDI2MjgxM2JjZjRlL3RhYmxlOjg1MDVmNWNhNDVjNDQ1ZjQ4NWMwZmRmYjdhNjZiOGNiL3RhYmxlcmFuZ2U6ODUwNWY1Y2E0NWM0NDVmNDg1YzBmZGZiN2E2NmI4Y2JfNS0yLTEtMS05NTU4_720a3b83-65b9-4f98-a558-db21838b1bf5">1,406,829</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Interest</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80My9mcmFnOjk4YzU1ZDJjY2UxMDQ3MWZiZDE5MDI2MjgxM2JjZjRlL3RhYmxlOjg1MDVmNWNhNDVjNDQ1ZjQ4NWMwZmRmYjdhNjZiOGNiL3RhYmxlcmFuZ2U6ODUwNWY1Y2E0NWM0NDVmNDg1YzBmZGZiN2E2NmI4Y2JfNi0yLTEtMS05NTU4_5d86e601-a637-4f97-9354-bd1465bb2393">83,037</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80My9mcmFnOjk4YzU1ZDJjY2UxMDQ3MWZiZDE5MDI2MjgxM2JjZjRlL3RhYmxlOjg1MDVmNWNhNDVjNDQ1ZjQ4NWMwZmRmYjdhNjZiOGNiL3RhYmxlcmFuZ2U6ODUwNWY1Y2E0NWM0NDVmNDg1YzBmZGZiN2E2NmI4Y2JfNy0yLTEtMS05NTU4_a41f1f70-093b-4656-99e8-82c60f0845f6">1,323,792</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rent expense is recognized over the expected term of the lease, including renewal option periods, if applicable, on a straight-line basis as a component of general and administrative expense. <ix:nonNumeric contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" name="cpix:ScheduleofRentExpenseandSubleaseIncomeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80My9mcmFnOjk4YzU1ZDJjY2UxMDQ3MWZiZDE5MDI2MjgxM2JjZjRlL3RleHRyZWdpb246OThjNTVkMmNjZTEwNDcxZmJkMTkwMjYyODEzYmNmNGVfMTk4MQ_a07552b5-81b7-4736-b9cc-308851fc4066" continuedAt="iff5578d4c721480bb7b9b6c777ec77f4" escape="true">Rent expense and sublease income were as follows:</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:center"><ix:continuation id="iff5578d4c721480bb7b9b6c777ec77f4"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rent expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80My9mcmFnOjk4YzU1ZDJjY2UxMDQ3MWZiZDE5MDI2MjgxM2JjZjRlL3RhYmxlOjg1MmFmZTE3YmM5YzQzMjFhZjFkNWUzYmIzOTg5YmVlL3RhYmxlcmFuZ2U6ODUyYWZlMTdiYzljNDMyMWFmMWQ1ZTNiYjM5ODliZWVfMi0yLTEtMS05NTU4_8485dfdd-3037-4ef3-bba8-bb574a0c3dfe">910,975</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80My9mcmFnOjk4YzU1ZDJjY2UxMDQ3MWZiZDE5MDI2MjgxM2JjZjRlL3RhYmxlOjg1MmFmZTE3YmM5YzQzMjFhZjFkNWUzYmIzOTg5YmVlL3RhYmxlcmFuZ2U6ODUyYWZlMTdiYzljNDMyMWFmMWQ1ZTNiYjM5ODliZWVfMi00LTEtMS05NTU4_55241f73-83e6-4f7b-b9df-e0aabd4c2ecb">871,441</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SubleaseIncome" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80My9mcmFnOjk4YzU1ZDJjY2UxMDQ3MWZiZDE5MDI2MjgxM2JjZjRlL3RhYmxlOjg1MmFmZTE3YmM5YzQzMjFhZjFkNWUzYmIzOTg5YmVlL3RhYmxlcmFuZ2U6ODUyYWZlMTdiYzljNDMyMWFmMWQ1ZTNiYjM5ODliZWVfNC0yLTEtMS05NTU4_611e8fc1-afa2-4c67-8e71-090664bde8a9">526,868</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SubleaseIncome" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80My9mcmFnOjk4YzU1ZDJjY2UxMDQ3MWZiZDE5MDI2MjgxM2JjZjRlL3RhYmxlOjg1MmFmZTE3YmM5YzQzMjFhZjFkNWUzYmIzOTg5YmVlL3RhYmxlcmFuZ2U6ODUyYWZlMTdiYzljNDMyMWFmMWQ1ZTNiYjM5ODliZWVfNC00LTEtMS05NTU4_6a8b050e-4a9d-4c02-86b9-097156bea41c">491,391</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div id="i8e8bdb91dc894234b9d87e17a18b54fd_46"></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(6) <ix:nonNumeric contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80Ni9mcmFnOmJhNTMxMmRhZDAwNjQ3MmVhMDhkNmM5OTg4NDRkNWE5L3RleHRyZWdpb246YmE1MzEyZGFkMDA2NDcyZWEwOGQ2Yzk5ODg0NGQ1YTlfNzgyMQ_8c6372ab-cab9-431c-b845-9b651f6d39d6" continuedAt="i548a0f76fb814dfaa542b9683241a2d8" escape="true">SHAREHOLDERS&#8217; EQUITY AND DEBT</ix:nonNumeric></span></div><ix:continuation id="i548a0f76fb814dfaa542b9683241a2d8" continuedAt="iaf3051136c9041bab61fc8905e1d2ff5"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share repurchases</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland currently has a share repurchase program to repurchase up to $<ix:nonFraction unitRef="usd" contextRef="i6b60adc716c54226bd1b0d9f82b62a4c_I20100513" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80Ni9mcmFnOmJhNTMxMmRhZDAwNjQ3MmVhMDhkNmM5OTg4NDRkNWE5L3RleHRyZWdpb246YmE1MzEyZGFkMDA2NDcyZWEwOGQ2Yzk5ODg0NGQ1YTlfMTMz_ba3f64fa-d60b-4ff9-b70f-3cf9b8753d17">10</ix:nonFraction> million of its common stock pursuant to Rule 10b-18 of the Securities Exchange Act of 1934. In January 2019, the Company's Board of Directors established the current $<ix:nonFraction unitRef="usd" contextRef="i2d045c0da7504a3081ac01dc90d95aed_I20160131" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80Ni9mcmFnOmJhNTMxMmRhZDAwNjQ3MmVhMDhkNmM5OTg4NDRkNWE5L3RleHRyZWdpb246YmE1MzEyZGFkMDA2NDcyZWEwOGQ2Yzk5ODg0NGQ1YTlfMjk0_f678e4c8-a8f2-4356-884c-b1b9cb73b5be">10</ix:nonFraction> million repurchase program to replace the prior authorizations.  During the nine months ended September 30, 2021 and September 30, 2020, the Company repurchased <ix:nonFraction unitRef="shares" contextRef="i3eac19ab71204baa8b814cd80e8e55ab_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80Ni9mcmFnOmJhNTMxMmRhZDAwNjQ3MmVhMDhkNmM5OTg4NDRkNWE5L3RleHRyZWdpb246YmE1MzEyZGFkMDA2NDcyZWEwOGQ2Yzk5ODg0NGQ1YTlfNDAw_73296c1c-97fa-4ffc-a460-0f989cbe74bc">326,537</ix:nonFraction> shares and <ix:nonFraction unitRef="shares" contextRef="i545187d4937e41ec99d80966b809dd78_D20200101-20200930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80Ni9mcmFnOmJhNTMxMmRhZDAwNjQ3MmVhMDhkNmM5OTg4NDRkNWE5L3RleHRyZWdpb246YmE1MzEyZGFkMDA2NDcyZWEwOGQ2Yzk5ODg0NGQ1YTlfNDE0_15811f22-c3a0-4556-9429-51b724444c33">407,683</ix:nonFraction> shares, respectively, of common stock for approximately $<ix:nonFraction unitRef="usd" contextRef="i3eac19ab71204baa8b814cd80e8e55ab_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80Ni9mcmFnOmJhNTMxMmRhZDAwNjQ3MmVhMDhkNmM5OTg4NDRkNWE5L3RleHRyZWdpb246YmE1MzEyZGFkMDA2NDcyZWEwOGQ2Yzk5ODg0NGQ1YTlfNDcz_9cfa7502-61ab-47e0-b1ba-c818b27b3958">1.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i545187d4937e41ec99d80966b809dd78_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80Ni9mcmFnOmJhNTMxMmRhZDAwNjQ3MmVhMDhkNmM5OTg4NDRkNWE5L3RleHRyZWdpb246YmE1MzEyZGFkMDA2NDcyZWEwOGQ2Yzk5ODg0NGQ1YTlfNDgw_aa52c0d5-afa4-473f-8330-856d30d985a8">1.5</ix:nonFraction> million, respectively.  At September 30, 2021, approximately $<ix:nonFraction unitRef="usd" contextRef="i56aafc7718c145c8b150a8e54f33a5d2_I20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80Ni9mcmFnOmJhNTMxMmRhZDAwNjQ3MmVhMDhkNmM5OTg4NDRkNWE5L3RleHRyZWdpb246YmE1MzEyZGFkMDA2NDcyZWEwOGQ2Yzk5ODg0NGQ1YTlfMTA5OTUxMTYzNTY0NA_9dedc84d-11d4-4922-988e-3accc0a508b2">5.2</ix:nonFraction> million of common shares was left to repurchase under this program.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share purchases and sales</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the Company's March 2021 trading window, several members of Cumberland's Board of Directors entered into share purchase agreements of the Company's stock pursuant to Rule 10b-18 of the Securities Exchange Act of 1934. These purchases are designed to increase ownership in the Company by the members of the Board.  </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share Sales</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2017, Cumberland filed a Shelf Registration on Form S-3 with the SEC associated with the sale of up to $<ix:nonFraction unitRef="usd" contextRef="i4b890701c9304f309d867768f2a90a7b_D20171101-20171130" decimals="-6" format="ixt:num-dot-decimal" name="cpix:StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80Ni9mcmFnOmJhNTMxMmRhZDAwNjQ3MmVhMDhkNmM5OTg4NDRkNWE5L3RleHRyZWdpb246YmE1MzEyZGFkMDA2NDcyZWEwOGQ2Yzk5ODg0NGQ1YTlfMTA2OA_4c7de529-a4f9-4d42-8a56-f199caf47357">100</ix:nonFraction> million in corporate securities. The Shelf Registration was declared effective in January 2018. It also included an At the Market ("ATM") feature that allowed the Company to sell common shares at market prices, along with an agreement with B. Riley FBR Inc. to support such a placement of shares. The Company filed an updated Form S-3 with the SEC in December 2020, which was declared effective in January 2021. The Company does not currently have an ATM feature in place.  Cumberland plans to continue to evaluate the market for its common shares, and if favorable, will further evaluate whether or not to enter into an ATM feature through B. Riley FBR, Inc. that would allow the Company to issue shares of its common stock.  The Company did not issue any shares under an ATM during the nine months ended September 30, 2021 or September 30, 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Share Grants and Incentive Stock Options</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2021 and September 30, 2020, the Company issued <ix:nonFraction unitRef="shares" contextRef="ib59b0ab18a9847a48768cc76def0c5ce_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80Ni9mcmFnOmJhNTMxMmRhZDAwNjQ3MmVhMDhkNmM5OTg4NDRkNWE5L3RleHRyZWdpb246YmE1MzEyZGFkMDA2NDcyZWEwOGQ2Yzk5ODg0NGQ1YTlfMTk1NA_8bcf9678-fe0e-4b49-8484-996291110dd8">36,850</ix:nonFraction> shares and <ix:nonFraction unitRef="shares" contextRef="i7109429b4bb94262ab81694be586f875_D20200101-20200930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80Ni9mcmFnOmJhNTMxMmRhZDAwNjQ3MmVhMDhkNmM5OTg4NDRkNWE5L3RleHRyZWdpb246YmE1MzEyZGFkMDA2NDcyZWEwOGQ2Yzk5ODg0NGQ1YTlfMTk2OA_73466c05-659c-4db3-a7a7-b3179610f089">230,491</ix:nonFraction> shares of restricted stock to employees and directors, respectively. Restricted stock issued to employees generally cliff-vests on the fourth anniversary of the date of grant and for directors on the <ix:nonNumeric contextRef="i448fcba2bca740069897cf519754695f_D20210101-20210930" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80Ni9mcmFnOmJhNTMxMmRhZDAwNjQ3MmVhMDhkNmM5OTg4NDRkNWE5L3RleHRyZWdpb246YmE1MzEyZGFkMDA2NDcyZWEwOGQ2Yzk5ODg0NGQ1YTlfNzgxOQ_f7c65f96-fee8-4b79-8bad-5ee313476e7c">one-year</ix:nonNumeric> anniversary of the date of grant.  During the nine months ended September 30, 2021, the Company also issued <ix:nonFraction unitRef="shares" contextRef="ie91a73f23b39413ca4897ecef5e9c6b9_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80Ni9mcmFnOmJhNTMxMmRhZDAwNjQ3MmVhMDhkNmM5OTg4NDRkNWE5L3RleHRyZWdpb246YmE1MzEyZGFkMDA2NDcyZWEwOGQ2Yzk5ODg0NGQ1YTlfMjI1Mw_87214b05-94bd-4f76-ad7b-47faea6bfb95">174,800</ix:nonFraction> incentive stock options to employees that cliff-vest on the fourth anniversary of the date of grant, that are set to expire in March and May 2031. Stock compensation expense is presented as a component of general and administrative expense in the condensed consolidated statements of operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt Agreement</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 28, 2021, the Company and Pinnacle Bank entered into a Fourth Amendment to the Revolving Credit Note and Fifth Amendment ("Fifth Amendment") to the Revolving Credit Loan Agreement to renew the Revolving Credit Loan.  </span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The original Pinnacle Agreement was dated July 2017.  Beginning on August 14, 2018, and continuing until October 7, 2020, the Company and Pinnacle Bank entered into a series of amendments to extend and update the Revolving Credit Note and Revolving Credit Agreement. The most recent amendment dated October 28, 2021, extends the maturity date three years through October 1, 2024.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistent with prior Amendments, the Fifth Amendment provides for a principal balance available for borrowing of up to $<ix:nonFraction unitRef="usd" contextRef="ie35d5d79a31d4a97ada4dc5eb118435d_I20211028" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80Ni9mcmFnOmJhNTMxMmRhZDAwNjQ3MmVhMDhkNmM5OTg4NDRkNWE5L3RleHRyZWdpb246YmE1MzEyZGFkMDA2NDcyZWEwOGQ2Yzk5ODg0NGQ1YTlfMTY0OTI2NzQ1NTc1OQ_c3038ab4-da2d-4b1c-ade8-9e3ba9509a53">15</ix:nonFraction>&#160;million. The Company has the right to request an increase of up to an additional $<ix:nonFraction unitRef="usd" contextRef="ie35d5d79a31d4a97ada4dc5eb118435d_I20211028" decimals="INF" format="ixt:num-dot-decimal" name="cpix:LineOfCreditFacilityMaximumBorrowingCapacityIncreaseAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80Ni9mcmFnOmJhNTMxMmRhZDAwNjQ3MmVhMDhkNmM5OTg4NDRkNWE5L3RleHRyZWdpb246YmE1MzEyZGFkMDA2NDcyZWEwOGQ2Yzk5ODg0NGQ1YTlfMTY0OTI2NzQ1NTc0Nw_3185ae6b-bd95-4c31-b6d7-66ca9a182154">5</ix:nonFraction>&#160;million providing a maximum principal available of up to $<ix:nonFraction unitRef="usd" contextRef="ie35d5d79a31d4a97ada4dc5eb118435d_I20211028" decimals="INF" format="ixt:num-dot-decimal" name="cpix:LineOfCreditFacilityMaximumBorrowingCapacityTotalCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80Ni9mcmFnOmJhNTMxMmRhZDAwNjQ3MmVhMDhkNmM5OTg4NDRkNWE5L3RleHRyZWdpb246YmE1MzEyZGFkMDA2NDcyZWEwOGQ2Yzk5ODg0NGQ1YTlfMTY0OTI2NzQ1NTc3Mg_6a4b7f13-2028-469c-a8c0-781290ece41d">20</ix:nonFraction>&#160;million upon the satisfaction of certain conditions and with the approval of Pinnacle Bank. Also consistent with prior Amendments, the Company is required to maintain either a Funded Debt Ratio covenant or a Tangible Capital Ratio covenant. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest rate on the Pinnacle Agreement is based on LIBOR plus an interest rate spread. The pricing under the Fourth Amendment provides for an interest rate spread of <ix:nonFraction unitRef="number" contextRef="i433310853533429eb0bd0de42c8cb8c0_D20200814-20200814" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80Ni9mcmFnOmJhNTMxMmRhZDAwNjQ3MmVhMDhkNmM5OTg4NDRkNWE5L3RleHRyZWdpb246YmE1MzEyZGFkMDA2NDcyZWEwOGQ2Yzk5ODg0NGQ1YTlfNDU2MA_13cb7560-a435-4e9f-832d-f16665891a2a">1.75</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i7857ace04dd14acd90de8bfdfc44e2ad_D20200814-20200814" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80Ni9mcmFnOmJhNTMxMmRhZDAwNjQ3MmVhMDhkNmM5OTg4NDRkNWE5L3RleHRyZWdpb246YmE1MzEyZGFkMDA2NDcyZWEwOGQ2Yzk5ODg0NGQ1YTlfNDU2Ng_51026c1a-824b-4d54-9b38-9a25058087c7">2.75</ix:nonFraction>% above LIBOR with a minimum LIBOR of <ix:nonFraction unitRef="number" contextRef="ia066a8f68c2c4b2bb8d23f93616af446_D20200814-20200814" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80Ni9mcmFnOmJhNTMxMmRhZDAwNjQ3MmVhMDhkNmM5OTg4NDRkNWE5L3RleHRyZWdpb246YmE1MzEyZGFkMDA2NDcyZWEwOGQ2Yzk5ODg0NGQ1YTlfNDYwNQ_d013790f-b4c3-4b49-bdec-497369f4088d">0.90</ix:nonFraction>%. The applicable interest rate under the Pinnacle Agreement was <ix:nonFraction unitRef="number" contextRef="i0c79a3c371c84f16b64c6d20ef3f26bd_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80Ni9mcmFnOmJhNTMxMmRhZDAwNjQ3MmVhMDhkNmM5OTg4NDRkNWE5L3RleHRyZWdpb246YmE1MzEyZGFkMDA2NDcyZWEwOGQ2Yzk5ODg0NGQ1YTlfNDY3MQ_38ab6b8e-37e5-4857-b49c-d9fd0e5c894d">3.65</ix:nonFraction>% at September 30, 2021.  In addition, a fee of <ix:nonFraction unitRef="number" contextRef="i29e07103e7b54d69af01f448919f0979_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80Ni9mcmFnOmJhNTMxMmRhZDAwNjQ3MmVhMDhkNmM5OTg4NDRkNWE5L3RleHRyZWdpb246YmE1MzEyZGFkMDA2NDcyZWEwOGQ2Yzk5ODg0NGQ1YTlfNDcwNA_aba009bb-7351-49e8-bfa8-8c0659d42168">0.25</ix:nonFraction>% per year is charged on the unused line of credit.  Interest and the unused line fee are payable quarterly.  </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2021 and December 31, 2020, the Company had $<ix:nonFraction unitRef="usd" contextRef="i5729693e898c46118beacc910390b13c_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LongTermLineOfCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80Ni9mcmFnOmJhNTMxMmRhZDAwNjQ3MmVhMDhkNmM5OTg4NDRkNWE5L3RleHRyZWdpb246YmE1MzEyZGFkMDA2NDcyZWEwOGQ2Yzk5ODg0NGQ1YTlfMTA5OTUxMTYzNzEwNQ_ef5585e4-2165-4512-834e-32005b7646ea">15.0</ix:nonFraction> million in borrowings outstanding under its revolving credit facility.  The Company was in compliance with the Tangible Capital Ratio financial covenant as of September 30, 2021.  </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the line of credit are collateralized by substantially all of our assets.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><ix:continuation id="iaf3051136c9041bab61fc8905e1d2ff5" continuedAt="i8e003613d8ac49a9906ea5da8fcac683"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Paycheck Protection Program Loan</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 20, 2020, Cumberland received the funding of a loan from Pinnacle Bank in the amount of $<ix:nonFraction unitRef="usd" contextRef="i8f0ec15fc71f49aca22d17a26142e958_D20200420-20200420" decimals="0" format="ixt:num-dot-decimal" name="cpix:TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80Ni9mcmFnOmJhNTMxMmRhZDAwNjQ3MmVhMDhkNmM5OTg4NDRkNWE5L3RleHRyZWdpb246YmE1MzEyZGFkMDA2NDcyZWEwOGQ2Yzk5ODg0NGQ1YTlfNTA0OA_1da139ea-f756-4e1a-8669-4516fdb4a578">2,187,140</ix:nonFraction> pursuant to the Paycheck Protection Program (the &#8220;PPP&#8221;) under the Federal Coronavirus Aid, Relief, and Economic Security Act ("CARES Act"), which was enacted March 27, 2020.  The PPP is administered by the U.S. Small Business Administration ("SBA").</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the PPP requirements, loan funds were used to maintain payroll, continue group health care benefits, and pay for rent and utilities during the pandemic. We applied for this loan after carefully considering, with our bank, the eligibility criteria to participate in this program, and determining that Cumberland met those criteria. We evaluated and provided information on our payroll and other qualifying expenses to determine the amount of PPP funds to apply for. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the PPP, certain amounts of the loan may be forgiven if they are used for qualifying expenses as described in the CARES Act. Cumberland used the PPP loan funds for such qualifying expenses. Due to assistance from our PPP loan, the Company did not lay off or furlough any employees as a result of the COVID-19 pandemic.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland elected to account for the proceeds of the loan as a government grant under </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">International Accounting Standard 20 ("IAS 20"), Accounting for Government Grants and Disclosure of Government Assistance. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The permitted analogous use of  IAS 20 outlines a model for the accounting for government assistance, including forgivable loans. As a result, the Company recorded the $<ix:nonFraction unitRef="usd" contextRef="i8f0ec15fc71f49aca22d17a26142e958_D20200420-20200420" decimals="0" format="ixt:num-dot-decimal" name="cpix:TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80Ni9mcmFnOmJhNTMxMmRhZDAwNjQ3MmVhMDhkNmM5OTg4NDRkNWE5L3RleHRyZWdpb246YmE1MzEyZGFkMDA2NDcyZWEwOGQ2Yzk5ODg0NGQ1YTlfNjQ5NQ_d6a212ef-2458-4366-8178-0386b71460d8">2,187,140</ix:nonFraction> as a deferred income liability, which was included as a component of other current liabilities on the condensed consolidated balance sheet at December 31, 2020. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, Cumberland submitted a request for the loan&#8217;s forgiveness. On June 11, 2021, the Company received a formal notice from the SBA that the full amount of the loan was forgiven. The Company accounted for the forgiveness of the PPP loan under IAS 20 and recorded the $<ix:nonFraction unitRef="usd" contextRef="i8f0ec15fc71f49aca22d17a26142e958_D20200420-20200420" decimals="0" format="ixt:num-dot-decimal" name="cpix:TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80Ni9mcmFnOmJhNTMxMmRhZDAwNjQ3MmVhMDhkNmM5OTg4NDRkNWE5L3RleHRyZWdpb246YmE1MzEyZGFkMDA2NDcyZWEwOGQ2Yzk5ODg0NGQ1YTlfNjkzOQ_d6a212ef-2458-4366-8178-0386b71460d8">2,187,140</ix:nonFraction> as other income.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Joint Venture Agreement</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify"><ix:continuation id="i8e003613d8ac49a9906ea5da8fcac683" continuedAt="i892dbf29d9f948768157aed023cda2d9"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, Cumberland entered into an agreement with WinHealth Investment (Singapore) Ltd creating </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">WHC Biopharmaceuticals, Pte. Ltd</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i892dbf29d9f948768157aed023cda2d9">. The joint venture, as a limited liability company, will focus on acquiring, developing, registering, and commercializing development stage and commercial stage biopharmaceuticals for China, Hong Kong and other Asian markets.  The agreement provides for initial investment from WinHealth in the form of a $<ix:nonFraction unitRef="usd" contextRef="i7f3eb3a61d724b16837687fe50bb6592_I20200831" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80Ni9mcmFnOmJhNTMxMmRhZDAwNjQ3MmVhMDhkNmM5OTg4NDRkNWE5L3RleHRyZWdpb246YmE1MzEyZGFkMDA2NDcyZWEwOGQ2Yzk5ODg0NGQ1YTlfNzQyNQ_2a0d5b15-3e25-4b82-a442-1d8962f94a7e">0.2</ix:nonFraction>&#160;million equity contribution and an initial investment from Cumberland in the form of a $<ix:nonFraction unitRef="usd" contextRef="i10ede8aae6b6477eb6df1f13d1f8042a_I20200831" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80Ni9mcmFnOmJhNTMxMmRhZDAwNjQ3MmVhMDhkNmM5OTg4NDRkNWE5L3RleHRyZWdpb246YmE1MzEyZGFkMDA2NDcyZWEwOGQ2Yzk5ODg0NGQ1YTlfNzUwNw_027896fa-37c5-41ab-b0ed-802eeef9025a">0.2</ix:nonFraction>&#160;million convertible note, which was funded during the first quarter 2021. The joint venture will seek additional future capital from additional investors and has entered into exclusive option agreements to license intellectual property from both Cumberland Pharmaceuticals Inc. and Cumberland Emerging Technologies.</ix:continuation>   </span></div><div id="i8e8bdb91dc894234b9d87e17a18b54fd_49"></div><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(7) <ix:nonNumeric contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80OS9mcmFnOjIwYTZlMDE2NzJiODRhMmJhZDBlYmZiMmE5NTk4Mzc4L3RleHRyZWdpb246MjBhNmUwMTY3MmI4NGEyYmFkMGViZmIyYTk1OTgzNzhfNjM3_aefd03d2-4c10-402c-92ed-1179f799f7f2" continuedAt="ia95b10adf9794e929105da4b0863c77c" escape="true">INCOME TAXES</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia95b10adf9794e929105da4b0863c77c" continuedAt="i90e9d51a2ac343e1b947ad79267b26b7">As of September 30, 2021, the Company has approximately $<ix:nonFraction unitRef="usd" contextRef="ic25c3441c5a0477ebd8c769c3ea98555_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80OS9mcmFnOjIwYTZlMDE2NzJiODRhMmJhZDBlYmZiMmE5NTk4Mzc4L3RleHRyZWdpb246MjBhNmUwMTY3MmI4NGEyYmFkMGViZmIyYTk1OTgzNzhfNjI_3db0aa8b-d565-4727-8e06-406c0492c7df">56.5</ix:nonFraction> million in federal net operating loss carryforwards including approximately $<ix:nonFraction unitRef="usd" contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80OS9mcmFnOjIwYTZlMDE2NzJiODRhMmJhZDBlYmZiMmE5NTk4Mzc4L3RleHRyZWdpb246MjBhNmUwMTY3MmI4NGEyYmFkMGViZmIyYTk1OTgzNzhfMTMz_063fd305-aa10-4eb0-be91-efc233c5669c">44.1</ix:nonFraction> million of net operating loss carryforwards resulting from the exercise of nonqualified stock options. These have historically been used to significantly offset income tax obligations. The Company expects it will continue to pay minimal income taxes during 2021 and beyond, through the continued utilization of these net operating loss carryforwards, on any taxable income generated from our operations. </ix:continuation></span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i90e9d51a2ac343e1b947ad79267b26b7">The Company does not allocate any portion of its income tax expense (benefit) to discontinued operations.</ix:continuation> </span></div><div id="i8e8bdb91dc894234b9d87e17a18b54fd_52"></div><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(8) <ix:nonNumeric contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF81Mi9mcmFnOjkxYTMyNzA3NTQwODRlNzdiM2VmZjk4YWYwYTBhM2UxL3RleHRyZWdpb246OTFhMzI3MDc1NDA4NGU3N2IzZWZmOThhZjBhMGEzZTFfMTAyNg_6b27aa50-4a22-41f8-b835-f7fd88901262" continuedAt="ide6ffa74dfb64afcbffc2a1b31a77697" escape="true">COLLABORATIVE AGREEMENTS</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><ix:continuation id="ide6ffa74dfb64afcbffc2a1b31a77697"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland is a party to several collaborative arrangements with research institutions to identify and pursue promising pharmaceutical product candidates. The funding for these programs is primarily provided through Federal Small Business Administration (SBIR/STTR) and other grant awards. The Company has determined that these collaborative agreements, with the exception of the collaborative payment received related to RediTrex, do not meet the criteria for accounting under ASC Topic 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The agreements do not specifically designate each party&#8217;s rights and obligations to each other under the collaborative arrangements. Except for patent defense costs, expenses incurred by one party are not required to be reimbursed by the other party.  Expenses incurred under these collaborative agreements are included in research and development expenses and funding received from grants are recorded as net revenues in the condensed consolidated statements of operations.</span></ix:continuation></div><div id="i8e8bdb91dc894234b9d87e17a18b54fd_55"></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(9) <ix:nonNumeric contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF81NS9mcmFnOjNjYzExNDcyMGE1YTQxZDQ4MGQ2OWI3MjIxMWIwYTFiL3RleHRyZWdpb246M2NjMTE0NzIwYTVhNDFkNDgwZDY5YjcyMjExYjBhMWJfNTg0MA_f24487e3-6f8c-4766-8223-21f98b90ef57" continuedAt="i591f039c0ac14589a9653e5a508d99e2" escape="true">ADDITIONS AND RETURN OF PRODUCT RIGHTS</ix:nonNumeric></span></div><ix:continuation id="i591f039c0ac14589a9653e5a508d99e2" continuedAt="i01059d77cfe8401493354b0c8a1fe8d6"><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vibativ</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During November 2018, the Company closed on an agreement with Theravance Biopharma ("Theravance") to acquire the global responsibility for Vibativ including the marketing, distribution, manufacturing and regulatory activities associated with the brand.  Vibativ is a patented, Food and Drug Administration ("FDA") approved injectable anti-infective for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia and complicated skin and skin structure infections. It addresses a range of Gram-positive bacterial pathogens, including those that are considered difficult-to-treat and multidrug-resistant.  </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland has accounted for the transaction as a business combination in accordance with ASC 805 and the product sales are included in the results of operations subsequent to the acquisition date. The Company made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i57f795672a2a465e9209a65e0162f0b4_D20181101-20181130" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF81NS9mcmFnOjNjYzExNDcyMGE1YTQxZDQ4MGQ2OWI3MjIxMWIwYTFiL3RleHRyZWdpb246M2NjMTE0NzIwYTVhNDFkNDgwZDY5YjcyMjExYjBhMWJfOTcw_7e4f4541-973e-41c9-a96b-acda0c69e7b1">20.0</ix:nonFraction>&#160;million at the closing of the transaction and a $<ix:nonFraction unitRef="usd" contextRef="i57f795672a2a465e9209a65e0162f0b4_D20181101-20181130" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OtherPaymentsToAcquireBusinesses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF81NS9mcmFnOjNjYzExNDcyMGE1YTQxZDQ4MGQ2OWI3MjIxMWIwYTFiL3RleHRyZWdpb246M2NjMTE0NzIwYTVhNDFkNDgwZDY5YjcyMjExYjBhMWJfMTAxMw_c6c619d0-5a9a-4862-93bd-bac082c859aa">5.0</ix:nonFraction>&#160;million milestone payment in early April 2019. In addition, Cumberland has agreed to pay a royalty of up to <ix:nonFraction unitRef="number" contextRef="i57f795672a2a465e9209a65e0162f0b4_D20181101-20181130" decimals="2" name="cpix:TieredRoyaltyPaymentsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF81NS9mcmFnOjNjYzExNDcyMGE1YTQxZDQ4MGQ2OWI3MjIxMWIwYTFiL3RleHRyZWdpb246M2NjMTE0NzIwYTVhNDFkNDgwZDY5YjcyMjExYjBhMWJfMTExNg_5fd215db-2c05-4ad5-b957-dc4f3234dda8">20</ix:nonFraction>% of on-going net sales of the product.  The future royalty payments were required to be recognized at their acquisition-date fair value as a contingent consideration liability, as part of the contingent consideration transferred in the business combination. Cumberland prepared the valuations of the contingent consideration liability utilizing significant unobservable inputs.  As a result, the valuation is classified as Level 3 fair value measurement. </span></div><div style="margin-top:6pt;text-align:justify"><ix:nonNumeric contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF81NS9mcmFnOjNjYzExNDcyMGE1YTQxZDQ4MGQ2OWI3MjIxMWIwYTFiL3RleHRyZWdpb246M2NjMTE0NzIwYTVhNDFkNDgwZDY5YjcyMjExYjBhMWJfNTg0MQ_63cc83b6-0c84-430b-a0a8-ef4bdcc80d71" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the fair value of the contingent consideration liability that is remeasured on a recurring basis.  The contingent consideration earned and accrued in operating expenses is paid to Theravance quarterly.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.345%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i890f0fecec4a4eb899b3171ad304df32_I20201231" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF81NS9mcmFnOjNjYzExNDcyMGE1YTQxZDQ4MGQ2OWI3MjIxMWIwYTFiL3RhYmxlOjUyYWJlY2FiYzBlZDQ5NDRhNzg4YWIwNGI1NGUwMGFiL3RhYmxlcmFuZ2U6NTJhYmVjYWJjMGVkNDk0NGE3ODhhYjA0YjU0ZTAwYWJfOS0xLTEtMS05NTU4_c401baa2-4241-454e-a8e6-3422141524c2">8,200,552</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payment of royalty during the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id08ba9ef8fce4ef0b1aebddae7a819be_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRoyalties" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF81NS9mcmFnOjNjYzExNDcyMGE1YTQxZDQ4MGQ2OWI3MjIxMWIwYTFiL3RhYmxlOjUyYWJlY2FiYzBlZDQ5NDRhNzg4YWIwNGI1NGUwMGFiL3RhYmxlcmFuZ2U6NTJhYmVjYWJjMGVkNDk0NGE3ODhhYjA0YjU0ZTAwYWJfMTAtMS0xLTEtOTU1OA_71c82430-fe1a-4523-a9f5-0a188f0f9b04">1,792,573</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration included in operating expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id08ba9ef8fce4ef0b1aebddae7a819be_D20210101-20210930" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF81NS9mcmFnOjNjYzExNDcyMGE1YTQxZDQ4MGQ2OWI3MjIxMWIwYTFiL3RhYmxlOjUyYWJlY2FiYzBlZDQ5NDRhNzg4YWIwNGI1NGUwMGFiL3RhYmxlcmFuZ2U6NTJhYmVjYWJjMGVkNDk0NGE3ODhhYjA0YjU0ZTAwYWJfMTEtMS0xLTEtOTU1OA_8b843a3f-4aba-4599-b011-5eb43b1a13ae">632,646</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration earned and accrued in operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id08ba9ef8fce4ef0b1aebddae7a819be_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="cpix:BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF81NS9mcmFnOjNjYzExNDcyMGE1YTQxZDQ4MGQ2OWI3MjIxMWIwYTFiL3RhYmxlOjUyYWJlY2FiYzBlZDQ5NDRhNzg4YWIwNGI1NGUwMGFiL3RhYmxlcmFuZ2U6NTJhYmVjYWJjMGVkNDk0NGE3ODhhYjA0YjU0ZTAwYWJfMTItMS0xLTEtOTU1OA_65741f33-d908-4e37-a326-ec83e12aa2ec">1,134,333</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2021</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d7014c036534d1ab07ea1c7138ece74_I20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF81NS9mcmFnOjNjYzExNDcyMGE1YTQxZDQ4MGQ2OWI3MjIxMWIwYTFiL3RhYmxlOjUyYWJlY2FiYzBlZDQ5NDRhNzg4YWIwNGI1NGUwMGFiL3RhYmxlcmFuZ2U6NTJhYmVjYWJjMGVkNDk0NGE3ODhhYjA0YjU0ZTAwYWJfMTMtMS0xLTEtOTU1OA_ce52186d-c37c-470b-ba63-7b153ebc19ac">6,909,666</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr></table></ix:nonNumeric></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contingent consideration liability of $<ix:nonFraction unitRef="usd" contextRef="i5d7014c036534d1ab07ea1c7138ece74_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF81NS9mcmFnOjNjYzExNDcyMGE1YTQxZDQ4MGQ2OWI3MjIxMWIwYTFiL3RleHRyZWdpb246M2NjMTE0NzIwYTVhNDFkNDgwZDY5YjcyMjExYjBhMWJfMTg2Mw_58008847-255d-4a78-a316-fa566ad4af7d">6.9</ix:nonFraction>&#160;million was classified as other current liabilities of $<ix:nonFraction unitRef="usd" contextRef="i0463cd68913447b0aec736a9a21b1701_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF81NS9mcmFnOjNjYzExNDcyMGE1YTQxZDQ4MGQ2OWI3MjIxMWIwYTFiL3RleHRyZWdpb246M2NjMTE0NzIwYTVhNDFkNDgwZDY5YjcyMjExYjBhMWJfMTkxMw_e02dcf8f-caeb-4136-9ec8-9659b0b2055f">2.6</ix:nonFraction>&#160;million and other long-term liabilities of $<ix:nonFraction unitRef="usd" contextRef="icf562c30b2d9493a84db87baebada783_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF81NS9mcmFnOjNjYzExNDcyMGE1YTQxZDQ4MGQ2OWI3MjIxMWIwYTFiL3RleHRyZWdpb246M2NjMTE0NzIwYTVhNDFkNDgwZDY5YjcyMjExYjBhMWJfMTk1MQ_c38a5770-195c-4619-a4be-92536441a70c">4.3</ix:nonFraction>&#160;million on the condensed consolidated balance sheet as of September 30, 2021.  </span></div></ix:continuation><div style="margin-top:8pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><ix:continuation id="i01059d77cfe8401493354b0c8a1fe8d6"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RediTrex</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2016, the Company announced an agreement with the Nordic Group B.V. ("Nordic") to acquire the exclusive U.S. rights to Nordic&#8217;s injectable methotrexate product line designed for the treatment of active rheumatoid arthritis, juvenile idiopathic arthritis, severe psoriatic arthritis, and severe disabling psoriasis. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As consideration for the license Cumberland paid a deposit of $<ix:nonFraction unitRef="usd" contextRef="if7d1c3dbcd4b4c6eabe94af067f29d41_D20161101-20161130" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF81NS9mcmFnOjNjYzExNDcyMGE1YTQxZDQ4MGQ2OWI3MjIxMWIwYTFiL3RleHRyZWdpb246M2NjMTE0NzIwYTVhNDFkNDgwZDY5YjcyMjExYjBhMWJfMjQwOQ_8fb3a4e5-219e-441b-96b5-99345081c6ac">100,000</ix:nonFraction> at closing.  The Company provided $<ix:nonFraction unitRef="usd" contextRef="if7d1c3dbcd4b4c6eabe94af067f29d41_D20161101-20161130" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF81NS9mcmFnOjNjYzExNDcyMGE1YTQxZDQ4MGQ2OWI3MjIxMWIwYTFiL3RleHRyZWdpb246M2NjMTE0NzIwYTVhNDFkNDgwZDY5YjcyMjExYjBhMWJfMjQ0Ng_6a25e1fb-d000-4426-9285-cd2deeea1d71">0.9</ix:nonFraction>&#160;million in consideration through a grant of <ix:nonFraction unitRef="shares" contextRef="ibb1ab73ec0354946b843823c167cac73_D20161101-20161130" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF81NS9mcmFnOjNjYzExNDcyMGE1YTQxZDQ4MGQ2OWI3MjIxMWIwYTFiL3RleHRyZWdpb246M2NjMTE0NzIwYTVhNDFkNDgwZDY5YjcyMjExYjBhMWJfMjQ4NQ_376179ad-b353-4db2-a58c-98ba484c18c2">180,000</ix:nonFraction> restricted shares of Cumberland common stock to be vested upon the FDA approval of the first Nordic product. Cumberland also agreed to provide Nordic a series of payments tied to the products&#8217; FDA approval, launch and achievement of certain sales milestones. Under the terms of the agreement, Cumberland is responsible for the product registration and commercialization in the U.S. Nordic is responsible for product manufacturing and supply.  </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 27, 2019, Cumberland received FDA approval for the first Nordic injectable product and authorization to market them under the RediTrex brand name.  The <ix:nonFraction unitRef="shares" contextRef="ibb1ab73ec0354946b843823c167cac73_D20161101-20161130" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF81NS9mcmFnOjNjYzExNDcyMGE1YTQxZDQ4MGQ2OWI3MjIxMWIwYTFiL3RleHRyZWdpb246M2NjMTE0NzIwYTVhNDFkNDgwZDY5YjcyMjExYjBhMWJfMzA5Ng_170486f0-3188-4903-b50d-941bb79e6dd6">180,000</ix:nonFraction> shares of restricted Cumberland common stock previously provided to Nordic vested upon approval and were valued at $<ix:nonFraction unitRef="usd" contextRef="i9fbce1ec780d49a78a390da0ae5f4c6c_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF81NS9mcmFnOjNjYzExNDcyMGE1YTQxZDQ4MGQ2OWI3MjIxMWIwYTFiL3RleHRyZWdpb246M2NjMTE0NzIwYTVhNDFkNDgwZDY5YjcyMjExYjBhMWJfMzIxNA_9bd7c5af-5bc2-4dd2-b7ba-9cb4a7cebe1a">0.9</ix:nonFraction>&#160;million on the vesting date. The FDA approval also resulted in a $<ix:nonFraction unitRef="usd" contextRef="i0a2ac195a36045adacdf507f9366ba39_I20200731" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF81NS9mcmFnOjNjYzExNDcyMGE1YTQxZDQ4MGQ2OWI3MjIxMWIwYTFiL3RleHRyZWdpb246M2NjMTE0NzIwYTVhNDFkNDgwZDY5YjcyMjExYjBhMWJfMzI3NA_994c2cb0-774d-4e92-b009-1c78a3f5f6d5">1.0</ix:nonFraction>&#160;million milestone payment due to Nordic.  During December 2020, Cumberland introduced RediTrex and the launch that will take place in late 2021 will result in a $<ix:nonFraction unitRef="usd" contextRef="i0899d206bf0144cb8f97b035bbc59bdc_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF81NS9mcmFnOjNjYzExNDcyMGE1YTQxZDQ4MGQ2OWI3MjIxMWIwYTFiL3RleHRyZWdpb246M2NjMTE0NzIwYTVhNDFkNDgwZDY5YjcyMjExYjBhMWJfMzQzMA_3bf9017b-3a43-424d-b1de-5b5a7f6c6e64">1.0</ix:nonFraction>&#160;million milestone payment due to Nordic.  This milestone payment will be paid during 2022 and is included as a current liability at September 30, 2021.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland has approximately $<ix:nonFraction unitRef="usd" contextRef="iab3199a2232b4c38950a9c717c8b9171_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF81NS9mcmFnOjNjYzExNDcyMGE1YTQxZDQ4MGQ2OWI3MjIxMWIwYTFiL3RleHRyZWdpb246M2NjMTE0NzIwYTVhNDFkNDgwZDY5YjcyMjExYjBhMWJfMzU5Ng_991683b6-233c-4928-af4f-17b9d058d786">2.7</ix:nonFraction>&#160;million in net intangible assets related to RediTrex at September 30, 2021.  </span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ethyol and Totect </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, Cumberland entered into an agreement with Clinigen for the rights and responsibilities associated with the commercialization of Ethyol in the United States.  In 2017, the Company entered into another agreement with Clinigen for the rights and responsibilities associated with the commercialization of Totect in the United States.  </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Early in 2019, Cumberland announced a strategic review of the Company's brands, capabilities, and international partners. This review followed an accelerated business development initiative, which resulted in a series of transactions. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During May 2019, Cumberland entered into the Dissolution Agreement with Clinigen in which the Company returned the exclusive rights to commercialize Ethyol and Totect</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the United States to Clinigen. Under the final terms of the Dissolution Agreement, Cumberland was no longer responsible for the distribution, marketing and promotion of either Ethyol or Totect or any competing products after December 31, 2019.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In exchange for the return of these product license rights and the non-compete provisions of the Dissolution Agreement, Cumberland is receiving $<ix:nonFraction unitRef="usd" contextRef="i3c783d360e1948c18a55f375b9840bca_D20191001-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromSaleOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF81NS9mcmFnOjNjYzExNDcyMGE1YTQxZDQ4MGQ2OWI3MjIxMWIwYTFiL3RleHRyZWdpb246M2NjMTE0NzIwYTVhNDFkNDgwZDY5YjcyMjExYjBhMWJfNDgwOA_ebb4201e-3fc7-4588-94e9-1841362a7215">5</ix:nonFraction>&#160;million in financial consideration paid in quarterly installments over the two-years following the transition date. Cumberland recorded the first four quarterly installments totaling $<ix:nonFraction unitRef="usd" contextRef="i54eac56082574a4c986a915dc06c3af5_D20210101-20210630" decimals="-5" format="ixt:num-dot-decimal" name="cpix:ProceedsFromSaleOfIntangibleAssetsInstallmentPayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF81NS9mcmFnOjNjYzExNDcyMGE1YTQxZDQ4MGQ2OWI3MjIxMWIwYTFiL3RleHRyZWdpb246M2NjMTE0NzIwYTVhNDFkNDgwZDY5YjcyMjExYjBhMWJfNDk4Ng_6c047bc2-19b9-467a-82a2-09a37b7365dd">3.0</ix:nonFraction> million during 2020 and the next three installments totaling $<ix:nonFraction unitRef="usd" contextRef="i45bdfab35dd74d60ac86fc023b908b73_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF81NS9mcmFnOjNjYzExNDcyMGE1YTQxZDQ4MGQ2OWI3MjIxMWIwYTFiL3RleHRyZWdpb246M2NjMTE0NzIwYTVhNDFkNDgwZDY5YjcyMjExYjBhMWJfNTA0MA_8a646cfd-70b9-46ad-a20c-f4a22a2f4631">1.5</ix:nonFraction> million during the nine months ended September 30, 2021, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as discontinued operations.  The Company will record the last remaining quarterly installment in the fourth quarter of 2021.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exit from Ethyol and Totect meets the accounting criteria to be reported as discontinued operations. December 31, 2019, as the transition date, was the final day Cumberland was responsible for the products. Cumberland was responsible for the products through December 31, 2019 and beginning on January 1, 2020, the products' rights transitioned back to Clinigen. As a result, January 1, 2020, was the first day of discontinued operations for the Ethyol and Totect products.</span></div><ix:nonNumeric contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930" name="us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF81NS9mcmFnOjNjYzExNDcyMGE1YTQxZDQ4MGQ2OWI3MjIxMWIwYTFiL3RleHRyZWdpb246M2NjMTE0NzIwYTVhNDFkNDgwZDY5YjcyMjExYjBhMWJfNTg0Mg_3c327a04-eb39-4424-bbb1-9960eed76f96" escape="true"><div style="margin-top:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The dissolution payments from Clinigen are reflected as revenue from discontinued operations.  The Company does not </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">incur expenses associated with these payments from Clinigen. </span></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.590%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.499%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three months ended September 30,</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb58760ea84940319b35492cd1910735_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF81NS9mcmFnOjNjYzExNDcyMGE1YTQxZDQ4MGQ2OWI3MjIxMWIwYTFiL3RhYmxlOjI5OWQ0MTYwMGM5YTQ3MDlhNjZiNjg3MzFkMGNlNjQ0L3RhYmxlcmFuZ2U6Mjk5ZDQxNjAwYzlhNDcwOWE2NmI2ODczMWQwY2U2NDRfMy0yLTEtMS05NTU4_86849bd9-9c34-42dc-a4b6-2061e77af27b">496,787</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca7f9fa06d14f85a52cbd81ac170d2c_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF81NS9mcmFnOjNjYzExNDcyMGE1YTQxZDQ4MGQ2OWI3MjIxMWIwYTFiL3RhYmxlOjI5OWQ0MTYwMGM5YTQ3MDlhNjZiNjg3MzFkMGNlNjQ0L3RhYmxlcmFuZ2U6Mjk5ZDQxNjAwYzlhNDcwOWE2NmI2ODczMWQwY2U2NDRfMy00LTEtMS05NTU4_0fe8db84-b272-4c9f-a304-4c34cd7b14a3">777,916</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45bdfab35dd74d60ac86fc023b908b73_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF81NS9mcmFnOjNjYzExNDcyMGE1YTQxZDQ4MGQ2OWI3MjIxMWIwYTFiL3RhYmxlOjI5OWQ0MTYwMGM5YTQ3MDlhNjZiNjg3MzFkMGNlNjQ0L3RhYmxlcmFuZ2U6Mjk5ZDQxNjAwYzlhNDcwOWE2NmI2ODczMWQwY2U2NDRfMy01LTEtMS05NTU4_1acd7b61-10d3-4d57-a3bb-db27abac79f0">1,491,004</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8c8802e62b74a919450a1c6017bba7e_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF81NS9mcmFnOjNjYzExNDcyMGE1YTQxZDQ4MGQ2OWI3MjIxMWIwYTFiL3RhYmxlOjI5OWQ0MTYwMGM5YTQ3MDlhNjZiNjg3MzFkMGNlNjQ0L3RhYmxlcmFuZ2U6Mjk5ZDQxNjAwYzlhNDcwOWE2NmI2ODczMWQwY2U2NDRfMy03LTEtMS05NTU4_841b8fa5-722e-49de-805f-6e1ba99049bf">2,334,811</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs of products sold</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb58760ea84940319b35492cd1910735_D20210701-20210930" decimals="0" format="ixt:fixed-zero" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF81NS9mcmFnOjNjYzExNDcyMGE1YTQxZDQ4MGQ2OWI3MjIxMWIwYTFiL3RhYmxlOjI5OWQ0MTYwMGM5YTQ3MDlhNjZiNjg3MzFkMGNlNjQ0L3RhYmxlcmFuZ2U6Mjk5ZDQxNjAwYzlhNDcwOWE2NmI2ODczMWQwY2U2NDRfNC0yLTEtMS05NTU4_b370ba5e-0f89-4b8c-8e72-b4654071f9b9">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca7f9fa06d14f85a52cbd81ac170d2c_D20200701-20200930" decimals="0" format="ixt:fixed-zero" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF81NS9mcmFnOjNjYzExNDcyMGE1YTQxZDQ4MGQ2OWI3MjIxMWIwYTFiL3RhYmxlOjI5OWQ0MTYwMGM5YTQ3MDlhNjZiNjg3MzFkMGNlNjQ0L3RhYmxlcmFuZ2U6Mjk5ZDQxNjAwYzlhNDcwOWE2NmI2ODczMWQwY2U2NDRfNC00LTEtMS05NTU4_4f087064-ec6f-423b-b86f-0953ea7019c3">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45bdfab35dd74d60ac86fc023b908b73_D20210101-20210930" decimals="0" format="ixt:fixed-zero" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF81NS9mcmFnOjNjYzExNDcyMGE1YTQxZDQ4MGQ2OWI3MjIxMWIwYTFiL3RhYmxlOjI5OWQ0MTYwMGM5YTQ3MDlhNjZiNjg3MzFkMGNlNjQ0L3RhYmxlcmFuZ2U6Mjk5ZDQxNjAwYzlhNDcwOWE2NmI2ODczMWQwY2U2NDRfNC01LTEtMS05NTU4_155b8afc-8ab1-457d-92e1-03a857618626">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8c8802e62b74a919450a1c6017bba7e_D20200101-20200930" decimals="0" format="ixt:fixed-zero" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF81NS9mcmFnOjNjYzExNDcyMGE1YTQxZDQ4MGQ2OWI3MjIxMWIwYTFiL3RhYmxlOjI5OWQ0MTYwMGM5YTQ3MDlhNjZiNjg3MzFkMGNlNjQ0L3RhYmxlcmFuZ2U6Mjk5ZDQxNjAwYzlhNDcwOWE2NmI2ODczMWQwY2U2NDRfNC03LTEtMS05NTU4_c03493ea-11f9-4d62-83fb-b13be2887ec5">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, Marketing and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb58760ea84940319b35492cd1910735_D20210701-20210930" decimals="0" format="ixt:fixed-zero" name="us-gaap:SellingAndMarketingExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF81NS9mcmFnOjNjYzExNDcyMGE1YTQxZDQ4MGQ2OWI3MjIxMWIwYTFiL3RhYmxlOjI5OWQ0MTYwMGM5YTQ3MDlhNjZiNjg3MzFkMGNlNjQ0L3RhYmxlcmFuZ2U6Mjk5ZDQxNjAwYzlhNDcwOWE2NmI2ODczMWQwY2U2NDRfNS0yLTEtMS05NTU4_7f78e0b8-872e-4890-b770-0a08422c7bcd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca7f9fa06d14f85a52cbd81ac170d2c_D20200701-20200930" decimals="0" format="ixt:fixed-zero" name="us-gaap:SellingAndMarketingExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF81NS9mcmFnOjNjYzExNDcyMGE1YTQxZDQ4MGQ2OWI3MjIxMWIwYTFiL3RhYmxlOjI5OWQ0MTYwMGM5YTQ3MDlhNjZiNjg3MzFkMGNlNjQ0L3RhYmxlcmFuZ2U6Mjk5ZDQxNjAwYzlhNDcwOWE2NmI2ODczMWQwY2U2NDRfNS00LTEtMS05NTU4_11ac3d95-7e50-479f-ab22-21b3694b4b6a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45bdfab35dd74d60ac86fc023b908b73_D20210101-20210930" decimals="0" format="ixt:fixed-zero" name="us-gaap:SellingAndMarketingExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF81NS9mcmFnOjNjYzExNDcyMGE1YTQxZDQ4MGQ2OWI3MjIxMWIwYTFiL3RhYmxlOjI5OWQ0MTYwMGM5YTQ3MDlhNjZiNjg3MzFkMGNlNjQ0L3RhYmxlcmFuZ2U6Mjk5ZDQxNjAwYzlhNDcwOWE2NmI2ODczMWQwY2U2NDRfNS01LTEtMS05NTU4_34178999-de8e-4b4e-ac90-824fd32e5090">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8c8802e62b74a919450a1c6017bba7e_D20200101-20200930" decimals="0" format="ixt:fixed-zero" name="us-gaap:SellingAndMarketingExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF81NS9mcmFnOjNjYzExNDcyMGE1YTQxZDQ4MGQ2OWI3MjIxMWIwYTFiL3RhYmxlOjI5OWQ0MTYwMGM5YTQ3MDlhNjZiNjg3MzFkMGNlNjQ0L3RhYmxlcmFuZ2U6Mjk5ZDQxNjAwYzlhNDcwOWE2NmI2ODczMWQwY2U2NDRfNS03LTEtMS05NTU4_edecd593-95d2-431b-81e9-20a787b68ed8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb58760ea84940319b35492cd1910735_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF81NS9mcmFnOjNjYzExNDcyMGE1YTQxZDQ4MGQ2OWI3MjIxMWIwYTFiL3RhYmxlOjI5OWQ0MTYwMGM5YTQ3MDlhNjZiNjg3MzFkMGNlNjQ0L3RhYmxlcmFuZ2U6Mjk5ZDQxNjAwYzlhNDcwOWE2NmI2ODczMWQwY2U2NDRfNi0yLTEtMS05NTU4_bbd547b7-4377-470d-90d9-78decf2db53b">496,787</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca7f9fa06d14f85a52cbd81ac170d2c_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF81NS9mcmFnOjNjYzExNDcyMGE1YTQxZDQ4MGQ2OWI3MjIxMWIwYTFiL3RhYmxlOjI5OWQ0MTYwMGM5YTQ3MDlhNjZiNjg3MzFkMGNlNjQ0L3RhYmxlcmFuZ2U6Mjk5ZDQxNjAwYzlhNDcwOWE2NmI2ODczMWQwY2U2NDRfNi00LTEtMS05NTU4_3386f327-073b-4e39-8b3a-fea616e5490c">777,916</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45bdfab35dd74d60ac86fc023b908b73_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF81NS9mcmFnOjNjYzExNDcyMGE1YTQxZDQ4MGQ2OWI3MjIxMWIwYTFiL3RhYmxlOjI5OWQ0MTYwMGM5YTQ3MDlhNjZiNjg3MzFkMGNlNjQ0L3RhYmxlcmFuZ2U6Mjk5ZDQxNjAwYzlhNDcwOWE2NmI2ODczMWQwY2U2NDRfNi01LTEtMS05NTU4_b296a3be-7468-4125-abbc-ab4924871a99">1,491,004</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8c8802e62b74a919450a1c6017bba7e_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF81NS9mcmFnOjNjYzExNDcyMGE1YTQxZDQ4MGQ2OWI3MjIxMWIwYTFiL3RhYmxlOjI5OWQ0MTYwMGM5YTQ3MDlhNjZiNjg3MzFkMGNlNjQ0L3RhYmxlcmFuZ2U6Mjk5ZDQxNjAwYzlhNDcwOWE2NmI2ODczMWQwY2U2NDRfNi03LTEtMS05NTU4_4f55d8cf-b278-4038-beef-abe1a03978de">2,334,811</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><div id="i8e8bdb91dc894234b9d87e17a18b54fd_58"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disclosure regarding forward-looking statements</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following discussion contains certain forward-looking statements which reflect management&#8217;s current views of future events and operations. These statements involve certain risks and uncertainties, and actual results may differ materially from them. Forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ significantly from the results discussed in these forward-looking statements. Some important factors which may cause results to differ from expectations include: availability of additional debt and equity capital; market conditions at the time additional capital is required; our ability to continue to acquire branded products; product sales; management of our growth and integration of our acquisitions and impacts on our business as well as national and international markets and economies resulting from the COVID-19 pandemic. While forward-looking statements reflect our beliefs and best judgment based upon current information, they are not guarantees of future performance. Other important factors that may cause actual results to differ materially from forward-looking statements are discussed in the sections entitled &#8220;Risk Factors&#8221; and &#8220;Special Note Regarding Forward-Looking Statements&#8221; of our Annual Report on Form 10-K for the year ended December 31, 2020, and our other filings with the SEC.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not undertake to publicly update or revise any of our forward-looking statements, even in the event that experience or future changes indicate that the anticipated results will not be realized. The following presentation of management&#8217;s discussion and analysis of financial condition and results of operations should be read in conjunction with our unaudited condensed consolidated financial statements and related notes included in this report on Form 10-Q.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div><span><br/></span></div><div id="i8e8bdb91dc894234b9d87e17a18b54fd_61"></div><div style="-sec-extract:summary;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OVERVIEW</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Business</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland Pharmaceuticals Inc. (&#8220;Cumberland,&#8221; the &#8220;Company,&#8221; or as used in the context of &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221;), is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. We are dedicated to providing innovative products that improve the quality of care for patients and address poorly met medical needs. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary target markets are hospital acute care, gastroenterology and rheumatology. These medical specialties are characterized by relatively concentrated prescriber bases that we believe can be served effectively by small, targeted sales forces. We promote our approved products through our hospital and field sales forces in the United States and are establishing a network of international partners to register and provide our medicines to patients in their countries.</span></div><div style="margin-top:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our portfolio of FDA approved brands include:</span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Acetadote</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">acetylcysteine</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) Injection, for the treatment of acetaminophen poisoning; </span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Caldolor</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ibuprofen</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) Injection, for the treatment of pain and fever;</span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Kristalose</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">lactulose</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) for Oral Solution, a prescription laxative, for the treatment of constipation;</span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Omeclamox</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">-Pak</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">omeprazole, clarithromycin, and amoxicillin</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) for the treatment of Helicobacter pylori (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">H. pylori</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) infection and related duodenal ulcer disease;</span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">RediTrex</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">methotrexate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) Injection,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the treatment of active rheumatoid, juvenile idiopathic and severe psoriatic arthritis, as well as disabling psoriasis;</span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Vaprisol</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">conivaptan</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) Injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; and</span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Vibativ</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">telavancin</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) Injection, for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to these commercial brands, we have Phase II clinical programs underway evaluating our ifetroban product candidates being used by patients with cardiomyopathy associated with Duchenne Muscular Dystrophy (&#8220;DMD&#8221;), a degenerative disease, Systemic Sclerosis (&#8220;SSc&#8221;), a deadly autoimmune condition, and Aspirin-Exacerbated Respiratory Disease (&#8220;AERD&#8221;), a severe form of asthma. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland has built core competencies in both the development and commercialization of pharmaceutical products. We have established the capabilities needed to acquire, develop and commercialize branded pharmaceuticals in the U.S. and believe we can leverage this existing infrastructure to support our expected growth. Our management team consists of pharmaceutical industry veterans experienced in business development, product development, regulatory, manufacturing, sales, marketing and finance. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business development team identifies, evaluates, and negotiates product acquisition, licensing and co-promotion agreements. Our product development team creates proprietary product formulations, manages our clinical studies, prepares all regulatory submissions and staffs our medical call center. Our quality and manufacturing professionals oversee the manufacturing, release and shipment of our products. Our marketing and sales team is responsible for our commercial activities, and we work closely with our distribution partners to ensure availability and delivery of our products.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:8pt"><span><br/></span></div><div style="margin-top:8pt"><span><br/></span></div><div style="margin-top:8pt"><span><br/></span></div><div style="margin-top:8pt"><span><br/></span></div><div style="margin-top:8pt"><span><br/></span></div><div style="margin-top:8pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Growth Strategy</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland's growth strategy involves maximizing the potential of our existing brands while continuing to build a portfolio of differentiated products. We currently feature seven FDA products approved for sale in the United States.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through our international partners, we are working to bring our medicines to patients in their countries. We also look for opportunities to expand our products into additional patient populations through clinical trials, new presentations and our support for select, investigator-initiated studies. We actively pursue opportunities to acquire additional marketed products, as well as late-stage development product candidates in our target medical specialties. Our clinical team is developing a pipeline of new product candidates largely to address poorly met medical needs.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are supplementing these activities with the earlier stage drug development at Cumberland Emerging Technologies (&#8220;CET&#8221;), our majority-owned subsidiary. CET partners with academic research institutions to identify and support the progress of promising new product candidates, which Cumberland has the opportunity to further develop and commercialize.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specifically, we are seeking long-term sustainable growth by:</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Supporting and expanding the use of our marketed products </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to evaluate our products following their FDA approval to determine if additional clinical data could expand their market and use. We will continue to explore opportunities for label expansion to bring our products to new patient populations. As examples, we have secured pediatric approval, expanding the labeling for both our Acetadote and Caldolor brands. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Selectively adding complementary brands - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our product development activities, we are also seeking to acquire products or late-stage development product candidates to continue building a portfolio of complementary brands. We focus on under-promoted, FDA-approved drugs as well as late-stage development products that address poorly met medical needs. We will continue to target product acquisition candidates that are competitively differentiated, have valuable intellectual property or other protective features, and allow us to leverage our existing infrastructure. Our acquisition of Vibativ is an example of this strategy.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Progressing our clinical pipeline and incubating future product opportunities at CET -</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We believe it is important to build a pipeline of innovative new product opportunities, such as we are doing through our ifetroban Phase II development programs. We are also supplementing our acquisition and late-stage development activities with early-stage drug development activities at CET. CET partners with universities and other research organizations to develop promising, early-stage product candidates, which Cumberland has the opportunity to further develop and commercialize. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leveraging our infrastructure through co-promotion partnerships - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our commercial infrastructure can help drive prescription volume and product sales. We look for strategic partners that can complement our capabilities and enhance opportunities for our brands. For example, our co-promotion partnerships have allowed us to expand support for Kristalose across the United States.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">    </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Building an international market -</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We have established our own commercial capabilities, including two sales divisions, to cover the U.S. market for our products. We are also building a network of select international partners to register our products and make them available to patients in their countries. We will continue to develop and expand our network of international partners while supporting our partners&#8217; registration and commercialization efforts in their respective territories. The acquisition of Vibativ resulted in several new international partners and market opportunities.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Managing our operations with financial discipline -</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We continually work to manage our expenses in line with our revenues in order to deliver positive cash flow from operations. We remain in a strong financial position, with favorable gross margins and a strong balance sheet. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were incorporated in 1999 and have been headquartered in Nashville, Tennessee since inception. During 2009, we completed an initial public offering of our common shares and listing on the Nasdaq stock exchange. Our website address is www.cumberlandpharma.com. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make available through our website our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and all material press releases and other reports as soon as reasonably practicable after their filing with the U.S. Securities and Exchange Commission, (&#8220;SEC&#8221;). These filings are also available to the public at </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">www.sec.gov</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RECENT DEVELOPMENTS</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19 Pandemic </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In early 2020, the U.S. declared a health care emergency following the outbreak of SARS-CoV-2, a novel strain of coronavirus that causes COVID-19, a respiratory illness. The Company has managed through the resulting COVID-19 pandemic, continuing to operate our business &#8211; keeping facilities open and our organization intact. We moved quickly to ensure the health and safety of our team. We also maintained our ongoing compliance with the many laws and regulations that apply to us as a publicly traded pharmaceutical company.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Throughout the pandemic, Cumberland faced the same challenges affecting other companies that rely on hospital admissions and patient visits to drive revenue. Our business and our clinical studies were impacted, as fewer patients sought elective surgeries and our access to medical facilities was substantially limited. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We carefully monitored our supply chain, including the flow of raw materials and the batches of finished products emerging from the facilities that manufacture our products. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Several of our brands were negatively impacted by the lockdowns and postponement of physician office visits and elective procedures. However, we are fortunate to have a diversified product portfolio that includes other brands that have delivered a strong performance during the pandemic.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Overall, we have been able to continue the delivery of our products while addressing the interests of our shareholders, employees, partners and community.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RediTrex Launch</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In late 2019, we received approval from the U.S. Food and Drug Administration (&#8220;FDA&#8221;) for our New Drug Application for RediTrex, our methotrexate product line. RediTrex is a new line of pre-filled syringes specifically designed for ease of handling and dosing accuracy for the subcutaneous administration of methotrexate in patients with arthritis and psoriasis.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In late 2020, we received initial product supplies and then provided shipments of RediTrex to select accounts. Due to the pandemic, we delayed the national launch of the product, which was implemented during the third quarter of 2021.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RediTrex treats patients with severe, active rheumatoid arthritis, and polyarticular juvenile idiopathic arthritis who have difficulty tolerating or responding to orally delivered methotrexate. It is also approved for symptomatic control of severe, recalcitrant, disabling psoriasis in adults who are not adequately responsive to other forms of therapy.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With more than 54 million Americans living with some form of arthritis, the disease is among the most common causes of work disability in the U.S., according to the CDC. The oral form of methotrexate is typically the first line of treatment for rheumatoid arthritis. As the disease progresses, the dose must be increased to stay effective, often causing intolerable gastrointestinal side effects. Injectable methotrexate has been proven to be more effective than oral delivery, with fewer gastrointestinal reactions. Because of the increased efficacy and tolerability, injectable methotrexate can delay the need to move to costly biologics, lowering overall patient treatment costs. Once disease progression requires the use of biologics, continuing the treatment of injectable methotrexate along with the biologic has been shown to increase overall efficacy.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other injectable methotrexate options available may not optimally meet the needs of arthritis patients who are offered either a vial and syringe for self-injection, or the use of an expensive autoinjector. The vial and syringe method can be difficult for a patient to handle due to limited dexterity in their hands. Additionally, obtaining the exact dose needed while preventing skin exposure to the caustic methotrexate can be quite challenging for many patients. The autoinjectors provide a better alternative to the vial and syringe, but they remove injection control from the patient and can be painful to administer. They are also the most expensive methotrexate delivery.</span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ESG Report</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, we released our second annual Sustainability Report (the "2020 Sustainability Report"), which details Cumberland&#8217;s activities pertaining to our environmental, social and governance (&#8220;ESG&#8221;) matters. After issuing our inaugural ESG report last year (the "2019 Sustainability Report"), we remain committed to sustainability and to maintaining transparency of our corporate operations. As the largest biopharmaceutical company founded and headquartered in the Mid-South, we hold ourselves to the highest standards of ethical practices and understand the importance of recognizing and addressing our impact on our constituents, the community and the environment.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2020 Sustainability Report notes that in 2020 we provided nearly 2.5 million patient doses of our products, safely disposed of over 4,000 pounds of expired and damaged products and had no product recalls. We also had no Company brands listed on the FDA&#8217;s MedWatch Safety Alerts for Human Medical Products, no Company product issues identified by FDA from their Adverse Event Reporting System and no clinical trials terminated due to failure to practice good clinical standards.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2020 Sustainability Report also highlights several initiatives we implemented as part of our commitment to delivering high-quality pharmaceutical products to improve patient care. For example, we continued a program to serialize all commercial products sold in the United States, allowing us to track every unit distributed, which helps to prevent counterfeit drugs from entering the market under the Cumberland brand. In addition, through our coupon program, Cumberland can cover up to 90% of patient prescription costs for our gastrointestinal products.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2020 Sustainability Report also highlights our investment in our employees through our continuing education programs, employee development initiatives and employee recognition awards. Cumberland&#8217;s workforce is 46% women &#8211; and 18% of our employees are minorities.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ifetroban Clinical Studies</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have been evaluating our ifetroban product candidate in a series of clinical studies. We are sponsoring Phase II clinical programs to evaluate our ifetroban product candidates in 1) patients with cardiomyopathy associated with Duchenne Muscular Dystrophy, a rare, fatal, genetic neuromuscular disease that results in deterioration of the skeletal, heart and lung muscles, 2) Systemic Sclerosis or scleroderma, a debilitating autoimmune disorder characterized by diffuse fibrosis of the skin and internal organs and 3) Aspirin-Exacerbated Respiratory Disease, a severe form of asthma. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Enrollment in these clinical studies was interrupted due to the COVID-19 pandemic. However, many of our clinical study sites have reopened and resumed screening of patients for potential participation into our studies. We are awaiting results from the studies underway before deciding on the best development path for the registration of ifetroban, our first new chemical entity.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, our Board of Directors approved a new clinical program for the use of ifetroban to treat Progressive Fibrosing Interstitial Lung Diseases (&#8220;PF-ILDs&#8221;). Nonclinical studies are complete, and the resulting manuscript has been prepared and submitted for publication. A Phase II clinical study is planned and an application to the FDA is in preparation to support this new clinical program.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional pilot preclinical and clinical studies of ifetroban are underway, including several investigator-initiated trials. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Omeclamox-Pak Supply Update</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland has partnered with a select group of FDA-approved facilities to manufacture its line of branded pharmaceutical products and has been carefully monitoring its supply chain during the pandemic. The packager for our Omeclamox-Pak product encountered financial difficulties due to the impact of COVID-19, and their operations are currently suspended. We are awaiting the resumption of those operations, while also exploring other alternatives to restart the product&#8217;s packaging. Meanwhile, we informed the FDA of a shortage of the Omeclamox-Pak effective October 14, 2020 and have not provided a date for the availability of new inventory.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Renal Colic Study</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A clinical trial studying the comparison of intravenous ibuprofen with injectable ketorolac in renal colic pain management demonstrated that ibuprofen is the more rapid-acting drug in controlling pain caused by kidney stones. The study also indicated that the complete relief from pain with ibuprofen was twice as much as that of ketorolac. The findings build upon a body of medical evidence supporting the use of our Caldolor product for the treatment of patient pain. </span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Hyponatremia Publication</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Health Outcome Predictive Evaluation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(HOPE)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> COVID-19 Registry Analysis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">an international study of over 4,000 patients published in November 2020, found that patients hospitalized with COVID-19 had a high risk of developing hyponatremia. These COVID-19 patients also had a higher incidence of mortality due to their hyponatremia. The study results support the use of an intravenous vaptan to treat hyponatremia in critically ill patients afflicted with COVID-19. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hyponatremia, an imbalance of serum sodium to body water, is the most common electrolyte disorder among hospitalized patients. Our Vaprisol product is one of two branded prescription products indicated for the treatment of hyponatremia, and the only intravenously administered branded treatment. Vaprisol has a proven day-1 response rate to normalize serum sodium levels in hyponatremic patients and move them out of the Intensive Care Unit as efficiently as possible.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New Line of Credit</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 28, 2021, we entered into an amendment to renew our Revolving Credit Loan Agreement with Pinnacle Bank. The amendment extended the term of the loan agreement for a three-year period ending in October 2024. The facility provides for a principal balance available for borrowing up to $15 million and an opportunity to request an increase in availability to $20 million. The interest rate on funds borrowed under the facility ranges from 30-day LIBOR plus 175 to 275 basis points depending on the funded debt ratio.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Vibativ International Agreements</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">On August 25, 2021, we signed an agreement with Verity Pharmaceuticals International Limited to license and commercialize Vibativ in Puerto Rico. Verity is a specialty pharmaceutical company with commercial operations in the U.S. and Canada.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vibativ is a patented, FDA-approved injectable anti-infective for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, and complicated skin and skin structure infections. It addresses a range of Gram-positive bacterial pathogens, including those that are considered difficult-to-treat and multidrug-resistant. In November 2018, Cumberland reached an agreement to acquire Vibativ from Theravance Biopharma and assume global responsibility for the product.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">SciClone Pharmaceuticals (Holdings) Limited has licensed our Vibativ product for sale and distribution in China. In February 2021, SciClone completed an initial public offering and listing of their shares on the Hong Kong stock exchange. In June 2021, SciClone submitted an application to the Chinese regulatory authority for the approval of Vibativ in that country. In October 2021, we were informed by SciClone that the filing was accepted by the regulatory agency for review. SciClone expects a review period of up to twelve months for their application and believes that the potential for Vibativ in China may be significant.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Despite the challenges of operating during a pandemic, Cumberland remains committed to our mission of providing innovative products that improve the quality of care for patients and address poorly met medical needs. We are working to fulfill this mission by building a portfolio of innovative and differentiated products through a multifaceted strategy that includes development of new candidates and acquisition of established brands. Our resulting, diversified product line has enabled us to weather external challenges, while our team has remained responsive to the evolving medical market. We are prepared for and look forward to future opportunities to carry out our mission.</span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><div id="i8e8bdb91dc894234b9d87e17a18b54fd_64"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CRITICAL ACCOUNTING POLICIES AND SIGNIFICANT JUDGMENTS AND ESTIMATES</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please see a discussion of our critical accounting policies and significant judgments and estimates in Note 1 to the Company's Condensed Consolidated Financial Statements accompanying this report and the section entitled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in our 2020 Annual Report on Form 10-K.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounting Estimates and Judgments</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. We base our estimates on past experience and on other factors we deem reasonable given the circumstances. Past results help form the basis of our judgments about the carrying value of assets and liabilities that cannot be determined from other sources. Actual results could differ from these estimates. These estimates, judgments and assumptions are most critical with respect to our accounting for revenue recognition, inventories, fair value of contingent consideration liability associated with a business combination, share-based compensation and intangible assets.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><div id="i8e8bdb91dc894234b9d87e17a18b54fd_67"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESULTS OF OPERATIONS</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three months ended September 30, 2021 compared to the three months ended September 30, 2020 </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the unaudited interim statements of operations for continuing operations for the three months ended September 30, 2021 and 2020:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.753%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.131%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,072,540&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,250,689&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,178,149)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and expenses:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,328,027&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,142,839&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(814,812)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling and marketing</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,800,288&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,587,842&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212,446&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,453,873&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,230,335&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223,538&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,039,799&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,381,273&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(341,474)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,013,948&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,117,086&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103,138)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total costs and expenses</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,635,935&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,459,375&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(823,440)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,563,395)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,208,686)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(354,709)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,394&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,004&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,610)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,021)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75,210)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,189&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from continuing operations before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,576,022)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,271,892)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(304,130)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax (expense) benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,458)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,728)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,730)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,583,480)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,275,620)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(307,860)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes net revenues by product for the periods presented: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.753%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.131%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Products:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kristalose</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,012,746&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,615,557&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">397,189&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vibativ</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,896,584&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,813,249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(916,665)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Caldolor</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,255,669&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,416,146&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(160,477)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vaprisol</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325,774&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">406,162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80,388)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acetadote</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368,733&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218,462&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,271&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Omeclamox-Pak</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,689&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">516,066&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(493,377)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RediTrex</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,459&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,459&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,886&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265,047&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86,161)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net revenues</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,072,540&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,250,689&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,178,149)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net revenues.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Net revenues for the three months ended September 30, 2021, were $8.1 million compared to $9.3 million for the three months ended September 30, 2020.  As detailed in the table above, net revenue increased for two of our marketed products: Kristalose and Acetadote during the quarter.  </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Kristalose revenue increased by 11.0% during the third quarter of 2021 to $4.0 million, when compared to the prior year period.  The increase was primarily the result of growth in shipments of the product to our wholesale customers.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acetadote revenue includes net sales of our Acetadote brand and our share of net sales from our Authorized Generic. During the quarter, there was an increase of $0.2 million in the product's revenue when compared to the prior year period as a result of higher sales volumes for the Authorized Generic.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vaprisol revenue was $0.3 million for the third quarter of 2021, a decrease of $0.1 million. This decrease of net sales compared to the third quarter of 2020 is primarily due to cyclical buying trends.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Caldolor revenue was $1.3 million for the third quarter of 2021, a decrease of $0.2 million compared to the same period last year. The decrease was the result of lower international shipments of the product, due to order timing.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vibativ revenue was $1.9 million for the three months ended September 30, 2021, compared to $2.8 million the same period last year.  The decrease was a result of customer buying patterns during the year.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Omeclamox-Pak had no sales for the third quarter of 2021, as Cumberland is currently out of commercial inventory of this product. The packager for our Omeclamox-Pak product encountered financial difficulties, and currently is under new management and a reorganization. We are in discussions about the resumption of packaging the product.  Net revenue for the third quarter of 2021 was positively impacted by various revenue adjustments.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of products sold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Co</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">st of products sold for the third quarter of 2021 and 2020 were $1.3 million and $2.1 million, respectively. Cost of products sold, as a percentage of net revenues, were 16.5% during the three months ended September 30, 2021, compared to 23.2% during the three months ended September 30, 2020.  This change in costs of products sold as a percentage of revenue was attributable to a change in the product sales mix, particularly the increase of Kristalose product sales.  </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling and marketing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Selling and marketing expense for the third quarter of 2021 increased $0.2 million compared to the prior year period.  This increase is primarily attributable to an increase in marketing spending for Kristalose and Vibativ.  Lower royalty costs were partially offset by an increase in direct promotional spending, meeting costs and travel expenses during the third quarter of 2021. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Research and development costs for the third quarter of 2021 and 2020 were $1.5 million and $1.2 million, respectively.  A portion of our research and development costs is variable based on the number of trials, study sites, number of patients and the cost per patient in each of our clinical programs. We continue to fund our ongoing clinical initiatives associated with our pipeline products.     </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and administrative</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  General and administrative expense for the third quarter of 2021 were $2.0 million, which were $0.3 million lower than the third quarter of 2020. There were declines in salaries and stock-based compensation expense.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the statements of operations discussed above reflect the following impacts from Vibativ:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Impact of Vibativ</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended September 30,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,896,584&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,813,249&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407,386&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">945,067&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty and operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">455,814&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">650,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vibativ contribution</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,033,384&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,217,682&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> The Vibativ inventory included in the costs of product sold during the period was acquired and paid for by Cumberland as part of the acquisition of the brand during 2018.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amortization.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Amortization expense is the ratable use of our capitalized intangible assets including product and license rights, patents, trademarks and patent defense costs.  Amortization for the three months ended September 30, 2021, and three months ended September 30, 2020, totaled approximately $1.0 million and $1.1 million, respectively. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Income tax expense for the three months ended September 30, 2021, was comparable to the income tax expense for the three months ended September 30, 2020.  </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2021, we had approximately $44 million of net operating loss carryforwards resulting from the exercise of nonqualified stock options that have historically been used to significantly offset income tax obligations.  We expect to continue to pay minimal income taxes during 2021 and beyond, through the continued utilization of these net operating loss carryforwards, on any taxable income generated from our operations. </span></div><div id="i8e8bdb91dc894234b9d87e17a18b54fd_70"></div><div><span><br/></span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESULTS OF OPERATIONS</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nine months ended September 30, 2021 compared to the nine months ended September 30, 2020 </span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the unaudited interim statements of operations for continuing operations for the nine months ended September 30, 2021 and 2020:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,665,182&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,179,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">485,582&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and expenses:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,486,005&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,387,002&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(900,997)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling and marketing</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,709,445&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,160,924&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548,521&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,071,638&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,374,392&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(302,754)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,367,438&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,608,321&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(240,883)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,354,080&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,284,610&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,470&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total costs and expenses</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,988,606&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,815,249&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(826,643)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,323,424)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,635,649)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,312,225&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,411&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,553&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51,142)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,187,140&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,187,140&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70,297)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(227,730)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,433&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from continuing operations before income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,187,170)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,792,826)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,605,656&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax (expense) benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,375)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45,423)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,048&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,209,545)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,838,249)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,628,704&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes net revenues by product for the periods presented: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:48.680%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.154%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Products:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kristalose</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,286,729&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,387,046&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,899,683&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vibativ</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,799,891&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,551,125&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248,766&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Caldolor</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,734,273&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,677,434&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,839&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vaprisol</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,861,130&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">790,817&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070,313&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acetadote</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">638,704&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,527,173&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(888,469)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Omeclamox-Pak</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(451,683)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">640,435&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,092,118)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RediTrex</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,291)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,291)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">809,429&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,605,570&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(796,141)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net revenues</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,665,182&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,179,600&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">485,582&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net revenues.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Net revenues for the nine months ended September 30, 2021, were $27.7 million compared to $27.2 million for the nine months ended September 30, 2020.  As detailed in the table above, net revenue increased for our marketed products:  Kristalose, Vibativ, Caldolor and Vaprisol during the first nine months of 2021 resulting in an overall 1.8% revenue increase.  </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Kristalose revenue was $12.3 million during the first nine months of 2021, an increase of $1.9 million when compared with the prior year period.  Revenue increased due to continued strong sales volume from our Foxland distributor and other wholesalers.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vibativ revenue was $8.8 million for the nine months ended September 30, 2021, an increase of $0.2 million over the same period last year.  The 2.9% increase in net revenue was a result of improved sales volume for the product during the first quarter of 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vaprisol revenue was $1.9 million for the first nine months of 2021, which is an increase of net sales of $1.1 million compared to the first nine months of 2020 primarily due to increased sales volumes which is the result of increased utilization in supporting patients impacted by COVID-19 infections.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Omeclamox-Pak had no sales for the nine months ended September 30, 2021, as Cumberland is currently out of commercial inventory of this product. The packager for our Omeclamox-Pak product encountered financial difficulties and currently is under new management and a reorganization. We are in discussions about the resumption of packaging the product.  Net revenue for the first three quarters of 2021 was negatively impacted by product returns during the period.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acetadote revenue includes net sales of our Acetadote brand and our share of net sales from our Authorized Generic. There was a decrease of $0.9 million in the product's year to date revenue for the nine months ended September 30, 2021, when compared to the prior year period as a result of lower sales volumes for our Authorized Generic.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Caldolor revenue was $3.7 million for the first three quarters of 2021, an increase of $0.1 million compared to the same period last year. Domestic shipments of the RTU bag product increased in the third quarter of 2021.  </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of products sold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Co</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">st of products sold for first nine months of 2021 and 2020 were $5.5 million and $6.4 million, respectively.  In 2021, we have realized savings for the Authorized Generic of $0.4 million, Omeclamox-Pak of $0.2 million and Vibativ of $0.3 million.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling and marketing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Selling and marketing expense for the nine months ended September 30, 2021, increased $0.5 million compared to the prior year period.  This increase is primarily attributable to increases in royalty costs as well as an increase in direct sales promotion costs and dispensing fees.  </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Research and development costs were $4.1 million for the first nine months of  2021 compared to  $4.4 million for the same period last year.  A portion of our research and development costs is variable based on the number of trials, study sites, cost of the per patient study protocol and patients involved in the development of our new product candidates. We continue to fund our ongoing clinical initiatives associated with our pipeline products.  We experienced a decrease in study activity and salaries offset by an increase in our consulting fees.      </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and administrative</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  General and administrative expense for the nine months ended September 30, 2021, remained consistent with $6.4 million from $6.6 million during the nine months ended September 30, 2020.  In 2021, we experienced lower salary and non cash stock based compensation expense.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the statements of operations discussed above reflect the following impacts from Vibativ:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"></td><td style="width:57.767%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.721%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.722%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Impact of Vibativ</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,799,891&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,551,126&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,542,348&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,765,812&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty and operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,725,889&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,403,677&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vibativ contribution</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,531,654&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,381,637&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> The Vibativ inventory included in the costs of product sold during the period was acquired and paid for by Cumberland as part of the acquisition of the brand during 2018.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amortization.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Amortization expense is the ratable use of our capitalized intangible assets including product and license rights, patents, trademarks and patent defense costs.  Amortization for the nine months ended September 30, 2021, and nine months ended September 30, 2020, totaled approximately $3.4 million and $3.3 million, respectively. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Income tax expense (benefit) for the nine months ended September 30, 2021, as a percentage of income (loss) from continuing operations before income taxes, was 1.9% compared to 0.9% for the nine months ended September 30, 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div><span><br/></span></div><div id="i8e8bdb91dc894234b9d87e17a18b54fd_73"></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIQUIDITY AND CAPITAL RESOURCES</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Working Capital</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary sources of liquidity are cash equivalents, cash flows from operations and the amounts borrowed and available under our line of credit. We believe that our internally generated cash flows, existing working capital and our line of credit will be adequate to finance internal growth, finance business development initiatives, and fund capital expenditures for the foreseeable future. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our liquidity and working capital as of September 30, 2021 and December 31, 2020:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:58.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.458%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.461%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:7pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,843,231&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,753,796&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Working capital (current assets less current liabilities)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,270,145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,302,146&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current ratio (multiple of current assets to current liabilities)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:13pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revolving line of credit availability</span></td><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:11pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our net changes in cash and cash equivalents for the nine months ended September 30, 2021 and September 30, 2020:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:58.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.458%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.461%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,382,763&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,561,140&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(475,098)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,441,768)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,818,230)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,685,477)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,089,435&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,566,105)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net $1.1 million increase in cash and cash equivalents for the nine months ended September 30, 2021, was primarily attributable to cash provided by operating activities, partially offset by cash used in investing and financing activities.  Cash provided by operating activities of $4.4 million was positively impacted by decreases in inventory of $2.6 million and accounts receivable of $2.5 million, as well as the add back of non-cash expenses of depreciation, amortization and share-based compensation expense totaling $4.0 million.  Operating activities were also offset by the decrease in accounts payable of $2.9 million and the forgiveness of our PPP Loan of $2.2 million.  Cash used in investing activities was the result of additions to intangibles of $0.2 million and the payment of $0.2 million to the WHC JV.  Our financing activities included the $1.0 million in cash used to repurchase shares of our common stock as well as the $1.8 million used for the payment of royalties to Theravance for sales of Vibativ. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net $1.6 million decrease in cash and cash equivalents for the nine months ended September 30, 2020, was primarily attributable to cash used in investing and financing activities.  Cash provided by operating activities of $4.6 million was positively impacted by decreases in inventory of $1.7 million, as well as the add back of non-cash expenses of depreciation, amortization and share-based compensation expense totaling $4.3 million.  Cash used by investing activities was the result of additions to intangibles of $1.8 million, including the payment of $1.0 million for RediTrex, equipment of $0.1 million and partially offset by proceeds from surrender of life insurance policies of $0.4 million.  Our financing activities included the net repayment of $1.5 million on our revolving line of credit, the $1.6 million in cash used to repurchase shares of our common stock as well as the $0.8 million used for the repurchase of a portion of CET's shares. </span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="margin-top:8pt"><span><br/></span></div><div style="margin-top:8pt"><span><br/></span></div><div style="margin-top:8pt"><span><br/></span></div><div style="margin-top:8pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Debt Agreement</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 28, 2021, the Company and Pinnacle Bank entered into a Fourth Amendment to the Revolving Credit Note and Fifth Amendment ("Fifth Amendment") to the Revolving Credit Loan Agreement to renew the Revolving Credit Loan.  </span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The original Pinnacle Agreement was dated July 2017.  Beginning on August 14, 2018, and continuing until October 7, 2020, the Company and Pinnacle Bank entered into a series of amendments to extend and update the Revolving Credit Note and Revolving Credit Agreement. The most recent amendment dated October 28, 2021, extends the maturity date three years through October 1, 2024.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistent with prior Amendments, the Fifth Amendment provides for a principal balance available for borrowing of up to $15 million. The Company has the right to request an increase of up to an additional $5 million providing a maximum principal available of up to $20 million upon the satisfaction of certain conditions and with the approval of Pinnacle Bank. Also consistent with prior Amendments, the Company is required to maintain either a Funded Debt Ratio covenant or a Tangible Capital Ratio covenant. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest rate on the Pinnacle Agreement is based on LIBOR plus an interest rate spread. The pricing under the Fourth Amendment provides for an interest rate spread of 1.75% to 2.75% above LIBOR with a minimum LIBOR of 0.90%. The applicable interest rate under the Pinnacle Agreement was 3.65% at September 30, 2021.  In addition, a fee of 0.25% per year is charged on the unused line of credit.  Interest and the unused line fee are payable quarterly.  </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2021 and December 31, 2020, the Company had $15.0 million in borrowings outstanding under its revolving credit facility.  The Company was in compliance with the Tangible Capital Ratio financial covenant as of September 30, 2021. </span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Paycheck Protection Program Loan</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 20, 2020, Cumberland received the funding of a loan from Pinnacle Bank in the aggregate amount of $2,187,140 pursuant to the Paycheck Protection Program (the &#8220;PPP&#8221;) under the Federal Coronavirus Aid, Relief, and Economic Security Act ("CARES Act"), which was enacted March 27, 2020. For a summary of the material terms of the Paycheck Protection Program loan, see Note 6 to the accompanying unaudited condensed consolidated financial statements.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under the terms of the PPP, certain amounts of the loan may be forgiven if they are used for qualifying expenses as described in the CARES Act, including qualifying payroll costs, covered rent payments, and covered utilities.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cumberland used the PPP loan funds for such qualifying expenses. Due to assistance from our PPP loan, the Company did not lay off or furlough any employees as a result of the COVID-19 pandemic.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, Cumberland submitted a request for the loan&#8217;s forgiveness. On June 11, 2021, the Company received a formal notice from the SBA that the full amount of the loan was forgiven. </span></div><div id="i8e8bdb91dc894234b9d87e17a18b54fd_76"></div><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OFF-BALANCE SHEET ARRANGEMENTS</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2021 and 2020, we did not engage in any off-balance sheet arrangements.</span></div><div id="i8e8bdb91dc894234b9d87e17a18b54fd_79"></div><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;3. Quantitative and Qualitative Disclosures about Market Risk</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Rate Risk</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to market risk related to changes in interest rates on our cash on deposit in highly-liquid money market accounts and our revolving credit facility. We do not utilize derivative financial instruments or other market risk-sensitive instruments to manage exposure to interest rate changes. The main objective of our cash investment activities is to preserve principal while maximizing interest income through low-risk investments. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our interest rate risk related to our cash and cash equivalents is not material. The risk related to interest rates for these accounts would produce less income than expected if market interest rates fall. Based on current interest rates, we do not believe we are exposed to significant downside risk related to a change in interest on our money market accounts at September 30, 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest rate risk related to borrowings under our line of credit is based on LIBOR plus an interest rate spread.  The pricing under the Fourth Amendment of the Pinnacle Agreement provides for an interest rate spread of 1.75% to 2.75% above LIBOR with a minimum LIBOR of 0.90%. The applicable interest rate under the Pinnacle Agreement was 3.65% at September 30, 2021.   As of September 30, 2021, we had $15.0 million in borrowings outstanding under our revolving credit facility. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exchange Rate Risk</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we operate primarily in the United States, we are exposed to foreign currency risk.  Currently, we do not utilize financial instruments to hedge exposure to foreign currency fluctuations.  We believe our exposure to foreign currency fluctuation is minimal as our purchases in foreign currency have a maximum exposure of 90 days based on invoice terms with a portion of the exposure being limited to 30 days based on the due date of the invoice.  Foreign currency exchange gains and losses were immaterial for the nine months ended September 30, 2021 and 2020.  Neither a five percent increase nor decrease from current exchange rates would have a material effect on our operating results or financial condition.</span></div><div id="i8e8bdb91dc894234b9d87e17a18b54fd_82"></div><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;4. Controls and Procedures</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management, with the participation of the Company&#8217;s Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the Company&#8217;s disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act")), as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on such evaluation, the Company&#8217;s Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of such period, the Company&#8217;s disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC's rules and forms and is accumulated and communicated to the Company&#8217;s management, including its Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2021, there has not been any change in our internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><div id="i8e8bdb91dc894234b9d87e17a18b54fd_85"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II &#8211; OTHER INFORMATION</span></div><div id="i8e8bdb91dc894234b9d87e17a18b54fd_88"></div><div style="-sec-extract:summary;margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1. Legal Proceedings</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i8e8bdb91dc894234b9d87e17a18b54fd_91"></div><div style="-sec-extract:summary;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1A. Risk Factors</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition to the other information set forth in this quarterly report, an investor should consider the risk factors included in the Company's Annual Report on Form 10-K for the year ended December 31, 2020.</span></div><div id="i8e8bdb91dc894234b9d87e17a18b54fd_94"></div><div style="-sec-extract:summary;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2. Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Purchases of Equity Securities</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have a share repurchase program to purchase up to $10 million of our common stock pursuant to Rule 10b-18 of the Exchange Act. In January 2019, our Board of Directors established the current $10 million repurchase program to replace the prior authorizations for repurchases of our outstanding common stock.  </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity, by month, during the three months ended September 30, 2021:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:37.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.574%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.598%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.207%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.577%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Period</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number&#160;of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares or Units</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Purchased, which were also Part of the Publicly Announced Plans or Programs</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Price&#160;Paid</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">per&#160;Share</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(or Unit)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maximum&#160;Number</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(or Approximate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dollar Value) of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares&#160;(or&#160;Units)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">that May Yet Be</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Purchased&#160;Under</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">the Plans or</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Programs</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,264</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.28&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,273,299&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,424</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.98&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,200,518&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,720</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,164,448&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,408</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Of this amount, 281 shares were repurchased directly through private purchases at the then-current fair market value of common stock.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><div id="i8e8bdb91dc894234b9d87e17a18b54fd_97"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;6. Exhibits</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.617%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:73.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.722%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="pinnaclelocrenewal4thloa.htm">Fourth Amendment to Revolving Credit Note and Fifth Amendment to Revolving Credit Loan Agreement, dated as of October 28, 2021, by and between Cumberland Pharmaceuticals Inc. and Pinnacle Bank</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="pinnaclelocrenewal4thloa.htm">.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2021q3-exhibit311.htm">Certification of Chief Executive Officer Pursuant to Rule 13-14(a) of the Securities Exchange Act of 1934 as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2021q3-exhibit312.htm">Certification of Chief Financial Officer Pursuant to Rule 13-14(a) of the Securities Exchange Act of 1934 as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2021q3-exhibit321.htm">Certification of Chief Executive and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">INLINE XBRL INSTANCE DOCUMENT - THE INSTANCE DOCUMENT DOES NOT APPEAR IN THE INTERACTIVE DATA FILE BECAUSE ITS XBRL TAGS ARE EMBEDDED WITHIN THE INLINE XBRL DOCUMENT.</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">INLINE XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">INLINE XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COVER PAGE INTERACTIVE DATA FILE (FORMATTED AS INLINE XBRL AND CONTAINED IN EXHIBIT 101)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith.</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furnished herewith.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><div id="i8e8bdb91dc894234b9d87e17a18b54fd_100"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"></td><td style="width:8.288%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.980%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.184%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.669%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.207%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.072%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.184%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.416%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumberland Pharmaceuticals Inc.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 12, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ John Hamm</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John Hamm</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer and Duly Authorized Officer</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>pinnaclelocrenewal4thloa.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML>
<HEAD><!-- Document generated by Workiva Inc -->
<TITLE>pinnaclelocrenewal4thloa</TITLE>
</HEAD>
<BODY bgcolor="white">
<DIV align="center">
<DIV style="margin-left:1em;width:1055;"><!-- pinnaclelocrenewal4thloa001.jpg -->
<DIV style="padding-top:2em;">
<IMG src="pinnaclelocrenewal4thloa001.jpg" title="slide1" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- pinnaclelocrenewal4thloa002.jpg -->
<DIV style="padding-top:2em;">
<IMG src="pinnaclelocrenewal4thloa002.jpg" title="slide2" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- pinnaclelocrenewal4thloa003.jpg -->
<DIV style="padding-top:2em;">
<IMG src="pinnaclelocrenewal4thloa003.jpg" title="slide3" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- pinnaclelocrenewal4thloa004.jpg -->
<DIV style="padding-top:2em;">
<IMG src="pinnaclelocrenewal4thloa004.jpg" title="slide4" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- pinnaclelocrenewal4thloa005.jpg -->
<DIV style="padding-top:2em;">
<IMG src="pinnaclelocrenewal4thloa005.jpg" title="slide5" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- pinnaclelocrenewal4thloa006.jpg -->
<DIV style="padding-top:2em;">
<IMG src="pinnaclelocrenewal4thloa006.jpg" title="slide6" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- pinnaclelocrenewal4thloa007.jpg -->
<DIV style="padding-top:2em;">
<IMG src="pinnaclelocrenewal4thloa007.jpg" title="slide7" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- pinnaclelocrenewal4thloa008.jpg -->
<DIV style="padding-top:2em;">
<IMG src="pinnaclelocrenewal4thloa008.jpg" title="slide8" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- pinnaclelocrenewal4thloa009.jpg -->
<DIV style="padding-top:2em;">
<IMG src="pinnaclelocrenewal4thloa009.jpg" title="slide9" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- pinnaclelocrenewal4thloa010.jpg -->
<DIV style="padding-top:2em;">
<IMG src="pinnaclelocrenewal4thloa010.jpg" title="slide10" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- pinnaclelocrenewal4thloa011.jpg -->
<DIV style="padding-top:2em;">
<IMG src="pinnaclelocrenewal4thloa011.jpg" title="slide11" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- pinnaclelocrenewal4thloa012.jpg -->
<DIV style="padding-top:2em;">
<IMG src="pinnaclelocrenewal4thloa012.jpg" title="slide12" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
</DIV>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>a2021q3-exhibit311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="iec8d24f8977245be9e2e34239cfc7104_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="-sec-extract:summary;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION&#160;302 OF</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, A.J. Kazimi, certify that&#58;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I have reviewed this Form 10-Q of Cumberland Pharmaceuticals Inc.&#59;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div></td></tr></table></div><div style="padding-left:30pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:30pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="padding-left:30pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:30pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div></td></tr></table></div><div style="padding-left:30pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:30pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:50.295%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.164%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 12, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; A.J. Kazimi</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A.J. Kazimi</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr></table></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>a2021q3-exhibit312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i505c341806a14ae8b2571f5af0ece1f6_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="-sec-extract:summary;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION&#160;302 OF</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, John Hamm, certify that&#58;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I have reviewed this Form 10-Q of Cumberland Pharmaceuticals Inc.&#59;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div></td></tr></table></div><div style="padding-left:30pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:30pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="padding-left:30pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:30pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div></td></tr></table></div><div style="padding-left:30pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:30pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:50.735%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.158%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.164%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 12, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; John Hamm</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John Hamm</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr></table></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>a2021q3-exhibit321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i5acacdbde8d243829df171f957781a98_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="-sec-extract:summary;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE AND</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO 18 U.S.C. SECTION&#160;1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION&#160;906</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report on Form&#160;10-Q for the fiscal quarter ended September 30, 2021 of Cumberland Pharmaceuticals Inc. (the &#8220;Company&#8221;), as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, A.J. Kazimi, Chief Executive Officer and John Hamm, Chief Financial Officer of the Company, certify, pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. section 1350), that&#58;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Report fully complies with the requirements of Section&#160;13(a)&#160;or 15(d)&#160;of the Securities Exchange Act of 1934&#59; and</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:38.888%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; A. J. Kazimi</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A.J. Kazimi</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 12, 2021</font></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; John Hamm</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John Hamm</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 12, 2021</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:right"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>cpix-20210930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:719f38f6-81ec-4e77-a876-c86386f0dd09,g:3c5f884f-ec0b-48db-97a2-96993ede30b3-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:cpix="http://www.cumberlandpharma.com/20210930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.cumberlandpharma.com/20210930">
  <xs:import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cpix-20210930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cpix-20210930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cpix-20210930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cpix-20210930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.cumberlandpharma.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>1001002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperations" roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations">
        <link:definition>1003004 - Statement - Condensed Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlows" roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows">
        <link:definition>1004005 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementofEquity" roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity">
        <link:definition>1005006 - Statement - Condensed Consolidated Statement of Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandBasisofPresentation" roleURI="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentation">
        <link:definition>2101101 - Disclosure - Organization and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandBasisofPresentationPolicies" roleURI="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies">
        <link:definition>2202201 - Disclosure - Organization and Basis of Presentation (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandBasisofPresentationOrganizationDetails" roleURI="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails">
        <link:definition>2403401 - Disclosure - Organization and Basis of Presentation Organization (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsLossPerShare" roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShare">
        <link:definition>2104102 - Disclosure - Earnings (Loss) Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsLossPerShareTables" roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareTables">
        <link:definition>2305301 - Disclosure - Earnings (Loss) Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsLossPerShareDetails" roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails">
        <link:definition>2406402 - Disclosure - Earnings (Loss) Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsLossPerShareDetailsTextual" roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetailsTextual">
        <link:definition>2407403 - Disclosure - Earnings (Loss) Per Share (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenues" roleURI="http://www.cumberlandpharma.com/role/Revenues">
        <link:definition>2108103 - Disclosure - Revenues</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesTables" roleURI="http://www.cumberlandpharma.com/role/RevenuesTables">
        <link:definition>2309302 - Disclosure - Revenues (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesDetails" roleURI="http://www.cumberlandpharma.com/role/RevenuesDetails">
        <link:definition>2410404 - Disclosure - Revenues (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventories" roleURI="http://www.cumberlandpharma.com/role/Inventories">
        <link:definition>2111104 - Disclosure - Inventories</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesTables" roleURI="http://www.cumberlandpharma.com/role/InventoriesTables">
        <link:definition>2312303 - Disclosure - Inventories (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesNarrativeDetails" roleURI="http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails">
        <link:definition>2413405 - Disclosure - Inventories (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesScheduleofInventoriesDetails" roleURI="http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails">
        <link:definition>2414406 - Disclosure - Inventories (Schedule of Inventories) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.cumberlandpharma.com/role/Leases">
        <link:definition>2115105 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.cumberlandpharma.com/role/LeasesTables">
        <link:definition>2316304 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.cumberlandpharma.com/role/LeasesNarrativeDetails">
        <link:definition>2417407 - Disclosure - Leases (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesLeasePositionDetails" roleURI="http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails">
        <link:definition>2418408 - Disclosure - Leases (Lease Position) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails" roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails">
        <link:definition>2419409 - Disclosure - Leases (Schedule of Lease Liabilities Maturity and Future Minimum Lease Commitments) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1" roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1">
        <link:definition>2419409 - Disclosure - Leases (Schedule of Lease Liabilities Maturity and Future Minimum Lease Commitments) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesRentExpenseDetails" roleURI="http://www.cumberlandpharma.com/role/LeasesRentExpenseDetails">
        <link:definition>2420410 - Disclosure - Leases - Rent Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityandDebt" roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt">
        <link:definition>2121106 - Disclosure - Shareholders' Equity and Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityandDebtShareholdersEquityDetails" roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails">
        <link:definition>2422411 - Disclosure - Shareholders' Equity and Debt (Shareholders' Equity) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityandDebtDebtDetails" roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails">
        <link:definition>2423412 - Disclosure - Shareholders' Equity and Debt (Debt) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.cumberlandpharma.com/role/IncomeTaxes">
        <link:definition>2124107 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetailsTextual" roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual">
        <link:definition>2425413 - Disclosure - Income Taxes (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAgreements" roleURI="http://www.cumberlandpharma.com/role/CollaborativeAgreements">
        <link:definition>2126108 - Disclosure - Collaborative Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AdditionsandReturnsofProductRights" roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRights">
        <link:definition>2127109 - Disclosure - Additions and Returns of Product Rights</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AdditionsandReturnsofProductRightsTables" roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsTables">
        <link:definition>2328305 - Disclosure - Additions and Returns of Product Rights (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AdditionsandReturnsofProductRightsNarrativeDetails" roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails">
        <link:definition>2429414 - Disclosure - Additions and Returns of Product Rights - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AdditionsandReturnsofProductRightsChangeinConsiderationDetails" roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails">
        <link:definition>2430415 - Disclosure - Additions and Returns of Product Rights - Change in Consideration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AdditionsandReturnsofProductRightsDissolutionPaymentsDetails" roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsDissolutionPaymentsDetails">
        <link:definition>2431416 - Disclosure - Additions and Returns of Product Rights - Dissolution Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="cpix_FifthAmendmentMember" abstract="true" name="FifthAmendmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_VIBATIVMember" abstract="true" name="VIBATIVMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_EquityAndDebtAbstract" abstract="true" name="EquityAndDebtAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cpix_LineOfCreditFacilityMaximumBorrowingCapacityTotalCapacity" abstract="false" name="LineOfCreditFacilityMaximumBorrowingCapacityTotalCapacity" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_MethotrexateMember" abstract="true" name="MethotrexateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_OmeclamoxPakMember" abstract="true" name="OmeclamoxPakMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" abstract="false" name="BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_AcetadoteMember" abstract="true" name="AcetadoteMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_AssetsAndLiabilitiesLesseeTableTextBlock" abstract="false" name="AssetsAndLiabilitiesLesseeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="cpix_WinHealthInvestmentSingaporeLtdDomain" abstract="true" name="WinHealthInvestmentSingaporeLtdDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_TieredRoyaltyPaymentsPercentage" abstract="false" name="TieredRoyaltyPaymentsPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="cpix_OtherLongTermObligationsExcludingCurrentPortion" abstract="false" name="OtherLongTermObligationsExcludingCurrentPortion" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_ProceedsFromSaleOfIntangibleAssetsInstallmentPayment" abstract="false" name="ProceedsFromSaleOfIntangibleAssetsInstallmentPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_RediTrexMember" abstract="true" name="RediTrexMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" abstract="false" name="StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_VaprisolMember" abstract="true" name="VaprisolMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_OtherProductsMember" abstract="true" name="OtherProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_ClinigenHealthcareLimitedMember" abstract="true" name="ClinigenHealthcareLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_ProductsAbstract" abstract="true" name="ProductsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cpix_ShareholdersEquityTextualAbstract" abstract="true" name="ShareholdersEquityTextualAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy" abstract="false" name="IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_IfetrobanClinicalMember" abstract="true" name="IfetrobanClinicalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_LeaseLiability" abstract="false" name="LeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_IncentiveStockOptionsMember" abstract="true" name="IncentiveStockOptionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_KristaloseMember" abstract="true" name="KristaloseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived" abstract="false" name="TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_DenominatorAbstract" abstract="true" name="DenominatorAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cpix_IncreaseDecreaseInCurrentOperatingLiabilities" abstract="false" name="IncreaseDecreaseInCurrentOperatingLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock" abstract="false" name="ScheduleofRentExpenseandSubleaseIncomeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="cpix_CaldolorMember" abstract="true" name="CaldolorMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseAmount" abstract="false" name="LineOfCreditFacilityMaximumBorrowingCapacityIncreaseAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_NumeratorAbstract" abstract="true" name="NumeratorAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cpix_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree" abstract="false" name="LesseeOperatingLeaseLiabilityToBePaidAfterYearThree" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_PinnacleBankMember" abstract="true" name="PinnacleBankMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>cpix-20210930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:719f38f6-81ec-4e77-a876-c86386f0dd09,g:3c5f884f-ec0b-48db-97a2-96993ede30b3-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="cpix-20210930.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_e4003107-004c-4714-940c-b61f654c9bd3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLineOfCredit_64972964-85b1-487a-a055-fd804563a77b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermLineOfCredit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e4003107-004c-4714-940c-b61f654c9bd3" xlink:to="loc_us-gaap_LongTermLineOfCredit_64972964-85b1-487a-a055-fd804563a77b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_5be4e0d0-c95e-4755-86c8-6247a813dc2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e4003107-004c-4714-940c-b61f654c9bd3" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_5be4e0d0-c95e-4755-86c8-6247a813dc2d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_f35fc2e0-24d5-4cbe-96d9-1e6e85bb2518" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e4003107-004c-4714-940c-b61f654c9bd3" xlink:to="loc_us-gaap_LiabilitiesCurrent_f35fc2e0-24d5-4cbe-96d9-1e6e85bb2518" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OtherLongTermObligationsExcludingCurrentPortion_2555fe07-2204-4110-a53d-05b767e7fb02" xlink:href="cpix-20210930.xsd#cpix_OtherLongTermObligationsExcludingCurrentPortion"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e4003107-004c-4714-940c-b61f654c9bd3" xlink:to="loc_cpix_OtherLongTermObligationsExcludingCurrentPortion_2555fe07-2204-4110-a53d-05b767e7fb02" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_fe4ab760-0063-4a61-ad29-24523e3f5326" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_3477e6cb-c241-4d81-b772-4848b710b367" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_fe4ab760-0063-4a61-ad29-24523e3f5326" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_3477e6cb-c241-4d81-b772-4848b710b367" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_43ce7d8b-f775-483d-8c93-36ddd5d4cf0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_fe4ab760-0063-4a61-ad29-24523e3f5326" xlink:to="loc_us-gaap_AccountsPayableCurrent_43ce7d8b-f775-483d-8c93-36ddd5d4cf0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_11217f44-8f4f-4b68-99b0-488b44217d04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_fe4ab760-0063-4a61-ad29-24523e3f5326" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_11217f44-8f4f-4b68-99b0-488b44217d04" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_144ccf69-e450-421c-a845-4cb95334bdf9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e48e6dfd-abee-45e3-87b8-195510677691" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_144ccf69-e450-421c-a845-4cb95334bdf9" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e48e6dfd-abee-45e3-87b8-195510677691" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_f20594d5-49cf-41b9-9160-2033a580198d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_144ccf69-e450-421c-a845-4cb95334bdf9" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_f20594d5-49cf-41b9-9160-2033a580198d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_d702f0b9-bb74-4d2d-bbdb-acb7037b65bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_144ccf69-e450-421c-a845-4cb95334bdf9" xlink:to="loc_us-gaap_OtherAssetsCurrent_d702f0b9-bb74-4d2d-bbdb-acb7037b65bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_49e1087b-e824-423f-a61a-1afc490b63ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_144ccf69-e450-421c-a845-4cb95334bdf9" xlink:to="loc_us-gaap_InventoryNet_49e1087b-e824-423f-a61a-1afc490b63ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_95412670-2e88-4884-a56d-a46d91b00d4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2fb17838-81f5-4ba6-9b75-3865a0e39914" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_95412670-2e88-4884-a56d-a46d91b00d4e" xlink:to="loc_us-gaap_StockholdersEquity_2fb17838-81f5-4ba6-9b75-3865a0e39914" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_827cdc1e-d407-4334-8434-47e90c1327e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_95412670-2e88-4884-a56d-a46d91b00d4e" xlink:to="loc_us-gaap_MinorityInterest_827cdc1e-d407-4334-8434-47e90c1327e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2d5bc770-4ee4-4158-a751-b355e66ff249" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_1bf45b1f-5e8f-4b49-9eb6-f509bf380212" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2d5bc770-4ee4-4158-a751-b355e66ff249" xlink:to="loc_us-gaap_CommonStockValue_1bf45b1f-5e8f-4b49-9eb6-f509bf380212" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_7498f726-0989-41a4-85eb-caadaa8f13d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2d5bc770-4ee4-4158-a751-b355e66ff249" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_7498f726-0989-41a4-85eb-caadaa8f13d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_54478ead-aece-4391-b8f5-4608f90c02ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1092dc2b-8386-40bc-ac38-a3f0d0a56db2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_54478ead-aece-4391-b8f5-4608f90c02ca" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_1092dc2b-8386-40bc-ac38-a3f0d0a56db2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_705325fc-f0eb-43b7-930c-258ee1edf509" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_54478ead-aece-4391-b8f5-4608f90c02ca" xlink:to="loc_us-gaap_Goodwill_705325fc-f0eb-43b7-930c-258ee1edf509" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_d99c7d67-a956-4c56-a68a-0e26dd58b6a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_54478ead-aece-4391-b8f5-4608f90c02ca" xlink:to="loc_us-gaap_InventoryNoncurrent_d99c7d67-a956-4c56-a68a-0e26dd58b6a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_7f3540b2-5dbe-44ab-80df-b6365ad1e934" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_54478ead-aece-4391-b8f5-4608f90c02ca" xlink:to="loc_us-gaap_AssetsCurrent_7f3540b2-5dbe-44ab-80df-b6365ad1e934" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_8e39237d-5674-490e-887c-08dfd2292415" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_54478ead-aece-4391-b8f5-4608f90c02ca" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_8e39237d-5674-490e-887c-08dfd2292415" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_59498bfe-40e1-4628-845d-1adc45942c5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_54478ead-aece-4391-b8f5-4608f90c02ca" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_59498bfe-40e1-4628-845d-1adc45942c5d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_da7b1abf-d135-4079-be75-07ebca09be00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_54478ead-aece-4391-b8f5-4608f90c02ca" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_da7b1abf-d135-4079-be75-07ebca09be00" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_fccd38fc-a457-4fd3-b5a2-1140c9149677" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_ec42281e-1571-46e4-8f17-e5617d58ba3a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_fccd38fc-a457-4fd3-b5a2-1140c9149677" xlink:to="loc_us-gaap_Liabilities_ec42281e-1571-46e4-8f17-e5617d58ba3a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_eba1a74b-a051-43a1-894d-af5b4877fb69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_fccd38fc-a457-4fd3-b5a2-1140c9149677" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_eba1a74b-a051-43a1-894d-af5b4877fb69" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_24efd215-4a48-42be-ad47-7a82c74d3ed5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_fccd38fc-a457-4fd3-b5a2-1140c9149677" xlink:to="loc_us-gaap_CommitmentsAndContingencies_24efd215-4a48-42be-ad47-7a82c74d3ed5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="cpix-20210930.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ed75a6bc-0d7f-4806-85a7-a3fbdf52ccd3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_d97e4eb5-2b80-48bb-b209-ef62fdde52bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_ed75a6bc-0d7f-4806-85a7-a3fbdf52ccd3" xlink:to="loc_us-gaap_ProfitLoss_d97e4eb5-2b80-48bb-b209-ef62fdde52bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_3da773fd-7511-4c98-b99f-6406284ac318" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_ed75a6bc-0d7f-4806-85a7-a3fbdf52ccd3" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_3da773fd-7511-4c98-b99f-6406284ac318" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_86782b05-5094-45e4-990b-e29d8f6f2343" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_1fc60daa-b2f0-48c7-8244-d3d98c87cbdc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_86782b05-5094-45e4-990b-e29d8f6f2343" xlink:to="loc_us-gaap_OperatingIncomeLoss_1fc60daa-b2f0-48c7-8244-d3d98c87cbdc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncome_da778fb1-aa9f-45be-ac2f-cbdaf592291f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncome"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_86782b05-5094-45e4-990b-e29d8f6f2343" xlink:to="loc_us-gaap_OtherIncome_da778fb1-aa9f-45be-ac2f-cbdaf592291f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_365dd086-28bb-48f2-a427-396f19c52129" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_86782b05-5094-45e4-990b-e29d8f6f2343" xlink:to="loc_us-gaap_InvestmentIncomeInterest_365dd086-28bb-48f2-a427-396f19c52129" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_e30205b1-8903-4cb3-aacc-2ad6ac638bb3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_86782b05-5094-45e4-990b-e29d8f6f2343" xlink:to="loc_us-gaap_InterestExpense_e30205b1-8903-4cb3-aacc-2ad6ac638bb3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_2c59603e-855a-408e-9af9-7309a3f307a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_bd2ac9c4-bb33-4e6b-b122-0390ff8d5e3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_2c59603e-855a-408e-9af9-7309a3f307a5" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_bd2ac9c4-bb33-4e6b-b122-0390ff8d5e3f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_5f5bf62c-8ff7-49d1-8657-237351144468" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_2c59603e-855a-408e-9af9-7309a3f307a5" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_5f5bf62c-8ff7-49d1-8657-237351144468" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_5121d56d-600e-4acb-9103-04ad3ea2f2e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_01490ee9-53c4-4ebf-94f9-51c2b302afac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_5121d56d-600e-4acb-9103-04ad3ea2f2e3" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_01490ee9-53c4-4ebf-94f9-51c2b302afac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_7a5ead24-35cb-4129-b9ce-8c190f350b1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_5121d56d-600e-4acb-9103-04ad3ea2f2e3" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_7a5ead24-35cb-4129-b9ce-8c190f350b1a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_4b0c1e5f-2789-473c-bb13-a664505cf619" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b3faedc2-c010-4242-b086-9f4afbc8c3fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_4b0c1e5f-2789-473c-bb13-a664505cf619" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b3faedc2-c010-4242-b086-9f4afbc8c3fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_8eb5830f-8121-4cf8-9e6c-4699744433a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_4b0c1e5f-2789-473c-bb13-a664505cf619" xlink:to="loc_us-gaap_CostsAndExpenses_8eb5830f-8121-4cf8-9e6c-4699744433a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_e2c63134-b726-447f-9056-f56dff03392a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_0cfca2ed-04a9-4f1e-9c34-9d3e3ff844d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_e2c63134-b726-447f-9056-f56dff03392a" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_0cfca2ed-04a9-4f1e-9c34-9d3e3ff844d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_461d80e3-7035-423c-b6a7-ad4d629b226f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_e2c63134-b726-447f-9056-f56dff03392a" xlink:to="loc_us-gaap_SellingAndMarketingExpense_461d80e3-7035-423c-b6a7-ad4d629b226f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_58b33898-f4bf-4761-8359-f10996d4c571" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_e2c63134-b726-447f-9056-f56dff03392a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_58b33898-f4bf-4761-8359-f10996d4c571" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_7ab9ef31-a24c-4f65-ac40-df0b47d80d3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_e2c63134-b726-447f-9056-f56dff03392a" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_7ab9ef31-a24c-4f65-ac40-df0b47d80d3f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_33654aa3-bc14-4827-bc51-28e7a9bcb955" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_e2c63134-b726-447f-9056-f56dff03392a" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_33654aa3-bc14-4827-bc51-28e7a9bcb955" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="cpix-20210930.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6949e094-1464-42be-a52f-964eb36a978f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_63a4717d-40c0-4f27-a001-1893b0aae178" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6949e094-1464-42be-a52f-964eb36a978f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_63a4717d-40c0-4f27-a001-1893b0aae178" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e167ff76-956c-491c-b9da-cca9367466ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6949e094-1464-42be-a52f-964eb36a978f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e167ff76-956c-491c-b9da-cca9367466ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_29cb7dc7-78f7-41f1-80e3-aa0728ba3e9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6949e094-1464-42be-a52f-964eb36a978f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_29cb7dc7-78f7-41f1-80e3-aa0728ba3e9f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_daf39174-d00a-4398-9db5-2c7e398f651e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_52f0222c-6d31-47f2-9d91-4700e3d34d24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_daf39174-d00a-4398-9db5-2c7e398f651e" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_52f0222c-6d31-47f2-9d91-4700e3d34d24" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_0b38b3d6-5f1a-45bd-82fc-8e6d60837122" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_daf39174-d00a-4398-9db5-2c7e398f651e" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_0b38b3d6-5f1a-45bd-82fc-8e6d60837122" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_3823a233-ef8f-458a-8ae7-281871ee92dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfLinesOfCredit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_daf39174-d00a-4398-9db5-2c7e398f651e" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_3823a233-ef8f-458a-8ae7-281871ee92dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_d08f452b-7617-4d27-89d2-29251e55cafa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_daf39174-d00a-4398-9db5-2c7e398f651e" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_d08f452b-7617-4d27-89d2-29251e55cafa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest_5394ce0e-6282-459e-a76e-80be63bd484f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_daf39174-d00a-4398-9db5-2c7e398f651e" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest_5394ce0e-6282-459e-a76e-80be63bd484f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_deae3397-f9ad-4fb8-b177-bdd36de6b429" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IncreaseDecreaseInCurrentOperatingLiabilities_e5048cd4-70fa-4712-99ff-efa4bb7c1869" xlink:href="cpix-20210930.xsd#cpix_IncreaseDecreaseInCurrentOperatingLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_deae3397-f9ad-4fb8-b177-bdd36de6b429" xlink:to="loc_cpix_IncreaseDecreaseInCurrentOperatingLiabilities_e5048cd4-70fa-4712-99ff-efa4bb7c1869" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy_b861336b-f091-4724-acba-56963599811e" xlink:href="cpix-20210930.xsd#cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_deae3397-f9ad-4fb8-b177-bdd36de6b429" xlink:to="loc_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy_b861336b-f091-4724-acba-56963599811e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_273ca052-5376-43a8-815d-a2f241cd6960" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_deae3397-f9ad-4fb8-b177-bdd36de6b429" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_273ca052-5376-43a8-815d-a2f241cd6960" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_f5fad902-5811-4398-a656-e7274f809ab2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_deae3397-f9ad-4fb8-b177-bdd36de6b429" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_f5fad902-5811-4398-a656-e7274f809ab2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_2ea25a2d-722e-4fbc-ae58-a53ee94a8f16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_deae3397-f9ad-4fb8-b177-bdd36de6b429" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_2ea25a2d-722e-4fbc-ae58-a53ee94a8f16" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_15e7615f-24ec-4fcf-9145-af7c3230cedb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_deae3397-f9ad-4fb8-b177-bdd36de6b429" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_15e7615f-24ec-4fcf-9145-af7c3230cedb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_986322b6-9757-411e-9321-5dc50e92e340" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_deae3397-f9ad-4fb8-b177-bdd36de6b429" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_986322b6-9757-411e-9321-5dc50e92e340" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_49461836-13c8-47a6-9e86-4137705f7320" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_deae3397-f9ad-4fb8-b177-bdd36de6b429" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_49461836-13c8-47a6-9e86-4137705f7320" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_7707ed01-b965-4b73-821c-b2104a9b8ecb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_deae3397-f9ad-4fb8-b177-bdd36de6b429" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_7707ed01-b965-4b73-821c-b2104a9b8ecb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities_04ebf13b-2a29-4c47-94c4-3e06c0c2a5ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_deae3397-f9ad-4fb8-b177-bdd36de6b429" xlink:to="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities_04ebf13b-2a29-4c47-94c4-3e06c0c2a5ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_8d5fd757-5b72-4e59-b7f7-2d8d1dc23490" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_deae3397-f9ad-4fb8-b177-bdd36de6b429" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_8d5fd757-5b72-4e59-b7f7-2d8d1dc23490" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_42c52023-3e07-4382-8abd-82a3733d2d4b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_deae3397-f9ad-4fb8-b177-bdd36de6b429" xlink:to="loc_us-gaap_ShareBasedCompensation_42c52023-3e07-4382-8abd-82a3733d2d4b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a65cec70-b375-4a42-8b49-32e875e4fb43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_a8dc8e78-a9ad-4d5c-b8bf-6d0582a9feeb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a65cec70-b375-4a42-8b49-32e875e4fb43" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_a8dc8e78-a9ad-4d5c-b8bf-6d0582a9feeb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_102fe69b-9f94-4d98-8494-36ac7ff5b051" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a65cec70-b375-4a42-8b49-32e875e4fb43" xlink:to="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_102fe69b-9f94-4d98-8494-36ac7ff5b051" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_90a6702f-b088-42dc-8d29-2167786813c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_f0bcf3f1-9e23-4a6a-b014-390e615e6e83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_90a6702f-b088-42dc-8d29-2167786813c6" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_f0bcf3f1-9e23-4a6a-b014-390e615e6e83" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_4384f04a-5f7b-4a9f-920b-4d0ea51cbd6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_90a6702f-b088-42dc-8d29-2167786813c6" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_4384f04a-5f7b-4a9f-920b-4d0ea51cbd6f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_6d12cd8a-f99c-4dfa-b1a9-66f372496bff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_90a6702f-b088-42dc-8d29-2167786813c6" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_6d12cd8a-f99c-4dfa-b1a9-66f372496bff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_b8fd5b3e-9a59-432d-b0bf-1cb1f5fe8f58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_90a6702f-b088-42dc-8d29-2167786813c6" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_b8fd5b3e-9a59-432d-b0bf-1cb1f5fe8f58" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails" xlink:type="simple" xlink:href="cpix-20210930.xsd#EarningsLossPerShareDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f541458d-2b5b-4ca2-8325-b81776d69c83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d899237b-05c1-4530-b4cb-fc1c1521615b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f541458d-2b5b-4ca2-8325-b81776d69c83" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d899237b-05c1-4530-b4cb-fc1c1521615b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_c3cb0ad8-53c5-47f0-9e1d-49513579c1f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f541458d-2b5b-4ca2-8325-b81776d69c83" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_c3cb0ad8-53c5-47f0-9e1d-49513579c1f6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="simple" xlink:href="cpix-20210930.xsd#InventoriesScheduleofInventoriesDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_0ab44e21-04c4-49b8-80d1-c1651bf4fd64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_014e6776-600d-42ec-82c0-9d4f06601713" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_0ab44e21-04c4-49b8-80d1-c1651bf4fd64" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_014e6776-600d-42ec-82c0-9d4f06601713" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_1c9b9ac0-1194-4567-8eb6-18b5747b60af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_0ab44e21-04c4-49b8-80d1-c1651bf4fd64" xlink:to="loc_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_1c9b9ac0-1194-4567-8eb6-18b5747b60af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_57b6da38-0f82-43de-9ea4-d5ba097bbcfd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_0ab44e21-04c4-49b8-80d1-c1651bf4fd64" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_57b6da38-0f82-43de-9ea4-d5ba097bbcfd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails" xlink:type="simple" xlink:href="cpix-20210930.xsd#LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_08fbcbca-4b07-487a-b90c-371d46dc62c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_fa946240-7a89-447b-a8f7-0c0b7e957894" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_08fbcbca-4b07-487a-b90c-371d46dc62c6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_fa946240-7a89-447b-a8f7-0c0b7e957894" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0cf579d3-e96a-4a97-9241-0a865c0d76d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_08fbcbca-4b07-487a-b90c-371d46dc62c6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0cf579d3-e96a-4a97-9241-0a865c0d76d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_b971c154-086b-4a1c-ab14-8f7ef7d4b1b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_08fbcbca-4b07-487a-b90c-371d46dc62c6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_b971c154-086b-4a1c-ab14-8f7ef7d4b1b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree_f658ec76-ee52-4ebf-979e-14bfa6d7a58c" xlink:href="cpix-20210930.xsd#cpix_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_08fbcbca-4b07-487a-b90c-371d46dc62c6" xlink:to="loc_cpix_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree_f658ec76-ee52-4ebf-979e-14bfa6d7a58c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1" xlink:type="simple" xlink:href="cpix-20210930.xsd#LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a2734bc3-caae-4b08-a965-7d9d24d86acc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_7d9096df-2b76-4ad9-9046-a0ac1ac1778d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a2734bc3-caae-4b08-a965-7d9d24d86acc" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_7d9096df-2b76-4ad9-9046-a0ac1ac1778d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_db9d7923-8f0f-43b8-bff7-0f87b61f6148" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a2734bc3-caae-4b08-a965-7d9d24d86acc" xlink:to="loc_us-gaap_OperatingLeaseLiability_db9d7923-8f0f-43b8-bff7-0f87b61f6148" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>cpix-20210930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:719f38f6-81ec-4e77-a876-c86386f0dd09,g:3c5f884f-ec0b-48db-97a2-96993ede30b3-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity" xlink:type="simple" xlink:href="cpix-20210930.xsd#CondensedConsolidatedStatementofEquity"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity" xlink:type="extended" id="i6a54cc750a854548a9c68e4a1f8736a9_CondensedConsolidatedStatementofEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f7c2e9a6-a36a-4563-a86c-80c1462f6f63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1beabf0f-f1e7-4ae4-8f05-4e00568019c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f7c2e9a6-a36a-4563-a86c-80c1462f6f63" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1beabf0f-f1e7-4ae4-8f05-4e00568019c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2eea1cc5-8e2f-4469-8b3e-02b3f9ab92ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1beabf0f-f1e7-4ae4-8f05-4e00568019c7" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2eea1cc5-8e2f-4469-8b3e-02b3f9ab92ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_3fc53be7-de5a-4bc2-a466-e48647c29ebf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1beabf0f-f1e7-4ae4-8f05-4e00568019c7" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_3fc53be7-de5a-4bc2-a466-e48647c29ebf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_9ac63f16-655b-43be-a4e3-fef0c786814f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1beabf0f-f1e7-4ae4-8f05-4e00568019c7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_9ac63f16-655b-43be-a4e3-fef0c786814f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_a616b102-9203-43f3-ad9a-8794e1dea0b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1beabf0f-f1e7-4ae4-8f05-4e00568019c7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_a616b102-9203-43f3-ad9a-8794e1dea0b8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_02261b60-5b81-4cea-97de-5518756f4827" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1beabf0f-f1e7-4ae4-8f05-4e00568019c7" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_02261b60-5b81-4cea-97de-5518756f4827" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_50403b23-09a6-463c-a646-4a8a4af80ca6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1beabf0f-f1e7-4ae4-8f05-4e00568019c7" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_50403b23-09a6-463c-a646-4a8a4af80ca6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_0cf9e5e3-0e1f-4fb2-86c3-a5c4f6c85d03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1beabf0f-f1e7-4ae4-8f05-4e00568019c7" xlink:to="loc_us-gaap_ProfitLoss_0cf9e5e3-0e1f-4fb2-86c3-a5c4f6c85d03" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7a25ff65-d2f8-40b3-8800-bc96f35ea165" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_115063ec-ba4d-423a-891f-54a20007d878" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_48306e8f-4abb-4cef-95d8-dd77dd686950" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_f7c2e9a6-a36a-4563-a86c-80c1462f6f63" xlink:to="loc_us-gaap_StatementTable_48306e8f-4abb-4cef-95d8-dd77dd686950" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_b3dd39aa-22ee-4410-b263-056381d6530c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_48306e8f-4abb-4cef-95d8-dd77dd686950" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_b3dd39aa-22ee-4410-b263-056381d6530c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b3dd39aa-22ee-4410-b263-056381d6530c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b3dd39aa-22ee-4410-b263-056381d6530c" xlink:to="loc_us-gaap_EquityComponentDomain_b3dd39aa-22ee-4410-b263-056381d6530c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_9b72bcee-bd37-4a30-b13d-9f72fa193fca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b3dd39aa-22ee-4410-b263-056381d6530c" xlink:to="loc_us-gaap_EquityComponentDomain_9b72bcee-bd37-4a30-b13d-9f72fa193fca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_94341e32-a24a-4a97-b865-262cfefbee68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9b72bcee-bd37-4a30-b13d-9f72fa193fca" xlink:to="loc_us-gaap_CommonStockMember_94341e32-a24a-4a97-b865-262cfefbee68" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_a8892951-fb38-4532-a2ab-f15f8516eb75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9b72bcee-bd37-4a30-b13d-9f72fa193fca" xlink:to="loc_us-gaap_RetainedEarningsMember_a8892951-fb38-4532-a2ab-f15f8516eb75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_97242877-524d-4dce-ae96-c586ca3ab29e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9b72bcee-bd37-4a30-b13d-9f72fa193fca" xlink:to="loc_us-gaap_NoncontrollingInterestMember_97242877-524d-4dce-ae96-c586ca3ab29e" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RevenuesDetails" xlink:type="simple" xlink:href="cpix-20210930.xsd#RevenuesDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/RevenuesDetails" xlink:type="extended" id="ic1019e4191f0414d8243fc457f1074ba_RevenuesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_734d2712-5858-4a27-a866-f899e4111979" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_cabf3418-a5ae-4f2d-bfa2-00edf4297517" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_734d2712-5858-4a27-a866-f899e4111979" xlink:to="loc_us-gaap_RevenuesAbstract_cabf3418-a5ae-4f2d-bfa2-00edf4297517" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductsAbstract_b7f59a5d-573f-4c4b-907f-2d14d80f41f7" xlink:href="cpix-20210930.xsd#cpix_ProductsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_cabf3418-a5ae-4f2d-bfa2-00edf4297517" xlink:to="loc_cpix_ProductsAbstract_b7f59a5d-573f-4c4b-907f-2d14d80f41f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a9b697b5-652d-4f60-a2d7-25b146d15337" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ProductsAbstract_b7f59a5d-573f-4c4b-907f-2d14d80f41f7" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a9b697b5-652d-4f60-a2d7-25b146d15337" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_e425ca26-2d14-444f-b7fd-a4ca025fb0e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_734d2712-5858-4a27-a866-f899e4111979" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_e425ca26-2d14-444f-b7fd-a4ca025fb0e4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ea85ad4b-cddd-4c70-a69b-d422c9f973f7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_e425ca26-2d14-444f-b7fd-a4ca025fb0e4" xlink:to="loc_srt_ProductOrServiceAxis_ea85ad4b-cddd-4c70-a69b-d422c9f973f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ea85ad4b-cddd-4c70-a69b-d422c9f973f7_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_ea85ad4b-cddd-4c70-a69b-d422c9f973f7" xlink:to="loc_srt_ProductsAndServicesDomain_ea85ad4b-cddd-4c70-a69b-d422c9f973f7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c5dd95e8-54d6-4959-883d-f9a456f42934" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_ea85ad4b-cddd-4c70-a69b-d422c9f973f7" xlink:to="loc_srt_ProductsAndServicesDomain_c5dd95e8-54d6-4959-883d-f9a456f42934" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AcetadoteMember_da36bad0-a580-4de6-bc72-a3d26324cd1b" xlink:href="cpix-20210930.xsd#cpix_AcetadoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c5dd95e8-54d6-4959-883d-f9a456f42934" xlink:to="loc_cpix_AcetadoteMember_da36bad0-a580-4de6-bc72-a3d26324cd1b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OmeclamoxPakMember_c27b32ff-3a9d-4ae8-9470-f838a0bc70a1" xlink:href="cpix-20210930.xsd#cpix_OmeclamoxPakMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c5dd95e8-54d6-4959-883d-f9a456f42934" xlink:to="loc_cpix_OmeclamoxPakMember_c27b32ff-3a9d-4ae8-9470-f838a0bc70a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_KristaloseMember_8d10004d-9f1a-4b2f-8c06-0d85a0805803" xlink:href="cpix-20210930.xsd#cpix_KristaloseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c5dd95e8-54d6-4959-883d-f9a456f42934" xlink:to="loc_cpix_KristaloseMember_8d10004d-9f1a-4b2f-8c06-0d85a0805803" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VaprisolMember_a433841e-56a8-4f31-a0f5-1c9ac4523065" xlink:href="cpix-20210930.xsd#cpix_VaprisolMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c5dd95e8-54d6-4959-883d-f9a456f42934" xlink:to="loc_cpix_VaprisolMember_a433841e-56a8-4f31-a0f5-1c9ac4523065" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CaldolorMember_b0abc34d-da75-403b-a6be-5392060ff765" xlink:href="cpix-20210930.xsd#cpix_CaldolorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c5dd95e8-54d6-4959-883d-f9a456f42934" xlink:to="loc_cpix_CaldolorMember_b0abc34d-da75-403b-a6be-5392060ff765" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_453c4bfa-ffbc-4f55-a4a0-59ed179c71c4" xlink:href="cpix-20210930.xsd#cpix_VIBATIVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c5dd95e8-54d6-4959-883d-f9a456f42934" xlink:to="loc_cpix_VIBATIVMember_453c4bfa-ffbc-4f55-a4a0-59ed179c71c4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_RediTrexMember_f65bdec8-433e-480f-96ba-4ca60e7d5249" xlink:href="cpix-20210930.xsd#cpix_RediTrexMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c5dd95e8-54d6-4959-883d-f9a456f42934" xlink:to="loc_cpix_RediTrexMember_f65bdec8-433e-480f-96ba-4ca60e7d5249" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OtherProductsMember_6c40e545-0aff-4bd1-bad2-a8cc67cad621" xlink:href="cpix-20210930.xsd#cpix_OtherProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c5dd95e8-54d6-4959-883d-f9a456f42934" xlink:to="loc_cpix_OtherProductsMember_6c40e545-0aff-4bd1-bad2-a8cc67cad621" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember_6fa6505e-2e11-48e7-9bb7-b40fa8f1d88d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c5dd95e8-54d6-4959-883d-f9a456f42934" xlink:to="loc_us-gaap_GrantMember_6fa6505e-2e11-48e7-9bb7-b40fa8f1d88d" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails" xlink:type="simple" xlink:href="cpix-20210930.xsd#InventoriesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails" xlink:type="extended" id="id49804daf3d24475bdbf1f8d946201e9_InventoriesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_2677b945-1379-4f43-b473-fcbb33c8672a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves_6ceb65bc-3f32-448c-bd36-e8d24a182c40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryValuationReserves"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_2677b945-1379-4f43-b473-fcbb33c8672a" xlink:to="loc_us-gaap_InventoryValuationReserves_6ceb65bc-3f32-448c-bd36-e8d24a182c40" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_bdc2f651-0530-4433-920f-195aa7565b4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_2677b945-1379-4f43-b473-fcbb33c8672a" xlink:to="loc_us-gaap_InventoryNoncurrent_bdc2f651-0530-4433-920f-195aa7565b4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_bbf4892d-163a-4e3d-a2e7-2b4988289caa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_2677b945-1379-4f43-b473-fcbb33c8672a" xlink:to="loc_us-gaap_InventoryFinishedGoods_bbf4892d-163a-4e3d-a2e7-2b4988289caa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_0db0db49-31ad-434a-8794-a060fe279721" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_2677b945-1379-4f43-b473-fcbb33c8672a" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_0db0db49-31ad-434a-8794-a060fe279721" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_a0b336b1-ce47-4233-8c49-b2149cbf97b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryCurrentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_InventoryLineItems_2677b945-1379-4f43-b473-fcbb33c8672a" xlink:to="loc_us-gaap_InventoryCurrentTable_a0b336b1-ce47-4233-8c49-b2149cbf97b0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_14e80154-b32c-4526-a987-e7dae298d58a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InventoryCurrentTable_a0b336b1-ce47-4233-8c49-b2149cbf97b0" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_14e80154-b32c-4526-a987-e7dae298d58a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_14e80154-b32c-4526-a987-e7dae298d58a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_14e80154-b32c-4526-a987-e7dae298d58a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_14e80154-b32c-4526-a987-e7dae298d58a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_080a77a9-fbcc-4871-ad9a-9b29db13a53f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_14e80154-b32c-4526-a987-e7dae298d58a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_080a77a9-fbcc-4871-ad9a-9b29db13a53f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IfetrobanClinicalMember_762200de-c65f-4d46-92dd-adda1c9d1347" xlink:href="cpix-20210930.xsd#cpix_IfetrobanClinicalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_080a77a9-fbcc-4871-ad9a-9b29db13a53f" xlink:to="loc_cpix_IfetrobanClinicalMember_762200de-c65f-4d46-92dd-adda1c9d1347" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_d981f915-b2c0-4e48-8935-37217a2cc260" xlink:href="cpix-20210930.xsd#cpix_VIBATIVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_080a77a9-fbcc-4871-ad9a-9b29db13a53f" xlink:to="loc_cpix_VIBATIVMember_d981f915-b2c0-4e48-8935-37217a2cc260" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis_12a92061-068d-47a8-b4fa-e0f6209b630d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PublicUtilitiesInventoryAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InventoryCurrentTable_a0b336b1-ce47-4233-8c49-b2149cbf97b0" xlink:to="loc_us-gaap_PublicUtilitiesInventoryAxis_12a92061-068d-47a8-b4fa-e0f6209b630d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_12a92061-068d-47a8-b4fa-e0f6209b630d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_12a92061-068d-47a8-b4fa-e0f6209b630d" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_12a92061-068d-47a8-b4fa-e0f6209b630d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_62ea1003-d7f0-4193-9fa7-15a5f1339c82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_12a92061-068d-47a8-b4fa-e0f6209b630d" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_62ea1003-d7f0-4193-9fa7-15a5f1339c82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IfetrobanClinicalMember_f4ca23e0-d093-45be-91fe-e13d47a86b56" xlink:href="cpix-20210930.xsd#cpix_IfetrobanClinicalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_62ea1003-d7f0-4193-9fa7-15a5f1339c82" xlink:to="loc_cpix_IfetrobanClinicalMember_f4ca23e0-d093-45be-91fe-e13d47a86b56" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="cpix-20210930.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/LeasesNarrativeDetails" xlink:type="extended" id="i8937210d1feb445ab11fbac33ab5b41d_LeasesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_1605487e-e0f6-4306-b5ca-7782f823edcd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_2d366c01-a172-4ddd-becb-3cd44be795e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1605487e-e0f6-4306-b5ca-7782f823edcd" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_2d366c01-a172-4ddd-becb-3cd44be795e9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_bc317288-facc-46d7-8afe-50d71f1d6181" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1605487e-e0f6-4306-b5ca-7782f823edcd" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_bc317288-facc-46d7-8afe-50d71f1d6181" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_47cadbee-2542-4917-9e1b-fac050365ff2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1605487e-e0f6-4306-b5ca-7782f823edcd" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_47cadbee-2542-4917-9e1b-fac050365ff2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_677942a7-adcf-467b-be5c-ee7208957a17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1605487e-e0f6-4306-b5ca-7782f823edcd" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_677942a7-adcf-467b-be5c-ee7208957a17" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_3bd25538-a25a-4f95-ac3a-183935816b0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1605487e-e0f6-4306-b5ca-7782f823edcd" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_3bd25538-a25a-4f95-ac3a-183935816b0d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_744461e7-343f-4ce0-88e8-462cd55aea36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_3bd25538-a25a-4f95-ac3a-183935816b0d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_744461e7-343f-4ce0-88e8-462cd55aea36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_744461e7-343f-4ce0-88e8-462cd55aea36_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_744461e7-343f-4ce0-88e8-462cd55aea36" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_744461e7-343f-4ce0-88e8-462cd55aea36_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8fb4ce31-a05c-40ef-92f7-f9e38d139381" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_744461e7-343f-4ce0-88e8-462cd55aea36" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8fb4ce31-a05c-40ef-92f7-f9e38d139381" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_3fc8fde7-facd-4ec6-81d3-b7eed954ffac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8fb4ce31-a05c-40ef-92f7-f9e38d139381" xlink:to="loc_us-gaap_BuildingMember_3fc8fde7-facd-4ec6-81d3-b7eed954ffac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OfficeBuildingMember_d1b199e9-1204-4946-b7ca-596cc966f447" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OfficeBuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8fb4ce31-a05c-40ef-92f7-f9e38d139381" xlink:to="loc_srt_OfficeBuildingMember_d1b199e9-1204-4946-b7ca-596cc966f447" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" xlink:type="simple" xlink:href="cpix-20210930.xsd#ShareholdersEquityandDebtShareholdersEquityDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" xlink:type="extended" id="ie40cd2367fa14173b739e55366816b88_ShareholdersEquityandDebtShareholdersEquityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0e2d7da7-4ea8-4146-be48-882ec29b6419" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ShareholdersEquityTextualAbstract_dce969f5-2d4b-419b-a3a1-22d26930068b" xlink:href="cpix-20210930.xsd#cpix_ShareholdersEquityTextualAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0e2d7da7-4ea8-4146-be48-882ec29b6419" xlink:to="loc_cpix_ShareholdersEquityTextualAbstract_dce969f5-2d4b-419b-a3a1-22d26930068b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_a899ac8b-6845-402d-a04e-be85c00dec06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_dce969f5-2d4b-419b-a3a1-22d26930068b" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_a899ac8b-6845-402d-a04e-be85c00dec06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_5f8700fb-8183-4a3e-8204-72cad17effcb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_dce969f5-2d4b-419b-a3a1-22d26930068b" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_5f8700fb-8183-4a3e-8204-72cad17effcb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_28de0e93-1d84-4a8d-bcbd-f9fc6ee2438a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_dce969f5-2d4b-419b-a3a1-22d26930068b" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_28de0e93-1d84-4a8d-bcbd-f9fc6ee2438a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_157796a8-03d2-4355-9e26-67e8f44f04c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_dce969f5-2d4b-419b-a3a1-22d26930068b" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_157796a8-03d2-4355-9e26-67e8f44f04c4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities_a02c5b3f-77e9-406d-ad14-19bcc22189b9" xlink:href="cpix-20210930.xsd#cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_dce969f5-2d4b-419b-a3a1-22d26930068b" xlink:to="loc_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities_a02c5b3f-77e9-406d-ad14-19bcc22189b9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_0125cc7e-b8e5-4a55-b545-65ed3bb675d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_dce969f5-2d4b-419b-a3a1-22d26930068b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_0125cc7e-b8e5-4a55-b545-65ed3bb675d6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_36ce7cc7-bbb1-4df2-891c-29d7f7bccfdd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_dce969f5-2d4b-419b-a3a1-22d26930068b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_36ce7cc7-bbb1-4df2-891c-29d7f7bccfdd" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_41dc7f81-ea80-40fe-9466-2dfb24a12be8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0e2d7da7-4ea8-4146-be48-882ec29b6419" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_41dc7f81-ea80-40fe-9466-2dfb24a12be8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_d32074c5-5f6d-47b6-9172-975d23300470" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_41dc7f81-ea80-40fe-9466-2dfb24a12be8" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_d32074c5-5f6d-47b6-9172-975d23300470" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d32074c5-5f6d-47b6-9172-975d23300470_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d32074c5-5f6d-47b6-9172-975d23300470" xlink:to="loc_us-gaap_EquityComponentDomain_d32074c5-5f6d-47b6-9172-975d23300470_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6d214517-3496-46ea-b310-30f77abd0996" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d32074c5-5f6d-47b6-9172-975d23300470" xlink:to="loc_us-gaap_EquityComponentDomain_6d214517-3496-46ea-b310-30f77abd0996" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_3dccb701-ecec-4cf5-a759-0ec3baa98c2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6d214517-3496-46ea-b310-30f77abd0996" xlink:to="loc_us-gaap_CommonStockMember_3dccb701-ecec-4cf5-a759-0ec3baa98c2a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_41ae3094-cee4-4790-8a7f-6effec343507" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_41dc7f81-ea80-40fe-9466-2dfb24a12be8" xlink:to="loc_srt_TitleOfIndividualAxis_41ae3094-cee4-4790-8a7f-6effec343507" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_41ae3094-cee4-4790-8a7f-6effec343507_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_41ae3094-cee4-4790-8a7f-6effec343507" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_41ae3094-cee4-4790-8a7f-6effec343507_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_710fbba4-f8bf-413c-b4d8-a4a63861569e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_41ae3094-cee4-4790-8a7f-6effec343507" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_710fbba4-f8bf-413c-b4d8-a4a63861569e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_c81f76fa-d84c-4861-870c-10246eb57530" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_710fbba4-f8bf-413c-b4d8-a4a63861569e" xlink:to="loc_srt_DirectorMember_c81f76fa-d84c-4861-870c-10246eb57530" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_bf4734b9-db34-4a30-b055-516c4bd90cda" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_41dc7f81-ea80-40fe-9466-2dfb24a12be8" xlink:to="loc_us-gaap_AwardTypeAxis_bf4734b9-db34-4a30-b055-516c4bd90cda" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bf4734b9-db34-4a30-b055-516c4bd90cda_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_bf4734b9-db34-4a30-b055-516c4bd90cda" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bf4734b9-db34-4a30-b055-516c4bd90cda_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c91843c0-6910-4bf2-91ce-aecef678f90a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_bf4734b9-db34-4a30-b055-516c4bd90cda" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c91843c0-6910-4bf2-91ce-aecef678f90a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_fa712a3e-6ba7-4031-9718-f1b31b804988" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c91843c0-6910-4bf2-91ce-aecef678f90a" xlink:to="loc_us-gaap_RestrictedStockMember_fa712a3e-6ba7-4031-9718-f1b31b804988" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IncentiveStockOptionsMember_f1b2e523-068c-4244-afae-aa23f410c504" xlink:href="cpix-20210930.xsd#cpix_IncentiveStockOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c91843c0-6910-4bf2-91ce-aecef678f90a" xlink:to="loc_cpix_IncentiveStockOptionsMember_f1b2e523-068c-4244-afae-aa23f410c504" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_cd0a5b70-ff7b-4dc1-8255-7fc05e87e5e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_41dc7f81-ea80-40fe-9466-2dfb24a12be8" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_cd0a5b70-ff7b-4dc1-8255-7fc05e87e5e5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_cd0a5b70-ff7b-4dc1-8255-7fc05e87e5e5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_cd0a5b70-ff7b-4dc1-8255-7fc05e87e5e5" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_cd0a5b70-ff7b-4dc1-8255-7fc05e87e5e5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_b1874aba-29cf-4026-bf29-9e9098194f28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_cd0a5b70-ff7b-4dc1-8255-7fc05e87e5e5" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_b1874aba-29cf-4026-bf29-9e9098194f28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PinnacleBankMember_aca55c95-33f0-41d2-93f8-44354c26b34b" xlink:href="cpix-20210930.xsd#cpix_PinnacleBankMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_b1874aba-29cf-4026-bf29-9e9098194f28" xlink:to="loc_cpix_PinnacleBankMember_aca55c95-33f0-41d2-93f8-44354c26b34b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" xlink:type="simple" xlink:href="cpix-20210930.xsd#ShareholdersEquityandDebtDebtDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" xlink:type="extended" id="ie57126931e58445e89c8a08ae64ab57d_ShareholdersEquityandDebtDebtDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_107d8361-6c54-4f69-82ff-ae58438b3065" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_4342889b-966b-49b2-a0d0-a0209fd6d59c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_107d8361-6c54-4f69-82ff-ae58438b3065" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_4342889b-966b-49b2-a0d0-a0209fd6d59c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseAmount_b15a0fc3-1dd8-4590-b882-1c6b5fc45389" xlink:href="cpix-20210930.xsd#cpix_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_107d8361-6c54-4f69-82ff-ae58438b3065" xlink:to="loc_cpix_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseAmount_b15a0fc3-1dd8-4590-b882-1c6b5fc45389" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LineOfCreditFacilityMaximumBorrowingCapacityTotalCapacity_0411c40d-3134-458d-9a69-815c52a7e0c8" xlink:href="cpix-20210930.xsd#cpix_LineOfCreditFacilityMaximumBorrowingCapacityTotalCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_107d8361-6c54-4f69-82ff-ae58438b3065" xlink:to="loc_cpix_LineOfCreditFacilityMaximumBorrowingCapacityTotalCapacity_0411c40d-3134-458d-9a69-815c52a7e0c8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_22d0e154-ec5d-40b7-96df-ed7ae7b5f597" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_107d8361-6c54-4f69-82ff-ae58438b3065" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_22d0e154-ec5d-40b7-96df-ed7ae7b5f597" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_3502b971-58b5-484a-996d-f56df0013cfc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_107d8361-6c54-4f69-82ff-ae58438b3065" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_3502b971-58b5-484a-996d-f56df0013cfc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_5a321987-37bf-48e5-8a47-082f153f030f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_107d8361-6c54-4f69-82ff-ae58438b3065" xlink:to="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_5a321987-37bf-48e5-8a47-082f153f030f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived_cc8ecf62-dd77-4011-9a81-87d2e3da5973" xlink:href="cpix-20210930.xsd#cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_107d8361-6c54-4f69-82ff-ae58438b3065" xlink:to="loc_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived_cc8ecf62-dd77-4011-9a81-87d2e3da5973" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLineOfCredit_4d15000e-ff90-49dc-b56d-4e2dc6257ec7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermLineOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_107d8361-6c54-4f69-82ff-ae58438b3065" xlink:to="loc_us-gaap_LongTermLineOfCredit_4d15000e-ff90-49dc-b56d-4e2dc6257ec7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_a4e49abf-46a3-44d7-82d5-edc64d35e2fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_107d8361-6c54-4f69-82ff-ae58438b3065" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_a4e49abf-46a3-44d7-82d5-edc64d35e2fc" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_47b529f0-bd21-4b1d-943b-5af2709f30ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_107d8361-6c54-4f69-82ff-ae58438b3065" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_47b529f0-bd21-4b1d-943b-5af2709f30ba" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_01c9923a-72fd-45af-ac69-a5257d0f792e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_107d8361-6c54-4f69-82ff-ae58438b3065" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_01c9923a-72fd-45af-ac69-a5257d0f792e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_6864e921-e812-4edd-873e-8260d55a21f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_01c9923a-72fd-45af-ac69-a5257d0f792e" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_6864e921-e812-4edd-873e-8260d55a21f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_6864e921-e812-4edd-873e-8260d55a21f7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_6864e921-e812-4edd-873e-8260d55a21f7" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_6864e921-e812-4edd-873e-8260d55a21f7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_d92cf7c3-acf0-445d-91b4-98ece5460a4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_6864e921-e812-4edd-873e-8260d55a21f7" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_d92cf7c3-acf0-445d-91b4-98ece5460a4d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PinnacleBankMember_9426523c-ee34-44cb-9b21-e8ee279e6bda" xlink:href="cpix-20210930.xsd#cpix_PinnacleBankMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_d92cf7c3-acf0-445d-91b4-98ece5460a4d" xlink:to="loc_cpix_PinnacleBankMember_9426523c-ee34-44cb-9b21-e8ee279e6bda" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_cc405239-fcb9-47f7-9cf9-039cbdb4c098" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_01c9923a-72fd-45af-ac69-a5257d0f792e" xlink:to="loc_us-gaap_DebtInstrumentAxis_cc405239-fcb9-47f7-9cf9-039cbdb4c098" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_cc405239-fcb9-47f7-9cf9-039cbdb4c098_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_cc405239-fcb9-47f7-9cf9-039cbdb4c098" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_cc405239-fcb9-47f7-9cf9-039cbdb4c098_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_bbf31dc4-f31a-4748-9d12-c3ba40937f45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_cc405239-fcb9-47f7-9cf9-039cbdb4c098" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_bbf31dc4-f31a-4748-9d12-c3ba40937f45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_8de6865d-d462-41cd-af3e-15f891b60a13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bbf31dc4-f31a-4748-9d12-c3ba40937f45" xlink:to="loc_us-gaap_LineOfCreditMember_8de6865d-d462-41cd-af3e-15f891b60a13" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_FifthAmendmentMember_bbea2c9b-79d3-445d-a3ca-aaccf7d2c846" xlink:href="cpix-20210930.xsd#cpix_FifthAmendmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bbf31dc4-f31a-4748-9d12-c3ba40937f45" xlink:to="loc_cpix_FifthAmendmentMember_bbea2c9b-79d3-445d-a3ca-aaccf7d2c846" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_e9f6b071-ea2f-4d19-9f4e-86307cb14ddd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_01c9923a-72fd-45af-ac69-a5257d0f792e" xlink:to="loc_us-gaap_CreditFacilityAxis_e9f6b071-ea2f-4d19-9f4e-86307cb14ddd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_e9f6b071-ea2f-4d19-9f4e-86307cb14ddd_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_e9f6b071-ea2f-4d19-9f4e-86307cb14ddd" xlink:to="loc_us-gaap_CreditFacilityDomain_e9f6b071-ea2f-4d19-9f4e-86307cb14ddd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_af38b56e-af38-48bb-8364-72b3186bbee3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_e9f6b071-ea2f-4d19-9f4e-86307cb14ddd" xlink:to="loc_us-gaap_CreditFacilityDomain_af38b56e-af38-48bb-8364-72b3186bbee3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_95918447-3505-47af-ad1b-0592d35373b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_af38b56e-af38-48bb-8364-72b3186bbee3" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_95918447-3505-47af-ad1b-0592d35373b6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_37e49cb7-02f9-4b86-b101-165a22600ed8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_01c9923a-72fd-45af-ac69-a5257d0f792e" xlink:to="loc_srt_RangeAxis_37e49cb7-02f9-4b86-b101-165a22600ed8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_37e49cb7-02f9-4b86-b101-165a22600ed8_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_37e49cb7-02f9-4b86-b101-165a22600ed8" xlink:to="loc_srt_RangeMember_37e49cb7-02f9-4b86-b101-165a22600ed8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7a943b86-710f-4c02-94a4-ba6342b423a5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_37e49cb7-02f9-4b86-b101-165a22600ed8" xlink:to="loc_srt_RangeMember_7a943b86-710f-4c02-94a4-ba6342b423a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_58342083-abf1-44ec-88f7-c13fc3267a80" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7a943b86-710f-4c02-94a4-ba6342b423a5" xlink:to="loc_srt_MinimumMember_58342083-abf1-44ec-88f7-c13fc3267a80" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ea1f666b-786a-4341-8820-986b3dc0ec6b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7a943b86-710f-4c02-94a4-ba6342b423a5" xlink:to="loc_srt_MaximumMember_ea1f666b-786a-4341-8820-986b3dc0ec6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_bfdfb4ef-0c0b-47f0-bd51-0f4cd6edaf10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_01c9923a-72fd-45af-ac69-a5257d0f792e" xlink:to="loc_us-gaap_VariableRateAxis_bfdfb4ef-0c0b-47f0-bd51-0f4cd6edaf10" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_bfdfb4ef-0c0b-47f0-bd51-0f4cd6edaf10_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_bfdfb4ef-0c0b-47f0-bd51-0f4cd6edaf10" xlink:to="loc_us-gaap_VariableRateDomain_bfdfb4ef-0c0b-47f0-bd51-0f4cd6edaf10_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_9f544c4e-7e90-4a11-8f60-9d1e9aba05a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_bfdfb4ef-0c0b-47f0-bd51-0f4cd6edaf10" xlink:to="loc_us-gaap_VariableRateDomain_9f544c4e-7e90-4a11-8f60-9d1e9aba05a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_f5d724d4-b1b7-422d-98c9-5860decfec72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_9f544c4e-7e90-4a11-8f60-9d1e9aba05a7" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_f5d724d4-b1b7-422d-98c9-5860decfec72" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_a3b1fa9d-4cf7-4b7e-a15d-3b8cf5214470" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_01c9923a-72fd-45af-ac69-a5257d0f792e" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_a3b1fa9d-4cf7-4b7e-a15d-3b8cf5214470" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_a3b1fa9d-4cf7-4b7e-a15d-3b8cf5214470_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_a3b1fa9d-4cf7-4b7e-a15d-3b8cf5214470" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_a3b1fa9d-4cf7-4b7e-a15d-3b8cf5214470_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1b4f56ad-9040-494c-b289-ae859ad917ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_a3b1fa9d-4cf7-4b7e-a15d-3b8cf5214470" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1b4f56ad-9040-494c-b289-ae859ad917ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_d831bec9-5b8a-483f-9710-600e88c1faa1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1b4f56ad-9040-494c-b289-ae859ad917ba" xlink:to="loc_us-gaap_ConvertibleDebtMember_d831bec9-5b8a-483f-9710-600e88c1faa1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_41974df7-1702-4478-8286-3fc979ad0750" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_01c9923a-72fd-45af-ac69-a5257d0f792e" xlink:to="loc_srt_CounterpartyNameAxis_41974df7-1702-4478-8286-3fc979ad0750" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_41974df7-1702-4478-8286-3fc979ad0750_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_41974df7-1702-4478-8286-3fc979ad0750" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_41974df7-1702-4478-8286-3fc979ad0750_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ba476a30-0ed1-47b3-bce0-757a8d98986a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_41974df7-1702-4478-8286-3fc979ad0750" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ba476a30-0ed1-47b3-bce0-757a8d98986a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_WinHealthInvestmentSingaporeLtdDomain_f6a8060e-a0bf-4a73-b18a-df0d3777553c" xlink:href="cpix-20210930.xsd#cpix_WinHealthInvestmentSingaporeLtdDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ba476a30-0ed1-47b3-bce0-757a8d98986a" xlink:to="loc_cpix_WinHealthInvestmentSingaporeLtdDomain_f6a8060e-a0bf-4a73-b18a-df0d3777553c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_735b1b51-6332-4d24-b5a6-497cfb878f10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_01c9923a-72fd-45af-ac69-a5257d0f792e" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_735b1b51-6332-4d24-b5a6-497cfb878f10" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_735b1b51-6332-4d24-b5a6-497cfb878f10_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_735b1b51-6332-4d24-b5a6-497cfb878f10" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_735b1b51-6332-4d24-b5a6-497cfb878f10_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_675fa301-8020-4ef1-9e39-0531b0875be7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_735b1b51-6332-4d24-b5a6-497cfb878f10" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_675fa301-8020-4ef1-9e39-0531b0875be7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_87926cf0-c5a8-4783-9759-8a912f95af1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_675fa301-8020-4ef1-9e39-0531b0875be7" xlink:to="loc_us-gaap_SubsequentEventMember_87926cf0-c5a8-4783-9759-8a912f95af1a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual" xlink:type="simple" xlink:href="cpix-20210930.xsd#IncomeTaxesDetailsTextual"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual" xlink:type="extended" id="ie423d75232c545b38dde00ca44b48be9_IncomeTaxesDetailsTextual">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_2b9fa7b0-59ff-4c6e-8458-84e58541a496" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_dc041ee2-e7fb-4b58-8b16-73fad793b169" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_2b9fa7b0-59ff-4c6e-8458-84e58541a496" xlink:to="loc_us-gaap_OperatingLossCarryforwards_dc041ee2-e7fb-4b58-8b16-73fad793b169" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_12e749c2-0c29-434c-bf52-a0475ce44ac0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_2b9fa7b0-59ff-4c6e-8458-84e58541a496" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_12e749c2-0c29-434c-bf52-a0475ce44ac0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_f82cd8d9-ea8d-4bd9-a01b-3925e3e0ca63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_12e749c2-0c29-434c-bf52-a0475ce44ac0" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_f82cd8d9-ea8d-4bd9-a01b-3925e3e0ca63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_f82cd8d9-ea8d-4bd9-a01b-3925e3e0ca63_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_f82cd8d9-ea8d-4bd9-a01b-3925e3e0ca63" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_f82cd8d9-ea8d-4bd9-a01b-3925e3e0ca63_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_13c626d2-9a2c-4fa7-aa11-4dcefbe71155" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_f82cd8d9-ea8d-4bd9-a01b-3925e3e0ca63" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_13c626d2-9a2c-4fa7-aa11-4dcefbe71155" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_f3ec2b82-7017-45e2-b743-54380977ea69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_13c626d2-9a2c-4fa7-aa11-4dcefbe71155" xlink:to="loc_us-gaap_DomesticCountryMember_f3ec2b82-7017-45e2-b743-54380977ea69" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails" xlink:type="simple" xlink:href="cpix-20210930.xsd#AdditionsandReturnsofProductRightsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails" xlink:type="extended" id="i20c93a90b4b247b39e45a0618edad295_AdditionsandReturnsofProductRightsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_d8dec2bb-d3fa-4dde-b4f3-6296f7e75fe5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_9c1a2f96-471d-456e-ab80-76d6f344d483" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d8dec2bb-d3fa-4dde-b4f3-6296f7e75fe5" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_9c1a2f96-471d-456e-ab80-76d6f344d483" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPaymentsToAcquireBusinesses_42c4ef9e-6ea8-4026-b173-751816282868" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPaymentsToAcquireBusinesses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d8dec2bb-d3fa-4dde-b4f3-6296f7e75fe5" xlink:to="loc_us-gaap_OtherPaymentsToAcquireBusinesses_42c4ef9e-6ea8-4026-b173-751816282868" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_TieredRoyaltyPaymentsPercentage_7d7fe71d-78db-4b6a-92e7-6fbdd81abe94" xlink:href="cpix-20210930.xsd#cpix_TieredRoyaltyPaymentsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d8dec2bb-d3fa-4dde-b4f3-6296f7e75fe5" xlink:to="loc_cpix_TieredRoyaltyPaymentsPercentage_7d7fe71d-78db-4b6a-92e7-6fbdd81abe94" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_4c947c7b-a8c5-4ab8-8c75-4f62023e5331" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d8dec2bb-d3fa-4dde-b4f3-6296f7e75fe5" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_4c947c7b-a8c5-4ab8-8c75-4f62023e5331" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_c13db486-f28a-43f0-a8c5-3c47cb6bebfc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d8dec2bb-d3fa-4dde-b4f3-6296f7e75fe5" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_c13db486-f28a-43f0-a8c5-3c47cb6bebfc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_2dfdf1f2-5e47-4999-870f-25da027166c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d8dec2bb-d3fa-4dde-b4f3-6296f7e75fe5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_2dfdf1f2-5e47-4999-870f-25da027166c4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_5cd5359e-b410-455f-bc81-0bf641fa18bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d8dec2bb-d3fa-4dde-b4f3-6296f7e75fe5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_5cd5359e-b410-455f-bc81-0bf641fa18bd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_dadd1450-b296-4708-9488-b0b765216fcc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d8dec2bb-d3fa-4dde-b4f3-6296f7e75fe5" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_dadd1450-b296-4708-9488-b0b765216fcc" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_93993c6c-dabe-4afe-97ed-ffcfb855715a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d8dec2bb-d3fa-4dde-b4f3-6296f7e75fe5" xlink:to="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_93993c6c-dabe-4afe-97ed-ffcfb855715a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProceedsFromSaleOfIntangibleAssetsInstallmentPayment_2b94563c-3af2-4bb3-980a-d08fa6701ba1" xlink:href="cpix-20210930.xsd#cpix_ProceedsFromSaleOfIntangibleAssetsInstallmentPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d8dec2bb-d3fa-4dde-b4f3-6296f7e75fe5" xlink:to="loc_cpix_ProceedsFromSaleOfIntangibleAssetsInstallmentPayment_2b94563c-3af2-4bb3-980a-d08fa6701ba1" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_9a9f1ec0-c15a-4466-bfc2-d6a3d5f17cbe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d8dec2bb-d3fa-4dde-b4f3-6296f7e75fe5" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_9a9f1ec0-c15a-4466-bfc2-d6a3d5f17cbe" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_20673524-8b4c-43bb-97aa-412ed7e82950" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d8dec2bb-d3fa-4dde-b4f3-6296f7e75fe5" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_20673524-8b4c-43bb-97aa-412ed7e82950" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_310c4c54-a67c-4ea0-9ce2-0558ce1d9672" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_20673524-8b4c-43bb-97aa-412ed7e82950" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_310c4c54-a67c-4ea0-9ce2-0558ce1d9672" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_310c4c54-a67c-4ea0-9ce2-0558ce1d9672_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_310c4c54-a67c-4ea0-9ce2-0558ce1d9672" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_310c4c54-a67c-4ea0-9ce2-0558ce1d9672_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_559237ab-2ebb-4cd0-90d2-9ecb0f6b87ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_310c4c54-a67c-4ea0-9ce2-0558ce1d9672" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_559237ab-2ebb-4cd0-90d2-9ecb0f6b87ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_0e55168e-d2e5-42e5-8203-c9e286e0ae59" xlink:href="cpix-20210930.xsd#cpix_VIBATIVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_559237ab-2ebb-4cd0-90d2-9ecb0f6b87ba" xlink:to="loc_cpix_VIBATIVMember_0e55168e-d2e5-42e5-8203-c9e286e0ae59" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_MethotrexateMember_1518488e-ed09-4d1e-9ef3-1d35173e328d" xlink:href="cpix-20210930.xsd#cpix_MethotrexateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_559237ab-2ebb-4cd0-90d2-9ecb0f6b87ba" xlink:to="loc_cpix_MethotrexateMember_1518488e-ed09-4d1e-9ef3-1d35173e328d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_da3d62f9-c1f6-4a0d-abbf-c43ee51cca4a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_20673524-8b4c-43bb-97aa-412ed7e82950" xlink:to="loc_srt_CounterpartyNameAxis_da3d62f9-c1f6-4a0d-abbf-c43ee51cca4a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_da3d62f9-c1f6-4a0d-abbf-c43ee51cca4a_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_da3d62f9-c1f6-4a0d-abbf-c43ee51cca4a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_da3d62f9-c1f6-4a0d-abbf-c43ee51cca4a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_270d9c0e-fa4a-4b7c-b301-e2e484aaeb6b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_da3d62f9-c1f6-4a0d-abbf-c43ee51cca4a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_270d9c0e-fa4a-4b7c-b301-e2e484aaeb6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ClinigenHealthcareLimitedMember_f2507615-d2bc-4876-ba61-957136b2a54c" xlink:href="cpix-20210930.xsd#cpix_ClinigenHealthcareLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_270d9c0e-fa4a-4b7c-b301-e2e484aaeb6b" xlink:to="loc_cpix_ClinigenHealthcareLimitedMember_f2507615-d2bc-4876-ba61-957136b2a54c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_05d54064-360d-4db8-bae2-91d4d395ae72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_20673524-8b4c-43bb-97aa-412ed7e82950" xlink:to="loc_us-gaap_AwardTypeAxis_05d54064-360d-4db8-bae2-91d4d395ae72" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_05d54064-360d-4db8-bae2-91d4d395ae72_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_05d54064-360d-4db8-bae2-91d4d395ae72" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_05d54064-360d-4db8-bae2-91d4d395ae72_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a30148bf-073f-49d7-832b-fe0dcfbb21d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_05d54064-360d-4db8-bae2-91d4d395ae72" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a30148bf-073f-49d7-832b-fe0dcfbb21d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_bb345acd-2fb3-430f-9e10-86d8e893249a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a30148bf-073f-49d7-832b-fe0dcfbb21d5" xlink:to="loc_us-gaap_RestrictedStockMember_bb345acd-2fb3-430f-9e10-86d8e893249a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_a7064d94-240e-4007-b5ef-bfaea09e4900" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_20673524-8b4c-43bb-97aa-412ed7e82950" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_a7064d94-240e-4007-b5ef-bfaea09e4900" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_a7064d94-240e-4007-b5ef-bfaea09e4900_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_a7064d94-240e-4007-b5ef-bfaea09e4900" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_a7064d94-240e-4007-b5ef-bfaea09e4900_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_61ac4cd5-5856-473a-b95d-c6f63d95effa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_a7064d94-240e-4007-b5ef-bfaea09e4900" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_61ac4cd5-5856-473a-b95d-c6f63d95effa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_42c04725-0271-4d1e-8d37-a546c8bf8b98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_61ac4cd5-5856-473a-b95d-c6f63d95effa" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_42c04725-0271-4d1e-8d37-a546c8bf8b98" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_43dd8daf-1c8d-447e-9574-9fb2ec91c375" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_61ac4cd5-5856-473a-b95d-c6f63d95effa" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_43dd8daf-1c8d-447e-9574-9fb2ec91c375" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails" xlink:type="simple" xlink:href="cpix-20210930.xsd#AdditionsandReturnsofProductRightsChangeinConsiderationDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails" xlink:type="extended" id="ibf2a4a012fa649b1acd99e8b536466d8_AdditionsandReturnsofProductRightsChangeinConsiderationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_c7d7c39f-2747-4349-8157-5084f6d99ab4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualRollForward_69719e0a-48c0-4796-8d5c-2b42027ad89a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyAccrualRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c7d7c39f-2747-4349-8157-5084f6d99ab4" xlink:to="loc_us-gaap_LossContingencyAccrualRollForward_69719e0a-48c0-4796-8d5c-2b42027ad89a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_907d8116-5347-41c8-b2d7-f03415937612" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_69719e0a-48c0-4796-8d5c-2b42027ad89a" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_907d8116-5347-41c8-b2d7-f03415937612" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRoyalties_121ee9c3-7bc9-491f-8e79-2c926aa6ef59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_69719e0a-48c0-4796-8d5c-2b42027ad89a" xlink:to="loc_us-gaap_PaymentsForRoyalties_121ee9c3-7bc9-491f-8e79-2c926aa6ef59" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_ee318128-bf86-4927-8e67-51fdc5b47ff7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_69719e0a-48c0-4796-8d5c-2b42027ad89a" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_ee318128-bf86-4927-8e67-51fdc5b47ff7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_ac1ee07e-698f-46a8-b06e-ec16d17c1e15" xlink:href="cpix-20210930.xsd#cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_69719e0a-48c0-4796-8d5c-2b42027ad89a" xlink:to="loc_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_ac1ee07e-698f-46a8-b06e-ec16d17c1e15" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_e049554e-8d44-4e09-bba3-7f63810708ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_430dbb52-e367-4e81-b9fd-a4c71bfa1577" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c7d7c39f-2747-4349-8157-5084f6d99ab4" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_430dbb52-e367-4e81-b9fd-a4c71bfa1577" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_7e648ce0-f9b4-4737-8d54-25bf96ed4285" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_430dbb52-e367-4e81-b9fd-a4c71bfa1577" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_7e648ce0-f9b4-4737-8d54-25bf96ed4285" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7e648ce0-f9b4-4737-8d54-25bf96ed4285_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7e648ce0-f9b4-4737-8d54-25bf96ed4285" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7e648ce0-f9b4-4737-8d54-25bf96ed4285_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1a447d0a-5e08-4530-bd4d-f58a112f826a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7e648ce0-f9b4-4737-8d54-25bf96ed4285" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1a447d0a-5e08-4530-bd4d-f58a112f826a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_3c730611-9292-4681-9abc-9973fbe40a2d" xlink:href="cpix-20210930.xsd#cpix_VIBATIVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1a447d0a-5e08-4530-bd4d-f58a112f826a" xlink:to="loc_cpix_VIBATIVMember_3c730611-9292-4681-9abc-9973fbe40a2d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsDissolutionPaymentsDetails" xlink:type="simple" xlink:href="cpix-20210930.xsd#AdditionsandReturnsofProductRightsDissolutionPaymentsDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsDissolutionPaymentsDetails" xlink:type="extended" id="i8f29be8322af466f882c541ec9191580_AdditionsandReturnsofProductRightsDissolutionPaymentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_5ffaf73d-e852-4b6a-8166-b950defb28eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_27d02636-cbfb-4208-b0e4-bf1d6e6f3ef7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5ffaf73d-e852-4b6a-8166-b950defb28eb" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_27d02636-cbfb-4208-b0e4-bf1d6e6f3ef7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_874ee80e-526b-4260-8434-d695346293fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5ffaf73d-e852-4b6a-8166-b950defb28eb" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_874ee80e-526b-4260-8434-d695346293fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_176d68d4-abc5-412b-b5c1-941628452b93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5ffaf73d-e852-4b6a-8166-b950defb28eb" xlink:to="loc_us-gaap_SellingAndMarketingExpense_176d68d4-abc5-412b-b5c1-941628452b93" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_96bb49e8-f2af-4ba7-a358-17a73cab9569" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5ffaf73d-e852-4b6a-8166-b950defb28eb" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_96bb49e8-f2af-4ba7-a358-17a73cab9569" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d5178dc6-a611-4ff8-a504-8d579dab36f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5ffaf73d-e852-4b6a-8166-b950defb28eb" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d5178dc6-a611-4ff8-a504-8d579dab36f5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_9a4992ae-e38f-4cfd-955b-251316829cd8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d5178dc6-a611-4ff8-a504-8d579dab36f5" xlink:to="loc_srt_CounterpartyNameAxis_9a4992ae-e38f-4cfd-955b-251316829cd8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9a4992ae-e38f-4cfd-955b-251316829cd8_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_9a4992ae-e38f-4cfd-955b-251316829cd8" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9a4992ae-e38f-4cfd-955b-251316829cd8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_23e661db-e953-4963-8450-a34584c2c841" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_9a4992ae-e38f-4cfd-955b-251316829cd8" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_23e661db-e953-4963-8450-a34584c2c841" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ClinigenHealthcareLimitedMember_39221abf-bb00-4648-9275-c66638c9b9f0" xlink:href="cpix-20210930.xsd#cpix_ClinigenHealthcareLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_23e661db-e953-4963-8450-a34584c2c841" xlink:to="loc_cpix_ClinigenHealthcareLimitedMember_39221abf-bb00-4648-9275-c66638c9b9f0" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>cpix-20210930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:719f38f6-81ec-4e77-a876-c86386f0dd09,g:3c5f884f-ec0b-48db-97a2-96993ede30b3-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_53122c63-c5a3-41e5-bbc1-911cb6a6584e_terseLabel_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Square feet of office space</link:label>
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_label_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of Real Estate Property</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AreaOfRealEstateProperty" xlink:to="lab_us-gaap_AreaOfRealEstateProperty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_eff59604-03d3-4522-9111-f311736e5ace_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock granted in period, shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_43bc5064-c5b9-4aef-8965-51bcfc38c3ca_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_63e20f0a-b79c-4d47-b116-0a8ff569973c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LEASES</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_4973da7e-5c5b-46b6-a73d-2486c06af413_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_IfetrobanClinicalMember_2edb8e68-3877-45fd-aa10-c1d7240dbab2_terseLabel_en-US" xlink:label="lab_cpix_IfetrobanClinicalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ifetroban Clinical</link:label>
    <link:label id="lab_cpix_IfetrobanClinicalMember_label_en-US" xlink:label="lab_cpix_IfetrobanClinicalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ifetroban Clinical [Member]</link:label>
    <link:label id="lab_cpix_IfetrobanClinicalMember_documentation_en-US" xlink:label="lab_cpix_IfetrobanClinicalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ifetroban Clinical</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IfetrobanClinicalMember" xlink:href="cpix-20210930.xsd#cpix_IfetrobanClinicalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_IfetrobanClinicalMember" xlink:to="lab_cpix_IfetrobanClinicalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree_8e924892-a943-4c92-be31-aec73fcce9dc_terseLabel_en-US" xlink:label="lab_cpix_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After 2023</link:label>
    <link:label id="lab_cpix_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree_label_en-US" xlink:label="lab_cpix_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Three</link:label>
    <link:label id="lab_cpix_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree_documentation_en-US" xlink:label="lab_cpix_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree" xlink:href="cpix-20210930.xsd#cpix_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree" xlink:to="lab_cpix_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_ca73dfbc-dec0-4ce7-87e0-6edeaac0a643_verboseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of products sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_902ce8d6-96ca-44c3-953f-f0dc920959c5_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs of products sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_59b45991-fdac-4ec5-a269-3325f5bc3482_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from discontinued operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_cf194dac-92a8-4022-a379-393e6a9a3959_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total costs and expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_75c770e2-4d64-4450-988a-7fd50929863a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_f20ccdaa-f327-411b-ac0a-8196c7ef3eff_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_cc024dd2-2d7d-4706-ac01-551833edacf6_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_2797d25c-a67e-4bbe-bfe8-23b9f9959e38_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy_186dde54-7ee2-4127-b73f-e24067a294dd_negatedTerseLabel_en-US" xlink:label="lab_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Cash Surrender Value Of Life Insurance Policy</link:label>
    <link:label id="lab_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy_label_en-US" xlink:label="lab_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Cash Surrender Value Of Life Insurance Policy</link:label>
    <link:label id="lab_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy_documentation_en-US" xlink:label="lab_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Cash Surrender Value Of Life Insurance Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy" xlink:href="cpix-20210930.xsd#cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy" xlink:to="lab_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_7fc27b9f-f7fc-4e5a-8f75-f8fef606c9dc_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_82c55899-bef0-4440-b140-e9b8d8e58848_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings on line of credit</link:label>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Repayments of) Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:to="lab_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_76f14be2-0c6c-4adb-a6aa-76ddaf7987e9_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_0724d942-bc2d-4049-8e62-6f0476b44fa8_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_e00ae53a-5f11-493d-a9da-e0160138de0a_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from surrender of life insurance policies</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_de881763-e3c9-45b4-8cfb-bde81b51bf1b_negatedLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of shares (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_0c385398-6e15-4cc4-88c3-47be1cc27ed9_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of shares (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_7de0ab09-7540-4fbf-8bb2-dc5c6a84e9d7_terseLabel_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_label_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_ae169b19-35ec-4b57-aeea-b5b1a31754be_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments on line of credit</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfNotesPayable" xlink:to="lab_us-gaap_RepaymentsOfNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_034fd878-7ca2-46eb-a4a7-c32f7ce86145_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease current liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_AcetadoteMember_933bb8c8-b7e8-46c4-879b-d8b15932f474_terseLabel_en-US" xlink:label="lab_cpix_AcetadoteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kristalose</link:label>
    <link:label id="lab_cpix_AcetadoteMember_label_en-US" xlink:label="lab_cpix_AcetadoteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acetadote [Member]</link:label>
    <link:label id="lab_cpix_AcetadoteMember_documentation_en-US" xlink:label="lab_cpix_AcetadoteMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acetadote</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AcetadoteMember" xlink:href="cpix-20210930.xsd#cpix_AcetadoteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_AcetadoteMember" xlink:to="lab_cpix_AcetadoteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_NumeratorAbstract_aaa0984d-2083-48f0-8d53-f43ad5f98271_verboseLabel_en-US" xlink:label="lab_cpix_NumeratorAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_cpix_NumeratorAbstract_label_en-US" xlink:label="lab_cpix_NumeratorAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator [Abstract]</link:label>
    <link:label id="lab_cpix_NumeratorAbstract_documentation_en-US" xlink:label="lab_cpix_NumeratorAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NumeratorAbstract" xlink:href="cpix-20210930.xsd#cpix_NumeratorAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_NumeratorAbstract" xlink:to="lab_cpix_NumeratorAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_29163441-182c-48a5-9789-6000af328134_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e4132c0b-77b3-4b85-a208-3c8d22c6694d_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_b85ea0dd-0e95-484d-8e66-6124b8c422d5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_932cd9e8-e40e-4865-9e96-4c16c508bb04_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_2d18257b-e985-44b9-9df3-3227bb78a7b3_negatedLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (income) loss at subsidiary attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c2ca5d23-d16c-4be3-aec1-dc2aaf070515_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_6026a0e6-e2a3-4199-a380-3c77e08fb91b_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_bd9e2a9e-a621-4fb7-a454-401a337625e0_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_8cea7edc-4721-417d-9dc0-36829c8aa653_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Revenues</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_3253751f-36ed-4e40-8817-0b5c74cccb4e_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_04520593-6701-4e1a-ab0c-980acd2d50e1_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_871941ac-f9ba-4688-b304-e375d8ca0ea8_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SHAREHOLDERS' EQUITY AND DEBT</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_ca8e10b2-1b6c-46fc-bb17-9055bfa51eab_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income (loss)</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_1b228318-748c-46d8-96c9-7b897fd3928e_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_0def3d0d-f004-4221-bae9-e52d6dd30926_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_7cc02fa3-82cd-428f-85f8-7e0222bf6664_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_80a4f38b-7154-43e1-b1aa-71eda255297a_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_76babdfb-6f70-4f96-afd6-cb349e55bd85_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ProductsAbstract_577cfc08-f57f-44d0-962e-70b47c8e5961_verboseLabel_en-US" xlink:label="lab_cpix_ProductsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products:</link:label>
    <link:label id="lab_cpix_ProductsAbstract_label_en-US" xlink:label="lab_cpix_ProductsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products [Abstract]</link:label>
    <link:label id="lab_cpix_ProductsAbstract_documentation_en-US" xlink:label="lab_cpix_ProductsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductsAbstract" xlink:href="cpix-20210930.xsd#cpix_ProductsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ProductsAbstract" xlink:to="lab_cpix_ProductsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_78efe3c5-bf5f-4d20-bf71-4ecff3496ea6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of remaining lease payments, percent</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_d9cc8467-ced2-4518-a965-74efa932c96f_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_7e8d0cc7-a455-45c7-b9df-050c0f4a7411_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities from continuing operations</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_9e0b0331-76a5-48f2-99be-16c179ca2c08_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2956d5e8-236e-4ebd-b1f4-d8eb68be6d8a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_194ff133-87cb-4304-851c-74a6679db44a_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrantMember_e464a8cd-1bd0-4f5f-99a9-7deee6df99ec_terseLabel_en-US" xlink:label="lab_us-gaap_GrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant</link:label>
    <link:label id="lab_us-gaap_GrantMember_label_en-US" xlink:label="lab_us-gaap_GrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrantMember" xlink:to="lab_us-gaap_GrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_2d4081cd-ac25-49c5-840b-5e45400bbbcf_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common shares</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_0ee5fdfc-31d2-4fc4-a90c-2071865f7de7_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_8f02c089-5cd5-4372-8702-4d01626d8868_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock awards, vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_8d67fdeb-9d79-4305-b19e-9d9b7e23e14a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of contingent consideration included in operating expenses</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_2780d72f-a690-4a3a-92d2-8f0bb1103a81_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_5d662eaa-05b3-4a7f-ba94-92a5bd4a5d75_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_3ad2a2c3-f707-48b8-925a-72eafec43ae8_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubleaseIncome_5fb414be-e4fd-4f6a-90b0-6d958478338a_terseLabel_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease income</link:label>
    <link:label id="lab_us-gaap_SubleaseIncome_label_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubleaseIncome" xlink:to="lab_us-gaap_SubleaseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_VIBATIVMember_0c30a938-8a43-4b66-ad4f-445a9ad71dff_terseLabel_en-US" xlink:label="lab_cpix_VIBATIVMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vaprisol</link:label>
    <link:label id="lab_cpix_VIBATIVMember_label_en-US" xlink:label="lab_cpix_VIBATIVMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VIBATIV [Member]</link:label>
    <link:label id="lab_cpix_VIBATIVMember_documentation_en-US" xlink:label="lab_cpix_VIBATIVMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VIBATIV</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember" xlink:href="cpix-20210930.xsd#cpix_VIBATIVMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_VIBATIVMember" xlink:to="lab_cpix_VIBATIVMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_c0e8db43-8229-4ea3-9373-5a8be6ebf61d_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings (deficit)</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ProceedsFromSaleOfIntangibleAssetsInstallmentPayment_388ff33f-2455-4e6f-8bc7-547888fe53ca_terseLabel_en-US" xlink:label="lab_cpix_ProceedsFromSaleOfIntangibleAssetsInstallmentPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial consideration received in exchange for product license rights, installment payments</link:label>
    <link:label id="lab_cpix_ProceedsFromSaleOfIntangibleAssetsInstallmentPayment_label_en-US" xlink:label="lab_cpix_ProceedsFromSaleOfIntangibleAssetsInstallmentPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Intangible Assets, Installment Payment</link:label>
    <link:label id="lab_cpix_ProceedsFromSaleOfIntangibleAssetsInstallmentPayment_documentation_en-US" xlink:label="lab_cpix_ProceedsFromSaleOfIntangibleAssetsInstallmentPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Intangible Assets, Installment Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProceedsFromSaleOfIntangibleAssetsInstallmentPayment" xlink:href="cpix-20210930.xsd#cpix_ProceedsFromSaleOfIntangibleAssetsInstallmentPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ProceedsFromSaleOfIntangibleAssetsInstallmentPayment" xlink:to="lab_cpix_ProceedsFromSaleOfIntangibleAssetsInstallmentPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_9c6f561e-2381-4f60-85fa-b95dbc4c3e5c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_8f0141da-d70e-448e-95f4-2e16634382c7_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_499b7bbb-86a7-46e4-b1d4-25f74007fad4_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_8f7493b6-8c21-42c1-bed8-44d208ba0f13_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods" xlink:to="lab_us-gaap_InventoryFinishedGoods" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9c1148e8-bbbf-4268-b9b3-59a7afc85052_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_DenominatorAbstract_6dd54e52-1e80-4dd5-bbd2-d9292db52182_verboseLabel_en-US" xlink:label="lab_cpix_DenominatorAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_cpix_DenominatorAbstract_label_en-US" xlink:label="lab_cpix_DenominatorAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator [Abstract]</link:label>
    <link:label id="lab_cpix_DenominatorAbstract_documentation_en-US" xlink:label="lab_cpix_DenominatorAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DenominatorAbstract" xlink:href="cpix-20210930.xsd#cpix_DenominatorAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_DenominatorAbstract" xlink:to="lab_cpix_DenominatorAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_FifthAmendmentMember_db5d7000-7dc4-4192-ab57-6e26c21d6855_terseLabel_en-US" xlink:label="lab_cpix_FifthAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fifth Amendment</link:label>
    <link:label id="lab_cpix_FifthAmendmentMember_label_en-US" xlink:label="lab_cpix_FifthAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fifth Amendment [Member]</link:label>
    <link:label id="lab_cpix_FifthAmendmentMember_documentation_en-US" xlink:label="lab_cpix_FifthAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fifth Amendment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_FifthAmendmentMember" xlink:href="cpix-20210930.xsd#cpix_FifthAmendmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_FifthAmendmentMember" xlink:to="lab_cpix_FifthAmendmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ClinigenHealthcareLimitedMember_d4521e68-1558-4ba1-983a-e14d277ee585_terseLabel_en-US" xlink:label="lab_cpix_ClinigenHealthcareLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinigen</link:label>
    <link:label id="lab_cpix_ClinigenHealthcareLimitedMember_label_en-US" xlink:label="lab_cpix_ClinigenHealthcareLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinigen Healthcare Limited [Member]</link:label>
    <link:label id="lab_cpix_ClinigenHealthcareLimitedMember_documentation_en-US" xlink:label="lab_cpix_ClinigenHealthcareLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinigen Healthcare Limited</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ClinigenHealthcareLimitedMember" xlink:href="cpix-20210930.xsd#cpix_ClinigenHealthcareLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ClinigenHealthcareLimitedMember" xlink:to="lab_cpix_ClinigenHealthcareLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2f0508eb-0369-4b0b-887e-e1570b32b80d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualRollForward_8d565fed-ddc7-4cee-bf13-5502bc15466d_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualRollForward_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyAccrualRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward" xlink:to="lab_us-gaap_LossContingencyAccrualRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_bd876098-12f8-4dc0-bc49-f590db8fe2f2_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_2cf58d3b-73da-418e-ae8a-41f1da3f4831_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OfficeBuildingMember_0be6bd85-529d-47f0-9209-93f2a4f85ac8_terseLabel_en-US" xlink:label="lab_srt_OfficeBuildingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wet Laboratory and Office Space</link:label>
    <link:label id="lab_srt_OfficeBuildingMember_label_en-US" xlink:label="lab_srt_OfficeBuildingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Building [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OfficeBuildingMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OfficeBuildingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OfficeBuildingMember" xlink:to="lab_srt_OfficeBuildingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_fc38147a-1ece-40ab-b6f6-2bbf76a4aff3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (loss) per share attributable to common shareholders - Continuing operations - diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_29a9c681-c184-42b4-9079-c5d5a3ab9909_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets_ec570636-5157-4b18-86f4-2454f8a12347_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial consideration received in exchange for product license rights</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:to="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_479010e3-6255-4b58-bd81-7c2ee7b66cda_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (loss) per share attributable to common shareholders - Discontinued operations - diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingMember_db7f47ee-7b0d-41de-9304-1f152b916967_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Space</link:label>
    <link:label id="lab_us-gaap_BuildingMember_label_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BuildingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingMember" xlink:to="lab_us-gaap_BuildingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_47e98205-d595-49c1-b514-b0fc1f88faa3_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_d5511c93-44b3-499f-8846-37e213b4af11_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_011a541b-c545-4bac-8c67-d9814fd60df5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible note</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_LeaseLiability_29470c5d-3f12-46f1-a710-924280a09a27_terseLabel_en-US" xlink:label="lab_cpix_LeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_cpix_LeaseLiability_label_en-US" xlink:label="lab_cpix_LeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Liability</link:label>
    <link:label id="lab_cpix_LeaseLiability_documentation_en-US" xlink:label="lab_cpix_LeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LeaseLiability" xlink:href="cpix-20210930.xsd#cpix_LeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_LeaseLiability" xlink:to="lab_cpix_LeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_ca085ba4-f858-4f35-b0de-fb41296b034a_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid and other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_OtherProductsMember_87455a0e-6fb9-42f7-80fa-68ecfc487f4c_terseLabel_en-US" xlink:label="lab_cpix_OtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenue</link:label>
    <link:label id="lab_cpix_OtherProductsMember_label_en-US" xlink:label="lab_cpix_OtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products [Member]</link:label>
    <link:label id="lab_cpix_OtherProductsMember_documentation_en-US" xlink:label="lab_cpix_OtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OtherProductsMember" xlink:href="cpix-20210930.xsd#cpix_OtherProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_OtherProductsMember" xlink:to="lab_cpix_OtherProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_35198936-37d3-4483-8844-459b5a79fecb_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_ae3792e2-c631-4387-8e9a-e086e8681833_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_4215c038-be8d-4958-acbc-e3fa1409bd00_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventories classified as current</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8ef24e24-1f0a-441c-81ac-3a9a7902c116_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8b35a748-7af9-4335-a0c6-60d41f586cd1_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryLineItems_5e311987-f4a3-4651-87f2-c6e39bb6bd40_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:label id="lab_us-gaap_InventoryLineItems_label_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryLineItems" xlink:to="lab_us-gaap_InventoryLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_8c85971e-a199-4f1a-ab5f-6de319bfc1d0_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis" xlink:to="lab_us-gaap_LineOfCreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_c21a0324-ce5f-4b94-ad50-638643793965_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest, Total</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_a0d22e60-1e7c-42bd-a4ea-326d56868c8d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) from continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_VaprisolMember_c9c862c1-56ff-4dff-855b-0ea2131d4a0d_terseLabel_en-US" xlink:label="lab_cpix_VaprisolMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acetadote</link:label>
    <link:label id="lab_cpix_VaprisolMember_label_en-US" xlink:label="lab_cpix_VaprisolMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vaprisol [Member]</link:label>
    <link:label id="lab_cpix_VaprisolMember_documentation_en-US" xlink:label="lab_cpix_VaprisolMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vaprisol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VaprisolMember" xlink:href="cpix-20210930.xsd#cpix_VaprisolMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_VaprisolMember" xlink:to="lab_cpix_VaprisolMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_da4fa6dd-8bb1-4616-95c9-7a4ec23b1c15_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (loss) per share attributable to common shareholders - Discontinued operations - basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_41786e5c-8e2e-4d69-ae25-8913442822f3_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ShareholdersEquityTextualAbstract_0df057f4-e969-4b18-b174-2debcbdab9c3_verboseLabel_en-US" xlink:label="lab_cpix_ShareholdersEquityTextualAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders' Equity (Textual) [Abstract]</link:label>
    <link:label id="lab_cpix_ShareholdersEquityTextualAbstract_label_en-US" xlink:label="lab_cpix_ShareholdersEquityTextualAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders Equity (Textual) [Abstract]</link:label>
    <link:label id="lab_cpix_ShareholdersEquityTextualAbstract_documentation_en-US" xlink:label="lab_cpix_ShareholdersEquityTextualAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders Equity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ShareholdersEquityTextualAbstract" xlink:href="cpix-20210930.xsd#cpix_ShareholdersEquityTextualAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract" xlink:to="lab_cpix_ShareholdersEquityTextualAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryAxis_fc48ad6b-a3e7-4e51-9e8a-0a1fd1871f3c_terseLabel_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Axis]</link:label>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryAxis_label_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PublicUtilitiesInventoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis" xlink:to="lab_us-gaap_PublicUtilitiesInventoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_5f1d2149-001e-446a-81ca-d157736b5ead_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_f3eea710-2a1b-4013-9bae-79d29ca7802e_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested restricted shares (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_1ba101f8-38d5-4e66-b961-0185c06cf471_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d2d0e05f-0175-4841-9431-bb263e56d795_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">- diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_cb3b2c63-a2e1-47a6-8111-0390a4c05cd8_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares outstanding &#8211; diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_cfed52b7-113b-424f-bd21-ab95c6b0e930_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (loss) per share attributable to common shareholders - basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_c5ffd64a-98b6-432d-8e0d-a4cf6ae7d5b7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on forgiveness of debt</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_89510c6b-fb33-443d-92e9-e8e1f510c33c_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_cc029bc6-ab88-4096-8b26-d5db26edeb24_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_33cf3bc7-a2c9-47d6-ad32-af45a43963ac_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_e98adeb8-bf70-4ab4-9b8a-79ccab7f208a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryCurrentTable_213e8445-5319-4962-9e77-084c80a447c9_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:label id="lab_us-gaap_InventoryCurrentTable_label_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryCurrentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryCurrentTable" xlink:to="lab_us-gaap_InventoryCurrentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_f66c38f3-3aaf-4a5d-a1a7-fe90627dac85_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingAndMarketingExpense_126fb9c2-7ff2-48f7-b1b8-cce378809263_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling and marketing</link:label>
    <link:label id="lab_us-gaap_SellingAndMarketingExpense_0b6e8a4a-7489-4476-8cd5-227c49296b6a_terseLabel_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, Marketing and other</link:label>
    <link:label id="lab_us-gaap_SellingAndMarketingExpense_label_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling and Marketing Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingAndMarketingExpense" xlink:to="lab_us-gaap_SellingAndMarketingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityTotalCapacity_d86e6bfa-978e-41a4-96a7-2c477b6f927e_terseLabel_en-US" xlink:label="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityTotalCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total capacity</link:label>
    <link:label id="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityTotalCapacity_label_en-US" xlink:label="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityTotalCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity, Total Capacity</link:label>
    <link:label id="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityTotalCapacity_documentation_en-US" xlink:label="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityTotalCapacity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity, Total Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LineOfCreditFacilityMaximumBorrowingCapacityTotalCapacity" xlink:href="cpix-20210930.xsd#cpix_LineOfCreditFacilityMaximumBorrowingCapacityTotalCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_LineOfCreditFacilityMaximumBorrowingCapacityTotalCapacity" xlink:to="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityTotalCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_9a053f9f-f28b-4f3e-a29e-1e344d80163c_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_IncentiveStockOptionsMember_bbbabc3e-4bfd-4d13-97d6-6e8e666e9464_terseLabel_en-US" xlink:label="lab_cpix_IncentiveStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive Stock Options</link:label>
    <link:label id="lab_cpix_IncentiveStockOptionsMember_label_en-US" xlink:label="lab_cpix_IncentiveStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive Stock Options [Member]</link:label>
    <link:label id="lab_cpix_IncentiveStockOptionsMember_documentation_en-US" xlink:label="lab_cpix_IncentiveStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive Stock Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IncentiveStockOptionsMember" xlink:href="cpix-20210930.xsd#cpix_IncentiveStockOptionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_IncentiveStockOptionsMember" xlink:to="lab_cpix_IncentiveStockOptionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockNoParValue_f88d40a1-3671-4c59-b0f8-e2c12659a1d7_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockNoParValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockNoParValue_label_en-US" xlink:label="lab_us-gaap_CommonStockNoParValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, No Par Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNoParValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockNoParValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockNoParValue" xlink:to="lab_us-gaap_CommonStockNoParValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_6bbab2a5-c081-44d3-97b5-8cf3a2e8cc72_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_1f00f27b-75c0-42c6-af3d-353a4fa6b743_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_efe1153e-f2db-4b6e-8d95-0069fa0f6f9d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Dissolution Payments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:to="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_16f76502-81df-4faf-8ef4-a27d5d6de634_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived_0557589b-b9d7-425c-a3a3-f660a4df3408_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future minimum sublease income under noncancelable operating subleases</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payments to be Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryValuationReserves_790c3166-66cc-4ea3-ac52-06912fc900c2_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Obsolescence and discontinuance losses</link:label>
    <link:label id="lab_us-gaap_InventoryValuationReserves_label_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Valuation Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryValuationReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryValuationReserves" xlink:to="lab_us-gaap_InventoryValuationReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_OmeclamoxPakMember_88b68286-41ed-48c0-be03-fdaa4361e43f_terseLabel_en-US" xlink:label="lab_cpix_OmeclamoxPakMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vibativ</link:label>
    <link:label id="lab_cpix_OmeclamoxPakMember_label_en-US" xlink:label="lab_cpix_OmeclamoxPakMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Omeclamox-Pak [Member]</link:label>
    <link:label id="lab_cpix_OmeclamoxPakMember_documentation_en-US" xlink:label="lab_cpix_OmeclamoxPakMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Omeclamox-Pak</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OmeclamoxPakMember" xlink:href="cpix-20210930.xsd#cpix_OmeclamoxPakMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_OmeclamoxPakMember" xlink:to="lab_cpix_OmeclamoxPakMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_753f970b-cf92-42f1-b10b-1aa7071d06f6_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_01e7975c-887c-4e32-8413-f12209ee87f7_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_c2186f9f-5606-487d-90b3-e1de896d6ff8_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock&#8212;no par value; 100,000,000 shares authorized; 15,555,865 and 15,723,075 shares issued and outstanding as of June 30, 2018 and December 31, 2017, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_974abd40-3b52-46d2-bb40-ff8d6c7d4bd8_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_581e7106-c4bd-48e7-9d0e-7332600be996_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_23abc5cd-f288-4a26-b2e9-fe0dd0e5657c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity of Lease Liabilities at September 30, 2021</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_64a498df-d457-4bf3-b66d-59cc46f97099_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_6222381c-aafd-45b0-8d00-19b3a3eede08_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_27a2b547-750c-4944-89a9-4d66282b5b64_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_f474eade-6414-4f83-a24b-954e49e53a39_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of numerator and denominator</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRoyalties_32b66644-bd13-4d6b-9e00-ac9d0dffe640_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRoyalties" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash payment of royalty during the period</link:label>
    <link:label id="lab_us-gaap_PaymentsForRoyalties_label_en-US" xlink:label="lab_us-gaap_PaymentsForRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRoyalties" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRoyalties" xlink:to="lab_us-gaap_PaymentsForRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_fbcba11d-525b-4e51-bb21-7c2ce2a8b792_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_d032a8bb-14c4-4387-9cfd-674232a4718d_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares outstanding</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_fa250b4d-859a-43de-aa0b-41c92e933c09_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_15c9bcf1-c1b0-45d0-8481-2cc92d2038e0_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncome_62fcabf4-dcc0-468c-a4a2-4d74ae3852e8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income</link:label>
    <link:label id="lab_us-gaap_OtherIncome_label_en-US" xlink:label="lab_us-gaap_OtherIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncome" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncome" xlink:to="lab_us-gaap_OtherIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived_c3f4abd5-bfd8-46e3-a0c7-edb264cb63e7_terseLabel_en-US" xlink:label="lab_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate amount</link:label>
    <link:label id="lab_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived_label_en-US" xlink:label="lab_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Coronavirus Aid, Relief, and Economic Security Act, Loan Proceeds Received</link:label>
    <link:label id="lab_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived_documentation_en-US" xlink:label="lab_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Coronavirus Aid, Relief, and Economic Security Act, Loan Proceeds Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived" xlink:href="cpix-20210930.xsd#cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived" xlink:to="lab_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_8b54bad9-4bc8-4992-9237-288d26785db0_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COLLABORATIVE AGREEMENTS</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ed62aaa9-66c4-4bf0-b522-d8bd20a6a283_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_b69d3bfc-0892-4865-b9e2-86aab2a2a7a6_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_28a66349-4256-4a05-9343-4b0d751f404c_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_RediTrexMember_ea39a773-977d-4589-8635-f829d585bc85_terseLabel_en-US" xlink:label="lab_cpix_RediTrexMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RediTrex</link:label>
    <link:label id="lab_cpix_RediTrexMember_label_en-US" xlink:label="lab_cpix_RediTrexMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RediTrex [Member]</link:label>
    <link:label id="lab_cpix_RediTrexMember_documentation_en-US" xlink:label="lab_cpix_RediTrexMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RediTrex</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_RediTrexMember" xlink:href="cpix-20210930.xsd#cpix_RediTrexMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_RediTrexMember" xlink:to="lab_cpix_RediTrexMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_7e354796-622f-421c-b64a-a4a17bb4be67_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_6cf2f345-fbb0-4021-8928-4aab3e4a981d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_72b38963-a29b-478f-9dc4-78925c1a54f9_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_5702aadc-db1e-4f1c-8b5c-fa0c7c2eb191_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_734c4912-f826-49d8-810c-b72bbe62f5e9_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_a95036f7-7e62-480b-a7e1-48528b67a884_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_TieredRoyaltyPaymentsPercentage_452914e2-5636-44e4-bb03-5b6852fb5f79_terseLabel_en-US" xlink:label="lab_cpix_TieredRoyaltyPaymentsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of tiered royalty payments (up to)</link:label>
    <link:label id="lab_cpix_TieredRoyaltyPaymentsPercentage_label_en-US" xlink:label="lab_cpix_TieredRoyaltyPaymentsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tiered Royalty Payments, Percentage</link:label>
    <link:label id="lab_cpix_TieredRoyaltyPaymentsPercentage_documentation_en-US" xlink:label="lab_cpix_TieredRoyaltyPaymentsPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tiered Royalty Payments, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_TieredRoyaltyPaymentsPercentage" xlink:href="cpix-20210930.xsd#cpix_TieredRoyaltyPaymentsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_TieredRoyaltyPaymentsPercentage" xlink:to="lab_cpix_TieredRoyaltyPaymentsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_787956c0-989a-4f42-ab0b-8625ed858c7a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_627ded66-2b20-45bf-8720-4d27db773279_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_8176324e-e5d3-403d-b002-ad16d0abaaef_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INCOME TAXES</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_f2498cd1-de8f-4a96-b43a-8d22b62200bd_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_f04e246e-dd53-4b66-9941-0e38e0a26f20_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions to intangible assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_c7ca7495-dd4f-4ad2-be6b-3f597acfcb7c_verboseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7e035316-0a75-4965-8f3c-d15efb6b3b5c_verboseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock available for purchase through restricted stock awards and options (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_7f28e411-a27a-4033-98cf-e84d7186a512_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:to="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_PinnacleBankMember_37236e05-8837-4980-b7a6-1bb51feeeb3c_terseLabel_en-US" xlink:label="lab_cpix_PinnacleBankMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pinnacle Bank</link:label>
    <link:label id="lab_cpix_PinnacleBankMember_label_en-US" xlink:label="lab_cpix_PinnacleBankMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pinnacle Bank [Member]</link:label>
    <link:label id="lab_cpix_PinnacleBankMember_documentation_en-US" xlink:label="lab_cpix_PinnacleBankMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pinnacle Bank</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PinnacleBankMember" xlink:href="cpix-20210930.xsd#cpix_PinnacleBankMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_PinnacleBankMember" xlink:to="lab_cpix_PinnacleBankMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3b92cfad-eb68-4831-a810-ffd6e7025ab0_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_dd58aa43-c0e0-41b6-b7c3-cb9386bfb8a1_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive effect of other securities (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number Diluted Shares Outstanding Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_e4778377-dc94-4b1f-8619-52427a54565b_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_cc980832-3ecf-4e14-9aa9-5f8526027d9f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of net revenue</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_c02e0115-3c5b-4caa-8b63-0a61890eb63f_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested common stock, value</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_9df3209b-ef22-4c70-a086-5f32ed13eb19_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_OtherLongTermObligationsExcludingCurrentPortion_e668ff77-257b-47d5-95c1-53ed3836143d_verboseLabel_en-US" xlink:label="lab_cpix_OtherLongTermObligationsExcludingCurrentPortion" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_cpix_OtherLongTermObligationsExcludingCurrentPortion_label_en-US" xlink:label="lab_cpix_OtherLongTermObligationsExcludingCurrentPortion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long Term Obligations, Excluding Current Portion</link:label>
    <link:label id="lab_cpix_OtherLongTermObligationsExcludingCurrentPortion_documentation_en-US" xlink:label="lab_cpix_OtherLongTermObligationsExcludingCurrentPortion" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long Term Obligations, Excluding Current Portion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OtherLongTermObligationsExcludingCurrentPortion" xlink:href="cpix-20210930.xsd#cpix_OtherLongTermObligationsExcludingCurrentPortion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_OtherLongTermObligationsExcludingCurrentPortion" xlink:to="lab_cpix_OtherLongTermObligationsExcludingCurrentPortion" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_e84ae1de-2dbb-4daf-8133-7a58abc10328_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_KristaloseMember_28f4d89a-c15d-41d9-b246-3894a0fc9c09_terseLabel_en-US" xlink:label="lab_cpix_KristaloseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Caldolor</link:label>
    <link:label id="lab_cpix_KristaloseMember_label_en-US" xlink:label="lab_cpix_KristaloseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kristalose [Member]</link:label>
    <link:label id="lab_cpix_KristaloseMember_documentation_en-US" xlink:label="lab_cpix_KristaloseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kristalose</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_KristaloseMember" xlink:href="cpix-20210930.xsd#cpix_KristaloseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_KristaloseMember" xlink:to="lab_cpix_KristaloseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8048c023-ff10-4ca2-834a-df5a64db3fe6_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_3fbf62b6-edc2-4f6a-a45c-bc78a871ea46_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_4e8ca241-b7fa-466b-9e86-c25408db27c3_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_ceb28ef1-a50c-4722-a67b-08fba54503ce_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_c09cc14f-554e-4944-abe4-452878647dca_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_f5f788e8-64c4-4151-9f0e-60134d4d2801_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) attributable to common shareholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_99abd81b-81c8-4b1f-9427-aeaae3b6db7d_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) attributable to common shareholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_dcad1441-9055-40a9-924f-8b7dcd84b56c_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityTable" xlink:to="lab_us-gaap_LineOfCreditFacilityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_955f9b93-9103-45fb-a044-f44937c7398c_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net changes in assets and liabilities affecting operating activities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_45b500b7-58e4-4d1b-85e9-9a5eb44f34cc_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_964865b5-0c07-4ccc-aba7-31122dc9aa23_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_118fcbbb-6bc4-48b5-880c-53759a8adc33_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_2e49a2c9-5628-403e-9357-97ce4ade7986_terseLabel_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIBOR</link:label>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_label_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">London Interbank Offered Rate (LIBOR) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:to="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_f4151a42-98b4-4c9f-a9c9-6bb3b8eae40c_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVENTORIES</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_AssetsAndLiabilitiesLesseeTableTextBlock_846bef98-c898-48b7-97ba-5ebd041261fa_terseLabel_en-US" xlink:label="lab_cpix_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Position</link:label>
    <link:label id="lab_cpix_AssetsAndLiabilitiesLesseeTableTextBlock_label_en-US" xlink:label="lab_cpix_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets and Liabilities, Lessee [Table Text Block]</link:label>
    <link:label id="lab_cpix_AssetsAndLiabilitiesLesseeTableTextBlock_documentation_en-US" xlink:label="lab_cpix_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets and Liabilities, Lessee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:href="cpix-20210930.xsd#cpix_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:to="lab_cpix_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_f898277b-1b5e-4c0d-ad20-9bded4577a39_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">REVENUES</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_cdb82503-acbe-464b-8ade-fb5c39eca066_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_bf7e6ff1-d7ca-4b6d-87cf-9bd05cbe78df_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_2ba3cf16-3699-401d-b9e0-415fee2936c0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consigned inventory</link:label>
    <link:label id="lab_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_label_en-US" xlink:label="lab_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Inventory, Materials, Supplies and Merchandise under Consignment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:to="lab_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_0093c07b-6df3-424c-aa63-27e96a59dc91_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_157b5115-f2b5-4356-9962-509836b105c4_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_3b552ea7-e388-4755-86ac-bbe858b59fbb_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_5c7f472a-87d5-4dce-8c51-56cc2e7ac5f8_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (loss) per share attributable to common shareholders</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_5ad20417-31f7-464c-b944-5e5274966e34_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_389394dd-e6f7-420b-84c0-dbe48e359d99_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued operations income</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:to="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_472cddc5-0309-4aeb-8a3c-6a4b62ca08d9_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_88d20df3-958e-492d-988d-7726396c5e1b_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_c239c088-c75b-4f42-9f67-bd8e3a086884_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_3a2cf5a6-5a04-4b35-b04e-54db2d742d2d_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_85e96250-22c4-4fa9-a820-df01471f2ebc_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_723c9a4f-ac0f-42de-a4dc-30a6d52a9f8c_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization expense</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock_300e36e1-2e37-406e-91bd-25a16b8587d3_terseLabel_en-US" xlink:label="lab_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Rent Expense and Sublease Income</link:label>
    <link:label id="lab_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock_label_en-US" xlink:label="lab_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Rent Expense and Sublease Income [Table Text Block]</link:label>
    <link:label id="lab_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock_documentation_en-US" xlink:label="lab_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Rent Expense and Sublease Income [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock" xlink:href="cpix-20210930.xsd#cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock" xlink:to="lab_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_11c9b705-b2a3-407b-b731-9fc8613db225_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_7e5c542a-1085-486a-80ed-c9ed03da2dac_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_acf1393a-281a-4a2b-baee-ca5b97551eaf_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:to="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_8c8982b7-34b0-407a-ab9d-665dc133b1ab_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_350c8871-fd1f-4ec9-9394-3622893f9962_verboseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_667f8d3d-d872-47f8-9147-f4429967ff50_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_6074a57f-12d0-4deb-9683-56bf1953bcbd_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_834d7af3-ffe2-43f8-9afc-04c6b51fe35d_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_cf059fdd-947d-4a92-bd8c-c32b58fb741b_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest_e9eb1be1-8a8f-4908-8071-c94861326816_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of subsidiary shares from noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Redeemable Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryTypeDomain_74c9d446-7d65-48a2-a8ee-48734df7c320_terseLabel_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Domain]</link:label>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryTypeDomain_label_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:to="lab_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_e5b06698-4ce9-4ef4-bd20-004b766ec9c1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rent expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_829ba49f-6d0a-49b0-b93a-1f0b7c3f6e0a_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtMember" xlink:to="lab_us-gaap_ConvertibleDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_7bb1f357-e7aa-4c5e-a3b3-687ebb5276db_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities_ccccbeb9-5041-4ea4-a31e-9740c8c97bb2_negatedLabel_en-US" xlink:label="lab_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in non-cash contingent consideration</link:label>
    <link:label id="lab_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities_label_en-US" xlink:label="lab_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Excess Tax Benefit from Share-based Compensation, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" xlink:to="lab_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_4c759502-6053-4212-a375-c2d9ff0066d8_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials and work in process</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_2e004447-bf76-4e62-89ad-37cf69b59a59_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_e0cc4439-0b79-48a9-be11-40081737af33_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate spread</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryGross_5bca70dd-6014-4c11-9f2b-db921bf491f5_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventories</link:label>
    <link:label id="lab_us-gaap_InventoryGross_label_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryGross" xlink:to="lab_us-gaap_InventoryGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_dd9315fe-768f-4e11-a03b-1d69610d366a_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income (loss) from continuing operations to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_3e342199-0521-4d51-ab27-d8e0202a9462_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (loss) per share attributable to common shareholders - Continuing operations - basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Basic Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f41eac8d-50e6-48e8-95ae-8bbde1361621_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_f74f781c-0801-4210-94a1-13a1a886c4ca_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ADDITIONS AND RETURN OF PRODUCT RIGHTS</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_72c5fce0-715a-486e-b07e-b94630c158da_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_a13079af-7b72-4e72-a526-07d5afd9ffb3_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, Beginning of Period (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_9c319f54-bc96-434f-8699-f06bcd1e6b7a_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, End of Period (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_c3ca7a72-edd8-44de-a947-f1f089b17a59_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturity of Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_2270b6a2-1d6e-43b3-a6ed-0d71cc99980b_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_307a4a61-a132-4842-be56-82d52f7b1974_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">- basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c98eb447-b910-4e00-bb4b-7651cbb73059_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares outstanding &#8211; basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_78d60bd6-0a4d-40c9-955d-311d1b9f131d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5fc8fd6f-85b1-4e05-b553-6f4fda3b320b_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) from continuing operations before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_217e1296-6bbc-4278-a5c0-a55cf788925a_verboseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_9075284b-544d-4680-b5ef-9b7e01633aa4_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial investment in joint ventures</link:label>
    <link:label id="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_label_en-US" xlink:label="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:to="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_735c9824-8609-4598-b51d-0a8b6a669153_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_f38136b6-78d1-43a2-bc32-7831e2185b5e_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_2d648eea-bd0e-49ee-87f7-61204c5f2205_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_011337ce-4e43-4806-8109-692ef37df91d_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_847bdad1-9c7a-4d8c-a9c4-813ed553fd8c_terseLabel_en-US" xlink:label="lab_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration earned and accrued in operating expenses</link:label>
    <link:label id="lab_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_label_en-US" xlink:label="lab_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Earned and Accrued in Operating Expenses</link:label>
    <link:label id="lab_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_documentation_en-US" xlink:label="lab_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Earned and Accrued in Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" xlink:href="cpix-20210930.xsd#cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" xlink:to="lab_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_MethotrexateMember_35b03d9d-a9fb-4116-a681-93eb5684b774_terseLabel_en-US" xlink:label="lab_cpix_MethotrexateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Methotrexate</link:label>
    <link:label id="lab_cpix_MethotrexateMember_label_en-US" xlink:label="lab_cpix_MethotrexateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Methotrexate [Member]</link:label>
    <link:label id="lab_cpix_MethotrexateMember_documentation_en-US" xlink:label="lab_cpix_MethotrexateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Methotrexate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_MethotrexateMember" xlink:href="cpix-20210930.xsd#cpix_MethotrexateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_MethotrexateMember" xlink:to="lab_cpix_MethotrexateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d89f28a9-1c25-48a1-9089-f8966b08780c_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3f6321e6-14db-4fc8-b348-b5e6a0733b1c_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, Beginning of Period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_594691ae-a5a6-4cab-bc14-9b99d9cc2ae5_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, End of Period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_b01b0015-0479-45c5-a66e-953576f6002b_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ORGANIZATION AND BASIS OF PRESENTATION</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_2538648d-3d3f-4b88-9adb-2efd2a42c284_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability recorded</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Liabilities Incurred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_505de6ae-d947-4964-b8c1-6dda926cb69c_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax (expense) benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d779209d-254a-4f0f-97e7-b0caa099a54a_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9b63a889-7a60-40f3-9b0d-441e727f3807_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_4e879178-8e8d-43ac-ba8a-9797f0ee9117_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Relationship to Entity [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_16199268-8b0a-4640-8c66-436a05aa8106_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease noncurrent liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_1240090f-1bdc-4d52-908b-7c633bc16826_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (loss) per share attributable to common shareholders - diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_1f04919e-8c17-4d51-9fa8-7e1745b6322f_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_0223f264-0fc8-44f6-8754-317a3872d05b_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net intangible assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_4a91b963-fdcf-42c2-af73-dadc7f651e3b_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment to acquire business upon closing</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_9f911661-7a86-4dc9-a5f5-b5e60fc586f6_terseLabel_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued operations</link:label>
    <link:label id="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Provided by (Used in) Operating Activities, Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:to="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_8e14c0a8-52b2-4559-9424-3518a5ba3708_verboseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_86323d48-24c8-4d73-8ed4-50e8d2fb071b_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_13127d95-71ca-46d1-b69b-01b00fc754f3_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_672c9548-8914-44be-be5b-30e81f996ea0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_cf1ecb56-e0a5-45a2-a0f9-8cd01689b134_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_5ab4b95a-5302-45b5-970c-7d6e555894ac_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_208c3654-6896-44e2-a5c1-5ab56906304c_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares left to repurchase</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Remaining Authorized Repurchase Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_d8db75ed-c5b7-44f9-b55b-97cd68e22da2_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_f042ac14-da1c-41af-be7f-7adc6c63ff11_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_EquityAndDebtAbstract_label_en-US" xlink:label="lab_cpix_EquityAndDebtAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity and Debt [Abstract]</link:label>
    <link:label id="lab_cpix_EquityAndDebtAbstract_documentation_en-US" xlink:label="lab_cpix_EquityAndDebtAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity and Debt [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_EquityAndDebtAbstract" xlink:href="cpix-20210930.xsd#cpix_EquityAndDebtAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_EquityAndDebtAbstract" xlink:to="lab_cpix_EquityAndDebtAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPaymentsToAcquireBusinesses_6f099b64-1c7b-4475-985e-8733e660de80_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPaymentsToAcquireBusinesses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Payments to Acquire Businesses</link:label>
    <link:label id="lab_us-gaap_OtherPaymentsToAcquireBusinesses_label_en-US" xlink:label="lab_us-gaap_OtherPaymentsToAcquireBusinesses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Payments to Acquire Businesses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPaymentsToAcquireBusinesses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPaymentsToAcquireBusinesses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPaymentsToAcquireBusinesses" xlink:to="lab_us-gaap_OtherPaymentsToAcquireBusinesses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermLineOfCredit_217c3632-1526-4638-9605-71663238639f_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermLineOfCredit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving line of credit</link:label>
    <link:label id="lab_us-gaap_LongTermLineOfCredit_label_en-US" xlink:label="lab_us-gaap_LongTermLineOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Line of Credit, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLineOfCredit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermLineOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermLineOfCredit" xlink:to="lab_us-gaap_LongTermLineOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseAmount_3b2d8ef7-1149-49ad-a167-2f0464643434_terseLabel_en-US" xlink:label="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase amount (up to)</link:label>
    <link:label id="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseAmount_label_en-US" xlink:label="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity, Increase Amount</link:label>
    <link:label id="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseAmount_documentation_en-US" xlink:label="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity, Increase Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseAmount" xlink:href="cpix-20210930.xsd#cpix_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseAmount" xlink:to="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_9c9bcaa5-e6d9-45a2-bb88-7b1fe1a477a1_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of credit, maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_4868713f-e24a-4a83-b90b-7853da6f36de_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_a06368eb-4775-48fc-8826-fc7df6922418_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_285e4a77-60d3-4482-9d72-6bce3782c149_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions to property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_IncreaseDecreaseInCurrentOperatingLiabilities_323bdd80-9781-4e97-82fd-5d95c2dc2d50_verboseLabel_en-US" xlink:label="lab_cpix_IncreaseDecreaseInCurrentOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and other current liabilities</link:label>
    <link:label id="lab_cpix_IncreaseDecreaseInCurrentOperatingLiabilities_label_en-US" xlink:label="lab_cpix_IncreaseDecreaseInCurrentOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IncreaseDecreaseInCurrentOperatingLiabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IncreaseDecreaseInCurrentOperatingLiabilities" xlink:href="cpix-20210930.xsd#cpix_IncreaseDecreaseInCurrentOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_IncreaseDecreaseInCurrentOperatingLiabilities" xlink:to="lab_cpix_IncreaseDecreaseInCurrentOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_0bac5b57-6a98-4755-9c3b-4e3996763336_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_2cf3ca75-43ce-41b4-9f50-6b09a3d6642e_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_94549b6d-975a-4014-9c43-e2cd5fa7b163_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash interest expense</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_c5d673f9-e10c-4112-a427-bcc94ec6afe2_verboseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_55f4da64-5a56-4846-b6d5-5ccab035469e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_b42afebc-2bf7-4d96-a070-a7a979757be5_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_205776a3-dcc9-493d-8bb9-5b06f3761d2d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_3fd89bf6-b24b-4774-85ad-50d4241e0291_periodStartLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_12c7bec0-5458-4829-8651-d46866019ee5_periodEndLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_6b41d781-2a3d-47db-a0ed-6ebbed5accac_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_29ae0167-a02d-43fc-9060-7051bac97b85_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash payment of contingent consideration</link:label>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Contingent Consideration Liability, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:to="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_6a064833-cb99-4852-af28-10527e15ff3e_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_1c21148b-8706-41f9-a398-fe2c091fbccf_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Note receivable investment funding</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_DirectorMember_3a3d4089-0f5f-4671-b480-cb0578108ee8_terseLabel_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director</link:label>
    <link:label id="lab_srt_DirectorMember_label_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_DirectorMember" xlink:to="lab_srt_DirectorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_f91ec9fe-5eb2-447b-8624-0be96211903c_verboseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase outstanding common shares</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_56862f30-5e72-476e-8cca-e0bc829db362_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_b97a80b4-4ccd-44fb-ad73-6eaf7c4ddeed_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_a87bffb9-93e9-40d1-80ed-c65f2925c0f0_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_04068c5b-b4f1-46b5-8892-a16cd6a60ed2_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d3cc080c-61a4-46eb-970b-7e5d6aa3047f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_07a406bc-237b-416b-9cec-6699b39a1f7c_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_3d7a4ee2-4f5e-409c-9577-116a3be0abee_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_960c23ec-ed4c-41af-90e1-649e121ffb15_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of credit, unused capacity, commitment fee percentage</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Unused Capacity, Commitment Fee Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:to="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_9476bb3f-7abe-4a1b-bc7f-1b29353fd34c_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_551797b4-0db6-45dd-9849-0e3a9a6c0b49_negatedLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common shares</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_c47972b7-fb0b-402a-854b-3534748e497a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of shares, value</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_3d4f1449-7ae5-498f-ab6f-fdcaf7b6e972_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_CaldolorMember_134a520a-14a6-4cf4-9a2b-fd95b8a7773f_terseLabel_en-US" xlink:label="lab_cpix_CaldolorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Omeclamox-Pak</link:label>
    <link:label id="lab_cpix_CaldolorMember_label_en-US" xlink:label="lab_cpix_CaldolorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Caldolor [Member]</link:label>
    <link:label id="lab_cpix_CaldolorMember_documentation_en-US" xlink:label="lab_cpix_CaldolorMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Caldolor</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CaldolorMember" xlink:href="cpix-20210930.xsd#cpix_CaldolorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_CaldolorMember" xlink:to="lab_cpix_CaldolorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNoncurrent_d6f1665d-623a-485b-bbf5-036a9476a272_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNoncurrent_2832f2c1-039c-4688-8d62-4d8e2a942115_negatedLabel_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Noncurrent</link:label>
    <link:label id="lab_us-gaap_InventoryNoncurrent_label_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNoncurrent" xlink:to="lab_us-gaap_InventoryNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_WinHealthInvestmentSingaporeLtdDomain_1ba0964d-de37-4b05-a2f0-3f097078b38c_terseLabel_en-US" xlink:label="lab_cpix_WinHealthInvestmentSingaporeLtdDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WinHealth</link:label>
    <link:label id="lab_cpix_WinHealthInvestmentSingaporeLtdDomain_label_en-US" xlink:label="lab_cpix_WinHealthInvestmentSingaporeLtdDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WinHealth Investment (Singapore) Ltd [Domain]</link:label>
    <link:label id="lab_cpix_WinHealthInvestmentSingaporeLtdDomain_documentation_en-US" xlink:label="lab_cpix_WinHealthInvestmentSingaporeLtdDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WinHealth Investment (Singapore) Ltd</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_WinHealthInvestmentSingaporeLtdDomain" xlink:href="cpix-20210930.xsd#cpix_WinHealthInvestmentSingaporeLtdDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_WinHealthInvestmentSingaporeLtdDomain" xlink:to="lab_cpix_WinHealthInvestmentSingaporeLtdDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_864fb04f-df21-4edb-87ec-96118fbc2200_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EARNINGS (LOSS) PER SHARE</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_06434ada-7380-46cf-96e6-8590b71c8f40_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net, Items Net of Reserve Alternative [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract" xlink:to="lab_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_99ebd9d1-895d-4622-a1bd-2f986c8a7b3b_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_ada52eea-fe3d-474d-be7c-9ecdbd9821c1_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities_3aec3ae6-0286-4705-9553-d6074cbac219_terseLabel_en-US" xlink:label="lab_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shelf Registration, sale of corporate securities (up to)</link:label>
    <link:label id="lab_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities_label_en-US" xlink:label="lab_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" xlink:href="cpix-20210930.xsd#cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" xlink:to="lab_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_69298c49-f1b9-4cce-a646-91a6cb3a7016_verboseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_97129af1-f923-4cc7-9bfc-2b4c675383eb_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyTable" xlink:to="lab_us-gaap_IncomeTaxContingencyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_88e03e95-b182-43c2-9362-6f74f7ae9170_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Guidance</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>cpix-20210930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:719f38f6-81ec-4e77-a876-c86386f0dd09,g:3c5f884f-ec0b-48db-97a2-96993ede30b3-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CoverPage" xlink:type="simple" xlink:href="cpix-20210930.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_ec77c3b6-0b4c-46b2-bddf-8f659c32e585" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_767fc1c4-937c-48e9-bf82-adb4cb8171ce" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ec77c3b6-0b4c-46b2-bddf-8f659c32e585" xlink:to="loc_dei_DocumentType_767fc1c4-937c-48e9-bf82-adb4cb8171ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_5af611e3-8bbd-4052-9a61-9afa0afededa" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ec77c3b6-0b4c-46b2-bddf-8f659c32e585" xlink:to="loc_dei_DocumentQuarterlyReport_5af611e3-8bbd-4052-9a61-9afa0afededa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_f2af0356-c9c1-4b04-81c0-671d3af10137" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ec77c3b6-0b4c-46b2-bddf-8f659c32e585" xlink:to="loc_dei_DocumentPeriodEndDate_f2af0356-c9c1-4b04-81c0-671d3af10137" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_ea12d151-9211-45f4-9fd4-e021878ea7ee" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ec77c3b6-0b4c-46b2-bddf-8f659c32e585" xlink:to="loc_dei_DocumentTransitionReport_ea12d151-9211-45f4-9fd4-e021878ea7ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_66a80edd-38cf-436f-8e1d-b08729caff81" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ec77c3b6-0b4c-46b2-bddf-8f659c32e585" xlink:to="loc_dei_EntityFileNumber_66a80edd-38cf-436f-8e1d-b08729caff81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_7c2487bc-3812-4f32-80a2-e98548dbc446" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ec77c3b6-0b4c-46b2-bddf-8f659c32e585" xlink:to="loc_dei_EntityRegistrantName_7c2487bc-3812-4f32-80a2-e98548dbc446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_87bca601-5ef8-46aa-89cb-32ded20a85c1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ec77c3b6-0b4c-46b2-bddf-8f659c32e585" xlink:to="loc_dei_EntityIncorporationStateCountryCode_87bca601-5ef8-46aa-89cb-32ded20a85c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_b83f941b-5e39-4a2d-aca0-c83b7e88a686" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ec77c3b6-0b4c-46b2-bddf-8f659c32e585" xlink:to="loc_dei_EntityTaxIdentificationNumber_b83f941b-5e39-4a2d-aca0-c83b7e88a686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_60b0f726-fb04-4bd7-a166-6c4041c2433a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ec77c3b6-0b4c-46b2-bddf-8f659c32e585" xlink:to="loc_dei_EntityAddressAddressLine1_60b0f726-fb04-4bd7-a166-6c4041c2433a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_343e35ed-2b94-4058-9c8b-9fb2b1807cfb" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ec77c3b6-0b4c-46b2-bddf-8f659c32e585" xlink:to="loc_dei_EntityAddressAddressLine2_343e35ed-2b94-4058-9c8b-9fb2b1807cfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_9b7c82b8-6ec5-4e6e-b793-0a3efef089a3" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ec77c3b6-0b4c-46b2-bddf-8f659c32e585" xlink:to="loc_dei_EntityAddressCityOrTown_9b7c82b8-6ec5-4e6e-b793-0a3efef089a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_70046838-485c-4afc-87af-25a3dd7db0c6" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ec77c3b6-0b4c-46b2-bddf-8f659c32e585" xlink:to="loc_dei_EntityAddressStateOrProvince_70046838-485c-4afc-87af-25a3dd7db0c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_34c70c34-d6e9-4e2d-a381-c560789a6ec0" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ec77c3b6-0b4c-46b2-bddf-8f659c32e585" xlink:to="loc_dei_EntityAddressPostalZipCode_34c70c34-d6e9-4e2d-a381-c560789a6ec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_e5355c8d-bf8d-4356-b157-f62dec2038d9" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ec77c3b6-0b4c-46b2-bddf-8f659c32e585" xlink:to="loc_dei_CityAreaCode_e5355c8d-bf8d-4356-b157-f62dec2038d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_3ae34a21-7bda-4c2c-9a3d-13466df9b610" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ec77c3b6-0b4c-46b2-bddf-8f659c32e585" xlink:to="loc_dei_LocalPhoneNumber_3ae34a21-7bda-4c2c-9a3d-13466df9b610" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_ff175e12-5981-4d36-bf5c-f5a0871281d7" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ec77c3b6-0b4c-46b2-bddf-8f659c32e585" xlink:to="loc_dei_Security12bTitle_ff175e12-5981-4d36-bf5c-f5a0871281d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_fc19c8f4-9603-47d2-af10-36e92925c9fa" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ec77c3b6-0b4c-46b2-bddf-8f659c32e585" xlink:to="loc_dei_TradingSymbol_fc19c8f4-9603-47d2-af10-36e92925c9fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_570cae4a-bc73-4c6b-8ae0-c2c4de1428a7" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ec77c3b6-0b4c-46b2-bddf-8f659c32e585" xlink:to="loc_dei_SecurityExchangeName_570cae4a-bc73-4c6b-8ae0-c2c4de1428a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_4b35b9d8-1ba8-4af0-b050-a90a8a696787" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ec77c3b6-0b4c-46b2-bddf-8f659c32e585" xlink:to="loc_dei_EntityCurrentReportingStatus_4b35b9d8-1ba8-4af0-b050-a90a8a696787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_e1a61dd7-c3c8-4b8c-80c8-d59732708fc4" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ec77c3b6-0b4c-46b2-bddf-8f659c32e585" xlink:to="loc_dei_EntityInteractiveDataCurrent_e1a61dd7-c3c8-4b8c-80c8-d59732708fc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_c592aa78-c078-4244-ae0a-544c6e648f67" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ec77c3b6-0b4c-46b2-bddf-8f659c32e585" xlink:to="loc_dei_EntityFilerCategory_c592aa78-c078-4244-ae0a-544c6e648f67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_3f18086c-dd9b-4b2b-9466-51ca4e29e7ce" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ec77c3b6-0b4c-46b2-bddf-8f659c32e585" xlink:to="loc_dei_EntitySmallBusiness_3f18086c-dd9b-4b2b-9466-51ca4e29e7ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_ad268d6d-6c12-4951-9ede-648e419df4d6" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ec77c3b6-0b4c-46b2-bddf-8f659c32e585" xlink:to="loc_dei_EntityEmergingGrowthCompany_ad268d6d-6c12-4951-9ede-648e419df4d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_452e9e5d-3130-4aef-8947-fe13eb2740f1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ec77c3b6-0b4c-46b2-bddf-8f659c32e585" xlink:to="loc_dei_EntityShellCompany_452e9e5d-3130-4aef-8947-fe13eb2740f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_691b8e9f-0fbd-4d3e-a096-9f702fea5b79" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ec77c3b6-0b4c-46b2-bddf-8f659c32e585" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_691b8e9f-0fbd-4d3e-a096-9f702fea5b79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_cc87a5aa-16b4-4a96-be38-b6196277767b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ec77c3b6-0b4c-46b2-bddf-8f659c32e585" xlink:to="loc_dei_DocumentFiscalYearFocus_cc87a5aa-16b4-4a96-be38-b6196277767b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_af286829-e724-408f-bc85-a4719d1cbccb" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ec77c3b6-0b4c-46b2-bddf-8f659c32e585" xlink:to="loc_dei_DocumentFiscalPeriodFocus_af286829-e724-408f-bc85-a4719d1cbccb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_46d78685-c3de-4e12-91f6-26b850a2faec" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ec77c3b6-0b4c-46b2-bddf-8f659c32e585" xlink:to="loc_dei_AmendmentFlag_46d78685-c3de-4e12-91f6-26b850a2faec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_a266276b-71ff-4388-ab47-c6ca7bd450d7" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ec77c3b6-0b4c-46b2-bddf-8f659c32e585" xlink:to="loc_dei_EntityCentralIndexKey_a266276b-71ff-4388-ab47-c6ca7bd450d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_1eccfaab-8ff8-49c1-b8d4-5cdb585ce839" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ec77c3b6-0b4c-46b2-bddf-8f659c32e585" xlink:to="loc_dei_CurrentFiscalYearEndDate_1eccfaab-8ff8-49c1-b8d4-5cdb585ce839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="cpix-20210930.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_ffe66e6e-0f52-4929-a4c1-2d8e7ebba50f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_892ecf04-a4d5-41b5-baa6-e8ab6d880d3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ffe66e6e-0f52-4929-a4c1-2d8e7ebba50f" xlink:to="loc_us-gaap_AssetsAbstract_892ecf04-a4d5-41b5-baa6-e8ab6d880d3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_571b98b9-c605-4830-ace9-d3808da40a6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_892ecf04-a4d5-41b5-baa6-e8ab6d880d3b" xlink:to="loc_us-gaap_AssetsCurrentAbstract_571b98b9-c605-4830-ace9-d3808da40a6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_57679b11-f7bc-4532-952a-ce77d3d59bfb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_571b98b9-c605-4830-ace9-d3808da40a6c" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_57679b11-f7bc-4532-952a-ce77d3d59bfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_f31798e1-097c-47a2-984e-ba70c4de8c87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_571b98b9-c605-4830-ace9-d3808da40a6c" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_f31798e1-097c-47a2-984e-ba70c4de8c87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_07becde2-a4a1-4c3a-8b22-e20ec4c41a9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_571b98b9-c605-4830-ace9-d3808da40a6c" xlink:to="loc_us-gaap_InventoryNet_07becde2-a4a1-4c3a-8b22-e20ec4c41a9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_06bbda03-f407-480b-8284-f9ae255c7d8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_571b98b9-c605-4830-ace9-d3808da40a6c" xlink:to="loc_us-gaap_OtherAssetsCurrent_06bbda03-f407-480b-8284-f9ae255c7d8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_9cd36b5d-776b-48ff-94a7-b26179c4d756" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_571b98b9-c605-4830-ace9-d3808da40a6c" xlink:to="loc_us-gaap_AssetsCurrent_9cd36b5d-776b-48ff-94a7-b26179c4d756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_6149ec1f-e60a-447e-83e1-ca63a3cfcc8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_892ecf04-a4d5-41b5-baa6-e8ab6d880d3b" xlink:to="loc_us-gaap_InventoryNoncurrent_6149ec1f-e60a-447e-83e1-ca63a3cfcc8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_cb49b72e-3833-4463-9054-85238d2f419c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_892ecf04-a4d5-41b5-baa6-e8ab6d880d3b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_cb49b72e-3833-4463-9054-85238d2f419c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_45b8de28-2fdf-443b-87de-087656f66870" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_892ecf04-a4d5-41b5-baa6-e8ab6d880d3b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_45b8de28-2fdf-443b-87de-087656f66870" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_0db4b9af-9714-4607-b35a-bc6f195db5c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_892ecf04-a4d5-41b5-baa6-e8ab6d880d3b" xlink:to="loc_us-gaap_Goodwill_0db4b9af-9714-4607-b35a-bc6f195db5c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_558f0fae-488a-48a4-8f2e-964357a7aac4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_892ecf04-a4d5-41b5-baa6-e8ab6d880d3b" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_558f0fae-488a-48a4-8f2e-964357a7aac4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_4862fe3c-8a94-4700-8d7c-57876d9b2a08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_892ecf04-a4d5-41b5-baa6-e8ab6d880d3b" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_4862fe3c-8a94-4700-8d7c-57876d9b2a08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_ed80c8ea-4ca3-4bec-a421-f8a4fe0d89cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_892ecf04-a4d5-41b5-baa6-e8ab6d880d3b" xlink:to="loc_us-gaap_Assets_ed80c8ea-4ca3-4bec-a421-f8a4fe0d89cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_aaf21e52-670c-4128-a958-0ecb72348703" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ffe66e6e-0f52-4929-a4c1-2d8e7ebba50f" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_aaf21e52-670c-4128-a958-0ecb72348703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_859badf4-f8a0-4329-b157-0c687ab700ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_aaf21e52-670c-4128-a958-0ecb72348703" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_859badf4-f8a0-4329-b157-0c687ab700ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_1b0455ef-cd46-49e7-9808-41dce04c4c53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_859badf4-f8a0-4329-b157-0c687ab700ed" xlink:to="loc_us-gaap_AccountsPayableCurrent_1b0455ef-cd46-49e7-9808-41dce04c4c53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_8250df14-4c01-45bd-abd4-034f9329ae5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_859badf4-f8a0-4329-b157-0c687ab700ed" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_8250df14-4c01-45bd-abd4-034f9329ae5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_9d7204a1-83ba-4245-b862-ac8bb61c299e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_859badf4-f8a0-4329-b157-0c687ab700ed" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_9d7204a1-83ba-4245-b862-ac8bb61c299e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_0a21f21a-2f11-438a-b78b-9ef6e3e5d75f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_859badf4-f8a0-4329-b157-0c687ab700ed" xlink:to="loc_us-gaap_LiabilitiesCurrent_0a21f21a-2f11-438a-b78b-9ef6e3e5d75f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLineOfCredit_67990b7d-e67b-480d-ae8d-ebf22c58a672" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermLineOfCredit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_aaf21e52-670c-4128-a958-0ecb72348703" xlink:to="loc_us-gaap_LongTermLineOfCredit_67990b7d-e67b-480d-ae8d-ebf22c58a672" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_da227c5f-3d02-49c5-b923-8103da7ee81c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_aaf21e52-670c-4128-a958-0ecb72348703" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_da227c5f-3d02-49c5-b923-8103da7ee81c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OtherLongTermObligationsExcludingCurrentPortion_e7653d40-136b-4397-9131-4a0ccb711d3a" xlink:href="cpix-20210930.xsd#cpix_OtherLongTermObligationsExcludingCurrentPortion"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_aaf21e52-670c-4128-a958-0ecb72348703" xlink:to="loc_cpix_OtherLongTermObligationsExcludingCurrentPortion_e7653d40-136b-4397-9131-4a0ccb711d3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_6cfd5b66-7030-4f77-a2d0-864b595f9c2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_aaf21e52-670c-4128-a958-0ecb72348703" xlink:to="loc_us-gaap_Liabilities_6cfd5b66-7030-4f77-a2d0-864b595f9c2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_7d650878-0416-4782-a75a-b5b84f1e68ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_aaf21e52-670c-4128-a958-0ecb72348703" xlink:to="loc_us-gaap_CommitmentsAndContingencies_7d650878-0416-4782-a75a-b5b84f1e68ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_5eb4e3a3-7b1a-4670-91fc-06b7488cfcaa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_aaf21e52-670c-4128-a958-0ecb72348703" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_5eb4e3a3-7b1a-4670-91fc-06b7488cfcaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_e9d74649-c0cb-4aef-b24f-4d6de9c4ba96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_5eb4e3a3-7b1a-4670-91fc-06b7488cfcaa" xlink:to="loc_us-gaap_StockholdersEquityAbstract_e9d74649-c0cb-4aef-b24f-4d6de9c4ba96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_c3563566-badb-4809-9864-cd5fe9b79deb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e9d74649-c0cb-4aef-b24f-4d6de9c4ba96" xlink:to="loc_us-gaap_CommonStockValue_c3563566-badb-4809-9864-cd5fe9b79deb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_7ff49158-360b-4d6b-8283-307fb2e30ab4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e9d74649-c0cb-4aef-b24f-4d6de9c4ba96" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_7ff49158-360b-4d6b-8283-307fb2e30ab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2b17e17d-c6d4-4195-9ee1-21b0f5c82d9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e9d74649-c0cb-4aef-b24f-4d6de9c4ba96" xlink:to="loc_us-gaap_StockholdersEquity_2b17e17d-c6d4-4195-9ee1-21b0f5c82d9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_833211f3-34bd-46e2-a1e5-16f480bee880" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_5eb4e3a3-7b1a-4670-91fc-06b7488cfcaa" xlink:to="loc_us-gaap_MinorityInterest_833211f3-34bd-46e2-a1e5-16f480bee880" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_062692e4-deef-4252-94b9-cf21359314ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_5eb4e3a3-7b1a-4670-91fc-06b7488cfcaa" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_062692e4-deef-4252-94b9-cf21359314ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_88010f5d-a973-4ec5-9ac1-dafb30e231c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_aaf21e52-670c-4128-a958-0ecb72348703" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_88010f5d-a973-4ec5-9ac1-dafb30e231c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="cpix-20210930.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_3661f40e-d655-494e-8ced-ac1809f45286" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNoParValue_fb033667-066d-4f2e-96c6-4a789810cedb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockNoParValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3661f40e-d655-494e-8ced-ac1809f45286" xlink:to="loc_us-gaap_CommonStockNoParValue_fb033667-066d-4f2e-96c6-4a789810cedb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_2e1f6b0f-508f-45f9-8e01-d1feaabd6c6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3661f40e-d655-494e-8ced-ac1809f45286" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_2e1f6b0f-508f-45f9-8e01-d1feaabd6c6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_01bc9d98-e6da-4a6e-be17-d88027f6ec2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3661f40e-d655-494e-8ced-ac1809f45286" xlink:to="loc_us-gaap_CommonStockSharesIssued_01bc9d98-e6da-4a6e-be17-d88027f6ec2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_47fabfcc-02d1-4c2e-a748-34fbf6d3fe0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3661f40e-d655-494e-8ced-ac1809f45286" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_47fabfcc-02d1-4c2e-a748-34fbf6d3fe0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="cpix-20210930.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_1fdd9377-64c7-47d2-9a44-c30c010757d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_99474948-f526-46e9-9f68-30e3eb05ca03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1fdd9377-64c7-47d2-9a44-c30c010757d1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_99474948-f526-46e9-9f68-30e3eb05ca03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_d10b269e-78e8-4a58-9465-f7bf9ad50f92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1fdd9377-64c7-47d2-9a44-c30c010757d1" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_d10b269e-78e8-4a58-9465-f7bf9ad50f92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_c72dd1e3-964f-4ff3-afc4-766a1eb81a5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_d10b269e-78e8-4a58-9465-f7bf9ad50f92" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_c72dd1e3-964f-4ff3-afc4-766a1eb81a5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_201b65f7-187a-4152-9383-77f749bf68b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_d10b269e-78e8-4a58-9465-f7bf9ad50f92" xlink:to="loc_us-gaap_SellingAndMarketingExpense_201b65f7-187a-4152-9383-77f749bf68b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_34d87d3c-cdb8-4922-8520-693903d8eb33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_d10b269e-78e8-4a58-9465-f7bf9ad50f92" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_34d87d3c-cdb8-4922-8520-693903d8eb33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_160b52e5-46fa-4155-99a4-74bf2eec6b65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_d10b269e-78e8-4a58-9465-f7bf9ad50f92" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_160b52e5-46fa-4155-99a4-74bf2eec6b65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_f8940f0e-c2b0-47cc-aaf7-58fd11a65b35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_d10b269e-78e8-4a58-9465-f7bf9ad50f92" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_f8940f0e-c2b0-47cc-aaf7-58fd11a65b35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_69033937-7a5d-41b9-b290-8965675f8b98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_d10b269e-78e8-4a58-9465-f7bf9ad50f92" xlink:to="loc_us-gaap_CostsAndExpenses_69033937-7a5d-41b9-b290-8965675f8b98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_de92a41f-aa67-4cc5-be0a-93555b7a083b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_d10b269e-78e8-4a58-9465-f7bf9ad50f92" xlink:to="loc_us-gaap_OperatingIncomeLoss_de92a41f-aa67-4cc5-be0a-93555b7a083b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_9328ed96-381b-464a-b9cc-a432a2c97d84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1fdd9377-64c7-47d2-9a44-c30c010757d1" xlink:to="loc_us-gaap_InvestmentIncomeInterest_9328ed96-381b-464a-b9cc-a432a2c97d84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncome_679076d1-bef2-4a45-a136-cd9459d7bffc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncome"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1fdd9377-64c7-47d2-9a44-c30c010757d1" xlink:to="loc_us-gaap_OtherIncome_679076d1-bef2-4a45-a136-cd9459d7bffc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_7eb9064b-34b9-4dc9-87d7-2633c719c352" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1fdd9377-64c7-47d2-9a44-c30c010757d1" xlink:to="loc_us-gaap_InterestExpense_7eb9064b-34b9-4dc9-87d7-2633c719c352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_90b2c91b-6591-4449-a9cc-aa82209cb625" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1fdd9377-64c7-47d2-9a44-c30c010757d1" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_90b2c91b-6591-4449-a9cc-aa82209cb625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_beefc4bc-fcf0-44b0-aa11-ba03e9647061" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1fdd9377-64c7-47d2-9a44-c30c010757d1" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_beefc4bc-fcf0-44b0-aa11-ba03e9647061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_94b6d8ad-d542-4fb4-be01-83ad45b6327e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1fdd9377-64c7-47d2-9a44-c30c010757d1" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_94b6d8ad-d542-4fb4-be01-83ad45b6327e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_48531f36-3b42-4c0a-841d-4e4800b1ec06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1fdd9377-64c7-47d2-9a44-c30c010757d1" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_48531f36-3b42-4c0a-841d-4e4800b1ec06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_f6ceeb65-6f20-4490-940e-f464bc0f6afa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1fdd9377-64c7-47d2-9a44-c30c010757d1" xlink:to="loc_us-gaap_ProfitLoss_f6ceeb65-6f20-4490-940e-f464bc0f6afa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_51f57c3a-faba-4611-a8b8-30c7afc3fb7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1fdd9377-64c7-47d2-9a44-c30c010757d1" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_51f57c3a-faba-4611-a8b8-30c7afc3fb7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_67c78635-0713-484b-81f9-666132a14f67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1fdd9377-64c7-47d2-9a44-c30c010757d1" xlink:to="loc_us-gaap_NetIncomeLoss_67c78635-0713-484b-81f9-666132a14f67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_d77a4f96-046d-453c-966e-9b1c0baace8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1fdd9377-64c7-47d2-9a44-c30c010757d1" xlink:to="loc_us-gaap_EarningsPerShareAbstract_d77a4f96-046d-453c-966e-9b1c0baace8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_fc89de75-287d-4f15-a5ce-0170f50d0bb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_d77a4f96-046d-453c-966e-9b1c0baace8a" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_fc89de75-287d-4f15-a5ce-0170f50d0bb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_1aac7f2a-6814-429a-9d97-d1cebdd36318" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_d77a4f96-046d-453c-966e-9b1c0baace8a" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_1aac7f2a-6814-429a-9d97-d1cebdd36318" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_b462ed0e-2216-4d34-a695-9fc6c74edd40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_d77a4f96-046d-453c-966e-9b1c0baace8a" xlink:to="loc_us-gaap_EarningsPerShareBasic_b462ed0e-2216-4d34-a695-9fc6c74edd40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_c10f21f6-6877-4fe0-b67d-9b3210a5d631" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_d77a4f96-046d-453c-966e-9b1c0baace8a" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_c10f21f6-6877-4fe0-b67d-9b3210a5d631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_995d2976-8851-4581-9743-eb291d3c04bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_d77a4f96-046d-453c-966e-9b1c0baace8a" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_995d2976-8851-4581-9743-eb291d3c04bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_1946fcbf-99f0-4bfd-9a3c-1b37b82ad853" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_d77a4f96-046d-453c-966e-9b1c0baace8a" xlink:to="loc_us-gaap_EarningsPerShareDiluted_1946fcbf-99f0-4bfd-9a3c-1b37b82ad853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_35d525fc-a104-4455-8cf4-22e30a13c7ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1fdd9377-64c7-47d2-9a44-c30c010757d1" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_35d525fc-a104-4455-8cf4-22e30a13c7ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_022a5d48-1e7c-4cff-91da-74030de19aa4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_35d525fc-a104-4455-8cf4-22e30a13c7ce" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_022a5d48-1e7c-4cff-91da-74030de19aa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_54124938-8b3e-4308-b636-181f9643661e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_35d525fc-a104-4455-8cf4-22e30a13c7ce" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_54124938-8b3e-4308-b636-181f9643661e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="cpix-20210930.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_3eaa57e0-d418-4736-b236-4d02b7ae1a48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b3b0e183-55b4-49f3-bd42-0ac6af7a2068" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3eaa57e0-d418-4736-b236-4d02b7ae1a48" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b3b0e183-55b4-49f3-bd42-0ac6af7a2068" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_3d31516b-441c-40f0-8ced-17cfd62e661b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b3b0e183-55b4-49f3-bd42-0ac6af7a2068" xlink:to="loc_us-gaap_ProfitLoss_3d31516b-441c-40f0-8ced-17cfd62e661b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_24968a04-237e-40d5-a399-722efdc58451" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b3b0e183-55b4-49f3-bd42-0ac6af7a2068" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_24968a04-237e-40d5-a399-722efdc58451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_25190442-77d4-4ca3-9912-d720884f6183" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b3b0e183-55b4-49f3-bd42-0ac6af7a2068" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_25190442-77d4-4ca3-9912-d720884f6183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f73dc048-4ff5-4fbf-a67e-32499150f2fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b3b0e183-55b4-49f3-bd42-0ac6af7a2068" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f73dc048-4ff5-4fbf-a67e-32499150f2fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_9b8253d2-2c06-40c4-9703-13d87adc0ec8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f73dc048-4ff5-4fbf-a67e-32499150f2fe" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_9b8253d2-2c06-40c4-9703-13d87adc0ec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_7a201ee6-2657-4420-9eb3-292c8ee8c1e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f73dc048-4ff5-4fbf-a67e-32499150f2fe" xlink:to="loc_us-gaap_ShareBasedCompensation_7a201ee6-2657-4420-9eb3-292c8ee8c1e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities_192964bb-d347-4510-9915-4a68285ad8e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f73dc048-4ff5-4fbf-a67e-32499150f2fe" xlink:to="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities_192964bb-d347-4510-9915-4a68285ad8e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy_5f136bcd-f385-4aa7-83fb-73859436fb35" xlink:href="cpix-20210930.xsd#cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f73dc048-4ff5-4fbf-a67e-32499150f2fe" xlink:to="loc_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy_5f136bcd-f385-4aa7-83fb-73859436fb35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_e0177350-6e8c-4202-bf7b-a2a89a6b001b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f73dc048-4ff5-4fbf-a67e-32499150f2fe" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_e0177350-6e8c-4202-bf7b-a2a89a6b001b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_17221856-b7ec-4ba2-809d-8c8562b40f07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f73dc048-4ff5-4fbf-a67e-32499150f2fe" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_17221856-b7ec-4ba2-809d-8c8562b40f07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_69a67b3d-a6fb-4d48-95c4-48f2c464472d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f73dc048-4ff5-4fbf-a67e-32499150f2fe" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_69a67b3d-a6fb-4d48-95c4-48f2c464472d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_ebf147ad-9afa-4512-876c-3a99e1d37f16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_69a67b3d-a6fb-4d48-95c4-48f2c464472d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_ebf147ad-9afa-4512-876c-3a99e1d37f16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_8a70a9b6-1317-455b-af54-c98847331cd6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_69a67b3d-a6fb-4d48-95c4-48f2c464472d" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_8a70a9b6-1317-455b-af54-c98847331cd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_9ea3cbdc-e10e-449b-8efc-26568a0b52e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_69a67b3d-a6fb-4d48-95c4-48f2c464472d" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_9ea3cbdc-e10e-449b-8efc-26568a0b52e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IncreaseDecreaseInCurrentOperatingLiabilities_8efc18d1-ed61-4478-aa4e-2e4bc45953da" xlink:href="cpix-20210930.xsd#cpix_IncreaseDecreaseInCurrentOperatingLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_69a67b3d-a6fb-4d48-95c4-48f2c464472d" xlink:to="loc_cpix_IncreaseDecreaseInCurrentOperatingLiabilities_8efc18d1-ed61-4478-aa4e-2e4bc45953da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_fa91f269-91c6-402c-8887-9b86356892ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_69a67b3d-a6fb-4d48-95c4-48f2c464472d" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_fa91f269-91c6-402c-8887-9b86356892ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_b3a849b5-bcd9-4138-9567-4fe8b7530b39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b3b0e183-55b4-49f3-bd42-0ac6af7a2068" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_b3a849b5-bcd9-4138-9567-4fe8b7530b39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_78b3b31c-4500-4aee-946b-3d29f6f7bca1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b3b0e183-55b4-49f3-bd42-0ac6af7a2068" xlink:to="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_78b3b31c-4500-4aee-946b-3d29f6f7bca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c25f78a2-9fb8-4dad-880d-c3030c722bc6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b3b0e183-55b4-49f3-bd42-0ac6af7a2068" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c25f78a2-9fb8-4dad-880d-c3030c722bc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5579325a-03fc-4aed-8e84-42be530dc37f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3eaa57e0-d418-4736-b236-4d02b7ae1a48" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5579325a-03fc-4aed-8e84-42be530dc37f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6bff0715-f497-419d-883e-60ad3fdb7617" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5579325a-03fc-4aed-8e84-42be530dc37f" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6bff0715-f497-419d-883e-60ad3fdb7617" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_f49586e2-da3d-4892-840c-7eaea82ab584" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5579325a-03fc-4aed-8e84-42be530dc37f" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_f49586e2-da3d-4892-840c-7eaea82ab584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_99110fb5-84a5-44ee-bdc1-f7f728991af5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5579325a-03fc-4aed-8e84-42be530dc37f" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_99110fb5-84a5-44ee-bdc1-f7f728991af5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_a2b72f66-cbda-4f3e-8c90-18947fe1696e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5579325a-03fc-4aed-8e84-42be530dc37f" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_a2b72f66-cbda-4f3e-8c90-18947fe1696e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_61657335-41ff-44c2-926a-fdb4870ca4e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5579325a-03fc-4aed-8e84-42be530dc37f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_61657335-41ff-44c2-926a-fdb4870ca4e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ecef48a7-878c-4c9b-ad9f-fd2a67ba4642" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3eaa57e0-d418-4736-b236-4d02b7ae1a48" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ecef48a7-878c-4c9b-ad9f-fd2a67ba4642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_308233e3-e8a9-498b-a786-895cf90d31fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfLinesOfCredit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ecef48a7-878c-4c9b-ad9f-fd2a67ba4642" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_308233e3-e8a9-498b-a786-895cf90d31fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_c3d47f14-df8c-40f6-9215-50d3dff2f26c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ecef48a7-878c-4c9b-ad9f-fd2a67ba4642" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_c3d47f14-df8c-40f6-9215-50d3dff2f26c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_199b14e1-dde3-4da4-b145-01912edfb1cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ecef48a7-878c-4c9b-ad9f-fd2a67ba4642" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_199b14e1-dde3-4da4-b145-01912edfb1cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest_cb3365f7-0231-4b1f-a240-a91d61a3292c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ecef48a7-878c-4c9b-ad9f-fd2a67ba4642" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest_cb3365f7-0231-4b1f-a240-a91d61a3292c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_b0135a9d-52a7-4174-8320-f49e40c03a07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ecef48a7-878c-4c9b-ad9f-fd2a67ba4642" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_b0135a9d-52a7-4174-8320-f49e40c03a07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6e1ec59c-d032-4dbd-81e2-78a8c70abfbd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ecef48a7-878c-4c9b-ad9f-fd2a67ba4642" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6e1ec59c-d032-4dbd-81e2-78a8c70abfbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_84448874-d3b8-4397-997a-be5f0a54616a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ecef48a7-878c-4c9b-ad9f-fd2a67ba4642" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_84448874-d3b8-4397-997a-be5f0a54616a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4ebbc035-1114-4da6-b815-2c7f52d47ac7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ecef48a7-878c-4c9b-ad9f-fd2a67ba4642" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4ebbc035-1114-4da6-b815-2c7f52d47ac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f4ba7273-b488-4d40-a2a6-e2e3cd0ef937" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ecef48a7-878c-4c9b-ad9f-fd2a67ba4642" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f4ba7273-b488-4d40-a2a6-e2e3cd0ef937" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity" xlink:type="simple" xlink:href="cpix-20210930.xsd#CondensedConsolidatedStatementofEquity"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_5dd9e7cd-72a8-41fe-b34e-002ec0a0a883" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_48306e8f-4abb-4cef-95d8-dd77dd686950" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_5dd9e7cd-72a8-41fe-b34e-002ec0a0a883" xlink:to="loc_us-gaap_StatementTable_48306e8f-4abb-4cef-95d8-dd77dd686950" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_b3dd39aa-22ee-4410-b263-056381d6530c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_48306e8f-4abb-4cef-95d8-dd77dd686950" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_b3dd39aa-22ee-4410-b263-056381d6530c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_9b72bcee-bd37-4a30-b13d-9f72fa193fca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b3dd39aa-22ee-4410-b263-056381d6530c" xlink:to="loc_us-gaap_EquityComponentDomain_9b72bcee-bd37-4a30-b13d-9f72fa193fca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_94341e32-a24a-4a97-b865-262cfefbee68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9b72bcee-bd37-4a30-b13d-9f72fa193fca" xlink:to="loc_us-gaap_CommonStockMember_94341e32-a24a-4a97-b865-262cfefbee68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_a8892951-fb38-4532-a2ab-f15f8516eb75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9b72bcee-bd37-4a30-b13d-9f72fa193fca" xlink:to="loc_us-gaap_RetainedEarningsMember_a8892951-fb38-4532-a2ab-f15f8516eb75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_97242877-524d-4dce-ae96-c586ca3ab29e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9b72bcee-bd37-4a30-b13d-9f72fa193fca" xlink:to="loc_us-gaap_NoncontrollingInterestMember_97242877-524d-4dce-ae96-c586ca3ab29e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f7c2e9a6-a36a-4563-a86c-80c1462f6f63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_48306e8f-4abb-4cef-95d8-dd77dd686950" xlink:to="loc_us-gaap_StatementLineItems_f7c2e9a6-a36a-4563-a86c-80c1462f6f63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1beabf0f-f1e7-4ae4-8f05-4e00568019c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f7c2e9a6-a36a-4563-a86c-80c1462f6f63" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1beabf0f-f1e7-4ae4-8f05-4e00568019c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2eea1cc5-8e2f-4469-8b3e-02b3f9ab92ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1beabf0f-f1e7-4ae4-8f05-4e00568019c7" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2eea1cc5-8e2f-4469-8b3e-02b3f9ab92ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_3fc53be7-de5a-4bc2-a466-e48647c29ebf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1beabf0f-f1e7-4ae4-8f05-4e00568019c7" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_3fc53be7-de5a-4bc2-a466-e48647c29ebf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_9ac63f16-655b-43be-a4e3-fef0c786814f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1beabf0f-f1e7-4ae4-8f05-4e00568019c7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_9ac63f16-655b-43be-a4e3-fef0c786814f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_a616b102-9203-43f3-ad9a-8794e1dea0b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1beabf0f-f1e7-4ae4-8f05-4e00568019c7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_a616b102-9203-43f3-ad9a-8794e1dea0b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_02261b60-5b81-4cea-97de-5518756f4827" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1beabf0f-f1e7-4ae4-8f05-4e00568019c7" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_02261b60-5b81-4cea-97de-5518756f4827" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_50403b23-09a6-463c-a646-4a8a4af80ca6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1beabf0f-f1e7-4ae4-8f05-4e00568019c7" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_50403b23-09a6-463c-a646-4a8a4af80ca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_0cf9e5e3-0e1f-4fb2-86c3-a5c4f6c85d03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1beabf0f-f1e7-4ae4-8f05-4e00568019c7" xlink:to="loc_us-gaap_ProfitLoss_0cf9e5e3-0e1f-4fb2-86c3-a5c4f6c85d03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7a25ff65-d2f8-40b3-8800-bc96f35ea165" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1beabf0f-f1e7-4ae4-8f05-4e00568019c7" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7a25ff65-d2f8-40b3-8800-bc96f35ea165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_115063ec-ba4d-423a-891f-54a20007d878" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1beabf0f-f1e7-4ae4-8f05-4e00568019c7" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_115063ec-ba4d-423a-891f-54a20007d878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentation" xlink:type="simple" xlink:href="cpix-20210930.xsd#OrganizationandBasisofPresentation"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c794028d-83c8-45f3-96f9-72978d0066c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_2ce6a5ed-d482-4711-b050-accbef7e9886" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c794028d-83c8-45f3-96f9-72978d0066c5" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_2ce6a5ed-d482-4711-b050-accbef7e9886" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies" xlink:type="simple" xlink:href="cpix-20210930.xsd#OrganizationandBasisofPresentationPolicies"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8d1bfef8-14db-4a0c-878f-68c1aca74543" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_f449f3bd-e568-4551-9e6c-6ca5771be21b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8d1bfef8-14db-4a0c-878f-68c1aca74543" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_f449f3bd-e568-4551-9e6c-6ca5771be21b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_425c6430-f7e8-4143-9a06-6a914a2b0b90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8d1bfef8-14db-4a0c-878f-68c1aca74543" xlink:to="loc_us-gaap_UseOfEstimates_425c6430-f7e8-4143-9a06-6a914a2b0b90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_374c61ac-504b-400c-b17e-8c094c724ec6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8d1bfef8-14db-4a0c-878f-68c1aca74543" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_374c61ac-504b-400c-b17e-8c094c724ec6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails" xlink:type="simple" xlink:href="cpix-20210930.xsd#OrganizationandBasisofPresentationOrganizationDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2b9c767a-d92a-4cf8-9e40-b2163b7a1c40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_5944d2e0-a8e9-4a72-810f-ceaea5607020" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2b9c767a-d92a-4cf8-9e40-b2163b7a1c40" xlink:to="loc_us-gaap_NumberOfOperatingSegments_5944d2e0-a8e9-4a72-810f-ceaea5607020" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShare" xlink:type="simple" xlink:href="cpix-20210930.xsd#EarningsLossPerShare"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_ae68cec4-8864-470a-82f2-2667df4514df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_5cee2f2a-35f5-4b7b-b59e-0e713f1663a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_ae68cec4-8864-470a-82f2-2667df4514df" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_5cee2f2a-35f5-4b7b-b59e-0e713f1663a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareTables" xlink:type="simple" xlink:href="cpix-20210930.xsd#EarningsLossPerShareTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_10f5c7f2-a8b0-4127-9405-d01c694c5762" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_9a1b6629-35d3-46ba-a925-9d54c8a655e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_10f5c7f2-a8b0-4127-9405-d01c694c5762" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_9a1b6629-35d3-46ba-a925-9d54c8a655e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails" xlink:type="simple" xlink:href="cpix-20210930.xsd#EarningsLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_12d1d28a-bea4-46ba-be33-ae526af00379" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NumeratorAbstract_86730865-95e6-42f5-835f-6c23ec3e2bf6" xlink:href="cpix-20210930.xsd#cpix_NumeratorAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_12d1d28a-bea4-46ba-be33-ae526af00379" xlink:to="loc_cpix_NumeratorAbstract_86730865-95e6-42f5-835f-6c23ec3e2bf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_f6c74408-8944-4be2-867f-fd536510202a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_NumeratorAbstract_86730865-95e6-42f5-835f-6c23ec3e2bf6" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_f6c74408-8944-4be2-867f-fd536510202a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_15818b69-e2d0-42d8-8b60-de7f91753b4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_NumeratorAbstract_86730865-95e6-42f5-835f-6c23ec3e2bf6" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_15818b69-e2d0-42d8-8b60-de7f91753b4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_66342459-6ec3-4360-9a72-1f003dd37c43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_NumeratorAbstract_86730865-95e6-42f5-835f-6c23ec3e2bf6" xlink:to="loc_us-gaap_ProfitLoss_66342459-6ec3-4360-9a72-1f003dd37c43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_89b1cf34-683f-4e8c-b96c-ab7a232e46f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_NumeratorAbstract_86730865-95e6-42f5-835f-6c23ec3e2bf6" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_89b1cf34-683f-4e8c-b96c-ab7a232e46f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_08e838db-5a4a-4624-b629-f21d3c2de662" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_NumeratorAbstract_86730865-95e6-42f5-835f-6c23ec3e2bf6" xlink:to="loc_us-gaap_NetIncomeLoss_08e838db-5a4a-4624-b629-f21d3c2de662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DenominatorAbstract_fdb25247-c122-48c7-af6d-ec8d2c7df86c" xlink:href="cpix-20210930.xsd#cpix_DenominatorAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_12d1d28a-bea4-46ba-be33-ae526af00379" xlink:to="loc_cpix_DenominatorAbstract_fdb25247-c122-48c7-af6d-ec8d2c7df86c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_48d45f0f-ffd9-42cc-9a9b-0a43c97a8572" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_DenominatorAbstract_fdb25247-c122-48c7-af6d-ec8d2c7df86c" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_48d45f0f-ffd9-42cc-9a9b-0a43c97a8572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_122aa0e3-2196-46bf-b354-f70cb294a817" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_DenominatorAbstract_fdb25247-c122-48c7-af6d-ec8d2c7df86c" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_122aa0e3-2196-46bf-b354-f70cb294a817" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a199ebda-d62a-4cb4-9120-91270a02c4c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_DenominatorAbstract_fdb25247-c122-48c7-af6d-ec8d2c7df86c" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a199ebda-d62a-4cb4-9120-91270a02c4c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetailsTextual" xlink:type="simple" xlink:href="cpix-20210930.xsd#EarningsLossPerShareDetailsTextual"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_15eeb482-8725-450a-b2f2-a714c83d016b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0e858139-342a-4307-8e5e-1bcd8fd82bf9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_15eeb482-8725-450a-b2f2-a714c83d016b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0e858139-342a-4307-8e5e-1bcd8fd82bf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Revenues" xlink:type="simple" xlink:href="cpix-20210930.xsd#Revenues"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/Revenues" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_8205e82a-c4a5-4c7b-8ffa-f88bbdcee8f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_69a633d1-300f-4481-8ff0-c28dd9c8dd3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_8205e82a-c4a5-4c7b-8ffa-f88bbdcee8f9" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_69a633d1-300f-4481-8ff0-c28dd9c8dd3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RevenuesTables" xlink:type="simple" xlink:href="cpix-20210930.xsd#RevenuesTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/RevenuesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_484aaab1-7e41-4e41-b42e-651e36d71fd1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_cb22c3c7-74f8-4284-b941-3366be25968a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_484aaab1-7e41-4e41-b42e-651e36d71fd1" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_cb22c3c7-74f8-4284-b941-3366be25968a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RevenuesDetails" xlink:type="simple" xlink:href="cpix-20210930.xsd#RevenuesDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/RevenuesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_acf50e2a-fec3-4c13-847e-e2331b8fdc1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_e425ca26-2d14-444f-b7fd-a4ca025fb0e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_acf50e2a-fec3-4c13-847e-e2331b8fdc1a" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_e425ca26-2d14-444f-b7fd-a4ca025fb0e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ea85ad4b-cddd-4c70-a69b-d422c9f973f7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_e425ca26-2d14-444f-b7fd-a4ca025fb0e4" xlink:to="loc_srt_ProductOrServiceAxis_ea85ad4b-cddd-4c70-a69b-d422c9f973f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c5dd95e8-54d6-4959-883d-f9a456f42934" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_ea85ad4b-cddd-4c70-a69b-d422c9f973f7" xlink:to="loc_srt_ProductsAndServicesDomain_c5dd95e8-54d6-4959-883d-f9a456f42934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AcetadoteMember_da36bad0-a580-4de6-bc72-a3d26324cd1b" xlink:href="cpix-20210930.xsd#cpix_AcetadoteMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c5dd95e8-54d6-4959-883d-f9a456f42934" xlink:to="loc_cpix_AcetadoteMember_da36bad0-a580-4de6-bc72-a3d26324cd1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OmeclamoxPakMember_c27b32ff-3a9d-4ae8-9470-f838a0bc70a1" xlink:href="cpix-20210930.xsd#cpix_OmeclamoxPakMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c5dd95e8-54d6-4959-883d-f9a456f42934" xlink:to="loc_cpix_OmeclamoxPakMember_c27b32ff-3a9d-4ae8-9470-f838a0bc70a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_KristaloseMember_8d10004d-9f1a-4b2f-8c06-0d85a0805803" xlink:href="cpix-20210930.xsd#cpix_KristaloseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c5dd95e8-54d6-4959-883d-f9a456f42934" xlink:to="loc_cpix_KristaloseMember_8d10004d-9f1a-4b2f-8c06-0d85a0805803" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VaprisolMember_a433841e-56a8-4f31-a0f5-1c9ac4523065" xlink:href="cpix-20210930.xsd#cpix_VaprisolMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c5dd95e8-54d6-4959-883d-f9a456f42934" xlink:to="loc_cpix_VaprisolMember_a433841e-56a8-4f31-a0f5-1c9ac4523065" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CaldolorMember_b0abc34d-da75-403b-a6be-5392060ff765" xlink:href="cpix-20210930.xsd#cpix_CaldolorMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c5dd95e8-54d6-4959-883d-f9a456f42934" xlink:to="loc_cpix_CaldolorMember_b0abc34d-da75-403b-a6be-5392060ff765" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_453c4bfa-ffbc-4f55-a4a0-59ed179c71c4" xlink:href="cpix-20210930.xsd#cpix_VIBATIVMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c5dd95e8-54d6-4959-883d-f9a456f42934" xlink:to="loc_cpix_VIBATIVMember_453c4bfa-ffbc-4f55-a4a0-59ed179c71c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_RediTrexMember_f65bdec8-433e-480f-96ba-4ca60e7d5249" xlink:href="cpix-20210930.xsd#cpix_RediTrexMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c5dd95e8-54d6-4959-883d-f9a456f42934" xlink:to="loc_cpix_RediTrexMember_f65bdec8-433e-480f-96ba-4ca60e7d5249" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OtherProductsMember_6c40e545-0aff-4bd1-bad2-a8cc67cad621" xlink:href="cpix-20210930.xsd#cpix_OtherProductsMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c5dd95e8-54d6-4959-883d-f9a456f42934" xlink:to="loc_cpix_OtherProductsMember_6c40e545-0aff-4bd1-bad2-a8cc67cad621" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember_6fa6505e-2e11-48e7-9bb7-b40fa8f1d88d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c5dd95e8-54d6-4959-883d-f9a456f42934" xlink:to="loc_us-gaap_GrantMember_6fa6505e-2e11-48e7-9bb7-b40fa8f1d88d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_734d2712-5858-4a27-a866-f899e4111979" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_e425ca26-2d14-444f-b7fd-a4ca025fb0e4" xlink:to="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_734d2712-5858-4a27-a866-f899e4111979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_cabf3418-a5ae-4f2d-bfa2-00edf4297517" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_734d2712-5858-4a27-a866-f899e4111979" xlink:to="loc_us-gaap_RevenuesAbstract_cabf3418-a5ae-4f2d-bfa2-00edf4297517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductsAbstract_b7f59a5d-573f-4c4b-907f-2d14d80f41f7" xlink:href="cpix-20210930.xsd#cpix_ProductsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_cabf3418-a5ae-4f2d-bfa2-00edf4297517" xlink:to="loc_cpix_ProductsAbstract_b7f59a5d-573f-4c4b-907f-2d14d80f41f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a9b697b5-652d-4f60-a2d7-25b146d15337" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ProductsAbstract_b7f59a5d-573f-4c4b-907f-2d14d80f41f7" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a9b697b5-652d-4f60-a2d7-25b146d15337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Inventories" xlink:type="simple" xlink:href="cpix-20210930.xsd#Inventories"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/Inventories" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_7f909bb7-9d3f-4cf0-9236-838dc6dab25a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_270b7c96-7876-46d0-9231-9ee55bbe146c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_7f909bb7-9d3f-4cf0-9236-838dc6dab25a" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_270b7c96-7876-46d0-9231-9ee55bbe146c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesTables" xlink:type="simple" xlink:href="cpix-20210930.xsd#InventoriesTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_8cc79562-fe62-43bb-aabc-ae7826777a2f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_2e5dce13-95ab-45b6-b7bd-88abe506ae76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_8cc79562-fe62-43bb-aabc-ae7826777a2f" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_2e5dce13-95ab-45b6-b7bd-88abe506ae76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails" xlink:type="simple" xlink:href="cpix-20210930.xsd#InventoriesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_2a12e4ce-4331-4b43-b869-cea6438adddc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_a0b336b1-ce47-4233-8c49-b2149cbf97b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryCurrentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_2a12e4ce-4331-4b43-b869-cea6438adddc" xlink:to="loc_us-gaap_InventoryCurrentTable_a0b336b1-ce47-4233-8c49-b2149cbf97b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_14e80154-b32c-4526-a987-e7dae298d58a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_a0b336b1-ce47-4233-8c49-b2149cbf97b0" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_14e80154-b32c-4526-a987-e7dae298d58a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_080a77a9-fbcc-4871-ad9a-9b29db13a53f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_14e80154-b32c-4526-a987-e7dae298d58a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_080a77a9-fbcc-4871-ad9a-9b29db13a53f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IfetrobanClinicalMember_762200de-c65f-4d46-92dd-adda1c9d1347" xlink:href="cpix-20210930.xsd#cpix_IfetrobanClinicalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_080a77a9-fbcc-4871-ad9a-9b29db13a53f" xlink:to="loc_cpix_IfetrobanClinicalMember_762200de-c65f-4d46-92dd-adda1c9d1347" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_d981f915-b2c0-4e48-8935-37217a2cc260" xlink:href="cpix-20210930.xsd#cpix_VIBATIVMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_080a77a9-fbcc-4871-ad9a-9b29db13a53f" xlink:to="loc_cpix_VIBATIVMember_d981f915-b2c0-4e48-8935-37217a2cc260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis_12a92061-068d-47a8-b4fa-e0f6209b630d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PublicUtilitiesInventoryAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_a0b336b1-ce47-4233-8c49-b2149cbf97b0" xlink:to="loc_us-gaap_PublicUtilitiesInventoryAxis_12a92061-068d-47a8-b4fa-e0f6209b630d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_62ea1003-d7f0-4193-9fa7-15a5f1339c82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_12a92061-068d-47a8-b4fa-e0f6209b630d" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_62ea1003-d7f0-4193-9fa7-15a5f1339c82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IfetrobanClinicalMember_f4ca23e0-d093-45be-91fe-e13d47a86b56" xlink:href="cpix-20210930.xsd#cpix_IfetrobanClinicalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_62ea1003-d7f0-4193-9fa7-15a5f1339c82" xlink:to="loc_cpix_IfetrobanClinicalMember_f4ca23e0-d093-45be-91fe-e13d47a86b56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_2677b945-1379-4f43-b473-fcbb33c8672a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_a0b336b1-ce47-4233-8c49-b2149cbf97b0" xlink:to="loc_us-gaap_InventoryLineItems_2677b945-1379-4f43-b473-fcbb33c8672a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves_6ceb65bc-3f32-448c-bd36-e8d24a182c40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryValuationReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_2677b945-1379-4f43-b473-fcbb33c8672a" xlink:to="loc_us-gaap_InventoryValuationReserves_6ceb65bc-3f32-448c-bd36-e8d24a182c40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_bdc2f651-0530-4433-920f-195aa7565b4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_2677b945-1379-4f43-b473-fcbb33c8672a" xlink:to="loc_us-gaap_InventoryNoncurrent_bdc2f651-0530-4433-920f-195aa7565b4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_bbf4892d-163a-4e3d-a2e7-2b4988289caa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_2677b945-1379-4f43-b473-fcbb33c8672a" xlink:to="loc_us-gaap_InventoryFinishedGoods_bbf4892d-163a-4e3d-a2e7-2b4988289caa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_0db0db49-31ad-434a-8794-a060fe279721" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_2677b945-1379-4f43-b473-fcbb33c8672a" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_0db0db49-31ad-434a-8794-a060fe279721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="simple" xlink:href="cpix-20210930.xsd#InventoriesScheduleofInventoriesDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_89ce02ce-599b-4087-880d-428939e90eb6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_8d8d0011-6408-4a14-a8e6-edd268f2f8bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_89ce02ce-599b-4087-880d-428939e90eb6" xlink:to="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_8d8d0011-6408-4a14-a8e6-edd268f2f8bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_849ecab8-2876-45e1-ac41-957c2f94e0ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_8d8d0011-6408-4a14-a8e6-edd268f2f8bf" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_849ecab8-2876-45e1-ac41-957c2f94e0ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_908374e2-cef1-4937-87aa-466657568eed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_8d8d0011-6408-4a14-a8e6-edd268f2f8bf" xlink:to="loc_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_908374e2-cef1-4937-87aa-466657568eed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_edfbfea3-6315-4cb1-8439-8102fd8137cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_8d8d0011-6408-4a14-a8e6-edd268f2f8bf" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_edfbfea3-6315-4cb1-8439-8102fd8137cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_a47530a9-4676-481b-8ad4-425ff1a6cd1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_8d8d0011-6408-4a14-a8e6-edd268f2f8bf" xlink:to="loc_us-gaap_InventoryGross_a47530a9-4676-481b-8ad4-425ff1a6cd1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_bbee3e60-5f78-4998-8356-b47cacb7edac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_8d8d0011-6408-4a14-a8e6-edd268f2f8bf" xlink:to="loc_us-gaap_InventoryNoncurrent_bbee3e60-5f78-4998-8356-b47cacb7edac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_ca4f3c80-d7d9-479c-a995-9c34c04519e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_8d8d0011-6408-4a14-a8e6-edd268f2f8bf" xlink:to="loc_us-gaap_InventoryNet_ca4f3c80-d7d9-479c-a995-9c34c04519e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Leases" xlink:type="simple" xlink:href="cpix-20210930.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_9f093e96-382a-4296-919e-8b61c7a4a0b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_ad175d67-48a7-4380-b869-a14b80ee4179" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9f093e96-382a-4296-919e-8b61c7a4a0b0" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_ad175d67-48a7-4380-b869-a14b80ee4179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesTables" xlink:type="simple" xlink:href="cpix-20210930.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_e68d60a7-a88e-4d1a-b56e-2910ec3117f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AssetsAndLiabilitiesLesseeTableTextBlock_52331d12-f6b7-417e-8819-fc08c9b352fb" xlink:href="cpix-20210930.xsd#cpix_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e68d60a7-a88e-4d1a-b56e-2910ec3117f0" xlink:to="loc_cpix_AssetsAndLiabilitiesLesseeTableTextBlock_52331d12-f6b7-417e-8819-fc08c9b352fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_f55bbd5c-8aaa-4e58-842b-2887a81f62fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e68d60a7-a88e-4d1a-b56e-2910ec3117f0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_f55bbd5c-8aaa-4e58-842b-2887a81f62fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock_940cf193-130a-48c9-bcb7-192c357ec192" xlink:href="cpix-20210930.xsd#cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e68d60a7-a88e-4d1a-b56e-2910ec3117f0" xlink:to="loc_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock_940cf193-130a-48c9-bcb7-192c357ec192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="cpix-20210930.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_11ad2850-6117-4824-846c-ea3e74a633b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_3bd25538-a25a-4f95-ac3a-183935816b0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_11ad2850-6117-4824-846c-ea3e74a633b0" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_3bd25538-a25a-4f95-ac3a-183935816b0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_744461e7-343f-4ce0-88e8-462cd55aea36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_3bd25538-a25a-4f95-ac3a-183935816b0d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_744461e7-343f-4ce0-88e8-462cd55aea36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8fb4ce31-a05c-40ef-92f7-f9e38d139381" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_744461e7-343f-4ce0-88e8-462cd55aea36" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8fb4ce31-a05c-40ef-92f7-f9e38d139381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_3fc8fde7-facd-4ec6-81d3-b7eed954ffac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BuildingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8fb4ce31-a05c-40ef-92f7-f9e38d139381" xlink:to="loc_us-gaap_BuildingMember_3fc8fde7-facd-4ec6-81d3-b7eed954ffac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OfficeBuildingMember_d1b199e9-1204-4946-b7ca-596cc966f447" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OfficeBuildingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8fb4ce31-a05c-40ef-92f7-f9e38d139381" xlink:to="loc_srt_OfficeBuildingMember_d1b199e9-1204-4946-b7ca-596cc966f447" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_1605487e-e0f6-4306-b5ca-7782f823edcd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_3bd25538-a25a-4f95-ac3a-183935816b0d" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_1605487e-e0f6-4306-b5ca-7782f823edcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_2d366c01-a172-4ddd-becb-3cd44be795e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1605487e-e0f6-4306-b5ca-7782f823edcd" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_2d366c01-a172-4ddd-becb-3cd44be795e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_bc317288-facc-46d7-8afe-50d71f1d6181" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1605487e-e0f6-4306-b5ca-7782f823edcd" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_bc317288-facc-46d7-8afe-50d71f1d6181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_47cadbee-2542-4917-9e1b-fac050365ff2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1605487e-e0f6-4306-b5ca-7782f823edcd" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_47cadbee-2542-4917-9e1b-fac050365ff2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_677942a7-adcf-467b-be5c-ee7208957a17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1605487e-e0f6-4306-b5ca-7782f823edcd" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_677942a7-adcf-467b-be5c-ee7208957a17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails" xlink:type="simple" xlink:href="cpix-20210930.xsd#LeasesLeasePositionDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_275e5ded-3c47-464d-ab05-f19b3914315e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_e4d46404-3f3f-4ba1-a47f-92cd3d79cb8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_275e5ded-3c47-464d-ab05-f19b3914315e" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_e4d46404-3f3f-4ba1-a47f-92cd3d79cb8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_ad6a6870-6979-417a-9f69-ecdfa83458a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_275e5ded-3c47-464d-ab05-f19b3914315e" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_ad6a6870-6979-417a-9f69-ecdfa83458a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_de22e49c-5bc4-44fd-96a1-29039a065f8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_275e5ded-3c47-464d-ab05-f19b3914315e" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_de22e49c-5bc4-44fd-96a1-29039a065f8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LeaseLiability_70e790ed-cbe8-4db6-869b-36eb05ecdb9b" xlink:href="cpix-20210930.xsd#cpix_LeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_275e5ded-3c47-464d-ab05-f19b3914315e" xlink:to="loc_cpix_LeaseLiability_70e790ed-cbe8-4db6-869b-36eb05ecdb9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails" xlink:type="simple" xlink:href="cpix-20210930.xsd#LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_c557d582-cbd0-4ddd-9a90-e2a3b70b2db2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b3493c17-e86d-4929-83f7-3a21f8b65ffd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c557d582-cbd0-4ddd-9a90-e2a3b70b2db2" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b3493c17-e86d-4929-83f7-3a21f8b65ffd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2707376e-9766-4a7f-9974-cc459e830724" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b3493c17-e86d-4929-83f7-3a21f8b65ffd" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2707376e-9766-4a7f-9974-cc459e830724" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2ff68d75-40ba-4ad0-8053-b417324a27e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b3493c17-e86d-4929-83f7-3a21f8b65ffd" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2ff68d75-40ba-4ad0-8053-b417324a27e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_7173fe7b-5726-45bf-914d-f34acf5f88aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b3493c17-e86d-4929-83f7-3a21f8b65ffd" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_7173fe7b-5726-45bf-914d-f34acf5f88aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree_74714087-3411-4d29-bbf6-e1767fb7ee48" xlink:href="cpix-20210930.xsd#cpix_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b3493c17-e86d-4929-83f7-3a21f8b65ffd" xlink:to="loc_cpix_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree_74714087-3411-4d29-bbf6-e1767fb7ee48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_91b3d778-7999-4905-a18e-197d4a0b8aa9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b3493c17-e86d-4929-83f7-3a21f8b65ffd" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_91b3d778-7999-4905-a18e-197d4a0b8aa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_4c2a873a-6b85-4732-b948-71dda70989a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b3493c17-e86d-4929-83f7-3a21f8b65ffd" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_4c2a873a-6b85-4732-b948-71dda70989a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_0ddcab65-1ecd-4d27-9081-343ca5edc556" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b3493c17-e86d-4929-83f7-3a21f8b65ffd" xlink:to="loc_us-gaap_OperatingLeaseLiability_0ddcab65-1ecd-4d27-9081-343ca5edc556" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1" xlink:type="simple" xlink:href="cpix-20210930.xsd#LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesRentExpenseDetails" xlink:type="simple" xlink:href="cpix-20210930.xsd#LeasesRentExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesRentExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_1ab5ec62-00d0-457e-a54b-68cdfc1f36b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_a68fd26b-1112-466d-b8f6-597b2df5b09a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1ab5ec62-00d0-457e-a54b-68cdfc1f36b3" xlink:to="loc_us-gaap_OperatingLeaseExpense_a68fd26b-1112-466d-b8f6-597b2df5b09a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_9f14da69-c232-4d66-bd63-cb42a0987ea3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1ab5ec62-00d0-457e-a54b-68cdfc1f36b3" xlink:to="loc_us-gaap_SubleaseIncome_9f14da69-c232-4d66-bd63-cb42a0987ea3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt" xlink:type="simple" xlink:href="cpix-20210930.xsd#ShareholdersEquityandDebt"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cpix_EquityAndDebtAbstract_b0f72f43-3386-4fb5-83ee-abf29b7446bb" xlink:href="cpix-20210930.xsd#cpix_EquityAndDebtAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_ba90729d-fc19-447a-97bf-d645b49ac822" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_EquityAndDebtAbstract_b0f72f43-3386-4fb5-83ee-abf29b7446bb" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_ba90729d-fc19-447a-97bf-d645b49ac822" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" xlink:type="simple" xlink:href="cpix-20210930.xsd#ShareholdersEquityandDebtShareholdersEquityDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cpix_EquityAndDebtAbstract_6f64fc3b-18f2-464a-b72b-7f003b3d83f6" xlink:href="cpix-20210930.xsd#cpix_EquityAndDebtAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_41dc7f81-ea80-40fe-9466-2dfb24a12be8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_EquityAndDebtAbstract_6f64fc3b-18f2-464a-b72b-7f003b3d83f6" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_41dc7f81-ea80-40fe-9466-2dfb24a12be8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_d32074c5-5f6d-47b6-9172-975d23300470" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_41dc7f81-ea80-40fe-9466-2dfb24a12be8" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_d32074c5-5f6d-47b6-9172-975d23300470" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6d214517-3496-46ea-b310-30f77abd0996" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d32074c5-5f6d-47b6-9172-975d23300470" xlink:to="loc_us-gaap_EquityComponentDomain_6d214517-3496-46ea-b310-30f77abd0996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_3dccb701-ecec-4cf5-a759-0ec3baa98c2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6d214517-3496-46ea-b310-30f77abd0996" xlink:to="loc_us-gaap_CommonStockMember_3dccb701-ecec-4cf5-a759-0ec3baa98c2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_41ae3094-cee4-4790-8a7f-6effec343507" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_41dc7f81-ea80-40fe-9466-2dfb24a12be8" xlink:to="loc_srt_TitleOfIndividualAxis_41ae3094-cee4-4790-8a7f-6effec343507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_710fbba4-f8bf-413c-b4d8-a4a63861569e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_41ae3094-cee4-4790-8a7f-6effec343507" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_710fbba4-f8bf-413c-b4d8-a4a63861569e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_c81f76fa-d84c-4861-870c-10246eb57530" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_710fbba4-f8bf-413c-b4d8-a4a63861569e" xlink:to="loc_srt_DirectorMember_c81f76fa-d84c-4861-870c-10246eb57530" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_bf4734b9-db34-4a30-b055-516c4bd90cda" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_41dc7f81-ea80-40fe-9466-2dfb24a12be8" xlink:to="loc_us-gaap_AwardTypeAxis_bf4734b9-db34-4a30-b055-516c4bd90cda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c91843c0-6910-4bf2-91ce-aecef678f90a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_bf4734b9-db34-4a30-b055-516c4bd90cda" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c91843c0-6910-4bf2-91ce-aecef678f90a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_fa712a3e-6ba7-4031-9718-f1b31b804988" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c91843c0-6910-4bf2-91ce-aecef678f90a" xlink:to="loc_us-gaap_RestrictedStockMember_fa712a3e-6ba7-4031-9718-f1b31b804988" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IncentiveStockOptionsMember_f1b2e523-068c-4244-afae-aa23f410c504" xlink:href="cpix-20210930.xsd#cpix_IncentiveStockOptionsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c91843c0-6910-4bf2-91ce-aecef678f90a" xlink:to="loc_cpix_IncentiveStockOptionsMember_f1b2e523-068c-4244-afae-aa23f410c504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_cd0a5b70-ff7b-4dc1-8255-7fc05e87e5e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_41dc7f81-ea80-40fe-9466-2dfb24a12be8" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_cd0a5b70-ff7b-4dc1-8255-7fc05e87e5e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_b1874aba-29cf-4026-bf29-9e9098194f28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_cd0a5b70-ff7b-4dc1-8255-7fc05e87e5e5" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_b1874aba-29cf-4026-bf29-9e9098194f28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PinnacleBankMember_aca55c95-33f0-41d2-93f8-44354c26b34b" xlink:href="cpix-20210930.xsd#cpix_PinnacleBankMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_b1874aba-29cf-4026-bf29-9e9098194f28" xlink:to="loc_cpix_PinnacleBankMember_aca55c95-33f0-41d2-93f8-44354c26b34b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0e2d7da7-4ea8-4146-be48-882ec29b6419" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_41dc7f81-ea80-40fe-9466-2dfb24a12be8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0e2d7da7-4ea8-4146-be48-882ec29b6419" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ShareholdersEquityTextualAbstract_dce969f5-2d4b-419b-a3a1-22d26930068b" xlink:href="cpix-20210930.xsd#cpix_ShareholdersEquityTextualAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0e2d7da7-4ea8-4146-be48-882ec29b6419" xlink:to="loc_cpix_ShareholdersEquityTextualAbstract_dce969f5-2d4b-419b-a3a1-22d26930068b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_a899ac8b-6845-402d-a04e-be85c00dec06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_dce969f5-2d4b-419b-a3a1-22d26930068b" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_a899ac8b-6845-402d-a04e-be85c00dec06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_5f8700fb-8183-4a3e-8204-72cad17effcb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_dce969f5-2d4b-419b-a3a1-22d26930068b" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_5f8700fb-8183-4a3e-8204-72cad17effcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_28de0e93-1d84-4a8d-bcbd-f9fc6ee2438a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_dce969f5-2d4b-419b-a3a1-22d26930068b" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_28de0e93-1d84-4a8d-bcbd-f9fc6ee2438a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_157796a8-03d2-4355-9e26-67e8f44f04c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_dce969f5-2d4b-419b-a3a1-22d26930068b" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_157796a8-03d2-4355-9e26-67e8f44f04c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities_a02c5b3f-77e9-406d-ad14-19bcc22189b9" xlink:href="cpix-20210930.xsd#cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_dce969f5-2d4b-419b-a3a1-22d26930068b" xlink:to="loc_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities_a02c5b3f-77e9-406d-ad14-19bcc22189b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_0125cc7e-b8e5-4a55-b545-65ed3bb675d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_dce969f5-2d4b-419b-a3a1-22d26930068b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_0125cc7e-b8e5-4a55-b545-65ed3bb675d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_36ce7cc7-bbb1-4df2-891c-29d7f7bccfdd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_dce969f5-2d4b-419b-a3a1-22d26930068b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_36ce7cc7-bbb1-4df2-891c-29d7f7bccfdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" xlink:type="simple" xlink:href="cpix-20210930.xsd#ShareholdersEquityandDebtDebtDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cpix_EquityAndDebtAbstract_c09e9f12-4874-4f92-93c5-ea4f4ae3d877" xlink:href="cpix-20210930.xsd#cpix_EquityAndDebtAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_01c9923a-72fd-45af-ac69-a5257d0f792e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_EquityAndDebtAbstract_c09e9f12-4874-4f92-93c5-ea4f4ae3d877" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_01c9923a-72fd-45af-ac69-a5257d0f792e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_6864e921-e812-4edd-873e-8260d55a21f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_01c9923a-72fd-45af-ac69-a5257d0f792e" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_6864e921-e812-4edd-873e-8260d55a21f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_d92cf7c3-acf0-445d-91b4-98ece5460a4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_6864e921-e812-4edd-873e-8260d55a21f7" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_d92cf7c3-acf0-445d-91b4-98ece5460a4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PinnacleBankMember_9426523c-ee34-44cb-9b21-e8ee279e6bda" xlink:href="cpix-20210930.xsd#cpix_PinnacleBankMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_d92cf7c3-acf0-445d-91b4-98ece5460a4d" xlink:to="loc_cpix_PinnacleBankMember_9426523c-ee34-44cb-9b21-e8ee279e6bda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_cc405239-fcb9-47f7-9cf9-039cbdb4c098" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_01c9923a-72fd-45af-ac69-a5257d0f792e" xlink:to="loc_us-gaap_DebtInstrumentAxis_cc405239-fcb9-47f7-9cf9-039cbdb4c098" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_bbf31dc4-f31a-4748-9d12-c3ba40937f45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_cc405239-fcb9-47f7-9cf9-039cbdb4c098" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_bbf31dc4-f31a-4748-9d12-c3ba40937f45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_8de6865d-d462-41cd-af3e-15f891b60a13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bbf31dc4-f31a-4748-9d12-c3ba40937f45" xlink:to="loc_us-gaap_LineOfCreditMember_8de6865d-d462-41cd-af3e-15f891b60a13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_FifthAmendmentMember_bbea2c9b-79d3-445d-a3ca-aaccf7d2c846" xlink:href="cpix-20210930.xsd#cpix_FifthAmendmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bbf31dc4-f31a-4748-9d12-c3ba40937f45" xlink:to="loc_cpix_FifthAmendmentMember_bbea2c9b-79d3-445d-a3ca-aaccf7d2c846" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_e9f6b071-ea2f-4d19-9f4e-86307cb14ddd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_01c9923a-72fd-45af-ac69-a5257d0f792e" xlink:to="loc_us-gaap_CreditFacilityAxis_e9f6b071-ea2f-4d19-9f4e-86307cb14ddd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_af38b56e-af38-48bb-8364-72b3186bbee3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_e9f6b071-ea2f-4d19-9f4e-86307cb14ddd" xlink:to="loc_us-gaap_CreditFacilityDomain_af38b56e-af38-48bb-8364-72b3186bbee3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_95918447-3505-47af-ad1b-0592d35373b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_af38b56e-af38-48bb-8364-72b3186bbee3" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_95918447-3505-47af-ad1b-0592d35373b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_37e49cb7-02f9-4b86-b101-165a22600ed8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_01c9923a-72fd-45af-ac69-a5257d0f792e" xlink:to="loc_srt_RangeAxis_37e49cb7-02f9-4b86-b101-165a22600ed8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7a943b86-710f-4c02-94a4-ba6342b423a5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_37e49cb7-02f9-4b86-b101-165a22600ed8" xlink:to="loc_srt_RangeMember_7a943b86-710f-4c02-94a4-ba6342b423a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_58342083-abf1-44ec-88f7-c13fc3267a80" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7a943b86-710f-4c02-94a4-ba6342b423a5" xlink:to="loc_srt_MinimumMember_58342083-abf1-44ec-88f7-c13fc3267a80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ea1f666b-786a-4341-8820-986b3dc0ec6b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7a943b86-710f-4c02-94a4-ba6342b423a5" xlink:to="loc_srt_MaximumMember_ea1f666b-786a-4341-8820-986b3dc0ec6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_bfdfb4ef-0c0b-47f0-bd51-0f4cd6edaf10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_01c9923a-72fd-45af-ac69-a5257d0f792e" xlink:to="loc_us-gaap_VariableRateAxis_bfdfb4ef-0c0b-47f0-bd51-0f4cd6edaf10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_9f544c4e-7e90-4a11-8f60-9d1e9aba05a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_bfdfb4ef-0c0b-47f0-bd51-0f4cd6edaf10" xlink:to="loc_us-gaap_VariableRateDomain_9f544c4e-7e90-4a11-8f60-9d1e9aba05a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_f5d724d4-b1b7-422d-98c9-5860decfec72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_9f544c4e-7e90-4a11-8f60-9d1e9aba05a7" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_f5d724d4-b1b7-422d-98c9-5860decfec72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_a3b1fa9d-4cf7-4b7e-a15d-3b8cf5214470" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_01c9923a-72fd-45af-ac69-a5257d0f792e" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_a3b1fa9d-4cf7-4b7e-a15d-3b8cf5214470" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1b4f56ad-9040-494c-b289-ae859ad917ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_a3b1fa9d-4cf7-4b7e-a15d-3b8cf5214470" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1b4f56ad-9040-494c-b289-ae859ad917ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_d831bec9-5b8a-483f-9710-600e88c1faa1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1b4f56ad-9040-494c-b289-ae859ad917ba" xlink:to="loc_us-gaap_ConvertibleDebtMember_d831bec9-5b8a-483f-9710-600e88c1faa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_41974df7-1702-4478-8286-3fc979ad0750" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_01c9923a-72fd-45af-ac69-a5257d0f792e" xlink:to="loc_srt_CounterpartyNameAxis_41974df7-1702-4478-8286-3fc979ad0750" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ba476a30-0ed1-47b3-bce0-757a8d98986a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_41974df7-1702-4478-8286-3fc979ad0750" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ba476a30-0ed1-47b3-bce0-757a8d98986a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_WinHealthInvestmentSingaporeLtdDomain_f6a8060e-a0bf-4a73-b18a-df0d3777553c" xlink:href="cpix-20210930.xsd#cpix_WinHealthInvestmentSingaporeLtdDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ba476a30-0ed1-47b3-bce0-757a8d98986a" xlink:to="loc_cpix_WinHealthInvestmentSingaporeLtdDomain_f6a8060e-a0bf-4a73-b18a-df0d3777553c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_735b1b51-6332-4d24-b5a6-497cfb878f10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_01c9923a-72fd-45af-ac69-a5257d0f792e" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_735b1b51-6332-4d24-b5a6-497cfb878f10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_675fa301-8020-4ef1-9e39-0531b0875be7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_735b1b51-6332-4d24-b5a6-497cfb878f10" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_675fa301-8020-4ef1-9e39-0531b0875be7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_87926cf0-c5a8-4783-9759-8a912f95af1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_675fa301-8020-4ef1-9e39-0531b0875be7" xlink:to="loc_us-gaap_SubsequentEventMember_87926cf0-c5a8-4783-9759-8a912f95af1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_107d8361-6c54-4f69-82ff-ae58438b3065" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_01c9923a-72fd-45af-ac69-a5257d0f792e" xlink:to="loc_us-gaap_LineOfCreditFacilityLineItems_107d8361-6c54-4f69-82ff-ae58438b3065" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_4342889b-966b-49b2-a0d0-a0209fd6d59c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_107d8361-6c54-4f69-82ff-ae58438b3065" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_4342889b-966b-49b2-a0d0-a0209fd6d59c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseAmount_b15a0fc3-1dd8-4590-b882-1c6b5fc45389" xlink:href="cpix-20210930.xsd#cpix_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_107d8361-6c54-4f69-82ff-ae58438b3065" xlink:to="loc_cpix_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseAmount_b15a0fc3-1dd8-4590-b882-1c6b5fc45389" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LineOfCreditFacilityMaximumBorrowingCapacityTotalCapacity_0411c40d-3134-458d-9a69-815c52a7e0c8" xlink:href="cpix-20210930.xsd#cpix_LineOfCreditFacilityMaximumBorrowingCapacityTotalCapacity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_107d8361-6c54-4f69-82ff-ae58438b3065" xlink:to="loc_cpix_LineOfCreditFacilityMaximumBorrowingCapacityTotalCapacity_0411c40d-3134-458d-9a69-815c52a7e0c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_22d0e154-ec5d-40b7-96df-ed7ae7b5f597" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_107d8361-6c54-4f69-82ff-ae58438b3065" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_22d0e154-ec5d-40b7-96df-ed7ae7b5f597" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_3502b971-58b5-484a-996d-f56df0013cfc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_107d8361-6c54-4f69-82ff-ae58438b3065" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_3502b971-58b5-484a-996d-f56df0013cfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_5a321987-37bf-48e5-8a47-082f153f030f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_107d8361-6c54-4f69-82ff-ae58438b3065" xlink:to="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_5a321987-37bf-48e5-8a47-082f153f030f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived_cc8ecf62-dd77-4011-9a81-87d2e3da5973" xlink:href="cpix-20210930.xsd#cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_107d8361-6c54-4f69-82ff-ae58438b3065" xlink:to="loc_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived_cc8ecf62-dd77-4011-9a81-87d2e3da5973" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLineOfCredit_4d15000e-ff90-49dc-b56d-4e2dc6257ec7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermLineOfCredit"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_107d8361-6c54-4f69-82ff-ae58438b3065" xlink:to="loc_us-gaap_LongTermLineOfCredit_4d15000e-ff90-49dc-b56d-4e2dc6257ec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_a4e49abf-46a3-44d7-82d5-edc64d35e2fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_107d8361-6c54-4f69-82ff-ae58438b3065" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_a4e49abf-46a3-44d7-82d5-edc64d35e2fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_47b529f0-bd21-4b1d-943b-5af2709f30ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_107d8361-6c54-4f69-82ff-ae58438b3065" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_47b529f0-bd21-4b1d-943b-5af2709f30ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxes" xlink:type="simple" xlink:href="cpix-20210930.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_ce0d0b0f-c128-46d8-b2f9-372029be3a99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_af305417-447c-4022-aac0-490a9da59466" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ce0d0b0f-c128-46d8-b2f9-372029be3a99" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_af305417-447c-4022-aac0-490a9da59466" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual" xlink:type="simple" xlink:href="cpix-20210930.xsd#IncomeTaxesDetailsTextual"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_f6ebda8e-8616-4e4c-893e-28c78f9dace3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_12e749c2-0c29-434c-bf52-a0475ce44ac0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f6ebda8e-8616-4e4c-893e-28c78f9dace3" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_12e749c2-0c29-434c-bf52-a0475ce44ac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_f82cd8d9-ea8d-4bd9-a01b-3925e3e0ca63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_12e749c2-0c29-434c-bf52-a0475ce44ac0" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_f82cd8d9-ea8d-4bd9-a01b-3925e3e0ca63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_13c626d2-9a2c-4fa7-aa11-4dcefbe71155" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_f82cd8d9-ea8d-4bd9-a01b-3925e3e0ca63" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_13c626d2-9a2c-4fa7-aa11-4dcefbe71155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_f3ec2b82-7017-45e2-b743-54380977ea69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_13c626d2-9a2c-4fa7-aa11-4dcefbe71155" xlink:to="loc_us-gaap_DomesticCountryMember_f3ec2b82-7017-45e2-b743-54380977ea69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_2b9fa7b0-59ff-4c6e-8458-84e58541a496" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_12e749c2-0c29-434c-bf52-a0475ce44ac0" xlink:to="loc_us-gaap_IncomeTaxContingencyLineItems_2b9fa7b0-59ff-4c6e-8458-84e58541a496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_dc041ee2-e7fb-4b58-8b16-73fad793b169" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_2b9fa7b0-59ff-4c6e-8458-84e58541a496" xlink:to="loc_us-gaap_OperatingLossCarryforwards_dc041ee2-e7fb-4b58-8b16-73fad793b169" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CollaborativeAgreements" xlink:type="simple" xlink:href="cpix-20210930.xsd#CollaborativeAgreements"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/CollaborativeAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_48f9da30-4449-4233-8765-dcd99f3390c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_3b113f4d-6bc6-4b8a-b9f2-da34a73ac59d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_48f9da30-4449-4233-8765-dcd99f3390c8" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_3b113f4d-6bc6-4b8a-b9f2-da34a73ac59d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRights" xlink:type="simple" xlink:href="cpix-20210930.xsd#AdditionsandReturnsofProductRights"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRights" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_e8df8145-a24a-4de8-ae8f-8472d6dbac3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_bb59baa3-6eb3-4333-8a16-86ea562aec46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_e8df8145-a24a-4de8-ae8f-8472d6dbac3f" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_bb59baa3-6eb3-4333-8a16-86ea562aec46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsTables" xlink:type="simple" xlink:href="cpix-20210930.xsd#AdditionsandReturnsofProductRightsTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_b91027c4-ebc1-45b6-a14e-a0be68517371" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_7a63d797-e7b7-4124-a794-e0e68af96d77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_b91027c4-ebc1-45b6-a14e-a0be68517371" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_7a63d797-e7b7-4124-a794-e0e68af96d77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_32885043-b411-4575-a33d-23fae15e7173" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_b91027c4-ebc1-45b6-a14e-a0be68517371" xlink:to="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_32885043-b411-4575-a33d-23fae15e7173" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails" xlink:type="simple" xlink:href="cpix-20210930.xsd#AdditionsandReturnsofProductRightsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_94ecfb0d-2da9-497e-8f6c-a30e45b95377" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_20673524-8b4c-43bb-97aa-412ed7e82950" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_94ecfb0d-2da9-497e-8f6c-a30e45b95377" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_20673524-8b4c-43bb-97aa-412ed7e82950" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_310c4c54-a67c-4ea0-9ce2-0558ce1d9672" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_20673524-8b4c-43bb-97aa-412ed7e82950" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_310c4c54-a67c-4ea0-9ce2-0558ce1d9672" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_559237ab-2ebb-4cd0-90d2-9ecb0f6b87ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_310c4c54-a67c-4ea0-9ce2-0558ce1d9672" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_559237ab-2ebb-4cd0-90d2-9ecb0f6b87ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_0e55168e-d2e5-42e5-8203-c9e286e0ae59" xlink:href="cpix-20210930.xsd#cpix_VIBATIVMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_559237ab-2ebb-4cd0-90d2-9ecb0f6b87ba" xlink:to="loc_cpix_VIBATIVMember_0e55168e-d2e5-42e5-8203-c9e286e0ae59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_MethotrexateMember_1518488e-ed09-4d1e-9ef3-1d35173e328d" xlink:href="cpix-20210930.xsd#cpix_MethotrexateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_559237ab-2ebb-4cd0-90d2-9ecb0f6b87ba" xlink:to="loc_cpix_MethotrexateMember_1518488e-ed09-4d1e-9ef3-1d35173e328d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_da3d62f9-c1f6-4a0d-abbf-c43ee51cca4a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_20673524-8b4c-43bb-97aa-412ed7e82950" xlink:to="loc_srt_CounterpartyNameAxis_da3d62f9-c1f6-4a0d-abbf-c43ee51cca4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_270d9c0e-fa4a-4b7c-b301-e2e484aaeb6b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_da3d62f9-c1f6-4a0d-abbf-c43ee51cca4a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_270d9c0e-fa4a-4b7c-b301-e2e484aaeb6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ClinigenHealthcareLimitedMember_f2507615-d2bc-4876-ba61-957136b2a54c" xlink:href="cpix-20210930.xsd#cpix_ClinigenHealthcareLimitedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_270d9c0e-fa4a-4b7c-b301-e2e484aaeb6b" xlink:to="loc_cpix_ClinigenHealthcareLimitedMember_f2507615-d2bc-4876-ba61-957136b2a54c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_05d54064-360d-4db8-bae2-91d4d395ae72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_20673524-8b4c-43bb-97aa-412ed7e82950" xlink:to="loc_us-gaap_AwardTypeAxis_05d54064-360d-4db8-bae2-91d4d395ae72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a30148bf-073f-49d7-832b-fe0dcfbb21d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_05d54064-360d-4db8-bae2-91d4d395ae72" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a30148bf-073f-49d7-832b-fe0dcfbb21d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_bb345acd-2fb3-430f-9e10-86d8e893249a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a30148bf-073f-49d7-832b-fe0dcfbb21d5" xlink:to="loc_us-gaap_RestrictedStockMember_bb345acd-2fb3-430f-9e10-86d8e893249a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_a7064d94-240e-4007-b5ef-bfaea09e4900" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_20673524-8b4c-43bb-97aa-412ed7e82950" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_a7064d94-240e-4007-b5ef-bfaea09e4900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_61ac4cd5-5856-473a-b95d-c6f63d95effa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_a7064d94-240e-4007-b5ef-bfaea09e4900" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_61ac4cd5-5856-473a-b95d-c6f63d95effa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_42c04725-0271-4d1e-8d37-a546c8bf8b98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_61ac4cd5-5856-473a-b95d-c6f63d95effa" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_42c04725-0271-4d1e-8d37-a546c8bf8b98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_43dd8daf-1c8d-447e-9574-9fb2ec91c375" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_61ac4cd5-5856-473a-b95d-c6f63d95effa" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_43dd8daf-1c8d-447e-9574-9fb2ec91c375" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_d8dec2bb-d3fa-4dde-b4f3-6296f7e75fe5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_20673524-8b4c-43bb-97aa-412ed7e82950" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_d8dec2bb-d3fa-4dde-b4f3-6296f7e75fe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_9c1a2f96-471d-456e-ab80-76d6f344d483" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d8dec2bb-d3fa-4dde-b4f3-6296f7e75fe5" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_9c1a2f96-471d-456e-ab80-76d6f344d483" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPaymentsToAcquireBusinesses_42c4ef9e-6ea8-4026-b173-751816282868" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPaymentsToAcquireBusinesses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d8dec2bb-d3fa-4dde-b4f3-6296f7e75fe5" xlink:to="loc_us-gaap_OtherPaymentsToAcquireBusinesses_42c4ef9e-6ea8-4026-b173-751816282868" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_TieredRoyaltyPaymentsPercentage_7d7fe71d-78db-4b6a-92e7-6fbdd81abe94" xlink:href="cpix-20210930.xsd#cpix_TieredRoyaltyPaymentsPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d8dec2bb-d3fa-4dde-b4f3-6296f7e75fe5" xlink:to="loc_cpix_TieredRoyaltyPaymentsPercentage_7d7fe71d-78db-4b6a-92e7-6fbdd81abe94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_4c947c7b-a8c5-4ab8-8c75-4f62023e5331" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d8dec2bb-d3fa-4dde-b4f3-6296f7e75fe5" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_4c947c7b-a8c5-4ab8-8c75-4f62023e5331" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_c13db486-f28a-43f0-a8c5-3c47cb6bebfc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d8dec2bb-d3fa-4dde-b4f3-6296f7e75fe5" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_c13db486-f28a-43f0-a8c5-3c47cb6bebfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_2dfdf1f2-5e47-4999-870f-25da027166c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d8dec2bb-d3fa-4dde-b4f3-6296f7e75fe5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_2dfdf1f2-5e47-4999-870f-25da027166c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_5cd5359e-b410-455f-bc81-0bf641fa18bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d8dec2bb-d3fa-4dde-b4f3-6296f7e75fe5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_5cd5359e-b410-455f-bc81-0bf641fa18bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_dadd1450-b296-4708-9488-b0b765216fcc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d8dec2bb-d3fa-4dde-b4f3-6296f7e75fe5" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_dadd1450-b296-4708-9488-b0b765216fcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_93993c6c-dabe-4afe-97ed-ffcfb855715a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d8dec2bb-d3fa-4dde-b4f3-6296f7e75fe5" xlink:to="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_93993c6c-dabe-4afe-97ed-ffcfb855715a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProceedsFromSaleOfIntangibleAssetsInstallmentPayment_2b94563c-3af2-4bb3-980a-d08fa6701ba1" xlink:href="cpix-20210930.xsd#cpix_ProceedsFromSaleOfIntangibleAssetsInstallmentPayment"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d8dec2bb-d3fa-4dde-b4f3-6296f7e75fe5" xlink:to="loc_cpix_ProceedsFromSaleOfIntangibleAssetsInstallmentPayment_2b94563c-3af2-4bb3-980a-d08fa6701ba1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_9a9f1ec0-c15a-4466-bfc2-d6a3d5f17cbe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d8dec2bb-d3fa-4dde-b4f3-6296f7e75fe5" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_9a9f1ec0-c15a-4466-bfc2-d6a3d5f17cbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails" xlink:type="simple" xlink:href="cpix-20210930.xsd#AdditionsandReturnsofProductRightsChangeinConsiderationDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_aea67cc1-ddf8-4fd0-829b-7a38d8a1a549" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_430dbb52-e367-4e81-b9fd-a4c71bfa1577" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_aea67cc1-ddf8-4fd0-829b-7a38d8a1a549" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_430dbb52-e367-4e81-b9fd-a4c71bfa1577" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_7e648ce0-f9b4-4737-8d54-25bf96ed4285" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_430dbb52-e367-4e81-b9fd-a4c71bfa1577" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_7e648ce0-f9b4-4737-8d54-25bf96ed4285" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1a447d0a-5e08-4530-bd4d-f58a112f826a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7e648ce0-f9b4-4737-8d54-25bf96ed4285" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1a447d0a-5e08-4530-bd4d-f58a112f826a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_3c730611-9292-4681-9abc-9973fbe40a2d" xlink:href="cpix-20210930.xsd#cpix_VIBATIVMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1a447d0a-5e08-4530-bd4d-f58a112f826a" xlink:to="loc_cpix_VIBATIVMember_3c730611-9292-4681-9abc-9973fbe40a2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_c7d7c39f-2747-4349-8157-5084f6d99ab4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_430dbb52-e367-4e81-b9fd-a4c71bfa1577" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_c7d7c39f-2747-4349-8157-5084f6d99ab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualRollForward_69719e0a-48c0-4796-8d5c-2b42027ad89a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyAccrualRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c7d7c39f-2747-4349-8157-5084f6d99ab4" xlink:to="loc_us-gaap_LossContingencyAccrualRollForward_69719e0a-48c0-4796-8d5c-2b42027ad89a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_907d8116-5347-41c8-b2d7-f03415937612" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_69719e0a-48c0-4796-8d5c-2b42027ad89a" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_907d8116-5347-41c8-b2d7-f03415937612" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRoyalties_121ee9c3-7bc9-491f-8e79-2c926aa6ef59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRoyalties"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_69719e0a-48c0-4796-8d5c-2b42027ad89a" xlink:to="loc_us-gaap_PaymentsForRoyalties_121ee9c3-7bc9-491f-8e79-2c926aa6ef59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_ee318128-bf86-4927-8e67-51fdc5b47ff7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_69719e0a-48c0-4796-8d5c-2b42027ad89a" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_ee318128-bf86-4927-8e67-51fdc5b47ff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_ac1ee07e-698f-46a8-b06e-ec16d17c1e15" xlink:href="cpix-20210930.xsd#cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_69719e0a-48c0-4796-8d5c-2b42027ad89a" xlink:to="loc_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_ac1ee07e-698f-46a8-b06e-ec16d17c1e15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_e049554e-8d44-4e09-bba3-7f63810708ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_69719e0a-48c0-4796-8d5c-2b42027ad89a" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_e049554e-8d44-4e09-bba3-7f63810708ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsDissolutionPaymentsDetails" xlink:type="simple" xlink:href="cpix-20210930.xsd#AdditionsandReturnsofProductRightsDissolutionPaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsDissolutionPaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_b53702ec-5b65-4b3f-97cc-ff54b6fceeb9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d5178dc6-a611-4ff8-a504-8d579dab36f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_b53702ec-5b65-4b3f-97cc-ff54b6fceeb9" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d5178dc6-a611-4ff8-a504-8d579dab36f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_9a4992ae-e38f-4cfd-955b-251316829cd8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d5178dc6-a611-4ff8-a504-8d579dab36f5" xlink:to="loc_srt_CounterpartyNameAxis_9a4992ae-e38f-4cfd-955b-251316829cd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_23e661db-e953-4963-8450-a34584c2c841" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_9a4992ae-e38f-4cfd-955b-251316829cd8" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_23e661db-e953-4963-8450-a34584c2c841" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ClinigenHealthcareLimitedMember_39221abf-bb00-4648-9275-c66638c9b9f0" xlink:href="cpix-20210930.xsd#cpix_ClinigenHealthcareLimitedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_23e661db-e953-4963-8450-a34584c2c841" xlink:to="loc_cpix_ClinigenHealthcareLimitedMember_39221abf-bb00-4648-9275-c66638c9b9f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_5ffaf73d-e852-4b6a-8166-b950defb28eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d5178dc6-a611-4ff8-a504-8d579dab36f5" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_5ffaf73d-e852-4b6a-8166-b950defb28eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_27d02636-cbfb-4208-b0e4-bf1d6e6f3ef7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5ffaf73d-e852-4b6a-8166-b950defb28eb" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_27d02636-cbfb-4208-b0e4-bf1d6e6f3ef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_874ee80e-526b-4260-8434-d695346293fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5ffaf73d-e852-4b6a-8166-b950defb28eb" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_874ee80e-526b-4260-8434-d695346293fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_176d68d4-abc5-412b-b5c1-941628452b93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5ffaf73d-e852-4b6a-8166-b950defb28eb" xlink:to="loc_us-gaap_SellingAndMarketingExpense_176d68d4-abc5-412b-b5c1-941628452b93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_96bb49e8-f2af-4ba7-a358-17a73cab9569" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5ffaf73d-e852-4b6a-8166-b950defb28eb" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_96bb49e8-f2af-4ba7-a358-17a73cab9569" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>pinnaclelocrenewal4thloa001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pinnaclelocrenewal4thloa001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@"!&S.Z^@%3U7C_X_)1Z**L4 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110!7C_X_9?]T58J!/\ CZD^@J>@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** *Z?\ 'S)] *L57CYN)?\ @-6* "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH KQ?\?$OX58JM!_KI?J/Y59H
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"K!_KYAZ,/_0:M
M55M_^/FX_P!\#_QVK5 !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 58/^/FX_ZZ#_T&K55H/]=,?]L?^@U9H **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@"M;_ .NF_P"N@_\ 0:LU5MO]?<?]=/\ V45:
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"I;?ZZ<_]-/Z
M8JW52TY><_\ 30U;H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@"I8];C_KJ:MU3L>MQ_UU-7* "BBB@ HHHH **** "BBB@ HHHH ****
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M8%CS^=0'P/KQSF\\-DDY.=#3D_\ ?=.A\'>)+299K>^\-QRJ<JZ:*%9?H0U
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M*^MGMKJQ\)S0/+YSQ/'*5=_[Q'0GZTVR\/\ B_39%DL=.\'VSJ,*T4$BE1W
M(Z4 =?X?@GL?#>EVEVV^Y@M8HIFSN^<( >?K6G5/3A??8HO[1,)N]O[WR00A
M/MGG%7* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** *6GG*SY_Y[-5VJ.G?<E_Z[-5Z@ HHHH
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MLX^JU4T>ZTO1(M<MK/Q;IRV>JERUN]C+MAW9'R<]@<?@*VSK'@RXU?0]6O\
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M2K+/(Y9I'Q\QR>>3FN \&:I=?$/5M7U&^O;V#3[2416ME;7#P  Y^9V0AF.
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MG:3M#.-@4^H.WMZ?\!-<[_PF>M^&?%P.NW!N?#E[=SVL,QB13;,DK)R0HR,
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M.F#]1[U>T_?HW@*[\+275E?D1S1VES:WD*##9*EPTBE2&/;/3\P"]XROM?\
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M_P"%<>#_ /H6=/\ ^_0_QIO_  K3P:>/^$9L1_VS_P#KUUU% '(?\*Q\'?\
M0NV/_?L_XT?\*R\']O#]F/HI']:Z^B@#D?\ A6?A#_H VOY'_&E'PU\(C_F
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MM,O"%7)CD*&)PH #'&0>_P"E;D$Y6ZM1:>')H7QY3S.L<8BBSEAD,2>>P[U
M?#Z:UX;N]+U2UD@+W5Q+$Y92T9:5W212I."-P_4=* ,V_P!0UJ'2+ZZ.K-#*
M=96TM=L41 B:=(\$%3D@%^_8&K/B34=3\(62:RU_+J.GQ.JW=O<)$LFUCM#1
MLJJ,@D<$'/M6'JFC>)%\ 0V!AEO-8CU/SS+&%&X).6$G)P,@ X]ZZ#Q%97GB
MS3TT<6%Q:65Q*K7=Q/L!5%.[:JAB=Q( SC !)H KW&O7FE>/(K>ZU%)=&NV^
MRJC(H-M=%0ZJ6 '#+TR3UY[5'KOB'4&\?:+H.FW0@MI'=;V145F+",R!!N!
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MC('V>7YB@R.#VVKO(]P*K_#J^MHX=4\,1W/VE-*G(MW)SOMGY3GO@DJ>W H
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MK,T>JSRB4.JYCCC#!P?FX(;;TSP#C/% '5O;021+$\,;1K]U"H('X5(%"@
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M.&!YFF:- ID8 %L=R!Q^58^I^')M1\166KKJ;VS643QPI'"I^_C<6+9ST7'
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M/GI"^SS'3&01AL<CIDBL^X\:V]MI<FHR:5J8M8K9+F5]D?R*W0'+_>Q@X&<
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MA-:M_H.DZI"D-_IMK<Q([.J2Q!@&8Y) ]2>]$.@Z3;7T=[!IMK'=1QB))DB
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MPWI,&K7&J1682^N 5EG#MN<'J.O_ .JK.GZ79Z59"SLH?*MP21'N+ 9Z]2:
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M*** "BBB@ HHHH **** "BBB@ HHHH R_#O_ " K7_=K4K,\/C&B6N/[M:=
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MB&43K=E,8DW9) ZC@D#GTYJ]8_#^UT_QS!K]O*!!%9+ (""6,BKL#D]#\G%
M"-\1].&J&!+:1[%;\:<UX'7 G(Z!/O%<X&[I5>P^)!U74[S3K'P[J5Q<6EU]
MFE:(J8T&XKN+=NAXJ7P]X2UCPSK.I&SN[";2KZ\^U;9HV\Z+)RP&.#QP,GC
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ML^ +.;PVMMI-O#!JEOY;VL[2,HCE4@ANA]^W>MJTAU>?4M-O;ZUM83':2Q7
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &?HO\ R!;/_KF*T*H:
M+QHUH#U\H5?H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110!1TC_D%VO\ UR%7JHZ1_P @NU_ZY"KU !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M6T@O+HQ".18G?R79$=L8!8 @'D=^,C-<3#IVM1^!KS3SH5Y]JEU;[2L>Z/\
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M7'S,6/' !Q[XKD?#.A2V[6=EJ?A:5M3L;H$:@\C&!D4Y\T?-]\C@ #KUP,X
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MU<G<>V.<9% 'IJ.LB*Z,&5AD$'@BN57Q!JT_B_5M#AALXTL[9+B*:7?^\W=
M>>!G/(STZ5T]O"MM;10*25C0(">N ,5Y;K&@CQ'\0_$=D]S>6;W%A%%:3QO)
M&C.HRRG'RN,9R#G@G'/- ':^#_$W_"3>%X=8FMOLFXLKAF^7Y3@L#_=X_G6B
MFNZ1)$)$U6Q:,OY89;A""V,[<YZXYQ7 :AJ%Y<?#L6EKH]Q8W>G7$/V[3K:
MINB60%O*XY4\'CMG/?-JSTK0/&ECK0T\WLT>H6T:O?W0;'FKG9M5@,E.Y'TS
M0!Z"+B(NJ"5"[KN5=PR1ZCVJO::MIU_*\5GJ%I<2(,LD,RN5'N >*\_N=/\
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M]P6C6!2HW.RJ<,2V, 'ZU'9>,+C4TMK6WTJ2#59S*3;73%%CCC(!D)QDJ25
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M%%% !1110 4444 5-/&VPM5](U_]!JW56Q_X\K?_ '%_]!JU0 4444 %%%%
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MKGI[?TK3TC7[+5?#=MK8FCBMI81*[.X C_O GM@Y!^E-@\5Z!<2&.+6+)G$
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MZW4$_P!I2^%P3.9-H4DL<@Y4 8QC':KFA>'K?0/MIANKRY>\G^T3/<R!B7(
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M** "BBB@ HHHH **** "BBB@ HHHH **** "HYW:.WD=$+NJDJ@_B..E244
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MGA:[BN;6T@F^UI+:[6+(S G;),WWR6.<''4<4ZPD\.KHGAB\L#9"[/B 1&1
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M^J0:+H]WJ=UGR;:)I'"]3CL/<]*NU5U'3[?5=-N=/NU+6]S&T4@!P=I&#@T
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M#("<GG#'\11+X6U[6M"GLM?UN(W)5/L\EE"46-T8,)&!/S-E1Z <XZT 7_\
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MB>6U>2U<+.J#<2G'/'..^1ZTNF^-]'U:]T^VM/M1&H1N]O,]NRQN4&64,>I
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M Y P..]=%=Q7DVN>(IUT^[\NYT:**)BGWI )24'/7]XOMG//% &U9^+=!O\
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MF15=@<'9N(W@<\CCCC-:6D:G%K.EP:A"DD<<P)"2##+@D$$=CD5@_#NXL?\
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M@QCRM@VX^G2H8]+T^*19(K&U1U.5985!!^N*YH?$73F$TBZ;JGD6]Z+*YG:
M*D#D@9;)SC)'3)'<#(S>T77KW4_$FMV,FGM%96,JQ17&Y2&;:I8$9SGY@1QT
MZ\T :YTO3C"T)L+4Q,<E/)7:3TSC'O4CV=K+(DDEM"[Q_<9HP2OT/:JFK:U;
M:0D D26:XN'\NWMH #)*W4[02. .220 *Y#0O$_V2Y\5:AJ,&I11QWT,4-G<
M?-*KLB@(HR1\S'C!Q@CM0!V3Z)I,CW#OI=DS7/\ KV:W0F7G/S<?-SZU(=*T
MXQQQFPM2D2A$4PKA%'0 8X%<OJOCMK;1H[RRTNXDN!JB:=-;2[=T;EAD<-@D
M@C!!QDC/>I]8^(.E:+(8KF&Y,L4:274:F,-;!AD;@6&3CG"[C^8R ;G]AZ0;
MC[1_95CYVPIYGV=-VTC:1G&<8)&/2F'PYH9@6 Z+IQA1BZQ_94VAC@$@8QDX
M'/L*PO$_BFV'AO4_[/\ MD\BV)F,UH,?9]Z$HS'(([' R<<XYK;\,2R3>%-'
MEF=GE>Q@9V8Y+,4&2?>@"TVEZ<]\EZ]A:M=H %G,*F10.F&QFHI-"T>43B32
MK%Q<.))@UNA\QAG#-QR>3R?4UQUCKNIZ?\3+O3[ZYFETB]E:WM/,*D0S+&DA
M7('0ACC)]!3IM9U&_P#BI96$-[-#I*1S*8$  FDC +,3C.W+[< ]8SZ\@':Q
MZ980W?VR*QMDN=@C\Y8E#[0,!=V,XX''M5JL*/Q9I\NJI8K'<X>Y>T2Y\O\
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M##O"3\PR,#('H.2<8XJWKFMW-EX8T&3SI(VU&XM;>>Z4#,2N 6;T&<8SVW4
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MTFV1">F""OS8SP>!UK>E\2:3=:3J$]EK=C']F0J]P[!D@8C"LPR,C/3GGH*
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M[=*T=5UK3M#@BFU&X\B.601(VQFW.>B\ \G%/AU6SFU 6"R.MT8C,(Y(G0E
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M&^_M(:AIMS(RN$=50#.TDC[A!_W@><8J6/P[?Z=XPT":SLWFT^PM)+>:X:5
MS-(<E\$Y/.2?J<5W-% 'F::'XGF\36NH7FF>=)::LTOVA[X;/L[!U BCZ* "
MI.1N)%:>H62:CX_MH].GMGMIH5GU6-3G/DN#"3@]2Q(Y[)["NYJEIVCZ=I/G
M_P!GV4%MY\AEE\I NYCW- %P\ G!..P[UQ/AOP_>S_#^^T#5;26QEG:Y3+NC
M\2,S!AL8]-PX..17;U1TO6+#6HIY=/N!.D$S02, 1M< $CGZB@#G[;3]8U'4
MM";4K7[*FD!WE=9%9+F;9Y:E,'(7#,?F /08[UK^'=9FUS3I+BXL6LIHKB2!
MXC() 2C8RK#@C^H([5KT@  P  /:@#E-;.O3ZP$301?:;;[)(5%ZD8DE'.YP
M1G .,#ID9YXQ&=*U.#Q3:>*C:&2XFTX6=W8PNA,;;@X*LQ (!R#^&,UV%% '
M'RZ'J-KX"U*QMX?.U;4EGDFVNH59I@2W+$#:,XX].E:@LO.\(0V6H:2+MA;I
M%)9LR'<0 .I.WMG.?UK<HH XC2-!3P3HVLZU%I]J;^<><UM',(XXT4?+&)&X
MP.26.,D].E==I]R][IMK=2P-;R30I(T+')C) )4^XSBII$22)DD0.A&&4C((
M^E<]%X]\,32%!JT:[7V,9(W15;.,$LH .?6@#EH=(\42ZGI=WJ.D//=VNK-)
M-=+=H$,!5U4QQ[L*H# D?>R.^3B6^L=?N/"]Y;Q>'KK[3)K0O$B:> 9C\[S<
MD[R!P,8]3Z5Z.*6@#S'4=)\46^E^*-*MM(>_AUF62XMYO/B4P>: &1PS#[N.
M"N17HEAYW]FV_GPF&?REWQM)OVMCD;N_UJU56_U"UTNU-U>S"&$,JER"1EB
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M4<>TJK$@_)G\:77X;J/Q7H.I)8S7-K;)<I(84#-&SJH4XSG'!'%=,Q55+,0
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M-O%K)N;6:W\_5;B>(2K@M&Q!4U#\2+2\U'P+J-AI]H]U=W 1(XE7/\:DGT&
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MR/;++>:?;FU<[<S'+9V'O\N.G;%=Y3=B9!VC*]#CI3J "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *R_$O_(JZQ_UY3?\ H!K4J"\M(;^RGL[A2T,\;1R ,5)4
MC!&1R.* /+5C?P%:PZC$&_X1S5K-?MB 9%K<&,!749SAB>< ]/I70VNH7&J^
M)+;P\EW/9VUKI,5T[0$*\KL0H&X@X4#TZD^U=3_8]FVA_P!C21M+9&#[.4D<
ML2F-N"W7.._6J][X<L+R:SN );>ZLU\N"X@?:ZH1@J3SE3Z'/J.: ."L;Z_U
M[4?!_P#:-_+YZ7]] Y@(C\SRHW <X'7 P<<8)X&:U(+[7O$ESKDNEZI%:SZ;
MJ+VL$+2 1A4P"9%V$MN^;G/&!C&#733>%=(FBT^/[,T8L"QMS#*\;+N&&^92
M"=P/.>O>JMWX%T&\UN35I;:474I5I?+G=$E*]-R@X- %GQ3?MINA23I?I8OY
MD:"4Q^8QRP!5%P<L1D#@\UQ-YK^LV_AGQFJ7EY#)I;Q_96N!&TR*ZJQ#$9!^
M\<'J..:]!UC1K+7; V5_&SQ;U<;'*,K*<A@0<@BLM_ VB26-]9LET8KX(+HM
M=R%I2O0LQ.2>!D^U &!K.O:GX4NM2N)+^6^0:3]L6*=%"+*950;=H!"\CC)]
M>M(]O-;_ !*\+?:-6N;Z66TN9&$FW8IV#YDV@  ^F.PKJ)_"FF75TUQ=B:Y+
M6OV1DFD)1HN/E([\C.>N>]5;'P)HNGZE9ZA%]N>>S4I;^=>RR+$I&-H!; &.
MW2@#*^*=O/=Z/HEO:N$GDUJW6-B<88A\'-7/$NN:KX7T#6]8N4M[@6XC%ELB
MVCYMJG<-Q.-Q!/(XK:UOP_9>((;>*^\[;;S">/RI6C*N.C9'<9JW>V%MJ6GS
M6%Y'YUM,ACD1CC<IZ\C^E ')7%SJ'AWQ#96+:O=7EEJ-M=2L]PJ,]LT2JVY6
M"\@[L;2#4FE:MJT^G>#)[F\/FZFA^TJ$3#YMWD#=.#E5Z8'7BMO3?#EGII4B
M2XN6CA^SQ-<R;S%%_<4XZ'C)Y)P,DX%9MC\/=#T^6TDB;4";.0O:A[^4B$$8
M*J-V I[COWS0!QG]H:YK/@>]U/4O$-Q'%]M-JD,%O&F_]\J@E@N>Y'&/?OGL
M=0M;R;QK80VVHO;O_9<^Z?RD=R/-BZ9&T'I_"?IWJ['X/TJ+P]<Z&B3"RN&9
MV!D+,K$[BRD]#GGZU/%X=AAO(KQ;Z^:XCMVMQ(\H<E&.3G(Z[L'/L!TXH B\
M':I<ZSX4LKZ\96N'#J[*N-Q5V7./4[<US'C&S7Q?-J5C%)<LFE09@%O&YW7I
M^8<@8^50H_[:'TKL]$T:WT#28M-M'E>"(L5,K;F^9BQYP.Y-.TK28=(MY88)
M)I!+,T[M*^YB[<L<^YY_'TP* ./NO%>J7_P]TG6=(ECCO[BXM[>5)(LCS#((
MW7';YL_ATQUJ*XU'Q&M_XLLX]<VQZ1;1W,4OV6,R$M&S;>FW;E#V)YZUKP_#
MW38;=[<7^IF%[H7NSSP LX.0XPHP<\X''M6DWA>R>[U:Y>6Y9]5C$5T/, !0
M#  P., L,]?F/M@ YRS\6ZCK%WIUA:K/]H.DP7]S]FCBR6D X'F,  ,CH#U[
M8YDLM0\77.L:9IM[<V=E/-ITT]TL<(DV.DH4%3NQR&7CMS6C/X"TN>UTZ);K
M4K>;3X?L\%U;W31S>5_<+#J.G;M5JU\)6EC?07EK>7L<L%L]LF9 XVNVYB=P
M.6+?,2>I]N* .>T?Q?J.M0>'; 74,5]?BYDN)T@_Y9PNR JIX!8J.N<<\=*R
M='NO$&E:7>-;W,!NKKQ3);N\\8<2*VU=WRGC&WI^'%=/:_#K2K6RTZ%+S4/.
MTZ5Y;6Z$JK+'O.67(4 J22<$'J>W%.3X?V,-LD$&J:K&$OQJ.[SE8F89]5(P
M2<D8ZT 9-YK?B*%O%\<>IP!="B6:)S:@M*3#YFUN< =1P,\]>.;K^)-7O]0_
MLJR@F6\@T^&XG:%8B!+(#\O[Q@-HQVSUQD8YU9O!]E/+K;O=7G_$Y0)=*'4#
M &T;?EX^7Y?I[\U#?^"+.^NM/O!J&HVU[91>2+JWF5))8_[KG;@C\!0!G6=]
MXLN=:@TV^NK2QE;2OM$JQ0B0I,)-O!S@@\']/>L_1=5U37[_ ,#ZC<W3@7-O
M<RS0Q( F]!MW=">=V/;/&,UUD'A>VM=534(+N\25+0684R!EV9SG!!RV>2>I
M/6H+/P98V$>C1VMW?1KI)?R,2CYU<@LC\<KD#TZ4 5_'TEVFD:>EI<2PM-J=
MK$_E $LID''(/H#^'ID5-::C>ZEX@U?2(KPP?V7%"IE$:LTKR)NW$'C XX&.
MIK5UG1K;7+#[)=&15$B2I)$VUT=6#*0?7(JK+X:MFOS?P75U;7KPB":XA9=\
MRCINW*1D>H ZT )X0UB?Q!X2TW5+F-8Y[B+<ZJ,#()!(]CC/XUY+:7%[+X6O
MM&F@B@T;4]=EMY]2WEF@RZG!3'&2  V<<\BO;;6R@L;&*SM(U@@B01QH@X0
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MY$3H. <(0&/)P2.1Q]*?:>*?$4.EZ=<ZO:60FU=XELX;.*5VB!C9W,BD@D@
M< ^O-0:)H\UY8W.G6-Y+_9=U;213R3:.EJ<G &T;$W<;P>".GTK=U#P@FI:!
MIVGSZE<K=:>Z26]]$%6167@'&,'C@CO0!GMXMU:WFBL[O3#'<W=X\5HZPLV^
M!5W-(8MVX$<+C/4YZ"HG\2^*Q<VUNNDVD;7&I&UB>Y5XA)%Y;2!P,D@@(V1]
M,=>-&X\&->6D)N=<U&74K>X^T07Y*!HFV[<*@78%(ZC'.3FG?\(G=M=:;=3^
M(+RXN+*=YR\J+B1F39C:,*H"D@8'5B>] &)>^+_$UC;^(Y'M](9=#==TF747
M"LJL %)^5MK=<GD@ 'K6IJ7BR[&O:EH^E6IEN+"V21R8&E#2."53Y2-HP!SS
MU]J??^"5U&SU^VGU&0+K4D;RE8@#'L"@!>?10.:+_P (W\NL1ZOIFORV%^\*
MP7CBV61+A5Z':2 K#)YY^E &=%XJ\376KRZ>FF6%H\.F1WTIG9V,3,#F,J,9
M.X$9SP!GGI2Z;K>K:MXP\/2>?'%9W6A"]FMD5B-[E,Y^;_ODGI\WK6C'X0N;
M?6Y[^#5W,4^GK8R)/#YDA"@X?S-PRV22<@YIVD^$)=+GTF==5D:6PL_L+;85
M43P@Y0-U((X&0?7IF@"[KVLS6%UIFG62QM?ZC,4C\U2RHBC<[D C.!@8R.6%
M<AH%UK.G7'C&Y\FTFO#J<<>\OY5NGR+EVW'( 4@D DD\#UKKM?\ #B:W<Z=>
M1WDUG>Z?*9()XL'AAAE(/!!P,_2L.[^']S<"XD3Q!.EQ+J,6I*6MU,8E3 ^9
M 067 7C/4 T 9NL>+=6U'PY<'3)[:*5=<33!<(K@.A*$,.<K]X ]<C..M:&M
M^+M8LIY[#3K2&[OK*"-KLQVL\JF1P2$4)DCH#DGH14P\"W#6>J0S:T97N[Z/
M4;>0VH!MYTQEB <.#M48XP/?FK5UX4O_ .W5UG3-;-C>S0)#?#[,)([G:.&V
MEAM8=CD_SR 9=[X@U#Q)H.JV]I906K6^G![R*_C9B))$+>4 ""I4 Y)'=>.]
M=##<G3/ 4=S B@VNF"2-<<?+%D#Z<5DW/@B]2\OY]*UUK;^T;5;>\%U;_:#(
MRKM$@.Y<-M_#VKH=$TR72]!M-,NKH7C6\*PF4Q[-Z@8&5R>WO0!SW@72+.[\
M&VM]?PQWMYJ<?VB[GN$#M*S=B3V X Z8%9'A;Q3?QVG]AP0B6\_M*ZL[%KAC
ML6&'!)8_>;:"!ZGCFNBLO#NJZ%:?V=H>I6T>G@GRDO+=YGMP>RD2#<OH#T]3
MTJK/X!5++1_[,U.2TU'2Y7E2\>(2><TG^M,BY&[=]>* *MUK?BDW_AZWDM+>
MUN)=1G@N$RVR=$1B'7N$(R>><@5<U#Q/J[?VM=Z+96EU9:1(T5PDKLLL[JH9
MU3 P, ]3G)S^,LWA/4)KC3]0?7"^J6ER\_GR6VZ/:\?ELBQAAM7 !ZGG)YS3
M9O">H03ZQ'I>J);V>KNTMPLL.]H9&&&:/! Y'KG!Y]J ,DZO>7GC(W_AVP@N
MI;K08+C%Q+Y0"EW90< DL00!V]2*MVWCR2_TO27M;+;?WMO)<212)(ZQ+&VQ
M_P#5JS$[NG XZD' -S_A$[S3M62]T&^MK91916!BN;=I=D<9."I#KSSWR*K/
MX#EL)-/O- U9K/4+.![=Y;B+SEN(V8N0ZY&/G).1_A0!%_PF^LO_ &-;Q^&R
MEYJD<P2.XG:$QRQ?>W*R9V$8(/4@]*ZBXL/[9T1;35854S(AN88WW+D$%DS@
M94XQ[BLQ_#-[-K6AZG/JRS2Z;YQD#VW^N,HPV,, @ ' P?<FNEH XW1/#>CV
MOCB]O=,LK:UCL+5+,I!$%!D?]XQ)'<+Y?O\ ,:[*L"RTF]TGP[?I'=1G5+AI
MKE[E8"5\UR2"$Y) &T =3MJ[HKZC-X?LWU$*FH- IERF 'QW4'],T <CJ?A>
MQL/$WATZ+&Z:L+HS75QOR\ML,^:93_%DE0/<^@XPI+MKKP-XF\2SH)-2M=5D
M:VF;EX%1T551NJC'&/<^M=7IOA_Q58ZP]S+K>G3Q33B2X?[$PE= 1\@)<A1@
M8&.G7KS3I/!<H^V6$-U$-&OKX7UQ"Z'S VX.R*P(^5BHZ] 30!5\8Z!IDVAZ
MGJ<P>ZU*Y"BPF0CS8G( C2(CH-W)QU!8FH;2)M:\<W6B:VJ7MOINEP@12 ,C
M2N/GDP1][L#V!/K6GJ^A>)[K6TOK+5]-6&$$6\,]DQ\DG(+##X+$'&[ XX &
M3F:7P]J<&LIK%CJ$!OGLEM+K[1"2DI4Y$@"D8.2>.ASVQ0!%\.;FXN/ ]D+N
M7S98&EMS(3G(CD91U]@*PAK.HR?#;Q#XHM;@"[NGG:%S(66*)&,:[,< @*2#
MW)R:[C1-'M]"T2VTNW9WBA4KND.68DDDGW))-<I9>&97\$:KX+9ELRC2I:RJ
M"0\+/O5O?DE2/;W&0"AJ$^H+\1?"UQ%:12W\NES!T$^U&XS\S[<X[_=/TK7C
M^($1L+8S6D<.HS7<UJUJ9V98S$Q#L75"2.!CY>2P'J1:@\/:JOB32=6FNK-A
M9V+6DL:1LN_<0<KDG'W5ZY[UF#P5K4-K!=6VIV<6LVEY<7,$WDDQ.LY+/&X.
M3C)."/;C/- '0^&=??Q!9W,LEDUK);W#0E2697 P0ZDJI((/H*IQ:'K:_P!F
MF;4+.=K2Z=I-\+ 2Q-_%C=@2?>YY'S'@5LZ1;ZC;V 75;R.ZNRQ9WBC\M!Z!
M1UQCU).<_07FSM.T MC@$X&: /%-0BU;P'KS^+;!I[G0Y+R>&]M _P L2B5E
M&!G&.F/0\=#70:=XPTK1?#WB/Q-"!=13ZJ4ME0[3,3'&57)Z<EB>..>,UU^C
MZ7>_V7?6>NQ6,J7-Q,_EP%F4QR,6*MN R<DC\JYT_"ZQ/@N?P[]H(47KWEK,
M!S&W1=W][ .T^H]* %F\?W]LNMV-UI=M#K&FV'VY81=%HW3&2,[ =R@CCH3W
M'44- \;ZCIW@G1;C5X(I;W4K@16KS7A7S0S,2[DJ=BJ,#^+MTK07P)?:A>^(
M-4U>YM4U+4[%K"(6H9HH4* ;CNP2<C\JS[CX?:]/X9T.V-WIO]H:'*'M1M9H
MIEXX?(SG@=!Z_@ ;.FW2^.&T_5(2;632K^:&Y6*Y9EW* "%( $BL-O)Q@$\9
MJIJNE2>"?"USJEI=S3RZ?<FXA\V0L3 [*'B8G.X8+$?[6#7::;'=16*"]%L+
MDY+BV4A!ST&>3QCFL+QY9R:SX>.@6[[;G4Y4B4@XVHK!W8^P52/J0.] '312
M)-$DL;!D=0RD'((-.JA:IJ$6HS12"U_LU8D%L4!$H;D,&[8Z8QBK] !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MM.>Y6?[.RPK,KA2L;<>9'\PY'Y\U8T[6?$"CP[<ZG<:>8-2=HY(X86! \AY
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M6OVF4*%CF)("_>RPR"-P&/?K@ Z^BN/U+XB:5IEQ=J\<LT-G,L%Q)%)&2K'
MR$W;BH) ) ZYZX-27?CRTM'O=^EZEY=A<K;W<WEKLBW%<-G=\P^8' R1W XR
M =917.Z9KUU?>--=T=[4K;:?';F.4$<EU9CGG// &!_"<XR,]%0 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1145Q<0VD#SW$J11)]YW; 'XT 2T5QVD>+([S
MQ+X@#ZG!)H]C!#(LC)Y:PL=VX,QZ_=!_&M/4?%VE6.B:AJ:2F<6*;I844[P3
M]T%<97/&"1C'/2@#>HK-&O:<+*WNWN56.X0O$"#N8 9.%Z\=^.*1]=TQ]/BN
MH=1@:*X#""6,^8'(SD@#KC'/IB@#28$J0"02.H[5SEKX)TVQ2[2VN=1C2\E:
M:X5;IAYCM]XDCD9]L5-X.U*XU;PS#>7-W'=R--<)]HB0*LBI,Z*P Z JH]?Q
MK6N[ZUL(/.N[B*"+(7=(P4$GH/K0!GVOAC2K""Q@LX'MH+&1I(8H9G52QZEA
MGY_7G-;%4$UO2Y+-KR._MVMUD\HR"0$!\XV_7D<5/9WUKJ$)FL[B.>,,4+1M
MD!AP1]10!8HJ.>>*U@>>>18XD&6=C@ 5E3>)]+72;Z_AO(9%LT8RH6VLC#HK
M \J2>.10!LT5S?A:^U+5[>WU.34+2XL;BU5S%'%AHIC@D!L\J <<\YK7UB[E
ML-%O[R (9H+>25 X)4E5)&<=N* +M%8?AS6Y-1T;2IM2>WAU"_M_M"VZ?+E>
M"< DDX#+S[U7U?Q X72)=(NK6:"YU-+2=\;^,G< 0>#\I'.>M %G4/#%EJ6L
MVVK33727ELK) \4NS8K#!' YS[YIMOX1TF&[O;N6.:[NKV$V\\US*SL8C_ .
MP'T%7(M>TF>2\CAU*UD>R!-T%E!\D#.=WIT/Y59-SYNG_:K()=;XO,A"N LN
M1D8;T/K0!DZ?X3LK"&TB^T75R+%"EF;AE<VX(QE?E&2 ."V2.G2H!X)L%\(G
MPR+R]&GL3N.]-Y4L6*YV],G/3/OBJ^F:YXB'C5]#U:TT]H39FZ6>S+_NQOVA
M6W=S@^G2K>F>(;B\\::QH4MO$D=C%%)'*C$EPXSR.U %G5?#D.JFQF:[N8;^
MQ),%[%L\P$C#9!4J0>XVX^E+;^&K&#2[^Q;S)QJ&\W<TI!>9F&TD\8'&
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M4Y-2BM@+V2,1/,6)9E&, Y/M5Z@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J
M]_>Q:=I]Q>SD^5!&TC8ZD 9P/>K%9>M:3)J\%O"MX]O''.DSJJ!O-V,&"G/;
M('2@#@_#6K1Z?XZB\R[$S>)+?SID$N_[/<)DA!Z#80H_W:V?$?BW4].FUW[
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M\"2)I.O6#ZNQ&KWC7;R);@&-F() R2".!0 LGC&[TSQ#?:;J]M;JD.E-JB-
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M)&7<%)& 2.] '/Z;JT6C?#W1KJ0!G-C;1Q1E@OF2,BA5R?U] ":YWP#YL/Q
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MVTM^LBLJNTS@$ $EER0-WKTS7JW45Q&G^#=2AT*TT"\NK633X+PW,DL8(DF
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M7R!"4?.UA@GJ5(QUR*HW]GXLU72BMS;::DQN+:9+=)VVH(9!(V7VY)<JH P
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MT[2M3O=*FM=-U*400W(E5PCDD .."H)!YY'KBNUKQ+PVBZ;X9\*:OJ]Q->:
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M ]L\HU"[%J'5@!&Q!()[GH:\^T&>2ZL])UM?%"O?@LLEFL,AEGF*DM%(#(>
M1_= & 1@5$MQI]_8> M7^WF>^GU&,W#R3ECO97WC!/ 5_E'H.!0!ZB=0CB2[
MEND:VAMY-GF2X"N-JG<OMEL?4&K,C,L;,J%V )"@@%CZ<UYCXBMX[GPQXLCD
MN;FY%OK<"QB2Y=_+4_9R5'/ !>08[?A7I=O;Q6EM';P@B*-0J@L6( ]SR?QH
M P_#GB.#7+N_M[;3+BU^R2M%<O)L $X/S+\K')[YZ>]=%7&> 'B)\4,C(6_M
MZZ+%2,X^7&?UJ&2>#Q)XZETVZN9VT\:8EQ:Q13/$LI,A#/\ *1NQA0.PS[T
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M_B!XPCNKLW4@6R(E9%0[=DF 0O&1ZUV] !1110 4444 %%%% !1110 4444
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M<^[$#\:YSP+J%Y#-JWAS5[O[3J>G7!<R]/-BD^=6 ^I(QVXH ZQ[&TD<N]K
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M=E<3.;A67;M??@;<$G'/(7GCGH;G7;;1-NGL+W4;J"W\^80)YCK'_?;)'7G
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M#]W)(SZ@ULT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M2W#JA9(FD.6.!PH)Z\?C0!R<>F>(K_Q!J^J7>D0V@N-'-G%&+M9"T@+$<@<
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MMM9JMT%_<@ LV(V/+/GKSA5KJ*P9O&GAR":2&75[99(Y3"X)/RR XV_7(/%
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M+70=(5;55TRT46A!MML*@P\Y^4XXY].M$V@Z/<0W$,NEV3QW+%YU,"_O&/\
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MQM&$8;"!NZ,1\Q-4]&O/$NNV6CZ];ZQ!#;W?%U%)*AC"DD;8U\O(<$\9)R0
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MU&:\U$7%FZ0LR3H-OE R#A-FT#DC&* .STOQ1I&LZAJ%C97<<D]C)LE7<.<
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M"DM[09N;R1+2,_W?,8*S?@I9OPH ?X8U>XUW08-2N+>. S%BBQN75D#$*P)
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M+!;W:ZQ%]JC)\MUQ.V=QX.0HZ]0,=.*GUZ672-=\7Z?I*/:V2O827$-LJ_+
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MK+"-/M#'9LH!59$+_7@D\^_X5OZYJ=S!JFDZ39R"&;4'DS.R;]B1KN; SU/
M&>!S0!MU3M=5L;Z\N[.VN4EN+0JMPB]8R<X!_(UY_K6JZY<7@T22]2.:UURT
MB%U%""98W!D7<N>"I4 ],X].NEJ=QJFG>(/$M]I\EF@MM+@GF,T3.9"JSD
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M4-I%$&Q<"3&TD9) /.2.F"><4 =IBDKBKKQO=R2:DFCZ9)?M8/Y!$<,CK+,
M"RAE!"@9QSW]JTO%M]?Q^!;V[TYC:WCP*4,@(:(L0#TZ,,_@: -YKJW2Y2V:
M>);AU+)$7 9@.I ZD5+7 7=KJT7C+PW))#97&L+I]T)958I&0&C&22"Q #'C
MU/84O_"R5;2],:*Q9]1O99HS!&KRA/*)#'"*6.>,<=#D]* ._P 48K%\-:M?
M:Q93S7^G263)+LCWJZ^:FT$.%<!AU(Y':LYO%LK>*Y=#B2V2XBG1?)G9D>6$
MA2TL9(VM@L1MZ_*: .KQ1BN//C"[@\26VEW-M9(US=R6\<(N=TJJ%+)(X (
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M'HS&)-:L8Q+N\MGF55?:<'!/!P>.*(/%GAZZD=(-:L9"D;2OMF4A44X9B>@
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M/,X.,C/O7*:2;F:]GU"VO;&35IKQYTL+W2Y/.#]-IPVU6  &X#@<D]:]EHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!@^+O$!\.:$US$B2WDTBV]K$[8#RN<+GV'4_2J.
MH:7XJMM,N;K3]>>ZU(1?N[:2WB6!F[@<!AWQEC[YJ;QUX<F\2: L=FRKJ%I.
MEU:%C\OF+T!^H)%3VVM:O=6<8/AZYM[]AATGE3R8SW.]221Z8&3Z#L ;RY*C
M<,-CG%+56&ZFEO;F![.6*.+;LG9E*RY'.W!R,=\@5:H **** "BBB@ HHHH
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M1,@G.,N,#N<<M?Q)XT^UZ)92Z/:65S?R7$,AERZKL0,DGR,< Y/RDD_*>>]
M'H%0_:K<W9M!/%]I""0P[QO"9QNV]<9&,UPNH^+?$\=Y>6&G:2MS=V$<:3^5
M:M+%+,R!R _F(47##^%C5J+Q'JS:]J<$NE6UM+#HT=['YF2RN=W[MV'4!MPX
M]">] ';45PNG^+M:^W^%8]3M;$1Z] [!;??NB94#ALDX((/W<<>IKNJ "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M;OSZU/10!"MI;(R,EO$K(,(0@!4>WIU-2D @@C(/4&EHH @%G:JH5;:$  @
M(. >OYTZ&V@MP1!#'$#U"*%S^52T4 8?BG0IM?TZ"V@GMXC%<QW!^T0F5&V'
M(4@,."<5JK9VPM_)-O#Y9Y9!&-I/KBIZ* (7M+:2U-L]O$UN1M,10%2/3'2G
M0P16\2Q0Q)'&O1$4 #\!4E% $,MI;3VS6TUO%) WWHG0%3SGD'CK5>31M*FM
MX[>73;-X8O\ 5QM I5/H,8%7J* *#Z)I3V#6#:99FS8[C!Y"["?7;C&:)]%T
MNYLHK*?3K26TB(,<#PJ43'3"XP*OT4 5;/3;'3@XLK*VM@^-P@B5-V.F<#FK
M5%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %8<VA7+^)6UJ+4WC;[*;983"I
M503G.>I.X _I6Y10!Q,7PZB@L=-6+6+J._TR1VM+U(T#(C\M&1C#*<GKZ^G%
M7D\'-%?:5>)K%X\UA)+*[S!7-PTF V[L.!@8 P.E=110!S&H^#5NM?EUBQU>
M^TR>Y1([M;4KMG"\ G(.&QQD=*KR^!W:]O9X=;NHTN=/&GB-D5_+B'3#'DMR
MW)Y^:NOHH Y)/!++)X;D?5YW?0@RQ,8D!E4X&&_X  O'/?K70:997%C;-%<W
M\UZYD9A+,J@@'HOR@# J[10 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH ***,C.,\T %%%% !1110 4444 %%!( R3@44 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M 8_BN*.?PAK,<J*Z&RF)##(X0D?K7GVH/<>"M%UKPK?R-+I%SI]TVD73_P !
M\MF,#'U')!/7I[#TK6M,.LZ1<:?]JFM5N$*/)#MW;3U R".1QTJIK?ANU\1>
M'9-'U21YU=1^_(4.''1Q@8!_#% '/:7(=0^*%[#=_.FG:= UFC'A"X^=P/[W
M.,^G%/U4&Q^*^@"T'EKJ5M<I?*HXE6-<H6'J">OOBNANO#\$VI6FI02O:WUN
MGE&>)5)EC_YYOD'*Y /J#TQ3+'P[%:ZS+J]S=3WM^Z>4DLX4"&/.=J!0 !GO
MU/K0!YH;)K?2/$O@ )&;F;4%.GI(-O[J3]YN'J%"-R.AXKI?"FL/XM&@^:@5
MM,@:6]C*<K<C,*@CMTD;'^[Z5U4OAVQE\4P>(6#?;8;9K9>FW:3G/U'(_P"!
M&C2/#]GHMYJES:KAM1NC<RC'1BH!'Y@M]6- &M4=Q;PW=M+;7$:R0RH4D1AD
M,I&"#^%9'AJ#58+2\&JRS.6NY&MQ.R,ZQ<8!*<==Q [ @=JVZ .+O+:W_P"%
MI:/#Y,?E)I-P%3:, ;T'3Z$C\:SM:M[;0/'OAE=-T9[A8;*Z6.WM0@91E>A=
M@,#<W?N:Z6X\.7$_C&V\0#4V06\)@6U$*E2C<MELYR3@Y]A[Y+WPW->>+K#7
MO[3>,6<;1);"(%65OO9/7GCZ8% '-:5<'4/C))<7&ESV4RZ'D)<E&;_7 ;AL
M) X)'7-)H=_=6=AXE@A\.W&H0-K%VI\LQE&!8 @J6W$8ZX4\5TK>&ICXT/B-
M-3=6^R_9?LQA!79UZYS][YOTJ#2/"^IZ-8WEO;Z\7:ZN'N'FEM5+!W^\1SCK
MSR* .6\2BVT3XAZ"L6D37]M:Z/+&MK"JR/Y:@C^,_-A?<D^^:U/ NEA_!>I3
M[HDL]8DFNH+:$[EMHY%QL' &1SD 8K5C\(R1Z_I.K'5'>73K3[+AXLF8$?,S
M'/WB>>.GO26WA"73I-5CT[5&M['4-S?8VBWI S##%/F&,G)QT]J ,/PB?-\&
M>';*3P[)-;W$,<<EWF,!1@G=\K;P<@8.!CU%5HYY;3XG>,)+?19-2<6ULP2,
MQC:?+SSN(//L":ZC3_#.HZ;X>MM%M]=9(($\L2K; 2[,] V[ .,C.,_CS4UA
MX:>Q\7:EKXOBYOXTCDM_*PH" !2#G.<?GF@#G)K6WN?'^CZ ]FT6EP6<NI_9
MF_U;W#29R0>NTLQQT!-6_% CT7Q=X7O[%!#+=W?V&X6(8$L; D!AWVGD'MS7
M1:OH<>ISV=W'*;:_LI-\%PJAB >&0@]58=1]#VJO#X<:?4[74]9NUOKRT)^S
M;(C%'%D$$A-S98CN2>@QB@#R_49(/[)\6:2^C!A>Z]+##J$BH(+>5@@7<WWE
M(Y.<8^;&>377>.+![+P!I5O<G[;<VES9IYA W2,'521GIGGJ>];-GX-ACL=:
ML;^Y%[:ZM</<S(T(78[8SM(/;:,>A%5KOP9J-[H-II%QXBDDBMI(Y%E:U7S&
M*'*[CG!Q@=LG% &A8G[5KP$OA^6Q^S0"2.X?9AF?(9 4)!P ,Y/I[&N@K)O+
M'4)BDIU-HA"DA"VT.-S%2 2"QW8R2%Z$X]!3O#J:DF@6:ZO(TE_M/FNRJI/)
MQD+P#C&0.] %^Z,PM)C;QI+,$.R-VVJS8X!.#@?A7'Z?KMW;Z)X932-#L8H]
M3W(+<3F-(&V-(<80Y'RL3W/XUV<H=HG6-PCD$*Q7(!]<=ZYFV\*7-K;Z'#'J
MWRZ2S,A-L/WF59/FY_NL1QWYH T] U.YU2VNFNX(H9K>ZDMV6)RRG:<9!('6
MK]U<QV=G/=3$B*&-I'(&3@#)_E6?HFD3:2U^9;P7 N[I[D 1;/++8^4?,<C@
M?CFM22-)8GCD4,CJ58'N#0!S=IXBU"YM=/U4V4(T>Z@DGEE$HW6R!=R,QS@Y
M'4#H>YJG%XOO19Z/K%Q;6ZZ5JD\<,:(6,T/F?ZMF/0Y. 0!QGJ<4_1_!,^EH
MMC+KMS=Z+$3Y%@\2KM4@C:[CEU&>G Z=:FM?!HM[6PTZ6^\_2K"=9[:!HOW@
M*Y**SYY52<CY0>!SZ@%.X\6:W##>W+:79);V.I1V<W^DL[2*[(N5^48(\Q>O
MOQ5R7Q7*-??2D@A2X2ZCC$$[F.22$X#3)D , 2>!D\=NE0R^#;ZXTK4;*76P
M6OKY;UY5M "C*58*HW=,HG7/ /KD3W7A2YU#4K:YOM3BGCMKU+V$&UQ)&5Q\
MBONX0D9Q@GWH IV_B5;&#5"-)MK>_;6A810Q2<7,KA")&8+G[K;CP>%K/2]G
MT#QEXHUC58+81V^EP2LUHI'F#=)MW9_C.TCZ 5IW7@:6]@U$3ZMLN)]074K2
M>"#8;695" X+'>,*!@X[^O#D\'7]U<ZJ^LZU'?0ZG:I:S11V0BVJH;:5.\X(
M+L?K^% $'_"9ZLC2LV@2O"MB]T)MDT4:LHR8V9XQU'0CJ?2I8?%.N2:7:ZC/
MI%E:VMWY;12S7V%BC92Q:3Y>.P &<YIT/A37ETR:SN/%CW&;<V\!>Q0+&" "
MS -\[;<@9..<X-27/A&[FT_P_"FK(EQHY&UVM=T<N$V@F/?PP&,')P<^M &0
M/%^JZW;>&[O2DMD2[U&6WG4RL%?8LG0[<[2%W= > ,<G&E/X@L]$N/%-_)I<
M4<EG) DDD)&^Z+JOE[C@8.7 [XJ*T\#WME8VD-OK,:S6>I27T,K68(PX<%&4
M,!_&>1CZ5/<^#9]3'B*+4KZ)K?5FC9/(B9'A,84(V2QR1M!Z<G\J ))_$]_I
MNJ'3M3LK07$MG+=6OD7#$2&, LC90;3@Y!&>AJ+1/&-WJR:)=2Z7'!9:N72(
MK<;W1U1G^8;0,$(XX]!ZU8N/"UQ>W*7U[?PW%]!8R6EO(+<HJLXPTC#<220
M, C&3Z\0:5X/O-+T[P_9+JD#IH\SR FU.9@RNF#\_P IQ(WKSCZ$ ZX5C7VM
M3Q:]!H]C9I<W+6[7,K23^6L29VKG"L3N;(Z=B:V:PK_0KF3Q)!KMA>I!<):M
M:RQ2Q%TF3=N7.&!4@D\\]: .5U[Q%=Z_H&G+:V443/K4>GW]K<RG&]7YC.%.
MY#QD\<=CDBNXTG2K/2;9TM+*&T,\AGFC@)*>80-Q' ]/0?05S4W@N]33+:&U
MO[<W8U;^UKB:6%MLDN[. H;Y1T'4]*[-<[1NQNQSCIF@#E_'6KZIH^FZ>^E)
M$TUQJ$%N?,?;D,X^7H>N,$]@>]<Q#=W^E?$SQ1<6.E)=3?8+>::);GRUR%R<
M,1R3SC@>^*[/Q5H=QKVGVL5K<QV\]M>17<;2QEU)C.0" 0<5GIX7U*/Q%K&K
MB\M&?4+-+<(8F 1E &[[QXZ\?3F@!K^/;5OL2V]N'DN+"/4'21V!2-Q\H&U&
M+-UXP!QUYKH-'U+^U]'M=0%O-;>>FXPSKAT/H17*6?@O5]+GTN^TW5;6.]M;
M!-/N%EMR\4\:?<.-P*D=3@\_S[#3K>XM;"*&ZN6NK@#,DQ&-S'DX'8>@[#%
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M,Z!C&^-RDCH<=Q7(+I/B=O$VAZA=_8KB.V2873*^S!EQP@VYPF .3\WM79T
M9NKZS;Z1]D65)))KR=;>"*/&6<Y/4D   $\GM6/;>.;6X_M-?[.ODEL+I+,Q
M'RR99F. J8;'IR<#!K.^),Y)T"Q@-HMY-?B:%KF8P@>6I)VR#[I)*KZG=BLV
MPL;S6+2^MH+.PM]7T^^CU".>WO#/%//DY65L9!P""#R 1P* .L?QAI]HU^FI
MQS:?+9(LLD<P#%XV.U7783D%OEQUSVI4\5PQ7AMM3L;K2V-L]RC710JZ)]_!
M1FY4$$@\X-8>K>"K[Q.^IWM_,FG7D]O%;VR0/YHC$<GF!V; R2W88P!WJU>^
M'-3\330MK*0V2PV%Q;'[/+YID:9=C'E1@ *"/<X[<@&;<:[+K7C7P9-%9ZC9
MV5S]IE1I9 JSKY)9<JKGT!^8#K7HE>>VFB>+Y-5\+RWUOI@31MZ23K<L3.K1
M^7G;L&TX]SSZ5Z%0!S^O>*X-"NQ;-8W=RXMGNI#"$"QQJ0"2SLHR2> ,GCZ5
M7NO&]E#J%E96UC?WLU]9B\MOL\:X=#T'S,,'!SS@#UJAXN\.:UKNL$)%97FD
MM9-"EO<SLBPSDG]]M"D,0.!Z>U5],\-:W;:]X;U"2VMQ'IVD"RG7S_FW[<<8
M&".!^?M0!M6?C6PU'2[*ZLX+B:YO'>.*Q&P3;D)#Y!8 !<<DG'(]15;X?3RW
M&FZN\PN%8:M<*$N9"\B $ *22<X''4UAZ7X4\2Z;=6>IQP68N[>^NG> W!*2
MP3D,<-MX92,<CMFNE\':;JVFQZK_ &K#:Q&ZOY+N-8)C)@.<D$E1TXH Z.1R
MD3NJ,Y4$A%QEO89P,US]OXRL+G1KC4D@NP(+O[$T#*OFF7<%V@;L=6]>QKHJ
MXZ#PC<P>/)]3CFC72)66\-N!R;L*T9;Z;6W$]SCTH T&\8Z<E\+9XKM$-\-/
M\]HL)YY&0O7<?3<!CW[UB0Z\?#.J>*I]1>_NK&*]A*["9?LZR1J>A/"Y/;I6
M9>^%_%-UJ27-S;07LUKK27L%U)=X)MU;B-$QA,#D^OO5C5_"VNZM9^-+86RQ
M'4IX9;-WF4AQ$5^4XY7(3C/K0!UESXIT^RU#4;2[$\!T^U%W+*Z?(T1SRN"2
M>01TZBL7Q#XB_M#PCK_V3^T--OK*S%R-Q"/@ABC J3P=I%5;[3?%]]?:M?P6
M%E97%WI4=M ?M/F&-UD8E2=N.0YYZ<#WJC_PBFNS-K4::7#;1ZEI M0TM^9F
M65=V"Q(R<[ASVQ0!T6A>+['4WM-)<WT-Y-:AHIIX2BW!"_.8V/4@@GI[\BJ7
MA/Q*EGX#LKW5[N:XN)9[B*,$EY9F660!0.YPOT '.*GM=,U>ZU'0;JZT\6J:
M/;R J9U=IW:/9M7' '4Y)].*YI?"&O1^%]"<Z3!<7VDWMS*^GSS(4N$D9CP>
M5R,C&<=Z /0-!\1Z?XCMII;%I T$ABGBE0J\3CLP_P ,UK5B^&K:XAM)I;G2
M+/2FF?*VMN%)10 /G9>&;.3QT! K:H **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ J*6XA@*B6:.,N<*'8#<?05+7F-]<Z8GBOQ-IWBZ"3R+Y(Q8RFW9@T03E8V
M )#;NP_B]\4 >DRW,%N%,TT<88X7>P&3[9ISRQQC,DBH,$Y8XX'4UYW9C2K/
M6]7MO$T:QVEQ;0?V>NH $>0(\-&N>C@CE1R3@\UE:/80)KG@ZTU^WC\]=(F6
M6.[ )SN&P-GO@' /3'M0!ZN]S!' )GGC6(@$2%P%.>G-5;NYNQ-IYLEMI8)I
M<3,\F"$VDY3^\>!^%>3Z2UO+HVE6]KJJ65U#?WYLOM"A[0@./DD!Z91_E(]3
MZ\ZUG?PR_P#"#W#64-C>^;=A8V8[5S%*HVLV2$=RNWZ@#- ':>*-?_L+3DEA
M:![E[B"(12-R5>14)P#G@$_E6R]Q#'(D;RHKO]Q68 M]!WKQQ=0TM_!MK::O
M$8O$-OJ\+WJO#B=I#.&>0<<C9GGH!@>E3WBZ=<:QXHL/%MY?0-<7'G6RQVZ-
MY]N /+$;F-FW#&, CD\<YH ]=:6-"H=U4L=JY.,GT%,^U6^91Y\68AF3YQ\@
M]3Z5Y]8Z3X=3Q;XBU#[$MUJ&G+#/"JDF0[81DC'5BV0>ISC-8/@^YLV\0:/'
M9QP117.C7$+6\43,5)8/LD=AEGX)/0>G!&0#TNW\01:KI5OJ&BM!=0RW(A+2
M2>6 H<JQ'')XR!WXK6>XABD2.26-'?A%9@"WT'>O)+"?3$\">"A-+%%)9ZM!
M]IX :)@')W9Z?PY/I4]U%%,GCNWUNW)UAWD>P>1"2\6T" 0GU#8R%YRPH ]4
M>>*/=OD1=J[FW,!@>I]J>"",@Y!KS6STW1;GQ5%!KT4#W:Z#;FZ6Y?(:09W%
MP3AF  /.2!S6OX#\0:0?#&@:;'?(UQ-$\4,8!.3$/F&<8! P>>HZ9H [">:.
MV@DGF=8XHU+N[' 50,DFN<N/%JG4O#4=BD,UCK1<K,S%7"B,N"$(^G)_*M'Q
M0C2>$=:1%+.UA.%51DD^6W KS*:/1M1E^&5INM9+1XI8YXXW 4N84RK8[EN"
M#US@]: /8LC&:1)$D7<C*RGNIR*\ANKVWM-,N[:UE5=%L_$9%_%:X80VV!CY
M0#\F\<C&#@BNS\%QZ MQJTGA^_>ZMYI$DE"!1#&Y!&$"J "0 2![4 =82!UH
MW#UKAOB)8Z=J%]X6M[]XU$NJK&5>1EWH4;*\<\G:/JPZ9KF;^QTJW\4Z]HFN
M7:Z5I0LX$TS?$A'E!3O$3."=P=L_+SGGM0!Z_D49 ZUY+9RZ&UWJ]CXMN9XX
MVLK8Z=+J7R2>0(A\T9[2[B2V.=WT-+J4MA?^(]6TSQ/J!TVW>TB_LXW$:9:'
M:<LK.#MEW'G&&R!UQ0!Z>LM[_:CQ-;1"Q$(99_-^<R9Y79C@8YSFK6X>M>6S
MI;KK?B"Q:XED*^&8BIF8K*Q0-\S8P0WW2:IZ=I&CNOA"XT643ZG-$!?D3F4M
M;^2?,60%N%#;5 Q@9 ]J /5K#4+75+-;NRF6:W9G19%Z$JQ4X_$'FK/2N-^%
MC6C?#[3!;F'S$0K.$QN#ACPV._UJ+QO<V/\ ;N@V5RZK+(9G3[8^+(87K*IX
M=A_"N1SSD4 =OFC->0V$%E?Z'X#$UV\@>XEMGD2X>,L@60@<-QR%_05234FT
M[3==M?.D&EP^*?*ODC<DPV6>>ARJ$@*<=02* /4[/6I;KQ/J6D&T"16<,4HG
M$F=_F;L#;CC[I[FMBN&\)2:(GCSQ+#H\EF(Y+>SDV6Q7:2!)N( X_B3..YK1
M^(%W9VWA=H[X3>1=7$4!:.3RU7<XYD?!VIQR?3CO0!U%8T>LW#^+Y]%:U001
MV2W2W ER26<KM*XX^ZW<]/>O-CJB6?A_Q)';WEN]I'JENMW_ &9E5CMV2,2^
M4 3M&=PSG'WJOWUW9V>OZV/"4MDUY/H2/;);2+AG#ON*X.-P7#?D: /4LBES
M7CD1TR/3;K7?#NLM<ZO_ &-(AM[2!%9>A9I=JY#!B""<$D=35VSO--O?$^A1
M^')(9[9]&N!=)&VYL;5V[P>=V[ YYY- 'JV:3->3Z7KVFS7_ ,. NHPF>*"2
MVNE:3#K((-@5P><[^!GJ>E1Z#J^E7/BG1]2M);>!;F]NXR+B8F[<LK<2'("J
M6"A4P>V#G- 'KN:,UYCX6OM%U&TTV35[R:/Q-%?L;BWWD3M*Y*[2G4Q!2O3Y
M0%]C2C3[BU\07/@J&UF32[VY2_6X )"VX4&1-S=_,5%'<!_:@#TVBCM7C\-V
M;CX<W>J322)XNM+PB5@?WZ3^=@1@==I4@8Z8S0!Z!JGB*ZM]5FTS2M,&H7D%
ML+J5&N!#A22%520<L<'@X'O6]&Q>)&9"A8 E3U'M7!Z3!IS_ !=UG;;0+/%9
M0/C:,B0EBQ'OAADUV6K:?'JVDW6GS%@EQ$T993@KD<$'U!YH N9K'N]>^R>*
M--T4VK-]NBEE6?> %V8R,=3U'IUKR+3[V_L;C3KX6&;JTC?0KN-F9O-NRKK&
M?_'8P6_V\=J[270=/@\4>%=&GD9UM=.N24,Q!D;=%G=SD@G=QT/(Z<4 =Q>7
M,UNL1AM)+DO*J,$91L4]7.XC('MS5G->=CR8M%\/'[3+$MIK9MDW7/#H))%
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MW?(3NQD8'3':N,C\2:E8_P!E37-[JC/HEZ;?6G-PXC,)EVHSH3RQW9]P/I@
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M HHHH **** "BBN'UHR:I\0(]$N],@N],.F-)+Y]P0@5I%!?9@Y8;>._?(H
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MA74KC:",9!.>OM5C4-*\;:QX:U&RO)M&CN)X5ACC@+^6<D;W9BN0<9  &.:
M+MWXXM[**#[383VLUQ(PBBO)HH"T:XS)EV&!RO!^;GIP<+!XWM;VQL)K*QN)
M[F]CE>*VWHK'RR X!+8/)XQG/7I4>N:/KUYJ&DZWI:Z?'J%M"\4]K>,S1$/M
M) 91G(*]<53UWP]KVM:?;PZA::5?$QL75)6@:UE+#:T,FPG '7/)Q^% %ZS\
M3:A=^.5T<Z<T=DVFK=B0NNX;FP"1G@<$8ZYYKJ78I&S!&<@$A5QD^PS7*:7H
MNLZ=XDLKJ9;:\C.E0V5S=O(1('C9V) P=P8L.I'3-=7+Y@A<Q*K2!3L5C@$]
M@3VH Y.T\?0W]C]MM-%U5[9UQ;N8E'GR;]FQ?F.#GG)P, ^E5-7\=7<>E2_V
M?I4PU.+4X;"6WE=/D9R"#G."&!P,'C/.,57LO#7B.U^&]AH\:PQWUM<[YH1.
M0ES%YC.R;P,KD-^GO55? ^N26FKJD.F6+3W]O?VL4$K;%:,+E#A1@<?> Z]J
M .BUOQQ9Z(ZP30!KM8!/-;M=0QM$#T'S, Q.#PN>GN,[ND:K:ZYI%KJ=DY:V
MN4#H2,'W!]P<C\*YF\T3Q+;ZZVMZ3_93SWMM'%?6MX[^6KIG:8V5<G[S#D#_
M  ZNQCN(K"".[E66X5 )71=JEN^!V% &)J7BS[)J\NG6NDWM_);B-KEH-@$0
M<_*<$AF'7.T'%5-2^(>C:9>M!*ZM'%<?9IY!-&#&V0,^66WE03@D#L3R*SO%
MGA75]9UZ*ZL[>TBECFB:WU..<QS0(N-Z,H7YP><<]_SGL]#\4:1JNH6NGG37
MTF\NVN8[B8MYUMO.7 7&&.2<9./7TH T_"VOZAK=[K*7>GFWM[2[,,$FY3N
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MFX-G# ]<C^=1Z;I*VSW7A[5_#>I7]V]\\T=P9'-K,C2$B5B&VJ0.HP3P.N:
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MG.:J>%5U+1]!\%R+JDLUI>)Y4EF84" &"252IQNW ICK@YZ"@#TFFLZJRJ6
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MD%B&!.,8Q@>]8U\VJ6_B/X@7^FZE]C^Q06]P5$*N962WW!26Z+P0<#//7CD
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M<R7$-A;7NE17"W;VC20"Y89*2,#^[7E,''<^E=?XA\Z3PSJ+VET8)?LSNDR
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M)+&X+,K0N&'0XW#< <'&1D X-:= !1110 4444 %%%% !1110 4444 %%%%
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M?.H7)()& 0"#@_E7+^#O&UFVEZ=9:UK23:K=O+M+H%Z2,JJQ'R@G' XSZ=*
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MJ;4(4OI2 D!/S$GH/J?2@"&Y\*Z1=ZC=7\D$JW-W#Y%PT5Q)&)4VE1N"L 2
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MKK50-UD$C,;/N&& 5 05 ZYYQSDUNV>EK'I:ZK-<:C>W"Z?Y4,=Q$%>,%1N
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M.1GL,\GH*VGU"SC,ZO=P!H$+R@R#,:@9)8=A4.G:U8:K9VES;7"%;N,2Q(S
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M !T 'I5VBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MJD":7'+9W331! I,2)O&3]WC.>_09-1+H^HW/@V'PA'H]U!J"WOFRW3P[8$
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MQA0O4U+IVFZO+I>K:?9V>HO82:'-%;Q:C;;)K25QQ DC@-(G';(&%]J]:HH
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M>OIY@:>\A\ER0ZMY"YY*G#<]!D>IJX;U->U?2;VSL[ZTBTZUF:\,MLT>U&3
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M7DW]K%?2FY,=NS(K.K$AE894;G4#=VQF@#TU]<TF-(F?5+)5E0/&6N$ =2<
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M:AN6P/R_&L%IM,U3QMXLGE@\Z,Z1&(S+"=WW3N"@C(/S*,=<\4 >CW6I6%A
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MX8U/P_&@\_3O[*EB2VU5Q&0ID&U\L, G&,8SM'3M0!ZQ+/#!$9994CC'5W8
M#\:=O0 '<,'H<]:\C2/1M)TWPOIL<VGW&5NBNH^9YELKD<H!D!WQA5R<C X/
M2J^BVFD>(M)\!V>M+:EXTN(I+>1MKMM!5%/(/H<=Z /4/$NJ7&C^'+[4;1+>
M2:WA:55GD**0HR>0#DXZ#N>XHTK4+W48=/NF@A2UN;%)W8.2PE;:=H']W!/-
M>8>(;O2K&V\9Z1JRV\5['"/[*$\8'[@1JJ+$S>A!X'?)]:O:5=Z7_:]BAN+9
M3<>$@CC> 788R#[A5_(>U 'JH93P&!_&D\V/S?*WKYF-VS/./7'I7B7A;^RM
M,T?P'J*3PQ7<][+%<SF7YMN)!L)SPN2O'3)'K4RII>J/>Z3>ZCIR74>ON[WM
MU=QI+)"'YC&2'S_".,>] 'M60*3<O/S#CK6+XLAM7\':NEU&K6Z64K$$<#:A
M((QZ8R,5YWK=CIFBZ'X<OK3,>CW\L7]JW"L;A9 (R$+AMP*@EN.G XX% 'KP
M92 0PP>E&X$9!&/6O')],\+VLFC&TU26?3'UR1'F\X10H6A.Y(]FT;"=H)7C
MJ,TZ>+3]*LO$=K"['P]-J-I'9A9RD'F,N9 TG.8L[=V/<<=: /8/,3&=ZX]<
MTNX X)&>M>6:;H6E^+/#_BG05N]-GD34#+:M9HJI"?*CVE%!.U=P921UPWJ:
MKZC)_P )%X.U_P 3:I:&VNX+ Z?")"!ATYD92.YDRO']WZT >M[EY^8<=:-P
MQG(QZUY@N@>'AXST6TS&]M<Z0[3JUP2+LHR;#)SA^K'GT]JY^SU".?0?"$&H
M7GDZ +F\@N&D5)8T(9A LFX$8 /&1CC/&,@ ]O!! ((YZ53U+5K+2+5;F]G$
M<3RI"IP3EV8*  /<UY;_ &1X;74?#<%GJ<]Q;3:I<QB3[1Y2E#$24BV;1Y>X
M@97^\5SSBHM8L=(315TY9(/L-KXKCC =PZP1/@L,D\+DMUXZT >R53O)[R*Z
MLDMK5)89)"MQ(T@4Q+M)! _BYP,>]%MJ&GR7;V%M=6[3PQJ[01N"40_=.!T'
M_P!:N8\6O$GC'P:SR!6-[*N"^ <Q,!QTSDX'UH [.L/Q#KLVB3Z2J6BS1W]_
M'9LYDV^7OSSC'/0^E<=H%Y%#XXM_EM[^*_N;L6]ZCLMS"ZY+QS+T*@#"\<#%
M:_Q)CAGM?#T%Q(4BDURV#%9"A PV2&!!'U'2@#MJ*\@UB];1[;QOI>D3M!:V
ML]FVR!BS11NBB8CG(X'/IS3-5M-)A\*:Y=Z=XF^U[VLVQ9N(8H6\P $!#C>1
MDD'G@$CI0![%6%<:]/!XTL]"-HGD7-K).MQYGS90@%=N/<<YKB-<T[3-'\1Z
M;I3WXT[1Y;62:.XO&\^*2<D;]QE;&=H7!]SC&:I6NBZ3+XE\-6,VI3WVF_8;
MI4N);AH_/"RY"C!Y3TP2& '84 >PT5Y3%X>.H^$=:CLII9H]+U*2;1Y7<L"B
MA6:,-_$A;>O?D>U=3X.FCUZ>[\6*DT:WZI%;QR?PQH!D_B^_GN * .MHKR?X
ME:I:MJ&K012*M]9Z8#NNGV)'EL@P#&6E.1E@<#:!US6E+96>N?$&VMKZ>>6U
ME\/K,\:W;JKMY@&2%89X.?UH ]&HKRG0XK>QTKP9J\^JRR7MU>"%Y7N6(:-H
MW"QXSC VQCZ\GK5707AU^V%[JVO+9:]%J6Z>&--MR&#[4B7+9,94J, 8_$&@
M#V"LOQ%JYT'P]?:JML;G[+$9#$'";@.O)Z<<UYI>6-LOA7Q!J'GW!N[#776V
MD:ZD)B'GQCCYNN.YR:=XDN+/7-+\<KJTRF^T]BME$S[/+A"AD91WW-G)[\#I
M@4 >KVL_VJS@N-NWS8U?;G.,C.*+N<VMG/<"-I3%&SB-2 6P,X&>/SKR^>\M
MM7U_^Q]4U6VLK0:5;R6#2GY9<CYW5MP <, !WP#VS45O]EU#7[K1-<U&>\TV
MVT:.73Y9;AH_M*D9,O!P6YQSD_+GUH ]$\-:XGB3P[9:O'"85N4+>66W;2"0
M1G SR*UZY3X;/!)\/=&%NT958 K!"#M;))!QWR>:XY]05O%^C:MIMW+Y=SJ\
MEI/+<W),TH^8%/+QM6)<8'?.#UYH ]<K/UO54T31+S4Y())X[6(RO'$0&('7
MJ0*\TUBT2T\,Z_K%OJE\U_9:QLA87\K+#^^C7;M+$'Y3SNS^%)KEQ;:[9>.Q
MK3 7^GK)'9VKR%?+B5=R2*N>2QY)QTXZ'% 'JME=QW]A;WD0(CGB650W7# $
M9_.IZQO#H2Y\':6JR':]A$N^-L$?(!P1T->:6:W5E\,+?7EU._\ M%S(+:ZN
M)[J5UA@^TE2P .0< #((.">: /9*@N;RWM/)\^4)YT@BCS_$YZ#]#7FQM9XX
MK^+3_%]C<27DMLT%JK2"W!&XF/?O<KY@1L\]OI5&[LK+4H](>\BO[:9/$AMK
MF":]8B$M"698W5ON9"D'J,GH#0!Z]44=U!+/-!'*K2PX\Q >5R,C/X5Y7XCU
M%XM;N;BQO;PO:ZM:0/++=%%A4D9CCC'WE(;YBW7/?%6;TKH%IX\UO2F?^U4N
MUC8^:\GEQLL1+["<<;I&!QQC X&* /4*REUR ^*6T#R9A<"S^V>80-A3?LP#
MG.<^U>=W%]JOA[1[S4AXFAN+>YMX1&D#S7!@5I%!N,RLY7Y6/' )QQD5NZ1I
M%GI?Q.26RN9IXKG1&?=-<O.S'SD^;<Q/!!!XXZT =Y17,^*[I3<Z3IL=W<I<
MW,[%;6WE,37"JC$@R*044'!)'/&,'-<CI.HZWJ/A#0I%NY;Z:.2Z^UV*7QBN
MKA$D95*N"&8IQGD;LC- 'JE%9/AG48M5\,Z?>PS33I)"/WDZA9&(X.X#@'(.
M<5K4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 55N-2L;.58KF]MH)& *I+*JD
MY.!@$^O%6J\U1S9ZIXYU36X;.YL(&B$D6&9B8XD>-1GC&6S[-S0!Z3FJBZMI
MS1I(M_:F.23R483+AGZ;0<\M[=:P%\1:A9^(-)TO5X+0Q:M%(89+?=B-U&XH
MV[[V0>O'/:N3:SB3PII?DP@-_P )86 5>F+IQQZ#"CIZ4 >KYHS7+/XBU.YO
M=<73;&WDM]*'EEII"K33;0Y5< X ! R>Y]*S_P#A/+A[C39$LH%L=2TR6\MW
MDE(;S(T#&-N,#'/(SQSVH [FBN-\->-IO$=EHDT5@BO?"X>X19"WV=(V*@YQ
MR2=O''WJE\.>+;KQ'O\ L]O9@K [/&)SYEO," (I5*@C.6Y&1\IH ZWK1BJF
MF/?2:; ^IPPPWI7]['"Y=%/L2*MT %%%% !1110 4444 &*,444 &*,444 &
M*,444 &**** ,S4-%BU#5--U![FXBET]W>-8BH5]R[2&R"2,9Z$=:T\444 &
M*,444 8E_P"&TO-5.I6^IZA8731"%VMG0AU!R,AU8#KU&*NZ;I<&EPR)$TDD
MDS^;/-(<O*^ "S8P,X4= !QP*O44 &*RX-$CM_$%SK"7EUYES$L4D!V>40N=
MIQMSD9/?O6I10 8HQ110 8HHHH *,444 &*,444 &*3&:6B@! H48  'H*7%
M%% %5]/AEU&*^D+M+"A6)2WRIGJ0/4CC/ITZG-JBB@!"H.,@''(R*YG5O"^H
M7>NMJVFZ_)8RR1)#)&]JDZ;%)(VAL;3DGUKIZ* ,_2M(BTNV>,.TTLLIFFF=
M5!DD( +8  '  X':KQ1202H)'0D4ZB@!K1HQRRJ3[BHS:6S2-(UO$79=A8H,
ME?3/I[5-10!!-96MQM\ZVADV'*[XP<'VS7(VO@.XMPUO)J\$UG([O+OTV/SW
MW$EOWON2>=N:[6B@!KQI)&T<BJR,"&5AD$>AI$ACCB$2(JQJ,! N !Z8I]%
M'/Z]X:.M:AI-R+B".+3Y6E\F6V\P2EE*X/S# P3V/-;B011Q+%'$BQKT15
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MMD",PZ$KC!/ I7\.:')IZV#Z/8-9K)YJVYMT*!^1NVXQGD\^]:=% &1=>%=
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBD#!B0""0<'':@!:*** "BBB@
MHHHH **** "BBB@ HHII=595+ ,W"@GD_2@!U%%(S!5+,0 !DD]J %HH!! (
M.0>AHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MGW2LLS&0J6? 7;G* ]1]XTWPYX?\3Z*EKI,E_I[:-9M^[GC1OM,D8.51@1M
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M[B(%6:,(%7+X897//8COQ0!KI\0=#DM+.\!O?LMXYCAF^R2%6D&?DX&2QP<
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M=L+26:5 )C$V6'!.,]L_CBI]9\/:CXKUM[W[--IT::3<6:?:"NYI900/N,V
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M&4V2:A=B]="MN_EPKL09*E\L< GJ!R*] \,W]_=VEY#J3PRW5G=O;-+"A19
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M[<]NM:M_KFDZ7*D5_J-K;2/RJS2A2><=_>@"E#X3L;<Z48[B]']EJ4MA]H.
MI&,$?Q#  Y[4V#P=H]L%CBBE%JMQ]I6T\UO)63.[<%^O..F>U7KG7]'LXS)<
MZK91(LGEEGG4 /\ W>O7VJ+Q!KEIHFDS7,UY:V\OE.8//88=@N0,9&?PH I3
M>"]+N(-5@DDN_*U23S+M1.<.?;TZ <=A3X_!]A#>7=U'<WZ2W=NEO-MN" X5
M=H8C^]MXS^/7)JOX>\503>"]+UG7+VUM9+M,LSL(U+9/ R?0?I6N_B#1H[>.
MXDU6R2&2,2H[3J R'HPYY% %2W\*V=M)I4BW-XSZ9$8;<M*/N'&0P P> H_
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M4FG1WGA!+"YM(S'->RR))P%*_NB&+98XST&,^U=<-7TY[^.Q2^MWNI Q6%9
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M,$<BL[7+J&S^*FBRS6\\P_LV<#R8&E9#N7G"@G';(]:[2.\MI;F6VCN(GGA
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M?A/0M+E>/[98^(-TEN48- HG8[C@?*,,/KT]:]OIGE1AR_EKN)R6QR3C'\J
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M5D=#D,"."#5BD50JA5   P .U+0 4444 %%%% !1110 4444 %%%% !1110
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MWVMF$\$<!@,8P A8C!Z]78_C3?$ND7&O:'/IMO?"R,^ \OD^8=N<D $CKZT
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M.T2L<,\CG.T#'7VJ3_A6<%AH'B*QTMXEGUB0_O)00(8LY"  '.,GTSGVJ%O
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MU<1E2^0>80!GYN-N*IVR:%!I5[JSR6B7A\4JPN&E 8*;I3P2>%,9)XX(Y]Z
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M-Z/]IEN!I\(EE@^SNP&,Q8V[/]W'&*YG2?$RVVN>)[K4+C4!9026BI'<0G=
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M+>0Y=3@J0%X(((Y]*L1>+='EL[RY:>2%;.013I/"\<BN0"J[& ))R, #G/%
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M)&DBP_-,1(X4+&@R3M7H!VJ\_C3PW'907DFLVD<$X<Q,[[2VS[PP><CIC&:
M-R-!'&D8+$*  68DG'J3U-.JO8WUMJ=C#>V<RS6TRAXY%Z,/6K% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '(:SX/O-1U?5+N'4
MX4AU&S%JR3VWFM!@$9C.X 9W$GBHU\):Q9:N=5TO5[6"ZN+:*WO%EM"\;F,8
M#J-X(...2:ZN>\BA\Y ?-GCB,WV>,@R,O.,#/<@@>]5= UJW\1:+!JEK#/%#
M-NVI<(%<;6*G(!/<>M &"_A/5+'6#J>B:V$GG@2&\^W1&83%/NOP5PP!(].:
MNV>A:C;>*(=3DU%9[:/3TLF21#YCD'=YA.<;B>O'2NCK+U_7;/PWI$NJ7XD^
MRQ%0YC7<1N( XSZD?G0!R.H^ -6NM(U/1[;6[>+3[R]:[ :U)D!9PY4L& QD
M>E:3>%M:M=7U*YTK6;>UM]3V/<QM;%FCEVA6>,[N"0,\YY]:ZFSN5O;*&Z1'
M1)D#JL@PP!&1D=JGH X2Z\#ZDEIXAT_3=2MHM/UF1I62>!G:%G&)"I##.??I
M78VMO/%I4-M-,K7"PA&EC3:-V,9 )./SJU10!P.F>!M6LM0T6[GU2PE?3)97
M+BT827)D4JS2-OY;GK_^JBU\#ZM:>'7TJ/4;,EM36_,C0-VD$FW&[^\J\^F:
M[/4]0@TG2[K4+HL(+:-I9"HR=H&3@5C-XTT^/0HM<EMKZ/3) I%P800%/1B%
M)8+SUQ0!D7?@?45TS6M*TW4K2/3]6D>:1)[=G>)W W[&##C(R,CBNW@1H[>)
M'(+J@#%1@$X[4L,L=Q"DT,BR12*&1U.0P/0@^E/H \]'@WQ+-%96LNJ:;#;Z
M;J7VVT9('D9QN<XD!(' ?&![\T+X.\0/I?B6SDFTN,ZS>?:%="Y$:G[V1M&3
M\J_7)S[^A44 >:VLVL7GC;Q)::=<:+]HFM[:.[625V,;",AB@ ^8 L1SCMTJ
M>X^'=S%&+&PN+.33CI_V-1?1M(]LWS;I(P#C<V[)/&,#KTKT$(@8L%4$]\4Z
M@#B+;PQKADT.WO9-->RL]-EL+DQ-('<.JJ2@(QP$3DGG+' X%06WA#Q%;:58
M:.FI:>++3+N.>UE,;F2548E4D4$ 8R.A.<#I7?4QY8XR@=U4NVU QQN."<#U
M. ?RH @U&&6YTRZ@AV>;)$R)O)"Y((Y(!XKBM*\(Z[ING^%8,Z<TFBS2&0^<
M^)4=64X^3@X8_E7?T4 <'<>$M;N()I =-CNEUQ-6A D=D? V['.T$' '(!_#
MK5B3PWXAL/$E[J>AWVG1QZHL9O5N878QR(NW=& >>I.&-=I10!S.CZ+JMAXF
MU*ZN9[>XT^ZMH(E+.QE+1J1N88V_-N.<'L*I:#X<\2:*D>DC5K5M%@E+PRB,
M_:1'G(BY^4#G&?08 ';LZ* //+3P-JDT]U/?_P!E6D]QILUG--8;\W+N -\B
MD*O&">.I-=AX>L[O3O#NGV-]Y!N;:!86,#$H0HP""0#T SQUS6G10!YSX@\"
M:UJDNMF*[TZ4WTT4D,UTKF2%48-Y0(R%7*CD=<GBM2XT/Q#</XE+_P!F,-4M
MDMX,3.NS"LI+?(?[Q/?T]Z[*B@#@M,\*^(M)N))[:ZT_-[9QV]W#(TC)&\:"
M-)(^!G*@94X],]ZZ;PQIUWI'AG3]-OG@DGM8%A+09VD*,#KSG &?>M>B@#S^
MY\(:Y-?/<O\ V5<2KJZ7L=Q,7:7R5<$1\KA-J@8QG..QYIT_A+79M(\56F[3
MEDUBY\Z!A,^(Q@ [ODZ@*O3KD],<]]10!P?B6VL]=U?2-,6^A36XV\N\B@<%
MOLS)F96.,A2,8.!R1T[=TJA%"J % P .@%-6W@2=YDAC65\!W"@,WU/>I* .
M*?PGJ3:=JN@&2V;2=0N'F-QN99HUD<NZ[<$,<\ Y'7D'&"D_A75H5\4Q6$ED
M\6L0JL)G=U:)O+$;!L*<C;R"._&.]=M10!P]SX3U:]UGP]>3FR2*PLI;6X"3
M.68R)L)3*=A@\XZX[9,FAZ#XITS2H=&N+^PDL;162&:,,)9D (1'!&%'(R1D
MX&/>NTHH P_"&DWFA^%K'2[XP--:IY>Z!BRL,\'D U5U?2]4M_%$'B'28X;E
MOLAM+FTEE\O>@8NA1L$!@Q/7L:Z:B@#@E\(ZI9"UU2V2UGU5-6GU%X))F2,+
M,A1HP^TG(&TYQV-5%\,>*8](U^*6+3II[O4XM2MUCF90S+)&S*<C@8C !KTB
MB@#SW7_#NN:OJT=Y%816=\)(/)U*SN]KPQX7S$D! \Q<[B/7CIWN7>E>)5M/
M%%I8+%%]KF%Q97*3;78L$#H1CY>%(#>]=M10!Y;<^'?$ALO$$<'ARRA?5K&*
M",0WBMY9&X,9&8 L<,3D ] />M'7O"^I>)-:9I[1K6VN=%:QDD$J,8I2ZR=
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M<BWC.U2NX[=V-SCW;IVJFV@:Y<6GBY/[)U$+?"RN+47=PLKOY14NI.\C<<'
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH #13617(+9XZ<TZ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!DTJ00R2OG8BEFP"3@#/
M0=:QV\46#:)9ZG;++<+?D+9PJNV2=CD@ ,0!P"<D@ "M:X4M;2JHR2A 'X5P
MNGZ?J,7AWP5=/:7"?V3@7=J8_P!Z/W31;@.IP3G Y(.: .A/B[31:V4H2YED
MNP^RW@@:612APX*KG&UN#[UH'58/[2AT]%EDN'3S'"+D0K@X,A_AS@@>I!]#
M7$:AH4EUX;%K)HMT=7N);JYLKF,JILI)9FD7=(#E,94G'7!'7BG2:'JUIXDN
M)HUNY;Z[U""X%_$Y6$VRXWQ.N[&% <*""3N'O0!U">*; ZM<Z=-'=6TD$#7/
MF7$!1)(U.&92>< ^H'7(R*?H_B.TUB9H$@N;:X$*7 AN8PK&)R0KC!(P<'C.
M1W K(%G<:MXO-U]CO;>R:RDL[^.["A91GY!'@GU?)!QC'>J^C^%-3L]7U&_3
M4YXW6WCL+%[M$E81(VXLP7:""20,\XY//% '0:IXBMM(U*PL[FVNR+V588[B
M.+=$KL<*K'.03]/KBFV?B?3[W4?LD)D(:1X8IRO[N65,[T4^H )Y !P<9P:R
MM9M[V_U#2;1;6]>\L;J"<WH'EV[ID>:<!B"2NY0",@GCCFJECI5XUUI.GR6E
MQ$--U2YNY+C $;HPE*;6[Y,H&.O#9QQD Z1_$6FQV5]=RRO'!93FWF9XV'SC
M:, 8YR6 !%1CQ+8KI=[?3+/"+%S'=0NF9(FXZA20>&!R">#7-RZ??ZGHFOPM
MIUPCIK(N8HY^3<Q1O&WRY[,$8 =.@IVIVE[>>'/%UPEA=$ZC*/LT/ED2NHBC
MCSMZCE2?7'- '3:GX@L]*F\N997V()9S$H(@B)($C\YVY!Z9/!., D:M<9JU
MA?+J&N&WM994UC3(K:!\$B.1?-4A_08D!R?0CK7665M]CL+>UWE_)B6/<1C=
M@8S^E $]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %&*** #%&*** #%&*** #%&*** #%&***
M #%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
C 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>pinnaclelocrenewal4thloa002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pinnaclelocrenewal4thloa002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#WE/\ CYD^
M@J:H$_X^9/H*GH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@"!/^/J3Z"IZ@3_CZD^@J>@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** *Z?\?4GT%6*@3_ (^9/H*GH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@"NG_ !\R_5:L57CYN)?^ U8H **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@"O%_Q\2_A5BJ\7_'Q+^%6* "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH K0?ZZ7_ '@/TJS5>'_7
M3?\ 73_V6K% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 5
MH?\ 7S?]=/\ V6K-5H?]=-_UT_\ 9:LT %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110!6M_]=-_UT'_H-6:JVW^ON/\ KI_[**M4 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110!4MO]=.?^FG],5;JI:<O.
M?^FAJW0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %2S^]/
M_P!=35NJECUN/^NIJW0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4453U'5+/2;<3WLIC1FV*%1G9FQG 5023@'H
M.U %RBJ.D:QI^NZ>E_IETMQ;.2 Z@CD=00<$'ZU>H **** "BBB@ HI"0H))
M  Y)/:L&'QCI$\T"!KI([B18K>=[6013,QPH1\8.>WMS0!OT444 %%0SW45O
M;S3.6985+.(U+L,#.-HR2<=J=#,L\$<R!@LBA@&4J<$9Y!Y!]C0!)1110 45
M3O-5L=/N+2WNKA8I;R3RK=#G,C8S@5<H **P[/QAH%_JBZ;;:@K73EQ&IC=1
M(4)#;&("MC!Z$]*W* "BD) !)( '4FL^RUJTO[A8K<3D/%YT<IA81R)G&5;&
M#V_ @]#F@#1HK/UC6;+0]+N-1O786]OCS3&A<KDCL.>XJ\CK(BNI^5@"* '4
M45E:MXCTK0Y[2#4+AXY;MMD"I!)(9&XX&U3SR* -6BBB@ HHHH ***KVM]:W
MIG%M<1RF"4PRA#G8XZJ??F@"Q1110 4444 %%%% !1110 4444 %%%% !111
M0 45#=W=O86DUW=2K%;PH7DD;HJCJ:ACU6PE>SC6ZCWWL1EMD)P9$ !) /H&
M'YT 7**** "BHYIHK>"2>9U2*-2[NQX50,DFBWN(;JVBN+>19(94#QNIR&4C
M((]L4 24444 %%%% !1110 45%-=6]N\*3S1QM,_EQ!V WM@G ]3@$X]JEH
M**KW=_:6 B-W<Q0^=(L,>]@-[L<!1ZDFK% !1110 45 ][:QWD5F]S$MS*I:
M.$N-[ =2!U(J>@ HHHH **** "BBB@ HJ"\O;73[5[J\N(K>WC&7EE<*J_4F
MIE964,I!4C(([T +14<\\-M!)//*D4,:EGD=@%4#J23TI8I8YX4FAD62*10R
M.IR&!Y!!]* 'T444 %%075Y;648DNKB*!&8(&D<*"QZ 9[GTJ>@ HHHH ***
M* "BBB@ HIOF1^;Y6]?,V[MF><>N/2G4 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 5+'I/\ ]=35NJECTG_ZZFK= !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4<JL5)0)Y@
MY0L. :DJCJ6DV^JI$)WN(S$^]'MYWB8>HRI!P: ,+P+&UE9:GIL\4*7EI?R?
M:&@SLE9PL@<9Z9#CCMBNKJ@-&T\:<=/-N&MF8.RLQ)=MP;<Q)R3D Y)S5^@
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M02.1E:W;:?-C^;*D*Q)!W=/PKHH_"\<,-H4U&]-Y;2/(+N5E=W9QAMP(QC&
M  ,8%1W=K'H>DW<=KIESJD]])(TJ@*3-(X_Y:'@!<87.. !0!;T[5'U/5;P6
MSP2:=;HD8D4'<TQ&YAG.-H4Q]NI//%9?BK7]3T3[5);?81%#827,:RH\LDSI
MR1M4C:H&,L<C+#TYU?#.B1^'O#ECI:;28(P'91PSGEC^9-4=9\()K%_=W/\
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M5+BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** #%&*** "BBB@ Q1110 4444 %%%% !1110 48HH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *
M.F\QRG_IL]7JH:5_Q[N?^FK_ /H57Z "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "@T44 )2T44 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 9NB\Z>/]]O\ T(UI5F:'_P @
MR/\ WF_G6G0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZ)<W5CHNH&.:_LVDN+J.5YYV1OF_=L"0JIQNXSDCM7>?\(U9?W[[_P #I?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!E
MZ$<Z9&?]IOYUJ5E: <Z5$?4L?UK5H **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@#)T#C2(/Q_G6M69H&/['@^E:= !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 9=AKEMJ6IZE9VP9ET]UBFE_A\P@DJ/]
MT8S]:L1:C:WRSQZ=?6D\\8Y"2!]A[;@#D5PWAUC;>#/%EK>6,E_=6]]=K<P1
ML=]UN .<CYN58#/7CBI?!\Z?\),1^\'FZ5"D:_8I($3RW;<B[QD[=R\DG.[\
M* .PT;5%U:Q,NP1SQ2-!<1!MWERJ<,N>_J#W!!K0KD? 09E\23E&6.;7;EHR
MPQN V*2/;*D?A774 %%%% "'I7*:[X@U*T\5Z+HMB+<+J'F%Y)024"*6. /I
M75M]TUP?B42+\2O"<XCE,"K<*\B(6525.,D= 3B@#L/[2M58(;N#>6V &11E
MO0>_(XJ&TURSOKR^M+>=7ELGV3 ?PDC->=W&GZ?'I&L21Z?MN%UQ94;[.Q?;
MO3YEXSC[W3M5B[6[V>-K?38)8]0GD66#"$&5?+4G:W09Y'UH ]";4K,*[&\A
M 1=S'S%&T>I]J<E] ZEDN8G4-M+*P(!QTX[UY9>_V-JWA[4[NVL]1:8:4T$J
M20LBQ\C"%<?,^[.,=,5>U:P32%\.7-K!)9Z*BE[UK*+E7* ([@ ENA&<'K0!
MZ'_:5H81-]L@\HD@.)!@XZ_EWJ+^V['^T8K 749N)8?/0 Y#)G&0?QKS&\LM
M+BTZUN=)GGM=D]Q/$U_;EK>Y+*N]67'RANW'K6]H4\3:_HMQ<Z>MB]SI(CC@
M$9*QN&!"@XXXZ9H [R9W2%V4C< <;NAXKAO^$[U"/PL^OR6=NT$-PT,D*.=Q
M DV9!QC/?%=R[!8V+-A1UX[5XOIVB2#PU;ZO';SWALM1FEN=,EWE9D+G+A#_
M !C@C\: /89-1MX(T:XN(X"P! D8#T_3FHGUJSCU6#37N$%U/&\D<>>2H(Y_
M6O/O%.H0:K<RBVM6"R:6[PW,EN[L^2?W2KCY3G&2>:M6<MNOBKP_?SJ<R:0T
M*2O&VXR;E&WIP1[^] '?M?6Z7(MFN8O/;.V+<-Q^@JRIRH)KRGP_';7$D-KK
MRW_]O6NHM+PAY.]BI#@<ICCKCBO3=/O[;4;7S[60O%O9-Q1EY4D$<^X/- &3
MXL\07/AZUL9;:V@N'N[R.S5)93'\SD@'(4],<\=*W!*JJ/-=%8 ;ANX!KAOB
MC>6EM:^'A<3(C+K5O/@N 51=VYR/[H!Y/;(K,U5?#][XF\7M</83D:3#*@?:
M0'VR#<.Q/S)\W4;@.] 'HQU&T74DTXW"?:WB,PBSSL! S^9%6/,3?LWKO_NY
MYKS[0Y-'D\0>&[N7[&TUUHH$,SA2TDJE 0&/)8#(]1S6!X;AT[5+^T_M;5K^
M+Q#:WADN;1[:(2,P8Y)<1[_*VG!RV-N1T H ]@5T8X5U)Z\&A98V!*NI ZX/
M2O)+6PMQ\-K_ %+P\BB^CN+B*2:U(,HMOM)=E /^P 0#U'UI]I'X6N--U>YA
M\4W,L<UI!!/-':I$D(:3$>X1HH//!!_A)!XH ]+U'6=/TJVCN+RZCBBDF2!"
M6'+LP 'ZY/H,GM5_K7DLMU8)I\B7VCZ,]O:ZO9K-?640^RNC$$N <A2  K<G
M@UZM"\4EO&\#(T+*#&4^Z5QQC';% #C(@<(74,>@SS6?I.J'4+:229(X9$N9
MH-BR;@=CE<@D#KC/2N(6YMH?&\WD3P:CY^IJDUM<';=6L@'#QD<M$ ,XZ  ^
M]8LQT>+P9>:U!]D>^@\0ES<%@Q3_ $O(P<\ I@\8R.: /83(@<(74,>@SS7,
MWOBN:UM_%+_8EW:+&'CS)Q-F+?SQQZ5Q6LZMI!\275VDUO:S6NMV8G>>1FF9
M%8!G&3A(L,1QD')SC(J[K%_8M:_$L1SP@B&-6^8#+&#;_P"A<?7B@#TJSEDG
MLH)I4\N22-69/[I(R14I95QN8#)P,GJ:@L+B*ZT^WN()%EADC5D=#D,"."#7
MF_Q#O[*XDURR2:&VU*TL8IHGNLEF(WN/LR]0V =SCI@ C@D 'IY=5(#, 3P,
MGK0S*N-S 9.!D]:\VN=4\/ZAJFHV_B2\A6"XMH9--NG;@1[/F:)CG$F_=TYX
M7K@4MW?:/<Z]K>F>*3]EC>&'^S'GW!_+*8W1;LXE#'L-V<<'% 'I#.J#+L%'
MJ3BA6#*&4@@]P:X/^Q?#^J>/;ZPU"%+MUT^UFCBG<G+!I S%<_>P(\Y%8IU[
M2['0M L%U&W@FL]=/VBW60*T,8EESN4=%P1UXH ]5WJ'";AN/.,\TZO(;=M-
MO]8OX=8UJYM-9@U<^7"(4,[J9?W0C;:7V;<<*< 9[&O7)-_E/Y>/,VG;GIGM
M0 NY=^W<-V,XSS0"#G!Z=:\NLW@NO"]E>1K&?&*7T44Y/RW'G>:/-1L<[?+#
M''W0HZ<4S5(--BT7QU>0NT5Y:WFZ)OM3EHV$415ERW!+!L'VQT&* /5:*9'(
MLL:R1N'1@&5E.00>A!KRCQGJ=M%=:O>6MVD%[;7]K$6N;@^<""AVPQ\!(\%F
M+<[OFXQR #OH/$#3^(=8TD6>UM/ABF64R<2AU)Z8^7!!'>KFAZE_;.@V&I^5
MY7VN!)O+W9V[@#C/?K7+Z=<P2?$+Q8Z31LB6%KN8,"%^5SS^!K8\"LK> M!*
MD$?88AD'N% - '045YYXXU2P'B!=.DN5CNETV67_ $V79:Q@G ?:1\\F1@<\
M#-0Z:MAK^N^&X[NZ-P)?#QDDC6Y8!W#1 $A3R<[_ ,1[< 'I-(64$ L 3T!/
M6O)+<6]GH'A^]AN7^U+XC%I)(TY8I$)Y%\OD\+LQQ[YK0N([6^M/%]QJ@SK5
MA-.UH9>'MXP"(#%Z X'(ZDGZ4 >F45YYI>MV^F^(K[_A(;BWL)I]&LY9$F/E
MB23]YYAP>IW$#CT [5#HZ:9J=OX'-QJ,QN)=.*>7'>NOFE8UR"%;G# Y]Q@]
M,4 >ARW,,$T$4DBK).Q2)3U8A2Q _!2?PJ:O,;.2QDGT-]1GC=+;7M0MUDN9
M=VP 2[$W,?9,#V%6GO1;^-TE:.WU*TGU/[.DT<S)/93[""C+G#)A2>PY)H ]
M$HJ&[GCM;.>XE<I%%&SNP&2H R37D^DZR;/4-(N+"XB::]TNZ=83/YLUP0JO
M&\H&!YA8-P 3U&3V /3-1U5M/U#2[;[*TB7\[0>:' $9$;N..IR$-:5>46>I
MZ%>7W@:_AOK>2^N)V^UNTW[QI# RG<">/GX''? ZUI):WUEKU_X2MXG6SO;B
M.^AFR<1V^1YR@GT954#_ *:>U 'HM%>4W&L6K>*)GAU+$D&OQ0.]S=E92,@/
M'&@P!$.G.<X)Z\T:E#''I?CRZAU#4?,LKC]PINY,0GRT8D8;G+$]>P'O0!ZM
M17F]YJ-CJ6N^(+'Q!J1TT>3$^FRB8IB$#=YL9/&_=U[]NU0ZC?KJ'B'6;#5-
M>@TR$01/9"X5PPC,?^MC8NH#Y+9X)&,<CB@#O];U%M'T.^U);<W'V2!IC$&"
ME@HR>3[ U:MIOM%K#.%V^8@?&>F1FO)WNUNM'\96NLZG--<6-@%M!-<-&7B-
MO\CE,C+.Q!.03E@#Z5Z?HL\5UH=A/!(LD3VZ%64\$;10!>HKA]=U6*UN_%L-
MS?\ D!-+ADA5IMFUB)1E>>#NV#COBJEE'_:M[X09]4O##=Z0QFACNI$\QE6,
M[CAO<@^OK0!Z'67I.MPZO/J<443H;"[:U<OCYF"J21[?-7!KK)CNM#TR74IE
MTJ?5KZ!IO.8EPC$11&3.<$MZ\[0.E0K?)X8CUBW@G9+:?Q/%!/.96S#$\<;,
M2V<CD;22>YZ4 >K45YWJEC?6EG=+;^*9";B^LA&MLS#[*LDH1L%G;(8'.#QD
M'L<5W.GV":=;F&.:XE4NSEKB5I&R>3R>WM0!.TT:SK 7 E=2ZIW(! )_\>'Y
MU5TG4X]7L?M444L0$LL+)+C<&C=D;H2.JGO6');QO\48I&:7<FD,R@2L%!\T
M _+G'IV["N;22[TS3]/O[>_N<W'BB2V,7F8B$3W4JLNT<-GKELD'IB@#TZBO
M.[74]1UM-2N?[7M],DL=1:-S-,X\E$?@&/(5E9/7USG(KT2@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** ,KP^P.B6N#_#6K61X<7_B1VI_V?ZU
MKT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !17-?$"UBN_ >LK+"LI2U>2,$9*N <$>
M]<LNHW.DZ+JW@[Q!*;BX&G32Z?=2 '[1"$) ;_;7!_+/U /3J*YZ359(=2ET
M30;&U>6R@669'8PQH&SL1<*>3@GT&/>J&G>*KC7-;T)]/6-=-OK&XFECE;$B
MLCHG0 ]"2!S@Y/H,@'845QL?CF:YO&DL]*>ZTV.]-B\D)=YMP;!D"!"/+!!Y
MW9X_"NDU6^FT^P:>"REO)=RHL49QU(&2>RC.2>P% %ZBN#U?QO>_V+-<:7;6
MQN+?5HM/D_T@2(P;:<HP&#D,!R!CGTKLFENO[-,P@C6[\K=Y+2?*'Q]TL!TS
MQG'X4 1Q:5:0:K-J,">5/.@6<1@!9L=&88Y8= ?0X],6IHS+"\8D>,LI&],;
ME]QGO7FUSK$VN^$_"6L:E9+]IEU:V:+[,=Q)W'^\ %W$8QDCWKHI?&JZ?9:A
M)J]F+2YM;E+=81*'$ID ,9W <9!Y]-IH Z.RLX=/LH;2V39#"@1!G/ ]^YJQ
M6)HWB$ZK?75H]E)$80KI<)N>"93_ '7*KD@\$8_^MSVI-;I\6X5GM9KB-M&:
M3RXXRXWB7&YE]=O&?H* .\HKSKP]XIM;.;Q?=,9DM+2[C,-C*-DB%E52 C?=
M#.>.@Y[5IW_C/4-(L]1GO=!>3['"+C=;R$QE"2"I9E'SC'( /!S0!V+9*G'6
MLB\T%+RZ-S)J&HP\#Y(;ID08]!VJA_PF,=M?75MJEA+9>3I[:D"7#DPJVTA@
M/NOG' SUZU7UG4+Z^T75;6^T?R[673);B.99-ZJ0O"/P 'SSP2./QH T&\*P
M.^XZGJY_[?6I4\+QI,L@U75R1ZWC$'ZUFZ!XHN9=.TN&XTIHGNM,%S:[;A6,
MNQ$)!'\.=PP3^.#Q3;7QU<74&BW"Z!<B'5U*P,9ER)-I8*1V4@$[O09Q0!JO
MX<+%]NJZDN_JHD7'_H-.F\//,B*NL:E$%&,)(H&/^^:KP^*)Y]-EECTF4WD5
M[]BD@$H*(XP2Q?'" 'KCVQ567QS&FBQ:A%ILMRS:A_9[Q6\JOA\D95OXAG&.
MG7M0!=/AABFQM9U0KZ&5"!^&RIXM!:%<'4]0F(^ZTDPR/R6N4DUI[+XB+>ZE
M:-:7#:"P6S\T2,\GVC"HI7AF; QCU]J[NPENI[-)+VU2VG89:%)?,V^Q; Y^
MG'N: ,J;PU]H<LVKZO&>X2\(!J+_ (1-/^@QK8^E\W^%6?$6O2Z%%:-%IEQ?
M-<W"VZK"Z+M9LXR6(]/I[USGB77_ .U/"OB:PELI[*\L(X_,CD*L"KG*LK*2
M"#M/Y4 ;?_"*(.FL:UUZ_;F_PI#X2C(7_B;ZR-O3_33Q^E7SJY_MNZTI+<M<
M0VBW2'?A7#,RA<XX.5/KQBLN'QM;7,&E-%:N)-3M6N8%FD6,';CY QX+G(P!
M]: +-MX;^S7B7 U/5'*?PRWA<-['(Z5O#IS57[3,VE?:EM66<P^8+>1@I#;<
M[2>W/%<'=:O<7NB>"M4U*RD>[FO8&C6"0'S2T+'=MR%&3V/3U% 'HQ16SN4'
M(QR.WI35BC5RZQH'/!8#DUSLWC.TL=,O+K4[:6REM+A+>2"1T8EG"E<,#MP0
MV<YXP<U+X=\66?B*ZO+:V3Y[4(S.DBR(P?.,,IZ_*<CZ4 ;HBC!4B-04^[Q]
MWZ4OEIYGF;%WXQNQSCZUD^)+Z6UTY+>TD$=[?2BUMW(SL9@27_X"H9O^ UF>
M"M8N)] GL;TR7.J:1(UI<A3DRE?N,"Q&=RX.3CG- '5!57. !DY.!U-(L:1J
M51%53V P*Y:V\<PW+:4XTG4$L]3 6VN650K2%2P3!.1G!P2 #CTYJK%\1[6?
M2(]831=332C.()+J41*(R6"YVAR2,G&0* .R$<:Q^6$4)_= X_*GUPT5Y#!X
MA\>R7:226EM:V[21HYRR^2[,!SP3D],5KVNO0B#3;32[&>X>:R2Z6)I0#%$0
M-N]F)R3G ZYP?2@#H#&AD$A1=X& V.<4S[/ $*>3'M)R5VC&:P9_%R1V5O<I
MI5^WFVCWCJZ*GE1KC(8DXW<\ 9S6;J.HR1>.]*O+2TN[TW.D3;((B!_RTB8,
M=Q 7@\G/H* .Q,$+$DQ(2<9)4<XZ4&WA;=F&,[OO94<_6N.E\00Z_)X7O;1;
MB!&U:2&6*4;65EAF!5@"1U'K6G>^,M/LIFW*SV\=R+669)$.QRP7[F[<0&.#
MQQUY'- '0JJHH50 HZ #I36BC=MS1JS8QDC/'I6+XQBNKCPQ<VUG=O:7%Q)#
M D\9(,9>5$SQ@_Q5BZ)XDOE\%21W,;2Z[93'3"GWO-N!A48_[)!#$^FX]J .
MU9$<J6125.5R.GTI&BC=E9T5F7E21G'TK@_!&JW.G^!S>:G->:C>R7TL)(+2
M,[A_+4#/W5^4>@')K6?QU8P:8;R>RO59=0_LZ2&-%=UFR..#\PY!R,_3/% '
M3^5'YGF;%WXQNQS^=((T1F944%N6('7ZU@2^+!'-;V?]E7G]J3Q23K8LT8<1
MH<;B=Q7GL 34/_"36&I+HDWD:E$EY>-' <!/G56R)!NSMX;CGE: .E\J/S/,
MV+OZ;L<_G3ZY5O'=DDU^C:9J@2PNEM;B4PJ$1F95#9+<@[@>,G'..E=50!$+
M6W%P;@01"<C:9 @W8],]:/LMN01Y$6"<GY!R:S=5\00:2\RO:7<_D6K7<K0H
MNU(U/<L0">#P,G@^U17?BBTMYC#!;W5Y,+07ICME4OY1) (5F!8G:>%R>/<9
M -I$2*-8XU5$4855& !Z 57GTZQNG9[BRMYG90I:2)6) .0.1TJ6YN8;.UEN
M;B18H(4,DCL<!5 R2?PKE(=8FOO'>E@66IVMO+IUR^+@JL<@#Q;6VAS@C)Z@
M,-XX] #J(["SBFDFCM($EE!$CK& SCW..:EBAC@B$<,:1QKT5%  _ 5SD?CS
M1)9K%$DD*7TWDP2 *59O4C.0#SR0*LVGBRPN[7[9Y5Q%8_9Y;D7<@7RS'&VU
MCPQ/?(R.1^5 &Q+:V\[J\T$4C)]UG0$CZ9^IIBV-FDL<JVL"R1@A'$8!7/7!
M[9R?SK$?QA;Q)(\^EZI$JV9O5+0J=\8QG #$AN<X;!K)OO&VE:GHR3R6FOVU
ME+)"8KF.W:(2%F&T!L],X!SU[9'- '9+9VJ!@MM" SESA ,L>I^OO2RVEM/*
MDLUO%))']QW0$KSG@]N0*XF3Q*OA_P 6>(8Y;?5M03]Q*(;5#-Y*["6;!("K
MG'3\N#6U/XTTE+>TEMV>[^U0?:8UB**1'_>.]EQSP!U)S@<' !MRV5I-<)<2
MVT,DR#"2/&"R_0]13&TVPDFCF>RMFECQL<Q*67!R,'''/-8Z^++"^L;>33X+
MR^-U 9ECM4&]%R5.XD@(<@C!(.0<=#3O ]T]YX+TJYDEEE>6'<7E;<[<GJ?6
M@#4&E:<(_+%A:A-_F;?)7&[^]C'7WJ3[#9_:OM7V6#[1U\WRQO\ 3KUK O\
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MW\Y/!VIW-O=7%M<6L#SQ202%"&521G'4>H/% &I=:1IE].L]WIUI<3*,+)+
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MEW.D2MG;GJV 2<#J> 3^%/L[RWU"SAN[259;>9 \<B]&4]#0!/1110 4444
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M01D]!W["MJ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,[0O\
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MRC$9. _/\.>,]*X*VTRXU?0[NUBT#5+36EL)K9KG4+F1D1F4 K&S,<ACCH
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M%4-&_P"01:?]<A5^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MVU/D'S1#<G&/X)#QVS7K>Q<8VC'IBC8N,;1CTQ0!P%S;>&=1\9:_/>VMI/\
M\2N$J[P[M_$GF%#CYCM,0RN3T%<['JUCIDOA2\U*:!(V\/-9O;7NY8U9=JDY
M"M\S=",=!U['V/ ]*Q+[0)KC6#J5IJUQ:2/&(I(Q%'(C 9Q]]25Z]B,\9Z4
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M=UNS\U(KY=599(]V'#_:,@?7:N?H,UZWHFD/I<,K7-[+?WL[;I[J5%5GQP
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MN,AXI>=S+P3R.!C&,5ZM4"V-HEV]VEK MRXPTPC =AZ%NIJ>@ HHHH ****
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MA;S?OH41F62,'. 0O<Y&<50;QEXAM]-FU:[TZP33[746LY0DCF251-Y6Y,X
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** #%%%% !1BBB@
MHHHH **** "BBB@ HHHH ,4444 &*,444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!4T_
M_D'VO_7-?_0:MU5L?^/&W_W%_E5J@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[EK>%_-@+#<K9"D8('7IVK0U#Q/IFF7%Q!/)(7MHEFN/*B9_*1CA2V!QG\\
MGI0!LT5S2WES_P +*>R^U2-:_P!DB;R"1M5_-VYQZX]:Z6@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** *UB,64"^B"K-068_T6+_<%3T %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !161K'B"#2KJSL4B>ZU&]8BWM8B S #+,23A5 ZG
M\LU%_;6HV^LV&GWNDJBWC.JW,%SYD:E49L'*JV?E],>_:@#<HI-PSC(SZ49Y
M'O0 M%97B+63H&A7>IK;?:?LT9D:(2!"5'4YP:T+:;[3:PSA=HD17QGID9H
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MMVD-("TFFRE)5D&&)&>&[YKUA=K*&7!!Y!'>DEDBAB>65E2-%+,S' 4#J2:
M/.K^>?4[G1YKN\<_8KEKB4+ILG/& %^F>IJG?6$=UINM(MY/'?ZI<AY+@V$A
MVP@C$>,<\#\S7H$FL1)K%CIXMY'6]A>6.X!7RSMP2.N<X(/3'/6M(H"../I0
M!X[KWB*RN]?,CR6D26T7V>2WO/-MI9LX.1M!RIQ@ ^M=MX<\4:>V@VG_ !+[
MJP4)M6W^SN0@' Q@=/3VKJ3;QL59E#,O1B,D?B:<$QGD\F@#(_X2?3_2Z_\
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MA-N&>1W_ '9X*$,3D8XP: .3,,\GBSP+=RZQ/?RW,%TQFP@3)@SN15&!U]^
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MK*GVA]55D D8DDKMSP#QSUH ] DU2\L_"$%_/ DVI-;1?N4.%DN'  4'L"Y
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M<GB5@%.\!<C:?6J>C>'=8LO^$26XM;;_ (E%O+#.Z7!/WEVC:-O/W0?QQ[T
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M9)?M0Q*@+891C(X.>>^.#SC2O?#^L76CZ_H8LU5-3OI)4O#(A1(G*DDKG=N
M!XQUQS0!I6^IS1>+?%"7,]P]I:VUH\<<:ES'N$FXJJ@G)P#^'H*N6>LV=KH^
MCB.:]O6O84-MO7?/*NT-N?H!@$9)P.?4UE0Z;J]CXTUJ\CLII=/NK"**+$J9
M=X^.<MQP['GT/M65%HOB/1G\.:U:Z:+JXLM-72[S3_/4':"/WB-TSD D'MB@
M#N=&UBSUW38[^Q=VA<E<.A5E8'!!!Z$$5?JGICW\MH9-1@C@F9V(A1MVQ<\
MMT)QR<<<X[9JY0!F:QKMIH@MQ.D\TURY2&"WC,DDA +'"CL "360GC2&?Q'I
M6FP6-V\5_9&Z$GDG*9957</X0,MDGIQ2^---DU*&R4:7<WL,+F4R64ZQ7,$@
MQL:,LP!ZMD'M6=I6D>)+3Q%HNIZA&EY+_9CV5U*) #&QE#AFXY^4 ''?/UH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH ;)%'-&T<J*Z,,,K#((]Q3JX_6AK5
M]XVM]*L]<FL+*33WN)%AAC9@RN%&&92?XAGZ>]9=M=>)/$D.H7&F:W'92V%]
M):'S-I0",@99=AR6&23D8R,=* /1**\TN_\ A*%TWQ3J)\5SH-*ED:VB6VAV
MG9&LA5CMR0<[>,>O/2IX+_7-;\2RI_;=QI]K%IEK?/;PP1M\S9+*"PS_  G\
M_3B@#T2BO._#U]XKUN/3-?2_M18SS%IXGN%,?DEB-@01 JZ\#)<\@YJI9^)M
M8TJ6^FU2\NY;ZWLIKM]/98VM[E!C9);R*H(0#.023R/2@#TX@,"" 0>"#3(H
M8H(4AAC2.)%"HB+A5 X  ["O.]/U#QA/:VVI37MM;V5Q:.[R3W,4F6V%U:%5
MC7!&&R&+<=<XS3_#FI^()XO"EU?:[+=+K(E$\1MHD"8A=U*E5!R"O?(/I0!Z
M&K!L[2#@X.#T-#.J+N9@H]2<5YYHLLFE>!KF^77[K==ZC*J2S1I*Y/VED_=J
M%&7=1T.1GG &:QM7O]1UGPEJ-K>75[";3Q!#:QL619O++(0'*_*2-V?J!UQ0
M!ZH+^$ZH=/Q)YXA$Y/EG9M+%?O=,Y!XZU:KDQ=ZBWCVXT4:C*+<:*DR-L3<L
MID*%_NX)^7.",>U9VA>(-2U.VL["XO94U;3[F;^U"L:#>D6>,8( ;?'C&#][
M'2@#O:*\T\/ZCXN\2V>G:[#?P6EG=3N)4:=2%B+,H5$,7WQ@$$L<D<\'%6+.
M]UJ'2M$U6[U^>4RZF+62$P1K'(C2LGS87.[..00!Z=Z /0Z*\VT_7?$_B3[9
MJ>EW-G;6]K?M $N)ML:QH1D.GEDY(YSO')[5H6&M:LGBB2QU>ZFL[EO.,$#P
MJ;2Z0#*&.3&Y2JC+ G\J .YHKBO!>IW]Q?W%IJM[>_VDENCW%G<Q*%5L\R1.
MHP4.<8Y(P*V?%^N2^'/"U[JL, FE@4;5;.W)8+DX[#.3]* -RLF/Q'I\NJ1V
M$;3.\CO&LJPL8BZ#YEWXQD8(^H(ZBL:2\U;2_%&DZ6^IRZA::M#,#,\<2O;O
M&FX.FQ "ISC# \XY[%/AQ92VWAE9GO[BX$T\[>7*$VH?.?)!"@Y/4Y)]L4 =
MA17-^,M=GT6TTZ&V/ESZE?PV"SX!\C>3E\'@D ' /&>OI6?/-KZZWJ>@6^L2
M/,VG"]LKJ2*(/&X8IL8!-I4D YQD<\T =I17 VGBJ\O-%BU2&\,O]EZ2]SJ<
M&U%\VX"D!#\N5^:.0G&.W'-5[/4/&3V-OJCWB+:3V$DS^>(642;-Z>6J@-C@
MC#$\4 >C5#=745E:2W4[%884+N54L0 ,G@9)_"O-[C4O%UOHGAC5E\0I(^JS
MV<+VQL8P@\U<DD_>_(COC' %_P#M?7+6V\:63ZJ9[C1[=)[:[DMXPWS0ER"J
M@*>5XX[]Z .]CD66))$.5<!@2,<&J=SJ]C::I9Z;//LN[S?]GCV,=^T;FY P
M, 'J:Y75O$4\%YIMK=:L=)MY]-:Z^VA(_P![,,?N_G4J, EL 9/&,=\T#7=6
MNO UW=7,5OJDD=U.S26W$>Z$#&P,.<-W/7MVH ]$N[6&^M);6YC$D$JE)$)(
M#*>H..U0I)9:8MK8(5A781#&,D!4'/T &.OM7 ^9KFHQ:3#<:[,MU;Z]-9&X
MA@C42!8Y2&9"I&<#&.G/0D UNWUM;ZOJ6NSWMSY&G6M@]@9AA3$77?,X8],+
MY?/L?>@#7L_$VC:A-!#:W\4CW&[R."!-MY.PD8;&#TS6M7F]D^H>&=2T70M?
MMH]0TP3K%I6JPC8T<FTA4D4'KM)&>X]><+>:YXJ@T?6-974+/R]&OI8S;"VP
M+J)",AB22IP3C'X^P!Z/17"0>(-3\1KKEYI>H?8(M)E:*.%HD99F50Q,I8$A
M3R,*01UR:31)[S5_'-OJ@OYX8+C0[:Z:SPK(/,+_ "Y(SP1G/4_3B@#NV8*I
M8YP!G@9JEIVLZ?JXF-A=1S&!_+E49#1MZ,IY!^M7J\P:RO-%GO/%VBQF:2*_
MNH]3LHP?])A$[X8?[:@Y!';CUR >A6&K66IM<+9SB5K>3RI1M(*-Z'(ZU=KS
M2P\0RIHT]SHS"1M;UV1+27C[I3);#< _(1@]^W:M6XNO&=KX<U6ZN);*"XLP
M9K=I%5A-&%RP?!PK<'!''/2@#MJ*\WNM3U?Q#X GUF/5&LDN[N$V\4 1C#$9
M%C*,V.222Q'X=,BO0[=)([>..68S2*@#2%0"YQR<#@9]J ):J6>J6-_<74%I
M=132VK^7.J-GRV_NGWX-6ZX;P3QXL\;?]A!/_0* .YHKB]=\<1KX<UFYT5G6
M^TZ(2.EY92H!SC&&"\_G]*4W_B(>,9=!&JV!,UB;U7%H<V^'5-H7?\P.<Y)]
M?I0!V=%<)IOBS4=7NM"TV*:"*YN[::>YG6$L/W;[,*"<#+ D]<8]Z8_BO6U'
MV,BU2\AUU=,>5X6*21LNY7 ##!VD9&?RH [ZJD>IV<NIS:<EPC7D*+))".JJ
M>A-<1K5_K4NE:AI\]_$MQ;:O9P"Y@@V[HY&B8 J2>07]><8[U/<1:W/\2M0&
MFSVL0CTF!9)Y8=Y#%Y"H"AAU(/))P!0!W=%9/AC59M;\,Z=J5PB1S7$"O(J?
M=#=\9[9K6H SXM=TB?4VTV+4[-[Y<[K=9E,@QU^7.>*T*X/6[8:;XVT"].BV
MT&F0W!A6\MBH<RS*8U#* "%R<=3R0:UF\:Z1?/>V.D:C!-JEO%(WDO&^ 4ZY
MX'TZT =-BDKA8?$WB,VWAN64Z66UQ $58) (&,7F!B=_S#@Y7CKU];*>++Z.
M$65PENVHOJQTM)HXV$6=@?>4+$_=.,;N2.HSP =C17"ZUXHUG04UFS+V5U>V
M=B-1MY'C95>+<5964'[P(X(/.1TYJY%X@U9-1^S7@M!%/I$FH1/!&VZ)E*@J
M<M\P^<'^'I0!TEWJ5G8S6T-U<1Q274GE0*QYD;K@5;KR_P#XFFH>&O ,K744
MU[+=Q2I).K=H)&.\Y)8\'TS^M=KX>O-2GDU.TU26UFGLKD1"6VC**ZF-'&5)
M."-^.O:@#;J*XN(+6!I[B:.&)?O22,%4=N2:EKSF]GUW5_B3J:6?D26F@6\;
M16L[,%EGD3<#A>^"P!.<>G- 'HB,KH'5@RL,@@Y!%+7,6?CS0Y--TNXO[R*Q
MN-0A61+>5OF!.1CZ9!&>*RK_ ,3>)[33_$%^L6E&#1YRN"DFZ= JL1][Y" W
M7D$]ACD [W%&*XR3Q;J&D+<3ZS%:O;C3#J$8M58,I# &,[B=WWEPWR]^*L1Z
M]JMO+H+WC64D&KDQA8H61HG,;2*<ER&&%P>!Z^U '5XJM>W]GIL'GWMU%;Q9
M"AY7"@D] ,]_:N)M?%OB+R].NKR+2EMKG6'TQTC5PQPSJ'4EN.4^[@YZY':E
MJ(UB^\">)SJ-U:S>7?2"'9$RG]W,O4EC@?+@ =!W- 'IE%<_IFI:N?$MWI>I
M)9%%M4N8WM@P*AG9=C;B=WW<Y&/I6OJ$\UKI]Q/;Q+--'&62-Y @8@="QX ]
MZ +-%<+IOC'4KG^T4<V%P\&F?;HI((G2/?E@4W%B) "OWU.#S4]GXIU:WO=+
M36H+".WOK":\+6[-F'RPK$'=P1M8?YZ@'5W%[:VDD*7%Q%$\[^7$KN 9&]!Z
MFK%>5:IJM_KMUX#U:YA@MX+O4A)%"A+.@(^7+=#D<]!7JM $?GQ?:/(\U/.*
M[_+W#=MSC..N,]ZAFU&RM[E+:>\MXIY!E(GE568>P)R:YQ1$OQ;=4A19#H@=
MY .7S-@9^FVJ?CKPWI%[I5S']AAFUK4I%CM97YE$F!@ANJJJ@L0., ^O(!W.
M*,5CMXAT:QU"#1[C5;9-0(1%A=\.Q(XX]ZYP>+O$BV$VH2Z+9?9X=2^PE([H
MEY/WWDY4D ##^O7T% '=T5QMUXVFT>75HM9T](GL+.*['V:4R"0.Q0+DJ/X@
M!GZ^E6I/$&KV&NV&EW]A;.^HQ2M;/!(P1947=Y3D@\8_B ]?EH ZBF22)$NZ
M1U1<@98X&3TKB]*\;:E?Z3I.JS:1!%9W]X+3Y;DEUW.RA@-N",C'7-9VMWNH
MWG@O7KO4K>TG>RU(?9%0$E2DRC'(^O(]3TH ](HKG]*U^^N/$-QHVIZ=':3K
M;+=PF*<RAHRQ7!.T88$#.,CGK704 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MP(PJM@C<=B@L0"<9)Z_2M2\MA>64]JSNBS1M&70X901C(]^:=/.D$1=Y(T[
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0?EV-P<="?6O2O"-MI]MIEPFF07D=N]U))OND*&5FP2Z@@':2>.!T/:M_%%
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M4@<<8^E>2^.M3M9[_P 1Q_8Q;WENMJBO=1F22X42<M#GB-5^8DCKD=*]CHH
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ML8C,4+?NBG )RW.0!Z4 /U+QC+IMS'IKVL#ZK]F^T21K+(T2C=@#<L9;)]U
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M1K)Y<F-RY&<''&:X76M,LO$/CK2DTZXBFABA>/55A<,OE1NK1QN1T/F#H>2
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M[7 \/F8SMW#&<5S5OI.N7L^@-JELD4NBEWDEBD5ENF\LHNP<$9SD[@,=!GL
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M375S*L4$*%Y';HJ@9)JAX>TYM.TL&52+JZ=KJYR<_O7.6'T'W1[ 52\>*S>
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M YVR(&&?7!KG!XXLIIUAL]/U&[>2R6^B\J)0)(F[@LP Q[XYX&:C7QD+R_\
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MXZYH TI=%TN;3/[-DTZU:Q[6YA7RQSGA<8'/--CT+1XHI8H]*L4CF4)*BVZ
M2*.@88Y ]ZH6'C#3M0U2UL(X[F-[N%IK9Y(\+,B]2.<@X.<, <5G_$*[;3M*
MT^[74KBPC_M""*>6&3;^Y9L/GJ.G.<9&* .@@T+2;:RN+.#3K6*VN,^=$D0"
MR9ZY'>JX\+:"!:*-)M,69W6X\L?NCG.5].>:RM+O-*DUD-IOBI[Y+>!Y;F(W
M(GCV'@$L#A2"/RSQWK2L?%.G:@RK"+D.]H;R-'@8-)%G&Y1C)[<=3D4 6GT+
M29-474WTRT:^7I<&%=X]\XSFM'%<'JOC*SU[PGJ4NCOJ4!2U-Q%=^0\*MM8
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M=G!7&,Y!X/'%21^*M*M+#4]3N=3FDL;>[\EW:U;$#;5.WY%R5^8?,1U.,]*
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH YF31M5'B;5=3B6S,5U8K:QAIF# KO()&SH2_8\8[U4M_#FL0GPFY^PE
MM&C:*8"5\2*8Q'E?DZX&<'OQ[UT6I:M#I]A>W*HUT]G'YDL$#*9 ,9Z$@#C)
MY/;BI=,ODU/2K._C1D2Z@295;JH90<'\Z .4F\)ZGJ>GZW9W\EK +V[%[;2V
M\K.89%";005&1E 2<]\8[U+J/AW5=;47.HBQ2]M[">VMQ!*^QI)E"N[$KD#
M&%YZGD\5V&:2@#C%\.ZW!X$T71H!8F\LY;=IF>5O+Q%('X(7)R5 Z=S6BVF:
MS%K&MW=M]A,=[;HD D=]RR*",MA<;>2<#G@>O'1T9H \_G\(>(;B".&YGTNZ
MC7218JDV_;#-@@S(N,$D8]#[@==/2- UC3CX=>1K)WT_3VL+C#ORI,6&7Y>3
MB+H<<FNMS1F@#@HO!VK36VH&>6WM[L:T=5T^1)6D52>-C@J, C(XS][VYGUG
MPQJFLP:Q>2QVD>I7>F_V=;Q+.QC1"Q9F9MF<Y.1QV [UVV:* ..MM U=?%>A
MZE-!9>19::;27;<'>KG&2/D^8?* ,D=2?KH>)]'U#4;K1KS3'M1/I]WYQ6Y#
M89"I1L$=\-G'? K=EGA@"F:5(P[!%+L!N8G  SW)[4\],XS[4 <<WAO5H/[>
MT^VEMGTS5YFEWNY66W\P8EP-I#9Y*\C!ZUUMM EK:PV\6?+B0(N3G@# KGK?
MQK9W%O<W/]G:G';6LCQW$S0#$3)][(#%N/8&N@MKF&\M(;JWD$D$R"2-UZ,I
M&0?RH Y#3/"%['I6A:/?M;&RTB=;@20RL7G9-VS*E0%&6#'D_=QWI_A_0/$G
MA^4:5!>Z>^AI.TL<K(WVA$9BQCQ]T\DC<3W/'05V-+F@#'\3Z?=ZIH$]G8^2
M;AWC*^<Q5<+(K') )Z ]JQ=:\+7^NW^K>>T%O;W=E!'!+%,QDCFA=W5B-HXR
M_KGY??C=U+7;?2]3TRQFAG:3496BB=%!16"[OF)/' [9K4H YVUTS4;_ %^R
MU?58+>WDL8)8(XX9#()&?;N<' P,+@#&>3FH?%NAZCK.H:!-9+;F/3[];N7S
M92I('884^M=31F@#BAX9U.ULM9T*W6%]+U265Q<-,0]NDH D7;M.X\L5Y[\X
MJ-O"-_!?Z^]H(/LU[I4=A:J\[$J54J-WR\#!SQGI[UW%9FAZ[;:_;7$]K'*B
MP7,ELPE !+(<$C!/% ' Z@=7M_$.DPI'8"^L-)$-Q''J @9@[ <.Z'<N(\X"
M@@GKTJ>QTK4K^/2M=\.65C8S6,,FG/8W4AD@EA#9#)(HR1D9#8YSU]>]O])T
MW4U7^T-.M;P)RHG@63'TR#4EA<_;+&&X^S3VV]<^3.H5T]B 3B@#"L]-UTZ_
MI=[?K8,EO;W,<S0.R[3(R%0JE>0!&!DD$[B>W.SK4-U<:+>P621/<RPM'&)7
M*KDC&20">^>E7:Q-#\46FOWE]:VUK>0R6+^7/Y\84*_]W@G)H R+[PWK,WAC
M0$M);2'5]'"%(Y27@E(0QD$X!P5)(../UJOK2Z]#%I$]S%IJWC:M"(K:%F\H
M 1R9RY4$L<GM@8'OG;D\7:?!::M=7<5U:P:9)Y<SS18W,0" @SDDAEQ_O"J[
M:IHVO/Y-]H5Q)=V\37,5M?6'SE00"4W#;G) P#F@#-UCPGJ.JIK%\L5NM]?M
M;+%#),0L<<+!\LP4Y8G=T&!QR:OZWHFJOXBL=?TD6<EQ' ;6YM;MR$>(MN^5
M@IPP/?!J&Q^)&D7]D;Z.RU5;!6*O=FT)C0CKN*DD?E74V5[;:C9Q7EG.D]O*
M-R21G(84 <AK_A_5=9L8H;NQLYSL:2)K><PO9SY)0H^,E0#@G@G&=O:JEKX8
M\3Z+JZ:M;26&J7%Y:0PZC'=R%,RQKM$B,%/'J,<_CQU$WB.WA\2Q:$UI>M<R
MQ^:LBQ9CV#&6W9Z D \=34GB+7[3PSI+ZG?1SO;(P5S FXKG@$C(XS@?B* ,
MN'2=9CU_[;.+293I2V;R(Y0M*&+$A-N N2>_:L_0_"NKZ9!X6:5;1IM(AN+>
M9%F;:RR;<,IV]1MZ8[]:U+SQOIUG+IT!M-1ENM0A\Z"VBM29-N,G(Z9'<9XK
M1TOQ!I^K336\$CQW=NJF>VGC,<L61D94_P QD>] ')1^%_$;ZSIE]>1Z=//;
MZBUQ/>-<N7:+YE5$79A %;D#@E1FK6L>&=8OO">NZ- MF'O+UKBWE>9L%6E$
MAW#;P1C'&<^U= WB;3/(N+A'GEM[=BDDT-M(Z C[V&"D$#!R1D"H]4\5:7I,
M>G2S/++%J,JQ6\EO&95=F&1]WU[8H J>)O#U]K4.G75E<QV>J6K%3+R5\N1=
MLJ^_'(SW4?6J.O>&+Z/7-*U?1;2QNEL[;[$]C=G:IBR""C8.UA@=NE=)I^MV
M&IW,]K;R2"Y@ ,D,T+Q.H/0[6 .#@\]*T: *>G1W4=D@O?)%P26=8?N+DDA0
M<#.!@9QSC-<./"NO3>(=.U"Z@M)9+75))Y+M[DEW@(8(JKM^0 $#:.I&?>N\
MN;N&UAFD<LWDIYCI&I9]O/.T<]C^5,TS4(=5TNTU&W#B&ZA29 XPP5@",^_-
M '++HNLCP])9&SM_/BU@7R8N/EEC^T_:.#MX;^#![C.<5D7'A'Q!!H7B;0+6
MWM)[;5+B6YM[EKC84WD':R[>3\HZ<<UZ7FJ6K:K::+ILVHW\C1VL(S(ZQL^T
M9QG"@F@".]L9;WP[<6#%(YI[1H20=RJS(1[9&37,:=:WVI_#6TTB-(EU*U2&
MVGBE?9Y;1,O!P">54$<<@@UN6_B[1[A[)1-/$+[;]F>>UEC2;<,J%9E )(Z#
M/-:ZV\,<\DZ0QK-* )) H#.!TR>^,G'UH Q&TV[7QN-:80K9+IQMG)DPP;?O
MSC&,=NM4_!=C,EQKVK2,3%J=^TMOGG=$ORJV?0@9'MCUKJ)H8KB)HIHTDC;J
MCJ"#^!IXP!@=* ..GT+5?,\6VT,$#0ZNA:"9YMNUC"L>TK@GJ"<U6U+PUJ%_
MJ5G:?8VCL5T2;3I;A958(T@4< D,<;?3O75P:Q9W.M7>DQLYNK2-))04(4!\
M[<$]>G:M"@#B_"NFZY8S6MG>Z'I=I%8QB-[^%U=[O"[1M4 %.<$EL^@'.0WX
MEZ+JFNZ/IUKI=B;J2&_CN9!YB( JAA_$1DG=7;9HS0!RLLFMW33FP\/IIETU
MM(@NKIXFYVML4>6Q/WRI.1C /?%8>A:%KMEXEM];N-'9673)+>;??K++++N#
M DG@ E<  X&>V*] N[F*SM)KJ<L(H4+N54L0 ,G@<G\*BTS4K75]-@U"QD\V
MVG7?&^TKD?0\T <?#I6L1_"5-%.E2?VFMK]F\@31XSTW;MV,?K[4_P 8VLVI
MPZ3+8SBQ\0[Q#'&) 6195Q*#CJ%7+9'=0:["\O(-/LIKRZ?9!"A>1]I.U1U.
M!SQ6'9ZIX8FUFWO;?R4U#48@L-R]LT;7"  X5V4!N,=#Z4 ;EC:1:?86]G ,
M0P1K$@]%48'\JY[2-*N?"<VH6]E93WNG75RUU$(I$#PLV-R'>RC;D9&.>3GU
M/4YHS0!YYKV@R0Z)XJU^^A'V[4(D5;<2!ECB3:%7. -Q(R>PSQTR9=<\/:EX
MNGFN9M/?3&@TVXM8%EDC=I9)0!R48@*H'<CEO;GIM4DTG4+Z/P_J$7GO<0M/
MY+H2C(I Y/0\D<5JQQI#&D<:A40!5 [ =* .7TSPZ]_X:TFWU1=1T^YLK9+=
MH[>_:/.U0"3Y38.<<9JK+IVK+XNUB_BTNX:V?25M('\^(-+(K,>,MD9W=3Z&
MNUS10!P5AIFM)+X)\W1I8QI<+Q79\^(A,Q>4",-STW<=CZ\5L>/M.OM8\%:A
MING6QN+JY541 ZJ!\P))+$#'%=+10!RUB;\2:7GPN\%Q$ODR7,TL!$49V[L;
M7)).T=JR]-TS6X=&\813Z1,L^I7=Q+:H)HCO21 BY._@C&3G\,UWM% 'G%WX
M=U9XO"U\=!BOSI]H;.[TVY>+)!51O5B2AP5^O/Y.DTG6M(UG3O$.G^'[=88T
MEMIM*LV56CB9@5<8(0OD?-CM@<XS7H@((R#D'O2T <;)IVKS>*/#NK/I:1QP
M"[6XC@D3,(E*["<D;CQEMN><XS2Z/H%S<6OBG3]9LW2VU*_EFB=I%;?&ZJH^
MZ201M[X[5UMQ/%:VTMQ.X2&)"[N>BJ!DG\JH_P!NZ=]KTZU^T?OM1C,EJNQO
MWBA=Q.<<<>N* ./M_"6M:CX#U*QU&9(M7NH8[9"2"GEP'$>>OWL,Q_WZVO#H
MN[F\CNKGPO!I,J0-#-,PC,CL&'RH5YV9#'G&?EQ6YI^J66J+<-93B5;>9H)"
M 1MD7&5Y],BKE '#>.;'4KK7_#5Y9Z;/=6^FW1N+EHB-P4D !06&X\$GCBK%
M_IFI>*/$>D7%Q9/8Z3IDHNQYSKYL\P'RX52=JCOG!.>E=C10!YMI5IK<FH:#
MJ%]H]ZL]I?3)<*'1(HT>-U#1QJ<;1E26//7KFF7V@ZU=>%YK"/2Y3<:?K+WR
M1O*JQWL9E=]H(.>C@\@<@=Q7H5OJ-I=7MU9PSJ]Q:[?/C&<IN!*Y^H!JU0!P
M^GWB:#87NM#PK=6,4AB25-X:X(!;+OEL;%!&.<]>,8KM)I/)@DEV.^Q2VU%R
MS8'0#N:)K>&X4+/%'*JL' =0P# Y!Y[@\U)0!Y7:I?Q?#WPU;MH^J?:+#4H9
M;B+[*V]5CDWL0.I&&&,=>?2O4HW\R)7 90P!PPP1]1VIU% 'E4D-Z/!_A&QF
MT34FELM4B>YB^R,^$C+!FXSQ\PQGKSCI4>MZ3JNKZGXL>TTV]V?;+.YCBE1X
M5O$@7:Z*PQU(R,'G (KUFJ]Q?6EK-!#<74$,MPVV%)) K2'T4'J?I0!R_@NT
ML1/=7MGX=U'2B\:1R2:A(YDD(R=H5F;Y1G[W&<].*["BB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M2WG:YMDV0S?;)M\:XQA3OR.*MV.B:;IL\MQ:VB+<R\27#DO*X]&=LL1P.":
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M-+%BH&=NQOSX[5I^([#4M9E\9VNGV-ZDLT=H89'A>))_*.75'(P21P/7Z<T
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M5PQ\0ZE;^*X[+4[F:UBFU!H[,Q1));7$6,"-G ++(",XR.3W&*S],\1>*_$E
MM%J^D^3':F^9#'/-$(Q"&V[6&W>'Z'[W4],<4 >D$A>IQ4)NX!?+9ECY[QF4
M+M."H(!YQCJ1QG->2W#:C-X+U&Z;6;U3-XA\O8A0!5\_9@';D]C@G'RCC&<]
MT]WJ4'C6ST@7[26TFERRDR1)N,JNBAR0!_>/ P.?I@ Z>BO.],U?Q.;/PSJ-
MWJ*3"\OFM+JT6V101F3YLC)RNSL0.!QU)KW7BW7+B5[:RNUCUD:N;0Z;Y*G%
MOGB3!&[[N&W9V]?P /3**100H#')QR<8S7.^)M6O+74=%TFQF2VEU2X>-KIU
M#>4B(6.T'C>> ,@CV- '1,RHC.[!549))P *R]/\1:7JEV+6SN6>5H!<H#$Z
M!XB<!U+ !AG'(SUKF+VYU8Q^*M!O+ZXDCMK 75O>B.(2,CJX*-A=O5&&0H.,
M].#71>%+:2W\+Z8);J6Y8VT;!Y50%047Y1M4<#WR?4F@#:HJKJ<MW#I=W+80
MI->+"Q@C<X5GQ\H)],UY_!XBU&YTO4I8M=U"*]LYK59;*[LH4EMR[A6#'9AD
M;.00 1@<\T >E56O[ZWTRPGOKMS';P(9)'"%MJCJ< $UQ6K^*=0T'6O$HDO%
MEM;2SMY[=)XUVPO(Y3&5 )7..IS[BK6MVNLVWAWQ)]KU1+_3I-(F:(R1JDJ2
M;&W ;% *8P1G)_F0#KK6YBO+2&ZMWWPS(LD;8(RI&0<'GH:EKCM$N-6TW5M#
MT^\OTN[>^TYW\L0+&(6B$?W2.2"'P0<]!C%=E0!F3>(-+MM2.G27)^V;=YA6
M-F8+P-V /NY(&[IGO44]OHOBVP0M(E[;13;E,,[ +(ONI!R#VKF+R6__ .%S
M%+%;=Y%\/DA9V*KS.,\@$]A61H^M7&BR>+WGA$.N-J-NLT2*#;Q^<P2-DZ%N
M"6)(!)Q[T >K 8 %%>=ZYK'B[PYH^HW+S6\D:) UM)=;&F#-(B.K+&%4K\_#
M #I[\6=5\3:MX;N]8BNIXKX1VUM/ 3#Y8C:65HL'!Y0%=W//)&>F #H/$MCH
MDUE'?:Z&^SV+B=7\R11&PZ/A#U'KVYK7MYX[FWCN(7#Q2H'1AT92,@UP_BNV
MUFR\(>(UO]0CU&P;3F,;21K',LO0_< 7;T([YX.:BT:YU^Q&G6S:K;R6UUH+
MSVZ-;!1;R1B( DYRPQ)SD]NU 'H-%>;6&O\ BEX_"MQ)J=E(NM(8GC-GQ&VP
MN'!# D\8QP/;O5Q_$&M1:-<03:C9I>0:L=.-UY!\R5-@;,<8R#*<\ _+P2>!
M0!WM4_[3L_[7_LKSQ]N\DW'DX.?+!"[L].I KAX/%'B&30[-4V+?MKO]FL]U
M!@M%R0SH" &VX) Q[8JMK>LW?A;QC97&I3)>73:5)!]H6 QPH7N8PKR#)VH.
M,G/\Z /3:*@LUF6V7[1.D\AY+HFQ3]!D\?B:I>)-8'A_PY?ZL8_,^RQ%PA.-
MQZ 9^I% &I17)G6-5TW6M$L;J[MKR/5HY )([<KY4BIOW##'*'ICK[UCZ=XE
M\2?9/#=_>W-C)%JE]]D>"*W*X7Y_GW%NOR=,8^M 'HE%%<MXLU^\T.XM7;-M
MI3HWGWZVYG\F3(VAE'1#SEN?3CK0!U-%<IIOB.^N?$$FGRFSDB72(;X20 D-
M(Q(.#GE.,CCO5+0O%VH:_'HMIB"VN[_3GO99TC+*NUP@55)]3G))Z>_ !U\V
MHVD%];V,LZK=7(8PQ=V"C)/X59K@KE/$5SK_ (1:]-E!J:+>FX\G<T.W:%'&
M03U4XSUKH?#&J7&I6U]'=R12W-C?2VDDD2;%?;@@@9..& /N#0!N55N-2L[2
M\MK2>X1+BZ8K!&>KD DX_ &I+RY2RLI[J7/EP1M(V/11D_RKAQ/K&I3>#M6O
MKNV,%W=B46L,&/++6\I7#EB3@9!]3Z=* .^HKSZ/QO?IXCTRSF>VDBO+R6TE
M6WA9HX2,[-LV<.W3< .,XX(YNP>*]0:>_P!%E-J-?AO5MX 866.2-P763;N)
M("*Y//5<=Z .THI!G'/6L'Q%JMS975A:6US# UR9"QV&69@JYQ'$!\W)&3V
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MUAM1UC5+..W406#I$;@29WR%0S+C'&W(SR:U: "BBB@ HHHH **** "BBB@
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MM-::]M#J<]LLLMO&X# E03A<Y[UHR:]I$5R;>34[1)067:TJCE1EA]0.3Z4
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M?;;A(C<S"&(,<;F/]/4UEZ?XE^T^*=>TRX\B"VT[[,L4K/@R-(A<Y)./3 %
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MSC-=#0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MT:WT^ZMM7TR[MVN%DMW00>7GS'+XVD-@D8/S;A7IL4L<\*30R))$ZAD=&!#
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M7=T4 >0I-(O]B7HM]031[?4[]9A!"Q>V\R0F%]I4D  ]0. WOBI[G1=%>_\
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M>,K@$9[C/;-6]8@GBU>^G\"I$EI)HCM,-.4"-I=QV8"#'F8)QCGBO5:9%#%
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M3>9!DE0X8G Y!XP>.XK;M/$&K:W#/?:)!:2VD%^;4PR@AY45@KN'W +_ !$
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M7DKM$IV/E20HXX.Q>N>E277@^0ZU/JFF:S=Z9-=JJWB0HC),0,!@&!"MCN*
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M:VZ,7#[<;NFY1^'%1>+]%NH]+\2ZM+>"9KK2_LB6\<&/NY*X.222SMQ[CTH
MNQ>)M475+6RU71K>&"_MII8'BNO-/R*&*N"H R#V)K'\/^)3I'@SPC906S37
M6HPL$ 1G$:("S,50%FQD# ]>HK:T?1;Z\M+&\U74XKJ2&V9+;R+<Q*-Z %F!
M8[FQQV')X]*<G@.YCT71[>PUC[-J6C%EL[P0 C8PPRNA)!R/Z4 =%H.H7NI:
M>TM_8M:3)*T84A@)%'1P& (!]#TKSG4-,MO#]]K$?BO1TN=,U*YDDAUV&-7E
MMO,Z*W!9-O8CC/8UZ3HVGW.G6;)>ZC-J%U*_F2S2*%&=H&%51A5^4<>I)[U@
MS>$-1.F7&D0ZU&=,NY)6G2:T#R*LC%BL;9P.IQN5L9^F "M9S?VU\2;VRN72
M?3]*LX9+2(@,A=P#YA]6 X![ \4ZXV:=\1?L%M$BV>HZ9+-<P8^1Y%8#=MZ9
M(.#QS6O<^&_+OK74-)N?L=Y;P"V.]=\<T0Z*XR"<=B"",FF0^'+C^T+K6+J\
MCGU>6V-M"WE%88$SG"IG)R>22<_04 >>_#NTT[5?"-C9W7AEI&NKB=#J2P1@
M0YW'<CY+J1M !P,''/ ID\&DZ-XO\;76JZ,MQ;(+=86,"/Y;2*0&Y^[D]6'>
MO0_ WAFY\)>'QI,]Y%=I'(SQND10@,<D').>?I533/!MQ;>)]>U.^N[:YM=8
M0)+;"!E*@#"C=N/\.<\=?2@#8\+65[IOA;3;/4;DW-W% !+*6W9/7&>^.F>^
M*N:I=W%EIL]Q:VC7<Z+\D(<)N/N3P!ZGT[&N;CTWQ#H.D6%A::E]M$=_%&A:
MV!?[)SN1VSC(7G?Q]T#J:UO%&A/XAT9K&.\:U?S$E5MNY6*G(5U[J3U&10!R
M6O>*%UGP+XOBEMH"U@GD[HI/,CDW*"K E1T)].HK3O(T3XE^&BJ@'^S;E<^P
MV8_F:;>>#-4N[+7H&U6TSJ\42,?L9"Q%5VG:-W3 &,]#6G)H%_-XGTC6)+RW
MVV-J\$D2PMEV?&X@[N!\JX'/>@";Q*%>+3X9-,AOHI+Z$-YDFSRCN!#CCDCT
MXK-O_%FK03ZS%:Z LBZ5\\DLMX%1X]F_C"D[L=L8]ZU?$.EZAJD5FEA>Q6I@
MNH[AR\9??L.0O!& >_M6?+X>U:5_$.Z_LO+U9-B@6[ Q#9L!)W_-\OTYH :-
M<U8^,)(BEF-#CT];IGWMYB@D_,1M//RG XXSR3Q533/'TVJ7UFL.C3O:7I<0
M2HLF4 ^X9,H% ;U#''>KT'AO4EU!)IM2MY+:6R6SN[?[.1N5=V"C;LK][G.[
MO4>A^&=9T-8;.+75DTJTW_9;=K<!\$':LCY^95SV )P.: *<'CV]_L$ZU>Z"
M]M9L/+A"S^9))/YFP)M R%Z\GG@\=,R?\)[)!8ZC/>:6\8M#"%F'F+#)YC;<
M[G16 7^+Y3Q4B>"IY/ T?AZXU/;/#*)H;R",J482;P<$G)R2.M66T7Q++9*)
MO$,#W8=.EGB%D&=P9-V26SSSC@8 H R]9\2Z[MT%K*&R7[3J@MW:.ZWQ3KL)
M&UPGW3SDXR"N,=ZZCQ!J[:%H%YJ@M6N?LT9D:)7"D@=>37-CP'-!%;FQN[:V
M>'5O[26(0$PI\FW8J[@0._7J3Q6KX\=5\!:X&8 M9R*N3C)*G 'O0!7L/&%Q
M/KFGZ=?:)-9+J4#36<WG+('VKN*L!]TX/O4-AXUGN=772KC3HH[ZXM'N;6!+
MH,V1SY<O'[M\8]1U].6)X8N=:L],N9]7C5K73Y(;2>P4KAI4"^9DDYP!P!CG
MO4.F>%KOP]>Z?JM[J-A]DTNQEAF\JT:,LA 8R'#'YLKD\<\^M %[2?&,NIZ9
MI\XTY4O;N^DM'M#.<P["V\D[>H"YQ[]:J1^.[V2U^W#PY<+9QWQL9S]H0R!]
M_EKM4?>^8J#DC&>,CFG^%]/M+[Q'JOBC3Y9C9W6%MDD5E1G(7S)55N>=JKGC
M[C=L4U/!^KII'V,:K:>8VK?VG(XMFVL?,$NS&[IN'7/0"@"Q)XZBLK;63JEB
M;2YTL1%X1,'#^:/W8#8')((/8>IJM<>.[VPL=0FO-!D=[2 7.;64M$T>[:1O
M95PPZXP>*-7\!RZU/XA>XOT1=5CM_+$<9S"\.=I))^89/(XHO/#/BG6-%O;+
M5->M"\]N;5?(MRJ;21ND8$\N0,8& ,G% %JX\77D2:JDFD/:S6NFMJ$ FF4F
M1!GA@N=IR.F35:'Q?J-OIV@VT]A;MJNH0>8%FNPB, %Z/M.7;<"% ]>>*M:I
MX5O=3U>YO7O8$2?1Y-,:-8FZOSOSGL>V.E5KGPSKEYH-IIEY)H]W#';&WD@E
M@<(3@!)%;)8,,'TZ]J .K2XN)-,6X6UQ<M"'%N[[<,1G:3CCGC.*YBT\>+=-
MX?8Z<8X=7DDA9VG&;>5,@H1CGE<9XKH]&L7TS0["PDF\Z2VMXX6EQC>54 G\
M<5Q]Q\.!,=9DBO\ R)KJZ%S8.BY^QME68J/5F7G!Z8]Z +NI>(;.Y@T6ZN])
MGEMY]76"UF2< (VXI'*0""03DXY&.O8&E*L36_Q"C1614!. Y^]]F#$^W)Z5
MJZ]X:N;K2]"L=):W2/2[VVGVW#$;DBZ %0>?PJ"30-=>3Q2OF6'E:NH$!:1R
MT7[L1D-\O3 R,=Z +^@H)_AYID<F2LFE1!OF()S$,\CFN9\#^+%M/"OANUO-
M/OUBN\6L=ZP4QM*2<#[V[!Z9QBNWTZP:ST&UTXA$,-LL'R$LHVKMX)Y/3O7,
M:5X3U6#3-!TB^DLC8Z3,)S-"[^9,R$F,;2N%&3SR<X[4 +-\4O#L-Q'&9PZO
M=?9OW;JS@Y(WE0<[,CKUY'%;?B3Q-!X:BL9+BTNK@7ETMK&+<*2';. 02.N#
MT]*P]'\.>*-%GDTRVU#3QH/VDRPNRNUS%&6W&,#&TCJ,D]"3[5%\4!*;/PV(
M'@6<:[;M&9W*IN"N1N(R0,XH UHO&EJ?[3AN;"]M[W3@C36C(KNP?A"NPD$'
M/KQWIUSXOCM=.U>YDTV[,NE%?M-NA1F"E0VX$-@C:<G\:R-8\'ZUJ9U:_AO+
M>UU&],,0B61S$;>/DHSA0V6).2!TP*ET>QD\*2ZO?ZX=$L-*NQ#A+=F5(V"A
M-I#* 0?7OZ4 ;,WBFTA>WS;W$D4MBU\9(DWA(QC ('))SQC.<'TK-N?%$>I6
M>KZ7):7=A?QZ8UXJNZAC&00&#(QP00*R] \-7H\'ZK_9&IO%/?;HM-N92<PV
MJNQB&<9'#.0>P8>E2:?X+U*'5[B[E@TJUCN-'>PD%J[LQE9MQD;*#=DYZG/U
MH F\,>++:UTSP]IM];ZC$;NVBC@O+E24GFVC*Y)W Y)QD 'MQBFZ%XBM-"T"
M^EU&Y=RVLW5M;K)-EW(E(5=SG& !U)  [U>_X1[4M0&@Q:I'8K%I++/NMYG9
MI)47:F,H-J]SR><#WK+E\':W<:/;2*]C!JMEJLNHVJ-(SPD22%RDA"@Y&XC(
M]/R .D\.>*[+Q(][#;HT=Q9,JSQ%T<#<,J0Z%E(.#T/&#FMVLC0O[><7$NNK
M91,Q40P6A9@@ Y)8@9)/;L />M>@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH SH;R:&2^DU">QCM8I
M(F20@JN /WA/ .?3U%74GADD:-)8V=?O*K D?45XWJ%M$NA_$6V6UQYUZK6\
M8A/SG/51CU!Z5T^G'38/B3I;Z<D26MUHK!7A3"RN75QDCJVU6///!H ]!JO!
M>VMT\BV]S#,T9PXCD#%3Z''2HM7G:VT6]G6VFN6C@=A# VUY, \*1R#].?2O
M+-'O7N]S>'Y%6[?0'AM(4@9!#)E2L8D;&]@ ?F)ZC/'2@#UM+F"20Q)-&TB]
M55@2/PHCN;>9RD4\3N.2JN"17F"W5GJ7AJ&/0;&Z3Q/9:?+;;!$ZM;.5S(')
MP-Q(.TDY);/K4D<VEZGH8_X16RDA\21:8]L!!$T/V;(#,KD[5!W=.^3D=R #
MTF*]M9YY((;F&26/EXTD!9?J!TJ031,^P2H7.?E##/'!KS2V&EZO#X8GT&UM
MK;5+>XB^WQ)$$DA@\LB9),@''89^]P1GK6;:6-G-X%\5WWAVSM9=0CO;N*&2
MV"AUMVDY52/X?+R0!^% 'H$OB(KXRL]%B6"6"YMI)C*LF61D(!!'3'(_6MQ+
MB"5F6.:-RGW@K X^M>5KJFA2ZUHNHZ!8RO NC7*^5:Q%7)"@K%O4</\ *XZ]
M?K5?0;[2[C7M*N9WLTT>31989(?*(A@^928I';.]OO9)QDYXYH ];6Y@=PB3
M1LQ&X*&!)'K2F>+SO)\U/-QG9N&[\J\E\*/HFEZ/X)NQ+9I*\\ZRW*J <NDB
MA6;&>"57GC@5;\*W.BO'I^F:WIDJ^*[.\R_[IC,[[O\ 7ESUC(.3DXP, =*
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MB,9A0PE3%M&S9TQVQ[4 /HKS_4+>VO\ XFWNF7NI7<-M)I*3+"EZ\8+;V!(
M;L #@<<9(K&T:S.J3>$[/4]2U!FGLKT.OVUXVEC24>4QVD9RI)SW [XH ]9H
MKQO5K^QBU*YN;*=Q<V6LP6?VB\NSY\:JRADB7C$6-V22=V3G. 1J0ZAINLGQ
M%:>)-:DTV_AU)C;[+HQ21P*%,?E#."& )P <Y]<4 >CM=QM]J6#$\]OP\*,
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M+)%+!<B96#9RK< JZXY'(YZFHK[Q2]CXADTAM/8O]B>\BF,H5)%0@%>1P?\
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MPZU2[>*6TG.G23>66P\3A"P&1W!_E0!O+:6RF)EMX@8@1&0@^0>WI22V-I.
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M0XC (&,8S].*L44 116MO#(\D4$2._WV5 "WU/>I:** *RZ?9)$\2VD"QO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !112
M9H 6BDS2T %%%% !1110 44POAMH&32AL@''7IF@!U%%-=@@R>G<GM0 ZBD4
MYZC!%+0 44T-],9QUIU !1110 44TM],_6D#Y/']: 'T4@;D>]+0 4444 %%
M%% !149DPX4<TY6W#/H<4 .HHHH **0G%"G.: %HHHH **"<"F[AG&>: '44
M44 %%%% !1110 4444 %%%% !111F@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M1]-UKR(DVQA9$WQ@A\+R,,1QC%:WA6U=/B!XQE:YF;%Q -A;Y2&B##CU&<4
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M8M!<1+-&Q!&58 @X/3@T 9EEX>MK/Q#<ZM'%!&SP+;QK#'M.P!?O>N-H Q@
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M %E/#FCI>W%X-.MS<7*>7-(R[C(O'#9ZC@57C\&^'(;*>SCT:S2WG8-+&L>
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MP\.JBM)K%I%NE,.V5]C!QU4J<$'D=1WJ+4/&>DV>D/J,,XNHDN4M6$()*NS
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M6*6*2X>-6LW"!2CY)R. 25S[9KT^B@#@]&TO5AXSU^6?3Y+6VN[*&V@N4V!
MT:;20 V[&3D9&<#M6?X5\+ZCI<EEI]SX5TV*>SRK:T&5MRX."B_>#Y(Z^YKM
M(_%6AS:X=%BU*%]1#%3;KDL"!DCIC@5HWM[;:?9R7=W,L,$8RSMT'.!^I H
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M&)[B8NBHI#$0L>X],C\:Y1;O6M,'CC5--NK>..RU$S&%X-S2X1"P+%@ -O3
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M%:6NZ2FNZ)=:7)/)!%<IY;O& 6VGJ!D$<T <A;Z/IVJ?!NS2]AA^325D25@
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M=O<+H/@ZS@TS4;>]MX[A99C92JL!:%T^?Y>[M&<X/W2>U:7A*[N(+32M%O\
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MTA+A&O88EE>,$<!LX'UXSCT(]: ,6X\%O?:)=:9?:_J-R+B!;?S7V H@()P
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M6L?9]&M;W6HUTV>4HCPM('VR,=H4$=<GTIMIK3W'B?4-&>U$?V6"*=9A)GS
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M#TA2VW2[$;D\LXMTY7;MV].F.,>G%-_X1_1MI7^R;#:R>65^SI@KUVXQT]J
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MK7#[WM/OQY?(.265",]%-=!XSU*YLAHUK&)8[6_U".VN;B)V1HU)X 9>5W'
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M[:\M/#]A!J%Q+<7JPKY\DI!8N>3T]"<?A6G110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MNL-PP2(0@$!D^ZV['.0<Y^E0VT6I^*/$5NL^O:GI\=WH=M?/;V4_E^7*3@@
M@D \]\DYR>* /2Z22-)HVCE171AAE89!'H17F[R7VDZGJ?A&34]3DN-2>*33
M+R2=WE2-B!)ALX'EA6;L2#7HT,7DP1Q;W?8H7<[99L#J3W- #+6RM;"(Q6=M
M#;QEBY2&,("QZG [U-7)>.9-4CM[$Z:LTZAW,]I;77V>>5=OWD8<G;G.WOQ6
M=X3U*.\U/19+35-1OK.[TJX):[D.6:.9 &9<XW#++D=: ._HKR^T?5;J#PW#
M#XDO$2[U"^MI&#B1FB4RE3N;)+ ( #SC(./6O)K^KZ.EYH1U&><#6XK&+4+E
MOFBB=0Y#/CKS@''<]., 'J]%>6ZW;:[I$4=HOBFX$EQJEDL:QR%Y($D+*=S-
M]Y25R%Z?*1TJ_>V\G@35-*U.^\0ZQ>:8QE@NOM4YD4.5+(Q'3MM[<D<T =Q>
M7WV2XLX?LMS,;F7R]T,>Y8OE)W.?X5XQGU(JY7GD?]L:5)X-%SJ5]Y]]=/\
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M3T1Y+>2!XF^?.P_,/NG!Y]C6A>>*--L(H6G:?S)83.(4@=I%C'5V4#(4>I%
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MJQ..@].]6KO7])L))([O4+>%H]OF;W ";ON[CT7/;- &?'X(T2+3VL8HKB*
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MR_>C60%A]1UH =;Q/# D<D\D[CK)(%#-]=H _(53US2(]<TI[*25X2722.5
M"T;HP96 .0>0*N2W$,#(LTT<9D;:@=@-Q]!GJ:%N8&:15FC+1$"0!AE#[^E
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M3.:K>*%FCG\5W#6U^B/J-A-8XMY DLB*JM@8&X9!SC). 1G@UZY6/K.EV'B
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MI8_,,C?E,\XSZUZJ+6W"E1!%M/)&P8-<Q+X,E.JZA>1:FFR^P'CN+*.;R@%
M 0GH!@'!!'MGF@#;\/VUK9^'K"WLYH9X(X%"RPD%)..6&/4Y/XUI54TS3H-)
MTRWL+8$0P+M7/6K= !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MUTV6%#$DDD@(Q(I=B I&<YY'3FGR>"OMNEW%EJNMW]^9(Q'#(^U#!A@P90H
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M??VC'I[I/<63F)T+8'F!0=I/X@$]N:\MO]5TIM;OKDK;V$EEK]NUPURIEN)
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MS22^,K"/43:&VO2HODL#/Y8$?G-T R0Q&>,@8H U'TFS?4+.]$2K+:(Z1;
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M@X#$$%@20""=H.!5>_\ '.DV"O($N;BVBMXKJ:X@12D44C81CD@G/)PH)P*
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M58#\J\C:"V><#MQUKJ$\%Z3#J.GWMO\ :8'L$9($CG8(-WWB1W+=SU/>HH_
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M_)\P/;!1CS@CCU&8[NTFM=<UK[?X;U'6+#6&CN+86V=H(0+LE5F78>!R>F:
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MZ)NS(0!D\HW Z\<X.: .QHQ7G]SX[URUM[7S/#N)KK4UL(1,[P>8&7*N RY
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M$GE^6 &YR?XNG7.!S2P?$?3BU['<PE9;=49!;2B9)]YVJJ-P-^XXP<=<YZX
M.THKD;CQG=6=QJ]M=:,4GTZP^W[5N@PDCR<\XX/RG\JF/C2"+4-)@N+5XH-1
ML'O1<%\B,*F]E(QS@'J/RH ZBBN%L_B?IEQ?I#);2);31/-#<1R++E%4M\ZK
MRA(' /Z5)J'C6];PEJ.K6&D3J([0W%M<-+&\3*<@'(8_,,9*_AWH [.2*.;;
MYD:OL8,NX9P1T(]Z?BJFF3W%UIEM/=0>1/)&&>/>&VGZCBN53Q;I^E6&OZI_
M9U^L=MJ8@N4+J[;RL:[@-W"Y*C SR<XY. #M:;L7?OVC?C&['./2N/UKQO)9
M:/K#P:9<PZA962W<<5T4 9'9E#_*QZ%22IP>U:2>)U$MA8M9W,FJ74!G-JFS
M*1C/SLV[: 2,#G.2/? !N&"(QF,Q(8R22NT8)SGI]>:J:CH]GJEK<6]Q$NVX
M4)*RJ-S*#TSC\/4=L'FH=!UZV\064MQ;QS1/!.]M/#, 'BD7JIP2#U!R"1S6
M7JWC6#2+^[ADTZ\EM;(QK=W2; L;28V@ D%N#SCI0!TZ(L:*B*%51@ =A3J*
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MSSBG4 <C<>#]0NFL9Y]?>>\M;U;PRS6P*L538%"*P"K@DGJ23G-==2$@ DG
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MN&N9K8P@R(['+"-_X0>!T.!GOS6_K^BV_B'0[K2;IY$AN5"LT1 88(((R#W
MK2S1F@#D!X2U/5=%N]-\2ZT;V.6'R4^SQ"( 95@[#G+@J,'H.?6K<&@:B]QI
M]U?WMO-<Z;#(EJ4B8!G9=N]\MD_*,8'J3GICI*JZE?+IFF7-\\4DJ6\32LD>
M-Q51DXR0.@]: .-M_!&JVWAWP]I::A9%M'O1=+(T+8D W8!&[C[[?I6Y/X5M
MI_&-MXA$TB211;'@4X25P&".WJ0'<?B/2JO_  FR#P[!KS:+J1TZ8!]\8C=H
MXS_&ZAL@=<XSC%=):7=O?6D5U:S)-;RJ'CD0Y# ]Q0!RP\)ZK8:MJ4VB:TEI
M9ZG(9[B*2W$C1RM]YXSD $\=0:M:3X<N['6O$%[/=1-'JK*RB)2&BVKM')//
M'/UKI<U6%S(=1-M]EE\H1>9]HR-A;.-G7.>_3% '&_\ "":BVAZ) -6BAU/0
MV_T&ZBA.PI@ JZ$\Y  .#5J^\*:MJ36.HW.J0'6+*Z\^$K"PME7 4IL+9Y'.
M=V<^U=CFC- &!H.D:GI^J:M?:A=VDQU"5)-D$++L*H$')8Y&%';KFLSQ'X2U
M/5]?DOK6]LUAET][3;=0F4P,V<O&,X!(."?3UKKIYXK:WDN)Y%BAB4O)(YPJ
MJ!DDGL *S;C7H+;7=+TKRI'?48Y9(I5(V ( 3GG/\0[4 8FG>&M:L]:T[49K
MNPF:TTQK A4=-_(*OWQRJ@CZGVK+O+&WT?X?MX7U2YMFU6<.UI#9L?,DE:0L
MC*#SD.1DXXQFO1<TTHA<.44N!@-CD"@"CH>F_P!D:):6!E:5X8P))&.2[GEF
M)]V)/XUS>L^$]1UG61=3G3RL-W%-:70#+<6\:E2T? PX;#=3QN/6NTS1F@#S
MO5O!&OW5CKVEV5_I\=AJ=Z;W=*CF4,2A*'' 7*]>3^?%^'PWXFTW5[Y]*U:R
MCT_4I?/N%FB9I()6&)&A[<]0&R/;U[7-5;"\:^MVE:TN+8B1DV7"A6.#C<,$
M\'J/:@#E;CPOJ[MXN:%[!7UI%CA<E@4 3R_G^7G@D\=SCWKI].@N;71K:WF$
M1N8H%0[&.PL!CJ1G''I5VJ"ZO;OK\NC!9/M$=JET6P-I5F90,YSG*GMW% '+
M6?A'5)_A]-H6H36EO?\ VA[B&:V!=$?SO.4X8#^(XQZ4E[X<\5Z_I$L6L:EI
MT-U Z2V0LHF\LR(VY6D+Y)Z 8&,9/6NYS1F@#S.VL]5U7QAKNG:R]BE]=>'E
MA;[&6V+N9U_BY[YZ=Q^-FW\'^(+_ /LJ+7'TL6MG836!6T:3S-LB*A<,1C=A
M1QCN>M='JVM66FZE((M*N-0U"*W\^06<*-*D9.T=2"<X. ,D[3QQ6[&_F1(^
MUEW '##!'U% '%:1I7C:QT==*EN=&6&TMS#:S(KLT@"%8Q(I& !\I./3ZYK6
M_@>^^SZV@ALK!-2T_P EK6VG=H3<\YD"E1M7H.,]Z]!S1F@"KIWVO[!#]NA@
MAN0,/';N71>>,$@$\8[5P]YX3U^;2/$=I#'I_F:EJD=[ SW#8559&(;Y.O[L
M=/[WMSZ%FC- '#Z]X;U[6KO5\"PAM]0TB.S.9F9EF5F;/W/N_O&'KP#[5,-#
MUZ+7-(UR);'[3%9-8WMKYS;&CSN0H^S.<X)R/:NRK.BUBWEUZXT<1S+<P0K.
M69,(RL<#:>_/% $'A_29-+BOI)ROVB_O'NY51MRH6 4*#@$_*J_CFN-\6^#O
M$FNWNI[$TJZAF>,V4MW-('M H&0JA2.2.3G)_EZ!=7JVDMM&8+B4W$OE@Q1%
M@G!.7(^ZO'4]R*M9H C@\[[/%]H"";8/,$9.W=CG&>V:DHHH **** "BBB@
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M#*]TS@0-)*#'R<;2%4\]^:U-%N#!XHMIYI?[1MK^^G6VU.*9E96"OFWEC/\
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M8^&-%TV\2\M-/ACND3RUFY9POIN.30!SWBY;^[\8>'=*M-8O-.AO(;HRM;,
M6V*I'4$9Y/-4DGOM6C\06AULV>HZ;<%$D:Z9?L\*HFV1D  <-\Q);C)([5VU
MSI-A=W]M?7%JDEU:Y\B4_>CSUQZ9[^M4[WPEH&I:FNI7>E6\MXN/WI7!;'3=
MCAN@ZYH YITGT_QEXFU'S9[B>VTF"X2".1@KL!-\F/0E<@?[54;";6=1T&QU
MP>)X+3[98S>8K3%M\NPL"H;Y4*%3G:.@.>F:[Y=&L$U1M22 K>.-KRAV&\=
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M\Q1@;%XQ@>O08% '0-\0-,C-TLMI>K);VAO"B^5(7C!^;!1R 1U()'%.?QQ
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MWZ0M(\Q6-X)EC2-CDJ=RG;G Q^'< L^,/%=NWA?64TF:\DN;>T$K7%F"! 6
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M!ZPK!E#*001D$=Z6JVGP&VTVU@,21&*%$,:$E4P , GD@59H **** "BBB@
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MQL?#MM?/8B2T>\DFB1&D;#!0B[U91U)/&>!0!T-Y>6]A:275S)LAC&6."3[
M <DD\ #DFJ^GZQ9:I)<1VS2^9;L%ECE@>)E)&1PX!Y'>O./$-WJ6J>&I+.\U
M"07%AX@ALFGA5%\X;D97(V\,-PZ<9'?I7I]K"]O;)%)<RW+J.990H9OKM 'Y
M 4 1S:E9P:C;Z?+<(EW<J[PQ$\N%QNQ],C_(JGK/B72] EMH]1EGC:Y;9"([
M667>W]T;%//MUKS?Q9<WMQJ<WBBTT^_EN-)NU-G)'$6@>VC!$HW _P 3%\G'
M11S74>,+E=2L/"M_I[0RK)J]M)"S\@[E;'(Z4 =%IWB'3-4FD@MKA_M$:[VM
MYH7BE"_WMC@-CWQBL*T\0^"Y-7GU:%Q%=AC;S7LEK-$@8$#8TC*%SG'&:S9;
MJ\M_B]I0UI(D\^QEAL#:L64MPS[\C/0<5S,=S<'PA>Z:5@M])O\ 6[FVO]0
M+M; R#!9< #/ W9P,B@#VD$$9!R#2U!9V\5G96]M!_JH8UC3)S\H&!^@J>@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JDFDV,>JRZFE
ML@O94$;S_P 3*.@^G%7:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M.Y^T3O(9% P.6)YXSGJ.V*Z*B@#FH? >@PZ7-8+!,R3;,RO.S2KL;<@5R<J
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M!'/7F@"/3/&^KZE:Z?+!!;L+G4WL@=K#>JLV7 SP JY_&C4?'6IK9:I?6MM
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MTRAH^V[N<C';BE/C34[2<VU[H[;YYX;>RGV20QS229RI#KE=N"<\Y I;_P
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MVF9+$J5;>) H'F$8W ?A[\T =C13(A((D$K*T@ W,J[03WP,G'YFGT %%%%
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MC5;&*5'$;*]PJE6/12">O(XKA/L.H'PEKWAV\ANI=9GNI#!</;N4F+,#'()
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M:*WB!$<2!%!))P!@<GDU)0 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10!F:_HD7B'2)--N+FYMX9&4NUN5#'!R!E@<<@'CGBK]O$T,"1O-).RJ 99
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J1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>pinnaclelocrenewal4thloa003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pinnaclelocrenewal4thloa003.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M '!4]01_\?3?[@J>@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** *\?_ !]-_N"K%5HS_IKC_8%6: "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH K1_\?LO^Z*LU G_ !]2?05/0 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% %=/^/J3Z"K%5HS_I<H] !5F@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** *T?\ Q^3?\!JS56/_ (_)
MO^ U:H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"K%S>3_
M / :M55A_P"/R?\ "K5 !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 58.;NX/N!^E6JJP?\?-Q_OC_T&K5 !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 58/\ CYG_ .N@_P#0:M54MO\ CXN/^N@_]!JW
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %6W_ ./BX_ZZ
M#_T&K55+;_CYN?:0?^@BK= !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 4[7_6W![^95RJ5A]ZX_P"NIJ[0 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !15"XUO2[6&\EGO[=$LL?:27'[G/(W#MG(QZT_P#M;3_MMM9_:XOM
M-U&98(]WS2(.I'MS0!<HJM?:A::;;?:+VXC@AW!=[G R>@^M6: "BBB@ HHH
MH **KQWUI+>S6<=S$]U"JM+"K@L@/0D=LU8H ***1F"J68@ #))[4 +14<$\
M-U;QW%O*DL,BATD1LJRGD$'N*9+>VL%U;VLMQ$EQ<;O)B9@&DVC+;1WP.30!
M/1110 4444 %%%% !114,-W;7+S)!/%*T+[)0C@E&ZX..A]J )J**"0!DG H
M **S8_$6AS2I%%K.GO(Y"JJW2$L3T &:TJ "BBB@ HJ&:[MK9XDGN(HFF;9&
MLCA2[>@SU/L*FH **** "BBHHKB"=Y$BFCD:)MD@1@2C=<'T- $M%%5X[^SE
MD$<=W [GHJR D_AF@"Q1110 45'+<0P-&LLT<9D;8@=@-S>@]34E !1110 4
M444 %%%% !1110 4444 %%%1R3PQ.B22HC2'"*S %C[>M $E%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %*P^]<?]=35VJ5A]
MZX_ZZFKM !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110!AZYJE[I6H:0T:0OI]S="VN<H?
M,0N#L8'=C&[ .0>M8VB>+=0U??:^7;)??VBT*$Q.$>U"AQ,!N_B0C'.,L.U=
M)KFBV?B#2)],OE8P3 9*$!E(.00>Q!%);Z%I]MK,FJPP!;N2W2V9ATV*<@8_
MST'I0!SFK7]U?^&?'-K>0P V<4\41C0@NAMPZELDY/S4[51CX@>#..?L][_Z
M+CK2G\)6UQ%K,4M_?LFKD&<;T^7 "_)\O'R@#OT%3?\ "-0OK&F:I-?7LUQI
MT+Q1!V3:P888MA>2<#D8Z"@"KX^S_P (5J&W&[,6,]/]:E4Y?$>KV7B*^T>X
M&FR21Z5_:$4N6A1,/M99"2QQC!W8'0\>G0ZUI$.NZ3-IUQ--%%+MW-"0&X((
MP2#W [5DZMX'TW6KV[O+RXNVGN;$6+%750$#APPPOWMR@^G;&* ([#7=4U*X
MU6TM3;-<6]I!/;O);21J[OYG!5FSM^08/'7O3-*\5R7NDV%Y.T",ME)=ZB!$
M?W6SY2@&[*G<&ZY^XW2M'2_#2Z9J\VIG4KZZN)X%AF^T.I#[3E3@  $9(X]3
M5FQT'3]/?4'@AYU"5I;@,<AB>H^G)./4GUH Q-&\0Z]JMUILO]C,FGW,1EFF
M8(HC5EW(582-OZ@$;1Z\8Q5OQD^H+IEG'IUZ+26:_MX6DV;OE9P"."/;/MD=
MZ=H_A*VT:9/+O[Z>U@8M:VL\H:.WR,87C) &0,DXS^-:.LZ1!K>G_9+B26,"
M1)5DB(#HR,&!&01U'I0!S-])J-MXXU.:R>T66/1(9)'FB9@2))CPH8=<>O'O
M5V'Q-=7]U:V=G;J;E]-COY1M# ;\@*,NN.1UYK2?0()=1NKYKJY\ZZM%M).5
MQL&[! V\'+,?3GI6?<^";2==.>'4+^UO+"(01WD#JLKQ?W&PN"/P]_6@#7T:
M?4;G2+>;5K1+2_8'SH$<.JG)Z$$]1@_C7/V>L>);TZK.ITE+6QN+B  Q2%W*
M<J?O8'O74VEJEE:16T9=EC7&YVW,WJ23U)ZDUGP>'[>WL-3M$N;K9J,LLLC[
MQN1I!@["!QCMG.,4 9,'B2ZSX8LV2UMY=5M#.TI0^6&5%;RT7<#GYL\GHO?/
M&7#JFJZX?"]])%;07#:I.D9"L4:)891N&3DY )'/<?6I==T2[6_T.SA.IKIN
MG6S*ES;QQ3%I#A0'1ACA5/(4_>[=]6RT>^O4TZZO-0NU>QN&F@$L,2NZF/9M
M=5&!PSCC!P1W% &1K6MZQ)I@A%W%;7D&O06+26\+;9E+1N,@ME1M?Y@"<XQD
M UW:[Q$ S*9,<D# )^F>GXUSLWA%9Q<[]4NU>:_34%=%0&*50 ,94@C"@8.>
ME=%&A2)%9VD( !=L9;W. !^0H XK0M=U"#P]H<-U=0W6JZO+)Y+R(RJGWI'+
M<\@8P -O4"MC1=9O)M;U#1-26!KRS2.7SK=2L<B/G'RDD@@@CJ?6H1X+M_[)
MMK!K^[)LKCS[*<;0]N>< $#YAR1@YR*V+/2XK6\N;UF$EW<[1)*5 .U1A5'L
M.3^)H H:KJ6J0:_8:;8QV92Z@ED,DY;*%"G8=1\_3//J.^1:^)]:-GI]U>6U
MD@?4O[-N8DW$E]YCWJ<X W#.TYX[UT=UI7VG6;+4A<R(]K'+&L84%6#[<D\9
MXVCH:R1X/(T^.T.K7)\O43J"R>6F[?NWX/&"-Q)_'':@"M?>)=5L]=CMV2Q%
MN;Z.U-LH:6?8YP)68,%CSU"D$X%9]KK36OC'Q!HU@T U:\OD>$3J?+5%MXBS
M'!!/? !SGV!-:<G@?<+J./6[Z&":_&H)$D<1$<N\/G+(2WS#H3TP*=>^!K>^
MN+ZYDU"X6XN+E+J*:-45[:10J@QMC(RJA2#G- #-1U[74U&ZLM,M(;F2RAC,
MA$#$2RL-VT?.-@QC!^;K[5U%I++/902SPF"9XU:2(G.QB.5SWP>*P+KPCY^I
M/J,&LZC9W<\*0W3VS(HG"]&(*D*W;(Q70)#Y5JL$;L-B!%9CN/ P"<]: /)K
M![H>!_%!@T2.^M9[Z]=)Q*A 7<1N"]3MQGCTXKIK+Q%<_P!DZ#8:.PU!Y-/6
M62]\DN,)M3.S<IR6SW&,5>LO!;66C7&DIKE[]DN&D,H\N+>?,)+X.WC.3^=+
M-X$TY(]*_LRYNM,FTM62VEMW!.UCEE8,"&!///K0!6M/$?B";4-)T^ZTVTLK
MJ\AN&D61RQ1H\;6"@_=.X'&<]1GCF;3_ !)J%[9PVS1VL>JR7EQ9[@&:$&$M
MN?&0<$#@9ZGK5V/PND>K:9J1U"ZDGL87BS*0QFWD%BQ/?('3 %5)/!0,!\C5
M[R"Z2_EOX+A%3=&\F=RD8PR'/0T 4/$<NL&#07N;&U;48M;"0@2;8Y5\N3:V
M?F* CDCD\4Z7QCJEMI6KO)96DE_IM]%:LB2,L<@?9@@D$@_/CGCC-:LOAB>:
M+3_-UBYFGM+X7K2RQJ3(P!7;@ !5VDC ^M07G@T3KJH@U&6$ZE=174F8PP5H
MRI '(X.T9S0 DNL^(EU6]TU++3O-B@%U%*9GV>62PVL,9W97J./Y4MQXIG&E
MZ=J"0VUK:WEDMSY]U(2 [*&6(*OS,2"3D=@>#6B^B2R:M/J#WS!IK$6;(D8
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M6*_ \R;+R#"E=S,><!NOY#M71Q^()KC3H;BWTUVFDEFA='E C@:)F5O,D (
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M8%]TH*L..<J,C'89J]J&F:59:EK-O:VC06<OAXAS91#<R[G&5/1GP>,G)XH
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M2L=U]KDPK@G;D9P,$ ' [&@#U"BN4\)7TOB&4ZU-:2VGE0"R6!\C;(#F7CN
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M<GONS]* /0:*\]L+=]>\9R0ZM<7:NFDV=Q);1SO$JS;F)P%() ./QZCI7H5
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MR&!V\<2 XQVZU-?^(-3BUB_T[3]&2Z>UMHK@2/="-6#EQ@\$@_(<8!![D<9
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M &0PQV\$<$*!(HU"(HZ* , 5S6O>&;[5=<%]!>6JPFR:U,-U;F4(2Q)D3Y@
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MN0Q2)-&49&'4$'Z@_C5V@#S\^']2M=>U0GPSI&IQ7ER;BWO;@H&@R.5<%2Q
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M_?:%I.I7$5Q?:9:7,T1!226%69<>Y%3'3+ WC7ALK?[4R[#/Y2^85]-V,XH
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MD*W2*+=PA09AC88.,C&<#G'X\U;/@S1#:7UKY%P(;Z?[1<J+N4;Y,YW?>XY
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M(++#R^7(Z#YMWR9VXX!P.<YYK>O-0U31F\/W,E]'+I<SK;WGFQ8D#.#L8,.
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M*** "BBB@ HHHH **** ,S0S_P 2\?[Y_GBM.LK03G3%;U=O_0JU: "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@# EUUW\8GPZ+698VL3<-<J/NDMM&".G1N3W K!\%^
M,+-O#NF17MS?2SW-P\"W$\;N&D:1]B%\8W;0..@XK4?3[^T^(<NKQV+W-G<:
M:L!D215,;J[-MVLPSG(Y['T&:QK71M:L?"&@Z>^F-)<66HK<W BDCVA!*7^4
M9YX;@>Q]L@'4W7B?3[-SY@G,"W M7N%C)C24XPI/7J0,@8!X)!JE\0;V;3O
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MNC9NQ@DPLP )4_+QP1STK,U8Z]*-$U;^P6:6SO7EDLH;A"ZQM$R9W$@%LMG
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 9.@?\@J/_ 'F/
M_CU:U9/A_P#Y!4?^\W_H5:U !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 8_AL@Z+#C^\W\ZV*QO#/&BPCW8_\ CU;- !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 8_AL?\2>#_@7_H5;%9'AWC1H/Q_F
M:UZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH ***JSZC96RL9[J&,+(L3%G P[8VK]3D<>XH M445$+B(W+6XE0S*@
M=H\_,%)(!QZ9!_*@"6BBB@ HHHH **K3WMM!<1027$:32G$4;. 7]<#O2?;[
M87J69N(_M+IO6+/S%?7% %JBBHIYX[=0TLB1J3MRS8&3T% $M%(IR*6@ HHH
MH **0Y X&35.?5+.WF\J6[ACDQDJ[@'']* +M%-C=9(PZL&4C((Z&G4 %%%0
MW5S%9P-//*D42?>=VPH^M $U%-C<21JZD%6&00<@CVIU !13)IH[>%YI9%CC
M099G. ![FDBD65%=&#(P#!@<@@^E $E%%1RS)"C.[!549)/0"@"2BJ]M=PW<
M6^WF290Q7<AR,CJ*L4 %%%0W%Q%;@-+,D2GNY 'ZT 3457@NX;E-\$J2KZHX
M;^56!TH **** "BBB@ HHHH **** "BBD/0T +148D7S A8!B,A2>3^%24 %
M%1O-'&0'=5STR<9IX.1F@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH RO
M#O\ R [7_=K5K+T#_D"6O^[6I0 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% &3XHU0Z+X7U/4ESOM[=W3&/O8PO7WQ7
M.O?3Z!X$T*=(+>6XN9;,7)F!??)(5WOG/+9).:ZS5=.AU?2;O3K@9AN8FB;C
M.,C&?J.M8'_".76K^%K/2-4GEM9[&6/;/;[#YIB(V2#((&0 2".N1TZ@#KSQ
M'>:/XHN;74Q -*:Q>ZM98XF#LR$;XR=Q!(!R.!G/M5'7M4U#3Y/"%]/#'%>W
M>H):W$:D@!)5.4//.#M/U6NAU?P[8:Y+I\E\C.]A.)XF! )(&,'CE3QD=\"J
M^JZ;)JWB'2=\/^B:=(;MG=1AY=I5%7Z;F8GL0M &]1110 49HJ.0%N!UP<'K
MC\* ."\=V\NH3SW]@/-N_#Z)=1A/O"0G<RY]XP>.OS#UIK^)]/\ MMQKL,*7
M$\K1V&G8/S2LPWLJGT^Z<^@-:-@MWI<^IO)IVJ7YO)_,^Y"H4;0F!\_3 SSZ
MUFQZ'#;Z586-OH6K)]AN?M<,F(<B3G.?GZ$-C\* -2?Q)<6<^J6T[6P-GIWV
MP3*"%7[PPWMQG/>J-G>:FUIX<LM9^S7EY?RM/-N3;LC4;@0H]-RC-0WNC-J.
MG7]O<Z5K337LB//<#R0[!6#*GW\;!C&/<U:FM)Y-;L]4_LK5S);6SVPAQ"$9
M6QD_>R"<#IZ4 :MMK-YJ$,MW8Q0M9QS^4KR-CS0K8DD!Z8&#CZ53L_%5QJSQ
M2:7$ES;/<B)=F6/EJQ#2LPX4<< ]?QK/T32[K1H_LD-CKC6 9BEM(8-B!LY7
M(;<1R:GTO0KO2[.6SAGU;[, ZP)L13&#G'(.6(SQG':@"[I&O:CJFMWEFT,-
MM]CN7BFAE5A+Y9&8Y0>A#&N@L7NFDF%U'&GSGR]CELIZG/0^U<Q:V=[;&]NU
MM-0.H-9_9HYWCB!?:#M8[6Y.3WK0T_5;Z'3[=+O2-1DN5C42/Y:\M@;N_K0!
MT,C!0"S #W^E><W</]D>+[N/4TCN](\2.L4=T<;H)2@41_[IZC'0DUTU_J,M
M]87%HVDZI&LT;1EUC7*Y&,CFL"WTV9%L(;B'5YK2QD22*%K9%+%/NEF!Y QF
M@"2T\1RZ>^KLH673["6/3K&W12'DD  (R?O'/7'H:L_\)1J4?B'5=+FM+<+9
MV N_-WL%4DG"-^1Y%8P\.LNFV]M#_;D,UM?/?1S"UC^9V)R&7.#U.*F?0M\>
MO*XUICK*A)F-NN4 7:<<]#C\-U %[3_'%Q>QZ),UBL-OJ,<DCR%R/+5!EFQ_
M=]S53Q#K-QK>E:=:Q)#]CURY6WAW?,[19W,_I@JIQZ9%27>GI=:@DS6>J+:1
MZ>]BELELORA\;F!SZ ?E4,.E2Q3Z++/_ &K.=*22.-5L44,K  =^" N/QH N
MZQXON--T.2_T>U@NK6WN([*/<Y E<N$)!'89J2;Q1JDOB#4='T^QMKB6S2-B
MWGL%3<,MO.,9'8=:QX-$-O:6%KC5FBL+K[3 K6*XVG.489Y/S'!]0*U-$6WT
M>+4@;'5)9]0N)+B:8VG.6X"]>@% %#Q!XCN]<\.%=-B@^P:A=K8)+,23*&;:
MS*/08./45LV>OW#^*)-!LK.*-+$HLBR'#&!DR)(_]D$;>_)KGM.T1;*VT2"1
M]6F72'9H-M@%# KC!YZCKGWK8LI'@U.VU"ZBU*ZN8+=[?S!9;"X9@V3R>FT#
M\Z .W& !D^W/>N+\5WLDWBO1=%#QI9RK)>W;LQ'[N$#"GV+.I_X#6K/XH@M[
M:2633]4"H,G%L2?PKFHI%U37-:U"_P!,U)K:\MDL[=?LN=L8!+'GD$EO_':
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MNB2WT\6\.EQ30Q?+Y:2[)0SJO0-CR^<9Y'K0!ZCFJMQJ5I:WMI9S3*EQ>%A
MG=]J[F_(5YLR^%]7\7Z1>ZE+8S6MYH9S)/, DTBR1@ Y(W,/FX/.1ZCBC8:5
MI]AXA\*/>);-IQO-02RDG1<>3D&!=QZ_,6*Y_O<4 >F:1JTNHWNKV\L"1?8+
MO[.I5]V]?+1PQX&#\_3^=:V:X6ST_3O$<_C71KEXI!+?#<HPS1Y@C <#L0RG
M!]0:E\(?:]6N(;C4;;RWT6)M/0D</,#MDD7CIA5 _P!YA0!VM)UKC?B=Y/\
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MIOHNICQ?'='RG,EFI8-.S*=P<-(>5;)X48QQ@4 =W.SPV\LJ1-*R(66-#RY
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M,84*K%@,\G:P( [=P3BM"RU>[G\9:II3QPBUM;:"6-E;+$N7SN]/N]/;/?@
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M?M.E65X8;:\*?-*F%_NCYCN; P.>*TI?&>F6LNHPWD=U:SV$ N98I(P6:(G
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M0!0T;_D$VO\ US%7ZHZ1_P @JV_ZYBKU !1110 4444 %%%% !1110 4444
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M!F"NP.0S)G:3D9R1FI?^$9TK^S[ZQ\B46]](TEPHN9 79CEN=V1GN 1QQTH
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MQ[S[%:O:B/[,$\U6&"6.3STY '0>^32/!]_H]O;6<?B2ZFL;,EK:!XE!4X(
M=E(+J,D[>.W88H M>$M;U?Q!81:C>:=:V=G-&3&$N&>0L&(Y&T # ]<_GQTE
M9?A[2&T+0K73&N?M'V<%1+LV9&2>F3ZUJ4 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110!1TG_D%6O\ US%7JHZ1_P @NU_ZY"KU !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110!S+?$'PLLA1M54%9O(<^3)A'SC#';A>>YP#@^AK0?Q-I,:
MZFS7$@_LO'VP?9Y"8P1D'&W+#'.5R,<]*\\M[>ZUO0O&/A^VTZ=Y+O6[E4N2
MJ^2O[Q22Q)XVXST],5M:G9:Q;:KXGMK32)[P:Q91QP3JZ)$C+$R$.2<@]QP>
MU '0ZAXS\/Z7<BVO-16*<Q"81^4[,4) !  .>O0<]?0U,/%&D-J"V*W$IG>1
MXDQ;2E6=%+,H?;M) !X!SP1UK(L8;@^--.N9-)NX3'I#6LT[A2BMN1E7(8@X
MP_(]1^%.VTO5+3QBLNGPZA;V\U[++>QSNDEJ4.[$D75E=B1D#'4Y'% '2IXE
MTF2#3YUN7\K4)3#;.8) &<$C:?E^4\'[V,X-.B\1Z3/J"V45V'F:5X5VQL4,
MBC+)OQMW  G&<\'TKA_)UPV.C6'_  CU[_Q+M:$\LNZ/:Z;Y"&7YN1AN<XQ^
M-1/_ &]=ZAITMWH6IK<V&L;YUME5;4QGS &C!(+GE26(]>1G% '7_P#"=^&B
MSJ-41MD_V>0K$Y$;Y ^8A?E&3C<<#KSP:DTWQ5::IXHU30XHIEET]4+.\; .
M3G=C(Q@?+CGYLDC@9KCXEOV\+>*;:'P_J0GN]5DEB0P[3(CL"'&XCLI)],@5
MT^D1W4'C/7&ETZX2"]$$T5T0NS"Q*I4\YW9SQCUH O>(?$=GX<@M);P2%;FX
M6W7RT9R"<DG"@DX /04M]XIT;39O*N[S8P57<B)V$2D@ R$ B,'/5L5F^-+2
M\E;0[RTLYKL6.I)<2Q08+E CC@$@'DCO5&S@U+2+WQ"DVEW5U#JLOVFW,2JV
MTM&%*/EN"" .XQWH [='61%=&#(PRK*<@CU%<;K'BLS^']=N;"XN+"?2I]C/
M+;X5\$#&77:02>W.,=,BNA\/:8VC>'=.TUW#O:VZ1,PZ$@ '%<EJ5MJ#:!KV
MG/H][.9-2\Y"BJRS1M*K_+\V>%4@Y [4 =$/%.CWECJCVVIF,646Z:<0M^Z#
M [77<N''RDC&0<=Z>WB'3M-TFUGO;Z6;-HLYF%JY=T 7,A1%ROW@2,#&?:N<
MU47-QJNN36^C:ELOM&%NKF+ >7#D C.1PX'3KFJFI6-[)I&ERZ;IVKVFJ6VF
M"*WFA5=H<#:89D;@KD#GGKGZ@'H8D2:W62-B4=0RD#J#]:\[T?Q%J^O&],6H
M06^IVUV4;2VBX6)9,9)/)RHSD<5WZ>>--3[3L%R(AYFPX7?CG'MFO-=7T^\U
MVWBGDT.[M?%-O*!#?P*%3:&ZF0'!3:3QUH [N]\1Z5I<CI>7/EM&H+_*3L!Z
M;B.E+?>)M'T_:;J^C0$*V0<A0WW2<=,UPU_I$UKXHUI]3T&YU>VU+8;>6W.X
M#";3'(-PP,\@C/%/MK2YT'4=6L[OP]+?66I&.2$6P5XUP@4Q/G!"J0,''K0!
MU%KXLL[W6=7TR-GC;3T4F5E)4[@3D?2K=OK5C#I-I<S7XN%GC#1RJI!EXSD*
M/:N;TFWO;'Q+XDFN=/G5+V*&2(QH60D1E2H/KG\*S])M=0TV7PYJ<NGW0MH=
M.-C/&(6,EN^1AMH[$\$_2@#N%\3Z,=.MKX7\7V:YD\J*0GAGY^7Z\&K6F:M8
MZO \UC.LJ(VQB 1@^F#7F=]H=Z([24:=/Y4WB07OD;/,\J(+@D@= 2,_C77>
M'&D7Q3XE+V=Q!')-$T<LB;5D 0*2OXT 3Z]J5_9>(M!M[?ROLMY.T4^X?-PA
M(Q^5=#*S"!VC4,X4E0>,G'%<GXJEE'B7PR8[.ZGCBNV>62*(LL:[&7+'ZD5M
MW.K&VO$MOL-[*&A>4RQ0Y0;<?*3G.XYX&.<4 <S%J'B?3_%>EV>I365U8ZB9
M%:.&,JUNRH7X)^\N!@GU-.N/$5SJ/A_Q!JFG7'EVME%*D#E.6D0'<Q]1Q@?2
MHM(U^;4M5@N+SP]K,5W.3"KRVFR*"/!.=Q/&<#^54_#UG=CX9:SH?E?\3"+[
M;;M%P26<L4X[Y#"@#I-)\16&K0)8Q7Z'4_LJ2RKLY!(&6 /! /85+X<UE]2^
MVV-V$%]I\YMYPGW6XRK =LK@X[5S]EI[ZEKWAFZ@LWMH](MY$N&FB,9W.BKL
M'K@@Y[#M5?3+_P#L/5?&7B>YM[F73Y+J-%\B/<Q1$VL^#C*@Y!/L: /1^U8M
MMKFGVVGQW-WKME<Q3W1ABN(RH0LS';&,$Y(Z=>Q)Q6TI#*".A&:\J%C?)X9L
M$?2[YFB\4?:Y(A:N6\D2LY;&.F"/Y4 >B6>OZ3?VEQ=VVH6[V]NQ6:3?@1D>
MN>E9&O\ B>(^$-8U'0[Z)KJQC+'*9*,.<,AP1D>HK UF'6+K6]:ELK"Z=+:\
MLKM$:%D6\CB'SQJ2 "0V&'K@8J?6KE=<\(>)+C3O#VH03WMNL69;4K-<OC ^
M3KA00-Q]_2@#MH-1M98MWGQ*ZQ+-(A<9C5@2"WH.#S[&H;K7])LM/COY]0MQ
M:R@&.57W"0'^[C.[\*YB:ZNM.U6&Z&D:E<QW.C1PKY%N24D5F.UP<;3AN_H:
MP_#Z:GH]QX6U&_TZ]_L^'2#9,B6[/)#.6!R44%L,%49Q]<4 ;WAWQ3/JV@+<
MW&K:?!/-J;VUO)*NQ9D5\!44L"6*].3R>]=!<>*-!M)9XKC5[..2W94E5I1E
M&/0'W_EWKSFWL[X^%H<:)J,;V_B5;WR3:,'$)E+95?9?2M.:W6+6_B#+-IMQ
MFYM8A;R_96;SAY.TJG'/SXZ>Q[4 =OJ7B#2=(\C^T-0@M_/_ -67;[P[GV'(
MYZ5<MKNVO81-:7$4\1X#Q.&4_B*\LU+56T"\TR=%=9+[0H;>>.:VDD\GT8JO
M((RP*\9QUXKO/!XL$\)Z;#IMP;BUAA$(E:,QEBORL2IY!R#Q0!<;7M)351I;
M:A;K?'&("X#9/0?7'..N.:8?$FAB;R6UBP63S?)"M<*"7P#M&3R?F7IZUYQK
M5[/<:Y';I9:C$+3Q)#,UM!8L\;1J06G:0*<LV<@ C (&#UJU+;QR>'_&7_$O
MN#))JRW$6VU<-*F8BI7C+#*/T_K0!Z/;ZE8W=S<6UO>V\T]N0)XHY59HB>S
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MN?,NB1&BYY8@<G R<<9Z9KD8O&^HQ6VO>9%%<36=W;VMH7MWMM[3!0"ZL20
M6]L@>] '<B]MC?&Q$R?:A$)C%GY@A) ;'ID$4MK=07MM'<VLR302KN21&RK#
MU!KC6:^M?B!J<SS02W": CQXB*H")'X(W$D9![C@X]ZETGQ->2R^#X&@M5CU
MFRDGE$:%?+9(U;Y><8);I[4 =G17'2^++^WT2;49;='C@U6:TG>&%V$,$;NI
ME*@DG&T$_6J<>MZIJ7B3PD+:_M);:YCO)+E[89BE1,!2 3D'D<9X).>E '>T
M5PDWB3Q1#I&H:B(-*E6TU#[(L*JZF8>:(\[BV$.3Z&K5SXFU/0FUAM9%G,EG
MI\=[&MLC)RQ=3&2Q.?F7AN.O2@#L:*XF7Q!XJAM[J\;28DLX]/>Y\R= FR51
MG;@2%F4@'L#3;3Q)K<R:2MW+IZG5[">>%K6)B875%8<LQ###>@Y% '<45S_@
MAKJ3P7I$UY<M<S36J2F1P=QW#=R23D\]:1M7OM1U[4])TR2V@?3DB,DD\32;
MWD&X+@,N!M'7)Z^U &[-"EQ"\,B[D<88'N*Q3X-T$EO^)?'\PP<$C(_.N=M?
M&&O:W+H\.FVVGV<M]!<--'=AW:%X7V,/E(X).!]#7::A?II>DW6H7()2V@::
M0(.H49./RH S1X.T,,&^PID'/!..F/7TJK)H'A.UN4M)!:Q7#D!(6N-K,3G&
M%SDYP?R-0?\ "1:O91Z'=:C#9M#JUREN(8%8/ 75F0ERQ#\+@X Z\>];PK!<
M7GB3Q0^H-:7"IJ,8Q]F(.](TV,"6.,8'&"<\YH V_P#A#M!QC[ @XQPS?XU6
MM_#7A6],R6T%K.T#^7*(YBQC8=5;!X/L:D\03ZI%K?AZ&PNX8(;BZDCF62$O
MOQ!(PZ,./E/'K@]L'FWU/5=*U#QK?V$=D8;2X2603!LOB!"5 7&#[DGKTH Z
ME?!^AKG;8J <=&(_D:7_ (1'1<_\>GU_>-_C6=J_B?4%U34M/T>U$]QI\"NR
MF!I?,D=2RI\K+LX ^8YZ].*Z*TO))=*AO+N VDC0B66%SDQ'&2I/?% &=_PB
M6C@Y6V8=_P#6OUQC^]Z4B^#]$0 +:O@$$?OY#TS_ +7N:RAXMOSH5EXB^SV_
M]EW5S&@@*D3+$[A%<MG!.3G;CH<9[U837=:U2.[N]$M[.6"UO#:^1+GS)=C;
M9&#[@%[X!!Z>^* +O_"'Z)\O^BMQCK*YZ?C4*^!M 2Z>Y%EB5U <K(Z[L=S@
M\U737M=U!)[O2=/M9K>WOWM&MY),22*C[&D#YVKR#\I!X'7G%1/XGU(>'O$=
M\$M?/TF\EA0&-MLB(%/(W9R0Q[_A0!I?\(=HA0J;5N?^FTG_ ,54UEX8TC3T
M*6UFJ(V-REF(.&W#@GUYK-NM6\13>)[[2M+@TPQ6T,$WFW3.#A]X*X7OE.O;
MWSQFKXN\06NAZEK.IV>FI:VDTMJJ0O(SO*)A$IZ?=W9SWXZ"@#O**XB^\5Z]
MI=CJMS/I:RP6EJ+B.Y:%K=6(.&C*EF.<8((.*E_X2W4-,N+C^VK>U$":4VI*
M;4MD;2 8SNZGYA@\4 =EBC%<Q<ZUK6D6]SJ&IVUFVFQ6+W.^%BK1R#!$1R3N
MR#]X#J.@XJ+1/$.N7VJVL=SI).GW4'FBY2-H_(;&=C;B=X[!ACZ"@#K,48K(
MUS6'T^6PLK58VOM0G\F 2?=4!2S.>F0%!X!&3@<=:P-1\7ZKI/\ ;ME<65K-
M?Z?8_;X)%9DBGAS@G'S%2"#QGG'4=: .VQ1BL_2Y=5F1WU2VM;<G!CC@F:0C
MU#$J!GITK U+Q)K:^(M1TC3-/LF-I:)=B>XG8 J<Y&T+UR..>WO0!J77AJWF
MU:34X+V^LKF956<VTH F"_=W!@1QR,C!YK3L[*&PM4M[=2$7)R226).2Q)Y)
M)R23UKF['Q3>:]]@BT>&U66:PCOIWN'++#OX5,#!8Y#<\=/>L^/QUJMTFFI:
M:+ ;BZNIK&59+K:(YXPQ.,*<K\N<]>V.] '>8HQ7-:9XPLWTNXN=9N+33WMK
MZ6QD+S8C:1"?NEL9R!F@^)+C4[^]M- CM;EK.WBF:260A)3(I:-4([$#.[W%
M &C!H5O!K4VJO/=3SN"(TFEW) #C<(U_AS@9K4KE+3Q9<:P+6#3+)%O9;,W<
ML=S(0L(W% N0.275AGMC/<4Z#Q%J]Y)!81:3%!JALA=7,<\_R0DL55.!DDE3
M[ #O0!U.*,5SNG>(KZYU#3K*^T@V,]W9RW+(\X9HF1U4J0!@@[P0<_A64WCN
M\DT31M0MM(1WU'4'L?):YP%8%U!W;>^S/3CWH [?%&*XRW\4^(IO$4VC-X>M
M5FABBFD*7^X!&?!.2@R< G&.W6IH/&%S>O;36&E37-E+=_9RZ))N"Y*^;G9L
MV@J<X8\$'(Z4 =;BC%<-#X]O6TZ349]#6"U@U 6$Q-YN8-Y@0LH"<@$CJ1[9
MZUJR>);N9;^72]*^WPV5X+20)/MD9AMWE5VX.TMCDC.T^V0#I,48KC-1\>/;
MR7OV#29;Z.RN?LT@0R!W8$!R@$; A22.6'0UUDUW%!8O>.6$*1F5B5.0H&>G
M7IVH GQ3&DC1PC.H9N@)Y-<NOB^>&VTF^U#34M=/U.411R_:=SQ;QF,NNT ;
M@.<$XR.M4-'MI==\5^(%UFQMI$L[V!H#Y[,T++&K)M^4<<ECR.21@]: .ZQ1
MBL[6M2ETNT2:&V28M($9I9A%'$N"2[N0< 8]#R17--\0'.AZ5J-OI0N6O[UK
M'9#=#:DH<JN&*C<IVDYX[4 =M16/H>MRZI-J%K=6@M;NPF$4J+)YBG*AE8-M
M&>#Z=J@UOQ-'I6I6VFPPB>\GB:;:Q<*D:D#)*HQY) ''KS0!OXHQ7%Q>.KI_
M[#>70I+:'4KLV<AGE9&ADYQA2GS*0,@Y&>F*GN?&C6HD+V"8DOVL;,B<D3%-
MV]FPA*@;2,#<2: .MQ17%0^/;E_LJ2^'+Q)9[U[(*&P&8+N5E+A<J0#R0,8-
M)+XQU.>P<V^FQPWMOJT6GW$37&X<LOW6V\Y#8Y QG- ';48IL99HU+J%8@94
M'.#Z9K-UG6ETDV<*0F>[O9O)MX=VT,V"Q);L  : (]>T:;6/[/,-[]E>SNUN
M@3%Y@8@,,8R/[QK7KDKS7)9=,@;6-!F@(U2&U=3<C8I+KME#<%ER1QCD\'C)
MJ67Q;<1:WJ%G_8TIL]/=?M=Z9T"11E ^\KU/!Z#)H ZG%&*Y;_A*]068;_#]
MP+66TDNX)Q*",*,[9./D)&,<GK]:MP>)//M] G6R<QZQ%OC D&8V\DRA3GKP
MI&<]<4 ;U&*XB?XA26UC#?3^'KV.U-ZUE*[2QY1PY3A<_-R#Z#/<]:T)/&(L
M[76I-1TNXM)M+A6X,18/YL;;MA!7(&2I!],=: .GHKBM5\7ZS#I4=Q8:-$SR
M7,$<<GV@21RI(P 9"H^;N.V.O-7M=\63:&UP[:/-+:VD*37%P9511N)&U,_?
M8 $XX_6@#I\48KF=2\57EIK5]IEIH5Q>26EJER769$5E8MZ]/NG'K@].I</%
M;7=K92:5IDMY-=60OC$9!'Y<9'&3SEB<@ >AZ4 =)BC%<E>>.[2V2R0V_DW=
MS;"Z,%[,MN8D)(P2W\601@#M6OX<UZ#Q)H=OJEO')$DH.8Y!AE8'!'OSWH T
M_)C\WS?+7S,8W[><>F::MM C.ZPQJSYW,% +?7UK"NO%8ANM06VT^XNK;3?^
M/VX0@!#MW$*#]\@8) ]1U/%0S^-K7^T8[#3["\U&>6Q34(OLX4"2%F ##<1Z
M].M &]I]A!IMFMK;+MC5F?H!EF8LQXXY))XXYJ86\*S&81()3P7"C<?QIEY>
M6^GV4UY=RK%;PH9))&Z*HY)KB+S6KJ_\<^#W2TO+2TN/M+*SS+LG0PEERJL>
M>AY% '<BUMP<B"+.[?G8/O>OU]Z%MH%#A88P)/O@*/F^OK6!9^+XKV^B@CTV
M\6*X>6.VG<(%F>,$LH&[(^ZV"0 <51TOQR7\.'5M8L&L5DG:*V!FC(G)9@JJ
M=W! 7DMM'4]* .MM[:"T@2"VACAA086.-0JJ/8#@5+6'X<\4V'B5;I;7<EQ:
M,JSPLROLW#(PR$J0<'D'L:W* "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH HZ1QI5J.WE"KU4=(_P"07:_]<A5Z@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH YG_A"[,//"MU<C3+BX^U3:?E3&TF=W!QD*6P2H."1Z9!OZ?X?M].U[4]6
MAN+@R:CL,T+%?+!10H*\9''OWK2^T0>>(/.C\X@D1[ANQZXI_F(2!O7)..O>
M@#,\0Z%;^(])?3KF:>&-G1Q);L%=65@002".H]*QT\ :>;36(+O4-1O6U4QO
M-+/(F]'C^ZR%5&"..W85J>)M9?1=$O+RW^S27-O"TX@GEV;U49;&.<XZ>^*U
MHGWQ(Y&-R@XH XN]T Z+??VH;W7]5NIK1K$*$CD79@D;PJ ]3G/J:EM?!DTO
MAWPW#<:A-9ZGI$2A;BVVY&5"LG(((P /?%=='-%*&,<J.%)!*L#@C@BE$L9.
M!(I.,XSVH YRT\(#3K2>&RUK4XVDO'O [NDFUV#;EP5Y4[B2#WYSFDMO!-E9
M_P!F/:WMY!-I[RLKQ[!Y@E<.ZLNW 4D=% P.E=)YL>S?O79_>SQ3L@#.>* .
M2E\$%M"N-*BUN]1+FZ-W)(50L'+ASMP!@;AG!S5V7PLMYJUY>7]Z]S!=V8LY
M;78%0H"3G(YSDMW[U:AU>:7Q3/I?EPFV2T6X25'RS$L5((Z#I[UJJZ,2%8$C
MJ >E ')6_@00VMY;S:_JMTDUL]M"+B4.+=&&TE1CEL<9/:IK7P7%:KH@&I73
M#286@C4JFUT88;/&<D #(/:ND>7,4GDLCR*I(4MQGMGTJ&QGN#IMO)J/D17+
M(/-$3Y0-W"D]10!7T#2#H6BV^F?:Y;E+==D;R  A!T7CT%076@>9K<FJV=]-
M9W$T"V\VQ58.H)(.".&&3@\_2M+S+@Z@B*(3:F(L6W'?OR,<=-N,\U,)$9RH
M=2PZ@'F@#GK;PC;6.M:9?6<[PPZ?:M;1VP0$,K<L2W7)(!S[>];US;Q7=K-;
M3+NBF0QNN<94C!%.$L9( =<GH,U#?ZA:Z99O=WLRPP)C<[=LG Z>] &!9>"X
M;4Z9$^HW5Q9:7(9;.VEVD(V"%W-C+!02%Z8]ZNZ%H$FBW>ISMJ$MR+^X-R\;
MH $<\';WQ@ 8]A6R9(U4,74*>A)X-.S0!EZQH[:I+I\T=Y):365QYZ/&JMG*
M,A!# C!#FLVY\)?:(-?A_M!U366S*1$,Q_*$PO\ P$=^];6GZI9ZI!)/9SK+
M%'*\3.O3<IP<'OSWJAXFUUM!T0ZC#"EQ^^BBVE\##N%SD ],T 49_![MJPU6
MVUN]M;Z2!8+J2)4VW 48!*D$!O<5T5O:Q6UG':1K^YC01JK'/R@8YSUJ>D#!
MLX(.#@XH YFU\&P6^F)I!O9I-*CN1<1V[(H*X<.J;A_"&&>F>V:9'X,%KJ=W
M/8:Q?6=E>S^?<V<) 5G[E6QE-W&<?IQCJ&=4&68*/4G%+D#O0!R\'@Q+*]O7
ML-6OK.RO9_M$UI 5 WYRVUB,J&[@8_"F7W@A;M]61-8OK:SU1O,GMH0F-^ "
M02I/..1WKJP00"#D'H11N7GYAQUYZ4 8]EH<EGK=UJAU"6:2XMH[=EDC7'R9
MPQVXR<LW3 YJF?!\$_A:_P!"O;N6XBNY9)C+C:RNS^9D8]'YK3US6(=$T2XU
M.1?,2)1M4'&YB0JC/.,DCFG:=<:C(9UU&TAMRCXBDBFWI*IZ'D @CH<CZ4 8
MC>#9Y_#][I5[K]_>?:H_)\V?:3&G'  P"3C[QR:L7'A07EX);J]9XFTY].DA
M6,*'C?J<Y)!X'Y5T.]2Q4,-PZC/-0VLMQ(9OM%N(=DI6/$F_S$XPW08SZ=L4
M <Y9^"A'IS:9J&LWVHZ?]F:V2WFVJ I[DJ 68 8!/2K6A>&9M&,"R:YJ%[!;
M1F*"&8J%53C&[: 7( P,].:Z&LK6-7-A/96-NB27]\[);I(VU?E7<S,>N !V
M'4@=Z #7-$368K4B=K>ZM)UN+>=5#%&'&"#U!!((XK,U#PB^J6^I&YU$_;-0
MMUM))TA $<())1%).,ECDDFMW3IKJ:PA>_MUMKL@B2)7WJ"">A[@XR.^#S5N
M@".!)$MXTED$DBJ [A=NXXY..V?2L8^'Y?\ A(]0U3[=^ZO;1;9K?RON[<X;
M=GG[S<8[UNT4 <CIG@R?14TZ6PU0?;+.T%DS2P9BFB#%AE0V0PR<$-]14]OX
M3:QDTQ[2]53:7$MU,9(-QN)) 0YR&&W[QQP<<>G/0&\MQ?"R\T?:3&9?+[[
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MM)I2JS(@4M-N4L-@SSP.^* *>I^&+O6/"TNF7NJE[YIA/'>+"%\EPX9=JY.
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MUSY%OM&%+,1\Q8 G ! ZD] :YC1)9->L/ 1N]3NPT\=U'.(;AD,H1> Q!Z\
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MNE8#Y,[L \?A6CI'@O7++4=%N;JYTESI]U/+--'"WG7(D5E+,QYW?-TZ=.N
M*L0>#]4.E?V!=SVLFE"]-SYZLXF*^;YH381@?-QG=T[9H V+?Q-]LUB6RM;3
MS4ANC:S.)1OB(7=O9,?=SP#GN*Q4^)VFSZO;VEK"+F*XN?LL;13 R%LD!BA
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MV L-IQDC/2N0A^(VCW.H6L%NRS175R;6-XYD+[\X!,>=P0G(#?F "">O4$H
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ML7TJR&V.Y4L9I4'W5*D87C R">E:'C'3K[5_"FH:;IR0M<74?E#SG*JH/4Y
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MD^E8=]H>K7:Z?=VVAV5B+35(+K['"Z*[QHKAB6'RDY?@>W7GAVL^']3UZ_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHI"0 2>@H 6BO,-$UG4+CQ/H<9O[LV>J0W;"::89N=O*NL7(B R<
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MY6W.P QR>YKD_%5M=W?C3PVUJ^H0+ +@275K;&18]X0*&)4K@X.?3KQ7:44
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MEMHW5S+<27#[(]B!G.2$7)VJ.PR:UJ** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH A@_X]X_]T5-4,'^J3_=%34 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 E+110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% #9)$BC:21U1%&69C@ ?6G9XS7(>(KZ6;QQX9T/ ^S2M+
M=S@]'\M#L&/9B&^JCTJ>Y\27.E^*;NPU,0K8?86O+61(F#/L/[Q2=Q!(&#@#
MG/Y@'1K<P/<O;+-&9T4.\08;E4YP2.H!P?RJ6N*URXO["V\,ZO<1P1:H]]!:
MW0A4@&.7(:/))) )4\]USQ7:T %%%% !2,P7KT]?2EJEJEW'8:=<7DO^KAB:
M1@!U"@G^E #K75+"^:1+2]MYWC.)%CD#%#Z$#I1:ZG97SR):74,[1,5D$<BL
M48=C@\&N1\$6UOI?A>77)U6*2_:2_N#M PI)8#..RX_&J=IK+:'-HD%MIT;R
M^());F6->)(\@,&( Y49 /UH ]#W =C2[AC/;WKB[#QA<7ME%&+>$ZC<7<\%
MM&CDI(D;$>9G'3 )_2F3>*=8ATC7+Q;*UF.DR^6S+*0)PJAGP,':0"!WS0!V
M^X>M&X5R5[XN73[VX3R%EA,<2VPC.&EG?)$7/? S[5%!XGO8M1UJUU&&W2#3
MK9+@SJQQEMQ*$>P7KW]!0!U%QJEE:0^=<744<6<>8[@+GIC/UXJR7'8$_2O-
MKV.WU/3/#&CI9QV_]H3B_N(-Q;8J@2D GG&XJ.W6M&[\9W@M8=1L+.":PFO8
M[2!B^#.&8 R+QP!SQWQVH [)KZU2Z6U>>-9W4LL98;F ZD#\:D,\:LJLP5VS
MM5B 3BO.M0OKN7QQK&H65G!(FA6!C225RJF1\.RYP>< 5I6.KPZ_XETMI=.C
M$D&GK>^9YIW0&3(VD8P<A?7IVH ZR+4[*X,HANH9/*;;+L<'8W8'T-6=XKRW
M1GAFTF"ZDLXIU\3:LTRQAC"5C )5N.3@+G'O6X=<UB;Q1K4=DMK+IVF6V A;
M!DG(W!2<<$?C0!V^><4$@#)Z5SFC^)7U:32S';($O+,W,N'RT7( &,=#SS[5
M-=>(0VNG1-/C2:]CB\Z<N^U84)P,\'DGM]: -MY%12QZ"J]MJ=C>1O);7<,J
M(<,R."%/OZ5P>N^(=1UW1](M-.CBBDU>Y,$A$I)58V/F,IQRN%(S[UU-QX>T
MJ;37MWM8XX&99)%CRJN5&1NQC(_G0!K"_M2>)X^N/O#KV_/-3@YKS/PO9Z/<
M>&M6\1ZC;Q"UN;Q[I& "A(HR F#QV7/XUT"^+G,M\4@A>&VLS=,ZRX"'@A&X
MX)'/?&* .MH-<+IGQ!:_GTGSM-^RVVH6+WAFDF_U049;(V]/?BK\'B\S6.G:
MA]D9;2_NA!"2WS%6!*OC'0XZ>] '59I:Y.W\77E[J=Y9V>D"X%I?K:RRK<KM
M5, M(>.V?N_RK0UWQ''H\MG:) UQ?7S^7;PJ<9(ZDG'  [T ;9; Y%0K>6[R
MO$DR-(GWD# D?A7':UXPNH= UJ:T@C^W6$ZVH5I#M+N%VD''/WQVK7T/1DT[
M2K::YBC^WB#,\V<L6/+<^F<T ;GVF'<5\Q-P.-NX9J6O$I+U+RUU74VM7636
M]1,&GWSG;% !\D;;NV2"<8Y/>O0[WQ4NG1W4%M#]LEL55)!YF"\A'"  $ECP
M>F.: .JHKB]1\?BQU/5K!--:673[5;HGS=JLA&3DX^7&/SQ6E!XG%Y)9V]M:
M,]U-"D\T>_ MT9<C<V/P H WI9XX2HD=5+G:H) +'!.![\&G@AAD5YMKOB$:
MAXB\+65Q9M'<JDFI26S-S&RKM0$CMEFY]NE:@^(&RR\/SOI<A.L@[$$HW(=I
M;ICD>_'6@#MJ*XC3/B)'J,=D/[.9)9[UK.55EW")QN[X^;A2?:I;_P =&WC2
MYL],:[LVO$LUF$P7>Q."R@CE0>_M0!V)8#%,6>-G,8=?, !*9&1GVKE)O&TC
M:OJ.DVFCSW5[9F,E(Y%PR/\ Q$]!CTZUA>&]66\\5:S?V4"7=S<7AMQ&DP'E
M6\7RB0@^KAAC H ],HI$.5S0Q"J23@ 9)H 7-%>:Z/K]U'X[MKZ>Y$FF^(XV
M6W0/D0&//E_]]ISCCECZ5U=IJ>I3>,]2TY[>+[!!;P.CB7Y@6\S)QCG)7&,\
M;<]Z -^BL7Q#K5WI$2&TL%N6*M(\D\_D0Q(HYW2$$ G(P._/I6?!XT^VVNB2
MV.E37#:M;R2QJLB@1E-N0Q/09;D^W0T =517(2>-Y(M'_M%](<)#?FQO5$X/
MV8APN_./F7)'3UKH+358KS5;ZQA&[[&(Q)(#QO8$[?J%VG_@5 %^BN9M-=U&
M?QAKVG_9$>PT^&$HRN Q=D+D<]<Y ZC&/>J.F^*[2#0?#\FDZ1=S6NJ/)'#&
MLH9HF 9L,6)[JW?  /IB@#M**XR3QY+#I]S>2Z%<+'87!@U B9"(#D#Y3_'P
MP. *L:_XZLM%OKBR1([BXM8A+/&9Q&0""0JY'S.0,X]QSR* .KHS6)J7B2"R
M\&R^(HXW>$6@N8XW&TMD94'T/(%91D2'PQHDFK"XNKF_N[5W9)2NR9R&!X/W
M%Z >@ ]Z .PHKD+SQR;>\UF&WT>YN8]&9#>3+*BA8RNYF )R2 #QWQUJ[J/B
MEH&O$TS3I=2DL462Z2)MK(&&Y548^9B.<#\\T =%17%R74Q^)-E+ L^V?1))
M3;/(5!82)C*DX#<XK4'BN!K#0+P6DWDZS(D<?(S$SH7&[GT4]/2@#H*,UP/B
MCQ =4T8MI]K=FTBU.W@-ZDHC7<)E5Q@$,5ZKR,$D8SUK9D\0:?97GB.X%O?-
M<:9%$UV@.X%=K,I0;L=,D]/?I0!TM%<[I?BR/4K^TMWTZ[M$O;;[3:33;=LR
M@*6X4DJ1N'7&:JOX^L%^Q3I97DNGW]Q]FM;N)0RRR9(P%SNQPW..U '649K'
M\47UIIWAN]N[Z6ZBMHT&][1MLJY8#Y3D8.35._\ &-CINJ7&EFTU&>YMH!.X
MAMRP,?\ >W$@<8/7\,T =)15;3[Z#4].MKZU8M;W,2RQL1@E6&1Q^-6: "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MN:;?V.E:O_9NE636]J#;A2\C\,Q!(YQU^IKH]9U"?4]'N+*WM-4M#,IB,QM
MQ4'@D?-742AUB<PHC2 ':KMM!/H2 <#\#7":?\0[R]\-R>(SX=":7"S"5UO
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M<\01>(H+Z5+5X&L[V2S=7(.63&2".W-:&I78T_3+F]\DR_9XFEV @$X&3R:
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M]?DW=/PK$MET:?6/#-SX9>W)5&CNQ X.+;RB<2@=]VW[W.:[]$6- B*%51@
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MSN/.!TJ;_A%="^RW%K_9=OY%Q)YLT>WB1_[S#N>:U8HD@A2*)0L:*%51T '
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MS(K,"77H<YSQ]:MW'AO2KJXO)Y[4R27L8BN-TKD.HZ#&<#';'3)Q0!HP1M#
MD;2O*5&#))C<WUP /TJ2H;2UBLK6.VA#".,8&YBQ/N2<DGW/-34 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M&D> ]6B\*_9+Q[6WUFSNGO+"\MY"P$C<[6!4?*>A'.1]* /2(RYC7S  ^!N
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MH<Y3!?+'GCK7H'B*_DT**PUR>65422.WNX58F,I(0"VWH&5B"#Z9'<8YO3/
M6IV^A7,<GV2WU:WU&34--NHG) 9L?+)QT.,'KD8]*UO%B7VL>&;+1;F.*WU#
M4;F**18SYBJ$82.Z]]HV=_49ZT =H*PM3U^2P\3Z5I*VLDJ7L<KN\:[BFTH
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MS4^('AE[?S_[2VH'$;[H)!Y3$X ?Y?DS_M8I-;T^^N/&OAJ_@LWEM;+[2)Y
MZ#9YB!5X+ GIS@&N:N?#^N2^%?&MI_9<OVC4[^2>U3SHR71MN#G=QPO3W&*
M.SU#Q3I&EW;6UU<.KHJM*R0NZ0ACA2[*"%R>F:L1ZYITNJW>F)<9O+2,2SQ;
M&&Q3T.<8/X5Y]XOT[Q'K-OK=BNDWC120V_V'[.T:(^,,YF.X,S#D!>1[9YK:
M\7:/>SZUIMYI4@@N]04Z=>*SD$VY!9F&#]Y,-@_[7TH Z_3[^VU2P@OK-S);
M3KOC<HR[E['# '%6:9##';P1PPHL<4:A$11@*!P !3Z "BBB@ HHHH ****
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M?D0BX-P(D\XKL,FT;BO7&>N*YKP(NHW'AZTU34=6N+V2^MHI/+D1%6([>=N
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M59:C+;RW< E>W??"Q)&QO48[U5MO#.C6=TES!8HDD;M)&-S%(V;JRJ3M4GU
M!J.P\5Z/J6H+8VMTSS.I>(F%U251U*.1M8#(Z&C_ (2K2!<P0&XD'VB5H8I3
M XC>0$@J'Q@G@]^<4 ;58E_X0T#5+^:]O=+@FN9H_*D=L_,O09 .,XXSU]ZB
ML_&WAW4)+=+741(;B3RHSY3A2_/RY*X#<'@\TRSUR;Q'I^J#2UDM+JSN7@C,
M\9"NR8(W CA2>"!SCTH OIX<TF.<3QV:QRBW^RAXV92(L8V#!X']>>M58_!?
MAV*.&./2XU6%62/:S#:K=5SG[IZXZ9R>IS5OP_K,>O:);:C&GEF0$21YSY;J
M<,N>^&!&:TZ ,Y=!TM-#.BBS3^SBA3[.22NTG..3GK^5)J>@Z9K#6S7]J)7M
M6+0,&9&C)&#@J0<$=NE-M_$.E74PCANP2T+7"LR,J-&IPS!B " 2.0>X/0U4
M?QIH2PM(+MG MGNE @?,D:9W,F1\W3M]>E "_P#"&>'Q:I:I8>5 EP;I(XII
M$"R_W@%88]L=.U3R^%]&N/MHGLA,+Y0MR)9'<2@'(SD]1V/4=L5DV?CRSN4\
M/[K6Y5M7B9QB%R(L*"1]W+<D#(XQSG%73XFTNR75KN[UA6MK2=8I 82/LS;0
M-F0,MD\Y]Z )HO">A0M<LNGH6NH/L\Y=F<RQ^C9)S]>M6+;0=.M$E6*%R98O
M)9Y)G=_+_NAF)('/0&HK7Q/HU[=3VT%_&TL$1G<,&4>6#@N"0 RY[C(J*W\7
MZ#=74-M%J"^=.BR1*T;KO1NC#(&1[T $G@_09=&BTB73UDL86WQ1O([&,_[+
M$Y7Z UH:;I=EH]F+2PMT@@!+;5[D]R3R3[FH-/\ $&F:K<&"SG=Y/+\T!H70
M,F<!E+ !A[C-:= %>^L;74K*6SO8(Y[:5=KQR#(853B\/:9#:2VRP2-%+%Y#
M>9/([>7_ ' S,2%]@0*34_$>E:/<+;WUV(I3&92HC9MJ X+MM!VKGN<"H]0\
M5Z'I5X]I>ZC%%<)%YQBP2VS.,@ <_0<XYZ"@#0T^PM=+L(;&RB\JVA7;&FXG
M:/3)YI;VS@U"SEM+E6:"9=KJKE<CN,@@U1D\2:4MC9W:WJM'?#_12B,YDXSD
M*!G@=>..^*S_  +K%UKF@2W=W<+<,+N>))50*&17(7@>U %R'PKI,%U9W*QS
MM+90^1 7N9&"IC!7!;!!'7/7 ]!3[+PSI.G2PO:VS(L 801F5F2'<<DHI)"G
MW&...]:]<S:^)(M4TO5M3BO%M-/MFDMXKAH]PW* #*<]0&) ''0DYR, $Z^#
M=%72GTWRK@VSW!N2#=R[O-SG=NW9SGGZ\]:U[RRBOK"6RF,GDRH8WV2,K$'K
M\P.:SHM0WSZ(O]K6Y^U0-)Y?DX:[PBG<G/R@9R1SU HTG5Y+K5=3TFZ11<V#
M(=Z\"6-QE&QZ\$''&0?H  G\*Z/=>'HM"N+7S=/A55CC>1BR;>A#9R"/K6#K
MW@B&6RTZTTR"7C4[>XNIWNF,OE)D']XS;L@'@ \=L5LR>)[4^*)/#L>1>"U\
MY78';N)("X[]">M97@7QE#KFCV%OJ6H6[:[*LKR0)@'"R,O0< X XZXYH V;
MCPKI5UI]U93I.Z7>/M$AN'\R4#HK/G<5'IG'YT[4_#&EZQ96MK?0R2K:D&"3
MSG61".,AP=V>.N:?-XDT:VOELIM1@2X:00A&;JYZ+GIGVK5H PV\):4?LY1+
MB)X%D421W,BNWF;=^]LY<G:O)STIEQX,T2X2R MI('LH1!!+;3O#(L>/N[E(
M)'U/K5?Q_K^H>&/"<^K:<EN\T+H&6=2RE68+V8'/(KHK=I&MHFE96D*@L57
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MAO)E49/E#*N0/96)_"NIHH YJZL[V7QEI^MV<,5U8BQDMV99@""[*P8=B/D
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MB@#SJ3P]K8TOQ3;V^DI'_:=O$MNKWHD;=L",'8\DXRV23GUJYXQ\,7GBC4-
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MTB[AU"SDM9'OYYD5W1LH[E@?E8CO^E=/4-U=V]C;/<W<\<$$8R\DC!54>Y-
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M!I.H6UQ#>N\X%A(#!PZEGPO RRG)ZCZ&O2(?$&BW$J10:OI\LCG"HERC%CZ
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MT+QI985+328V\XP%&WC %0ZAX*N;^2Y/]L^7'-J*:BJBU!*2(%"C.[D81>U
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M4+]I$:+:J[0Z'[VX@XQ@=^>U &XGBS1I+A8ENVP[%8YC"XBD8#)"28VL< \
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "C%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% &?:Z)866J7FI6\4BW=YC[0YF=@^.!\I) P.!@<"M"BB@ HHH
MH **** "BBB@ J-K>%[B.X:)&FC4JCD<J#C(![9P/RJ2B@ HHHH **** "LS
M5M!T[67MI;R%S-:L6@ECD>-XR>#AE(/.!6G10!4L=/MK!&$"N6?!>221G=L=
M,LQ)/YU;HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MA1D%54$\Y/*C&?:@#>HK@YO&OVG4_"5Q;W;VUGJ9F^T6\L. =L6[[S*#PS*
M1PW:NJ&OZ6=,;45O(WM0Q3>@+$N#@J% R6SQM S0!I45GZ7K>GZU',]A/YA@
MD,4J/&T;QN.S(P# _45SVBZKJU]\1?$.F37@.FZ:L)CC\M0Q,J;L$XS@<_I0
M!V-%4]0U2TTN))+N4KYC;(T1&=Y&]%5068^P!JM'XDT>73$U%;^(6SR>2K-E
M3YF<;-I^;=_LXS[4 :M%8\_BK0K738M1GU.W2TEF\A)2>"^=NWVP0<^F"3Q5
MRPU6QU/SA974<QA8+(%/*DC(R/<<CUH N45E^(=3ETG1+FYMHQ+=[=EM"?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M![@'(^F.] %CPUJ$5_9N1K:ZG<1D"XVHJ")_38 &4=<;LGCK53Q;J.I:9>:
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M]3;3[NWU.YBM@($:%XF<<'#,V\>O3'O4OQ&F*>!-4A2-Y9[F+R88HU+,['L
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M,YZTZ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MK@I]8\4WFM^)+.PO]-AATA5="UHQ:1F3>$;+8P!P6'?M3;;QAJ^O26T&FVIA
MEDTF._(C".=[L5"_.RC:,'/<Y[=P#OZ*\^@U;QG=^)+;1IKC3;&633?M4C);
M&81N) A'WQUY[\9QSC-4=0\8>)M/T#7]5DN--D&CZBMIY<=HR^>-R DDR';P
M_;/2@#T^JNGZC::K91WEC.LUO(6"R*#@X)4]?<$5SUOJVN#Q<VA7,M@QDTLW
MD<L<#CRY!($VD%_F7GV/':L.PU36M3G\$W%QJ0C:\EN3.D$0"/M5R,@Y[ #\
MSUH ]'HKSZ#6]1T;2/%FH/=_;VM]4,$"RQX(=A$@'WL;07'''0G/-7-0U[Q#
MHEM<W=Y;P?9'$4<#SA5DBE>0(=ZH[*R#<&X8'C!]: .HCU:PDU:32TNHVOHX
M_-> '+*F0,G\Q5VN1T^*6+XC7"WUU#<7?]D1^6R1>6=GFON&,GOM_3KU+M5N
M-2'Q&T*UMYO]">TN))H]H(7;M&[U_B4>V?K0!U=+7!R^*]7;PE<>*[46[6T$
M\G^@LG+0I(48[\YW_*6].V.];OC#5[S1_!U_JVG>5]H@B$B"92RXR,\ ]<&@
M#?HKB1K_ (BT[5[73]2;2IVO-/EN8I8U>!(I(P"58EFRG(^;COQ3="\2:OJ6
MHQ:8TUN\DVF-=BZ%JZQ"42*I"98%T^;KQT!R<T =I/#%<1-%-&LD;##*PR#6
M=_PCVD@1 :=;@1_<(3&WZ5SVA^*=5U6"PL98[:'6EO9H=0B,;!(XXC\Q7YNI
M#Q8.2/F]*UO$6NRZ;?Z/IMML%QJ=PT2R.I81JJEF;&1D] /K0!$9_#!747#6
M973FVW9VD^4?0_\ UJT3H6G,X)L+<E>02G3]:X:^U*^\.V'CG40+2XN;>]MR
MWFPDI(ABB RH(YPV?3.:Z6_\0W.F>(M/%TT*:+?6TC+*T1#I*J[]I;..5#$<
M=1B@#1FLM*AGMX)H+=9+ABL2E#\Q"EB/R!-17T.AZ5%')>I:6Z2RK"A<8W.W
M11SUJA%JNOK=^'%N%L5CU%Y/M"&)U>,>6TB <\$  '/?-<YXDU>\\0>$;75(
MW@CL'U>%$@,9\S:D^S);=C)9<XQT./>@#O?['LO^?.'_ +Y_^O1_9%C_ ,^D
M?^?QKFI?$?B&_O-470]/AN8[&[^S*K; '*[=X9C*"AY8#Y#VJG>>*?$4</B>
MY4Z='%H<P*IY+,TR[0^PG=A>#C<,\GH,<@'4W6G:/8VLMS=06T,$2EGD<[54
M>I.:6STK29;.&6TMH7@D021NAR&4C((YZ$5B:GK-]K%MKUKISV\$=E8AG$\1
M<R-)$7 !##: ,<X/)/ISG/XAO/#/A_P_9R26UG;MI4*1WUQ$TD+7 0 1L5(*
M# !W'.<GIB@#KI?#^F3NC2649*'*G)X_6I/[%L,Y-K&?P/\ C47B/6UT'PU>
M:MM63R8\HN>&8D!1GTR16?-K&JZ?KEAI5XUI+)J-M*T$D43 1S1J&8,"WS(<
MC&"#Q[Y !K?V/8_\^D?Z_P"-5V\-Z4Y<FQCS(0S'GG%4?!NHZ]K.E6^J:J;"
M."Y@#I!!$X=&SW)8C&!TQW]N<E]<O-(\3^+]1OKP2:9IUO;[;<1_-DH64 YX
MY8CGKGMB@#HO^$5T?M8I_P!]&@>%M('_ "Y(/HQK/?7-5TN\T,ZC]EGMM5D%
MN?L\3(T,K+N7DL=R\,#P#T/M4OBK6=4TN]T.WTQ;0_VA=_9I#<*QVC:2",$=
M,'CO[4 7/^$7TC_GR'_?1I/^$4T8_P#+F/\ OHU@2^)?$+W]YH]G!;3ZIIUO
M&]R8K<M&\KY95&Z12J[0.?F.2>..91JWC"[U$6$%OI-K.VGQW;+.'?R7)8&,
M[6^;D=1C'/7N 7T\":!%J<NH+9M]HE4(Q\Y\$?3.*M-X5T@_\NGY.16'X8\7
MZEKFIZ4LT$$=K?:?-.RJIW++%((V ;."I.3TSR*B_P"$J\0?V1HTJ)IKW5WJ
MTNG3%E=4&UY &4;O2,\$]< =: .@_P"$4TD=+0_]_#_C5>/1/#TU[-91+&]U
M JM+"L^60'ID9XS5=-4\27#7UA;_ -G-J6G0J\I\M_+N)'W%47+ H-H&22>3
MTXYH32ZN/%-[/I\.GVVH?V-;RW:S[I%1PTIV_+C=TQNSP.<'I0!O_P#"+:3T
M^Q8]_.?_ !H_X1/2O^>!_P"_LG_Q58VJ>+K^VTO3]0C-A:PW&G?;&\X-,[R8
M4B-44AL?-R_('<4FM^,+VQM=)E5K6QBOK3SOM5U"\D(F(4K$2&79G)^8GMTH
M VO^$3TK_G@?^_LG_P 52CPII(_Y=W/TF?\ ^*K(N/%NIW6HZGI^C::MQ=:?
M;Q,XX96ED7<%SN7"X'WN<YZ#'.UJFO?V)X3EUN_M71X;=99+96!(<@?)GI]X
MXS0 W_A%=)_Y]G_[_O\ _%4G_"*Z3_S[/_W_ '_^*JC)X@U33-7L=.U2*U:3
M4+:5[>2!&"I-&NYHVR3D8Z-QT/'I'X)U[7O$VFVVKWEMIT&GW"2;5B=S*&#E
M1G(QC /?L/7@ T_^$6TH=+=_^_[_ /Q5'_"+Z6>L$G_?]_\ XJJ=UK.NMXLG
MTBPM-/\ (@@BN7GN)G!*,Q4K@#@_*Y!Y' ]:R[#QKJ^I2VMY::0TFE3W1C+F
M%EV09(\[S,X.,9*[>G?O0!N2Z!H=L8UF_=&1@B![IUW,>@&6Y-2_\(QI?_/"
M7_P(D_\ BJY?4+V]UZW\/ZR;>R%C)JT)MP4)G2,OA7W9P"V!E0. 1R<5;7QE
MJUW>3OIFDFZM(+\V;(L;[V56VO()/NC!YVXZ=Z -S_A%],_YY7'_ (%2?_%4
M?\(MIG_/*X_\"I/_ (JL2W\9ZAJ4HN=)TPWEB+PVQ41N&* [3*),;1@\[<=.
MX/ K-XS\106B7MSI&GB#^TCIQC2Z8NS[S'N!VX W#OV]* .C_P"$6TS_ )Y7
M'_@5)_\ %4?\(MIG_/.Y_"[E_P#BJ9H>LZC=ZQJFEZG;6\<]D(G$EL[,C"0$
MX^8 Y&/QJCXB\676E:XFE6T-JDTEN)K<WCLB73[B#$K=%8 9R2<Y QSF@"6[
M\(:3?6US9+-=1NZ%7*7LFY ?;=Q2Z;X'TS3=.@LEDO95A&%:2Z<''X$"LF]N
M=1TKQ1XDO=,TZP<Q6$%Q/+-(5^Z)"5 5<L2 >21C ZU=UGQ=>6>E6^HV]M;1
M02V'VT&YDYE? (@0 AMQ!)W8(&!QSP :G_"*Z;_=NO\ P,E_^*I/^$5TW^[=
M?^!DO_Q59%SXLUR:^TJVTG2+.8ZAIXO0)[LH4'RY!^7MO'UYZ4Q_&FJS7,[Z
M?H_VFWM;U[*6)!(TLC(0'96"[% YX8\X[$XH VO^$5TWTNO_  ,E_P#BJ;_P
MB6EYS_IG_@9+_P#%55TKQ9)JOB&YTY(K:'[-=202PRR[9PJKE9 N,,K$=CP,
M?AHZYJUU8R6-GI]LD]]?2F.(2L5C0*I9G8CG  Z#J2* (?\ A%-,]+S_ ,#)
M?_BJA@\/Z'=-*MO<3S&)MD@COY&V-UP<-P?:LC5/$=[=^%/%ME=P"RU72[5O
M,:WE+(P="4=&X(R >#R*VO">DP66C6=S]BM8+Q[2*-Y(,_.BK\NXD DXH <O
MA?2VSM^U'!P?],EX/_?5._X173?2Z_\  R7_ .*KFWU35&T^U.E6=AIT\FOO
M;W2(Y*R%6;<=P4$[MO)QFM";Q9J'_"4RZ-!;61E@:(/!+*R2S(^S=)&2-I5=
MS<9R=IZ4 :G_  BNF^EU_P"!DO\ \52?\(IIGI>?^!DO_P 52^+?$)\-:*+\
M0"4&>.)F8D)$K'!=L G ]A7-:QXAUQKSPH()+.-;V_=7^SSEXID ^7Y@.5()
M.,=<4 =)_P (IIGI>?\ @9+_ /%4?\(IIGI>?^!DO_Q59NH>+K^.UU;4=-L;
M:?3](EDBN/-F99)60 OL 4@!<D<]2#TZE[^+;O4GO!X;L(;\V44;RK+-Y9=G
M&Y43@C.WJ2<<CKS0!HVWA^PM;U9(9+CSHQG:UV[8'NI-;E>;3:Q%HWQ$U"9;
M-%U&^TRV6"S#*K2SL[_*3TX[MZ#Z5WD5U/;:4;K51!#)%&TD_DN710.3@D G
MCVH NT5R$?B[45ETJ]N-*A31=4ECBMYDN"9HS)_JS(FT#YCC@$XSUXJ?1?$F
MJ:WJMQ%'I$,5C:7<UG<SM<Y.].A1=HR#QUQC/>@#IS2!@PR"#SCBN9GU#66^
M(":4([-M*-B9G#.V\C<%)QMP3G@#.,$G/:N;\":Q=:-X4T>U_LU&T^;4)+1)
MS<_.&::7!V;3D# '+ ^U 'IE%<G?^,SIVMVNGW%K;K]JO1:1H;H>>,@[9#&
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M;]IW,%(1NG'S#GK3](\6QZS:Z'+;VZ>9J2/))'YV3 J#YC]WG#87MR: .DI
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MWBQ6*MO64/*"B%7*$[N 02.#[T 5)/!%L9)Y8-4U&VENK1;2[:)TQ<*J; S
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MY5=K%<@GKP,T 5H?!(M+B:.SUF^MM,FNOM4EC%M4;LY(5P-RJ2!D ^H[U$/
MS_V(FFG6)66/4/[065H06#[M^.N,;LFNK#[EW*VY>Q&#GZ4W[0F\J)%++]X
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M+;.6@W*2%D<_,6)SD_=KUQKJT%PMNTD0FP65#PV/7'XU)((Q&_S!<CJ./UH
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M^*+=[JYFB6.T=%FEWA-PD)"C^$>U0Z#I?BVSO5-]+I)BED,EU+$9#)(>V,\
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M5[=7>S$A'F705D#$XP $8CZ\XH RO VOW-MX->_U:6^U*Z;4&M04R[,V_:H
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MD9 &/H2<=@:XS1KZSU/3K6_?61%XH@F=IK905N)IEW_N64L<IVP!@ "@#O\
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M>:'698U(\ORLRA2& Z!3G<3U(H ]!\1ZRWA_0[G4Q9R7:VZ[W1'52%'4Y/\
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MGC'//-3^&-;U>]UC23/---97EK<.9Y%"+<,&0JZ)U10&(&>2.30!T0\5Z?\
M8;&[,=RL=[>?8H@8CD2>88_F[*,J>O\ /BMRO.)GF3PQH'E[O+;Q/B4@<;?M
M<IY]!N"_I7<:XMTVAWOV&Z:UNA"S13*JMM8#(R&!&.,'CITP: +]%>9VVOZW
MI.IZ$]SJ5QJ::CH\MW+ \<:@.D8D 0(H/MR3UJW:ZOJ9T3PYX@35I+DZG=PQ
M7-NRJ(469MI5!C(*$@ Y.=ISF@#T!'23.QE;:=IP<X/I3JXSX=VTL-GK#2:A
M<W9&J7,6Z9@=VU\;N!U/?MZ8I\VHWFM>+]9T"&^FTXV-G&]NT87=*[@DR<@Y
M5?E7 XR3GM@ Z^JC:78/J2:B]E;M?(NQ;@QCS%'H&Z]S7+6FH7VM>)9M$.K/
M%'8V$4C3V93-Q*X(9LD$;01T Z]?2HM#U?5M0U#1FO+F2-Y/MEK<PH%".\+;
M1(!C(8_7'M0!W5(Q51EB /4FO+;G7]<BT;2A;ZU(TLOB4Z:T[1(2\6]@,@J.
MFWMC/-.\13:O]BU72I-7GE-IJEB(+AE17*RLIVOM4 @'D8 Z#K0!ZC1481A"
M$,KE@N/,(&XGUZ8S^&*\WT;4KK2/">A64-]<O/J^HR0-<SJNZ'+N7*Y R20<
M$Y&6[C H ],I"JD@D D=#Z5P=S/XAM)M;T2VUJ2:XM;%;^SN7CC,I)W@Q2#;
MM()7@@ \]:SX/B%-)K$TT,[SZ?>:<KV,31K\MYA28 P&2<.I.2<9/I0!Z;17
M ^(]4UC3H)D@UEY[ZPT_[0\%G;*SO*,Y:7((6,C& ,,<'&<4C:QXGU+6]'T^
MVU"RL8]0TH7CNMKYK1N NX+EL'EAC(_.@#L=5U>PT2R^V:E<K;V^]4\QP<9)
MP.E7:\NUV_O?%G@/6;A[ORK:*^%F(XT&)466-2Y)&0Q.2 . #CGK71:AXFNM
M-\2&PU%OL$$MQ"EE.T)>"X5L;D9Q]V3AL X'3K0!V%%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% &6VB6_]M2ZDORFX@\BZAV@
MI.!]TL/4<C/H<>E31Z-I<4!@CTVS2$DGRU@4+D\$XQ["N,UO6M2U/P]XPAGL
M+NR73O-%O<17 3!6)&4-L?<2=Q;IMP0#R,5N:/XGAG>WL[BSO+7_ $'[4L]T
M@19$0JK'&=PQD'Y@.#F@#4MM*$.KW.IRSO-<3(L2@\+%&.=JCW)R3GD@>E6K
MJSM;Z+RKNVAN(_[DL8<?D:YW3_'ND:CJ]EI\ E+7P8VT@9&#;06.X!BR9 R-
MP!^E5?%=U<V_CCP?'!=7$45Q/.DT:2LJ2 ("-R@X.#ZB@#IGT?3)# 7TZT8V
MX A+0*?+ Y&WCC\*DDTZQEB:*2SMWC9@[*T2D%AT)&.OO7-7'B33- @\0ZM-
M%JA%K<)'<Q.2X#%5VF,%L*I# ]NM36_CBSNK^.PBTS5/M<MN+F"%H54RQ%MN
MX9;"C_>VT ;J:7I\:LB6%JJLV]@L*@%O4\=?>I+FRM;U56[MH9U5MRB6,, ?
M49[UR]WXITC48/#<Y.HK%J5TK6K0_*I<$C9+@],]5YZ>U+IGC*26V\07FH:?
M/#;Z;>O;H(PKL^U4&P ,27+$]L?,.>#0!TLVGV5Q<1W$]I;RS1',<CQAF0^Q
M(R*EG@AN86AN(HY8F^\DBAE/?D&N/UOQX^GZ%JEU!I<ZWVGO"LMO,4.P2D!6
M.U^0>F <Y[8YK3DU2UD\4Z7:S)J$%W+:R311-@18XW!\$Y8<?3\: ---%TI)
MHIDTRR66+_5N(%#)R3P<<<DG\34L6GV4%U)=0VEO'<2_ZR9(P'?ZD#)K$;QI
M8(L5Q]GNVTZ6X%M'?J@,3.3@8YW;2>-V,9[U _C[3U@N9EL=1,=G<K;79:$)
MY#,0H)W$9R6'W<GN0* .EM[2VLT9+6WB@5V+L(D"AF/4G'?WIDFG6,MVMW)9
MV[W*?=F:)2X^AQFH]6U2UT72KG4KUBMM;IO<@9./8>M9LWBRULK"[NM2M;JQ
M%L$W+(%8N7^Z$*,0Q)XZT :\MA:374=U+:P/<1C"2M&"ZCV/44AT^R9YW:SM
MR]PNV9C$N91C&&XY&/6N.U+XC10B>UM-/F;489K=)(6>,A4E8 -D,0>H&,]2
M.W-=L780&3RG+!=WEC&[..G7&?QQ0!&MC:(T92U@4QC"$1@;1Z#TI%L+)+PW
MBVD"W3#!F$8#D>F[&:X71]3C^RV7B'4!JRZA/++%#;?:%*WA=R%18]Y " #J
M%Q@DD\FMRY\;V-C8ZE<7EG?12:;(B7, B#.H?[KC!P5/KGM0!M-H^EO=F[;3
MK-KDG)F,"E\_[V,U8N+>"[@:"XACFA?AHY%#*WU!KEE\9SW.O:;8V^AZFEO=
M-*K23PK&?E52&4%@=N&!)(]L9!%97AOQ%'HAUJTNTU:[CAUEX1<NK2K&K%54
M,['L<<#.,B@#N%TO3UL?L(L;46G_ #P$*^7US]W&.M,GT72[J.*.XTVSF2($
M1K) K!!Z $<4W7+N*QT&^N9_M/DQP,7-J/WH&.2OH1USVQFL<>,M.MKC2].B
M@U&ZGO;19[4I%O,JX&,L3C.#DDX [D4 =,Z+(C(ZAE88*D9!'I4%KI]E90/!
M:6=O;PN26CBB5%8D8R0!Z56T/6[/Q#HL&JV)D^SS [1(FU@02""/4$&N6N/%
MWV'1IK[2+6_OGEUC[)*ESC=$Q=5957(.,<*/7K[@'7+H^F1VC6J:=:+;.<M"
ML"A&/N,8H?2=.DLTLWT^T:UC.4A:%2BGU"XP.IK*U'QE8:8)_.M[DO;6ZW%U
M&NS= K D;@6&3P>%W=/<54?XAZ1YMQ';VNI7+P0)<N(;1L>4R[@V3@8QZX]L
M\T =!#I.FV\LLL.GVD<LP(E=(5!<$Y() YYI\FG64MJ;66SMWMR<F)HE*$_3
M&*Q=.\:Z9JFI65G;Q7BB^B:6UGDAV1S!0"VTDYXSZ4[Q5K%Y82:5ING*IO=3
MNO(5R1^ZC +.X!X) ' /?UZ4 :TFE:=-:PVLEA;/;PL'BB,2E$(Z$#&!BDET
MC39[^.^ET^UDO(R"D[0J74@8&&QFLKS[*;Q7+HYN-3%R--Y3S66(Q[@-X;.?
M,RV-P.>#SD5)X9U5KS^T=.GEDEN],N6MY'D7!=/O1L<<$E2,].0>.10!?N-$
MTJ\N3<W.F6<TY&TR20*S$8Q@DCGBK8AB$'D")!#MV>7M&W;TQCTJ2B@#,/AW
M13:S6O\ 9%B+>;'FQ"W0*^#D9 '.#S38_#6AQ26\B:19*]L"L!$"_NP<Y"\<
M=36K10!D)X6T"-$1-%L%5 X4+;J,!QANW<<&K,&CZ;:Z<VG0:?;1V39S;K$H
MC.>N5Z5>HH IZ?I=AI-N;?3K*WM(2VXI!&$!/K@5/<6L%W&L=Q#'*BNL@5U!
M 93D'GN" :EHH I:EI&G:Q"D6I6%O=QHVY5GC#A3ZC-5Y_#6B7*0I-I-E(L,
M7DQ!H5(2/^Z..![5JT4 49-&TV:[6[DL+=KE8_*64QC>$_N@]<>U5E\+:"L$
M4"Z/9"*%_,C00KM1N/F ['@5KT4 <SK?A6&YLW32K33H9)YTDNUFA^6Y0')1
MBO/) YYZ8Q5?PMX4?1=1>\-AIFG[H6C,-@\CB0E@=S%@.FWC _B-==10!0U+
M1=,UA8UU+3[:\$9)03Q!]N>N,]*Y36?!$,FO:!)INBZ:-+LWF:YA&(SEPH#
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MC,A?!920",CK_=%>D44 <&^@>(;+Q'JU[:6.DWL&J^6Y^TR$&UD"A3_ =Z\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !11FB@ HHHH **** "BBB@ HHS10 4444 %%%% !1110 4444 %%%% !11F
MC- !1110 4444 %%%% !1110 449HH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BC-% !111TH **0-GM2T %%%&>: "BFEP,9
MSS[4;U'4XH =10.110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M#<?QO8)%N-CJ8E$;S/;O;&.2.-3C>RN1@'!QW.#QP:?_ ,)MI4BQ-9I=7J/
MER[6T6[RHV) 9AD'J#T!Q@YK,UW1M2@\6_VW:Z/::U;3VR6\EM,R))"RLQ#H
MS@C'S'(Z\]ZS]7\-:O</ UMIJ6>J16Z1VVIZ9.L21,6)9)$)!:,<?PDGG@4
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MI=N<%!U#MP.2 ,DY[5TOP^L[W3?!=CIVH6DEK=6H:*1'*G/).05)!&#_ #H
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M0+^;Q%HL5Q8:V[B&\ DEDM0LC(I!:)U( 5CG!8?45U% !1110 4444 %%%%
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M[D G&.1Q@<5!:>$;*RFMQ%<W7V*UF:>"P++Y,;G)R!MR0"20"2 >F,"N@HH
MRY?#VF3:M/JCVJ&[GMOLLC[1S'S[=><?0 =JKOX6L3X?LM&BDGMX;(QM#+"P
M6163HV<8)SR>.<UN44 84?A:"*U,27]^DLEZ+V>XCE$<D[_W7*@#;@ 8 ' %
M;M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M;:C=J-:P)]H3Y %V83*\94 '.:K:AX#M=4DN);Z^GN9)M/%C^\1 JJ&W*^%
M^8-SUH Z:S%R+6/[8T+7&/G,*D)GVR2:GJIIEG+86,=M->SWK(,>=/MWL/?:
M #]<5;H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MUU(.1FO&WL)T^$>NZ%Y7_$S_ +4\CR%P6=VF1EQCKE2#]!7L,*E((U/55 -
M#Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MF7:1M+#<.2,'CTIL>I6LNI2Z>DH-U#&))(\'Y5/ .>G.#^5 %NBBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KF_%D
MT\YLM'MK::X^UR%[I(2H;[.F"XRS*/F)1>O1C7251CTBTCU634U67[7(-K.9
MG(VXQMVYP!WQCJ2>IH XSP8TUIJ&O>$;I+JSC7==6*LRK(L$I.[:R$CY6/!!
MX)]JP].L[A_!?@8KJM^C76HQ[BL@^4;)#@#'JO?/)->BW'AC3+GQ%#KTD<W]
MHPH(TD6=U 49^7:#@CD\8[U6/@?P^=*?3/L;_9&F$ZIY[YC8'(V'.5 R>!@<
MGUH PKR76O[3\6(NOW*0Z=;QW-NB)%E28W;:3MZ97IU/'/KTNCBXU"TTG5YK
MR8-)8(9+=<")W<*Q<C&<CG'/>JY\%:,9[^?9=B2_C\JX(O)0&3C"XW<  8&.
M@R.AJS8^&=,T^ZM+F!)_-M+<VT+23N^V,G.WDG/;Z8'I0!G>-],CUFVTO39E
M1H;F\:-MPS@FWFP1]#@_A7%)>W^K^"KKP_>QKYNA6URFI;LD-Y<3"#![Y.&_
M[9^]>G:CHUKJ=Q:3W)N-]I)YL7ESO& W3)"D \9'/8GUJ.[\/:9>0ZC');;/
M[1"B[>)VC:4 8 +*0>G'T)]: .9M+M['PCX0LH;F6.:>"(BVM8P9;A5B!95+
M'"@9!+$].F"164NL>(;GP]X7D.KSVUW>:I+8W&8XFRH>5<G"\L @&0<=^:ZY
M?!6B+9V-J(;CR[!R]JWVJ3?%D8*AMV0I 'RYQ3%\#:$@M0L-PHM+A[F +=2
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MG7O"-KJ,UQ?P:A#)Y26!F54E1V(5B^U0NP$YS[@5I>&I?%0U6YAUQ(Q9&(-
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MO$B@-G&2<'O6#IUWKL>E>'=5GUN[N9+G5/LDT9$:QF(R.,E=N2?E'(/&?04
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M@D&4EB<,K?0C@UR7Q5_Y)IK/^[%_Z-2NJBD6WTR.1AA(X0Q '8+0!9HK@_\
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MB-P%D1L9#C'(R >W(%:E% '+_P#"$61T:WTQ]0U!X[>\-[%(70.LI8MG(0#
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MX8IX8"DLZL /WSDG?@ 8QCFNOHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/"A<YXXR<0QI=V_@R'[/HNI)<6VO_:7A6U?S'C\]I-PX!8;"!GCIBO4L48H
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M*V@C@@C2*&-0J(BX50.@ '05R'@F?[-;>)'FBN(U&KW5R-T#@M&QRK*"/FR
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *@O
M'GCLYGM8A-<*A,<9;:&;' )[5/10!Q]G?^+K37].LM6?1)H;O>76T257C55R
M6^8D$9P.G\5=A7/:=;/=>+]6U602!(8TL+?((!4?.Y [_,P&?]FM;3M0CU*U
M^T10W$2[V3;/$8V^4XS@]O0T 6Z*** "BBB@ KD/%OB#6_#6AZCJWD6+10RH
MENAW,SAF5=S'(QR3P,].M=?7%?%6&>Z\!W=M;6UQ<3/)$52"%I#A7#$G:#@
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M_C6R>-)L?V"+<NT#J/,WJVW)&,XS6;<:BL7@WP?;FTOC<6%Y:+<1?9) R&)
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M4/% M3X5U47OE_9S:R!_,Z?=./UQ7"VK^&KV_P#!BWL]E*'TB0.K2@JS(L6
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M.-J[1QQW/YUT:9V+DDG')/6O-/ >JZ=:>*/&K7%_:PK)J99#),JAAE^1D\T
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M),?-MXZMQTY%3^$+71KN*QU";Q'(FJ?,M_ H6.61]I\Q93]\J/F.XG QD$4
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/'/KG/M0!VU%8>G^(TU.]L(;2V:2*YL5O7F#C;$K<(I]22&_[Y-;E !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ",
MJL,, 1UP12T44 )@ DX&3U-+110 A 88(!'O49MH&(+01DC."4'&>M2T4 1Q
MP10@B*)$!ZA5 S6/J.@F_N)I!JE]#YBA=D3KM&/8BMRC SF@# 70+A8_+&O:
MCMQC!"=/^^:3_A'9C%Y7]N7_ )>,;-L>,?3;6_M7^Z/RHVCT'Y4 8*Z!<(H5
M=?U$*.  $ '_ ([3%\-2K*9$UN^5SU8+'D_CMKH=H]!^5&T>@H YY?#4J;MF
MMWR[_O82/YOK\O--_P"$:D*JO]LW953D*8HL#_QVNCP/04M &%_8U\/^9@OQ
M_P  C/\ [+3$T*\B7;%K]XBYSA8HQS_WS6_@>@HP/2@# _L&\VLO]O7>USEA
MY,6&/O\ +4^F:1<:=*6;4Y9XV_Y9F)$&?7@"MG ]*,#TH 1D5U*LH92,$$9!
MJ/[/ (O*\F/R_P"YM&/RJ6B@!D<4<*[8HU1<YPHP*5D1R"RJ2,X)'2G44 0?
M8K7;M^S0[<YQY8Q3Q;PAU<0Q[U&%;:,@>U244 %4IM(TRXV^?IUI+MZ;X5;'
MYBKM% $3VMO)"(9((GB'1&0%?RI'L[:1(D>WB982&B!0$(1T*^F/:IJ* *AT
MO3V>)S86I>%MT;&%<H<YR..#GFI+>RM;,R&VMH8?,.Y_+0+N/J<=34]% %>>
MPL[J:.6XM()I(CF-Y(PQ3OP3TI+K3K&^9&N[.WN"GW#+$K[?ID<59HH XJ;P
M*T\MY'-)I=S;W<TDS2W6FB2XC+$\!RV#C. 2O  XKI[#1M/TU8S;6D*RI&(S
M,(U$C  #E@,GH*O44 5H]/LH;I[J*T@2X?.^98P';/J<9-(=,L&N)+@V5L9I
M5*R2&)=S@C!!.,D8JU10!1.B:48XXSIED4C)*+Y"X4GJ0,<=!^52)IMA&\SI
M96ZM.")F6)09 >N[CG\:M44 9\.A:1;V1LH=+LH[4MO,"P*$W>NW&,U*NEZ>
MD[3K86JS."K2"%0S C!!..F*MT4 16]K;VD(AMH(X8AT2- JC\!5:;1],N+\
M7TVG6LEXJ[1.\*EP,8QNQG&":O44 4;'1],TQLV&G6MJ2-N8853CTX'2I;ZP
ML]2MC;7UK!=0$@F.:,.I(Z<'BK-% %%-&TR.\2\33K5;J-!&DPA4.J 8V@XR
M!CC%0P^&]"MX;B&'1M/CCN !,B6R 2 '.& '/XUJ44 41HVF+I@TS[!;&P&<
M6S1@QC))^Z>.I-1)X=T:/3!IJZ7:?8@P80&%2FX=#@]_>M.B@#%GTRXTK23;
M^%[;3K>8R;RMRK>6V>"25YW<#GGIBK6B:4FCZ5'9J_F,&>223&-[NQ9CCMEF
M/':M"B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#'U;1IM1U32KZ&]%N
M;"5Y"ABWB7<NT@\C'&?SK.N_"=V/$EQK&D:S)IS7JHE[%Y*RB7:,*R[ONL!Q
MG!'M74T4 <TGA:X@U&_NK?4P%N;*.S5)8"Y0(" Q;?EC\S9Z9R/3FI_PA,[S
M^'))]427^Q(WB53:X$R,H0@_-Q\H ^O/M7844 <9!X#*:3;Z%<:D9]$MKA9X
MH6BQ+@-N$9DS@KG_ &0<<9K4U/PK:ZIXETS6I9'22R5@43@2\ADW'T5AD#U-
M;]% ')7_ (1U#_A)+G6M$UZ33I;U56\C>!9D?:H52H.-I 'O45QX*O8;R[ET
MC6VMH[ZU2WO$N(?/,A5=@D#;@0^/PKLJ* ,O1-,N=(\.VNFO>+<3VT B28Q;
M5X&%^4'H!COS7+P^ M1BT/1]._MBV+:9J1OTD^QG#_,S;2"_J[<_3TS7>44
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M/3"D''J3S72V<=Q%90QW<RSW"H!+*J; [8Y(7M]*GHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBD9@H)8@ =2: %HH!R,CI29&2,\B@!:*
M01D<BB@ HHHH **** "BBB@ HHHH ***0D @$C)Z#UH 6BBD+J&"EAN/09Y-
M "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MM8[.\M]0N7N+:YDG*-'O<,RNN.<<X(/_ -8 [34[^32M N;]8'N7M[<R^6"
M6P,]R/K_ (U0LO$OFZ/I<]Q:3?;[^$2):1;2[_*"S#YL!>>K,.H'4XJ_J5K<
MZAX=O+0B-;JXM'BP&)0.R$=<9QD]<?A7-0Z3KNG-X?U*&U266QL&L;RR$PRR
M84[HV.!NS&O!QG(&10!T6E:S:ZY8"[MC*@1RDL,R[)(G'!5U[$5P=YJ\LWBS
M4],UO5;O2)F?&CNLFR)DP?F!QAF/<'VKL?#^D2Z;)J=Y=8274;MKEHMP/E#:
M% SW.%R?K7):O=W.I6VKZ=J=CINI02S2?8Y%O8D,:_P[LG((]O2@#I[KQ%;Z
M-;VUG>SM<:@8062$C>P'!?!(P,@U"/&^E36,=W9BYO$: W+) F65 2"Q&>.0
M1CVKCY])DT[4-*U1)=+UZ2+34L;RWN[I-S%26#HS\=3SFK<4FH:-K"ZM9KI5
MS#=6B0SZ;#=QQBW922I0G"XPW(]: .@L?&*W_B.UL;2VFDLY[+[4MQM(!R0!
MU/0 G/OBF:5XATVRTB\O%O[RX0ZE);A9UW2>;N \M%&"1Z52M[N>W\2:;?3O
M8S1M8M;7'D7<:K =VX<$C(X"\=SFN?AT^Y2&*^#6:WVFZS-?00&\BQ=12'D9
M#85L=,X]\4 =O<>.-+LK"_N[L7,#63()X)$_>)N.%./0U:T_Q-::AK$NFQQW
M,5Q' MQB:/:'C;@%?QK@?$NGSZS!K=] ]J+F\A@MH;=KN($JC[V=OFV@D\
MFM^TO=WCA=0N%MH[.33HX6E-Y$3'(#N*X#9//'''% $^M7TU[XTL_#\MW-9V
M\MD\Z/$0#+(&Q@$^@YJ[X)U6YU70BUY(99X+F:V:7IYGEN5W8_*H/%,VG:I#
M!%$NG74X8F*>:Y14MCV8\[C]!U[TFD267AO3-+TVQN;.XB5\7,IND4KGEGQG
MDECT]* '"[O5^*/V$WSM:/IIF6$KPIW@9!KIKN^M]/LI;R[E6*")=SNQZ?\
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MB@ HHHH **** "BBB@ HHHH ,56_L^S^W?;?LD'VO;M\_P L>9CTW=<59HH
M**** "BBB@ HHHH **** $8;ACUK/70].W,S6-LQ8YYA7_"M&B@#/_L32_\
MH'6G_?E?\*/[$TO_ *!UI_WY7_"M"B@#/_L+2O\ H'6O_?E?\*/["TK_ *!U
MK_WY7_"M"B@#/_L+2O\ H'6O_?E?\*/["TK_ *!UK_WY7_"M"B@#/_L+2O\
MH'6G_?E?\*/["TG_ *!EF/I"O^%:%% &:V@:4S*?[/M>/^F*_P"%7XXQ$@10
MH4< *, "GT4 %%%% !1110 4444 %%%% !1110 4444 8=SX.T"[O#=RZ;&)
MF=I',;,@D8]2X4@,?J#6S##';P1PPQK'%&H1$48"J!@ #TI]% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
D% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>pinnaclelocrenewal4thloa004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pinnaclelocrenewal4thloa004.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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MAJ>J[_\ '[%_NFK% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 5V_X_8O]TU8JNW_'[%_NM5B@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** *[?\ '[%_NM5BJ[_\?L7^Z:L4 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110!7?\ X_8O]TU8JLQS?H/1#5F@ HHHH *2
MEI* %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"L?^0@O^Y5FJQ_Y""_[E
M6: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH JK_P ?X_ZY
M'_T*K555_P"/\?\ 7(_^A5:H **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@"FI_XF17TB_\ 9JN537_D*-_UR'_H57* "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH I+_R%&_ZY#_T*KM4E_P"0HW_7(?\
MH57: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH I(,ZH_M$
M!^N:NU3C_P"0K+_US%7* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH IQ?\A27_ *YBKE48?^0E/_N)5Z@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MR.K;]LLF5+$ #Y02HJ33_!%]!XUOO%UU>6S7\T12*UB1A$IV*H)8\GA>>.]
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M<6QA@G@B96<] TASQP,?+ZD]J )H_&+1QZRM]I<L-UI5NMS-!%,LF8V4MPW
MR IR/RS5NV\2K-J=M9S6%Q;K=6S7-O*Y!#JNW<" <J?F'!_2N?M_!>J1_P!O
M8;2K=-3L!9I#;HX6,A67=S_O$^_ZUK-HFKMJ.CW0ELT-A8RV[$%CF1PHW 8Z
M QK^9].0#0T/7?[:@BG6SDBAGA6>*4,&1D;H"1T?U7''J:KWNKW\7C&PTB*R
MWVD]K+,\PD P59!TZ@#</J6'H:K^'/#]WIFKWM]-#96:7,2*]M92,T<DH)+2
MD%5"D@@8 /3K5F\T:];QA8ZW:2PF-+5[2XBE)'R%E?<F!][*XY[4 86B^(5T
MFRF#6EU-8_VS-:_:GDW"/=,57[Q+, 2 3_.M"_\ 'NG6=[=V\:"X^QSI!.L<
MR>:"Q )6/.Y@N1D_7&<&HKGPQJ<OAM]*66TW#4C>1R%F V>>9L$8ZY.W]:+?
M0/$6E:M>#2KW3QI=_=-=3><C&:!WQOV?PMG&1NZ4 =#K U,Z:_\ 9'V?[:&0
MH+@D(P##<"0"1D9K(OM4UC0H]1U74;2"XL(X(W2.T<^:K ?.#N(4KG)!'/L:
MZ:N=\=R"/P1JS%T3]P0"YP,Y&* &KXNV:G)97NCWUI(;9[JW\S83<*GW@,-@
M,.."1U%9Z^+I-5T:TO)O#EZFG7CVRQS?:8URSR!1D!MP&XKVY!.0!5^71[[5
M;I=2NGL_-BL98+587+1EI<;G)*Y PJ@ 9[U63PUJ</@?3=$BEM/M=E);L)69
MMA$4BN#C&>=H&/?K0!>O_$TUMJ%]8VNBWEY/9PQSML9%5D;=R"3U^5N,9)'I
MS19>*XKV]LHQ8W,-G?6YGMKN4J%D  8_+G<O!SD@4@TK4X]:UC4(EL@;ZUBA
MB!=OE:/?@M\O.?,_)1^%>T\-WT</AR">:V,.F6CVUP%W9DS&$!4]NF3GUH 6
MT\>:1?WME!:2+.EW(8U:*5'9#S@NH)*J<<$X/J!6KKFLKH=G%<-:7%T))XX
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M=1:6#59DB+7!<&&.3;L93P<@'GKSG-=T>E<[X1T[4-*L+V"_@C1GO9KB+RY
MV4D<L ?<9H Y[PQXJM([SQ#;:[XEACECU.>UMHKB=(S'$A(!' YZ\G/05C6V
MNZM'\'+_ %U]9N6O6NR8+EB,[?-5 ,8P!C=Q[UUW@_2]3T5_$+7MD1]LU*6^
MA\N5&W*^/EZC##'? ]ZYQ?"&N+\)W\,FQC:_%P2"9UV%?,\S<#G\,$=3Z<T
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M?-2R:_ID5R;=[K#B86Y;8VP2'&$+XVAN1QGJ0*R((3:?$J_>4[5U#3XO(/\
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MKMM"@BMM'@CAT\V$7S%;8MDH"Q(SZ$YR1V)Q0!HT444 %%%% !1110 4444
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M5_WGEI!EXU:,)SYI.XDLV,9X)QBK&I3SRV_C^*6]:6*&TV16[$?N@;8L2/\
M>+'_ +YH ["QO(]0T^VO80PBN(EE0,,'# $9]^:A75H&UQ]("3"X2#SRQC(0
MKG'#=SSVKAGU*YBT33;>QNIS-!X?6X,43>6L!" K*[?Q9V[0N#WS5J..Y\1:
MOI4L>JW-I]IT)9I)K955WW,IX)!V\G/ ]N* .PNM4@M-0LK*193+>,RQ%4)7
M*J6.3VX!_*KM<#HU_>:C_P (M-?3K<3)?7D/GJN!*J)*JOZ<@ \4S1M6\1Z]
M#!JD-YI]O;?VGLF5K@Y6(/L,/EF/ASQ@[N2>P(  /0:*SM<EO(=$NWT]HUO
MG[GS& !;/ RW )Z#/&2*XB#Q1J!4V8EOH+F75(+*X2["&2R5U))5E&UMVW@G
MNW?&* /1988KB%X9HTDB=2KHZ@JP/4$'J*;;V\-K!'!;PQPPQC:D<:A54>@
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M[_F9W;O]K.:V&8*I9B !R2>U9=KXDT>\N6MX+Y&E6(S8(*YC'5@2,%>>HXH
ML:;I5EI,#164/EJ[;W9G9V=O5F8DL?<FN:N/#MW>?$6?49XKA-/:P2!9H;K8
M=P8DJ0"#@@_3O70V&O:9J;RK9WB2F)0[\$84YPPSU4X."..*SM3\3V;:3JIT
MJ_MVU"TM)+A8V4DX49W;>,KVR./K0!?&@Z:EU97$<#1/91F*W6*5T1$.,C8I
M"D' ZCL/2HKGPSIEU<W$SQ2K]JQ]IC29UCGP,#>H.#QQ[C@Y'%1:!XET[5X;
M:V34+>;43:QS311L,C(&3Q[G\*W: *5WI5C?6D5K<VL;P1.DD<>,!60@KC'I
M@<?A3;K1[*\U.SU&>-VNK/=Y#"5U";A@_*#@Y''(--U+7M+T<J-0O8K?(!^<
M] 3@$^@SQD\4EUX@TFRO8;.YU"".XF"E$9^3DX7Z9/3/6@#)N? &@7,<L+Q7
M2VTL_P!H:WCNI%B\S.20H.!D^GX8K1G\-Z;<+J(:.8-J,2PW+"=\N@!  R>.
M"1QCK3(=1NF\97>ENT9M4L8KF/"$,"SNI!.>?N9Z#K5B/Q!H\T\D$>IVK21Q
MF5E$HX0'!;Z \9H IW/AJ#S;*]ADG>^TV!X[(S3-M!*X^;'WLX )//%<QX=\
M.:K:16B+_;MG/'=*\YN=022#:,%E5%)RK<@# (SG/'/9VVOZ1>W4=K:ZE:S7
M$B>8D<<H+,N,Y ^E9NJ>)[2WU6PL;75++SGO%MYX#\\ASV&#P0>N0>O:@#9U
M+3;75K"6QO8S);RXW*'93P01RI!'(!XK/F\*Z5<V5Y;3Q2R&\\OSYFE8R/L(
M*'=G(P0,8JV-<THZC_9PU"V-YNV>3Y@W;L9QCUQSBB+7M)GO5LHM2M)+IG:,
M0I*I8LHRPQGJ!S0!23PAHJSW<SVTD[WD M[CSYWD\Q <\[B<GWZCMBHH/!.B
MVVF7&GQQW/DSPFW8M<R,RQ'JBDD[5X P.M=%61/XIT"VFDAGUFQCECD\IT:=
M05?T(SP: %@\.V4%[878>X:6P@:W@W3$@(<9R.YX'7T'I4FMZ%8>(;#['J,)
MDB#K(A5BK(PZ%6'(-36VK:=>WEQ9VM[;S7-L0)HHY S1_4#I38-:TRZNVM;>
M_MI9U4L8TD!.!U/T&: .;T_PXL7B76H)[.[ETR\L(K=I[F?S#,07W#)8M]UP
M!TZ&M.V\(Z9;7<-UNO)I8H7@!GNI) 8V&"I!/(J\FOZ1(\$::G:,]PY2%1,I
M+L"1@#//*D?A6)J7C6TETC76T.XAN+_3 %*MRN\XP>#R,DCZ@T :MIX;T^R>
MR*"9TL5*VB2R%U@!&/ESZ#@9S@<"J#^!=%?3UL=MV($NQ>1 73CRI06.4Y^7
MEB?QK9LM4L[V::UANX);NVP+F*-P3&Q[$=NAJ[0!R_\ P@>DBVU"!)]01;V=
M+EF%TQ:*9>1(C')#9 .3GH/2K4GA6SFUF?4I[F\F\^S^Q2V\D@,3Q<\$8R3D
ML<D]S4\OBG081<F75[-!:N(Y]TP'EL<X!]#P?R-1>(==73] U"YL+BV>]@LS
M=1QN=V4[-@$'!P>: (;+PC:V,4,:7U](+6)X;,R.A-HK#!*?+R0. 6W8'XU%
M#X)M8++2+1-3U+RM*F,UOEHR2>@#?)R "P'^\?;&M'JMFYNK9-0M7N[- ;@;
M@!&2."PSP/QK-N==N+?5/#5GOMY5U/S/-FB0[6VQ;P4R> ?QXH ETGPK;Z5/
M;2B_O[I;5&CMH[F166%6Z@84$\8'). *M:[H-IX@LXK>ZDN(C#,)X9K>39)%
M( 0&4^O)JT=2L5O/L9O+<77_ #Q,J[_7[N<U:H Y@>![%/->'4-4BGDN8[KS
M_M.]UD1"F07!ZJ2"#G/3H *UM(T:UT:&=+?S'>XF:XGED(+2R-C+'  '0<
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MPOOW]-N#G/M5FB@#R1C;7GA7PRT%SIUQ=6^DDFQU!5,,RA5$@#'[D@(Z^W/
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MB?4M2@O->M;?4&ABCT)[R(1A0\4BEAD'&<$+_/&*W9O#>GW.GWMG<B6<7O\
MKY9'S(V/NX;MM[ < \]2<Q0>$M,AN?M+FZGN&M3:/)-<NQDC.<[N>3R>O3MB
M@#GX;[5=)\->&G-Y=S6DEL&O)XH%DFC4QKL.P*244GD@$]/6DL;FYO?'7A^7
M^UWNH9-$:8M&BK'(VY S!<9&[KCJ.G%;T7A&Q@AM%@NK^*:TA,$5PMR2XC.,
MJ<Y!'RKVXP,4]/".DQ7&GS00R0&QB:&-8I2H9&.2K@?>!/)SU/7- &+8:YJ4
M_B'2]MX;JRO7N8VD2)1;?*&9!&>'8C;@G[IR<'BLZ/Q!X@6WL;R;4XW5_$']
MF-$MLJAX_-922>3G  &,?B>:Z73_  1HNF2V<MNEUOLBYMMUW(5B#$D@+NVX
MYQTY[YIX\':2;$V<JW$L/VL7JAIV!6;J7!4@C))..F3Q@8% '+^(+^]\0>#=
M;OUNOL\$%T;=+5 K;ECE"L9"1D,<9 !&!CKS6]=:MJ%IJWB.)KV(P6FFQW=N
M/)!\DGS<AN<M_JP>W!'XS77@;1+R>[DDCN4CO&\RY@BNI(XYGR#O95(^;C\>
M^:N/X9TV2YGG9)]]Q;?99_\ 2'(EC ( ;)Y(#'GKSUH P="U36I%\,W-WJ'V
MI-5LRTL/DH@5Q&'!! SZ@\XYSQTJII_B/7M2711%(([RXOIX]0M#"&^S1HS?
M0C "C)/):NC/ABSM$LI+(7 DTR(I90FY?8O!&#DG.00N3G '&*YK1_#6K6ZV
M)0:Y97 E62X#ZA$UL,OND 1220<M@8'7K0!Z'7'V<-^_CWQ'.]_*;-+6W1+<
MJNW)5SUZC!R??=[5N:)IDVF+?"6YEE6XNY)XUDE,GE*<?*">V06QVW8YQDLN
M/#MK/JESJ"W-Y#-<V_D2B&8JK  @-C^\ QP: .2\/:GJFDV/@Y+F[CELK[3R
MIMXX0OEK' )$;<3DMA<'H.> ,<S^']=\3Z^-,U>VMC_9UU)^^BE,01(\D%D(
M._<".^0<G@<5NP^$;. Z/MN[TKI(*VJF1< $;2#\N2-OR_2EL/"&F:;>>=;M
M<B$2&9+,S$P1N3G<J= <Y/MGZ4 :U_>+86$]VX+")"VT=6/8#W)X_&O-=&N7
MTOQMI6H-:7MJ=>22/44N;=T6.X),D8#,,-U*#'8 UZ%K&CPZW:);7$]Q%&LJ
MRGR)-I8J<@'CD9P<>PJ+7_#UIXCL8[.\EN$BCD64&"3:VY>AS@]* .4)O3\9
MKZ2TAMYGCT=$ GE:,*IDSP0K=_:J=E,7\(_$*.XMEMM0#7<ES#&=T:EH?E*M
MWR!DD@')/ KJCX/M_P"UY-574]22]DA6!Y5E0$HO0?=_&E_X0W35T6[TQ)+M
M$O69KN<2YFGR"#O8CD8.,4 <S8?:-7\3>&[75H(['^SK07=F8W,@O,HJL Q"
M[2O!(P3SZ5W]_.;;3[F=9(8FCB9@\[8C4@<%CV'K65<>$[&ZTBQT^>:[<V+B
M2VNO-Q-&1TPP [''(Y &<GFM&]TN#4M(FTR\+S031>5(2V&88P3D8YH Y'3-
M:UYWU.W2X-[.NEI=6C7-NL :4EQP!@["5&-V#_.M7PEJUQJANQ<W,[2PK$LE
MM=6PAF@?!W9P &4D9!'OZ4U/ FE)YC&?4)))+-K&222Z9F:(] <]QVQTK7TW
M1X=-DFF6:XGN)PJR33ON9@N=HX &!D]N] %:XO+Q?%UM8)+$+:73YY@ICR1(
MDD0!)SR,.>!CZ],<QINM^));'PYJEUJ%JT-]>?9I;:.VV[E;?@[B2<C;VP*Z
MNXT%)]?AUC[?>QSQ0M L:,OE[&QD8*GN%/7JH[<53M?!UC:Z9I.GK=7K0Z9<
M?:8BTB[G?<6^<A>1\Q&!C@T 6/%.KS:-H;3VRAKF66.WAW$85G8*"<D#C.>3
MVKGKA?%!\)>)8]7EVH+-GMYW2+>1L;>I5#CL,'K\WM74Z[H=EXBT>?3+]6,$
MH'*'#(1R&4]B#68G@V!='N["35M5G>ZC\E[R>97F$?=%)7 4\YXSSUZ8 .>\
M1VNJ+9>$HO[7Q))J4*B1;91M_=L5..AQ@_7/M5B[UCQ-J&K:E%X?6-TTV46Y
M1UBQ+)M#,7RP8 [L#:.QZ]*W;SPG'>QZ.DNJZCC2I$EB(,69'48#/E.3@D<8
M'-1ZIX*L-2U634$N]0L9IT"72V4_EK<J. )!@YXR,C!P: *4=]XCUJ*]N-,N
M+"WFL;K[.;-TW"1D WJ[]5SDXP/3UH\/-J$_C[Q09]2EDMK9H88[8HNT H'&
M#U&-S#WSS5F?P)ILNJW%[%=ZC:QW6/M-G;7'EP3X&/F4#/3C@BM*S\/6MAK=
MWJEM+<(]V$$L <>42J[0V,9SC ZXXZ4 5]<U2X75]/T*SF-M<WR2R"ZV!_+6
M/!("G@D[AU]ZYN?Q1KULUO8>?:R7D6M)IDTS0D+,KQ^8KX!^4CH0/PQ78ZGH
MEMJ=Q9W3M)!=V<F^"XAVATSPR\@@JPX((_6LZZ\&65U': WE[');WHOVEC9-
MTT^,;GRI'3C  'Z4 2>&[W4)KO6+#4;B.YDL+I8UG2+R]ZM&L@R,D<;\?A56
MUFOY/B5J4#7I-G#80.MOLXRS.,Y]<KU_#M6O8:-%I^JZGJ"7-Q(^H.CR1R%=
MB%5VC:  1P!G)/05$^@1GQ#)K45[=PW$MN+=XXRGEL!NVD@J3D%CWQ[4 <YX
M6O[ZQTWPK"\ENUA>V@B6/80Z,L1?=NSSG:1C [<T_0/%&N^(8K'4[/3<Z;<W
M#1ON" )$&8;PWF;B00!@H/:M5?"%LD&APIJ%\JZ.VZ#!CR_&WY_DY^4D<8Z^
MN*ATWP19Z9>L\%_?FP\[[0FG-*/(CDW;L@8S@-@@9QGGF@"?QMYO_"(WWDNJ
M-\@RRDC&]<C@BJTU]>67C.PT\P:<\M]:2NUTL!1RT>W /S'Y?FZ9-;.MZ0FM
MZ8]A)=7%O&[*6>#;N.#G'S*1C(':H[G1%N-:MM66\N([FWMW@10$*,&P26!7
M.<A3P1T^M ',6?B#Q2GAT:Y>0V,UL44>5:0R/(/WNUI"N1D!,G:#VZU8CUV]
MU6[T22PU2RDM;C4)HO,@B8K(BP.P#*6R""#QGT-:T/AG[+X?CTFVU:_C\F02
M0W)\LR(0VX#[@4KGL1T.*KV_@R"WBA*ZG?BZCO6OC<J8PS2LFQAMV;0I!/ %
M &IX@U=-!T&[U-XC*+=,A <;B2 !^9%8*'5;?QJLEXUI<S+H\S1K;HT66$D>
M5)9F[XP?TKH=:TFWUW1[K3+HR+#<)M9HVPR]P0?4$ U@?\(,TS%[[Q#JMU(;
M*2Q8L8UW1N,<X7J.#GJ2!DGI0 RP\4ZC>ZW%I(6T\^?3GN4D$4GEI*& V[B<
M2+\P&Y?0^N!+HOBB[U&'3K>>.!-4DN9HKR%$;; (L[^_J4 .<?.*2+PNNB3V
MNLRZGJE[-IMFUNL4<4;&2/CY0BIDG@=#DGOVI_AC35?6-6\0OI<MA)?E%CCG
MP)-H499E!(4L>W7Y1F@#1\0ZTVD0V4<,8>ZO[I+2#<,JK-D[FY'  )P.3C%9
MDFMZB+W6M#NF@6]@L?M=O<Q1LJO&<@Y0L2"&!'WO2M?7M"M]?L8[>>22&2&9
M9X)HL;XI%Y5AFHG\/+)-J%W)<L;^]M_LQGV#$48SA47ZL3SG)/I@4 5/!-K*
MOA71Y[L6CS"RC6%X82I2)E4[223D\ G& <#BJ\'BNXN/$TNE-]EM9$NC"EK<
M*RRS1 9\Y&R%(.>% )P"<]JW]'TXZ3H]IIWGM.+:)8ED90"548&0..F!69+X
M66XU"&XN=0N+A(+TWL*2JI:)N?D5\9"<_=_6@"@WBZ\3PQI^JO:P;[C4ELW0
M$X"><8R1[\9JY%KNI:G'<W.CVMO/!;W9MC'(Y5Y-K!78'H,<X!]/>LZ3X>L]
MG]B_X2'4%M$N_MD$(2+$3[R_4KDC)Z'CVJXG@TVMY=MI^M7]G8WDIFN+./85
M+-]_:Q4LF[V.?3% &+<:O?\ A^]\9:C9VEM);6UW%+-YDA5C^XBR% '7ODD=
M:[[S7DM/-A16=DW(KMM!.. 2 <?7!K O?"27UKKUL][((]8<-(=@S'A57"_@
MHZUN)!*E@(!-B58]@E"C@XP&Q_2@#D;3Q1XAN8- NSIVGI;ZME%3SG+(WELZ
MDMC !"GC!^M6V\63VMG,+N"'[;_:BZ9 L;'8[L%VL<\@?-D]>E6K;PL;6RT.
MU74)'CTB3?&6C7,F$9 &QCHK-T]JKW?@J"]BOUFOI]]Q>B_MY%4!K68  ,GK
MP!P??UH @U/Q9?Z,=:M+BWMKB\L-/&H0NFZ..6/)4@K\Q4@J>YS[4^V\2ZI)
MJ5AI\]M:13:CI[W4#(S.(W4+PXXR/F['_&K-UX3&I0ZDU_>>9>7]F+)YXH@@
M2(%CA5)/)+$DDGMTQ22^#[>?4;*]DNY2UM8-8%0H =&&"?8T 87VG5;SP_X$
MN]\=Q?S74<I9B4# VTI;<>>V<X'/I74>'=7NM5_M..\AACFL;UK4F%]RN JL
M&]OO].V*@M/##6ECHMJM^\BZ3)NA9XQE@(VC"G&/X6//7.*MZ+H:Z-+J4BW#
MR_;[MKMU90 C, "![<#K0!E65]+J/Q#UB"?<+72+>%80?N[Y%+,_UQ@>PSZF
MHQXNOFTZSUI+"&32+JZ6%2DI\U$9]BR$8P<G'R]LCFKD6G2Z=XSO+Q89);35
MX8UE91D12Q@@;NX5E.,] 5]ZAL?"#V5I'I*WJMH<,XGAMO)(D4B3S ADW<J&
MQ_#GCK0!+I.MZOJFL:A;_P!GVL5I8WIMI)&N&+L-BL"J[<?Q \D=:M:_<_9K
MC2-UC;W*27R)OE/S0L0<.@P>>HSD8S3]&T1M(N]5F^U&9;^[-UM*8,9*A2,Y
MY&%'I4FLZ7-J?V$Q7*0&UNDN/FBW[]N>/O#'6@#!-I)J7Q$U:"Y6";3QID$4
MD$H+95VD/ Z#E>?PK4\1:]_80M%(ABCN'*&YN"PAA(' 8@'&X\#.!_(RV^C3
MP>*+O6/M@,=S;QP-;^5C&PL5.[/^TW;O4FKZ7/J30B.ZB2!5=)[>>#S8YU8#
MAAN'3&10!7M-;NKB^%F]G"DC6"W:E;C>I8G&W(7IG^(9R.U4M.\5S:Q%IL%K
M:QPZA>V U QS2%DBB) '('S$D]..^>P,<'@VXT]K%=-UA[:*"S-G+F!7=EW%
MLH2<*02<9##'8U!'X'O+&+29M-UUX=1T^V-GY\EN'2:#=D(R9'3C!![4 .O)
M;V3Q!X9O7TF*'5)8KF.2)YA^[ 4'!D4'*]Q@=ZW/#VM?V[IKW)A$,D<\MO)&
M'W ,CE3@X&0<9Z=ZCBT*=;[2[J747G>R642&2/)F:0#)Z_+TX &*?X=T0Z#9
M7%N;D3^==2W.[R]F-[;B,9/0YH YGQAK#ZMX<\4V=G8V]Q;6$#Q7$LTI4B0)
MN.Q=ISM!!R2.>GK4EWXN?PUH5D\UG ;6/3HI1+-=B,S-MYCC7!+, ,\XZBK%
MYX*NGFUV/3]3CMK'6D;[3!);F0I(R[2Z-N&,]2"#4%YX#O;B.ZA764:*[TZ.
MQE$UL6,>Q2 T7S@(">2#GOSZ &LOB28>*(=/GM8X;"XT]KR"Z:7YG*E=R%<8
M! 8D\GC%:>C7ESJ&D6UY=VPMIIU\SR0V[8I.5!/'.W&??-<OJ=G:ZU+IOAJ2
M6X?4+':UQ<6\+PJL6PJXW'(PX(7:&/7/:NV50JA0  !@ =J ./N?%/\ 9>DW
M]_\ V=:V\@U3[)(QF.S/RKYTC!,\ #/!X YKI-*N[B\LA+<PQ1ON(!AE\Q'7
MLRM@9!'M6+#X=U2"+44&IVS"ZOVNU1[4E-C##1."_P P(^G/Z7_#F@IX>L)[
M:.0,)KA[@JB[8XRW\*+D[5&.GUH RM4\6ZAI[ZX4T:.2#2525Y&N]OFH5+':
M-IP0!T/'O5]]>N;G5+NPTJSAN9+2!))FEN/+ =\E4X5N<#)/&,CKGBC?^%M1
MOH_$<;:E;A=801IFW.8%"[<?>^8XSZ<^W%6;;P_?6.K2ZE:W]NLUW#''>(]N
M2CN@PKJ X*G'!&2#QTH S+#Q=>:WKVA'3XHUTV^M9I9$E8K(&1E5@>#RI)P.
M_J*ZK4KN6RL9)X;9KB08"QAMHY.,D]E'4GG@'@UAP>$GT^ZT6?3[Q$.G120R
M">(OYJR,K.1AAM;*GU STJ]XHT.;Q!I*6<%Y]E9)XYCN3>D@4YV.N1N4]QGL
M* %\/ZZ-=2^(BC0VETUN6BE\Q)!M5@RM@<$,*Y+Q;;63_$[P[]JT];N.6UN/
M-B$(D,F!\N1WQG\*ZO0-&O-)N-2EN;NWG%[.)]L-N8@C;%0@9=N,(,?C^%+5
M?#%[>>,[#Q%:W\,1L[=H5@EA+ABV[)R&'K^E &'HFM"QU3Q,NGVDD%EI]NDJ
M:7<-Y;A@"7=5.=BE=N!T)QTR:ZN;7U@N+!#;.T5W:R7 96^9=BABNWOD-ZU1
MD\)/>WVIW]_>))=7NGMIX6*'9''&<G."26.3ZU!!X<\0?:=,N+C6+/=96TEO
MMBM2!\P #@EL[N![<=.<T +:^*/[9\/W]\=.2:P^RO(ODW09F !W1N,#8^,Y
M'/UIEEXF\B#P_8:9H4[PW^GB>V G7$2JJ?*Q)S@!ER>?8&FVWA"ZCGU&Y=K&
M&XN[![25K9&59Y&_Y:NO0-],GYCS3[#PUJMC<^&G6YM#'I-BUI,,-F4,$&1Z
M8\M3^= #D\;H-'L[FXLU@O;FZEM/LTEPH5'C+!R7Q]T;3R!GD<4T>.H_LL,D
MEEY3RWS62O++LA8A20RR%>5.,#CK]*KQ^$-7CMX9X[ZTAU*TO[B\M7",\9$Q
M8NCC()'S8R/2M&YT76[^Q6/4+K3KPR.QN+5[<K R%0H5>2P((W9.>2>G& !U
MQXHG@-K;G3"FH7%M).MI-<*C,R$ QJ>0S'.>.,?6M^WE::WBE:-HV= Q1^JY
M'0^XKC;GP9J$WAZVT>2>RO(([+R ;E&#PS G$L;C)'! Q_LCGK77:?;/9Z;:
MVLDSSR0PI&TKG+2$  L?<XS0!9HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** ,S33F[O?:3%:=9>E_P#'U??]=OZ9K4H **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *YCQQX@O_#FCV]WI
M\,$TTMW';[)@2#OSTP1W%=/7$_$QXDTC2C,K/&NJV\DBH"244DL>/:@"WJ^O
M:MX9GL[C5!97.ESSI;R301O$\);.&*EF!7..^>:Z)]1LHKM;22\MTN7.%A:5
M0[=^%SFN2\7M_P )=I46@:2&N([V1&N+I5/E01*P8Y;^\<8"CGKTK"U>_!GU
M.=K*^M5AURWD>%+"1S.(Y(P9C)@_*57Y0NWIWS0!Z9'>6TTLD45Q$\D1Q(BN
M"4^H[5)%+'/$LL3K)&PRK*<@CV-<3X@TZ]@\21W&E92+7H#8W+*<&-P"RR_4
M()/Q ]:Z&WU/3;#5;;PW"'29+4/$NP[-B\ ;O7 Z>E $VI:W9Z5>:?:W$BK+
M?2F*+<P4<*23D_@,=22*SM.U]EUC6K75KRTA2WO8[>U)81[@\2NJ\GEOFK,\
M:QNOBGPA>-&QMX+V02.%+!"R +G'J17-:G#:SZ7\1)S LER+@")S'EON*HVG
M']X,./2@#U2XO;6TQ]IN88<\CS) N?SILNHV,&[SKRWCV@%M\JC .<9R>^#C
MZ&O,[U$_M^[77Y-9>SU*UB6S^PJ72:(1_-$=H)#%BQ[?>ZU9BMM)M?$.O[K0
M 6VB01PB2/>Z!4=67OE@"@/?F@#TL$, 000>014,=[:RSF".YA>89S&L@+#'
M7C\16/HKO?>!;1;-R)FL%B1F!7$@3;W'9JY:QMC=^'?!UA'9RQZGI]Y";B/9
MM:$1C$I<XX##!_VMR]: /0#?V:NB&[@#NQ15,@RS#J!SR?:F:EJ5KI.G3W][
M*L5O A=V8@?@/<]A7G).E6'A>^NU@07/_"1^;(0GSN%O WR]\>6 >.,9KLO&
M2"X\#:V$7S-UA*4 &<G8<8H @N?$^SQ+H]M#/:MIM[;3S22D\J8PO\6<8^;G
MCM6_]LMA;"Y^T1?9R,^;O&W'KGI7$WD5EJ7C+PF?)BN+1;&Y8[HPR#(3!Y&!
MR#^5<]YB1:7I+-'>KHT&JWPFEL /W#-*WE,5P?EVL3D#H1[4 >M07$-S$)8)
M4EC;H\;!@?Q%1-J-DKE&O+<.)/**F5<[\ [>O7!''O6+X/M-/MM/NY=-:^D@
MGNGD,MYD&5L#+J"!\I/L,XKC]<M;(:3X[NDLX9+J.^C>,B,%ON1=#C^]OY'?
M- 'I=Q?6EHR+<W4,)?[HDD"[OIGK2-J-DLDL;7EN'A7=(IE7*#U(SP.17FFI
MBRO=>UFVU]M7\J]59K,V:;X[B#8N(U(4G<&#'&?XL\<DS^++"*\OO[3TVV!3
M3(HX]6C+%6N8-RN8>GS$!>>?]GG.* .W7Q+I3Z_%HJ74;WDMN;A0K@@KD8'7
MJ0<X] 36F\T41022(A<[5#,!N/H*Y"SO+$^/8KJ)<6U_I,*6L@B(5F620LO3
M@A67@XJ;QVVFQ6NCRZBL)0:I H,B;L9))'TP#GV% '1KJ-B]L;A;RW, .#*)
M5V@^F<XH.HV*P-.;RW$*MM,AE7:#Z9SUKRKQ-IMH='\8W=C:Q_V?=M8K;^6G
MRR2HW[PH/H1DCT/H:V/$=C8:3XBT9Q%<6&B-!*BRZ9&%2&9BOS. I'S*,9Z\
M>E '?O>6T=N+B2XB6$C(D9P%(]<]*)+RVBMQ<27$20$ B1G 4@].>E>:6C6'
MA[6])FFM;Y_#<EG)#9RW$>_RIFE+,[+C*[E P<=.PYHN)=+TO4O#DA^VV?AI
M;65;69XMPBE,F<OYBL5!7H3@@'L,T >FR75O%!Y\D\:0\?O&<!>>G-8>B:QJ
M.K:3#<,ME'.+V6WG&YMK)'(R$IWR=H(S7(Z<=-TGQ'I*W'G#P\UG*=.FO?NB
M8R$L3G@;E(VY X/')HTG^ST\.:2T421Q0>()#"7C*^7&TLA&W(X&W% 'I4EU
M;PD"6>-"6"#<X&6/0?4^E$UU;V^SSYXXMYVIO<+N/H,]37FFIZ=HES_PL&Y^
MR0M>*A\EV3^+[.N"G^UYH;D<DTSQ%KMA8^(I(+F]M;P7FE+!MO)?+2 '/SAM
MI#;LY.T#&P=>, 'J8((R.17,Z?K>KZK<ZW#:P6*/IUX;:-96?$@P&R2/N\$=
MC5[PK;65EX6TZUT^YAN;:*%4$\)!61APS#'JV37%Z3::1?:KXLDOM2N;4/?G
M8T-]) "FQ1N 5@&YR,D'I0!VOAW7HM?T:"^V""1V>-XM^[#JQ5@#QN&1UK3:
M>)(GE:5%C3.YBP 7'7)[5Y;H]Y+I>@>&;[6X'ALK/4Y4BE:VVE83%(D;NH'&
M6(YQWS3HY=,O;'5X8[]K=G\0&YM9S"1"&,893(&P#'E'!]P#Z4 >D2SSS?9)
M+&2U>!Y/WKNQ.8\'[F."<XZ\8S5KS$_O+UV]>_I7F]I?6[1^$I;B*RM9(=7N
M(3)!Q#(3'+EXB?X'8@\<9('I63KL6FP^%O$^I1"'[;'K:M;R!QN3][$<Q\X4
MD!N1C.#GI0!Z\TB(0&=5)Z G&:3S8_,\O>N_^[GG\J\JU>;3;SQ+KMCXCU"\
MMFN/*^P""!'::#"E1$VQCG?D_*1SSUJ6UEMT\9+Y<T5]#-JQ5[:Z^6]M)U7&
M]2#\T6%[]C0!ZB)$9R@=2PZ@'D5SWBS7=1T0Z4FG6EM<R7]XMIB>0H%9@2&X
M!X^4Y_3-<QX,NHF\3PBWDL;^VNK>>>&ZC.+N+<ZLZ7 !/<@ ^U:WC^]M;2\\
M*FXGCB UF)R7; "A'!)]LD<^] %O_A)=2TG5+*S\16-M#%?.8H+NSF9XUD[(
M^Y5VD\X/.:Z?S$W[-Z[_ .[GFN(\62P>*Y-)T?2+B*Z<7T=U<30N'2"*/DEB
M.,DD #O^%<_::M8#7['4HYK>S637)EE2Y -UDQNOSL3^[7/"ICIMYXQ0!ZL)
M8V4LKJ0O4@]*SK/59)M9O=,N8!%+"JS1,K[EEB8D ]L$$$$?3DUQLVCG2_$5
MYX9LK-1IFOL+IM@XA1<"X!],C8!VR_M6Y<*!\3M/$:XV:3-OVCHOF)MS^38_
M&@#J2P52S$ #J36+<ZU/!XPL=&%LA@N;66<S[CN!0@8QCI\PYSW_ #Q?':QS
MWFDVZ7VGI=YD>*QU*/=;W@ 4,K'H",\=^>*R[*WT_7M;\+I>0/%%_8TY2W:X
M8DD/&N-P.7&-Q'KC/:@#T@$$ @Y!K,U;5FTRYTN,6XE2]NQ;%C)M,9*,P.,'
M/W3W%><:5JNFR:'INE33VH,=[>BU6\DQ:[%=@/,SG?M#C:N1V/& :E\/ZBD_
M@WP09[B,R#5V7_69P%$PQ[8!7CL,4 =]H^MOJFJ:S:- L:Z?<K K!LE\H&R?
M3K2?VV__  F8T$VZ[#IYO/.W\G]X$VXQQU)SFLGPA(C^)O%ZJZEAJ"$@'D?N
ME'\P?RJCK6F6&K_%!;/4MQMWT-B4$S1[L3@X)4@D=\>WM0!WN:*\>AO[F!="
ML-3OFC\/O<W<4%S=Q>8DBJQ6 2%L C;D@G@\'MFO0O"$%G:Z(T-AJ3ZA;K/)
MB9CD YY53_='08H =KGB6+3/#VIZI:1K=G3V*2Q%BGS#&X9P>@;/OZUM12"6
M)) ,!U#8^M>4S_9%^'WCSRXX8IA?W09 %#!=ZX!QV]*L7[W.@ZCJ%MX?F=)/
M^$=6XB@WF4M('8;EW9)(7\^* /4<T9K@?"2:7=:CI^H67B!)[EK/;+:6Y'SC
M YE&2=RG'S'!SP2>E3^,KJTEUB'3'>-[K[%+<+%>$"V1<X\P\9:3J%&1C)/U
M .WS1FO*;&:RU._\"PW6HSE+C2&$RK>NBRNJH IPPRV=X(ZG&#G%,N-.B:WT
MJRO+R==,/B.2"WE6]D/F0E7(4G//SKM!Z\<'KD ] \5:\?#/AN[U<6ANOLX4
MF(/LSE@O7!]?2KR7-R][&@M!]D:#S#<>:,A\C";<9Z<YKS'7EMM*\.^/K&W1
MGTN(0&-69F"3R<. 2>Q\LX[9KH=1N;BR\2W4ED\CW/\ PCSRQ0F0D&16&TA2
M<9X[#F@#N,U7OKEK2PN+E(O-:*-G$>X+NP,XR>E<-HM]X>;0M,UA=;E%W%8S
M23>7/ODE/EYE+JV22I&1GIQV.*R;75(+F*5UN%47GARX<(]WYDLK#!#2# 'F
M8W9P/7GT /2='U'^UM$L-2\OROM=O'/Y>[=LW*&QGC.,XJ/1]6_M:.\;R/)^
MS7<MKC=NW;#C=TXSZ5POAO3K6RTWP7?:9=W8N;I46XB^T.RRQ^2=^4)P K #
M( QD>U1:GJ%Q9>';X077V2&?Q-+!=W.UF$41<DD[64@$A03D<-U% 'J-<[>^
M*)+?Q2V@V^F27-R+/[:"LJJ&3=MP,_Q9[?K4'A"WBMKG41!KEOJ,;^6_E6J,
M(8#@@X)=^6P"1NXP#CGG)N[>6\^,$RVFH"UG300A*H';!F/0'H1\I_$4 =AH
M^KVVN:5#J-GY@AEW8$B[64ABI!'8@@BK,<DS7,R/!LB7;Y<F\'?GKQVQ^M>?
MZEX<AT[6O"7AZVU#5([*5;M9_+O'1IL+YF6VD G<S$G'.:+G;ID/C;3_ +9?
MBRL[&"6$F[D>2,F-R=K,V1DJ.,^M 'HV:,UY]8Z8DGB'1(OMVH^7>:,TMSMO
M9!YI0Q!3G.5^\3\NW\B<X<>N:B-)\,6%QJ[V\5Q?7<<][,SR*S1RL(T9U=6P
M?][G ZB@#UVN5/C*8Z_JFE0:%>7+Z:JO,T,D9)5EW+M4D9)].M6O"5LECIUS
M9KJZ:F8KEB73=B+=AA&-SN<#/=CUK@YEUF7QIX\?09MMU'';9C6,*\@V?,JM
MSM;&<'!YQ0!Z?I&JVVMZ3;:E:;_(N$WIO7! ]Q4]Q=06D:R3R!$:1(P3W9V"
MJ/Q) _&N+%[I$'@S0+;2KBZ6VN98X+>&WGV22M@DQN_5 #DL1@\8'7%<]*RZ
MMH45KJDDLS0^+1:0C[2[%$\W[N_(8@#< 3SZ8H ];S1FO,=2^TZ[XFUS3YO$
M46E)I_E-:;S(&1#&#YBXE0-SGE@U>A00F32(X;F=YBT 229=T3/\N"PP<J3U
MX.10!2TW7)M3D@DATV;[!/OV71D7C:< LN<@'!QU]\5LYKS'1Y5M/#_A*SAE
MN8M/U>=A<SBXE# A69$5B<IN8#[N,\^IJWKDEUINF>);2RU*\CBMFM6AE:X:
M1X6D(#KO8DXQ@X).-WH: /0\UD:QXAMM)TB?4=CW,<,RPR+$1E6+A.<GL2*L
MZ9IBZ9%*BW5Y<>9)YA-U,9"#@ @$]!QG'3GBO.7AAA^&NN7-OYB3R:NQD8R%
MQN6\ !"GY1QCMSCG- 'JF:,UY[XBU*_\,?\ "0FPO+J8QV%O=)Y[>=Y3O-(C
MN >P4 XZ#'2K_AVUNXM;@NSXA@N;.ZM25M4GDF\X@@^:"[';C.#MP.G% '9Y
MHS7%>)=0OY_%^GZ!%/';6UQ:O.'D>2+SI P 17C8'('. 1U'6H[:WU=-4T2Q
MN_$<]R'CNX[AK<*H<HPQSC.0#M)Z\=CG(!VSRQQE [JI=MJACC<>N!ZG@U#!
M=--<W$)MIXQ"P D< ++D9RO/('3G'->>2/->W_@XWEU<2LFJ7\!<RE2PC:54
MSMQDX4#/U]34FM:WJUOIWCQX=0F1]/DA^RL N8@R*2!Q[GW]Z /2,TUI$0J&
M8*6.U<G&3Z"N%UF35]+GT6R@UGS)=2F8R/?2;%+*@(C1D4%03DXZG&,U0.EZ
MM-X@T*'5-6CN9X=2G8K;S-B&/R=P0DX);GJ><'K0!Z7FBN"U#5-0T;Q%JNES
M7DS-JT:'1V<Y$<A.QU'^Z6#?0=:[BWB,%M%$TKRM&@4R/]YR!C)]S0!+1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 9>E_\ 'U??]=OZ8K4K,TKF
M6\/_ $W-:= !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1165J^JRV,MK:6=NMS?W;$11-)L4*OWG9L' &1VR20!0
M!JU%%<V]PSK#/'(T9VN$<$J?0XZ5Q6O^)KB?P3XF41FRU33HS#,B/O"EE!#*
MV!P0W'0CVKH]$T>VTZ$7 TVTL[V6)(Y_LS%@=N<?,0">O4C/N: %MM!B@U>3
M4Y;R]NICN\I+B4,D ;J$4 8Z =SBM![6&2ZBN73,T2LJ,2?E#8SQT["N9TKQ
ME+J]A=WMMI\)A@AED*F[_>(Z'B.5=F48C)XW#@_C;A\4I+_PCSM;B.+6;<S*
MS2<Q8B$F",8/&><CI0!T--5U=<HP89(R#GD'!'YUB:;K=[J7V*X&E%-/O Q2
M8S9=5VDJSIMP V./F/4>M<SX+U^>V\.6&-(,6FSZA- LQG&5,EQ)MPN.5!(7
M)(.3T- 'H=%8GBOQ!_PC&@RZI]D>[V.B>4K[<[F"]<''6LV;Q3K<5[?6?_"-
MQF:U@2ZR=0 4Q,7')V9#?(> #]>F0#K:*YJS\5MJOV&+3;-)+JYL$OWCGG,:
MQ1OC:"P5LDG/;L>G%5H_&TEU!I,EGI$DS:A--;%#.JF*6-6)7IR,H>?3GGI0
M!UU(""2 1D=17"7?C74YK>R2TL(;>\.MC3+J.2?<JL!O(5@O(9>,XR,]#UII
MU"\TKQGXIN;/2UNW6SM)95$ZQJ,+*3R1DD]N.W:@#OJ*@LKD7MA;W2J5$\2R
M!2>FX X_6IZ "BO.-#M=-CU;Q3%/I\UV(]1$<2I$\A171<@$?= +$]1@5T<N
MM367VG3])L3J/]EPQB<R701LXX4$@[GVC)S@<CGF@#I**Y!O&TMS=6-OH^CR
MW[WNG?;XMTZQ87<%VMGIUZ\]N#VUO$NN2^']$_M%=/DO")(XVBCD"D;V"YR>
MO) _$=!R #9K(UW0AK;Z:WVM[<V%VMVFQ0VYE! !SVP36++XVN;+^U(=2T8V
MMW96?V]8/M2OYT&2"0P& P(P1^M:B^(MVHV=H+3)O-/:\@Q* SLNW,>#@9PX
M.<^O3&: -VBN"_X6'??V!;:Y_P (Q.-/N"BH_P!K3)9I-GW>N.X/KQP.:OR>
M.!I]U?6VLZ;)82V]JMU&HF67S49]BCCHV[ QR.>N.: .NHQ6 OB*:VU$V6JV
M(M9&M'NXFBG\T.J8WJ>%PPROJ#G@\5!#XP@&B2ZS>0I#8+%'(DT<ZRARY*[,
MC # X![<]: .FQ17(IX[M@EV\UKB&W@6=9X9TDBD4L%8;Q@ J3S^==!IE]+?
MQ2R26WDJLFV)A*)%F3 (=2.QSC\#0!>K G\/W8UZYU2PU>2V-TL:SQ- D@(0
M$#:3RO7W')XYKGEUJ?0O$/C.>+3[B\M[5X)Y,2A5C3R%9L;CR>IP!_2MK7O&
MECHLSV^Z"2X2W^T-%)<K$2/X5&>K'!P/\10!O65E%86H@BR5W,Y)QEF9BS$X
M '))/ JQ7'Q^.)[FYCMK+P[?W$TEG%>*GF1H=CG'\3#&"&'N1Z<TDGQ&TA96
M$1$RK>+:?),A=LG:75,Y*AN.WJ,B@#L:*YA_&4*V\U^MG*=)@N#;RWI=< AM
MA8+U*AN">.F>:J7UNVM^-[O2;ZW:;3UTV-AB<IY+,\@W#'.X[%Y[8]SD [*D
M*J2"P!P<C/8]/ZTW!CA(C7<57Y5SUP.!FO/M6UF_U/PI9:A=VK6[+K4*HD,N
MXNJW.W&!C/3'/4C/% 'HE%<U)XRM;*QU"XU6UEL)+(H&BD=6+[_]7@J2,G!'
M7C!SQS4GA_Q=9^(+ZYLX(V2:W19#^\CD5E;(X9&89&.1UY% &^$169E50S?>
M(')^M1S6MO<X,\$4I7IO0-C\ZR/%4]Z=-33M,<QW^H,;>*7G]R-I+2<>@!QR
M.<54\+ZD_B'P8J7#%KZ%&M+M3(RD3H,-EEY!/!R/6@#I8XHX4$<2*B#HJC '
MX4>5&"3Y:Y)W$XZG&,_7%>1OXAS\+]/NTU;58]<<((IB\P22;?\ ==F_=D$>
MIQBMOQ#?V&F^/;,:SJ%Q:V4^F.\JBYE1#*& !PAX.-W_ .O% '5Z5HL]I=O>
MZCJ+ZC>E3%',T2QB.(D':%7CD@9/4X'I5Z'3K>'4KG4%#&XN$1'9FR J9P .
MPRQ/XUB>"7OI=&GENY+F2"2[D>Q>Y;,C6QP4)/4]\9YQBM&2YMT\2+!MN3=?
M8GD4!SY;('4'Y<XW9(YQT[T :$UK;W&//@BEV]-Z!L?G1]F@,JRF&/S$&%?:
M,J/0&L'3_&-GJ'V1DLM0AANIS;Q330A5,@!)'7/\)&<8R*TM9UFVT*Q6[NDG
M>-I4A AC+MN8X' YZD#\: +0L[54V"VA"[M^ @QN]?K2O:6T@ >WB;#%AN0'
M!/4_6LT>)+)%O&NDGM/LC(KB=0"Q?[NW!.[/0 <YXHL?$$=UK<VD3VEQ9W:1
M">-9MI$T><;E*DC@XR#R,B@#4CMX87=XH8T9SEBJ@%C[^M17FG6.H*BWMG;W
M*HVY!-$KA3ZC(X-5=2UVRTRZM[69\W-P"8H@R@MC ZL0.I QG)S6;9>-])O[
MC3881=?\3!Y(X7>+:HD3.Y&)/#<?CVH W[BSMKJV:VN+>*:!A@Q2(&4CTP>*
ME5510JJ H& !T K&G\3V$%PT#><9?M(M8U"C][)MW':<X(4=3P 015)_'FCQ
MJNY+SS#>&Q,:VY9EFQD*<9!R.F,T = ]G:R+('MH6$O^L#(#O^OK20V%G;F,
MPVD$9C4(FR,+M4#  QT '&/2N:U+QLMOID]Q::?=/<07T5E-#*H0QLY7D\X(
MPPQ@]2.W-=++>16VG27UUN@ABB,TN\9,:@9.<9Z#TS0 065K:R2R6]M#$\I!
MD:.,*7(X!)'6EFL[6XFAFGMH998"6B=T#-&3U*D]#]*X_P 9>(I&\$:K<V O
M+2:*&":.<?*&5W&"CJ2#QG(![^];%OXNTV>:ZCD6YMC;VOVP_:(2F^#)&]1U
M(X] >1Q0!!?>$;6[U_3KT6]D+*U@E@>T:W!602$'IT&"/3G)J7Q!X:76QI,(
M%JMI8W*S/;S6XD210I79CH!ACV/:I(_$5M>PWL:074,L5F+H+*-A>-@VT@@G
M'W3[CTKG=/N[N?1O -W)>7+2W$BI.3*V)@8)&.\9^8Y4'F@#MH["SALA91VD
M"6JC @6,! .N-O2G16=K!Y?DVT,?EH(TV(!M4<!1CH/:N<^(%]/IWAR.YMYY
MH&6]MPS1$[BID (XY.1VJ[;^+=*F.HK(\UK)IX#3QW,11]A&58+U(/;OGC%
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M:O<-'>96WG:W=(I& )*AB!S@'\L=>*UKR_CL1'OBN)&D)"K#"TAX&><#C\:
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M)+5E8RMD=, ;5XR02>U2ZKI-UJ'B!CY16SFTN:S><,N49V4CY<Y/ /Z5T5%
M' :/HNOZ7IT5@N@:/Y]E"Z1:AE2;C:A$>5P"I8[<DGU]:98>&-3L+?4UM=,C
M2VNK)=VF7$ZR6_VC=E@@YVIC/IUZ<5Z%10!S7A?1;O1[R^#37G]G2)%]GMKN
MY\YH6&[?M.3A>5QSV-4[_2M5\_Q<(K'SH]3M0MLRRH"SB'85()&.>_UKL:*
M//GT;7X?^$=EM-.(NK+19;5V>6,I%,8U"!ANY&Y>2,\&H],T;7CK=EJ=[I$R
M21:5-;SEKN.1Y)B5(Q\V #@XZ =#CBO1:* .$L-.UF"P\&0'19HCIK;;L">$
M^6!$8]WWOF!+;N.< ]ZW_%']KR:8+72+:1Y+E_*FFCD16@C(^9UW$9;L/0G/
M:MRB@#S[4/#]^UGHS:;H"+%HMR/*L;F6+-Q$8\,V02H?=G&3R>35J^L-2E@L
MI;/PS':#^UHKF:"%H!(8TZNY#!2Q.,8)X')[5V]% ')O#J>B^+M3OX].EO\
M3]2AB/[@KOBEC7;M(8CY2.<]CUJYX=T^]\/Z1I&D"W$\:QN;F<2@"%B=P !Y
M898@=, ?A7044 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% &1HG2[_Z[FM>LG1.EW_UW
M-:U !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M,MNZS7%TT9F^SVZAG$:_><Y(&!]<GMFJ<OC?1HDTD[[AVU6(RVB) S,X SC
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MS@U5\)^*[+4=&T6"YO\ S-2NK522R$"60("X#8VEAGD Y%58['4K#QMXHO\
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M>3[/;>7B,HF%(!/RAL$MZ>O?T'1OM3:;%+=WL=W)*!)YD*@1X/("^H]SU]J
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M'8X(_.MV[\0:/8W@M+K4K:&X)5?+>0 Y;H/J: &IH%FD^I3*]T'U$8GQ</\
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MQ736M_9WN_[)=P7&PX?RI ^T^^.E1:O<S66C7MW;A#-! \B"0$J2H)YP1Z4
M4-1\+6>J:OIVI7=Q<O+8(Z1QY38X==K[AMR<C@\XIWAOPW!X8L/L-K>WMQ;#
M_5I=2*_E]>%PHP.>E3:=JH;P_IU]JLEO:3W$$;R*SA%#LH)49/KGO5MM1L41
M':]MU1XS*K&50&0<EASR/>@"G>:#!>Z_8:P]S<I/8HZ11H5\LA_O9!4GG []
MA4.E^&+72KJ.=+J\N##&\4(N'5O*1V#%0<!B,@8R3C%::W]F]HMTMW ULW"S
M"0%#SC@].O%4;[Q-HUA9+=S:C;&%I$C#)*K9+,%'0],GGT /I0 [7="MO$%C
M':W,MQ#Y4Z7$<MNX5T=#E2"01^E0Z-X;M]%O[^]CO+VXGORC3FYD5LLHP",
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M6[6RPLB;959=C;^,\J .,=*2S\'0VT-C9S7DMSI^G3B>S@D'*,,[ SYRP7/
MX[9SBNC$T1+@2(2GWQN'R_7TJ&XGE4)]F$$A$J++OEV[5)Y(P#DX(P.,^M %
M71=)_L>WN(?M<MP)KF6XS(%&PR,68# '&XD\YZT>(-'37]$N-,DN9K>.? :2
M'&[ (..0>N*T&FB218VE02-]U2P!/T%,NKA;:V>5GC7:#CS&V@G' S0!BR>'
M)&UJTUJ._,>HQ0FWG=8ODN(\Y 9<\$'D$'_"H)_!Z-/I$EO?/$NGW3W;AHPY
MN)7)WLQSQG+=!W]A5_PKK$FO^&+#59HDBDN8][(A) Y(XS]*V* "N8@\(_\
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M#U [JLW6-#LM=ABAOO/,4;;MD4[QAN,8;:1D>U &3X*BU&;33JFK[?MMTJ(
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MT,3!A(S("QY9,D-C'7OQ6M<> _-ED>'7+Z '4SJ:H(XV"RD\]5R0.@R>.^:
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MAB^(J07=WJ2VLVF&7R;>XN-OF"0*"%C/'RY[8_&NUB,AB0RJJ2%1N56W 'N
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M]V-:E !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH RM _Y!4?^\:U:RM _P"05%]36K0
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MB@ HHHH **** "BBB@ HHHH *K2:?93-*TMI;NTP D+1@EP.F>.<8'Y59HH
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MRRD%E]C@G\Z]"OM&TK5&5M0TRSNV484W$"R$#VR#ZFFW6@Z/?QPQWFDV-Q'
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MDUT]]X.T#4M16_NM.C:X""-BI*B11T5U! <<#@@]!3[GPOI%S%J$;V\BKJ(
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MC+QYR%<X^8#@ 'H /05T] !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 9>@?\@BW_&M2LS0/^0/!]*TZ "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "N ;73H'C?Q,\L.I7=I%;6]PT<
M+&181AR[X=@%' X')QP.*[\UQ]QH>K_V_P")KR*&VD@U*QCM[?,Q5@ZJ1\PV
M\#+GD9Z=.: +VH>,;*QW%+6]NA'9B^E,"+B.$]"=S+R>>!D\&G7GBZTM&"QV
M=Y=M]C6^9;=4++"2<'#,"3P>%ST^E<U?^&O$]_;_ &::UTV>W?3%M$AGNW,=
MO* P,@4)AB1MP3@CUI-3\'ZQK%E;17=E8Q7EK9PQ6E_;73QRV\J@ACD#++TP
M/KWYH ]%5@R!AG!&>1@_E6/J/B**QDN8X;*\OY+6/S+A;14)B&,@'<RY)'.!
MDX^HSK1*Z0HLC[W"@,^,;CZXKE#HFKZ=X@UNYL1#<V.JQ!V6:8J\<X7;P<'Y
M,8^F.* +K>,-.DMXI=/CN-1\RU-YLM57<L0XR0Q7J00!U.#Z4J>+;2>SMKBT
ML[V[>>T%YY$2IYD<1Z%@S 9/0 $DX-<UIW@S7O"-Y;3^'I;*\C^PK:W,5X[1
MY=6+;U(!_O$8]ZU+O2?$]EK::SIK6%W<7%HMO>0SNT4>Y6+*R8!/&YAS0!J6
M'BNTU.>.&UM;MI)=/74(U954LA.W;RW#9'?CWJI+XZT^.VTR7[#J+R:D)/L]
MND*M(60_,I&[ /XU6N]&\1IXFL-=M&L9Y_L!M+J*21XHPQ;<&& 20"3P>>/>
MJ&G>&=>BN_"\U[;V;?V5)=-,4F/(EZ%1CJ.N,_C0!KP>.+>XU&6P31M9%Q"(
MVF5K91Y2OT9CNZ=3^!QFDM_B!HMQ>V<&9HXKW?\ 9[E]@C?:,DG#;E!'(W*,
MTEOHE_)XL\17-U"L5CJ-I%!%*DH+?*&4Y'8_-G\*R]'\.^(H=(_X1R]M]-CL
MHH'@748SNDEC(*JNT@;6P>6YZ=* %U#Q)+J7B3PJ;*#4K>QN+ER)WPD5TGED
MCY0V2.A&Y1[5WQX%>>V>@>)Q%X5M[FVL2=$F EF6<[9(MI0;1MSD+USCGZ\>
MA4 <?'\2-'<12&UU%+9[PV37+V^V**0''S-G@'_]>*TCXLL/[/U6\$=P5TN8
MPW2!!N4C!)'.",'/7M7%:#IE_KOA:YT9=.:"SGU:2:2_,J89$N"QPH.[=E O
M(QWSQ5_4_#OB.%?%%CIEG:SV^KR&=;B:?9MW( R;0.N1P<X]: .DN_%MK:Z_
M)HJ6.HW-Y'&DK"W@W*$8XW9)' [_ *9/%,;QE:+'<3"PU!K:*"2X2X6-3',B
M?>V'=U]FVYJM86&LKXWN=5N;&*.*XTZ* O','5)%)8\<,5RV,X[5BZ?X0U9I
MK@>0NE)>6EQ#?QPW&^WFE==JO''_  ]V/3KCF@#K(_$]E)?:3:A)Q_:MN;BU
ME*C8P"AB#SD':0>F.>M5M.\9Z=J-_:6R07<27HD-E/*BA+GR_O;<,6''/S 9
MKGK#1/%;77AJ6?3]/MAHL,EMN^UES(&B5 ^ G XSC/Y4W2O#?B$:GX?U34K"
MU>^LI9S>7!NR9)/,##(^7&T C"YXZ8 YH V[;X@:7=3VZQV>H>3/>_8%N&A
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MI9L'D%5_U2 #&\\<]L4 =K17)3:YJVLF^MM ,$-Q9V\$^9TW><TBEQ&.0%&
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M2#8LFP?(,9W,!U[#IUKKJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH SM$_P"01;?[M:-9^B_\@BV_W:T* "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "LBW\-Z?;>()]<C^T?;IUV2
M,T[E67L-N<8';CBM>LF3Q-HD5\MDVIVWVII_LXB#Y;S, [<#ZCZ4 00^#M#A
ML[ZR6S)LKUBTULTC&/<>I52?E/TQ6#KW@2TA\(7FE:)I[RR7<T)EWSDLR)(&
M(+N<XP#@#N?K72P>)M%NA<&WU.WE%O$9I=C9VH.K>XXZBH=-\6:3J.A1ZO\
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MO_VQIGF)'_:-IO=_+1?/7+-_= SR>1Q[T^XU*PM;A+:XO;:&>3E(I)55F[<
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M2WO(9FF:)W9D9&.UQD#",,8SR=XZ8YZ:XN;>SA,US/%!$O5Y7"J/Q- '+OX
ML9]&ETZYU/5KCSGC:2XEN=\I"$E%R0<*"<\ <U8NO!6GZA>WMQ?W%U=?;+=;
M::.1E"E%P5QA1@A@6R.Y/MB*]\420^,-$T^WDLY=+OX)I7N <D;!D$,#MQG'
M:NC:]M4M_M#W,*P?\]#( OY].U ',1^ K9=*NK*;6=7N6ND\F6XGN/,D\K.3
M&N00H/L,^])J/@0:E?6]Y)KNHI/#9FS#HL7S(1ALY3J>_P"F*U-8UB:TGT0V
M9MY;:^O!;R,<M\I1F!0@X_A]Z31M6O+W6]=L+J.$+87")"T2D;D>,.-Q)Y;G
MG&* *D'@Q;:30VBU>_"Z/$8H4Q'AP1@[OEY^7"_AZ\U6;X?6QM[=5UC5$N(+
MU[Y+A70,)'^_QMQ@GG&.Y[&NDNI;I+RR2!K81.[><)6(<J%.-@'4YQG/;-2F
M]M58*;F$,6*@&09)'4?6@#EH_A]9V\<$<&J:BJ0ZD=24,Z/^]/N5SCK]<FK.
MJ^";+6-3U"]N;JYS>6JVQC&W;'M.5=>,A@<D'/>NADNK>*58I)XDD;&U&< G
M/3BL?3M?:YU_7[&Y\B&WTV2!(Y"<%M\88[B3CJ<"@#3TRSDT_3H;26\GO&B7
M;Y\^-[#MG &3[UAZ=X,M[.XU9[F_N;^+5<FZ@N%38S=,C:H(XXX_H*Z02QM(
M8Q(A<#=M!YQZXK&OM:EA\2Z3IUNUI)!=-*EQ\^9494++@#@#@YS0!FR_#^SG
MT&#2IM3U%UM)A-97!D436V!@*K8Z#W_PK*\1>&IH9_#L%M<ZI<3#4A<7&H;/
M-D4*A +$+M Z#!&,$^]=^)X6F:$2H95&60,-P'N*DH YF\\&6U_HNI6%S?74
MDNI.K7-V0GF,%QM4?+M   & /7N:BU+P.FIS7TCZUJ,7V^V2WNUB\L"8(" 3
ME"1]XYQ@<UT\EQ#$Z))-&CN<(K, 6^GK2M+&DB1M(BN^=JE@"V.N!WH Y=O
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M*O6^K:I<S:Y EG:FXL)52W3SB!+E XW-CCAAVX]ZV6G2&)7N)(XLX!+-@9]
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MB/3]&>VF\R^CD>.8;=GR %AUSGD=N]:U !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 9^B_\@BV_P!VM"L_1?\ D$6W^[6A0 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 &N)M4C.K^,
M;I-$EGN<J\'GVC(MP%@5=BLPP<NK#CUS7;5$ES!+--#'-&\L) E16!*$C(R.
MV1S0!YCH27UQK&G2/IFIPM)HT\#(UCY%M;R,5(C0;05 VL,L>>,&LO[!K/\
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M+;6"MT#$%@#^%0Z1J%G!9:4L(2(KK-ZL5WY+R);[LX"QKPS,K +G('->RT4
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MBBB@ HHHH **** ,_1?^01;?[M:%9^B_\@BV_P!P5H4 %%%% !1110 4444
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M]"M$C^U75AYY>4$JD:CT&,DG^1K1TCP?<:1?PW:ZW/,T-A]A1)($"A0<J<
M\''?)]:@?P%BSTK[+K-U;:CID9B@O8XTR4(P59",,/K0!:@UW6(M8T73]2L+
M:![];CS5CD+E&BZ%3TPP*G!Y&<5@:]J%SK>@V[W5M"L]MXCBME$)W?<F"YYY
M!/-;4O@RY;^S;B/Q!>C4;*664W4J+)YGF !@5Z 8 P!P*A7P)+%I/V&'7;G=
M_:G]I>?+$KN6R"%.,9Y&2>_M0 NO>,+S1-2>)[:V$"RP1(C2[I9P[!2P"YV
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M[0,DX'/')J?4_!L^M7<DFHZC"\,^G?89TBMBC-\V_>K;SM.[!Q@B@"CXKO\
M5KKP=K,5[I$*0R:6\Z21S&4*>,JV5&& .X$9'RGTJ71O$6IVEAI]E<:1$#)I
M1N;79=9+B-4!5_EPI.X$8+4^+P?K,_ANZT;5?$(ND:U>U@<6VW"G&'D&[YV
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M"XG9Y%B2.!-S,S'CN!CU).!6$OCBU:34HUTO5"VF$"\ CC)BR,C@/R, GC-
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M-A=WT%[<6D4MS!_JI'&2G7I^9H \_P!#\_PO\13!=6 TZQUNW588Q.LB^?$
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MG 4$;0?5B, =<=:Q[?4M1UVRTA+W4+R*>#Q/)9<,@<HJ,P+8&"R\#/3KUXH
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M4 %%%% !1110 4444 5;#_CP@_W!5JJMA_QX0?[@JU0 4444 %%%% !1110
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MMFMKZUAN8&(+131AU..1P>*K#0-'61Y!I5D'>+R686ZY,>,;#Q]W'&.E:-%
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MH **** "BBB@"M8?\>$'^X*LU7L_^/6+_<%6* "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110!!9_\>L7^X*GJ"U^6VB_W0*GH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHS0 4444 %%%% !111F@ H
MHHH **** "BC-% !1110 4444 %%%% !1110 4444 %%%&: "BBB@ HHHH *
M*** "BBB@ HHS10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110!#!_Q[Q?[HJ:H8/\ 5(/]
MD5-0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% " Y)%+28&:6@
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M"H9%=W*G!)Z. >/7\:EOILTVG2RCP7]AO8K*:)FW(S&1EVA8<-T.3G=C ]:
M.IMO&.AWEQY%M>--*8/M"+'"[&1,9.S ^8CN!DU-X9\0P^)M&34H8)H4=W4+
M(A&<,1D$@9SCMTZ=JYBUT_43JW@TQZ9<V\=AI\T,[N%VPN8U50<$YY0],]16
MK\/+2^TWP?;:;J-E-;7-JTB-YFW$F7+;EP3Q\W?'>@#1?5;:'Q#>0S:LJK;V
M:RR6ACP(@6/[POWSC&.WXU#I_C30-5N[2UL[_P R6[5F@'E.H? R0"1C(';K
M6/<V6H1_$J^U5=.N);/^Q3;+(FWYY-^_:,D=N/K5'2M+U>ST'P/"VG3K-8W+
M&Z4[3Y2['0D\]]V1B@#M]6UBPT.Q-[J5RMO;*P4R,"0">G05"/$6E->7MH+D
M_:+&,RW*&)QY:#OTY]L=>U.U_1X=?T&]TJ<D1W,93<.JGJ#^! ->?1^$_$EY
M+I=[>/Y-S=V_]F7Z(W$5LNTYXZEMC\]C*!VH WY_%T5EXT5+G4E71YM(2\A4
MQ\EVD"@C W'Y1G';)_#H9?$&EPV-I>O=J8+P VY569I<KN^50,GCGIQ6,;&Y
MC^))U%;&0V4>D?9UE"@C>)"VT<YZ8_E7.>&['6=(D\/ZM=Z==&W@T^33KBU6
M/=+ WF;A(%')#;5!QTH ZC6==:;3-'U'1=00VUQJ5O"[(@821O($9>1\IY]C
MQCK6E>>)-'TZY>"\OXH7C"F0MG;'N.%W-T7/N17''3KNRL+R\_LV[SJ.OPWR
M6\41=HXDDC8LX'W20C''N!UJI+HDL&NZW8:KX=U#5XM1NS<VT\,[+;X;&$E&
MX!=I4<X)]NE 'J!8!=Q(VXSFLJT\3:-?77V>VU"&23RS,,9"N@ZLK'A@/4$T
MSQ-I=QK'A/4-,MI/)N)[<HA5N,XZ9]#T/L:YK9=:U%X9;^RKRRETF1;BZ,D!
M78JQE3&G]XL2, 9X'/;(!TNE>*]"URX^SZ9J<%U-Y9EV1DY"AMI)].:V:Y#X
M;Z?)8^#K6.ZT]K2\5Y5D$D>UV'F,03QGH177T %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110!%']Q/\ =%2TQ 550>PI] !1110 4444 %%%% !1
M110 4444 %%%% !1110 @()P",TM(% )(ZFEH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@"L+ICJ1M/LTVP1>9]HP/+SG&W.<[N_3I5FN1O)+G
M_A.;^T6]ND@?1#*J+(0(W\PKN4= < <U@:!]NMK?P3J$FKZE=3:DQ2Y6XN6:
M-E,+L!LSC((&#U]<T >FT4'D5Y;=V^I1>&=5UBTU_59KVRU*2.UB:Z)C*K.4
M$97^/<".N><8QW /4J*\K\3:I>Q7]U=Z=?ZA(MOJT%M).;HQQ1$D;H5A'#@!
MAEF]1UQ6G;Z=<:QXM\40W&N:NEM8SPM%;P79C7YH0Q!QSMSV!'Y\T =]#-%<
M1++#(DD;C*NC9!'L:?7+?#N*.#P%HY#OF6W5CYDC-R1T&2<#CH.*ZF@#-U+6
M;;3]/U"Z :Y:Q3?-!;X:1>-V".W'//;FK-C<1WMC;WD:;!<1)+@]<$ C/YUY
MH+8)'\4+CS)2WER( TCD8\@GN<'V[@<< U/]KOO#-MI]Y;7MY=^9X?FN6M[B
M0M&7B6,H0HX7 <@[<9 &>>: /3:*X7PU;7\EUHVKMXF$]M=0%7MS([BY?83P
M&8A2I!)V@="*[6X<QVTKB1(RJ$[Y/NKQU/M0!+17D\6IZM8Z=K=M?W&I0ZM%
MI$EQ%(+EIK>X*X_?Q-_#_#\HP.>E=0E_<S:QX9C349@NH:9*955E()"(1(,@
M_-ECS0!V%%>56DNMS:%X:O1XDU);B]U)[*0L491&#,,[=O+?(.3G^5=EX:6Y
MM=4UO3YK^YO(;::(PM<L&=0T8)&<#/.: .CHKF_'>M76@^$KJ^LFC2XW)$CR
M=$WL%W?AG//%9TLMQIOC?3-&CO[VXLM3L)0_F3%F1T Q(K=02,].,D&@#<LO
M$,.H7XM[>QOF@9Y$6\\H>22APPSG(Y! R!G'&:V:XCPCH+2>#C"FLZHAEN9&
M\U;@%EV3O]TD<!L?-ZY-=O0!2OM4M[&:VMWW27%R^R*&/!=O5L$_= Y)_J0*
MK7>OV]C;W%S<VUW%;V]P())6APJC /F>\8S@L/0]AFL"Q<W'Q?U838?[+IL2
MP9'^K#'+8^IJ]I FN='UZUO+Q[A4NKB 2W.#A-HP#@ 8&?2@#IE970.C!E89
M!!R"*S[_ %JUTZY2WDCN9)6C:7;!;O)A1P2=HXZUD_#NYEN_A]HLLS;G^SA,
M^RDJ/T K>OU/V"Z* ^886 *X#=#C!/'YT 9>E>+M+UE;-[/[4T-XS)!,ULZH
MY4,2-Q&.BM^5;M>:^$]5ET/X&6^J6\ GFM8)I$0C(SYKC)QV&<GV!I98O$=I
MI5QK \0JMO)I$LHB\_SGDD"%Q(F5 7MD#C'X8 /2:*\P2S\0Q:7X;U!_%NH-
M+J4]LDB;(]BJT98X!7D\=3]2#1?76MI9>,#_ ,)!>XT1@]J56-68^6'PY"_,
MOM@=3G/& #T^LV_UVRT^]CLI#-+=R1F58((6E?8."Q"@X&>/K6@A)C4GJ0*X
M_P 1:)/?>(UU3P_JHM=?LK=1)!)EHIX69BJ..P)5N1Z?0T ="FO:8^CC5OM0
M6R.1YCJR\ABN-I&<[AC&,YID&OV4UW%:NMS;33#,0N;=XA)[ L,9]NM>?2ZA
M+J6H>";F^LOL%N=3NDO+=6^47@)"G\7#'\36[\4I;J/PQ:+I[E=0DU&!;4*<
M,TF[( _*@#7?QGI:ZG>:='%J,]U9L%G2"QEDV$\C)53P1R/6F2>.=%CFLX1]
MMDEO$9X$BLY'9]I(<8"_>4@Y'4=ZYK38M9E^(GCA=(NK.W<_9 S7,+2'/E':
M5PPQCGJ#VJQXJ%W'\1?!XLA UT(;PJ)<A&;RQG./7F@#I]#O=!U2:[O-*B@6
MZ5S'='[/Y4RMUPX(#?GZ5M5Q7PY875EJFI7)VZO=7C'4(3&$,#J-H3&2< <C
M)[FNLO[A;73[FX::* 11,_FS?<3 ZM[4 6:*\\T'6-7N-5O+6:]O6B?1ENXI
MIXXU+.6(,D:@953V5QG@9%)IFH:Y81>$KW4-5FNAJ416XMS&NT#R6D5AA=Q;
M@9Y.<\"@#MM2U>STDV@O'9/M=PEM%M0L#(QPH.!Q]35ZO*+FZO=>T7PIXAN-
M1E9;S7;=OL:A/*C7S"%4<;LC;R2>23QZ>K"@""2]MXKR&T:3_2)@Q1 "3@#D
MG'0=LGN0.IJFOB"P?2UU%#,]NTPA&V%MVXOL^[C.,]_2N=\)22:AXN\7WTLC
M&2.Z2RB!Y\M(U/3ZDYJK>:SK%OX$L[X:BQO!J?V>641*/,3[2T>,8XX Z4 =
MK:ZE;7=S<VT3,)K9MLB.A4C/0C/53V(X.#5NN/U=Q:_$WPV\;('N[:YMY5Q\
MS(JAU_ $?^/&NGU%IETR[:WSYXA<QXZ[L''ZT 4QXDTDZFNGBZ_?,YB#;&\L
MR#DQA\;2_P#LYS6E--';PO--(L<:#<SL< #U)KRNRG6V^$7ALV_SW,NH6YC
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MN]4U?3]0CMQ)8RQA)(,@.CH&&02>1S6Y0 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH SKC0=,NKV2]F
MM%:YDA,#2Y(8QGJO!Z567PEH2I9(NGH%L6WVRAVQ$<YR!GK3O$E[>6FE^3IA
MC_M.Z<06GF= YY+'V50S'@]*I>&/$@U+P;#JEV7>X@0QW@CC)82IP_R@=2>>
M!CF@#I:XCP=X,&EI/)JNG6RWGVMKE)8KAG#DDD;EP!N7=@'!]JW+?Q5IEU8Z
M7>0M,T&IN4MV$1Z@$G=_=&%8Y/I4&G^-=)U*\2W@6["RQR2V\[6[".X5/OF,
M]3CCMSGC- $]WX0\/7UQ//=:1:RR7!#2ED^\1CG'KP.>IJU9Z%IEA>W=Y:VB
M1W%WCSW!),F.F<GM7//JZ7'AFUO]'U>[GC.K11M)*H#.'NE5HR&4$* Q   .
M *TK[QEH^GW\MI-),3 \<<\L<3-'"[G"JS#H3_6@".;P3I/V2RM;2!;:*UO4
MNU(W%@5(.%.>.@7OA> !QCI*X"'Q@FB^+/%%OJEW?7-M:O T2K;^9Y"LA9C\
MB\(,J,G]>M;CW\\WC+2OLM\\FFW.G3S&--AC.UHMKYQGH_KZ<=: +\OAS2)I
M;Z62QC+WZ>7=$9'FK@#G!]A1%X<TF&XLYTLU$MG$8;<EF/EH>" ":K1>+=+F
MU"UM$:?%VS);7!A80S$ DA7(P>AQZ]LUNT 9&F>%M#T:[DN].TRWMIY 0SHO
M."<D#T'TK4EB2:%XI5#QNI5E/0@\$5QGC:37]'T'5M:MM>E@\DJ;>VBMX2BJ
M2B_,70L3DL>N.E;4<=UH7VB^U3Q!-=V"1<K<0Q*4;/4&-%SGIC!YQCK0!+8>
M%]'TT.MM: (\9BV2.TBK&<910Q(53@9 ZU7M?!7ARQNH;JVTN..>%2L4@=LH
M"",#GC@FH_\ A.-$2RNKJXEGM!:NBS17,#12)N^Z2K#(!['IP:L0>+=&N);Z
M-;ID-E&)IC+$R#R_[Z[@-R\=1G/;M0 X>%-%6SMK1;+;!:RF:!!*X$;G^(<\
M'D_F?4UH6UA:VEQ<SP1!9;EP\S9)+D# Z^W%9MEXKTJ]D= \T#K#]H5;B!XV
MDBY^=0PRPX[<C(]13- \8Z'XG=H]*NI)G1-[!K>1 !G'5E //H: -B[M(+ZT
MEM;J))8)5*21N,A@>H-4=.\/:;I4;I:12+N3RPS3.S(G]Q23E5]ABM2L5_%>
MD17IMGGE \X0>?\ 9Y#!YA.-GF@; V>,$]>* %C\+:1%I;:8ELPLFE680F5R
M%8,&&WGCD9X[Y]:V:X>^U:^U?QM<Z!9W^I:>D-O&Z2PV>5$FYRQ<NF-I"X!S
MM)/>NX' ZYH P[S19QXFMM=L'C$QC%K=QRDA9(=V[(P#\ZGIV()''6F3^'1:
MZ/>V.C@1/?,PGEGGD<J'SO<9)RV#P,C/&3Q5C4_$VE:3)+'=W$F^%/,F$-O)
M-Y2^K[%.T?7%,N/%FB6LL4<E^K--;FYB$:-)YD?'*[0=W4<#)//I0!HZ=86^
ME:;;6%HA2WMXQ'&I.< #'6IIHDGA>)\['&#AB#CZCFLO_A)](;2K74TN_,M;
ML@6YBB=WE/HJ*"Q/!R,<8.:M:7JUCK-JUQ83B:-7,;_*5*L,94@@$$9'!% $
M>G:%INE:?)I]G;!+-R<P%BR $8( ). ?3IR?6LJS\ ^'+"RN;2VLGCBN8VB?
M$[DA&QN53G*@X&<8S707=W!86<UW=2K%!"A>1VZ*!U-8</CKPY.RB/4D(>'S
MHW*,%D&<80D?,PR,J.><8H FF\):3/I^G6+QW'D:<X>U"W,@*$=#D')QVS3)
M/!NCRQZG&Z73+JA!N\W4G[S'3^+CCCCMQTJQ#XFTJ?1X]42Y)MI'\M1Y;&0O
MG&P(!N+9!&T#/%1R^+M#ATR?4);]4@MW\N;>C*\;GHK(0&4^Q H UK:W2TM8
MK>,N4B4(ID<NV!ZD\D^YK.O?#FFWVH?VA)'-'>^6(OM$$[Q/L&3MRI'')_3T
MK-U#QWI%KHNJZA;RM<'3P-T:QL-Q;A"#CE&/\0XJK<>,8++Q%8M>W;6VG7&E
MR3^7+"5/F*Z] 1O)QNP .>PH Z!= TM=(_LHV4367.8G&[))R6)/.[/.>N:;
M:>'[&TGCGS<SRQ?ZIKJYDF\OC&5WDX..,CFL_P#MR6\UC2[RPNX7\/S6=Q-/
M/CY<J4"DL>F,MQQT;/2M'2M?T[6MXL9I&9%5RLL#Q-M;.U@'4$J<'!''!H 9
M:>'-.L=:N]7MUF2[O"#.?/<K)@8&5SC@=..*9J'A?3-4U>UU6Z6X-Y:?ZATN
M'01^N #CGOZULUQ7C;QE'I>GRV^EWQ74HYX48I;-(J@NH92^THK8/0G/MR*
M.AB\/:=!KTNM0Q/'?3($E9)&"R =-R@X)]R*N7ME;ZC936=W$LMO,I22-NC
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 <Y<Z')JGC"+4+Z-UM;"#;9,
MEP5/FL3YC84@_=VCKZ^M9WAS0[_P[XQUB"UL"OA^\"3Q2F<-LFQAA@G=S_05
MUE]?6VFV,U[>3+#;0J7DD;HHJ:.1)8UDC8,C ,K Y!!Z&@#B]"\)ZAHU_>LD
MD+6MJLPTF-B2%,K;SN&>,'"_3)[UFZ'I/B/_ (2'0M6U329A=PPSPWT\EXC
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M_FQPG&P2#HYXR2,G'..^,@&KN><4 <-\7#;GX>WL<SQ))))"L)?KN\Q2<?\
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M<2J$N/L5R8A<*!@*X'48XXQ0!C'Q%XHU:74K72[6..[L(X4(0QLAG9 SABS
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M71:[JT.A:'>ZK.I:.UB,A4=6/8?B<#\:;H^AV^C->21RRSW%Y-YT\TVW<[8
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M:#!XCT=]/GGG@!=9%EA;#*RG(//!Y[5C2> HY+/6(GUO49)=6$?VF601'E,
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MZA<:A]J!!>X\T!5B"YW;LD+Z':/7 VM(UC3[?5GBO=Z:Q>2K'<$ O'%)L+I
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M6)YMK06IR^W?SM.T#G&1N/&175^$=3ADN=1T0Z/#I5YIIC$L,,@D1E<;E8,
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M8K@WW]GI%Y90QR9& ZX/L&'O^-8<@T;7-#O[JUTO5IM1329K>1[N-P(CL^5
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MDLW[,Q4[/O>^.OXUYI9107_AOPV^E0QQ>*(;]!=-L G5AN$S2Y&=I&2<^HH
M]9%S T@C$\9<YPH<9..O'M4M>??#K2M'DFUG48+*W:XAUBY6"?R_F2,XP%)Y
M *L>GK7H- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQZTV:9(8&E=T50,[G;:OXF@"2BL;POKC>(=%%^\4<3>=+$4CDW@;'*]<#.0
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MNEOXN\.3-8J(X-'903:D!)<K@'Y>#C>1G^M>C/+''M\R14W,%7<<9/H/>GT
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MM45 M[<[E5-O_+5@/_'0!^%6OB+%=3?#_68[,.9C!T09)4,"W_CN:Z8 *,
M#.>*1T5U*,H96&"",@B@#A?$,UC#X2\*W=TT,"QWE@Z,[8"#<I."?10?P!JQ
MX<N+;_A8_B^&.:(N5M&"!P3PC;CCV)&?<UT&EZ';Z78"P#&XM8W)MTF4-Y*'
MH@/<#M[8':I[[3DN[2XAAD-K+.NQKB%1Y@!ZX)'7'?MUH YWX;"3_A$MSY*/
M>7+1'/!0RMR/;.:;\4H(9OA_?&:-'\N2!E+#.T^:@)'IP2/H37565G!I]E!9
MVT8C@@C$<:#LH&!4S*KJ590RD8((R#0!YG=6NB:E\6;2UD%K)IQ\/8CC20")
M@)6(& <$;<G'3C/:N>34;:[LO#-KJ5_%'X?\F>+SG031+<"0[5?.0,)MQGH"
M3]/:/LMONW>1%NQMSL&<8QC\J:]C:26Y@>U@:$G)C:,%2?7'2@#'\&6EI9>'
MDAL+^:]LQ*_DRR8QMST3'&P'.,4WQK$MQX>\AKRVMC)/&J_:E+0RMGB.3'\+
M'@UT*JJ*%50J@8  P!4=Q;07<)AN8(YHCU21 RG\#0!X^LUC>PZ!'=6S:5!!
MKD]M/''=GRU(C.0C*5PF3M&.@SS1KFGQ:9HWBRTL97CTFWO[(V2K,V(IRZF5
M4.><;@<=C[CCT'Q!X:DU>^T9X39I:6%P9I()H-XD!&T@#.!P3VZXK:_LRP-D
M+,V-M]E!R(/*79G.?NXQUH \W\566G:=XCT[1[JYCTW1)K25TDNAYT3W&Y?O
M[^.% Y)[]N^=G0H3INFS:LNI0VUI/<K/J$FVV$8D8!XXQR[@A@N&'R@D=J]=
MN+6WNXO*N;>*:/\ N2(&'Y&HGTS3Y3#OL;9_)&V+="I\L>B\<?A0!YKINJ07
M]_X6LM=N$.EMH:3QM/(!'-=#:&W,3RR@'CL370_"^6WD\'E+:1'2*]N$^5MV
M/WA(&?\ =(/XBNJFTVPN(EBGLK:6-#N5'B5@I]0".M2P6T%JA2WACB0L6*QJ
M%!)ZGCO0!D^,+Z/3O"&J74DD\:I 1NMV"R GY1M8\ Y/7MUKS.75KO2AXCBT
MF6"&%;&UD,=A<><MN&<B5P>[A226 ]#7LDL4<\3131I)&XPR.H(8>A!J"'3+
M"V!$%C;190H=D2KE3R1P.GM0!YUIUKX>@^*MO'I)A6&_T1V:2&;'G,S]00<[
MMJDDCGO4.B7?V31O"-]=7;+"NKW<$LTTI)(/GA0S$\C*CK[5W<F@Q64:-H%I
MI5A<*WWVL@05[@;2I'YTNG^&=.M- BT>>WAO+=27=9XPRNY8L6VG./F)/M0!
MYY#>?VE<>([72]9M5;^V8FMH9IB8K@;"?*R#PK%3ST)&.]1O<65W)X2>[LI+
M$V^KW,,PFN2ZP,N2RA\CY=V,?[N.:]2ET32IXYHY=,LY$F(:56@4AR!@$\<G
M'%*-(TT6D-J-/M/L\)S%%Y*[$/\ LC&!0!Y?(673?'>HI?7\5Q87Q2V;[=*1
M'MVXX+8.3V(/7'2M34I;O0_$NKP:-=74K_\ ".M=*CRM.6F5\*^&)YQZ<>U=
MS/H6CW,<L<^EV4B3-OE5[=2';.<MQR<^M$&AZ1;7JWL&F6<5TJ!%F2!0X4#
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MLGLYHA:D&4. K,#O^4X5<=<$'\ #&UC4-0U+6_!.KO96]O:SWH,)+[I@LB'
M8%<#*YZ$X-7K+XB7&J:I9)8Z1-+I]Q=F S>3-E4R5\S.P)C(!^\2!2V_@+54
M_L**X\0I-;:-<"6W!M,.R#HK-OQP,#.*N:+X.U+0[@6MKXBF_L-)?-2S:$&1
M>=VSS,_=+<D8Z<=S0!AZSK%[XBM-#U2.QM!I$FMVHM96<^?M$VW<5*X 8CIG
M.",UU7CJ&*?P)KBRQJX6RE<!AG#!20?J#6)'X!U.VTVVTFUU^)=-L[U+NU22
MSWR)M?>$+;QN /M76ZUI8UG0[S3'G>$74+1-(@&0",'@T <T/%.M6FIV^DS:
M)"LUW:O+I[?:LB5D&2CX7Y6V\\9'O5C1O&,VM:;HDT%@GVJ_GD2X@\T_Z,D9
M(=B<<X.P8P.7%++IDFG7D/B+Q#J44L>E6S+!';V[1JA889R-S%F(X ]Z;X0T
M^";4-3\0P+<1VVH2EK6*52NU"%WOM/(WLN?H%H G\87VL63Z*-)-N!/J"0RB
M9F7<""0N0#@'!S^'O7,KJFIZ/XN\;WFGZ5;3I;I;37 >X\OA8F)*X4Y)Y/..
ME=GXCT6YUB*Q-G?+:3V=VETC/%YBL5!&",@_Q>M8S>#=1\WQ3*FJ6P?755,F
MV.(5"E.F_DE2?3GGVH 75O'8MYYK73+)KNZAM8[ET99#G>"50;$;#$ =<#GZ
MXWX;T:IX:%V]O)#]HM2S0S(0R$KRI!].17.1^#-:L=174-,\016US-:Q6]YN
MLPZ2F,85E!;Y3CC&375?8Y(])^QQSL\@A\H33_,6.,;FQC)[GI0!XCX26/5?
M#N@Z7IL4EKK_ -J>?[<08@T*N=X#CF3C V\_I7J/B+Q>=)U Z;8VPN[Y(#<2
M(1(0J\A1\B,=Q([X&._2LRT^''V?P7:Z(VI?Z;8W#7%E?QQ;3"Y.>F[D<G(S
MSQZ5?N/"NJ_VS'KEAK$%KJDD0AO,VN^&=1]W"ELKCV:@#+M]4CU#QQH6L36L
MMB9-'N6ECN$VO'M=<@Y[#G'M4]IX]O[V^LQ;Z'(]G?<02@2[H]PRC29C"A2>
MI5FQ[UH/X5O9M<L;^YU&*X2&SDM9U> [IO,.7((;"\C@8.!Q3= \,ZUH[0V<
MVO?:-)M9"UO$8<3%>0L;OGE1QVR<=AQ0!#I?C*]U#2+&X;3H$O;K4FL3:K.2
M8PI.]F.W@@*3C'3'/-)%XXG'B.RT^[TU+:"^EDA@$DV+A2HX:2+'RJQ!QSZ&
MM.Q\,1V7BK4M968[;H*8X1TCD( D?'J0J<_7UKG;7P%K$5WI$D^K6<R:??O=
ML_V9A+<;CDEVW8W8XZ>E &B/&MYOM9I-#DAL7OVT^>9KA"5D\PQ@JH^\-PY/
M'MFK'AK5M8U/7->6[2U_L^UO&MH3%(2RLJKQC;S][).>#QBL]_"FOR: +%KW
M3FN%U;^T5D,;A<>89=I'^^3^%:_AW1-1T;4=7:>>UDL[Z[>\545A(COM!!)X
M(XH S]4N9-:\?V_AN0LFGVUG]ON%5B#.V[:J''\(/)'?O45ZWA[P_P"-]*AA
MBDLKNX1P([>$^3*N#DD @*5P"6QTZ^VIKGAJ6\U>UUS2KI+35[9#$'ECWQRQ
MG.4<#!ZGJ#Q55O"U]J?BVRUS6);/99021106ZL=Q=2K%BW;!/&._M0 T>,YA
M%:ZJ=.!T"ZF6&*Z64^:-S;%=H]O"$XQ@DX(X[59M_%I-_K]M>V)M?['B21F,
M@/G!@Q!7VPH_$XJGIWA'4+/2H= EN[6318+@21D(WGF-9/,5">G7:-P[ ]SD
M7M7\*+JGB?3M6%QY4<"%+J(#_CY4,'C4^RN,^_2@#/UGQ^FFW#6,-D)-1BMU
MN)[>24IMR,[ P4@MC/7 S@9R<4+X\N+[5#I^D>'[J\E%O#=$O,D6(WY.=QX(
MZ8[GVY,FI>&-:C\5SZ[H&IVMN]W D-S#=P&13MZ,I!!Z=JFTOPSJ&G^,+O69
M;Z.ZCFLH[8;UQ(S+CYFP,<G=T'I0!!'X\+VUO=RZ-<06KWWV"222>/*2;RG"
M@DMR.?QQD#-1S?$"2"UU2\?0+H6FF79M[J3SH\J/E^8 'D_,./U]*TO@C59_
M#T%C)=V7VB'6/[2#*&"$%F<KZCENOI2W'@S6+K0O$NGO=6*'6+D7"$!R(B=N
MX$]^%&./6@#:C\6"+4[NSU&PELO(LFOU9I%<M"IP3A>A'ISUZU0'Q"MO-3_0
M)9(9K=[B)X)5<X5=Q5QP$8CIR1[TNI^$;O6M>:ZOI;864VE-ITT<9;>-S!BZ
MG&.& P#VJ/3O#_BN/29=*U'5K":TBM9+>W,43*\N5*J93C "@]%ZD#GU +%A
MXSGO3HOF:'<6\>KH[02/,C*,1F09QDC('I^%4?#'C/5=1\)6NJW6EF:6\NGB
M@\I_E"[WY<X^15"XR<YP/6I8O"6K)IOA6U>[M';1I=TK8;]XH4HH7T.TGKW
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MB+LVX[;3SGZ9JO>Z5J6G^-F\0V%L+Z*YL_LL\'FB-XRIW*REN"#T(ZCKSTH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MD=BQ9\?,<GWS0!>HKRO2]7NKCQ5X;FM[R[?3=1FO%\^>\8M=A58Y\G[L:J0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MSC:RBV*"?8?+,F=N['&<=LUQ,*:]HOC30[6XUR?4(-1CG^UPR1KMB9$+!DP
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M8K<M*-3=\N\3-N*; ,[NO)( SWQ7;6&G66EVBVMA:Q6UNI)$<2A5!/7@59H
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MCJ&&UAG/WI&.>1@?2M[3K34+;P?;V2A(-1ALA"OS!E614V@YQTR >E;-% '
M-H>LZ_-HTFK:1#9ZIIL\4CZFEPK"1%P6"!?F^8Y!#  9)!/2H]/\/:YHFJZK
M!!H^G:A#J-Z]W'J$[J/LX;JKH1N;'8 \^HS7H=% '":!8>*]!N[[24L+.:PF
MNY+F#4&G 6-7;<5:/[S$?@/?O44VE>(K72/&%C%IOVA]2N9I;26*>,;A(BJ
M0Q&-H7DD_0'K7H%% '"Z?I>N:3KEMK1T^2ZCGTR*TGM$G3S;9D&?E+,$92<]
M&'4GFLQ?#&O:7+HPM[+[6AUB75+W9+&HA+C:%!9@6P&)R!S7IM% '+^%[74X
M]<\17FH::]G'>7*26^Z6-]RJ@3G:QP?E!Q[U7\3Z=JE[XR\,7=IITDUI832/
M<3"6-0H<!> 6#'&,GCITR:["B@#)N[_58=1FB@T9KBT2V,B3K<(K22YXC"DC
M''.XD"N<T7_A)KG49)-6\.&VN+I#%+?->Q.L,?)"(B\XR?J2<D],=S10!Y;I
M6G7^K?"&^\-1QC^UK)S;M#)^[)VRAUZ_WEZ$\5U,=I?:EXFL]<O[/^S+73K:
M1%BFD1I&=P-S$H2H0 <<YZ\#OT2V=LMZ]XL""Y=!&TH'S,H)(!/IDFGW%O#=
M6[P3QK)#(-KHPR&'<$=Q[4 >-WFAS3V0\6X;R)_$:7S$_P -FK%4<CMU)/L0
M:[_4+2]N/'NB:E;6;S:?#:S))<I)'M4R8V\%MQ^[V'<=><=,T4;0F%HU,17:
M4(X(Z8QZ5#'8VT5@+&.%4M1'Y8B3@!<8P,=.* .!MKRZTK4_&/C'[$]U:[XX
M+=$D5/,2(8=P3U&>F,YP0,UVE]/>W/AN>?381]NEM2]O%+C&\KE0<\=?6KD=
MG;16<=HEO&+>)55(MHVJ%QMP/; Q]*GH \MTW0O$=KXBM-8FT:[D==+DMIQ-
M?1,QEZC:-VU5)X 7 '?%6CH6O/HOA"RCTN2"6QBDBN9?,BS QA:(,"'R1EMW
M&>!Z\5Z110!YA;V/B6#0= T=_#UQ-/H]]'++.L\(BEC0M@H2X))!'4#%>G+G
M:,C![BEHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHS1D4 %%%% !1110 4444 %%&:
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M ***,T %%&:,T %%&:,T %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110!R.@SW/BBPU#5?MC0B>:6VLS'G]S"
MK[=V#QO."<G../I5/2-(NM+\>7=A9W]U=Z3)8"2\2[G,K1RLS!=K'D9 )Q^)
MZK4GAIK[2]'U/P[:)&VJV$TIM1=DHDL3N623(!R!NP<=QC(SFI_#MGXCTJ15
MU"'1X;([YKVX2>22::3:/G)(4#ISU&!@8H E\'ZO//=:SH=Y-YUQI-UY22,<
ML\##,98]VQD$]\5U5<;X(L&DU+7_ !$\>Q=5N_\ 1^?OP(-J/CMNY/TQ794
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M8SB%G!  &#D=>I_"@#T,45S_ (ONFMM(BB2^FM9+FYC@7[.N9I<GF.,Y&UB
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MLY)E6WC8-$Z*K#+%B""#TP,>^,G9\6>(F\/V=IY$!GN[RY2VAC"[N3U;&1G
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M4EA'Y=N\4KQLBYS@E2"PSSSGJ?4UC^!_&]KK6A:6FIZC:_VS=1R.85PI8*[
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M4/#FGW]^\#7%U DY\F,HJAU# 8)/3/7- $=SX5TB[@U.&6U!34Y%DNL'!=E
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ME' P*WH;^SN#&(;N"0RIYD820'>O]X8ZCWI5O;5H'G6YA,2$AY!(-JD=B>U
M&=HGAZ+1([Z-;RYNTO)WN)!<[#AF^]C:HX/OFHXO".CP^&)/#JVW_$ND#!DX
MR<G.<^H/0^PJ#7_$4NGKH\NGM:SP7NI16<KEMV%<\E<'&>#UK>@N8+I"]O-'
M*H."8V# 'TXH Q?#OA.T\. F*\OKQPGE1O>3>88H^NQ.  N0/R'H*T-9TBTU
M[2+C3+Y"UO.N&VG!&#D$'U! -7ZYC0O&=KK?B;5M'CC*&TPT$C CST'RNPSU
M <$9'!XH MZMX7M=3;3'CN+FPETQRUL]F57:"NTK@J1C'&,5EM\.]-%O%#%J
M&I1B+4AJ:-YJN1,.^74Y&>>>IZUU*7EM)</;I<0M,@RT:N"R_4=12/?V<<44
MKW4"QRL%C<R !R>  >Y- '-ZOX L-8GU)Y-0U*&/4@GVJ&"551V0 *W*DYP!
MQG'M1>^ ;*ZOH;Z'5-6L[Q+<6TEQ;7.UYD'3>2#D^XQ6_+->#588XS:?9&B8
ML&<B4OD8VCIMZY_"L[P[K[:EH37^HFUMVCN)H':.3]W\DA0$%L<'% &K:V-O
M9V$=C#$!;1IY:H?F^7&,'/7\:P=.\%6VGM;0B]N)M/LY6GM+.4*5AD.<$'&2
M!N; .<9]JLZYK[Z;)HAM4@GAU&_2U:3?G:K!CE<<'[I[U/XBU6?2O#UWJ%DD
M,TL(!59'(4_, <D9[&@!/#_A^+P]!=10W=S<BYN'N7-P5)WL<L<A1U]Z@USP
MO'K>JZ=J+7LL<NGL6AB*J\18C&YE(Y/H<\8K<,BHJF1E4D?WN*=G- ')WW@<
M:C%'+/K-\NIQ3M/%?P[4D3<H4H !C9@#BI[;P?\ 9-4TV]AU>\(LUDWK+M<W
M#2??9V(SDX4<= O&*K:SXIUK2U>Y&BVWV+[:MG&TUTZ2N68('V^61MR<CYNE
M;]A=:A))=)J-G#;B)E\N2*8NLBD9)Y ((/% &3)X-@,NIK!>S066J2>9>VR*
MN)"1A@&QE0PZ_4X(IMSH<M]XTT>[2'[/I^BP2"+& )9)%"[0O]U5'7CDX'>N
MF$BD A@0>A!ZT;UV[MPV^N>* ,;PQ9:I8Z;+%JEW-<N;AVA:<@R+$?NABO!/
M4\=B*KS^%GEU76+Y-2DC;5+9;9T\I2(P 0"OORW7UKH0ZE=P8;?7/%*"#T.:
M .9MO"+6K^'S'J<N-%B:*-?+&)58!3N]]H R/?UJYXF\-P>)=.CMI+F>UEAF
M6>"X@.'C=>A!_$ULLZJ,L0!ZDUFZWK,>D6D+X1YKF=+>!'?:K.YP,GG [D@'
MITH QIO!<UR]M<W&NWD]_;W2W*3R(F!M4J%" !0.2>.<DU!<_#N&ZMY%EUK4
M3<?;?M\-SE \4I&#C"C(/''0  #'?IM+GU">"4ZC9Q6TBRE4$4WFK(G&'!P,
M9YX([5=W+NVY&[&<9YH Y>Z\&F\MXQ/JUQ)<B]BO))W13O:/[BA1@*H]!UJ]
MI_AU=/\ $^K:VMTSOJ2QB2$H J^6NU<'KTSGZUM9&<4%@&"DC)Z#/6@#G];\
M,R:AJUMJ^G:G+INHPQF$RI&)%EC)SM=3UP>1Z50D\!1?:UNHM5O%F-A)82R.
M%=G5W9V?)'#%F/L..*T]!\1-K6IZS9M:>0=-N!!GS-WF<9STXK=H XR'P-/!
MH\.G+K DC6Q^PR">U#HR98A@NX ,,@ G/3G-(O@ V%['>:+KM[I\QMH[6X)1
M91.B*%5B".'P/O?IUK5C\07$^OZAH\.F[IK&-)6<S@*X?.T#C.>#UQTZ]*L:
M!X@AUZ*ZV6\UO/9W#6UQ#*!E'7KR.".1R* *^FV^J6OB&:W6YDDT6"UBB19X
M_F$H Y5^KC'+$YY. >#4^M:))JMUIEU!>?9I["<S(3%O#94H01D=F/-:X8'H
M<TN: .1G\$M/;^([=M2_=ZVV]_W',1QC@[N1@#M5&Z^'M[.NJB+Q R?VE#"D
MP-L#\T0 !!+$@<9Q[]:ZO6]4_LC0K[4U@^T?9(6E:,.%W!1D\_0&K=K/]JLX
M+@+M$L:OMSG&1F@#'L/#\UAXGO\ 5UO5:._CB^T1&'!,B*$!#9X7';U[T:WX
M>FU;6M'U&.^6W.F2M(J&$OYA88()W# Q6]FC- '$CP+>I-+,FMQK*VJ-J:?Z
M'E1(R[2I!?D8QCH01FGQ>$=7M?M1@UN)_.O9+MHIK7,<V]-K)( W*YY&.F._
M;LJR5UB7_A*CHSV+)&;0W,=T9 0^&567;U&-XY- #?"^A+X<T&+3A*LA5WD8
MHFQ068L0H[*,X%;-%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% ')_$#2I]4TG3C!;O<"TU."YEC1-Q,:DAOEZG@]!DUS7B/PYJ7
MB"X\2:AI5I)"ES;6\2)*AB>Z:-P['# %> %!.,D>G->HTR::*WA>::1(XHU+
M.[L J@=22>@H \OU;2IO$6AZA)I/AK4;&]\F,2-?2%)+C:X8PC<Q)7 )SP,X
M]>'ZA#+JOAS6+BR\(:E;7LFF/;L]VS-*S%E_=Q@DEE'S-G S@8ZUZ<CI(BNC
M*R, 593D$>HJ*YO;:S, N9XXC/*(8@[8WN<D*/4\'\J .02SN&\8>&KT65T(
M(-->&1_*91&[!<!OR/TKI=>19/#^HHUK)=JUM(#;Q,0\HVGY5(Y!/05HT4 >
M/7>C>(KK2[V&!+_4+6UFM+F)[JW,%S<1HS,T#,2&;;G(/7/2M348HM3\*^(I
MM.\,:K9W4]FL):[AD,\[$\*J_,2H]?>O3:;)(D,3RRNJ1H"S,QP% ZDGL* /
M,5BO;#4XKG4M$U;4K*_TRV@!M$=9('C4ADD4%3@EB<MZU-:23^'=1N+>]\-7
MTFDZG86\<5O:HUR+<HA4P.?<GK[_ %QZ):W4%[;1W-K,DT$@W)(C95AZ@U-0
M!Y]/I=Z?%MR(M/GLS>>'Q96\\"EH[:3YCM+C&,?+@\9P*R-,M;C5= MM#_X1
MV^@U[3;)X%N[PL(8"8RFZ-LD$MA> /7GBO6** /+[2;4)1X'M'T'5(IM+E$5
MWFV;9'B,QAM_W2#UR"<"O39E+P2*.I4@4^B@#RKPUH\C^&_#.B7&F3Q:KINH
M?:)Y);9@L"K*[Y\S&T[A@#!.<^U:E[HMY_PL!].MI ND:D(]2O(\YVO"P! '
MHY\O/K@]<5Z#6-8Z5IGAYI)VN9#-<R"/[1?7)D=LD[8PSG.,DX4?J: -FO*[
MX3VG@_QC9W&FWQEGU>62)!:N1,CR*05.,,,*2<=OJ*]1EFC@A>::18XD!9G<
MX"@=R:(I8YX4EB=7C=0RLIR"#R"* /,O%*W&LS:Y8:+9W@DNM'M!#BW:-"$E
M=F3<P !V2+Q]1UXK8\,3Z7J>MPW]MH6M0WB6S1276HO-B)<@^6-[$-D\\=,=
MJ[BB@#G_ !L2?!&LQJKN\MI)&B(I9F9E(  '/4UF>'_$UK:^&-&L([>]EOTM
M;>W,!M)4P^U5.6*;0!SDY[5U\T\-M"TT\J11+]YW8*H^I-24 >1V.EQ+JFIZ
M=K&EZW<7KZNUU D3R"WF4L"LA;[@V@<Y],=>*BBMD@\+>,HGL)Q-+KK2P*MJ
M^63S%*,N!]T8;IT_&O8:* /+-1O);1_&EIJ-A?3/JD!DL9X[9W62,Q[4CX'R
ME2>AQW_&G#9+:WD$^M6NM_8+S1K:")K)90043;)$Z*,C).1D8ZUZ_10!YKI.
MC:4WC>PAFT)XX8M%2***Y@,HC?>6PS8*[MF.IXZ5Z-.QCMY'6,R,JDA!U;CI
M4E% 'D6@W5S/K7AZ:6QOX+9(KJ%K)-/=(K3<ORH'V[F)')8G'?CFM?P)#<V6
MM06D$DMUI T]C"]S:-'/:'>O[EF( (ZD=^/3KZ-10!S_ (X@EN? ^M0PQ/+*
M]JX5$4L2<=@*P[Y[34OB)X=O39S2VHLIC&\EJX$;DC:2& VG ;&:[RB@#Q>T
MMKB"WT2YFM]473+2_O5G6S65)(?,8^7(%4 [<$C([-[XKT;P=9V-EHTB:;:W
MEO:/</(@NRV]\XR^&Y4$@\'Z]ZZ*B@#C-7L+.^^)&F"[L([F(:?,K&6WWH&+
MH5!)&,X#8_&N4M+2V,VH:7J^GZS-JL>J/<6\$+R+%/EQLE# ;5"C')Z ?A7K
MC.B%0S*I8X&3C)I3TZXH \66UTV^\+Z]HVGVT;:VVMR&W2*'#+MF&&W <*J[
MN_ S70:U(8=9\;2MID]_%+9VD:PHCXEP2K8*\G;N!(!S@&NM\,Z"?#T-W;G4
M9+QKBX:Z;>BJ59SEN!V)S6[0!XY>0:Q<2^+1IZW=W+.ME(,V;0BZAC!$B)E<
M8Y QG)&>M;?B%+?7M$UJ]\/Z1?-?S6\(N'>-XC*BNI,(5NIV[ONCVR:](HH
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M1A%R>IP.*LT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M;F73XT:X>ZW!2SC<J+M]AR>V1P>:Q7\ WZ:%K&BV^M1BQU"=Y%66UW-"&.2
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M_P"4'/'3KTY_I69XFM=,D\8>&IM1\E=GVD1M*^T;MJX'7GOQ7%S6\?\ 9OQ
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M_:(BOV6VM%)!WG#<<G &.N.>F>: .YHJ"TN1=VL<XBFA#C_5S)L=>>X[5/0
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MO4]+UAO%\]UIMA>VEW+>Q;Y%8/:7=NJCYI,DA6 ! P!VQSS7I5% 'E%_IOB
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M<+;-<"%C"DIZ*7QC/('H"<=:Y_7=%U'Q!XAT&[M-)DTQK*X$\]Y-+&'*<9B
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MP3@$_,<<^E<E-I=S;?V=K>C>%[VVL[:_6>XL9B7N;D["OF;2QQLW$ 9YR3@
M5U/AR[O+CQ;KDTFCWEI9W*P20S3QA-Q5,,",Y!Z?D<XH W=1UW2M(FBBU#4+
M>VDF#-&LK@%@HR<5%#XFT6X@AGAU*"2*:<6T;*V092<!/8Y[&N;\;RK!XM\'
M2O;M.%NIB52-I&'R#Y@J\G'7OTK(GT;4HUU+6(K"Z>VFU^UOH[58<3&.-AO?
M8><L>0#S@9XS0!WDOB/1H([MYM2MXTLY!%<%WP(W/13[TR+Q3H4\9DAU2VD4
M2-'E'W<KC=T[#(R>@R.:\_\ $K:MJ^E>*XX?#VJ1/>BT>TWP;O,V,N<@9P<
MG!Z8YP>*W?$]E)>W-G<64>I6-_'9-)#?VUNSJ>A,$D>WH>#@CMB@#K$UG3I9
MI(8[N.22. 7#*AW?NST88Z@^U0R^(]'AM;>Y;48##<H7A96W;U')(QV'<]JY
M%9=8L-8T^^N-"N&6?0A;/%8Q K%.'R$QD;!@GKQ^58>D+?V.A:/IT^A:M9F/
M3+B-I[>TW2M(7SY><$HIQG)QDD<@9R >F7'B#1[583/JEG'Y\7G1!IE!D3&=
MRC.6&/2J&H^,M)L;?39TG%Q#?W(MXY(N54]220.,>G7/XXY#2=,O8M5^'C-8
M7JI8V<\=TTENP\EVCV@-QQ\P./;![TVVM[RWT^TEFTZ_58/%4ETP^RN6,+"3
M#A0,D?,!TH ].EGCAMWGD;;$B%V;'0 9S61IOBG3-0\.0:V\\=M:S#@RN!@Y
M.!]?:M.Y#36$P13N>)@%/!R1TKSK1EO[+1?!D\FGW@BTQYH+^)K=]\3&,J'"
M@98#GY@#PQ]\ 'HUG>VNH6ZW%G<1SQ-T>-LCZ?7VJ*\U;3]/D2.\O8('<959
M' )&<9QZ>_2L#PC9746J^(]1D22.TO[T26T<BE20$ +[3R,GUY^7/I535;V?
M1O%U]->Z/>W^FZC9Q0I):0&784+[D91SSOSG@4 7KC7KM/B%IFD120MIUU8/
M<'"Y8L#P0V>F,5L0Z]H]R9A!JEE+Y"&279.IV(.K'!X ]:XYFN+/QII=S%HE
MPBQZ#)%';HA*Q/N#+$7 V@X7%9GAF2Y.O^''.GWT2"QN('B:PDB@M&;:PC!9
M<D?*?F)/4<T >C)K&F/]D*:A:M]LS]FQ,I\['79S\V/:I%U.P:[%HM[;-<L6
M A$JER5^\,9SQWKS"TFN$T_P7I[Z7J2W&GZA_I>+*39#]]<[L8(.X'(SQUQ5
MFU^VIKR6>E&>:.66Z*PW=J1)I<K!_P!Z)< %6). 3DAAS0!Z+'JFGRWALX[Z
MV>Y!(,*RJ7!')XSGBH=<UFUT#1[G4[QB(85SM7EG8\!1[DX%><^#[2SDDT6T
MO+#6TUC392KP2!A!"VT[I=V-N&Y.,\D^G-=)\3(?,\.6DD@S:0:C;2W0W$#R
MM^#G';)% &EK.I:OI/AQ;Y8[.6Y61/.5MRJB,X&%[L0"!R1G!/'2K'B/5+C0
M]-_M2.-);6V.^[C_ (S%W9#TR.N#U&>^*H^/KQ+3PA<L5:1G>(*B#+-^\4G
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*#110!GWNB:=J-Y;W=W;"6XM_P#4R%F!CYSE<'@^OJ..E:%<UXKU:[T&;2M0
M%PJZ:;I;>\B\L$X?(5PQZ8.,CWK T3Q9JNHWD^F/=1&[;44CMV$2_-9[?,\W
M&>=R \],L.!0!Z)17"3^(]7N?#FI^([&YC2*PGE'V%X@0\<3$,&;.0Q SD=.
M!@]:DD\1:CL\4.MQY;6>FQ7MK$\:YB+1NY!XYY4#F@#I[K6["RU:RTN>8I=W
MN[[.FQB'VC+<XP,#WHU?6K#0K,7>HS&&$NL88(S98]!P#7'/J$NJWOP[U"<
M37/F2OCIN-N2?UK(\4:Q?Z]\/#K#3K#:W-^D26BH#A$GP"S$9W93/'&.* /3
M[_4+72[":^O91%;PJ7D<@G _"I+6YAO+2&ZMWWPS1K)&V,;E(R#^1K-\5?\
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M;9()4B,3S2R(S?.S;6'E #@%@<FIXM7\2WGC/4=(A_LN.UL7MY"S*Y=X7))
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MW*[7VK$PR)0-W/ 8XSVK6UWQ-,FA:WJ LK*]TZUNH[6%)<GS&W*KL>,$+(V
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M=.MX)5OIY%E$LI3(6-FQG:< ?>]?EQWS0!KZ;!!96JV$-R\WV?Y3YLN]U!Y
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M)-0LHDF>2\MT6#_6LTJ@1_[W/'XTQ=7TUWD1=0M6>-BCJ)E)5@,D'G@@<XH
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MM;B^N;*&=7N+79Y\8ZIN&5S]0,U9I JABP4 GJ<=:6@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MW"DJK+(!C<H;&3C/6KY=0,D@#US7@?BVYL+G3]&MECE>]3PVC*T@WP[=G\"
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MO_ OB7Q0);BQ:^M\VQ$Q4JB* N/3<P/8$@B@#T$W<2S+;EE^TM&95AW#<5!
M)'L"P&?>J/AS6T\1:#;ZK' T"S%P(V;)&UV7K_P'-<L8+2\^,T5PS+*@T,30
MD,=N?. # C@\&L7PO&MCX9\(WT5Y<Q2W&JO"Z?:6\MT+S KLSMZ@'IUH ]8H
MH-<4^D#5/B#J@FU+4!';6MM+%;P7KQHK,9,Y4'_8''3F@#M:,UY=X?OKG7;6
MRU>[\2+9WL>IXN[6,NS,/,*K 5WX ( Y"=!D]&-4WO=3L]#U2&YENENFT>:[
MM]3M[UGCO%!0[\'E&&X  8X8T >NYHS7E<<^L:9<>&[RQU&^O)=2TF:>]BFD
M,H++"'5PIX7YF X S@#DDY;'=WL?AZP\3V7B)9KYK&9GM55W-Y)Y7\2%R 49
M23M ].!0!ZKFFQ2QSPI-$ZO&ZAD=3D,#T(-<-;26E[I-C>1>([B<7>ERQO;&
M8OY[!,L_7Y&4Y!(QU XZ5M^!K467@?1HA)YF;6-BPD+#) /&>@]N@H WIIHX
M(S)*ZH@(!9C@9)P/U-/S7%?%%-W@[=OD4K=V^"DC+UD4<X//7OWP>HIRPMK7
MB;6M'FN[ZV@TV"W6U,%W(CY=6)E)SESG ^;</E]S0!V=%<_X)U"_U3PC8W>I
M!?M+JP+J"!(H8A7Y_O  _C3/%ES(BZ;:03W(N+FZ 6WMG$;7 52S*9,C8N!D
MD'/&.] '1YHS7F@O-1N?#&C&35;NUN)-=:S8PW.\LGG.NS>1\^%7@GKC-6_L
MVJ:A<^,]$L=4O(I+5K=K&1KART;M"&(W$YVD]NV: /0,T5QOA'66\3S6]]'-
M.L%E9I%+$7;#7+ %PV>I0*.N?O\ K794 <M!X[L+E+R2/3=6,=DYCN6^R_ZH
MCD@C.>!R< UT%A?VFIV,5[8SI/;2C<DB'(8=*X+2+/79_P#A+3I.I:?;))JE
MPN+BU9V#;5YWAP!VZJ<8_"L3PSKT[>&_!^CV#+9V]S+<PSM),R^:Z<A5D4 C
M<SY&WGC&>M 'L.:,UYC>0Z[;RZ%I;^*96:;5989)K5PSK'LW"-B0<LN",G^\
M,BE37KVSN'T6[UF7RGUW[&+Z5E$J1"(2!<@  LV%SCHQ]J .YUS7K;0(+::Z
MAN)$GN$MU,* [6<X!;)&!FM3-><^+K)[/0)+(:Q)=.=8M7B$C>9):JSKA26)
M)Y!(SZU7U'4=2L?^$TL8M>O(VTV.WN;:20HS@NA++DK]TMC &,=O2@#T[-&:
MX7['JR^,6T9O$VIM!+IINFD(B#+()-ORX0 #G./;TJG!K=_=V.B1MJEQ/=3Z
M=+*]O:A$D<@X$[.>%48/'<]C0!Z-FLVPURUU'5-2T^%)EGTYT2;S$V@[AN!7
MU&*XV*;6O$%OX4=?$%W8G4+)I)Q;I'@LJ*<C*YR<\\X] *IOJ,^F>,;S1WN)
M;2VN[R"*;6&9=[LEK&1%DCAF/<_WCCDT >H44R)/+B1-S-M &YCDGZFGT %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%<'X^&G0:
M]X9N;V&63=<R1R)%&\A>/RVR-J@YY([=S[TG@:;_ $G7=4M/-A\+R;'L$E;A
M=BD2E5)RJ[@>..G2@#O:*XFV^(MO<M;-'I\DD%W"\D#12J[ J,A9%Z(2!ZD9
MX-+:>/WN(]&NI="NX-/U2184NG<$)(W"@J.=I/ )QGGVR =K361'QN4-@Y&1
MG!]:X7P_=C1Y?&=S':W-T(M4++! "[L61. /J?P%:/\ PG5E ^L17L+13Z88
MPT4,@F,OF'"!<?Q9P".Q(YH ZED1]NY0VTY&1G!]:&17QN4-@Y&1G!]:Y^X\
M4'38[^75M.GLX;58V67<&2;?P%4\?,#P1T'KBLV7X@1VT.IR2Z;+*+&-9R;:
M575XCU.XX&5/!'N,9'- '9[5W;L#=C&<<XH "C   ]JY.#QG/+J\6EMH5TEW
M/:K=P)YT?,9.#N)(VD'MS23_ ! TR'3],G?;!/J"L\<5W*(@@4X;>W(&#QQD
MG\Z .J:WA8(&AC(3[@*CY?IZ4YXTD #HK8.1N&<'UKC;+XA1ZE%8/8Z+>W/V
MN66 !'CPLB DC)8 C !W=,'UXJMJOC:^FL["72;,QS_VVNF7D$[J&5AR4!&5
MYX^8=* .\VKN#;1N P#CG%+2#)49&#CD5%=W M+.:X:.601(7*1+N=L#.%'<
M^U "QVT$3%HX8T8]2J@$TZ.*.%=L4:HN<X48%<W;>,!+=W-I-ITL=U#8B_$*
MRJS;,X*MG 1P>HSCWINE^,CJ;::5TB[BBU*%I+:9W0J[*FXKP<CO@D#.* )_
M%7A1/$[:<7NS;_8;@7";8@Q9AT!)/3VK=%M!Y7EF&/83DKL&"?7%<Y:>,X[K
M3+JY-A+%<P7_ /9XM'D7>TI*@=. .2?H":ZB@"/[/!Q^YCX78/E'W?3Z4&"$
MQ>48D,8_@VC'Y5S-IXIFBNO$DFK11V]AI4H"RQL&.W:#R <[CG..W2F)\0=(
M6:2*Y;RF6W:Y'ERQS JO5248@-TP#USP30!U)@A:(1-$AC'1"HP/PH:W@?9N
MAC.S[N5!V_3TKD]8UM]1TG7-,N=,O[&>+3'NE=F !&#C#HW# CD>QZBET'Q:
MLT6EV,NG7R/<:>+BVD?8?M 15W8&[(/.1NQF@#J?LMN=W^CQ?/RWR#GZTDEE
M:RQI');0NB'<JM&"%/J!VKG-&\<6^M)IDT.F7\5IJ,CQ0W$P0+O4,V,!B>B-
MSC'&*99>)=,M(=7N5CO_ #!JIM##*V]Y+@A %C&X@*>,#(QR>* .HDMH)FW2
MP1NV,99 30+:!8VC$$81NJA!@_A6$OBM5^U1W&E:A#<V\T<'D[ _F-)RNUE)
M!&.I)&.]8GB3Q%%K/@C67M#/;7-A=QVTRA\%7$J X93R"#0!WBJJ*%4 *!@
M#@4N**0G )H AAL[6WD>2"VABD?[S(@4M]2.M*]G;27$=Q);PM/']R5D!9?H
M>HK#TWQ9%?WD$,MA=6<=S!)<027&U=R(P!++G*\$'D=#7/ZOK+ZMKG@Z]M;>
M\ALI[UO+F:4*LR%">4#=\ @D=,],T =X]K;RN7DMXG8]2R FC[);% GV>+:#
MD+L&,UR]UX_M+.TN+R73-06SM+LVMU.R*JQ'?MSRV6'(/R@]:O)XC6Z:_M9=
M,U*WEAMA<!"JAY8VR 4PW#<'@X(H VKBSMKM56YMX9E0[E$B!@I]1GO3F@B>
M19&B1G7[K%02/H:Y>S\3V.G:?X>M(K'5)5U*U#VG E; 3<%=BWWL=^GJ0 :9
M?^(=*U;2+2::/5(XFU1+3$!V/'.LFT!RK8V9ZD$@_6@#JI+:WE;=)!&[=,L@
M)IOV.UV[?LT.W.<;!C-9/_"31-J<EI%8W<J1W(M'GC"%4D(SR-VX+R!NQUK+
MLO'0&@OJNIZ;=0Q_;7M4\A5DW'S&10 &))X / R3QQ0!UGV6W+%O(BR1@G8.
M13196JD$6T((Y!$8KG)?&\4<#N-%U</% ]S/'+"L311*<%CO8 YP2 "3QVJ>
MW\1S77B=+&&T>2QDTU+U)5QN^9B.02.PZ 'O0!S4GPGM94EMS)8K')-YINUM
M6%T/WF[ ;?M''RYV].U>D"N)LO&&GZ;X7M]26SUB>SENY(2\FV22-C(5^?+<
M+G@>G ]*VK[Q38Z=/>17$5P!:M%&9 J[9)),;8UYY;D9S@#/6@#9EBCFC:.5
M%=&&&5AD'\*C@L[6UB,5O;0PQG@I'&%'Y"LW1_$=MJ]_>6"Q/#=V81I$9E96
M5LX*LI((XYZ8JYJVJ6NBZ9-J%ZY6"(#.T9)).  .Y)( ^M $PLK0$$6L((Z$
M1BG-;6[[MT$;;CELH#D^]<\/&4$-W<65_IU]9WL5JUXL#!',L2YR5*L1D8Z$
MBK7AWQ+'XDCDGM].O[:V$<<D4UU%L68."?EY.<8Y^M &L]I;2-N>WB9O5D!-
M<OXH\"6?B*XTV0K;K!8F3%F\9$4F_&22A!!X!_"N@U?5K;1;!KRZ\PJ&"*D2
M%WD8G 55'))K&NO'.G:?%J!O[:^M;BPC6:2V>-6D:-B '7:Q#+DX)SP>N* #
MPOX,LO#4&H0QB)X;V42- $/EH ,;0&+$^N2?P%;CZ7I\EJMJ]C;-;J=RQ&%2
M@/J!C%8]EXTTV]U2*P:"^M6F@:X@ENH#&DR+U*D\\ 9Y X^M5E^(.C&>W0K<
MB*Z1WMYMJLLH1=QPH8L"1TW*,T =1#!%;0K#!$D42C"HBA0/H!4E<II_CVPU
M.SBN[?3=6$$VP0R/;;5D=GV!%.<9SWSM [U6UKQ_'I^@WFH6VFW+S6=ZEG<0
M2[08V)&3D,0>",8/4CWH ZVZLK6^C$=W;0W" [@LL8< ^N#2/86<C2,]I S2
MIY<A:,$NO]T^H]JQ6U>Q_P"$IMXIWO[6Z737N&BE;; L>Y<E^<%U/&1G'/-+
M!XPT^:33B8;N*VU)MEG=/&/+F8]!P25)YQN Z&@#2FT32KBR%E-IEG):@[A
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M,NJ$Z+J-C)*D0BSO<;=I7 WDD-]WVH Z30M*_LC3%MV9'G=WFG=%VAY'8LQ
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M6O+FV(D1K=%=W>,JF#GHQX.,<XZ43WT4%U:V[+*S7)8(R1EE&!GYF'"^V>M
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M,,"#D=#Q721^'_#-YJ6H*FGH9PR_:TV.D;L?F&5X1SW/7KSUKHP     !V%
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MP0I (R.QP:S9?"NF274TZ_:HA.YDFAANI(XI6/4LBL 2>_K6S&B11K'&H5%
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MIO9/*8GDY7//XT <1X-O;U?"MM96NI2VMO/JMPEHD"(UQ/"!G$08%5 ;))/
MYYJ^=>\1S_#_ $[7TOIHS8W3KJ,:1QEYH4D*EB2I 8 9..#S7;7_ (6TN_\
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M^P&._3(!V?\ PG/A7>%_M_3P3MQF=1][I_GMWJ1_&/AU+<SMK%J(PYC)W]&
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M0@]Z@OM3LM-1'O+E(1(VQ Q^9SZ*!R3]*I>%OMO_  B^GC4(%@NA$!)&L0C
MQP/E'W>,<5D^,?M/]I:*T.ESSQ)+(\M[:P"6:V 7@("#C>>">P]\$ &XWB#1
MU@M9VU.U6*[!:!FE \P 9)'T'7TH@\0:3<::^HQ:A ;.-RCREL!6!QM.>^2.
M/>N%T2QN['1/#EK>:7?&6VUF>:96MV<QH1* Q(!!YD0Y&>_I1>VNK)J-U?6^
MFWMS!::\+R2UV,IGC\I4#QY #%6!.,\X!Z8H Z;PWK[:OK^OVHNEG@LY(?)
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M:);@/&%2$;@-W\9P 1CZBIO#?VJ7Q=I5W<1:JL9TEH'66Q:*"*3<A\I1MR%
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M&BZI8?#Z&\^SSR"!HV1FSG$)!5AW&X 8/?BLJ2[L[7PY/Y=Y;16=CXL+BT!
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MC@G:7>T48E) !).!@DGUZG-:>KC3[_7?$6E7U[I_VN6\BF@U&YNDB-M& IV
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%&: "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH *,444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
*%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>pinnaclelocrenewal4thloa005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pinnaclelocrenewal4thloa005.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** *R_\?W_;(_\ H56:K+_Q_?\ ;(_^A59H **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@"LO\ Q_?]LC_Z%5FJR_\ ']_VR/\
MZ%5F@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *H.+[_@
M'_CU6JK+_P ?I_W!5F@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** *R_P#'ZP]$%6:K)S?R?[@JS0 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% %6/_C_D_P!P5:JK%_Q_R?[@JU0 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% %6/_C^E_W15JJD1']H3#_96K= !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 4XAC4)S_LJ*N54A.Z
M_N >VVK= !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 4[?_
M )"%S]!5RJ5M_P ?]U]5_E5V@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** *5K_ ,?UU_O+_P"@U=JE:\WER?5E_P#0:NT %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9FLZW!H
MD5M)/!<S"XN%MT$"!SO;.,C(XXK3K$\2:9?:DNF?8?L^ZUOXKF3SW9047.0,
M \G- %.Y\9PV=L#=V4EK=+%YTMO<3Q1F)2Q5<L6VDMM. #VYQ4D7C"TU".W.
MC6\FI22PBX:*-E1HXSG!;<1R2, ?TYJ#4]#UN#Q4=<T*>Q8SVPM[FWO=P7Y2
M2K*R@G/)R/\ (CBT+7[#Q&-8@O=/G^UV\<.H"=&3:4SAH]N?[S<$CMSWH NZ
M;XMM]2;1S':7"0ZK'(\$C%?E*<[6&<YP">XJO_PG6G1:/=ZC>QO:K;W[V'ER
M.N6E4XX.< =>2>U8?AO3]5O?!_A#4=,:T>>QBDREV[*K*RE."H)X^E68/!FM
M0Z?<NM_9)J::Q+J=HZ(WE9?(*N#S@AB.,X]30!IVWCBRN4(6-1*UT;6$^>GE
M3-M# K)T((...<\8I?\ A(]2EUG1K:/298HKR":69)F"/&49%(/TW9XZY%,O
MM'US5M,,.K6^C7_F29>S<ND2+MP"DFTL'SDYQ[#'6HM.\,ZOIUSX=G%S;W#6
M-M):W7FR.?E=E.4.,L1MQSCM]* -72O$:ZQ) ]M93-93B39=!E*@HQ7# '*Y
MQD9^G!K;KCM(\+7]MXGBUBX%G;.L<BW)LY'Q>EL!6="H"$8SP6R?2NQH YJ^
M\96M@DMV]K*^DPSBWFOXV4I&^=I.W.2H8A21WS4Z>*8I]=N-)M=.OIIK:2-9
MY J".-9 2KY+<C /09K*B\*:E!H=[X<1[-M(GF8QS,S>;'$[%W4IC#$$D [A
MP<D<8.KI&DWMGXFUO4)TM%M[WR1#Y3L7 C4K\P*@=\\$XYH WJY6\\<P6DFI
M@Z/JCQZ7(J7<PC38BG!W#YLL-I#<#IUQ755YUID6K:C?^-;.Q^Q&*XO_ "3-
M/(VZ/,:JQVA2&PN,#(Y% '0GQA#+JITZSTO4+N40Q7!>-4">5(1ALE@?7C&>
M#]:JK\1]!>]@MHW>0W%S]EC9)(F)?) R@?> 2,9*@<CUJSI?A^ZT[Q;<7X,'
MV!K"&TB'F$R9C)Y(VX[GOV]^*OAO0?$.@V\6C_:[$Z3;RLT4ZAOM#1[BVQE(
MVCJ06ST[9Y  6WQ$TRZMK.Z6PU)+2ZN1:BX>%0B2%MN&^;U[C(K3F\2"'5K>
MT;3[E8)KDVHN) $!D"EOE4_,R\8W#BN,\'Z3J&K^#M/T\P6D>F"\-S)=).QE
M?;,SA0A3 .X*"=Q&.G/34'A?Q FJI=2-IET8]2^U"YDDD$SQ?,!']TA0H;@#
M(X[4 :]IXPMY[/5KB:RN8#IUW]D:$X,DC$J%VC/\6X8YJ&[\:_9IM80:'J,B
M:3S<2CRPFS:')!+<D*<X'./K53[+:ZU\0ENK"[2>SMX%>^6,AXVG0L(03_>&
MYR0#QM7/:K-UH>KW-GXL@\NQ4ZN"MN?M#G:#"(LO^[XX4-QGKCMD@%RU\66T
M^I16LMI=VJ7%JUU;S3J LR+][ !)& 5.#@\]*I0?$+1[K5+.QM3]J:\61H#;
MRQNQ*KN 90V4)&<;L=.<<XBN/#.IW]YHHN5LUM+73IK.Y\NX<N3*JJ2GR8(
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MWO&2W:TGM9I?*+(S!@RO@X((]* +UMXJTV\BLFM?/EEO5=HH!$5DPGWB0V,
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M22ZNY1'"F-S$9ZG 'N22!^-9WAVT2WM9Y(]%ATE9I?,6%-N]AM'S2!> V<\
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M=(N-5E,#Z])9?VC,<,8E16"EACDL2NX$?=- 'J54XQ;VVI&&&Q*/.AEDGCB
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MNDT(M3#-;R.V'C(/\/(PX)[_ %KIM0U;Q#'XJL?#=I>V2R3:<;A[N6V)RX8
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M^NW_ +**OUGZ;\TMV3U\X_RQ6A0 4444 %%%% !1110 4444 %%%% !1110
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MY0[F#!E )!(!'(]N]>F5E-H$#>)UU[[3<BY6W^S>6&7RS'DG!&,]3G.?TXH
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M,P&YP&P0"<]0,X)[YI/%DL=M-H-W,CF"#4@TC)$S[08)E!(4$XW,H_$5T=%
M'GVHO';)XNT_58)I9[YS+9*(FD\U#$B($('4..G&.O3FNST>WN;71+"WO9!)
M=16\:3./XG"@,?SS5LRQK*L1=1(P)52>2!UP*?0!QNJV^D:A\2+"WO[.*Y==
M/E $MN74,74J"<8SM#GGI^-<G!9VL^HW^E:U!KTFI#4Y)H8+=66&<%\HX<#&
M  .21@#CTKUUF5%+,P51U). *.",B@#CX+JQ_P"$H\4HX<#[)$7,<9RVU7W[
M3CDC<!7)Q^8GAGP==W']JQZ7;6LD-RUB&62&;  )4#..&&??WY]<)5<9(&3@
M9/4TM 'F<#VN@7VC:A'9:D_A_-TIFN$:1UED92)BF-P#;6 ./XB>-W.@TUE#
MK?AN\M]/N;?3_-NQ&6MW8EI-I#;<$J&8M@$#\!7>44 )7G.J.XT?X@V\BNMS
M)(S1@(1N0P1JN"!@YQC'<\5Z/38Y$E7=&ZNN2,J<C(."/P((H \UNX(@FGP:
M'&EO=S>'+B.'RT\O+L8B@S@88D2'GG.:N^#_ .R[Z^TV>.+5CJ%E9M"R7,'E
M);#@%3\JYR1QC/0]*[^B@"IJKF/2;QQ:R716%S]GC.&EX/R@^IZ5Y;I=S<7&
MLZ8=,2>*6;1+BVAB%J\45H^U61%9A\S K@L2<\=*]=IJ.D@RC*P!QD'/- 'D
MJ7MG=)X&A2QN8KNSN"EQ$ULYDA<)C<W&<;\-_P#J-6K>.XNO J:5=I<1^)XM
M1^_Y1\SSS,6\T$?P;"<MTQD>E>I44 >.7%EI5SI?CFU>TBGU>;49([95AS(Q
MPFS;@<?,2>/QXKI='LX;+QEXD2_CS-/96VPO$65D2';(=V,8R<$'KBNITC11
MI$]_(EY/,MY<-<-'(%Q&[==N #C@=2>E:M 'E?AJ7^SM.\&7.HLZZ9';30R;
MUQ';7!8;&DS]W(+*">F?>H-2TOB"":,/HD_BB.:VA;E1#L82, .!'N/';GWY
M]8\R/S/+WKOQG;GG'TI=R[]FX;L9QGG% ''^#H_L_B;Q9 D"6\ O(FBC2+8N
M/+ )'8YQV[Y]:TO'%Y!8>"]4N+FWFN(5B :*%RC-E@.HY YY]LUT%'48- 'C
MLUS%/;>,7BN+.2V?18G0V:&.'> X&WDY(( S[8[8K66:STM])N='2TBU>_T*
M=@J$%II0D;1@Y.6.X,!GT->E;$VA=J[5Q@8X&.E#(C[=RAMIR,C.#ZT >1F^
MTBXN_A_/;20&Z6?;=DX\U9"@!$G<$OGKU->O4U(XXRQ1%4L<L0,9/O3J "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH SM+_ -9>?]=C6C6=IG)N
ML?\ /<UHT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %8VL7MW::QH44$JK;W5T\,Z%,EAY,CK@]L%/UK9K-U'1TU
M*]LKF2ZN8C9R>;$D14+OP5R<J2?E9AC..: .*\0>(/$MAH.M:Q%J%HB:5?>4
ML*VN?/3=&,,2QQ]X]*U;K4->TRZU2*XU*UE9-*>]C)MMB0NI(Q][)7ZG/\JT
M)_!UA=:/J6F7-Q>36^HRB:??(-V[(/RX''W1^50:]X9,VG:A<6]Q>SWK:5+9
M1QM(")<H0,\=2V#G(YH S;/6?$MJWAB]O[NSN;/5_+@FA2$HT;NA=74YYX7G
M/'H/2"WUU]$T6=8=OGWOB&[M8\D#!,TAR-Q SQ@9XR1UZ5K^%O"L=AI^E3WL
MU[/<VMNHBANY%9;5RH#[,#ZCDG X&!5B7P5I5SI%WIET;BXM[FX:Y)D<;HY6
M)8LA &#DD_CZ4 8<^J^+M.-E'>-%$EQJ\-M').(V>2%U;((0@9!7MC(/L:KS
MZKXIME\4)_;4,AT';.KM9J#<*8A)L.#@<9&0,\]:Z.3P7820VJ/=W[26]R+I
M9WGW2/(HPI9B#G R .G)J6?PE93IK"&YO$CU?'VE%E&.F#MXXR.#ZB@##U#Q
M%KFJ:Q?:3H:&&>SMH92Z^4Q9Y%W#(<CY1P..>>HXR^/4?$]YXF_LB6\M["0Z
M/'=R". 2^5*7*L 2>1QW['\:U;KP7IUS?07R7%]:WD<(@>>UN#$\R  #?C[W
M3_.!B5/"EE#J7VZWGNX)19"Q41R#"1#D8R#SG)R<G)H YK1]2U37O$?AV];4
M9[6*71S=SVH50C'>BG@@\-G(/7'3%6+'Q%J?_"3Z=;75\D\6HO<1!+:$&"(H
MNY=DI +D ')Y&3[<:MAX'TW3'LWM;B]1K6$VZ_O0=T1?>4;CD9^AIEAX#TS3
MCIWDW6H$:;,\MHKSY$8?JF,<KUZ\\GF@#-L;W6++X>M?-J0NKPW+ 2W$(.%-
MP4Q@$>N?;I6B=2U+7-:U>PTR\^P?V44CW-")//D==PW!NBCIQ@G.<]*?-X*M
MI=%FTI=5U2*VEG\[]W*FY?G+[5RIP-QSZ\ 9P,5<N?#,,VHG4+>_O;.YDA6&
MX>W9!]H4="X92-PR<,,$9ZT <YIOBG6=>U'2;>U>&Q6]TQ[B3S8"[1R)($8C
MYAD'G'L<\]*Z;POJ=QJ_ARTO;L(+A]ZR>6,*2KLN0.V=N:;%X9M+?4+2\M9[
MBW:UM1:1QQE=GE=<$%3W .?:I] T6+P]I$6FP7-Q<11%BKW#*S_,23R ,\DT
M 8%_J^LW5GK&J:9=10PZ5++&+0Q!S<&(9;<V?ESR!CIP3G.*; 9]7\:Z7J4-
MY+!;RZ0)_(\M3N5G4[#D>X]ZUI?"EF]U=R17-W!!>N7N[6)E\J<D '.5)&0.
M=I&:LG08!KD6K)<7,<D4/D+"C 1>7_=VX]>: (/%6H7VE:#)<:=;33RAE4B"
M,.Z*3RRH?O$>E8-IXGO9(O#OV34(=374+^2!Y5M_+W0JK$DJ<%7&,^G7VKJ=
M7TB/6((8WN;FV>"431RVSA65@".X((PQX(K,_P"$)TW^S+>S\^\$D%R]TEVL
MH6;S6SN;<  ,Y/  % %"X\2WMK<7&GM-$;B765TZVF=,"-6A23)'\1&X@=,G
M%5/%,>O6OA'4(]0OK:X/VRT%K.D91F4RQY\Q1@=?3M6T_@C29+&[M2UYFYG6
MY,_VEC+',JA1(C$\-QG/?OQQ33X*LY-*EL;C4-2N&FECEEN9IPTKE#E 3C
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M&!P >_ J.'Q;K*1^&;V[L[,V6M-'$4@+&2)W3<K9) QUR,<#N:EB\(G0M+N
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MNM+AM)+32G>.:.;=YD[H@=@I'"]< D'GTK3UO15U@63"YDMI[*Y6YBE0 G<
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MAX@\2B\EC>TMKP6]NJY!3:H)X]\@YSUS5O5;W4X/%.BVMJ83:7 F,R.Q5B5
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M)%<&)[^7-MY:EE#R#_EHX &T9!'7(HTJ>V\1-X$MKV=KDS6-RERBW+ -M10
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MI>-M,O;BXG\R7P]%.R!\+N+C/ XP>M=_0 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% &5HO^JN?^OAZU:R]%_U$O_7=ZU* "BBB@ HHHH ****
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M@_0FKJZ!HZQ0Q+I5DL<,AFB06Z@(_P#>48X/N*M7=E:ZA;-;WEO%<0-]Z.5
MRGZ@\4 <#K=W?^'=8UH:?=W5S,VAF[Q.YDQ*K[=P7HO!)P !QTJY91?V;KGA
M=]/NYI8]2@D%YYDKR"4"+>),,3M.['3'WL?3JQHNEK=170TVT%Q%&(HY1"NY
M$QC:#C(&"1BI+;3+"R8-:V5O P78#'&%PN<XX[9[4 8WBA7DO- ACO+BV,VH
M&-C!)M++Y,A(QT/*CMQVQ7,ZE%/;>&O$=X-4U&6?1KIS9-)<L=A54<;L??\
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MKV_F$Y6(/Y8+XQ@%03@D>F<UZ;;6T%G;1VUM$D4$2A4C08"@=@*IIH.EQB[
MLXRMYN^T*Q+"7/7<"><T <MK$NH:#JKVUA=W<UK<Z5<S.TTYE:WDB4;9%+9(
MR6QCIGH.*U_!45XWAG3K^]U2ZO9KNSAE;SMNU25!XP >^"23G&:T+30--LK>
M2"&W)BDB\EEDE>3]W@C8"Q.%Y/ XJW965MIUG':6D0BMXQA(UZ*/0>U ''P0
MC_A(_'#&28[((=JF5B!F!B>,^I/';M5/3;N^T.?P=:G4+B>*_L)?,@8*4S'
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M#]NMA:R1QN%18P, *,<8&0/J:6U\(:=:3Z/,LETYTB)XK4/+D!6&#GCGC _
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MV=O82Q/('09=F!  )S_#].1[X )[#QEHFI"T:UGF>.[E,,4AMI%0R#)VEBN
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M)_)CFF6!&VELNW0<#CH>:OUS_BRRN;RWTS[-9O=^1J,$\D:% 0B$DGYB!Z4
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M.>':?M& ""S?Q'(Z]>M>CT %%%% !1110 4444 %%%% !1110 4444 %%%%
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MUT+F)8P2\HVO\NW:!C X':KMMX8BMSKF;VX<:N2TO"@QDKMRI ],=<]*WZ*
M.-LO *VUY:33:W?745M926*Q2K&,Q,,8R%!XXYZ\#\9%\"0+IND6(U.[\O2;
ME;BV8JF05& I^7D=3ZY/X5UU% '--X/MB^HPBZE_L[49O.N;)N4+$@MM/50Q
M'([Y-3MX:4WVL72WLRG5+=+=U"+B-5!"E>.N&;KGK6]10!GVFEK!HJZ7<3-=
M1"+R2TB@%DQC!P .G%96F^$5L;:QLY]2NKVSL)A-:QS8W*0,*&88W!<G _/.
M!CI:* ,/1M DTC5-5N_M[3IJ$PG:)H@-CX X([8 XI;K09)?$T6MV^H26\BV
MIM98A&K+(N2PY/(()S[UMT4 <;%X%E@TO3["'690EEJ!OTD:!2[,23@]L?.W
M;OVQ4ECX'.E:C.^FZW?6>FSW'VF2PB";2^02 Y&X*<=!CZUUU% &3XET4^(=
M NM*^TFV6Y 5Y FXA<@X S[57M-$U*$6,,^MM):V@4>5%;B,R[1\NYLGCCH,
M9K>HH Y*R\$_9+2WTN346N-&M[CSXK62'YP02RJ9 ?NAL'& >.N.*J3_  _N
M)8DAC\1744,6HG4(5\B-BLA)/+'EL$\?R/&.XHH X^;P3-/IM_9R:N6%YJ"W
MY8VX^1@0VT#=TRJ_KZUMZ_H[:]X>NM*>Y\G[3'Y;RA,\=\#-:M% '++X1FGT
MBUT?4-6>?2X(UC:WB@$/G(N-JNP).!@<+C/>I[CPS)%KD>JZ/?+82"V%M+"T
M'F12(OW/E#+@KG@@^U=%10!Q<_@ 01Z<^AZQ<:7>V<30FX6,2><C.78,IXY8
MD^V>E6KSPG?32:5<V_B"YCU"P,NZZEA64RK)C<"O"CH,8&!@<5U5% '"1?#^
M]A>R(\0F46NI/J(\ZT!W.W4':R^I.??C XJS>>"[Z[B\2I_;,,?]ME,E;,_N
M0H"X_P!9\V5&.W?Z5V5% '%MX+U2&^-_IOB5[*[N(8XKUEM%=)V1=H<*S?*V
M,=S5E?"=Y'J>K7::K&RZA9I:[9;9F9 H(#%O,^8_,<\#M75T4 <?IW@NYTV]
MT:ZCU6,R:?8_V?)FU.)HMP((^?Y&XZ\CVJ2S\,S:?JEKK.I:C%=364$D9FBL
MBDLP;'WR&;=@#@ 5UE% '(^'="O[>PO+T3?8;[4]1^W3!H@[+%N!$1!/!VC&
M>VXUUU%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110!EZ /^)1;GZUJ5F: /^)-!]*TZ "BBB@ HHHH
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M110 4444 %%-DD2*-I)&5$499F. !ZDTH((!'(- "T5'#-%<1"6&1)(VZ.C
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MU73/MJBU1P8P49QDL3DX3!'3FMR?P,USX2N- N-<O9XY8TB268*3&B$$
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MS^UZ9=K!]U_+E!=5SM)#+PW<]JZCQ1X4?Q/9Z=#+J<UJ]I.L[/ @Q(P']TY
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M<]I,D+VL\'[UF<90*%)!W=N>W.!S0_C;3X-(OM0NK2_MQ8S_ &>X@>$-(CD
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M:WMO!=37*B*&X8JET0"?*)'(S_,"N$,MMJ&J>#HYK2YM(HM2OHIH+F;=Y<F
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M444 %%%% !1110!G:)_R"+;_ ':T:SM"YT6T/<Q@UHT %%%% !1110 4444
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MF.9+5"OGS-/*2?O.<9/H. !@8'%9VG^*H;[5X;!K&ZMA<PM/:33!0MPB[<D
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MV!OL\I>,K(1VP&+*2.FX#-=50!%<6T%W;O;W,,<\+C#1RH&5A[@\&DAM;>V
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MN_U!=0GMO]+6,Q>='(R,R'/RDJ1D<G@U+_8NG"[M+I;54FLXS% R$J(T(P5
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M110 4444 %%%% !1110 4444 %%%% &=H7_($L_^N0K1K/T3_D"V?_7(5H4
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MC##8B/59TD@=[A@5 2-#N&STC!X]:=K?AO5]:U*"Y>SL()X)87M[V&Z9985
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MG!R,[A@D8^7G%6_$]IXF\2^"M1M7T2.VNKDQ)':I<([?*X9G9R0N,+@ 9/\
M3JKCQ%I%J\JRWL?[EMLK*"RQ'!/SD A>!WQ5ZUNK>^M8KJUF2:"50R2(<JP]
M0: .,\26NMW]WJOV30KB2.ZT9K*-S/"O[Q\DY!?@#=UYR0<<8-$6FZP/%/AJ
M_.D,EO:Z<UO<@21?NG8#A1NY *]1V-=S10!YQ:Z9XFM]/LX1I,L-K_:5S<75
MM;WB1S%'9FC"N&QM!;YAD$X]*HV/AGQ%;Z=X:MI='P=,U>2XD\NYC8>46+!A
MEA_>/'7CMG%>JT4 >8>(O"GB"[\<7^O:? YDMXX'T\N\;12N@^9&4L"!R<'C
M!&:ZZ+Q#>KK&DZ=>:+/;-?12L[F5&$3H 2/E)X]_<>^.AINU=^_:-V,;L<X]
M* '5S7C/3K^_L]+?3[4W,MGJ=O=O$)%0LB$DX+$#-=+10!PL^DZL^I^,Y1I<
MI35;&.*U;S8OF=8F0@_-D<MU/'!]LX]OX9U/3-7T^_NO#<>KV\NEP64]L[0E
M[>6,!<C<=I4@=CWYQCGU*L[5M<T[1(EDU"Y\I6#, $9V(498X4$X ZGH* )-
M(ADM])M8I;6WM9%C&ZWMQB.(_P!U<>G3/>KC':I."<#.!U-,AFBN($FAD62*
M10R.AR&!Y!!]*BEU"SAOH+*2ZA2ZG!,4)<;W !)('4@ &@#SW3O#>KW7P@GT
M*2REMM15Y&6&5T'F?O3(!D<8(..<<^U)K-DMYX0U7S/",6DM+:)$5C6,333E
MUV(A3.5# =1\Q(X&*],JIJ.G6>K6,EE?0+-;R8W(<CD'(((Y!!'44 <'9^;J
MTEY;7UCJD&IWNDOI\5Q<68AA8 ,>F]OFRV>H'':ETNVUV;6O"#W&@7-M!I-K
M+!/(\L9^8QJF0 WW?E!SUY/'%=5%9Z#X8"2RW$=LS_NTEO;LLQ[[5:1C^0K0
ML]4T_46=;&^MKDQX+B"97VYSC.#QG!_*@#@;2W\0Q:'86QTF\ACBU.X>8P^5
M]H$3L[J8R6PN=^TD8."<55TCPWK6E:;HH?39Y'L]<FGDC616?RF5@&R6P>OK
M7J=58=2LKB^GLH;J&2ZMP#-$C@M'GID=J .%_L?5+#3_ !;HIL9[K^V;B>:S
MN$ *?O4"_.2?EVG'4=!QFM/0='N-'\300R6DTL$&CV]DE[P5+(6+#KE<_+VY
MQ78T4 <'=Z',?B*]K"R'2M1C2^OH"<8>(X7CN&;9GUVFN]K#L-.T'PH!% T=
ML][-A?/G+/*Y/W06))Y).!W)/<UN4 4M85GT6^5;4W9:!Q]G#;3+E3\N>V>E
M>977A?5;OPAXATG3TU.2S:& V<6I*HE5UD+O&ISRN N#TR>*]%3Q-H$LX@CU
MO37F9MHC6[C+$^F,]:U* /-M<74K[4=3U>31KRTL3X9N;??.T8(<G=@J&)'
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M_D"V?_7(5H5GZ+_R!;/_ *Y"M"@ HHHH **** "BBB@ HHHH **** "BBB@
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M[@5*DX [4 <O=:W-XA\/>$]0N8XTG_X2&*)BBD E6D7(!Y&<9P>E>F5Q=O\
M#Y+32K#3X=9NS'9:C_:$;2(C,7SD*>!QR3[DFNS.2IP<'UH \6EO(XK7Q?IL
MMBK+J>N2V:7DI416[O@!G/48Z@XQD=17=ZIK-QX=AT#P_8J]Y?W4)B2;8K';
M%&"S[2R@D^FX>O/0NL? L$%KK5K?7\E];:O(TT\;Q(H$C=64CH>!CTP*CN?
M*75C9Q2ZWJ+7>GOFQOB5\Z%< %20 '!QU/- %*7Q=KVD:;8/K]C'8&6XEBFO
M6@,D4:@#RV94<[=Q;^\<;3QSD69_%NI2W%GI^FVD-U?OIRWMPT 66,%N %S(
MG&[^+)XQQSD6Y/!DH13!KU^L[+(MS+,L<PN ^W.Y67'1%  X SQR:A?X?6<
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M]QJDLLMC((6=9UDCVH@8 @;" .2 .O2@#N+[7](TUF2]U.T@=45V2250P4G
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M%)^=@#R,\XJ#1M4M],L=#OQ:7$VAV=W?12+' 7^S,\A:)RN,X"$\CIN([XH
M]..NZ0#:@ZI99NSBV'GK^^/ PG/S=1T]:LQWMK-=S6D=S"]S %,L*N"\8/(W
M#J,]JX/6=%TZ]\%KJFA:<]F^EW+:C9"5#&6*MN?"MRJM@X!QT' &*Z;PK;RG
M3YM4ND*7>J2_:I$)!,:D 1ID>B!?QS0!NU5NM2L;)E6[O;>!G(51+*JDDG
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MCY_D8N,].@Z\XKM-5\67RW]]9Z-8FZELD0MN@E=9690VP,@VJ=I'))Z] .:
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M:_U.>2.U6"YW0R1H"QEWX^Z%YQC.>* -PVUC8SW6HLL4,DH4SSN<9"C R3T
M_+D^M7!7GOB;Q!<7WA+Q7875L+74-,6/>8I"Z,KD,C*2 >QXQQBNGAUN:Y\0
M:OI$-L@DL;>*5)'<XD:0-@' X VCGF@#;IBNCE@KJQ4X8 YP>N#^8KB=+\3Z
MMKVN:!):P6\-A=:=)=SQ/*=WWU4X^7G&>.F<G.,"G6/BFUT^TOF71X;6\FUI
MK%;:&4'SYVVY=FVC&<Y)P>!ZT =O17*:GXRETHZO#/I@-UI]J+P(EQE9822,
MAMO!!!&"/Q-7-+U^[N]=;3;VPCM2]FMY"!/YC%2VTAL# (..A/6@#?HK)US5
MY=*C@,<,9$K$//<2^7# H&=SM@XST'J361I'C&XU2QT2[%A"D6H74EI(5N"Q
MC=!(<J-OS*?+/.1UZ4 =;3!+&TK1"13(H!9 >0#ZBN"\2^*]4.GR0V445G/'
MK<.G-*TY*LIVOG.W(!S@\' SUI/MMWI?COQ%/9:-'=W3:?;32HDP097>" Q'
M)/&..=O:@#T&BN;@\5MJ1L(](LEN9[JR6^99I_*6*-N%R0K$DL", =CS6>/B
M!YZZ6ECHT]S<WLT]L\ G16AFB7+*23@_7/3GVH [/(SC/-+7"GQ#<K>:]*/#
MT=CK-IIB3N\URK;U&X@90'@8;'KWQ5NV\4WECI?A8ZA9AVU7RX9+D3?+&[+E
M2WR]6[#UR,\9(!LZQH$6N-"MU>7B6R?ZRUAD"QSC(.)!C)''3([UJ@!0   !
MP *HZ=J+:A/>JL(6&WF,*2A]WF$#YN,<8)QU/(/I6/J7BY],U75+*33&(LK#
M[>C^>H\] <-M&.,8/7T]\T =/2 @C(.:YJR\4KK$%J+;39)DNM.-[(!(O[M3
MPJ$GC<Q##K_"?2LB#7)[.7P/8:)806^GZK$\Q@:4_*@BWE<[3TW Y'4C' H
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N.M/
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M=<MM[],^U6=/T#Q%H^KW\%A<6']F7MP]R+F1#Y\!<[F4#&&Y)P3T]#TKM**
M,KQ'9ZC?^'KVUTF\^R7TD>(IC_"<C/TR,C/;.:XNZ\"ZMJDFJ07":;96M]IT
M, :V=F998WW MD#=DYR3VQUQ7I-% '"3Z5XOO;^PU&>'3([FWL+BWD\N=CN=
M]N&&5 '*@]\<]:=HWAK6K/3/"MM*EFC:1([S_OF.\%70;<+Z.3SW&/>NFU'7
M+338K65A)/'<7:6@: !@CLVP;CG@!N#W]JTZ //M6\-Z_<Z#K6FP6UFS7NI_
M:XI#<$ ('1\$;>OR8JY=:1KMQXDU/4_L5L([C2A8QK]IYW[B<GY>GS'\J[6J
ME_?IIZ0N\,\OFS)"!#&7*ECC)]%'<]J .'TSPUK]OJ_AVZFM;1$TO3#8OBXW
M;FV[0P&T<<#CWJG%X%U:2+41!!!I:WFFR6]Q:Q3%H)KEO^6B+_ N?Q]O7TQ9
M(W=XU=2Z8W*#RN>F1VI] '#)H>MQ:CX*?[)"4TFWDANV68$#=&J97."?NY_&
MLWQ-X9\3:TNLP2VL%WNN8Y=/F>[*+%&K*=@CQ@-@'+'KD^U>ET4 <+J7AK5=
M7F\0V<UO#;V^L6T+?:XYMQBE10-A7 ++D=>.":(M,UG6;O07U72#9G1B9G=9
MT<7$@7:HC .0">?FQT KNJ* ,'P=8WFF>%;&QOK<07$"E60.&'WB<Y'KFMZB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *FF_P#(,MO]P5;J
MIIO_ "#[?_KF*MT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %>33I&MCXZ.@16AU"*[_ .6&SS5@V1^8%QSV<<=\
MXYKUFF+'&C%E15)ZD#&: .!^R:5-XIT2[\/BWBL9+*;^TDML"-H"G[OS O .
MXMC/)PW/%2_"G2M+@\'6.I6L<37L\/EW$ZL23AC\ISTQQP*[I8T0$*BJ#UP,
M4JJJ+M50H'8#% 'GGQ#$;ZI;^3<Z>][!8RN;#4D_<W$+,N[:QX5\J,=_PS6=
M%J-C:>([:ZOK==-6^\+JBPRJ<LX?&SIEFV@<=<8KU)XHY""\:L1TW#-*45F#
M%02O0D=* /(/#^L62Q^&AK[QOH<VD&VBDN.85N0_SA\\ [0 "??'4U.NG:,W
MB[P5IL$4LFF1PWBPB[;)E7DAO=2<D \$8XQ7JYBC9 AC4J.@(X%+Y<>\/L7<
M.C8Y% '+?#V:TD\-21V++]GAOKF..-7W>6GFL57V^4C\,5B>(9;5OB]I,<VH
M&T\O3)"TBRA,98@ D\<X/%>B*B("$55!Y.!BFM!"[%FBC)/4E10!XW.VJZ7'
MXW30YI[^!EBE&HHN^9B2HD42 8;:N_@?=Z\&G31^&6\/:[J%AK<UW-=Z0S20
M^5'$B%3A#((U4"3<<#/)R>HKV555%"J  .@ IGDP[2OE)M/)&T<T >/7072]
M:TR?0&5;NZ\-RMNCD+&>0)E<G.6;CCZ#TK9\+S^$YTTC4K&X8:P]B\=VL+<L
M0GSO<#V8<,W4D=>,>DB&(,&$: CH=HXH$,0# 1(-W7Y1S0!Y1IUG8:0_PZOK
M7;'<746RXG:3<SAH!E22>@/ '0=L5EV%EIC>#;"]GN%%Y)X@$,4ZSGS1&TNU
MT#9RH*EF.#W![YKVHP0D &*,@=!M'%'V>':%\J/ .<;10!Y/>G0?#]_XKTS"
MQ:9*]C$+6";:/,8'=O/.U2 -Q],]S6==S62^%/',"7VGN$E@GA%B?+A5F51^
M[&>>F,CJ17M1AB)8F),MU^4<T&&(C!B0CCC:.W2@#S#Q!IQ\/7VA)X3BMX[N
MYBNY?GDRTS%(MQ4L3ER%XSQ7:>$=2T34]!@ET-T,&P;X]V9$;'(D[[O<]>O-
M;GEH6#;%W+T..E(D4<>=B*N>NT8H X>X-M??$J^L-?2"2R%A&;"&Z ,;\GS&
M ;@MVSUP*Y!+,73>!;#5B9+=[F\AC+RD-+;](LD$<$8 ]1CUKVAXTDQO16QT
MW#-(8HV*DQJ2O0D=* (K>VM].T^.VMH_+MK>,)&BY^50. /PKR3PMJ&F/XI\
M.WMC/:HEY/=QN))=]VV5)'GMD DL%VC'3 !->QTQ8XT^ZBKSG@=Z .8^(-[=
M:?X5>XMQ+Y*SQ"[,.0X@W#?@CD<=QTKE-8N-&M-%O+WPI<E[.YDM'U"*W;$,
M-OG:Q &-K$## G.,Y KU0@,I! (/!![U%%:V\$'D0P11PG/[M$ 7GKP* /+O
M$>FV]G?:V= "II\N@/-/#:_ZH2AOW;@#C<0#T],U?TS6=&N];\(6]MJMO/)_
M9<D,VV8;R=D856P<AL[^.O6O0;>TMK2,QVUO%"A.2L:!03]!21V-I$4,5K A
M0$(5C VYZX]* /%Y=#TJY^$<FO7"FYU".3RA/-,TGEI]K"X )P/E_'D^M>U6
MOV?[+']E\O[/M'E^5C;CMC'&*:EC:1VS6T=K L#9W1+& ISZCI4R(L:!$4*J
MC  & !0!Y/=O]N\*:QJ <CQ9::FT4<N0LL;^:JHB9_@*;1CH>:V_#EG%J/CC
MQ']OEGFN;&:T>-//?9$QBR2%!V_>W5VC:9I[:@NH&RMS>("%N/*&\ C!^;KT
MJ:*UMX)))(8(HWE.9&1 "Y]21UZG\Z .>\>W]E8>$[A[][I89'2,?9I/+8L6
M! +X.U3C!/IGN:\]NC#;Z1X\M8+BVA@B6T>*+3YBL,>X?-MP??GC!/:O998H
MYXVBEC62-AAE<9!'N*@.FV#(R-96Q5@%8&)<$#H#QVH Y#1=.L])^(GDZ?-,
M\%QHJRN9+AI?-82 *Y))R<']:G^(>I3Z98:8_P!H-K827T:7LX7=L3DC(!R5
M+ 9 ZCCO75QV5I#-YT=K"DNT)O6,!MHZ#/IP.*?-#%<1/#-&DD3C#(ZY!'N#
M0!Y%JVE6%CI9CTKQ TL;ZO:L5LI#'!:[V.X*%;';=C/'!XS47BB""RC\::9"
M6>T@DT^=8I)"_DN[C>06)/(QW_BKUB/1M,BLTM$TZT6V0Y6(0KM4],@8Q4K:
M?9.\CO9V[/*NV1C&I+CC@\<C@?E0!QEXME#X[L1;S?Z%_8URZV\4I\N3#*,*
MH.!P2>/3VK*L+ 7'PATR?1)0]_I\4=YY4<S$.ZD,\;J#SD C:?:O2$T^SCEC
ME2TMUDC7:CB, J.F <<#FL[5-,U"2.&WT:ZMM.MV+?:2L&7(..4P0%;KR<]J
M *GA.X.M?:O$9$R17I"VL;NV!"H W;3P"S;CTY&VLOXCPO9V^E^($GN5ATV\
MB>[BBD8"2$N,Y4'!(..U=G9VL5E906D((B@C6- ?[JC _E4DD:31-'(BNC##
M*PR"/>@#ROPF]]=ZU_8-TM[$8;O^U6\V9W9+=HU\N(L>3\S#(_V&'-5-9.?#
MLT<LTDL,7BX([32%\1AL#<S$G'3K7KBV\27#SK$@FD55=P/F8#. 3[9/YFJ9
MT'23'=1G3+/R[O!N%\E<2XZ;ACG'O0!Q5WI5CJOCK5 TSFV@T6(PQ03LBL&9
MR#\I&0,9],D&NG\%7DNH>"M'N9Y3+,]JF]V;<6(&"2?7BK;^&]$DGDG?2;)I
M9(Q$[F!<L@  4G'3 ''M5JPTZRTNV%M86D-K "6$<*!5R>IP* //));JU\9"
M[N+J6^TVXU=;>&>UN75[:7[ODR1$[2@(Y('O[5!J)=/A_K*'4+E'CUUHK9_M
M;%]OVA4"Y)RWR[N#GIGWKT/^P=(%^U\-,M/M;MN:;R5WDXQG..M5O^$1\.>1
MY/\ 8>G^47\S9]G7&[&,XQU]Z .2OM$6WUG7K./4M4-M%I*7BH;^0E9B9EW9
M)W?P@XSC/4=,2:7?7<VI_#Z22\G;[7IDS3J9#MD98D()'0G+'FNP'AW1A)/(
M-*LQ)<1^5,WDKF1./E8]QP./:F0>&=#MIH)8-(LHY(,^2R0*#'GKMXXZF@#S
MO0+F&/PF]K)+<H]WXAEC2.WE$7FD-N*,_P#"N!DD<\8'7%-ENKF7PS':KJ5S
M \/B9+/S;>]=RL;,. YY8 -QN';I7HG_  BN@?97M?[%L/L[N)&B^SKM+#OC
M'7GK2OX5T"165]%T\JTGF,/LZX+_ -[IUH MZ9IT6E62VL,MQ)&K,P,\K2-R
M<XW-SCFO,-:OKZ*+XD^7J%XAMFM6@*SL#%D9(7G@'/05ZW65+X:T2=KII-+M
M6-VP:XS&,3$'(+#^+D]Z .#NV?0M4LF_MN^ACO-!G:::YG>8+( NV3!R<@MV
M["J<NM:AH.DZA;217=I?1?8UNR+QIXC"[,K30EB2I/0\\<=Q7I$GAK1)BAET
MBR<I%Y"[H%.V/&-HXZ8[5-;Z-IEI:2VMOI]M%;S+MDB2(!7&,8([C% ')R6[
MZ5XFU#3[.]GDTZ;1I+B2WEG,OER A58%B6 8;O;BL..*73/"7@SQ+'-<BWLT
M@2^C%PXC,+#;O*9Q\I(/3GOTKTBWT;3+2WEM[:PMHH9AMD1(P XQC!]1BG)I
M.GQZ8=,2QMUL"I7[,(QY>"<D;>G6@#@-6U#4TL=',^H-9IKUZTLLEQ*Z);1;
M,QPY5@5R-N<$9.><&GM8:IIL.G:?!XE:X=M91#Y3G,$3QNS(2Q8M@#*[B>H]
MJ[Z_TRRU2Q>ROK6*XM7 #12+E>.E43X5T/[+:6O]F0""S?S((P,!&SG/USZT
M <)>Z[-X5&LZ7;7UT\,.J6D1NKIVF:"*:,%SN/(P5;KZ^M:NMZ'>3Z?K%KHW
MB74&NU1+JR@2Y=FAP""IDR68/S@$\'I73GPMH;7%[.VFPO+>J5N6?+>:"0><
MGV%5Y-'GT/21:^$;'3+9VE#.+@.$ /4X7DG\10!G>$-9_P"$IG_M6"2X%G;V
ML=MY;NP!N,;I,J3AL H,GOFI_%.I30ZYX>T?S98+74II5GFA?8PV)E4#=MQ/
M;!XXK:T73$T?28+%&#E 3(X7;O<G+-CMDDG':GZII-AK5G]DU&V2XAW!@K9!
M5AT((Y!]QS0!YUKE_K&FSZMI=MJEZEI;WMBL$[-OD43$^8A=@2P'!&>1D=J]
M#TG2QI-FUN+R[NRTC2&6[EWN2>V<#CVJM-X6T2XT\6$VG126HD\TQMD[GQC<
M3G)./6M95"J%48 & !VH \_DGO3X@\8W#7U],FCB&YM+59,)N\@OM*C&03V[
M\=ZS?#5SJMQ;Z=KH\2V<<5S&XN(WEEFWS,F2&0G;'M*D_*   >HKT2TT33K'
M4;K4+:T2.[NN9Y1G+_6JEMX1\/V=U/=6^D6L<\ZLLCJG)#?>'MG/:@#S=O%&
ML:#;:B\PU+^V(=,$NR:<W-K-F1!]HC.<+]YCM P!]"*ZQH[C2_%>@/I>I7-U
M::H)!=17%R90ZJFX2J&^[Z'&!R!BNBL/#>D::DB6MC&JR1>2P8E_W?)V#<3A
M>3\HXYINF>&=(T:1I+"S$+&/R@?,9MJ9)VKN)VC))P,4 <!H.J7.F^$/!/D7
M1@CN=4DMYQC*NC22\'\0.:D\074VKIK>G7%_<+%#KMG!;M%)M\L.4W D8R 2
MQ'H0/2NS;P7X<?2FTQM*@-D9?.\K)P'Z;@<Y!^E2#PAX?%O<VZZ3:K%<E#,J
MIC?LQM_+'\_4T 8FJ:E>Z5XQGA@GGFM[;P[-<QVSN6#2(Z@$]V) QDDGD^M9
MBW=W:1^$]=L]6NKN;6+F"WO$=]T<JNI+$(!M0ICMC&#G/-=LGA_2H[Z"]6RC
M%S;P^1%)DDI'_='/3FF:?X9T?2[@SV-DL+_-M"NVU-W78N<)GOM H X*RU/6
M%\/Z+K,VLWDT[:R+-XV*B-XC,T9!4*,G !R<D=L5Z/JMTEEI%Y<O=1VJQ0LW
MGR+N6/ ^\1WQZ=ZSSX/T V269TV,VR2^>L1=MHD_O 9ZUJW=I!?6DMK=0I-!
M*I62-QD,#V- 'E]EJ>K6^OR6:7NHM%<>'VO%>YF#M)*.1*BY81@_W?TKH8=8
MO)F\%027C9U*S=[L @-(?LX;/'(^;G(Q6O8>"_#VF7L5Y::8D=Q%&8T?>S$*
M1@CDG/'K3+;P+X9M)898=(@$D,GF1.Q9BA]B2<#VZ#TH \YT6.1OA9X6=+B5
M9KC7829&<OM;[0XR >/0XZ$\ULZCX@U+P_>ZYI:7UU/#'=6$,=S.0[VXGW>8
MY.,8^7C(P"1VXKL1X-T!;3[(FG*EO]H%R(TD=0) <AA@\8/8<59?PWI,MQ?S
MR6:O)J"".Z+NQ$J@8 ()QP.F* .1U>ZU30=4UC3[34KJ2V;1)M0CDG?S9()D
M)'#,#A6]#GH<8IOVG6M.T#P]JDVO7=S)J%W9I-"4B$>V3&0,)N'4=Z[)/#^F
M):3VQMVDBGB$,OFRO(SQC.%+,2<<GC/<U%-X7TBXTNTTR2U?[':,KP1K/(NQ
ME^Z<A@>.V3Q0!R6FV6H:CK/CG[#J=S:WGVE4@92I56$8*Y!!XX ^E7/"?B*Z
M\3W5BB2SP?V=:_\ $RC;&7N"2@1N.VQV[?>7WK<N=)32KB\UC1M*2XU2YVB5
M&NFB60<#)SE0< <XR?6I?#FFW&G:?*UZ(1>W<\ES<"'[BLY^Z">3@8&>^* *
MWBW6IM'L[!8-R/?7\-GYX4$0*[<N<\=,XSQDBLRYFUO_ (2C4_#]MJDA6?2C
M>6T[HF^"7S-N 0N-I]P2.U=3J6FVFK6,EE?0B6WDQN7<5Y!R"",$$$#D4VRT
MNVL'>2%7,KHD;RR2,[LJ A022?4_B2>] '#:1XPU&\T>WEN6D^U:7;7$^KHB
M+EGCW(L9 '!)&[C'2I-.U/Q=>II>J&\L8].N(R9@\\;JY9<J(@(P0P.>"S>E
M=K:Z596<][-#;HKWTGF7!QG>VT+S[8'3W/K678>"="TMW-G;21JVXI'Y[E(B
MPPQ12<*2.XYH J>!+C6M3T&TU?5=46Y%W &$"VZQA#D\Y')./P^E=95#1M'M
M-"TV/3[+S1;Q<(LDA?:/0$]JOT %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110!4TW_D'V_\ US%6ZJZ?Q80#_8%6J "BBB@ HHHH **** "BBB@
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M<T^FWUNR:%+*MJ\JMO!E3&T;MH<X(.2.W-3Q?$:WFBTJ9=%U(P:H"MJX\O\
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M5_YK(LEO(^S?'N&[!R,,!D@YZ@5Q2^%?$,2Z:5CN;BSTS5HY[2VN9XVG6W"
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MLX''RC@5N>-M9ETJUTN&.22"._U"*UFN$X,4;'DAN@/ &?3- '445YCXJO\
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M'D#B@#-?X:^'Y-+GT^07;Q2W)N@S7#%XY3GYE/K@]\YP,YQ5I_!%@\$"&]U
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MC1--8M(@\T+&4<A@<9Y)'/?D9XK3M-!;4M>UW4;^R:*UO[6.T2.;:7*@-O)
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M\MH[FVE2:"1=R2(<JP]0: .#\9:=J+ZS-?Z+;:A%J8ABCC=%$EM>#<<QRJ>
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MV/G"@$GMQ7;JRLH92"#T(-9.K^'K;6K[3;NXGN(WT^;SX5B*@%O]K()/I^-
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M4 %%%% !1110 4444 %%%% !1110 4444 -4;1BG444 %%%% !1110 4444
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MU'@V)8?!.A(F<?8(6Y]T!/\ .HKKP?97-]J=Z+J\BGU*W-M<LCKADV[1@%2
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M-D)!)VJ-N,?,??WY.;-CX"T[3-1>XL[[4X;5I1,=/2YQ;[P<YVXSU&<9Q^%
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M(^;_ (%TIGBK5#I>A2-'.D$\[""*5P2$9NK8'7:H9OPK8BB2&%(HE"1HH55
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M/XOU%M4L;#3M"%U+>6 OE\R[$6Q<J"&RI[M5!_ >KLP9-?B5VTM=.9FL]Y0
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MXUC6HQ"(H 2FX1^7&HSV[LQQW/ %;7A?1CX?\,V&E&02-;Q;68# +$DG]2:
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MEDQ!VE1C!91L0$\?+G!H Z:_\0V4OA[^TK#6K&W@>0(MW.-R9#?,NW(); (
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M$LK6T#S"-GVAMHSC.#CIZ5R]IXG\13?V&SZ78[=7MRT:B9P87"!\N2/NE<\
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MZ>Y,:[-^TY 4\YK.M/'][J,MI/8:!=7&GSW7D%TBE+(F2/-W;-A''(#<>O7
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M*1EMN1R?0]3ZUL6?C2[OO#]O?)IT$,[32P7+7%SMM[8QD@EI #G.!C []>*
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M1MP!C)V]N6P>*]<FMX+B+RIH8Y(_[CJ"/R-,FL[6X5%GMH90GW Z!MOTSTH
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MW.TD-DNP48(QR>>V:KI\2M$EALY+>#4+@W<LD,:0P;SYB $KP<$\C&"1SUH
MZ>STRPT_?]BL;:VW_>\F)4W?7 YI]U9VM]#Y-Y;0W$6<[)D#KGZ&N6O_ (D:
M'IIE6X%PLD"(T\9,8>(MT4H7#%@,9"@X[UU'VI'L/M=NIG1HO-C"$ R#&1C.
M!S[XH 1-.L8[I[J.RMTN'&UI5B4.PQC!.,GBEM;&SL5=;2U@MP[;G$483<?4
MXZFO-+OQ??:IX;\+ZU=6EQ9B76D5OLSEEEC!?C:I).<8P1U4X&#79Q^,=-^P
M7]U=1W-E]AE6&:*YC"N&8*5Q@D'.X8YH VK:SMK*(Q6EO#!&26*Q(%&3U.!2
M2V=K/,DTUM#)+&"$=T!90>H!/2LG0?%FF>(;JZM;-F$]LJM(I9'&&Z$,C,IZ
M>O%8/Q$^T1W?AUK:]OK<W.I1VTPMKQX0\1R2" P&??K0!V\$$-K"D-O%'#$@
MPJ1J%51[ 5!=:5IU\ZO>6%K<.G*M-"KD?3(]A^5.O+RUTO3YKN[E\JVMXR\D
MC9.% _,_S-<V?B-H*-<K*TZ&"W%U\J"0/$6V[@4+#@D9!P?:@#I;C3[*[DBD
MN+2":2(YC:2,,4/L2.*8FF:?&8#'8VR&WSY.V)1Y>>NWCC/M658^,=,O9IHV
M6YM/*M!>[KN+RPT)S\XSS@8[XK%N-=EOO'OAE;9-1MK.XBNF/FYCCN%" J=F
M>W)^90>10!UQTC33.\YT^T,TC!GD\E=S$'()..2#S4D&GV5K/-/;VEO#-,<R
MR1QA6D/7+$#)Z]ZQ4\:Z2\MK@S_9KN8V\%UL'ER2#/R 9W9.#C*X/8UD:AX@
MN/%ND1Q^%QJ$9:6*0W?E&)&02A70.>X!R0.P(ZY% '50Z'I%M<BY@TNRBG!R
M)4MT5@?7(&:;_86EQS&YM],L(KO)9)_LR[@_][( /7WJ&W\16EUJ)M(HK@IY
MK0+<B/,32KG<F0<@C:W4 <=>1FQK6L6F@Z3/J=[YGV> 9?RT+GKCH* *>B:1
M>VEU<ZAJUY'=ZC<(L1>*'RTCC4L0JCD]6).3U-6=*T>'2I+V2/;YEY<&>0H@
M1<X & /8#)[G)[UEKXYTQ[DVRVFI&=H1/!&+1MUPA[H.N/KBIO\ A,=)DL-/
MNK=I[DZA&\EM##$3(X4?-P< 8Z<D"@#3O](TW5&B.H6%K=F$DQ^?$K[2>N,B
MI[6TMK* 06EO%;P@DB.) BC/L*YZ;Q'I5XWAZ[BO;U8M0E/V984(28[3\LAQ
MQCKC(.1WQ1)X^T*)+EV:\\NUN!;W#_9) L3$@#<2. 210!K7^@:/JCE[_2K*
MZ<@ O- K-@=.2,T^YT;3+RPCL;G3[66TCQL@>)2BXZ8&,#%72P52Q(  R2:Y
M^/QGI$EQ;)NG2WNY?)M;MH2(9WZ;5;Z@X)P#C@F@#2_L32?)EA_LRR,4KAY$
M,"[78# )&.2*>-)TP232#3[0/.GERMY*YD7^ZQQR.!P?2N*-_<ZGKWB7S)M4
MB72)HWMUMY#&A"1ABC#.&#G/4'CIBJ^BZO!=V/A[7M1U?6K2XOIE@%NKL;>Y
ME9C@;<$*O;^'@=\4 =G;>&-!LWE>VT:PB:92DA2W4;E/4'CI[4P>&]-L4,VD
M:9IUI?QQ.EO-]G4>63GTP<9/-,OO%FDZ?)*LTDK)!*D-Q+'$S1PNQ  9@,#J
M/ID9QD4[4O%.E:4MQ)<RR^3;,$N98X6=(2<8#$ X/(X[9&<9H ?HFEW5EY]U
MJ5RESJ5R5\Z6--B!5R%55YP!DGKU)J;1]'MM%@GAM$2..6=IMD:!%7.!@ >P
M'U.3WJ^[B.-G;.%!)P"3^0ZUS6E>(]+AT.PFAO;[41>RR+;M)&6FF*LV[Y0!
M@#![#  H V-0T32]5EAEU#3[:Z>'<(S-&'VYX/6I[*QM--M4M;*VBMK=,[8H
MD"J,]>!18WL.H64-W!N\N5=P#J58>Q!Z&N>TG4)8/$?BF.^OW>SLV@=#.P"P
MJT>]N@&!_A0!JZAX<T35;@W&H:59W,Q3R_,EA5FV\\9Z]S39_"^@7)B,^BZ?
M)Y4?E1[[=3M3^Z..G)HM?$>FW5Y]D$DL4Y@^T*D\+Q;HN/G&X#CGGN.XJ-?%
MFB'RR;PHDENUU'))"Z(\2_>8,0 0,@]>A'K0!#)HEX]S!91&PM=!MI(I8X((
MF$C%#N"GG:%W@'@<XQ[UT KGU\9:5-;7$L'VEVBLS?)&;=T:6'LR;@,@GC_Z
MU)I?BVSO-'TN\N4F@GU!%,4 @=F9M@9MH R5&?O8Q0!?NO#^D7NH_P!H76G6
M\UWY1A\UT!.PYR/U/YFJ@\&>'1%:Q#2H!%:R&6!.=L;$Y) SZT^/Q7HL]G#=
M0W;2)-,T$:I!(9&D4$LNP+NR #GCBL_P/J=QJD&M237$UQ%%JDL4#S JX0!?
ME*X&,9/&* +Z>#O#<=W]J31+%9Q*)@XA (<="/3_ !YZU=L-'T[2Y[J:QLH;
M>2Z</.8EV[VYY/YG\Z+S5[.QNH;:9Y#<3*S)%%"\C%5ZG"@X'(Y/K6;=>-_#
MUE9VMW<7Y2&Z+K"?(D)9DX92 N00>,'!S0!?U;0M,UR.*/4[..Y2%M\8?/RM
MZ\4R/P[H\.K'5(]/@6])9O."\Y/4XZ9.3D]>3ZU<M;V"]L(KVW9G@EC$B'80
M2I&1\I&?PQFO.K[QS+JGAW2=7M9Y].0:U';W&Z,A&BWMU)'(V@$@'@Y% 'HU
MY9VVH6DMI=P1SV\J[7CD7*L/<53T_P .Z/I-S]IL-.M[:;RA"7C3!* YP?7G
MOUID/B729[6\N%NMJ63!;@21NC1D@$ JP!YR,<<]JEL-<L-3NKFUMI9/M-L%
M,T4L+Q.H894X< X/K0 _5=(L-;M!::E;+<0;@_EL2!D=.AJI>>$] OWMWNM)
MMI7MT$<3,G*J!@+GN,=C6%XY\276B7VE6[33Z?I=R[B[U.*(2&+"G:H!5@"3
MCG']:8^NW_A;0K[4]0OGUJTDGB73YD1<M&X RVQ<<$GG'/&.N* $U7P-_:7B
M&_U&ZTW2M36X1%A^TRR1- %7&,*&##J<\'GVK2L_ .@QV%M!?6%M>30QF,RN
MAR5))V\DD@9P,DD8'-6[OQCH=A)Y=S=2HZPB>1?LTI,49. T@"_(/][%-A\4
M03>+KC05MY]T-NDYG\MMAW9.,XP!@=2<$\=10!9M_#.C6EW:W5O81Q3VL7DP
M,A(V)S\H&>G)J[?V%KJEE+97L(FMI1AXR2 PZX.*SK;Q9HMWJ$5E%=MYTY80
MEX)$2;;UV.RA7_X"36C?7]KIMJUS>3K#""!N;N2<  =22>@')H H)X5T..\B
MNQI\9N(H?(1W+,1'@KMY/3!(Q[T_3?#6CZ3(CV-DD1C#",;F81AL%@@)(4'
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M/4C<?YUU]M-]IM8IS%)%YB!O+E&&7(Z$=C5&XUN"V\06>CO%*9KN*26.0 ;
M$QD'G.>1VH H>"-$OO#?A>WTB^:W=K9G$<D#,0ZEBV2"!@Y8C'/2H]5T"_G\
M;:3KUG);&*VA>":.8L#M8_>7 .3[''UKIJR-,\0P:IK.J:7%;W$<VFLBS-*J
MA6W#*[<$D@CGI0!S/_"':Q!X6NM+M9+!)SJ0OH'WN$7$@D"D;2>J@=^OMRZQ
M\,>)]%U/48],OM..F:A<&Y9KA6::V=^7V #:WMN..!QUKNZ* *M_%<RZ9<Q6
MC1_:6B98VF&4W$8!88Y&?:O/9OA[JUU8ZO%')9::+ZR2(VMM,[P/.'#&7!1=
MF0N, '[Q_'M[G78+7Q%9:*\,OGWD4DL<@V[,)U!YSGD=OZU:OK\6*P$VUS/Y
MTRP@6\1?9G^)O11CDT <9J?A;Q)JJ6WVHZ5,HL&MVMI9)###-R!,@V_.=I_B
M QV-6M#\/^(-*NM#>0Z:\-IIPL+E%D?< ""'0[>>%'! [\UVE% '$^&-#\3:
M 8]'\S37T6VDS!=$,;@Q9+;2O3/;/;WKK[NTAOK.:TN$#PS(T;J>ZD8-3U5L
M[X7DMTGV:YA^SRF+=-'M$G .Y#_$O/6@#S^#X:7YMM,^V:JDUS"YM[E\']Y9
M8 6$<<\(,Y_OMSZ]%=Z9J@\>+K%O:Q26@TM[0EI@K;RX<8&.1E0.W7/:NHIL
MDB1(7D=44=68X H \NL? WB#3](\/7"6^FSZCI1N(WM)GS%+'*Q;.<<,,].1
M_*MFZT'7KK6_#-Y+:6 BL)I9IXX)-BQ[QM"KQEMO4G R?2NR^UC^T!9^3/GR
MO-\WRSY?7&W=TW=\>E31R)*@>-U=3T93D&@#A6\,ZYIGB74;C3[;2[[3]2E\
M\F]SOMI#@,1Q\R^V>W;J>W,)>U,,C[B4V,X&,\8)Q3V=4&68 9QR:@%XIU$V
M7E3[Q%YOF>4WEXSC&_&-WMUQ0!YS9^$?$5OH/A;3VL[;=H^H_:'876=\88G^
M[P?F/'/3WJ[K7A+6=:N-;9(X+9Y;V"]L9'FW(SQ*J8D4#H0">AKT*B@# \-V
M^KH9I=5T_3+ E518K+YBQ'5BV!QTP.V#S5'QGI&JZK=:$^FVT<JV-\EW*7E"
M95>-H]<@FNMJIJ-_'IFGS7DL4TJ1#)2",N[<XP%'7K0!SWB'2]7\4Z5>Z7);
MQ6-O);DH[3;F:8,I3(7^#@YZYR..*SIM(\2W_AN]M)M+TJTNVMA$K6[@^?)N
M!W$[1M4 =.<D^U=[10!Y[XA\(ZMXCUZ2Y>-((9]%:Q=S*,I,6W@X'5<X']*4
M:/XJN=2\-2W-C9Q_V9%+!<2QW7W@ZA"Z#;U &<'OQ[UZ#5.VU."Z:Y"B6/[-
M-Y#F:,H"W'W2>&!R,$4 <AX7T+7M M[?2Y-*TF:WM9#LU 2?O'CR2/DV_?YQ
MG=@>]:W@/2-0T+PG;Z;J803PO)C8^X;2Q8<_C6I#K5K/KUSHR"7[7;PK,^Y"
M%VMTP>_X>E:- 'G\?AS5QXRM]4L[)M,W7+O?O%=#R+F+)Q^['/F$;<G@9S71
M>-=.N]7\':GI]C%YMS<1;(T+!<G([GBMZB@#E8K;54\76VHOI1-NFDF!F6="
M5EW!MH!(R.,9_E7+:3X=\76'A_0=.GM#):6IF6[M(KM8F<EB4)<'E.<%>O!Z
MUZG10!YKI7A[Q%9:/X1L9--0'3+^22X*3(0(_F (Y&<B0^_R^IIFL^&=<O?#
M'B[38=-<S:EJ8N+8F:,!DW(<GYN/]6?^^A[X]!U34K?1],N-0NS(+>!"\ACC
M+D =\ 9_P[U/;7$=W:PW,1)CE0.A(QP1D4 1RP?:].>WDS&98BC#@E<C!KB;
M3P]K%QX<TCP[J-F -.NHF:]\U"CQ1-E=H!W!B %P0,<\]J[^D) (!(!/3WH
MY&U@UB*;Q3')I$GDWLAFM'$T>9"8EC((W<?<!'MG.#@'G8_#GB!?"?A/3O[(
M?[3I&I17,X-Q%AD0L?E.[ON_2O4<44 >?V.F^)_#FH:AIUAIMK?V6H7;WD5[
M/.$%LS8)$B8);! QCKZCM5B\,ZUH^LZRL&@Z9K$&I7+W$5Y<NBF O]Y74J2R
MCT'I[UZ51B@",EXK<L0TKJN2% !8@=LG'/UKS"W\-ZI'X3TK2[SPW.1;SS23
M36EW&MS"Q.4DB.[&?F(()_AKU.C% &5X<M[ZU\/V<&I2O)=HI#M(P9R,G;N(
MX+;<9([YZUR.M^%-5UNZ\66_E/;0:BMO):SLZ%6>$#@@'< Q'7T'X5Z'10!P
ME_I.K>+EBDN]/?2WATVYMF$TB,7FF15^4*3\@P>203D<4EI+XRFT2:RD\.V%
MO>6EHT,-S)<+(L[8 &Q<< @9^8XZ5WF*SKG6K"TU>QTN:8K>7P<VZ!"0X0;F
MY P./6@#@M'\.:VNH--)IMQ$D^B2V<DMW>K(XF)!Y R N> %XQSQTJ.;P]K;
MVOAC4V\/07$FE6WV.YTR=T/F+M WH22O4' )]*]2Q1B@#SN32M;L]9TCQ!:>
M'K>.* 2Q2Z7:RHKQH^/G!X0OQR,^@SU-;/@NUU*UFUU]1TQ[+[5J+W,6Z5'+
M*P P=I.",?K6_=ZG:65W96L\A6:\<QPJ%)W$*6/3IP.]7* .1OM.U/3O'J>(
M+:U>^LY[(VDT43*)(2&#*PW, P)X([5CKX=U>TNM(NTL))B=:N-2N(UD0&".
M4D!3D\L P)QD<'GIGT6J6JZQ8:)9B[U&X$$!=8PVTMEF. , $T 7J\MLM#UR
MV\,:-ILFB3";3]=6YD:.2,B2(2,Y<?-Z,!SZ5ZE10!YCXA\-:MJVI^))+72R
M!+-9W%OY[+Y=T8<AE.&R,@\9'..V:Z?PO!)YTUW)X8BT5WC5'RZ/)(P]U_A'
MOSGM73XHQ0!S^O2:D-1L88M*_M'2)8Y4OHAY9(.4V'#D;OXLCT^@KBCX1U6U
M\*Z_::?87*VLU]!-8:?-,A=%216<CG:H..!G.!SS7JN*,4 >;>*+3Q'K3ZS
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MW)=/!/Y\EM]E=ENI5W1?W3AOUZUHZ=IUKI5E'9V4;1V\?"(79MH]!DG ]NU
M' Z+J&N>)X;'7X-8BLK9;XB>!YSCR]^T0F/8 &QC!W');Z 9/B.]U'4/"6I0
M7FHSRM;>)EM$D 5&\M=N =H ."<].N*]"B\'>'X=7DU6/3(ENY'$C,&;:7!R
M&V9V[L\YQFB;P?H5Q9W=I+9%H;N87$RF:3YI <[P=V0WN,9H YF]L[Z7XB:D
MEIJL]F8M%B9I41&=R&?&=P(QGD\<^U06OBC6M:OM TZ*YAADNM(6^E=)1&9I
M"=N%)C8 K@DKCO[<]G+X:TN:^DO6AF%S+;_9GD2YD4M'C&#AN?KUJA-\/_#-
MQI]E92Z:6ALB3;_OY \>3D@/NW8SSC- '/Y\5KK6C:-/XH42W-I<>?-;VT;#
M?&_!&1UP0#Z$'UKKM;DU"P\*W+65S"VH16^(Y[DJBL_ W'. ,_EFF1^$M%AO
M[*]BM7BGL4*6_ESR*J Y)^4-M.<\Y'/?-:&I:;9ZQI\MA?PB:UE #QDD9P01
MR.>H!H \Z/BG4%TN63[?J%M=V^K6L%Q;7L48>%&P&&X##*W)!X/'IUN>(?&%
M_P"']5\3L)O.CMK>U-K"X7;$\A*EN "1G!()_*NFD\&Z%+I]W8S63307>SS_
M #9Y'=]GW/G+%AC'&#3;?P5X?M7NG33PS7</DW!EE>0RI_M;B<GWZ]* ,?Q%
M:W]KX<\02S:[]ML9M'D\J&5$WAPF"ZLH&5.1Q@\D?2JNB:CJ>G>)_#NE27TU
MW::AI9F:-D15@*J"NW W8P,<D]<UNP^ _#EOI]S8Q6+B"XC$4@-S*QV @[0Q
M8E1D#@8!Q5BW\):3!J%C?A+A[FP@6WMW>YD.Q ",8S@YSSG/04 5_&=[JMC8
M6TNF1W$BB;_2([3;Y[1[3]P,"#@X)&,XKE[#[1K&N>#;Z/Q%>WT<D%V6G6W6
M'=L89RA4XZ[#_N\$9KO]1TFTU1[=[E9=]NY>)XIGB9205/*$'H2*J1>%M(MT
MTY(;>2,:<S-;%+B0%2S;FR=V6!/)#9!H XFU\3ZU_P )/HL3:A)=6NH7,\$L
ML<*+:M@?+Y!/SG;CDG()SR:AL-8U#P_X&LKE-0N)Y]2U9[3S+HILM\SRAGSM
MXSC)+;@">F.*ZRV^'WA^TN+.:&&Z!LYFFMU-W*5C)Y( W8 SV[]\U;;P9H+Z
M=>:>]ANM+R3S986E<KOR3N4$_(<G^'% #/#\.OP:CJ2ZQ>6\]NQ1[6-90\D0
M((8,0B @D<<=C7/^-M<U6RGU,:9JD@>SL1.MM:0HS1'))DF9Q@+@8"@Y.>!7
M6Z+H%AH,+QV22Y<*'DFE:1V"C"C<Q)P,G ' R?6J>I>"]%U;5)M0NH)C-/!Y
M$XCN'C65,8PP4C/% &#/=>)-7\7_ -F6.N)I]M_9<-VQ^RK(0S,00,XZX[^M
M4K/7/%7B+RM6T>XBBLDOF21)IXQ%Y*N1AE\O>K8QSN/7@5UUKX3TVRUJ+58&
MNQ<16XME#7+LOECHI!//KSGFH3X(T(ZU+J@MG669Q)+"LK"&5QR&:/.TG///
M?F@"QXKO;C3_  U=W-M?06,ZA=L\REE7+#.!@[FQG QR<5PMQXDUZV\/^*V&
MH7R2Z9-;_9GNX(EE"OC(8!=N.<C@'I[BO0];T.P\0Z<;'48B\.]9%*L596!X
M((Z&L_\ X0G1&745EAN)EU&-8[D2W,CA]O1N3][@<^U ',^*M6U/^W/$NFQ:
MC-':1^'GO(U0)\L@.."5S@@<_7C'%5M0L[I?%'P\MX=1F\]H+H_:)41F \E2
M0  %Z9 XXX)SWZRV\":%;222^3<32RVC6;O-=2.6B.<J<GWQ[8&,4H\$Z8+K
M3+DSZ@TVF@BV9KMR5!ZCD]", CT&* .<T[Q3JTL^FZ)<7X^TWFI7D!O_ "5!
M$<#'Y0N-N]NF<<>AJOK?BCQ'HUKXGMUO$>72YK66"ZFB3YH92!M8* ,@]^"1
MGI73IX!T1;>2(K=,S7/VM9FN&\R.4G)9&_A)[XZU8O/!VDW^E7>GW"SO'>RK
M+=2>:?,F9<;=S>@P..G% &(UUXCT3Q-H-K?:W#J-OJ=Q,'1;-8M@$>0 V3P#
MT[^I-(]WKL_B.WT*PUV::YA_?:G/]GB$,$9/RHHV9WD$8RW8GZ=+=>'K2\N=
M-N))KL2Z<,0LDY4G( .['WL@8/XUGV?@73+!I#;W6IJLLWGRH+Q\2OD$EO7.
M!0!SMAK_ (I\37+ZAHLD M+?43"8?,CV/ IPV[*[PYX(.<<]*Q_$NKWGB;P7
M-K#7+1V?]KQPV]HJH1Y:N &8X+;B><9'T[UW\7@K1(-7GU*&&:*2XD$LT*3L
M(I7!R&9,X)SS]:JS_#O09S=C;=QPW=P+F:"*X98S(#G<!VY]/Z"@#7\2:ROA
M_P .WVJM'YGV:(N$SC<>@'YD5S$VMZS8:CX9=K\7%OK4?E21/"H\F4H&#H5
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M"K*I)*@,0V,\#MSR>* +FD^(M,B\/:=.NH7=^+MG2W>2$F:X(+9^4*.!@\X
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M,X4-AFZX(SCWH [411B4RB-1(P"E\<D#H,T^L;0+R]G\/QZCJFY)9PUQY14
MPQGE4XZD+CGK7(S^*]</A!O&=E<P361ER--:$9$?F>7PX.=W0\\=: /1Z*\S
MO_$OB@)XMN8;^TA@T9E$2?9,E^ Q!);CCCOU[5Z#(]S<:2TEJ4CNI("T1<;E
M5RO&1QD9H GEABF4++&C@,& 90<$'(/U!JO<ZK96=[:65Q<I'<W;%8(SG,A
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M4<GF##.3C:/?VK*UWQ,DWA35;_PYJ-I-<60^=A^\"XZ\9ZXS@\CZT %Q\/\
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M I:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MEM:KK$$]R9EEEN)-J-EBC%F55SC.>?R)TO$?AN\U'Q,1:63I::_9+#?RL/\
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MI^G^!]'M+AI(I_,6T93 _P#KF)(4D+UQC)Z#OBN[HHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MCHQ49'XUBZCH-WJFLQ2W6J,VD1['_LT0J \BG*LS]2,@';TX% $OAG26TG2
M)\&^NI&NKQQT:=^7(]!V'L!6#<-I5K\6S->FTBF;28O):7:&+^:X^7/?  ^@
MKMQ4;P12/N>)&;&,LH)QZ4 >(>&9-.MO#/AC7[F\'VU=;*32RRD%$??N49.
MN2&/3J?6KFBKI^N21R:YK,\&N)JC.UK!$OV@L'X (4R! #V.  ?3->P_8[7
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M+WXR:XEMJLFGM%I\2JZ1H^0=IP0P/<D^M>C6=E:Z?:I;6=O%;P(,+'$@51^
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MQJEW9?#K=>3N;EYQ<8<_O0BD#=ZX [U6U#[<GAWQ5K"ZSJ8N--UIDM4%R=B
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M/O5:V\-Z3:17D<5J?],79<.\KN\JXQ@NQ+8P<8SQ0!P45_KET_@"R.MW4/\
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MD?[O.*=J.B>)_$MYJOVG2X=/AO=*2TW2W"N5E5F?(V9^4DXY[<^U '02>/\
M1+=YX[DW,,L4)N/+:$EGB'5UVYX'/7!XZ5HZ#XBM?$,4LMI;7L4:;2KW-NT0
MD##(*9ZBN*70->N/#M_;MX3T?3[EK"2VW6IC\RXD8!000 $3&203GBNZ\/P7
M%MX=TVWNH3#/#;1Q21E@V"J@=1QVH SO$^N6T&FZK90W%R+V&S:9_L:[I(%Q
MPQ]/YXR>V:CT37HX?"^@+<-/=ZA<Z;%-Y:G=))B-2S$L0.O<GDFLN;2/$>E^
M+-=N;&SAU#3]9B7EK@1M!(J;1G/53[9XQZ<XH\(^(;630=0FT33=6ELM.&G3
MV4LRXVJWRNI9<9QQ_C0!V<'C32;W38;RP%S>^;"TZP01$R!%.&)!QC!!'7D]
M,U#:>)](UK6=&-EJ-WNN;>6:&%8RL4R]#OR.JE3C\?6L9M*\3Z3XBM==LM(L
M;D26)M)["WG$*P_O"ZD,1@X!P3CGGBK<FF:]<:_H$EY8PF.V@N4N+BU=5CC,
MO"JJ,0Q"@ $]_2@"CXK\5W4FI^'1HC7HMI-52"6X"8@G&[#)N/)Z'V.#UKI;
MSQAHUE=>1+/(2+A;5I$C)196( 4G\><9QT/(KBH_#GBC^R/#>B7&CQ2+I&II
M,UX+E/+>%"<$+D-G#'M_"/6K%GX8US3->U*,>'M'OX;N^>Z@U.XV%K8.V[E2
M-S;>> >O>@#LK?Q1IMU?16L)G?SIY+>.41'RS(@)9=W8@*W7KCBD\5Z^?#6A
M/J"VSW#>8D2J.@+,!D^W/YX'>N:TWP]J<'C:VU2#39-,A::X.H+'<H;>X4@B
M-P@).\G:3P.E;OCK3+_5_"5U::9"LUX9(7CC9PH;;(K'D\= : ,.^\03:7\2
M[833:@]C=:4T@LA&S['#]0BCKA3R<XR>0*Z"/QCI%Q8VEW;/-<+=PO/$D419
M_+0X9B.V"0*R39:Q<?$&SUV31Y8K:+37MW7SXF;>6+ ?>],#/J?3FN9LM \7
MPZ/8:7<Z,TFG017*RV\-ZD;2R.S,I8YP4&X< ]0<]@0#MI?%\)U?0K2VM+B>
MWU:$SI<K&2H7 (X]>03GH*W+^_M=+L)KZ]G2"VA7=)(_0"N&T;1?$%@/"#2:
M;\NFP36UU']H3*[@H#CG!'!X'/M75^)XM2F\-WT>D112W[H%B27&TG(SUXSC
M.,]\4 5(_&NDFUU">9;RW_L^-);B.2V8NB/DJV%!R" 3[=\41^-M&FEGCB:Z
M=XK7[8!]F<>9#G!=,CYAD]JY1=!UM8O%$<.@SH-2TR.WB,U\DDCR .I+L6QG
MY\]>@'<X&UY.IR>.=(OY-%N8K5-->WF;S8RL3L5.#AOF VD=.XQ0!LVWBG3+
MO3M,OH7F:'4IO)MOW1W,WS=1V&%8Y/85H:AJ%MI=C)>7;E(8\9(4L220  !R
M220 />N%\(:%)!XSU<)<F31])N'2PA &V.295>0#_=SM_P"!'WKJ?%<,MQX?
MF@CTL:FLCHLMMO"EDW#<5)(PPZCGJ!0!7/C?2$*B=;V!FNH[,K-:NI61QE00
M1P"#UJ]_PD6FK/J44TS0'3BGVAID**-X^7!/WLX[5YY)X<\4GP[-'''?7,5E
MJEO=6%K?3)]HDB0?,K,"5QDC'/\ "3BI-7T'Q/KM_KE[#I/V,R_9)+>.XF0^
M:826VG:3@DD>W'6@#=\4^+89?#7B"+2;NZM=2T^W65M\#1.H8\$!U[\CUK3\
M->*K#5TMK 33?;UM(YF$T+)YJD %U+ ;AGN*P];_ .$B\0^%M7B;PP+*:>U$
M*QF='FEDW#N, (!GJ<^@];>GZ?J,?BW0KJ33YTMX=%^S2R$IB.0E3M/S9XVG
MIQTH ZN^U"UTZ))+F3;YCB.-0"S2.>BJ!R3P>!Z&LV'Q=HTVG27HN'5([DVC
M1M$WF"8''EA ,EO8 U3\96.K2KI6I:- EU<Z;=^>;5F"^:I4HP!/ .&/6LS5
M+77[W^S=:M]#2WEL+\S_ &#S4,DT;IM=B?N[_F.!GMUS0!MMXUT**SFN9KJ2
M%;>9(+A)8'5X&?[N\$?*#G[QX]Z2/QMH,EOJ-Q]IF6+3@C7)>UE4HKC*MM*[
MB/?'OTKE=:\/ZI=+XBU.WTVYW:I/9"*SS&' A969W^;'.T@<Y_.M>QT^^E^(
M6N7%UIDXTJ_LXH=\FPHY4<@C=GN1T]: .CCUW3Y%L#YKK]NC:6W#1,,H "6/
M'RC!'WL=15)/&6BO?QVAGF1Y86G@=[=U29%&YBC$88 <\=>V:Y[2/"&I+H.J
M:?=2NDT5I+IFGS,^28<LP?C[N<HN.PC%5=%T6ZCTZVMY?!D5M?VD#QR7KR1M
MO(C*[HR#DLYQU  &>: .IL_&_A[4)+:.UOVD-T&,!^SR@2;>H4E<%N/N]?:L
MJ'QI9ZSX;EU WESI,/VL1)<_9V;<!(0 ,J1E@N#Z;AWKG['0M;AT/P/;2:/<
MB73+TR78W)\B[CS][GAL\>AI$\.:Y!\-7T$Z5.U[#J(<;60K(GG;]RG=TP.^
M#R.* .^U7Q+IFC>9]JDF;R5#S^3 \ODH<X9]H.T<'KZ5'=^,?#]E-##-J4?F
MS0"XB1%9V>,C(("@YX[=:Q+==2T?Q#KDD^C75[::OLF@,&UBI$80QR9(V_7I
MUYJCH7AC4]'\4^'S+;M+;V.C&VFG4@J)2Q;:,\X[9Q0!W>G:C9ZMI\-_87"3
MVLPW1R)T(SC^8(Q69#JMI%JVLS3:[');VBQB6V*!1:'!ZMU);TJG\/K2^T[P
ME;V&H6,UI<022Y60J=P:1G!&TGLV*Q[O3;\^(_%[3:1/=6&H6]N(E4A?-* *
MVUL\,-Q(SUQ0!V>FZQ8ZMY_V.5V:WD\N9)(GC9&QG!5@#T(-5]1\3Z+I%ZME
M?ZC#!<O'YBQMG)7....N>@ZFL?P/#K%LNH6]\;J33XY$%A-?*%N67;\P<#J
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MW]LMM/;R.GEE5QM( 4$$$9SGJ34:^ -);3)[&ZN+^]26,0B2YN-SQQ AA&A
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MB'15\0Z'<:6]S);I/@-)&H)P"#CD>U:E% '/)X;G36Y]6_MFZ:YEL5LQF*+
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M"H#TSP>M6[NQOW\47%]I>FZK97@DM$$4T1EM[N(!,ER<JKH >=W5>.37J5%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MLTJ00232-MCC4NQ] !DUX_IHM=6.=;UZ2UU>UU0RM9F!?M3.&^41G[Y4J0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH :9$#;2R[L9QGG%*"#R"#7GOQ'6T;Q%X/CET];J6
M6_(QL4ED &5^;C!+ \\<54BU"#3?B;??9;*32XXM*DE:S=1&MY(I+;U"Y4X
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M '3W%S!:0M-<SQPQ+]YY'"J/J33XY$FB26)U>-P&5E.0P/0@]Q7">()+J_\
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MECC*AW52YVJ&.-Q]!3ZXZXOT&L^$K?5M-M9[RY$SQ7(D+?9RD6XD9')(V_Y
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M_:6L-C:16MLFR&)0B+DG 'N>34W4<5@V.LW6JFT<:4XTN_1C'/YGSJN"073
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M)/)$ 4ABBYV\G@\CD\>]94OQ"MH=,AN3I-^\[7W]GS6D84R138R%Y(!SQC%
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M,K<X (.1G'!( -0Q^.;"<WGD6&JRK9RM#,R6;85E )SGIU[\\?3(!T)M;<W
MN#!$9P,"38-P'UZT^2*.:-HY45T88*L,@_A7-6/CO3;W38;TVFHVZ3F-;=9K
M8@SL^=JQXX8\$G!X'/2I9_&>GVEIJ$UU!=Q2:=L^V0&,,\(<$JQP2"#CJI-
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MB3&Y*@CKC(!KT*B@#SW7O"NMZM9ZW>);62:EJ<<5JL1G)6"%&W$E]OS,Q[
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M Q\C;263VP"<=J%\/>)='O==;3Q9WT>K1!C))*8'AFV;2< $%>XQC'2N]HH
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MH4ECCZ>]=%IDU_/:%]1M$M9_,<"-)?,&S/RG/J1BKE% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !12*RNH92&4C((.012T %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 44A.".>O2EH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M!;'3)[]34U% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445SWC
M;7Y/#GA:YOK?8;IBL-N'/'F.< ^^.3CVH Z&BN&\9Z?)I?PUOC!>W<5U!$)7
MGCF(>63(#%CWS^'MBM?6XYKSPDM]83RP7=O +JV<?,V0F=K9/(89!^N: .BH
MJAHFJ1:UHEEJ<!_=W,*R >A(Y'U!R/PJ_0 4444 %%%<N_C2&+5[*TGL+F&W
MO;AK6">3"LTBG'^K/S!#R WZ8YH ZBBL_6-8M=#L/M=VS89UCCC09:61N%11
MZDUQUKJ:V/CSQ!JFH)=6-K;:7%)-%.^_DLWS*%9AT7&!WS^(!Z#17GNK_%+3
MXM*U!M-3S+R&U$\1WI)'DL%P2C-AAG.#C..M;5WXUT_28-/35"+>[NX#+Y<D
ML:;0!U)+ <GH ?Y' !U%%<;%\1+*\MK.33M+U*\DO8I7@C1$!+1D!E.6X^\#
MGI@\9Z4\^/X=VJJNAZJ6TI!)>#$0\L%=W_/3DX'04 =?17,VOC.VN]3L+-+"
M]5-0MGN+261%42A>2 ,Y''(SCJ*S[#QCIEAX?L)[;3=6>WN;Q[-%?#R"7<1A
MMSYY(./3VH [:BN<_P"$O@-O>;=/O6O;6Y6U:S5 \AD90R\J2H4@_>) &#6)
MJWC^YBTH/::>8[V/58].N(GD5PC'D[2.&R.!TP3STH [ZBN6?6=,A\9^5>6M
MU;7ZZ89S+,ZF*.$-ENC'!SD$X_A],5*/%\0N=/$NGW4=IJ7%G=$H5D8@LH(S
ME2P (SZ\XYH Z2BN07XAV!6*9M-U%+1[W[ URZQ[4FSC! <L1[@$5/\ $1GC
M\":K-%--%+%%O1XI&0@Y'=2,]>E '445S,'BR%;Q],_LG4XKI+?SK:&9%#7*
M+P=A+8R.,AB#S5BS\56M_IVCWEO;7+C5)?+BCPNZ/AF+.,\ !3G&>HH WJ*Y
MCQKXCO/#=EI\MG9BX>ZOHK8DD?*&/. 2,D@$#L.IK#&LW&G?$[6"\&H7%LNF
M1S-!&X98L<DX9@HX';K0!Z'17+W/CS1X8+=X6>XDGM/MBQ*R(PB/0G>RC)[#
MK6SHFKVNO:-:ZI9[_L]RFY0XPPYP01Z@@B@"_17%>!(9C>^(I9]2U"Z\C4Y;
M2%+FZ>18XU"D8!/7YNOM]:UM<\7:;H4SV\Q>:YCA-P\,;(K"/GGYV4'H> 2?
M:@#?HKE8O'VEW;1KI]KJ-\\MK]JB%O;$[TW;2 20,@C!JW;^+M/O+339;-)[
MF748C-!;QA?,V#[Q.6 &#QUZ],T ;]%<)X1\0PVWAR6>[>Z:2;4KF."">3?,
M<,3M)8_PJ"22<#!YK0;X@Z.EJ9GBO05O?L+Q+!O=)<9Y"DY&/3.: .KHK-75
MPVA2:I]BNXPD;R&WF01R_+G@@GCIZUPNI>*KZYA\#:H\=U;"\N<S00\^:"@Z
M*"<CGC/- 'IE%<_'XOTZ2SEG$=T)([P6)MVBQ(9CC"@9QR"#G.,=<5GZGXY6
M#3%N=/T^:>X&IIITUO*51HG+ $'G!R#P02.1SUH ["BJ\]W%:V,EY<DPPQ1F
M64MSL4#)SC/3VS6&WC*S%O>G[)>)<VUB;_[/*@#20\X8$$CJ",$Y]J .DHK,
M\/:H=;\/V&I-$8FN8$D*]@2,G'MFN>T75UL]=\8S7^H2-965S%M:5B1$I3)5
M1Z;B0 /:@#M**Y=_'FCP/=177VBWN+:)96@= 7968*NW:2"2S 8SQGG%6%\7
MZ=_9US=RI<PM;SK;/;R1_O?-;&U  2"3N&.>_:@#H**Y6_\ &:6_]EBWL;IG
MO+\64B21[6B.W)!&>O3&,CKSQ73L3LSTH ?17EVBW<E_H^CZWJ&K^(+:YN[H
M0F.*4"&X9W) "G*J@ QD;3QCD]>ZC\2:>]_JEF3*DNF1B2ZW1D!5()!'KD G
MB@#7HKG+GQII=I%&\BW)+0"YD18\M#$>CN,\#@\#)]JV+?4;.ZTR/4H;A&LY
M(O.68\#9C.3GIQZT 6Z*Y^/QCI<L\4*BZ\R>W:Z@!MV'G1KR2F>O!SCK4]KX
MFTZ\.D^49<:K&TEJ60X8*NXY]#CF@#9HKD?^%CZ$\,LT":C<0PH[RR164A6,
M*<')(X_SG%6+?QSI%Q#%(%O4,S*L"26S*TV5W94$<C'?I^8H Z:BN4?XB>'8
MU@+7%QNFN9+4(+=RRR(!N4@#KRO3.<CWJ/4?'EK!ID%Y8VEU<%]233Y(VB*-
M$Y(W!@<$'!X]3@4 =?17&1ZQ+:^.];:>:\:QM]+AN/LY!(0Y;<54=\#GOG-;
M=OXETZZ@TJ> S21ZF2+8K$3G R2W]T8!ZT ;%%4]2U2UTFV6>Z=@'<1QHB%W
MD<]%51R2:S1XOT<6=W=2S2P+92I#<I+"RO$S$!=RXS@DC!Z4 ;U%8&M>+=-T
M4WL$CR/>VMFUZ;=8F):,'&X'&,9XZ\<^E267B6TGTG3[RX\V*2[M_.$0MY">
M%!<@;<X&1ST.1CK0!MT5S%OXTL[SQ+;:7;0W$D$UD+L77DN%PQ&WJ.!C.2>
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MJ#>%];$WC-DCLBNN(([?,[#9\A3+?)Z'/&?3WKNA(C.R*ZEUQN4'D9Z9IV:
M.'C\.Z[%JOAB]V6;C2=/>WEC^T, TC(%ROR'CY1S_A56'PMXC&B:/93)IYDL
M]8_M"0K<-C9O9]J_)URYZ^GOQV4VL6D&N6ND2>8+JYB>6(E#L8+C< W0D9'
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M2<Y4KQ@'W R>* .M_P"$QT6RC@@U+5(8KS[*D\B-G."%YX&.2PX_PJQ:^+M
MOKRVM+75()9[E=T*+GYAM#8SC ."#@\URNF&]3Q];WUQI%_%;0>'1 [&U)_>
M!PY3*Y#' X )YXZY%9MNEU#X;\&H-%U-9+35#+/$+%]T2 N"Q '3YU/OSZ4
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M6#P*_EG#!05& !C /./6KFHW,4?B+2=4U%M0_L*;2?LD;V\4AV3;QNRH7(#
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M MF]F?$;HR.&\PAY4C.", 8R",YS[8YO:AXSU=[O5H=%TB2[-A.+=1Y+,)7
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M$TLLMQ.(8UP1\N[!R[$\9[]30!T=%<DGC*[NO[#^PZ(T_P#:]J;B,M<J@C(
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MH-86CWBWC6L#72C:LQC!<#T#=>]11Z1IL*3)'I]HB3C$RK"H$G^]QSU/7UH
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MT ,P:<J%;>XW=?EP-N<?7O65H%K865KX!U"*Z<7=UN25GG+>:&@<L#D_PN%
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G HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>pinnaclelocrenewal4thloa006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pinnaclelocrenewal4thloa006.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M '!4]01_\?3?[@J>@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** *\?_ !]-_N"K%5H_^/V0>B@59H **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@"O'_P ?LO\ NBK%5X_^/V7_ '15B@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** *\?_'[+_NBK%5H_^/Z7_=%6: "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH K1_\?LWT JS56/_
M (_)O^ U:H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"M#
M_P ?<_X59JM#_P ?<_X59H **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@"K <W=Q]0/TJU52W_X^KC_>'_H-6Z "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** $)P*6@C-% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110!4M_\ CZN/]X?^@U;JK!_Q\W'_ %T'
M_H-6J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH JV__'Q<
M?]=!_P"@U:JK;?ZZ<^L@_P#0:M4 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110!5MO\ 73_]=/\ V45:JI:<R7!'_/2K= !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 445!)>VL7G^9<Q)Y"[YMS@>6.N6].G>@">BL^VUW2;VRFO;7
M4K2:UASYLT<JLJ8&>2.E:'6@ HHHH **** "BFR2)%&TDCJB*"S,QP !W-,M
MKJ"]MH[FUFCF@D&Y)(V#*P]0: ):*** "BBH+>]MKMYTMYTE:WD,,H4YV. "
M5/O@C\Z )Z*** "BHC=6XNQ:&>/[04,@BW#<4!QNQUQD@9J6@ HHHH **ABN
M[:>::&&>.26 A941@2A(R 1VXJ:@ HHHH **ABN[::YFMHIXWG@V^;&K M'N
M&1N';(J:@ HHJM>:C8Z>%-[>V]L'X4S2JF[Z9- %FBD5E= RL&5AD$'((I:
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M"%_+WJAKME<:58>)-4MI6EEOHD"QB#?Y1"B/=CG< #N(QT!Z]* )(_$]S'K
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MY)GA<RRJ=V5=L]@V !Z=NE6-0\-Z[=:'J]@@T[==ZBEW"S3N J"17(;Y#SE
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M!ZFM>2>*$J)940L<+N8#/TKRS795D\/>-+*_M93J<MT7MR\)8S0Y7RMA .0
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MNG6\=F>V%@MN)?,\SY@<G)/;;C'/UJM%XDTJ6#3)1=H%U/\ X]0W!?Y2Q^F
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MY@MY9E6:X)$2$\N0,G'T%>;VXTK1;G3=,O-4^W>'+J2X<2S8%JLN$*1Y^Z4
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MV8$MR%&]B!RV..M '84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M50"?K4M% $4-M;VY8PP1Q%_O%$"Y^N*8UA9M=K=M:0&Y7[LQC&\=N&QFK%%
M$+6EL\CR/;Q,[C:S% 2P]#Z]!^5)/96ES+%+/:PRR1',;R1ABA]B>E3T4 0-
M9VK2/(UM"7<;78H,L/0GO4L<:11B.-%1%Z*HP!^%.HH KQV-I"\KQ6L"--_K
M66, O]?7\:&L+-K5[5K2 V[_ 'HC&-C?4=#5BB@"M)I]E-9BSDM+=[50 (&C
M!0 =!MQCBG265I*(!):POY#!H=T8/ED="OH?I4]% %-=)TU#<%-/M%-R")R(
M5'FYZ[N/FSD]:%TC34LFLDT^T6T8Y: 0J$)]2N,=A5RB@"C#HNE6]Q'<0Z99
M1S1C"2) H91C& 0,CBK$UK;W$D4DUO%(\+;HF= 2A]03T/TJ:B@"H^EZ?)>B
M]DL+5[L8Q.T*EQCI\V,U8FABN(7AGC26)QM='4,K#T(/6GT4 4FT?3'ECE;3
MK0R1IY:.8%RJ<_*#C@<GCW-1_P!@:-]F%M_9-A]G#^8(OLR;=V,;L8QG'&:T
M:* (X8(;>!((8DCA0;5C10%4>@ Z5FOX7\/R.'?0]-+ DY-JG7\JUJ* *MSI
MME>68M+FT@EM@01$Z J,=,#VJO-X?T>>Q%C+IEJ]H'\SR6B!7=ZX]?>M*B@"
MG+I6GSWMO>2V4#W-L,0RL@+1C_9/:F3Z)I=S>B]GTZUDNAC]\T0+<'(Y]JOT
M4 1RP0SF,RQ1R&-MZ%U!VMZCT//6E2*./=Y:*F]MS;1C<?4^]/HH I)HVEQ&
M<QZ;9H;@$3;8%'F@]0W'/XTX:7IXLA9"QMA: Y$ A79G.?NXQUYJW10 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 9VE?ZF3WF:M&L[2O]0Q_P"F
MK5HT %%%% !1110 4444 %%%% !1110 4444 %!SVHI&.%R 3]*  '/:EKC]
M*UW4KSQYJVGR0NEA;Q 1LR\%@>3GWKKU.0<^M "T444 %%%% !1110 4444
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M3K)99Y+.6\>.>78$2-@K#(!RV>!T]3B@#K**RSK(;^S4@@:2:^"R>7N \N/
M+.WL,@>Y(%:E !131(C,%#J6(W8!YQZTBRQLY19%+KU4'D4 /HIJNC'"NI.,
MX![4-(B,JNZJ6.%!.,_2@!U%(S*@!9@ 3CD]Z6@ HI"P#!21D]!ZT@="H8.I
M#=#GK0 ZBD5E<95@P]0<TM !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110!F:,<VK?]=6K3K,T/_CQ
M8]C(V/SK3H **** "BBB@ HHHH **** "BBB@ HHHH *" >M%% #=BY)VCG@
M\4ZBB@ HHHH **** "BBB@ HHHH *:T:.RLR*S(<J2,E3C''X4ZB@#R?XXB&
M#POI=O&(X_\ 3"RQJ . C9('U(_.NEN]+BTKP+XGG34Y+Z&_MY[I)IGW':T
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M#33&A))122,$XZT >::9-HMG-X*N8KJT>_N+9U>X9P7F;R<89B<_> 4 G@C
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MP R.1D#VJ]80Z+KGCM9KN2WO(3X?ADE+3;D+[SN+<X)  //3&:]*$$*@A8D
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@#+T3_D&J?\ ;;_T*M2LK03NTN/_ 'F/_CU:M !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 96@?\@N/_>;^=:M96@8.E1_4_SK5H *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH *P[_Q18Z=>W]M,0'LK,W;KO4.Z@,2$4G+8"DD]!Q^&Y44EK;RRB62")Y
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M,<5U$LB+)@$9'0^]7Z\7\2V\47CT>';^:VT[11IWD::]U%YD4.5'SJ2Z[7#
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MV 5&G2\N!;K)$5*HV"<GG_9(XSS7$6"RQZAX-+7]]+_;&FRK>"2[<A\0*P(
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MV0=%AQ_>8_\ CU;%8WAD;=&@'^]_Z%6S0 4444 %%%% !1110 4444 %%%%
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M$FR^NO+( 9\1LXC!. 7*@A03T+8SS3;_ ,3:-IMQ]GNK^-)O*\X1J"[%,@9
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M>&-)O;E@T]Q9PRR,!C+,@)..W)J2;6]+M[Q;2:_MTN&<1B-I #O/(7ZGTZT
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M:,':3D ].H!K?K#/B[1FURRTF"]@N;B[\S;Y$JN$*#)#8/&><?2MR@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** ,?PW_R!X/\ @7_H5;%9/AP
M:);GO@_SK6H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MX+D;0!@DJ!UZ'/M7I) (((R#VJK8:98:7"T.GV5O:1,V\I!$$4MTS@=^!^5
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!FZ!_R!+7_=
MK2K/T7_D$6W^[6A0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 5!)>VT2RL\Z 1,J/S]UCC"_4[EP.IR/6IZYF_\
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M'G2-VE@924=]I*AL@YQ_^L ]3IL<B2QK)&ZNC@,K*<@@]"#7D&K^)=<E\/\
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M%%% !1110 4444 %%%% !1110!GZ+_R!;3_KF*T*S]%_Y ]H/2,5H4 %%%%
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M?1D6T1AD26WWQ3J0!\R;ATQZFM>YEFB1#!!YS&158;PNU20&;WP,G'?%39H
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M%7ZHZ1QI5K_UR%7J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M$W>YP3C\*X+3_ &I6_@ZUTJ6ZM8]1TVX-SI]Y"6.URQ8AP1TYP>N1].0#?\
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MD22.5L[?E8':<=CC!K'M]"NCXO'B;5(=/L1;6CQ'[/,7\S)SO=BBX  /K]:
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MN?6@"[=>.M(M+N.%Q<-#)<"V%TD8:+S,D;<YSU!&<8SWIDOCW2X;6.X>VO\
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M#;7\O83P<$9YZUE6.G:SJ;^'(M0L)+6717W7,[NC).1&4'E[3DY)R<@8Z<T
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MZN^EQ74C7:3>04\B3&_&<9Q@<9Y..AK=KD_",%Y#J_B1[BPN+>*YOO/ADE4
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ I" RE2 0>"#WI:* $50BA5
M"@8  X I:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M*.D?\@NU_P"N0J]5'2/^07:_]<A5Z@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ K*F\,:%<3233:19/++()'=H5)
M+#H<XZUJT4 9;>'-'=;Q6TZW87I!N=RY\W!S\WKS5)M(U&XU:VCD.GPZ'9NL
MEO!#&QE9E7"AB?E !.>!V%=#10 5FV7A[2--E\VSTZWA?!7*)T!Z_G@5I44
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M 4444 %%%% !1110 4444 %%%% !1110 4444 4],YTVU]HQ5RJFF\:?;_\
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M0?G()WGY1SQWZUTU !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\T^]BTQ[O491-*O^A6TF.MO"S*I]MQR?<!34OQ.9D\ 7[JA=EDMR%'<^>G%
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M0!V,VM:;8S+;7FHVL=S\H96<*<G@<9XR>F:;>>(=&T^5HKK4[6*5 "T;2C<
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M6_%M%C^Z*GH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M.HSR*=7$>'(=GQ/\8LB80I:<@<9,9)K:\:+&W@C6_,C#JME*^T^H4D'\" :
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M3U5TALKB;,<092I P 3\I(&2<9]:ET;P9;:1]E1M0O[VWLPPM(+EU*0Y!!/
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M(N=(FL]'T^ZT>YCU_2W>.1# P,3,IWR.QXVL#GD\D\ \5Z73&=$/S,J_4XH
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M8;2,GG 'J*]9FTZRN(%@GL[>6)1M6-XE90/0 BHY='TR>6.6;3K222)0L;O
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MFBMUM+N.%4*RL9,Q@C)4K@9!]>WO4'B#1;R_U_0-2M8K>5=/EE9TFF:/[Z@
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MU(.6R!\X/([-[9B>PUP2>&YH=+VS6%C-%*6EC(21HU5?XLE<KDX[8H UM/\
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M,@2 ?>0@\E@, >Y[=<BTTW4[#P9IUG/H-[+.->6ZDB2$.5B$@<MP<<CCGWH
M](TC7],UT7!TZY,WV=_+E!C9"I(R.& ."._2M*N2T$7/_"?>)II+*[BMKA+8
M0RRQ%4<QJRM@GKR1]<5UM !1110 4444 %%%% !1110 4444 %%%% !1110
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MBBB@ J)[:"2XCN'AC::,$)(5!9 >H!ZC.!4M% !1110 4444 %%%% !1110
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M-I_AC3+/2H+"6WBNECF-R6FC!W3$DE\=CDG'H.*V:** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MJJ,EB< "EH **** "BC-% !115*YU>RM+ZRLIIBL]ZS+;J$)#E1N/(&!P.]
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M3?4ETNT%[)G=/Y0W'/7GU/K4,/A'P[;RQ2PZ)81R1,6C=(%#(3Z$#(Z_AVH
M\^L9]2A\-:9K UW4IYO[<%N5EN"R/%YQ3:1WX /-:ME?W2^.8$U.2[DAGO;A
M;&[MKMC!)MW+Y,D712NWJ!R5[]:Z_P#X1;0?LAM?[)M!;EQ)Y8B 4,/X@.Q]
MQ4\.AZ7;WIO(K"W2X+M)Y@09#-]YAZ$Y.2.N: +R2)*F^-U=<D94Y&0<']:X
M[XB64%]::'%-)<(9-7MXU:&4H1N)R>#UQG!Z@_C70:#HEOH&G&SMO]6TKRX
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MPO>:C9:O;P%5B=<Q,L>UHY%) ^ISCZ\X .HN/&'AVU:19=7M=T<8D94?>0A
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M^(=8MH[I-3FMH P"?NUVA<XZ<D\G^E:G@&VO+/P]-!?64UI(+V=U6;&65G+
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 9UKHEC9ZC<:A%&YNIR2SR2L^T$Y(4,2%!(' QT'I6C110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% %#6-,.KZ;)9B^O+(N0?/LY?+D7!SP:DT[3K?2K&.SM581
MIDY9BS,Q.2S$\DDDDGWJW10 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 45GZVNIMI,W]CM"+X;3'YV=K8()!
MQTR,C/O7-WTWB.TDUF_OHHX[!-),D<D%P=T4BQY90O0G=N.[TV\]10!VE%>9
M_#B:ZU3P%J>I7U_>SW<S3(TCW+_* N1M&<+UZC%9.L:[?:#HO@^:[.ISZ'/:
MI/?2Q7#B625US@R;LX!.0N0#T^@![%17FHU6-_A_XAU/2=?N[FWB'F6;^<3-
M;D(OR.6&?O9ZYR#USS6#!KGB"+X50^+(=8NWOH+G$JRL'CDC\S9@J?J.1S0!
M[116=H.J+K>@V.IJA07,*R;#V)'(_.N"GU34V^-\>B_VE=C36C\TVZR87(B+
M8^F1TH ].HKG?'=Y<Z?X(U2[LYW@N(8@R2(<$'<*\VGU[6E^#EMKZZO>C4FN
MBC2^:>5WLN,=.@% 'M=%>0:7XGU:7QKH%GI.J3W]M<6D+ZC%=-E48@[R"0"#
MW '!.!6IX6UO4OB!KNL/+>3V>BV9$<$-JYC9V.<,SCYNBYQQ]X4 >ET5Y?I'
MBG58=?\ $WA:_O3.UE;RS6=V2!+@ $*3CYCA@<X['\.5T_Q/J<WP[N]5E\47
MW]N+>"&UMUE4^8/DXV8R>"W/M0![U17)Z9%KVHQ^'=1NKFZMW-L?M]L B1Y,
M9PQ4C=OW%3CH,'IWUO#EKJ-GI7D:G=27,RROLDF*F0QY^7=MXSCTH UJ*YW4
M?&6GZ=JEUIIMM0N+RW@$[16UJSDH>X/0]>O3WJ.Q\=Z-J%W800"[ OR5MY9+
M=EC=@NXKD]QT^O% '345S3>.=&348K1FF"RW/V5+C:#&TO\ =!SGKQG&,@\T
MZR\::;?ZC!:PPWNRY:1+>Y: B*9HP2X4YSD;6Z@9QQ0!T=%<O9^/='O3"8H[
MX1RW(M1*]LRH)"2 I)]P?IWQ5V#Q187&JII\:7&Z2:6".4Q_NWDC!+J&]MI_
M*@#;HK'\4:TWA[PW>ZJENUPUO'N$8.,G..3Z<\USEWX@O(O$GANXG6^2.YL+
MAI[&*(L6=0O1!DGDG&3TQTYH [NBN?'C'2&T:TU-9)6BNW,<,8C/F,P)##;V
MQ@YSP*NZ)K]AX@M99[&1CY,K0RHXPR..H(H TZ*XW7GO5^(GANVAU&\AM;I)
MVG@C;Y&\I0R]N,D\^O KI]2U*TTBPDO;V7RX(\ D*6.20  !R220,"@"W16&
MWBK3HXK]YUNH&L8?M$T4L#!_*Y^<#N.#],<XHTWQ7IFJWD5M:FX_>VYN8I7A
M9(W0%0=K'@XW#/UH W**X?4_%#7'BSPU:V$MVEK<W$H=O+Q#<H$/*M_$ <8Q
MP<YYX-;-QXPTFUD!G>9+4SBW^V&(^1YF<8W].N03T!!&: -^BN=O_&^BZ?+>
MQRO<N]D1]H$5L[^6#SN.!PN.<]/3-;\,T=Q#'-$X>.10Z,IX8$9!% #Z*YF7
MQ/ING7_B"6YU*ZDCTY83<6YM_EM]P.-N%RV[J220/84^+QKI=Q]M%O'>RO:6
MXN2HMF4R1GN@(&X?2@#HZ*YNQ\8V=QX:L=8N+>XA:\P([58V>1W(SA!@%QC)
MR!C S49^(&@"&%_-N=\MPUMY0MG\Q)5&61EQP1D<4 =117GEKX[CM?%&L&^N
M+\Z;';0310/:'?#N&6)55W  8SNZ5TM_XQT>QLXKKS9;F.6V-THM8FE/DC&7
M./NJ,]3B@#>HK"N/&.AVSVB27;%[RW^TVZ)"[M*G^R #D^W6LB3Q,^H^(?"L
MNFW<PTO41<F4&-0K>6A(!)&000>,]J .THJCI>KV>LV[W%DTCPJY3>T3(&([
MKN W#W'%)JFLV>D1QFY,C23,5A@AC,DDI R0JCD\?@.] %^BN0\2>,HK7P9+
MK&D/YK-,MN"5(:)RVULJ1D,.>".N*I7&HW>F:_INC?VEJTT%_'-<F5K??-$,
M *O"< $DG(R.,X&<@'>45S>G^(;&PCLM.O=3DNIB?L_V]X2D4TP)!4-]W=D$
M8S[<G-2V?C7P_?F3[-J"NL:R-(YC8*@C^]EB,#KGW'- &_16';^+M(GFN(9)
M9;22"+SF2[A>$M'_ 'U# 9&>/K61I/B2YU7XD7-C!)<C2X],67RI[8Q;92X
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M 4444 %%%% !1110 4444 %%%% !1110 55U.Q34M+O+"0X2Y@>%CZ!E(/\
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MJ=^X@@>X!K)G\,>(+'1;;08H);JV_L:2WWVSI&OVERV?,8D,4 88 X)ZBO4
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M@I(R,D=/0UJZ<UWJ>MG5Y+.XM+:*U:WBAN%"RNQ8,S8SP/E4#)SUZ#&>@HH
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M=!GC)%=510!R/@$[+75X3'?*W]HRR[KRW,3.'P0>@'8\#IQD"NNHHH ****
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M0%KJ:T-FYSQY9SGCUYQGTJ"\\'Z7=^$1X9 E@TX*B8A(#85@W4@\DC)..>:
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MU"YAG<Z?<2?NH=@4G;D=3D<#%:%K\/='@TR339Y[^]LFC:)(+JXW+$I(/R
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M::9:KB&VC"#W/<GW)R3]:S9?",+^)9M?BU34(+Z6'R"8S$5$>0=H#(>X!]:
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M2RU1FDO+955]S,"&*,V=NX'G@^V.,7M9\,66LIIJ2%X5L)EDC\HX)4#!3/\
M=/&?I0!@-XNUQEMK!+.#^UWM&O9HTMWE6&,MA$*A@=Q!Y.>HX!J>P\1>(=82
M/3X].M;'5%L_M%V+Q6:-"S%44*&#?,%8^W'6K^N^$VU358-6L-4N-+U&*(PM
M- BMYD9.=K ]<'I41\&M%J%IJ%IK-Y#?16YMKB=@LC7"$ELL&& 022#CCIC
MH I_"7_DG&G9_OS?^C6K!T+5M=T+P]+>VEC8RZ1!J<ZW"EV\[:9B"5 &T!<]
M\Y'I7=^%]!'AK0XM+6]GNTB)*O, "H/88[9SZ]:S(_!*)!-I[ZE-)I,MS]J:
MT:),E]XDQOQG;N&<8]LT 0S>+;ZPU7Q#97L-LKV5ND]@B@@W"N2JY)/7?M7
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M:UJ&JV6OZ?I4=JL=C8DWCW2,VXO&6V)@C!"\[CD9(&*O3^#I;FWU^&75,KK
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M;5Y=/F<VRGS549#8['C'&.2.E=IX8O+ZX.KVU_<_:7LM0:WCF**K,FQ'&X*
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M2WVG2KJ5]]A,0M6"Y)<!RV[/!7H!^)H ]*HK@[[QA?:'8:I'<R17M[!JD5E
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MWM_%#(65#D$A2W0,0,+GW(H UJ*Q)/%^@Q3WL$FH*LMD5%PAC?*%B !TYR2
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MY<",X92S=R3CCG^5=?--'# TTDJ1QJ,EW.% ]2?2@#%N?!^D7-]=W1CFB:]
M%VD,S(EQC^^H.#_7)S4TWAJPFUDZKFXCN6MC:GRYF53'SQ@>F21Z&H-+U^QC
MT:SFU'7M.GDG+[;A&$:2[6;.T$]% QGVS6KI^IV.JVYN+"[AN80Y0O$P8!AU
M'UH P)/A]H#VNGPI%<0G3V)MIHKAA(@))V[\YQD].W:I!X$T-=,_LY4O!;?:
M/M.!>2Y\SKNSNSUY^O/6F7GBR"X'B&RTR>$7^EPE@9,,K/L+$  Y.,8/H:G\
M,>);/6=+TU'U"UEU26RCGGAC<;@2H+?*.G)Z=LT 32>%-,=M1(^TQ_VBNVY"
M7#@/P%SC.,X&,TA\):45TT[)Q-IL9BMIUG82*I&,%@<D8]:MPZ]I-QJ3:=#J
M5K)>#.85D!;CKQWQW]*H^(?$#Z;>:?I=C%'/JFHR%(4D;"HJC+2-CG '8=:
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MKI_[4T_RX9/M]KLG7?$WG+B1<9RISR, GCL*(]5TZ;3SJ$5_:O9*"3<K,IC
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M "BBB@ KS[QK;ZG>ZQ=VD&FWQ@DTMTCN;")-TSY;]W)(WW4']T==Q]J]!HH
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M5!ZX]*D50HPH 'M0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^S_Z,5)/R@E 1_>#=/K6@((H?$%N-*MF@GNO"SP0F&(I^_."@) PK<'DXZ4
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MH8H[RQ-J]L9/*#9F<Y&&'.-F.^.II8M=TF;4VTV+4;9[U0<P+("PQUX]1Z4
M:%%9R:_HTDD4<>JV3O*_EQJLZDNV<8 SSS4C:OIJZC_9[7]L+SC]P90'YY''
M6@"[14-S<P6EN]Q<S)##&,N[M@*/<U1DU[3O[$N]5M[N&YMK:-W=XG# ;1DC
MCH: -2BN>\+:G?:Q9K?RWUA=6DT2,HMHV5HI",LAR3D#(]#ZBL;6OB#;C3!=
M:%<6TS1ZC'9W"R@Y56)!8#((Y!P3UP: .ZHJK;ZE8W0F-O>VTPA.)?+E5O+_
M -[!XZ'KZ5%I^N:5JSRIIVHVMT\6/,$,H<KGIG% %^BN.\1^)-8T[QEHFB:?
M'9&+4E;,DZ,S(5Y8X# $8[5U[.L<99V"JHRS'@#WH =156TU.PU!'>ROK:Y6
M/[[0RJX7ZX/%,M]8TN[BEEMM1M)HXAF1HYU8(/<@\4 7:*J0:KIUS<FV@O[6
M6X"[_*CF5FVX!S@'.,$?G6)XR\07WAVVT^:RMH+C[5>):%96*X9\X((^E '3
M45R.M>*=0\+2VTVL6-O)IDTJQ-=VLAW0L?[R$9(]P:Z.YU33[.:.&ZOK:"63
M[B2S*K-] 3S0!;HJM=ZC96 0WEY;VP<X3SI53<?09/-/6[MFDFC6XB+PX\U0
MXS'GD;AVS[T 345"]W;1A#)<1(),["S@;L DX]< $_0&HUU*P=8&6]MBMP<0
MD2KB4_[///X4 6J*@FO+6WEBBFN88Y)3B-'< N?8'K2SW=M:H7N+B*) 0"TC
MA0">@Y]: )J*H_VO9'6O[($P-[Y'V@QCLF<?Y^E6(;NWN6D6"XBE,3%) CAM
MC>AQT- $U%0W%U;VB![F>*%"P4-(X4$GH.>]/::)?O2(.-W+#IZT /HICRHL
M?F%U"XX8G _.L7POKD^O6E]+<010R6M]+:%8I"ZG80,@D#/Y4 ;M%,:6-&5&
MD56;H">30TL:,JNZJS?=!.": 'T4UI$0$NZJ!ZG%)YL?F>7YB[^NW//Y4 /H
MJ/SXA)Y?FIYG]W<,_E2K-&[E%D1F7JH.2* 'T53N-4M+74+6PEDQ<708QICL
MHY)]!R!]2*S_  ]KDNK_ -I_:(8H#9ZA+9*%<G?L YY YYH W**8TL:NJ,ZA
MFZ*3R:K6VJ6=W?W=E!,KW%H5$R#^$D9'Z$4 7**:\B1XWNJY.!DXR:=0 445
MDG5Y1XM31C GE-8M=";S,MD.J[=N.!\W7O\ A0!K4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MK>D-:Z1%=7D-K/!/>>1$Q62+=\R#CYCT) ["O0B0 23@#J30I5U#*P(/0@T
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MXT%5B:9@8UN Q#9)X#!0 ">G3O5[3=-T&_\ %FE60DNKFQ31'\MKN0J;@"?
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M@=B# )^Z.IX&>G--M_&FH:E%HS:9I$4G]JVLDL1GN=@C=#A@V%/R\\$9)SC
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MLVYV^4$GT XX ]*K>(O"FK:[>B8QZ6)$>)[>]WND]K@+O487]XI(8@$C[Q_
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M(IMOFQ))M.5W*#@^HJ2BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *, ]J** #%)@4M% &+9>'S!K7]K7FH7%[=+"T$9D
M2-!&A8,0 JC)R!R:V<#.:6B@!,#.:6BB@ I  .@I:* $(!ZBC:!V'-+10 F
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%4BX+*/,8L0!QP&)X.3ZU6MO#]Q;ZKX,L-5U6_N+BYAN_M;)?RD-A00H(;C
M.W*XSBM_6/ OV_7ENUMM+NK 6Z01VEW&RBVVDG,>SJ#DY!_.M+0?!FFZ5801
MW-M:W5Q%(\L<A@&V$N<E8@<E5'ID]SWH X?2[^$Z38:+=WTT[2:C>P6]N]R4
MB9$SA9Y/O87(( /.5JOIGV>Z\*^%KF_GAE^RZ^T"S>>2%B^<X))Z?*,9[8]:
M]0'AG0A!' -&L/)BD,J1_9TVJYQE@,<'@<^U2R:'I,UNUO)IEF\+S>>T;0*5
M,G]\C'WO>@#S/5-4AL].\?VK:D87CEC:TC^TE67*@C9SD#=V''X5I)IL&O\
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MRX@^SF1X3AHR<LA(.1GUY_EBGHW@K[/K%CJ+Z9I^EO:$DBQN9)/.RI7:0P4
M9;/0GY10!E^%)=9NY]%U>7Q/:/;WF?-MA)([7#[22H5R0A4YX0*!CIC%:WPX
M^[XI_P"Q@NO_ &6MNW\-Z7HSW%[HVCV4=\ZG&/W88GG&X [03CH*I^#-#U#1
M(-6.HBW$E]J,MZJP2%P@?'RDE1G&.N* .GHHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** &@'/6G444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
G 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>pinnaclelocrenewal4thloa007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pinnaclelocrenewal4thloa007.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@"K'_Q^3?\  :M573FYE^JU8H **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@"O%_P ?$OX58JO%_P ?$OX58H ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"M <SS?[P'Z59JM#_KI
MO^NG_LM6: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH K0_
MZ^8?]-/_ &6K-5H/]?.?^F@_]!JS0 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% %:W_ -;-_P!=!_Z#5FJUO_KIO]\?^@U9H **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@"K;?Z^X_ZZ?^RBK55;7F2<C^
M_BK5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 5+/K/_UU
M-6ZJ6/)N/^NIJW0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% %.QZW'_74U<JG8\B?_ *ZFKE !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 4]/^[/_P!=35RJ>G',<I]9#5R@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** *&F,3"_\ UU:K]9^E?\>[?]=6K0H ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M:RC9U"?;#YS%>P79C)^M4_A_>6.C1ZGI6JF*TUR"X+7LT\W-WG)64%NH(/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% &=H__'JW_71C^M:-9NC'-D".F]O_ $(UI4 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH S=&&W3U'^VW\
MZTJSM'_X\!_OM_Z%6C0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%<=<?$.UA\3W?A^'2-2N;ZU4NRPK&0RA0V1EP3P1QUJ;3?B%H>I>%K
MKQ KRPVMJQ29)5 D5N,# )SG(QS0!U=%<=-\0[6STBTU>^T;5K;3;D_+<O$A
M"@]"RJQ8 ]N.?RJ;7?'EAH-]IEM):75R-3Q]EEMRA1\D <EA_>'/O0!U=%<W
MIWC*UOO$EQX?EL+VSU&&+S1'.J$2+Q]UE8CN*R(?BA8SRZG'%HNJ/_9>XWC*
M(OW04D$_ZS) P>F: .[HK!7QCHI\*+XE:Y*::RYW,OS9SMV[1_%GC_ZU4?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH S- '_$G@^E:=9N@_P#(&ML?W:TJ "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*W==:TK3[M1*O*W"D1^6X]SM_P ]!T7PN^RGX?Z<;8@L=YG/?S=QW9]_Z8H
MZ?3=1MM6L8[VSD\RWDSL?!&<$@]?<&K=0P?9T0) 8PI9L!,8+9.[IWSG/OFI
MJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** ,KPZ?^)%:?[M:M9/AT?\2&T'HM:U !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !37!*$  GT/2G44 9%SX<TV\O&NIK11.PPTJ$JS >N.OX
MU9ETFRGTYK"6UB>U88,3KD$>]7J* ,FST"QL65X;?YD^[OD+[?IGI3X]$L8[
MN[N!;+OO.)\G(D'N#Q6G10!B7GAC2KV>TEFLE+6A!M]K;?+(Z%<=/2HF\)Z5
M)?W%\;1EN;G'G2+(REP.@.#T'^-=!10!AS>%=)N-(DTI[")+&5][PQ_*&.<Y
M;'WCP.33H?#5C!-%*(Y&:(@H'F=@I[8!..*VJ* ,2Q\+Z;I<-W%:6Y$=VQ:=
M&=F$A/4X)QSWJH? VB-;V]JUK(8+:3S($^T28A;& 5^;C&3^==-10!@MX5T]
MMQ?[0Q:-HBSW,C$*>N"6XS5G^SK*ST)K KY5DD)0KO. N.Q/-:C8QS7 ?$G5
M)FM[3PW8,?M^JN$.WJL0/S&JA%SGRB;LCAA)<S6]G>Z,'L_#5CJ<<<$)D)\U
MB^T^X /->U7>F6U\UM)<1!WMI/-B)ZJV,<'\:Y'Q'I$&G^'M"T*R5%5M0MD"
M]-P5MS-]>*[O/%:UY1:7(NY$;O<PQX6TX7]U>JDRSW1#3D3,-Y'3//:M.PL+
M73;?R+6%8D)+$#^(GJ2>YHU#4+;3+1[J[D$<$8RSGM69X:\567BJRFN]/27R
MHI6B)D7&2.X]JPLVN;H7=7L3GPWII\0+K@2<:@$\OS!<R %.NTKNP5SSC&,T
MFL^&],U][=M02=S;.)(O+N9(PKCHP"L!D>O6KMWJ-I81F2[N(X4'\4C 9^GK
M2V6H6NHVXGM)TFB)P&0Y%.SM<+HSM3\*Z5J\]I<7:7)GLQB"5+N5'CSP<$,#
MDX&3U-3:1H%AHDES)9_:"]TP>9Y[F24NP& <N3SCC\!Z5J4UC@$]A2&<Y+X'
M\.S3W<C6TZ_;&WW2)=S*DYR3EU#8;DGK6A<^&])O-/M;*YM3+!:N'@WRN7C8
M="'SN&/K7,>'KR?7/B!KMTTKFUT_;:PH&.W<<EB1ZUW8^Z,<U4X.+LR8NYG6
MV@:?:_:MD4KB[7;<":XDE$@QMY#L<\ #/H,55N?"&C7=QIT\EO(K:: +18IW
M18L8Z*I [#\JW:*DHS]/T:STRZO;FV67SKQQ).\DK.6(&!]XG''&!5:#PQI=
MOJ]YJB13-=7J[+@R3NZR+TP5)VX X'' Z5LT4 <W#X&T*VC:&"&ZBM7)+6L=
M[,L#9Z@QAMI![C'-3W_A'2M1U./49A=I=11^7$\%Y+%Y:^BA&&,]\=:W:* ,
M:U\+Z5:QWB&"2Y%ZJI<&\F>X,BKG"DN2<#)X]ZAL_!VD63P&)+MH[=@T,$UY
M+)%&1T(1F*C';CBM^B@#,US0-/\ $=A]AU..26VWARB2L@8CIG:1GZ&F:IX<
MT[6=&72=0CFGM%VG:T[[FV]-S9W'\36M10!B7?A32+ZSL[:X@E?['C[/-Y[B
M:/Z2 [OUI+7PK86UK/"T]_<23IY<EQ<7DCS;,YVA\Y4>RXK<HH SDT.Q30/[
M$6-Q8>1]G\OS&SY>,8W9STXZUC+\//#RV5M9K#>+;VTOG01K?3 1/_>7YN#R
M>GK7544 82>$M+'G";[;=":![=Q=7TTP\ML%@-S'&=HZ>E%EX0TBPGMI88[D
MBU.ZWBENY9(X3@C*HS%0<$CIQFMVB@#/UK1;'Q!ICZ=J,;R6LA!=%D9-V#D9
M*D<9P<>U5XO#.GP75E<H;KS;*+R86-U(<)D$J>?F' ZYZ#TK8HH J2:9:2:G
M#J30*;R&-HDEZ$*V"1[C@5GCPII4=Y-=6\=Q:O.VZ5;6ZEA1V]2J,!GWZUMT
M4 9Z:+81W%C.D&U[&-H[?#G"JP /&>>@Y/-:%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &7X=XT*T]TK4K,T
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
MS=!_Y EG_P!<A6E6=H7&B6>?^>0K1H **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M .HIN_\ S@T;_P#.#0 ZBF[O\X-&[T% #J*** "BBB@ HHHH **** "BBB@
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MP<,<< >QK.I/VDW)CBK&\= LQ_'=<_\ 3P_^-9TW@[1;[4([J22>6:V^5/\
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MY*!Y"..A_2NGET6R6-I)+BY51R6-PP Q[YKD_&N@6>EZ2UW9Q;6FU.UE:$'
M)5@HV>F<U>OO$=W!:>(H[_2K>;^S;;[0J;\I-&5W '@X/%8SFYN[*4>78Z :
M#9OAUDN>1U%R_/ZTV;2;"UB::>YGBC7J[W;@#\2:R+GQ9Y$RV5G;$W"6:SL-
MCE%R/E3Y1Q]:Q[J^U/6_$/A/?8I )X;I[BTNB2%P$'([]\9Z5)1UITW3FMO-
M^V3^0X&'-VP4_CFB.QTR5ECCOY';H%6]8D_K6-\0;&UM_ACJEM#!&D$,*F*-
M5P$PZXQ46@V6E37>DK'X,:SD2+SQ?FWCBVNJC'*$D[MQZXZ=#V .C.@VY/\
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M&NKR-)!DS(+XDQ@==PSQ^-+:6VE:@SK9ZR]RP&2(;[>5'O@\5YQ+I5Y'\/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MZEFYQ^'2NKQ2 "EKGE)R?,S1*RL%%%%2,**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@"GI@(TVV!Z^6*N55L/^/"#_<%
M6J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "HYHDN()(9 2DBE6
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MM-&M;/3W$\UQ"+L.TLSCC!Q\HW<_YQ22^"AXA^'^GZ)KL*6]Y:0K'')!)O\
M+9%VALXY! Y'O^- ' ^)DFM/A?H5_:ZE?K<2:A)$THNG)=6,G7GG C7'X^M=
M'KMQ<^ _&V@&RO+J72]48V\UI/,T@4@H"ZEB2#\P/X'UJ/Q!X$UVY\!^'O#]
MBD#R63^;<$S87< >A(R?O-6W>^%M4\4>*]+U76HX+.PTSYX;6.8RN\F0<L<
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M/FER\O02BD[A1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 5;#_CP@_P!P5:JM9<64'^X*LT %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MB3R<I!;QD>4.>&8L=QQCI@#GK0!LT444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 0P?ZB,>BBIJB@'[I/\
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MEJD.1+NMG6)\?Q*Q&!]"?I768I: "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH ***;NR>WYT .S1FHGE5#\Q 'J6 JO+JEE
M"</=VX)[&09I68%VBHX9DG3>C!E]0:DI@%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 R, * .@XI]%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M8,1_]>ML-5ES2DWLF95(K1)$_P 4LSZ+I5D@R;K4H8]N/?/\JS/'+_VAXO\
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M0****!A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MD@5)=66DVMG+=W-I;K##&9'8Q_=4#). * +?]J:?_P _UK_W^7_&D_M;3?\
MH(6G_?Y?\:H:;;:-JVF6VH6MA ;>XC$D9:, X/MBK?\ 8]A_SY6__? _PH E
M_M73O^?^UY_Z;+_C4D-Y:W+%8+F&4@9(1PV/RJL=)L#@&RM_8%!_A4UM86UH
MS-!;11$C!* #/Z4 6J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MWTYN)XKB: RM@%MCE02/7'-.\>:1::[H,=A<Z@MA*UU&;69AD&;D*,=\Y/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 &***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M[*[O=8U2&2[UJ.TMPY3<;9NA8,N0W#=>>G%;WB+P&\D>GVFE:=976CVRR?\
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M</VA4!CE:1H\_*H&!C.,>U=.?!>@FRN+,VDQM[B<7$R&[F^>0'.X_/G.>?J
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MRIN+AQ:2B*Y=+23;"2<?,=N ,U<TWQ*FH>)-3T@6=S']B\L"5X6"N6!).<8
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M"]T'4K)+",/:VTD<FJN5R(H7;8H^I.3^ KJ]1U>QTJP^VWEPL<!("L 6+D]
MH&2Q/8"N(M?"DNN:-K&JZE<:M976J^8;BS54^XA81+M*$Y"XZ'DUSM_>:N?
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M'4+MKJ2PU2>T25U =D7&"V !GD]JZVN%^&JQ@^*6!'FG7;D-SS@8QQ^)KNJ
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !36[4ZB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "@T4&@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "@T4&@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "FMVIU% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
44 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>pinnaclelocrenewal4thloa008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pinnaclelocrenewal4thloa008.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W=?\ C\;_
M '!5BJ\?_'TW^X*L4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110!7C_ ./IO]P58JM'_P ?KC_8%6: "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH KQ_\ 'VW^X*L57C_X^F_W!5B@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** *Z?\ 'U)]!5BJ\?\ Q^2CT458H **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"O'_ ,?LO^Z*L56C
M_P"/V;_=%6: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH J
MQ_\ '[-_P&K558_^/R;_ (#5J@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** *L7-Y/_ ,!JU56'_C\G_"K5 !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 5(/^/R?\*MU4@YN[C_>7^56Z "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH J6W_ !]7'^\/_0:MU4M^+JX_
MWP/_ !VK= !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 5;?
M_CXN/^N@_P#0:M54MO\ CYN?^NO_ +**MT %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%-\Q#(8]Z^8!N*YYQZXH =1135=7SM8-@X.#G!]* '44E (SC(SZ4 +12$@
M8R1STHR,XR,^E "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 4[7_ (^;G_KK_P"RBKE4[0[I[EO^FG],5<H **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"CIW6Y_P"NIJ]6?IC!
MC=8_Y[&M"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!A
MEC!P9%!^M.!!&0017SZ\,$WQ%\9S+HC:I;Q17 :"+!VON W=<_>!/&2/2H)?
M$U[I_P *-,TJPOR[7=S+'/+&S@P*-I$62!C.[/'& ?6@#Z BU.PGN6MH;ZVD
MN%R&B252PQP<@'--N=7TVSF\JZU"T@DQG9+,JG'T)KS?XE>&M+T7X=PS6%O!
M9W5A+$8IHH\2,2<$;QSSG=D_W:Y[QO>-J'_"O=6NK4/=7**\P6(,TN#$<;?X
M@<D@?[7O0![?!=VUU")K>XBFB/1XW#+^8JHNOZ,[!5U:P9F. !<H23^=>8^
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M/[,@M/@MIGB*Q46FK6URQ^U0#9(X,S+AF')QQU]* /?R0!DG IHDC8X#J3Z
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MP(]/BD2($*))74'&?5G;K[U+-X.CU;P';^'M72W$L$"QQRV^2(V485E+#(X
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** ,K00!8''_/1JU:R?#_.G'_KH:UJ "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &/X<_P"0-%_O
M-_Z%6Q61X=XT:+/]YOYUKT %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110!D^'_\ D#Q?[S?^A5K5E: /^)1![DG]:U: "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M4MA5" @KM(^\V<?C4FDWWBV6.UUNXU33UL;F"1]DUPOEEC&2@4>6I7!'.6/
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M,T<>X8;:I.!D<'VXZ56L_AYX>L8;B&&"?RIT=-CSLPC#C#;03@$CC/6NJHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@"AI'_ ""[;_<J_5#1SG2;;_<%7Z "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "N.\.S2:SXS\0W]RI:/3YQ8V8
M8\187,A ]6)'/7'%=C7(Z'976A>,M9M94>2RU60WUM,H!"N !(C>AY7'J!ZY
MH J>$8DA^(_CE$&%WV;=<\F-B?U)JYHRC2_'NL:5"NRTN;:*_CB! 5')9'VC
MMDJ"??/K6AI>@3Z=XDUC5#?)+#J3(QMQ!M,910H.[<<\#GBJ&C:9<7?C;5O$
M5U&\<0C6QLD=2&\M>7;![%NGM0!UE%%% !1110!Y[\6+>*33M#E:SCGE&JPH
M"0N_:<DJ,^N!QTJA;2QV_P 784M=..BNVGN/LLH5%OFY*X\LLHQCKU^7&*ZS
MQ;X8N_$JZ>MOJBV'V*Y6Z5OLYD8NN0.=ZX')XQ^-,/A2YN]=M]:U34HKF\LX
MW2S6*V,44188+%=Y9O\ OH4 9.E^+_$NHZ)_;7]C6"V)5U_X^\%760KO8G $
M8 )/4\4:?\0VFM-0$T-K<W4.H1V-J;-V\JY>3[N"02  #D\CCCM4G_"OKB+P
M%:^&X-9(>UN//2?R,*_SEMKIN.1DGOV%1W/PXFN8=69];;[5>745[#+';[/L
M\Z C( 8Y') ';W- &1?F^/B#QB-1ALTN1X<?+VN[;(/GP3NYSCY?^ CZ58LO
M&9T7PUX;TBSB1[V72HIVDDCDD2)-H RL:EB2>.P]ZU!X(U:YNM2O+_Q#%+<Z
MAIYL)!'8A452",_?R3R3VY/IQ3!X U"RATRYTO7A;ZM86GV(W)M@4FA!RJLA
M8X(]<G)_0 33?'6ISS:!)J.D)96>IRR6TCNS!HY@6VC! X;"XS[^E=3HFJOJ
M\-S<"!$MEN)(K>19-WG*C%2_08!(..3FN/\ %RP2Z/%X3N+B\U+6[MTFCD$1
M7:Q<9DW*-J*O/'88]:[K3["WTO3[>QM$\NW@01QKG. * .*^)LWVVP.C1W\5
MK_H\EY*7D"%M@S&HSURX[?W?SGE\<S1?"^'Q3;VT=U<>7&)8M^T"0L$;H,_>
M/2M_2]$DL]4U:^NYXKE[Z=70B+:8T5 JIR3G&#^))QS7+2?#F^.EZ]I,.MQ0
MZ=J=T+F./[*6: [P^ =X_NJ/P[4 6[SQ/XCT_3C+J&FZ9ITCR2%9[J\Q!%&
MI4,1DL[$L H Z57@\?:I?P>'Y[+0HO+U@2(AFNMOER+NX/R_=^7.>X[>NCK7
MA35-2UK3]4MM:CMYK:V:!EEM?-3+#EU&X8/UJAIW@/4K&+PVIUFW?^Q9)64&
MU.'5QC'W^H'\S0!EZMXR\27=O86UG;V]C>'7#ITSEV,<K*> IVYV$]2,'C'<
MUV?BV/S? VM+<)&[#3YF88RNX1DY&?0C(K /@34Y8B\VK6PN8M6_M2V*6[%%
M<DEE8%\D<\8(_'-=3J^FW&H^&[O3$N5$]Q;-;F>1,YW+M+$#'/)Z4 >.7KVM
MO\*]%D31IK2]8Q^7K*1J%A._EV="7QCC!&37IDWB'5;B]N[70K.UO!IT,;7$
MD\K)YKLN\)'A3D[<')X^8>]9:>!=:G\+0>%[W5[$:2BJKM;VK"=U5MP&YG*C
MD#G;6G_PBE[IFM76HZ!>P6XO+>.&>*YB:0 QKM1UPPY XP: (-"\;RZYJ>DP
M)IZ10:A8/=!C*2R,K!2I&W&,YY[\<#I6+K=^WB6T\$ZJ;-(;@Z\J; ^_:$=P
MV&(&0?+!Z=JUY/ UWI[Z._A[519MI]L]JQN(?-\U&.XDC(&<Y/XU G@34X=/
MT>S35XI4TW4SJ"F2':2-Y8)\IZ'<V3ZGTXH N^$-:UW5=<\00ZE#;):V=T88
MS&Q)4X&%' !&.23SENF*I32+XA^*=SHU^!+IVF6*RK:N,QR2N5^9AT; ;C(X
M-;>BZ!?Z3KNK71U"*2QOKAK@6X@PZN0H^_NZ +TQ5/7_  A=W'B"'Q'H%]'8
MZNB>5*)4W17$?HX'/IS[#TS0!%K6EVGA&2]\6Z99Q*T%FZ36:?NDE&Y3NR 0
MI 7TYX]*F;QA=?VII=C'I2ROJ6GF\@VW&#N"AMARN!UQG/X5/<:%JVM:/JEK
MK-] KW=N\$45JI\J+(^^<_,S9YZXQQW)K"L_!7BB+4M)U&?7; SZ;:O;1(+4
ME-I7:N>03ZD\=.!0 \?$#5Q!HT[>&5$6K/Y4 %\N_?CCC;C:?7.<=J=/\0-0
MM]-U"5]#B-Y8:A'936Z7F1AP-KAB@SR0,<?44A\'^(?[+\/VOVO2C+H\_G*Y
MCD_>8.%'7CY2<^^/3EE_X'U^YDU6*+4M.2VO[Y+[<T+EXV0@JH&<$?*N3GUX
MH M2>,M=CU+4--_X1N$WEI;B[VB_^5HCG/S;.&R  ,<\\\<HWB>"_P!2\'W,
MFD0O_:<,DD,SOEK>3RP2J\=^F[BK4_AO6WUW4]334+%3>V(M GD-\A&<-G=S
MRS<?2J%MX+UFU_X1@&\T^9=#+A1Y;H9%9=O7)Y&!_G@@"P_$&^98KB?0/)LC
MJATV6;[5EE?=M#!=OS#/7GK3=8^(=S9Q:A=Z?IL-S::=?_8)Q+.8Y'DZ94!2
M H) R>O/3%1P^"M=713;-<Z4MR=7_M,NL3LK'=NVG/XCZ ?6N.DOYSXKUS4X
M;C1_M:7;"/3[Z&;S)&CX1ECCP&)SQG)[T =_%XXFN?%+:-;65N\D#QQ74+3E
M9E)QO>,%<.BY]03UQCK#\7Q"?AW>&9"Q66(QD?PMN S^1/YTE]X-U77=7MKS
M4Y[$)%=+<QRQQE;F!1SY(8<%?<^YQ6KX[\.7GBGPT^E6<L$3R2(S23$@ *<\
M  YH W-+LK73=,MK.S@2"WB0!(T& /\ )YKA?A':VD>E:U+#:QQS+JDT+2 ?
M,R@*0,]@,]*Z&VM?%DDUL+VZTJ*WA^9UM5DW3$*=JDM]U=V"<9)QCO6%X<\,
M^+_#5G?V]K<:'(+NY>ZW2"7*.P /3J.!^M &5XP&C2?%O38M3T]+BW_LZ1[@
M+:M,SY#A20H).-O!QQ71_#"QU2P\)M%J2W$8:ZD>UBN?]9'"<8!!Y'.X\^M5
MK;P7K$'CO3M>EO[>YAM+06SF0MYLN5;<YX(!W,<#.,8%=Y0 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% &?HW_()M?^N8-:%9^B_P#(
M&LS_ -,A6A0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7,>(?%<VB:YIFE1:9
M]IFU)F6W<SA$RN-V[@D8R.U=/7">+Y88OB1X':9E"![P9;H"8U _7% '=#.!
MGK17#^/_ !+'!H5]9Z?<RM<1")[MK4%G@@9P&;((P2,XYZ5QFNKIUKX=UV^T
M/Q/+-B""3R+)GCAB<R*H.=QPQ7?\A/OC@4 >UUB:CXA_L_Q5HVB?9M_]IK,1
M-OQY?EINZ8YS7G/B*YN_"VK:A_84EP'E\/I.P,[2,7\W:9!NSRJY/T!JS/\
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M30[>XMPTACW2M&K/*&!&67GZ<].:Z3X5M&WPZTL1R^85$@;YL[3O8X]NHXH
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MXDGN$T+3/MDNG6$OVDRMJ4TA!F$A_=-(K*Q"YXR1_#GG%*TFJ6EO!96VL_\
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MX-*N]++7#02N)7F* !G*G<1EA[9/-5X;GQ!I5IX6TN^UITEU:6:>6:[N9#P
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MA:/J4PFOM*L;J4#;OGMT=L>F2*T** *%MHFDV4,T-KI=E!%,,2I%;HJN/]H
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M79Z19BULHO+CW%V))9G8]69CR2?4U<HH **** "BBB@ HHHH **** "BBB@
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M2_M=U=FYU)KBZA\B:1KQR73&,'GTJ.P\!:5IT]M-#=:F9+6-H8"UX_[M#_"
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !111F@ HI,C.,C-*"#T.: "BBB@
MHI-PYY''6ER..>O2@ HHS10 44F0.XH!!Z'- "T444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110!2TG_D%6O\ UR%7:I:4
M,:7:C_IF*NT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M"]3UCP_>V\LEF#DLA8!AC*D9!!Y[_E7*:V+^W^'S:S>:8+C4-2O8KJ;]WO\
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M[S294#.<+'(9/-"D]OE8_E71?#ZWN437KR>%XX[_ %:>YA##&4X4'\=I(]:
M.SHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@"GI?_(,MO\ KF*N53TS_D&6W^X*N4 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ME^GY5JZ7I\UAYPFOI+G>1M#JJB, =!M XJ_M'H*7OF@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"IIO&GV__ %S%
M6ZJV'_'A!_N"K5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 5;#_CP@_W!5JJUD,6D*]@@JS0 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH A@_U2?[HJ:HH/\
M5)_NBI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M(XAB-/I4E1Q?<3Z5)0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% #4! YIU%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %5[Z1HM/N9$.'2)F4^A -6*JZE_P @J\_ZX/\ ^@F@
M#E_#6H_V=X5L-5U+4;Z]N=4\K;'(P;,K_P ,:X  ZG\*==^*-,U2+30MUJMB
M9=2^S+Y46PF5>#&Y(("G<..^#Z&LM-+?5_AEX<MQIOV^(+"\R)($E1=I^>,D
M@;@2.O49%5/[#\1VN@Z%#)9W=]+:ZP+[:TL9>*!<X5V+ %SNSQGOSTH ZO4?
M'&CZ9<74<YN6CM)$BN;B.$M'"S= 3Z^N,X^M5Y/B'HD=Q<P"+47FMH_-EC%E
M(&1.I)! (&.<GM7$:G!=WNJ>)/L>GW-]X<GN0]QY$L:[Y4"EAEOFP&_N]<<5
MIP0ZIJ>M>(==L-(NGL]7TH1V;L8P2WEJ!E2WK_*@#K[_ ,9Z58JK 7-RIMA=
MN;>$OY<)Z,_H#^?%4Y?'$4?B==,CL;J:W-B;M9XHL[QC.5YY7'&?[W%<C-H?
MBNZT./39](F: :4+:&-+M8Q',O!:3:WSYQ\HR1R,CDUT=EIFL1:W82-I86)]
M%6SFD:9?W$@8GMDG.>WK0!LP>,-*N/[)V&?&J([VQ\H\[!E@<=#5*V^(OAZZ
M,QCFN!%"KM),]NP1=O8G'4]AUY'>N9TK1/$MO<>%(I-#VIHK3I+(;I,2!N-P
M]L<^O7IWCL?!^MWGPWU;19K-K2\DO#<Q+*ZD2#*G&5)QT[T =='X]T4O<QW
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M2QV6I0P2B<N,1LD>"I]3N)''I69KU\^G_&73YDLKB[_XE.TQVZAG +R<X)%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH *:Z+)&R.H96!!![@TZB@"AIFBZ;HT;QZ;9Q6R.<LL8QDU?HHH P)
M?!'AJ:^:\DT>V:=F+,<':Q)R25S@G/M6\JA5"J % P .@I:* "BBB@ HHHH
M**** "BBB@ HHHH **** "LR?P_IMSK<&LR0O_:$"[$F65Q\O/RX!P1R>,5I
MT4 %9>K^'=)UX1_VG8QW!BSY;'(9<]<$$'M6I10!1TW1[#25E%E;B,RL&D<L
M79R!@99B2<?6G:CIEKJMM]FO$=X<Y*K*R9X(Y*D9'/2KE% %>QL;;3;&&RLX
MA%;PKMC0$D*/QJQ110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
910 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>pinnaclelocrenewal4thloa009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pinnaclelocrenewal4thloa009.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W?_E]'^Y5
MBJX.;X?]<\_K5B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* *JG_3Q_P!<C_Z%5JJJ_P#'^/\ KD?_ $*K5 !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 55_X_Q_UR/_ *%5JJJ_\?W_ &S_ *U:H **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"LO_ !_,/1!5FJR?
M\A!_^N8JS0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %9/
M^0@__7,59JM'_P ?TG^X*LT %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!6C_X_I/\ <%6:K1_\?TG^X*LT %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110!5C_X_P"3_<%6JJQ_\?TO^Z*M4 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110!5C_ ./^;_=%6JIQ'_B93_[J
MU<H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"E#_R$I_\
M<6KM5(AB_G/LHJW0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% %.$YU"X'LM7*IV_\ R$+GZ"KE !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !112,RHA=V"JHR23@ 4 +14<4\4
MZ;X94D3.-R,"/TJ2@ HHH% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 4K?_D(W/T%
M7:HVQ_XF%T?]T5>H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** *-KS?W7^\O\ +-7JHVG_ !^W7^\O_H-7J "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH HVG_'Y=_P#74?\ H-7J
MH61#7EYCM*/_ $$5?H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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ML7>YN5CU1&>ZE\O8JGC '0_51^/<G0M(;KI=D?\ MW3_  IO_"/Z,>NDV/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1@9Z?2MXZE:I'J2:7X4U*V6XM':>;[$8=S ;44+CYB<GZ#K0!AQ^+-<A\/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 96B]+O_ *[M6K67HO\ J[G_ *[M6I0 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M44 8^@,&AN<'_ENU;%8OAT8MK@^L[5M4 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!D>'O^/!_^NK5
MKUD>'O\ CP8^LAK7H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHIJ[OXA0 ZBBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "LWQ"@?PWJ:G/_'K(>"000I(Y%:54=9M[B[T6\M;58C/-"T:^:Y5?F&,D
M@$]_2@#Q2UUBSLOAWIE_;/J<?B SA$NCYXB=O-.59S\A&S((YKU=/$[)XM;0
MKNQ-NOV5KJ.[:4;)%&T''ODMG/0+GO7-KX/\2S>"X?"=P=&CL@BQR7,;R/(
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MI=)@U*YCTB<LK6>%*A&^\JL>0#DUV=&* ..TWX?Z7HFM6]_I32VJP6C6J0(
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M+HN%6/)50G3J22>I-=O10 V,,L:JS;V  +8QD^M.HHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,O0/^0:
M/]\UJ5EZ"-NF)[L:U* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH S-#_Y!D?U-:=9FA_\ (,C^IK3H **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@#,T/_ )!D?U-:=9FA'.EPGU)K3H **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110!EZ#_R"+?\:U*R] _Y \%:E !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%%  >E<QXMTB]UFVM[>TMM+N0KEI$U!2R]." .]=/28%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MU@6%H]JQ@="&0[LG).<\T :7ATZG,=0N]8LX+:Z>Y,:+%S^Y4?)\Q W<ESG
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4449H **0D8/-
M4[?4K6XU&XL(YE:YME5I4'50PROZ4 7:*** "BBB@ HHR/6B@ HHHH ****
M"BBDR/6@!:*** "BBDW G&1F@!:*,CUHS0 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!G:)_R![7_ '*T:S]%_P"01;?[@K0H **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M&DVW^X*OU1TG_D%6W^X*O4 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%<]XM\6VWA&QM[NZM;BX6>80*(=N0Q!(SDCT- '0T5SEMXM!\06VBZA
MI5[I]W=HSVYE,;I)M&6 9&/(':NBH 6BBB@ HHHH **** $8X&365KFIG3K)
M2@#7$SB*",_QN02!^&"?H*U6Z'C-<%XNO%^WW,S$YTVT(B0?Q3S?(GXC./\
M@55"/-)$S=D6O!6G0"\U;4U@3?/*(S=+)O\ M.WJWM\Q(_"HO%-TEWXNT?26
M)^SVBOJ=VWHJ#:BGZLQ/_ :W/"^E#0_#%A8?=,,(#GC.X\MG\2:Y3PZ/[>UK
M5[Z;,JZA*H1L8"VL9(4?B236U^:HY=$3T2(?$=K<#P;:Z6TN;S7]11)&QT5W
MWD?0( *]#4Q65L-[*D4:@;F. !C%<M?K]I^)6D6Y&8K6RFN53MNR$!^HR:7Q
M49]1UW1=$A($4TQNKH9_Y9H!@?0DC\JF5ZC2?J-::G43ZA;6UI]JFF1(#@!R
M>.3@591@PR#D5YK\1=2#S:3I=N28TU"$7*IT&3\J_P!?PKJ+G5IX/%6E:7#+
M'Y<D$TEPN/FPH&T_G4^Q?(GWN-25['24T_=-(-V#S2G@$UDRO,X_PHT<.I^(
M]%#$BVO#(J.<_+*-^/IDFI=)EFT#69=%F!>TG9YK"0]L\M%^!R1[52TN'[)\
M6]7'\-UI\4B^Y0E3_,?E70^(M/DO-+9[8#[9;'SK8^CKR!^/3\:WEO9]2.ET
M;"G.?K5>\O8K"%I[AU2(=6.?Y#K46CWJ:CI5O>1XVRH&P#T..1^=+J&G1:A#
MY<K2+AMRM&VTJ?7-8^I=[F3+XI7S-MKI=_=Y4$&*$A3^)P*Y/QGKFJRV>G))
MH9LT-]$\<D]PI;*_,?D'/;UKTB*+RT"%BY ZFN%^(-F=3UCPQIBNZB>\=G*G
M^ +S^F:WHN/M%H9RO;<Q-:M/$-SX/\Z>YM('U>XBW0PP-N_>,,?,3V7FK-SH
M,MY\1=-TN_UJ_ND@LWNU;>$*,6VC&T#C!(K?\1A9/$/A;35RJ?:FN613T$49
MQ^&2/RJE;O#)\3X-3#GR;K3Y+>,]@8W)('\_PK6,G:Z71D\JT2-S_A!]"<#[
M1;27/'_+>9W_ )FN8GU_P[I5UK-K9>'X-VF1!RZQ@+*Q8+M!QU!8?K77^)=4
MDT7PY=WJ$M-''MB4?Q2'A1^)(KA[G1%@U+P[X>16>[NE2XU.8G/RQ?.2?]Z3
M K.B^;63T*E9'1^,K>"3X<:LZ0) 6L6)"@97*YZT_P"'ME);>$K2:<8GN5\^
M3GC+8_IBF_$J5;3X<ZRPZFW\M<=R<#^5;FEK%9Z':*&_=QV\8!]0%&*ES?LK
M+JPLE*YR&B.NL?%G6[PL773;9+./T4D[FI/%MGJGB6:YMM-+)%I#+/$P?_CX
MNE^81GT X_%A57X>7:VFF^)=5OC'',VI2^80>.,!1_*NWT'3FT[28XI6WS,6
MDE<_Q.QR?YU=1N$K]K($N8@T#Q+::_;_ +O,5W&=EQ:2';)"W<$?R/0UM ?/
M@'('OTK&U7PUIVHR+<%&M[P#Y;FW;9(!Z%AU'L<BJHL?$MB?]#U.VO(P -M]
M%ACC_:7_  K%I/6+'%M;G3@4N*YDWOBM JKI=A,2,EENBHS[96HH]2\9''F:
M#8J,\XOLD#_OFER,?,=717.?VAXI\T*-'L-G]XWC9_\ 0*?]K\4$L!IVFKC[
MK&Z<Y_#8,4<C#F1T&*1CM&:Y]G\5.4XTN$9^;&]SC]*F%OK<DC"74K=$9?E$
M4!#9_$T<OF%S860,,].^#3L BL^RT_[-+).\TT\T@PS2$=/8#BM$=!4C&@ #
MJ:=110,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH HZ3_R"K;_ '!5ZJ.D_P#(*MO]P5>H **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MO]KW A9QI%]D=(\+D_K35UNY+(/[#U!0>K$)Q^M9J;47%=2K7U,J4@?%:WY
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M8/\ PEEH/^7'5/\ P#>D_P"$ML_^?'5/_ -_\* -^BL'_A+;+_GSU+_P#?\
MPI#XOL$QOMM012<;FM' 'Z4 ;]%8I\5:4&*^9-D?],6_PI/^$KTG_GK+_P!^
M6_PH VZ*QO\ A*M'VD_:6X_Z9-_A2?\ "5Z-G_CZ/7'^J;_"@#:HK&_X2K1_
M^?H_]^V_PH_X2O1_^?H_]^V_PH V:*S[+6K#49&CM96=E&3\C#^8K0H ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"CI/\ R"K7_KF#5ZJ.D?\
M(+M?^N0J]0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 <]XVN[[3O"=_?:;=);74"!T=HU;/(^7D$<]/\YK+\'^+I+[P
MC=W6L!H;W22\-\O&2R#.[ ]?Y@U?^(5M<7?@/5K>UMYKB>2-52*%"[,=Z] .
M:Y:Y\*75_P",X+ZVMYX-#U...ZU&.6(AO,A;(4IZL=O&#GYJ +/@CQ)J&NZ?
MK>L>([Z.WL;>=X#9R1(J0 !22S$9)YQ@_P#ZND@\8>')+.YNDU>W6&U"^<6R
MA4-]W((!Y[8K@+6'6]-\(^*+*W\.7-S>76HR7"1W%L6C:)L8=01AV&T';UZ<
M=JJW&FZJ\'BO;I.N2"^TZV2W>YMLR.R[05(7H>3P!P!SB@+:W.OU3QC'<ZSX
M?&@ZK%/:W%_]FNPB!L@J& R1Q^%=9I^JV&IRW,=E=?:#;N8Y2H)56[KNQ@D=
MP#Q7G/C#2[JYT+PI%IEAJ%M(A#RO:6;>9!^["Y8 <$'\:Z7X?W=W#I7]BZAH
M\UA<V)9/,6V9(9U!QO5L8).<GUY- &>-1\1W_P 1=2\/P:S':VMI MRC+9JS
M$';A#D]/FY/4X[5<\/>(M5_X2R\\+:^ML]W#")X+F!"JSQY[J2<'G]#]3G12
MSZ9\6M9U.?3-4>RELXX4FAL99%9QLR!M7GH>:N:?;WEQXKU+QI<Z?=1VT-B;
M6SLS#BYE53N9MA(P200 >3GMW+ =I,A\I@A"L1A3MS@UQ/@?Q;>ZQ<ZAIVK1
MQ1W=L^^)D7"S0EBH<?BO-=C#=&ZTV*Z\BX@,D8?R94Q(F1G:5Y^;VKS6]T>_
MN[71-5T*WN+6Z0RV4ZNNUE@D)R^#UVDY'UHMK<#:T3Q7=ZYXXU"QB$<6E6MN
MLJ,5^:8'C.>PX)^E;\?B71YA.L=["_D1-*ZKSE1U9?4?2N1TFPNM+\8>(?L^
MES2VYTZ&*V+1E4D,:[2@;IU%8VE6NIW6J65TNE7T8.C7-LT36OEQ0R$\1KQD
MCW).: .YM_&^E7%KHEP@D UARELNS!Z,<G\%_6MAM8T_[;]B%W$;G)4(#D[N
MN![^U>::?9W\6B_#V5].O(QI3E+Q3 =T?[HJ,CTW<9]ZNP6=]:>*?,T:.[6V
MO;Z5;NWNX!^Z;;CSHWZ@<CCF@+'76=QX>TW4YK>T:TAN[J0O(L9VF1\>O0MQ
MTS5I_$FCQ2&-]3M=ZR>6RB495O0^]>=V6FWU_P"#]*T%[&:#6K&[B>9Y%(P
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M4*!VZTM% #=BYSM&:4  8I:* $P*-H]*6B@"N+.!;DW 0>:0%+=\#M5BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ I*6B@ HHHH **** "BBB@ HHHH **** "BBB@"II
MO_(.M_\ KF*MU3TPYTVW/K&*N4 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110!3TO_D&6W_7,5<JGIG_ !X6X_Z9"KE !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 5;#_CP@_W!5JJMA_QX0?[@JU0 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %:R&+.%?1!5FJ]G_Q
MZQ?[@JQ0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %>S_X
M]8O]P58J"VXMHL_W14] !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 0P?ZB,>BBIJB@_P!4G^Z*EH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@"*#_5)_NBI:B@_U2?[HJ6@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** (XQ\B_0"I*:J[5 ]*=0 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %-;M3J* "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "L/6]>N-,U/3-.L].-[=7WF%09A&J*@7<23G^\.@]:W*Y?6?^
M2@>&/^N%[_Z#%0!'=>-674]5M-.TF;4(]*C#7DL4R+M8@G:JG[Q !STZ'OUU
M[35;F]ATJXATYVMKV 32R^:H\C*AE!!Y;.<<5P7B&VMI-8UK7O#NJ'2];TM\
M7D$S 1W:A P)7/0C(![X[=:M6U_)?^*/ NIRAK5[RRG$EJ'(08C&TA<X&=QQ
MQG&/2@#T<$$<$'M2UX38(VMS&T>\0ZH-;9[G4ENQ&KV_0JK!@3G@  #VJ._T
M^%-*\=W'VBZWZ;>JED6NY#L^< ]6Y.,#)R: />JJQ:A;3W]S8QRAKFV5&F0
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MJ\=EON6\M5\T?>[N3SG.?:@#V^BO(-2NM3\1>(]?MGUVWTIM/<>0)9Y8S'&
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M+I=-M!<7*E)Y1"NZ53U#'&2#[TS2O#^DZ'YW]EZ?;VGG$&3RDQNQT_F:TJ*
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
K **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>pinnaclelocrenewal4thloa010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pinnaclelocrenewal4thloa010.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@JQ5=/\ CZD_W15B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** *\9_TR4>BBK%5H_^/Z7_ '15F@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** *T?_'[-_P !JS5:/_C[F/\ NU9H **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@"M'S<R_\  :LU6A_X^IAZ8JS0 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %6#FXF/?<!^E6JJP?
MZ^;_ 'Q_Z#5J@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M*L'_ !\S_P#70?\ H-6JJP?\?,__ %T'_H-6J "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH JV_-Q<?]=!_Z#5JJMO_ *Z8^L@_]!JU0 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 !Y%-1=@QDGZTZB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"K;?ZZ
MX_ZZ?^RBK54[3YI+@C_GI5R@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH ***;N&<$\TK@.HINX>M&]?[P_.F ZBF[U_O#\Z-Z_W
MA^= #J*;O7^\/SI-Z_WA^= #Z*;O7^\/SHWK_>'YT .HIGF)_?7\Z/,3^^OY
MT /HIGF1_P!]?SH\Q/[Z_G1J%Q]%-\Q/[Z_G1N7U% 7'44W<OJ*-R_WA^= #
MJ*;N7UHW+ZB@!U%-WKZBC>G]X?G0 ZBF[U]11O3^\OYT .HIN],9W#\Z Z'H
M10 ZBF;U]:7</6@!U%-W"C(]: '44W(]:,B@!U%-R!2[A1<!:*;D>AI<BBX"
MT4F:,BBX"T4F11GVHN M%)D4FX47 =13<BC</6E<!U%(#FDS]:+@.HINX49%
M%P'44W(]:6BX"T4E&:+@+1331^!H =13?SHIAJ.HIN?K0#0&HZBFYI<T@%HI
M,TF?K1<!U%-S2YIAJ+13<T9H#4=13<T9H =13<T9H =13<_6B@-1U%-S[4N?
M:@!:*:"#2YI +13<_6C/UIAJ.HIN><44 .S1FFT?YZ4 .S1FFTN*0"YHS24E
M,!V:,TVC/O0 [-%-S1N% #J*;N Q[\4X'(R* "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** *=AUN/^NIJY5.PZW'_74U<H **** "BBB@
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M/^_AK&16R-@ZCFGJH*@AJ3I0[(?-+N:7]LWXDQ]NN./^FAJ0ZQ?E"1>S@_\
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M++OZU?U>C_*A>UGW.@_X337UP!J$I&<DDT\>-=>:7 U&0\YKF\_,-QP*>S
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M% %.Q_Y;_P#74U<JG8\B?_KL:N4 %%%% !1110 4444 %%%% !1110 4444
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MFJ_6?I7^IE_Z[-6A0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M4BXRD@"D9&1P?8TK ?6N?>C-?(__  LCQD/F/B&ZQ]5I/^%C>,>_B"\/T9:
M/KG/O1GZ5\E)\1?&;CY-<O&QZ<TP?$7Q?WUV\Q]:=@/KC)HR?_UU\CM\0_%Q
MZ:_>_G2#XB>+U_YC][CUS18#ZYS]*,U\F3>.?&T$\T+ZQJ*R09\U2#E,'!SZ
M<D"HA\1O&(_YF"Z_-:+ ?7&11FODH?$OQCG_ )&"Z_-:7_A9?C-B,>(;O\UH
ML!]:9I:^3&^)/C3H=>O%]S@4G_"S?&(^;_A(;K'U6BP'UI17R9_PL_QI_P!#
M#<_]\K2_\+,\;! YU^\V$D!MBX)'7^'W'YT6 ^LJ*^31\3_&?_0PW7_?*_\
MQ-/7XH>,P/\ D/W)_P" K_\ $T6 ^KZ*^3C\4O&B'(UZY/MM7_XFD/Q/\;8_
MY#]S_P!\K_\ $T6 ^LJ*^2_^%H>-N_B"Z'_ 5_\ B:3_ (6AXT_Z&*Z_[Y7_
M .)HL!]:T5\E?\+0\:?]##<_]\K_ ("C_A:'C3_H8KK_ +Y7_"BP'UK17R3_
M ,+0\:?]#%=?]\K_ /$TO_"T?&HZ>(+D_55_P%%@/K6BODH_%3QM_P!!Z?\
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MY_X4AX-_YXWO_@2:3_A1_@S_ )XWO_@23_2O1Z* /.!\$/!RYQ%><_\ 3?\
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MV_X49X-Q]R^_\"/_ *U(?@9X.[+J ^EQ_P#6KTJB@#S7_A1G@[^[?G_MX_\
MK4?\*,\&_P!R^_\  C_ZU>E44 >;K\#_  <ISY=]^-Q_]:G?\*2\'?\ /*]_
M[_\ _P!:O1J* /.&^!_@YO\ EG>_A<?_ %J:/@;X.'\%\?\ MX_^M7I-% 'F
M_P#PH[P;_P \[[_P(_\ K4A^!O@TG[E]_P"!'_UJ])HH \T/P+\'GI_:"_2X
M'^%)_P **\(?W]2_\"!_\37IE% 'F9^!7A _QZD/^W@?_$T?\**\(?W]2_\
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M;2O]J:E^:?\ Q->M44 >1_\ #/WA\?\ ,5U/\T_^)H/[/WA\_P#,5U/\T_\
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M%RU_',EC;26\4<5H(BQ<C<[D,=S'% %'X?\ B>*ZL[?1;6(S?8XI)+ZX+X6
MF1]BXZLQP3Z =\\5'8_%.WO]4T^.&*SDM+^Z^RQI'=@W,9W;5=X\<*<$]>./
M6M?0O 5IX?>Q>SNY5,-L]M=84 7:DDJ7 XRI)P>N#BD\/^#;SPY/#!9ZQ&VE
MQ.6$#V2><R\X0RCJ 3G.,^^.* *4WQ!NX#J%P-&273-/U/\ L^XN4N@'!+!=
MRIMYQN7/(Y/UQL^/;JXLO FL7-K/)!/';EDDC8JRG(Y!'2HHO!D$>F7UBUP'
M2\U;^TY"8AR?-6381GD?)MSZ=JTO$VB?\)'X<O-(^U-;"Y4*957<5 8$\9'7
M&/QH X7PYK,Z>-9;:RN=6GLO[)\U;;5)) \]P#G]UYO.,<$] <UTUAXSBU7^
MPA96Q9]3BDF=&E -NJ<-GCD[B%[5+I_ABZBUNUU35-6:^EL[=H+9$@$*INQN
M8@$Y)  [#CI65X0\-367B/Q#JK&X2&>YDBLHYU*^4A;>[*IZ*SL<<<A<]Z .
MNTZ>ZN;)9;NV-M,S']T6#;1D@<C\ZN53TZWNK:S6*[NC<S#.92H7//H*MY H
M 6BDR/44%E'4C\Z %HI-RGN/SHR/44 +129'J*-P]10 M%)N7U'YT;AZC\Z
M%HI-P]1064=2!0 M%-#J<X8''7!I=R@<L!]: %HI P(!!R#W%&1C- "T444
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MNU[_ * EG_X'_P#VNC[;KW_0$LO_  /_ /M=;FVC;[T 89OO$';1+'_P//\
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MZT.F@1_^!B__ !-;>P>_YFC8/?\ ,T 8GV_6S_S (O\ P-7_ .)I/M^NY_Y
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M2-QT96&0?R->)ZQ->:CH7_"-W, ?_A&;2YDO6?E7*1LEN?J0=WX5MW>I1_\
M"-^'M,A;5)+M=!2[,5I>BVC2,(H\QVR"<$' SZT >I/<0QS10O-&LLN?+1F
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M^=(<D[@3@ CC'&1FK=S:74_QDMI8M<GA5M)\WR$B0YC$HRAR. QYSC/! /H
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MCMKF5H=HV><$SM'4';GC\ZT?#SZ1I]EXJEU5+=-.L=<F=!*@*1?(GW5]<L<
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ML?\ GXU#_P #9?\ XJD_X1.Q_P"?K4__  83?_%4 ;N1ZT%@.I%87_")V/\
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MK>I,/0NG_P 35B;23,NTZA?*,8RLVT_H* -#>OJ*7(K#'AA /^0OJQ_[>O\
MZU'_  C"_P#07U?_ ,"VH V]Z^HHWJ?XA6*?#$9_YBVK?^!7_P!:D/AE#UU;
M5N?^GK_ZU &X&!Z&D+J.I%8H\.R(,1:WJBKZ&56_4BE_L&Z[>(-2'_?H_P T
MH V?,3^\*/,3^\*QSHEX2/\ B?ZCQ[1?_$4AT.\+9_M_4"/0K$1_Z!0!M @G
M%+52QM)K57$U[+=%CD&14&!Z?*!5N@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@#*\._\@*U_W:U:R_#O_("M?]VM2@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***\\MO'^IW$<-_]ALAI
M\^K_ -FQIYK>><OMW8QC@<X]J /0Z*P]9\7Z%X?G$&I7XBF*&0QI&\C*@_B8
M("5'N<47_C#0=,^Q_:M113>Q^;;!$:0RKD<KM!S]X?J>QH W**QSXHT8:Z-$
M^W*VI;MI@5&8K\H;YB!A1@CDD#MUJ"S\:^'K^_BLK741)+,[1Q,(G$<K+U"R
M%=C'Z$T ;]%9/_"3:,+.&[.HPB">X^S1.3]^7)7:/4Y!J6]U[2].BNY;R^AA
MCM-OGLYXC+<J#[GCCKR* -&BL6W\5Z)<Z?>WT=\!;V/_ !\F2-XVBXSRK -]
M..>U96L^,HI-"2X\.2I>3W%]'812!6V"1NI!(PP R<C(R/8B@#KZ*RI_$>EV
MVK+I<EPYNR54HD#N$+?=#,JE5)]R*K:%JMQ=:SK^FW4JRR6%VHC94VXBDC5U
M!]2,L,]\4 ;U%<9J_C:;2/'5OI$]K$-*:*/SKLM\T<DA<)D9^Z2F.G>K6E^+
MTN)->?45CM+73;]K2.09)DPH/XM[#U% '4T5CV_BG1;K29=4BOT^QPN(Y9'5
MD\MB0,,& *_>'4=\U07XA^%&2X8:S$?(^^NQ]Q&"<JN,N, G*Y&* .GHK*N/
M$FD6NF6VHRWJFVN@#;LBL[2Y&1M506)QV I4\1:3)IMIJ*7T;6EW*D,$@!^=
MV.T+C&0<\8/3OB@#4HHHH **Y.W\1:UKMQ?MH%E9&QM93 L][(Z^?(N0VT*I
M^4'C/>MQ]9L8!>+<744;V,2RW8R<1*P)!)].#^5 &A16%=^,?#UCY(N=5@C,
MUNMU&#G+Q'HP&.G^!]*DM/%>@W]W#:VFJVTTTXS&J-D-QG /3..<=?:@#9HK
MB[#XA:,NHWUAJFJ0072ZG):01,I!PI &<9P"<\G K;U/Q5HFC7B6FH7Z0SN
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MC%I\FKV0O)9#$L(F!;>/X2!T/;F@#6HK*U'Q)HNDWL%GJ&IVUM<S_P"KCED
M)_P_'K6K0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!E^'AC0[/\
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MH  .&Z 5T6KZ ]S\1O#=VFGH^G6=M.&;8-D38&SCL<]/_K5N?9_$'_/[I_\
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M!%I_X'G_ .-T?:=?[Z1:_P#@:3_[(* -NBJEBUV\>^[MXX)#_"DN_P#H*MT
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MI-YB0OUW%1FE\M#N^1?F^]QUH S!)++X4$D^?->QW/D8.XIS^M>-:_8W>E^
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M(3;R7LDBF-3&"6A(=0,/DGN>_%;:V!O_ (K1V5_//=VUKHL,^#(PC>99" [
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M(Q_Q\LR D$CY<J-HPO KNZJP"RM8A%;BWAB'1(\*!^ J;[1#_P ]H_\ OH4
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MD&%4=A5BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MH/(HHH S;W1K;4)A).TX*C \NX=!^2D57_X1?3_[]Y_X&2__ !5;5% &(?"V
MGY^]=?C=R?XTG_"+6'K<_P#@5)_C6Y10!B?\(MIHZ+< ^OVE_P#&C_A%]//W
MOM)'I]JD_P :VZ* ,3_A%=,_N7'_ ($O_C1_PBNF?W+C_P "7_QK;HH P_\
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M-7:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *6D_\
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MMO$>BW=A-?P:I:-:02>7+.90$1L@8)/ Y(QZY%6FU&R6ZEM6NX5GBB$TD9<
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M.?O #)'H1[UYY::=>0_#SQ?H?]DWB7XN)9% MSME5G&W8P^]P#TKHHX9]/\
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MI:3::O';QWB,\<$Z7"H&(!=>5SCJ ><>H%/N=3L+*:.&ZOK:"63[B2RJK-]
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MW$4[)CMU.[)S67X1\-RVU[HEIJ<7B87^FREO+;RS9P_>^97QRIZ8!SS7K]%
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MGW-344 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MMSI\$$DZ3H!%)&7ZJ3DC#=A47BZRU6+Q-H&OZ=92:A'8&:.:UB<*Y$B8##)
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH @MN+:+']T5/4,'_ ![Q?[HJ:@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** $Q2T44 %%%% !1110 4444 %%%% !1110
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MY;[Q)/8+.D"?N8ACA5(P6)/4YZTNN>(M4TO1?&VF7-[_ &E+I?V9[>YFAC)
ME*_*P"[25/(XYKH]!\"1#PO/IWB*."YGN;V6^D$#,%BD8\%&X88'>MJ#PAH<
M&BSZ1]A$MI<$-.)79VE(((+,3N.,#'/&!0!R6O:MKTVI^(H].UW[';Z3I,=V
M8XX(W8RE';&6!P"%&?J,8J+5H=2UOQ5X#N!K$]J;FSEGVQ1J0CB)2S#(()8.
M5YSC''4UWD^@:9<"_P!]JH;4+<6URRD@R1A2H&?8,>:JZCX1T;58M-CN;=\:
M:-MJT<SHT8P 1D')!"C\J *WC76+W2=*M%L'CBN+Z]BLA,^,0A\Y?GC(QQGC
M-8GB*3Q-X8\/1^3K[7][=:C!!#+-:(I17X*D+P<GGM79:OH]AKVF2Z?J5NL]
MM+]Y2<$'L01R"/6J5KX2T>UMA!Y$DX%PEUON)WD<R)C:Q9CDXP,#I0!QFN:K
MXHL-6M?#=K>:C?7$-A]JFO+*W@$LKM(RKN5_E"#';GIS5ZYU/Q/=KX4T5KH:
M7J&H02RWUP(U9T,2CY55LC)+#-=)K?A+1_$%S#<WT,@N(5*+-!,T3[3SM)4@
MD>QINI>#M%U:RL;6[MY"MB,6\B3.LB<8/S@[N>_/- 'F6DWEQIGA^:)WCGGF
M\;BWDE>%2&.5)8*<[2=O;D9X-=?X)L-0C\4>)[BXUB>XB2_:-H#$JJS>7&0_
M R" 0N!P<5O6_@S0+6T2UBL ($OAJ"H78XG P&Z_I0/!^D#5-5O_ "YO,U2
MP72><VQE( ) [$@#F@#>HJ.W@2VMHH(]VR) B[B2< 8&2>M24 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 A8+3?,7COGTK$\92/#X5O72
M0Q$A%WC@C+@?UKF;JWLM&N6LM0LFFGF<#3W2YD4W+$?=QN^4CN>F.: /0A(I
MQ@BG5Q_A&&>TU34[2;8KQ>475)&=067.!N)QCU[^U=A0 4444 %%%<OXZUJ^
MT/1;:XL;BWMC->PV\MS<+N6"-S@O@D9QQWZ9H ZBBN(\)^*6N+K7K>\URTU2
MRTN*&4:C$BH"K*Y;=MR#C9U'K6CIOCBPU+4+2U6RU&WCO@6L[FY@V17( W?(
M<YY'(R!D=* .FHKF+;QWH]Y%?7$*7ILK&.1[B\-LPB4H0"@)Y9N<X / I(O'
M>F2Z8M]]DU)%GE\JSB>V(DO#M# Q+G)7!ZG ]: .HHKED\?:/]@DNYTO+80W
M:6EQ%/ 5>!WZ;QV'ODU9NO&>C6;:RLT[!M'5&NEV\C<,KM]>P^IH Z"BN9U7
MQQIFE2SQ^1>W36L:RW?V6#<+9&&X,Y)&..<#)]JDU#QII6GZA9V %U=W5[")
M[>*TA,AD0D\@CC'!//:@#HJ*Q?$^LKH>C"]:X6WS-'&&> S<LP&-H9>??/'O
M1;^)[&[UR?2;:.ZFFMW\N>1(3Y<+;=P#-[@?2@#:HK/U?5DT>S-PUG?79SA8
MK*W:9V./0<#ZD@5ES>.=$MO#UOK=Q)<0VL\YMD5H&\SS06!0J!D'*-^5 '24
M5S47CC2I+#5;J2.\MVTM5>[MYX"DJ*PRIV^X_E4+^.+"Z2]M[-+J.[2PDO;9
MKBV9$F0#AUSU&<=<4 =717)>$?%<&H:-8P7MP3J*:9%>3LZX#(PY<>O(Y^M7
M(/%%M>7VE?9Y6^S7]G)=(C0'<57;\Q;=\OWNF#G/48H Z&BN9TOQWHFKW.FP
M6K76=15S;.]NRHY099=Q&,@9_(TP>/\ 2&O;.WCAOI([RY^RV]TMN?)E?.#M
M8GD YY]CC- '4T5QGQ)\0W6@Z%:K9RW$$UY=QP&>"#S&C0GYMN>-Q'0=^<5*
MWC'3=#M(;2X;5;R:WMXY+J3[(SO K#AIL#"$X)Q[4 ==17-WOCG1++4+2P$L
MUS=7D"W%O':PM+YJ,< @@8Z9/T!J_K^K)H]E!</<)"'NHH?FB,F_<P&T ,,$
M^O;K@T :M%<M/\0O#MO>W%J]S.9+:X%M<,+:39"Y;:-S8P!G/.><&F^*/&VG
MZ);ZG:QRS/J-M:--B*W>18B0=A<@$*"<=?6@#JZ*XU?%XL?[/-]=B0'1?[0N
M(4M29#@#+A@=N#S\NWL3D"MJ7Q)IVVP6*Z4OJ,#SVC;"59%0,6..@ (ZXZT
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MAI$VHW(A\XD1J$9V<CKA5!)QD4 :5%8#>-/#ZZ+#JPU%'M9R5B\M69W8=5"
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MI4VI"\98(;G[(ZO"ZR";C]WL(W%N>@'\JU[.]CO;-;J..XC1L_+- \;C'JC
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M8 %.HHH **** "BBB@ HHHH **** "BBB@ HHHH ,48HHH ,48HHH ,4444
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MBBB@ HHHH **** "BBB@ HHHH *,T48H **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MS GR2I56 P1S\V03VQQS3?&'C+QWX7O0QT_1#87-X;>S9A(SL"3MW8<8..M
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MAO3DO]:F =A+GRXE//.".<#/4 #'7I5W0=0\<GQ#]B\0Z7I@L&A+K=V#-M#
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MMWUKITETRR6%NQ"2[0IR<G&<^H/05[\0""",@]0:;%#% FR&-(USG:B@#]*
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M&H(R7.E(^$8CY58G<O'HP)_X%6/?Z9/I?@3PYXNLE+/):SV%WGD;7\Q%8_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MQ"NW?N4[L8P#\W6N6^(^I6^O>,-:@E6[GCTRT$%G]GB+JEQE68L1TZ,OX>U
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\>XU:\=[75K<27ULX\ID9AG:-@*;<\J<XXR3TH ]EJ**WA@:0Q1)&97WR%5
MWM@#)]3@#GVK@-9N?$*Z?XHU"RU>Z_T*5+:R@2)-JJ5A9Y"=N6X=N>@Y_"KJ
MGB._EU&XN8M9N;?P[+J*0&]@B7$,0MPQ9692-K2G&[!Z8!YH ])MK:"TMTM[
M:&.&&,82.-0JJ/8#I4M>3WE[?:?K^OZAI>J7UW<0Z);RVT,JY,W##>R;!]W[
MW;ENF#BF6OB75X?"R7ESXA62SN-1@BEO;?\ >R6D31G>"QB"@[@.<'&['7%
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M/O@B@">BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ IJ(L:A44*HZ # %.HH **** "BBB
M@ IAAB964QH58[B"HP3ZT^B@ I H!)  ).3[TM% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_*7_  HV>-?^>FA_E+_A7344 <SM\:CG?H;>W[T?TH_XK;TT/_OJ7_"NFHH
MYH'QH.J:&?\ @<W]!2[O&?\ SST+_OY-_P#$UTE% '-;O&?_ #ST+_OY-_\
M$U=TH^(#<O\ VJFG"#'RFV9RV?\ @0K8HH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH \[\?:WXK\.75I/IU[8&UOKR.T
M@@DMB60LO4MNYY![=ZV;3Q0-,U:'P]KLYDU1K=[G[3';^7!(JY)"Y8G<%'/T
M-0>//"^H>)+C07L7A5;&^6>82L1E01TP#D\&N>^--L6LM$GM)O+U-[IK.$*?
MF:.5"KCZ= ?]Z@#=G^*&C1Z9I5_#::A.FIO+';1QP9=F3@C&>[$ 8]?:GVOQ
M+T6?PS<ZW+%=VZVUQ]EDMGC_ 'OF]E !Y//Z'TKE/%^FW^D:W\/]&T.*W>ZL
MTE\EKC/ENRJF[/UP3]33K_X7:OJ7A2]%Q/9_VU>:H=2DC#-Y!X8;,XR/O$_I
MGO0!W7AOQA9^(OML?V6ZL+NQ(^T6UXH1T!&0W7IBO-QXFUJ#P=XD\<VUTZ/?
M7L<5DDHW+'"C;<A3D G)'U%3:EINL>%/!.H6L&C:?9ZAK$\5G"FE&1R00Q9F
M+$]LCCUKI?%?@2YO?AQ9^&=$:)&MWCYE<J& SN)('4DYH SM \:ZO8>(=2TW
M7]1L]3MK33#J#W-G& 4Q@E..#P>^.U2:E\2/[5\)2:EHL.HZ>T=Q;J)KFU79
M+N?!53D@]#D]JW[CP1IMEX3U;3=#T^UM;J]LW@+C(W,5(&6.3C)K(U7P3JMW
M\.=!T&!K<7=C-!)-ER$(4'=@XYY- &CKGQ*TK0M8O-):PU*[O;2-99$MH XV
ME0V<YX !&2?6L7Q#\64LQX=GT;3YKRWU,^8^^$[B@;843!YD# C'(Z=<BM.Z
M\&ZA)XG\5:O'-;!=5TS[);#<P='\L+EN.!D=B:P#\/O$=KX=\'K9O8-J6A3S
M2O'*Y\M]\F\8..V .G?CI0!V_C#6;K2/ VH:M9#RKF* /'YJ9*$D#D>HS7#Z
M5\3-3N=#L8+OR8M;&L06%R&0!3&Y)W'TR PR/3/>NV\=:)>^(_!>H:38-&EU
M<"/:9&*KQ(K$$@>@-<MK7PWO+GQ=X>UFQE@5+9[9M0C9R YA(PX&.3MR.<?J
M: -S6_B/IF@W$Z7FEZS]G@D$3W:V9$(;..&8C/U Y[9IFL_$_0=%U&]L)8=0
MGN+,*TRV]ON"JP!W9)  &1DG'45Q?B?X:^*->N]0><VE[-)=%[6]FO'7R8>T
M8B VCZ\UMZAX$UF;5/&-Y;O:AM6LX[:U+R'IM4/N&.,A>* -K1OB=H&N:W;Z
M7;+>QR7,9D@EGAV1R  D[23D]&'3&5-)%\4- GU6*RC2^:&:Y^R1WWD?Z.\O
MH'SS^7Z5DI\/]2?4_"XFN(EL]*TQ[>22-L2>:R,IQQR.1WK"\,_"^]T;5K6.
M^\/V-X8;M91JG]H2+M0,#Q$,9(P>O?KQ0!ZKKNNV'AS29=3U*4QVT9 )5<DD
MG  '<URY^*&E2V.JE+34;:^L;7[1]FNK7:[*< , #TRRYY'!S5WXB^&[SQ/X
M7%KIYB-Y;W"7,22XVN5R-ISQT)Z\5SUMX4\6:QJNJ:_K1L[.^DTJ33[6V@;(
MRRG#%LG W$GOU]N0"_\ ";6K_7_#UU?ZC?75U</<'<)H@B1^T9'5<8],'/U.
M/H?C3Q'JWB6>UNM8T#3XX-2:U-E-Q.ZJV"%YY)Z ^M=UX-TFXT'PCINEW?E_
M:+>+;)Y9RN<D\'\:X'P=X9\6>&[^2*[\.:1>Q2WAF^W/*HDCR1EE."<8&0,
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MXZ5TU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %-**Q!902.02.E.HH 0JI()4$CH
M2.E+110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5!+9
MVLUQ%<2VT,DT.?*D= 63/7!ZC\*GHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHKC]&M-7UNRFOI_$FH0;KRZCCBMXH
M J(LKH!\T;$\+U)H ["BN4B34=)\3:3:7.NWM^MV)ALEBA1 J(#SM0$MDCG/
MKQ5_Q-XB_P"$=CTM_LWGB^U&&R^_MV;\_-TYQCI0!N45C7GBSP_I]RUM=ZQ9
M0SK((VB:4;@Q .".O<5#XH\6:9X8L9&N[VWCO&A=[:"1N9& .!@= 3QF@#?H
MKDM+\7O-IFAWNH-8VT5[8/=W+M-LV;0I^53DE>>3GCBN@?5;)5@Q=P;KF)I;
M=3(!YJ@ DCU !!)]Z +M%<XGC/2+71M.OM7U&QLVO4W(JS[U/KM; R!QSC%0
M>#/%PU[PMI6HZF]K;7E_))''$A*AV5F&%!)/1<T =516=)KVDQ6U[<OJ-LL-
MD_EW,AD&(GX^5CV/(X]ZY_Q#X[M;;P'?^(_#\]M?_9F1%SG:&+JI##@]&SCC
MM0!V-%8OBG7CX;\*WFL_9_M!MT5O*W[=Q+!>N#CK6=HWBK4+KQ"FBZMI"V4\
MMK]K@EAN/-CD3(!'W00030!U=%9%MXHT.\UJ71[;4[>74(LAX$;)!'4>A([^
ME.?Q-H4=Y):-K%@+F)7:2+[0NY @RVX9XP 2<^AH U:*R[;Q+H=Y:W%U;:M9
M2V]L 9I4F4K&",C)S@<4R'Q3H-QI[7\6KV;VBRB%IA*-H<XPN?7D4 :]%51J
M5B;Z6R^UP_:H8Q+)#O&Y$/\ $1V%5;WQ)HFFVT%Q>:M900W W0N\Z@2#U7GD
M<CD>M &I16=J&OZ/I4,<NH:I9VR2KNC,LRKY@XY7)YZCIZU?CD26-9(V#(P#
M*PZ$&@!U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !7(:?>^*=<MGO["^T>"T:>
M:.*.6TDD8*DC("6$@!SMST'6NO-<9X7\2:'8Z1+:WFKV-M<1WUX'BFG5&7-Q
M(1P3Z$&@"S#?^(['Q-IFGZI=:9<6]ZLQS;6KQLI10>ID8=_2M;7M?LO#M@MU
M>F1M\BQ111+NDE=CPJKW-84^KZ;J_CGP^--O[:\\F.Z:7[/*)-@*J 3CIDU4
M^),%Q#)X=UM(Y9;32]16:ZCB0L1'W? [+C_QZ@#<TGQ'>:CJ/V6Y\.:IIZ%"
MRSW 0H<=B58X/M6X+B%EC82QD2_ZLAA\_&>/7BO*FUO4=7\7W5KH^NW.KZ3+
MI4\DBB) L3D.$3Y5'/W<9YK&T#6[34I_AQIEL7:ZLGE^TIM/[O (&?K@GZ4
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MAIU<=\,M"L]&\$:;)#;JES=P)-<2;<,Y;YAGZ X%=C0 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M$4TLLJ*D*EY"3]Q0,Y/X4 2T57M;^UO+>WN+>='CN8Q)">A=<9R >>A%6,T
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%9?B/5_[ \.W^J^3YQM
M83((]VW<1VSSBH+KQ7H^EV%I<:MJ-K9-<1+(J228)R!G ZGK0!MT5Q_B;QO;
MZ'/X>ECN+5M.U&=A+<%LJ(@N=RL..I%;L/B'1[C2TU.+4[4V+L$6<R )N)QC
M)Z'/&* -.BL_2M<TS7(I9=+OH+N.)_+=HFR%:JYUQAXS70/(&TZ>;WSMW.1(
M$VXQ[YSF@#8HKFK#QA:SWNO17PBL;?2+A86N)9AM?<,Y.0-OIC)J_9^)]#O]
M.FU"UU6TDLX/]=,)0%C_ -[/3\: -:BL%?&OAEENF&N6)%I_KCYP^7_'\,U9
MD\2Z)%IT.H/JMFMI,K-%*91M? )./4@ \4 :M%8,7C3PW-]C\O6K-C>,5@'F
M<N0<8]N>.:WJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH #7DVFZ>=5TW3;+1-
MUMK-G<7C?VB@5A:1M/* K\8<L#PO_ N._K-<X_@/PM)(\C:+;%G8LQP1DGD]
MZ .<T9)D\6^&K9K66TN;2SO$O5D.?-D/E9?=_&&;Y@>I_"N@\8:3_:T>G"WU
MB/2]4@NO.LI7P=[!2"NTD;@03FKNF^$M!TB\6\L-+@@N%4J)%!R >N,U9U70
M]+UR!(=4L8+N-&W()5SM/J#U% 'F<OC37+S_ (1E)9X[>Y'B#^S[TVC9BN%!
M7IGL0WK_ /6R-%U"]\5>*+%1JUY+<PZJ\EP_VWR[=K8,2JJ@;.3MX&.G7CFO
M8H] TB*WLX(],M%BLGWVR>2N(6SG<O'!SSFN*TGX8RZ?/IJ2WE@UOIUY]KCE
MBL0ES+R2%>3=TY].PH YJYU+5_LNIZZ=9OC/8>)VLK>+S3Y:Q;AE2O1@00.>
MF*DUF^\0^(/$6NPVER+.;3KKRK69]3%LENB_Q&+!W[N/F/'('%>KG0M):"6!
MM,M#%+/]ID0PKAY?[Y&.6X'/6H+_ ,+Z%JM_'?7^DVEQ=1XVRR1 MQTSZX]Z
M .)M8[W6OBS>6E[J%ZEI;6%O<I!;W#+$SC:>WWAEF^M:GCF\N6\0>&]%:]DL
M=,U"6474\<OE%MJ@J@?MDGMUKLDLK6.[>[2WB6YD0(\H0!F4= 3UP,FH=3TC
M3M:M/LNIV4%W!G<$F0, >F1Z'D\T >27^L:UI'A3Q;;6&J7#0:=J,$-C=/+O
MD 9AN0MW R/S-=3X6?4;#XC:YHCWES=V$=K%<%KB0R%)FQG![ _,<>U=;'X?
MT>+25TI=,M/[/4@BV,0*9SG.#U.><U;CLK6*\FO([>)+F8*LLRH [A>@)ZG%
M 'F7BA-2E^+C1Z7>6%I,WA\J\E\NY"AE;( ]>AYXP#UK"T?6KV/PQX+T*QAG
MAM;MKI)O*N?*:Y*L>$D., LQ/Y#Z^MZKX8T/7)1+J>E6EU*%""26(%PH.0 W
M7&2?SJ2]\/:1J.GPV%WIUO+:0D&*$H L>.!MQT_"@#R+7M-UR70M"TW5KIC*
M/$2P6S^<LTRQ$<;F&1N7GK[5O6.O2:!!XUAU36=4FLM,GA6&;<LEPN\?=4L,
M<G Y''7CK7?V_A_1[6VM[:#3;5(;:7SH5\H'RY/[X_VO?K2S:!I-Q%?1S:=;
MR)?$-=!HP?-(  )^F!CTH \>FU&\70?'&E7,E^T1LH;R%+ZX2:2/?C=EE]<J
M<=L?B=#3M/N)OC#H[?:KQ(_[$AG^23 V* -G3[A8<CU)KTBU\(^'[&SN[2VT
MFVCM[Q0MP@7B0#.,_3)J['I.GPWT=[':1+=1VXMDE"_,L0.0F?3- '*^+=3N
MV\8>'/#T5Y/86E^99)[B%@C/L7*QJW;)ZXYY%<=K!O\ 6?"FMZ-/JL]U'8ZY
M#:V]TQ4[U=U 5SC+%">N<Y_*O6M4T73=;MU@U.Q@NHU;<HE0':?4'L?I4?\
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M +]-_A1_PENB][LG_MBW^% &[16%_P );HG_ #\M_P!^6_PI/^$NT3_GZ/\
MWY;_  H WJ*PO^$MT3_GZ;_ORW^%'_"6Z+_S^'_ORW^% &[16%_PEVBCK>'_
M +]-_A0/%^A][W_R&P_I0!NT5A_\)=H?_/\ #_OAO\*/^$NT+_G^'_?#?X4
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MYC+8Z9:6TK#!>&%4)'U JIVYM!&G1114C"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !3')!&*?10!S<G
MBBXCD9!X>UEPI(W+$F#[CYNE,_X2JX_Z%O6_^_2?_%5T^:* .:/BR88_XIS6
M^21_Q[KV_P"!TJ>*YI&VCP[K0)[M @'_ *'7244 81UZX&/^)#JI_P" )_\
M%5')XDEAB>671=1CB3EV?8 JXR3]ZN@8@#)KB?$[-XC\10>&+:5DAA$=WJ3
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M;SE++HNL#G!S !_[-3)/%@BD*'0]9)7N+4']=U=+10!RP\8(Q'_$EUD9./\
MCT_^RK(TF>ZA\5:MK4VF:B\5W%#%;K]G 95 8D?>Z=*] I*%H(\N^*%_+>^#
MI+B#3=2@N[*>*X@E,.,,& Z@D]#5_P"'NHR:?X(TVT;2M4D=8RS.L(PS%B2>
M3ZUZ Z!U(*@CT(S2HH50  !Z"GS>[R@CGQXG)F\K^QM8#8SGR!C_ -"J$^,$
M&<Z-K''_ $Y__95U%%(9S"^+U,8D&CZO@G;C[)S_ .A4T^,HUZZ/K'_@&?\
MXJNIHI <M_PFD/?2=9_\!"/ZTZ'QA'-,(X](U@N02 UK@<>^:Z>BF!SZ^)0P
M!&DZMCWM_P#Z]._X23/_ #"=5_[\#_XJMZB@#!_X2+_J$ZK_ -^!_C1_PDF/
M^83JO_?@?XUO44 8'_"2_P#4)U7_ ,!Q_P#%4I\1X&?[)U7_ +\#_&MZB@#
M_P"$E'?2=5'_ &[_ /UZ0^)E_P"@5JO_ (#_ /UZZ"B@#GSXF4;?^)5JO/\
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MQOIA.!;:K_X 2?X5U5% '+'QMIHZV^J?^ ,G^% \;:;C<+?5/_ &3_"NIHH
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M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %-9MI
MP>E.J.8 KSCV.,\T <K8>-I-6OYDT[1;NXLH;HVDER&4;6'#':3G K=AU6-A
M>-<(+:.VD*%I)%P0 #N/H.>]>8ZE+;6&O6]UX0FO8]0N+]1=Z8(7,<H9OWC,
M#\J<9.>]9FLI-:6FJF:W8K/XH5BD@8+,NT<$<EUX]* /9H=4LKB(RPW4$D0P
M2Z2J5Y]\T^#4+6Y5VAGBD6,E7*2!MI]#@\&O&)+"P?PEXD6R&+N[U"W>:SMX
M74V\1D7"A2%(^4$DXKH9+*+PWJ/BB73M*>Y@.FP2_9%0JLS_ # \]SC!..:
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH PO$OB>/PQ:_:9]+U*[@"EY)+2)66
M-1U+$L,5%I7BU=6L8KQ-#UF&&:2-(S+;KEE<9$G#'Y ,9/N*/'O_ "(.O?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ I*6B@#G]>\(:3XD>.34+8^?"<Q7$3E)$^C#FJ^D^!=*TF[%TJSW4ZG,<
MEY.TIC_W0>!7444^9[!8:JX-.HHI %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !124M !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>pinnaclelocrenewal4thloa011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pinnaclelocrenewal4thloa011.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* *\7_'Q+^%6*K0_\?4X],59H **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@"K;_ /'S/]1_*K55H/\ 72_[P'_CM6: "BBB@ HHI* %HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@"O#_KIO\ KI_[+5BJ\/\ KIO^NG_L
MM6* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH K6_,LV?[_
M /2K-5K7_63_ .]5F@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** *UK_K)O]^K-5;3EIO\ KH:M4 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110!4L_O3_]=35NJEG]Z?\ ZZFK= !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M#ZE3/)#\-]7)'SQ'%,'PVU@ #?%7KV*,>]/^TZ_D+ZE3/(#\--7 R'BS2?\
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MN(\)%(&.#7J"C"BEV^]+BN6OB)5Y)R-J5%4MA:***P-@HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** *&EG_0P?\ ;;_T*K]9^D\V _WV_G6A0 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &=H__'@O^^W\ZT:S
M-&(-@A'3+?\ H5:= !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 445'/<0VT+S3RI%$@RSNP55'N30!)156PU*QU2V%Q87<%U"?X
MX9 X]>U6J "BBH;B[M[7RO/F2/S9!%'N.-SGHH]Z )J*,T4 %%07%W;VGD^?
M*$\Z011Y_B<]!^AJ?- !11FF2S1P0O-*X2.-2SLQP% Y)- #Z*AM+J"^LX+N
MUD$MO/&LD;CHRD9!_*F6^HV-W(\=M>6\TB'#+'*K%3[@'B@"S14-M>6UXCO;
M3QS*CM&Q1@0&4X(^H-34 %%%% !1110 45!/>VMK)%'<7,,+RMMC620*7/H
M>IJ>@ HJ#[9;?;C9>?']J$?FF'=\VS.-V/3/&:GH **,U!=7MK8Q"6[N8;>,
MG&Z60(,_4T 3T5%;75O>0B:UGBGB/ >)PRG\14M !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MMV+R-3<'_6AR^2>I^8DXZ4 0_P#"2:A967B*WU#5+2*XTRZBB2]:T)#K(B,
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MKF6:=LL'5<IU^Z!Q@Y[^M<]J>IZM>1_$&XFU_5($T;4=UI'!+M&YYFC /?:
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M** "BBB@ HHHH HZ1_R"[7_KD*O52TG_ )!=K_US%7: "BBB@ HHHH ****
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M/$PBM9]!FT\2!L%9'<$<>F!0!J:=XQT;5+V*UMYYE>>%IX&F@>-9HU."R%@
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M !1110!2TSC3;7WC'\JNU3TW_D'6H](U_EBKE !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** (8/]4G^Z*FJ* ?ND_P!T5+0 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 13J7C=5=D)&-R]16(- NR,_
MV_J?/HZ__$UT%% &!_PC]V/^9@U/\U_^)I?[!N^VOZE^:_\ Q-;U% &#_85[
M_P!!_4OS3_XFE_L*]_Z#^H_^.?\ Q-;M% &%_85[_P!!_4?_ !S_ .)I/["O
M>VOZC_XY_P#$UO44 8/]AW__ $'[_P#\<_\ B:#H=_\ ]##J ^BH?_9:WJ*
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MI&@V6DZ;JNIWVKS@3S6=@B,8Y)/F.YR,*,GJ:ZS3]&\;ZA*T^H:\VGVY/%M
MJ22#V+X _(5T?AOPKI?A:R-KIEL(D8DLY.YVY[MWK<' IRDN;04=CCK#P[K$
M.HW\DOB34FBE91"K,C8 7G (P.:TFT/42I \0Z@#C^['_A7044KE'G7B31+W
M4=0TW1'UN]FCG;S9U<1X\M>0>GKBM\>'K_I_PD6H ,.FV/\ GBMG^S8/[674
MC'FX6'R ^>BYS_.KM#;:L*W4\\T#X9G0=3O;ZTUNZ22XXR(UZ=>_O71C1-2P
M,^(+_P#[XC_PKH**<I.3O($DMCG_ .PM0_Z&#4/^^(_\*/[#U'_H8=0_[YC_
M ,*Z"BI&8']AZC_T,.H?]\Q_X4AT34?^ACU ?\ C_P *Z"B@#G_[$U+_ *&.
M_P#^^(_\*7^P]1_Z&'4/^^8_\*WZ* ,#^P]1_P"AAU#_ +YC_P */[#U'&/^
M$AU#_OF/_"M^B@#!_L74?^@_?_\ ?$?^%+_8NH_]!^__ .^(_P#"MVB@#!&B
M:B/^9@O_ /OB/_"E_L74?^@]?_\ ?$?^%;M% &%_8NH_]!Z__P"^(_\ "D_L
M74?^AAOA_P  C_PK>HH P3HNHDC'B&^'_ (_\*#H^IX(_M^\YX_U2<?I6]10
M!!:1R0PK'+,\KJ,%WQEO?BIZ** "BBB@ HHHH CD!*D!BIQ@'TK%_L?5O^A@
MN/\ ORG^%;U% &#_ &/JW_0PW'_?E/\ "FOHVL&-MGB*<-C@F!/\*Z"B@#GH
M]&UH(-_B*=FQR1 @_I3_ .R-8_Z#\_\ WY3_  K>HH P3I&L8_Y&"?\ [\I_
MA3?[%UG"_P#%1W'_ 'X3_"N@HH YM='UP-)GQ),<\+_HR'%+%HFN!@7\2S,.
MX%L@KHZ* , Z3JNUE_M^?)YR8DX_2G'2-7).-?G'_;%/\*W:* .?_L76<?\
M(QW'_?A/\*!HVL#&?$5QT_YX)_A7044 <\VDZR!E?$4V01]ZW0@_@*633==E
MF21=>,:J>8UM1AOKGD5T%% '.RZ3KT@?9XA9-Q^7%LORTP:-XB#*?^$E<@=0
M;5>:Z6B@#FI-'\1.X*^(V4#L+5>:?-IFO,25UTH=N !;C&<CFNBHH YMM*\0
MECM\0\8Y'V5>#4L5CK\<A9M;A<$<(UH./R:M^B@#&-MKO;4[8?\ ;H?_ (JD
M^RZ_VU6U_P# ,_\ Q5;5% &)]BU_?N.K6WT^R'_XJG&UU_/_ "%;7'_7F?\
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M&4&/IDU<HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M9$,1J/04^D P*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH KW_ -I_L^Y^Q[?M7E-Y.[IOP=N?QQ7GO@+4K>YO%CO]3UR+Q!';
MG[;87\A5)7P 71",<;1C;T!YS7HMRDTEK*EO,(9F0B.4IO"-C@[<C./3-<G!
MX6UJ^U_3=5U_4[.5],$HMUL[=HS(9%VEG)8]OX1Q]: *6C^.)9M*T"VL;&:^
MO]0MY+C;=W04K$A(+-($PS9X "CZCN^W^)!GTG0KT:'<-)K4TL5M!',I/RG
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MC3K"2X"CH6<A?Y9KL7)'0=JXW0XC/\1_$M_N#)&D%HI]"%W,/S(JH]27NCM
M, "@]*6BI*$ -+110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !7GFJ?VW;?$'1]''BC4Q:7\$\HVQ
M6^Y'09Q_JL%<>H)KT.N?U#P[)>^-='UWSE6+3X)XS'_$S. !^ &: .<UWQ;J
M&AMXJ6TDGOY],M;9D66.()"75LN2"I.< D>I&!BGW/B>^N-2\$W4J2:9!?R3
MM<6\LH*L@A)4L5X(YR/PSBKFK>"KG4)O%TJ7<*G6[6&"$%"/+,:D98]\D_E1
M=^$]1UAO#4NHM80-ICR?:(;3?Y;*R;0J9 (X_*@!]E\1=-OM2LX(K*\^R7MP
M;>VOB$\N1QGMNW '!P2O-=C7G?A?X=MX?O[42:;H=Q#:NS)?[7%T>25)&-H(
MR!G/:O1* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *BE@CFC>.1 Z."K*>A'I4M)0!PV@7#>$]4'AJ^D*V<KL^F3G/*G),;'H
M".P]*[=6)QG/XUG:WH]KK>ES6-U$&23!##@JPZ,#V(/>N2@U_5?!J?8_$D$]
MY8I\L.IVZ%R5])%'((]:M^]JMR4[;G=7$R01O+*=L:*68GL!R?Y5S/@56FT"
M349>6U&YENP<<E"WR'_OD+6%?^))?'<3Z+X;CN&@D^2\U"2,QI'&>H7/)8CB
MO0K2WBM;.&WAC"11H$10, *. ,4FN6(+5E@<"BBBI*"BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "FNNY<$ CT-.HH 9'&D2D(JJ#S@#%/HHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** &22+&-S,JCW..:9]IA[S1@^FX4V[LK>^B\JZ@CF
MCSG9(H89^AJH/#VC 8_LJS_[\+_A0!=^U6YZ31Y_WA2_:(O^>J?]]"L__A&]
M%/\ S#+3_ORO^%)_PC.A_P#0*M/^_2_X4 :/VB+_ )ZI_P!]"FF[MU4LTT8
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MX*\,'_F"V/\ WZ6C_A"_#.W;_8UEMSG'E+0!L?;;;_GXB_[[%'VRV_Y^(O\
MOL5C_P#"%^&?^@+8_P#?I:/^$+\,_P#0%L?^_2T ;'VRV_Y^8O\ OL4?;+;_
M )^8O^^Q6/\ \(7X9_Z MC_WZ6C_ (0OPS_T!;'_ +]+0!L?;+;_ )^(O^^Q
M1]LMO^?F+_OL5C_\(5X9_P"@+8_]^EH_X0OPS_T!;'_OTM &Q]MMA_R\Q?\
M?8H^W6I_Y>8O^^Q6/_PA7AG_ * MB?\ MDM'_"%>&?\ H!V ^D*_X4 ;'VVV
M_P"?F+_OL4?;;;_GYB_[[%8__"%^&?\ H"V/_?I:/^$+\,_] 6Q_[]+0!L_;
M+;_GYB_[[%(+N%ONS1L.^'%8_P#PA?AG_H"V/_?I:>GA#P[$"(])LU!ZXC H
M U1>V^ ?M$7/^V*7[9;?\_$7_?8K&_X0OPSC']BV/_?I:/\ A"_#/_0%L?\
MOTM &S]LMO\ GYB_[[%'VRV_Y^8O^^Q6-_PA?AG_ * MC_WZ6C_A"_#/_0%L
M?^_2T ;/VRV_Y^8O^^Q1]LMO^?B+_OL5C?\ "%^&?^@-8_\ ?I:/^$+\,_\
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M! XYVG QQGK0![%17DO@3Q1XUUK7-+FO([J?1[R.1IY7L4BBB(5BOENI)89
M&6YKUJ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQS:G>O8W>H'49+3Y IE+!C\VW=MXZ9[T +X2C<>-O&LA!V-=VZ@^XA&?YBN
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M<W<>QL_([97/O6!J.A^(K?QQJ>LZ=I6EWUO=P0Q+]LN""FP<D#:<9)Z>V>]
M&_J_BJQ\/QVEO=?:KZ_GA+Q06=LSO/M W$ <#KGDBLJ[^(MG''X=GM+"]NK?
M668!HHB6CP#\N.[;A@@'@!CZ9TDTO4;GQ3I.LW44,/DZ=+#/&DF[;([1G"G
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MR:YC_A";#_H(:O\ ^#&7_&E_X0FP_P"@AJ__ (,)?\: .EW#_)HWC_)KFO\
MA";#_H(:O_X,9?\ &D_X0BP_Z"&K_P#@QE_QH Z;</\ )HS[US7_  A%A_T$
M-7_\&,O^-+_PA5B/^8EK'_@QE_QH Z3/O1N_#ZUS?_"&60Y_M+6?PU&7_&D_
MX0ZS/74];_&_E']: .G%%1P1"&)8U+$*, LV2?<GO4E !1110 4444 %%%%
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M>7:O;W!4[.,JQ[@XY_&I+KP1H=Y;:I#+;OG4IA<32!SN60#Y70_PD=L5T5%
M&7HNB_V-#(K:EJ-^\A4M)>S^81@8  P /? Y/7-:E%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 45'YR><(BZ
M^81D+[>M24 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 F!
MG.!GUI:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBC/.* "BLJ[UL6DY
MB.GW\V.=T$!=?SJ#_A)%_P"@7JO_ ("'_&@#<HK#_P"$DC_Z!NK?^ ,G^%*?
M$T*C)T[5<?\ 7E)_A0!MT5ACQ/;G_F'ZH/\ MQD_PI#XHMP?^0?JI_[<9/\
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MTG_"367_ #ROO_ &;_XF@#:HK%_X2:R_YY7W_@#-_P#$T?\ "36/_/*^_P#
M&;_XFF!M45C?\)-8_P#/.\_\ YO_ (BI[;6K6[F$42W&\_W[:1!^;*!0!I44
M@I: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MU==R,&'J#FG4 &!Z4F!Z4M% !@>E)@>E+10 FT>@I<"BB@ P*,444 %&***
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:VWD($0F4*)'(&21NX'3@9SFMW9XGTCQ#9:1)XEDOVU+3KDJ\L$:F&>,+AU
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ML7N5X:)'SN8>AP/;ZU?MO#5^-6L;[4?$5W?BR=I(H7MX8UW,C)DE%!Z.:O\
MB#0+#Q-HT^EZBC-!+@Y0X9&'1E/8B@#C;:Q\*^&O&NEV5MX8U"WNY7>.WO\
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MK:W2,N/(D&"0!D<Y_"HOB)J>J:3X;CNM,:=!]JC6[EMX@\D5N<[W4$$9''-
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M.M;RZ74O.N0LCO?S>89#L4%TY.U"02!QZXYKF? _B&^U_42+WQ;="Z2]E3[
M+./8Z(<@;]G<>^: /5**XK5?B5IVE7>H0OI>J2PZ=,D5Y<QQ)Y<1;H<ELGKZ
M46OC*^NOB7=^&X],=K.WMU=YLJ&0G!#GYN4((QCGGI0!VM%>:MX_N;.R\,-8
MPW6L0:I=30R7$L*)(X5V7"A6"AN.,]0/7-=+)XWTNVM-:GO8[JT.CE1=13(-
M_P X^0K@D$-T'- '2T5'!*)[>.8*R"1 P5QAAD9P1ZU)0 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M=>1%?1]7,=QYR9#K'*S8QCG*,OMS0!G7WB768_#'C2*SUPZI;V"PFTU2,JC
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M:#4XX1<K>!]T3QC:&0+]X8SP2O..: +NL>,VT6]C6ZT/4!8-<);-?X78K,<
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M8[T /7XCZ4UPC"UOO[.ENA91ZB(QY+3$D8Z[@,CKC%=-J=^=-L'NA:75V5(
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@#"\8^'3XK\*WFBK<BV-SL_>E-^W:ZMTR,_=QU[UC_ !.TV2\\&9M3,-0M
MKB&2S:!<L)=P7MVPS<]NO:NUHH \X\2^&;S3]&\&:3HLS1RV5_$@G6WWHI$;
MYD9/KGO_ !&I[[X>7>M:7KJZIJL?]HZK+#)OAA/E0B+[BA6))')STZUZ!10!
MY_<Z+KNB^'=3>PTW1#J$UNMM!_9=EY,A9B%+LV<8&=V,=NM:6J^!H;[P%;>%
MK:X6UB@$6)#'O!V,&/&1U.>_>NNHH RM7T.'4/#FH:/;".T2[@DAW)&,*67&
M=HQFLF_\&"^\-^'](>Z0KI,]K*[-%E9A$,$8SQD9]?2NKHH Y"Z\%/=:7XIL
MC?*HUN8RJ_EY\G*JN",\_=]NM(_A2_M?$^C:OIUU:G[)IXTZX6X1LM&"#N7!
M^]QT/K7844 <[XF\.3:[>:'<0W,<)TV_6Z8.A;>H!R!@C!K-M/ $=A\1;CQ1
M:W?EP7$3[[7;TE; 9@<\ X!^N:[2B@#SGP[\.[W3-?TS4KV;33)ISRDW$$3F
M>]WHR[I68\$9SQG\*?%\-KB#P+!X=&IH[QZB+LS-&0 H?=M S_DDUZ'10!PN
MM?#M-9NO%$TUXH_MA;?R5V']R\*X!//S GMZ5H^%?#UWI$KR7=AX>MCY8C4Z
M79F-SSU9R>AP/EQ^)KJ:* .7O?!MMJ_BR;6-59;B%;9+>UA4LABY)9B0>22?
MRK$G^&LRZ'>:3IVJFTA;55U"S;:6-O@#Y1SV;G.:]#HH X"^^'MYK\6K3ZWJ
MD8U&\2%('M(BL< B.Y3ACELL23D_3%:>E>&-2;7H]9\0W]O=W,-D;.*.WA*(
M03EW;)Y8],< >E=910!P^A_#N/3+37;2YOFG@U"%K.W &#;6QWX09]"[?I2^
M$?!]]X?FMH[NU\//':+Y<5Y;V92Z<;=H+-T#>IYS^-=O10 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%)FC/TH 6BDR:-WL: %HII;T_EF
MC<?\@T .HINX_P"0:-Q_R#0 ZBF@GO\ RI<Y[XH 6BFY]Z7GUH 6BFY]Z-WL
M: '44F[V-&[V- "T4F[V-&30 M%)N]C2;O8T .HI-WL:-WL: %HI-WL:,Y[?
MG0 M%)D^M)GZT .HIN?K1G'?- #J*;G/M1F@!U%)GWHW>QH 6BF[O8TN?8T
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M?\(Z,8_M75O_  ,:D'AM%X.KZN?K>-6Y10!AGPXA_P"8OJW_ (&-1_PC2_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/':NTK"T'1=6TV9Y-3\1W.JC8$C1[>.)4]2=HRQX')/KZUNT %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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5%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>pinnaclelocrenewal4thloa012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pinnaclelocrenewal4thloa012.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH K+_ ,?K'_8%6:KQ_P#'VW^X*L4 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110!7C/\ ICCT0"K%5H_^/Z7_ '15F@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *T?_'[+_NBK-5H_
M^/Z7_=%6: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH JQ_
M\?TWT%6JJQ_\?L__  &K5 !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 58>;R?_ (#5JJL'_'Y/^%6J "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH J0?\?D_X5;JG;?\ 'U<?[P_]!JY0 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% %.V_X^KC_ 'A_Z#5RJEM_Q\W!
M_P!L#_QVK= !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 -+8%,$Z$XW+GTW43?ZF3G'RGD?2OF:%[^_UP11
M7DJW%Q.RJ3*P&<FNS!X-XGFL[6.7$XI4+75[GTUYJ^Q/H"*=O&*\-?P'XRM9
M%S>D(3N:5;HX4>IS6]%K'B&^\#M#X9U*#4KY;IK:6]F<1K& ,D(3U(XYJ:^&
MC2CS1FI>@4<1*I+E<6CU!;J%YFB61"ZXW*&Y&?:IJ\N^%?A_Q!H4NLW/B&1&
MGNY(V#^>)"QYSD]J],$Z'.'0XY.&' KE.HEHJK;:C9WFX6UU!,5X81R!B/RJ
M8SQ@X+H#C."<&@"2BJMQJ%K:$"YN88=WW?,D"Y^F3S4RRAD#*0RD9!7H1[4
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MG:G-S<X_YZ_^RBKE !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[=Q+$DXR<=?6N<3X7V;>#+SP]=WK3&>\>\2X6+:8G. ,#)S@#'7G)KOLT9H
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M(J3Q[GV9) )R%4$D<@FE@U"YL?'^L0Z?=G5[WR[I[8K+<*UL40E8GC/R,H(
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M/1O^NAK2K-T;FS8CH9#6E0 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%>->#K34=2\9ZM>W-A>WEE;:M.!>'46182K9"^5GYQ
MT_.@#V7-%?/<=SJNL>#-!M[#5[I+W4-7N2I-P0VX*-JDYSCI]-U=1X.\4ZMX
MC\2ZA-;R![^+153[-.S+$MRK8;*]@2,\=C0!ZY29KF_&.K:CHW@.^U*#8FH1
M0*<@;E5R5!(!],G&?2J^FQ6;B]T6XM+ZPF%O%/-*]X3)(I9N?-5LYRISR.M
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MZCE)M3:.ZQB(C=C)!;@+D$@T >M44@I: "BBB@ HHHH **** "BBB@ HHHH
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M#?64%W;MNAGC66-L8RK#(./H: .7M?A[HSZ'ING:S"NJ26$1ABGDW(=F[(&
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M MIED^SS&"7'\+@ D?AD54@\2:+=:BFGV^IVTMT^[;&D@);;]X#L2,'(Z\4
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M'B\=;?1Q_P!MG'_LM'VGQ=_SPT?_ ,"'_P#B:Z7<-Q7(R!DC-+0!S7G^,/\
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M&_\ B*Z*B@#G?MOBO_H$:=_X&-_\11]M\5_] C3O_ QO_B*Z*B@#G?MOBO\
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MH **** "BBB@ HHHH **** "BBB@#'\.?\@:'_>;_P!"K8K'\-_\@>'ZL?\
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MYJ:7Q%I,.I+I\EZ@NFE$(3!/SD9"YQC..V: &?VQ-_T"[_\ "'_Z]-.L2_\
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MO9L\-NR0^X G"C@=36[+XIT.&WM+B34H5BO 3;DY_>X(!P.O4C\Z &_VP_\
MT#-3_P"_ H_MA_\ H&:G_P!^!4U]K L=;TG3C;L_]H-*HE#8$91-_([YP?RK
M%M_'UC/I6NZD82+;3+DV\95MQN6PNW:,<;F8 =>QH U/[8?_ *!FJ#_M@*4Z
MRP_YAVJ_^ XK,A\;V4?B2[TG4I([.6**V"QMEB99 21D#&!E!SCGZUI_V_;P
M2:A)>W%I%:6UPMNDBREF:0J"5*[>&^88 )S0 G]MMWTW5/QMJ/[;/_0,U7\+
M852N_&^DVMS8,UW$MA<PRRFY?(^XP4*!U))+=N I^M:VIZY8:3H<NL7,W^AQ
MQ^9O09W ],?7C'UH J_VW_U"]5_\!J4:WZ:9J@_[=JS[OQUIEI=:5YLJ0V=[
M;27+33 J5"E0 %QR26_)3]:T[WQ/HNG0V\UUJ,*1W$?FQ$9;>F =PQGCD<]*
M &_VT1Q_9VIG_MVH_MLC_F&ZG_X#&M59XF@$XD4Q%=X?/&W&<Y],5@>'O%L/
MB";4MMJ]M;VFQXYI6P)HG4E9,?P@X/7M@^U %@ZYS_R#=5_"UH_MUO\ H':I
M_P" II8O%F@SZ=/J$>IPM:0,%DEYP">G;G/M1+XKT*#3K?4)-3@%K<9\F3).
M_!P<#KP>OI0 AUTCDZ=JI_[=#33XA[_V9J_/I9M_A6A;:K87BV[6UW%*+B$S
MP[6^_&" 6'L"R_G52X\4Z%:645Y/JMLEO,I>-R_WU! )7U&2.E $/_"1#_H&
M:Q_X!-_A3AX@!'_(-U7\;)ZBN/&VA6^KZ9IINP\NI1"6!D&5VG&PGTW9X^AK
M4O;_ .R7=E /(_TF1E/F2["%5"Q*C!W'CV^M % >(U)Q_9FK?^ 3TO\ PD _
MZ!NJ?^ 3U>L-5T_5%=K"\AN50@,8G# ?E6!=^,WAN=0,.F&:RL+I+26?S@K-
M(VW(1,98C>.,\]J - ^(E'_,,U4_2R>D_P"$C7_H%ZM_X!/5N77M*@U:+2I+
M^!;^7[D&[YCQG\. >M4W\4Z=:1W$VHW=G:VZ7+V\,GG[O,*#+ C PP(88&>G
M7G% "_\ "1K_ - O5O\ P"DH_P"$C7_H%ZM_X R5,OB;16TA=5&I0?878JLQ
M; 9AG( ZYX/'M5RTU.QU#3UO[.[AGM&!(FC8%2!UY]L&@#-_X2-/^@;JW_@#
M)_@:NRZI'#&':&ZP0.D#%OR KG7\:WC6\.J6^B>9H,DZ1"]>Z5'*LX02",C[
MNX]R#CG%;=QXFT.VU)=.FU2T2]:18_(,@+!F^Z".V>,9H ?)K5M$B2/%>;7Z
M;;61L?4 <5%_PD=B./+O?_ 27_XFI9-=TJ+68](DOH/M\OW+?JW0G\. 3SZ4
MV#Q%HMSJ:Z;;ZC;2WC!F$,;ACA20W3T(/Y4 ,_X22Q_YYWO_ ("2_P#Q-*OB
M&R;[L=[^-I+_ /$T^U\0:1?:K-IEM>PRWL()DA4Y*X(!]N"1FLX^,]+F\2Z?
MHEA<6]Y-<M,)FAF5O(\M<_,!ZGC\#0!IQ:U;ROL6*\Z9R;60#\R*G6^C9<B&
MX '_ $P;_"IX)H;FWCGAD66*10R.I!# ]"#Z5)B@"@=43SUA%M>?,,[_ +,^
MT?CBFC5$9)#]DO0$8@#[,^3CN..:T:* ,JVUJ.YDV?8=1C&,YEM)%'ZBK?VY
M"@)BG'&<>2W^%6Z3 /6@#(?Q#91N5:*]!!P1]DEX_P#':/\ A(K#^[>?^ LO
M_P 36MCVHQ_LT 9/_"1V!_AO/_ 67_XF@^([ ?P7O_@)+_\ $UK;?;]*,?[/
M\J ,D>(K _P7O_@)+_\ $TG_  D=B>/+O>/^G27_ .)K7Q_LT8_V: ,9/$MA
M(.([]?\ >LY1_P"RTP>*M/,QB$&I9 SN-C-M_/;6YC_9HQ_LT 8S>);!&"^7
M?GW%G*1_Z#2KXFL&D9/*OA@9R;.7!_';6QC_ &:,?[- &/\ \)+89QLO>H'_
M !Z2_P#Q-*/$.G'H]T#_ ->DO_Q%:^WV_2C8/0?E0!D'Q%IRCYIKD#WM9/\
MXBD_X232O^?B?_P&D_\ B:V-GH!_*DVGT'YT 9IUVP$ F\R;8>C>1)_+%0Q^
M)+.69(TAO06.-[6<H7ZYQTK9V9&#C^=&V@#)?Q#:1RF,PWS,.Z6<K _CMI/^
M$CM,@?9=1Y_Z<)?\*U]M+CV% &./$5J6V_9M0ZXYL90/Y5>AO8IGVH'W?[4;
M+_.K./84NWC@ 'Z4 +1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 9>@?\@2U_P!VM2LS0!_Q)+7_ ':TZ "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** //=0\/>)+C6_$[1V=@\6L0):07
M;S8-O$%*ME0,DG). >N*[#1K2YL+7[#*L0M;94AM&5RSM&J 9?@ -D'IQ6E1
M0!Q5[X5U*YLM;N?,@_M6?4DOK)MQ**(=OE*V0,<*0>OWCUJC8^$==T:;PW)
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M,8DZ8 #$@5/I_@G4=.L-"M[4"*>TM+J:YG,H!-W-'M !7L"S=N@')->C8HH
M\IM/"VLCP==6ZPZLFL6VG&WA%Q-"(0[?ZSRMG4G!^9N>>O>MS0M)U&&_&L2Z
M&L+VFEQ6=E:F2-69LYDSC(7HH!STSZUW6** (X46."-%C6)54 (N,+[#%244
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110!FZ!_P @2U_W:TJSM$_Y!%M_NUHT %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%4KK5]-L;F.WN]0M;>>7'EQ2S*K/SC@$Y/-7:
M"BBHFN8$N([=I4$T@+)&3\S 8R0/09'YT 2T45!>WMMIUE+>7<RPV\*[I)&/
M"B@">BD5@ZAAT(R*6@ HJ)KF!+F.V:51/*K.D9/+*N-Q'L-R_F*KW&L:9:7<
M=I<ZC:0W,I CADG57<G@ *3DYH NT57M;ZUO3.+:=)3;RF&78<[' !*GW&15
MB@ HHHH **** "BBH)KVUM]OG7$4>Z585W.!EVZ+]3D<4 3T45%+<P020I+*
MJ-._EQ!CC>VTM@>^%)_ T 2T44BLKC*D$=,@T +1110 450BUO29Y+B.'5+*
M1[92TZI<(3$!U+ 'Y0.^:+77-(OHYI+/5+*X2!=TK0W".(QSRQ!X'!Z^E %^
MBLV'Q#HUQIC:E%JMFUBK;&N/.41JWH6)P#R/SJS!J%E<V7VV"\MY;3!;SXY5
M:/ ZG<#CC!S]* +-%0BZMR\*">+=,I:(;QF0#DE?4<CIZTL-S!<>9Y$T<OEN
M8WV,&VL.JG'0CTH EHHI"ZA"Y8!0,DD\"@!:*H6.N:3J<K16&J65W(HW%(+A
M)"!ZX!Z5?H **AANK>XDFCAGCD>!_+E56!*-@'!]#@@_C2I<P27$L"31M-$%
M,D:L"R YQD=1G!Q]* ):*** "BJE[JFGZ<8Q?7UM:F4XC$\RIO/H,GFK= !1
M3$ECD4,CJRGH5.0:?0 456?4;&.^CL7O+=;N0;DMVE42,/4+G)Z&I$N8))3$
MD\;2+G*!P2/PH EHJK;ZGI]W<RVUM?6TT\/^MBBE5F3_ '@#D?C4L]Q!;('G
MFCB5F"!I&"@L3@#GN2< 4 2T4@=2Q4,"R]0#R*6@ HJ&&[M[B6:.&>.1X'V2
MJK E&P#@^AP0?QJ5F"J68@ #))[4 +15/^U=/+!1>P$GRP,2 Y\S[G_?7;UJ
MY0 44R26.%-\LB(H_B9L"HTO;23[EU"W('$@/)Z4 3T4F]2Y3<-P&2,\X_R#
M4#W]G'>QV3W<"W4H+1P-( [@=2%ZD4 6**@2]M))!&EU"SGHJR D_A1!>VET
M\JV]U#,T1VR".0,4/H<=#0!/15>*^LYX7EANX)(HV*NZ2 A2.H)'0U-'(DJ!
MXW5T/1E.0: '4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M"$2.1D 0#.=R@=<]J[M=:N]S./#UX&(Y.Z/)_6E&NWQS_P 2"^X&?O1__%4
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ME76I8UPGAO45 .<+'&.?^^J ,WP!JEU?6]];W]V+R\MG027,-TL\$NX$@H5
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MC'AK4/+/)41QX/X;J .3@LM(OK.YU2XUS3+22_U>&Y,<<D<T*,BGRXGP<%B
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MA<E\1LERQQ.^XJ=N"57)R <G%==X5O;B*&:#4M2AN'GNW%D/M*S/L"!BA*@
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M ',OS_\  3AL=\5K0ZR8"YA\.7\9<[FV0H-Q]3@\U)_PD$QQG0=3XZ?NU_\
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M^'<E_<^-M>;5E*ZC96EO9SX.1(R[OG!]"%!_&K6MI /'FCW,"Z-+ -1$;K:
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MH/'=H?\ F#ZU_P" +4I\=V@Q_P 2C6N?^G%J .JHKDSX]M <?V/K?_@"U/\
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M-G@$@"G:?,0H<_C0!=HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^FU+5_M5Q$ZI+9O9"!K-^<KD'Y@<'KSQVZ4 =FMW:R7LMFEQ&US$H>2)7RR
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MWBWQ!K?C&]TK3].M$T^PEC2ZNY68E?ERZ 9&6SD>V,G.:D\5>+M6M-?A\/\
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M%&T>_P"=+10 @4#IP/2@J#P>1Z4M% "8'I1M'_ZZ6B@ HHHH **** "BBB@
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M;C&WYB<5W5% &'8^&XK+Q9JGB#[3))+?QQQ>4P&V-4 '!Z\XS6Y110 4444
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M.X'J-O3FNIH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MT3QLCMC *L <G<#T[T_4==MK430P7%L;R.2&(QRLP >0X4':"<D9('TS@'-
M%2[\&Z5>9=_/2;[=]O6>.3#K+@#(..F !BGV/@_1].CLTA@D86EP]U'YDK.3
M*P(+L3]XX)P3TJ:W\3Z5=7%S'%.QBMHVDEN2A6%=K;6&\\$@]<=*L:=K>GZL
M\J65QYCQ!6=2C(0&SM.& X.#@^U %*W\(Z5:-J[PQR+-JN_[1+O^8!\Y"'^$
M98GZG-5K[P+I&H._F27L<,EM':RP0W#)'*B?=W >G2MV^O[73;1KJ\F6&%2
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M!: &002*S$G[J@9Y)P<4V;QII46GPZB)XFLGM'NW?S0'5%(4 )W)8[>O!&*
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MHO$MI?3:[X;N;:P:\M;6[DDN K*"F8F16PQ&0"V?48XK?%M"L[SK$BS2 !Y
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M&1%<*TB+C>JD\ D ]>*S+CPG<ZEX>D@BL]1CN+^ZMH;YM2N8S(;:)MW C.T
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M0O\ Q+(9&TY-/EE'F2VR[3L=N3DKP3GJ>]7J* "BBB@ HHHH **** "BBB@
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MC- !11FB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***8)00".XS0
M^BF>8/\ $@\"@R8[?K0 ^BFAP<X'_P!>D,@ Z$\X..U #Z*0,#C@\TM !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0(U8$[><9(&>*U+G2O"%YI.L:;/JL4D>J7#3R,T@W))P 5X[4 ;?P_O[G4?
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M'^U+'_H(6W_?P?XT?VI8_P#00MO^_@_QH O452_M2Q_Z"%M_W\'^-']J6/\
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M@K, >1O<Y9OK4.D>#M2U76M)F\1Z;BS@^UWLD4CJZ^?+,2J, ><+\W3';VH
M] GUZPM)A%=RFV+W(M8C,I42R%00$]1SUZ9!K0#J<88'/3GK7EMKX>N[J_\
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M?'/V"7_T-* -^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ KF?'<7G>&)EPN?.BQD?[:UTU<QX]G\CPV#MSONH$Z^L@H Z5/N+]*=
M2+]T?2EH **** "BBB@ HHHH **** "BBB@ KGYP?^$[MCZ6#_JXKH*Y^8_\
M5W /2P8_^/B@#?'04M(.@IEPTB6\KQ)OD5"43.-QQP,T 5[C5M.M+J*UN+^U
MAN)6"QPR3*KN3T !.3FKF:\K\/\ B/1+/P+-J'F6M_XD9);RXAE3,S7"9;YE
MZ@+CC&  .*S+[Q-JT.D7&J:5KT]\!I*O=RE@8H+B26-0%P,*5!8X[ 4 >SYJ
MG;:;8V%U>7<$"QSWCB2XDR27(&!DGT';I^=>;:IXGU:^U"\31]4FBCGO+&PL
MI8XU9'WAFE=-PPWU] *K:Y<7-QH?V:_UBZ33I_$JVB733 %H5'S[F  QO1L>
MA^E 'KV:,UY==W6N1V'B;6EU>]@M=,ODAM(F8%62(JLI;@EMWS?B/RZ;1M6U
M&?0=7\0SI+)#*9)]/M=IW>0B_)Q@'<^"V/\ :% '5YJC::SIM^;K[+>PS"T;
M9.R-E8SC)!/3COZ5YE8>*;F3=JD&N7-];_V-/=7^.(K:<@%$7C"L#D 9SQGO
M5^XT>X\,_!]M)65[B]O]EO\ (<C?.X4[>.F&)YZG/K0!Z6K*ZAE(*D9!!X(I
M<UY3-XJ>QU_4=(_X2&TC2*"4:=<?:D6&!D0)LF3&=P;)!)(/IQ5?2_';I=>'
MQ?WUS:6CW%T;VXNKA9$G,<8QL<  H6;@ =10!Z]FC->0IXRO/L,9U'7VTV'^
MS7U!90%,L[R2L(T0.IRJJ!P.>1VI)=3\8R:?>7RZM<0R6EM96J1B)")KN7RR
MV1M/ $@!QZB@#U_-%>:GQ5->:KXBN&U>:VDTAY1;:0NQ3<"*(N6;*E\,0>A
MP*N>"]?N9[>2_P!6\0V%U!LAB*PSK)MF=CU 1=F<A0N6Z=: .^HKC_%WB%M,
MUW1=.DU--+L[H32W%TVW.(U!" L" 23U]JQ=$U'6]:\2Z;IAU6\6QBL'OKIS
M&B23;Y6$2,0/E^4 \8.,^N: /2J*** .>\-'-YXA/_45;_T5%70USWAK"W6O
M<YW:J_\ Z+C']*Z&@ HHHH **** "BBB@ HHHH Y7P@ZOJ'B-E+'.J.#GL0B
M UU5<CX+&+SQ&?75YOY)774 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %<U8.'^(&J)@;HK&!3CW+&NEKEM, 'Q$
MUPXY-G;9_P#'J .IHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** #M7/ZP1_PDF@J6',DQ _[9FN@KE]7>,^-?#BL3NVW13W.P
M?T)H Z<#'%+2#I2T %%%% !1110 4444 %%%% !1110 5S;SH_Q!MH ?G73I
M'/T+J!^H-=)7(X ^+*X'_,&_]K&@#KJ*** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "N3^(8W>'8E_Z?K;_ -&"NLKE?'T,DNA0+']X
MWUM^D@- '4K]T?2EI%.5!]12T %%%% !1110 4444 %%%% !1110 5SLQ_XK
M^$?]0\_^C!715SLNW_A8$/)W_P!G'CMCS!0!T0Z45A^*-7NM(L+46,2/=7EW
M%:1&0_*A<_>(R,X /&>3BN'U;6?$-X7T,:G$JOK<-C'J$:!&D79YD@ !P"K*
M%/KN([4 >G)';">0QI$)>/,V@;O;-2>6@7:%4*>V.*\NL+_5;7Q1=ZM'?0_9
MM2UN+3Q"81OG6)?+=@<_*!M)Q]?45;LO&'B+4()=>6&WMM$BCN93YI0AT13Y
M97:Q?=N W9"C!X]: /1]J\<#CIQTICP12J%DB1U#!@&4$ CG/UK'TA];3P\;
MK5+BVDU"6$2K$L?EQQ,5X0G<21GJ<UR=OXHNY;/3AJ 6ZNOM\@NH9[5%, AA
M,C[-K$'DIAN>&H [O4]-MM6L6LKM2UN[*9$!P' 8':?4''([BK0"11A0%1%&
M !P !7F\'B#Q=<Q64\M[86HNM/FU"=/LV?LL*E3&1EOF9@2#G@<\<5D:CK=]
MXFTV:RGMK9;VXL-/M6F6$ATDN7!<;NR[,,0,X_"@#T[5]$L]<L!9W#RBT=@T
MD<+[1*.NUL=0?;%:010H4*,#H,=*\VB\6ZQ<S:1/ITUG#:7>IM8II\D>YQ;Q
M[M\NX'(8!&XQCD?CT?@_5=3UK2/[=U"XA2TN/,:"WCBQLC#G:S-DDG ]OI0!
MT'V&SW2-]E@W2_ZP^6,O]?6I%AA$:HL:!%&%4*, >U>6P>+]9G\/2RQS6FF2
MV^FR:K<R"#<KM*[&% "W&X<D\\L!QTINE:QXH73+70= L@)].M+7[1/)Y91I
M95#D/N8$##=5!);/3N >JF*-L913C@9%'E1Y)V+R0QXZGL?KP/RK@=+\3:]>
MZMIDSW-FMAJ.I7-O;VWE?,UO&KGS-X/7*8QCO5+1)M6O([*?4KV*]CU35Y)_
M)=2%MHX-XROS\C,:8!R!G/)YH ]'$%JETT@BA%Q(/F;:-[ 8')ZGM5>;1].G
M>!I+2(^1-Y\:@8428(W$#@GD]?KUKRK1=1FT[38M?U>.VOKB\>\U4LUN%D"0
MKM3#9)P28RO& #75S:WK21Z7;#5=..H:P4";(-T=HHC>1VX<[^-H&2 <9Z&@
M#LYK:"Y4+<0QRJ#D"10P!]>:E"J#D 9KS*QU7Q)X@N] @&L6\.;N\D>:WM^)
MXH&$:L5)_B)/&<<@XXHT3Q)JFIA;2QFM[![B&XU>XNY(C(%A,I6, $CD@9).
M, 4 >G45Y>WC+Q/>>'WNX?L=F]MI$=]/(T!<O*Y;9&HW8&Y0#GDC/N*].C+&
M-2XPQ'(H YWPMAY];<-G_B:S=/95']*Z2N:\'JBV^JE>"VJ7))]3OQ72T %%
M%% !1110 4444 %%%% '(^"MWVSQ'D8_XF\Q!]L)775S/@__ )C9[_VI-_2N
MFH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH *YC3%/_"P-=;'R_9K89]_FKICG!QUKG-,,A\=Z[Q^[\BVP??#T =)
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 !.
M!FN6U>/?XU\.-WC2Z/\ XXH_K74GI7*:L6_X3WPR /O17N3]%CH ZJEI!2T
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M*-H]* ,+^V-9_P"A?;_P+2E_M?6O^A<D_P# N.MS HVCTH PO[8UK_H7)/\
MP+CH_MC6O^A<E_\  J/_ !K=VCTHVKZ"@#"_MC6O^A<E_P# J/\ QIW]L:Q_
MT+LW_@5'_C6WM7T%&U?[H_*@##_MC6?^A<F_\"H_\:0:SK/_ $+<_P#X%1_X
MUN[5]!1M'I0!A_VQK'_0N3?^!4?^-']L:Q_T+DW_ (%1_P"-;>P>E&P>E &(
M^LZML;'AVX)QT\^/_&N?U/4]3_X3;0&_L*8LL-W\OG)G&(^:[ME&T\#I7/WG
M_(\:,,?\NMU_.*@"7^V-6[>'9S];B,?UI?[9U;OX=N!]+B,_UK;VCTHV+Z4
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MTC0-(B-!$YR!T +.22?Z4 :)UK4NWAZ[)_Z[1?\ Q5)_;>I#KX=NQ_VVB_\
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M^$D/_0%U?_P&_P#KT?\ "2'_ * NK_\ @*?\:V\"C H Q/\ A)#_ - 75_\
MP%/^-'_"2'_H"ZO_ . I_P :V\"C H Q/^$D/_0%U?\ \!3_ (T?\)+_ -07
M6/\ P%/^-;>!2XH X+0/%,5O;7*-I6KL1>3_ ';-CUD)_K71)XEA90S:;JJ
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MT"*?'=\Y+9%A",=OOO70FL&W_P"1XOCGC[##Q_P-Z -X=*6D'3IBEH ****
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M0:7J"^#KO3)= O NH:M,5F:P!>TMF";F6, [2V" !C'7(XKTO[!KW_0:B_\
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MGL:O7_A>]L)-3L;*SN;B!/#4=G"^W/FR"1B5STSSG'O7;&RU['_(9B_\ _\
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MS;!S)(HZ_,W ]E]ZRM U.'7/%QUB_P!+U6WO%A:"TCFLI42WB&22S8P6;].
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M"K??D*A6=B0>,@= 376_9/%FP[=7TT'/R@V;=/\ ONA+7Q8?OZSI8'M9-_\
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M !5 '3;O8_E1N]C7-?9O&/\ S_Z/_P" LG_Q5)]F\8?\_P!H_P#X#2?_ !5
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M\:7_ (0#P]_S[3?^!#_XUTU% ',_\(#X>_Y]I?\ P(?_ !H_X0'P]_S[2_\
M@0_^-=-10!S/_" >'O\ GVE_\"'_ ,:3_A7_ (?_ .>%P/I=2?XUT]% ',_\
M(%H/_/*Y_P# J3_&G1^!="BD618;@E3D;KF0C^==)10!C_\ "+Z3C'V=CSG_
M %C?XT?\(MI'_/L?^_C?XUL44 8W_"+:1_S[-_W];_&C_A%M)_YX/_W];_&M
MFB@#''A?2A_RP?\ [^M_C0?"^E'_ )8/_P!_6_QK8HH QO\ A%]*_P">4G_?
MUO\ &E_X1C2L?ZE_^_K?XUL44 8W_"+Z5_SRD_[^M_C1_P (OI?_ #SE'TF;
M_&MFB@#&/A?2^FR;_O\ O_C3/^$3TK.=EQ_X$/\ XUN44 8G_")Z4#G;<?\
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MK-D);6P4>F=Y/ZT 6?\ A$=+];O_ ,"I/\:/^$0TL][O_P "G_QK>HH P?\
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M  L?7VKNZY?Q< ;_ ,,@_P#063_T5+0!<'A73RH_?7W3_G[D_P :/^$5T_\
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M #]ZC_X&/_C6Y10!@_\ "*6G_/[J?_@8_P#C1_PBEI_S^ZG_ .!C_P"-;U%
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M!U'K_P!LQ76'I7,>%@1JOB'WOV_]!6@#IZ*** "BBB@ HHHH **** "BBB@
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M_P#7"#_V:MYNF:P;#_D<-6./^6, _P#0J .@[44#I10 4444 %%%% !1110
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M  F7AW_H,6?_ ']%'_"9>'NVL67_ ']%:7]F6'_/G;_]^Q_A1_9=A_SY6_\
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M^"N:\)>']'/AVW=M+LF9WD8DVZ=Y&XZ=*W/^$>T7_H$6/_@.G^% %G^T+/\
MY^X/^_@H_M"S_P"?N#_OX*K?\(]HO_0(L?\ P'3_  H_X1[1?^@18_\ @.G^
M% %G^T+/_G[@_P"_@H_M"S_Y^X/^_@JM_P (]HO_ $"+#_P'3_"C_A'M%_Z!
M%A_X#I_A0!:%_9GI=0?]_!2?;[7/_'S!_P!_!5?_ (1_1ATTFQ_\!T_PI/\
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M ,)=KZXXS <^^R@#HJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M;H?^8#K8_P"W7_Z](?'" _\ ( UO_P !?_KT =717+#QO%C_ ) >M#_MS/\
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M(>*[$C_CVU#_ , Y/\*#XKL0,FVU#'_7G)_A0!NT5@CQ=IQ_Y8W_ /X!2_\
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MB@!NQ<YQS2[1Z4M% ";11M%+10 FU?2DV+Z4ZB@!-B_W1^5&Q?[H_*EHH 3
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MJL6\9P=Q'(!' SU]JCUGXCV^E07=U%I-[=V=EL2ZN(V15AE;'[LY/+#*YVY
MS5V?P5%<V>LV\U](PU6^2ZF;8 0BE2(P<],(!GW-49_AV;DS6[ZN_P#9D^IG
M49K06Z@R,6W%2X.2/\!Z4 6];\=1:1'>RPZ7=7T6G[%O)(60+"[8PG)^8C(S
MCID54F\>6]A?:@]Q%J$Q%S;V$-E%$A/GLA<JIR,GD Y/88K"N/#NJW_B&ZL;
M6#4H-.N]66^OA=P1K#(BD;E617+,#@8&![XP:ZR#P3;1ZK;ZA+=/))%?SWY&
MP ,\@V@'V4=/Z=*0%:+X@6\B&!M,N4U0WS6"6'F1EWD50S'=NV[0&&3FM;PQ
MXB7Q+87-R+*>S:WNGM7CF()W)C.".",G'X&N6U'PJ=%U>RU*S&IW-X;J[N7F
MM[6*55:;&00S K@ !3STYXXKHO ^C7.A^$[2UO23?/NGN2Q!/F.Q9LD=2,XS
M[4P.8O?'6N3^$=6U!-'>S877V6QE616\P^:L17&<[_OG.,<=:V5^(%O''>)?
M:=/:7UO=1VBVDDL9:661=R@,#M P<DDX%+9^!!;:7I6G2ZF\L&FZC]OB'E;2
MQW,VUN>?F8G-%_X!M+UTF,T9G74I=0/GVXE1RZ[=A4D< !>_\.: -7PSXEMO
M$UC/<6\+Q&"=H'!8.I8=U=258<]0:Y;1?&TD5I>7%V6N[B[OKF6UM_-6,1VL
M9V[LO@!<K^)/UQW%M:26VF+:J\".J%5:&'8B^F$R< >F:XZ/X;+9SV,MC>VS
MFVLUM&6_L5N%;#%O,4;EVMECZ]: +8^(-K<6-O+I^EWUY<RV7VZ2V3:C0PYQ
MEMQ&<G. ,DCGH10GQ!MKC28+JSTN\NKF2T-[):QE T,(.-S%B!SC@#)/I6!X
MK\.:M_;VI7&AM?\ VR_L$LV*VRB+C'*R[QL&!R-I[XZBM63X<O%/<MINL?8X
M[O3H]/G MMS;44*&4[@%) YX/?&#S0!/IOBB?Q%XET$63/;64FG2W]Q P!9L
MD)&">W.3Q_A4VN_$+3=&NI;=(7NS;R)%<-'*BB-V. H#$%B,Y(4' ZUHZ-X8
MMM&U*6[AD+YLX+.-2H!1(@>XZDYR>!T%4-+\%G2M>N-0AN+&2.XO);M_-L 9
MU+DDJLN[@<^A_6@"*_\ B':6E]>6\6EW]Q#974=K<W2;!$CN0  2V6()Y '%
M0P^-K\W_ (G-[I;6NE:0K*MTK*S%U7)!&[DD,I  ^IJ^O@N,6(M6O6(DU8ZG
M<-Y8S*=Y=4^@(3GG(4],\41X"N_['UO2FUF/[-JEZUV["T_> ,X9U9M^&R !
MG [_ $H JQ^.-3T[5+NRN]*N[RTTVP2XO+P*B2;BI8G:&Q@@8"CG(/05U5IX
MBM+[7#I=LDKNMFEW)+CY4#GY%/\ M$9./05B7OAFYLKCQ5J,4[7<6L6@C^Q+
M#^\#K&44*^[&.3V[]>.;O@KPW+X>T51?3M<ZI<A7NYF.3D* J#_94# _$]Z
M,J^\27AU76X(+J2!1=V>F6;I&LFV9LM(V#QT<#GIM'':K-QXZ==&U#5+/1+Z
MXL+6W>6.Z8QJLS*<$ %MV <DG'13QTS)!X+D@OOM2ZED_P!I7.I;&@!!DD0I
M&#SDA ?Q]JS[OX?76I:?K:W5_:P7FJ0QQNUG;&.,LCEM[*6.68G!Z<?G0!:_
MX3T6FDV+ZCIDL6J7,1E-D)8D(11\TF6< *>W))Z>M2WGC^TAL;>YL],U"^,E
MF+Z:*)%#6\)7(+Y. 3SP"3P?2J^H^"[_ %#6K;5YIM&N+HVR6]PMWIQEC&UF
M.Z,%\J?F(P2:-;\$ZA?7FLMINKP6%MJ]M%!<*UJ9&01@J A#J "K$'(/M0!I
M:+K$UGX$L=6UN25YY(%E<"/+LTA^1 HZL=RJ!ZUF:IX]CA\/:[(UC?:?J%A;
M;O+G125:3*PG@D')Y]L&M7Q'X<EUC1[&TL[I+:>QN8;F%VCW)NC/ *@CBL6^
M^'^H:CI^IK=:['->WUY%<M*UIB,)%]R+9O\ NY[YH M6'CRTM["Y75X+VUN+
M&"%W$T/[RX#X5655SRS<;3R.X%.MOB#:F=[74-+O]/NUFMXO)F523YS%4.58
M^ASFH+_P1?:HTFH7.I6XU9KFWN%(MR8%$&XI'M+9()9B3GOTXJ>Z\&7&H0:G
M<7.I1IJ]\;=DN(8/W=OY+!D"H2=WS DDGG/84 6KCQQIL5U=VD,5Q=7,-Q]E
MBCA4$W$P3>R(<X^4$;B< 9K3T#6H?$&CQ:A#%+"'9D:*7&Y&5BK#C(/(ZBN5
MN_ATGD:2+=K&[>S67SUU* R)<22$%I2 1ALCWX..U=)8PZC#JD5LD=O!I5K:
MJC+'%M$DQ_N#/RHH_4X[9H V:*** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M"][!9@R7P*'$C$;D4#D< $D<'% &_1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 &*,444 &*,444 &**** "BBB@ HHHH **
M** "BBB@ Q1110 4444 %%%% !1110 48HHH ,4444 %%%% !BBBB@ HHHH
M,4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 &****
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M%KI+RVUK;37M]%>06;PHI #R@,.>A.TG ]>.* .KHKG;GQ596FII%//+&=D
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M<@(.2!D@$^_:J'_"9ZF^IZ=IUS>75FWV,WVHR_V:4\C@ )AP<)PQ+<\]#VH
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M9LV%E=BY:*[!V2$*0H. >YS72U6%\AU1[ 13>8L*S&38?+P6( W=-WRGCTH
MY?6?"NI^)-$AT;4)[&RL2&:X%@C99@?W:KNX"@X8GJ<8XZUD2^ ]5.JV-Y-;
MZ3J"IIT5E-%+-+"$*=UV@Y4YY!%=W;ZK;7.K7NF1,QN+-(GFXX'F;MHSZ_*?
MS%7<T <=:^'=:TKQA>WNF#2TTR\B@C*R*^^ 1KMVHHP,'KU[UG1>"]?-TUO+
M>6(TPZY_:C\LTLZ[MP1AC P0/7/MCGO+N]M;"#S[RYAMX<A?,F<(N3P!D^M3
M@YH X"Z\&ZW?:3XGTN6XM(8]6U#[1'<+(S,(BRY4KMP"$0#J<DGI5M/!$_\
MPF5QJ+WJ#1WDCNDLD7DW"H$#-[#DX'?'I726NM6%V-0,4X"Z?,T-RS@J$95#
M'D]@".:9I^NVFJS1+9)<20RVPN4N#"RQE22 ,M@Y."<8Z<]QD Y7P1X*O/#D
ML<>H6FG7!MS*8K]9Y&E;<Q.?+8;4.#@D'V[FM'6=&UR+Q?%X@T,V$K-9?8I[
M>\=D&T.75E95/.2:ZRHYYH[>"2>9UCBC4N[L<!5 R2: /.K[1[B&YM;"X?[7
MK6L:I;WVHF%&\J.")@=N<<( FT9Y)-23:/>^+K?Q9<6["*/4C!9V<UPA \B,
M_.P'7!+28]<"NAT7QSH6O7R6=C//YTB&2(2VTD8D4=2I(P1T_.NDQ0!QOA_P
M[K/A_P 0ZFT)L9=,O9TE$KR/YT:J@79MQ@@8P/FX';M67X1\!WF@P>5>6&F3
MSPK*8+XW,LC>8QX;RV7"=LD'/YUZ-52+4(YM2N+!8YA) B.[F,A#NS@!NA/'
M/I0!SNB6>I>'-/\ #GAZSM876.(G4+C#%$ &3M/&69SQ[9.*F\4:%J5]JVBZ
MSI$L'VS3))"(+EF6.5)%VMR <''0XK8M-6M;W4]0T^!F,]@46?*X +KN ![\
M5?H Y5-&US4-?T?5=6-@GV!+@^3;,Y =P%3EA\V%!R>.O KG_P#A7.IS>'M/
MTV:]M8VM+&[0.FX_Z1<,=QZ#Y I(]>37HSSQ12QQ/*BR2DB-68 N0,D =^ 3
M3R0JECT R: /.7T>7PUX5OHX](LX=5N;86-FT%S)<22.^01O=05494@9QP<U
MTM_X>FD\ /X=LI8XI38BT5V)"@;0I/ STSVIMGX[\/W^JMIEO<W#78=4V&SF
M')Z'.W 'N<"NC% ')ZUX+MY=#ATO1;6QLT:YMVNF\H*9(HV#'.T?,>!UXZU2
M;P7J$^E3VLTEH)+[6Q?WA7/, ?<$!QRWRKZ=_P >ZHH \VC\&>(RRZ;*=,&D
M-K)U&>197,TJ>9O";=N!T'>M,^#KUQ$'DM\RZ\=3NR';YXU+&-.1SC"<'@8X
M/2NVHH \^T[POXHLO!^H^'"^F&*6*Z2*Y\UR[F5F(W#;A?O'/6HKSP1K\=QK
M46DW=C#;ZA96UI'/([^9"D2;64*!_%GKG\#7HU9]WK%M9ZQIVF2AS<7_ )IA
MVC@>6H9LGMU% &7H'AA]%UJ[NS+&\!L[:SM5 ^9(XE(.?J3T'I6:NC^*=*U;
M65T@:8]IJ<YN5N;AV62W<J%8%0#OZ9 R.ASUKMJ* /-;2WL])\2Z79QS2/I?
MARRFDN+F56PUS*VT]N6Y8]_O5<T'P]>ZAHFA7-Q&+<MJ,FKW:2$[RS%VC7&/
M]I<Y/&.]=]BB@#SC3?"?B9?!>H>%IS86L+13+%>12LTDSL^[)&!A2"0>2:=%
MX-U"Y\.W5D^FVME<SQQ6K3R7TEQ(8=RF10S [5X("Y/09KT6B@#*ANKK^WO[
M/M[,1Z;;6_[R9E(S(<;$3U 7)/U K#U;2M>LO&1U_1+:TO5N+-;6:"XG,10J
MQ8,#@\<]*[&B@#D;GPWJ=[J.JZE-+;+>3Z,-/MO+9MJ.=S.3D9 W%,>PY%8.
MM_#G4[[3[F"VNK;$>F6MA;*2P+)$VYU8X^4,0/7WKTRB@#R_5--FM= DTLZ5
M%;ZOK4R6B'[:]U.UN&'F,TC#.%7/'09!]JZ[Q=H-QJ_ADV6F^3'<P2136RR$
MB/=&P8*<=L#%=%10!Y]JT&MS1GQ)X@M;6S31+:>>VMK:8RM)*4QO8X   ' '
M<]:I^&O#.OW&CZ/;W5K9Z=;Z?;2202PR[Y)9Y(RHD8;1C&]F/.<XKTQE5U*L
M RG@@C(-+0!YMX>\&ZC8>'[RUDTM8;Y-.D@M)Y=1:X D=2#M0C;&I.,X_6M&
M_P#"NHVMUX/;2X[>:#1(Y4DBDD\L.S1!%;H>A!)[\\9KN** //\ 3?#.NV-S
MX;N9H8)I+>YN[J_V2A<RSDC=T^;"LWOP!4D?@J\FNHI+SR62779-3N@)"<HJ
ML(5'K_"2/;K7>44 >7>)8KG0+RTU:\N=.$S:S/>_9[J?RUEC""*/#$'#! I]
MB:Z'X<1WC^&Y]2U"(176J7DMZR@$##$!<9YQA1CVQ77NBNI5U#*1@@C((I<4
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 <3\0()WO/#ES+:3W6DVM_YUXENC.ZD+^[;:O)4,3G\*J:MJ?]IZ
MQ)K:V<ZZ1H>G7,ADN;=HOM,CI@HH< D +SD=3CFO0:HZKI%EK5JMK?QO) '#
MF-9617QV8*1N'L<B@#RW1/".E0:AX3TR]T^'[3#83:I>AE!9V.T*K*,Y +'
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M(8Y8F.4CR#G W#@G. :]1I* /%/#]E:2ZMX0TO6#.J_8+BXBCFDDC;=)+\B
M@@DA1],?A7L6GW]OJ=DEY:/YD$A.QL8S@D9_2IIX4N()(9 VR12K;6*G!]QR
M*;:VMO96L5K:PI#!$H2.-!@*!V H X(7-PEAX[\163()96:"U= =V88]@/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@9IYXUCES,X5U&,94$#C _*NCQ10!C2>%M&D2_5[)2+\1BY^9@75  JYSP
M.![U'+X/T2?7'UA[5_MDAC:0K.ZI(4QL+(#M;&!U':MVB@#GSX+T)H)H&MI6
MMYKD73PM<2&/S Q;(7=@#))('!I%\$Z"-4?4/LC^:\_VEXS.YB:7^^8\[<^^
M*Z&B@#&'A72!"(OL[;/MW]H$>:WS3YW;FYYYYP>.!Q4+>#=&DFNI94NIFN8I
M(7\V\E<*CXW! 6.W.!TQ6_10!#:VT5E:0VL"E888UC122<*!@#)Y/ J:BB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH *0LHZD"EK@?%E]+)XX\,Z2DTL41,UY)Y9(#E%PH/MDY
MQ[4 =[N [BC(]:\/MM5U?5]3\#VTEX\L5Q->-*))60R&.8@9*]0 .!78^/\
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MR(I2I'+ KN&#C(J2^^*=UI5M?0:EI4%MJ=O>):JAN"\0W+NWLP7. .P!/(H
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M1VK.T;QLMYI^D2WT4-O-<1W#7N6(6W,'RN><X!;'4]".M,#7_P"$LTWTNO\
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M9'J,Y_E4OEI_='Y5@>$QLTE@"3NNKACG_KJU '0T444P"BBB@ HHHH ****
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M'=*COS'O3[3#%(,$D*[A20!WP>* -NF2_P"I?_=-/IDW^ID_W3_*@#FOA_\
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M-W$TEA]IE&^$E7GEZ.1NSA<L,9Y!ZBGWOCS2K2TFU 2)+I\-L)W=2RRDLQ5
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M7-!IDD;L'O1"[I)PH$;*S-MVYZXXZUZ710 4444 %%%% !39/]4WT-.IDO\
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M=.?^?JV_]')715S?C*39H"<?>O+8?^1DH Z%.@I],2H-1U*STFR>[OIUA@7
M+-DY)Z  <DGT'- %JN>\<6E]J'A*\T_3X6EGN]D!VD#:C, S<^BYK6T[4K75
M;8W%H[M&&*'S(FC96'4%6 (/U%6Z //]:\)W-G9V;)+J&L;[F%-0,C*TCVJE
MF\M5X&W<1D#DBN;N/"NI1Z?>>3H=Y;74NJ27=I:QPPSVX4+M1)5W[0IRQSCC
M/M7LE0Q7EM/<SVT5Q$\\&WSHU8%H]PR-P[9% 'F=\]YINO:CKD6C3V\,%G(K
MFZM8_+A>.(K&8) =P5F 7;COGBL>S\+ZNFAF?1?#]SINI6VC-;RS3-LDNIY&
M7>1AN<*'()QRP'88]DN;:"\@,%S$LL3$%D<9!P01D?4"IJ /(W\(SW^H9L-!
MFTK1[N2TM9[?:J.Z1LTKRNH/'*HN<YY[]#U&E^'+"T^(%Y<1^'X;:""S@2SG
M2 !-P,F\J0.#AE7U.*Z+5-<L-'EM(KN1Q->2>5;Q1QL[2-U. !V'<\5<6Z@:
M\DM%D4W$<:R/'W"L6"G\2K?E0!Y[KNCZU-=:YKUA9R)J-M>P&R4?>GCCC*-C
MKP?-?MVK*DL-:T&S-G9Z-?W%Q_PCT=E 8$R@F=F:9BW !!(XZG'OD>NTE 'E
MNK>"+G4;F:?[).)UOK.TM9D?:;>WB">9*G/&2&P>O Q[P:AX;N-.O!'!H]TV
MA/K*SR6]O&S,(HX!&6(7YF#L2??&3G->M44 >17&@ZF#IMG);7=KH-P]Q<?9
M(+'[2L!=_DC>/!VX4D\C"L3Z5TNA^$+2/Q++=W5G))#IEO;V6F-<\X5%RS@=
M,[CC/L<5W%% ' ^*]%U_Q'?7_P!F$$-C;6<UM"EPK$S221X:10.A .P$^K<5
MCRZ?KNI)<>(7L+J+4-/M]/>UA:,[Y61&:9<$ L?WSK]?<5ZM10!YOI=K?Z)?
M:'-=Z3J5R+/13C[/'N_TF5MT@.2,-\OTY[5UOA;3+G3-(<7@1;JYN);N6-#D
M1M(Y;8#WQG&:VZI1ZO83:C'817227,EM]J14R0T60NX,.,9/K0!=HHHH *Y[
MPD/^),GO/<'_ ,BM70US7@J1IO"]I<, &DDF; ]Y6I =+1113 **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "N1\.@'QMXL;;_P M[9?RA!KKJY'PV<^,O%O_ %]P?^B!
M0!UU%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0!ROC=F%GIN#C_B9VW_HQ:ZJN3\<D"STO)QG5+;_ -&+764 %%%% !1110 4
M444 %%%% !1110 U^E<Q82.?B!K*[?E%M!@_B:Z=^E<UI^1X\UKT^SV_]: .
MF7H*6D487%+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4R;_4O]*?3)O]1)_NF@#F?AY_R)MH>Q>;_T8U=37+?#O_D2;+_>E_\ 1C5U
M- !1110 4444 %%%% !1110 4444 %<UXS!.D6P#!<ZA:]^O[U>*Z6N9\:B(
M:7:&4#_D(6H0'^]YJXH Z1>N/K_.N-\4W!L/&>@:A?\ G_V1!'/EHXFD59R
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MIY&ES+M[ G@#T'7'K7944 >/7-VUUX<UJXLM4O[ZQDTB*.XN)KE\+=/)CCH
M "=P48Q@=S534],F2:_NM+U#4D73H[#3;&99FS<-)(LC9;.2H#CCIR/05[93
M$ECD+!'5BC;6VG.T^A]#R* /-C=ZGK?C^6UFU<Z=]FO-L%K'-*'DAC&XGRP
MI#X.68GC@ 8YWO -O>3Z,-<U&[O);O4MTOE32DQQ1ER454Z+\I'O[UUU037E
MK;SP037,,<TY*PQNX#2$#)"@]>/2@">N6\ ?-X.TTGTD(_[^-745S'@ ?\49
MIG^X_P"KM2 ZBBBBF 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M5T'VGQ)_SX6/_?YO\* -RBL3[5XC[V%C_P!_F_PI/M7B/_H'V/\ W_;_  H
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MTPP [A%YXV@^N-N*0'):AK?B.*#['%K\0:TTR[U*YNH5CF#J'(A3?L"YX()
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MC&0<?,WI4@=-1115 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MNK:Q<KA'!RH+@;BH)R 30!%9^/+B\.GWJZ-C1-0O/LEO>?:@9"Q)4,8MO +
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MI0L4LJ.\LDJA3]PD!0!U/))Z4 ==1110 4444 %%%% !1110!SWB;FYT,?\
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M"WFU Q)<Z@EX$@90!DO&'R^T9&-O)[]Z=XHT.75;B:#3O"?DZCYL(@UIC#A
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MYI%^S^2!AR!O(Y'& NZJB^$/%MIXJTN]6_L;J$:C+=SS"#:RATVG=\W.4^4
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MP/2@# _LW6?^@\__ (#+1_9NL_\ 0>?_ ,!5-;V!Z"C ]* ,$:;K/_0=<_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M=(/*#JIQ[X+ <9H T5\(ZNDUO,FNV:26Q<PLND1 QE_O[<'C.3GUJ>+0?$L
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M_9DA#;RV/4K@>N>W2H_#'Q'B\0ZW%I\FFM:1W<;2V4OVA)#*J]=ZKS&<<X-
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MQR,"H_C122N>.I[U4T/XFQ:UJ6EVYT2[MK?4C+'!<R2*59XQEP .<#IG].M
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M]O WAAM.?3SHMK]D>;SS&%.-^,9'<<<<5L6-A::;9QVEC;16]O&,)%$H51^
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MR%F@:W654&_<203ALCC!I_A3P=#X8L=0@^UM<O?S--*PC6) 2,81%X45TU%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\"C[!:?\^L/_ 'P* ,;_ (3KPQ_T&(!]0P_I2CQQX9/36;;\S_A6N=/M"/\
MCVA'_ !2#3K,?\NT)^L:_P"% &3_ ,)QX9_Z#-K_ -]4O_";^&?^@U:_]]5K
M?V?9_P#/K!_WZ7_"D_LZS_Y]8/\ OVO^% &5_P )MX:_Z#-K_P!]U9LO$^B:
MC<K;6>I03S-R$1LFKG]G6?\ SZP?]^U_PIR6-K$X>.VA1AW6, T 3@YI:0#
MI: "BBB@ HHHH *XSQOH6KZGJGA[4-)MK:X?3+EIW2>8QY^[@#@^G7M@5V=%
M 'EL_A'QN++5]9AU"VCU_4I8_-@MWV*L"!AY:.1PQRO/&,=:R'^'/B;^S-0N
MQ!$;UM5AU""TDN_-9U0/E6D;J?G')/.*]IHH \BU?P?XDN_$USJDNC"]L]7M
MXEN[%-6:!8'4 89AC>HP>@/4_CZ7IMO=69CLQ;P1:?;VT4<)$K/)N P0<CH
M!@YR>:TJ* ,&\\5>&E,]G=ZK9C@I+&[]CP0:YNQE\)V0@MW\6BXTVT=7M+*6
M==D14Y7+ !G"G&T,2!@=<#'<-IUF[;FM8&;^\8P2?TIO]EV/_/I!_P!^E_PH
M \Z.G^#C!=67_"8.-,E\XQ64<Z!(6E!#$8'(Y. >!D]^:E%KX+>WE@G\5EHK
MD0_;(4G2..X:, !B N1G SM(S@9KT$:98CK9VY_[9+_A0=+L>UG;C_MDO^%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZ*PK+Q7I]WX4D\1R%H+&/SF)?KMC=DS]3MX'N!6$_C^\32-1N[C0VM9(M/\
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MD#:OF E5/.=V!G&.A%<--X[U>RU+Q 9WM7L$M[HZ8Z*/]="P38>><E@>OL*
M/3J*Y:#QC D")/#</*NI1Z29 J@/,0-S 9X4'.?I5.+XBP7-W;P6VC:A-]JG
MGM[5QY8$SQ'YL?-PN.=QX&#Z4 =K17G:_$6:ZUBUDL-.N[FP;1GOI8(Q&&1O
M,P"S,1C 1^ >=PX]-B^\?:=::M%IZ037#F2&*4QE,QO+C8-I.6X()VYP#^%
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M)@Q0+M<@\*>_%5O$WCB2QTF_33+"[?4(52)F"QLEM/+@(C_-AFR1D+N R,T
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MC[3:"]6* )O2$C(9MS ?@"2<'&<&@!L/P_TFV>1;:>\AM9HH8KBU61?+G6(
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M-W)%=QO]J^R+;/&!*TN =H&<=#GDC&* +6D^'+#1&NWL1(CW0C5V)!($:!$
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M3"4R[0VT)MW=".V.13I/&>E6NZ2\G,,;7"6T:>3(9/,,2R;64#(.&''KQUH
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M=ZK$%\I4"9VQ;%3DXQG)R?[W?%6?"N@-H6E[;FX:ZU&XVR7=PPP7<*% ]@
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M4R;HG#C8<$+G!^Z#CK5>\\!7.HG57NM5@66^MOLY>WL_+W?.&#2KO(D88QG
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M9/#-$LH+(_EJ0%..>^<^H%=!10!B>&='O-)MKUM0N8KB\O;M[J5X4*J"0 %
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M^DAMW2)0D8$2AF!!.X+P#G@]*;:>"9='M]3DNTM)DD%U,+V,2RW"-(#@I'R
MP'!*\G:!7HM% 'DNE>'M<UNUN;<K;PQV>G6EA9S2VTD:2A'5Y-P<!N=@!P,<
M^U="WA/6[B:?4+JZLFOVU.&]CC4OY/EQH56,Y&>,EL@=>:[FB@#CM-\(7T6J
M6]]J5]!<2+?37\OEQD!I&C$:* Q. JY[]A5"#P5KBZE DFH67]EQ:O)JC*JL
M99&))13GC _STKT"B@"MIXOA81#4FMVN\'S#;AA&>3C 8D],59HHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **R-?UO^Q(;,K:274UY=+:PQ(X7+E6;DG@#"FJMKXS
MT>32DO[VX33U:62'9<2+G?&VU\$$@@'N..E '0T52?5;%8GD6[MWVR&+ F7F
M0#=LR3C=CG%5[;Q#I4\D<'V^U6Y: 3M")U8JI4-G(..ASGTYZ4 :M%9:^(]%
MDLYKQ-4M6MH'\N242C:K<$#/OD8]<U3B\66C^%_[>,,A@:5HHHX\.TA\TQ(!
MT&6./89Z]Z .@HKFCXJF6QO93HMU]HL7*7, DCQ'B,2;MV[!!4CISGM5BY\2
M1QQZ,UM:R7#:I\T<88*RQB,R%N>"0,#&>K=: -VBN7C\8@Q&*?2;RWU(W MX
MK%RA>1BI92""1MV@DGM@T3^.=/M=*AOIK2^&^Z^QRQ+#DP2;]A#M]T $COSG
MC- '445@W7BFTM-4^Q/;7+(+J.S>X15*)-(H95/.>C+SC'S 5O4 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M</:P6L"W,-Y/+%?2LTLD87 \K:$ZJHW')VKT!Z==110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
? %%%% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>cpix-20210930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cpix="http://www.cumberlandpharma.com/20210930"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="cpix-20210930.xsd" xlink:type="simple"/>
    <context id="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i997bd44925334429a7698804c0800bcd_I20211108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2021-11-08</instant>
        </period>
    </context>
    <context id="i5fc3bb3df16548c98cacace445d903da_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="idb172cb6365440839665fd6ec022472c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5cfdffb6c8a4411a95e4596b0bd91b7c_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie2722c94900c4f68be9dd446637b8348_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ieb58760ea84940319b35492cd1910735_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:ClinigenHealthcareLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ifca7f9fa06d14f85a52cbd81ac170d2c_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:ClinigenHealthcareLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i45bdfab35dd74d60ac86fc023b908b73_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:ClinigenHealthcareLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib8c8802e62b74a919450a1c6017bba7e_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:ClinigenHealthcareLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6fa410e0219e41c3b8a23d8140a1ca8c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1ae7216a773d47d889c5f34d67e867fe_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i90ac8e9aca0748058577add35fc3a6f9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7f67242cec184569be979f0eab3bb2dd_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1925af7a08774bc4a2752a9cd6b75c35_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iaf2c0f582f1a48b1b7132666868a1789_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i4167fc9dfbd441ed853e3173c4f077bf_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ic4f1350ea2fc4eb18dc553f1c359d775_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i94a852cb675745e89723e30ec61bfcee_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i98ca8db1bbc14991a38ad2f127cdc3f7_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="id9ade7c2b96049c891663efff729f1ef_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ia79d5a078419401d86bc7174c913bcf6_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="if8cac0f57d4c4aa1bf61accf6f74bfda_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i62b7e40824ec46c1a5d32166d46d8910_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i374ad433cb0d4675ae41fef76147919d_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ia7d9f053c7b34fd799481310c6ca1498_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i06622f546c724e4289669409575c7f9d_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ib5c699d5da91427e80a66ec6b1991b3a_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i70a1ecea99f7485195b3405682bd0c55_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i9fb60215b0504a758fcf2dfe00ea4b97_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i00b5fc7364e347f39acdca8004cef0f9_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i786c6ae7dd8d4840bb2995fce1423b07_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i8c344dec4461400991796893b71c39f3_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id1cdf0875abf4833a9b0038791a1ea6c_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i1e43169536834b7daa78040307754845_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i1adc976609fe48d4b014ec48f05e022c_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i169b3e774913430bb6c450a8d1cd8300_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i659fa119f70c4793a43053cddb879d71_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i50909170032a4c00a004f6dd1808751c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i42e8ab4712444a43a1f231cb65ac3dcd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idecbe529c8e14131b56433eb5e130916_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i5c8473bff64c498ab624fafa4cca5132_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i781a96ef93c24d05bb7f12625a033ec0_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i38154999f15f41cca19a77a5f4d0ccac_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i9d845908b01747ac9d721fff45f53abf_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i32deafcb20a948cf995118abdf3ce1a4_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i2593ac397b63496686231e5a4d277b3b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i8320ae6bb40c49b4b91522210805d996_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ief227cab10a245ff9baa903632237a80_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i83fce5d3edda4b1cbab16d0e4a53c979_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ibe562d54463741e8949d25484a516053_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i1f91139b751f41ee943e86bdb734f2f4_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7ea7194dbc454dbdbc6632db38bf6066_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ic49c90ad54954ba9a5f89e54eb1dfedb_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ie1e3b4d188524c1791c80059e8f7515a_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i64b2d71ddb0c448d9959f1b9a74a7dad_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i10df7b4f9a35418da7673ef6ae315d51_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iae1347d2d1d84aa3a135e3245bdf0d90_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9cc79eb883d54f61bdec225f436b82c9_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i56aafc7718c145c8b150a8e54f33a5d2_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ib1da3f9dccc043f1b509c4e381803002_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ied663adb59564577989ed6d27ea6493f_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i2b064560ae764b05aee16232fc2b982f_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:AcetadoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if9189ef3c405466780ff2b301ce69072_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:AcetadoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib543c8c5c4a0438eb3b83a9549c72767_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:KristaloseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i851181d1e03446adb4d2b6f666a489e7_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:KristaloseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i343ad32279094a2585bfa47056ea0769_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OmeclamoxPakMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="idf76fee1053a41f897bb2b308eda43b7_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OmeclamoxPakMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0a175b2126f3439e978ef755a5187703_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1221e6e62b0d4437aa038a1593455cdb_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ide5a86375216464d9ebfdf112640aff3_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:KristaloseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2d2eab230e924fb094455dfdb93d19f6_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:KristaloseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib32ee538452d4d108fd0d0249f232e4e_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:CaldolorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie38185217cb649a98c782f849b956b81_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:CaldolorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="icb5e5973ac81495ca434caa4250ad1e6_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6f2cff2563f6434383fad1a3433a95bf_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i87b67bdb94e6413eab1ada4bb36a71b7_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VaprisolMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i70e186cdc2a444de9d34c6b0a9840fa3_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VaprisolMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0301ef84e6814fc1afd5bda0bb02be0c_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VaprisolMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i10d6fa0a80234f6fbdf7f486df4beed1_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VaprisolMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iba2b0e3ce8dc46a892511cbd1f0b38cf_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:AcetadoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2075e961d64a4c4184f2117135160c9e_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:AcetadoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i67bca755a168477fb7af6f54edd41311_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:CaldolorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i369b52ac1f754a4a9275b8917dc3bb9d_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:CaldolorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i2206c2c78e3347cf9fd2bb7625961847_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OmeclamoxPakMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i64299c3a88d84d888de7a4e8264da6a1_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OmeclamoxPakMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ica59276837544b3e89921005c9db373f_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:RediTrexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8d8203f933864c8d869320c4b6ce16d2_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:RediTrexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if79d16ca01cf493f84c3a1bcbcf07c1d_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:RediTrexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id3900d92fcea4358838f65d608ad8088_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:RediTrexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5d6efd6bd2c041769f9fbf0d1a3e5685_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OtherProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1571108ca25f4e179a9d14073629ae96_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OtherProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i8cf12a139ea74881b685de000f63434e_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OtherProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="idbd3b5d4865547179a8bf7fbe50a430c_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OtherProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7beb09efdc954e3387adf27b4cc99538_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9c591eb458184e3baae21c9c26245264_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i32601382eaeb463ba862531b12def23c_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i76c8b1e743d441a3ad6f81bc894366dd_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i890f0fecec4a4eb899b3171ad304df32_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5d7014c036534d1ab07ea1c7138ece74_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i2fb3c2ea35a146918884002eb0319cb9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">cpix:IfetrobanClinicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i85407d87b0cc40608f88c792ee3187bc_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">cpix:IfetrobanClinicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ifd0c03fd249e4e64a76675f06c950be1_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i67e0bde90efc45a7a814f5c68fb0096f_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">srt:OfficeBuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i6b60adc716c54226bd1b0d9f82b62a4c_I20100513">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2010-05-13</instant>
        </period>
    </context>
    <context id="i2d045c0da7504a3081ac01dc90d95aed_I20160131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-01-31</instant>
        </period>
    </context>
    <context id="i3eac19ab71204baa8b814cd80e8e55ab_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i545187d4937e41ec99d80966b809dd78_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4b890701c9304f309d867768f2a90a7b_D20171101-20171130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2017-11-01</startDate>
            <endDate>2017-11-30</endDate>
        </period>
    </context>
    <context id="ib59b0ab18a9847a48768cc76def0c5ce_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7109429b4bb94262ab81694be586f875_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i448fcba2bca740069897cf519754695f_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie91a73f23b39413ca4897ecef5e9c6b9_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cpix:IncentiveStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie35d5d79a31d4a97ada4dc5eb118435d_I20211028">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cpix:FifthAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-28</instant>
        </period>
    </context>
    <context id="i433310853533429eb0bd0de42c8cb8c0_D20200814-20200814">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-14</startDate>
            <endDate>2020-08-14</endDate>
        </period>
    </context>
    <context id="i7857ace04dd14acd90de8bfdfc44e2ad_D20200814-20200814">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-14</startDate>
            <endDate>2020-08-14</endDate>
        </period>
    </context>
    <context id="ia066a8f68c2c4b2bb8d23f93616af446_D20200814-20200814">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-14</startDate>
            <endDate>2020-08-14</endDate>
        </period>
    </context>
    <context id="i0c79a3c371c84f16b64c6d20ef3f26bd_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i29e07103e7b54d69af01f448919f0979_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5729693e898c46118beacc910390b13c_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i8f0ec15fc71f49aca22d17a26142e958_D20200420-20200420">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-20</startDate>
            <endDate>2020-04-20</endDate>
        </period>
    </context>
    <context id="i7f3eb3a61d724b16837687fe50bb6592_I20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:WinHealthInvestmentSingaporeLtdDomain</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="i10ede8aae6b6477eb6df1f13d1f8042a_I20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:WinHealthInvestmentSingaporeLtdDomain</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="ic25c3441c5a0477ebd8c769c3ea98555_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i57f795672a2a465e9209a65e0162f0b4_D20181101-20181130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-01</startDate>
            <endDate>2018-11-30</endDate>
        </period>
    </context>
    <context id="id08ba9ef8fce4ef0b1aebddae7a819be_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0463cd68913447b0aec736a9a21b1701_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="icf562c30b2d9493a84db87baebada783_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="if7d1c3dbcd4b4c6eabe94af067f29d41_D20161101-20161130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-11-01</startDate>
            <endDate>2016-11-30</endDate>
        </period>
    </context>
    <context id="ibb1ab73ec0354946b843823c167cac73_D20161101-20161130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-11-01</startDate>
            <endDate>2016-11-30</endDate>
        </period>
    </context>
    <context id="i9fbce1ec780d49a78a390da0ae5f4c6c_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0a2ac195a36045adacdf507f9366ba39_I20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="i0899d206bf0144cb8f97b035bbc59bdc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iab3199a2232b4c38950a9c717c8b9171_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i3c783d360e1948c18a55f375b9840bca_D20191001-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:ClinigenHealthcareLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i54eac56082574a4c986a915dc06c3af5_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>cpix:Segment</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <dei:DocumentFiscalYearFocus
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80L2ZyYWc6ODk0NTg5NTU0MWNiNGQzYWFjY2U2ZDFkODcxNmI4ODYvdGFibGU6NTczZThlZjFjZTVkNGNkNzljZTcwYWE4ZDQ3OWMyNWMvdGFibGVyYW5nZTo1NzNlOGVmMWNlNWQ0Y2Q3OWNlNzBhYThkNDc5YzI1Y181LTEtMS0xLTk1NTg_cb626646-506a-4773-ac71-5f2cad713dc8">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80L2ZyYWc6ODk0NTg5NTU0MWNiNGQzYWFjY2U2ZDFkODcxNmI4ODYvdGFibGU6NTczZThlZjFjZTVkNGNkNzljZTcwYWE4ZDQ3OWMyNWMvdGFibGVyYW5nZTo1NzNlOGVmMWNlNWQ0Y2Q3OWNlNzBhYThkNDc5YzI1Y182LTEtMS0xLTk1NTg_c6478a7c-da3a-4b2d-a18c-094fdad418d7">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80L2ZyYWc6ODk0NTg5NTU0MWNiNGQzYWFjY2U2ZDFkODcxNmI4ODYvdGFibGU6NTczZThlZjFjZTVkNGNkNzljZTcwYWE4ZDQ3OWMyNWMvdGFibGVyYW5nZTo1NzNlOGVmMWNlNWQ0Y2Q3OWNlNzBhYThkNDc5YzI1Y183LTEtMS0xLTk1NTg_28954d82-22f1-466a-afde-42cf97abdc80">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80L2ZyYWc6ODk0NTg5NTU0MWNiNGQzYWFjY2U2ZDFkODcxNmI4ODYvdGV4dHJlZ2lvbjo4OTQ1ODk1NTQxY2I0ZDNhYWNjZTZkMWQ4NzE2Yjg4Nl83OA_2bdee78c-154e-4d86-88a8-03ce3ee1095d">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityCentralIndexKey
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80L2ZyYWc6ODk0NTg5NTU0MWNiNGQzYWFjY2U2ZDFkODcxNmI4ODYvdGV4dHJlZ2lvbjo4OTQ1ODk1NTQxY2I0ZDNhYWNjZTZkMWQ4NzE2Yjg4Nl83OQ_bfd22206-570a-4a0c-9502-ece83f38b7bb">0001087294</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xL2ZyYWc6M2RkOWU5NmIzN2E5NDFiYmJmZGQzMTAzZmZiYjNmYzQvdGV4dHJlZ2lvbjozZGQ5ZTk2YjM3YTk0MWJiYmZkZDMxMDNmZmJiM2ZjNF8xOTc0_413f7ba7-e2d7-436a-8c53-feb9f8cd07ef">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xL2ZyYWc6M2RkOWU5NmIzN2E5NDFiYmJmZGQzMTAzZmZiYjNmYzQvdGFibGU6ZmZkZGI4YTQ0NDg5NGE1NmJhY2FlNTk3YzhhNjRkYjYvdGFibGVyYW5nZTpmZmRkYjhhNDQ0ODk0YTU2YmFjYWU1OTdjOGE2NGRiNl8wLTAtMS0xLTk1NTg_0193c29b-07e6-4626-b4b6-5b4b054e6863">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xL2ZyYWc6M2RkOWU5NmIzN2E5NDFiYmJmZGQzMTAzZmZiYjNmYzQvdGV4dHJlZ2lvbjozZGQ5ZTk2YjM3YTk0MWJiYmZkZDMxMDNmZmJiM2ZjNF8xMzA_b4ca3137-0810-4842-98d1-620cf0993095">2021-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xL2ZyYWc6M2RkOWU5NmIzN2E5NDFiYmJmZGQzMTAzZmZiYjNmYzQvdGFibGU6YWM5M2U4YzMwNDdiNGJiMGE0MDNhYjdjMzdhZWY4YzAvdGFibGVyYW5nZTphYzkzZThjMzA0N2I0YmIwYTQwM2FiN2MzN2FlZjhjMF8wLTAtMS0xLTk1NTg_ce9f6d89-702f-45c0-8e61-a2522acd25a8">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xL2ZyYWc6M2RkOWU5NmIzN2E5NDFiYmJmZGQzMTAzZmZiYjNmYzQvdGV4dHJlZ2lvbjozZGQ5ZTk2YjM3YTk0MWJiYmZkZDMxMDNmZmJiM2ZjNF8xOTc4_36805ec4-cee7-4afa-801f-1742a659163e">001-33637</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xL2ZyYWc6M2RkOWU5NmIzN2E5NDFiYmJmZGQzMTAzZmZiYjNmYzQvdGV4dHJlZ2lvbjozZGQ5ZTk2YjM3YTk0MWJiYmZkZDMxMDNmZmJiM2ZjNF8xOTY5_4cf731a1-abc1-422a-9c7b-5330e5e0ce7c">Cumberland Pharmaceuticals Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xL2ZyYWc6M2RkOWU5NmIzN2E5NDFiYmJmZGQzMTAzZmZiYjNmYzQvdGFibGU6YTM3MjY2MzViN2FiNGVjZmIzOGE5YzQzM2IwZDMyMjgvdGFibGVyYW5nZTphMzcyNjYzNWI3YWI0ZWNmYjM4YTljNDMzYjBkMzIyOF8wLTAtMS0xLTk1NTg_8583c7e4-a8b7-4425-9c38-63f67826b600">TN</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xL2ZyYWc6M2RkOWU5NmIzN2E5NDFiYmJmZGQzMTAzZmZiYjNmYzQvdGFibGU6YTM3MjY2MzViN2FiNGVjZmIzOGE5YzQzM2IwZDMyMjgvdGFibGVyYW5nZTphMzcyNjYzNWI3YWI0ZWNmYjM4YTljNDMzYjBkMzIyOF8wLTItMS0xLTk1NTg_6f20bc22-eb7c-4658-b1b3-084391b2a373">62-1765329</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xL2ZyYWc6M2RkOWU5NmIzN2E5NDFiYmJmZGQzMTAzZmZiYjNmYzQvdGFibGU6YTM3MjY2MzViN2FiNGVjZmIzOGE5YzQzM2IwZDMyMjgvdGFibGVyYW5nZTphMzcyNjYzNWI3YWI0ZWNmYjM4YTljNDMzYjBkMzIyOF8zLTAtMS0xLTk1NTgvdGV4dHJlZ2lvbjo5ZTFmYTY1YWJjMTY0YmZlOTVlYWE5ZDY1N2EyMTdhNl81_b5979669-f620-46bc-9dbf-9c4cabcab966">2525 West End Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xL2ZyYWc6M2RkOWU5NmIzN2E5NDFiYmJmZGQzMTAzZmZiYjNmYzQvdGFibGU6YTM3MjY2MzViN2FiNGVjZmIzOGE5YzQzM2IwZDMyMjgvdGFibGVyYW5nZTphMzcyNjYzNWI3YWI0ZWNmYjM4YTljNDMzYjBkMzIyOF8zLTAtMS0xLTk1NTgvdGV4dHJlZ2lvbjo5ZTFmYTY1YWJjMTY0YmZlOTVlYWE5ZDY1N2EyMTdhNl85_e78457b9-2afe-4c2b-b82e-2f2567bd5d4c">Suite 950</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xL2ZyYWc6M2RkOWU5NmIzN2E5NDFiYmJmZGQzMTAzZmZiYjNmYzQvdGFibGU6YTM3MjY2MzViN2FiNGVjZmIzOGE5YzQzM2IwZDMyMjgvdGFibGVyYW5nZTphMzcyNjYzNWI3YWI0ZWNmYjM4YTljNDMzYjBkMzIyOF8zLTAtMS0xLTk1NTgvdGV4dHJlZ2lvbjo5ZTFmYTY1YWJjMTY0YmZlOTVlYWE5ZDY1N2EyMTdhNl8xMw_75339330-5a44-452f-9806-700c80e6b3bf">Nashville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xL2ZyYWc6M2RkOWU5NmIzN2E5NDFiYmJmZGQzMTAzZmZiYjNmYzQvdGFibGU6YTM3MjY2MzViN2FiNGVjZmIzOGE5YzQzM2IwZDMyMjgvdGFibGVyYW5nZTphMzcyNjYzNWI3YWI0ZWNmYjM4YTljNDMzYjBkMzIyOF8zLTAtMS0xLTk1NTgvdGV4dHJlZ2lvbjo5ZTFmYTY1YWJjMTY0YmZlOTVlYWE5ZDY1N2EyMTdhNl8xNw_4323f3b1-7adb-4ac9-b793-7e689744eb90">TN</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xL2ZyYWc6M2RkOWU5NmIzN2E5NDFiYmJmZGQzMTAzZmZiYjNmYzQvdGFibGU6YTM3MjY2MzViN2FiNGVjZmIzOGE5YzQzM2IwZDMyMjgvdGFibGVyYW5nZTphMzcyNjYzNWI3YWI0ZWNmYjM4YTljNDMzYjBkMzIyOF8zLTItMS0xLTk1NTg_de47de8e-7def-40af-a663-b858ad864ead">37203</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xL2ZyYWc6M2RkOWU5NmIzN2E5NDFiYmJmZGQzMTAzZmZiYjNmYzQvdGV4dHJlZ2lvbjozZGQ5ZTk2YjM3YTk0MWJiYmZkZDMxMDNmZmJiM2ZjNF8xOTcw_431485a3-0c85-4366-8baf-d5389ef35036">615</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xL2ZyYWc6M2RkOWU5NmIzN2E5NDFiYmJmZGQzMTAzZmZiYjNmYzQvdGV4dHJlZ2lvbjozZGQ5ZTk2YjM3YTk0MWJiYmZkZDMxMDNmZmJiM2ZjNF8xOTc5_d4442311-1438-4c31-8204-2a61f56d85ca">255-0068</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xL2ZyYWc6M2RkOWU5NmIzN2E5NDFiYmJmZGQzMTAzZmZiYjNmYzQvdGFibGU6OGVkMTI3NTMwNjQ2NDJhZjhkMDQ1M2M3Y2JlNDExMTQvdGFibGVyYW5nZTo4ZWQxMjc1MzA2NDY0MmFmOGQwNDUzYzdjYmU0MTExNF8yLTAtMS0xLTk1NTg_dbc6485a-9b04-48d9-ab1e-933fafa8d685">Common stock, no par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xL2ZyYWc6M2RkOWU5NmIzN2E5NDFiYmJmZGQzMTAzZmZiYjNmYzQvdGFibGU6OGVkMTI3NTMwNjQ2NDJhZjhkMDQ1M2M3Y2JlNDExMTQvdGFibGVyYW5nZTo4ZWQxMjc1MzA2NDY0MmFmOGQwNDUzYzdjYmU0MTExNF8yLTItMS0xLTk1NTg_ce24b53b-7247-410b-ad91-432b01c6b5ac">CPIX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xL2ZyYWc6M2RkOWU5NmIzN2E5NDFiYmJmZGQzMTAzZmZiYjNmYzQvdGFibGU6OGVkMTI3NTMwNjQ2NDJhZjhkMDQ1M2M3Y2JlNDExMTQvdGFibGVyYW5nZTo4ZWQxMjc1MzA2NDY0MmFmOGQwNDUzYzdjYmU0MTExNF8yLTQtMS0xLTk1NTg_a291ec19-e1df-41ae-9b90-3e40561e3ef8">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xL2ZyYWc6M2RkOWU5NmIzN2E5NDFiYmJmZGQzMTAzZmZiYjNmYzQvdGV4dHJlZ2lvbjozZGQ5ZTk2YjM3YTk0MWJiYmZkZDMxMDNmZmJiM2ZjNF8xOTcx_a1197e3d-0243-4955-858b-e5861b80cc79">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xL2ZyYWc6M2RkOWU5NmIzN2E5NDFiYmJmZGQzMTAzZmZiYjNmYzQvdGV4dHJlZ2lvbjozZGQ5ZTk2YjM3YTk0MWJiYmZkZDMxMDNmZmJiM2ZjNF8xOTcz_0ecac0a7-c30d-45ed-afd0-a854de4113ed">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xL2ZyYWc6M2RkOWU5NmIzN2E5NDFiYmJmZGQzMTAzZmZiYjNmYzQvdGFibGU6MTlkZWY3YjM0OGE0NGQxMTg0Y2I0MDVkNjk3MTJlOTEvdGFibGVyYW5nZToxOWRlZjdiMzQ4YTQ0ZDExODRjYjQwNWQ2OTcxMmU5MV8xLTAtMS0xLTk1NTg_a13d1c57-8798-413c-b5aa-c8cb048eeeff">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xL2ZyYWc6M2RkOWU5NmIzN2E5NDFiYmJmZGQzMTAzZmZiYjNmYzQvdGFibGU6MTlkZWY3YjM0OGE0NGQxMTg0Y2I0MDVkNjk3MTJlOTEvdGFibGVyYW5nZToxOWRlZjdiMzQ4YTQ0ZDExODRjYjQwNWQ2OTcxMmU5MV8xLTUtMS0xLTk1NTg_e9748f51-9a1a-4a17-b634-37be966893d1">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xL2ZyYWc6M2RkOWU5NmIzN2E5NDFiYmJmZGQzMTAzZmZiYjNmYzQvdGFibGU6MTlkZWY3YjM0OGE0NGQxMTg0Y2I0MDVkNjk3MTJlOTEvdGFibGVyYW5nZToxOWRlZjdiMzQ4YTQ0ZDExODRjYjQwNWQ2OTcxMmU5MV8yLTItMS0xLTk1NTg_821ed55f-0c00-421e-a584-5e383491ef49">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xL2ZyYWc6M2RkOWU5NmIzN2E5NDFiYmJmZGQzMTAzZmZiYjNmYzQvdGV4dHJlZ2lvbjozZGQ5ZTk2YjM3YTk0MWJiYmZkZDMxMDNmZmJiM2ZjNF8xOTcy_0ec90156-7610-4193-b1bb-515ad245e4fb">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i997bd44925334429a7698804c0800bcd_I20211108"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xL2ZyYWc6M2RkOWU5NmIzN2E5NDFiYmJmZGQzMTAzZmZiYjNmYzQvdGV4dHJlZ2lvbjozZGQ5ZTk2YjM3YTk0MWJiYmZkZDMxMDNmZmJiM2ZjNF8xOTM0_ab701435-31e9-4fbd-bbbe-411e26afa1cb"
      unitRef="shares">14809628</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfMy0xLTEtMS05NTU4_787d08f4-2adf-45cf-8ada-8543d9c4b7c2"
      unitRef="usd">25843231</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="idb172cb6365440839665fd6ec022472c_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfMy0zLTEtMS05NTU4_20b75322-7cc4-45af-a7b9-5bad822d5257"
      unitRef="usd">24753796</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfNS0xLTEtMS05NTU4_6164065d-c25f-42e4-aed6-8dd4a5841b0f"
      unitRef="usd">9850530</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="idb172cb6365440839665fd6ec022472c_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfNS0zLTEtMS05NTU4_e5d96494-3cdc-41c5-8e4a-906eb5f179a1"
      unitRef="usd">12377713</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfNi0xLTEtMS05NTU4_4091615e-1774-4c16-aa12-07e5ffc72fe1"
      unitRef="usd">10262769</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="idb172cb6365440839665fd6ec022472c_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfNi0zLTEtMS05NTU4_13de659e-a85f-4081-b06d-3f0c52b59079"
      unitRef="usd">10638157</us-gaap:InventoryNet>
    <us-gaap:OtherAssetsCurrent
      contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfNy0xLTEtMS05NTU4_568cd97a-6a6c-4229-9766-4c44f00313a8"
      unitRef="usd">1259098</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="idb172cb6365440839665fd6ec022472c_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfNy0zLTEtMS05NTU4_b5991ed0-da52-464e-8879-f96ae93c44a2"
      unitRef="usd">2199926</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfOC0xLTEtMS05NTU4_4f9a7cdd-26b3-4189-ab38-3d0c2752e571"
      unitRef="usd">47215628</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="idb172cb6365440839665fd6ec022472c_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfOC0zLTEtMS05NTU4_65f340e6-74d7-4cfb-8680-658c8b0c7355"
      unitRef="usd">49969592</us-gaap:AssetsCurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfOS0xLTEtMS05NTU4_0a7c4539-54b6-4642-9ec1-09646f9defe7"
      unitRef="usd">9476737</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="idb172cb6365440839665fd6ec022472c_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfOS0zLTEtMS05NTU4_a3509e15-8629-4f7b-bfda-f1d4dc62d644"
      unitRef="usd">11656742</us-gaap:InventoryNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfMTAtMS0xLTEtOTU1OA_004f0d13-8464-41b7-9449-bf9485368979"
      unitRef="usd">493488</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="idb172cb6365440839665fd6ec022472c_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfMTAtMy0xLTEtOTU1OA_c827415f-8dde-4bd9-9046-8ad08abe9049"
      unitRef="usd">574169</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfMTEtMS0xLTEtOTU1OA_920a2aaf-4d92-4bf8-a5dc-58ff9573a845"
      unitRef="usd">24918830</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="idb172cb6365440839665fd6ec022472c_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfMTEtMy0xLTEtOTU1OA_1a9fc573-d3af-4646-aafd-ca0c7bba6963"
      unitRef="usd">28118316</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:Goodwill
      contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfMTItMS0xLTEtOTU1OA_7254f054-db53-436c-9ae6-407968371295"
      unitRef="usd">882000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="idb172cb6365440839665fd6ec022472c_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfMTItMy0xLTEtOTU1OA_713236f1-498e-41a5-9fa9-38897a12caf9"
      unitRef="usd">882000</us-gaap:Goodwill>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfMTMtMS0xLTEtOTU1OA_03898100-deee-4659-8993-7d7a00a7e0cb"
      unitRef="usd">1282275</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="idb172cb6365440839665fd6ec022472c_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfMTMtMy0xLTEtOTU1OA_863fa60a-3bd3-4571-9ab0-fd2514ae1214"
      unitRef="usd">2028148</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfMTQtMS0xLTEtOTU1OA_801dd865-0a0e-49e3-bc13-7bd89a23b7d2"
      unitRef="usd">3301816</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="idb172cb6365440839665fd6ec022472c_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfMTQtMy0xLTEtOTU1OA_3f1cd0a6-9066-4941-82a0-79fd010cd287"
      unitRef="usd">3234338</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfMTUtMS0xLTEtOTU1OA_6706308c-7f71-4f21-972f-a8ad2870ec2e"
      unitRef="usd">87570774</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="idb172cb6365440839665fd6ec022472c_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfMTUtMy0xLTEtOTU1OA_82aecfa9-2487-419d-a33e-917eac28150e"
      unitRef="usd">96463305</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfMTgtMS0xLTEtOTU1OA_e8ba911c-7e76-467c-b067-eb434552668d"
      unitRef="usd">9233383</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="idb172cb6365440839665fd6ec022472c_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfMTgtMy0xLTEtOTU1OA_be938f19-8780-42e5-8abd-ed1477094964"
      unitRef="usd">13396286</us-gaap:AccountsPayableCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfMTktMS0xLTEtOTU1OA_2e433f39-34c1-4921-a1eb-2c04de7596b4"
      unitRef="usd">1094187</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="idb172cb6365440839665fd6ec022472c_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfMTktMy0xLTEtOTU1OA_bf87e2d5-b8e2-423f-a2f7-8d0c2eb7ad8b"
      unitRef="usd">1016779</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfMjAtMS0xLTEtOTU1OA_3a3e9276-4446-462c-a7f5-4e7eef72aa6d"
      unitRef="usd">7617913</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="idb172cb6365440839665fd6ec022472c_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfMjAtMy0xLTEtOTU1OA_725654e5-26d7-4902-9849-bd17c75541fc"
      unitRef="usd">11254381</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfMjEtMS0xLTEtOTU1OA_d3d1b324-a332-4b6d-a876-cb7d8d486075"
      unitRef="usd">17945483</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="idb172cb6365440839665fd6ec022472c_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfMjEtMy0xLTEtOTU1OA_b49161b8-b618-488e-b4a6-773df0e33080"
      unitRef="usd">25667446</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermLineOfCredit
      contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfMjItMS0xLTEtOTU1OA_af71ed23-ef84-4ab4-95f6-8d24a4bf3e9c"
      unitRef="usd">15000000</us-gaap:LongTermLineOfCredit>
    <us-gaap:LongTermLineOfCredit
      contextRef="idb172cb6365440839665fd6ec022472c_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfMjItMy0xLTEtOTU1OA_7a2cac12-dbbc-42cb-9a68-445a8d1da521"
      unitRef="usd">15000000</us-gaap:LongTermLineOfCredit>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfMjMtMS0xLTEtOTU1OA_ac21f239-47a9-4048-b4e5-fb6a30904c23"
      unitRef="usd">229605</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="idb172cb6365440839665fd6ec022472c_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfMjMtMy0xLTEtOTU1OA_04dacca8-58ff-48be-bfca-d19061523658"
      unitRef="usd">1059693</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <cpix:OtherLongTermObligationsExcludingCurrentPortion
      contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfMjQtMS0xLTEtOTU1OA_c19e5623-3ca3-42df-8206-a6ce00f2578f"
      unitRef="usd">7749421</cpix:OtherLongTermObligationsExcludingCurrentPortion>
    <cpix:OtherLongTermObligationsExcludingCurrentPortion
      contextRef="idb172cb6365440839665fd6ec022472c_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfMjQtMy0xLTEtOTU1OA_a62c5665-b11d-4da6-a66d-afb64849d36e"
      unitRef="usd">7862772</cpix:OtherLongTermObligationsExcludingCurrentPortion>
    <us-gaap:Liabilities
      contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfMjUtMS0xLTEtOTU1OA_73ff469a-33c7-4e34-b6de-c03e5cbf5c37"
      unitRef="usd">40924509</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="idb172cb6365440839665fd6ec022472c_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfMjUtMy0xLTEtOTU1OA_21c45af4-7bbb-4e9f-93c5-e8cc48452fdc"
      unitRef="usd">49589911</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfMjYtMS0xLTEtOTU1OA_66f332c8-513c-4391-89f7-80f43f532cdc"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="idb172cb6365440839665fd6ec022472c_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfMjYtMy0xLTEtOTU1OA_339a1c3d-e189-4d33-8982-7a811ac1d9a2"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockNoParValue
      contextRef="idb172cb6365440839665fd6ec022472c_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfMjktMC0xLTEtOTU1OC90ZXh0cmVnaW9uOjVjNjY5YmEwMWIwNzRiZWE5ZWZmYWFhMWRlZDI3YmRhXzE3_9a3bc384-8dfc-4d87-8e86-c41e535e62b9"
      unitRef="usdPerShare">0</us-gaap:CommonStockNoParValue>
    <us-gaap:CommonStockNoParValue
      contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfMjktMC0xLTEtOTU1OC90ZXh0cmVnaW9uOjVjNjY5YmEwMWIwNzRiZWE5ZWZmYWFhMWRlZDI3YmRhXzE3_d7c4882b-b860-43a2-8bfd-14b2f3796291"
      unitRef="usdPerShare">0</us-gaap:CommonStockNoParValue>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfMjktMC0xLTEtOTU1OC90ZXh0cmVnaW9uOjVjNjY5YmEwMWIwNzRiZWE5ZWZmYWFhMWRlZDI3YmRhXzMx_1c740f40-7da7-456f-95fa-9268f3238850"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="idb172cb6365440839665fd6ec022472c_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfMjktMC0xLTEtOTU1OC90ZXh0cmVnaW9uOjVjNjY5YmEwMWIwNzRiZWE5ZWZmYWFhMWRlZDI3YmRhXzMx_53125269-be7e-42ef-9921-6f2a51910e59"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfMjktMC0xLTEtOTU1OC90ZXh0cmVnaW9uOjVjNjY5YmEwMWIwNzRiZWE5ZWZmYWFhMWRlZDI3YmRhXzUz_6b190ba3-e572-4622-ba7a-b37fdcadfb15"
      unitRef="shares">14850526</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfMjktMC0xLTEtOTU1OC90ZXh0cmVnaW9uOjVjNjY5YmEwMWIwNzRiZWE5ZWZmYWFhMWRlZDI3YmRhXzUz_bb67aab8-19d8-476d-8916-e107f319fb15"
      unitRef="shares">14850526</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="idb172cb6365440839665fd6ec022472c_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfMjktMC0xLTEtOTU1OC90ZXh0cmVnaW9uOjVjNjY5YmEwMWIwNzRiZWE5ZWZmYWFhMWRlZDI3YmRhXzYw_4c6882e3-b738-41e7-a85b-56aacaf9ed05"
      unitRef="shares">14988429</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="idb172cb6365440839665fd6ec022472c_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfMjktMC0xLTEtOTU1OC90ZXh0cmVnaW9uOjVjNjY5YmEwMWIwNzRiZWE5ZWZmYWFhMWRlZDI3YmRhXzYw_8d49a5ab-c46e-42ea-a4f8-80205bda09b4"
      unitRef="shares">14988429</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfMjktMS0xLTEtOTU1OA_9c6d8501-d714-4356-87c0-7924d6ddc4ef"
      unitRef="usd">48612935</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="idb172cb6365440839665fd6ec022472c_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfMjktMy0xLTEtOTU1OA_769b8ef2-f306-486a-9e63-a06957175847"
      unitRef="usd">49121523</us-gaap:CommonStockValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfMzAtMS0xLTEtOTU1OA_3b15b693-c359-4ce7-b87f-511e55fa1eef"
      unitRef="usd">-1790903</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="idb172cb6365440839665fd6ec022472c_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfMzAtMy0xLTEtOTU1OA_5d68e1b4-1c75-4931-a323-8e5fc3315e24"
      unitRef="usd">-2131013</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfMzEtMS0xLTEtOTU1OA_c5e3a62d-c398-4bf2-bdea-affe7c7df09f"
      unitRef="usd">46822032</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idb172cb6365440839665fd6ec022472c_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfMzEtMy0xLTEtOTU1OA_c9407c7c-e82b-42a2-ab9c-ea2529d40ef9"
      unitRef="usd">46990510</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfMzItMS0xLTEtOTU1OA_cad970f6-47ee-4c47-b6c9-68e9a38d0b2f"
      unitRef="usd">-175767</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="idb172cb6365440839665fd6ec022472c_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfMzItMy0xLTEtOTU1OA_1ea42f2e-d2d2-4282-b4f5-ac7cb8cbeda9"
      unitRef="usd">-117116</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfMzMtMS0xLTEtOTU1OA_423074bc-2abb-4837-80ba-f1b03dfed65d"
      unitRef="usd">46646265</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idb172cb6365440839665fd6ec022472c_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfMzMtMy0xLTEtOTU1OA_0ee8ed29-747b-41b1-85ea-72ef916138ac"
      unitRef="usd">46873394</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfMzQtMS0xLTEtOTU1OA_0ab55b8c-68bc-426b-8dd2-9ef966d2fbfe"
      unitRef="usd">87570774</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="idb172cb6365440839665fd6ec022472c_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xNi9mcmFnOjFjODBkZjVjNWZjYzQ1ZmM5NTFmODhlNGUzYjZlN2YzL3RhYmxlOjk5MmE0M2QzNThjYjRmNzZhOTVhZDk3MTlkYjBkZWJjL3RhYmxlcmFuZ2U6OTkyYTQzZDM1OGNiNGY3NmE5NWFkOTcxOWRiMGRlYmNfMzQtMy0xLTEtOTU1OA_72a379ed-af9c-48c1-b7a0-22bff9f116e2"
      unitRef="usd">96463305</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5cfdffb6c8a4411a95e4596b0bd91b7c_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMi0xLTEtMS05NTU4_6f46574a-47f1-4e7e-83a2-11d516edf5df"
      unitRef="usd">8072540</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie2722c94900c4f68be9dd446637b8348_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMi0zLTEtMS05NTU4_781307c7-4873-440a-a67f-16f5e8051428"
      unitRef="usd">9250689</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMi01LTEtMS05NTU4_8fe8b1e2-7d0e-48d4-832c-abcbb47375bc"
      unitRef="usd">27665182</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMi03LTEtMS05NTU4_b207bca1-855a-42c8-a38f-b516c62c0810"
      unitRef="usd">27179600</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i5cfdffb6c8a4411a95e4596b0bd91b7c_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfNC0xLTEtMS05NTU4_30ab3989-a784-4170-8210-f4be533b3726"
      unitRef="usd">1328027</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ie2722c94900c4f68be9dd446637b8348_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfNC0zLTEtMS05NTU4_1c21b574-e3de-4cec-ad57-4f7203ac943f"
      unitRef="usd">2142839</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfNC01LTEtMS05NTU4_2b82165b-3391-40fe-a80f-40a5f1978c1e"
      unitRef="usd">5486005</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfNC03LTEtMS05NTU4_e0b06033-3b40-42d4-9e09-9da2d367ea4e"
      unitRef="usd">6387002</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:SellingAndMarketingExpense
      contextRef="i5cfdffb6c8a4411a95e4596b0bd91b7c_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfNS0xLTEtMS05NTU4_d52d2797-a9a4-423f-8498-e0bc613433b4"
      unitRef="usd">3800288</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="ie2722c94900c4f68be9dd446637b8348_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfNS0zLTEtMS05NTU4_f398d241-1297-4a49-8c83-c0fda68dc2e6"
      unitRef="usd">3587842</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfNS01LTEtMS05NTU4_1e12fbb7-fcb2-46f9-a167-e40e704bcd35"
      unitRef="usd">11709445</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfNS03LTEtMS05NTU4_5730eef7-534c-4101-962f-a45a5ba9752c"
      unitRef="usd">11160924</us-gaap:SellingAndMarketingExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i5cfdffb6c8a4411a95e4596b0bd91b7c_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfNi0xLTEtMS05NTU4_05867931-330e-4627-af39-5446206d6911"
      unitRef="usd">1453873</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ie2722c94900c4f68be9dd446637b8348_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfNi0zLTEtMS05NTU4_2e927709-7a9e-45c2-971b-eedb8d26f8cd"
      unitRef="usd">1230335</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfNi01LTEtMS05NTU4_3c87e122-3c97-43b7-b1da-8b80290d7f0a"
      unitRef="usd">4071638</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfNi03LTEtMS05NTU4_707984ff-0726-49c9-bee3-3fb751c02d13"
      unitRef="usd">4374392</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i5cfdffb6c8a4411a95e4596b0bd91b7c_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfNy0xLTEtMS05NTU4_7ad913a9-6ea3-457d-a36c-183a1bc3f50e"
      unitRef="usd">2039799</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ie2722c94900c4f68be9dd446637b8348_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfNy0zLTEtMS05NTU4_cd118aae-c492-4977-9b43-f06bef4041a6"
      unitRef="usd">2381273</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfNy01LTEtMS05NTU4_51a66d19-bed2-4820-943b-44d902fd58d7"
      unitRef="usd">6367438</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfNy03LTEtMS05NTU4_2dea87ad-3e9a-4662-a320-d4b528758da6"
      unitRef="usd">6608321</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i5cfdffb6c8a4411a95e4596b0bd91b7c_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfOC0xLTEtMS05NTU4_9eddcd2e-8186-4a8b-83dc-8a4d3cdabb2d"
      unitRef="usd">1013948</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ie2722c94900c4f68be9dd446637b8348_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfOC0zLTEtMS05NTU4_a8010101-60c6-47cc-bc0d-16bc9147d98f"
      unitRef="usd">1117086</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfOC01LTEtMS05NTU4_cefad2e7-9dff-44fd-bdce-dfe606df4451"
      unitRef="usd">3354080</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfOC03LTEtMS05NTU4_887a51b6-b6be-4f90-b32b-ea605eea9dec"
      unitRef="usd">3284610</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:CostsAndExpenses
      contextRef="i5cfdffb6c8a4411a95e4596b0bd91b7c_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfOS0xLTEtMS05NTU4_9c2c75c1-9664-463c-b7ef-84f47727fa13"
      unitRef="usd">9635935</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ie2722c94900c4f68be9dd446637b8348_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfOS0zLTEtMS05NTU4_30f0355f-3abd-47b9-b804-f2432eeab0bc"
      unitRef="usd">10459375</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfOS01LTEtMS05NTU4_91cbb7d5-4f2f-4682-9016-39e0ee0e3387"
      unitRef="usd">30988606</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfOS03LTEtMS05NTU4_10c21e8b-bb5c-47c1-927b-370d46368b2a"
      unitRef="usd">31815249</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i5cfdffb6c8a4411a95e4596b0bd91b7c_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMTAtMS0xLTEtOTU1OA_ae1a9867-e350-43ac-bfe5-1bea13f9f96e"
      unitRef="usd">-1563395</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ie2722c94900c4f68be9dd446637b8348_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMTAtMy0xLTEtOTU1OA_aed8b499-3963-46c0-8e86-e674dbcf5105"
      unitRef="usd">-1208686</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMTAtNS0xLTEtOTU1OA_7f0a5665-0b83-4f2a-bc2b-9d5a18a632c0"
      unitRef="usd">-3323424</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMTAtNy0xLTEtOTU1OA_285e5679-4ce2-4028-bb45-76b0e4029e6f"
      unitRef="usd">-4635649</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i5cfdffb6c8a4411a95e4596b0bd91b7c_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMTEtMS0xLTEtOTU1OA_b79c0005-d793-42ad-8871-3e5affea3b4c"
      unitRef="usd">7394</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ie2722c94900c4f68be9dd446637b8348_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMTEtMy0xLTEtOTU1OA_33714327-17f9-432a-bbd7-05e7bdb63b6b"
      unitRef="usd">12004</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMTEtNS0xLTEtOTU1OA_e5c8d4b5-17d5-4c4a-8a7f-2f627a542e07"
      unitRef="usd">19411</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMTEtNy0xLTEtOTU1OA_41104900-f351-491a-bab1-b30b9fd15234"
      unitRef="usd">70553</us-gaap:InvestmentIncomeInterest>
    <us-gaap:OtherIncome
      contextRef="i5cfdffb6c8a4411a95e4596b0bd91b7c_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMTItMS0xLTEtOTU1OA_dd85f6d7-3a80-400d-b618-f051b8483b96"
      unitRef="usd">0</us-gaap:OtherIncome>
    <us-gaap:OtherIncome
      contextRef="ie2722c94900c4f68be9dd446637b8348_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMTItMy0xLTEtOTU1OA_9d09f8e6-d7c4-4f40-a2a4-b171d5f6123e"
      unitRef="usd">0</us-gaap:OtherIncome>
    <us-gaap:OtherIncome
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMTItNS0xLTEtOTU1OA_0e4fd688-c910-4bc8-a68f-9b8c0c944e76"
      unitRef="usd">2187140</us-gaap:OtherIncome>
    <us-gaap:OtherIncome
      contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMTItNy0xLTEtOTU1OA_55a923b2-ca81-4b0e-a82e-ebace9edccc2"
      unitRef="usd">0</us-gaap:OtherIncome>
    <us-gaap:InterestExpense
      contextRef="i5cfdffb6c8a4411a95e4596b0bd91b7c_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMTMtMS0xLTEtOTU1OA_67f8592b-00b5-4034-a33b-ecd29f48ef95"
      unitRef="usd">20021</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ie2722c94900c4f68be9dd446637b8348_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMTMtMy0xLTEtOTU1OA_1ddd391c-88a9-4c1f-bbe0-4f9e226a4b32"
      unitRef="usd">75210</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMTMtNS0xLTEtOTU1OA_65623fa4-671a-43c5-bde5-8562e9b49515"
      unitRef="usd">70297</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMTMtNy0xLTEtOTU1OA_bc5b3654-4886-420f-a374-45cc9684a22a"
      unitRef="usd">227730</us-gaap:InterestExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i5cfdffb6c8a4411a95e4596b0bd91b7c_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMTQtMS0xLTEtOTU1OA_0c797158-a708-4ac6-8d37-0262cd0dd6fa"
      unitRef="usd">-1576022</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ie2722c94900c4f68be9dd446637b8348_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMTQtMy0xLTEtOTU1OA_2569ea11-8714-4d6c-baf4-e91df255bc78"
      unitRef="usd">-1271892</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMTQtNS0xLTEtOTU1OA_5e69759b-231d-41c7-ba19-5564cd6e1ce0"
      unitRef="usd">-1187170</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMTQtNy0xLTEtOTU1OA_8b452270-9963-4838-9755-92ce0bae4762"
      unitRef="usd">-4792826</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i5cfdffb6c8a4411a95e4596b0bd91b7c_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMTUtMS0xLTEtOTU1OA_b869375d-639f-4754-abf2-01920f3599d8"
      unitRef="usd">7458</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ie2722c94900c4f68be9dd446637b8348_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMTUtMy0xLTEtOTU1OA_aa81b9db-f796-42d9-83d8-c60ef02c0315"
      unitRef="usd">3728</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMTUtNS0xLTEtOTU1OA_30ff0664-3748-402f-8681-afd87fbec2c7"
      unitRef="usd">22375</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMTUtNy0xLTEtOTU1OA_335dcc55-efaa-477d-9b65-d9261b0045d2"
      unitRef="usd">45423</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5cfdffb6c8a4411a95e4596b0bd91b7c_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMTYtMS0xLTEtOTU1OA_3656b68a-e37c-4633-8dd8-a003efd3e39e"
      unitRef="usd">-1583480</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie2722c94900c4f68be9dd446637b8348_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMTYtMy0xLTEtOTU1OA_ec6850d2-e817-4b14-9487-ff3e910e4c91"
      unitRef="usd">-1275620</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMTYtNS0xLTEtOTU1OA_4c64bffd-ba77-41a6-8d18-51bfc653c845"
      unitRef="usd">-1209545</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMTYtNy0xLTEtOTU1OA_85fb5be7-0aae-4020-9da3-9e25c9015f6a"
      unitRef="usd">-4838249</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ieb58760ea84940319b35492cd1910735_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMTctMS0xLTEtOTU1OA_86849bd9-9c34-42dc-a4b6-2061e77af27b"
      unitRef="usd">496787</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifca7f9fa06d14f85a52cbd81ac170d2c_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMTctMy0xLTEtOTU1OA_0fe8db84-b272-4c9f-a304-4c34cd7b14a3"
      unitRef="usd">777916</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i45bdfab35dd74d60ac86fc023b908b73_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMTctNS0xLTEtOTU1OA_1acd7b61-10d3-4d57-a3bb-db27abac79f0"
      unitRef="usd">1491004</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib8c8802e62b74a919450a1c6017bba7e_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMTctNy0xLTEtOTU1OA_841b8fa5-722e-49de-805f-6e1ba99049bf"
      unitRef="usd">2334811</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ProfitLoss
      contextRef="i5cfdffb6c8a4411a95e4596b0bd91b7c_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMTgtMS0xLTEtOTU1OA_ff808f60-a689-42b1-b71a-d3683b123ee4"
      unitRef="usd">-1086693</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ie2722c94900c4f68be9dd446637b8348_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMTgtMy0xLTEtOTU1OA_4509f6be-b34d-4bbe-b84e-cdb293c90119"
      unitRef="usd">-497704</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMTgtNS0xLTEtOTU1OA_ae2476e8-c4f3-48c3-8213-5c212995ddb4"
      unitRef="usd">281459</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMTgtNy0xLTEtOTU1OA_3a624214-4eec-4a5b-928a-eb7a9881e84b"
      unitRef="usd">-2503438</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i5cfdffb6c8a4411a95e4596b0bd91b7c_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMTktMS0xLTEtOTU1OA_95b61dfc-d977-4115-94c6-54e0d0af5a99"
      unitRef="usd">-31415</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ie2722c94900c4f68be9dd446637b8348_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMTktMy0xLTEtOTU1OA_2141b745-6e38-4f81-959c-3756a18c45c0"
      unitRef="usd">-15967</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMTktNS0xLTEtOTU1OA_ce0a12c3-7567-454b-93ce-355822e98dea"
      unitRef="usd">-58651</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMTktNy0xLTEtOTU1OA_f17bcff7-0f96-4279-931e-32336eb1034d"
      unitRef="usd">-47806</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i5cfdffb6c8a4411a95e4596b0bd91b7c_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMjAtMS0xLTEtOTU1OA_8e25e5e8-98f3-44fe-bcfe-7cb6ae67a6e0"
      unitRef="usd">-1055278</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie2722c94900c4f68be9dd446637b8348_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMjAtMy0xLTEtOTU1OA_4df57ef8-bc72-4d47-97d5-a0535ac6e0d4"
      unitRef="usd">-481737</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMjAtNS0xLTEtOTU1OA_5cb25c6b-5d1e-43e1-a9db-72676163fbcd"
      unitRef="usd">340110</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMjAtNy0xLTEtOTU1OA_f7aef4bc-6f7d-491b-8a3f-1c613544acf4"
      unitRef="usd">-2455632</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i5cfdffb6c8a4411a95e4596b0bd91b7c_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMjItMS0xLTEtOTU1OA_c3ee7aaf-3a59-42cd-940a-86344d472155"
      unitRef="usdPerShare">-0.10</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="ie2722c94900c4f68be9dd446637b8348_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMjItMy0xLTEtOTU1OA_e9a75676-a793-4eb3-85fb-048dbf56209e"
      unitRef="usdPerShare">-0.08</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMjItNS0xLTEtOTU1OA_b0a294d3-17b1-4601-a366-4fe9f21c4be0"
      unitRef="usdPerShare">-0.08</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMjItNy0xLTEtOTU1OA_cda5bd02-15e1-473c-812c-74665fa1fe4d"
      unitRef="usdPerShare">-0.31</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i5cfdffb6c8a4411a95e4596b0bd91b7c_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMjMtMS0xLTEtOTU1OA_37f3b733-baaf-4885-bf03-c35f039ca671"
      unitRef="usdPerShare">0.03</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="ie2722c94900c4f68be9dd446637b8348_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMjMtMy0xLTEtOTU1OA_bab9de8c-5909-4833-b95a-6100886a552d"
      unitRef="usdPerShare">0.05</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMjMtNS0xLTEtOTU1OA_928e6367-0e20-47fc-9aa7-165419cb71eb"
      unitRef="usdPerShare">0.10</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMjMtNy0xLTEtOTU1OA_a5dbfd8d-da81-4d2e-99b3-639e22d701d2"
      unitRef="usdPerShare">0.15</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:EarningsPerShareBasic
      contextRef="i5cfdffb6c8a4411a95e4596b0bd91b7c_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMjQtMS0xLTEtOTU1OA_faad5f17-3f38-4945-98da-5539c2be542d"
      unitRef="usdPerShare">-0.07</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ie2722c94900c4f68be9dd446637b8348_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMjQtMy0xLTEtOTU1OA_86b37b93-22c3-4dfd-bfe1-cd362d65aa78"
      unitRef="usdPerShare">-0.03</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMjQtNS0xLTEtOTU1OA_a166b8d6-4829-434d-b0a4-41dcc0e1ab67"
      unitRef="usdPerShare">0.02</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMjQtNy0xLTEtOTU1OA_989cb314-176e-4a6d-903b-7ce71e9e7714"
      unitRef="usdPerShare">-0.16</us-gaap:EarningsPerShareBasic>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i5cfdffb6c8a4411a95e4596b0bd91b7c_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMjYtMS0xLTEtOTU1OA_2551170e-c478-440a-807a-3ecc39c0c8e9"
      unitRef="usdPerShare">-0.10</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="ie2722c94900c4f68be9dd446637b8348_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMjYtMy0xLTEtOTU1OA_e55be91d-017f-4f3b-8125-0783557edcc2"
      unitRef="usdPerShare">-0.08</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMjYtNS0xLTEtOTU1OA_ed699d40-1314-4c13-bdb5-9ff9f8c481c8"
      unitRef="usdPerShare">-0.08</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMjYtNy0xLTEtOTU1OA_65b47aa0-3662-4ea9-9da8-c2b69a32a832"
      unitRef="usdPerShare">-0.31</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i5cfdffb6c8a4411a95e4596b0bd91b7c_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMjctMS0xLTEtOTU1OA_9765f3af-225f-496c-97ee-9241f98051c2"
      unitRef="usdPerShare">0.03</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="ie2722c94900c4f68be9dd446637b8348_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMjctMy0xLTEtOTU1OA_15fc1ada-b89e-4061-a698-326ecf4cfdb3"
      unitRef="usdPerShare">0.05</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMjctNS0xLTEtOTU1OA_b4bac775-1172-46db-b64d-6c3011ba516d"
      unitRef="usdPerShare">0.10</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMjctNy0xLTEtOTU1OA_3624f2a6-007b-41dc-ac2a-0f85f44e9264"
      unitRef="usdPerShare">0.15</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i5cfdffb6c8a4411a95e4596b0bd91b7c_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMjgtMS0xLTEtOTU1OA_07e652a8-0c5b-47b7-9c3a-111848dece26"
      unitRef="usdPerShare">-0.07</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ie2722c94900c4f68be9dd446637b8348_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMjgtMy0xLTEtOTU1OA_fe830645-ab82-48af-85e3-456b5dcbc53d"
      unitRef="usdPerShare">-0.03</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMjgtNS0xLTEtOTU1OA_51ea79d0-37ad-4ad4-8e73-5b994ed87c28"
      unitRef="usdPerShare">0.02</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMjgtNy0xLTEtOTU1OA_0307a832-9abe-4cc4-8ea6-470da96f1710"
      unitRef="usdPerShare">-0.16</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i5cfdffb6c8a4411a95e4596b0bd91b7c_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMzAtMS0xLTEtOTU1OA_b5e1a767-1b86-4012-89bc-7628a19420c8"
      unitRef="shares">14880887</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ie2722c94900c4f68be9dd446637b8348_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMzAtMy0xLTEtOTU1OA_7ddc136a-92bb-439a-a38a-0bfad779387e"
      unitRef="shares">15134583</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMzAtNS0xLTEtOTU1OA_8cdb33ce-1515-4327-ae98-f1d30f78e45a"
      unitRef="shares">14939919</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMzAtNy0xLTEtOTU1OA_3cebfc23-7264-4ddc-9953-b2de72843968"
      unitRef="shares">15206179</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i5cfdffb6c8a4411a95e4596b0bd91b7c_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMzEtMS0xLTEtOTU1OA_206d45ec-0dfd-4dad-a09c-708e034903c8"
      unitRef="shares">14880887</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ie2722c94900c4f68be9dd446637b8348_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMzEtMy0xLTEtOTU1OA_3069879d-a3f8-4c09-bc47-66a88a16ffee"
      unitRef="shares">15134583</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMzEtNS0xLTEtOTU1OA_680872eb-8fa6-4a35-8e4b-96a35c60f7b4"
      unitRef="shares">15139904</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8xOS9mcmFnOjJjNzgxMTExNjhiNzQ4ZmM4NDAyMWNiYWEzM2M3NDBhL3RhYmxlOmVkYWExN2U2OTVkZDRhNTE4ZWJiMTc0ZGU4MzQxYmViL3RhYmxlcmFuZ2U6ZWRhYTE3ZTY5NWRkNGE1MThlYmIxNzRkZTgzNDFiZWJfMzEtNy0xLTEtOTU1OA_74c47ba6-d296-4d83-a36d-d18b2064f105"
      unitRef="shares">15206179</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ProfitLoss
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfMy0xLTEtMS05NTU4_89bfef20-b1e6-47a1-9dc7-06a201e0829a"
      unitRef="usd">281459</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfMy0zLTEtMS05NTU4_fee615d1-5da9-49f1-89bc-c9c0d4a4e145"
      unitRef="usd">-2503438</us-gaap:ProfitLoss>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfNC0xLTEtMS05NTU4_34dd9ba9-dc08-41b3-82bc-363744572af1"
      unitRef="usd">1491004</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfNC0zLTEtMS05NTU4_5d8096f7-9702-46a6-93db-e69127d604a8"
      unitRef="usd">2334811</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfNS0xLTEtMS05NTU4_5f0e04d7-a344-4a4b-9c88-542330d012a4"
      unitRef="usd">-1209545</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfNS0zLTEtMS05NTU4_960860b7-f805-41c7-895a-ac3c5e8bf7e7"
      unitRef="usd">-4838249</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfNy0xLTEtMS05NTU4_ee98fdcd-e62c-4b78-a6f6-82432089e45e"
      unitRef="usd">3529245</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfNy0zLTEtMS05NTU4_c94fdef7-2015-4ca1-ac13-6e31fcd40fd2"
      unitRef="usd">3524684</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfOC0xLTEtMS05NTU4_a3a99d85-8b3f-4c71-b706-09dbc9f771e0"
      unitRef="usd">517081</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfOC0zLTEtMS05NTU4_7ad89641-b6e2-4fd2-a657-a14bc60fad4f"
      unitRef="usd">805338</us-gaap:ShareBasedCompensation>
    <us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfOS0xLTEtMS05NTU4_4e9f354a-5943-4277-a009-e945dcf7cb59"
      unitRef="usd">632646</us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities>
    <us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities
      contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfOS0zLTEtMS05NTU4_0e2e4688-563d-479b-87bd-e057de35e705"
      unitRef="usd">806390</us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities>
    <cpix:IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfMTAtMS0xLTEtOTU1OA_9afe2f51-0b85-42b2-9a50-dbbce7721d86"
      unitRef="usd">52070</cpix:IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy>
    <cpix:IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy
      contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfMTAtMy0xLTEtOTU1OA_33d45e09-c9b4-436b-9181-f8a415404be2"
      unitRef="usd">-169406</cpix:IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfMTEtMS0xLTEtOTU1OA_9ebcbfae-b3f1-4dd6-9460-56a8bb51eefe"
      unitRef="usd">33943</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfMTEtMy0xLTEtOTU1OA_e65dfc73-2a12-4051-ad8f-221d3db3618d"
      unitRef="usd">36197</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfMTItMS0xLTEtOTU1OA_a4383df0-61d1-447f-af4c-33329a82adb5"
      unitRef="usd">2187140</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfMTItMy0xLTEtOTU1OA_40ed77d8-fec4-414d-a305-19e4a0be869b"
      unitRef="usd">0</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfMTQtMS0xLTEtOTU1OA_2e2d328c-bd25-44f4-9295-f1401a59a137"
      unitRef="usd">-2527183</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfMTQtMy0xLTEtOTU1OA_b0ea097f-859d-472a-8adb-5d2e95b91f6b"
      unitRef="usd">1817490</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfMTUtMS0xLTEtOTU1OA_57d3a116-49a7-439a-89e8-e5e19e852dd6"
      unitRef="usd">-2555393</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfMTUtMy0xLTEtOTU1OA_a03c6e2d-7ef8-4f3b-82ac-4a8639060a8d"
      unitRef="usd">-1696668</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfMTYtMS0xLTEtOTU1OA_9310532c-e3ef-4b11-9d1a-3db005ddf056"
      unitRef="usd">-1627350</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfMTYtMy0xLTEtOTU1OA_ce8bf223-c5ed-4abe-a55f-0c73f0333954"
      unitRef="usd">-1962024</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <cpix:IncreaseDecreaseInCurrentOperatingLiabilities
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfMTctMS0xLTEtOTU1OA_f73493d4-2516-49ec-8d56-5424edcf497a"
      unitRef="usd">-2873596</cpix:IncreaseDecreaseInCurrentOperatingLiabilities>
    <cpix:IncreaseDecreaseInCurrentOperatingLiabilities
      contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfMTctMy0xLTEtOTU1OA_90aee167-8384-48a9-b892-c44c544c27f9"
      unitRef="usd">3248450</cpix:IncreaseDecreaseInCurrentOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfMTgtMS0xLTEtOTU1OA_0fb1458a-c29a-41df-a17b-c96348b3efa4"
      unitRef="usd">-943439</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfMTgtMy0xLTEtOTU1OA_62404fce-cf1b-44c8-ab3e-c0704d7899d9"
      unitRef="usd">-1585584</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfMTktMS0xLTEtOTU1OA_3bf04005-f194-4bbd-9382-7d432fd4761a"
      unitRef="usd">2891759</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
      contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfMTktMy0xLTEtOTU1OA_c76cd51f-6dd2-4cd4-87e6-10a6acff5d68"
      unitRef="usd">2395054</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfMjAtMS0xLTEtOTU1OA_e654619d-3272-4f04-b314-4c818df3b60e"
      unitRef="usd">1491004</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
      contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfMjAtMy0xLTEtOTU1OA_d3129d7a-782c-4e0c-91fc-872a74d1f0d0"
      unitRef="usd">2166086</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfMjEtMS0xLTEtOTU1OA_870ac2ae-ade4-471d-852e-ec36975d6c63"
      unitRef="usd">4382763</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfMjEtMy0xLTEtOTU1OA_da16e351-3095-4cfd-a84b-3d53cf653613"
      unitRef="usd">4561140</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfMjMtMS0xLTEtOTU1OA_ebcb64fe-ac43-4ffc-84db-23880130db8c"
      unitRef="usd">94485</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfMjMtMy0xLTEtOTU1OA_c915a898-b0c5-4818-98ef-324aa659c261"
      unitRef="usd">95189</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfMjQtMS0xLTEtMTA1NDY_f298de6e-c85e-4bb4-ab7a-380f560ce1f3"
      unitRef="usd">0</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfMjQtMy0xLTEtMTA1NDY_2ad0b218-2536-4817-9596-c380cf4d417b"
      unitRef="usd">460888</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfMjQtMS0xLTEtOTU1OA_eda3c378-0513-4882-ae8b-862d975224d5"
      unitRef="usd">200000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfMjQtMy0xLTEtOTU1OA_6ee9712a-80e4-48a6-a397-7907f29acbc2"
      unitRef="usd">0</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfMjUtMS0xLTEtOTU1OA_926d3e0c-7e31-4710-8d16-a3218196a913"
      unitRef="usd">180613</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfMjUtMy0xLTEtOTU1OA_c5095c68-b18f-4f34-a68d-5cf4036cb471"
      unitRef="usd">1807467</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfMjYtMS0xLTEtOTU1OA_ffc6f38a-fb40-46d2-ac84-cbfe38356f13"
      unitRef="usd">-475098</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfMjYtMy0xLTEtOTU1OA_6f7754a7-2950-49c4-baa9-9a2c64dc0c97"
      unitRef="usd">-1441768</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromRepaymentsOfLinesOfCredit
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfMjktMS0xLTEtOTU1OA_ae85fed8-ca82-4f11-982e-bdfcaea8dc0c"
      unitRef="usd">45000000</us-gaap:ProceedsFromRepaymentsOfLinesOfCredit>
    <us-gaap:ProceedsFromRepaymentsOfLinesOfCredit
      contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfMjktMy0xLTEtOTU1OA_d8c83a67-e135-47b0-ab0b-00cc3a205b5b"
      unitRef="usd">44000000</us-gaap:ProceedsFromRepaymentsOfLinesOfCredit>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfMzAtMS0xLTEtOTU1OA_f4a8db35-27de-4a2e-ab10-732838abc052"
      unitRef="usd">45000000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfMzAtMy0xLTEtOTU1OA_a51d2968-02b4-430b-8aa3-9eeccb17cc54"
      unitRef="usd">45500000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfMzEtMS0xLTEtOTU1OA_27389069-bbbc-4c75-888a-953e490697fe"
      unitRef="usd">1792573</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfMzEtMy0xLTEtOTU1OA_48a6634a-dce4-400b-8685-2f29b34ee020"
      unitRef="usd">834014</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentsForRepurchaseOfRedeemableNoncontrollingInterest
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfMzItMS0xLTEtOTU1OA_3b6a4a18-d9aa-4aab-9615-0a1d8230b5ff"
      unitRef="usd">0</us-gaap:PaymentsForRepurchaseOfRedeemableNoncontrollingInterest>
    <us-gaap:PaymentsForRepurchaseOfRedeemableNoncontrollingInterest
      contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfMzItMy0xLTEtOTU1OA_1802f395-adcf-41ce-beb8-248285472068"
      unitRef="usd">800000</us-gaap:PaymentsForRepurchaseOfRedeemableNoncontrollingInterest>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfMzMtMS0xLTEtOTU1OA_74417a53-889d-4979-88af-96c305f4ae88"
      unitRef="usd">1025657</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfMzMtMy0xLTEtOTU1OA_d948002e-b969-4bdc-8231-cc4de64dc7d0"
      unitRef="usd">1551463</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfMzQtMS0xLTEtOTU1OA_f00c6231-ecc8-41b8-a509-e8f50d9ec00b"
      unitRef="usd">-2818230</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfMzQtMy0xLTEtOTU1OA_1980d3ac-9334-43dd-936f-70067baf296b"
      unitRef="usd">-4685477</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfMzUtMS0xLTEtOTU1OA_24c47d4f-6042-4d09-a4f6-f84d25ec3405"
      unitRef="usd">1089435</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfMzUtMy0xLTEtOTU1OA_7b68fff9-947a-49a5-be2d-249a99935a48"
      unitRef="usd">-1566105</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="idb172cb6365440839665fd6ec022472c_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfMzYtMS0xLTEtOTU1OA_0919de68-75d1-4a72-9895-f28f493019e9"
      unitRef="usd">24753796</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i6fa410e0219e41c3b8a23d8140a1ca8c_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfMzYtMy0xLTEtOTU1OA_860d7006-5a2c-4bbb-990c-33f7a028878c"
      unitRef="usd">28212635</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfMzctMS0xLTEtOTU1OA_f5e31f82-39b9-4de8-92d4-0c82043a1730"
      unitRef="usd">25843231</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i1ae7216a773d47d889c5f34d67e867fe_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yMi9mcmFnOjdmNmJmOWVkYmI0NTQ4YTY4Zjc1ZWM2N2QyNzhkYzcyL3RhYmxlOmRkNWYzZGQwZjdkMTRhNWQ4ZDFlMzIwZWE5YTEyNGM4L3RhYmxlcmFuZ2U6ZGQ1ZjNkZDBmN2QxNGE1ZDhkMWUzMjBlYTlhMTI0YzhfMzctMy0xLTEtOTU1OA_978bbe5f-89a2-4ad4-924d-4fe9b1a75eb2"
      unitRef="usd">26646530</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i90ac8e9aca0748058577add35fc3a6f9_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjNkOGQ1NGE4MzFlZTQzNjlhOGI4OTg1Y2JkZDdkOGYyL3RhYmxlcmFuZ2U6M2Q4ZDU0YTgzMWVlNDM2OWE4Yjg5ODVjYmRkN2Q4ZjJfMi0xLTEtMS05NTU4_249ec781-bdca-4a10-8125-8603765510a3"
      unitRef="shares">15263555</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i90ac8e9aca0748058577add35fc3a6f9_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjNkOGQ1NGE4MzFlZTQzNjlhOGI4OTg1Y2JkZDdkOGYyL3RhYmxlcmFuZ2U6M2Q4ZDU0YTgzMWVlNDM2OWE4Yjg5ODVjYmRkN2Q4ZjJfMi0zLTEtMS05NTU4_870e48c4-b831-428c-aeff-6b2a40dc00cb"
      unitRef="usd">49914478</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7f67242cec184569be979f0eab3bb2dd_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjNkOGQ1NGE4MzFlZTQzNjlhOGI4OTg1Y2JkZDdkOGYyL3RhYmxlcmFuZ2U6M2Q4ZDU0YTgzMWVlNDM2OWE4Yjg5ODVjYmRkN2Q4ZjJfMi01LTEtMS05NTU4_567665d0-f88c-4f2f-b952-5721a65712f5"
      unitRef="usd">1208395</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1925af7a08774bc4a2752a9cd6b75c35_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjNkOGQ1NGE4MzFlZTQzNjlhOGI4OTg1Y2JkZDdkOGYyL3RhYmxlcmFuZ2U6M2Q4ZDU0YTgzMWVlNDM2OWE4Yjg5ODVjYmRkN2Q4ZjJfMi03LTEtMS05NTU4_36f12a5f-6da4-44a5-94e5-e768c1bca7fc"
      unitRef="usd">-37620</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6fa410e0219e41c3b8a23d8140a1ca8c_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjNkOGQ1NGE4MzFlZTQzNjlhOGI4OTg1Y2JkZDdkOGYyL3RhYmxlcmFuZ2U6M2Q4ZDU0YTgzMWVlNDM2OWE4Yjg5ODVjYmRkN2Q4ZjJfMi05LTEtMS05NTU4_77241509-dc84-4f83-b3f4-a8f8e12ef9f3"
      unitRef="usd">51085253</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="iaf2c0f582f1a48b1b7132666868a1789_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjNkOGQ1NGE4MzFlZTQzNjlhOGI4OTg1Y2JkZDdkOGYyL3RhYmxlcmFuZ2U6M2Q4ZDU0YTgzMWVlNDM2OWE4Yjg5ODVjYmRkN2Q4ZjJfMy0xLTEtMS05NTU4_aa9262da-6fcb-458a-b15e-7dc3624dd465"
      unitRef="shares">219850</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="iaf2c0f582f1a48b1b7132666868a1789_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjNkOGQ1NGE4MzFlZTQzNjlhOGI4OTg1Y2JkZDdkOGYyL3RhYmxlcmFuZ2U6M2Q4ZDU0YTgzMWVlNDM2OWE4Yjg5ODVjYmRkN2Q4ZjJfMy0zLTEtMS05NTU4_6563001a-87be-4d8b-82e2-adb204cbd866"
      unitRef="usd">264574</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i4167fc9dfbd441ed853e3173c4f077bf_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjNkOGQ1NGE4MzFlZTQzNjlhOGI4OTg1Y2JkZDdkOGYyL3RhYmxlcmFuZ2U6M2Q4ZDU0YTgzMWVlNDM2OWE4Yjg5ODVjYmRkN2Q4ZjJfMy05LTEtMS05NTU4_2f4d8726-1de5-4065-8f2e-477ffc8fbfa2"
      unitRef="usd">264574</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="iaf2c0f582f1a48b1b7132666868a1789_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjNkOGQ1NGE4MzFlZTQzNjlhOGI4OTg1Y2JkZDdkOGYyL3RhYmxlcmFuZ2U6M2Q4ZDU0YTgzMWVlNDM2OWE4Yjg5ODVjYmRkN2Q4ZjJfNC0xLTEtMS05NTU4_1775f463-8b18-4147-90cb-757703376146"
      unitRef="shares">164866</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="iaf2c0f582f1a48b1b7132666868a1789_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjNkOGQ1NGE4MzFlZTQzNjlhOGI4OTg1Y2JkZDdkOGYyL3RhYmxlcmFuZ2U6M2Q4ZDU0YTgzMWVlNDM2OWE4Yjg5ODVjYmRkN2Q4ZjJfNC0zLTEtMS05NTU4_f53c8451-abaa-44b6-a448-fbbbb3a488f4"
      unitRef="usd">441624</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i4167fc9dfbd441ed853e3173c4f077bf_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjNkOGQ1NGE4MzFlZTQzNjlhOGI4OTg1Y2JkZDdkOGYyL3RhYmxlcmFuZ2U6M2Q4ZDU0YTgzMWVlNDM2OWE4Yjg5ODVjYmRkN2Q4ZjJfNC05LTEtMS05NTU4_88fcf9e9-412f-4903-88c1-e80ad0d62b0f"
      unitRef="usd">441624</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:ProfitLoss
      contextRef="ic4f1350ea2fc4eb18dc553f1c359d775_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjNkOGQ1NGE4MzFlZTQzNjlhOGI4OTg1Y2JkZDdkOGYyL3RhYmxlcmFuZ2U6M2Q4ZDU0YTgzMWVlNDM2OWE4Yjg5ODVjYmRkN2Q4ZjJfNS01LTEtMS05NTU4_e05d9dae-6d70-4646-b1a5-c4246b2829b5"
      unitRef="usd">-1055620</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i94a852cb675745e89723e30ec61bfcee_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjNkOGQ1NGE4MzFlZTQzNjlhOGI4OTg1Y2JkZDdkOGYyL3RhYmxlcmFuZ2U6M2Q4ZDU0YTgzMWVlNDM2OWE4Yjg5ODVjYmRkN2Q4ZjJfNS03LTEtMS05NTU4_df04729c-97ac-4b13-85aa-2902531e1579"
      unitRef="usd">-9525</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i4167fc9dfbd441ed853e3173c4f077bf_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjNkOGQ1NGE4MzFlZTQzNjlhOGI4OTg1Y2JkZDdkOGYyL3RhYmxlcmFuZ2U6M2Q4ZDU0YTgzMWVlNDM2OWE4Yjg5ODVjYmRkN2Q4ZjJfNS05LTEtMS05NTU4_494a1d21-b392-46e3-8a13-738fde1c33ee"
      unitRef="usd">-1065145</us-gaap:ProfitLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i98ca8db1bbc14991a38ad2f127cdc3f7_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjNkOGQ1NGE4MzFlZTQzNjlhOGI4OTg1Y2JkZDdkOGYyL3RhYmxlcmFuZ2U6M2Q4ZDU0YTgzMWVlNDM2OWE4Yjg5ODVjYmRkN2Q4ZjJfNi0xLTEtMS05NTU4_54089366-d285-48d9-a06a-eb833875fbd1"
      unitRef="shares">15318539</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i98ca8db1bbc14991a38ad2f127cdc3f7_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjNkOGQ1NGE4MzFlZTQzNjlhOGI4OTg1Y2JkZDdkOGYyL3RhYmxlcmFuZ2U6M2Q4ZDU0YTgzMWVlNDM2OWE4Yjg5ODVjYmRkN2Q4ZjJfNi0zLTEtMS05NTU4_8611b822-a493-4416-8f88-f23e7f8414ac"
      unitRef="usd">49737428</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id9ade7c2b96049c891663efff729f1ef_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjNkOGQ1NGE4MzFlZTQzNjlhOGI4OTg1Y2JkZDdkOGYyL3RhYmxlcmFuZ2U6M2Q4ZDU0YTgzMWVlNDM2OWE4Yjg5ODVjYmRkN2Q4ZjJfNi01LTEtMS05NTU4_eab4248e-a346-4ea9-8ea5-e8e431160c1d"
      unitRef="usd">152775</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia79d5a078419401d86bc7174c913bcf6_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjNkOGQ1NGE4MzFlZTQzNjlhOGI4OTg1Y2JkZDdkOGYyL3RhYmxlcmFuZ2U6M2Q4ZDU0YTgzMWVlNDM2OWE4Yjg5ODVjYmRkN2Q4ZjJfNi03LTEtMS05NTU4_0aee0b40-0b28-41c0-8fc8-11f58ff8bd26"
      unitRef="usd">-47145</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if8cac0f57d4c4aa1bf61accf6f74bfda_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjNkOGQ1NGE4MzFlZTQzNjlhOGI4OTg1Y2JkZDdkOGYyL3RhYmxlcmFuZ2U6M2Q4ZDU0YTgzMWVlNDM2OWE4Yjg5ODVjYmRkN2Q4ZjJfNi05LTEtMS05NTU4_f134c8c7-20db-4387-bd25-7f968ffc3628"
      unitRef="usd">49843058</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i98ca8db1bbc14991a38ad2f127cdc3f7_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjA5YTFmYmRmMmVhMzQ1ODM5ZmJlYWM5NDVjM2RjNjI2L3RhYmxlcmFuZ2U6MDlhMWZiZGYyZWEzNDU4MzlmYmVhYzk0NWMzZGM2MjZfMS0xLTEtMS05NTU4_5bfae5c9-3e1a-4eef-a52c-4ba0f1f3ec03"
      unitRef="shares">15318539</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i98ca8db1bbc14991a38ad2f127cdc3f7_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjA5YTFmYmRmMmVhMzQ1ODM5ZmJlYWM5NDVjM2RjNjI2L3RhYmxlcmFuZ2U6MDlhMWZiZGYyZWEzNDU4MzlmYmVhYzk0NWMzZGM2MjZfMS0zLTEtMS05NTU4_b5ef76f9-1ec4-433c-b5b6-17af7dd32a3f"
      unitRef="usd">49737428</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id9ade7c2b96049c891663efff729f1ef_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjA5YTFmYmRmMmVhMzQ1ODM5ZmJlYWM5NDVjM2RjNjI2L3RhYmxlcmFuZ2U6MDlhMWZiZGYyZWEzNDU4MzlmYmVhYzk0NWMzZGM2MjZfMS01LTEtMS05NTU4_fe236be2-a610-49ec-87d8-5280e1433e0d"
      unitRef="usd">152775</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia79d5a078419401d86bc7174c913bcf6_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjA5YTFmYmRmMmVhMzQ1ODM5ZmJlYWM5NDVjM2RjNjI2L3RhYmxlcmFuZ2U6MDlhMWZiZGYyZWEzNDU4MzlmYmVhYzk0NWMzZGM2MjZfMS03LTEtMS05NTU4_df26d6b8-d73e-4ab8-9f83-bbed51a74fd1"
      unitRef="usd">-47145</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if8cac0f57d4c4aa1bf61accf6f74bfda_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjA5YTFmYmRmMmVhMzQ1ODM5ZmJlYWM5NDVjM2RjNjI2L3RhYmxlcmFuZ2U6MDlhMWZiZGYyZWEzNDU4MzlmYmVhYzk0NWMzZGM2MjZfMS05LTEtMS05NTU4_c915cc4c-08d2-4087-bb3e-42c158d86c4f"
      unitRef="usd">49843058</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i62b7e40824ec46c1a5d32166d46d8910_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjA5YTFmYmRmMmVhMzQ1ODM5ZmJlYWM5NDVjM2RjNjI2L3RhYmxlcmFuZ2U6MDlhMWZiZGYyZWEzNDU4MzlmYmVhYzk0NWMzZGM2MjZfMi0xLTEtMS05NTU4_d4cfa378-3e97-4226-9f36-cfada6799107"
      unitRef="shares">4200</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i62b7e40824ec46c1a5d32166d46d8910_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjA5YTFmYmRmMmVhMzQ1ODM5ZmJlYWM5NDVjM2RjNjI2L3RhYmxlcmFuZ2U6MDlhMWZiZGYyZWEzNDU4MzlmYmVhYzk0NWMzZGM2MjZfMi0zLTEtMS05NTU4_478d70a1-0421-4ea7-bace-469cc002673c"
      unitRef="usd">278349</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i374ad433cb0d4675ae41fef76147919d_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjA5YTFmYmRmMmVhMzQ1ODM5ZmJlYWM5NDVjM2RjNjI2L3RhYmxlcmFuZ2U6MDlhMWZiZGYyZWEzNDU4MzlmYmVhYzk0NWMzZGM2MjZfMi05LTEtMS05NTU4_6b0d670b-02c0-42cc-9616-e33cb046b7bd"
      unitRef="usd">278349</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i62b7e40824ec46c1a5d32166d46d8910_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjA5YTFmYmRmMmVhMzQ1ODM5ZmJlYWM5NDVjM2RjNjI2L3RhYmxlcmFuZ2U6MDlhMWZiZGYyZWEzNDU4MzlmYmVhYzk0NWMzZGM2MjZfMy0xLTEtMS05NTU4_548841a5-a7fe-4c8f-9b0d-aed043cc0421"
      unitRef="shares">141463</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i62b7e40824ec46c1a5d32166d46d8910_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjA5YTFmYmRmMmVhMzQ1ODM5ZmJlYWM5NDVjM2RjNjI2L3RhYmxlcmFuZ2U6MDlhMWZiZGYyZWEzNDU4MzlmYmVhYzk0NWMzZGM2MjZfMy0zLTEtMS05NTU4_5e038516-2bee-4e44-b618-aafe273d4184"
      unitRef="usd">769648</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i374ad433cb0d4675ae41fef76147919d_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjA5YTFmYmRmMmVhMzQ1ODM5ZmJlYWM5NDVjM2RjNjI2L3RhYmxlcmFuZ2U6MDlhMWZiZGYyZWEzNDU4MzlmYmVhYzk0NWMzZGM2MjZfMy05LTEtMS05NTU4_1fe53f37-d0ff-4dfa-8134-e5bf6512d102"
      unitRef="usd">769648</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:ProfitLoss
      contextRef="ia7d9f053c7b34fd799481310c6ca1498_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjA5YTFmYmRmMmVhMzQ1ODM5ZmJlYWM5NDVjM2RjNjI2L3RhYmxlcmFuZ2U6MDlhMWZiZGYyZWEzNDU4MzlmYmVhYzk0NWMzZGM2MjZfNC01LTEtMS05NTU4_ea0a7385-18e0-45e3-9407-ab943f001e46"
      unitRef="usd">-918275</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i06622f546c724e4289669409575c7f9d_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjA5YTFmYmRmMmVhMzQ1ODM5ZmJlYWM5NDVjM2RjNjI2L3RhYmxlcmFuZ2U6MDlhMWZiZGYyZWEzNDU4MzlmYmVhYzk0NWMzZGM2MjZfNC03LTEtMS05NTU4_c202d4bd-4445-42ef-b424-f112d53358b5"
      unitRef="usd">-22314</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i374ad433cb0d4675ae41fef76147919d_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjA5YTFmYmRmMmVhMzQ1ODM5ZmJlYWM5NDVjM2RjNjI2L3RhYmxlcmFuZ2U6MDlhMWZiZGYyZWEzNDU4MzlmYmVhYzk0NWMzZGM2MjZfNC05LTEtMS05NTU4_9e4e5268-37ae-4e06-9ed6-0bb9098f08ee"
      unitRef="usd">-940589</us-gaap:ProfitLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ib5c699d5da91427e80a66ec6b1991b3a_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjA5YTFmYmRmMmVhMzQ1ODM5ZmJlYWM5NDVjM2RjNjI2L3RhYmxlcmFuZ2U6MDlhMWZiZGYyZWEzNDU4MzlmYmVhYzk0NWMzZGM2MjZfNS0xLTEtMS05NTU4_ba6e9aef-46ff-43b9-b878-63a20e112f39"
      unitRef="shares">15181276</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib5c699d5da91427e80a66ec6b1991b3a_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjA5YTFmYmRmMmVhMzQ1ODM5ZmJlYWM5NDVjM2RjNjI2L3RhYmxlcmFuZ2U6MDlhMWZiZGYyZWEzNDU4MzlmYmVhYzk0NWMzZGM2MjZfNS0zLTEtMS05NTU4_ae912d4a-a419-4caf-8c49-de60e29cfb21"
      unitRef="usd">49246129</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i70a1ecea99f7485195b3405682bd0c55_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjA5YTFmYmRmMmVhMzQ1ODM5ZmJlYWM5NDVjM2RjNjI2L3RhYmxlcmFuZ2U6MDlhMWZiZGYyZWEzNDU4MzlmYmVhYzk0NWMzZGM2MjZfNS01LTEtMS05NTU4_b0ee6887-8eef-4bbb-8054-7681ab6e31ec"
      unitRef="usd">-765500</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9fb60215b0504a758fcf2dfe00ea4b97_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjA5YTFmYmRmMmVhMzQ1ODM5ZmJlYWM5NDVjM2RjNjI2L3RhYmxlcmFuZ2U6MDlhMWZiZGYyZWEzNDU4MzlmYmVhYzk0NWMzZGM2MjZfNS03LTEtMS05NTU4_28ea7e25-8915-42e9-b1b1-e76c15087935"
      unitRef="usd">-69459</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i00b5fc7364e347f39acdca8004cef0f9_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjA5YTFmYmRmMmVhMzQ1ODM5ZmJlYWM5NDVjM2RjNjI2L3RhYmxlcmFuZ2U6MDlhMWZiZGYyZWEzNDU4MzlmYmVhYzk0NWMzZGM2MjZfNS05LTEtMS05NTU4_cd97b5f7-7028-4dea-9797-50d5b9f33f13"
      unitRef="usd">48411170</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ib5c699d5da91427e80a66ec6b1991b3a_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjkxZTY2MTlmZmQ3ZDRiNTJhYTAxZDEyOWMyM2M1NjJmL3RhYmxlcmFuZ2U6OTFlNjYxOWZmZDdkNGI1MmFhMDFkMTI5YzIzYzU2MmZfMC0xLTEtMS05NTU4_1c203fe2-7e6c-4fcb-9c67-a0836994c554"
      unitRef="shares">15181276</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib5c699d5da91427e80a66ec6b1991b3a_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjkxZTY2MTlmZmQ3ZDRiNTJhYTAxZDEyOWMyM2M1NjJmL3RhYmxlcmFuZ2U6OTFlNjYxOWZmZDdkNGI1MmFhMDFkMTI5YzIzYzU2MmZfMC0zLTEtMS05NTU4_99d65948-277a-4607-b69e-c3fb47ca8650"
      unitRef="usd">49246129</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i70a1ecea99f7485195b3405682bd0c55_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjkxZTY2MTlmZmQ3ZDRiNTJhYTAxZDEyOWMyM2M1NjJmL3RhYmxlcmFuZ2U6OTFlNjYxOWZmZDdkNGI1MmFhMDFkMTI5YzIzYzU2MmZfMC01LTEtMS05NTU4_4a10dfdb-303d-467b-83df-a3dcab39e02d"
      unitRef="usd">-765500</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9fb60215b0504a758fcf2dfe00ea4b97_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjkxZTY2MTlmZmQ3ZDRiNTJhYTAxZDEyOWMyM2M1NjJmL3RhYmxlcmFuZ2U6OTFlNjYxOWZmZDdkNGI1MmFhMDFkMTI5YzIzYzU2MmZfMC03LTEtMS05NTU4_132d0d50-1764-4f1d-a4a1-6f70c7c05f5a"
      unitRef="usd">-69459</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i00b5fc7364e347f39acdca8004cef0f9_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjkxZTY2MTlmZmQ3ZDRiNTJhYTAxZDEyOWMyM2M1NjJmL3RhYmxlcmFuZ2U6OTFlNjYxOWZmZDdkNGI1MmFhMDFkMTI5YzIzYzU2MmZfMC05LTEtMS05NTU4_8d4cc7d0-10d9-4e36-a097-78c1845f90af"
      unitRef="usd">48411170</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i786c6ae7dd8d4840bb2995fce1423b07_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjkxZTY2MTlmZmQ3ZDRiNTJhYTAxZDEyOWMyM2M1NjJmL3RhYmxlcmFuZ2U6OTFlNjYxOWZmZDdkNGI1MmFhMDFkMTI5YzIzYzU2MmZfMS0xLTEtMS05NTU4_f5763c6c-263b-4113-af40-f9c3eb0a0921"
      unitRef="shares">4450</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i786c6ae7dd8d4840bb2995fce1423b07_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjkxZTY2MTlmZmQ3ZDRiNTJhYTAxZDEyOWMyM2M1NjJmL3RhYmxlcmFuZ2U6OTFlNjYxOWZmZDdkNGI1MmFhMDFkMTI5YzIzYzU2MmZfMS0zLTEtMS05NTU4_69e7894c-997a-43c8-9c42-5e40f06986e0"
      unitRef="usd">262415</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ie2722c94900c4f68be9dd446637b8348_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjkxZTY2MTlmZmQ3ZDRiNTJhYTAxZDEyOWMyM2M1NjJmL3RhYmxlcmFuZ2U6OTFlNjYxOWZmZDdkNGI1MmFhMDFkMTI5YzIzYzU2MmZfMS05LTEtMS05NTU4_7e1d0225-6b3d-4e13-ac7c-b5fc997896f9"
      unitRef="usd">262415</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i786c6ae7dd8d4840bb2995fce1423b07_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjkxZTY2MTlmZmQ3ZDRiNTJhYTAxZDEyOWMyM2M1NjJmL3RhYmxlcmFuZ2U6OTFlNjYxOWZmZDdkNGI1MmFhMDFkMTI5YzIzYzU2MmZfNC0xLTEtMS05NTU4_90846027-9740-4424-9c38-aec27c588373"
      unitRef="shares">101354</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i786c6ae7dd8d4840bb2995fce1423b07_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjkxZTY2MTlmZmQ3ZDRiNTJhYTAxZDEyOWMyM2M1NjJmL3RhYmxlcmFuZ2U6OTFlNjYxOWZmZDdkNGI1MmFhMDFkMTI5YzIzYzU2MmZfNC0zLTEtMS05NTU4_dfb96313-1a84-4e4d-a62b-78e38155311d"
      unitRef="usd">332504</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="ie2722c94900c4f68be9dd446637b8348_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjkxZTY2MTlmZmQ3ZDRiNTJhYTAxZDEyOWMyM2M1NjJmL3RhYmxlcmFuZ2U6OTFlNjYxOWZmZDdkNGI1MmFhMDFkMTI5YzIzYzU2MmZfNC05LTEtMS05NTU4_55cd4e29-c0f6-4bfc-9a74-b3af62d6a38e"
      unitRef="usd">332504</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:ProfitLoss
      contextRef="i8c344dec4461400991796893b71c39f3_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjkxZTY2MTlmZmQ3ZDRiNTJhYTAxZDEyOWMyM2M1NjJmL3RhYmxlcmFuZ2U6OTFlNjYxOWZmZDdkNGI1MmFhMDFkMTI5YzIzYzU2MmZfNS01LTEtMS05NTU4_62f43be1-5943-4466-a95c-8abde503d415"
      unitRef="usd">-481737</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="id1cdf0875abf4833a9b0038791a1ea6c_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjkxZTY2MTlmZmQ3ZDRiNTJhYTAxZDEyOWMyM2M1NjJmL3RhYmxlcmFuZ2U6OTFlNjYxOWZmZDdkNGI1MmFhMDFkMTI5YzIzYzU2MmZfNS03LTEtMS05NTU4_1e0050b6-80e6-45f8-9b89-20b381a71206"
      unitRef="usd">-15967</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ie2722c94900c4f68be9dd446637b8348_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjkxZTY2MTlmZmQ3ZDRiNTJhYTAxZDEyOWMyM2M1NjJmL3RhYmxlcmFuZ2U6OTFlNjYxOWZmZDdkNGI1MmFhMDFkMTI5YzIzYzU2MmZfNS05LTEtMS05NTU4_4f3390c0-88a2-4ae0-994d-e8d11a4352d8"
      unitRef="usd">-497704</us-gaap:ProfitLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i1e43169536834b7daa78040307754845_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjkxZTY2MTlmZmQ3ZDRiNTJhYTAxZDEyOWMyM2M1NjJmL3RhYmxlcmFuZ2U6OTFlNjYxOWZmZDdkNGI1MmFhMDFkMTI5YzIzYzU2MmZfNi0xLTEtMS05NTU4_321a406d-5ff5-4794-ad2d-02192e50d59f"
      unitRef="shares">15084372</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1e43169536834b7daa78040307754845_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjkxZTY2MTlmZmQ3ZDRiNTJhYTAxZDEyOWMyM2M1NjJmL3RhYmxlcmFuZ2U6OTFlNjYxOWZmZDdkNGI1MmFhMDFkMTI5YzIzYzU2MmZfNi0zLTEtMS05NTU4_6cf60caa-0d71-47b9-b84e-0c83df3122c6"
      unitRef="usd">49176040</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1adc976609fe48d4b014ec48f05e022c_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjkxZTY2MTlmZmQ3ZDRiNTJhYTAxZDEyOWMyM2M1NjJmL3RhYmxlcmFuZ2U6OTFlNjYxOWZmZDdkNGI1MmFhMDFkMTI5YzIzYzU2MmZfNi01LTEtMS05NTU4_c01b96b7-c824-405a-b3ad-bc340d6c26b0"
      unitRef="usd">-1247237</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i169b3e774913430bb6c450a8d1cd8300_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjkxZTY2MTlmZmQ3ZDRiNTJhYTAxZDEyOWMyM2M1NjJmL3RhYmxlcmFuZ2U6OTFlNjYxOWZmZDdkNGI1MmFhMDFkMTI5YzIzYzU2MmZfNi03LTEtMS05NTU4_4e47f670-e308-4daf-8767-cc9dfb6e4532"
      unitRef="usd">-85426</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1ae7216a773d47d889c5f34d67e867fe_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjkxZTY2MTlmZmQ3ZDRiNTJhYTAxZDEyOWMyM2M1NjJmL3RhYmxlcmFuZ2U6OTFlNjYxOWZmZDdkNGI1MmFhMDFkMTI5YzIzYzU2MmZfNi05LTEtMS05NTU4_bfde1c53-8ddb-4a1c-a27e-5c5949897d3e"
      unitRef="usd">47843377</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i659fa119f70c4793a43053cddb879d71_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjU5NDcxYjdiMDhkZjRjYzJiMjY1ODFjOTMyOTY4YmJiL3RhYmxlcmFuZ2U6NTk0NzFiN2IwOGRmNGNjMmIyNjU4MWM5MzI5NjhiYmJfMi0xLTEtMS05NTU4_7057cc7e-0b59-4ae3-9bff-60cdd185c2d1"
      unitRef="shares">14988429</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i659fa119f70c4793a43053cddb879d71_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjU5NDcxYjdiMDhkZjRjYzJiMjY1ODFjOTMyOTY4YmJiL3RhYmxlcmFuZ2U6NTk0NzFiN2IwOGRmNGNjMmIyNjU4MWM5MzI5NjhiYmJfMi0zLTEtMS05NTU4_04aad0b1-30c4-4ea9-8c85-7eadc6329b3a"
      unitRef="usd">49121523</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i50909170032a4c00a004f6dd1808751c_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjU5NDcxYjdiMDhkZjRjYzJiMjY1ODFjOTMyOTY4YmJiL3RhYmxlcmFuZ2U6NTk0NzFiN2IwOGRmNGNjMmIyNjU4MWM5MzI5NjhiYmJfMi01LTEtMS05NTU4_134c4d4b-8582-480c-abfd-edc4fc3b5b73"
      unitRef="usd">-2131013</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i42e8ab4712444a43a1f231cb65ac3dcd_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjU5NDcxYjdiMDhkZjRjYzJiMjY1ODFjOTMyOTY4YmJiL3RhYmxlcmFuZ2U6NTk0NzFiN2IwOGRmNGNjMmIyNjU4MWM5MzI5NjhiYmJfMi03LTEtMS05NTU4_2844278d-dff4-4ebd-95ec-f5bdda877b84"
      unitRef="usd">-117116</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idb172cb6365440839665fd6ec022472c_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjU5NDcxYjdiMDhkZjRjYzJiMjY1ODFjOTMyOTY4YmJiL3RhYmxlcmFuZ2U6NTk0NzFiN2IwOGRmNGNjMmIyNjU4MWM5MzI5NjhiYmJfMi05LTEtMS05NTU4_38a0f3f4-23af-4b4f-b382-4f44689f4eee"
      unitRef="usd">46873394</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="idecbe529c8e14131b56433eb5e130916_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjU5NDcxYjdiMDhkZjRjYzJiMjY1ODFjOTMyOTY4YmJiL3RhYmxlcmFuZ2U6NTk0NzFiN2IwOGRmNGNjMmIyNjU4MWM5MzI5NjhiYmJfMy0xLTEtMS05NTU4_f7574844-4415-4104-a39e-24dc40d3967f"
      unitRef="shares">187759</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="idecbe529c8e14131b56433eb5e130916_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjU5NDcxYjdiMDhkZjRjYzJiMjY1ODFjOTMyOTY4YmJiL3RhYmxlcmFuZ2U6NTk0NzFiN2IwOGRmNGNjMmIyNjU4MWM5MzI5NjhiYmJfMy0zLTEtMS05NTU4_39c408b4-5326-4ef0-8db1-91b7443aef10"
      unitRef="usd">162960</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i5c8473bff64c498ab624fafa4cca5132_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjU5NDcxYjdiMDhkZjRjYzJiMjY1ODFjOTMyOTY4YmJiL3RhYmxlcmFuZ2U6NTk0NzFiN2IwOGRmNGNjMmIyNjU4MWM5MzI5NjhiYmJfMy05LTEtMS05NTU4_80dd1e2a-1faa-4304-bacb-a245970d3b8f"
      unitRef="usd">162960</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="idecbe529c8e14131b56433eb5e130916_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjU5NDcxYjdiMDhkZjRjYzJiMjY1ODFjOTMyOTY4YmJiL3RhYmxlcmFuZ2U6NTk0NzFiN2IwOGRmNGNjMmIyNjU4MWM5MzI5NjhiYmJfNC0xLTEtMS05NTU4_1efaf449-3113-4fb4-8146-3e31a727ee9a"
      unitRef="shares">91724</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="idecbe529c8e14131b56433eb5e130916_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjU5NDcxYjdiMDhkZjRjYzJiMjY1ODFjOTMyOTY4YmJiL3RhYmxlcmFuZ2U6NTk0NzFiN2IwOGRmNGNjMmIyNjU4MWM5MzI5NjhiYmJfNC0zLTEtMS05NTU4_6b4b8000-6c07-4605-89cd-79d6da8ce99d"
      unitRef="usd">303088</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i5c8473bff64c498ab624fafa4cca5132_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjU5NDcxYjdiMDhkZjRjYzJiMjY1ODFjOTMyOTY4YmJiL3RhYmxlcmFuZ2U6NTk0NzFiN2IwOGRmNGNjMmIyNjU4MWM5MzI5NjhiYmJfNC05LTEtMS05NTU4_bf24bea5-836f-44bd-8f74-ec90a1aaab61"
      unitRef="usd">303088</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:ProfitLoss
      contextRef="i781a96ef93c24d05bb7f12625a033ec0_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjU5NDcxYjdiMDhkZjRjYzJiMjY1ODFjOTMyOTY4YmJiL3RhYmxlcmFuZ2U6NTk0NzFiN2IwOGRmNGNjMmIyNjU4MWM5MzI5NjhiYmJfNS01LTEtMS05NTU4_31948089-7fbc-4e01-89b3-e4de20e48278"
      unitRef="usd">166828</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i38154999f15f41cca19a77a5f4d0ccac_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjU5NDcxYjdiMDhkZjRjYzJiMjY1ODFjOTMyOTY4YmJiL3RhYmxlcmFuZ2U6NTk0NzFiN2IwOGRmNGNjMmIyNjU4MWM5MzI5NjhiYmJfNS03LTEtMS05NTU4_edf6efd5-2f19-4adb-933f-aa4d76c1d65a"
      unitRef="usd">-22167</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i5c8473bff64c498ab624fafa4cca5132_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjU5NDcxYjdiMDhkZjRjYzJiMjY1ODFjOTMyOTY4YmJiL3RhYmxlcmFuZ2U6NTk0NzFiN2IwOGRmNGNjMmIyNjU4MWM5MzI5NjhiYmJfNS05LTEtMS05NTU4_f3adc67d-9fcf-484c-b8e3-4b3953e8bfcd"
      unitRef="usd">144661</us-gaap:ProfitLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i9d845908b01747ac9d721fff45f53abf_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjU5NDcxYjdiMDhkZjRjYzJiMjY1ODFjOTMyOTY4YmJiL3RhYmxlcmFuZ2U6NTk0NzFiN2IwOGRmNGNjMmIyNjU4MWM5MzI5NjhiYmJfNi0xLTEtMS05NTU4_eed539f4-4f00-4335-8742-e54d7ee5d7fe"
      unitRef="shares">15084464</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9d845908b01747ac9d721fff45f53abf_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjU5NDcxYjdiMDhkZjRjYzJiMjY1ODFjOTMyOTY4YmJiL3RhYmxlcmFuZ2U6NTk0NzFiN2IwOGRmNGNjMmIyNjU4MWM5MzI5NjhiYmJfNi0zLTEtMS05NTU4_3681e437-53cd-4eff-aae2-556ddd42dab1"
      unitRef="usd">48981395</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i32deafcb20a948cf995118abdf3ce1a4_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjU5NDcxYjdiMDhkZjRjYzJiMjY1ODFjOTMyOTY4YmJiL3RhYmxlcmFuZ2U6NTk0NzFiN2IwOGRmNGNjMmIyNjU4MWM5MzI5NjhiYmJfNi01LTEtMS05NTU4_83fef89f-98c5-4766-b63f-489ddd93e58a"
      unitRef="usd">-1964185</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2593ac397b63496686231e5a4d277b3b_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjU5NDcxYjdiMDhkZjRjYzJiMjY1ODFjOTMyOTY4YmJiL3RhYmxlcmFuZ2U6NTk0NzFiN2IwOGRmNGNjMmIyNjU4MWM5MzI5NjhiYmJfNi03LTEtMS05NTU4_3ceb856f-31f0-4939-bf14-e49625105dd7"
      unitRef="usd">-139283</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8320ae6bb40c49b4b91522210805d996_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjU5NDcxYjdiMDhkZjRjYzJiMjY1ODFjOTMyOTY4YmJiL3RhYmxlcmFuZ2U6NTk0NzFiN2IwOGRmNGNjMmIyNjU4MWM5MzI5NjhiYmJfNi05LTEtMS05NTU4_d82bb52f-c66b-46c2-8206-2f24681b9542"
      unitRef="usd">46877927</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i9d845908b01747ac9d721fff45f53abf_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjhkYTkyNzEzNWJjODQ1YzViYzNkZTcxOTdhN2RiOWZlL3RhYmxlcmFuZ2U6OGRhOTI3MTM1YmM4NDVjNWJjM2RlNzE5N2E3ZGI5ZmVfMS0xLTEtMS05NTU4_eed539f4-4f00-4335-8742-e54d7ee5d7fe"
      unitRef="shares">15084464</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9d845908b01747ac9d721fff45f53abf_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjhkYTkyNzEzNWJjODQ1YzViYzNkZTcxOTdhN2RiOWZlL3RhYmxlcmFuZ2U6OGRhOTI3MTM1YmM4NDVjNWJjM2RlNzE5N2E3ZGI5ZmVfMS0zLTEtMS05NTU4_3681e437-53cd-4eff-aae2-556ddd42dab1"
      unitRef="usd">48981395</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i32deafcb20a948cf995118abdf3ce1a4_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjhkYTkyNzEzNWJjODQ1YzViYzNkZTcxOTdhN2RiOWZlL3RhYmxlcmFuZ2U6OGRhOTI3MTM1YmM4NDVjNWJjM2RlNzE5N2E3ZGI5ZmVfMS01LTEtMS05NTU4_83fef89f-98c5-4766-b63f-489ddd93e58a"
      unitRef="usd">-1964185</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2593ac397b63496686231e5a4d277b3b_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjhkYTkyNzEzNWJjODQ1YzViYzNkZTcxOTdhN2RiOWZlL3RhYmxlcmFuZ2U6OGRhOTI3MTM1YmM4NDVjNWJjM2RlNzE5N2E3ZGI5ZmVfMS03LTEtMS05NTU4_3ceb856f-31f0-4939-bf14-e49625105dd7"
      unitRef="usd">-139283</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8320ae6bb40c49b4b91522210805d996_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjhkYTkyNzEzNWJjODQ1YzViYzNkZTcxOTdhN2RiOWZlL3RhYmxlcmFuZ2U6OGRhOTI3MTM1YmM4NDVjNWJjM2RlNzE5N2E3ZGI5ZmVfMS05LTEtMS05NTU4_d82bb52f-c66b-46c2-8206-2f24681b9542"
      unitRef="usd">46877927</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ief227cab10a245ff9baa903632237a80_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjhkYTkyNzEzNWJjODQ1YzViYzNkZTcxOTdhN2RiOWZlL3RhYmxlcmFuZ2U6OGRhOTI3MTM1YmM4NDVjNWJjM2RlNzE5N2E3ZGI5ZmVfMi0zLTEtMS05NTU4_0ea014be-e665-481a-a9d0-b00ea2aa91b8"
      unitRef="usd">191954</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i83fce5d3edda4b1cbab16d0e4a53c979_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjhkYTkyNzEzNWJjODQ1YzViYzNkZTcxOTdhN2RiOWZlL3RhYmxlcmFuZ2U6OGRhOTI3MTM1YmM4NDVjNWJjM2RlNzE5N2E3ZGI5ZmVfMi05LTEtMS05NTU4_881bb181-1369-496b-8b7d-14238b167570"
      unitRef="usd">191954</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="ief227cab10a245ff9baa903632237a80_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjhkYTkyNzEzNWJjODQ1YzViYzNkZTcxOTdhN2RiOWZlL3RhYmxlcmFuZ2U6OGRhOTI3MTM1YmM4NDVjNWJjM2RlNzE5N2E3ZGI5ZmVfMy0xLTEtMS05NTU4_5d25d73a-3bd3-4372-b246-162f8e5bec85"
      unitRef="shares">158405</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="ief227cab10a245ff9baa903632237a80_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjhkYTkyNzEzNWJjODQ1YzViYzNkZTcxOTdhN2RiOWZlL3RhYmxlcmFuZ2U6OGRhOTI3MTM1YmM4NDVjNWJjM2RlNzE5N2E3ZGI5ZmVfMy0zLTEtMS05NTU4_a8b15ca7-722b-4183-94ca-19c176e2260a"
      unitRef="usd">484965</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i83fce5d3edda4b1cbab16d0e4a53c979_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjhkYTkyNzEzNWJjODQ1YzViYzNkZTcxOTdhN2RiOWZlL3RhYmxlcmFuZ2U6OGRhOTI3MTM1YmM4NDVjNWJjM2RlNzE5N2E3ZGI5ZmVfMy05LTEtMS05NTU4_f0f44ab9-6591-48bd-a1e1-071a34ce8e9e"
      unitRef="usd">484965</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:ProfitLoss
      contextRef="ibe562d54463741e8949d25484a516053_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjhkYTkyNzEzNWJjODQ1YzViYzNkZTcxOTdhN2RiOWZlL3RhYmxlcmFuZ2U6OGRhOTI3MTM1YmM4NDVjNWJjM2RlNzE5N2E3ZGI5ZmVfNC01LTEtMS05NTU4_2d024e0b-c223-46cc-96f3-231eb3a685d2"
      unitRef="usd">1228560</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i1f91139b751f41ee943e86bdb734f2f4_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjhkYTkyNzEzNWJjODQ1YzViYzNkZTcxOTdhN2RiOWZlL3RhYmxlcmFuZ2U6OGRhOTI3MTM1YmM4NDVjNWJjM2RlNzE5N2E3ZGI5ZmVfNC03LTEtMS05NTU4_22fe06fd-d63c-49af-a421-db55884b35bb"
      unitRef="usd">-5069</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i83fce5d3edda4b1cbab16d0e4a53c979_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjhkYTkyNzEzNWJjODQ1YzViYzNkZTcxOTdhN2RiOWZlL3RhYmxlcmFuZ2U6OGRhOTI3MTM1YmM4NDVjNWJjM2RlNzE5N2E3ZGI5ZmVfNC05LTEtMS05NTU4_c23b1e29-ce32-40a8-b16b-34dedbbf01db"
      unitRef="usd">1223491</us-gaap:ProfitLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i7ea7194dbc454dbdbc6632db38bf6066_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjhkYTkyNzEzNWJjODQ1YzViYzNkZTcxOTdhN2RiOWZlL3RhYmxlcmFuZ2U6OGRhOTI3MTM1YmM4NDVjNWJjM2RlNzE5N2E3ZGI5ZmVfNS0xLTEtMS05NTU4_dcc08780-96f8-4ffe-9174-8c6bfdb9acb0"
      unitRef="shares">14926059</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7ea7194dbc454dbdbc6632db38bf6066_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjhkYTkyNzEzNWJjODQ1YzViYzNkZTcxOTdhN2RiOWZlL3RhYmxlcmFuZ2U6OGRhOTI3MTM1YmM4NDVjNWJjM2RlNzE5N2E3ZGI5ZmVfNS0zLTEtMS05NTU4_705b4090-f883-42e7-97b6-503eae1789be"
      unitRef="usd">48688384</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic49c90ad54954ba9a5f89e54eb1dfedb_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjhkYTkyNzEzNWJjODQ1YzViYzNkZTcxOTdhN2RiOWZlL3RhYmxlcmFuZ2U6OGRhOTI3MTM1YmM4NDVjNWJjM2RlNzE5N2E3ZGI5ZmVfNS01LTEtMS05NTU4_6476049d-65f5-4999-aa4b-150e410bba73"
      unitRef="usd">-735625</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie1e3b4d188524c1791c80059e8f7515a_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjhkYTkyNzEzNWJjODQ1YzViYzNkZTcxOTdhN2RiOWZlL3RhYmxlcmFuZ2U6OGRhOTI3MTM1YmM4NDVjNWJjM2RlNzE5N2E3ZGI5ZmVfNS03LTEtMS05NTU4_a9046c90-144e-4d48-be67-98e3ee61a55b"
      unitRef="usd">-144352</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i64b2d71ddb0c448d9959f1b9a74a7dad_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjhkYTkyNzEzNWJjODQ1YzViYzNkZTcxOTdhN2RiOWZlL3RhYmxlcmFuZ2U6OGRhOTI3MTM1YmM4NDVjNWJjM2RlNzE5N2E3ZGI5ZmVfNS05LTEtMS05NTU4_97ec6cbf-7a4f-49be-b398-310dbe615c6b"
      unitRef="usd">47808407</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i7ea7194dbc454dbdbc6632db38bf6066_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjBjNDExMWRjOGQyZTQ0MzdhZTc0YmI5YzNjNjc5YmIwL3RhYmxlcmFuZ2U6MGM0MTExZGM4ZDJlNDQzN2FlNzRiYjljM2M2NzliYjBfMS0xLTEtMS05NTU4_4e8dc3a0-51a6-4572-a2bd-824edb0988e6"
      unitRef="shares">14926059</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7ea7194dbc454dbdbc6632db38bf6066_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjBjNDExMWRjOGQyZTQ0MzdhZTc0YmI5YzNjNjc5YmIwL3RhYmxlcmFuZ2U6MGM0MTExZGM4ZDJlNDQzN2FlNzRiYjljM2M2NzliYjBfMS0zLTEtMS05NTU4_a3b29f55-e4d1-4600-98ba-bfe88d4b8015"
      unitRef="usd">48688384</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic49c90ad54954ba9a5f89e54eb1dfedb_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjBjNDExMWRjOGQyZTQ0MzdhZTc0YmI5YzNjNjc5YmIwL3RhYmxlcmFuZ2U6MGM0MTExZGM4ZDJlNDQzN2FlNzRiYjljM2M2NzliYjBfMS01LTEtMS05NTU4_142089ed-56e3-477f-9f4d-9163676c17c7"
      unitRef="usd">-735625</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie1e3b4d188524c1791c80059e8f7515a_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjBjNDExMWRjOGQyZTQ0MzdhZTc0YmI5YzNjNjc5YmIwL3RhYmxlcmFuZ2U6MGM0MTExZGM4ZDJlNDQzN2FlNzRiYjljM2M2NzliYjBfMS03LTEtMS05NTU4_507da33e-e52a-46bb-a4b2-c010cdec7854"
      unitRef="usd">-144352</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i64b2d71ddb0c448d9959f1b9a74a7dad_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjBjNDExMWRjOGQyZTQ0MzdhZTc0YmI5YzNjNjc5YmIwL3RhYmxlcmFuZ2U6MGM0MTExZGM4ZDJlNDQzN2FlNzRiYjljM2M2NzliYjBfMS05LTEtMS05NTU4_e33e63bd-631c-4d12-93c3-91b8d135ad90"
      unitRef="usd">47808407</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i10df7b4f9a35418da7673ef6ae315d51_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjBjNDExMWRjOGQyZTQ0MzdhZTc0YmI5YzNjNjc5YmIwL3RhYmxlcmFuZ2U6MGM0MTExZGM4ZDJlNDQzN2FlNzRiYjljM2M2NzliYjBfMi0xLTEtMS05NTU4_81d6eb07-e689-4ff0-9df5-18284e21cc0d"
      unitRef="shares">875</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i10df7b4f9a35418da7673ef6ae315d51_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjBjNDExMWRjOGQyZTQ0MzdhZTc0YmI5YzNjNjc5YmIwL3RhYmxlcmFuZ2U6MGM0MTExZGM4ZDJlNDQzN2FlNzRiYjljM2M2NzliYjBfMi0zLTEtMS05NTU4_f24ef08c-4098-4b4e-90e9-ca8f2947a940"
      unitRef="usd">162167</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i5cfdffb6c8a4411a95e4596b0bd91b7c_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjBjNDExMWRjOGQyZTQ0MzdhZTc0YmI5YzNjNjc5YmIwL3RhYmxlcmFuZ2U6MGM0MTExZGM4ZDJlNDQzN2FlNzRiYjljM2M2NzliYjBfMi05LTEtMS05NTU4_169057ed-308d-4e43-bcac-1ee1eceedb54"
      unitRef="usd">162167</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i10df7b4f9a35418da7673ef6ae315d51_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjBjNDExMWRjOGQyZTQ0MzdhZTc0YmI5YzNjNjc5YmIwL3RhYmxlcmFuZ2U6MGM0MTExZGM4ZDJlNDQzN2FlNzRiYjljM2M2NzliYjBfMy0xLTEtMS05NTU4_0f04d063-90b1-4855-9ea8-e0b45a74bb2d"
      unitRef="shares">76408</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i10df7b4f9a35418da7673ef6ae315d51_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjBjNDExMWRjOGQyZTQ0MzdhZTc0YmI5YzNjNjc5YmIwL3RhYmxlcmFuZ2U6MGM0MTExZGM4ZDJlNDQzN2FlNzRiYjljM2M2NzliYjBfMy0zLTEtMS05NTU4_5f9244e3-7211-427c-b9a3-053f221d3623"
      unitRef="usd">237616</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i5cfdffb6c8a4411a95e4596b0bd91b7c_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjBjNDExMWRjOGQyZTQ0MzdhZTc0YmI5YzNjNjc5YmIwL3RhYmxlcmFuZ2U6MGM0MTExZGM4ZDJlNDQzN2FlNzRiYjljM2M2NzliYjBfMy05LTEtMS05NTU4_9ddf6a86-bd00-480e-8c87-2b6bc6f20ce4"
      unitRef="usd">237616</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:ProfitLoss
      contextRef="iae1347d2d1d84aa3a135e3245bdf0d90_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjBjNDExMWRjOGQyZTQ0MzdhZTc0YmI5YzNjNjc5YmIwL3RhYmxlcmFuZ2U6MGM0MTExZGM4ZDJlNDQzN2FlNzRiYjljM2M2NzliYjBfNC01LTEtMS0xMDI2Nw_cbeaa059-71c9-4b37-b89d-73d8fd6d7c0f"
      unitRef="usd">-1055278</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i9cc79eb883d54f61bdec225f436b82c9_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjBjNDExMWRjOGQyZTQ0MzdhZTc0YmI5YzNjNjc5YmIwL3RhYmxlcmFuZ2U6MGM0MTExZGM4ZDJlNDQzN2FlNzRiYjljM2M2NzliYjBfNC03LTEtMS0xMTgyMw_bba45812-ec40-4220-90ee-24ee4964cd26"
      unitRef="usd">-31415</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i5cfdffb6c8a4411a95e4596b0bd91b7c_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjBjNDExMWRjOGQyZTQ0MzdhZTc0YmI5YzNjNjc5YmIwL3RhYmxlcmFuZ2U6MGM0MTExZGM4ZDJlNDQzN2FlNzRiYjljM2M2NzliYjBfNC05LTEtMS05NTU4_341bb227-f07f-4bc9-9d1b-3939ea4b1db3"
      unitRef="usd">-1086693</us-gaap:ProfitLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i56aafc7718c145c8b150a8e54f33a5d2_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjBjNDExMWRjOGQyZTQ0MzdhZTc0YmI5YzNjNjc5YmIwL3RhYmxlcmFuZ2U6MGM0MTExZGM4ZDJlNDQzN2FlNzRiYjljM2M2NzliYjBfNS0xLTEtMS05NTU4_8dc93544-2123-452a-829f-d0d73c3b0bef"
      unitRef="shares">14850526</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i56aafc7718c145c8b150a8e54f33a5d2_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjBjNDExMWRjOGQyZTQ0MzdhZTc0YmI5YzNjNjc5YmIwL3RhYmxlcmFuZ2U6MGM0MTExZGM4ZDJlNDQzN2FlNzRiYjljM2M2NzliYjBfNS0zLTEtMS05NTU4_909af3b1-353b-4168-8cfa-408168fb7c16"
      unitRef="usd">48612935</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib1da3f9dccc043f1b509c4e381803002_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjBjNDExMWRjOGQyZTQ0MzdhZTc0YmI5YzNjNjc5YmIwL3RhYmxlcmFuZ2U6MGM0MTExZGM4ZDJlNDQzN2FlNzRiYjljM2M2NzliYjBfNS01LTEtMS05NTU4_41b7e1e7-83aa-4dbd-a223-934a3f5e6d50"
      unitRef="usd">-1790903</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ied663adb59564577989ed6d27ea6493f_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjBjNDExMWRjOGQyZTQ0MzdhZTc0YmI5YzNjNjc5YmIwL3RhYmxlcmFuZ2U6MGM0MTExZGM4ZDJlNDQzN2FlNzRiYjljM2M2NzliYjBfNS03LTEtMS05NTU4_b0d20a4f-9c66-44f0-8a11-94010dd8c102"
      unitRef="usd">-175767</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8yNS9mcmFnOjAyZWRiZDUwMGNiMTQ1YzBiNmRkNjQxZWJiZWQ3NDFiL3RhYmxlOjBjNDExMWRjOGQyZTQ0MzdhZTc0YmI5YzNjNjc5YmIwL3RhYmxlcmFuZ2U6MGM0MTExZGM4ZDJlNDQzN2FlNzRiYjljM2M2NzliYjBfNS05LTEtMS05NTU4_270319a0-ab49-4b31-8eaa-3c63149042c5"
      unitRef="usd">46646265</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zMS9mcmFnOjc4MTgyYzdiODkwMzRkOTdhYWUyNDJlZGY3MzU3NmU5L3RleHRyZWdpb246NzgxODJjN2I4OTAzNGQ5N2FhZTI0MmVkZjczNTc2ZTlfMTAwMzE_454135b1-1a94-46f8-8aba-ffa26ed95177">ORGANIZATION AND BASIS OF PRESENTATION&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumberland Pharmaceuticals Inc. (&#x201c;Cumberland,&#x201d; the &#x201c;Company,&#x201d; or as used in the context of &#x201c;we,&#x201d; &#x201c;us,&#x201d; or &#x201c;our&#x201d;) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products.  The Company's primary target markets are hospital acute care, gastroenterology and rheumatology. These medical specialties are characterized by relatively concentrated prescriber bases that the Company believes can be penetrated effectively by small, targeted sales forces. Cumberland is dedicated to providing innovative products that improve quality of care for patients and address unmet or poorly met medical needs.  The Company promotes its approved products through its hospital and field sales forces in the United States and is establishing a network of international partners to bring its medicines to patients in their countries.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumberland focuses its resources on maximizing the commercial potential of its products, as well as developing new product candidates, and has both internal development and commercial capabilities. The Company&#x2019;s products are manufactured by third parties, which are overseen by Cumberland&#x2019;s quality control and manufacturing professionals. The Company works closely with its third-party distribution partners to make its products available in the United States.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the opinion of management, the accompanying unaudited condensed consolidated financial statements of the Company have been prepared on a basis consistent with the December 31, 2020, audited consolidated financial statements and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly present the information set forth herein. All significant intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements have been prepared in accordance with the regulations of the Securities and Exchange Commission (the &#x201c;SEC&#x201d;), and certain information and disclosures have been condensed or omitted as permitted by the SEC for interim period presentation. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes included in our Annual Report on Form 10-K for the year ended December 31, 2020 (the &#x201c;2020 Annual Report on Form 10-K&#x201d;). The results of operations for the three and nine months ended September 30, 2021, are not necessarily indicative of the results to be expected for the entire fiscal year or any future period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Discontinued Operations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As discussed further in Note 9, during May 2019, Cumberland entered into a Dissolution Agreement  ("Dissolution Agreement") with Clinigen Healthcare Limited ("Clinigen") in which the Company returned the exclusive rights to commercialize Ethyol&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and Totect&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the United States to Clinigen. Under the terms of the Dissolution Agreement, Cumberland is no longer involved directly or indirectly with the distribution, marketing and promotion of either Ethyol or Totect or any competing products following December 31, 2019. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's exit from Ethyol and Totect meets the accounting criteria to be reported as discontinued operations and the discontinued operating results have been presented in the financial statements and footnotes to reflect the discontinued status of Ethyol and Totect. Refer to Note 9, for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revision of prior period condensed consolidated statement of cash flows presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has made a revision to prior period amounts to conform to the current year presentation of the cash surrender value of life insurance policies over premiums paid on the condensed consolidated statement of cash flows.  The revised amounts were previously included as net changes in assets affecting operating activities.  These revisions have no net effect on the reported net cash provided by operating activities nor any impact on the reported operating results or balance sheet for the 2020 period presented.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;COVID-19 Pandemic &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, the U.S. declared a health care emergency following the outbreak of the SARS-CoV-2, a novel strain of coronavirus that causes COVID-19, a respiratory illness.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumberland has remained open for business, as the Company is considered to be essential by the United States Department of Homeland Security. The Company has implemented measures to address the impact of the novel coronavirus on the business and taken appropriate action to protect its employees, secure the supply chain, and support the patients who can benefit from its medicines.  All of the Company's employees have been given the opportunity to work remotely, and those that wish to work from Cumberland's office and laboratories are encouraged to practice the behaviors outlined by the Centers for Disease Control.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Throughout the pandemic, Cumberland has faced the same headwinds affecting other companies that rely on hospital admissions and patient visits to drive revenue.  Our business and our clinical studies were impacted as less patients sought elective surgeries and our access to medical facilities was substantially limited.  During 2020 and 2021, we carefully monitored our supply chain during the pandemic including the flow of raw materials into the plants that manufacture our products as well as the batches of finished product emerging from those facilities. Several of our brands were negatively impacted by the lockdowns and postponement of physician office visits and elective procedures. However, we are fortunate to have a diversified product portfolio, with other brands delivering a strong performance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumberland relies on third-party organizations around the world to supply components, manufacture and distribute its products. The Company is aware that it may experience revenue loss, supply interruptions, time delays and incur unplanned expenses as a result of the impact of the ongoing COVID-19 pandemic.   The Company continues to monitor the COVID-19 pandemic situation both in the U.S. and internationally in order to maintain its employees&#x2019; safety and well-being, while also keeping its business operating.  Given the uncertainty, magnitude and impact of such changes, the Company is unable to quantify the impact on the future results as of the date of this filing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Guidance&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent Accounting Pronouncements - Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the Financial Accounting Standards Board ("FASB") issued ASU No. 2016-13, &#x201c;Financial Instruments-Credit Losses,&#x201d; which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other instruments, companies will be required to use a new forward-looking &#x201c;expected loss&#x201d; model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, companies will measure credit losses in a manner similar to what they do today, except that the losses will be recognized as allowances rather than as reductions in the amortized cost of the securities. Companies will have to disclose additional information, including information they use to track credit quality by year of origination for most financing receivables. Companies will apply the ASU&#x2019;s provisions as a cumulative-effect adjustment, if any, to retained earnings as of the beginning of the first reporting period in which the guidance is adopted.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Related to ASU No. 2016-13 discussed above, in May 2019, the FASB issued ASU 2019-05, "Financial Instruments-Credit Losses (Topic 326): Targeted Transition Relief" which provides transition relief for ASU 2016-13 by providing entities with an alternative to irrevocably elect the fair value option for eligible financial assets measured at amortized cost upon adoption of the new credit losses standard. Certain eligibility requirements must be met and the election must be applied on an instrument-by-instrument basis. The election is not available for either available-for-sale or held-to-maturity debt securities. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company will adopt both ASU 2016-13 and ASU 2019-05 on January 1, 2023. The adoption of ASU 2016-13 and ASU 2019-05 are not expected to have a material impact on the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounting Policies:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management of the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period.  Actual results could differ from those estimates under different assumptions and conditions.  The Company's most significant estimates include: (1) its allowances for chargebacks and accruals for rebates and product returns, (2) the allowances for obsolescent or unmarketable inventory and (3) valuation of a contingent consideration liability associated with a business combination.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Operating Segments&lt;/span&gt;&lt;/div&gt;The Company has one operating segment which is specialty pharmaceutical products. Management has chosen to organize the Company based on the type of products sold. Operating segments are identified as components of an enterprise about which separate discrete financial information is evaluated by the chief operating decision maker, or decision-making group, in making decisions regarding resource allocation and assessing performance. The Company, which uses consolidated financial information in determining how to allocate resources and assess performance, has concluded that our specialty pharmaceutical products compete in similar economic markets and similar circumstances.  Substantially all of the Company&#x2019;s assets are located in the United States and total revenues are primarily attributable to U.S.&#160;customers.</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zMS9mcmFnOjc4MTgyYzdiODkwMzRkOTdhYWUyNDJlZGY3MzU3NmU5L3RleHRyZWdpb246NzgxODJjN2I4OTAzNGQ5N2FhZTI0MmVkZjczNTc2ZTlfMTAwMzI_3a7841ca-7519-41ae-91eb-bbe84bc731f4">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Guidance&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent Accounting Pronouncements - Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the Financial Accounting Standards Board ("FASB") issued ASU No. 2016-13, &#x201c;Financial Instruments-Credit Losses,&#x201d; which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other instruments, companies will be required to use a new forward-looking &#x201c;expected loss&#x201d; model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, companies will measure credit losses in a manner similar to what they do today, except that the losses will be recognized as allowances rather than as reductions in the amortized cost of the securities. Companies will have to disclose additional information, including information they use to track credit quality by year of origination for most financing receivables. Companies will apply the ASU&#x2019;s provisions as a cumulative-effect adjustment, if any, to retained earnings as of the beginning of the first reporting period in which the guidance is adopted.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Related to ASU No. 2016-13 discussed above, in May 2019, the FASB issued ASU 2019-05, "Financial Instruments-Credit Losses (Topic 326): Targeted Transition Relief" which provides transition relief for ASU 2016-13 by providing entities with an alternative to irrevocably elect the fair value option for eligible financial assets measured at amortized cost upon adoption of the new credit losses standard. Certain eligibility requirements must be met and the election must be applied on an instrument-by-instrument basis. The election is not available for either available-for-sale or held-to-maturity debt securities. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company will adopt both ASU 2016-13 and ASU 2019-05 on January 1, 2023. The adoption of ASU 2016-13 and ASU 2019-05 are not expected to have a material impact on the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zMS9mcmFnOjc4MTgyYzdiODkwMzRkOTdhYWUyNDJlZGY3MzU3NmU5L3RleHRyZWdpb246NzgxODJjN2I4OTAzNGQ5N2FhZTI0MmVkZjczNTc2ZTlfMTAwMzU_2fff1938-59dd-444d-801f-b299631abdd1">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management of the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period.  Actual results could differ from those estimates under different assumptions and conditions.  The Company's most significant estimates include: (1) its allowances for chargebacks and accruals for rebates and product returns, (2) the allowances for obsolescent or unmarketable inventory and (3) valuation of a contingent consideration liability associated with a business combination.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zMS9mcmFnOjc4MTgyYzdiODkwMzRkOTdhYWUyNDJlZGY3MzU3NmU5L3RleHRyZWdpb246NzgxODJjN2I4OTAzNGQ5N2FhZTI0MmVkZjczNTc2ZTlfMTAwMzY_7ccfbc10-8b2c-455c-a58c-8d7144bc8c96">Operating SegmentsThe Company has one operating segment which is specialty pharmaceutical products. Management has chosen to organize the Company based on the type of products sold. Operating segments are identified as components of an enterprise about which separate discrete financial information is evaluated by the chief operating decision maker, or decision-making group, in making decisions regarding resource allocation and assessing performance. The Company, which uses consolidated financial information in determining how to allocate resources and assess performance, has concluded that our specialty pharmaceutical products compete in similar economic markets and similar circumstances.  Substantially all of the Company&#x2019;s assets are located in the United States and total revenues are primarily attributable to U.S.&#160;customers.</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zMS9mcmFnOjc4MTgyYzdiODkwMzRkOTdhYWUyNDJlZGY3MzU3NmU5L3RleHRyZWdpb246NzgxODJjN2I4OTAzNGQ5N2FhZTI0MmVkZjczNTc2ZTlfOTIyNQ_1e7893e3-e3b9-4055-b4eb-4c6de5ad02f0"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNC9mcmFnOmQyY2ZkOGMzZjBkMzQxZWY4NWM0ZDRkYzM2OTQ3NjNlL3RleHRyZWdpb246ZDJjZmQ4YzNmMGQzNDFlZjg1YzRkNGRjMzY5NDc2M2VfNDI1_26b21939-0832-4e2d-99c4-98d2376f2724">EARNINGS (LOSS) PER SHARE&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reconciles the numerator and denominator used to calculate diluted earnings (loss) per share for the three and nine months ended September 30, 2021 and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,583,480)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,275,620)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;496,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;777,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,086,693)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(497,704)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (income) loss at subsidiary attributable to noncontrolling interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) attributable to common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,055,278)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(481,737)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares outstanding &#x2013; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,880,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,134,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive effect of other securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares outstanding &#x2013; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,880,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,134,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,209,545)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,838,249)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,491,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,334,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;281,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,503,438)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) at subsidiary attributable to noncontrolling interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) attributable to common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;340,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,455,632)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares outstanding &#x2013; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,939,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,206,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive effect of other securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares outstanding &#x2013; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,139,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,206,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September 30, 2021 and 2020, restricted stock awards and options to purchase 158,900 and 197,210 shares of common stock, respectively, were outstanding but were not included in the computation of diluted earnings per share because the effect would be antidilutive.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNC9mcmFnOmQyY2ZkOGMzZjBkMzQxZWY4NWM0ZDRkYzM2OTQ3NjNlL3RleHRyZWdpb246ZDJjZmQ4YzNmMGQzNDFlZjg1YzRkNGRjMzY5NDc2M2VfNDI3_45196b7b-e2ff-4caa-a182-02ca58cf409d">The following table reconciles the numerator and denominator used to calculate diluted earnings (loss) per share for the three and nine months ended September 30, 2021 and 2020:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,583,480)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,275,620)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;496,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;777,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,086,693)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(497,704)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (income) loss at subsidiary attributable to noncontrolling interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) attributable to common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,055,278)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(481,737)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares outstanding &#x2013; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,880,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,134,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive effect of other securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares outstanding &#x2013; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,880,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,134,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,209,545)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,838,249)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,491,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,334,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;281,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,503,438)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) at subsidiary attributable to noncontrolling interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) attributable to common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;340,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,455,632)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares outstanding &#x2013; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,939,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,206,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive effect of other securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares outstanding &#x2013; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,139,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,206,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5cfdffb6c8a4411a95e4596b0bd91b7c_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNC9mcmFnOmQyY2ZkOGMzZjBkMzQxZWY4NWM0ZDRkYzM2OTQ3NjNlL3RhYmxlOjYxZTdjZDNjMmM5ZTRkYzQ5MzI4MWE4ZjQ5MzgzMjA2L3RhYmxlcmFuZ2U6NjFlN2NkM2MyYzllNGRjNDkzMjgxYThmNDkzODMyMDZfMy0xLTEtMS05NTU4_3656b68a-e37c-4633-8dd8-a003efd3e39e"
      unitRef="usd">-1583480</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie2722c94900c4f68be9dd446637b8348_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNC9mcmFnOmQyY2ZkOGMzZjBkMzQxZWY4NWM0ZDRkYzM2OTQ3NjNlL3RhYmxlOjYxZTdjZDNjMmM5ZTRkYzQ5MzI4MWE4ZjQ5MzgzMjA2L3RhYmxlcmFuZ2U6NjFlN2NkM2MyYzllNGRjNDkzMjgxYThmNDkzODMyMDZfMy0zLTEtMS05NTU4_ec6850d2-e817-4b14-9487-ff3e910e4c91"
      unitRef="usd">-1275620</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ieb58760ea84940319b35492cd1910735_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNC9mcmFnOmQyY2ZkOGMzZjBkMzQxZWY4NWM0ZDRkYzM2OTQ3NjNlL3RhYmxlOjYxZTdjZDNjMmM5ZTRkYzQ5MzI4MWE4ZjQ5MzgzMjA2L3RhYmxlcmFuZ2U6NjFlN2NkM2MyYzllNGRjNDkzMjgxYThmNDkzODMyMDZfNC0xLTEtMS05NTU4_86849bd9-9c34-42dc-a4b6-2061e77af27b"
      unitRef="usd">496787</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifca7f9fa06d14f85a52cbd81ac170d2c_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNC9mcmFnOmQyY2ZkOGMzZjBkMzQxZWY4NWM0ZDRkYzM2OTQ3NjNlL3RhYmxlOjYxZTdjZDNjMmM5ZTRkYzQ5MzI4MWE4ZjQ5MzgzMjA2L3RhYmxlcmFuZ2U6NjFlN2NkM2MyYzllNGRjNDkzMjgxYThmNDkzODMyMDZfNC0zLTEtMS05NTU4_0fe8db84-b272-4c9f-a304-4c34cd7b14a3"
      unitRef="usd">777916</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ProfitLoss
      contextRef="i5cfdffb6c8a4411a95e4596b0bd91b7c_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNC9mcmFnOmQyY2ZkOGMzZjBkMzQxZWY4NWM0ZDRkYzM2OTQ3NjNlL3RhYmxlOjYxZTdjZDNjMmM5ZTRkYzQ5MzI4MWE4ZjQ5MzgzMjA2L3RhYmxlcmFuZ2U6NjFlN2NkM2MyYzllNGRjNDkzMjgxYThmNDkzODMyMDZfNS0xLTEtMS05NTU4_06c37d4c-3b8e-4e9d-9a49-fdc7ea9995d1"
      unitRef="usd">-1086693</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ie2722c94900c4f68be9dd446637b8348_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNC9mcmFnOmQyY2ZkOGMzZjBkMzQxZWY4NWM0ZDRkYzM2OTQ3NjNlL3RhYmxlOjYxZTdjZDNjMmM5ZTRkYzQ5MzI4MWE4ZjQ5MzgzMjA2L3RhYmxlcmFuZ2U6NjFlN2NkM2MyYzllNGRjNDkzMjgxYThmNDkzODMyMDZfNS0zLTEtMS05NTU4_1cc0f468-27ca-4623-bd4d-04fecde16f42"
      unitRef="usd">-497704</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i5cfdffb6c8a4411a95e4596b0bd91b7c_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNC9mcmFnOmQyY2ZkOGMzZjBkMzQxZWY4NWM0ZDRkYzM2OTQ3NjNlL3RhYmxlOjYxZTdjZDNjMmM5ZTRkYzQ5MzI4MWE4ZjQ5MzgzMjA2L3RhYmxlcmFuZ2U6NjFlN2NkM2MyYzllNGRjNDkzMjgxYThmNDkzODMyMDZfNi0xLTEtMS05NTU4_95b61dfc-d977-4115-94c6-54e0d0af5a99"
      unitRef="usd">-31415</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ie2722c94900c4f68be9dd446637b8348_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNC9mcmFnOmQyY2ZkOGMzZjBkMzQxZWY4NWM0ZDRkYzM2OTQ3NjNlL3RhYmxlOjYxZTdjZDNjMmM5ZTRkYzQ5MzI4MWE4ZjQ5MzgzMjA2L3RhYmxlcmFuZ2U6NjFlN2NkM2MyYzllNGRjNDkzMjgxYThmNDkzODMyMDZfNi0zLTEtMS05NTU4_2141b745-6e38-4f81-959c-3756a18c45c0"
      unitRef="usd">-15967</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i5cfdffb6c8a4411a95e4596b0bd91b7c_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNC9mcmFnOmQyY2ZkOGMzZjBkMzQxZWY4NWM0ZDRkYzM2OTQ3NjNlL3RhYmxlOjYxZTdjZDNjMmM5ZTRkYzQ5MzI4MWE4ZjQ5MzgzMjA2L3RhYmxlcmFuZ2U6NjFlN2NkM2MyYzllNGRjNDkzMjgxYThmNDkzODMyMDZfNy0xLTEtMS05NTU4_8e25e5e8-98f3-44fe-bcfe-7cb6ae67a6e0"
      unitRef="usd">-1055278</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie2722c94900c4f68be9dd446637b8348_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNC9mcmFnOmQyY2ZkOGMzZjBkMzQxZWY4NWM0ZDRkYzM2OTQ3NjNlL3RhYmxlOjYxZTdjZDNjMmM5ZTRkYzQ5MzI4MWE4ZjQ5MzgzMjA2L3RhYmxlcmFuZ2U6NjFlN2NkM2MyYzllNGRjNDkzMjgxYThmNDkzODMyMDZfNy0zLTEtMS05NTU4_4df57ef8-bc72-4d47-97d5-a0535ac6e0d4"
      unitRef="usd">-481737</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i5cfdffb6c8a4411a95e4596b0bd91b7c_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNC9mcmFnOmQyY2ZkOGMzZjBkMzQxZWY4NWM0ZDRkYzM2OTQ3NjNlL3RhYmxlOjYxZTdjZDNjMmM5ZTRkYzQ5MzI4MWE4ZjQ5MzgzMjA2L3RhYmxlcmFuZ2U6NjFlN2NkM2MyYzllNGRjNDkzMjgxYThmNDkzODMyMDZfOS0xLTEtMS05NTU4_b5e1a767-1b86-4012-89bc-7628a19420c8"
      unitRef="shares">14880887</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ie2722c94900c4f68be9dd446637b8348_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNC9mcmFnOmQyY2ZkOGMzZjBkMzQxZWY4NWM0ZDRkYzM2OTQ3NjNlL3RhYmxlOjYxZTdjZDNjMmM5ZTRkYzQ5MzI4MWE4ZjQ5MzgzMjA2L3RhYmxlcmFuZ2U6NjFlN2NkM2MyYzllNGRjNDkzMjgxYThmNDkzODMyMDZfOS0zLTEtMS05NTU4_7ddc136a-92bb-439a-a38a-0bfad779387e"
      unitRef="shares">15134583</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i5cfdffb6c8a4411a95e4596b0bd91b7c_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNC9mcmFnOmQyY2ZkOGMzZjBkMzQxZWY4NWM0ZDRkYzM2OTQ3NjNlL3RhYmxlOjYxZTdjZDNjMmM5ZTRkYzQ5MzI4MWE4ZjQ5MzgzMjA2L3RhYmxlcmFuZ2U6NjFlN2NkM2MyYzllNGRjNDkzMjgxYThmNDkzODMyMDZfMTAtMS0xLTEtOTU1OA_bf99d36d-91d8-4d26-9d88-a39c983f0874"
      unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="ie2722c94900c4f68be9dd446637b8348_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNC9mcmFnOmQyY2ZkOGMzZjBkMzQxZWY4NWM0ZDRkYzM2OTQ3NjNlL3RhYmxlOjYxZTdjZDNjMmM5ZTRkYzQ5MzI4MWE4ZjQ5MzgzMjA2L3RhYmxlcmFuZ2U6NjFlN2NkM2MyYzllNGRjNDkzMjgxYThmNDkzODMyMDZfMTAtMy0xLTEtOTU1OA_2f272c37-da51-4356-beb0-a57c619788e9"
      unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i5cfdffb6c8a4411a95e4596b0bd91b7c_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNC9mcmFnOmQyY2ZkOGMzZjBkMzQxZWY4NWM0ZDRkYzM2OTQ3NjNlL3RhYmxlOjYxZTdjZDNjMmM5ZTRkYzQ5MzI4MWE4ZjQ5MzgzMjA2L3RhYmxlcmFuZ2U6NjFlN2NkM2MyYzllNGRjNDkzMjgxYThmNDkzODMyMDZfMTEtMS0xLTEtOTU1OA_206d45ec-0dfd-4dad-a09c-708e034903c8"
      unitRef="shares">14880887</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ie2722c94900c4f68be9dd446637b8348_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNC9mcmFnOmQyY2ZkOGMzZjBkMzQxZWY4NWM0ZDRkYzM2OTQ3NjNlL3RhYmxlOjYxZTdjZDNjMmM5ZTRkYzQ5MzI4MWE4ZjQ5MzgzMjA2L3RhYmxlcmFuZ2U6NjFlN2NkM2MyYzllNGRjNDkzMjgxYThmNDkzODMyMDZfMTEtMy0xLTEtOTU1OA_3069879d-a3f8-4c09-bc47-66a88a16ffee"
      unitRef="shares">15134583</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNC9mcmFnOmQyY2ZkOGMzZjBkMzQxZWY4NWM0ZDRkYzM2OTQ3NjNlL3RhYmxlOjliMDI5ZWFiYjZiNDQ3MDhhMmJmMGYzZDEyNTk5ZGViL3RhYmxlcmFuZ2U6OWIwMjllYWJiNmI0NDcwOGEyYmYwZjNkMTI1OTlkZWJfNC0xLTEtMS05NTU4_4c64bffd-ba77-41a6-8d18-51bfc653c845"
      unitRef="usd">-1209545</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNC9mcmFnOmQyY2ZkOGMzZjBkMzQxZWY4NWM0ZDRkYzM2OTQ3NjNlL3RhYmxlOjliMDI5ZWFiYjZiNDQ3MDhhMmJmMGYzZDEyNTk5ZGViL3RhYmxlcmFuZ2U6OWIwMjllYWJiNmI0NDcwOGEyYmYwZjNkMTI1OTlkZWJfNC0zLTEtMS05NTU4_85fb5be7-0aae-4020-9da3-9e25c9015f6a"
      unitRef="usd">-4838249</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i45bdfab35dd74d60ac86fc023b908b73_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNC9mcmFnOmQyY2ZkOGMzZjBkMzQxZWY4NWM0ZDRkYzM2OTQ3NjNlL3RhYmxlOjliMDI5ZWFiYjZiNDQ3MDhhMmJmMGYzZDEyNTk5ZGViL3RhYmxlcmFuZ2U6OWIwMjllYWJiNmI0NDcwOGEyYmYwZjNkMTI1OTlkZWJfNS0xLTEtMS05NTU4_1acd7b61-10d3-4d57-a3bb-db27abac79f0"
      unitRef="usd">1491004</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib8c8802e62b74a919450a1c6017bba7e_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNC9mcmFnOmQyY2ZkOGMzZjBkMzQxZWY4NWM0ZDRkYzM2OTQ3NjNlL3RhYmxlOjliMDI5ZWFiYjZiNDQ3MDhhMmJmMGYzZDEyNTk5ZGViL3RhYmxlcmFuZ2U6OWIwMjllYWJiNmI0NDcwOGEyYmYwZjNkMTI1OTlkZWJfNS0zLTEtMS05NTU4_841b8fa5-722e-49de-805f-6e1ba99049bf"
      unitRef="usd">2334811</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ProfitLoss
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNC9mcmFnOmQyY2ZkOGMzZjBkMzQxZWY4NWM0ZDRkYzM2OTQ3NjNlL3RhYmxlOjliMDI5ZWFiYjZiNDQ3MDhhMmJmMGYzZDEyNTk5ZGViL3RhYmxlcmFuZ2U6OWIwMjllYWJiNmI0NDcwOGEyYmYwZjNkMTI1OTlkZWJfNi0xLTEtMS05NTU4_4dba1ef6-53d1-42f8-8c8d-2ffd0332f6c6"
      unitRef="usd">281459</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNC9mcmFnOmQyY2ZkOGMzZjBkMzQxZWY4NWM0ZDRkYzM2OTQ3NjNlL3RhYmxlOjliMDI5ZWFiYjZiNDQ3MDhhMmJmMGYzZDEyNTk5ZGViL3RhYmxlcmFuZ2U6OWIwMjllYWJiNmI0NDcwOGEyYmYwZjNkMTI1OTlkZWJfNi0zLTEtMS05NTU4_72f6cf1b-b278-4755-bba1-690b049afff5"
      unitRef="usd">-2503438</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNC9mcmFnOmQyY2ZkOGMzZjBkMzQxZWY4NWM0ZDRkYzM2OTQ3NjNlL3RhYmxlOjliMDI5ZWFiYjZiNDQ3MDhhMmJmMGYzZDEyNTk5ZGViL3RhYmxlcmFuZ2U6OWIwMjllYWJiNmI0NDcwOGEyYmYwZjNkMTI1OTlkZWJfNy0xLTEtMS05NTU4_ce0a12c3-7567-454b-93ce-355822e98dea"
      unitRef="usd">-58651</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNC9mcmFnOmQyY2ZkOGMzZjBkMzQxZWY4NWM0ZDRkYzM2OTQ3NjNlL3RhYmxlOjliMDI5ZWFiYjZiNDQ3MDhhMmJmMGYzZDEyNTk5ZGViL3RhYmxlcmFuZ2U6OWIwMjllYWJiNmI0NDcwOGEyYmYwZjNkMTI1OTlkZWJfNy0zLTEtMS05NTU4_f17bcff7-0f96-4279-931e-32336eb1034d"
      unitRef="usd">-47806</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNC9mcmFnOmQyY2ZkOGMzZjBkMzQxZWY4NWM0ZDRkYzM2OTQ3NjNlL3RhYmxlOjliMDI5ZWFiYjZiNDQ3MDhhMmJmMGYzZDEyNTk5ZGViL3RhYmxlcmFuZ2U6OWIwMjllYWJiNmI0NDcwOGEyYmYwZjNkMTI1OTlkZWJfOC0xLTEtMS05NTU4_5cb25c6b-5d1e-43e1-a9db-72676163fbcd"
      unitRef="usd">340110</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNC9mcmFnOmQyY2ZkOGMzZjBkMzQxZWY4NWM0ZDRkYzM2OTQ3NjNlL3RhYmxlOjliMDI5ZWFiYjZiNDQ3MDhhMmJmMGYzZDEyNTk5ZGViL3RhYmxlcmFuZ2U6OWIwMjllYWJiNmI0NDcwOGEyYmYwZjNkMTI1OTlkZWJfOC0zLTEtMS05NTU4_f7aef4bc-6f7d-491b-8a3f-1c613544acf4"
      unitRef="usd">-2455632</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNC9mcmFnOmQyY2ZkOGMzZjBkMzQxZWY4NWM0ZDRkYzM2OTQ3NjNlL3RhYmxlOjliMDI5ZWFiYjZiNDQ3MDhhMmJmMGYzZDEyNTk5ZGViL3RhYmxlcmFuZ2U6OWIwMjllYWJiNmI0NDcwOGEyYmYwZjNkMTI1OTlkZWJfMTAtMS0xLTEtOTU1OA_8cdb33ce-1515-4327-ae98-f1d30f78e45a"
      unitRef="shares">14939919</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNC9mcmFnOmQyY2ZkOGMzZjBkMzQxZWY4NWM0ZDRkYzM2OTQ3NjNlL3RhYmxlOjliMDI5ZWFiYjZiNDQ3MDhhMmJmMGYzZDEyNTk5ZGViL3RhYmxlcmFuZ2U6OWIwMjllYWJiNmI0NDcwOGEyYmYwZjNkMTI1OTlkZWJfMTAtMy0xLTEtOTU1OA_3cebfc23-7264-4ddc-9953-b2de72843968"
      unitRef="shares">15206179</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNC9mcmFnOmQyY2ZkOGMzZjBkMzQxZWY4NWM0ZDRkYzM2OTQ3NjNlL3RhYmxlOjliMDI5ZWFiYjZiNDQ3MDhhMmJmMGYzZDEyNTk5ZGViL3RhYmxlcmFuZ2U6OWIwMjllYWJiNmI0NDcwOGEyYmYwZjNkMTI1OTlkZWJfMTEtMS0xLTEtOTU1OA_605da32d-fcf5-4109-8a79-0d27864d7f97"
      unitRef="shares">199985</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNC9mcmFnOmQyY2ZkOGMzZjBkMzQxZWY4NWM0ZDRkYzM2OTQ3NjNlL3RhYmxlOjliMDI5ZWFiYjZiNDQ3MDhhMmJmMGYzZDEyNTk5ZGViL3RhYmxlcmFuZ2U6OWIwMjllYWJiNmI0NDcwOGEyYmYwZjNkMTI1OTlkZWJfMTEtMy0xLTEtOTU1OA_b7b9a4ed-aabc-4e09-b4f1-13c2ea1d4302"
      unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNC9mcmFnOmQyY2ZkOGMzZjBkMzQxZWY4NWM0ZDRkYzM2OTQ3NjNlL3RhYmxlOjliMDI5ZWFiYjZiNDQ3MDhhMmJmMGYzZDEyNTk5ZGViL3RhYmxlcmFuZ2U6OWIwMjllYWJiNmI0NDcwOGEyYmYwZjNkMTI1OTlkZWJfMTItMS0xLTEtOTU1OA_680872eb-8fa6-4a35-8e4b-96a35c60f7b4"
      unitRef="shares">15139904</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNC9mcmFnOmQyY2ZkOGMzZjBkMzQxZWY4NWM0ZDRkYzM2OTQ3NjNlL3RhYmxlOjliMDI5ZWFiYjZiNDQ3MDhhMmJmMGYzZDEyNTk5ZGViL3RhYmxlcmFuZ2U6OWIwMjllYWJiNmI0NDcwOGEyYmYwZjNkMTI1OTlkZWJfMTItMy0xLTEtOTU1OA_74c47ba6-d296-4d83-a36d-d18b2064f105"
      unitRef="shares">15206179</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNC9mcmFnOmQyY2ZkOGMzZjBkMzQxZWY4NWM0ZDRkYzM2OTQ3NjNlL3RleHRyZWdpb246ZDJjZmQ4YzNmMGQzNDFlZjg1YzRkNGRjMzY5NDc2M2VfMjQ4_c4b236a3-aad2-42f6-9b3f-a778532730c3"
      unitRef="shares">158900</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNC9mcmFnOmQyY2ZkOGMzZjBkMzQxZWY4NWM0ZDRkYzM2OTQ3NjNlL3RleHRyZWdpb246ZDJjZmQ4YzNmMGQzNDFlZjg1YzRkNGRjMzY5NDc2M2VfMjU1_c475d801-9266-4d56-8a11-b84fca1875bd"
      unitRef="shares">197210</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNy9mcmFnOmZhYjQ3ZTJiZjBhZTQ3MTc4YjdkOGZjNmZmMzExMzYwL3RleHRyZWdpb246ZmFiNDdlMmJmMGFlNDcxNzhiN2Q4ZmM2ZmYzMTEzNjBfMjU3NQ_1531aca6-8f7d-4f5a-92b9-225d8b4fdab2">REVENUES&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for revenues from contracts with customers under ASC 606, which became effective January 1, 2018. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s net revenues consisted of the following for the three and nine months ended September 30, 2021 and 2020:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.397%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Products:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Kristalose&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,012,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,615,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,286,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,387,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vibativ&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,896,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,813,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,799,891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,551,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Caldolor&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,255,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,416,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,734,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,677,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vaprisol&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;325,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;406,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,861,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;790,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acetadote&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;368,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;638,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,527,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Omeclamox-Pak&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;516,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(451,683)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;640,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RediTrex&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,291)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;265,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;809,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,605,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,072,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,250,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,665,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,179,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Omeclamox-Pak revenue for the first, second and third quarter of 2021 was the result of Cumberland currently being out of commercial inventory of this product.  The packager for our Omeclamox-Pak product encountered financial difficulties due to the impact of COVID-19.  They are under new management and are in the process of a reorganization. Discussions with the packager are ongoing.  In the third quarter of 2021, the amounts noted were normal adjustments by channel partners.  Net revenue was  negatively impacted by product returns during the periods. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has agreements with international partners for commercialization of the Company's products with associated payments included in other revenues. Those agreements provide that each of the partners are responsible for seeking regulatory approvals for the product, and following approval, each partner will be responsible for the ongoing distribution and sales in the respective international territories. The Company provides a dossier for product registration and maintains responsibility for the relevant intellectual property. Cumberland is typically entitled to receive a non-refundable, up-front payment at the time each agreement is executed as consideration for the product dossier and for the rights to the distinct intellectual property rights in the respective international territory. These agreements also typically provide for additional payments upon a partner&#x2019;s achievement of a defined regulatory approval and sales milestones. The Company may also be entitled to receive royalties on future sales of the products and a transfer price on supplies.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contractual payments associated with the partner&#x2019;s achievement of regulatory approvals, sales milestones and royalties on future sales are recognized as revenue upon occurrence, or at such time that the Company has a high degree of confidence that the revenue would not be reversed in a subsequent period.&lt;/span&gt;&lt;/div&gt;Other revenues also include funding from federal grant programs including those secured by CET through the Small Business Administration as well as lease income generated by CET&#x2019;s Life Sciences Center. The Life Sciences Center is a research center that provides scientists with access to flexible lab space and other resources to develop biomedical products. Grant revenue from these programs totaled approximately $0.02&#160;million and $0.1 million for the three months ended September 30, 2021 and 2020</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNy9mcmFnOmZhYjQ3ZTJiZjBhZTQ3MTc4YjdkOGZjNmZmMzExMzYwL3RleHRyZWdpb246ZmFiNDdlMmJmMGFlNDcxNzhiN2Q4ZmM2ZmYzMTEzNjBfMjU3OQ_6e8723dd-0e9c-4e15-94e7-da617c69baec">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s net revenues consisted of the following for the three and nine months ended September 30, 2021 and 2020:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.397%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Products:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Kristalose&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,012,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,615,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,286,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,387,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vibativ&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,896,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,813,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,799,891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,551,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Caldolor&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,255,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,416,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,734,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,677,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vaprisol&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;325,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;406,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,861,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;790,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acetadote&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;368,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;638,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,527,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Omeclamox-Pak&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;516,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(451,683)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;640,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RediTrex&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,291)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;265,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;809,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,605,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,072,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,250,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,665,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,179,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2b064560ae764b05aee16232fc2b982f_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNy9mcmFnOmZhYjQ3ZTJiZjBhZTQ3MTc4YjdkOGZjNmZmMzExMzYwL3RhYmxlOjc1ZWU0YjlmNmU1YjRhYTZhZWEwZTM1ZGQzZmE4NTUwL3RhYmxlcmFuZ2U6NzVlZTRiOWY2ZTViNGFhNmFlYTBlMzVkZDNmYTg1NTBfMy0xLTEtMS05NTU4_b715d0d9-0526-4ec0-b9c5-9d63854e4b5b"
      unitRef="usd">4012746</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if9189ef3c405466780ff2b301ce69072_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNy9mcmFnOmZhYjQ3ZTJiZjBhZTQ3MTc4YjdkOGZjNmZmMzExMzYwL3RhYmxlOjc1ZWU0YjlmNmU1YjRhYTZhZWEwZTM1ZGQzZmE4NTUwL3RhYmxlcmFuZ2U6NzVlZTRiOWY2ZTViNGFhNmFlYTBlMzVkZDNmYTg1NTBfMy0zLTEtMS05NTU4_40ba5e81-fcb0-4362-9f31-7b796c2c6e45"
      unitRef="usd">3615557</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib543c8c5c4a0438eb3b83a9549c72767_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNy9mcmFnOmZhYjQ3ZTJiZjBhZTQ3MTc4YjdkOGZjNmZmMzExMzYwL3RhYmxlOjc1ZWU0YjlmNmU1YjRhYTZhZWEwZTM1ZGQzZmE4NTUwL3RhYmxlcmFuZ2U6NzVlZTRiOWY2ZTViNGFhNmFlYTBlMzVkZDNmYTg1NTBfMy01LTEtMS05NTU4_c4cec850-b5cd-4b3e-a364-57a695a932fc"
      unitRef="usd">12286729</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i851181d1e03446adb4d2b6f666a489e7_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNy9mcmFnOmZhYjQ3ZTJiZjBhZTQ3MTc4YjdkOGZjNmZmMzExMzYwL3RhYmxlOjc1ZWU0YjlmNmU1YjRhYTZhZWEwZTM1ZGQzZmE4NTUwL3RhYmxlcmFuZ2U6NzVlZTRiOWY2ZTViNGFhNmFlYTBlMzVkZDNmYTg1NTBfMy03LTEtMS05NTU4_c3aff0bd-99da-4696-a1fb-f112b43c42d9"
      unitRef="usd">10387046</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i343ad32279094a2585bfa47056ea0769_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNy9mcmFnOmZhYjQ3ZTJiZjBhZTQ3MTc4YjdkOGZjNmZmMzExMzYwL3RhYmxlOjc1ZWU0YjlmNmU1YjRhYTZhZWEwZTM1ZGQzZmE4NTUwL3RhYmxlcmFuZ2U6NzVlZTRiOWY2ZTViNGFhNmFlYTBlMzVkZDNmYTg1NTBfNC0xLTEtMS05NTU4_d2a514f6-bc85-4d76-84a3-581ae3ca6690"
      unitRef="usd">1896584</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idf76fee1053a41f897bb2b308eda43b7_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNy9mcmFnOmZhYjQ3ZTJiZjBhZTQ3MTc4YjdkOGZjNmZmMzExMzYwL3RhYmxlOjc1ZWU0YjlmNmU1YjRhYTZhZWEwZTM1ZGQzZmE4NTUwL3RhYmxlcmFuZ2U6NzVlZTRiOWY2ZTViNGFhNmFlYTBlMzVkZDNmYTg1NTBfNC0zLTEtMS05NTU4_63f7b646-7f06-4718-81cf-677173d193cd"
      unitRef="usd">2813249</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0a175b2126f3439e978ef755a5187703_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNy9mcmFnOmZhYjQ3ZTJiZjBhZTQ3MTc4YjdkOGZjNmZmMzExMzYwL3RhYmxlOjc1ZWU0YjlmNmU1YjRhYTZhZWEwZTM1ZGQzZmE4NTUwL3RhYmxlcmFuZ2U6NzVlZTRiOWY2ZTViNGFhNmFlYTBlMzVkZDNmYTg1NTBfNC01LTEtMS05NTU4_797af799-1dd4-496c-b11b-64ff4c9660b0"
      unitRef="usd">8799891</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1221e6e62b0d4437aa038a1593455cdb_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNy9mcmFnOmZhYjQ3ZTJiZjBhZTQ3MTc4YjdkOGZjNmZmMzExMzYwL3RhYmxlOjc1ZWU0YjlmNmU1YjRhYTZhZWEwZTM1ZGQzZmE4NTUwL3RhYmxlcmFuZ2U6NzVlZTRiOWY2ZTViNGFhNmFlYTBlMzVkZDNmYTg1NTBfNC03LTEtMS05NTU4_18885835-bca3-4034-ae40-ec1503683622"
      unitRef="usd">8551125</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ide5a86375216464d9ebfdf112640aff3_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNy9mcmFnOmZhYjQ3ZTJiZjBhZTQ3MTc4YjdkOGZjNmZmMzExMzYwL3RhYmxlOjc1ZWU0YjlmNmU1YjRhYTZhZWEwZTM1ZGQzZmE4NTUwL3RhYmxlcmFuZ2U6NzVlZTRiOWY2ZTViNGFhNmFlYTBlMzVkZDNmYTg1NTBfNS0xLTEtMS05NTU4_4ecd3416-3be0-4137-b77a-084667a1bde0"
      unitRef="usd">1255669</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2d2eab230e924fb094455dfdb93d19f6_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNy9mcmFnOmZhYjQ3ZTJiZjBhZTQ3MTc4YjdkOGZjNmZmMzExMzYwL3RhYmxlOjc1ZWU0YjlmNmU1YjRhYTZhZWEwZTM1ZGQzZmE4NTUwL3RhYmxlcmFuZ2U6NzVlZTRiOWY2ZTViNGFhNmFlYTBlMzVkZDNmYTg1NTBfNS0zLTEtMS05NTU4_96821b96-9f8c-4cda-8d66-222bf9410a62"
      unitRef="usd">1416146</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib32ee538452d4d108fd0d0249f232e4e_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNy9mcmFnOmZhYjQ3ZTJiZjBhZTQ3MTc4YjdkOGZjNmZmMzExMzYwL3RhYmxlOjc1ZWU0YjlmNmU1YjRhYTZhZWEwZTM1ZGQzZmE4NTUwL3RhYmxlcmFuZ2U6NzVlZTRiOWY2ZTViNGFhNmFlYTBlMzVkZDNmYTg1NTBfNS01LTEtMS05NTU4_63e26ee5-444b-420f-bbdf-8d62b3f3f1f9"
      unitRef="usd">3734273</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie38185217cb649a98c782f849b956b81_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNy9mcmFnOmZhYjQ3ZTJiZjBhZTQ3MTc4YjdkOGZjNmZmMzExMzYwL3RhYmxlOjc1ZWU0YjlmNmU1YjRhYTZhZWEwZTM1ZGQzZmE4NTUwL3RhYmxlcmFuZ2U6NzVlZTRiOWY2ZTViNGFhNmFlYTBlMzVkZDNmYTg1NTBfNS03LTEtMS05NTU4_f35bed30-7729-4eee-ae38-6037a38c4f22"
      unitRef="usd">3677434</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icb5e5973ac81495ca434caa4250ad1e6_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNy9mcmFnOmZhYjQ3ZTJiZjBhZTQ3MTc4YjdkOGZjNmZmMzExMzYwL3RhYmxlOjc1ZWU0YjlmNmU1YjRhYTZhZWEwZTM1ZGQzZmE4NTUwL3RhYmxlcmFuZ2U6NzVlZTRiOWY2ZTViNGFhNmFlYTBlMzVkZDNmYTg1NTBfNi0xLTEtMS05NTU4_bcdc676d-e769-47f8-9e93-4a6af5dae191"
      unitRef="usd">325774</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6f2cff2563f6434383fad1a3433a95bf_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNy9mcmFnOmZhYjQ3ZTJiZjBhZTQ3MTc4YjdkOGZjNmZmMzExMzYwL3RhYmxlOjc1ZWU0YjlmNmU1YjRhYTZhZWEwZTM1ZGQzZmE4NTUwL3RhYmxlcmFuZ2U6NzVlZTRiOWY2ZTViNGFhNmFlYTBlMzVkZDNmYTg1NTBfNi0zLTEtMS05NTU4_14b486ec-0bd1-4898-bb20-f5e8383adc00"
      unitRef="usd">406162</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i87b67bdb94e6413eab1ada4bb36a71b7_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNy9mcmFnOmZhYjQ3ZTJiZjBhZTQ3MTc4YjdkOGZjNmZmMzExMzYwL3RhYmxlOjc1ZWU0YjlmNmU1YjRhYTZhZWEwZTM1ZGQzZmE4NTUwL3RhYmxlcmFuZ2U6NzVlZTRiOWY2ZTViNGFhNmFlYTBlMzVkZDNmYTg1NTBfNi01LTEtMS05NTU4_531a4f67-3812-4d7b-b851-f55ca5fa72ea"
      unitRef="usd">1861130</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i70e186cdc2a444de9d34c6b0a9840fa3_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNy9mcmFnOmZhYjQ3ZTJiZjBhZTQ3MTc4YjdkOGZjNmZmMzExMzYwL3RhYmxlOjc1ZWU0YjlmNmU1YjRhYTZhZWEwZTM1ZGQzZmE4NTUwL3RhYmxlcmFuZ2U6NzVlZTRiOWY2ZTViNGFhNmFlYTBlMzVkZDNmYTg1NTBfNi03LTEtMS05NTU4_c31d8057-e712-41e2-9a8c-fb2cec4a248d"
      unitRef="usd">790817</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0301ef84e6814fc1afd5bda0bb02be0c_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNy9mcmFnOmZhYjQ3ZTJiZjBhZTQ3MTc4YjdkOGZjNmZmMzExMzYwL3RhYmxlOjc1ZWU0YjlmNmU1YjRhYTZhZWEwZTM1ZGQzZmE4NTUwL3RhYmxlcmFuZ2U6NzVlZTRiOWY2ZTViNGFhNmFlYTBlMzVkZDNmYTg1NTBfNy0xLTEtMS05NTU4_be1eda32-358a-4637-973c-011b99e02535"
      unitRef="usd">368733</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i10d6fa0a80234f6fbdf7f486df4beed1_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNy9mcmFnOmZhYjQ3ZTJiZjBhZTQ3MTc4YjdkOGZjNmZmMzExMzYwL3RhYmxlOjc1ZWU0YjlmNmU1YjRhYTZhZWEwZTM1ZGQzZmE4NTUwL3RhYmxlcmFuZ2U6NzVlZTRiOWY2ZTViNGFhNmFlYTBlMzVkZDNmYTg1NTBfNy0zLTEtMS05NTU4_8332fef3-e4a9-44d8-ad11-1ef54e387727"
      unitRef="usd">218462</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iba2b0e3ce8dc46a892511cbd1f0b38cf_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNy9mcmFnOmZhYjQ3ZTJiZjBhZTQ3MTc4YjdkOGZjNmZmMzExMzYwL3RhYmxlOjc1ZWU0YjlmNmU1YjRhYTZhZWEwZTM1ZGQzZmE4NTUwL3RhYmxlcmFuZ2U6NzVlZTRiOWY2ZTViNGFhNmFlYTBlMzVkZDNmYTg1NTBfNy01LTEtMS05NTU4_40b59073-22bc-4624-b110-4dcc10f7f41d"
      unitRef="usd">638704</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2075e961d64a4c4184f2117135160c9e_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNy9mcmFnOmZhYjQ3ZTJiZjBhZTQ3MTc4YjdkOGZjNmZmMzExMzYwL3RhYmxlOjc1ZWU0YjlmNmU1YjRhYTZhZWEwZTM1ZGQzZmE4NTUwL3RhYmxlcmFuZ2U6NzVlZTRiOWY2ZTViNGFhNmFlYTBlMzVkZDNmYTg1NTBfNy03LTEtMS05NTU4_f267816f-c3dc-49ff-b1c1-3e8d6c459f9a"
      unitRef="usd">1527173</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i67bca755a168477fb7af6f54edd41311_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNy9mcmFnOmZhYjQ3ZTJiZjBhZTQ3MTc4YjdkOGZjNmZmMzExMzYwL3RhYmxlOjc1ZWU0YjlmNmU1YjRhYTZhZWEwZTM1ZGQzZmE4NTUwL3RhYmxlcmFuZ2U6NzVlZTRiOWY2ZTViNGFhNmFlYTBlMzVkZDNmYTg1NTBfOC0xLTEtMS05NTU4_45967abd-c12f-4676-9e2c-1e3bc25499eb"
      unitRef="usd">22689</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i369b52ac1f754a4a9275b8917dc3bb9d_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNy9mcmFnOmZhYjQ3ZTJiZjBhZTQ3MTc4YjdkOGZjNmZmMzExMzYwL3RhYmxlOjc1ZWU0YjlmNmU1YjRhYTZhZWEwZTM1ZGQzZmE4NTUwL3RhYmxlcmFuZ2U6NzVlZTRiOWY2ZTViNGFhNmFlYTBlMzVkZDNmYTg1NTBfOC0zLTEtMS05NTU4_a978c324-8dac-4cc2-adbe-bf474d3b5e4d"
      unitRef="usd">516066</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2206c2c78e3347cf9fd2bb7625961847_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNy9mcmFnOmZhYjQ3ZTJiZjBhZTQ3MTc4YjdkOGZjNmZmMzExMzYwL3RhYmxlOjc1ZWU0YjlmNmU1YjRhYTZhZWEwZTM1ZGQzZmE4NTUwL3RhYmxlcmFuZ2U6NzVlZTRiOWY2ZTViNGFhNmFlYTBlMzVkZDNmYTg1NTBfOC01LTEtMS05NTU4_eed0fb91-555b-4171-94dc-a07afa3ca379"
      unitRef="usd">-451683</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i64299c3a88d84d888de7a4e8264da6a1_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNy9mcmFnOmZhYjQ3ZTJiZjBhZTQ3MTc4YjdkOGZjNmZmMzExMzYwL3RhYmxlOjc1ZWU0YjlmNmU1YjRhYTZhZWEwZTM1ZGQzZmE4NTUwL3RhYmxlcmFuZ2U6NzVlZTRiOWY2ZTViNGFhNmFlYTBlMzVkZDNmYTg1NTBfOC03LTEtMS05NTU4_dacbc3b7-5e42-48e1-b1ab-ebba0035bb20"
      unitRef="usd">640435</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ica59276837544b3e89921005c9db373f_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNy9mcmFnOmZhYjQ3ZTJiZjBhZTQ3MTc4YjdkOGZjNmZmMzExMzYwL3RhYmxlOjc1ZWU0YjlmNmU1YjRhYTZhZWEwZTM1ZGQzZmE4NTUwL3RhYmxlcmFuZ2U6NzVlZTRiOWY2ZTViNGFhNmFlYTBlMzVkZDNmYTg1NTBfOS0xLTEtMS05NTU4_2feb4625-fa02-4d92-9863-fbba89eb19a8"
      unitRef="usd">11459</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8d8203f933864c8d869320c4b6ce16d2_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNy9mcmFnOmZhYjQ3ZTJiZjBhZTQ3MTc4YjdkOGZjNmZmMzExMzYwL3RhYmxlOjc1ZWU0YjlmNmU1YjRhYTZhZWEwZTM1ZGQzZmE4NTUwL3RhYmxlcmFuZ2U6NzVlZTRiOWY2ZTViNGFhNmFlYTBlMzVkZDNmYTg1NTBfOS0zLTEtMS05NTU4_90e04b12-42da-42f9-ad8f-f506afdf6003"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if79d16ca01cf493f84c3a1bcbcf07c1d_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNy9mcmFnOmZhYjQ3ZTJiZjBhZTQ3MTc4YjdkOGZjNmZmMzExMzYwL3RhYmxlOjc1ZWU0YjlmNmU1YjRhYTZhZWEwZTM1ZGQzZmE4NTUwL3RhYmxlcmFuZ2U6NzVlZTRiOWY2ZTViNGFhNmFlYTBlMzVkZDNmYTg1NTBfOS01LTEtMS05NTU4_1a62f132-804a-4a37-8260-0b224d0637d8"
      unitRef="usd">-13291</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id3900d92fcea4358838f65d608ad8088_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNy9mcmFnOmZhYjQ3ZTJiZjBhZTQ3MTc4YjdkOGZjNmZmMzExMzYwL3RhYmxlOjc1ZWU0YjlmNmU1YjRhYTZhZWEwZTM1ZGQzZmE4NTUwL3RhYmxlcmFuZ2U6NzVlZTRiOWY2ZTViNGFhNmFlYTBlMzVkZDNmYTg1NTBfOS03LTEtMS05NTU4_4a6e8da3-122d-455f-b241-eaff3c73e5ab"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5d6efd6bd2c041769f9fbf0d1a3e5685_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNy9mcmFnOmZhYjQ3ZTJiZjBhZTQ3MTc4YjdkOGZjNmZmMzExMzYwL3RhYmxlOjc1ZWU0YjlmNmU1YjRhYTZhZWEwZTM1ZGQzZmE4NTUwL3RhYmxlcmFuZ2U6NzVlZTRiOWY2ZTViNGFhNmFlYTBlMzVkZDNmYTg1NTBfMTAtMS0xLTEtOTU1OA_fc5c19a4-ab1e-4bd2-b9cf-4004082f324d"
      unitRef="usd">178886</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1571108ca25f4e179a9d14073629ae96_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNy9mcmFnOmZhYjQ3ZTJiZjBhZTQ3MTc4YjdkOGZjNmZmMzExMzYwL3RhYmxlOjc1ZWU0YjlmNmU1YjRhYTZhZWEwZTM1ZGQzZmE4NTUwL3RhYmxlcmFuZ2U6NzVlZTRiOWY2ZTViNGFhNmFlYTBlMzVkZDNmYTg1NTBfMTAtMy0xLTEtOTU1OA_79c09d38-4aa3-4992-8f2c-de5df9d3ffc3"
      unitRef="usd">265047</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8cf12a139ea74881b685de000f63434e_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNy9mcmFnOmZhYjQ3ZTJiZjBhZTQ3MTc4YjdkOGZjNmZmMzExMzYwL3RhYmxlOjc1ZWU0YjlmNmU1YjRhYTZhZWEwZTM1ZGQzZmE4NTUwL3RhYmxlcmFuZ2U6NzVlZTRiOWY2ZTViNGFhNmFlYTBlMzVkZDNmYTg1NTBfMTAtNS0xLTEtOTU1OA_558f692d-3089-4277-8ea5-29151151b7f3"
      unitRef="usd">809429</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idbd3b5d4865547179a8bf7fbe50a430c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNy9mcmFnOmZhYjQ3ZTJiZjBhZTQ3MTc4YjdkOGZjNmZmMzExMzYwL3RhYmxlOjc1ZWU0YjlmNmU1YjRhYTZhZWEwZTM1ZGQzZmE4NTUwL3RhYmxlcmFuZ2U6NzVlZTRiOWY2ZTViNGFhNmFlYTBlMzVkZDNmYTg1NTBfMTAtNy0xLTEtOTU1OA_fac5f00f-89f8-4736-a229-122f163e68dc"
      unitRef="usd">1605570</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5cfdffb6c8a4411a95e4596b0bd91b7c_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNy9mcmFnOmZhYjQ3ZTJiZjBhZTQ3MTc4YjdkOGZjNmZmMzExMzYwL3RhYmxlOjc1ZWU0YjlmNmU1YjRhYTZhZWEwZTM1ZGQzZmE4NTUwL3RhYmxlcmFuZ2U6NzVlZTRiOWY2ZTViNGFhNmFlYTBlMzVkZDNmYTg1NTBfMTEtMS0xLTEtOTU1OA_b6ac83bd-0458-4369-9a85-f470187e7f82"
      unitRef="usd">8072540</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie2722c94900c4f68be9dd446637b8348_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNy9mcmFnOmZhYjQ3ZTJiZjBhZTQ3MTc4YjdkOGZjNmZmMzExMzYwL3RhYmxlOjc1ZWU0YjlmNmU1YjRhYTZhZWEwZTM1ZGQzZmE4NTUwL3RhYmxlcmFuZ2U6NzVlZTRiOWY2ZTViNGFhNmFlYTBlMzVkZDNmYTg1NTBfMTEtMy0xLTEtOTU1OA_19f350b8-1c28-49a7-bf10-2f42e94db843"
      unitRef="usd">9250689</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNy9mcmFnOmZhYjQ3ZTJiZjBhZTQ3MTc4YjdkOGZjNmZmMzExMzYwL3RhYmxlOjc1ZWU0YjlmNmU1YjRhYTZhZWEwZTM1ZGQzZmE4NTUwL3RhYmxlcmFuZ2U6NzVlZTRiOWY2ZTViNGFhNmFlYTBlMzVkZDNmYTg1NTBfMTEtNS0xLTEtOTU1OA_0094e52f-9c3c-4142-a794-86eaf014acc6"
      unitRef="usd">27665182</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNy9mcmFnOmZhYjQ3ZTJiZjBhZTQ3MTc4YjdkOGZjNmZmMzExMzYwL3RhYmxlOjc1ZWU0YjlmNmU1YjRhYTZhZWEwZTM1ZGQzZmE4NTUwL3RhYmxlcmFuZ2U6NzVlZTRiOWY2ZTViNGFhNmFlYTBlMzVkZDNmYTg1NTBfMTEtNy0xLTEtOTU1OA_bc779da5-b1ab-41b7-b6de-50878abe327d"
      unitRef="usd">27179600</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7beb09efdc954e3387adf27b4cc99538_D20210701-20210930"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNy9mcmFnOmZhYjQ3ZTJiZjBhZTQ3MTc4YjdkOGZjNmZmMzExMzYwL3RleHRyZWdpb246ZmFiNDdlMmJmMGFlNDcxNzhiN2Q4ZmM2ZmYzMTEzNjBfMjUxNQ_e38456b6-7808-436d-8cb6-1af633fc202d"
      unitRef="usd">20000.00</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9c591eb458184e3baae21c9c26245264_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNy9mcmFnOmZhYjQ3ZTJiZjBhZTQ3MTc4YjdkOGZjNmZmMzExMzYwL3RleHRyZWdpb246ZmFiNDdlMmJmMGFlNDcxNzhiN2Q4ZmM2ZmYzMTEzNjBfMjUyMg_484f8b73-8f0c-41ba-ae46-dd3d1f82e948"
      unitRef="usd">100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i32601382eaeb463ba862531b12def23c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNy9mcmFnOmZhYjQ3ZTJiZjBhZTQ3MTc4YjdkOGZjNmZmMzExMzYwL3RleHRyZWdpb246ZmFiNDdlMmJmMGFlNDcxNzhiN2Q4ZmM2ZmYzMTEzNjBfMTA5OTUxMTYzMDM3MQ_e3a1a333-4731-4893-82f3-be05efc8581a"
      unitRef="usd">300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i76c8b1e743d441a3ad6f81bc894366dd_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF8zNy9mcmFnOmZhYjQ3ZTJiZjBhZTQ3MTc4YjdkOGZjNmZmMzExMzYwL3RleHRyZWdpb246ZmFiNDdlMmJmMGFlNDcxNzhiN2Q4ZmM2ZmYzMTEzNjBfMTA5OTUxMTYzMDM4NA_1550654f-ba5a-4006-b699-93b2f67aeb94"
      unitRef="usd">700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80MC9mcmFnOjQ4NGJiOWQyMmRlMzQ5OThiNGViZDhkOWVmNTk4Y2EwL3RleHRyZWdpb246NDg0YmI5ZDIyZGUzNDk5OGI0ZWJkOGQ5ZWY1OThjYTBfMjE2NQ_f9f5755f-ff5c-4d39-8f56-b7c16e52bfc6">INVENTORIES&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company works closely with third parties to manufacture and package finished goods for sale.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based on the arrangements with the manufacturer or packager, the Company will either take title to the finished goods at the time of shipment or at the time of arrival at the Company&#x2019;s warehouses.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company then holds such goods in inventory until distribution and sale. These finished goods inventories are stated at the lower of cost or net realizable value with cost determined using the first-in, first-out method.&lt;/span&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company continually evaluates inventory for potential losses due to excess, obsolete or slow-moving goods by comparing sales history and projections to the inventory on hand. When evidence indicates that the carrying value may not be recoverable, a charge is taken to reduce the inventory to its current net realizable value.  At September 30, 2021 and December 31, 2020, the Company had recognized and maintained cumulative net realizable value charges for potential obsolescence and discontinuance losses of approximately $0.3 million and $0.2 million, respectively.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is responsible for the purchase of the active pharmaceutical ingredient (&#x201c;API&#x201d;) for Kristalose and maintains the inventory at third-party packagers. As that API is consumed in production, the value of the API is transferred from raw materials to finished goods.  API for the Company's Vaprisol brand is also included in the raw materials inventory at September 30, 2021 and December 31, 2020.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consigned inventory represents Authorized Generic inventory stored with Perrigo until shipment.   &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the Vibativ acquisition, Cumberland acquired API and work in process inventories of $15.6 million that were all initially classified as non-current inventories at the date of acquisition.  At September 30, 2021 and December 31, 2020, total non-current inventory, including Vibativ and ifetroban, was $9.5 million and $11.7 million, respectively. The Company had $0.2 million and $2.1 million of Vibativ finished goods included in non-current inventory at September 30, 2021 and December 31, 2020, respectively.  The Company also has obtained $0.4&#160;million of finished goods in non-current inventory for API related to its ifetroban clinical initiatives at September 30, 2021 and December 31, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At September 30, 2021 and December 31, 2020 the Company's net inventories consisted of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.121%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.430%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.681%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.431%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials and work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,782,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,223,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consigned inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,812,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,943,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,739,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,294,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;less non-current inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,476,737)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,656,742)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventories classified as current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,262,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,638,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:InventoryValuationReserves
      contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80MC9mcmFnOjQ4NGJiOWQyMmRlMzQ5OThiNGViZDhkOWVmNTk4Y2EwL3RleHRyZWdpb246NDg0YmI5ZDIyZGUzNDk5OGI0ZWJkOGQ5ZWY1OThjYTBfMTAzOA_fa408c45-20a7-4a34-a5ed-e06b546e3fa2"
      unitRef="usd">300000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryValuationReserves
      contextRef="idb172cb6365440839665fd6ec022472c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80MC9mcmFnOjQ4NGJiOWQyMmRlMzQ5OThiNGViZDhkOWVmNTk4Y2EwL3RleHRyZWdpb246NDg0YmI5ZDIyZGUzNDk5OGI0ZWJkOGQ5ZWY1OThjYTBfMTA0NQ_127d42c6-8d00-406d-9c1e-194145fbe302"
      unitRef="usd">200000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryNoncurrent
      contextRef="i890f0fecec4a4eb899b3171ad304df32_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80MC9mcmFnOjQ4NGJiOWQyMmRlMzQ5OThiNGViZDhkOWVmNTk4Y2EwL3RleHRyZWdpb246NDg0YmI5ZDIyZGUzNDk5OGI0ZWJkOGQ5ZWY1OThjYTBfMTYzNA_d3cebd19-55eb-470b-bfec-5b243c70155c"
      unitRef="usd">15600000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i5d7014c036534d1ab07ea1c7138ece74_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80MC9mcmFnOjQ4NGJiOWQyMmRlMzQ5OThiNGViZDhkOWVmNTk4Y2EwL3RleHRyZWdpb246NDg0YmI5ZDIyZGUzNDk5OGI0ZWJkOGQ5ZWY1OThjYTBfMTA5OTUxMTYyOTk0NQ_4ab0569c-c14e-4492-9b69-18f6d19f72c8"
      unitRef="usd">9500000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i890f0fecec4a4eb899b3171ad304df32_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80MC9mcmFnOjQ4NGJiOWQyMmRlMzQ5OThiNGViZDhkOWVmNTk4Y2EwL3RleHRyZWdpb246NDg0YmI5ZDIyZGUzNDk5OGI0ZWJkOGQ5ZWY1OThjYTBfMTA5OTUxMTYyOTk1NA_874de2f0-2f47-4f8f-9188-998b4b02e087"
      unitRef="usd">11700000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoods
      contextRef="i5d7014c036534d1ab07ea1c7138ece74_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80MC9mcmFnOjQ4NGJiOWQyMmRlMzQ5OThiNGViZDhkOWVmNTk4Y2EwL3RleHRyZWdpb246NDg0YmI5ZDIyZGUzNDk5OGI0ZWJkOGQ5ZWY1OThjYTBfMTg0OQ_2ed9aba5-9edc-492b-8cdc-1e3a690c1101"
      unitRef="usd">200000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="i890f0fecec4a4eb899b3171ad304df32_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80MC9mcmFnOjQ4NGJiOWQyMmRlMzQ5OThiNGViZDhkOWVmNTk4Y2EwL3RleHRyZWdpb246NDg0YmI5ZDIyZGUzNDk5OGI0ZWJkOGQ5ZWY1OThjYTBfMTg1Ng_5eea83b7-3275-4299-b37f-fff4ff11c4fa"
      unitRef="usd">2100000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryNoncurrent
      contextRef="i2fb3c2ea35a146918884002eb0319cb9_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80MC9mcmFnOjQ4NGJiOWQyMmRlMzQ5OThiNGViZDhkOWVmNTk4Y2EwL3RleHRyZWdpb246NDg0YmI5ZDIyZGUzNDk5OGI0ZWJkOGQ5ZWY1OThjYTBfMTk3OA_b3d9ee24-5d32-4dfb-8196-00c2d48a3aba"
      unitRef="usd">400000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="i85407d87b0cc40608f88c792ee3187bc_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80MC9mcmFnOjQ4NGJiOWQyMmRlMzQ5OThiNGViZDhkOWVmNTk4Y2EwL3RleHRyZWdpb246NDg0YmI5ZDIyZGUzNDk5OGI0ZWJkOGQ5ZWY1OThjYTBfMTk3OA_f0bd8122-1a02-4f83-ac77-b4afdd80cd26"
      unitRef="usd">400000</us-gaap:InventoryNoncurrent>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80MC9mcmFnOjQ4NGJiOWQyMmRlMzQ5OThiNGViZDhkOWVmNTk4Y2EwL3RleHRyZWdpb246NDg0YmI5ZDIyZGUzNDk5OGI0ZWJkOGQ5ZWY1OThjYTBfMjE2Ng_6d16846e-cb06-47a4-8900-fd09792f72f2">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At September 30, 2021 and December 31, 2020 the Company's net inventories consisted of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.121%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.430%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.681%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.431%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials and work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,782,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,223,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consigned inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,812,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,943,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,739,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,294,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;less non-current inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,476,737)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,656,742)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventories classified as current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,262,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,638,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80MC9mcmFnOjQ4NGJiOWQyMmRlMzQ5OThiNGViZDhkOWVmNTk4Y2EwL3RhYmxlOjliYjQyZTEwYmNiNzRlNjU5OWM1MWRiOTZhNTIxMmQ0L3RhYmxlcmFuZ2U6OWJiNDJlMTBiY2I3NGU2NTk5YzUxZGI5NmE1MjEyZDRfMi0yLTEtMS05NTU4_52255f9a-f9a5-44b9-a075-0b0113724cc3"
      unitRef="usd">13782630</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="idb172cb6365440839665fd6ec022472c_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80MC9mcmFnOjQ4NGJiOWQyMmRlMzQ5OThiNGViZDhkOWVmNTk4Y2EwL3RhYmxlOjliYjQyZTEwYmNiNzRlNjU5OWM1MWRiOTZhNTIxMmQ0L3RhYmxlcmFuZ2U6OWJiNDJlMTBiY2I3NGU2NTk5YzUxZGI5NmE1MjEyZDRfMi00LTEtMS05NTU4_082938bd-a415-430e-947d-2f7f7b9e89ca"
      unitRef="usd">16223162</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="idb172cb6365440839665fd6ec022472c_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80MC9mcmFnOjQ4NGJiOWQyMmRlMzQ5OThiNGViZDhkOWVmNTk4Y2EwL3RhYmxlOjliYjQyZTEwYmNiNzRlNjU5OWM1MWRiOTZhNTIxMmQ0L3RhYmxlcmFuZ2U6OWJiNDJlMTBiY2I3NGU2NTk5YzUxZGI5NmE1MjEyZDRfMi00LTEtMS05NTU4_906783ec-d2af-4d21-9732-091f7e7352c1"
      unitRef="usd">16223162</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment
      contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80MC9mcmFnOjQ4NGJiOWQyMmRlMzQ5OThiNGViZDhkOWVmNTk4Y2EwL3RhYmxlOjliYjQyZTEwYmNiNzRlNjU5OWM1MWRiOTZhNTIxMmQ0L3RhYmxlcmFuZ2U6OWJiNDJlMTBiY2I3NGU2NTk5YzUxZGI5NmE1MjEyZDRfMy0yLTEtMS05NTU4_0d78d7c6-ff7a-4083-890b-d2408268a4cc"
      unitRef="usd">144583</us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment>
    <us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment
      contextRef="idb172cb6365440839665fd6ec022472c_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80MC9mcmFnOjQ4NGJiOWQyMmRlMzQ5OThiNGViZDhkOWVmNTk4Y2EwL3RhYmxlOjliYjQyZTEwYmNiNzRlNjU5OWM1MWRiOTZhNTIxMmQ0L3RhYmxlcmFuZ2U6OWJiNDJlMTBiY2I3NGU2NTk5YzUxZGI5NmE1MjEyZDRfMy00LTEtMS05NTU4_51de1e87-e7ef-4372-b545-96bb85039d94"
      unitRef="usd">128005</us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment>
    <us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment
      contextRef="idb172cb6365440839665fd6ec022472c_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80MC9mcmFnOjQ4NGJiOWQyMmRlMzQ5OThiNGViZDhkOWVmNTk4Y2EwL3RhYmxlOjliYjQyZTEwYmNiNzRlNjU5OWM1MWRiOTZhNTIxMmQ0L3RhYmxlcmFuZ2U6OWJiNDJlMTBiY2I3NGU2NTk5YzUxZGI5NmE1MjEyZDRfMy00LTEtMS05NTU4_564a45e6-e8c7-4bb4-8024-c3d990ff3216"
      unitRef="usd">128005</us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80MC9mcmFnOjQ4NGJiOWQyMmRlMzQ5OThiNGViZDhkOWVmNTk4Y2EwL3RhYmxlOjliYjQyZTEwYmNiNzRlNjU5OWM1MWRiOTZhNTIxMmQ0L3RhYmxlcmFuZ2U6OWJiNDJlMTBiY2I3NGU2NTk5YzUxZGI5NmE1MjEyZDRfNC0yLTEtMS05NTU4_7fdd8ea8-8cfa-497a-9b82-c7679d7efe1f"
      unitRef="usd">5812293</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="idb172cb6365440839665fd6ec022472c_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80MC9mcmFnOjQ4NGJiOWQyMmRlMzQ5OThiNGViZDhkOWVmNTk4Y2EwL3RhYmxlOjliYjQyZTEwYmNiNzRlNjU5OWM1MWRiOTZhNTIxMmQ0L3RhYmxlcmFuZ2U6OWJiNDJlMTBiY2I3NGU2NTk5YzUxZGI5NmE1MjEyZDRfNC00LTEtMS05NTU4_2c8730e5-fba8-4578-a00b-a080bdb48a68"
      unitRef="usd">5943732</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="idb172cb6365440839665fd6ec022472c_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80MC9mcmFnOjQ4NGJiOWQyMmRlMzQ5OThiNGViZDhkOWVmNTk4Y2EwL3RhYmxlOjliYjQyZTEwYmNiNzRlNjU5OWM1MWRiOTZhNTIxMmQ0L3RhYmxlcmFuZ2U6OWJiNDJlMTBiY2I3NGU2NTk5YzUxZGI5NmE1MjEyZDRfNC00LTEtMS05NTU4_a80a1ef7-1394-4e54-a23b-aadacdab3e00"
      unitRef="usd">5943732</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryGross
      contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80MC9mcmFnOjQ4NGJiOWQyMmRlMzQ5OThiNGViZDhkOWVmNTk4Y2EwL3RhYmxlOjliYjQyZTEwYmNiNzRlNjU5OWM1MWRiOTZhNTIxMmQ0L3RhYmxlcmFuZ2U6OWJiNDJlMTBiY2I3NGU2NTk5YzUxZGI5NmE1MjEyZDRfNS0yLTEtMS05NTU4_663fc4b7-39e2-46f6-8f84-d3070a4649d0"
      unitRef="usd">19739506</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="idb172cb6365440839665fd6ec022472c_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80MC9mcmFnOjQ4NGJiOWQyMmRlMzQ5OThiNGViZDhkOWVmNTk4Y2EwL3RhYmxlOjliYjQyZTEwYmNiNzRlNjU5OWM1MWRiOTZhNTIxMmQ0L3RhYmxlcmFuZ2U6OWJiNDJlMTBiY2I3NGU2NTk5YzUxZGI5NmE1MjEyZDRfNS00LTEtMS05NTU4_3adbed54-4d5e-4360-b3d0-2d5d89425076"
      unitRef="usd">22294899</us-gaap:InventoryGross>
    <us-gaap:InventoryNoncurrent
      contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80MC9mcmFnOjQ4NGJiOWQyMmRlMzQ5OThiNGViZDhkOWVmNTk4Y2EwL3RhYmxlOjliYjQyZTEwYmNiNzRlNjU5OWM1MWRiOTZhNTIxMmQ0L3RhYmxlcmFuZ2U6OWJiNDJlMTBiY2I3NGU2NTk5YzUxZGI5NmE1MjEyZDRfNi0yLTEtMS05NTU4_1b1b0259-48c4-487b-b5cf-3651f88ef0e4"
      unitRef="usd">9476737</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="idb172cb6365440839665fd6ec022472c_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80MC9mcmFnOjQ4NGJiOWQyMmRlMzQ5OThiNGViZDhkOWVmNTk4Y2EwL3RhYmxlOjliYjQyZTEwYmNiNzRlNjU5OWM1MWRiOTZhNTIxMmQ0L3RhYmxlcmFuZ2U6OWJiNDJlMTBiY2I3NGU2NTk5YzUxZGI5NmE1MjEyZDRfNi00LTEtMS05NTU4_e8de5d18-2729-4ad0-b514-412dd551c3b3"
      unitRef="usd">11656742</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNet
      contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80MC9mcmFnOjQ4NGJiOWQyMmRlMzQ5OThiNGViZDhkOWVmNTk4Y2EwL3RhYmxlOjliYjQyZTEwYmNiNzRlNjU5OWM1MWRiOTZhNTIxMmQ0L3RhYmxlcmFuZ2U6OWJiNDJlMTBiY2I3NGU2NTk5YzUxZGI5NmE1MjEyZDRfNy0yLTEtMS05NTU4_ff6d04fc-6a3f-4dfd-bfc0-a29604136553"
      unitRef="usd">10262769</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="idb172cb6365440839665fd6ec022472c_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80MC9mcmFnOjQ4NGJiOWQyMmRlMzQ5OThiNGViZDhkOWVmNTk4Y2EwL3RhYmxlOjliYjQyZTEwYmNiNzRlNjU5OWM1MWRiOTZhNTIxMmQ0L3RhYmxlcmFuZ2U6OWJiNDJlMTBiY2I3NGU2NTk5YzUxZGI5NmE1MjEyZDRfNy00LTEtMS05NTU4_bf4ebc7e-94e4-46f3-badc-bae858aaf1d8"
      unitRef="usd">10638157</us-gaap:InventoryNet>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80My9mcmFnOjk4YzU1ZDJjY2UxMDQ3MWZiZDE5MDI2MjgxM2JjZjRlL3RleHRyZWdpb246OThjNTVkMmNjZTEwNDcxZmJkMTkwMjYyODEzYmNmNGVfMTk3OA_fd0673d3-5ce2-4535-a5d9-f1aeac19171d">LEASES&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumberland&#x2019;s significant operating leases include the lease of approximately 25,500 square feet of office space in Nashville, Tennessee for its corporate headquarters.  This lease currently expires in October 2022.  The Company's operating leases also include the lease of approximately 14,200 square feet of wet laboratory and office space in Nashville, Tennessee by CET, our majority-owned subsidiary, where it operates the CET Life Sciences Center.  This lease currently expires in April 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease liabilities are recorded as the present value of remaining lease payments not yet paid for the lease term discounted using the incremental borrowing rate associated with each lease. Operating lease right-of-use assets represent operating lease liabilities adjusted for lease incentives and initial direct costs. As Cumberland&#x2019;s leases do not contain implicit borrowing rates, the incremental borrowing rates were calculated based on information available at January 1, 2019. Incremental borrowing rates reflect the Company&#x2019;s estimated interest rates for collateralized borrowings over similar lease terms.  The weighted-average incremental borrowing rate used to discount the present value of the remaining lease payments is 7.42%. The weighted-average remaining lease term at September 30, 2021 is 1.2 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Lease Position&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At September 30, 2021 and December 31, 2020 , the Company's lease assets and liabilities were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Right-of-Use Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,282,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,028,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Lease Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,094,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,016,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,059,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,323,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,076,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumulative future minimum sublease income under non-cancelable operating subleases totals approximately $0.1 million and will be paid through the leases ending in October 2022 and April 2023. Future minimum lease payments under non-cancelable operating leases (with initial or remaining lease terms in excess of one year) are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:77.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Maturity of Lease Liabilities at September 30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;295,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,019,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,406,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,323,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rent expense is recognized over the expected term of the lease, including renewal option periods, if applicable, on a straight-line basis as a component of general and administrative expense. Rent expense and sublease income were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.677%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rent expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;910,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;871,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sublease income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;526,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;491,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="ifd0c03fd249e4e64a76675f06c950be1_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80My9mcmFnOjk4YzU1ZDJjY2UxMDQ3MWZiZDE5MDI2MjgxM2JjZjRlL3RleHRyZWdpb246OThjNTVkMmNjZTEwNDcxZmJkMTkwMjYyODEzYmNmNGVfOTQ_ce1e9220-ef32-45fc-b7cf-e49ef510d576"
      unitRef="sqft">25500</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="i67e0bde90efc45a7a814f5c68fb0096f_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80My9mcmFnOjk4YzU1ZDJjY2UxMDQ3MWZiZDE5MDI2MjgxM2JjZjRlL3RleHRyZWdpb246OThjNTVkMmNjZTEwNDcxZmJkMTkwMjYyODEzYmNmNGVfMzAw_eb4a03e1-b8ae-40a3-85ec-d570c5113a29"
      unitRef="sqft">14200</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80My9mcmFnOjk4YzU1ZDJjY2UxMDQ3MWZiZDE5MDI2MjgxM2JjZjRlL3RleHRyZWdpb246OThjNTVkMmNjZTEwNDcxZmJkMTkwMjYyODEzYmNmNGVfMTI0OA_2d76f378-da2f-4b82-a7c3-0b40798dc339"
      unitRef="number">0.0742</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80My9mcmFnOjk4YzU1ZDJjY2UxMDQ3MWZiZDE5MDI2MjgxM2JjZjRlL3RleHRyZWdpb246OThjNTVkMmNjZTEwNDcxZmJkMTkwMjYyODEzYmNmNGVfMTMwMw_cb651dca-3da6-49f5-a8c2-d4898c278cdc">P1Y2M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <cpix:AssetsAndLiabilitiesLesseeTableTextBlock
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80My9mcmFnOjk4YzU1ZDJjY2UxMDQ3MWZiZDE5MDI2MjgxM2JjZjRlL3RleHRyZWdpb246OThjNTVkMmNjZTEwNDcxZmJkMTkwMjYyODEzYmNmNGVfMTk3OQ_ead4bb19-3276-4229-a689-d63dbe2018b6">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At September 30, 2021 and December 31, 2020 , the Company's lease assets and liabilities were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Right-of-Use Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,282,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,028,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Lease Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,094,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,016,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,059,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,323,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,076,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumulative future minimum sublease income under non-cancelable operating subleases totals approximately $0.1 million and will be paid through the leases ending in October 2022 and April 2023. Future minimum lease payments under non-cancelable operating leases (with initial or remaining lease terms in excess of one year) are as follows:&lt;/span&gt;&lt;/div&gt;</cpix:AssetsAndLiabilitiesLesseeTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80My9mcmFnOjk4YzU1ZDJjY2UxMDQ3MWZiZDE5MDI2MjgxM2JjZjRlL3RhYmxlOjAxNTUzNDY5NGIyNjQwNWNiODgzODJlYmJmZTZlZGI3L3RhYmxlcmFuZ2U6MDE1NTM0Njk0YjI2NDA1Y2I4ODM4MmViYmZlNmVkYjdfMS0yLTEtMS05NTU4_03898100-deee-4659-8993-7d7a00a7e0cb"
      unitRef="usd">1282275</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="idb172cb6365440839665fd6ec022472c_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80My9mcmFnOjk4YzU1ZDJjY2UxMDQ3MWZiZDE5MDI2MjgxM2JjZjRlL3RhYmxlOjAxNTUzNDY5NGIyNjQwNWNiODgzODJlYmJmZTZlZGI3L3RhYmxlcmFuZ2U6MDE1NTM0Njk0YjI2NDA1Y2I4ODM4MmViYmZlNmVkYjdfMS00LTEtMS05NTU4_37ee8221-5fb0-4021-9da4-00c47ee19b21"
      unitRef="usd">2028148</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80My9mcmFnOjk4YzU1ZDJjY2UxMDQ3MWZiZDE5MDI2MjgxM2JjZjRlL3RhYmxlOjU2YWY4M2IxZDI4ZTQ0YmJhNzYyMjhiYjFmYzhhNGQ2L3RhYmxlcmFuZ2U6NTZhZjgzYjFkMjhlNDRiYmE3NjIyOGJiMWZjOGE0ZDZfMS0yLTEtMS05NTU4_2e433f39-34c1-4921-a1eb-2c04de7596b4"
      unitRef="usd">1094187</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="idb172cb6365440839665fd6ec022472c_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80My9mcmFnOjk4YzU1ZDJjY2UxMDQ3MWZiZDE5MDI2MjgxM2JjZjRlL3RhYmxlOjU2YWY4M2IxZDI4ZTQ0YmJhNzYyMjhiYjFmYzhhNGQ2L3RhYmxlcmFuZ2U6NTZhZjgzYjFkMjhlNDRiYmE3NjIyOGJiMWZjOGE0ZDZfMS00LTEtMS05NTU4_5444717e-03d4-4aae-b706-03fe5eee67e4"
      unitRef="usd">1016779</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80My9mcmFnOjk4YzU1ZDJjY2UxMDQ3MWZiZDE5MDI2MjgxM2JjZjRlL3RhYmxlOjU2YWY4M2IxZDI4ZTQ0YmJhNzYyMjhiYjFmYzhhNGQ2L3RhYmxlcmFuZ2U6NTZhZjgzYjFkMjhlNDRiYmE3NjIyOGJiMWZjOGE0ZDZfMy0yLTEtMS05NTU4_ac21f239-47a9-4048-b4e5-fb6a30904c23"
      unitRef="usd">229605</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="idb172cb6365440839665fd6ec022472c_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80My9mcmFnOjk4YzU1ZDJjY2UxMDQ3MWZiZDE5MDI2MjgxM2JjZjRlL3RhYmxlOjU2YWY4M2IxZDI4ZTQ0YmJhNzYyMjhiYjFmYzhhNGQ2L3RhYmxlcmFuZ2U6NTZhZjgzYjFkMjhlNDRiYmE3NjIyOGJiMWZjOGE0ZDZfMy00LTEtMS05NTU4_33c77651-a926-495c-b2e7-10d92b256397"
      unitRef="usd">1059693</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <cpix:LeaseLiability
      contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80My9mcmFnOjk4YzU1ZDJjY2UxMDQ3MWZiZDE5MDI2MjgxM2JjZjRlL3RhYmxlOjU2YWY4M2IxZDI4ZTQ0YmJhNzYyMjhiYjFmYzhhNGQ2L3RhYmxlcmFuZ2U6NTZhZjgzYjFkMjhlNDRiYmE3NjIyOGJiMWZjOGE0ZDZfNC0yLTEtMS05NTU4_94ab13ee-3a95-4fd1-9cd5-7e087475d25a"
      unitRef="usd">1323792</cpix:LeaseLiability>
    <cpix:LeaseLiability
      contextRef="idb172cb6365440839665fd6ec022472c_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80My9mcmFnOjk4YzU1ZDJjY2UxMDQ3MWZiZDE5MDI2MjgxM2JjZjRlL3RhYmxlOjU2YWY4M2IxZDI4ZTQ0YmJhNzYyMjhiYjFmYzhhNGQ2L3RhYmxlcmFuZ2U6NTZhZjgzYjFkMjhlNDRiYmE3NjIyOGJiMWZjOGE0ZDZfNC00LTEtMS05NTU4_44b00de6-b348-4030-8772-2419a4261b7f"
      unitRef="usd">2076472</cpix:LeaseLiability>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceived
      contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80My9mcmFnOjk4YzU1ZDJjY2UxMDQ3MWZiZDE5MDI2MjgxM2JjZjRlL3RleHRyZWdpb246OThjNTVkMmNjZTEwNDcxZmJkMTkwMjYyODEzYmNmNGVfMTUxMA_061ec92c-9b5e-42ad-91fe-7b3b9071690b"
      unitRef="usd">100000</us-gaap:LessorOperatingLeasePaymentsToBeReceived>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80My9mcmFnOjk4YzU1ZDJjY2UxMDQ3MWZiZDE5MDI2MjgxM2JjZjRlL3RleHRyZWdpb246OThjNTVkMmNjZTEwNDcxZmJkMTkwMjYyODEzYmNmNGVfMTk4MA_c7686295-6060-4904-bb25-afd463471d17">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:77.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Maturity of Lease Liabilities at September 30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;295,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,019,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,406,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,323,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80My9mcmFnOjk4YzU1ZDJjY2UxMDQ3MWZiZDE5MDI2MjgxM2JjZjRlL3RhYmxlOjg1MDVmNWNhNDVjNDQ1ZjQ4NWMwZmRmYjdhNjZiOGNiL3RhYmxlcmFuZ2U6ODUwNWY1Y2E0NWM0NDVmNDg1YzBmZGZiN2E2NmI4Y2JfMS0yLTEtMS05NTU4_f3c41a5d-d2ee-41de-86f2-480ce6f9126d"
      unitRef="usd">295038</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80My9mcmFnOjk4YzU1ZDJjY2UxMDQ3MWZiZDE5MDI2MjgxM2JjZjRlL3RhYmxlOjg1MDVmNWNhNDVjNDQ1ZjQ4NWMwZmRmYjdhNjZiOGNiL3RhYmxlcmFuZ2U6ODUwNWY1Y2E0NWM0NDVmNDg1YzBmZGZiN2E2NmI4Y2JfMi0yLTEtMS05NTU4_898b543d-e22f-4964-8f2e-6b6b708fff94"
      unitRef="usd">1019313</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80My9mcmFnOjk4YzU1ZDJjY2UxMDQ3MWZiZDE5MDI2MjgxM2JjZjRlL3RhYmxlOjg1MDVmNWNhNDVjNDQ1ZjQ4NWMwZmRmYjdhNjZiOGNiL3RhYmxlcmFuZ2U6ODUwNWY1Y2E0NWM0NDVmNDg1YzBmZGZiN2E2NmI4Y2JfMy0yLTEtMS05NTU4_3235881e-2165-4f96-974f-908e882f6170"
      unitRef="usd">92478</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <cpix:LesseeOperatingLeaseLiabilityToBePaidAfterYearThree
      contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80My9mcmFnOjk4YzU1ZDJjY2UxMDQ3MWZiZDE5MDI2MjgxM2JjZjRlL3RhYmxlOjg1MDVmNWNhNDVjNDQ1ZjQ4NWMwZmRmYjdhNjZiOGNiL3RhYmxlcmFuZ2U6ODUwNWY1Y2E0NWM0NDVmNDg1YzBmZGZiN2E2NmI4Y2JfNC0yLTEtMS05NTU4_0d2752e6-9c2a-4171-a5f4-d3080d1919c7"
      unitRef="usd">0</cpix:LesseeOperatingLeaseLiabilityToBePaidAfterYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80My9mcmFnOjk4YzU1ZDJjY2UxMDQ3MWZiZDE5MDI2MjgxM2JjZjRlL3RhYmxlOjg1MDVmNWNhNDVjNDQ1ZjQ4NWMwZmRmYjdhNjZiOGNiL3RhYmxlcmFuZ2U6ODUwNWY1Y2E0NWM0NDVmNDg1YzBmZGZiN2E2NmI4Y2JfNS0yLTEtMS05NTU4_720a3b83-65b9-4f98-a558-db21838b1bf5"
      unitRef="usd">1406829</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80My9mcmFnOjk4YzU1ZDJjY2UxMDQ3MWZiZDE5MDI2MjgxM2JjZjRlL3RhYmxlOjg1MDVmNWNhNDVjNDQ1ZjQ4NWMwZmRmYjdhNjZiOGNiL3RhYmxlcmFuZ2U6ODUwNWY1Y2E0NWM0NDVmNDg1YzBmZGZiN2E2NmI4Y2JfNi0yLTEtMS05NTU4_5d86e601-a637-4f97-9354-bd1465bb2393"
      unitRef="usd">83037</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80My9mcmFnOjk4YzU1ZDJjY2UxMDQ3MWZiZDE5MDI2MjgxM2JjZjRlL3RhYmxlOjg1MDVmNWNhNDVjNDQ1ZjQ4NWMwZmRmYjdhNjZiOGNiL3RhYmxlcmFuZ2U6ODUwNWY1Y2E0NWM0NDVmNDg1YzBmZGZiN2E2NmI4Y2JfNy0yLTEtMS05NTU4_a41f1f70-093b-4656-99e8-82c60f0845f6"
      unitRef="usd">1323792</us-gaap:OperatingLeaseLiability>
    <cpix:ScheduleofRentExpenseandSubleaseIncomeTableTextBlock
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80My9mcmFnOjk4YzU1ZDJjY2UxMDQ3MWZiZDE5MDI2MjgxM2JjZjRlL3RleHRyZWdpb246OThjNTVkMmNjZTEwNDcxZmJkMTkwMjYyODEzYmNmNGVfMTk4MQ_a07552b5-81b7-4736-b9cc-308851fc4066">Rent expense and sublease income were as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.677%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rent expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;910,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;871,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sublease income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;526,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;491,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</cpix:ScheduleofRentExpenseandSubleaseIncomeTableTextBlock>
    <us-gaap:OperatingLeaseExpense
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80My9mcmFnOjk4YzU1ZDJjY2UxMDQ3MWZiZDE5MDI2MjgxM2JjZjRlL3RhYmxlOjg1MmFmZTE3YmM5YzQzMjFhZjFkNWUzYmIzOTg5YmVlL3RhYmxlcmFuZ2U6ODUyYWZlMTdiYzljNDMyMWFmMWQ1ZTNiYjM5ODliZWVfMi0yLTEtMS05NTU4_8485dfdd-3037-4ef3-bba8-bb574a0c3dfe"
      unitRef="usd">910975</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80My9mcmFnOjk4YzU1ZDJjY2UxMDQ3MWZiZDE5MDI2MjgxM2JjZjRlL3RhYmxlOjg1MmFmZTE3YmM5YzQzMjFhZjFkNWUzYmIzOTg5YmVlL3RhYmxlcmFuZ2U6ODUyYWZlMTdiYzljNDMyMWFmMWQ1ZTNiYjM5ODliZWVfMi00LTEtMS05NTU4_55241f73-83e6-4f7b-b9df-e0aabd4c2ecb"
      unitRef="usd">871441</us-gaap:OperatingLeaseExpense>
    <us-gaap:SubleaseIncome
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80My9mcmFnOjk4YzU1ZDJjY2UxMDQ3MWZiZDE5MDI2MjgxM2JjZjRlL3RhYmxlOjg1MmFmZTE3YmM5YzQzMjFhZjFkNWUzYmIzOTg5YmVlL3RhYmxlcmFuZ2U6ODUyYWZlMTdiYzljNDMyMWFmMWQ1ZTNiYjM5ODliZWVfNC0yLTEtMS05NTU4_611e8fc1-afa2-4c67-8e71-090664bde8a9"
      unitRef="usd">526868</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="iffc9469614ea454f887a8776d938bf3c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80My9mcmFnOjk4YzU1ZDJjY2UxMDQ3MWZiZDE5MDI2MjgxM2JjZjRlL3RhYmxlOjg1MmFmZTE3YmM5YzQzMjFhZjFkNWUzYmIzOTg5YmVlL3RhYmxlcmFuZ2U6ODUyYWZlMTdiYzljNDMyMWFmMWQ1ZTNiYjM5ODliZWVfNC00LTEtMS05NTU4_6a8b050e-4a9d-4c02-86b9-097156bea41c"
      unitRef="usd">491391</us-gaap:SubleaseIncome>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80Ni9mcmFnOmJhNTMxMmRhZDAwNjQ3MmVhMDhkNmM5OTg4NDRkNWE5L3RleHRyZWdpb246YmE1MzEyZGFkMDA2NDcyZWEwOGQ2Yzk5ODg0NGQ1YTlfNzgyMQ_8c6372ab-cab9-431c-b845-9b651f6d39d6">SHAREHOLDERS&#x2019; EQUITY AND DEBT&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Share repurchases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumberland currently has a share repurchase program to repurchase up to $10 million of its common stock pursuant to Rule 10b-18 of the Securities Exchange Act of 1934. In January 2019, the Company's Board of Directors established the current $10 million repurchase program to replace the prior authorizations.  During the nine months ended September 30, 2021 and September 30, 2020, the Company repurchased 326,537 shares and 407,683 shares, respectively, of common stock for approximately $1.0 million and $1.5 million, respectively.  At September 30, 2021, approximately $5.2 million of common shares was left to repurchase under this program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Share purchases and sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the Company's March 2021 trading window, several members of Cumberland's Board of Directors entered into share purchase agreements of the Company's stock pursuant to Rule 10b-18 of the Securities Exchange Act of 1934. These purchases are designed to increase ownership in the Company by the members of the Board.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Share Sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2017, Cumberland filed a Shelf Registration on Form S-3 with the SEC associated with the sale of up to $100 million in corporate securities. The Shelf Registration was declared effective in January 2018. It also included an At the Market ("ATM") feature that allowed the Company to sell common shares at market prices, along with an agreement with B. Riley FBR Inc. to support such a placement of shares. The Company filed an updated Form S-3 with the SEC in December 2020, which was declared effective in January 2021. The Company does not currently have an ATM feature in place.  Cumberland plans to continue to evaluate the market for its common shares, and if favorable, will further evaluate whether or not to enter into an ATM feature through B. Riley FBR, Inc. that would allow the Company to issue shares of its common stock.  The Company did not issue any shares under an ATM during the nine months ended September 30, 2021 or September 30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted Share Grants and Incentive Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the nine months ended September 30, 2021 and September 30, 2020, the Company issued 36,850 shares and 230,491 shares of restricted stock to employees and directors, respectively. Restricted stock issued to employees generally cliff-vests on the fourth anniversary of the date of grant and for directors on the one-year anniversary of the date of grant.  During the nine months ended September 30, 2021, the Company also issued 174,800 incentive stock options to employees that cliff-vest on the fourth anniversary of the date of grant, that are set to expire in March and May 2031. Stock compensation expense is presented as a component of general and administrative expense in the condensed consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 28, 2021, the Company and Pinnacle Bank entered into a Fourth Amendment to the Revolving Credit Note and Fifth Amendment ("Fifth Amendment") to the Revolving Credit Loan Agreement to renew the Revolving Credit Loan.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The original Pinnacle Agreement was dated July 2017.  Beginning on August 14, 2018, and continuing until October 7, 2020, the Company and Pinnacle Bank entered into a series of amendments to extend and update the Revolving Credit Note and Revolving Credit Agreement. The most recent amendment dated October 28, 2021, extends the maturity date three years through October 1, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consistent with prior Amendments, the Fifth Amendment provides for a principal balance available for borrowing of up to $15&#160;million. The Company has the right to request an increase of up to an additional $5&#160;million providing a maximum principal available of up to $20&#160;million upon the satisfaction of certain conditions and with the approval of Pinnacle Bank. Also consistent with prior Amendments, the Company is required to maintain either a Funded Debt Ratio covenant or a Tangible Capital Ratio covenant. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The interest rate on the Pinnacle Agreement is based on LIBOR plus an interest rate spread. The pricing under the Fourth Amendment provides for an interest rate spread of 1.75% to 2.75% above LIBOR with a minimum LIBOR of 0.90%. The applicable interest rate under the Pinnacle Agreement was 3.65% at September 30, 2021.  In addition, a fee of 0.25% per year is charged on the unused line of credit.  Interest and the unused line fee are payable quarterly.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September 30, 2021 and December 31, 2020, the Company had $15.0 million in borrowings outstanding under its revolving credit facility.  The Company was in compliance with the Tangible Capital Ratio financial covenant as of September 30, 2021.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Borrowings under the line of credit are collateralized by substantially all of our assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Paycheck Protection Program Loan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 20, 2020, Cumberland received the funding of a loan from Pinnacle Bank in the amount of $2,187,140 pursuant to the Paycheck Protection Program (the &#x201c;PPP&#x201d;) under the Federal Coronavirus Aid, Relief, and Economic Security Act ("CARES Act"), which was enacted March 27, 2020.  The PPP is administered by the U.S. Small Business Administration ("SBA").&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the PPP requirements, loan funds were used to maintain payroll, continue group health care benefits, and pay for rent and utilities during the pandemic. We applied for this loan after carefully considering, with our bank, the eligibility criteria to participate in this program, and determining that Cumberland met those criteria. We evaluated and provided information on our payroll and other qualifying expenses to determine the amount of PPP funds to apply for. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the PPP, certain amounts of the loan may be forgiven if they are used for qualifying expenses as described in the CARES Act. Cumberland used the PPP loan funds for such qualifying expenses. Due to assistance from our PPP loan, the Company did not lay off or furlough any employees as a result of the COVID-19 pandemic.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumberland elected to account for the proceeds of the loan as a government grant under &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;International Accounting Standard 20 ("IAS 20"), Accounting for Government Grants and Disclosure of Government Assistance. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The permitted analogous use of  IAS 20 outlines a model for the accounting for government assistance, including forgivable loans. As a result, the Company recorded the $2,187,140 as a deferred income liability, which was included as a component of other current liabilities on the condensed consolidated balance sheet at December 31, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2020, Cumberland submitted a request for the loan&#x2019;s forgiveness. On June 11, 2021, the Company received a formal notice from the SBA that the full amount of the loan was forgiven. The Company accounted for the forgiveness of the PPP loan under IAS 20 and recorded the $2,187,140 as other income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Joint Venture Agreement&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, Cumberland entered into an agreement with WinHealth Investment (Singapore) Ltd creating &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;WHC Biopharmaceuticals, Pte. Ltd&lt;/span&gt;. The joint venture, as a limited liability company, will focus on acquiring, developing, registering, and commercializing development stage and commercial stage biopharmaceuticals for China, Hong Kong and other Asian markets.  The agreement provides for initial investment from WinHealth in the form of a $0.2&#160;million equity contribution and an initial investment from Cumberland in the form of a $0.2&#160;million convertible note, which was funded during the first quarter 2021. The joint venture will seek additional future capital from additional investors and has entered into exclusive option agreements to license intellectual property from both Cumberland Pharmaceuticals Inc. and Cumberland Emerging Technologies.</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i6b60adc716c54226bd1b0d9f82b62a4c_I20100513"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80Ni9mcmFnOmJhNTMxMmRhZDAwNjQ3MmVhMDhkNmM5OTg4NDRkNWE5L3RleHRyZWdpb246YmE1MzEyZGFkMDA2NDcyZWEwOGQ2Yzk5ODg0NGQ1YTlfMTMz_ba3f64fa-d60b-4ff9-b70f-3cf9b8753d17"
      unitRef="usd">10000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i2d045c0da7504a3081ac01dc90d95aed_I20160131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80Ni9mcmFnOmJhNTMxMmRhZDAwNjQ3MmVhMDhkNmM5OTg4NDRkNWE5L3RleHRyZWdpb246YmE1MzEyZGFkMDA2NDcyZWEwOGQ2Yzk5ODg0NGQ1YTlfMjk0_f678e4c8-a8f2-4356-884c-b1b9cb73b5be"
      unitRef="usd">10000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i3eac19ab71204baa8b814cd80e8e55ab_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80Ni9mcmFnOmJhNTMxMmRhZDAwNjQ3MmVhMDhkNmM5OTg4NDRkNWE5L3RleHRyZWdpb246YmE1MzEyZGFkMDA2NDcyZWEwOGQ2Yzk5ODg0NGQ1YTlfNDAw_73296c1c-97fa-4ffc-a460-0f989cbe74bc"
      unitRef="shares">326537</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i545187d4937e41ec99d80966b809dd78_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80Ni9mcmFnOmJhNTMxMmRhZDAwNjQ3MmVhMDhkNmM5OTg4NDRkNWE5L3RleHRyZWdpb246YmE1MzEyZGFkMDA2NDcyZWEwOGQ2Yzk5ODg0NGQ1YTlfNDE0_15811f22-c3a0-4556-9429-51b724444c33"
      unitRef="shares">407683</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i3eac19ab71204baa8b814cd80e8e55ab_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80Ni9mcmFnOmJhNTMxMmRhZDAwNjQ3MmVhMDhkNmM5OTg4NDRkNWE5L3RleHRyZWdpb246YmE1MzEyZGFkMDA2NDcyZWEwOGQ2Yzk5ODg0NGQ1YTlfNDcz_9cfa7502-61ab-47e0-b1ba-c818b27b3958"
      unitRef="usd">1000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i545187d4937e41ec99d80966b809dd78_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80Ni9mcmFnOmJhNTMxMmRhZDAwNjQ3MmVhMDhkNmM5OTg4NDRkNWE5L3RleHRyZWdpb246YmE1MzEyZGFkMDA2NDcyZWEwOGQ2Yzk5ODg0NGQ1YTlfNDgw_aa52c0d5-afa4-473f-8330-856d30d985a8"
      unitRef="usd">1500000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
      contextRef="i56aafc7718c145c8b150a8e54f33a5d2_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80Ni9mcmFnOmJhNTMxMmRhZDAwNjQ3MmVhMDhkNmM5OTg4NDRkNWE5L3RleHRyZWdpb246YmE1MzEyZGFkMDA2NDcyZWEwOGQ2Yzk5ODg0NGQ1YTlfMTA5OTUxMTYzNTY0NA_9dedc84d-11d4-4922-988e-3accc0a508b2"
      unitRef="usd">5200000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <cpix:StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities
      contextRef="i4b890701c9304f309d867768f2a90a7b_D20171101-20171130"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80Ni9mcmFnOmJhNTMxMmRhZDAwNjQ3MmVhMDhkNmM5OTg4NDRkNWE5L3RleHRyZWdpb246YmE1MzEyZGFkMDA2NDcyZWEwOGQ2Yzk5ODg0NGQ1YTlfMTA2OA_4c7de529-a4f9-4d42-8a56-f199caf47357"
      unitRef="usd">100000000</cpix:StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ib59b0ab18a9847a48768cc76def0c5ce_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80Ni9mcmFnOmJhNTMxMmRhZDAwNjQ3MmVhMDhkNmM5OTg4NDRkNWE5L3RleHRyZWdpb246YmE1MzEyZGFkMDA2NDcyZWEwOGQ2Yzk5ODg0NGQ1YTlfMTk1NA_8bcf9678-fe0e-4b49-8484-996291110dd8"
      unitRef="shares">36850</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i7109429b4bb94262ab81694be586f875_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80Ni9mcmFnOmJhNTMxMmRhZDAwNjQ3MmVhMDhkNmM5OTg4NDRkNWE5L3RleHRyZWdpb246YmE1MzEyZGFkMDA2NDcyZWEwOGQ2Yzk5ODg0NGQ1YTlfMTk2OA_73466c05-659c-4db3-a7a7-b3179610f089"
      unitRef="shares">230491</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i448fcba2bca740069897cf519754695f_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80Ni9mcmFnOmJhNTMxMmRhZDAwNjQ3MmVhMDhkNmM5OTg4NDRkNWE5L3RleHRyZWdpb246YmE1MzEyZGFkMDA2NDcyZWEwOGQ2Yzk5ODg0NGQ1YTlfNzgxOQ_f7c65f96-fee8-4b79-8bad-5ee313476e7c">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ie91a73f23b39413ca4897ecef5e9c6b9_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80Ni9mcmFnOmJhNTMxMmRhZDAwNjQ3MmVhMDhkNmM5OTg4NDRkNWE5L3RleHRyZWdpb246YmE1MzEyZGFkMDA2NDcyZWEwOGQ2Yzk5ODg0NGQ1YTlfMjI1Mw_87214b05-94bd-4f76-ad7b-47faea6bfb95"
      unitRef="shares">174800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ie35d5d79a31d4a97ada4dc5eb118435d_I20211028"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80Ni9mcmFnOmJhNTMxMmRhZDAwNjQ3MmVhMDhkNmM5OTg4NDRkNWE5L3RleHRyZWdpb246YmE1MzEyZGFkMDA2NDcyZWEwOGQ2Yzk5ODg0NGQ1YTlfMTY0OTI2NzQ1NTc1OQ_c3038ab4-da2d-4b1c-ade8-9e3ba9509a53"
      unitRef="usd">15000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <cpix:LineOfCreditFacilityMaximumBorrowingCapacityIncreaseAmount
      contextRef="ie35d5d79a31d4a97ada4dc5eb118435d_I20211028"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80Ni9mcmFnOmJhNTMxMmRhZDAwNjQ3MmVhMDhkNmM5OTg4NDRkNWE5L3RleHRyZWdpb246YmE1MzEyZGFkMDA2NDcyZWEwOGQ2Yzk5ODg0NGQ1YTlfMTY0OTI2NzQ1NTc0Nw_3185ae6b-bd95-4c31-b6d7-66ca9a182154"
      unitRef="usd">5000000</cpix:LineOfCreditFacilityMaximumBorrowingCapacityIncreaseAmount>
    <cpix:LineOfCreditFacilityMaximumBorrowingCapacityTotalCapacity
      contextRef="ie35d5d79a31d4a97ada4dc5eb118435d_I20211028"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80Ni9mcmFnOmJhNTMxMmRhZDAwNjQ3MmVhMDhkNmM5OTg4NDRkNWE5L3RleHRyZWdpb246YmE1MzEyZGFkMDA2NDcyZWEwOGQ2Yzk5ODg0NGQ1YTlfMTY0OTI2NzQ1NTc3Mg_6a4b7f13-2028-469c-a8c0-781290ece41d"
      unitRef="usd">20000000</cpix:LineOfCreditFacilityMaximumBorrowingCapacityTotalCapacity>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i433310853533429eb0bd0de42c8cb8c0_D20200814-20200814"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80Ni9mcmFnOmJhNTMxMmRhZDAwNjQ3MmVhMDhkNmM5OTg4NDRkNWE5L3RleHRyZWdpb246YmE1MzEyZGFkMDA2NDcyZWEwOGQ2Yzk5ODg0NGQ1YTlfNDU2MA_13cb7560-a435-4e9f-832d-f16665891a2a"
      unitRef="number">0.0175</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i7857ace04dd14acd90de8bfdfc44e2ad_D20200814-20200814"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80Ni9mcmFnOmJhNTMxMmRhZDAwNjQ3MmVhMDhkNmM5OTg4NDRkNWE5L3RleHRyZWdpb246YmE1MzEyZGFkMDA2NDcyZWEwOGQ2Yzk5ODg0NGQ1YTlfNDU2Ng_51026c1a-824b-4d54-9b38-9a25058087c7"
      unitRef="number">0.0275</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ia066a8f68c2c4b2bb8d23f93616af446_D20200814-20200814"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80Ni9mcmFnOmJhNTMxMmRhZDAwNjQ3MmVhMDhkNmM5OTg4NDRkNWE5L3RleHRyZWdpb246YmE1MzEyZGFkMDA2NDcyZWEwOGQ2Yzk5ODg0NGQ1YTlfNDYwNQ_d013790f-b4c3-4b49-bdec-497369f4088d"
      unitRef="number">0.009</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i0c79a3c371c84f16b64c6d20ef3f26bd_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80Ni9mcmFnOmJhNTMxMmRhZDAwNjQ3MmVhMDhkNmM5OTg4NDRkNWE5L3RleHRyZWdpb246YmE1MzEyZGFkMDA2NDcyZWEwOGQ2Yzk5ODg0NGQ1YTlfNDY3MQ_38ab6b8e-37e5-4857-b49c-d9fd0e5c894d"
      unitRef="number">0.0365</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage
      contextRef="i29e07103e7b54d69af01f448919f0979_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80Ni9mcmFnOmJhNTMxMmRhZDAwNjQ3MmVhMDhkNmM5OTg4NDRkNWE5L3RleHRyZWdpb246YmE1MzEyZGFkMDA2NDcyZWEwOGQ2Yzk5ODg0NGQ1YTlfNDcwNA_aba009bb-7351-49e8-bfa8-8c0659d42168"
      unitRef="number">0.0025</us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage>
    <us-gaap:LongTermLineOfCredit
      contextRef="i5729693e898c46118beacc910390b13c_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80Ni9mcmFnOmJhNTMxMmRhZDAwNjQ3MmVhMDhkNmM5OTg4NDRkNWE5L3RleHRyZWdpb246YmE1MzEyZGFkMDA2NDcyZWEwOGQ2Yzk5ODg0NGQ1YTlfMTA5OTUxMTYzNzEwNQ_ef5585e4-2165-4512-834e-32005b7646ea"
      unitRef="usd">15000000</us-gaap:LongTermLineOfCredit>
    <cpix:TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived
      contextRef="i8f0ec15fc71f49aca22d17a26142e958_D20200420-20200420"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80Ni9mcmFnOmJhNTMxMmRhZDAwNjQ3MmVhMDhkNmM5OTg4NDRkNWE5L3RleHRyZWdpb246YmE1MzEyZGFkMDA2NDcyZWEwOGQ2Yzk5ODg0NGQ1YTlfNTA0OA_1da139ea-f756-4e1a-8669-4516fdb4a578"
      unitRef="usd">2187140</cpix:TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived>
    <cpix:TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived
      contextRef="i8f0ec15fc71f49aca22d17a26142e958_D20200420-20200420"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80Ni9mcmFnOmJhNTMxMmRhZDAwNjQ3MmVhMDhkNmM5OTg4NDRkNWE5L3RleHRyZWdpb246YmE1MzEyZGFkMDA2NDcyZWEwOGQ2Yzk5ODg0NGQ1YTlfNjQ5NQ_d6a212ef-2458-4366-8178-0386b71460d8"
      unitRef="usd">2187140</cpix:TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived>
    <cpix:TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived
      contextRef="i8f0ec15fc71f49aca22d17a26142e958_D20200420-20200420"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80Ni9mcmFnOmJhNTMxMmRhZDAwNjQ3MmVhMDhkNmM5OTg4NDRkNWE5L3RleHRyZWdpb246YmE1MzEyZGFkMDA2NDcyZWEwOGQ2Yzk5ODg0NGQ1YTlfNjkzOQ_d6a212ef-2458-4366-8178-0386b71460d8"
      unitRef="usd">2187140</cpix:TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="i7f3eb3a61d724b16837687fe50bb6592_I20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80Ni9mcmFnOmJhNTMxMmRhZDAwNjQ3MmVhMDhkNmM5OTg4NDRkNWE5L3RleHRyZWdpb246YmE1MzEyZGFkMDA2NDcyZWEwOGQ2Yzk5ODg0NGQ1YTlfNzQyNQ_2a0d5b15-3e25-4b82-a442-1d8962f94a7e"
      unitRef="usd">200000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i10ede8aae6b6477eb6df1f13d1f8042a_I20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80Ni9mcmFnOmJhNTMxMmRhZDAwNjQ3MmVhMDhkNmM5OTg4NDRkNWE5L3RleHRyZWdpb246YmE1MzEyZGFkMDA2NDcyZWEwOGQ2Yzk5ODg0NGQ1YTlfNzUwNw_027896fa-37c5-41ab-b0ed-802eeef9025a"
      unitRef="usd">200000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80OS9mcmFnOjIwYTZlMDE2NzJiODRhMmJhZDBlYmZiMmE5NTk4Mzc4L3RleHRyZWdpb246MjBhNmUwMTY3MmI4NGEyYmFkMGViZmIyYTk1OTgzNzhfNjM3_aefd03d2-4c10-402c-92ed-1179f799f7f2">INCOME TAXESAs of September 30, 2021, the Company has approximately $56.5 million in federal net operating loss carryforwards including approximately $44.1 million of net operating loss carryforwards resulting from the exercise of nonqualified stock options. These have historically been used to significantly offset income tax obligations. The Company expects it will continue to pay minimal income taxes during 2021 and beyond, through the continued utilization of these net operating loss carryforwards, on any taxable income generated from our operations. The Company does not allocate any portion of its income tax expense (benefit) to discontinued operations.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:OperatingLossCarryforwards
      contextRef="ic25c3441c5a0477ebd8c769c3ea98555_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80OS9mcmFnOjIwYTZlMDE2NzJiODRhMmJhZDBlYmZiMmE5NTk4Mzc4L3RleHRyZWdpb246MjBhNmUwMTY3MmI4NGEyYmFkMGViZmIyYTk1OTgzNzhfNjI_3db0aa8b-d565-4727-8e06-406c0492c7df"
      unitRef="usd">56500000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i5fc3bb3df16548c98cacace445d903da_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF80OS9mcmFnOjIwYTZlMDE2NzJiODRhMmJhZDBlYmZiMmE5NTk4Mzc4L3RleHRyZWdpb246MjBhNmUwMTY3MmI4NGEyYmFkMGViZmIyYTk1OTgzNzhfMTMz_063fd305-aa10-4eb0-be91-efc233c5669c"
      unitRef="usd">44100000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF81Mi9mcmFnOjkxYTMyNzA3NTQwODRlNzdiM2VmZjk4YWYwYTBhM2UxL3RleHRyZWdpb246OTFhMzI3MDc1NDA4NGU3N2IzZWZmOThhZjBhMGEzZTFfMTAyNg_6b27aa50-4a22-41f8-b835-f7fd88901262">COLLABORATIVE AGREEMENTS&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumberland is a party to several collaborative arrangements with research institutions to identify and pursue promising pharmaceutical product candidates. The funding for these programs is primarily provided through Federal Small Business Administration (SBIR/STTR) and other grant awards. The Company has determined that these collaborative agreements, with the exception of the collaborative payment received related to RediTrex, do not meet the criteria for accounting under ASC Topic 808, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Agreements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The agreements do not specifically designate each party&#x2019;s rights and obligations to each other under the collaborative arrangements. Except for patent defense costs, expenses incurred by one party are not required to be reimbursed by the other party.  Expenses incurred under these collaborative agreements are included in research and development expenses and funding received from grants are recorded as net revenues in the condensed consolidated statements of operations.&lt;/span&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF81NS9mcmFnOjNjYzExNDcyMGE1YTQxZDQ4MGQ2OWI3MjIxMWIwYTFiL3RleHRyZWdpb246M2NjMTE0NzIwYTVhNDFkNDgwZDY5YjcyMjExYjBhMWJfNTg0MA_f24487e3-6f8c-4766-8223-21f98b90ef57">ADDITIONS AND RETURN OF PRODUCT RIGHTS&lt;div style="margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Vibativ&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During November 2018, the Company closed on an agreement with Theravance Biopharma ("Theravance") to acquire the global responsibility for Vibativ including the marketing, distribution, manufacturing and regulatory activities associated with the brand.  Vibativ is a patented, Food and Drug Administration ("FDA") approved injectable anti-infective for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia and complicated skin and skin structure infections. It addresses a range of Gram-positive bacterial pathogens, including those that are considered difficult-to-treat and multidrug-resistant.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumberland has accounted for the transaction as a business combination in accordance with ASC 805 and the product sales are included in the results of operations subsequent to the acquisition date. The Company made an upfront payment of $20.0&#160;million at the closing of the transaction and a $5.0&#160;million milestone payment in early April 2019. In addition, Cumberland has agreed to pay a royalty of up to 20% of on-going net sales of the product.  The future royalty payments were required to be recognized at their acquisition-date fair value as a contingent consideration liability, as part of the contingent consideration transferred in the business combination. Cumberland prepared the valuations of the contingent consideration liability utilizing significant unobservable inputs.  As a result, the valuation is classified as Level 3 fair value measurement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the changes in the fair value of the contingent consideration liability that is remeasured on a recurring basis.  The contingent consideration earned and accrued in operating expenses is paid to Theravance quarterly.&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.345%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,200,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash payment of royalty during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,792,573)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of contingent consideration included in operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(632,646)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration earned and accrued in operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,134,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at September 30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,909,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contingent consideration liability of $6.9&#160;million was classified as other current liabilities of $2.6&#160;million and other long-term liabilities of $4.3&#160;million on the condensed consolidated balance sheet as of September 30, 2021.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;RediTrex&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2016, the Company announced an agreement with the Nordic Group B.V. ("Nordic") to acquire the exclusive U.S. rights to Nordic&#x2019;s injectable methotrexate product line designed for the treatment of active rheumatoid arthritis, juvenile idiopathic arthritis, severe psoriatic arthritis, and severe disabling psoriasis. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As consideration for the license Cumberland paid a deposit of $100,000 at closing.  The Company provided $0.9&#160;million in consideration through a grant of 180,000 restricted shares of Cumberland common stock to be vested upon the FDA approval of the first Nordic product. Cumberland also agreed to provide Nordic a series of payments tied to the products&#x2019; FDA approval, launch and achievement of certain sales milestones. Under the terms of the agreement, Cumberland is responsible for the product registration and commercialization in the U.S. Nordic is responsible for product manufacturing and supply.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 27, 2019, Cumberland received FDA approval for the first Nordic injectable product and authorization to market them under the RediTrex brand name.  The 180,000 shares of restricted Cumberland common stock previously provided to Nordic vested upon approval and were valued at $0.9&#160;million on the vesting date. The FDA approval also resulted in a $1.0&#160;million milestone payment due to Nordic.  During December 2020, Cumberland introduced RediTrex and the launch that will take place in late 2021 will result in a $1.0&#160;million milestone payment due to Nordic.  This milestone payment will be paid during 2022 and is included as a current liability at September 30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumberland has approximately $2.7&#160;million in net intangible assets related to RediTrex at September 30, 2021.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Ethyol and Totect &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2016, Cumberland entered into an agreement with Clinigen for the rights and responsibilities associated with the commercialization of Ethyol in the United States.  In 2017, the Company entered into another agreement with Clinigen for the rights and responsibilities associated with the commercialization of Totect in the United States.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Early in 2019, Cumberland announced a strategic review of the Company's brands, capabilities, and international partners. This review followed an accelerated business development initiative, which resulted in a series of transactions. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During May 2019, Cumberland entered into the Dissolution Agreement with Clinigen in which the Company returned the exclusive rights to commercialize Ethyol and Totect&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in the United States to Clinigen. Under the final terms of the Dissolution Agreement, Cumberland was no longer responsible for the distribution, marketing and promotion of either Ethyol or Totect or any competing products after December 31, 2019.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In exchange for the return of these product license rights and the non-compete provisions of the Dissolution Agreement, Cumberland is receiving $5&#160;million in financial consideration paid in quarterly installments over the two-years following the transition date. Cumberland recorded the first four quarterly installments totaling $3.0 million during 2020 and the next three installments totaling $1.5 million during the nine months ended September 30, 2021, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;as discontinued operations.  The Company will record the last remaining quarterly installment in the fourth quarter of 2021.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The exit from Ethyol and Totect meets the accounting criteria to be reported as discontinued operations. December 31, 2019, as the transition date, was the final day Cumberland was responsible for the products. Cumberland was responsible for the products through December 31, 2019 and beginning on January 1, 2020, the products' rights transitioned back to Clinigen. As a result, January 1, 2020, was the first day of discontinued operations for the Ethyol and Totect products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The dissolution payments from Clinigen are reflected as revenue from discontinued operations.  The Company does not &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;incur expenses associated with these payments from Clinigen. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.590%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.677%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.499%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Nine months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;496,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;777,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,491,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,334,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Costs of products sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, Marketing and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;496,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;777,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,491,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,334,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i57f795672a2a465e9209a65e0162f0b4_D20181101-20181130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF81NS9mcmFnOjNjYzExNDcyMGE1YTQxZDQ4MGQ2OWI3MjIxMWIwYTFiL3RleHRyZWdpb246M2NjMTE0NzIwYTVhNDFkNDgwZDY5YjcyMjExYjBhMWJfOTcw_7e4f4541-973e-41c9-a96b-acda0c69e7b1"
      unitRef="usd">20000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:OtherPaymentsToAcquireBusinesses
      contextRef="i57f795672a2a465e9209a65e0162f0b4_D20181101-20181130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF81NS9mcmFnOjNjYzExNDcyMGE1YTQxZDQ4MGQ2OWI3MjIxMWIwYTFiL3RleHRyZWdpb246M2NjMTE0NzIwYTVhNDFkNDgwZDY5YjcyMjExYjBhMWJfMTAxMw_c6c619d0-5a9a-4862-93bd-bac082c859aa"
      unitRef="usd">5000000</us-gaap:OtherPaymentsToAcquireBusinesses>
    <cpix:TieredRoyaltyPaymentsPercentage
      contextRef="i57f795672a2a465e9209a65e0162f0b4_D20181101-20181130"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF81NS9mcmFnOjNjYzExNDcyMGE1YTQxZDQ4MGQ2OWI3MjIxMWIwYTFiL3RleHRyZWdpb246M2NjMTE0NzIwYTVhNDFkNDgwZDY5YjcyMjExYjBhMWJfMTExNg_5fd215db-2c05-4ad5-b957-dc4f3234dda8"
      unitRef="number">0.20</cpix:TieredRoyaltyPaymentsPercentage>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF81NS9mcmFnOjNjYzExNDcyMGE1YTQxZDQ4MGQ2OWI3MjIxMWIwYTFiL3RleHRyZWdpb246M2NjMTE0NzIwYTVhNDFkNDgwZDY5YjcyMjExYjBhMWJfNTg0MQ_63cc83b6-0c84-430b-a0a8-ef4bdcc80d71">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the changes in the fair value of the contingent consideration liability that is remeasured on a recurring basis.  The contingent consideration earned and accrued in operating expenses is paid to Theravance quarterly.&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.345%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,200,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash payment of royalty during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,792,573)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of contingent consideration included in operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(632,646)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration earned and accrued in operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,134,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at September 30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,909,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i890f0fecec4a4eb899b3171ad304df32_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF81NS9mcmFnOjNjYzExNDcyMGE1YTQxZDQ4MGQ2OWI3MjIxMWIwYTFiL3RhYmxlOjUyYWJlY2FiYzBlZDQ5NDRhNzg4YWIwNGI1NGUwMGFiL3RhYmxlcmFuZ2U6NTJhYmVjYWJjMGVkNDk0NGE3ODhhYjA0YjU0ZTAwYWJfOS0xLTEtMS05NTU4_c401baa2-4241-454e-a8e6-3422141524c2"
      unitRef="usd">8200552</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:PaymentsForRoyalties
      contextRef="id08ba9ef8fce4ef0b1aebddae7a819be_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF81NS9mcmFnOjNjYzExNDcyMGE1YTQxZDQ4MGQ2OWI3MjIxMWIwYTFiL3RhYmxlOjUyYWJlY2FiYzBlZDQ5NDRhNzg4YWIwNGI1NGUwMGFiL3RhYmxlcmFuZ2U6NTJhYmVjYWJjMGVkNDk0NGE3ODhhYjA0YjU0ZTAwYWJfMTAtMS0xLTEtOTU1OA_71c82430-fe1a-4523-a9f5-0a188f0f9b04"
      unitRef="usd">1792573</us-gaap:PaymentsForRoyalties>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="id08ba9ef8fce4ef0b1aebddae7a819be_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF81NS9mcmFnOjNjYzExNDcyMGE1YTQxZDQ4MGQ2OWI3MjIxMWIwYTFiL3RhYmxlOjUyYWJlY2FiYzBlZDQ5NDRhNzg4YWIwNGI1NGUwMGFiL3RhYmxlcmFuZ2U6NTJhYmVjYWJjMGVkNDk0NGE3ODhhYjA0YjU0ZTAwYWJfMTEtMS0xLTEtOTU1OA_8b843a3f-4aba-4599-b011-5eb43b1a13ae"
      unitRef="usd">-632646</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <cpix:BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses
      contextRef="id08ba9ef8fce4ef0b1aebddae7a819be_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF81NS9mcmFnOjNjYzExNDcyMGE1YTQxZDQ4MGQ2OWI3MjIxMWIwYTFiL3RhYmxlOjUyYWJlY2FiYzBlZDQ5NDRhNzg4YWIwNGI1NGUwMGFiL3RhYmxlcmFuZ2U6NTJhYmVjYWJjMGVkNDk0NGE3ODhhYjA0YjU0ZTAwYWJfMTItMS0xLTEtOTU1OA_65741f33-d908-4e37-a326-ec83e12aa2ec"
      unitRef="usd">1134333</cpix:BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i5d7014c036534d1ab07ea1c7138ece74_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF81NS9mcmFnOjNjYzExNDcyMGE1YTQxZDQ4MGQ2OWI3MjIxMWIwYTFiL3RhYmxlOjUyYWJlY2FiYzBlZDQ5NDRhNzg4YWIwNGI1NGUwMGFiL3RhYmxlcmFuZ2U6NTJhYmVjYWJjMGVkNDk0NGE3ODhhYjA0YjU0ZTAwYWJfMTMtMS0xLTEtOTU1OA_ce52186d-c37c-470b-ba63-7b153ebc19ac"
      unitRef="usd">6909666</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i5d7014c036534d1ab07ea1c7138ece74_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF81NS9mcmFnOjNjYzExNDcyMGE1YTQxZDQ4MGQ2OWI3MjIxMWIwYTFiL3RleHRyZWdpb246M2NjMTE0NzIwYTVhNDFkNDgwZDY5YjcyMjExYjBhMWJfMTg2Mw_58008847-255d-4a78-a316-fa566ad4af7d"
      unitRef="usd">6900000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i0463cd68913447b0aec736a9a21b1701_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF81NS9mcmFnOjNjYzExNDcyMGE1YTQxZDQ4MGQ2OWI3MjIxMWIwYTFiL3RleHRyZWdpb246M2NjMTE0NzIwYTVhNDFkNDgwZDY5YjcyMjExYjBhMWJfMTkxMw_e02dcf8f-caeb-4136-9ec8-9659b0b2055f"
      unitRef="usd">2600000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="icf562c30b2d9493a84db87baebada783_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF81NS9mcmFnOjNjYzExNDcyMGE1YTQxZDQ4MGQ2OWI3MjIxMWIwYTFiL3RleHRyZWdpb246M2NjMTE0NzIwYTVhNDFkNDgwZDY5YjcyMjExYjBhMWJfMTk1MQ_c38a5770-195c-4619-a4be-92536441a70c"
      unitRef="usd">4300000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="if7d1c3dbcd4b4c6eabe94af067f29d41_D20161101-20161130"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF81NS9mcmFnOjNjYzExNDcyMGE1YTQxZDQ4MGQ2OWI3MjIxMWIwYTFiL3RleHRyZWdpb246M2NjMTE0NzIwYTVhNDFkNDgwZDY5YjcyMjExYjBhMWJfMjQwOQ_8fb3a4e5-219e-441b-96b5-99345081c6ac"
      unitRef="usd">100000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred
      contextRef="if7d1c3dbcd4b4c6eabe94af067f29d41_D20161101-20161130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF81NS9mcmFnOjNjYzExNDcyMGE1YTQxZDQ4MGQ2OWI3MjIxMWIwYTFiL3RleHRyZWdpb246M2NjMTE0NzIwYTVhNDFkNDgwZDY5YjcyMjExYjBhMWJfMjQ0Ng_6a25e1fb-d000-4426-9285-cd2deeea1d71"
      unitRef="usd">900000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="ibb1ab73ec0354946b843823c167cac73_D20161101-20161130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF81NS9mcmFnOjNjYzExNDcyMGE1YTQxZDQ4MGQ2OWI3MjIxMWIwYTFiL3RleHRyZWdpb246M2NjMTE0NzIwYTVhNDFkNDgwZDY5YjcyMjExYjBhMWJfMjQ4NQ_376179ad-b353-4db2-a58c-98ba484c18c2"
      unitRef="shares">180000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="ibb1ab73ec0354946b843823c167cac73_D20161101-20161130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF81NS9mcmFnOjNjYzExNDcyMGE1YTQxZDQ4MGQ2OWI3MjIxMWIwYTFiL3RleHRyZWdpb246M2NjMTE0NzIwYTVhNDFkNDgwZDY5YjcyMjExYjBhMWJfMzA5Ng_170486f0-3188-4903-b50d-941bb79e6dd6"
      unitRef="shares">180000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="i9fbce1ec780d49a78a390da0ae5f4c6c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF81NS9mcmFnOjNjYzExNDcyMGE1YTQxZDQ4MGQ2OWI3MjIxMWIwYTFiL3RleHRyZWdpb246M2NjMTE0NzIwYTVhNDFkNDgwZDY5YjcyMjExYjBhMWJfMzIxNA_9bd7c5af-5bc2-4dd2-b7ba-9cb4a7cebe1a"
      unitRef="usd">900000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i0a2ac195a36045adacdf507f9366ba39_I20200731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF81NS9mcmFnOjNjYzExNDcyMGE1YTQxZDQ4MGQ2OWI3MjIxMWIwYTFiL3RleHRyZWdpb246M2NjMTE0NzIwYTVhNDFkNDgwZDY5YjcyMjExYjBhMWJfMzI3NA_994c2cb0-774d-4e92-b009-1c78a3f5f6d5"
      unitRef="usd">1000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i0899d206bf0144cb8f97b035bbc59bdc_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF81NS9mcmFnOjNjYzExNDcyMGE1YTQxZDQ4MGQ2OWI3MjIxMWIwYTFiL3RleHRyZWdpb246M2NjMTE0NzIwYTVhNDFkNDgwZDY5YjcyMjExYjBhMWJfMzQzMA_3bf9017b-3a43-424d-b1de-5b5a7f6c6e64"
      unitRef="usd">1000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="iab3199a2232b4c38950a9c717c8b9171_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF81NS9mcmFnOjNjYzExNDcyMGE1YTQxZDQ4MGQ2OWI3MjIxMWIwYTFiL3RleHRyZWdpb246M2NjMTE0NzIwYTVhNDFkNDgwZDY5YjcyMjExYjBhMWJfMzU5Ng_991683b6-233c-4928-af4f-17b9d058d786"
      unitRef="usd">2700000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:ProceedsFromSaleOfIntangibleAssets
      contextRef="i3c783d360e1948c18a55f375b9840bca_D20191001-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF81NS9mcmFnOjNjYzExNDcyMGE1YTQxZDQ4MGQ2OWI3MjIxMWIwYTFiL3RleHRyZWdpb246M2NjMTE0NzIwYTVhNDFkNDgwZDY5YjcyMjExYjBhMWJfNDgwOA_ebb4201e-3fc7-4588-94e9-1841362a7215"
      unitRef="usd">5000000</us-gaap:ProceedsFromSaleOfIntangibleAssets>
    <cpix:ProceedsFromSaleOfIntangibleAssetsInstallmentPayment
      contextRef="i54eac56082574a4c986a915dc06c3af5_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF81NS9mcmFnOjNjYzExNDcyMGE1YTQxZDQ4MGQ2OWI3MjIxMWIwYTFiL3RleHRyZWdpb246M2NjMTE0NzIwYTVhNDFkNDgwZDY5YjcyMjExYjBhMWJfNDk4Ng_6c047bc2-19b9-467a-82a2-09a37b7365dd"
      unitRef="usd">3000000</cpix:ProceedsFromSaleOfIntangibleAssetsInstallmentPayment>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
      contextRef="i45bdfab35dd74d60ac86fc023b908b73_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF81NS9mcmFnOjNjYzExNDcyMGE1YTQxZDQ4MGQ2OWI3MjIxMWIwYTFiL3RleHRyZWdpb246M2NjMTE0NzIwYTVhNDFkNDgwZDY5YjcyMjExYjBhMWJfNTA0MA_8a646cfd-70b9-46ad-a20c-f4a22a2f4631"
      unitRef="usd">1500000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock
      contextRef="i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF81NS9mcmFnOjNjYzExNDcyMGE1YTQxZDQ4MGQ2OWI3MjIxMWIwYTFiL3RleHRyZWdpb246M2NjMTE0NzIwYTVhNDFkNDgwZDY5YjcyMjExYjBhMWJfNTg0Mg_3c327a04-eb39-4424-bbb1-9960eed76f96">&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The dissolution payments from Clinigen are reflected as revenue from discontinued operations.  The Company does not &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;incur expenses associated with these payments from Clinigen. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.590%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.677%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.499%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Nine months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;496,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;777,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,491,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,334,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Costs of products sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, Marketing and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;496,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;777,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,491,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,334,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ieb58760ea84940319b35492cd1910735_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF81NS9mcmFnOjNjYzExNDcyMGE1YTQxZDQ4MGQ2OWI3MjIxMWIwYTFiL3RhYmxlOjI5OWQ0MTYwMGM5YTQ3MDlhNjZiNjg3MzFkMGNlNjQ0L3RhYmxlcmFuZ2U6Mjk5ZDQxNjAwYzlhNDcwOWE2NmI2ODczMWQwY2U2NDRfMy0yLTEtMS05NTU4_86849bd9-9c34-42dc-a4b6-2061e77af27b"
      unitRef="usd">496787</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifca7f9fa06d14f85a52cbd81ac170d2c_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF81NS9mcmFnOjNjYzExNDcyMGE1YTQxZDQ4MGQ2OWI3MjIxMWIwYTFiL3RhYmxlOjI5OWQ0MTYwMGM5YTQ3MDlhNjZiNjg3MzFkMGNlNjQ0L3RhYmxlcmFuZ2U6Mjk5ZDQxNjAwYzlhNDcwOWE2NmI2ODczMWQwY2U2NDRfMy00LTEtMS05NTU4_0fe8db84-b272-4c9f-a304-4c34cd7b14a3"
      unitRef="usd">777916</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i45bdfab35dd74d60ac86fc023b908b73_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF81NS9mcmFnOjNjYzExNDcyMGE1YTQxZDQ4MGQ2OWI3MjIxMWIwYTFiL3RhYmxlOjI5OWQ0MTYwMGM5YTQ3MDlhNjZiNjg3MzFkMGNlNjQ0L3RhYmxlcmFuZ2U6Mjk5ZDQxNjAwYzlhNDcwOWE2NmI2ODczMWQwY2U2NDRfMy01LTEtMS05NTU4_1acd7b61-10d3-4d57-a3bb-db27abac79f0"
      unitRef="usd">1491004</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib8c8802e62b74a919450a1c6017bba7e_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF81NS9mcmFnOjNjYzExNDcyMGE1YTQxZDQ4MGQ2OWI3MjIxMWIwYTFiL3RhYmxlOjI5OWQ0MTYwMGM5YTQ3MDlhNjZiNjg3MzFkMGNlNjQ0L3RhYmxlcmFuZ2U6Mjk5ZDQxNjAwYzlhNDcwOWE2NmI2ODczMWQwY2U2NDRfMy03LTEtMS05NTU4_841b8fa5-722e-49de-805f-6e1ba99049bf"
      unitRef="usd">2334811</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ieb58760ea84940319b35492cd1910735_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF81NS9mcmFnOjNjYzExNDcyMGE1YTQxZDQ4MGQ2OWI3MjIxMWIwYTFiL3RhYmxlOjI5OWQ0MTYwMGM5YTQ3MDlhNjZiNjg3MzFkMGNlNjQ0L3RhYmxlcmFuZ2U6Mjk5ZDQxNjAwYzlhNDcwOWE2NmI2ODczMWQwY2U2NDRfNC0yLTEtMS05NTU4_b370ba5e-0f89-4b8c-8e72-b4654071f9b9"
      unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ifca7f9fa06d14f85a52cbd81ac170d2c_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF81NS9mcmFnOjNjYzExNDcyMGE1YTQxZDQ4MGQ2OWI3MjIxMWIwYTFiL3RhYmxlOjI5OWQ0MTYwMGM5YTQ3MDlhNjZiNjg3MzFkMGNlNjQ0L3RhYmxlcmFuZ2U6Mjk5ZDQxNjAwYzlhNDcwOWE2NmI2ODczMWQwY2U2NDRfNC00LTEtMS05NTU4_4f087064-ec6f-423b-b86f-0953ea7019c3"
      unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i45bdfab35dd74d60ac86fc023b908b73_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF81NS9mcmFnOjNjYzExNDcyMGE1YTQxZDQ4MGQ2OWI3MjIxMWIwYTFiL3RhYmxlOjI5OWQ0MTYwMGM5YTQ3MDlhNjZiNjg3MzFkMGNlNjQ0L3RhYmxlcmFuZ2U6Mjk5ZDQxNjAwYzlhNDcwOWE2NmI2ODczMWQwY2U2NDRfNC01LTEtMS05NTU4_155b8afc-8ab1-457d-92e1-03a857618626"
      unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ib8c8802e62b74a919450a1c6017bba7e_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF81NS9mcmFnOjNjYzExNDcyMGE1YTQxZDQ4MGQ2OWI3MjIxMWIwYTFiL3RhYmxlOjI5OWQ0MTYwMGM5YTQ3MDlhNjZiNjg3MzFkMGNlNjQ0L3RhYmxlcmFuZ2U6Mjk5ZDQxNjAwYzlhNDcwOWE2NmI2ODczMWQwY2U2NDRfNC03LTEtMS05NTU4_c03493ea-11f9-4d62-83fb-b13be2887ec5"
      unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:SellingAndMarketingExpense
      contextRef="ieb58760ea84940319b35492cd1910735_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF81NS9mcmFnOjNjYzExNDcyMGE1YTQxZDQ4MGQ2OWI3MjIxMWIwYTFiL3RhYmxlOjI5OWQ0MTYwMGM5YTQ3MDlhNjZiNjg3MzFkMGNlNjQ0L3RhYmxlcmFuZ2U6Mjk5ZDQxNjAwYzlhNDcwOWE2NmI2ODczMWQwY2U2NDRfNS0yLTEtMS05NTU4_7f78e0b8-872e-4890-b770-0a08422c7bcd"
      unitRef="usd">0</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="ifca7f9fa06d14f85a52cbd81ac170d2c_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF81NS9mcmFnOjNjYzExNDcyMGE1YTQxZDQ4MGQ2OWI3MjIxMWIwYTFiL3RhYmxlOjI5OWQ0MTYwMGM5YTQ3MDlhNjZiNjg3MzFkMGNlNjQ0L3RhYmxlcmFuZ2U6Mjk5ZDQxNjAwYzlhNDcwOWE2NmI2ODczMWQwY2U2NDRfNS00LTEtMS05NTU4_11ac3d95-7e50-479f-ab22-21b3694b4b6a"
      unitRef="usd">0</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="i45bdfab35dd74d60ac86fc023b908b73_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF81NS9mcmFnOjNjYzExNDcyMGE1YTQxZDQ4MGQ2OWI3MjIxMWIwYTFiL3RhYmxlOjI5OWQ0MTYwMGM5YTQ3MDlhNjZiNjg3MzFkMGNlNjQ0L3RhYmxlcmFuZ2U6Mjk5ZDQxNjAwYzlhNDcwOWE2NmI2ODczMWQwY2U2NDRfNS01LTEtMS05NTU4_34178999-de8e-4b4e-ac90-824fd32e5090"
      unitRef="usd">0</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="ib8c8802e62b74a919450a1c6017bba7e_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF81NS9mcmFnOjNjYzExNDcyMGE1YTQxZDQ4MGQ2OWI3MjIxMWIwYTFiL3RhYmxlOjI5OWQ0MTYwMGM5YTQ3MDlhNjZiNjg3MzFkMGNlNjQ0L3RhYmxlcmFuZ2U6Mjk5ZDQxNjAwYzlhNDcwOWE2NmI2ODczMWQwY2U2NDRfNS03LTEtMS05NTU4_edecd593-95d2-431b-81e9-20a787b68ed8"
      unitRef="usd">0</us-gaap:SellingAndMarketingExpense>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="ieb58760ea84940319b35492cd1910735_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF81NS9mcmFnOjNjYzExNDcyMGE1YTQxZDQ4MGQ2OWI3MjIxMWIwYTFiL3RhYmxlOjI5OWQ0MTYwMGM5YTQ3MDlhNjZiNjg3MzFkMGNlNjQ0L3RhYmxlcmFuZ2U6Mjk5ZDQxNjAwYzlhNDcwOWE2NmI2ODczMWQwY2U2NDRfNi0yLTEtMS05NTU4_bbd547b7-4377-470d-90d9-78decf2db53b"
      unitRef="usd">496787</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="ifca7f9fa06d14f85a52cbd81ac170d2c_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF81NS9mcmFnOjNjYzExNDcyMGE1YTQxZDQ4MGQ2OWI3MjIxMWIwYTFiL3RhYmxlOjI5OWQ0MTYwMGM5YTQ3MDlhNjZiNjg3MzFkMGNlNjQ0L3RhYmxlcmFuZ2U6Mjk5ZDQxNjAwYzlhNDcwOWE2NmI2ODczMWQwY2U2NDRfNi00LTEtMS05NTU4_3386f327-073b-4e39-8b3a-fea616e5490c"
      unitRef="usd">777916</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="i45bdfab35dd74d60ac86fc023b908b73_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF81NS9mcmFnOjNjYzExNDcyMGE1YTQxZDQ4MGQ2OWI3MjIxMWIwYTFiL3RhYmxlOjI5OWQ0MTYwMGM5YTQ3MDlhNjZiNjg3MzFkMGNlNjQ0L3RhYmxlcmFuZ2U6Mjk5ZDQxNjAwYzlhNDcwOWE2NmI2ODczMWQwY2U2NDRfNi01LTEtMS05NTU4_b296a3be-7468-4125-abbc-ab4924871a99"
      unitRef="usd">1491004</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="ib8c8802e62b74a919450a1c6017bba7e_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlOGJkYjkxZGM4OTQyMzRiOWQ4N2UxN2ExOGI1NGZkL3NlYzo4ZThiZGI5MWRjODk0MjM0YjlkODdlMTdhMThiNTRmZF81NS9mcmFnOjNjYzExNDcyMGE1YTQxZDQ4MGQ2OWI3MjIxMWIwYTFiL3RhYmxlOjI5OWQ0MTYwMGM5YTQ3MDlhNjZiNjg3MzFkMGNlNjQ0L3RhYmxlcmFuZ2U6Mjk5ZDQxNjAwYzlhNDcwOWE2NmI2ODczMWQwY2U2NDRfNi03LTEtMS05NTU4_4f55d8cf-b278-4038-beef-abe1a03978de"
      unitRef="usd">2334811</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140570218844312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Nov. 08, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Cumberland Pharmaceuticals Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">TN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">62-1765329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2525 West End Avenue<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Nashville<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">37203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">255-0068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, no par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CPIX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,809,628<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001087294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140570219965128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 25,843,231<span></span>
</td>
<td class="nump">$ 24,753,796<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">9,850,530<span></span>
</td>
<td class="nump">12,377,713<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">10,262,769<span></span>
</td>
<td class="nump">10,638,157<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Prepaid and other current assets</a></td>
<td class="nump">1,259,098<span></span>
</td>
<td class="nump">2,199,926<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">47,215,628<span></span>
</td>
<td class="nump">49,969,592<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Non-current inventories</a></td>
<td class="nump">9,476,737<span></span>
</td>
<td class="nump">11,656,742<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">493,488<span></span>
</td>
<td class="nump">574,169<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">24,918,830<span></span>
</td>
<td class="nump">28,118,316<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">882,000<span></span>
</td>
<td class="nump">882,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">1,282,275<span></span>
</td>
<td class="nump">2,028,148<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">3,301,816<span></span>
</td>
<td class="nump">3,234,338<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">87,570,774<span></span>
</td>
<td class="nump">96,463,305<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">9,233,383<span></span>
</td>
<td class="nump">13,396,286<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease current liabilities</a></td>
<td class="nump">1,094,187<span></span>
</td>
<td class="nump">1,016,779<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">7,617,913<span></span>
</td>
<td class="nump">11,254,381<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">17,945,483<span></span>
</td>
<td class="nump">25,667,446<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermLineOfCredit', window );">Revolving line of credit</a></td>
<td class="nump">15,000,000<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease noncurrent liabilities</a></td>
<td class="nump">229,605<span></span>
</td>
<td class="nump">1,059,693<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_OtherLongTermObligationsExcludingCurrentPortion', window );">Other long-term liabilities</a></td>
<td class="nump">7,749,421<span></span>
</td>
<td class="nump">7,862,772<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">40,924,509<span></span>
</td>
<td class="nump">49,589,911<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock&#8212;no par value; 100,000,000 shares authorized; 15,555,865 and 15,723,075 shares issued and outstanding as of June 30, 2018 and December 31, 2017, respectively</a></td>
<td class="nump">48,612,935<span></span>
</td>
<td class="nump">49,121,523<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings (deficit)</a></td>
<td class="num">(1,790,903)<span></span>
</td>
<td class="num">(2,131,013)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders&#8217; equity</a></td>
<td class="nump">46,822,032<span></span>
</td>
<td class="nump">46,990,510<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="num">(175,767)<span></span>
</td>
<td class="num">(117,116)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="nump">46,646,265<span></span>
</td>
<td class="nump">46,873,394<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="nump">$ 87,570,774<span></span>
</td>
<td class="nump">$ 96,463,305<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_OtherLongTermObligationsExcludingCurrentPortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Long Term Obligations, Excluding Current Portion</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_OtherLongTermObligationsExcludingCurrentPortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermLineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=99376301&amp;loc=d3e1336-112600<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=99376301&amp;loc=d3e1314-112600<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermLineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140570218595128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNoParValue', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">14,850,526<span></span>
</td>
<td class="nump">14,988,429<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">14,850,526<span></span>
</td>
<td class="nump">14,988,429<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNoParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount per share of no-par value common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNoParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140570218937496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">$ 8,072,540<span></span>
</td>
<td class="nump">$ 9,250,689<span></span>
</td>
<td class="nump">$ 27,665,182<span></span>
</td>
<td class="nump">$ 27,179,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of products sold</a></td>
<td class="nump">1,328,027<span></span>
</td>
<td class="nump">2,142,839<span></span>
</td>
<td class="nump">5,486,005<span></span>
</td>
<td class="nump">6,387,002<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Selling and marketing</a></td>
<td class="nump">3,800,288<span></span>
</td>
<td class="nump">3,587,842<span></span>
</td>
<td class="nump">11,709,445<span></span>
</td>
<td class="nump">11,160,924<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">1,453,873<span></span>
</td>
<td class="nump">1,230,335<span></span>
</td>
<td class="nump">4,071,638<span></span>
</td>
<td class="nump">4,374,392<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">2,039,799<span></span>
</td>
<td class="nump">2,381,273<span></span>
</td>
<td class="nump">6,367,438<span></span>
</td>
<td class="nump">6,608,321<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization</a></td>
<td class="nump">1,013,948<span></span>
</td>
<td class="nump">1,117,086<span></span>
</td>
<td class="nump">3,354,080<span></span>
</td>
<td class="nump">3,284,610<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total costs and expenses</a></td>
<td class="nump">9,635,935<span></span>
</td>
<td class="nump">10,459,375<span></span>
</td>
<td class="nump">30,988,606<span></span>
</td>
<td class="nump">31,815,249<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="num">(1,563,395)<span></span>
</td>
<td class="num">(1,208,686)<span></span>
</td>
<td class="num">(3,323,424)<span></span>
</td>
<td class="num">(4,635,649)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">7,394<span></span>
</td>
<td class="nump">12,004<span></span>
</td>
<td class="nump">19,411<span></span>
</td>
<td class="nump">70,553<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,187,140<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(20,021)<span></span>
</td>
<td class="num">(75,210)<span></span>
</td>
<td class="num">(70,297)<span></span>
</td>
<td class="num">(227,730)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) from continuing operations before income taxes</a></td>
<td class="num">(1,576,022)<span></span>
</td>
<td class="num">(1,271,892)<span></span>
</td>
<td class="num">(1,187,170)<span></span>
</td>
<td class="num">(4,792,826)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (expense) benefit</a></td>
<td class="num">(7,458)<span></span>
</td>
<td class="num">(3,728)<span></span>
</td>
<td class="num">(22,375)<span></span>
</td>
<td class="num">(45,423)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest, Total</a></td>
<td class="num">(1,583,480)<span></span>
</td>
<td class="num">(1,275,620)<span></span>
</td>
<td class="num">(1,209,545)<span></span>
</td>
<td class="num">(4,838,249)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,491,004<span></span>
</td>
<td class="nump">2,334,811<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(1,086,693)<span></span>
</td>
<td class="num">(497,704)<span></span>
</td>
<td class="nump">281,459<span></span>
</td>
<td class="num">(2,503,438)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net (income) loss at subsidiary attributable to noncontrolling interests</a></td>
<td class="nump">31,415<span></span>
</td>
<td class="nump">15,967<span></span>
</td>
<td class="nump">58,651<span></span>
</td>
<td class="nump">47,806<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to common shareholders</a></td>
<td class="num">$ (1,055,278)<span></span>
</td>
<td class="num">$ (481,737)<span></span>
</td>
<td class="nump">$ 340,110<span></span>
</td>
<td class="num">$ (2,455,632)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings (loss) per share attributable to common shareholders</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Earnings (loss) per share attributable to common shareholders - Continuing operations - basic (in dollars per share)</a></td>
<td class="num">$ (0.10)<span></span>
</td>
<td class="num">$ (0.08)<span></span>
</td>
<td class="num">$ (0.08)<span></span>
</td>
<td class="num">$ (0.31)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare', window );">Earnings (loss) per share attributable to common shareholders - Discontinued operations - basic (in dollars per share)</a></td>
<td class="nump">0.03<span></span>
</td>
<td class="nump">0.05<span></span>
</td>
<td class="nump">0.10<span></span>
</td>
<td class="nump">0.15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Earnings (loss) per share attributable to common shareholders - basic (in dollars per share)</a></td>
<td class="num">(0.07)<span></span>
</td>
<td class="num">(0.03)<span></span>
</td>
<td class="nump">0.02<span></span>
</td>
<td class="num">(0.16)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Earnings (loss) per share attributable to common shareholders - Continuing operations - diluted (in dollars per share)</a></td>
<td class="num">(0.10)<span></span>
</td>
<td class="num">(0.08)<span></span>
</td>
<td class="num">(0.08)<span></span>
</td>
<td class="num">(0.31)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare', window );">Earnings (loss) per share attributable to common shareholders - Discontinued operations - diluted (in dollars per share)</a></td>
<td class="nump">0.03<span></span>
</td>
<td class="nump">0.05<span></span>
</td>
<td class="nump">0.10<span></span>
</td>
<td class="nump">0.15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings (loss) per share attributable to common shareholders - diluted (in dollars per share)</a></td>
<td class="num">$ (0.07)<span></span>
</td>
<td class="num">$ (0.03)<span></span>
</td>
<td class="nump">$ 0.02<span></span>
</td>
<td class="num">$ (0.16)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted-average shares outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">- basic (in shares)</a></td>
<td class="nump">14,880,887<span></span>
</td>
<td class="nump">15,134,583<span></span>
</td>
<td class="nump">14,939,919<span></span>
</td>
<td class="nump">15,206,179<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">- diluted (in shares)</a></td>
<td class="nump">14,880,887<span></span>
</td>
<td class="nump">15,134,583<span></span>
</td>
<td class="nump">15,139,904<span></span>
</td>
<td class="nump">15,206,179<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868656-224227<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868656-224227<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1278-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 5.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398118&amp;loc=d3e355146-122828<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1278-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue and income classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140570219777576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 281,459<span></span>
</td>
<td class="num">$ (2,503,438)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Discontinued operations</a></td>
<td class="nump">1,491,004<span></span>
</td>
<td class="nump">2,334,811<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Net income (loss) from continuing operations</a></td>
<td class="num">(1,209,545)<span></span>
</td>
<td class="num">(4,838,249)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income (loss) from continuing operations to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">3,529,245<span></span>
</td>
<td class="nump">3,524,684<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">517,081<span></span>
</td>
<td class="nump">805,338<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities', window );">Decrease in non-cash contingent consideration</a></td>
<td class="num">(632,646)<span></span>
</td>
<td class="num">(806,390)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy', window );">Increase (Decrease) In Cash Surrender Value Of Life Insurance Policy</a></td>
<td class="num">(52,070)<span></span>
</td>
<td class="nump">169,406<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Noncash interest expense</a></td>
<td class="nump">33,943<span></span>
</td>
<td class="nump">36,197<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Gain on forgiveness of debt</a></td>
<td class="num">(2,187,140)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Net changes in assets and liabilities affecting operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">2,527,183<span></span>
</td>
<td class="num">(1,817,490)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="nump">2,555,393<span></span>
</td>
<td class="nump">1,696,668<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other current assets and other assets</a></td>
<td class="nump">1,627,350<span></span>
</td>
<td class="nump">1,962,024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_IncreaseDecreaseInCurrentOperatingLiabilities', window );">Accounts payable and other current liabilities</a></td>
<td class="num">(2,873,596)<span></span>
</td>
<td class="nump">3,248,450<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other long-term liabilities</a></td>
<td class="num">(943,439)<span></span>
</td>
<td class="num">(1,585,584)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash provided by operating activities from continuing operations</a></td>
<td class="nump">2,891,759<span></span>
</td>
<td class="nump">2,395,054<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations', window );">Discontinued operations</a></td>
<td class="nump">1,491,004<span></span>
</td>
<td class="nump">2,166,086<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">4,382,763<span></span>
</td>
<td class="nump">4,561,140<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Additions to property and equipment</a></td>
<td class="num">(94,485)<span></span>
</td>
<td class="num">(95,189)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from surrender of life insurance policies</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">460,888<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Note receivable investment funding</a></td>
<td class="num">(200,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Additions to intangible assets</a></td>
<td class="num">(180,613)<span></span>
</td>
<td class="num">(1,807,467)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(475,098)<span></span>
</td>
<td class="num">(1,441,768)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit', window );">Borrowings on line of credit</a></td>
<td class="nump">45,000,000<span></span>
</td>
<td class="nump">44,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayments on line of credit</a></td>
<td class="num">(45,000,000)<span></span>
</td>
<td class="num">(45,500,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Cash payment of contingent consideration</a></td>
<td class="num">(1,792,573)<span></span>
</td>
<td class="num">(834,014)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest', window );">Repurchase of subsidiary shares from noncontrolling interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(800,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchase of common shares</a></td>
<td class="num">(1,025,657)<span></span>
</td>
<td class="num">(1,551,463)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(2,818,230)<span></span>
</td>
<td class="num">(4,685,477)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">1,089,435<span></span>
</td>
<td class="num">(1,566,105)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">24,753,796<span></span>
</td>
<td class="nump">28,212,635<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">$ 25,843,231<span></span>
</td>
<td class="nump">$ 26,646,530<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Cash Surrender Value Of Life Insurance Policy</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_IncreaseDecreaseInCurrentOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_IncreaseDecreaseInCurrentOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for realized tax benefit related to deductible compensation cost reported on the entity's tax return for equity instruments in excess of the compensation cost for those instruments recognized for financial reporting purposes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11374-113907<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period for redemption of redeemable noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or cash outflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with either short term or long term maturity that is collateralized (backed by pledge, mortgage or other lien in the entity's assets).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140570218648584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statement of Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common stock</div></th>
<th class="th"><div>Retained earnings</div></th>
<th class="th"><div>Noncontrolling interests</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, Beginning of Period at Dec. 31, 2019</a></td>
<td class="nump">$ 51,085,253<span></span>
</td>
<td class="nump">$ 49,914,478<span></span>
</td>
<td class="nump">$ 1,208,395<span></span>
</td>
<td class="num">$ (37,620)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, Beginning of Period (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,263,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">264,574<span></span>
</td>
<td class="nump">$ 264,574<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">219,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of common shares</a></td>
<td class="num">(441,624)<span></span>
</td>
<td class="num">$ (441,624)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(164,866)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(1,065,145)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,055,620)<span></span>
</td>
<td class="num">(9,525)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, End of Period at Mar. 31, 2020</a></td>
<td class="nump">49,843,058<span></span>
</td>
<td class="nump">$ 49,737,428<span></span>
</td>
<td class="nump">152,775<span></span>
</td>
<td class="num">(47,145)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, End of Period (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,318,539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, Beginning of Period at Dec. 31, 2019</a></td>
<td class="nump">51,085,253<span></span>
</td>
<td class="nump">$ 49,914,478<span></span>
</td>
<td class="nump">1,208,395<span></span>
</td>
<td class="num">(37,620)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, Beginning of Period (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,263,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,500,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(407,683)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(2,503,438)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, End of Period at Sep. 30, 2020</a></td>
<td class="nump">47,843,377<span></span>
</td>
<td class="nump">$ 49,176,040<span></span>
</td>
<td class="num">(1,247,237)<span></span>
</td>
<td class="num">(85,426)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, End of Period (in shares) at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,084,372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, Beginning of Period at Mar. 31, 2020</a></td>
<td class="nump">49,843,058<span></span>
</td>
<td class="nump">$ 49,737,428<span></span>
</td>
<td class="nump">152,775<span></span>
</td>
<td class="num">(47,145)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, Beginning of Period (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,318,539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">278,349<span></span>
</td>
<td class="nump">$ 278,349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of common shares</a></td>
<td class="num">(769,648)<span></span>
</td>
<td class="num">$ (769,648)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(141,463)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(940,589)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(918,275)<span></span>
</td>
<td class="num">(22,314)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, End of Period at Jun. 30, 2020</a></td>
<td class="nump">48,411,170<span></span>
</td>
<td class="nump">$ 49,246,129<span></span>
</td>
<td class="num">(765,500)<span></span>
</td>
<td class="num">(69,459)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, End of Period (in shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,181,276<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">262,415<span></span>
</td>
<td class="nump">$ 262,415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of common shares</a></td>
<td class="num">(332,504)<span></span>
</td>
<td class="num">$ (332,504)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(101,354)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(497,704)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(481,737)<span></span>
</td>
<td class="num">(15,967)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, End of Period at Sep. 30, 2020</a></td>
<td class="nump">47,843,377<span></span>
</td>
<td class="nump">$ 49,176,040<span></span>
</td>
<td class="num">(1,247,237)<span></span>
</td>
<td class="num">(85,426)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, End of Period (in shares) at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,084,372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, Beginning of Period at Dec. 31, 2020</a></td>
<td class="nump">$ 46,873,394<span></span>
</td>
<td class="nump">$ 49,121,523<span></span>
</td>
<td class="num">(2,131,013)<span></span>
</td>
<td class="num">(117,116)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, Beginning of Period (in shares) at Dec. 31, 2020</a></td>
<td class="nump">14,988,429<span></span>
</td>
<td class="nump">14,988,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">$ 162,960<span></span>
</td>
<td class="nump">$ 162,960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">187,759<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of common shares</a></td>
<td class="num">(303,088)<span></span>
</td>
<td class="num">$ (303,088)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(91,724)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">144,661<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166,828<span></span>
</td>
<td class="num">(22,167)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, End of Period at Mar. 31, 2021</a></td>
<td class="nump">46,877,927<span></span>
</td>
<td class="nump">$ 48,981,395<span></span>
</td>
<td class="num">(1,964,185)<span></span>
</td>
<td class="num">(139,283)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, End of Period (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,084,464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, Beginning of Period at Dec. 31, 2020</a></td>
<td class="nump">$ 46,873,394<span></span>
</td>
<td class="nump">$ 49,121,523<span></span>
</td>
<td class="num">(2,131,013)<span></span>
</td>
<td class="num">(117,116)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, Beginning of Period (in shares) at Dec. 31, 2020</a></td>
<td class="nump">14,988,429<span></span>
</td>
<td class="nump">14,988,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(326,537)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 281,459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, End of Period at Sep. 30, 2021</a></td>
<td class="nump">$ 46,646,265<span></span>
</td>
<td class="nump">$ 48,612,935<span></span>
</td>
<td class="num">(1,790,903)<span></span>
</td>
<td class="num">(175,767)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, End of Period (in shares) at Sep. 30, 2021</a></td>
<td class="nump">14,850,526<span></span>
</td>
<td class="nump">14,850,526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, Beginning of Period at Mar. 31, 2021</a></td>
<td class="nump">$ 46,877,927<span></span>
</td>
<td class="nump">$ 48,981,395<span></span>
</td>
<td class="num">(1,964,185)<span></span>
</td>
<td class="num">(139,283)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, Beginning of Period (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,084,464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">191,954<span></span>
</td>
<td class="nump">$ 191,954<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of common shares</a></td>
<td class="num">(484,965)<span></span>
</td>
<td class="num">$ (484,965)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(158,405)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">1,223,491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,228,560<span></span>
</td>
<td class="num">(5,069)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, End of Period at Jun. 30, 2021</a></td>
<td class="nump">47,808,407<span></span>
</td>
<td class="nump">$ 48,688,384<span></span>
</td>
<td class="num">(735,625)<span></span>
</td>
<td class="num">(144,352)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, End of Period (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,926,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">162,167<span></span>
</td>
<td class="nump">$ 162,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of common shares</a></td>
<td class="num">(237,616)<span></span>
</td>
<td class="num">$ (237,616)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(76,408)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(1,086,693)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,055,278)<span></span>
</td>
<td class="num">(31,415)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, End of Period at Sep. 30, 2021</a></td>
<td class="nump">$ 46,646,265<span></span>
</td>
<td class="nump">$ 48,612,935<span></span>
</td>
<td class="num">$ (1,790,903)<span></span>
</td>
<td class="num">$ (175,767)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, End of Period (in shares) at Sep. 30, 2021</a></td>
<td class="nump">14,850,526<span></span>
</td>
<td class="nump">14,850,526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140570212692696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">ORGANIZATION AND BASIS OF PRESENTATION</a></td>
<td class="text">ORGANIZATION AND BASIS OF PRESENTATION<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland Pharmaceuticals Inc. (&#8220;Cumberland,&#8221; the &#8220;Company,&#8221; or as used in the context of &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221;) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products.  The Company's primary target markets are hospital acute care, gastroenterology and rheumatology. These medical specialties are characterized by relatively concentrated prescriber bases that the Company believes can be penetrated effectively by small, targeted sales forces. Cumberland is dedicated to providing innovative products that improve quality of care for patients and address unmet or poorly met medical needs.  The Company promotes its approved products through its hospital and field sales forces in the United States and is establishing a network of international partners to bring its medicines to patients in their countries.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland focuses its resources on maximizing the commercial potential of its products, as well as developing new product candidates, and has both internal development and commercial capabilities. The Company&#8217;s products are manufactured by third parties, which are overseen by Cumberland&#8217;s quality control and manufacturing professionals. The Company works closely with its third-party distribution partners to make its products available in the United States.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, the accompanying unaudited condensed consolidated financial statements of the Company have been prepared on a basis consistent with the December 31, 2020, audited consolidated financial statements and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly present the information set forth herein. All significant intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements have been prepared in accordance with the regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;), and certain information and disclosures have been condensed or omitted as permitted by the SEC for interim period presentation. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes included in our Annual Report on Form 10-K for the year ended December 31, 2020 (the &#8220;2020 Annual Report on Form 10-K&#8221;). The results of operations for the three and nine months ended September 30, 2021, are not necessarily indicative of the results to be expected for the entire fiscal year or any future period.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Discontinued Operations</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed further in Note 9, during May 2019, Cumberland entered into a Dissolution Agreement  ("Dissolution Agreement") with Clinigen Healthcare Limited ("Clinigen") in which the Company returned the exclusive rights to commercialize Ethyol</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Totect</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States to Clinigen. Under the terms of the Dissolution Agreement, Cumberland is no longer involved directly or indirectly with the distribution, marketing and promotion of either Ethyol or Totect or any competing products following December 31, 2019. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's exit from Ethyol and Totect meets the accounting criteria to be reported as discontinued operations and the discontinued operating results have been presented in the financial statements and footnotes to reflect the discontinued status of Ethyol and Totect. Refer to Note 9, for additional information.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revision of prior period condensed consolidated statement of cash flows presentation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has made a revision to prior period amounts to conform to the current year presentation of the cash surrender value of life insurance policies over premiums paid on the condensed consolidated statement of cash flows.  The revised amounts were previously included as net changes in assets affecting operating activities.  These revisions have no net effect on the reported net cash provided by operating activities nor any impact on the reported operating results or balance sheet for the 2020 period presented.  </span></div><div style="margin-bottom:8pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19 Pandemic </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the U.S. declared a health care emergency following the outbreak of the SARS-CoV-2, a novel strain of coronavirus that causes COVID-19, a respiratory illness.  </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland has remained open for business, as the Company is considered to be essential by the United States Department of Homeland Security. The Company has implemented measures to address the impact of the novel coronavirus on the business and taken appropriate action to protect its employees, secure the supply chain, and support the patients who can benefit from its medicines.  All of the Company's employees have been given the opportunity to work remotely, and those that wish to work from Cumberland's office and laboratories are encouraged to practice the behaviors outlined by the Centers for Disease Control.  </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Throughout the pandemic, Cumberland has faced the same headwinds affecting other companies that rely on hospital admissions and patient visits to drive revenue.  Our business and our clinical studies were impacted as less patients sought elective surgeries and our access to medical facilities was substantially limited.  During 2020 and 2021, we carefully monitored our supply chain during the pandemic including the flow of raw materials into the plants that manufacture our products as well as the batches of finished product emerging from those facilities. Several of our brands were negatively impacted by the lockdowns and postponement of physician office visits and elective procedures. However, we are fortunate to have a diversified product portfolio, with other brands delivering a strong performance.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland relies on third-party organizations around the world to supply components, manufacture and distribute its products. The Company is aware that it may experience revenue loss, supply interruptions, time delays and incur unplanned expenses as a result of the impact of the ongoing COVID-19 pandemic.   The Company continues to monitor the COVID-19 pandemic situation both in the U.S. and internationally in order to maintain its employees&#8217; safety and well-being, while also keeping its business operating.  Given the uncertainty, magnitude and impact of such changes, the Company is unable to quantify the impact on the future results as of the date of this filing.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Guidance</span></div><div style="margin-bottom:6pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements - Not Yet Adopted</span></div><div style="margin-bottom:6pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board ("FASB") issued ASU No. 2016-13, &#8220;Financial Instruments-Credit Losses,&#8221; which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other instruments, companies will be required to use a new forward-looking &#8220;expected loss&#8221; model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, companies will measure credit losses in a manner similar to what they do today, except that the losses will be recognized as allowances rather than as reductions in the amortized cost of the securities. Companies will have to disclose additional information, including information they use to track credit quality by year of origination for most financing receivables. Companies will apply the ASU&#8217;s provisions as a cumulative-effect adjustment, if any, to retained earnings as of the beginning of the first reporting period in which the guidance is adopted.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Related to ASU No. 2016-13 discussed above, in May 2019, the FASB issued ASU 2019-05, "Financial Instruments-Credit Losses (Topic 326): Targeted Transition Relief" which provides transition relief for ASU 2016-13 by providing entities with an alternative to irrevocably elect the fair value option for eligible financial assets measured at amortized cost upon adoption of the new credit losses standard. Certain eligibility requirements must be met and the election must be applied on an instrument-by-instrument basis. The election is not available for either available-for-sale or held-to-maturity debt securities. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will adopt both ASU 2016-13 and ASU 2019-05 on January 1, 2023. The adoption of ASU 2016-13 and ASU 2019-05 are not expected to have a material impact on the Company&#8217;s consolidated financial statements.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Policies:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Use of Estimates</span></div><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management of the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period.  Actual results could differ from those estimates under different assumptions and conditions.  The Company's most significant estimates include: (1) its allowances for chargebacks and accruals for rebates and product returns, (2) the allowances for obsolescent or unmarketable inventory and (3) valuation of a contingent consideration liability associated with a business combination.</span></div><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Operating Segments</span></div>The Company has one operating segment which is specialty pharmaceutical products. Management has chosen to organize the Company based on the type of products sold. Operating segments are identified as components of an enterprise about which separate discrete financial information is evaluated by the chief operating decision maker, or decision-making group, in making decisions regarding resource allocation and assessing performance. The Company, which uses consolidated financial information in determining how to allocate resources and assess performance, has concluded that our specialty pharmaceutical products compete in similar economic markets and similar circumstances.  Substantially all of the Company&#8217;s assets are located in the United States and total revenues are primarily attributable to U.S.&#160;customers.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140570212758808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) Per Share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">EARNINGS (LOSS) PER SHARE</a></td>
<td class="text">EARNINGS (LOSS) PER SHARE<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the numerator and denominator used to calculate diluted earnings (loss) per share for the three and nine months ended September 30, 2021 and 2020:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.987%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,583,480)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,275,620)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496,787&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">777,916&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,086,693)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(497,704)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (income) loss at subsidiary attributable to noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,415&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,967&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to common shareholders</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,055,278)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(481,737)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding &#8211; basic</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,880,887&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,134,583&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of other securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding &#8211; diluted</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,880,887&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,134,583&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"/><td style="width:58.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.516%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.518%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.987%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,209,545)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,838,249)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,491,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,334,811&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281,459&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,503,438)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) at subsidiary attributable to noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,651&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,806&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to common shareholders</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">340,110&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,455,632)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding &#8211; basic</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,939,919&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,206,179&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of other securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199,985&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding &#8211; diluted</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,139,904&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,206,179&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2021 and 2020, restricted stock awards and options to purchase 158,900 and 197,210 shares of common stock, respectively, were outstanding but were not included in the computation of diluted earnings per share because the effect would be antidilutive.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140570212698200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">REVENUES</a></td>
<td class="text">REVENUES<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Revenues</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for revenues from contracts with customers under ASC 606, which became effective January 1, 2018. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s net revenues consisted of the following for the three and nine months ended September 30, 2021 and 2020:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Products:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kristalose</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,012,746&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,615,557&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,286,729&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,387,046&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vibativ</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,896,584&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,813,249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,799,891&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,551,125&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Caldolor</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,255,669&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,416,146&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,734,273&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,677,434&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vaprisol</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325,774&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">406,162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,861,130&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">790,817&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acetadote</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368,733&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218,462&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">638,704&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,527,173&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Omeclamox-Pak</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,689&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">516,066&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(451,683)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">640,435&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RediTrex</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,459&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,291)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenue</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,886&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265,047&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">809,429&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,605,570&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,072,540&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,250,689&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,665,182&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,179,600&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Omeclamox-Pak revenue for the first, second and third quarter of 2021 was the result of Cumberland currently being out of commercial inventory of this product.  The packager for our Omeclamox-Pak product encountered financial difficulties due to the impact of COVID-19.  They are under new management and are in the process of a reorganization. Discussions with the packager are ongoing.  In the third quarter of 2021, the amounts noted were normal adjustments by channel partners.  Net revenue was  negatively impacted by product returns during the periods. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Revenues</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has agreements with international partners for commercialization of the Company's products with associated payments included in other revenues. Those agreements provide that each of the partners are responsible for seeking regulatory approvals for the product, and following approval, each partner will be responsible for the ongoing distribution and sales in the respective international territories. The Company provides a dossier for product registration and maintains responsibility for the relevant intellectual property. Cumberland is typically entitled to receive a non-refundable, up-front payment at the time each agreement is executed as consideration for the product dossier and for the rights to the distinct intellectual property rights in the respective international territory. These agreements also typically provide for additional payments upon a partner&#8217;s achievement of a defined regulatory approval and sales milestones. The Company may also be entitled to receive royalties on future sales of the products and a transfer price on supplies.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractual payments associated with the partner&#8217;s achievement of regulatory approvals, sales milestones and royalties on future sales are recognized as revenue upon occurrence, or at such time that the Company has a high degree of confidence that the revenue would not be reversed in a subsequent period.</span></div>Other revenues also include funding from federal grant programs including those secured by CET through the Small Business Administration as well as lease income generated by CET&#8217;s Life Sciences Center. The Life Sciences Center is a research center that provides scientists with access to flexible lab space and other resources to develop biomedical products. Grant revenue from these programs totaled approximately $0.02&#160;million and $0.1 million for the three months ended September 30, 2021 and 2020<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI http://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140570212871272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORIES</a></td>
<td class="text">INVENTORIES<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company works closely with third parties to manufacture and package finished goods for sale.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the arrangements with the manufacturer or packager, the Company will either take title to the finished goods at the time of shipment or at the time of arrival at the Company&#8217;s warehouses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company then holds such goods in inventory until distribution and sale. These finished goods inventories are stated at the lower of cost or net realizable value with cost determined using the first-in, first-out method.</span><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continually evaluates inventory for potential losses due to excess, obsolete or slow-moving goods by comparing sales history and projections to the inventory on hand. When evidence indicates that the carrying value may not be recoverable, a charge is taken to reduce the inventory to its current net realizable value.  At September 30, 2021 and December 31, 2020, the Company had recognized and maintained cumulative net realizable value charges for potential obsolescence and discontinuance losses of approximately $0.3 million and $0.2 million, respectively.  </span></div><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is responsible for the purchase of the active pharmaceutical ingredient (&#8220;API&#8221;) for Kristalose and maintains the inventory at third-party packagers. As that API is consumed in production, the value of the API is transferred from raw materials to finished goods.  API for the Company's Vaprisol brand is also included in the raw materials inventory at September 30, 2021 and December 31, 2020.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consigned inventory represents Authorized Generic inventory stored with Perrigo until shipment.   </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the Vibativ acquisition, Cumberland acquired API and work in process inventories of $15.6 million that were all initially classified as non-current inventories at the date of acquisition.  At September 30, 2021 and December 31, 2020, total non-current inventory, including Vibativ and ifetroban, was $9.5 million and $11.7 million, respectively. The Company had $0.2 million and $2.1 million of Vibativ finished goods included in non-current inventory at September 30, 2021 and December 31, 2020, respectively.  The Company also has obtained $0.4&#160;million of finished goods in non-current inventory for API related to its ifetroban clinical initiatives at September 30, 2021 and December 31, 2020. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2021 and December 31, 2020 the Company's net inventories consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:57.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.121%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.430%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.681%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.431%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and work in process</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,782,630&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,223,162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consigned inventory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,583&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,005&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,812,293&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,943,732&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,739,506&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,294,899&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">less non-current inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,476,737)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,656,742)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories classified as current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,262,769&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,638,157&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140570214167688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">LEASES</a></td>
<td class="text">LEASES<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland&#8217;s significant operating leases include the lease of approximately 25,500 square feet of office space in Nashville, Tennessee for its corporate headquarters.  This lease currently expires in October 2022.  The Company's operating leases also include the lease of approximately 14,200 square feet of wet laboratory and office space in Nashville, Tennessee by CET, our majority-owned subsidiary, where it operates the CET Life Sciences Center.  This lease currently expires in April 2023. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities are recorded as the present value of remaining lease payments not yet paid for the lease term discounted using the incremental borrowing rate associated with each lease. Operating lease right-of-use assets represent operating lease liabilities adjusted for lease incentives and initial direct costs. As Cumberland&#8217;s leases do not contain implicit borrowing rates, the incremental borrowing rates were calculated based on information available at January 1, 2019. Incremental borrowing rates reflect the Company&#8217;s estimated interest rates for collateralized borrowings over similar lease terms.  The weighted-average incremental borrowing rate used to discount the present value of the remaining lease payments is 7.42%. The weighted-average remaining lease term at September 30, 2021 is 1.2 years.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lease Position</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2021 and December 31, 2020 , the Company's lease assets and liabilities were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Right-of-Use Assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,282,275&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,028,148&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,094,187&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,016,779&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease noncurrent liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229,605&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,059,693&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,323,792&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,076,472&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumulative future minimum sublease income under non-cancelable operating subleases totals approximately $0.1 million and will be paid through the leases ending in October 2022 and April 2023. Future minimum lease payments under non-cancelable operating leases (with initial or remaining lease terms in excess of one year) are as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.554%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Maturity of Lease Liabilities at September 30, 2021</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295,038&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,019,313&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,478&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,406,829&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Interest</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,037&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,323,792&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rent expense is recognized over the expected term of the lease, including renewal option periods, if applicable, on a straight-line basis as a component of general and administrative expense. Rent expense and sublease income were as follows:</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.677%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rent expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">910,975&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">871,441&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">526,868&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">491,391&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140570212872392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity and Debt<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_EquityAndDebtAbstract', window );"><strong>Equity and Debt [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">SHAREHOLDERS' EQUITY AND DEBT</a></td>
<td class="text">SHAREHOLDERS&#8217; EQUITY AND DEBT<div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share repurchases</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland currently has a share repurchase program to repurchase up to $10 million of its common stock pursuant to Rule 10b-18 of the Securities Exchange Act of 1934. In January 2019, the Company's Board of Directors established the current $10 million repurchase program to replace the prior authorizations.  During the nine months ended September 30, 2021 and September 30, 2020, the Company repurchased 326,537 shares and 407,683 shares, respectively, of common stock for approximately $1.0 million and $1.5 million, respectively.  At September 30, 2021, approximately $5.2 million of common shares was left to repurchase under this program.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share purchases and sales</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the Company's March 2021 trading window, several members of Cumberland's Board of Directors entered into share purchase agreements of the Company's stock pursuant to Rule 10b-18 of the Securities Exchange Act of 1934. These purchases are designed to increase ownership in the Company by the members of the Board.  </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share Sales</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2017, Cumberland filed a Shelf Registration on Form S-3 with the SEC associated with the sale of up to $100 million in corporate securities. The Shelf Registration was declared effective in January 2018. It also included an At the Market ("ATM") feature that allowed the Company to sell common shares at market prices, along with an agreement with B. Riley FBR Inc. to support such a placement of shares. The Company filed an updated Form S-3 with the SEC in December 2020, which was declared effective in January 2021. The Company does not currently have an ATM feature in place.  Cumberland plans to continue to evaluate the market for its common shares, and if favorable, will further evaluate whether or not to enter into an ATM feature through B. Riley FBR, Inc. that would allow the Company to issue shares of its common stock.  The Company did not issue any shares under an ATM during the nine months ended September 30, 2021 or September 30, 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Share Grants and Incentive Stock Options</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2021 and September 30, 2020, the Company issued 36,850 shares and 230,491 shares of restricted stock to employees and directors, respectively. Restricted stock issued to employees generally cliff-vests on the fourth anniversary of the date of grant and for directors on the one-year anniversary of the date of grant.  During the nine months ended September 30, 2021, the Company also issued 174,800 incentive stock options to employees that cliff-vest on the fourth anniversary of the date of grant, that are set to expire in March and May 2031. Stock compensation expense is presented as a component of general and administrative expense in the condensed consolidated statements of operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt Agreement</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 28, 2021, the Company and Pinnacle Bank entered into a Fourth Amendment to the Revolving Credit Note and Fifth Amendment ("Fifth Amendment") to the Revolving Credit Loan Agreement to renew the Revolving Credit Loan.  </span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The original Pinnacle Agreement was dated July 2017.  Beginning on August 14, 2018, and continuing until October 7, 2020, the Company and Pinnacle Bank entered into a series of amendments to extend and update the Revolving Credit Note and Revolving Credit Agreement. The most recent amendment dated October 28, 2021, extends the maturity date three years through October 1, 2024.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistent with prior Amendments, the Fifth Amendment provides for a principal balance available for borrowing of up to $15&#160;million. The Company has the right to request an increase of up to an additional $5&#160;million providing a maximum principal available of up to $20&#160;million upon the satisfaction of certain conditions and with the approval of Pinnacle Bank. Also consistent with prior Amendments, the Company is required to maintain either a Funded Debt Ratio covenant or a Tangible Capital Ratio covenant. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest rate on the Pinnacle Agreement is based on LIBOR plus an interest rate spread. The pricing under the Fourth Amendment provides for an interest rate spread of 1.75% to 2.75% above LIBOR with a minimum LIBOR of 0.90%. The applicable interest rate under the Pinnacle Agreement was 3.65% at September 30, 2021.  In addition, a fee of 0.25% per year is charged on the unused line of credit.  Interest and the unused line fee are payable quarterly.  </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2021 and December 31, 2020, the Company had $15.0 million in borrowings outstanding under its revolving credit facility.  The Company was in compliance with the Tangible Capital Ratio financial covenant as of September 30, 2021.  </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the line of credit are collateralized by substantially all of our assets.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Paycheck Protection Program Loan</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 20, 2020, Cumberland received the funding of a loan from Pinnacle Bank in the amount of $2,187,140 pursuant to the Paycheck Protection Program (the &#8220;PPP&#8221;) under the Federal Coronavirus Aid, Relief, and Economic Security Act ("CARES Act"), which was enacted March 27, 2020.  The PPP is administered by the U.S. Small Business Administration ("SBA").</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the PPP requirements, loan funds were used to maintain payroll, continue group health care benefits, and pay for rent and utilities during the pandemic. We applied for this loan after carefully considering, with our bank, the eligibility criteria to participate in this program, and determining that Cumberland met those criteria. We evaluated and provided information on our payroll and other qualifying expenses to determine the amount of PPP funds to apply for. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the PPP, certain amounts of the loan may be forgiven if they are used for qualifying expenses as described in the CARES Act. Cumberland used the PPP loan funds for such qualifying expenses. Due to assistance from our PPP loan, the Company did not lay off or furlough any employees as a result of the COVID-19 pandemic.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland elected to account for the proceeds of the loan as a government grant under </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">International Accounting Standard 20 ("IAS 20"), Accounting for Government Grants and Disclosure of Government Assistance. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The permitted analogous use of  IAS 20 outlines a model for the accounting for government assistance, including forgivable loans. As a result, the Company recorded the $2,187,140 as a deferred income liability, which was included as a component of other current liabilities on the condensed consolidated balance sheet at December 31, 2020. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, Cumberland submitted a request for the loan&#8217;s forgiveness. On June 11, 2021, the Company received a formal notice from the SBA that the full amount of the loan was forgiven. The Company accounted for the forgiveness of the PPP loan under IAS 20 and recorded the $2,187,140 as other income.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Joint Venture Agreement</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, Cumberland entered into an agreement with WinHealth Investment (Singapore) Ltd creating </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">WHC Biopharmaceuticals, Pte. Ltd</span>. The joint venture, as a limited liability company, will focus on acquiring, developing, registering, and commercializing development stage and commercial stage biopharmaceuticals for China, Hong Kong and other Asian markets.  The agreement provides for initial investment from WinHealth in the form of a $0.2&#160;million equity contribution and an initial investment from Cumberland in the form of a $0.2&#160;million convertible note, which was funded during the first quarter 2021. The joint venture will seek additional future capital from additional investors and has entered into exclusive option agreements to license intellectual property from both Cumberland Pharmaceuticals Inc. and Cumberland Emerging Technologies.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_EquityAndDebtAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity and Debt [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_EquityAndDebtAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140570212824408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text">INCOME TAXESAs of September 30, 2021, the Company has approximately $56.5 million in federal net operating loss carryforwards including approximately $44.1 million of net operating loss carryforwards resulting from the exercise of nonqualified stock options. These have historically been used to significantly offset income tax obligations. The Company expects it will continue to pay minimal income taxes during 2021 and beyond, through the continued utilization of these net operating loss carryforwards, on any taxable income generated from our operations. The Company does not allocate any portion of its income tax expense (benefit) to discontinued operations.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140570212652200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Agreements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">COLLABORATIVE AGREEMENTS</a></td>
<td class="text">COLLABORATIVE AGREEMENTS<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland is a party to several collaborative arrangements with research institutions to identify and pursue promising pharmaceutical product candidates. The funding for these programs is primarily provided through Federal Small Business Administration (SBIR/STTR) and other grant awards. The Company has determined that these collaborative agreements, with the exception of the collaborative payment received related to RediTrex, do not meet the criteria for accounting under ASC Topic 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The agreements do not specifically designate each party&#8217;s rights and obligations to each other under the collaborative arrangements. Except for patent defense costs, expenses incurred by one party are not required to be reimbursed by the other party.  Expenses incurred under these collaborative agreements are included in research and development expenses and funding received from grants are recorded as net revenues in the condensed consolidated statements of operations.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140570214369000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Additions and Returns of Product Rights<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">ADDITIONS AND RETURN OF PRODUCT RIGHTS</a></td>
<td class="text">ADDITIONS AND RETURN OF PRODUCT RIGHTS<div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vibativ</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During November 2018, the Company closed on an agreement with Theravance Biopharma ("Theravance") to acquire the global responsibility for Vibativ including the marketing, distribution, manufacturing and regulatory activities associated with the brand.  Vibativ is a patented, Food and Drug Administration ("FDA") approved injectable anti-infective for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia and complicated skin and skin structure infections. It addresses a range of Gram-positive bacterial pathogens, including those that are considered difficult-to-treat and multidrug-resistant.  </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland has accounted for the transaction as a business combination in accordance with ASC 805 and the product sales are included in the results of operations subsequent to the acquisition date. The Company made an upfront payment of $20.0&#160;million at the closing of the transaction and a $5.0&#160;million milestone payment in early April 2019. In addition, Cumberland has agreed to pay a royalty of up to 20% of on-going net sales of the product.  The future royalty payments were required to be recognized at their acquisition-date fair value as a contingent consideration liability, as part of the contingent consideration transferred in the business combination. Cumberland prepared the valuations of the contingent consideration liability utilizing significant unobservable inputs.  As a result, the valuation is classified as Level 3 fair value measurement. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the fair value of the contingent consideration liability that is remeasured on a recurring basis.  The contingent consideration earned and accrued in operating expenses is paid to Theravance quarterly.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.455%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.345%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,200,552&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payment of royalty during the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,792,573)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration included in operating expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(632,646)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration earned and accrued in operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,134,333&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2021</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,909,666&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contingent consideration liability of $6.9&#160;million was classified as other current liabilities of $2.6&#160;million and other long-term liabilities of $4.3&#160;million on the condensed consolidated balance sheet as of September 30, 2021.  </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RediTrex</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2016, the Company announced an agreement with the Nordic Group B.V. ("Nordic") to acquire the exclusive U.S. rights to Nordic&#8217;s injectable methotrexate product line designed for the treatment of active rheumatoid arthritis, juvenile idiopathic arthritis, severe psoriatic arthritis, and severe disabling psoriasis. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As consideration for the license Cumberland paid a deposit of $100,000 at closing.  The Company provided $0.9&#160;million in consideration through a grant of 180,000 restricted shares of Cumberland common stock to be vested upon the FDA approval of the first Nordic product. Cumberland also agreed to provide Nordic a series of payments tied to the products&#8217; FDA approval, launch and achievement of certain sales milestones. Under the terms of the agreement, Cumberland is responsible for the product registration and commercialization in the U.S. Nordic is responsible for product manufacturing and supply.  </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 27, 2019, Cumberland received FDA approval for the first Nordic injectable product and authorization to market them under the RediTrex brand name.  The 180,000 shares of restricted Cumberland common stock previously provided to Nordic vested upon approval and were valued at $0.9&#160;million on the vesting date. The FDA approval also resulted in a $1.0&#160;million milestone payment due to Nordic.  During December 2020, Cumberland introduced RediTrex and the launch that will take place in late 2021 will result in a $1.0&#160;million milestone payment due to Nordic.  This milestone payment will be paid during 2022 and is included as a current liability at September 30, 2021.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland has approximately $2.7&#160;million in net intangible assets related to RediTrex at September 30, 2021.  </span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ethyol and Totect </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, Cumberland entered into an agreement with Clinigen for the rights and responsibilities associated with the commercialization of Ethyol in the United States.  In 2017, the Company entered into another agreement with Clinigen for the rights and responsibilities associated with the commercialization of Totect in the United States.  </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Early in 2019, Cumberland announced a strategic review of the Company's brands, capabilities, and international partners. This review followed an accelerated business development initiative, which resulted in a series of transactions. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During May 2019, Cumberland entered into the Dissolution Agreement with Clinigen in which the Company returned the exclusive rights to commercialize Ethyol and Totect</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the United States to Clinigen. Under the final terms of the Dissolution Agreement, Cumberland was no longer responsible for the distribution, marketing and promotion of either Ethyol or Totect or any competing products after December 31, 2019.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In exchange for the return of these product license rights and the non-compete provisions of the Dissolution Agreement, Cumberland is receiving $5&#160;million in financial consideration paid in quarterly installments over the two-years following the transition date. Cumberland recorded the first four quarterly installments totaling $3.0 million during 2020 and the next three installments totaling $1.5 million during the nine months ended September 30, 2021, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as discontinued operations.  The Company will record the last remaining quarterly installment in the fourth quarter of 2021.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exit from Ethyol and Totect meets the accounting criteria to be reported as discontinued operations. December 31, 2019, as the transition date, was the final day Cumberland was responsible for the products. Cumberland was responsible for the products through December 31, 2019 and beginning on January 1, 2020, the products' rights transitioned back to Clinigen. As a result, January 1, 2020, was the first day of discontinued operations for the Ethyol and Totect products.</span></div><div style="margin-top:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The dissolution payments from Clinigen are reflected as revenue from discontinued operations.  The Company does not </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">incur expenses associated with these payments from Clinigen. </span></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.590%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.677%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.499%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three months ended September 30,</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496,787&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">777,916&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,491,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,334,811&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs of products sold</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, Marketing and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496,787&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">777,916&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,491,004&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,334,811&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140570212636280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Guidance</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Guidance</span></div><div style="margin-bottom:6pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements - Not Yet Adopted</span></div><div style="margin-bottom:6pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board ("FASB") issued ASU No. 2016-13, &#8220;Financial Instruments-Credit Losses,&#8221; which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other instruments, companies will be required to use a new forward-looking &#8220;expected loss&#8221; model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, companies will measure credit losses in a manner similar to what they do today, except that the losses will be recognized as allowances rather than as reductions in the amortized cost of the securities. Companies will have to disclose additional information, including information they use to track credit quality by year of origination for most financing receivables. Companies will apply the ASU&#8217;s provisions as a cumulative-effect adjustment, if any, to retained earnings as of the beginning of the first reporting period in which the guidance is adopted.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Related to ASU No. 2016-13 discussed above, in May 2019, the FASB issued ASU 2019-05, "Financial Instruments-Credit Losses (Topic 326): Targeted Transition Relief" which provides transition relief for ASU 2016-13 by providing entities with an alternative to irrevocably elect the fair value option for eligible financial assets measured at amortized cost upon adoption of the new credit losses standard. Certain eligibility requirements must be met and the election must be applied on an instrument-by-instrument basis. The election is not available for either available-for-sale or held-to-maturity debt securities. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will adopt both ASU 2016-13 and ASU 2019-05 on January 1, 2023. The adoption of ASU 2016-13 and ASU 2019-05 are not expected to have a material impact on the Company&#8217;s consolidated financial statements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Use of Estimates</span></div><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management of the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period.  Actual results could differ from those estimates under different assumptions and conditions.  The Company's most significant estimates include: (1) its allowances for chargebacks and accruals for rebates and product returns, (2) the allowances for obsolescent or unmarketable inventory and (3) valuation of a contingent consideration liability associated with a business combination.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Operating Segments</a></td>
<td class="text">Operating SegmentsThe Company has one operating segment which is specialty pharmaceutical products. Management has chosen to organize the Company based on the type of products sold. Operating segments are identified as components of an enterprise about which separate discrete financial information is evaluated by the chief operating decision maker, or decision-making group, in making decisions regarding resource allocation and assessing performance. The Company, which uses consolidated financial information in determining how to allocate resources and assess performance, has concluded that our specialty pharmaceutical products compete in similar economic markets and similar circumstances.  Substantially all of the Company&#8217;s assets are located in the United States and total revenues are primarily attributable to U.S.&#160;customers.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140570214122664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Reconciliation of numerator and denominator</a></td>
<td class="text">The following table reconciles the numerator and denominator used to calculate diluted earnings (loss) per share for the three and nine months ended September 30, 2021 and 2020:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.987%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,583,480)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,275,620)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496,787&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">777,916&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,086,693)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(497,704)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (income) loss at subsidiary attributable to noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,415&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,967&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to common shareholders</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,055,278)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(481,737)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding &#8211; basic</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,880,887&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,134,583&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of other securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding &#8211; diluted</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,880,887&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,134,583&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"/><td style="width:58.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.516%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.518%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.987%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,209,545)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,838,249)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,491,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,334,811&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281,459&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,503,438)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) at subsidiary attributable to noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,651&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,806&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to common shareholders</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">340,110&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,455,632)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding &#8211; basic</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,939,919&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,206,179&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of other securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199,985&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding &#8211; diluted</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,139,904&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,206,179&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140570301522264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock', window );">Summary of net revenue</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s net revenues consisted of the following for the three and nine months ended September 30, 2021 and 2020:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Products:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kristalose</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,012,746&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,615,557&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,286,729&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,387,046&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vibativ</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,896,584&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,813,249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,799,891&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,551,125&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Caldolor</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,255,669&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,416,146&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,734,273&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,677,434&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vaprisol</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325,774&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">406,162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,861,130&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">790,817&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acetadote</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368,733&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218,462&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">638,704&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,527,173&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Omeclamox-Pak</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,689&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">516,066&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(451,683)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">640,435&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RediTrex</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,459&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,291)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenue</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,886&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265,047&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">809,429&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,605,570&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,072,540&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,250,689&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,665,182&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,179,600&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140570301442168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Inventory</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2021 and December 31, 2020 the Company's net inventories consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:57.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.121%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.430%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.681%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.431%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and work in process</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,782,630&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,223,162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consigned inventory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,583&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,005&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,812,293&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,943,732&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,739,506&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,294,899&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">less non-current inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,476,737)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,656,742)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories classified as current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,262,769&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,638,157&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140570212565464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_AssetsAndLiabilitiesLesseeTableTextBlock', window );">Lease Position</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2021 and December 31, 2020 , the Company's lease assets and liabilities were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Right-of-Use Assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,282,275&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,028,148&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,094,187&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,016,779&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease noncurrent liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229,605&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,059,693&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,323,792&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,076,472&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumulative future minimum sublease income under non-cancelable operating subleases totals approximately $0.1 million and will be paid through the leases ending in October 2022 and April 2023. Future minimum lease payments under non-cancelable operating leases (with initial or remaining lease terms in excess of one year) are as follows:</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturity of Lease Liabilities</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.554%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Maturity of Lease Liabilities at September 30, 2021</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295,038&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,019,313&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,478&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,406,829&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Interest</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,037&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,323,792&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock', window );">Schedule of Rent Expense and Sublease Income</a></td>
<td class="text">Rent expense and sublease income were as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.677%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rent expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">910,975&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">871,441&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">526,868&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">491,391&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_AssetsAndLiabilitiesLesseeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Assets and Liabilities, Lessee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_AssetsAndLiabilitiesLesseeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Rent Expense and Sublease Income [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140570214144696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Additions and Returns of Product Rights (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock', window );">Schedule of Business Acquisitions by Acquisition, Contingent Consideration</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the fair value of the contingent consideration liability that is remeasured on a recurring basis.  The contingent consideration earned and accrued in operating expenses is paid to Theravance quarterly.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.455%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.345%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,200,552&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payment of royalty during the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,792,573)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration included in operating expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(632,646)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration earned and accrued in operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,134,333&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2021</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,909,666&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock', window );">Schedule of Dissolution Payments</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The dissolution payments from Clinigen are reflected as revenue from discontinued operations.  The Company does not </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">incur expenses associated with these payments from Clinigen. </span></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.590%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.677%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.499%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three months ended September 30,</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496,787&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">777,916&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,491,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,334,811&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs of products sold</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, Marketing and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496,787&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">777,916&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,491,004&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,334,811&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=SL51724579-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1474-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5D<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721677-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721659-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721665-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721671-107760<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721663-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140570212763576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation Organization (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2021 </div>
<div>Segment</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140570215050584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) Per Share (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_NumeratorAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Net income (loss) from continuing operations</a></td>
<td class="num">$ (1,583,480)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,275,620)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,209,545)<span></span>
</td>
<td class="num">$ (4,838,249)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,491,004<span></span>
</td>
<td class="nump">2,334,811<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(1,086,693)<span></span>
</td>
<td class="nump">$ 1,223,491<span></span>
</td>
<td class="nump">$ 144,661<span></span>
</td>
<td class="num">(497,704)<span></span>
</td>
<td class="num">$ (940,589)<span></span>
</td>
<td class="num">$ (1,065,145)<span></span>
</td>
<td class="nump">281,459<span></span>
</td>
<td class="num">(2,503,438)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net (income) loss at subsidiary attributable to noncontrolling interests</a></td>
<td class="nump">31,415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,967<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,651<span></span>
</td>
<td class="nump">47,806<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to common shareholders</a></td>
<td class="num">$ (1,055,278)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (481,737)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 340,110<span></span>
</td>
<td class="num">$ (2,455,632)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_DenominatorAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares outstanding &#8211; basic (in shares)</a></td>
<td class="nump">14,880,887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,134,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,939,919<span></span>
</td>
<td class="nump">15,206,179<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Dilutive effect of other securities (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">199,985<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares outstanding &#8211; diluted (in shares)</a></td>
<td class="nump">14,880,887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,134,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,139,904<span></span>
</td>
<td class="nump">15,206,179<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_DenominatorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Denominator.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_DenominatorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_NumeratorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Numerator.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_NumeratorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140570214750072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) Per Share (Details Textual) - shares<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Common stock available for purchase through restricted stock awards and options (in shares)</a></td>
<td class="nump">158,900<span></span>
</td>
<td class="nump">197,210<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140570218928328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 8,072,540<span></span>
</td>
<td class="nump">$ 9,250,689<span></span>
</td>
<td class="nump">$ 27,665,182<span></span>
</td>
<td class="nump">$ 27,179,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_AcetadoteMember', window );">Kristalose</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">4,012,746<span></span>
</td>
<td class="nump">3,615,557<span></span>
</td>
<td class="nump">638,704<span></span>
</td>
<td class="nump">1,527,173<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_OmeclamoxPakMember', window );">Vibativ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">1,896,584<span></span>
</td>
<td class="nump">2,813,249<span></span>
</td>
<td class="num">(451,683)<span></span>
</td>
<td class="nump">640,435<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_KristaloseMember', window );">Caldolor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">1,255,669<span></span>
</td>
<td class="nump">1,416,146<span></span>
</td>
<td class="nump">12,286,729<span></span>
</td>
<td class="nump">10,387,046<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_VaprisolMember', window );">Acetadote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">368,733<span></span>
</td>
<td class="nump">218,462<span></span>
</td>
<td class="nump">1,861,130<span></span>
</td>
<td class="nump">790,817<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_CaldolorMember', window );">Omeclamox-Pak</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">22,689<span></span>
</td>
<td class="nump">516,066<span></span>
</td>
<td class="nump">3,734,273<span></span>
</td>
<td class="nump">3,677,434<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_VIBATIVMember', window );">Vaprisol</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">325,774<span></span>
</td>
<td class="nump">406,162<span></span>
</td>
<td class="nump">8,799,891<span></span>
</td>
<td class="nump">8,551,125<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_RediTrexMember', window );">RediTrex</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">11,459<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(13,291)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_OtherProductsMember', window );">Other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">178,886<span></span>
</td>
<td class="nump">265,047<span></span>
</td>
<td class="nump">809,429<span></span>
</td>
<td class="nump">1,605,570<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 20,000.00<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ProductsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Products.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ProductsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_AcetadoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_AcetadoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_OmeclamoxPakMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_OmeclamoxPakMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_KristaloseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_KristaloseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_VaprisolMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_VaprisolMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_CaldolorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_CaldolorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_VIBATIVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_VIBATIVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_RediTrexMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_RediTrexMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_OtherProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_OtherProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140570295982632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Obsolescence and discontinuance losses</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Non-current inventories</a></td>
<td class="nump">9,476,737<span></span>
</td>
<td class="nump">11,656,742<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Inventory, Finished Goods, Net of Reserves</a></td>
<td class="nump">5,812,293<span></span>
</td>
<td class="nump">5,943,732<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PublicUtilitiesInventoryAxis=cpix_IfetrobanClinicalMember', window );">Ifetroban Clinical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Non-current inventories</a></td>
<td class="nump">400,000<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember', window );">Vaprisol</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Non-current inventories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,600,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">2,100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Inventory, Finished Goods, Net of Reserves</a></td>
<td class="nump">$ 9,500,000<span></span>
</td>
<td class="nump">$ 11,700,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PublicUtilitiesInventoryAxis=cpix_IfetrobanClinicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PublicUtilitiesInventoryAxis=cpix_IfetrobanClinicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140570213317816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories (Schedule of Inventories) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract', window );"><strong>Inventory</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials and work in process</a></td>
<td class="nump">$ 13,782,630<span></span>
</td>
<td class="nump">$ 16,223,162<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment', window );">Consigned inventory</a></td>
<td class="nump">144,583<span></span>
</td>
<td class="nump">128,005<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">5,812,293<span></span>
</td>
<td class="nump">5,943,732<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Total inventories</a></td>
<td class="nump">19,739,506<span></span>
</td>
<td class="nump">22,294,899<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Inventory, Noncurrent</a></td>
<td class="num">(9,476,737)<span></span>
</td>
<td class="num">(11,656,742)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventories classified as current</a></td>
<td class="nump">$ 10,262,769<span></span>
</td>
<td class="nump">$ 10,638,157<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount of inventory owned by the entity but in the hands of a customer, typically a reseller.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140570214689048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Narrative) (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Present value of remaining lease payments, percent</a></td>
<td class="nump">7.42%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term</a></td>
<td class="text">1 year 2 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceived', window );">Future minimum sublease income under noncancelable operating subleases | $</a></td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Office Space</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Square feet of office space</a></td>
<td class="nump">25,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=srt_OfficeBuildingMember', window );">Wet Laboratory and Office Space</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Square feet of office space</a></td>
<td class="nump">14,200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payments to be received by lessor for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121576215&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=srt_OfficeBuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=srt_OfficeBuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140570212548344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Lease Position) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 1,282,275<span></span>
</td>
<td class="nump">$ 2,028,148<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease current liabilities</a></td>
<td class="nump">1,094,187<span></span>
</td>
<td class="nump">1,016,779<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease noncurrent liabilities</a></td>
<td class="nump">229,605<span></span>
</td>
<td class="nump">1,059,693<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_LeaseLiability', window );">Total</a></td>
<td class="nump">$ 1,323,792<span></span>
</td>
<td class="nump">$ 2,076,472<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_LeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease, Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_LeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140570214779832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Schedule of Lease Liabilities Maturity and Future Minimum Lease Commitments) (Details)<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Maturity of Lease Liabilities at September 30, 2021</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2021</a></td>
<td class="nump">$ 295,038<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2022</a></td>
<td class="nump">1,019,313<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2023</a></td>
<td class="nump">92,478<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree', window );">After 2023</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">1,406,829<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Interest</a></td>
<td class="nump">83,037<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 1,323,792<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, to be Paid, after Year Three</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140570214252824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Rent Expense (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Rent expense</a></td>
<td class="nump">$ 910,975<span></span>
</td>
<td class="nump">$ 871,441<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income</a></td>
<td class="nump">$ 526,868<span></span>
</td>
<td class="nump">$ 491,391<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140570297780168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity and Debt (Shareholders' Equity) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jan. 31, 2016</div></th>
<th class="th"><div>May 13, 2010</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ShareholdersEquityTextualAbstract', window );"><strong>Shareholders' Equity (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of shares, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (237,616)<span></span>
</td>
<td class="num">$ (484,965)<span></span>
</td>
<td class="num">$ (303,088)<span></span>
</td>
<td class="num">$ (332,504)<span></span>
</td>
<td class="num">$ (769,648)<span></span>
</td>
<td class="num">$ (441,624)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities', window );">Shelf Registration, sale of corporate securities (up to)</a></td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ShareholdersEquityTextualAbstract', window );"><strong>Shareholders' Equity (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock granted in period, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,850<span></span>
</td>
<td class="nump">230,491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cpix_IncentiveStockOptionsMember', window );">Incentive Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ShareholdersEquityTextualAbstract', window );"><strong>Shareholders' Equity (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock granted in period, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">174,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Director | Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ShareholdersEquityTextualAbstract', window );"><strong>Shareholders' Equity (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Restricted stock awards, vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ShareholdersEquityTextualAbstract', window );"><strong>Shareholders' Equity (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Repurchase outstanding common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,408<span></span>
</td>
<td class="nump">158,405<span></span>
</td>
<td class="nump">91,724<span></span>
</td>
<td class="nump">101,354<span></span>
</td>
<td class="nump">141,463<span></span>
</td>
<td class="nump">164,866<span></span>
</td>
<td class="nump">326,537<span></span>
</td>
<td class="nump">407,683<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of shares, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (237,616)<span></span>
</td>
<td class="num">$ (484,965)<span></span>
</td>
<td class="num">$ (303,088)<span></span>
</td>
<td class="num">$ (332,504)<span></span>
</td>
<td class="num">$ (769,648)<span></span>
</td>
<td class="num">$ (441,624)<span></span>
</td>
<td class="num">$ (1,000,000)<span></span>
</td>
<td class="num">$ (1,500,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Common shares left to repurchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ShareholdersEquityTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shareholders Equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ShareholdersEquityTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount remaining of a stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cpix_IncentiveStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cpix_IncentiveStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140570219960536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity and Debt (Debt) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 14, 2020</div></th>
<th class="th"><div>Apr. 20, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Oct. 28, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Aug. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermLineOfCredit', window );">Revolving line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cpix_WinHealthInvestmentSingaporeLtdDomain', window );">WinHealth</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Initial investment in joint ventures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | WinHealth</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Convertible note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember', window );">LIBOR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate</a></td>
<td class="nump">0.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermLineOfCredit', window );">Revolving line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=cpix_PinnacleBankMember', window );">Pinnacle Bank</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived', window );">Aggregate amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,187,140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=cpix_PinnacleBankMember', window );">Pinnacle Bank | Line of Credit | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate spread</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage', window );">Line of credit, unused capacity, commitment fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=cpix_PinnacleBankMember', window );">Pinnacle Bank | Line of Credit | Revolving Credit Facility | Minimum | LIBOR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate</a></td>
<td class="nump">1.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=cpix_PinnacleBankMember', window );">Pinnacle Bank | Line of Credit | Revolving Credit Facility | Maximum | LIBOR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate</a></td>
<td class="nump">2.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=cpix_PinnacleBankMember', window );">Pinnacle Bank | Fifth Amendment | Revolving Credit Facility | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit, maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseAmount', window );">Increase amount (up to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_LineOfCreditFacilityMaximumBorrowingCapacityTotalCapacity', window );">Total capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line of Credit Facility, Maximum Borrowing Capacity, Increase Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_LineOfCreditFacilityMaximumBorrowingCapacityTotalCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line of Credit Facility, Maximum Borrowing Capacity, Total Capacity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_LineOfCreditFacilityMaximumBorrowingCapacityTotalCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Coronavirus Aid, Relief, and Economic Security Act, Loan Proceeds Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity method investee and investment in and advance to affiliate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermLineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=99376301&amp;loc=d3e1336-112600<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=99376301&amp;loc=d3e1314-112600<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermLineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cpix_WinHealthInvestmentSingaporeLtdDomain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cpix_WinHealthInvestmentSingaporeLtdDomain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=cpix_PinnacleBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=cpix_PinnacleBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cpix_FifthAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cpix_FifthAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140570298423000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Details Textual)<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 44,100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 56,500,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140570296074664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Additions and Returns of Product Rights - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">24 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2018</div></th>
<th class="th"><div>Nov. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProceedsFromSaleOfIntangibleAssetsInstallmentPayment', window );">Financial consideration received in exchange for product license rights, installment payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cpix_ClinigenHealthcareLimitedMember', window );">Clinigen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfIntangibleAssets', window );">Financial consideration received in exchange for product license rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax', window );">Discontinued operations income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember', window );">Vaprisol</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payment to acquire business upon closing</a></td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPaymentsToAcquireBusinesses', window );">Other Payments to Acquire Businesses</a></td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_TieredRoyaltyPaymentsPercentage', window );">Percentage of tiered royalty payments (up to)</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Additional liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,909,666<span></span>
</td>
<td class="nump">6,909,666<span></span>
</td>
<td class="nump">$ 8,200,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember', window );">Vaprisol | Other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Additional liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,600,000<span></span>
</td>
<td class="nump">2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember', window );">Vaprisol | Other long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Additional liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,300,000<span></span>
</td>
<td class="nump">4,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_MethotrexateMember', window );">Methotrexate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payment to acquire business upon closing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Additional liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred', window );">Liability recorded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Vested common stock, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Net intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,700,000<span></span>
</td>
<td class="nump">$ 2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_MethotrexateMember', window );">Methotrexate | Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Unvested restricted shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ProceedsFromSaleOfIntangibleAssetsInstallmentPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Sale of Intangible Assets, Installment Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ProceedsFromSaleOfIntangibleAssetsInstallmentPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_TieredRoyaltyPaymentsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tiered Royalty Payments, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_TieredRoyaltyPaymentsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6405-128476<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=121600890&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPaymentsToAcquireBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with other payments to acquire businesses including deposit on pending acquisitions and preacquisition costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPaymentsToAcquireBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cpix_ClinigenHealthcareLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cpix_ClinigenHealthcareLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cpix_MethotrexateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cpix_MethotrexateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140570218889960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Additions and Returns of Product Rights - Change in Consideration (Details) - Vaprisol<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualRollForward', window );"><strong>Loss Contingency Accrual [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Beginning balance</a></td>
<td class="nump">$ 8,200,552<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRoyalties', window );">Cash payment of royalty during the period</a></td>
<td class="num">(1,792,573)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration included in operating expenses</a></td>
<td class="num">(632,646)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses', window );">Contingent consideration earned and accrued in operating expenses</a></td>
<td class="nump">1,134,333<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Ending balance</a></td>
<td class="nump">$ 6,909,666<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Contingent Consideration, Earned and Accrued in Operating Expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for royalties during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140570212935272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Additions and Returns of Product Rights - Dissolution Payments (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 8,072,540<span></span>
</td>
<td class="nump">$ 9,250,689<span></span>
</td>
<td class="nump">$ 27,665,182<span></span>
</td>
<td class="nump">$ 27,179,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Costs of products sold</a></td>
<td class="nump">1,328,027<span></span>
</td>
<td class="nump">2,142,839<span></span>
</td>
<td class="nump">5,486,005<span></span>
</td>
<td class="nump">6,387,002<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Selling, Marketing and other</a></td>
<td class="nump">3,800,288<span></span>
</td>
<td class="nump">3,587,842<span></span>
</td>
<td class="nump">11,709,445<span></span>
</td>
<td class="nump">11,160,924<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cpix_ClinigenHealthcareLimitedMember', window );">Clinigen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">496,787<span></span>
</td>
<td class="nump">777,916<span></span>
</td>
<td class="nump">1,491,004<span></span>
</td>
<td class="nump">2,334,811<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Costs of products sold</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Selling, Marketing and other</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Income from discontinued operations</a></td>
<td class="nump">$ 496,787<span></span>
</td>
<td class="nump">$ 777,916<span></span>
</td>
<td class="nump">$ 1,491,004<span></span>
</td>
<td class="nump">$ 2,334,811<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cpix_ClinigenHealthcareLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cpix_ClinigenHealthcareLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>61
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M#!M=*;DGRKX-:/8B\TUF#;.)A%W&A5'P- ([,YK('5=D#BM&VD1OF.+ZRC$
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M WB_5,J\WMASVOY<?O$?4$L#!!0    (  J*;%-).>:5@@(  - &   8
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M%_/\3[TG%+MX*U,V[?_1\QY+)M%JUUBSV3>&$6R*JON;O>R%.&H <? &;-^
M^0W$0 .^;\#?VH/8-Q!O[2'>-VBI3SONK7#SS&;7E[5YCFJ'AFCN0ZM^VQKT
M*BJ7*/>VAE\+:&>O9Z;*8=IU'L&GQI1%GEFXN+?P!_+!-I%YB'[=ZCIS\]I$
M9]'O]_/HP]\^7DXM=.^"3%?[KFZ[KMA 5SSZV51VW40+Z#)'VL_'VZ<C[:=
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M'0  &    'AL+W=O<FMS:&5E=',O<VAE970U+GAM;)5966_C.!+^*X0Q#SW
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MX8R=<%"'+\V@PX=7;7Y$7YJ>D!Y/;2N 2EKT5UZ=!/ICA_XM=P+>ZU.;-X5
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MT_)D$BV>ZZ;<=(UU!)N\V/U-_^@2T6M F*<![1K0L0U8UX#9#92G 70-P&I
MN:<![QIL3WVV._=MXF[2)KVZJ,J7J&K5NK?VQ3;[V]8Z7WG1#I3[IM+?YKI=
M<S4OBZ6^[-DRTJ_J<ITOTT:_N6_T'ST>FJA\B&Y_?\Z;/Z-I]-O]3?3N'^\O
M9HT^<MM^MNB.<KT["O4<Y=]EDZZ19O-PLWFYV>C!I).P^(RTO@FWOLL:/5'T
MR61I5>3%8XUT<1ONXM>R6)1%4Y5K_<UCE!=-5F5U8_4TTSG?)Y[N$T^W78.G
MZ^MTG1:+[+OH.GO,BS:^-M4?LRHOEU':1#?9XD/$R'<1C4F"97S7O=AVW]K!
MERM.8L4I9Q>S+_T<NT)($@(@U5!XXPH)C15+^%!WZ^JF3 H:[V6#A+!]0MCI
M"7F7ZV&P2G7RWX])SGQW*-X_%4X%XYSC0<(^2-BV9)X@?RH6VH[K+'JG0]B^
M>J]'A9XN>H2NRO4RJ^I_OLZ7_]WI81-I.WM)J^7_ T.&[P_.@QFZ;Q,P;6UQ
M&2W*C69%G;9NBXT.[B2 "N 2K+'!G4MIR0:!BGV@XJ1 ^Y<1NVK"#9HDBGL&
MEMQ'(X/1W&5/S]5BU5XU/: 6G:=LH\ R)YT@I@!$4#MUTIT%EFX0K=I'JXZ(
M=A?FH;PI-V0B0 F!AY+L0TF"H?RJ[U-R;8 ;/=S798T>^SI!CAT+3L!RC1M4
MR'G?-W;V@@@3;6OXN9#8@"X>YR^WQ7)HM;^DU:N;M,$@<(N=D"!1P&)N6>B\
M4P[-5C()U#9;I$]M45+:9HOHIB#[Z1WFHP=^<DH^+*<]E)MY=Y3A>3"B.$L\
M$1I"DJ^,R*Y_?IB19#0DD3YQ2B+"$":)X21Y0U"28TE)#"K)-V E,; D85H>
M9_MSXJ)P2GC<_O,DPM"0A'%XBJ43EX53B*50S!.-H2$)XW"4JQ.$@I3'#)CR
M'-_PC80!Y_?A^^Q)#]8XX,,NZ/0$!<:DM.>S0N8SD2*&V)[/&#PI2,JD/:$1
MI>) /90E!K,DS-EQ3GPH.W/B@E,/8)T>2?$(J6$G'<E.CQ,?)"@=35 ZFJ!(
MGRA!$5V(H-00E(XDZ @C/LA1>BQ'::_2I&]OQ-3PBH9Y=4S90ET<4:D8)/8H
M86[A,M0-@S70HO!52I>NV\$ ISYT4 ,Q>DZ(75.W[)M*D>A:P,X?0CM+.(S8
MP(Z>'W84@1T! L(#.VI@1\\ .XK +@%M38GM.)B0*.I:#H9/RHBG-J0&GO14
M>/[\7(3A21%X*B"$R-@>'!@\*0A"G80@2)2"\]BNZ3"A2(#[YJMA)ST'.P\E
M9TXQ=A)%J/30G1EVLOCMW9<92+$PI(YQ7^8RB H*Q!K>\TXG_+IAL(94+%SQ
MG>J^S*VU 'SK1JRW(ADFUY'NRUQX31G3M\WVTA%SZ64+AQ$;?+$PODYQ7^:B
M:TIBPK@O&D,O%J;7*/=E"+/T'9^TLW:#"A61SHTZ)B0\$=)S/H9M+,RVOU&Z
M,!=QGM*E4XXH79 ^/:4+I@R4+LSPE87Y>J;2A;F\#)<NS!"3C23FX44DSY5#
M:"B49"QQIC5:=%)=E##[RB$XI(2UL\Z^<EAY2B0AODMGR,E&DO.X921/DA!^
MZ@)/@7W+,!^C'#Z:,:2%;T!:,*2%\Y$67((201-AWXH=U@V#-:2%KT-:0)8_
ME:ZY?1?/L!;.REK 6!NS6-F5#F"L'0J'$?<>!9Z?M8"P5IN[[Z$1&-3"&5 +
M+A@)@!#$LB=,)X2R5V!N$9TN<X@/M&! "Z>"MK^.0M!S1$"K[5HFU 8M(*!5
MB2+.4OX-TN>4Z&*9*+OP0Y4LH;YE6S"DA7.0]E!ZYN A+0C?$#2DA:],6AA-
M6DR)DQ9&DQ93AD@+AK3PAJ2%T:0=HQSN0S"DY=^ M-R0EH=)>^2C'>Y"5!<X
M@4<[W&"4AS%Z"@,X]F"0"LX\MLD-0WF8H:,@P)&E4T6\2S'<\)"'>3BN.D)-
MN^MY./,%")T5>\,*HE3MRA2S39MC9:U,XB2V9SZNY-+',=[;L!.F\O'E$9X>
MC-N*Q[Q7P'7I&:$<GHMA,A_)Y!'/@/"S0'B+DQE3XF3FH\F,*@-DYH;,?"29
MCWP,A/*9'\MG;OC,U3<P;4-!'J;@4;O7$'0E).'.]K7$+8^&NN'^-0,X$7[@
M>60U(K!'C H2Q[Z$^W33%@XC-DP4QS!Q'(F$N]X[)5Q![(O&<%&$N3B*1 +;
M2D.9OI.S9CDN5-PNEV\1X93'PH,V8< J1FZY"3YV05U/N(4J2*5G=&R[GG#!
MK-&F%%/V2BC2YU0R+JAM>IA05WR,>Y;5A(&]. GV@><NJ-T)%[WZ'I6*V'<[
M(@Q[!7][NQ.]+;"G[8%%QXC+)B(&=727+9>+EFX8K$&8""/LY V[+JV4])F'
M 94X9@OL8?/%2CPF!;%OCH1;-=K"8<2&;2+,MI/,%]GG*@7$GG4I:=@EP^P:
MY;T2(1:)E1")74'C2LZIO37R%E,RXGTL* W;Y$E;5<?<.DNW]O-4%I@2KRP0
MI:>RP)7^RD(:P,J1>V/_7F4A$;+BE<48Y>Y<9KU?([4_-M/WO/J^N([6V8-N
M&G^0NH]J]_NMW9NF?-K^0.E3V33E9OMRE:7:H%N!_OZA+)O7-^UOGO:_HKOZ
M"U!+ P04    "  *BFQ3<)RXO$<0  !&*0  &    'AL+W=O<FMS:&5E=',O
M<VAE970W+GAM;*U::7,;-Q+]*RBE*I&K2.IR#I]5M&PGSL9'27:V=K?V S@#
MDHAF@#$P(XK^]?NZ&Y@94K+CI/:+1,X!]/GZ=8./-SY<Q;4QK;JI*Q>?'*S;
MMGEX=!2+M:EUG/G&.-Q9^E#K%E_#ZB@VP>B27ZJKH]/CXQ^.:FW=P=/'?.U=
M>/K8=VUEG7D75.SJ6H?M,U/YS9.#DX-\X<*NUBU=.'KZN-$K<VG:#\V[@&]'
M_2JEK8V+UCL5S/+)P?SDX;/[]#P_\+LUFSCZK$B3A?=7].55^>3@F 0RE2E:
M6D'CW[4Y-U5%"T&,CVG-@WY+>G'\.:_^DG6'+@L=S;FO_FG+=OWDX*<#59JE
M[JKVPF]^,4F?[VF]PE>1_ZI->O;X0!5=;'V=7H8$M77R7]\D.WS-"Z?IA5.6
M6S9B*9_K5C]]'/Q&!7H:J]$'5I7?AG#6D5,NVX"[%N^U3]^&E7;VDQ83N5(]
MT]%&Y9?J73#1N);O/#YJL1>]<52D=9_)NJ>?6?>!>NU=NX[JA2M-N?O^$63L
M!3W-@CX[_>*"EZ:9J;/CB3H]/CWYPGIGO>)GO-[95R@^4>?>15_9<K##6'TR
MQTOKM"NLKM0E+AK$91O5?^:+V 9$UG^_(-']7J+[+-']STET\?/\S:M_S]^_
M>OM&S=\\5\_FEZ\NU=N7ZMW%B\L7;][SG;M<\?]85YUW]<*$BG5?:P1\8;K6
M%KJ*ZI4K9NKPVV]^.CT]?C0\-^$K)X]4NS8JW_5UH]VVO^6#TE%UT93*.GZP
M0%R8FY9LFM[9F/[Q=*6+XP721=^%=/&>0HAJ%1M##FFWJMD1&%NP$&KI"][9
MR\ZZ^-C9:,7CI;D&(C7D1_8WWJE-H/5R-D# 1= 4O@IX%XM@&[[>!%]V!:!0
MO<>B2>'O(JY;PC75ZK "FN+SE4&,Z&#4VL?&MI!,%UT+$^#:1*TT8L=C?Q-\
MY5=;%B.L30>LX0N\032J-B6KE?6U1E8MH#5BSP3["3(NM@#)2A/(55NR<H&E
M T*U%Q]N8P2+L(9NV21)>K4PE85!(D1S^** ^2:];)9+4Z15L4>L=55-DI*X
M'76%UU ="@.+C(((+BI9<'JJ]62V:UM:MT(@.'_-@O:V%(EL30\9];&#%^!6
M>(!,1:NK!B]PSM':NBRA$N+*U; TW?4^0#[ZEJWEC"EW?42[U;Z%N);6:7BS
M<BQ#\-UJS7<'CV&[I375KJ8YF#\X2^HQ)(AH4-O$5B\J&]>DK(8@+54FTL:2
MLQV'%Y9N=&B="9&LLPAL&>S,\B.%^7*OM>QG QS;P:UVS]@2Z:(8+(-4(2$1
MK"@5MK:?:'%)OASE,%F+E>D3"=;&W@X3RM@-ZB3]3VE"[SN4V/0,A4E):&GH
M:>R_QJ,+WZZSAM47\@LO-WIAX6'68N0@2N^3'Q\-HG"8U]IU2\1Y%R3*V[4-
M)1O/TO:;M2W6_""\&:(QCAX:;-,OFJ.*  @9QU(-:Y.&V':)L&+O[(4.LR15
M5#Y2'FQL*V'"LDQ)EJTJ+?+9+CH!B9%O:WUE=BRL]+6V%6+$W!E',P N7R6[
M)R2"H.!(9,U)PK($<B1WYW17\@+0K01CDD^IHAD*X%R\XE"\L.H8 M8:F;<@
M\P$N(+[@IB;$0$S3<M"/O,G*TYO/36'(RNKLA,LRBO-(CC_9G7/%%5570AF*
MM?(/L!V^-\F[D6Z0TCN8W!$'JQ#<11?863LO.(@2(Z.O5TMM"0P:J> LJG7"
M7\F:$2"!;U!B;8*Q;J;FV#_:E;-+( ?>X"#.180LW66)@8DN:B:4<60QH">X
M&2L+AQ9C,B%A]/<\=(=+K&.!0HFGS>"*8%9=I46LY-=+LI258@')7]R@7+@5
M^[NV'.3J<%2X+U^<Y^HJ*5V8T(+4[YB.KB/,*0V0C6,!![6 QKZV+2D%4&A,
M2%\X<R'6BW/&<[:QK>D!Z\OLK,%D\>\:+:Y]![1>D%%T]L<?G9,NH+?87XM4
M)V5#XI47!<2JN7/ %'5A&H0390LU"NKD>/H/5I&VV1H=E&$2<2M==NS/%SZ_
M8/:-A!.,A:Z#78WV+"3'YSU1QXP1L5%'5"U$7(0 C6Z3%(E+3Q@[H6"?1!;)
M8QV7;JK1*9[RGE2LC#(W("-LLK0IU1(JU8@.:,!J$_<C%M81="='S]1S/ &)
MK.OP]MM!^GGDT.HBN7G9(3\-18EZ ].K!R!L@M&O]19BG^#"J/PQB6*_0#I-
M6\"G L3S%8S!5>CPX,[K!_<D*,[!F^T*H?R+ <=:,_'X#6E-2AX>Y+MX&C))
MS1FC9S!0TA'3(5O<($XBV2Y04\@V&_-+HUZTZRU*T+??G/QX_Q&[ZCW41&%-
M5^ZD%U@EBS'#K=(D=R/%^JR_4\7)'B]S7E4>6$#VO?85D: 2SBM:.)Y3L__6
MI\NXN$T2MV44=F6B5:E0&<N.2PIBM:18"@9"57FS+X9+7U5^0Y?V,N3DP3[%
M-C<6V(WM\OHCR]7&<$$V&;%I1;!>@AF=HC9P8@DRE>,X'&41P[QH?.L^5LQI
ML(/-!%U#A_-9%%EZWPJ20)Q@EC2:N+T7O=2Q0V\I.0,T+,GMOD\+RC_089LX
MY0BMZ>%K&Y-?T)T03Q:T_0R>]N(*\XYKM81GX@XX[[ BHGVUI@H.==)>3/5'
M>^E:RB?G $M''YF,HI+39@P6S5Z_S0^0")&?HF"_UE7'<%39)95TW.$JV$"!
M@NH<$4!:J+8=,J+1MF_]_IK"&62AD1D4V!A",;KJN\@0F:H!C ".KZ2^,E77
M #'RN;1.Q&+Z^.$QU$!]H^DMEV(*R4FK2=N5Y>\#ES<B0:6=DKIZU^I$F#CC
MT%3I.Q:Z'=&>NL.*+2KSP SM7)IVZ[0!D)^__?W5\^G) _6.FN3:%D1;7^L
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M7F9Z<C;)DX5AL5<.4=^Q&--S("5"^C?$KAE.6Z2QS4PVF\D&!I':(Y"YOM7
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M'[\_D .:_*7U#?]2#EC5^IH_T@3&!'H ]VE^G[_0!OU/)Y_^#U!+ P04
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MMC0F<PR]S!Q7HLO.(>B,H3L\(G%KN5X*M)QW;0"Q[=,R&#8^;12^;M!)I9B
M#39Y?BN8EUX)PD2['L7G/JQZ=#<S"^9R65)0\O[H$R#).Z[:Y2;:SS]-DWCR
M#B"Y%;FIG'#=':ZP5[/<*,1R59HW8:7&OU80E?92L4Q""G)>U1,"C-6TP)=[
M@EH^M IP">8\]_C80,-T(WX6+#4N9*(Q43$FE?S.YV "652B9C7LR(07%@T-
M#Y63>MGP9)T_E#IJGC!%62%\;K+=_%*TG=055U""(,] XK:2HP*7QN--@CQ(
M!@RQK KU$/>I<"YB9NZ, @C"ZH#^L#!WA*-.=DY!$,S2$I'B6 ZNR'D0EC7_
MUG/5M35^B XJ<VSJLK^H#.).9D*GM"&3:0#J\X:T%/5=4X2:G8*OF3:>S068
M2\V=L$1=Q#A+<VZA8^F"N#3%M"*KX'4W--8EQ)M6UI*@]M6@R\X\PZ#QHIBC
M8NVT"6E]$&FS&H?5_J[(<YX%8$LMOU/E84'GGN>AC&E55(K3(;._]G4.[E%Q
MZC*X-%!$'B')MKRTU!2/>J$$Z_<2)Q$-@(-^=X #0:E6N5A(VH4(T5TIPHFG
MUKO: 8?T$963A(W04(YE90'0A:X+PR 8LQ*@"TPH=$@*M*@5>)?$[1OJPJ3_
M[NSR(CS%[]X&9[];Z(33F-HAR#VJ5%  QM<AC:_U9JJ@D<\:@< Q@049^,4
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M!/*)IN OH?K2.9,IR?M7RB\%R6S9Z-N-PC(!'IKY8>V"(,$?2VO?S4LQYU_
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M[2+<0I-/>SBW4_&>K41I"\.<%&)VP=_F\50\MQ)ADVC6IDXMI3F-HQ&8'6W
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M-#P]&80JJ&^\*?FSX]QX;]9\N5(24$ #\'YAD*_QAA9HOD.__0]02P,$%
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MKG@L8B7EF,8"NIW>3 =-3RIN$ISW^XFD<=!AW53<"U+:>FXY>/&(&9=Q=,F
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MJ#BM#)>?32]E=%"6_/Y==I(8=DTLB\Z80.R0NN\>XO%1;A$.A&>ETV3(8RG
M=W5JN"&3@T;P'%?8MG/")Z6B6*_(GF&3'4YS<)92.L!^D08NM>$Q8$]/"3+B
MMPQ6%C?F!.MNH47%\7[M;-O$F2;?Z!:P:*W1A].XYVWK5$I>M7]-9;7Q/@]:
M$1KR^J#:QMFKEJO^"TIRX)4! /!2ZSC6;9""B$P^EGH@?G#\\.QQ"JE-55PF
MR<2.K^=%C ^S#03="P$F>V-KS&:I)M.AW4.E'698GE84]W5QTQ9\$73J!^CL
MAP+?]]%.HAV_2JC(17XAN,6K$:[B*WY651NB)G8:ZKB50:J<YC-"<+IHDU:
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MZ<KWPY;>6*B= .VOE;*'B3-P?+4M_P)02P,$%     @ "HIL4WL1>])W P
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MN*4O$[KH0.=K2Y=R4&*"X[=N\2]02P,$%     @ "HIL4UQ!^+G6 @    8
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M=D/M+M#WM5+VL'$$W6MP_@]02P,$%     @ "HIL4[EN[3OQ P  ? D  !D
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MD\9.#+]<V!F-RAG8^UQ*L]VXL5%/_=$O4$L#!!0    (  J*;%/W:XH:;0(
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M9:&G)0@3H/<WG*NC80[HYF_Z%U!+ P04    "  *BFQ3A%.-F,L$  #1%
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MZKT1CDOW4E96XU..?G8R98R[\AA")2-+L)7&M5J3A5:LRBSQK\F0&S+/J=P
MX9+,T9PST-37]>H>+.7"7*/-,RTU-TJ,0HML+D*8[3EF#4=\AF-('I6TN2&?
M) /VIW^(.;6)Q8?$9O%%P164MR2)/I(XBCM/JWMR]>'Z@FS2UBOQLLD9V0=E
MC"N Y5@,F>W(-,MT107YOE1"$.R4FFKVXT*D;ANIZR-UST2:P89+B6&PZP25
M&9PJ:B.1>@EW_[:3 5['7B\>A=L3L7MM[-[%V'-J<E+2'=X^ZYI!JQT5=D=8
MI1V0S8&4H+EBIY@:Z=X1TTVG/XQ[_>0T5-I"I9>AV@9<4Z[)EHH*'%QV>!O6
M+8\ZD\M,5-A-S@6GF#M%>'C#@6; G$)/WZ.G29QVT]/D_9:\?YG\'"%0+9'/
M73WJ^NA_6/OO6#N=I)LD9ZH\:%D'%UGQ_OVCYP;O>BX=1L,T_;M(X=%4*D!O
M_.PU6(%*VF9 M:?M>)\V4^VW>?-M>*0:+X,A M;H&MWV,6W=S-MF8U7I9]R+
MLC@Q_3+'3Q1H9X#/UTK9P\8%:#]ZDU]02P,$%     @ "HIL4TL\DY&H P
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MJM'5+ _J^X5P#5#W=XS)IPL=H/\B6OP/4$L#!!0    (  J*;%-WZGW2$0,
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M.],[7.^GMLMN'HYUR_5W_'W&1_T+<PB0'!(DQPU(CEN0'&.0''<@.>Y!<CR
MY. CE" H1.4H2.4H3.4H4.4H5.4H6.4H7.4H8.4H9!4H9!4H9!4H9!4H9!4H
M9!4H9!4H9!4H9!4H9!4H9)4H9)4H9)4H9)4H9)4H9)4H9)4H9)7_2=8/K9=_
M_7NV79-:E<W!GW7_P&=?4$L! A0#%     @ "HIL4P=!36*!    L0   !
M             ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    "  *
MBFQ3&'8OUNX    K @  $0              @ &O    9&]C4')O<',O8V]R
M92YX;6Q02P$"% ,4    "  *BFQ3F5R<(Q &  "<)P  $P
M@ ', 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    (  J*;%-<-U#>
M2 4   $6   8              " @0T(  !X;"]W;W)K<VAE971S+W-H965T
M,2YX;6Q02P$"% ,4    "  *BFQ3UD;)-2L&  "C%P  &
M@(&+#0  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ "HIL
M4TDYYI6" @  T 8  !@              ("![!,  'AL+W=O<FMS:&5E=',O
M<VAE970S+GAM;%!+ 0(4 Q0    (  J*;%-7E9#+I0<  .<B   8
M      " @:06  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4
M"  *BFQ3W<O28D8'   :'0  &               @(%_'@  >&PO=V]R:W-H
M965T<R]S:&5E=#4N>&UL4$L! A0#%     @ "HIL4S:A)7KL"   43<  !@
M             ("!^R4  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4
M Q0    (  J*;%-PG+B\1Q   $8I   8              " @1TO  !X;"]W
M;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    "  *BFQ3&=;9<E,$  "Y
M"@  &               @(&:/P  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL
M4$L! A0#%     @ "HIL4^%_(@S/!@  "P\  !@              ("!(T0
M 'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    (  J*;%/ AI"7
M.P8   \/   9              " @2A+  !X;"]W;W)K<VAE971S+W-H965T
M,3 N>&UL4$L! A0#%     @ "HIL4V++U: ;!@  Q X  !D
M ("!FE$  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    "  *
MBFQ3(N)PH3D,  "3'P  &0              @('L5P  >&PO=V]R:W-H965T
M<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    (  J*;%-?"TBJ'@,  -(&   9
M          " @5QD  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#
M%     @ "HIL4Y,:]&GO P  @ @  !D              ("!L6<  'AL+W=O
M<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    "  *BFQ3];X[?48+  "3
M'@  &0              @('7:P  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM
M;%!+ 0(4 Q0    (  J*;%/#L>>Q0P@  "84   9              " @51W
M  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ "HIL4Z^%
M_F+H P  P0D  !D              ("!SG\  'AL+W=O<FMS:&5E=',O<VAE
M970Q-RYX;6Q02P$"% ,4    "  *BFQ3>Q%[TG<#  #W!@  &0
M    @('M@P  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    (
M  J*;%-<0?BYU@(    &   9              " @9N'  !X;"]W;W)K<VAE
M971S+W-H965T,3DN>&UL4$L! A0#%     @ "HIL4ZU[QPX;!   &0H  !D
M             ("!J(H  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"
M% ,4    "  *BFQ3N6[M._$#  !\"0  &0              @('ZC@  >&PO
M=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    (  J*;%/-P46:)@(
M * $   9              " @2*3  !X;"]W;W)K<VAE971S+W-H965T,C(N
M>&UL4$L! A0#%     @ "HIL4S[35VUR!   ?!   !D              ("!
M?Y4  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    "  *BFQ3
MF(ZQVEH"  !1!0  &0              @($HF@  >&PO=V]R:W-H965T<R]S
M:&5E=#(T+GAM;%!+ 0(4 Q0    (  J*;%-5C7-M= 0  "<4   9
M      " @;F<  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%
M  @ "HIL4R_]OGKP @  N0D  !D              ("!9*$  'AL+W=O<FMS
M:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    "  *BFQ3#1[&D< "  "Z!P
M&0              @(&+I   >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+
M 0(4 Q0    (  J*;%-Q(&,6X0(   $(   9              " @8*G  !X
M;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ "HIL4_=KBAIM
M @  : 8  !D              ("!FJH  'AL+W=O<FMS:&5E=',O<VAE970R
M.2YX;6Q02P$"% ,4    "  *BFQ3*KB+'(T"  #4!@  &0
M@($^K0  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    (  J*
M;%/:S+2&10(  (L%   9              " @0*P  !X;"]W;W)K<VAE971S
M+W-H965T,S$N>&UL4$L! A0#%     @ "HIL4X13C9C+!   T10  !D
M         ("!?K(  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4
M    "  *BFQ3ZE*9S&4$  !.%   &0              @(& MP  >&PO=V]R
M:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    (  J*;%/%.R0L$P(  ! %
M   9              " @1R\  !X;"]W;W)K<VAE971S+W-H965T,S0N>&UL
M4$L! A0#%     @ "HIL4X^DL%4.!0  =14  !D              ("!9KX
M 'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    "  *BFQ3@=$:
M;-<"    !P  &0              @(&KPP  >&PO=V]R:W-H965T<R]S:&5E
M=#,V+GAM;%!+ 0(4 Q0    (  J*;%-+/).1J ,  !T-   9
M  " @;G&  !X;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @
M"HIL4W?J?=(1 P  +!$   T              ( !F,H  'AL+W-T>6QE<RYX
M;6Q02P$"% ,4    "  *BFQ3EXJ[',     3 @  "P              @ '4
MS0  7W)E;',O+G)E;'-02P$"% ,4    "  *BFQ3]T< AV@#  #S&   #P
M            @ &]S@  >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ "HIL
M4YD^HH1\ 0  EA8  !H              ( !4M(  'AL+U]R96QS+W=O<FMB
M;V]K+GAM;"YR96QS4$L! A0#%     @ "HIL4ZIG%&&8 0  "Q<  !,
M         ( !!M0  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     "T +0 R
)#   S]4

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>137</ContextCount>
  <ElementCount>257</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>34</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="cpix-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="cpix-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="cpix-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="cpix-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Condensed Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations</Role>
      <ShortName>Condensed Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="cpix-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="cpix-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Condensed Consolidated Statement of Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity</Role>
      <ShortName>Condensed Consolidated Statement of Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="cpix-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Organization and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentation</Role>
      <ShortName>Organization and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="cpix-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2104102 - Disclosure - Earnings (Loss) Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/EarningsLossPerShare</Role>
      <ShortName>Earnings (Loss) Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="cpix-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2108103 - Disclosure - Revenues</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/Revenues</Role>
      <ShortName>Revenues</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="cpix-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2111104 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/Inventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="cpix-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2115105 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="cpix-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2121106 - Disclosure - Shareholders' Equity and Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt</Role>
      <ShortName>Shareholders' Equity and Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="cpix-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2124107 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="cpix-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2126108 - Disclosure - Collaborative Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/CollaborativeAgreements</Role>
      <ShortName>Collaborative Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="cpix-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2127109 - Disclosure - Additions and Returns of Product Rights</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRights</Role>
      <ShortName>Additions and Returns of Product Rights</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="cpix-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Organization and Basis of Presentation (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies</Role>
      <ShortName>Organization and Basis of Presentation (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="cpix-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Earnings (Loss) Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/EarningsLossPerShareTables</Role>
      <ShortName>Earnings (Loss) Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/EarningsLossPerShare</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="cpix-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2309302 - Disclosure - Revenues (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/RevenuesTables</Role>
      <ShortName>Revenues (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/Revenues</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="cpix-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2312303 - Disclosure - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/InventoriesTables</Role>
      <ShortName>Inventories (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/Inventories</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="cpix-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2316304 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/Leases</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="cpix-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2328305 - Disclosure - Additions and Returns of Product Rights (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsTables</Role>
      <ShortName>Additions and Returns of Product Rights (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRights</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="cpix-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2403401 - Disclosure - Organization and Basis of Presentation Organization (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails</Role>
      <ShortName>Organization and Basis of Presentation Organization (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="cpix-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Earnings (Loss) Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails</Role>
      <ShortName>Earnings (Loss) Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/EarningsLossPerShareTables</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="cpix-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Earnings (Loss) Per Share (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/EarningsLossPerShareDetailsTextual</Role>
      <ShortName>Earnings (Loss) Per Share (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/EarningsLossPerShareTables</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="cpix-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2410404 - Disclosure - Revenues (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/RevenuesDetails</Role>
      <ShortName>Revenues (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/RevenuesTables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="cpix-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2413405 - Disclosure - Inventories (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails</Role>
      <ShortName>Inventories (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/InventoriesTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="cpix-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2414406 - Disclosure - Inventories (Schedule of Inventories) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails</Role>
      <ShortName>Inventories (Schedule of Inventories) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/InventoriesTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="cpix-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2417407 - Disclosure - Leases (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/LeasesTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="cpix-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2418408 - Disclosure - Leases (Lease Position) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails</Role>
      <ShortName>Leases (Lease Position) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/LeasesTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="cpix-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2419409 - Disclosure - Leases (Schedule of Lease Liabilities Maturity and Future Minimum Lease Commitments) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails</Role>
      <ShortName>Leases (Schedule of Lease Liabilities Maturity and Future Minimum Lease Commitments) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/LeasesTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="cpix-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2420410 - Disclosure - Leases - Rent Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/LeasesRentExpenseDetails</Role>
      <ShortName>Leases - Rent Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="cpix-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2422411 - Disclosure - Shareholders' Equity and Debt (Shareholders' Equity) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails</Role>
      <ShortName>Shareholders' Equity and Debt (Shareholders' Equity) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="cpix-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2423412 - Disclosure - Shareholders' Equity and Debt (Debt) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails</Role>
      <ShortName>Shareholders' Equity and Debt (Debt) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="cpix-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2425413 - Disclosure - Income Taxes (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual</Role>
      <ShortName>Income Taxes (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/IncomeTaxes</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="cpix-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2429414 - Disclosure - Additions and Returns of Product Rights - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails</Role>
      <ShortName>Additions and Returns of Product Rights - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="cpix-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2430415 - Disclosure - Additions and Returns of Product Rights - Change in Consideration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails</Role>
      <ShortName>Additions and Returns of Product Rights - Change in Consideration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="cpix-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2431416 - Disclosure - Additions and Returns of Product Rights - Dissolution Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsDissolutionPaymentsDetails</Role>
      <ShortName>Additions and Returns of Product Rights - Dissolution Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="cpix-20210930.htm">cpix-20210930.htm</File>
    <File>a2021q3-exhibit311.htm</File>
    <File>a2021q3-exhibit312.htm</File>
    <File>a2021q3-exhibit321.htm</File>
    <File>cpix-20210930.xsd</File>
    <File>cpix-20210930_cal.xml</File>
    <File>cpix-20210930_def.xml</File>
    <File>cpix-20210930_lab.xml</File>
    <File>cpix-20210930_pre.xml</File>
    <File>pinnaclelocrenewal4thloa.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>66
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "cpix-20210930.htm": {
   "axisCustom": 0,
   "axisStandard": 17,
   "contextCount": 137,
   "dts": {
    "calculationLink": {
     "local": [
      "cpix-20210930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "cpix-20210930_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "cpix-20210930.htm"
     ]
    },
    "labelLink": {
     "local": [
      "cpix-20210930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cpix-20210930_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "cpix-20210930.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 309,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2020-01-31": 5,
    "total": 5
   },
   "keyCustom": 14,
   "keyStandard": 243,
   "memberCustom": 15,
   "memberStandard": 18,
   "nsprefix": "cpix",
   "nsuri": "http://www.cumberlandpharma.com/20210930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210930.htm",
      "contextRef": "i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.cumberlandpharma.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210930.htm",
      "contextRef": "i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210930.htm",
      "contextRef": "i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2111104 - Disclosure - Inventories",
     "role": "http://www.cumberlandpharma.com/role/Inventories",
     "shortName": "Inventories",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210930.htm",
      "contextRef": "i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210930.htm",
      "contextRef": "i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2115105 - Disclosure - Leases",
     "role": "http://www.cumberlandpharma.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210930.htm",
      "contextRef": "i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210930.htm",
      "contextRef": "i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2121106 - Disclosure - Shareholders' Equity and Debt",
     "role": "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt",
     "shortName": "Shareholders' Equity and Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210930.htm",
      "contextRef": "i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210930.htm",
      "contextRef": "i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2124107 - Disclosure - Income Taxes",
     "role": "http://www.cumberlandpharma.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210930.htm",
      "contextRef": "i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210930.htm",
      "contextRef": "i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2126108 - Disclosure - Collaborative Agreements",
     "role": "http://www.cumberlandpharma.com/role/CollaborativeAgreements",
     "shortName": "Collaborative Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210930.htm",
      "contextRef": "i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210930.htm",
      "contextRef": "i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2127109 - Disclosure - Additions and Returns of Product Rights",
     "role": "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRights",
     "shortName": "Additions and Returns of Product Rights",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210930.htm",
      "contextRef": "i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210930.htm",
      "contextRef": "i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - Organization and Basis of Presentation (Policies)",
     "role": "http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies",
     "shortName": "Organization and Basis of Presentation (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210930.htm",
      "contextRef": "i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210930.htm",
      "contextRef": "i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Earnings (Loss) Per Share (Tables)",
     "role": "http://www.cumberlandpharma.com/role/EarningsLossPerShareTables",
     "shortName": "Earnings (Loss) Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210930.htm",
      "contextRef": "i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210930.htm",
      "contextRef": "i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2309302 - Disclosure - Revenues (Tables)",
     "role": "http://www.cumberlandpharma.com/role/RevenuesTables",
     "shortName": "Revenues (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210930.htm",
      "contextRef": "i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210930.htm",
      "contextRef": "i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2312303 - Disclosure - Inventories (Tables)",
     "role": "http://www.cumberlandpharma.com/role/InventoriesTables",
     "shortName": "Inventories (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210930.htm",
      "contextRef": "i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210930.htm",
      "contextRef": "i5fc3bb3df16548c98cacace445d903da_I20210930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210930.htm",
      "contextRef": "i5fc3bb3df16548c98cacace445d903da_I20210930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210930.htm",
      "contextRef": "i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cpix:AssetsAndLiabilitiesLesseeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2316304 - Disclosure - Leases (Tables)",
     "role": "http://www.cumberlandpharma.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210930.htm",
      "contextRef": "i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cpix:AssetsAndLiabilitiesLesseeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210930.htm",
      "contextRef": "i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2328305 - Disclosure - Additions and Returns of Product Rights (Tables)",
     "role": "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsTables",
     "shortName": "Additions and Returns of Product Rights (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210930.htm",
      "contextRef": "i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210930.htm",
      "contextRef": "i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403401 - Disclosure - Organization and Basis of Presentation Organization (Details)",
     "role": "http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails",
     "shortName": "Organization and Basis of Presentation Organization (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210930.htm",
      "contextRef": "i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210930.htm",
      "contextRef": "i5cfdffb6c8a4411a95e4596b0bd91b7c_D20210701-20210930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Earnings (Loss) Per Share (Details)",
     "role": "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails",
     "shortName": "Earnings (Loss) Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210930.htm",
      "contextRef": "i5cfdffb6c8a4411a95e4596b0bd91b7c_D20210701-20210930",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210930.htm",
      "contextRef": "i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Earnings (Loss) Per Share (Details Textual)",
     "role": "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetailsTextual",
     "shortName": "Earnings (Loss) Per Share (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210930.htm",
      "contextRef": "i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210930.htm",
      "contextRef": "i5cfdffb6c8a4411a95e4596b0bd91b7c_D20210701-20210930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410404 - Disclosure - Revenues (Details)",
     "role": "http://www.cumberlandpharma.com/role/RevenuesDetails",
     "shortName": "Revenues (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210930.htm",
      "contextRef": "i2b064560ae764b05aee16232fc2b982f_D20210701-20210930",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210930.htm",
      "contextRef": "i5fc3bb3df16548c98cacace445d903da_I20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryValuationReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413405 - Disclosure - Inventories (Narrative) (Details)",
     "role": "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails",
     "shortName": "Inventories (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210930.htm",
      "contextRef": "i5fc3bb3df16548c98cacace445d903da_I20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryValuationReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210930.htm",
      "contextRef": "i5fc3bb3df16548c98cacace445d903da_I20210930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414406 - Disclosure - Inventories (Schedule of Inventories) (Details)",
     "role": "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails",
     "shortName": "Inventories (Schedule of Inventories) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210930.htm",
      "contextRef": "i5fc3bb3df16548c98cacace445d903da_I20210930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210930.htm",
      "contextRef": "i5fc3bb3df16548c98cacace445d903da_I20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417407 - Disclosure - Leases (Narrative) (Details)",
     "role": "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails",
     "shortName": "Leases (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210930.htm",
      "contextRef": "i5fc3bb3df16548c98cacace445d903da_I20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "cpix:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210930.htm",
      "contextRef": "i5fc3bb3df16548c98cacace445d903da_I20210930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418408 - Disclosure - Leases (Lease Position) (Details)",
     "role": "http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails",
     "shortName": "Leases (Lease Position) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "cpix:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210930.htm",
      "contextRef": "i5fc3bb3df16548c98cacace445d903da_I20210930",
      "decimals": "0",
      "lang": "en-US",
      "name": "cpix:LeaseLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockNoParValue",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210930.htm",
      "contextRef": "i5fc3bb3df16548c98cacace445d903da_I20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockNoParValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockNoParValue",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210930.htm",
      "contextRef": "i5fc3bb3df16548c98cacace445d903da_I20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockNoParValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210930.htm",
      "contextRef": "i5fc3bb3df16548c98cacace445d903da_I20210930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419409 - Disclosure - Leases (Schedule of Lease Liabilities Maturity and Future Minimum Lease Commitments) (Details)",
     "role": "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails",
     "shortName": "Leases (Schedule of Lease Liabilities Maturity and Future Minimum Lease Commitments) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210930.htm",
      "contextRef": "i5fc3bb3df16548c98cacace445d903da_I20210930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210930.htm",
      "contextRef": "i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420410 - Disclosure - Leases - Rent Expense (Details)",
     "role": "http://www.cumberlandpharma.com/role/LeasesRentExpenseDetails",
     "shortName": "Leases - Rent Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210930.htm",
      "contextRef": "i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210930.htm",
      "contextRef": "i5cfdffb6c8a4411a95e4596b0bd91b7c_D20210701-20210930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockRepurchasedDuringPeriodValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422411 - Disclosure - Shareholders' Equity and Debt (Shareholders' Equity) (Details)",
     "role": "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails",
     "shortName": "Shareholders' Equity and Debt (Shareholders' Equity) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210930.htm",
      "contextRef": "i4b890701c9304f309d867768f2a90a7b_D20171101-20171130",
      "decimals": "-6",
      "lang": "en-US",
      "name": "cpix:StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210930.htm",
      "contextRef": "i5fc3bb3df16548c98cacace445d903da_I20210930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermLineOfCredit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423412 - Disclosure - Shareholders' Equity and Debt (Debt) (Details)",
     "role": "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails",
     "shortName": "Shareholders' Equity and Debt (Debt) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210930.htm",
      "contextRef": "i7f3eb3a61d724b16837687fe50bb6592_I20200831",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210930.htm",
      "contextRef": "i5fc3bb3df16548c98cacace445d903da_I20210930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425413 - Disclosure - Income Taxes (Details Textual)",
     "role": "http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual",
     "shortName": "Income Taxes (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210930.htm",
      "contextRef": "i5fc3bb3df16548c98cacace445d903da_I20210930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210930.htm",
      "contextRef": "i54eac56082574a4c986a915dc06c3af5_D20210101-20210630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "cpix:ProceedsFromSaleOfIntangibleAssetsInstallmentPayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429414 - Disclosure - Additions and Returns of Product Rights - Narrative (Details)",
     "role": "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
     "shortName": "Additions and Returns of Product Rights - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210930.htm",
      "contextRef": "i54eac56082574a4c986a915dc06c3af5_D20210101-20210630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "cpix:ProceedsFromSaleOfIntangibleAssetsInstallmentPayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210930.htm",
      "contextRef": "i890f0fecec4a4eb899b3171ad304df32_I20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430415 - Disclosure - Additions and Returns of Product Rights - Change in Consideration (Details)",
     "role": "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails",
     "shortName": "Additions and Returns of Product Rights - Change in Consideration (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210930.htm",
      "contextRef": "id08ba9ef8fce4ef0b1aebddae7a819be_D20210101-20210930",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:PaymentsForRoyalties",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210930.htm",
      "contextRef": "i5cfdffb6c8a4411a95e4596b0bd91b7c_D20210701-20210930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431416 - Disclosure - Additions and Returns of Product Rights - Dissolution Payments (Details)",
     "role": "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsDissolutionPaymentsDetails",
     "shortName": "Additions and Returns of Product Rights - Dissolution Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210930.htm",
      "contextRef": "ieb58760ea84940319b35492cd1910735_D20210701-20210930",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210930.htm",
      "contextRef": "i5cfdffb6c8a4411a95e4596b0bd91b7c_D20210701-20210930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Condensed Consolidated Statements of Operations",
     "role": "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations",
     "shortName": "Condensed Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210930.htm",
      "contextRef": "i5cfdffb6c8a4411a95e4596b0bd91b7c_D20210701-20210930",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210930.htm",
      "contextRef": "i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Condensed Consolidated Statements of Cash Flows",
     "role": "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210930.htm",
      "contextRef": "i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210930.htm",
      "contextRef": "i6fa410e0219e41c3b8a23d8140a1ca8c_I20191231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Condensed Consolidated Statement of Equity",
     "role": "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity",
     "shortName": "Condensed Consolidated Statement of Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210930.htm",
      "contextRef": "i4167fc9dfbd441ed853e3173c4f077bf_D20200101-20200331",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210930.htm",
      "contextRef": "i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Organization and Basis of Presentation",
     "role": "http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentation",
     "shortName": "Organization and Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210930.htm",
      "contextRef": "i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210930.htm",
      "contextRef": "i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2104102 - Disclosure - Earnings (Loss) Per Share",
     "role": "http://www.cumberlandpharma.com/role/EarningsLossPerShare",
     "shortName": "Earnings (Loss) Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210930.htm",
      "contextRef": "i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210930.htm",
      "contextRef": "i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2108103 - Disclosure - Revenues",
     "role": "http://www.cumberlandpharma.com/role/Revenues",
     "shortName": "Revenues",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210930.htm",
      "contextRef": "i6fe1f45e467a44adb0adbb9c65a6f6f2_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 34,
   "tag": {
    "cpix_AcetadoteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acetadote",
        "label": "Acetadote [Member]",
        "terseLabel": "Kristalose"
       }
      }
     },
     "localname": "AcetadoteMember",
     "nsuri": "http://www.cumberlandpharma.com/20210930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_AssetsAndLiabilitiesLesseeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets and Liabilities, Lessee",
        "label": "Assets and Liabilities, Lessee [Table Text Block]",
        "terseLabel": "Lease Position"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesLesseeTableTextBlock",
     "nsuri": "http://www.cumberlandpharma.com/20210930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Contingent Consideration, Earned and Accrued in Operating Expenses",
        "label": "Business Combination, Contingent Consideration, Earned and Accrued in Operating Expenses",
        "terseLabel": "Contingent consideration earned and accrued in operating expenses"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses",
     "nsuri": "http://www.cumberlandpharma.com/20210930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_CaldolorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Caldolor",
        "label": "Caldolor [Member]",
        "terseLabel": "Omeclamox-Pak"
       }
      }
     },
     "localname": "CaldolorMember",
     "nsuri": "http://www.cumberlandpharma.com/20210930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_ClinigenHealthcareLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinigen Healthcare Limited",
        "label": "Clinigen Healthcare Limited [Member]",
        "terseLabel": "Clinigen"
       }
      }
     },
     "localname": "ClinigenHealthcareLimitedMember",
     "nsuri": "http://www.cumberlandpharma.com/20210930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsDissolutionPaymentsDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_DenominatorAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Denominator.",
        "label": "Denominator [Abstract]",
        "verboseLabel": "Denominator:"
       }
      }
     },
     "localname": "DenominatorAbstract",
     "nsuri": "http://www.cumberlandpharma.com/20210930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cpix_EquityAndDebtAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity and Debt [Abstract]",
        "label": "Equity and Debt [Abstract]"
       }
      }
     },
     "localname": "EquityAndDebtAbstract",
     "nsuri": "http://www.cumberlandpharma.com/20210930",
     "xbrltype": "stringItemType"
    },
    "cpix_FifthAmendmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fifth Amendment",
        "label": "Fifth Amendment [Member]",
        "terseLabel": "Fifth Amendment"
       }
      }
     },
     "localname": "FifthAmendmentMember",
     "nsuri": "http://www.cumberlandpharma.com/20210930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_IfetrobanClinicalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ifetroban Clinical",
        "label": "Ifetroban Clinical [Member]",
        "terseLabel": "Ifetroban Clinical"
       }
      }
     },
     "localname": "IfetrobanClinicalMember",
     "nsuri": "http://www.cumberlandpharma.com/20210930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_IncentiveStockOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incentive Stock Options",
        "label": "Incentive Stock Options [Member]",
        "terseLabel": "Incentive Stock Options"
       }
      }
     },
     "localname": "IncentiveStockOptionsMember",
     "nsuri": "http://www.cumberlandpharma.com/20210930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Cash Surrender Value Of Life Insurance Policy",
        "label": "Increase (Decrease) In Cash Surrender Value Of Life Insurance Policy",
        "negatedTerseLabel": "Increase (Decrease) In Cash Surrender Value Of Life Insurance Policy"
       }
      }
     },
     "localname": "IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy",
     "nsuri": "http://www.cumberlandpharma.com/20210930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_IncreaseDecreaseInCurrentOperatingLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "IncreaseDecreaseInCurrentOperatingLiabilities",
        "verboseLabel": "Accounts payable and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInCurrentOperatingLiabilities",
     "nsuri": "http://www.cumberlandpharma.com/20210930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_KristaloseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Kristalose",
        "label": "Kristalose [Member]",
        "terseLabel": "Caldolor"
       }
      }
     },
     "localname": "KristaloseMember",
     "nsuri": "http://www.cumberlandpharma.com/20210930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_LeaseLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease, Liability",
        "label": "Lease, Liability",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "LeaseLiability",
     "nsuri": "http://www.cumberlandpharma.com/20210930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, to be Paid, after Year Three",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Three",
        "terseLabel": "After 2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearThree",
     "nsuri": "http://www.cumberlandpharma.com/20210930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line of Credit Facility, Maximum Borrowing Capacity, Increase Amount",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity, Increase Amount",
        "terseLabel": "Increase amount (up to)"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacityIncreaseAmount",
     "nsuri": "http://www.cumberlandpharma.com/20210930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_LineOfCreditFacilityMaximumBorrowingCapacityTotalCapacity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line of Credit Facility, Maximum Borrowing Capacity, Total Capacity",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity, Total Capacity",
        "terseLabel": "Total capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacityTotalCapacity",
     "nsuri": "http://www.cumberlandpharma.com/20210930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_MethotrexateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Methotrexate [Member]",
        "label": "Methotrexate [Member]",
        "terseLabel": "Methotrexate"
       }
      }
     },
     "localname": "MethotrexateMember",
     "nsuri": "http://www.cumberlandpharma.com/20210930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_NumeratorAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Numerator.",
        "label": "Numerator [Abstract]",
        "verboseLabel": "Numerator:"
       }
      }
     },
     "localname": "NumeratorAbstract",
     "nsuri": "http://www.cumberlandpharma.com/20210930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cpix_OmeclamoxPakMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Omeclamox-Pak",
        "label": "Omeclamox-Pak [Member]",
        "terseLabel": "Vibativ"
       }
      }
     },
     "localname": "OmeclamoxPakMember",
     "nsuri": "http://www.cumberlandpharma.com/20210930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_OtherLongTermObligationsExcludingCurrentPortion": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Long Term Obligations, Excluding Current Portion",
        "label": "Other Long Term Obligations, Excluding Current Portion",
        "verboseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLongTermObligationsExcludingCurrentPortion",
     "nsuri": "http://www.cumberlandpharma.com/20210930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_OtherProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Products",
        "label": "Other Products [Member]",
        "terseLabel": "Other revenue"
       }
      }
     },
     "localname": "OtherProductsMember",
     "nsuri": "http://www.cumberlandpharma.com/20210930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_PinnacleBankMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pinnacle Bank",
        "label": "Pinnacle Bank [Member]",
        "terseLabel": "Pinnacle Bank"
       }
      }
     },
     "localname": "PinnacleBankMember",
     "nsuri": "http://www.cumberlandpharma.com/20210930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_ProceedsFromSaleOfIntangibleAssetsInstallmentPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from Sale of Intangible Assets, Installment Payment",
        "label": "Proceeds from Sale of Intangible Assets, Installment Payment",
        "terseLabel": "Financial consideration received in exchange for product license rights, installment payments"
       }
      }
     },
     "localname": "ProceedsFromSaleOfIntangibleAssetsInstallmentPayment",
     "nsuri": "http://www.cumberlandpharma.com/20210930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_ProductsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Products.",
        "label": "Products [Abstract]",
        "verboseLabel": "Products:"
       }
      }
     },
     "localname": "ProductsAbstract",
     "nsuri": "http://www.cumberlandpharma.com/20210930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cpix_RediTrexMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "RediTrex",
        "label": "RediTrex [Member]",
        "terseLabel": "RediTrex"
       }
      }
     },
     "localname": "RediTrexMember",
     "nsuri": "http://www.cumberlandpharma.com/20210930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Rent Expense and Sublease Income [Table Text Block]",
        "label": "Schedule of Rent Expense and Sublease Income [Table Text Block]",
        "terseLabel": "Schedule of Rent Expense and Sublease Income"
       }
      }
     },
     "localname": "ScheduleofRentExpenseandSubleaseIncomeTableTextBlock",
     "nsuri": "http://www.cumberlandpharma.com/20210930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cpix_ShareholdersEquityTextualAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shareholders Equity.",
        "label": "Shareholders Equity (Textual) [Abstract]",
        "verboseLabel": "Shareholders' Equity (Textual) [Abstract]"
       }
      }
     },
     "localname": "ShareholdersEquityTextualAbstract",
     "nsuri": "http://www.cumberlandpharma.com/20210930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities",
        "terseLabel": "Shelf Registration, sale of corporate securities (up to)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities",
     "nsuri": "http://www.cumberlandpharma.com/20210930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Coronavirus Aid, Relief, and Economic Security Act, Loan Proceeds Received",
        "label": "The Coronavirus Aid, Relief, and Economic Security Act, Loan Proceeds Received",
        "terseLabel": "Aggregate amount"
       }
      }
     },
     "localname": "TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived",
     "nsuri": "http://www.cumberlandpharma.com/20210930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_TieredRoyaltyPaymentsPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tiered Royalty Payments, Percentage",
        "label": "Tiered Royalty Payments, Percentage",
        "terseLabel": "Percentage of tiered royalty payments (up to)"
       }
      }
     },
     "localname": "TieredRoyaltyPaymentsPercentage",
     "nsuri": "http://www.cumberlandpharma.com/20210930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cpix_VIBATIVMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "VIBATIV",
        "label": "VIBATIV [Member]",
        "terseLabel": "Vaprisol"
       }
      }
     },
     "localname": "VIBATIVMember",
     "nsuri": "http://www.cumberlandpharma.com/20210930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_VaprisolMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vaprisol",
        "label": "Vaprisol [Member]",
        "terseLabel": "Acetadote"
       }
      }
     },
     "localname": "VaprisolMember",
     "nsuri": "http://www.cumberlandpharma.com/20210930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_WinHealthInvestmentSingaporeLtdDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "WinHealth Investment (Singapore) Ltd",
        "label": "WinHealth Investment (Singapore) Ltd [Domain]",
        "terseLabel": "WinHealth"
       }
      }
     },
     "localname": "WinHealthInvestmentSingaporeLtdDomain",
     "nsuri": "http://www.cumberlandpharma.com/20210930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r64",
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsDissolutionPaymentsDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]",
        "terseLabel": "Director"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r203",
      "r205",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r340",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r203",
      "r205",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r340",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OfficeBuildingMember": {
     "auth_ref": [
      "r348",
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Office Building [Member]",
        "terseLabel": "Wet Laboratory and Office Space"
       }
      }
     },
     "localname": "OfficeBuildingMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r167",
      "r199",
      "r200",
      "r307",
      "r339",
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r167",
      "r199",
      "r200",
      "r307",
      "r339",
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r201",
      "r203",
      "r205",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r340",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r201",
      "r203",
      "r205",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r340",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsDissolutionPaymentsDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r172",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Relationship to Entity [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r22",
      "r35",
      "r173",
      "r174"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "verboseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Adjustments to reconcile net income (loss) from continuing operations to net cash provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r73",
      "r90",
      "r285"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "verboseLabel": "Noncash interest expense"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r90",
      "r183",
      "r185"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 5.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "verboseLabel": "Amortization"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "verboseLabel": "Common stock available for purchase through restricted stock awards and options (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetailsTextual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AreaOfRealEstateProperty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of a real estate property.",
        "label": "Area of Real Estate Property",
        "terseLabel": "Square feet of office space"
       }
      }
     },
     "localname": "AreaOfRealEstateProperty",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r96",
      "r147",
      "r157",
      "r163",
      "r176",
      "r260",
      "r265",
      "r274",
      "r311",
      "r325"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "verboseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r23",
      "r24",
      "r63",
      "r96",
      "r176",
      "r260",
      "r265",
      "r274"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "verboseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r208",
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r272",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BuildingMember": {
     "auth_ref": [
      "r186"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.",
        "label": "Building [Member]",
        "terseLabel": "Office Space"
       }
      }
     },
     "localname": "BuildingMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r202",
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r202",
      "r204",
      "r240",
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]",
        "verboseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsDissolutionPaymentsDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred": {
     "auth_ref": [
      "r244",
      "r246",
      "r247",
      "r250"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.",
        "label": "Business Combination, Consideration Transferred, Liabilities Incurred",
        "terseLabel": "Liability recorded"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredLiabilitiesIncurred",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r89",
      "r252"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "terseLabel": "Change in fair value of contingent consideration included in operating expenses"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r245",
      "r248",
      "r251"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Additional liability"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "ADDITIONS AND RETURN OF PRODUCT RIGHTS"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRights"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": {
     "auth_ref": [
      "r242",
      "r243"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles",
        "verboseLabel": "Net intangible assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r20",
      "r45",
      "r92"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r86",
      "r92",
      "r93"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r86",
      "r275"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations": {
     "auth_ref": [
      "r13",
      "r86"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Cash Provided by (Used in) Operating Activities, Discontinued Operations",
        "terseLabel": "Discontinued operations"
       }
      }
     },
     "localname": "CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r254",
      "r255",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "COLLABORATIVE AGREEMENTS"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CollaborativeAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r56",
      "r190",
      "r316",
      "r330"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r102",
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "verboseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockNoParValue": {
     "auth_ref": [
      "r34"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount per share of no-par value common stock.",
        "label": "Common Stock, No Par Value",
        "verboseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockNoParValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r34"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "verboseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r34"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "verboseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r34",
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Balance, End of Period (in shares)",
        "periodStartLabel": "Balance, Beginning of Period (in shares)",
        "verboseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock\u2014no par value; 100,000,000 shares authorized; 15,555,865 and 15,723,075 shares issued and outstanding as of June 30, 2018 and December 31, 2017, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtMember": {
     "auth_ref": [
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Debt [Member]",
        "terseLabel": "Convertible Debt"
       }
      }
     },
     "localname": "ConvertibleDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r75",
      "r307"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Costs of products sold",
        "verboseLabel": "Cost of products sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsDissolutionPaymentsDetails",
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total costs and expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "verboseLabel": "Costs and expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r30",
      "r31",
      "r32",
      "r312",
      "r313",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Variable rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r284",
      "r286"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Convertible note"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate spread"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r55"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r90",
      "r145"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "verboseLabel": "Depreciation and amortization expense"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax": {
     "auth_ref": [
      "r1",
      "r2",
      "r3",
      "r4",
      "r5",
      "r12",
      "r70",
      "r332"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax",
        "terseLabel": "Discontinued operations income"
       }
      }
     },
     "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "verboseLabel": "Earnings (loss) per share attributable to common shareholders"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r72",
      "r107",
      "r108",
      "r109",
      "r110",
      "r111",
      "r115",
      "r117",
      "r120",
      "r121",
      "r122",
      "r126",
      "r127",
      "r321",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "verboseLabel": "Earnings (loss) per share attributable to common shareholders - basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r72",
      "r107",
      "r108",
      "r109",
      "r110",
      "r111",
      "r117",
      "r120",
      "r121",
      "r122",
      "r126",
      "r127",
      "r321",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "verboseLabel": "Earnings (loss) per share attributable to common shareholders - diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r123",
      "r124",
      "r125",
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "EARNINGS (LOSS) PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EarningsLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue from External Customer [Line Items]",
        "terseLabel": "Revenue from External Customer [Line Items]"
       }
      }
     },
     "localname": "EntityWideInformationRevenueFromExternalCustomerLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r102",
      "r103",
      "r104",
      "r106",
      "r112",
      "r114",
      "r129",
      "r177",
      "r195",
      "r196",
      "r214",
      "r215",
      "r216",
      "r230",
      "r231",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r343",
      "r344",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities": {
     "auth_ref": [
      "r218"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for realized tax benefit related to deductible compensation cost reported on the entity's tax return for equity instruments in excess of the compensation cost for those instruments recognized for financial reporting purposes.",
        "label": "Excess Tax Benefit from Share-based Compensation, Operating Activities",
        "negatedLabel": "Decrease in non-cash contingent consideration"
       }
      }
     },
     "localname": "ExcessTaxBenefitFromShareBasedCompensationOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r184",
      "r308"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "verboseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "verboseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r181",
      "r182",
      "r310"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GrantMember": {
     "auth_ref": [
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award of money not required to be repaid.",
        "label": "Grant [Member]",
        "terseLabel": "Grant"
       }
      }
     },
     "localname": "GrantMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r69",
      "r147",
      "r156",
      "r159",
      "r162",
      "r165",
      "r309",
      "r318",
      "r323",
      "r336"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income (loss) from continuing operations before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r96",
      "r105",
      "r147",
      "r156",
      "r159",
      "r162",
      "r165",
      "r176",
      "r259",
      "r274"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      },
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income (loss) from continuing operations",
        "totalLabel": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest, Total"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": {
     "auth_ref": [
      "r67",
      "r72",
      "r105",
      "r107",
      "r108",
      "r109",
      "r110",
      "r117",
      "r120",
      "r121",
      "r317",
      "r319",
      "r321",
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Basic Share",
        "terseLabel": "Earnings (loss) per share attributable to common shareholders - Continuing operations - basic (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": {
     "auth_ref": [
      "r67",
      "r72",
      "r105",
      "r107",
      "r108",
      "r109",
      "r110",
      "r117",
      "r120",
      "r121",
      "r122",
      "r321",
      "r331",
      "r334",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Diluted Share",
        "terseLabel": "Earnings (loss) per share attributable to common shareholders - Continuing operations - diluted (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": {
     "auth_ref": [
      "r1",
      "r2",
      "r3",
      "r4",
      "r5",
      "r15",
      "r18",
      "r236",
      "r332"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Discontinued operations"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity": {
     "auth_ref": [
      "r1",
      "r2",
      "r3",
      "r4",
      "r5",
      "r12",
      "r15",
      "r259"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent",
        "terseLabel": "Income from discontinued operations"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsDissolutionPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare": {
     "auth_ref": [
      "r70",
      "r72",
      "r118",
      "r120",
      "r121",
      "r321",
      "r332",
      "r334",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.",
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share",
        "terseLabel": "Earnings (loss) per share attributable to common shareholders - Discontinued operations - basic (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare": {
     "auth_ref": [
      "r118",
      "r120",
      "r121",
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.",
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share",
        "terseLabel": "Earnings (loss) per share attributable to common shareholders - Discontinued operations - diluted (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxContingencyLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Tax Contingency [Line Items]",
        "terseLabel": "Income Tax Contingency [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxContingencyLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxContingencyTable": {
     "auth_ref": [
      "r223",
      "r224",
      "r226",
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.",
        "label": "Income Tax Contingency [Table]",
        "terseLabel": "Income Tax Contingency [Table]"
       }
      }
     },
     "localname": "IncomeTaxContingencyTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r221",
      "r225",
      "r227",
      "r232",
      "r234",
      "r237",
      "r238",
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r97",
      "r113",
      "r114",
      "r146",
      "r220",
      "r233",
      "r235",
      "r337"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax (expense) benefit"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "verboseLabel": "Net changes in assets and liabilities affecting operating activities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other current assets and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r68",
      "r144",
      "r283",
      "r285",
      "r322"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryCurrentTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about inventory expected to be sold or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Current [Table]",
        "terseLabel": "Inventory, Current [Table]"
       }
      }
     },
     "localname": "InventoryCurrentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "INVENTORIES"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/Inventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r59"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Inventory, Finished Goods, Gross",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r40",
      "r179"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Inventory, Finished Goods, Net of Reserves",
        "verboseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails",
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryGross": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Inventory, Gross",
        "totalLabel": "Total inventories"
       }
      }
     },
     "localname": "InventoryGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Inventory [Line Items]",
        "terseLabel": "Inventory [Line Items]"
       }
      }
     },
     "localname": "InventoryLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r21",
      "r60"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Total inventories classified as current",
        "verboseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Net, Items Net of Reserve Alternative [Abstract]",
        "verboseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryNetItemsNetOfReserveAlternativeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryNoncurrent": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.",
        "label": "Inventory, Noncurrent",
        "negatedLabel": "Inventory, Noncurrent",
        "terseLabel": "Non-current inventories"
       }
      }
     },
     "localname": "InventoryNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails",
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r41",
      "r179"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "verboseLabel": "Raw materials and work in process"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryValuationReserves": {
     "auth_ref": [
      "r60",
      "r101",
      "r178"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation reserve for inventory.",
        "label": "Inventory Valuation Reserves",
        "terseLabel": "Obsolescence and discontinuance losses"
       }
      }
     },
     "localname": "InventoryValuationReserves",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r77",
      "r143"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "verboseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures": {
     "auth_ref": [
      "r46"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity method investee and investment in and advance to affiliate.",
        "label": "Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures",
        "terseLabel": "Initial investment in joint ventures"
       }
      }
     },
     "localname": "InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Maturity of Lease Liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r294"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r294"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r294"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r294"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r294"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "verboseLabel": "Less: Interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "LEASES"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceived": {
     "auth_ref": [
      "r297"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease payments to be received by lessor for operating lease.",
        "label": "Lessor, Operating Lease, Payments to be Received",
        "terseLabel": "Future minimum sublease income under noncancelable operating subleases"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceived",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r51",
      "r96",
      "r158",
      "r176",
      "r261",
      "r265",
      "r266",
      "r274"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r39",
      "r96",
      "r176",
      "r274",
      "r315",
      "r328"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "LIABILITIES AND EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r53",
      "r96",
      "r176",
      "r261",
      "r265",
      "r266",
      "r274"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "verboseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityAxis": {
     "auth_ref": [
      "r50",
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.",
        "label": "Lender Name [Axis]",
        "terseLabel": "Lender Name [Axis]"
       }
      }
     },
     "localname": "LineOfCreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityLenderDomain": {
     "auth_ref": [
      "r50"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.",
        "label": "Line of Credit Facility, Lender [Domain]",
        "terseLabel": "Line of Credit Facility, Lender [Domain]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLenderDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Line of Credit Facility [Line Items]",
        "terseLabel": "Line of Credit Facility [Line Items]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r50"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Line of credit, maximum borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityTable": {
     "auth_ref": [
      "r50",
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.",
        "label": "Line of Credit Facility [Table]",
        "terseLabel": "Line of Credit Facility [Table]"
       }
      }
     },
     "localname": "LineOfCreditFacilityTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.",
        "label": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage",
        "terseLabel": "Line of credit, unused capacity, commitment fee percentage"
       }
      }
     },
     "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LineOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Line of Credit [Member]",
        "terseLabel": "Line of Credit"
       }
      }
     },
     "localname": "LineOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LondonInterbankOfferedRateLIBORMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.",
        "label": "London Interbank Offered Rate (LIBOR) [Member]",
        "terseLabel": "LIBOR"
       }
      }
     },
     "localname": "LondonInterbankOfferedRateLIBORMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermLineOfCredit": {
     "auth_ref": [
      "r55",
      "r191",
      "r192"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",
        "label": "Long-term Line of Credit, Noncurrent",
        "verboseLabel": "Revolving line of credit"
       }
      }
     },
     "localname": "LongTermLineOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r55"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r55",
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingencyAccrualRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Loss Contingency Accrual [Roll Forward]",
        "terseLabel": "Loss Contingency Accrual [Roll Forward]"
       }
      }
     },
     "localname": "LossContingencyAccrualRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r58",
      "r96",
      "r176",
      "r274",
      "r314",
      "r327"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Noncontrolling interests"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash used in financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "verboseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "verboseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r86",
      "r88",
      "r91"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations": {
     "auth_ref": [
      "r86",
      "r88",
      "r91"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations",
        "totalLabel": "Net cash provided by operating activities from continuing operations"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r18",
      "r65",
      "r66",
      "r71",
      "r91",
      "r96",
      "r105",
      "r107",
      "r108",
      "r109",
      "r110",
      "r113",
      "r114",
      "r119",
      "r147",
      "r156",
      "r159",
      "r162",
      "r165",
      "r176",
      "r274",
      "r320",
      "r333"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net income (loss) attributable to common shareholders",
        "totalLabel": "Net income (loss) attributable to common shareholders"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r65",
      "r66",
      "r113",
      "r114",
      "r263",
      "r268"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "negatedLabel": "Net (income) loss at subsidiary attributable to noncontrolling interests"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Guidance"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r102",
      "r103",
      "r104",
      "r196",
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "verboseLabel": "Noncontrolling interests"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r147",
      "r156",
      "r159",
      "r162",
      "r165"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating income (loss)"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r289"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Rent expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesRentExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]",
        "terseLabel": "Maturity of Lease Liabilities at September 30, 2021"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r288"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Present value of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r288"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease current liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r288"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease noncurrent liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r287"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r293",
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Present value of remaining lease payments, percent"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r292",
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r228"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r19",
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "ORGANIZATION AND BASIS OF PRESENTATION"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "verboseLabel": "Prepaid and other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "verboseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current liabilities.",
        "label": "Other Current Liabilities [Member]",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherCurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherIncome": {
     "auth_ref": [
      "r338"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue and income classified as other.",
        "label": "Other Income",
        "terseLabel": "Other income"
       }
      }
     },
     "localname": "OtherIncome",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount of inventory owned by the entity but in the hands of a customer, typically a reseller.",
        "label": "Other Inventory, Materials, Supplies and Merchandise under Consignment, Gross",
        "terseLabel": "Consigned inventory"
       }
      }
     },
     "localname": "OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r25",
      "r26",
      "r52"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "verboseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.",
        "label": "Other Noncurrent Liabilities [Member]",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherPaymentsToAcquireBusinesses": {
     "auth_ref": [
      "r79"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with other payments to acquire businesses including deposit on pending acquisitions and preacquisition costs.",
        "label": "Other Payments to Acquire Businesses",
        "terseLabel": "Other Payments to Acquire Businesses"
       }
      }
     },
     "localname": "OtherPaymentsToAcquireBusinesses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.",
        "label": "Payment for Contingent Consideration Liability, Financing Activities",
        "negatedLabel": "Cash payment of contingent consideration"
       }
      }
     },
     "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedLabel": "Repurchase of common shares"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow during the period for redemption of redeemable noncontrolling interests.",
        "label": "Payments for Repurchase of Redeemable Noncontrolling Interest",
        "negatedLabel": "Repurchase of subsidiary shares from noncontrolling interest"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfRedeemableNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRoyalties": {
     "auth_ref": [
      "r87"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid for royalties during the current period.",
        "label": "Payments for Royalties",
        "negatedLabel": "Cash payment of royalty during the period"
       }
      }
     },
     "localname": "PaymentsForRoyalties",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r79",
      "r249"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "terseLabel": "Payment to acquire business upon closing"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Payments to Acquire Intangible Assets",
        "negatedLabel": "Additions to intangible assets"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments to Acquire Investments",
        "negatedTerseLabel": "Note receivable investment funding"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Additions to property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromRepaymentsOfLinesOfCredit": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net cash inflow or cash outflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with either short term or long term maturity that is collateralized (backed by pledge, mortgage or other lien in the entity's assets).",
        "label": "Proceeds from (Repayments of) Lines of Credit",
        "terseLabel": "Borrowings on line of credit"
       }
      }
     },
     "localname": "ProceedsFromRepaymentsOfLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Proceeds from surrender of life insurance policies"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfIntangibleAssets": {
     "auth_ref": [
      "r78"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Proceeds from Sale of Intangible Assets",
        "terseLabel": "Financial consideration received in exchange for product license rights"
       }
      }
     },
     "localname": "ProceedsFromSaleOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r18",
      "r65",
      "r66",
      "r85",
      "r96",
      "r105",
      "r113",
      "r114",
      "r147",
      "r156",
      "r159",
      "r162",
      "r165",
      "r176",
      "r259",
      "r262",
      "r264",
      "r268",
      "r269",
      "r274",
      "r323"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income (loss)",
        "totalLabel": "Net income (loss)",
        "verboseLabel": "Net income (loss)"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity",
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r47",
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r28",
      "r29",
      "r187",
      "r329"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "verboseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r28",
      "r186"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PublicUtilitiesInventoryAxis": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of inventory held.",
        "label": "Inventory [Axis]",
        "terseLabel": "Inventory [Axis]"
       }
      }
     },
     "localname": "PublicUtilitiesInventoryAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PublicUtilitiesInventoryTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property that is held for sale in the ordinary course of business, in process of production for such sale or is to be currently consumed in the production of goods or services to be available for sale.",
        "label": "Inventory [Domain]",
        "terseLabel": "Inventory [Domain]"
       }
      }
     },
     "localname": "PublicUtilitiesInventoryTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.",
        "label": "Repayments of Notes Payable",
        "negatedTerseLabel": "Repayments on line of credit"
       }
      }
     },
     "localname": "RepaymentsOfNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r219",
      "r350"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Stock"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r36",
      "r196",
      "r217",
      "r326",
      "r346",
      "r347"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "verboseLabel": "Retained earnings (deficit)"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r102",
      "r103",
      "r104",
      "r106",
      "r112",
      "r114",
      "r177",
      "r214",
      "r215",
      "r216",
      "r230",
      "r231",
      "r343",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "verboseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r141",
      "r142",
      "r155",
      "r160",
      "r161",
      "r167",
      "r168",
      "r170",
      "r198",
      "r199",
      "r307"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenues",
        "verboseLabel": "Net revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsDissolutionPaymentsDetails",
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "verboseLabel": "Net Revenues"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Revolving Credit Facility"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.",
        "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]",
        "terseLabel": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r240",
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsDissolutionPaymentsDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": {
     "auth_ref": [
      "r0",
      "r6",
      "r7",
      "r8",
      "r9",
      "r10",
      "r11",
      "r14",
      "r16",
      "r17",
      "r18",
      "r188",
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]",
        "terseLabel": "Schedule of Dissolution Payments"
       }
      }
     },
     "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Reconciliation of numerator and denominator"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable": {
     "auth_ref": [
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular presentation of the description and amount of revenues from a product or service, or a group of similar products or similar services, reported from external customers during the period, if the information is not provided as part of the reportable operating segment information.",
        "label": "Revenue from External Customers by Products and Services [Table]",
        "terseLabel": "Revenue from External Customers by Products and Services [Table]"
       }
      }
     },
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": {
     "auth_ref": [
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.",
        "label": "Revenue from External Customers by Products and Services [Table Text Block]",
        "terseLabel": "Summary of net revenue"
       }
      }
     },
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r27",
      "r42",
      "r43",
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r208",
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r137",
      "r139",
      "r140",
      "r147",
      "r148",
      "r159",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r169",
      "r170",
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "REVENUES"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/Revenues"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r94",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "verboseLabel": "Operating Segments"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingAndMarketingExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.",
        "label": "Selling and Marketing Expense",
        "terseLabel": "Selling, Marketing and other",
        "verboseLabel": "Selling and marketing"
       }
      }
     },
     "localname": "SellingAndMarketingExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsDissolutionPaymentsDetails",
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Restricted stock awards, vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Restricted stock granted in period, shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r206",
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Equity Award [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r57",
      "r102",
      "r103",
      "r104",
      "r106",
      "r112",
      "r114",
      "r129",
      "r177",
      "r195",
      "r196",
      "r214",
      "r215",
      "r216",
      "r230",
      "r231",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r343",
      "r344",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r102",
      "r103",
      "r104",
      "r129",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "auth_ref": [
      "r33",
      "r34",
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.",
        "label": "Stock Issued During Period, Shares, Acquisitions",
        "terseLabel": "Unvested restricted shares (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r33",
      "r34",
      "r195",
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Share-based compensation (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueAcquisitions": {
     "auth_ref": [
      "r57",
      "r195",
      "r196"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued pursuant to acquisitions during the period.",
        "label": "Stock Issued During Period, Value, Acquisitions",
        "terseLabel": "Vested common stock, value"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r33",
      "r34",
      "r196",
      "r207",
      "r212"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "verboseLabel": "Repurchase outstanding common shares"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount remaining of a stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount",
        "terseLabel": "Common shares left to repurchase"
       }
      }
     },
     "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "auth_ref": [
      "r33",
      "r34",
      "r195",
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Shares",
        "negatedLabel": "Repurchase of shares (in shares)",
        "terseLabel": "Repurchase of shares (in shares)"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodValue": {
     "auth_ref": [
      "r33",
      "r34",
      "r195",
      "r196"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Value",
        "negatedLabel": "Repurchase of common shares",
        "negatedTerseLabel": "Repurchase of shares, value"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r34",
      "r37",
      "r38",
      "r96",
      "r175",
      "r176",
      "r274"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total shareholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "verboseLabel": "Shareholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r96",
      "r102",
      "r103",
      "r104",
      "r106",
      "r112",
      "r176",
      "r177",
      "r196",
      "r214",
      "r215",
      "r216",
      "r230",
      "r231",
      "r257",
      "r258",
      "r267",
      "r274",
      "r276",
      "r277",
      "r281",
      "r344",
      "r345"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Balance, End of Period",
        "periodStartLabel": "Balance, Beginning of Period",
        "totalLabel": "Total equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "verboseLabel": "Equity:"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r95",
      "r196",
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "SHAREHOLDERS' EQUITY AND DEBT"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubleaseIncome": {
     "auth_ref": [
      "r291",
      "r295"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of sublease income excluding finance and operating lease expense.",
        "label": "Sublease Income",
        "terseLabel": "Sublease income"
       }
      }
     },
     "localname": "SubleaseIncome",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesRentExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r282",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r282",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r282",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment.",
        "label": "Unrealized Gain (Loss) on Investments",
        "negatedTerseLabel": "Gain on forgiveness of debt"
       }
      }
     },
     "localname": "UnrealizedGainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r135",
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "verboseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "auth_ref": [
      "r122"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.",
        "label": "Weighted Average Number Diluted Shares Outstanding Adjustment",
        "terseLabel": "Dilutive effect of other securities (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r116",
      "r122"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "totalLabel": "Weighted-average shares outstanding \u2013 diluted (in shares)",
        "verboseLabel": "- diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "verboseLabel": "Weighted-average shares outstanding"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r115",
      "r122"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average shares outstanding \u2013 basic (in shares)",
        "verboseLabel": "- basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 6
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8657-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8844-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8981-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "http://asc.fasb.org/topic&trid=2134510"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4647-111522"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=d3e1314-112600"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=d3e1336-112600"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109126253&loc=d3e4852-112606"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11374-113907"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121610041&loc=d3e36027-109320"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109227538&loc=d3e44648-109337"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121600890&loc=d3e2207-128464"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6405-128476"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6904-107765"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e7008-128479"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.E)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120398118&loc=d3e355146-122828"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918638-209977"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121576215&loc=SL77919396-209981"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(20))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(11))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04.4)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r351": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r352": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r353": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r354": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r355": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r356": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(d))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(13))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868656-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(14))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>67
<FILENAME>0001628280-21-023213-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-21-023213-xbrl.zip
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M?.\1#4E$IXQ(-N5L!FE71UR1=T(FQ'-K_R4B)/T\&3,9TS0@'R,J$^JSW Q
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M4\.]$)R!+H65R= '&@1<@2P&LQ2J@R<0=F06\R F.L>/9?T94ZQH! >0<"U
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MO!(N'(1/:KHU__#1SA9HO1S,S^^]MS8M/I#0 <[#*=,0,;!J5@O>#ZDJRM2
MYGKW*J@7QPS@4?3D%*C,%30 V6/*M<U)8,52VPX>MBRSV6I&5$Q0B[="@BXQ
M4RVR)19RR&S@BY:"A_8X6>=CS4-.%<<!<">4;8Y.L:5<HWBUX:FMTK493&H&
M#AG(F%@IH\@PN:"8>&%8UHFE"(8:3E*O[@3@VYBA(>1&J,_"+;GP6>!V_'1P
MZ]4[F[#=F:<VT+L[P^T,8@#^E(>(3:IE:M4,U8!KW'XA8*D*2_  G#D=<\'-
M'-76MFXQE"S.+(1<%*R9KFS?;,:X+@:4Y2H#"&NK#H, A)1UP&[D)BP%T2<
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MGN>QNJ:VKYNI?[0.'X;3"=[N;;,-"'?7.!<W?==LMZUOQ;]M^[E;Y1.,J)Y
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MCZDC8&15*3[Q.@*\*K2:>!T!T7#9QQ5L3_]A>:XNO]]E[^1=1*S<T)],#]:
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M&/:!JQ1_UB'@ON;XM8/-,ZR1O/\SW+T^N-Z9EP'B]UK"*:<"M/=<>?HPG,V
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MJ%M-K&Q2) ;*4$R:(VX=1T8DB72@W'*76#0YDA*Y'<Z<M<0I$R*+2#)*&YZ
M#=_(AE@*6$LH"L[E;86]0\9*(!Q<6!U(WJV4S*D-+WU!]LUJCO;7A=)E0<>\
M\(KOS &7:]H?"5"WNEM93TFBS""N+/R%.41$.7N;G+0,&\P]S3UYJ:G*B2TM
M6M <QW);\PPK.DIK?KPUC],-S(/UWNJB03[BVD7DDK<H$(,E$12$JXNB#@'V
M;":5T"SS%O>NY6@!QT9](-EE-<>L*88_@^<83 (/ Y]M!X-C\S/U-B]\ZSP/
M[##=^J[3S9^7^/0@?+K5!<L3$X6D##%O&81#(2%-L416^HAQHD+IE$L\%#=5
M3N=I;KC,:"P0WRA->QJF/4X]K*1>@ R1(R0@X"'9JO.,*D027',3F(S9M+6D
M5:4FM=OY'"4Z%J;LHRSWF&=:<L>4;PE-#X*F6ZVC%$N)2V,18UXA'AE'3H:(
M/&91>)>$9VKE)<=50WE5X$G5NI=U'DME]%.N\RB-_J%&/\Y'*/%<V,21<LZ!
MT9N$#/,"1>T]\!%!4_!Y.^*JT*9JR)-CC;+ 8U)]<CJGI\U^WLNW5^R?GHT0
M'CRV_8\(R\.:$OV\==[SD(&+7G.MW6S]M=+OGL>;QG_MQ=?;X=7UURXAX!X0
ML'^K9:1,C%&OD2#,(\X,0=KD)6XX<98$',H0<,OPYZ%KUB05]"&.JU30YU70
M&PVEF;'$LX BT09B9L9 035%RFI"K"?!6/I=!5WZ^?F\IWO_LNR1MK">?/?(
M=N-1IP6@UOOO_]*4J#\J\0E"G2#4/MLUIFJ5H?EY=.'A]U$^>8WHXH%FQ=XZ
M^:X=?U+(G/[Q(U?U+G8++9E(K+55?ST>;:7F10SH*G8[=[FR3GLW/V6]\\YV
M/]I6]G=ER/4 =W;2K[VZYLY>&7SP[R/L3S^V[9XYW\[/?+PO]D\WO]3VMK[4
M87P.]C;%P=[!Z?[>ZR,8A];!QA;;/]TY^O?5)OMD+'.>:8YT2,#6@@:B%K5$
MGI,HF(B2.O-CWO,=97I<MJY4ID56IJ @R-?4(:<E!NIO*=(N!42XHXDI(ZDA
M*R_;G3NXU8T/*F>V6_F<)?I'Y;O*U\MJUWL>O?M)RNB:\A7*WUL_[Q]UN@#9
MH53!F:E@[>(3\8I#H(F1"E8A+F3*Y?L6&2IU8I1I+? /\.Q.E9J07RQ5:C%5
M2C!"!94&N:AB;A((*I6[<,E$K2"&X"C 19)!*?F=Y>2WX6V@9Q7[5<0+ G-;
MO=YYJ8\SU,</5Y^D(P8[RU 4BN:.+10YJRQR3*7@;4B.B(="W(S4:?N\W^O;
M=HZA2IV:I4XY)Y6U3B-B@D9<R8"T(1)%@E5BQ QTBO JN,\J@.$]("[/(BR$
MGRTQ;<;ZM__E$_<2 H>\/:=BH'\D*F2U<$A("T"43 SXP9@V(W4J,6U.=$H'
M;JRP#GDN"]YFD>5)(PU2%RY8;(K&J;QJM*YR>KL Y;NTK5D@1H%PG6_2KMA>
M7AB_&\_Z\=3%;H7A:B6[S>+$C>B'GY+B4S@&ESJ+<.7/L77Y-34;FI_+A3*S
M*?ZZ9LIE,NE1YCL^$VR\#, 7" J*<,29D$@KGW=NI3S($#R/:>4EUU5):-6P
M<J';$MOO-.JX2OM]JOW>6$8OC=,Q4908EHAK:9&)DB&+I1&***&Y*HJY""40
M%"SAPK8%Z%:\$_L6/@R5:+MM>/1>Y;<04],W^[__8BO<?IL&G>C!:_ZU@AZ$
M2R,1;0XEM.[]^>EYR_9CV!B(JD2JAR#5U>TFQHX()PU#G@F#N(?PT6F5D" D
M"I$LB9EID*HRN KRO054MTRE7-RVB%;]:))16O5\6/4X_Q!!ZD@<1\0K@;AA
M!%E&&=(QPS<C(E((X&F5L+QAPIQ8]:^VKJWWW7*S<IG;W&8ZBAAI*+1!P6>)
M50_"JEM=C;V(S$H*>LR,1MQ!U.1"SCBF%)57(6&3<QVRJBFM8O;DE;CE:K=E
MM/UI9$E*VW^Z[8_S%&\X!AOW*.;:-TXM1=89^-5204W@."93V+Z!\$.0)[<;
M+!>]3<@R<PLL.*G;:;7R_$T3++$;>_U?K370W"9.:LUVIPL M3443 E4#P*J
M6[V-O0U&X2015S$B[KE"3GJ#(,PRENF '<UI$B6J2M[>2+),DBR%!4\U25):
M\%,M>)QJD&@Y332B0$/>/U)#F,&30!;HA]/>Q6!S+2I154)N%VF5"9$I)$3*
MY,?")3^VVL/F9,.N9.O]?K?ISOO6M6*C,\X22R1[%)+=:H',*<.*.X^HS9U"
M-,L= IQ%B3@0=(I!BE $31+^4#FIXI R8;)4>#&;A$F)%]/ BQM-EF/4,5"#
M%%> %\01I$6T2-&8\J923%L_2+ J5F6&+PI>3+)291'HT;4^B$5=[-UTZ9Y-
M6P9#N<;@_4/G'*SOJVB>AHEW#=Q,(?%_SW" EL993+F!Y'H[E+GV)[J!6[VL
ML75"0*2+I"ZV]I$.Z0"AL $O(&6@R:6X\E*KJE"XJM23W<#$S6G&B; 26$M@
M74@67@+KI('UY@[REBD3<^MP \"J/4%.68PH=2F91(B,=.6ED54N@5\_?5>B
MN0'6@H"_*&*WT?*K:QV>3FWWL-DN;F]FT=Z)%BV]8JQ8[SNG<._+/%-9[_3A
MZOU.Y4/;0B#:CZ'RJM,.L=T;_%2,4JY$K+QNMFW;-X%X[_;A@Z*-X&IE?+79
MM=<=WI8+>*ZS3J^9);O6C2V;5ZG]\:49^D<C>+CVK:'T\+>O6 >/<-[__E=@
M*#P".67M6>N=G\(X7UX7G(\Y;I[1>),;J_&N_9U?H8 7';4+SI#@M>&4<6>"
M5I$H2[03/(5/)/=-&GSIJ/NM8=AA1*X;[0G8&;S@FFU]L9>]E1?C2@<:=UT2
MWQO$H7(.AU_"F=?4E="O^OKR3]>%.]SQ4O,G$76G1%Y]J/V]N?-VO;Y1>?>O
M]9W:^JO-#XVM5^MO=RM;]5>KE7Q@]\/?NUL;6^L[6YN[WU7PN7FAN\WUFY'F
MI:3#G;O@A+E_G]^^(M'O#WK6 G>_X4B!]?#,+7O6BVNC'_X(S=Y9RUZN-=O%
MG8LO_3&N_=E.;J8Z\OT&A[^9T"H>F-$PY3*\\_#P:G'HAN\:'.-RU1CSW<-X
ME7SWV(\N2\@JH_)1E_WQ,<&^?]/R8>?Q81F[UV5_DC#\Z82"N77J'7':P#YG
M%(_<0IA!^O"H"S3H%,X[ZE4BH&<87VI_C^:F2SLV=?CDOD/S5/VYEGQX #6?
MU0#J>XU?SOO=ISGN0UJ%_RH#AR=A>$LZ-J52342IEK\0.?8KW?@YML]O;[9Q
MSPS*KYZ0_97RK<*GD)*37EO.";%&1"Z,=-@%0YSRGS:*B2R%"7KZC-;.0"]?
M=SNG>?.)_'A[S?[1J_,>C%7L?MW8<;W7B_#_T+ 7<Y.+W=X=Y6+_.:Y?'5[4
M&IL7]6,X?O6>'YS6>'UC_;*V5V_N[VU>U6B-U3?^/OJ:BSW]> *?PS-\H-N-
MCR<'&SM']<8F/]C[IUEK>'SPY@.O7;V_V#_]V+R9BSW8@]\;F^R@L2_J>SLG
M]3>;!)ZKM7^Z=5&_VCDY:!Q>U3=>-^%:J=8<Y&%KNUC4&Q_X)YFX%(I;Q%4B
MB.>FHSJW4B8D"")C2"*DE9>ZBA6M"O[DU20/-:/%F, JX?#7@<-(%:7><(.Q
MYTEJ%TT(G$O)E-.,ZP(.\0@.<0F'<PZ'5V-PJ#1A>7D=XEHQQ#FVR$J5$)%)
M1(T%X52OO#15*G!5ZB=O(UG"80F'BPV',D62.%!"J8 >VN P_''&2V%EDHD.
MV2$IV>%BP"$9@T.=HG8D4J0"CH")@0,[I!Y9YYWCBBGA/(30JBJEJ!(]J2V_
M2SPL\7">7OP!>)@2<$-I).'1<L&3ULIJI60P3+O$_) >DI(>+@8>LC$\=!0K
MYVU>#2 @9,X;CUJF$W(0*WM)/=8$%WA(E*G*.S;GF%,\O.<TS=RG-E]U>L,M
MA>/%6:YXZ-UG&\('Y+U_I5-_G;:F66UR"<Q9MQ/./6@06%CXQ?IRS&M&.,MF
M.[WI=$)1BAN[GYL^]G9!0*4K>X KJ[^ZD?AEV#IFM$%6:8XX41AID!5*W$7!
MF&.*RMS%E%%=Q?1V@X['>;(Y(N^E/<\DI5G:\Z3L>3QS23PE3BB.(@NYW4Z$
M*#T(A7A2%#,+XF6IZ%_*:56S264N2WN>0WN>:DZNM.=)V?-XZHTZ<,=2.,28
M(8CC%)'5.,%/5B1BE/8DKKP45:YE%4]LA4QISW-HSU/-*97V/"E['D\=1>RP
MQ(PAYCA&G :.3,0&F6!I8%*!:,&>995I!?8\J4SZ])-#"Q#N[\9!"\Z<)SJU
MW9/8A]_N$>XO-\I,-:H?B@ 0IC82P.8@8U>BS$-09O=&5!\$#509A:RQ$-53
MEI#F1B- 'R\)XQ#8\Y67K*HQKE*M'X8RST<.'L !EML(IQJ*ET8X*2,<#\43
M,SI03A"A8(G<<H.TUPQYG(*5.G@:939" :Y>\P>Z^M((ERM^+HUP4D8X'C^3
M2&AR3J'D7=ZX/AEDB50H<AP5YLX'EC<9)U6%397S!P;0I14N5]1;6N&DK' \
MZA6*80A$%1*,>\2SL(RD"8%$K7#6*$%]885@:U5#']A!:]Y:(LYWV+L3>]%V
M_5$1]X;X.;8Z9[G[0SG1/1<A\4@\@$$;WX13HM C4.CF(B<LM%1Y1S_&<AFK
MI! ? TE' B(KBF60AI \U\T%RQU=YRCW5N;2%SG +DUZ@B8]'F/3:*@"ZHZ4
M-6#2PE-D%'$HQN @^)9)^Y!-FC)<9:R<'EMBDY[R$I32I"=FTN,1._.YIQVE
MB/F<-F,0NSL2+-).8VIP4 G;E9>\BA6I2O; W'5ITHMDTE->15&:],1,>CS\
M5U@9S5-"6%&)N/$&N1@98LDI03RF@;!LTDS!'U-.>C^C];V)[=BUK2+XM^&T
MV6[V^MVBTVHY\SW-,'\H!P";]3$IE'CS"+RYO!'H*PL28]8@&2V#J$ %9)GT
MB&AFB?,L"1QS$2QFIJK, XM@RYS_<D7GI25.U!+'XW,?"-'61N2YH>#YE4+&
M<882EBXFCCFQ,ELBTQ"C/S3E5EKB<@75I25.U!+'PVH!EB8#R<P[[^*J*48&
M@FO$>3"8IB!T4$7AJ515_M"PNK3$Y8J%2TN<J"6.1\,T1)"<#8A%8Q&P&@KL
M%,PQ<">H5F"(V2?*JL2ZRG([UW(N_+GL;_TT;Z9Y5>QW4,Y_ST5@?%TDVVFK
MW;?MPZ9KQ=R\I-\KD><!R+-]<[&WB2'X0"/21$O$K79(L^ 1R#4P'ZQSM)@M
MPX15#2]3ZTMLTU,-L4N;GJ1-CT?85N-!_"6Q!YM6WB/G<4!$.F\(5\'HE&V:
M$%7%6I8VO;PV/=5@O;3I2=KT>*SN8[+@IA4RP+L@0D\!N> C"BE*+$/B7)"\
M<H0)#C8]J?9BI4W/H4U/->PO;7J2-CT>]6?!">(D<M)%Q)/!R#'J4+02BQBM
M 9EDFZ::5R69)YM>EJZ C4[?MN -;O8&O$_@_Z0.K@L-0%/O\I;[30SSC"7D
M/ AR;JX"-YYZ)7Q>:R,YXI)!:*!B7@J>N%)4)9O+;DQ5,E$U#RZ.G4USYH<P
MAE_7:*?>RJTTVL<;[=6-AHP),R$28M8%B.>=04YCCA+EC )/ .#-2^5P%5"X
MRE1IM<MCM5-OV%9:[>.M=CQB-\0[IX( 8D\A8I>:(H.)1,Q$'.'_C&D%[!Y7
MC=95B.%+JUT:JYUZ6[;2:A]OM>,Q.<&>DJ@=<D[XG#L'JDR50TSA '09>!.U
M8+6DJHFH4O[0;JDS;M>_^%N4;I_%7'?2/JPTV[YS&BN_M3J]WN]/F:E?-J#Z
M;:JA? _>]Z\5]"#(^BK$K4*&;T&")6H]9/>1QGI&K"*TWVY\(-OKGVP$X>G<
MQ88)C#BS$-BG*!!Q$4+Z9)*1,<_Y"<FJS-P.$6Y9T,QW'IG!O,&OC 1/SP^4
M2# C)+B\@01!.VX,!!J20=SA,=)12Q2EXL'Y) @6Q?IW#&''';/_)1+\XDCP
M])Q#B02S08+Z."?(R^*%E )A0/"<AK#(>>J0"<(2;26C'A<U Y15^1T=MDHD
M^,61X.EYC!()9H0$XYR :A&%5";O_D(1QU0CY[A "B*]"+^:*%->;9^G_>0=
M28WY0X)EJ4#8 G/KQEY_F,XH5]Q/L[9@J_T9AC[W]!A S4@8_X^]-UUNXTC:
MA6\%P7/B.YZ(3DTM69L]P0AJL5\Z3,J6*"ND/Q.U2I"XZ 5 6]35?U5-4")
M4B8(D&@ Y1E))-;NSGZ>W#,KW<Q$-\^F@Q%.&9_O* %!F6QX,!L@JPX*/ J;
M4K3<H=_:5@TW2QCK69L*NU,G4 &X* !.ZGO.%47.%%"5LM+GQ?)W00$14;G@
M)'?2;6U3UA!2$=@U!#YHSK\B<$$(G/*]H_"Z=.]F!)82 (\6M%4)6)),68$L
M$I41:)ILY%0$=@R!#YJ_KPA<% (G=6 &%BE6#"0N**"A60=:1\%QXDP*5#".
MV0@EC1!+&#*S_HGZT?LXN+U7NZ&]/(MU=U/_<PSP)0Y.KL34BC3.^:7RRDR\
MLCOMW(:@19+9F.96$\AW0  GJ89$!'4:-7=&;F4"T8RRGSK4LU/[\#KM*5?L
MW@MV)VT"$XA).DH(RB-@0@*6601'%0T9U93Q6+&[ =A]4!^[ OCN )YRJTG$
M%*36X W-RM=Y#5;J!,9I3S(78U3M\$BJ54.Q2RVS%<*==M*K^KT7]$ZJ7R&L
M8=PQ\%9GE]R1"%:S"#'?PM'$X+UG752_:Y=L'O>YKV>V^6'KWV>*])U?_CHR
M\RYLLC?MB$N5M##, 2%.9$><(UC.'40?F$FH8S(BVP*D(==,S+RIHJ5&UU>A
MU+R"[N% -ZG":0B!&^I!:UO*R6@"YR(ITVLB8]*BXUF%*]&P:P;65-"M<E5W
M!=V#@6[*ZY5",IXL@E34 G(OP(4H0.?'HW%H!!5M*HL954'7(= ]<"*Y@FXN
MT$UJ.N>%XU(@H"Z3D1E)V;Q46#:*>B,U6E8ZP1E3C>(/J^HV9QC[[N4>[UX:
MG!RU^.H?GY8.\)/S1H&3XV'/Q0R4>-$3/K*?;S?#K39]=*4E_%NOQ\]9RD^^
M"OGY5QD_;D5\_KJ#(N!GGT<#FP75/[:#L]U1/!KNGQR74QF<'!ZV[2.UD.8.
M1/C'M)]-O#**"@U6$0UHO00=N +")/.!A""3;5O+E<RN]M55C=UK'JEM9"OF
M[U=&67%&F6I'$])$2REH1;-!%:0'9Q-"-#0D)H3S2K<MZHHV^IKEKY51-IQ1
MEM.B7AFE.XPR%2$141HEC /&:0"D7F5&H0:$D.B#C-1'TJZ\*'4!ZO;N6F64
M#6&4Y;2Z5T;I$*-,VBC:H6!,$3#M&!W--62&$6!8IA)G(RK)2LN\,JS1;!7&
MZ*Q/%<-%D*?WP[B0X5\]%X]CZH]J1<,#5S2,>6D<<WY\+H7*/3-QSZLK_?-:
M&JY$ ,E- E0"P;K$@%##2.+"F*!+_SR*JPOY:KIGE0,=%7L/C[VI\7E64V>"
M@Z1,2?L$4Q9B:O"2Q$28)[SD6GFC6,5>E[#WP/4-%7N+P-Z4%\])2J0LIN$*
M=1E3E4!+3<&FH%5RL2RO*2G7:Y=<5/"MLO=<P??PX)N>&2."]]G#C<G:;'2J
M ,9) <$P21TA*$)Q>$6#[&J_?"UW6 3D]N-H<JS]=TH>:GG#>I4WY%<<GI8+
M_WM9N'ERO#,:#?KN=&3=83PXJ3&^!5#>FVD_FTLAG=06(E>^;,/CH$.V]2TA
M/*; (S?G0_,U;_":I;K=B_'5K,&*.?R53%:73";MI^BE%B0PB)HJ0$<1#&H%
M*?%H*(GH#3TO:A"-9)5,*IFL2%%#)9,'().I2 AZB2ZE ,ZJ3";4EII+JD%0
ME_(-P;W&\1(/TPBLZWPJF:Q(/4,EDX<@DZE2!I&<<%$!L3:6L"H!$RP'$YGP
MAE"1I"VE#)KK:U<:=H],UJ64X6E_. [NQ#!;;&<%Z6L6O\H)K22)5J-!PJEQ
M7*!A/M!L22LN%EK$\"+^%;, +ABK'-[K_NC]D]-AOE9Q\.SSF+%VAL.8_Q\.
M[.?*2#,QDI\.O&B9!>N" >,YEB2K!XM.9F%*&I6RB2F7&<G(1NFK':UU//*2
M)R]YJY))ELA LV4AK&#>!4VMIRH[P'ZA90X5G0^ SDE[@:2H@],(CBD&Z$WI
M?"49IQFL/BA'T?*M;:548^B,:\LK.N\=G2A<2#8KS! 4!DFLUS)YPK@S1#O%
M%UH(4=%Y_^B<"@UDFLT8E!0H"1PP")71Z1R$C%:;37)E4MOJ@(;6]1X=Q*?3
M7FO"HF1.H374H""6>DFH<LZJN-!:B8K/!\#GE+>-U.ED!2C&LK=M0@1-1 (9
MJ;/&D&SXIC*BE//L<2]C^<<&UU/<2]'$NH<2EU,Q\?O@)/5'=?GGS(3T;MK9
M3DD3G20IDY)-=K;+#I0R1RIPJ;DK(\\C%H.!:-E(<_O:KCF1L@Z)A'6'_G+J
M&RKT[P[]J1U(@I@D703',0"Z\I/&"#X["X:7V#\U)<ZF&G6-IU"!OU; [VHS
M187[G>$^%1JPD:&244,FZ]*S[#EH1CD(SR@S1H3@LJ9GFC;9@%O0?/6*^2YC
MOOLE Q7]=T?_5 .'E0Q9&:@4HP>TPH%AI;C9*6NTIE&C*X$'07B#_/;=BTN"
M_KKD^$L0XH?S*,2_>B4*T;/Y6IVZ83_T[> L__:M J8W.ND=3]3 ]/KC(IA:
M%+"<.$06W[>JIEJMM' :^S@=KC#"21J2AV#:TD<JP*"7(#"20&P2UF2?A6<;
MAEZM>ZS)C57?B5@QVDF,3@UPI)@9%P7(R#5D4Y&"$<8#5T):JCT*7W*0HC&R
MEN]T#:/+Z3.H&+UOC$X% WPDEC+/(6,RZU&!V1W@/@(70C,6C0[1;FT+W4BQ
MA"1DQ6@'??&*T7O'Z*0>350YGY("DMIA0\IDC-*,4<:YC(X2CF%K&U6CR1(*
M[3:X4."*5YZ?.\J0';ZW@_C^Y##$P16'_'[;D:Z[8$MEL_][?^??;1KO?NW$
M!(]7CIZ%HS_L7.E5B$Q$$34879(JF")DSHZ@O),V9AM:GH^6)D(T3-UG6+5C
M297*=Y7O.AC_J7PW*]]-U8R$)%1,.K-<Z?X(J,"H(, 2P87UF>T"9IM4TT;Q
MVV\;K&Q7V6XEV*ZK53*5X^;AN.EU(=XQX:4#$;*WC3Q2L&7FKV)222IY<C[[
MW1Q)0Z]98[S@0IE*=)7H.F[6=2 <62EO5LJ;"C4J&Q,Z#S*I &BH VUY NHE
MY2*K+Y]*;6"#V8V5?!5VKJU+@= S.SC.!SJ\"#U^BH/S..-=@I#7:8!O@N#Y
M4H>3T_)QTY*X,>4R0W:F?N<MOG-SHNK0^S8!ZO*R9N@Y.^S[60EE VR+=3$?
M?H^#EX6D%AL-9Y?,B%GGCN4C>EQNNO%A55MB!EMB=SHD[GF,RMH$W(K24>@#
M&"06M.18 D:,"K&U31Y=XSO-;$:LD&=4":I+YW87@IHS?%T):FD$-36+V=A2
M]23!*L,!H^-0AB "01U<$I*1,MB=/"(+2-=5@JH$]6 $-6?(N1+4L@AJ*@"=
MY<8,!@Y4.0HHL[PLEQ(P19,8]>A*44$EJ$I0*T90<T:**T$MC: F+2@?K'"!
M,* B9H)2W(.FS(/*QK!(EJ98*E/)(WZU=GPI!#5;,'@E@F<W#(>^*7RV_C7R
M]Q95^A[37);"-Z[9CZ/GZ<!^KIQS=\[9N[*.2R7N%.?@2FP)M1;@$N'@N<C_
M&&^EHJU1='5&5>U7Z086YP^@5"PN"8N3^M]99T+4'H0A)F.QH-(("S+?&EI+
M*P1K]3^I/=A=Q>+\L8**Q>5@<2I88)B.DDL%)#*2;?'DP5BK@$J!U'BG:'0W
MI%LJ%KN!Q?G=XHK%)6%Q4B]:$5P*.D"P.OO%@44PQG&0W$3&0C9LRI;LC,4E
MZ,5Y*TL65@FZ"7&\6YY\MYFL4T4<%W5P%]_;DE;EJYGXZH\KPY^M#2)1!3R5
M22T&!1@=+ B1'6KFHL"Q'7^?K3RKE(*HI+:)I'9OA1^5U!9":E,K-J3+<C$<
M6)EO@Z'LR<W.+OC )0O9O[5*WQ HK*1626T52:T#\9]*98N@LNF1W51*IX,$
MU,P EC']64X(2(/W)%+KI&JI[&I'SAK/ZZY\MNY\UJG:DLIL"V&V22/-:.,=
MIPA4R0AH90!#N /EHZ+11*4HMI&RJY/-.F:DC>-J%T=Q<1^+EK+F;B&K+ZUM
M<C>TR87^X>DHAMHHMVE5E,MME'MZ?MO5?-'L6O#-=/R5"4&I(A$\*@W8=LD1
M98%'[[GQQ.MH:JM<I:B5HZCEMLI5BIJ'HJ::Y83(PJ,!"%4),&4;75,F@"C-
MA5 Q>,]J+TJEJ)6CJ.4VRU6*FH.BIJ*D,4AC A*@):" GG)PP0DP*9FD/6KJ
M=:6H2E$K1U'+;9>K%#4/14U:45(X5-82X%(RR.(T8(+5X)F3QG)F-6>U86Y)
M#7,W!-(VMAQYR2USE7?NS#O^RKI$)47B-@%C(GMO1GHP*D8P#&DRF@@Z]MYJ
MTUQ7T;CDIKF*QGG0.&D%4)$\M<&"TR8"$DG!2J.!,QE]PDR[CM>VN4ZC<<EM
M<Q6-<Z!Q>LH.9A-:*0&4EE46,CAP$@-(SPFES@HJ0VV<ZS0:E]PX5]$X#QHG
M=2.7#!.S$K(IX]H"1[">62!)BX08#9-86^<V(*:WL06,#]8Z-Z:MRE.WX*EW
MTQXU45$*9C40+S)/*:? >&ZS$4$UZBR.R&1MF:MDMN%D]F M<Y7,9B*SJ;4O
M47,B48!U.KM VB;0(G) (9T(WGG!0VV5JV2V1F36@9A/I;!Y*&QZ61^-5IE
M@"L;($L'04?%03AC, :M/-.U1:[RV+KQ6*?J22JCS<5HDT89X425>A PUD5
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M1_:D69N%F4),*@NKC!+REF:+EG*0D=/D Y(4V#FRL9%Z[F1 1Q.7W;9%V@Y
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M3N^@6C44:^!CA8"\-#LC]3_' %_BX*1"^%X@/&E;((E!J: A18^ %,N.'"*
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M>D(L(9ADL2/*_"?J;Z3&VHZQ*AQ)IU9SH\> #K30#% 3#]:E #%X3)X[X<H
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M-J"ZC/#<RQA[UI>QP/;X+)]0;_]DE#]]=-)[=6Q/0W\40^_)R7&(Q\/SG]K
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M:G4&3$Z7JX*FTR>884:^4QIJ%0RM/+:K+I]<\0RT)2S6%1>Z#":#%-O--<;
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M)6KP3CE:?G Z7?3!:'PRZ,]\B).CLQ'8+=.?6HU:&G)@=;ID,$ 0P62G-\'
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M%XO<BUPC2@&0+6"-L72C-:OEM)5,HL*8<AT-M?"OM<*:U+E<4F]=B(4,&ZT
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MG6NFG8$IHH#62F<%UT8K)Q6-BFNK"V$5:7SIQZ6=B[YT9(4-GF$D)=6(AQ#
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M3@:C'$A_-@S=O!'YQVGIQT?31)2Y;]7CP!=?,78TZ$[&UW_E2DXR-^HJ3O5
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M(GHNG<Z5(2A*"2JBQ8CC5%K:&YX:)7)XBVA+R<9SVL94M0E7CQ\]%W/V?B
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M&[^W8C"Y-=3XR*3O= >G=4!TBGX)LT.WNV3^X<.]ZD(GP](EW]1T!]E,@#K
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M>4K#$8_A;^2C0D64XTIOZ3R%.2[Z3N^N8JZS##[A<.QS L(0XOA]Q5!/0K*
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MNUJ>M89<ZM:T1)VIMORJ3TK.X?EGG[EQD%D.&MBAX?H1\*LP,8T@M.S(!)W
MM;#Y]:*9UJ>EZ5@:8&@=U9FD#\Q)XM6$41"U$#Q)^,J:>"!EMUT@2GC65X9V
MM%WT*R0WDLAM'(%X8UX)[QHFH='7>4[Q-U"OI^32(#/C! TI^, %+]!W1K+[
MC!7G.1(]T H:+7,W[6Q(,LFUVF\N.Q9I%->6>[=$$X8%C:G& 6[Y</#F^$0;
M#Z>U$#S=-]1@ [-4B"V,-PL5.)5X\0M&35]C6OXRI(B5#*>@(.Y\FH;C.)89
M>H[G.*X=\=B,4S/EKIV$20Q$+5WXH>4:ZH<?49&0B%J?T!O$K#^ED1\7?[(J
M1]X)U,/;1$?#?F'\YNCM'_;A[F?+2>+ \TV# ><W7!YAKBQH1YGE^[X71A:S
M&>;*+@%__"<>X]M101!Z 4NXZ::IY;(DC8 $PCA+L\1UN<W2+14\ 14<G7_V
M0-C[B<6,T'9CPTT]UXAB!S1C9GNF%YIA@,TY[>54P&+@P)(#B0P6#7UIJ+*(
M7]Z:63#3]UF8^6%B)VYLQW&8VDX6.;[EL\QU_2V9/#J9?+H\^OUS:EI.$)F9
M$8->*\*_,:RIX4:!XT>9:X8A*"3F3K2HDOQ3R)^VN<B<7&D%T@J?S^THR$Q0
MO4V<P$I"%WA9[+N)G]HFSYP,*Z"7I]?_&.&H3H-(*Z?H&4X_\@H=-^R<OVC2
M<0Y__XR&MQ]CVGS 0<Z '  B H4VC;+4Y!X"VP#I.#O^4@ZSK/IB1\/"965.
MZ\!U,LYOSVM %S$#RW1X$'MNZD<L,RW@,2#YHLR,@ON.<RTSC/XHIACWDA80
MZ,NC?(($]8[S+0513=?ET>YG%C/3C.+8"!S/ I;#0R/.6&B \NA[4>K:EA\B
M\[&74= 8" >=GZ@T)P-0_H7:C/QF2JNO47,C-(IH:XBX)']"FVC^1B0U2L5G
M,V)F_YVR"FZG6J%G8(;LDF=[1<)8DQ_J6,M<YP-VR]*YP([\R.%A%":N;UEA
MS%F21' D(S,&]70YJ[YEQ=R'LC@_X]6H>_Q>L*NA4^3T?1\E.\\\+_0XZ%.6
M#^S9LVPP US@UJ!=>7'@NSY',\"[JF82;/G&?0[T,YW4$R"7UMK$E->J"7>(
M<Z9ED@?.Y;^BQ"?/Q CT!?+3-UZ)%6Z +"_@OIP-6Z\!6T'%S^.,OFG7NE6>
M^ER,6!2UJ9I@H)L:Q<4S[,6%6S/)*:4)_J#H];3"R@P^F8]>+\>EVT*I=:'4
MK$V$4EL*-G4M>-0<V%3(31/L,B<-6>)&+(I,X!1>"M9;PA(_=)8.^BF"SK=,
M=OC(9LF )U^UCU4YX4*(R0):"K9O8OK#[KC*AYK=9'EWJBTPP@PG5B@ZV52P
M;0QN:T-,0\BJ<C07#Y>9,8P"0'CK;61^F)D\L;PL"4#7CEC";#NU F;[EFOS
MR%/E\JYM&NJ'VY=!4R "A,I>694%N\BK:;V;IR=\F/-LMTCW843E*$]D2=9L
M-YG@QJKBK1.Y(B\V8>SH;-<\WOULI<QR(LZ,+/!\P^7H)/+]"'4$/TMCEWD!
MJ-VV;H6!;KE+U(-N"2K9]U><K-=X R+GV>8O'S]^I)^L7W[JNJMY2CE;G4W5
M8%=U3>RKR/506ZOJ6V=4U/KZU=[NR?XI_OSJIVY=$V@+E  L"W=E0HC42& 8
M:#2H_##* 9$UK7_LG.YHIR,4H&^F-9RX&L;2R2.#B;U^=?IF]]5/-TVM6!]V
M\7%^UV 99/A&QG8$8YABN@DU\R3CJ!O8 =NH MU#;RNX$(%WK TX&X(NEZ!R
M$O."9_E$UFO!$Q1U("PQ2J&9R,[HW5(G6(V4P^[N:'])AQ(7F=54.$_#(OE*
M7\BFE+:-D2H@''B%+C1)5'=BX&/"=@': 9V2%%%0G7)X.&<XES%#5-]\C!XJ
M8GAM9;X8<<JQS2[!*8BTQ0Y/'6'VXJ"L>?-*&K&J/!-)0C+:@GE%@J7)TED<
MGUQ NJ^D(!F8F4.@"?R:S%"DI",U"C['DG'3Q YA[@&L%"WO]8&RM:/&/YKS
MCQ-MJLAA?GH3Q133;JX1'8R H&+*[#D'7EY@02!<FY%>3/2*9+-L4:G:L89]
MBVEKA(&KN,=.=Y<%V<L3TCD3^&:JS5SR^AWMK:AG!(4[1U4<[!L2L;CKZCU]
MJUH5! X99LUF&!'-IM60\KCP>J?< ?-<*UY/AY,&%>#XSX.WAA6U1V?C**"S
MXGPH&US#^B4)T;HX_80]1\*[1P2T(.?8(+L@;[(HQQ B1:W#>BB=Y'(JF$P/
MVA630\(Y14L:H2%L$T3*P>XI_( RK',++L'[=I*=<L<6 AB7I7//;D-].P^]
M$-<&O<?(P":"*[)A>5Z"7)^*U"E-S!<]"O@L[N:H3/FPV7767X7.5K?GJ]O\
M7+ #\MLA@<!QW&W/S#R48(( \>*$;S7<9Z;A?OG=PZB6SVS+YIEANUYHN([O
M&Z$5A(;IA'X<6*YOIE=KN,1@4I[Q2B0(4X/S8<Z$0M'5-%M$@85B!"'@%9"J
M>IIRC*^L05!YK/6 @[X!&LB">W8#Y?U!)U=_WE2MI['B%$VRI>($>)PE\';=
M2'U0RW<T,'__/04%R;*6I?XWYB\3QVZ(LC974IFP$=[L"@5/&,BHE35J5B-I
M+EG[U7Z:J&11C:+*NZ/KJ#/B/4(V2;8GS?,M&WJ^;.CK]^/[84."B0@.=",=
M;\U+COY=@BVI_0D<$;67%;5'5SJH;S+7I8[0:QV;\X[0R$[CS([2*(L([L#R
M L93TW823#>/GHZ3RG*8!4;:KVA90)WY*R]^$Y;Z08%E?** Z104*#8N*_Z3
M]@%;>56<&I^NF2+]UV][VIN\' \8,*^$3ZDU3ZUK'R>@ZL*X&P):()VGV*,5
M!'@M00D1\X7.R(4X([K0+(8YB$B*53/EU1""2*'@E,F4% N6H$N'W"(IO^##
M<DP_5P2;)/TEHGIJ-.(5AM?R[[C=\F:BB1K3$^;NDK^,%_: Y-_>("^8KOV&
MF$?_P3]:#\=NG9/=CM ^M73!M839RTW-0>SAI_*6/$E<MX2;J\+3:B2<V;<1
MG4'F\-AAOI4&MAM;<.1A#X*,>V8<^UXD$#I-,^SCT]\R+MT>K?J@V,TRV"S0
MZNK3:5SG:<ZPQFQ7P:75($N)(4I^^'(AQ(Z^_SX#Q=UF9NK%EF<XW/8,-PYM
M@[FN;5AI&/DVG!H6<,H(N29!GE,).>U^E<?3B0( IN3GY3368:,_1&26R;&5
M(Q:,^&X0\-A/,RL#J6-E(2AC[%Z(K)^F]@X.XPLOVSGZ_L?ET>5GTPZ 4#)F
M.$$"](-@T3'LAQ&:-N<\BTS;8S>A']A1:O^&#@6P&WC7XLM$44/'?9WE%4AC
MF3#404WK\7'!IFO.OW8+QK(I74MDX@-18N>R(%)$%D&Z'+ Y\%#^#8S/&JO;
M1=5^%SX4+H-DE27O$SY$%]L47@D,=PQ3FXEOQ<"CNZ3_<8ZW$Q(:7NC<LP\2
MX1SG?L:300$2]1PA^A8EK[8L*>.&W>^B9=WO-JH]6/#@[<%$@\HS]FW].H(=
MGZIFE0>7G\[^'AZ^W;>/OO\[/WY[,C@$EO#WVS?#3Z._\\/1OG=T]M4]_)ZX
M\\?_\,N;P='HC\O#,QCYZ, ]>K\_^S0"5O#^S_SOT<'LT]E7"]C']Z/O S"X
M#IW/C&>IZ:386]<R#=>T$R.R.:(\!U$61/!?9B]TUHI W,#29U$0N3RR(\L$
MB\"-S=!WDB!(YON!'1SM'1_N:V>[___^Z=6-OS8R VE%!LFUB]1?U,CD4>IA
MG4GBN ZWXL@-6!I$MA_$-EB^J[,1Y_,.ZQ_ 8T]L#S[O6HG'3!+$:9@$?I0X
MG$6AYWGWDH5X+!!"BO,/95WOL:J:P<,(8K,^JMSCG\6#SP[R,Q;&1NIA\F%@
M8Z]KTX=#Z2>F&]E)D&:O?O7\*P#[40O+9&I P2<*BP7$#K"Z&B/![5IW(@$_
M@-^?)4X<.Z"M^9X;)E&8,/@_[KI>&@%;8?>!W[\EEP5RH2YJIN]DJ6-Z!F/(
MNGEL&C&/+(-GB>TXB>?#N7WUJ^ON+ &-ZT#R7TLG(B!$$2/E!N;?T+X5<2EX
MKXCMY@UXG(1#4KCIA'8[R%$G0P5IB,%H7C29$@BC#D\GC*!QRRQ#O",9/IBP
M;UH9 Y-G[1L;5H=QY 2TMGPB],0N1"[F4%#Y%2F$ZEUM!D63QAWS65FD>H,&
M(F,,@C.+S(OO3)4*3V@^UZV83BX%!+QEWV2-#PU  "V1]UM%N3M@2=JRELB+
MWJ3%%LX9_>^7IQ5WUXNOI9#("!*<L(G ]D4@YTYSOPX)*!RJUS)1AN""4M#@
MFHWJH4XM*-5W5:D]>^-5ZO#!5>H]S*R.2P$9UH&J6SL-VSK,FW;PWSZ='<Z.
MON\Z1V>_7P*;'AY]3_-#^\_1W]@J_J]/P,;?# [AF_-L^OCLW>#P^X%S^#:Q
MCM[N IO^PSFR#[[__=??H^.SP>!O8..'[_>__WWV#BL,9D?GG_W8#ACS@$<S
M&Q1M*PN-.'0\ W3K- PCT[+]!1T[Y7Z6L<!-L]AW69;$&7!U9L6.Q0)0R()Y
M'7OO^,.'W3?')[MG!W_N:[OO3_;W#_>/SAY:WU[*"ZX=^Y/GSF F(V6U26AZ
MT8XDZ1*RQEI*KD4H #'T*#<R+V#^DVF#^0<S+G!!1"H;I@Q2#LXHKU% ]%V_
M>"&=)A,0&45*P6LIU52ZL8R,MBTD:P'@!Z*L@D5I4^64Q%*YH->D8)Z^.3CY
MU^G9V<E/'3^SQ&0EL;6(Z-,DU*5-T+?F\\O4>$_TMCB%?TOXN",TYYX9"^#*
M-MY,I1)"&SCA:7Y6\6\Z" D2$2/.1;BYR4@D1(8VV46$B7=/][2S<@S\+31#
M?<T",3T6V0;PZJ=,-]KI!Q5JM=X("TSJ&"IJHLD-"FC.@/#IR#29!03V)+QL
M'1V-X-_P9D%A;<[RZN.U@VUW@&!H9S'+%+'=>$8B/REK)*TF)1&T@FDELX_+
M@LM3C)F,./@NM$J,;:3S40SGL4U6%H.BAW8T^.S\6YOA7D'H]+4FAR4O6L8@
M<F';F%";2(FHQ_* -U1/6N"YS%"CIM<RO0&.'NJ8%;P)!$+]P_";BWKE;?4@
M;YD>=$.59UGIS;-^RZ-5@ZU-X9>]B85?:]%%[FKE/7IPY5VI"R#VXUSDW*Z?
MWG[4N%>.OGSZOO\-@UJ@8UN?SG[_]O?;W]W#][_;QW^!3O[EX-OA7^B">9<O
MN%?LHR^'9_OFT7>\_N?@Z.V[K]@F\^^WG[Q/7^!]7_:_?4+=_:]_9T=GY^;A
M[N?,=EW@@X[A9V%BN &F(MFV8]A6%H4Q6+R9%\SK[5YD9:83)2;#AI9AQ"+?
M<[B'_1'3*.+VO-Z^^_;MP=G!\=&IMGOT5CO9/_OCY$@[?J=]/#E^^\?>F79R
M\/ZWZ[3XI4KX]0/I#QRHQ(O2($@R'KJFY4:.X[FQF83,@M^D_LH*QF"]<Z?^
MS&/DNQN7^RGQ[KL]Y\*^IQ\/J<!O6,Q: M6N8A>4$=LD &FO7[6_%HC+(N]%
MU,N<#\L8K CL"X%E0C)A!C4RN80=AW';=TKDS*"9(5,&=+A03!%>3TQ Y&V>
M3T'ZE15F@,*;1$+OL@9X,6A#V!"Q^:0PU":$7:YK[\I2U N]K:;GBT5F[][N
MPKP$7A]I9E]X,B$/')9Y&WFA^G6I[-,)YFVI=F&J@@8W#//N8RR'JT3:0R8J
M]+I.\T%94_S9D(LH!H:!ZYSF:G3FU[YJ7/#IJ"S BI&90@0$1&K<UUSD6] /
MF*:0R+Y@ZN.B)5N:PA:13JF1!DW5#& F&D)O@-EUOL8F@_(<=$:]MWE8C-6@
MRZNB, S/YQDH_M/A!(Z#06M# QJA^S>%%3?@RU1(,+D!=L#:G:B._4]!LH5<
M9""DHI8Q#\H?BY4MG;32$95Q?+1*6SP&M#U#TVL@4I2)3_U=%ZP%PLDEG_J<
MPDZ(!)C*W=8;$FT)=9  K/LV^HBE7/2R U,"\\*D77W+,F0OR(+(\P.;V<SU
M/1[99L3@;]/R[<R,7>H=&:K>D>%"[\C;1?]DUXKZK-P5!T>I(+Q^7Y7UV@1U
M'EWK.#Y++C\'W 6-SK6,*'"XX5I)9(#DCH')I,Q,_(@'L85@ITL02/K9.#)'
M'X6$+&)?('',[5IC0J$.)E=0RXLEE,.SW6^'EY\3/_&M*#4-CT7,<$/?-B(G
M3@U@_V9H)Z$7,88=N:^C%/@;\Z6*UB^'<+2L&LX:J 0KVNFCC,WS4M0^4A5W
M \%4SMAP,FMQF6\'1O:#=&;W*S)RE&TG8D2*G-804.P)R B^<?[9RU+;\M+8
ML+$'&5B1GA%'7F"DB9LYMN.F*0N7PBO_DZ1789R7R&#0827DG60U4@C*Y&69
MLZ<(0U*:K)E?\-HEY7E!,#V"B^555Q :U,DA8_!;K"'GJHJ,O,%(ODJC$?*Z
M4X$&-Z+GKW5*KWB$N&13QR84TR6J0*\ >ESQ,76%Q;M%;3O)].N^U>:FBU@S
MKF4G(@XGI02EH+J0@>3QE/+!%RHUFR\2M-L0*SXI( ]3_H .2<WIKMB(,[3O
M17^-'RJ0>5COQ&DRX.ETR(\SQ?9W6SJHW\PZ_]IK%GBON[XOVH7Q^V??29+0
MB7T##'G7<!T3- F3A0;/W#B%2V8:6/,NB2<K?LY*;!E,)@I1NVQ:)3I+) ,T
M=AI?>(>8;W["R.8A '9Y (3UC QG6I&U&B/JK619*U\(LK&0YAY8 M54<(DV
M(Z2-52"_R8FM=0SR%B11G3PQW<8/7,&7# H^C&O^L_KA%["RQT,V^SDO:/GH
MH;FT _0X4PYV@G8I'54ZM>)RZTO=,84_=5+!?ZGZLKR\0Y?^-4D7KP71CNMY
M*R^;.];*:U>]U@IW'/=FK_T7#;F:<[5;+OEHL1*K'.*:_N\KYU7K=T[1[OW9
MU"RZ2WWCIK?*3ZYZ1FT+L$%^]=N7W;E]^?;EF_'RQ<2S).$\RWY1A\8>?\-C
MT]43ACQ;9$CE6/B2'UW0$,][HQI>+8$(F(L2]7G1C>9O:C=<!<&1'U_8TAK\
MHYGH7:;8G1JE *S5W&Z#"A"9F9D!$20N<WD<1A&V7+98ZIAN"K:/J#JS['[5
MV>V2EY?$UU9HJA^4FK(N" !WU5D'GT;?AL=?_IA]^NO?PT_VN_S3]S=#N-\[
M>GLR./I^[GZ">X]H7']<'KYOGX%O3?^V__"/SOX-__[S"SS_Y?#]GZ#C?C6/
MWN\[QV\'@T]?=F&\?YA_G^U>?D*GV:GY[</9_N3PU/2.SOYP/R>N:<6,V89K
MNY;A>BXW6,A]PW%MVW(MSW83^]6OH6Z;INYYJVK:?N2 P.G7;GE0[L9_9>+O
MG?CO4QS-/58/NCYJY0SH@MI1=^+YU6]6P[[=:BSEQNO'LE[?@F>E9ABSB&=A
MEG"79V9L,1ZG*>,!"ZTHYM?@]-^.>2EOV;NR$OZSO.-UW7*GZ[G3X=DN<B;B
M4,=G?UC'NY^Q%8<-AKB1(8:HZ]F.P:+,,TQFA2&(HR@VW5>_6GH0V;H7. O\
MZ:<;LZ;E[.%Q6-./J(9/PIK(NT#E4SW'PDH?0#>@MVCYWXF!W52=?.D,#+VC
M__O*>" UK%/ 4 NJ."@$3L!Q=IWF9FV9XZV8X_X\<PSCT'68DQDNBY$Y1I$1
MFY9E>#QV': 4RV%@KOJ.K?NN_P.L<:NUW8(U_J@;](5I<^NFS%$0].;\;Y]V
M=;=(=\6>'A1-_:W*EM]RN5MQN8-Y+N=[@6MECF.DD1D:+G<"@SFV;_ D=+AE
M@_'*$U0!+<?5'6=1!;REB;JI>N ZN @7T1;NYB.401W*38>UI^(-#6?R$KR'
M-YS\LV'K7AJ8EIN8CN\Y;FJQV PXLY+ <D*>\,"]#U"$K5_QH=GVX3S;3KAG
M6Z$/U.T$6 Y@QD;,?,<(8LMS>)Q8$0.V[>N1&>F^OZB>WLVS>+/#\X,,?2Z<
MZET13;U6OMP@S+KR'9W).C"CM)QB8+PWV\70[+\H$O[K8HW$IB0F7YELT&8O
MW#:K]TY<Z)8YFC_"AEY>VN:Y?7CYV0M-,PS=P+ ]+P5#-PA!^[-\("W/]UGJ
MLBQ(@8WL1->D;2*L7C_1ZPKL]-N1CNGZ3I+Z800:J!O$)N-)X/@L8K856T!5
M6])Y=-+YBAF_W+33!*Q%(P$[T7 MQS<B,!J,R/>BV(QMT_,R[$^^2O8TN>%-
M_?^P+,X-+/+_$7)),L^W$P<&D$9NY+#03>,PB&&,+ 7R=K;D\OCD8AW^_CEQ
M0N8%@6E8D0<*BV]%!G-C;D2VY_BN:[' 1("HG5469@,2=9O."S=M-GI3N/)P
M6W6]JNK:V<2JZZ7%JG<N/@T?LC;[EI6F"KED'1L.7 >.WRTS]?MEIJPH0%-/
MR-,[7V:*]QV!SIXGVGMJ:O=FY\\=[?4K\;O%&M,6>Y>:!DH $;A)/- @BW0J
M-T=\,B@GL*R8]*\*ZZB_K\ FZ=7O=:HYF:CTK 9\"B*F!*.)59-!!6>\UK4O
MTPM>Y)A0G^8E%DG"!#J7"1 (OE:750Y4VKM&%9KB>IK7,$2"^*$[*75XXW9_
MMYZS.)HN,A()N5OD@-G,V.2'N.5M]010;*W$2>,D=6,W\3F+>03JKND'B._O
M6E36XZNR'G^^K.=NN0O7EAENJ#?D[LK!E]\OCW__'&:QPUSN&;85<0.T@1C4
MR-@SHLAQ/3.T$A^]&2 !=""_)5U6)JJT<*YE>0-/]8B4<2^J9*=FI"W_^=!J
MQ0<2(NCE:I5??C<1S8[9'K>RV$B!,(!P;#!"[- SDM1..>?,PI*27\UK[5?J
M:]^KNI)X9DRBD@%W64E"]8!1YX<>%<6QQ>+ X8D)VD/D^AA,#FTGL?P@86#!
M7D-%!T?O;D5&IXAU>E#74YX*L(:/E+QV2D/KUBF]9%;C'OW^V0E\*XA8:L2.
MYQA@'-H&\\+$B,*8N:&;6"&F9%KA"E8#JSFI<NIU*;8=*:,CE+#=2EE(Z%E1
M08@- !#,:RQ-EW=O=R4L!!NJ>B'1@$!J+TVQ8N>]0!1EM[)5,#;U!".<"#&8
MIIIQDHM[._6/M51J>F/0M2$#G6H@@^>#'!2*!1@**J9LBG-!M5C1_K71R7IE
MN53F)*$\ABWBA=*@1&L;>?+F6]LT0 =->V<YZ24O52]<1/VHI]AJ]X9($6NE
M$AUW%6+J@VU%R_O$]PBKZ6G7I:R.*JN6BC9]"FIMI9::^D4CG H^/^I@YBF;
M0@"C$ .2\G;+&C>;-7[?]4"86H'IAGYF&HX5AH8;F8X1>V9J1*"/Q4'$_12-
MWY6LL>6''2:YBC6.*WZ!P#8]#%%E>O589D/1^ ZJT*:$2"K'OHU:%V5QPBV>
M!*&9NA$+0N9$9LI,QKT,U+SDFOR66ZIU*XCN3QSZ4II[<0K<]X-O1[N?HS@-
M$H]EAA<G-HCCU#;B(&9&E,0N"Q(><XO=1(&3LA4)AWJA-? T/:9(4E14JHL$
ML=M!CIB(*&Y%'G-\T_58RI(T\\P@BQS?CX&<9&>HX(<Z0VU]R[<B(@>)*'(3
M.XE-(PC<U, &)T9LFI%A)7C*,R_S4P\8UQW 1U(!X"_8$@@["836%.LM-'#,
MBPD)5B"O1EPJ)":I9E'A-_4(F+"O\*DA2RC9&U&'12L NBC;Q=^>2,,H2FW3
MCS/3<MTD#K,HB$'2QG'BP6E+EA>2;8GT 8GT]^^'NY^=.(M,*X@-A[D.%H2!
M"6*E'!B?QX+,3WSNN_=#I##7>LEM1%4Q%WZSMO.$K4D-?:X1]ESD=K8\ VTM
M.]K>"GGMSNUF6.Q84<1LV[%C-W'"R#-9E 16D(1Q9 4/%I@^:1!I#@34>XX*
M_6Y=\TDMW8N8,MOQ%L&UZ0BS9R>L.$=CZ26K'7^@JAM%V#PT]@UL3@.JKAT:
M+',S \YGE)I>F :AC\'KX'J_44$-8M3*(I D[,,R$/D5!^@>3-(5P<AUB47M
M3P:S4NCO9^4$#-#-@VL\*&0PZN:]FO?@+3F(P\82[R#4]W!-5\&/+CI!P+22
M:ZG<(06U%#Z=B,X-FAAFT(^9S8U3Y%H\RF#E;J\8[,81P3[!T.7%H@NF$Y;4
MR)'%S\&*11,7OBP]8W([_J<6[I-:QYZA#8L6L3SL\UD)+D^ J=6DX!7UPB!G
M%[U. !/)"&B2\*%LX]2 @G4Q_T6O7 P^J@:H?>NG=1MVP!@[@<.U:O8DE>]#
M-EO<@1Z1XW*_S6M*G4!2W%U![+ $8E&ZQZ7BDVE52.RT-D;<AH>[I,ZU!>;V
ME&TTUG/?EIU_7$BU#UUG<I8CY?=<RDMWLK?YF'U8E)0_!J]9YFF>!X66:-&B
M1TY5CDK%LGA.[%'N*CPM>1AV>2E$RW;QI/*H:Y3(,@_?8D4[3TH'ZTD(()[@
M0(GJYD;0T'%K^]FU614BX-\11'@[J&*&V 0N'(=U%]CP>E(A/HK^<MS#VVC[
M3A*$3NKX)K<B-TRLD'E>Y@1>'(6N&2>,G-:19:YR'_JW2QBHRH3SM'X'M'G*
M$'.P5=Z%IO]B-7C\_?'N9Q['+JPX-YPL"0S7"T,#6]L:5HBIJ#8+;,M[]>MB
M=](%_1TY3H'<?"X"3&8R7&\0\JC3%AL.97>;"Q7^NBR-&6=5W84,5.C&7;#L
M?LA&--=I(S09=F!<\:U)B:KV+0G6<SE+/-\,;2]PF9M$H<\BRTL3TT\<EGGS
M_F[_3G8J%71>3ZT'[71D+LP+IM^O+F8N)*8;H,_;BN+(0%A2([29;9@1<X(X
M<'PO35_]ZBQQ!S7]4EL?CMGR1]A_3%[@_!Y(R/7B-&.Q T,)W-0W61+Z66+:
M3AR982P"=?<7,GG;::%YK'#H18MT;+:+Q+7TEC<</L*;7NHOE[#.=K%13,A\
MUT^RU A,(BR6&LPV$R/#AH_,SES?L=#/>$7CY@X&4H')C2-8\T$-.C:RK&4]
MOY]2U\'6@"N:K_:3P:17'3FO=,?7F'HP8J"%PFR7\MX&X16X,U@.\AY4-WK.
MS[72LC;/L#XC2RN?B"9TB^XB[+I8RQ843:?%I@.CPNG&CKW">[V2'A:T=(+A
M7B*M=;(I6H,D!9MSSN"X(J&EWKG-S4VNV<+H9$]HV#.B4!C;OUD!)#C3)$:D
MWGO1_S1&:C,9T>[E:]_:ZN%U+[RQG3BJ)3AQH/85*]K,97'/FJ58: _U*!#=
M("G&9<V&E F.Z9*BW\Q2 5(+V7&J6A?*DOM3K"%![ G9:( -VV9D]8N&\C[_
M["2.'3#3-7CL1)AWZ1IQ'%M&%(&!Q-/ SR)_ <K[!SC1DS/5,^%$:*S+)LN.
M6%;C41*=,[,A3R0KDFTSQ6TWDU--/_*GE*K4@[33,G31Y5OS%8MPL[*#E=N^
M,?CC+NA0T>K+5^&/7WTMM)W[1S6W=]S(?_Z#?9(U\(/@808;W0:&_J$@Y[NW
M1@NW+@&)$86(CP.8$EW7N]04W!L-XM5FS$I4L V=[]'55EMONH](/8NW;L1J
M]I"67N3TS5M,?U/FM-W2128P5[X>/6 CDQ5@/-<"#*WA]U:^Y G&?34ZT7-&
M33X1EM9JA,];3'9^![9=-YXI.AZ/O3#P3<Y"-W)-QXIB+$FRDQ1#N8&C@F3!
MO2#82PK%0 8F2^/P_@)C>@],WW+$J_UOTDF%(3/X_Y2"&9OH79+@> <>C,,\
M//MT>?C^T(-GG,.WP\'1E[_SHR_GSN'W=U\/WQ\-C[[\;LZ#XQU^^>K!^[\=
M?=F]_/0=GGF;7![_M6\?C0[LX[?)]\._?K_\9/]A'[T]R0YGYJS7="/T83/C
M-#*BQ'$-UTX31)KQ80-]BP<!R^P@?O4K6()Z$*[*[WP*\.8MK]KRJBMQ"1(6
M9%'&3#^UW"STF&<G<1I:++$",[5% 9NI>)6YY55KR:O,'J\R$5$H#ETCM@/;
M<),H,YAC M<"UI6D06RYS'GU:Q $>F3=%XCG/?&J+9]YIGSF![,^MGQF+?B,
MU>,S("2 F_B689DIHEYXB/(>QT8*?(<!?0=19B+*NQM9NFFZZ\5IMEK1EENM
MY%9QF(2A:7/?C@.715;D>B:S$A]++6,6<*D564^G%6TVJ,1C\RVG;\NY5AQF
MS#,"V^:&&Z7<"$TO,WQNQ2R*3##T$&16=QQ7#RUKC?C6#<,J:^]6VROKB< 5
M4NE*=3E<W13Q%MY,>^EB/+_&.O?K8\KR;SPUOO.JG&=.N%/'V?NR3.O=(CWE
MU46>\/H4=FO+@V[!@X[VYOQ)L1.8,?.X869A9+@@<(R0@[46N[[GFH&517'T
MZE="UK)_N1T'>C@%:7OZ'L1KLCU]#W_Z^AX2-S/#P/1=@R=^9KA@A1HQV*.&
M&7D.9[!M4>*LR>E[*4?J?AT$VR/U\$=JSAG@>7'(,A!C+,:NY$%J1#:W#--A
MH1?X5NC;_IH<J:U >V"#=WOZ'O[T]4W:Q'3<"$2788'F: #_M(W0R4"J64[,
M[3 ,>.(]X>E[]GDBIWR(A9"Z=MA# 2!8E(?('7GF[;;7T!"6.PQ<J]EBV2UV
MR[ENP[E.YPSA( M";L:A$0;HC LCTXBQHX_)S-"U[22(D_2.G&L30@C;@_S8
M-O7V(-_70>[;U!;LE)-&GA%PSS3< +,.8MLV;"MV_,B-W=AGZWZ07_PA?"PK
M?'L([^L0]JUPQ[6",(HB(^4A2-/8Y09+0*2&MINEC@TG,S+7_1!NI>D&&?3;
M@WQ?![EOT'/8B]2+'"/R4MMP'2LV0HM'L%DL"(/8#WD:KN-!?BX1:H'><&6%
M_0^$J_L%-[*T?+X?^,WZHF]X7M%]K,"S8=J/6CAR Q"L^HA/CK,S]FUW(H N
M$1#AK#PA5!SD]/! !X-_R^AOP.CS^42 ./7<( Z QP?P1X"M<<PT,H(0]BVS
MT]AS[EQ8<@^'ZW'B+5M^N.6'3UV<LN6'3\0/^VXDQPG]S+$# P1>;+C<B8PP
M=IB1<>9;/@=YB"W=[U:\\K3\<,ODMDSNJ2MCMDSNB9A<WTT7VY'/G)@;@>N'
MAFO9GL'B.($_0-UWP\!B473WRIFMVK?EB)O,$1^U^F;+$9^((SIS&;F>EX9)
MAC7+P!%-)S1BSC&$R"UF.A&:PW>OR7E"CD@.T7\1R2CLRG_U\&K%OR75$;WU
MT"WE(7(1>')<"@#>GZD16'[!6[S)?_:A4.54S?81%A/,Z.I'%K"EG@BWV7+[
M2)_=/W&X=+9"'L9I'%EI$D:N[;AQE(8!MP)FA;'G9NEG+WRE'AI4K1PZYT9<
M<?;5H 8K/[/A)9O5K_[5QQ/-"S4BSX4AKUJP/C H]E+K()%:-DDZ,9'%1FH+
M(*:P6HD!.X#T_',]'<&K9K]<^06_^<##[= "T)?HN#+A(W'>[!WMD!6PJHC8
M*MO U]@P)9G6M>J[OENPX:S.J=[K7=,78Z\L! (RW7-"P-%TR_&B@WT%XNO*
M=7E4$')ZX\W[UK5PS]BAGE7(8%!>7<*/QK LO^*_:X4:?>T:K%TGS#,"ME<]
M2]*6%)##L;RHM038)<N+*R;==!4CS&-MM$ABJI$H-B\CJLFF$UQ2+*65C7VZ
M4,AGA"S<^4!>7)3#"]Z,I<KKK^(Q[+A&OVL;J,&1G#+5.[>&X<Q@7EG&*PT;
M?%9 S<.9B!1A;_L=[=WJB2&4\XBE7!M/JWK*8 :RLUC-,JX-6 7":$D+HH]5
M?H&-?$\Y3%STR_L ?YV+IC(GV*MBI.UB1ZE,LZ+(V\%_K!AS#3229R"OBDEG
MV,V=<L=$+S>!R+QZHW:T4XR2Y2/4A' V&:Q56:D-Q*\F;%JW;X?9RF'0AQ$*
M.IE(V'?9*O9GC5VP?*@:Q,*,6(.5#EI>/*$]X?^=XM6$C?'D_2*[;R&1B7MK
M;(Q)&/Q W-TWR"=$SR;1U_07#=ODJ ]2,S:A N+/3#0_%?WU>-I4K/[2-)6J
M0>NK?^E0*8X9WWA>E9>30=.#[[QJ>AC2]SH-V\4]HS'#4EB\!:XWK?<8+"<?
M#O'OIHO?8E\_L0#B31PF4(Z02L2Z$XM1&[UW_.?!6\.*M#%.:(3-??\:Y,.K
MMKDYB30N/LQY5LLV O5$^S)-SVG:,4.RF8[QL,OSF1="%:<.:?#U&9T Q"$_
MGS)8T0GGW>,+1Y;NAS.XHQU3T[1%VJ)6URUIS9W.EL+F#^<5\\-!S1.^!A)9
M; [VPYT,X0*R']O\Y028A?9.C(9^9?U"JR$OGP)-HX0[*N'$GC0\7G&%#_+S
M36> YAV2,':+ B<DS NDAG=XNBW3^$_3&0%;0TD,WKG^#MAL@;@?O$@TY<QR
M3-"HVZZ:I_M[#]1'SOZ!/G*/)9_^@ITNB0*GV!^0NJ4#S8S!'L@3()7I&%MU
M8&L^;(V)]%7,U,ZLIB"=)(^B'))"@DZ1PU4Y!X+&5THR%]WJD..EP(?A:W0K
MM2(!4DOR,6'B*XJF%C,X8&I(0@TB4Q)I'3D[AIOAFPV#62(RT[Y6QCI:6:];
M64<KJUJMK-.>HQZ4TV$J1T.G!9[Z G*3GB,RP\6:%FR:4G-&?"EF!-%/9%[1
M_-JO=D\B?5:T.88Y\TX'<5I<8MOS!^/WQ8;A5_8P?G3;:JEVOS8&E[?:X%IK
MV^GJ/;Z9G>A;KVYIC<D^$T]D>QW_N7_RY\'^7S?LAO%4HX3SKYK,KQSIVI@L
MG;9*'T$%'[&$3\FA4VL'!:A'KZ5@;^_3E<A&GJVNBDXKS25L[EIKTXY"(9V<
MR$[E,Y>\N5W^9EIW7R!_">Q4_O(G'157IM5"QP!U==P;,?6218F5E0E]NBQD
MBZM&V=1[O9QQTDO;;+?Z+J^3*A^+!C5-*RH0HZ0T<2'!J"<]V2VDZ^1%45X0
M%^TVI (9!]H<W,1I3/\%+4=J^ F^"Y4;D'QY(P= :Z]0 1Z7)790&W%LVI72
M- OL#/F#/6&>@M3P8(RK'/F)-H$QXI24X@Y+,"AK89VP!,0)+8NNG;-Z4I4D
M(6"4YS,A(P=\"@HN_4+9MVIQ%'%06W6A;B C@Q%_Q]9=,TV)N"'V'BY0^(AN
MWW*O49M$75[NV247.C^:R[!B,6K&U07<SD'-3N1[X*WU"'1M74X++I-=A+N:
M<$$PHB<R%];/F @A76Q8AE?;=2A03^##_MN6-G\7)(,^@!J]K7D]H"I,()7)
M95E]13);W@D=2;?BYWF-3?AD[V:@8S%.6E/D8T3@BCK%]_-*H\9QV.U\40.Y
M*RD^>5<JHE'0L$"[S$MRVKW=;?=+])EOC/6[^>AP(:1SW< @W<^!O71IQ*]R
M5!\G/QO68PBTY6M"[-?_99GA\HC[M4S8]M?1<G<\7*3=A$]8"H?M<4?LX]=O
M,.0%71N)PG!VEG370D:$+\ ]L +WJ;=@A4G[^JF&=4OO,R@*\$ R UX'U]9R
M+7\"I>N+<+WHC<-C H;'1/G6<!+PY:(<#\#F'I=Y76(KRU^N50>VS.A)F-$>
M&Z;X^2TOVO*BSD#S> HZ1<:+M5S&Z]G0& -'I*"":ES]LF4^:\E\_E/EV'B[
MK+>JT);]= <ZQ,#1X]/%C=D/\ISC"NS44]D>6 =CMN>-&;)O1#(K^!,ZVR<8
M2X![M]QI/;G3\8@G0S8JOVV9TV/XI8V/[.M:'G=]8]AF.>+CBGTOA\!V@'2K
M'/UVHUF2%S)9!H@Y3W)$!5C+E?YI.;/\#8@W*6-RDVKC&8PEWY@M^6U'CGA-
M%SPO,J%(]Z*[Z;0$<0'R;3I,8,W3O.; 0IY:4#WY<ETAP9Y24)WP-#^K^,N0
M4T^K*S\=(QGQR: $M@AJY5*M^"EL[R?-5'K*15CA^J2@JHK^Y:FN?9E>\ +S
M]_(T+T';'^0)\=D:O1)<&]<@&.!0P"\K$-5P3C"KM4TI!+Z+T3+,(:([Z[Q^
M03QXN9JX:5;$GVQ<Y74Y?!',^<DE],;HA4E9Y!=L/&'KJHEW/*P8@V>8;@DO
MFXZTNDQS^&N(F2H4;E<9 93"T,3A*=F03R_ &AE)MC>8C7FE?@'_* L&''24
M,\K1W;I!UI.!Y3&RABW_VO*OSD GL. 7F"*\ ?QKN0=65A?A!\IIK0GW F8\
M-R:QRJ1!!4SQ.$/6G*3$T#"7/ ?**RN#U769Y&0]MZ\:%Z + J=G/;4.\P"'
M,C6O_BH#5?1#/:FF":6AMX.X4?:2LTZ)= =%4]0C2ZAJWDEDE&E*.B:O#1AH
MS!\'<#2U@P,M@7=1EMRX*L\K-JI%'< EFVG\@@VQ A>V E._\HQ/JC)F3=HC
MIK^EE+P.6\GQ-DJQC&=S BG!BH]R-"-M?*9U=HTNOYTF UX47#N<ULETR"KM
M[0PS_,9PKTHU?7OXMLWX9%K*SWE!"?@77'E*=.T4TSA0S)TF0UZ5F,ROGC\]
M3?K/LW0((YF"R3 :30O>)OH+K]TN4%X%^[S_C0'1QC38$XZ_1,*;84DG?K-Y
M_^[^26^ TMB@.C0T4^K)8,0V,#^SDPH,!*/%TWR(1645T=:83SAP(Y%_")J"
M**>Y43;M7)9N+X^6Z+-)6L146LP59F-1D(:?PVQ7D6(K.4.3P[OPQ4ZAVEPJ
ML\J9W#G=D;5;(J?S4J1UHJI5L7,N:BSXM[R>B$S>K&(MRX AU-.QJ+^ (R+J
M]^!CHM1M1\/<P4XAW(2S$<6A<M7OL;\.H"K!=@-]7<#2PKCK3KT,I4TW17"=
M5=:;\]C[9<7/I\0F9SH.88KE8M.*FG)0[J@N,VU5;PY1?L(WD$B/N]6!7?*C
MY<Y1^\PSJEZ5'$T5LA;\O)SDQ+_4$O82PT%@<-@KN4!):8B,7?+<GE=<U7R*
M).:%+9"[C0)0? ",4C[!3&=U,[('W",4.;JDDYH(J>'*]01D(8YW7/$QJS"M
M=SCL["V07SS*Z[JIFH1SDV5UFZM+)9[PB"BI$8-5F>9X?X\T-$I H;?A$2GA
M"-1<9*?/D1 H?\0 Z9.#?-RM\VQ/LR#_+I6)M&6Q,52..<;3$(MR2S'U5FB1
M=R=O"X_A:%+J,A:,8Y)U4UL%(D @D5!2?B>/&;8/CVFO@A;?E,)AA\G-%H:\
MEIK538_D%45"VV>VE6Z+E6[^AE:ZK55QUWM1UGY*12/GLXT3GZV.]S^UJM&O
MY604, 0B)GS+1_EWY.,H#L;E!,4J,&G)01L-219$7%(-O40.H*=*4A]3S-KI
M5E.(ZG1ZV:13_T*JH"R;QXIUD*+(R6NJ*\8*C*90IBG%0 F"\F5I.<P++O$^
MZU02+2_Y(;L0:X50O*K-JI3A=^.:'ZJ"&]:EA@7A0J"3;HS89KEX'/1958[?
M;"",J>Q"4LA/ )F,E7;45$,UBM$$C7T8> %KU*WVKIMR?Z68$UEPQ&O0D9S!
MLD"@D+(R<AR6\ @(+4M,0)5P$20)7YR"0L#HC%CH.!WJ[?D>,+YO@%YVWC>.
MEEC1N8"Z4)5PB_5K0J5J%T'J4?*UHL!KG(_)Z8:'2ZS.PG>&^($A87M<6U2X
M<?Q,EF+B]@])19<\J^8=A;*%?^"L L,/I1UM4#4][YNP$ZUC!.^#:GJ.[SOC
MR:# :D-\5U,0NW_6.@'HY+ O904ZIU%>%DAFT[C.TQQ4@!T-[FTU51H,2QCA
MCZ!6#(-*!D .L(Z3J3P!I3)EA JKR)NX,?IN<!?1I 0;)2>C9?GFZQ*,9LZT
MQ]>TI$ZDD4TK0LQ8:5MO'FT0%@F"_0R'LX;I@8E#3&]8%N<&L,<1K&V-CDH$
MJ5,2,9Y=6]OWA+-=KIF<"A)1MI?@O4J"(U:,E-T+[.M)Q97Q=+D^3YSB\!?O
M02TI;T5?6K8@)T+\MM6H*!!*.*U(PLC_\QY45",T@ LP%-I#11'R11(RBD"_
M:DZRD*!6>D/Z-AZB]Z\O%%'"@GG-A^*%M71"MQI$6]1<"JZT*.%WM%WT=K'1
MF'Q3RD]=(\(74B;() 8R/VGFJL_1,PU @L<);R2!!ZG"3YJ7JKR22NI:^[I6
M'&E29(2"(B*'(K1!@@Y]2U+]-IZ4D.>B$>4*!UG7OR-Y,:F/BB%WE*V&@HC4
M;JI/=;'+R/B0&E+7_EBV?$3\!!FA$30OXJ'*:OU4QQ-G-$8'*@SUS;4]B2%P
M/93#LM,G]<(EOLK>I.D#C8L^E]32M[-T<;R(P\1D,DU@_%Q@AZ&ODE<(1:%
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M5X.V3KTRF ";1DV:5#2Q#+F*_U08\BF+#G)TVDL35Q%8=(O(+C'D2Y0VFM#
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M1V(C.<HI!ZJ"C4,R$SX;^-?3<I2E0U(=#J\Y2*W'Y4IS8KG[!,BQ(86>X;9
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MD-G3V(<?P0^#E"5+@RQ.T?.8,A1C%_[+05@MP\E(Z+14:$Y$4QK)-0'WB"U
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M+84L?9.<5*%.OQ.<X8->'Y:@)73$ +!,SNSM3-U.S"@.L.<2WP4L2S.Y\=O
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M1@NS%*5I'(2QF9KZZP!]A@]@69Q6^_GFYH;^4G\^SPI?&_X"HNSZ :C\1R<
M^=UQ+!FL0->Q1\Q0[8&>]2?.$&AUR RXSA ]AV[GMG>'?[\[EZ6GL3,<$V,
M=5-0[XL9P"<:MV85$/2H1+DG+F8T8'/\ -D"_F\2BD_7'0K!)X.U:S.3M2D
M@;%ZXD[&TF8,_$M!/3BLQ\)['EV5D:6:\B.(@8B$>[AL;KXZ85'IV=<$/?-
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MSHA7,260"4QWEI610OOGJWQ8;6Q;"VI\:?V1&P^CF VQ@O=D] ]2W*8_1?%
M7,8G'.%X+9[D1A;2TF_')EK'R7UO\AY@F79-LL!_3<4-Z'@?HQPL8LEY.I,U
MAX!-%AC8+,=OXG#A5E]<CA*Q8YME"O"?\U<  #XN[M06E/H 9@XSSW#XILCR
M=B9)F'GKSF0L=@W4)VZ)1V@_\8&?Z16Z!^LF>;MLY"=7G\G>F))E6CH!+=^6
M/1J!<A;*+\VE9>$X,@VS-TC\NGQG=\[03L>=TQ6I"X\'OLL0?X-)K19Z;YO$
M*@LEFS)7C$GHD9GY*"WD])*1DGG1',^RU^(ONV/''DF][_8P)IO_>@0&&9(P
M (E]]S$A*?Z=3/DB-ABF,;,[D&N)-#/%#7GOLA*?F=*:$F1,$V1(9[ RQ;51
M1* LLFP@:7;A<!MC%K1:-R_4QIE]3C]5&Q;_5ZKE^044^B>)<L*[*+0PVG6=
M3>.=,'ZFRZ]WV<?>G9_+_-:5#N99XD\^>ES<5% E".SP-W&?+MW:*,N0/T'V
M3"2U=O%;QE*F8W&HT;W_GM#!Q 0 -$FD-J.<$]#KV1'R7[T!=DA.)JAFKA^9
M=A**--\S^61NG@].?H_C482;:#";63.PQ1L%+#-).)[(KP9XAGP=,)(<2H,/
M>$@^S.!\#M&4PS/$^C<X*FT?I#S\F32J9(EN;'G\ EF&OS,"5N5@ DH$9P@<
ME/2^ZZ[7_1LL3H1(=0\^*C+\R\%Y],-X$C-;G%UI32:Q!R8IUU]Y0,\R;GJ#
MAF?;B3&1LC$="LP5/A/2Q%Z=="J7RB><D#*H\/(XL)CRX#A)\7\*OE(F:LIR
M")^MV4/-;9-H8UZKS6*EJ?>9G>,I6$1"89#1NHRFV)N!:'$UH;ZQHH98!RG.
M#QB5<JZ9@9WS#3%$(9N%Y^7MWKS&A:@N8^@RQEA]&;.%==1XMX<;'$+%\6YP
M7A\E*Q*!.K?W4K]/:2BJ^K-T??^I=ROUKSY>WW[IW/>OKW:V88UM;5B"K5X
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MGAAY8%O+18]OL6U_K=W>I73-4#1C_XWP-5UI&[L5F:W[3E-48_^S .I*LWF
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M)U[W5[S9&3JM1J?(&;)CA-@Q,F98J1UZQR:VQ$I,2:0SQKQ[TAZH_.X<V)?
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MX^(%OZVPWBJI?4(I<@-\A>B:_9A5DG]>U]7[S_%_ '+YX7]02P,$%     @
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M4)+$:R\;YYFL50N2F)X2B)!-2$82M$:[_SD<]WQ&W=:\'"^3UI?=%DW1M2*
M(FEOF$0RW74 Q1R"#\6#E<R3(2^9;94:TV(X8[;W8Q8A^:2 V$&L04.>,1<"
MF/2L%)<URB9&R-;L_;$;Q,W7QV6],0XV#:R#".BQ)GR.<RS3U407'8L1"5PI
M%I3/I!J-MB"DE>2M*Z5,DVC*-7A&%3,9+2\W$^-@G#H3.]1<\%PKA QC""JD
M")[3#LM4R!*#* *;V$37A6<WW3]>3I?I2-Z83\7].Z[>%IK\">,U<PH]:$GK
M6&$LX!6)4/,D(ID8H80FD8W[@!R3AE^3*3=KY0%E-'93CS0"ABP42$WSI<C+
M@>@3:9#$:<^0FD7>J*"\O:GWL &5)LQ\$+D/GY5W)@ZH(DL<=0%A:_&2E8FL
M%T[.DS%*,YV*X4VB*+>&<M<IH?N"I#).Y-2%M/ICNMI]<;!<T1VZ[\T(:PH<
M_<M5ET19 N8D(#%>6Q8H ;&&(7Q1H<3DDBQ-,E37P#HFM;\IDRY7V;45W8!Y
M,LL^$^/82EM.'$;M)"O@2,F 2L6!1Y- &>\M66=2AB:YK!>!C,J^'IH>&\UZ
M.]FC2$9R2?Y>K?Y4RI(APG0M%#:Y%":E%TTV[YMEO][ WI9:(M9G,&'W99IP
M^6$QRQ.62@H"<]TK26J%DTN3:,0^US9WQ2F5FZ3D7@]I3&IP(T9<1?(!I#!<
M\BKV)@MA^2UT?V)=SB?!5F5X=@PE6%;3QT5=RZ9F&625C?!1"-,D;'8]I#%9
MGH.R8B I#-BG8(ETF=K![R5MVK-%7R]\ DF[**7S#HHBKTQ9P\%)[:%PYKW)
M*FG;J$7!#:C&]&!N4&X,)XOAZK=Q3EO_C! ]RWO3^72YJH; %SP!94/T6"2'
M(&J+\6(TA*08Y,*BLD3GW";@?@NN,96%#DJ1(>4Q7%WP7O64_]5/QMMRL6AM
M(J71*@0),7$%R@E+KS0'X= &'VLSN2:/OVZ&-:8BTD$I,J TQI%E7CO+OIXM
MOK9),C^]^E9SS*\9U$ IYO7J%QKRTN:RZJ:)8!PW[#W_P9EOOL-NNLCDZG6U
MU/ E'OW_/2Q&SOLN40K?TV!>E8)I-3%>>:S/_+DRZKAR00OBK%$8I0G>NB:[
MP':'.4 &=87PKEM\F9*(GQ]^6M82W^_.];-$FORHNLW(H"RW&11+C-0X+=+
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M: BYW'%'/OZ\_HATKU]^^']02P,$%     @ "HIL4]RI-X8:*0  HJ8! !4
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M?4J4.ISZ[G+/#FN"HV!61Q(2S7_N,B4A<49D8.A72A&(\ID;ZK*@H4H8V29
MI\28081^EPRNAC%]&3= 672."T\,S[@N(A[B(T[9*UP=$\W&\3[I%X,8RX=M
M.W)0$WA[83^6@@3K9K.X(M962W#(9K",XXZ:$MI5B]*&FI;*]9SE.H;,(XOA
M&4C=?6-RMA'[,>(K^N#[=TS.;NK<-M!B%UT<@S/)\9A-%/AZE#@"J7!W9$$2
MA^X;**FIEW6Z7SVIF)RJ5-E&!0>(R7&2:\5%Z<U6+C]D#,2%Q=0!N'&@P^VL
ML*<<D[.5\!^(R=E&<A62^VY:P)>Q9%%21.1(CL$1:;(A+F9'J' QI" C=54B
M[NY".2T384]15[\SO![<W@-73:-@$[#C& /[*NY>'NPI]0K;_T9\(63!4I0$
M_\\C/FF)2[BUE5HH$I=QDV65R*_#LN&![?Y09-A&V)5MP.5.91.@28-[79(:
M[1D6$_$9[1FFLL7M#W<])FI;?<<R"891TSU&W@XR'CIZ[<=QGIV?X?Q2F>,2
M4 C@>72!&)?$I:GC1?3$^X@F4.+12MW+L%LW^A/7XS!2JU$G[*XS B[K0$W)
M-^*9R,0<<5FB,Z(%-3$PF>H4_3WU<Y\]15TAEN<FHB6]^V"J:="M W4<8VY?
MA=VK_SVD77T96&+#[<0&I:'L*Y9(&P*Q0I?F-D$PJW'E@BJ[^.$8\( !=P@"
M;"/D*J4!/C>3SR52]68<Z_+$097496F(4%3A5E>6N\0"H<KQ))0P(E0I&WHO
MJL.; OLK[DZJ_U!2'[B4Y+N2D[P@NC @T2<QA'+T3V2PF@2&FF):><XUI9#Z
M'.WT*M1U]=33V/!W%^2 P997(%;U27O &+JDX[7G'[Y<XXX:N*W#/<0W<"6]
MZW",+S$&"*+4C2,R4DZ<])($KX7D02)C^YRO/ XMWE,V<5@E;B.U@97W$TKJ
M8GZQ!*(L/H]:07S(#)T^B,3:;$AD(D?!M?%VL"J(-YY\V"*(.\N^&4)P V^-
MR]2>)1#P+.N2-FBL]D0*R4H'#$H<[OPB10I1]VG!V4^#UY_\!#6XL^ JV+O7
M<VF6M<)2#A(RH9&&<B); KD4(S3+F#0DGUF5OANW@9R&Z3.(F"OTA+N.YZJ>
MX,.(:IYSW(5TG%.._51UC][WD'/E%W^)S&4E943GW4 )(?<,EZ*L:3G-!>>#
MI\I7"7,[E.8?.-VHK?AMQ%OC6JJ9IF:ZR(,+?OK[VYP!%[F"[\WKEV_?K<JH
MJ62X3+B+,;0M)><)=Z+HB+*Z=/K.$ VOE+/Q,+K#GW3LJ\:[F1L#ZZ!"7$M)
M+T& %^7"YZJ$J!>!9>]2Z>2!F((!XIE*! V@F!5GLE([KG5@3LLTV%O<E=*Y
MKF-:'?'U0%4UX'4MK".%N>ZMM@=XL(?,Z^P>Z]"Q(+/2'A<H*DO6F8PD<(O$
M!ZN<3XZ9.ADVAV3"0T&L!R+"-J*NTD!K^AG:V1B7NP)LN54E*UB LC<%B]ZK
M%;E4XZ6DG#]9&U$&GE6Y$EN'Y@CAK@.HZDXGK7WE// YSZN2U07M)]_.OI:H
MCV6C%F=D0FHS0SE!-EMBN=5$Y.@,3I$:-=B!W3H IV$"#"+> 9-Y%R=<\&G>
MQO-2U^EC"XL$J]L0KSHP/0QR\!N4ON@.?[^ROR*;0VEAZ(N8WF"#ET:7]@,4
M$BMM)04)$2@QRGB;G'56]S$7G@)5[KG$.1)3MA'^T'DOOXVG_P?\9';^+='\
M_7CZT7]J6G@S2TN$67M+-45;B99D<F\0(</]+F6:A#%&*7&K#,"&B,E>CSOP
MS4$=/355A5SA=*&4%(!_S4OCV<_XSY7%;(0*+"A&M!#(_\0E"<IKM)Y,S,$:
M6^G>80.>TS PAA1ZA<(-:V"MVK_U %:UB]4F9$?JW3V$_A[FQ!["K]%9:B-
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ML..XNT,H[T$^["'Y0S*#B:BY+NVF/(]$XHI*?(DYDBE"1BN>,56E<L1A&?&
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M%20ZX%8#]:!<+]?LQK"/PN#=1^;-( (;NB/23S [;V8M?/&S5;U<IIB5%N%
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M;GO.O?QQ^2?@'/_^E_\/4$L#!!0    (  J*;%/8K%(9/H@  !V<!0 5
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MJYPPR<+#\7P/"(?\''0Q8]*O1@^<SC\N?9KJ&7*_3U?RW48^YHM81H&>5"=
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M<=,>Z8UJJR9)]]:GTRKIC<")ADG_UMR^2WFV67S6KY8LU#8(]>-($054B!F
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M#H -JWYCW_W$PCC.N%QJYK@W,6@M)#.3SS<GA4KVJTA2H)!22HSZ/C1G6'W
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M5)"U.")7%B=[H^>,JX=/,DO7HB@,5.2MYF7"]H+[H?2#( 81CQF G%* &8J
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MA%U*>Y?N78;*-)GKO96*.CV%=MH9&]F12:B$U)CN&=N](^-OO+WYWLY^;^?
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MFG4'W#JN3K<B,OQ*='UW+[#JW.IW_0IS^RT=Q0,?S6;;_]FI5%VH\G*?<!Y
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M\P$CD4'@'3Q!H[-!TR=R],6N-N&C=Z-]YC)5EK;ODXC["0-(J C $') *8I
MF$B":$P$)TY'K4]:G^?,ILIX[S[#<4MQ[PS))/.=$;+9:QT>?O[S(IGKM;[5
MSX;Z9:D;V:=="V_3G-.E20:]6XDWFBP609RPV%3G4R&+ 8QB! A!(8A]@B/$
M CTS@K;";4V=S"Z0V0W;TM R"5J;ZAE;[?7:&B%M'\M# 37RD.Z$D9-"VS40
M>HBS-38]F2[;->>.)=FN7MMQ)K1/"M<1X&N:9<]JG?U!,Y$O(A;'H:0)D!'&
M "9Q##"B'# F<8Q93!1S*OC>W-7<AKXY<WLX1VMD/#Q^;*_CA*898LO9RB#
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MVZ5<J\]FK:,<5/JE^++5L\BB^$.YO7(BF!3YOHR0#$ HHP1 'TE  B9 &-,
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M19F/6$&(,<X UQDQFAV)04Z9!$DF-*$\I2SU:QYU,L74#$:%*>1 8J<6 @U
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MXE2UI'66J<F%*C>B(O%F]T-DB8WNEXYJ0SNP[7)A,+@""X7.2'G%!5U$HD>
MT/FQ1XL4NLA>/63H\L/#;?]XEC*..4T92!-H38 \!32# F22J#1-<XJ94ZN1
MUEG^6VW_IS]6_;=_W&/[>\%US>W?AM0@VS\.N/WCZV__V&?[QQVW_TZI*.IP
M/JIG\V5\8QOUL%Y]7;/OC\HJ%M;QL&^#='CF]KMMM(9F,<Q%0E(,C#I S.U!
M&14A%0@8V9$2"DD"L9.,Z$_*U 3)AUH:P29:*%U$A:SW9'>H5MQMB=PN(>,
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M,I?F'+>$C",")Q5D7-_K)FM^72V_/JGU=VM=OM<?UDK.M[,892(A20Q0&A.
M29(#2J -)2,VHC0G"=5^L6--T_ALAG'BQA[5C]7B1U&BRKHV5CH2!:5^LJ01
M4C?YT1>FP#+#D@>,@/]>NGX,/B6)80I/M8$QI)QHG&=4V=#&Z5MYT/ILA\M
M?9R?F2C*4_V5_3G__O+]_6IMKAQF.WQ@YH,HF[85UHG2<#I+>"QSI3. $*8
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M"<;-QVSB[20/L_$A_SX5M4BBKVM5])'Z8#4<M7YFZ^WK9[.\57H0@R0AN>+
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M\?WAVF+]MK1!J+NV-$:'^3XO(E]^5NI!F6]UN65?U8P2*.+$: Y*8EN'B6E
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M@E4M'M8KH93<_&PH_L(6:J4_K-;/*_.7ZHL2YLVBD4C"E##_)P#&.3%;'::
MIFD")($9%IR)&%%GO^>@I$U-3!1<1'4V;J(-6U2)#A7YT69/?_3NY3G:KAP+
MD 586@>WZ]46++ (&Y2O@=R,0;!N=4<..^-X;LL@2!VY-\/,T#'=0'VUM[Y'
M]6P+\QE2S%U1O);_/#CN"(UI+C %&G%J2X8JP @F@")&!$]8!A'QS#YPF7=Z
ME[?[YZ(AFJV34S+@FUCF!+?;+6YP"$.+Q9+>:$_P3502&_U>_1FFUH@/3(,F
M+#A-/&[^@@\6)^D,7B]W]9'9NJ%/[,]]'T(S=E&2G&8HIDPCH&F<6!&4 <JU
M #''@F1IDB>*^\49GYEI:II?54K54!K52.U6(?X\O*[^K@% "^[8ZH17!]_5
M!2R&=5*=FVQD;]0%GD_=3I=>Z-HT](];(6RO#"N(UJNE^5&4]NOF(S7/%4P4
M30%'>0QP(F) $Q(#HC.L,Z8HRKR"NGP)F)I4>52B2!+<\Q#]\C*7S/#@VS74
M<R'<!$U(> /+'T-Z'=9CXL=1>;JB-VPW44\:1NXIV@VAT\ZB'<?I6@>D\M+5
M/'</J\V\\.WY^8!<AIK0KMJ3>^SQWE$<Q#'D ]&PI1(<YAVY6H([$J<%$SS>
M/;<MZHOZJ_GIW_]E]QOS#YOW_N__\O\ 4$L#!!0    (  J*;%..#.W"#%0
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MG%,X-"-N3O+GZ7Q:)53'TU\RQ V+6B %TJ9L5HD&3SX!6!6+0$R&UE +6/V
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MLEHV%%V%>&H3Q\DZ'T2161-2@K-&0T[9^R*EOY=@.="2'8+ZP_LTW%37]43
M;:=EM&ZX+"J#B<G4CH\!:/T*(.'5FLR0M&_3F7MW&L<U=L?'X_T6$&W4V;N5
M/,EYNAG)2C][C^NS)0F_O%LN\EE:OY^>?MK/8.[PU$%MYU.Y&,B,OCA;T8Y,
MF^CB<R1<;BBX0B.Z7!Q7&H)0@<(&=+472:$MVHIL<@Q)-DF&>XRH0XW>EF=O
M6R Q:A]#D& P2O)WZT(,Y$8X@T$;$3#=G4;1C/7N3-U@F+EKP1KHYOD;KTW\
MU<B$73S[R(9L&T?',&?1<R9L4H Q<5 Z&@A<;3I+H'&:6VF;=*!J:<X^I$^8
MSV;XMER^Y23]\VRZ.E?!B^\W_G45A:VK?S+-FQ!J,;]>5S8822&2I="I=C;D
M0D&PGL3%2#RA>)/OSNX=J#I\.!XZ-HQ/0=^]LO*1M-S!><LUZ[05?%FLPNPO
MR\79E]7K>9J=9>*T[A ;GL\P7YP+$./G9P]7'O:+0*8JX8=/B&MRR"]M5)A=
M[R^K&]ZQ<$XS)2&J>ERJ+>UF4F80L@3D&BV_FU,]]$(X&J_CGC<>8<'TB9KG
M[Y;\%I;GD>;6 ?-#.2CWWG)D5^5Q+H_AM'B%J41&,,K!UQXV6!L:)X(60UH3
M7LLVFW(G3LOY[8-@QDI-.Y6+*I'''R-X&T+=O3!;=,+OU >RI6?202[+8#@Z
MP/UXNKXZ\#&V<'4^YH:SI&HF<S U11 # Y]0 -/:)>39FS:MUQ^@9^2&24U!
M\,!)P"$:Z118]<LE7C:;TMH+:4,$@20?E3(QQ.J5/:;(BHFN43OM'U+6ARD[
M2/\[8&I_98Q=.?K[ZQ<G'U__?I&8P5!K;AQ"%JA!U3^<8!*21^$,LH!ZMPXU
MMQ[;'P8.T-=B$.&-K?:_XOK38KW$;Q2B7)#/-7?*$?F8F:\C/I$$4&IG'%F#
M)*2X).^D^_O/[B,Z; "  \788Z_T'&0VM3(B\6) !7+U0HP%DI*(FJ<4U& =
MK_?NE=X,*T?Q3@:1_;-IH2XLRS[5VN-0;W(B;;BQML5$@;4!2, XW*2[Y]I"
M_4F*WZN%^E.T,/;F])*^.SW%B[;>B43Z9OIYNL9\F3XJ-+.&:]IH(ZTY9TV=
M&\C!:\NEB2)HM5OS]!^\Z#FT37^27A>-A-Q!B'12T_:N>C<SG;5B1H$TM)14
MCHZ()__>\ZRR]#I@FXC[%A7C]KP[:IR]O_0[@,Z'3R30%Z&V!%I\_H+SU86.
MKC*?2%K7GWD7OM?O;3B^9GN>W\W"_,:ZK)V?E2,3SJPLM>.&!2=%A((LIQ*C
MX+E)74H+9L:-WP[ UMWSQ[$5W0'8W^-JO9PFLO,?UHOTCPMC'Z-4.J0,HFQ2
M85BAH(4S<"8[=%X*Y9L<'VVE9N3SR=%!LAA:8QW [N85Z)OZZ<N3N&!I,6>O
M0"AR8A1C%J+& K$$#,RC\JS)E<Q#!(W;(?2XA^-#Z*13;%W.8. AJ90U:*<I
MKK*RYB?K#,D4([,GIDJ;8_$'21KY+'00E>^ HSWDWP&2WJX_X?+EV;**\LTT
MQ-J6:(JK"Y.K1&+*"@U,6'Y^LN>RM$"1D$EDW%WT;8H\'J.J/SSMH_J[=5F#
MZ:$74/VVF*<'^9$YNQP*\%2KLY7%&F0K\"4*3)XG:9N$"C\B;.13^X;0&DH;
M':!KBY_PYJHVDABIA=81LBPUB3XC1%4D&.%-L6AUP2;(>HRH<;M@CYU]L)]N
MNFC)>1'JK#XN+F[/+MG#U5^6B]5JXA,/HOBZ(GD=4F000G0,K,FF2*6R<DW2
M77]$6'?7SWN"8-%0'QU8LHUE?H2INN\K+![!8!U_QH2!R*T$J[GC1M29L^W\
MKT<(Z^YV>QA\#:J/L:^4/DZ1WOA^\3W,UM\OF;K1[-UF6[ N$^MR+?<W ;Q
M"Z9$<@<X/<VKV]AZJ/WYXR\:]TY@<*P,+ML.[-"6]-<'BF$NG<?O$Y6\LLE&
M""YI4&1FP26K:^M:@HA$+>6Q2L)^1.NX!US-K%5KK74+S!NU6<LP7UU0=AW6
MO#X/=?(D<9FC<@:*<"1=6=@YWS*1$**)&-LT13^,[''#A2/#M8DN.T#NYN+B
M]6IUAOF7LR6M2=H=IHN\N4:Y%8!-1"ZY\") H[*@O/?@+"L@= [UN,>8I%J
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M\4FP>L(K'Y?+"D*L+"1<1(@Z<?"JDB@I+:)OTR5XYY!&3%)TBC3UA,$(I.F
M.TFKWY"V#NG=J_5Z.8V;=;4Z?E^0(;Q8WL^<?E!++$R,RJ.#(@(Y2C%8LG2U
M VZ#E2G0LIHF(<'>9C!B.J-39'48A-M?1GMX4/]%\L9^_.%O4$L#!!0    (
M  J*;%/F%WB-O $  "D/   <    <&EN;F%C;&5L;V-R96YE=V%L-'1H;&]A
M+FAT;=W7S6_;(!0 \'O^"L:A-Q:3Q/EPB*5.:9M([3I5T:8=L?UBLQ*P,%N4
M_O7#22I-<=L3EW%"?+S'XW=ZL-7FX3[ML=7-]3)EGPA!2YW_WH&RJ 0%AELH
M4'9 /[1Y%G\X6JL<$>("-NO-_4U:"Z5X+D'JW+CC>RY'MI*:L_YIO\?ZQ\P]
M]N5Q^1-E9:ZE-@N\KX0%[):7Z^^(2U&J!<[=I6!>%QM[D+# .VY*H8B$K4TH
M[.9[4=@JH5$<S_&IWO=*B"+Z^5==GJK])V/-BT*HDEA=)P.7L;UP_7"'&I.[
MS8^3862%;9,T4A1 ,3J6L\!M/1A5(,K*NMEP')^?D;+;QZ\;U(@7%^3.GVO8
M:F5)NYC0VLZ/)LF9!+%^&Y*R?AO>8]]2MGI"2C<5+R!UTXO'E$ R _R99+#5
M!A(N]_S0N%==J:RIYZ]ISL/'8 .?8(,NV" TL*%/L&$7;!@:V,@GV*@+-@H-
M+/8)%G?!XM# QC[!QEVP<6A@$Y]@DR[8)#2PJ4^P:1=L&AK8S"?8K LV"PR,
M1A[!3LDN&M<H-#&?K3Y]J]4/K=>G/GM]^D:O3__#9O]B:+^LQQ]L^T7^"U!+
M 0(4 Q0    (  J*;%,C9C>$A @  / P   6              "  0    !A
M,C R,7$S+65X:&EB:70S,3$N:'1M4$L! A0#%     @ "HIL4]V==S)\"
MZC   !8              ( !N @  &$R,#(Q<3,M97AH:6)I=#,Q,BYH=&U0
M2P$"% ,4    "  *BFQ3#K&TM3L%  #1&@  %@              @ %H$0
M83(P,C%Q,RUE>&AI8FET,S(Q+FAT;5!+ 0(4 Q0    (  J*;%/.DBV?"V\!
M ,H3$  1              "  =<6  !C<&EX+3(P,C$P.3,P+FAT;5!+ 0(4
M Q0    (  J*;%,8D26.!0L  &9J   1              "  1&& 0!C<&EX
M+3(P,C$P.3,P+GAS9%!+ 0(4 Q0    (  J*;%/YZT8=PA8  &[7   5
M          "  461 0!C<&EX+3(P,C$P.3,P7V-A;"YX;6Q02P$"% ,4
M"  *BFQ3W*DWAAHI  "BI@$ %0              @ $ZJ $ 8W!I>"TR,#(Q
M,#DS,%]D968N>&UL4$L! A0#%     @ "HIL4]BL4AD^B   '9P% !4
M         ( !A]$! &-P:7@M,C R,3 Y,S!?;&%B+GAM;%!+ 0(4 Q0    (
M  J*;%..#.W"#%0  /:D P 5              "  ?A9 @!C<&EX+3(P,C$P
M.3,P7W!R92YX;6Q02P$"% ,4    "  *BFQ3YA=XC;P!   I#P  '
M        @ $WK@( <&EN;F%C;&5L;V-R96YE=V%L-'1H;&]A+FAT;5!+!08
1    "@ * * "   ML (    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>